# ESC Guidelines 2024

<!-- 2024_Atrial_Fibrillation.md -->

# ESC Guidelines: Atrial Fibrillation (2024)

**Source**: `2024_Atrial_Fibrillation.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 101

---

## Table of Contents

- [2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)](#2024-esc-guidelines-for-the-management-of-atrial-f) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 6)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. Definitions and clinical impact](#3-definitions-and-clinical-impact) *(p. 13)*
    - [3.1. Definition and classification of AF](#31-definition-and-classification-of-af) *(p. 13)*
    - [3.2. Diagnostic criteria for AF](#32-diagnostic-criteria-for-af) *(p. 14)*
    - [3.3. Symptoms attributable to AF](#33-symptoms-attributable-to-af) *(p. 15)*
    - [3.4. Diagnostic evaluation of new AF](#34-diagnostic-evaluation-of-new-af) *(p. 15)*
    - [3.5. Adverse events associated with AF](#35-adverse-events-associated-with-af) *(p. 16)*
    - [3.6. Atrial flutter](#36-atrial-flutter) *(p. 17)*
  - [4. Patient pathways and management of AF](#4-patient-pathways-and-management-of-af) *(p. 17)*
    - [4.1. Patient-centred, multidisciplinary AF management](#41-patient-centred,-multidisciplinary-af-managemen) *(p. 17)*
      - [4.1.1. The patient at the heart of care](#411-the-patient-at-the-heart-of-care) *(p. 17)*
      - [4.1.2. Education and shared decision-making](#412-education-and-shared-decision-making) *(p. 18)*
      - [4.1.3. Education of healthcare professionals](#413-education-of-healthcare-professionals) *(p. 19)*
      - [4.1.4. Inclusive management of AF](#414-inclusive-management-of-af) *(p. 19)*
    - [4.2. Principles of AF-CARE](#42-principles-of-af-care) *(p. 19)*
  - [5. [C] Comorbidity and risk factor management](#5-[c]-comorbidity-and-risk-factor-management) *(p. 25)*
    - [5.1. Hypertension](#51-hypertension) *(p. 26)*
    - [5.2. Heart failure](#52-heart-failure) *(p. 26)*
    - [5.3. Type 2 diabetes mellitus](#53-type-2-diabetes-mellitus) *(p. 27)*
    - [5.4. Obesity](#54-obesity) *(p. 27)*
    - [5.5. Obstructive sleep apnoea](#55-obstructive-sleep-apnoea) *(p. 27)*
    - [5.6. Physical inactivity](#56-physical-inactivity) *(p. 27)*
    - [5.7. Alcohol excess](#57-alcohol-excess) *(p. 28)*
  - [6. [A] Avoid stroke and thromboembolism](#6-[a]-avoid-stroke-and-thromboembolism) *(p. 28)*
    - [6.1. Initiating oral anticoagulation](#61-initiating-oral-anticoagulation) *(p. 28)*
      - [6.1.1. Decision support for anticoagulation in AF](#611-decision-support-for-anticoagulation-in-af) *(p. 28)*
    - [6.2. Oral anticoagulants](#62-oral-anticoagulants) *(p. 30)*
      - [6.2.1. Direct oral anticoagulants](#621-direct-oral-anticoagulants) *(p. 31)*
      - [6.2.2. Vitamin K antagonists](#622-vitamin-k-antagonists) *(p. 32)*
      - [6.2.3. Clinical vs. device-detected subclinical AF](#623-clinical-vs-device-detected-subclinical-af) *(p. 32)*
    - [6.3. Antiplatelet drugs and combinations with anticoagulants](#63-antiplatelet-drugs-and-combinations-with-antico) *(p. 33)*
    - [6.4. Residual ischaemic stroke risk despite anticoagulation](#64-residual-ischaemic-stroke-risk-despite-anticoag) *(p. 33)*
    - [6.5. Percutaneous left atrial appendage occlusion](#65-percutaneous-left-atrial-appendage-occlusion) *(p. 33)*
    - [6.6. Surgical left atrial appendage occlusion](#66-surgical-left-atrial-appendage-occlusion) *(p. 34)*
    - [6.7. Bleeding risk](#67-bleeding-risk) *(p. 35)*
      - [6.7.1. Assessment of bleeding risk](#671-assessment-of-bleeding-risk) *(p. 35)*
      - [6.7.2. Management of bleeding on anticoagulant therapy](#672-management-of-bleeding-on-anticoagulant-therap) *(p. 35)*
  - [7. [R] Reduce symptoms by rate and rhythm control](#7-[r]-reduce-symptoms-by-rate-and-rhythm-control) *(p. 38)*
    - [7.1. Management of heart rate in patients with AF](#71-management-of-heart-rate-in-patients-with-af) *(p. 38)*
      - [7.1.1. Indications and target heart rate](#711-indications-and-target-heart-rate) *(p. 39)*
      - [7.1.2. Heart rate control in the acute setting](#712-heart-rate-control-in-the-acute-setting) *(p. 39)*
      - [7.1.3. Long-term heart rate control](#713-long-term-heart-rate-control) *(p. 39)*
      - [7.1.4. Atrioventricular node ablation and pacemaker implantation](#714-atrioventricular-node-ablation-and-pacemaker-i) *(p. 40)*
    - [7.2. Rhythm control strategies in patients with AF](#72-rhythm-control-strategies-in-patients-with-af) *(p. 40)*
      - [7.2.1. General principles and anticoagulation](#721-general-principles-and-anticoagulation) *(p. 40)*
      - [7.2.2. Electrical cardioversion](#722-electrical-cardioversion) *(p. 43)*
      - [7.2.3. Pharmacological cardioversion](#723-pharmacological-cardioversion) *(p. 43)*
      - [7.2.4. Antiarrhythmic drugs](#724-antiarrhythmic-drugs) *(p. 44)*
      - [7.2.5. Catheter ablation](#725-catheter-ablation) *(p. 45)*
      - [7.2.6. Anticoagulation in patients undergoing catheter ablation](#726-anticoagulation-in-patients-undergoing-cathete) *(p. 46)*
      - [7.2.7. Endoscopic and hybrid AF ablation](#727-endoscopic-and-hybrid-af-ablation) *(p. 47)*
      - [7.2.8. AF ablation during cardiac surgery](#728-af-ablation-during-cardiac-surgery) *(p. 48)*
      - [7.2.9. Atrial tachycardia after pulmonary vein isolation](#729-atrial-tachycardia-after-pulmonary-vein-isolat) *(p. 48)*
  - [8. [E] Evaluation and dynamic reassessment](#8-[e]-evaluation-and-dynamic-reassessment) *(p. 48)*
    - [8.1. Implementation of dynamic care](#81-implementation-of-dynamic-care) *(p. 49)*
    - [8.2. Improving treatment adherence](#82-improving-treatment-adherence) *(p. 49)*
    - [8.3. Cardiac imaging](#83-cardiac-imaging) *(p. 49)*
    - [8.4. Patient-reported outcome measures](#84-patient-reported-outcome-measures) *(p. 50)*
  - [9. The AF-CARE pathway in specific clinical settings](#9-the-af-care-pathway-in-specific-clinical-setting) *(p. 51)*
    - [9.1. AF-CARE in unstable patients](#91-af-care-in-unstable-patients) *(p. 51)*
    - [9.2. AF-CARE in acute and chronic coronary syndromes](#92-af-care-in-acute-and-chronic-coronary-syndromes) *(p. 51)*
    - [9.3. AF-CARE in vascular disease](#93-af-care-in-vascular-disease) *(p. 53)*
    - [9.4. AF-CARE in acute stroke or intracranial haemorrhage](#94-af-care-in-acute-stroke-or-intracranial-haemorr) *(p. 53)*
      - [9.4.1. Management of acute ischaemic stroke](#941-management-of-acute-ischaemic-stroke) *(p. 53)*
      - [9.4.2. Introduction or re-introduction of anticoagulation after ischaemic stroke](#942-introduction-or-re-introduction-of-anticoagula) *(p. 54)*
      - [9.4.3. Introduction or re-introduction of anticoagulation after haemorrhagic stroke](#943-introduction-or-re-introduction-of-anticoagula) *(p. 54)*
    - [9.5. AF-CARE for trigger-induced AF](#95-af-care-for-trigger-induced-af) *(p. 54)*
    - [9.6. AF-CARE in post-operative patients](#96-af-care-in-post-operative-patients) *(p. 55)*
    - [9.7. AF-CARE in embolic stroke of unknown source](#97-af-care-in-embolic-stroke-of-unknown-source) *(p. 55)*
    - [9.8. AF-CARE during pregnancy](#98-af-care-during-pregnancy) *(p. 56)*
    - [9.9. AF-CARE in congenital heart disease](#99-af-care-in-congenital-heart-disease) *(p. 57)*
    - [9.10. AF-CARE in endocrine disorders](#910-af-care-in-endocrine-disorders) *(p. 57)*
    - [9.11. AF-CARE in inherited cardiomyopathies and primary arrhythmia syndromes](#911-af-care-in-inherited-cardiomyopathies-and-prim) *(p. 57)*
    - [9.12. AF-CARE in cancer](#912-af-care-in-cancer) *(p. 58)*
    - [9.13. AF-CARE in older, multimorbid, or frail patients](#913-af-care-in-older,-multimorbid,-or-frail-patien) *(p. 58)*
    - [9.14. AF-CARE in atrial flutter](#914-af-care-in-atrial-flutter) *(p. 58)*
  - [10. Screening and prevention of AF](#10-screening-and-prevention-of-af) *(p. 58)*
    - [10.1. Epidemiology of AF](#101-epidemiology-of-af) *(p. 58)*
    - [10.2. Screening tools for AF](#102-screening-tools-for-af) *(p. 59)*
    - [10.3. Screening strategies for AF](#103-screening-strategies-for-af) *(p. 60)*
      - [10.3.1. Single timepoint screening ‘snapshot’](#1031-single-timepoint-screening-‘snapshot’) *(p. 61)*
      - [10.3.2. Prolonged screening](#1032-prolonged-screening) *(p. 61)*
    - [10.4. Factors associated with incident AF](#104-factors-associated-with-incident-af) *(p. 62)*
    - [10.5. Primary prevention of AF](#105-primary-prevention-of-af) *(p. 62)*
      - [10.5.1. Hypertension](#1051-hypertension) *(p. 63)*
      - [10.5.2. Heart failure](#1052-heart-failure) *(p. 63)*
      - [10.5.3. Type 2 diabetes mellitus](#1053-type-2-diabetes-mellitus) *(p. 63)*
      - [10.5.4. Obesity](#1054-obesity) *(p. 63)*
      - [10.5.5. Sleep apnoea syndrome](#1055-sleep-apnoea-syndrome) *(p. 63)*
      - [10.5.6. Physical activity](#1056-physical-activity) *(p. 63)*
      - [10.5.7. Alcohol intake](#1057-alcohol-intake) *(p. 64)*
  - [11. Key messages](#11-key-messages) *(p. 64)*
  - [12. Gaps in evidence](#12-gaps-in-evidence) *(p. 64)*
  - [13. ‘What to do’ and ‘What not to do’ messages from the guidelines](#13-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 66)*
  - [14. Evidence tables](#14-evidence-tables) *(p. 69)*
  - [15. Data availability statement](#15-data-availability-statement) *(p. 69)*
  - [16. Author information](#16-author-information) *(p. 69)*
  - [Appendix](#appendix) *(p. 70)*
  - [References](#references) *(p. 71)*
  - [References](#references) *(p. 71)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management 
of atrial fibrillation developed in collaboration 
with the European Association 
for Cardio-Thoracic Surgery (EACTS)
Developed by the task force for the management of atrial fibrillation of the 
European Society of Cardiology (ESC), with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC.  
Endorsed by the European Stroke Organisation (ESO)
Authors/Task Force Members: Isabelle C. Van Gelder  *†, (Chairperson) 
(Netherlands), Michiel Rienstra  
±, (Task Force Co-ordinator) (Netherlands), 
Karina V. Bunting  
±, (Task Force Co-ordinator) (United Kingdom), 
Ruben Casado-Arroyo  
(Belgium), Valeria Caso  
1 (Italy), Harry J.G.M. Crijns  
(Netherlands), Tom J.R. De Potter  
(Belgium), Jeremy Dwight (United Kingdom), 
Luigina Guasti  
(Italy), Thorsten Hanke  
2 (Germany), Tiny Jaarsma  
(Sweden), 
Maddalena Lettino  
(Italy), Maja-Lisa Løchen  
(Norway), R. Thomas Lumbers  
(United Kingdom), Bart Maesen  
2 (Netherlands), Inge Mølgaard (Denmark), 
Giuseppe M.C. Rosano (United Kingdom), Prashanthan Sanders  
(Australia), 
Renate B. Schnabel  
(Germany), Piotr Suwalski  
2 (Poland), Emma Svennberg  
(Sweden), Juan Tamargo  
(Spain), Otilia Tica  
(Romania), Vassil Traykov  
(Bulgaria), Stylianos Tzeis (Greece), Dipak Kotecha  *†, (Chairperson) 
(United Kingdom), and ESC Scientific Document Group  
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
* Corresponding authors: Isabelle C. Van Gelder, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Tel: +31 50 361 1327. 
Email: i.c.van.gelder@umcg.nl; and Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom & NIHR Birmingham Biomedical Research Centre, 
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Tel: +44 121 371 8124. Email: d.kotecha@bham.ac.uk
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
± The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing European Stroke Organisation (ESO).
2 Representing European Association for Cardio-Thoracic Surgery (EACTS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council of Cardio-Oncology, Council on Cardiovascular Genomics, Council on Stroke.
Working Groups: Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, E-Cardiology, Thrombosis.
Patient Forum
https://doi.org/10.1093/eurheartj/ehae176
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Nikolaos Dagres, (CPG Review Co-ordinator) (Germany), Bianca Rocca, (CPG Review 
Co-ordinator) (Italy), Syed Ahsan (United Kingdom)2, Pietro Ameri (Italy), Elena Arbelo (Spain), Axel Bauer 
(Austria), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Barbara Casadei (United Kingdom), 
Ovidiu Chioncel (Romania), Dobromir Dobrev (Germany), Laurent Fauchier (France), Bruna Gigante (Sweden), 
Michael Glikson (Israel), Ziad Hijazi (Sweden), Gerhard Hindricks (Germany), Daniela Husser (Germany), 
Borja Ibanez (Spain), Stefan James (Sweden), Stefan Kaab (Germany), Paulus Kirchhof (Germany), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Thomas Kumler (Denmark), Gregory Y.H. Lip 
(United Kingdom), John Mandrola (United States of America), Nikolaus Marx (Germany), John William Mcevoy 
(Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Denisa Muraru (Italy), 
Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Jonas Oldgren (Sweden), Maurizio Paciaroni 
(Italy)1, Agnes A. Pasquet (Belgium), Eva Prescott (Denmark), Filip Rega2 (Belgium), Francisco Javier Rossello 
(Spain), Marcin Rucinski (Poland), Sacha P. Salzberg2 (Switzerland), Sam Schulman (Canada), Philipp Sommer 
(Germany), Jesper Hastrup Svendsen (Denmark), Jurrien M. ten Berg (Netherlands), Hugo Ten Cate 
(Netherlands), Ilonca Vaartjes (Netherlands), Christiaan Jm. Vrints (Belgium), Adam Witkowski (Poland), and 
Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or 
www.escardio.org/guidelines for supplementary documents as well as evidence tables.
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and 
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, 
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant 
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged 
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do 
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated 
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s 
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC 
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational 
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written 
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of 
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Atrial fibrillation • AF-CARE • Comorbidity • Risk factors • Anticoagulation • Rate control • Rhythm 
control • Cardioversion • Antiarrhythmic drugs • Catheter ablation • AF surgery • Evaluation • Stroke • 
Thromboembolism
ESC Guidelines                                                                                                                                                                                          3315


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble .............................................................................................................. 3319
2. Introduction ....................................................................................................... 3321
2.1. What is new .............................................................................................
3322
3. Definitions and clinical impact .................................................................... 3326
3.1. Definition and classification of AF ...................................................
3326
3.2. Diagnostic criteria for AF ...................................................................
3327
3.3. Symptoms attributable to AF ...........................................................
3328
3.4. Diagnostic evaluation of new AF .....................................................
3328
3.5. Adverse events associated with AF ................................................
3329
3.6. Atrial flutter ..............................................................................................
3330
4. Patient pathways and management of AF ............................................. 3330
4.1. Patient-centred, multidisciplinary AF management .................
3330
4.1.1. The patient at the heart of care .............................................. 3330
4.1.2. Education and shared decision-making ................................. 3331
4.1.3. Education of healthcare professionals ................................... 3332
4.1.4. Inclusive management of AF ...................................................... 3332
4.2. Principles of AF-CARE .........................................................................
3332
5. [C] Comorbidity and risk factor management ................................... 3338
5.1. Hypertension ............................................................................................
3339
5.2. Heart failure ..............................................................................................
3339
5.3. Type 2 diabetes mellitus ......................................................................
3340
5.4. Obesity .......................................................................................................
3340
5.5. Obstructive sleep apnoea ...................................................................
3340
5.6. Physical inactivity ....................................................................................
3340
5.7. Alcohol excess .........................................................................................
3341
6. [A] Avoid stroke and thromboembolism .............................................. 3341
6.1. Initiating oral anticoagulation .............................................................
3341
6.1.1. Decision support for anticoagulation in AF ........................ 3341
6.2. Oral anticoagulants ................................................................................
3343
6.2.1. Direct oral anticoagulants ........................................................... 3344
6.2.2. Vitamin K antagonists ................................................................... 3345
6.2.3. Clinical vs. device-detected subclinical AF ........................... 3345
6.3. Antiplatelet drugs and combinations with anticoagulants ....
3346
6.4. Residual ischaemic stroke risk despite anticoagulation ..........
3346
6.5. Percutaneous left atrial appendage occlusion ............................
3346
6.6. Surgical left atrial appendage occlusion ........................................
3347
6.7. Bleeding risk ..............................................................................................
3348
6.7.1. Assessment of bleeding risk ....................................................... 3348
6.7.2. Management of bleeding on anticoagulant therapy ......... 3348
7. [R] Reduce symptoms by rate and rhythm control ......................... 3351
7.1. Management of heart rate in patients with AF .........................
3351
7.1.1. Indications and target heart rate .............................................. 3352
7.1.2. Heart rate control in the acute setting ................................. 3352
7.1.3. Long-term heart rate control .................................................... 3352
7.1.4. Atrioventricular node ablation and pacemaker 
implantation ................................................................................................... 3353
7.2. Rhythm control strategies in patients with AF ..........................
3353
7.2.1. General principles and anticoagulation ................................. 3353
7.2.2. Electrical cardioversion ................................................................ 3356
7.2.3. Pharmacological cardioversion .................................................. 3356
7.2.4. Antiarrhythmic drugs .................................................................... 3357
7.2.5. Catheter ablation ............................................................................ 3358
7.2.6. Anticoagulation in patients undergoing catheter ablation
3359
7.2.7. Endoscopic and hybrid AF ablation ........................................ 3360
7.2.8. AF ablation during cardiac surgery .......................................... 3361
7.2.9. Atrial tachycardia after pulmonary vein isolation ............. 3361
8. [E] Evaluation and dynamic reassessment ............................................. 3361
8.1. Implementation of dynamic care .....................................................
3362
8.2. Improving treatment adherence ......................................................
3362
8.3. Cardiac imaging .......................................................................................
3362
8.4. Patient-reported outcome measures ............................................
3363
9. The AF-CARE pathway in specific clinical settings ............................ 3364
9.1. AF-CARE in unstable patients ..........................................................
3364
9.2. AF-CARE in acute and chronic coronary syndromes ............
3364
9.3. AF-CARE in vascular disease .............................................................
3366
9.4. AF-CARE in acute stroke or intracranial haemorrhage ........
3366
9.4.1. Management of acute ischaemic stroke ................................ 3366
9.4.2. Introduction or re-introduction of anticoagulation after 
ischaemic stroke .......................................................................................... 3367
9.4.3. Introduction or re-introduction of anticoagulation after 
haemorrhagic stroke .................................................................................. 3367
9.5. AF-CARE for trigger-induced AF ....................................................
3367
9.6. AF-CARE in post-operative patients .............................................
3368
9.7. AF-CARE in embolic stroke of unknown source .....................
3368
9.8. AF-CARE during pregnancy ...............................................................
3369
9.9. AF-CARE in congenital heart disease ............................................
3370
9.10. AF-CARE in endocrine disorders .................................................
3370
9.11. AF-CARE in inherited cardiomyopathies and primary 
arrhythmia syndromes ..................................................................................
3370
9.12. AF-CARE in cancer .............................................................................
3371
9.13. AF-CARE in older, multimorbid, or frail patients ..................
3371
9.14. AF-CARE in atrial flutter ..................................................................
3371
10. Screening and prevention of AF ............................................................. 3371
10.1. Epidemiology of AF .............................................................................
3371
10.2. Screening tools for AF .......................................................................
3372
10.3. Screening strategies for AF ..............................................................
3373
10.3.1. Single timepoint screening ‘snapshot’ .................................. 3374
10.3.2. Prolonged screening ................................................................... 3374
10.4. Factors associated with incident AF ............................................
3375
10.5. Primary prevention of AF ................................................................
3375
10.5.1. Hypertension ................................................................................. 3376
10.5.2. Heart failure ................................................................................... 3376
10.5.3. Type 2 diabetes mellitus ........................................................... 3376
10.5.4. Obesity ............................................................................................. 3376
10.5.5. Sleep apnoea syndrome ............................................................ 3376
10.5.6. Physical activity .............................................................................. 3376
10.5.7. Alcohol intake ................................................................................ 3377
11. Key messages .................................................................................................. 3377
12. Gaps in evidence ............................................................................................ 3377
13. ‘What to do’ and ‘What not to do’ messages from the 
guidelines .................................................................................................................. 3379
14. Evidence tables ............................................................................................... 3382
15. Data availability statement ......................................................................... 3382
16. Author information ...................................................................................... 3382
17. Appendix ........................................................................................................... 3383
18. References ........................................................................................................ 3384


<!-- PAGE 4 -->

### Page 4

Tables of Recommendations
Recommendation Table 1 — Recommendations for the diagnosis of 
AF (see also Evidence Table 1) ....................................................................... 3328
Recommendation Table 2 — Recommendations for symptom 
evaluation in patients with AF (see also Evidence Table 2) ................ 3328
Recommendation Table 3 — Recommendations for diagnostic 
evaluation in patients with new AF (see also Evidence Table 3) ..... 3328
Recommendation Table 4 — Recommendations for patient-centred 
care and education (see also Evidence Table 4) ...................................... 3332
Recommendation Table 5 — Recommendations for comorbidity 
and risk factor management in AF (see also Evidence Table 5) ....... 3339
Recommendation Table 6 — Recommendations to assess and 
manage thromboembolic risk in AF (see also Evidence Table 6) .... 3342
Recommendation Table 7 — Recommendations for oral 
anticoagulation in AF (see also Evidence Table 7) .................................. 3344
Recommendation Table 8 — Recommendations for combining 
antiplatelet drugs with anticoagulants for stroke prevention (see also 
Evidence Table 8) .................................................................................................. 3346
Recommendation Table 9 — Recommendations for 
thromboembolism despite anticoagulation (see also Evidence 
Table 9) ..................................................................................................................... 3346
Recommendation Table 10 — Recommendations for percutaneous 
left atrial appendage occlusion (see also Evidence Table 10) ............ 3347
Recommendation Table 11 — Recommendations for surgical left 
atrial appendage occlusion (see also Evidence Table 11) .................... 3348
Recommendation Table 12 — Recommendations for assessment of 
bleeding risk (see also Evidence Table 12) ................................................. 3348
Recommendation Table 13 — Recommendations for management 
of bleeding in anticoagulated patients (see also Evidence Table 13)
3351
Recommendation Table 14 — Recommendations for heart rate 
control in patients with AF (see also Evidence Table 14) ................... 3351
Recommendation Table 15 — Recommendations for general 
concepts in rhythm control (see also Evidence Table 15) .................. 3355
Recommendation Table 16 — Recommendations for electrical 
cardioversion of AF (see also Evidence Table 16) .................................. 3356
Recommendation Table 17 — Recommendations for 
pharmacological cardioversion of AF (see also Evidence Table 17)
3356
Recommendation Table 18 — Recommendations for 
antiarrhythmic drugs for long-term maintenance of sinus rhythm 
(see also Evidence Table 18) ............................................................................ 3358
Recommendation Table 19 — Recommendations for catheter 
ablation of AF (see also Evidence Table 19) ............................................. 3359
Recommendation Table 20 — Recommendations for 
anticoagulation in patients undergoing catheter ablation (see also 
Evidence Table 20) ............................................................................................... 3360
Recommendation Table 21 — Recommendations for endoscopic 
and hybrid AF ablation (see also Evidence Table 21) ........................... 3360
Recommendation Table 22 — Recommendations for AF ablation 
during cardiac surgery (see also Evidence Table 22) ............................. 3361
Recommendation Table 23 — Recommendations to improve 
patient experience (see also Evidence Table 23) .................................... 3364
Recommendation Table 24 — Recommendations for patients with 
acute coronary syndromes or undergoing percutaneous 
intervention (see also Evidence Table 24) ................................................. 3366
Recommendation Table 25 — Recommendations for 
trigger-induced AF (see also Evidence Table 25) .................................... 3368
Recommendation Table 26 — Recommendations for management 
of post-operative AF (see also Evidence Table 26) ............................... 3368
Recommendation Table 27 — Recommendations for patients with 
embolic stroke of unknown source (see also Evidence Table 27) .. 3369
Recommendation Table 28 — Recommendations for patients with 
AF during pregnancy (see also Evidence Table 28) ................................ 3369
Recommendation Table 29 — Recommendations for patients with 
AF and congenital heart disease (see also Evidence Table 29) ......... 3370
Recommendation Table 30 — Recommendations for prevention of 
thromboembolism in atrial flutter (see also Evidence Table 30) ..... 3371
Recommendation Table 31 — Recommendations for screening for 
AF (see also Evidence Table 31) .................................................................... 3374
Recommendation Table 32 — Recommendations for primary 
prevention of AF (see also Evidence Table 32) ....................................... 3376
List of tables
Table 1 Classes of recommendations .......................................................... 3320
Table 2 Levels of evidence ................................................................................ 3320
Table 3 New recommendations .................................................................... 3322
Table 4 Revised recommendations ............................................................... 3325
Table 5 Definitions and classifications for the temporal pattern of 
AF ................................................................................................................................. 3327
Table 6 Other clinical concepts relevant to AF ....................................... 3327
Table 7 The modified European Heart Rhythm Association 
(mEHRA) symptom classification ................................................................... 3329
Table 8 Diagnostic work-up for patients with AF .................................. 3330
Table 9 Achieving patient-centred AF management ............................. 3331
Table 10 Updated definitions for the CHA2DS2-VA score ............... 3342
Table 11 Recommended doses for direct oral anticoagulant 
therapy ....................................................................................................................... 3345
Table 12 Drugs for rate control in AF ........................................................ 3352
Table 13 Antiarrhythmic drugs for sinus rhythm restoration ........... 3357
Table 14 Non-cardiac conditions associated with trigger-induced 
AF ................................................................................................................................. 3367
Table 15 Tools for AF screening .................................................................... 3373
Table 16 Factors associated with incident AF .......................................... 3375
Table 17 ‘What to do’ and ‘what not to do’ ............................................ 3379
List of figures
Figure 1 Impacts and outcomes associated with clinical AF. AF, atrial 
fibrillation .................................................................................................................. 3329
Figure 2 Multidisciplinary approach to AF management ...................... 3331
Figure 3 Central illustration. Patient pathway for AF-CARE (see Figures 
4, 5, 6, and 7 for the [R] pathways for first-diagnosed, paroxysmal, 
persistent and permanent AF) ................................................................................
3333
Figure 4 [R] Pathway for patients with first-diagnosed AF ................. 3334
Figure 5 [R] Pathway for patients with paroxysmal AF ....................... 3335
Figure 6 [R] Pathway for patients with persistent AF .......................... 3336
Figure 7 [R] Pathway for patients with permanent AF ........................ 3337
Figure 8 Management of key comorbidities to reduce AF 
recurrence ................................................................................................................ 3338
Figure 9 Common drug interactions with oral anticoagulants .......... 3343
Figure 10 Modifying the risk of bleeding associated with OAC ....... 3349
Figure 11 Management of oral anticoagulant-related bleeding in 
patients with AF .................................................................................................... 3350
Figure 12 Approaches for cardioversion in patients with AF ............ 3354
Figure 13 Relevance of echocardiography in the AF-CARE pathway
3363
Figure 14 Antithrombotic therapy in patients with AF and acute or 
chronic coronary syndromes ........................................................................... 3365
ESC Guidelines                                                                                                                                                                                          3317


<!-- PAGE 5 -->

### Page 5

Figure 15 Non-invasive diagnostic methods for AF screening .......... 3372
Figure 16 Approaches to screening for AF ............................................... 3374
Abbreviations and acronyms
AAD
Antiarrhythmic drugs
ACE
Angiotensin-converting enzyme
ACEi
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndromes
ACTIVE W
Atrial fibrillation Clopidogrel Trial with Irbesartan 
for prevention of Vascular Events (trial)
AF
Atrial fibrillation
AF-CARE
Atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and 
thromboembolism, [R] Reduce symptoms by rate and 
rhythm control, [E] Evaluation and dynamic 
reassessment
AFEQT
Atrial Fibrillation Effect on QualiTy-of-Life 
(questionnaire)
AFFIRM
Atrial Fibrillation Follow-up Investigation of 
Rhythm Management (trial)
AFL
Atrial flutter
AFQLQ
Atrial Fibrillation Quality of Life Questionnaire
AF-QoL
Atrial Fibrillation Quality of Life (questionnaire)
AFSS
Atrial Fibrillation Severity Scale
AI
Artificial intelligence
APACHE-AF
Apixaban After Anticoagulation-associated 
Intracerebral Haemorrhage in Patients With Atrial 
Fibrillation (trial)
APAF-CRT
Ablate and Pace for Atrial Fibrillation—cardiac 
resynchronization therapy
ARB
Angiotensin receptor blocker
ARTESiA
Apixaban for the Reduction of Thromboembolism 
in Patients With Device-Detected Sub-Clinical 
Atrial Fibrillation (trial)
AT
Atrial tachycardia
ATHENA
A Placebo-Controlled, Double-Blind, Parallel Arm 
Trial to Assess the Efficacy of Dronedarone 400 mg 
twice daily for the Prevention of Cardiovascular 
Hospitalization or Death from Any Cause in 
Patients with Atrial Fibrillation/Atrial Flutter (trial)
AUGUSTUS
An open-label, 2 × 2 factorial, randomized controlled, 
clinical trial to evaluate the safety of apixaban vs. 
vitamin k antagonist and aspirin vs. aspirin placebo in 
patients with atrial fibrillation and acute coronary 
syndrome or percutaneous coronary intervention
AVERROES
Apixaban Versus Acetylsalicylic Acid to Prevent 
Stroke in Atrial Fibrillation Patients Who Have 
Failed or Are Unsuitable for Vitamin K Antagonist 
Treatment (trial)
AVN
Atrioventricular node b.p.m.
Beats per minute
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure
C2HEST
Coronary artery disease or chronic obstructive 
pulmonary disease (1 point each); hypertension 
(1 point); elderly (age ≥75 years, 2 points); systolic 
heart failure (2 points); thyroid disease 
(hyperthyroidism, 1 point)
CABANA
Catheter Ablation versus Anti-arrhythmic Drug 
Therapy for Atrial Fibrillation (trial)
CAD
Coronary artery disease
CASTLE-AF
Catheter Ablation versus Standard Conventional 
Treatment in Patients With Left Ventricle (LV) 
Dysfunction and AF (trial)
CASTLE-HTx
Catheter Ablation for Atrial Fibrillation in Patients 
With End-Stage Heart Failure and Eligibility for 
Heart Transplantation (trial)
CCS
Chronic coronary syndrome
CHADS2
Congestive heart failure, hypertension, age >75 
years, diabetes; previous stroke (2 points)
CHA2DS2-VA
Congestive heart failure, hypertension, age ≥75 years 
(2 points), diabetes mellitus, prior stroke/transient 
ischaemic attack/arterial thromboembolism (2 
points), vascular disease, age 65–74 years (score)
CHA2DS2-VASc
Congestive heart failure, hypertension, age ≥75 
years (2 points), diabetes mellitus, prior stroke or 
TIA or thromboembolism (2 points), vascular 
disease, age 65–74 years, sex category
CKD
Chronic kidney disease
CMR
Cardiac magnetic resonance
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies (trial)
CPAP
Continuous positive airway pressure
CrCl
Creatinine clearance
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CTA
Computed tomography angiography
CTI
Cavo-tricuspid isthmus
DAPT
Dual antiplatelet therapy
DOAC
Direct oral anticoagulant
EAST-AFNET 4
Early treatment of Atrial fibrillation for Stroke 
prevention Trial
ECG
Electrocardiogram
ECV
Electrical cardioversion
EHRA
European Heart Rhythm Association
ELAN
Early versus Late initiation of direct oral 
Anticoagulants in post-ischaemic stroke patients 
with atrial fibrillatioN (trial)
ESUS
Embolic stroke of undetermined source
FFP
Fresh frozen plasma
GI
Gastrointestinal
GWAS
Genome-wide association studies
HAS-BLED
Hypertension, Abnormal renal/liver function, 
Stroke, Bleeding history or predisposition, Labile 
international normalized ratio, Elderly (>65 years), 
Drugs/alcohol concomitantly (score)
HAVOC
Hypertension, age, valvular heart disease, 
peripheral vascular disease, obesity, congestive 
heart failure, and coronary artery disease
HbA1c
Haemoglobin A1c (glycated or glycosylated 
haemoglobin)
HCM
Hypertrophic cardiomyopathy
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HR
Hazard ratio i.v.
Intravenous


<!-- PAGE 6 -->

### Page 6

ICH
Intracranial haemorrhage
ICHOM
International Consortium for Health Outcomes 
Measurement
IMT
Intima-media thickness
INR
International normalized ratio (of prothrombin 
time)
LA
Left atrium
LAA
Left atrial appendage
LAAO
Left atrial appendage occlusion
LAAOS III
Left Atrial Appendage Occlusion Study
LEGACY
Long-Term Effect of Goal directed weight 
management on Atrial Fibrillation Cohort: a 5 Year 
follow-up study
LMWH
Low molecular weight heparin
LOOP
Atrial Fibrillation Detected by Continuous ECG 
Monitoring (trial)
LV
Left ventricle
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy mEHRA
Modified European Heart Rhythm Association 
score
MI
Myocardial infarction
MRI
Magnetic resonance imaging
NOAH
Non-vitamin K Antagonist Oral Anticoagulants 
in Patients With Atrial High Rate Episodes (trial)
NSAID
Non-steroidal anti-inflammatory drug
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association
OAC
Oral anticoagulant(s)
OR
Odds ratio
OSA
Obstructive sleep apnoea
PAD
Peripheral arterial disease
PCC
Prothrombin complex concentrate
PCI
Percutaneous intervention
PFO
Patent foramen ovale
POAF
Post-operative atrial fibrillation
PPG
Photoplethysmography
PROM
Patient-reported outcome measure
PVD
Peripheral vascular disease
PVI
Pulmonary vein isolation
QLAF
Quality of Life in Atrial Fibrillation (questionnaire)
QRS
Q wave, R wave, and S wave, the ‘QRS complex’ 
represents ventricular depolarization
RACE 7  
ACWAS
Rate Control versus Electrical Cardioversion  
Trial 7—Acute Cardioversion versus Wait and See 
(trial)
RACE I
RAte Control versus Electrical cardioversion study
RACE II
Rate Control Efficacy in Permanent Atrial 
Fibrillation (trial)
RACE 3
Routine versus Aggressive upstream rhythm 
Control for prevention of Early AF in heart failure 
(trial)
RACE 4
IntegRAted Chronic Care Program at Specialized 
AF Clinic Versus Usual CarE in Patients with Atrial 
Fibrillation (trial)
RATE-AF
RAte control Therapy Evaluation in permanent 
Atrial Fibrillation (trial)
RCT
Randomized controlled trial
RR
Relative risk
SAVE
Sleep Apnea cardioVascular Endpoints (trial)
SBP
Systolic blood pressure
SGLT2
Sodium-glucose cotransporter-2
SIC-AF
Successful Intravenous Cardioversion for Atrial 
Fibrillation
SORT-AF
Supervised Obesity Reduction Trial for AF 
Ablation Patients (trial)
SoSTART
Start or STop Anticoagulants Randomised Trial
SR
Sinus rhythm
STEEER-AF
Stroke prevention and rhythm control Therapy: 
Evaluation of an Educational programme of the 
European Society of Cardiology in a cluster- 
Randomised trial in patients with Atrial Fibrillation 
(trial)
STEMI
ST-segment elevation myocardial infarction
STROKESTOP
Systematic ECG Screening for Atrial Fibrillation 
Among 75 Year Old Subjects in the Region of 
Stockholm and Halland, Sweden (trial)
TE
Thromboembolism
TIA
Transient ischaemic attack
TIMING
Timing of Oral Anticoagulant Therapy in Acute 
Ischemic Stroke With Atrial Fibrillation (trial)
TOE
Transoesophageal echocardiography
TSH
Thyroid-stimulating hormone
TTE
Transthoracic echocardiogram
TTR
Time in therapeutic range
UFH
Unfractionated heparin
VKA
Vitamin K antagonist
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of 
assisting health professionals in proposing the best diagnostic or thera­
peutic approach for an individual patient with a given condition. 
Guidelines are intended for use by health professionals and the 
European Society of Cardiology (ESC) makes its Guidelines freely 
available.
ESC Guidelines do not override the individual responsibility of 
health professionals to make appropriate and accurate decisions in 
consideration of each patient’s health condition and in consultation 
with that patient or the patient’s caregiver where appropriate and/ 
or necessary. It is also the health professional’s responsibility to verify 
the rules and regulations applicable in each country to drugs and de­
vices at the time of prescription and to respect the ethical rules of their 
profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated when warranted by new evidence. ESC 
Policies and Procedures for formulating and issuing ESC Guidelines can 
be found on the ESC website (https://www.escardio.org/Guidelines/ 
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- 
Guidelines). This guideline updates and replaces the previous version 
from 2020.
The Members of this task force were selected by the ESC to include 
professionals involved with the medical care of patients with this path­
ology as well as patient representatives and methodologists. The selec­
tion procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
ESC Guidelines                                                                                                                                                                                          3319


<!-- PAGE 7 -->

### Page 7

and inclusion, notably with respect to gender and country of origin. 
The task force performed a critical review and evaluation of the 
published literature on diagnostic and therapeutic approaches includ­
ing assessment of the risk–benefit ratio. The strength of every recom­
mendation and the level of evidence supporting them were weighed 
and scored according to predefined scales as outlined in Tables 1
and 2 below. Patient-reported outcome measures (PROMs) and 
patient-reported experience measures were also evaluated as the ba­
sis for recommendations and/or discussion in these guidelines. The 
task force followed ESC voting procedures and all approved recom­
mendations were subject to a vote and achieved at least 75% agree­
ment among voting members. Members of the task force with 
declared interests on specific topics were asked to abstain from voting 
on related recommendations.
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024


<!-- PAGE 8 -->

### Page 8

The experts of the writing and reviewing panels provided declaration of 
interest forms for all relationships that might be perceived as real or po­
tential sources of conflicts of interest. Their declarations of interest were 
reviewed according to the ESC declaration of interest rules which can be 
found on the ESC website (http://www.escardio.org/guidelines) and have 
been compiled in a report published in a supplementary document with 
the guidelines. Funding for the development of ESC Guidelines is derived 
entirely from the ESC with no involvement of the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises and 
co-ordinates the preparation of new guidelines and is responsible for the 
approval process. In addition to review by the CPG Committee, ESC 
Guidelines undergo multiple rounds of double-blind peer review by exter­
nal experts, including members from across the whole of the ESC region, all 
National Cardiac Societies of the ESC and from relevant ESC Subspecialty 
Communities. After appropriate revisions, the guidelines are signed off by 
all the experts in the task force. The finalized document is signed off by the 
CPG Committee for publication in the European Heart Journal.
ESC Guidelines are based on analyses of published evidence, chiefly on 
clinical trials and meta-analyses of trials, but potentially including other 
types of studies. Evidence tables summarizing key information from rele­
vant studies are generated early in the guideline development process to 
facilitate the formulation of recommendations, to enhance comprehension 
of recommendations after publication, and reinforce transparency in the 
guidelines development process. The tables are published in their 
own section of ESC Guidelines and reference specific recommenda­
tion tables.
Off-label use of medication may be presented in this guideline if a suf­
ficient level of evidence shows that it can be considered medically 
appropriate for a given condition. However, the final decisions con­
cerning an individual patient must be made by the responsible health 
professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Atrial fibrillation (AF) is one of the most commonly encountered heart 
conditions, with a broad impact on all health services across primary 
and secondary care. The prevalence of AF is expected to double in 
the next few decades as a consequence of the ageing population, an in­
creasing burden of comorbidities, improved awareness, and new tech­
nologies for detection.
The effects of AF are variable across individual patients; however, mor­
bidity from AF remains highly concerning. Patients with AF can suffer 
from a variety of symptoms and poor quality of life. Stroke and heart 
failure as consequences of AF are now well appreciated by healthcare 
professionals, but AF is also linked to a range of other thromboembolic 
outcomes. These include subclinical cerebral damage (potentially leading 
to vascular dementia), and thromboembolism to every other organ, all of 
which contribute to the higher risk of mortality associated with AF.
The typical drivers of AF onset and progression are a range of co­
morbidities and associated risk factors. To achieve optimal care for pa­
tients with AF, it is now widely accepted that these comorbidities and 
risk factors must be managed early and in a dynamic way. Failure to do 
so contributes to recurrent cycles of AF, treatment failure, poor patient 
outcomes, and a waste of healthcare resources. In this iteration of the 
European Society of Cardiology (ESC) practice guidelines on AF, the 
task force has consolidated and evolved past approaches to develop 
the AF-CARE framework (Atrial Fibrillation—[C] Comorbidity and 
risk factor management, [A] Avoid stroke and thromboembolism, [R] 
Reduce symptoms by rate and rhythm control, [E] Evaluation and dy­
namic reassessment). Comorbidities and risk factors is placed as the ini­
tial and central component of patient management. This should be 
considered first as it applies to all patients with AF, regardless of their 
thromboembolic risk factors or any symptoms that might warrant 
intervention. This is followed by considering how best to [A] avoid 
stroke and thromboembolism, and then the options available to reduce 
symptoms, and in some cases improve prognosis, through [R] rate and 
rhythm control. [E] Evaluation and reassessment should be individua­
lized for every patient, with a dynamic approach that accounts for 
how AF and its associated conditions change over time.
Patient empowerment is critical in any long-term medical problem 
to achieve better outcomes, encourage adherence, and to seek timely 
guidance on changes in clinical status. A patient-centred, shared 
decision-making approach will facilitate the choice of management 
that suits each individual patient, particularly in AF where some ther­
apies and interventions improve clinical outcomes, and others are 
focused on addressing symptoms and quality of life. Education and 
awareness are essential, not only for patients but also healthcare pro­
fessionals in order to constrain the impact of AF on patients and 
healthcare services.
With this in mind, the task force have created a range of patient 
pathways that cover the major aspects of AF-CARE. At present, these re­
main based on the time-orientated classification of AF (first-diagnosed, 
paroxysmal, persistent, and permanent), but ongoing research may allow 
for pathology-based classifications and a future of personalized medicine. 
Clinical practice guidelines can only cover common scenarios with an evi­
dence base, and so there remains a need for healthcare professionals to 
care for patients within a local multidisciplinary team. While guideline- 
adherent care has repeatedly been shown to improve patient outcomes, 
the actual implementation of guidelines is often poor in many healthcare 
settings. This has been demonstrated in the ESC’s first randomized con­
trolled trial (RCT), STEEER-AF (Stroke prevention and rhythm control 
Therapy: Evaluation of an Educational programme of the European 
Society of Cardiology in a cluster-Randomised trial in patients with Atrial 
Fibrillation), which has sought to improve guideline adherence in parallel 
to guideline production. The task force developing the 2024 AF 
Guidelines have made implementation a key goal by focusing on the under­
pinning evidence and using a consistent writing style for each recommen­
dation (the intervention proposed, the population it should be applied to, 
and the potential value to the patient, followed by any exceptions). Tables 3
and 4 below outline new recommendations and those with important re­
visions. These initiatives have been designed to make the 2024 ESC 
Guidelines for the management of AF easier to read, follow, and implement, 
with the aim of improving the lives of patients with AF. A patient version of 
these guidelines is also available at http://www.escardio.org/Guidelines/ 
guidelines-for-patients.
ESC Guidelines                                                                                                                                                                                          3321


<!-- PAGE 9 -->

### Page 9

2.1. What is new
Table 3 New recommendations
Classa
Levelb
Diagnostic evaluation of new AF—Section 3.4
A transthoracic echocardiogram is recommended in patients with an AF diagnosis where this will guide treatment decisions.
I
C
Principles of AF-CARE—Section 4.2
Education directed to patients, family members, caregivers, and healthcare professionals is recommended to optimize shared 
decision-making, facilitating open discussion of both the benefit and risk associated with each treatment option.
I
C
Access to patient-centred management according to the AF-CARE principles is recommended in all patients with AF, regardless of gender, 
ethnicity, and socioeconomic status, to ensure equality in healthcare provision and improve outcomes.
I
C
Patient-centred AF management with a multidisciplinary approach should be considered in all patients with AF to optimize management and 
improve outcomes.
IIa
B
[C] Comorbidity and risk factor management—Section 5
Diuretics are recommended in patients with AF, HF, and congestion to alleviate symptoms and facilitate better AF management.
I
C
Appropriate medical therapy for HF is recommended in AF patients with HF and impaired LVEF to reduce symptoms and/or HF 
hospitalization and prevent AF recurrence.
I
B
Sodium-glucose cotransporter-2 inhibitors are recommended for patients with HF and AF regardless of left ventricular ejection fraction to 
reduce the risk of HF hospitalization and cardiovascular death.
I
A
Effective glycaemic control is recommended as part of comprehensive risk factor management in individuals with diabetes mellitus and AF, 
to reduce burden, recurrence, and progression of AF.
I
C
Bariatric surgery may be considered in conjunction with lifestyle changes and medical management in individuals with AF and body mass 
index ≥40 kg/m2 c where a rhythm control strategy is planned, to reduce recurrence and progression of AF.
IIb
C
Management of obstructive sleep apnoea may be considered as part of a comprehensive management of risk factors in individuals with AF to 
reduce recurrence and progression.
IIb
B
When screening for obstructive sleep apnoea in individuals with AF, using only symptom-based questionnaires is not recommended.
III
B
Initiating oral anticoagulation—Section 6.1
Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
A
A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral 
anticoagulation.
I
C
A CHA2DS2-VA score of 1 should be considered an indicator of elevated thromboembolic risk for decisions on initiating oral 
anticoagulation.
IIa
C
Oral anticoagulation is recommended in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of 
CHA2DS2-VA score, to prevent ischaemic stroke and thromboembolism.
I
B
Individualized reassessment of thromboembolic risk is recommended at periodic intervals in patients with AF to ensure anticoagulation is 
started in appropriate patients.
I
B
Direct oral anticoagulant therapy may be considered in patients with asymptomatic device-detected subclinical AF and elevated 
thromboembolic risk to prevent ischaemic stroke and thromboembolism, excluding patients at high risk of bleeding.
IIb
B
Oral anticoagulants—Section 6.2
A reduced dose of DOAC therapy is not recommended, unless patients meet DOAC-specific criteria, to prevent underdosing and 
avoidable thromboembolic events.
III
B
Maintaining VKA treatment rather than switching to a DOAC may be considered in patients aged ≥75 years on clinically stable therapeutic 
VKA with polypharmacy to prevent excess bleeding risk.
IIb
B
Antiplatelet drugs and combinations with anticoagulants—Section 6.3
Adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for the goal of preventing ischaemic stroke or 
thromboembolism.
III
B
Continued


<!-- PAGE 10 -->

### Page 10

Residual ischaemic stroke risk despite anticoagulation—Section 6.4
A thorough diagnostic work-up should be considered in patients taking an oral anticoagulant and presenting with ischaemic stroke or 
thromboembolism to prevent recurrent events, including assessment of non-cardioembolic causes, vascular risk factors, dosage, and 
adherence.
IIa
B
Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke.
III
B
Switching from one DOAC to another, or from a DOAC to a VKA, without a clear indication is not recommended in patients with AF to 
prevent recurrent embolic stroke.
III
B
Surgical left atrial appendage occlusion—Section 6.6
Surgical closure of the left atrial appendage should be considered as an adjunct to oral anticoagulation in patients with AF undergoing 
endoscopic or hybrid AF ablation to prevent ischaemic stroke and thromboembolism.
IIa
C
Stand-alone endoscopic surgical closure of the left atrial appendage may be considered in patients with AF and contraindications for 
long-term anticoagulant treatment to prevent ischaemic stroke and thromboembolism.
IIb
C
Management of bleeding on anticoagulant therapy—Section 6.7.2
Specific antidotes should be considered in AF patients on a DOAC who develop a life-threatening bleed, or bleed into a critical site, to 
reverse the antithrombotic effect.
IIa
B
Management of heart rate in patients with AF—Section 7.1
Rate control therapy is recommended in patients with AF, as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as 
a sole treatment strategy to control heart rate and reduce symptoms.
I
B
Beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-choice drugs in patients with AF and LVEF >40% to control heart 
rate and reduce symptoms.
I
B
Atrioventricular node ablation combined with cardiac resynchronization therapy should be considered in severely symptomatic patients 
with permanent AF and at least one hospitalization for HF to reduce symptoms, physical limitations, recurrent HF hospitalization, and 
mortality.
IIa
B
General principles and anticoagulation—Section 7.2.1
Direct oral anticoagulants are recommended in preference to VKAs in eligible patients with AF undergoing cardioversion for 
thromboembolic risk reduction.
I
A
Cardioversion of AF (either electrical or pharmacological) should be considered in symptomatic patients with persistent AF as part of a 
rhythm control approach.
IIa
B
A wait-and-see approach for spontaneous conversion to sinus rhythm within 48 h of AF onset should be considered in patients without 
haemodynamic compromise as an alternative to immediate cardioversion.
IIa
B
Implementation of a rhythm control strategy should be considered within 12 months of diagnosis in selected patients with AF at risk of 
thromboembolic events to reduce the risk of cardiovascular death or hospitalization.
IIa
B
Early cardioversion is not recommended without appropriate anticoagulation or transoesophageal echocardiography if AF duration is 
longer than 24 h, or there is scope to wait for spontaneous cardioversion.
III
C
Electrical cardioversion—Section 7.2.2
Electrical cardioversion as a diagnostic tool should be considered in patients with persistent AF where there is uncertainty about the value of 
sinus rhythm restoration on symptoms, or to assess improvement in left ventricular function.
IIa
C
Antiarrhythmic drugs—Section 7.2.4
Antiarrhythmic drug therapy is not recommended in patients with advanced conduction disturbances unless antibradycardia pacing is 
provided.
III
C
Catheter ablation—Section 7.2.5
Sinus node disease/tachycardia–bradycardia syndrome
Atrial fibrillation catheter ablation should be considered in patients with AF-related bradycardia or sinus pauses on AF termination to 
improve symptoms and avoid pacemaker implantation.
IIa
C
Recurrence after catheter ablation
Repeat AF catheter ablation should be considered in patients with AF recurrence after initial catheter ablation, provided the patient’s 
symptoms were improved after the initial PVI or after failed initial PVI, to reduce symptoms, recurrence, and progression of AF.
IIa
B
Anticoagulation in patients undergoing catheter ablation—Section 7.2.6
Uninterrupted oral anticoagulation is recommended in patients undergoing AF catheter ablation to prevent peri-procedural ischaemic 
stroke and thromboembolism.
I
A
Continued 
ESC Guidelines                                                                                                                                                                                          3323


<!-- PAGE 11 -->

### Page 11

Endoscopic and hybrid AF ablation—Section 7.2.7
Continuation of oral anticoagulation is recommended in patients with AF at elevated thromboembolic risk after concomitant, endoscopic, 
or hybrid AF ablation, independent of rhythm outcome or LAA exclusion, to prevent ischaemic stroke and thromboembolism.
I
C
Endoscopic and hybrid ablation procedures should be considered in patients with symptomatic persistent AF refractory to AAD therapy to 
prevent symptoms, recurrence, and progression of AF, within a shared decision-making rhythm control team of electrophysiologists and 
surgeons.
IIa
A
AF ablation during cardiac surgery—Section 7.2.8
Intraprocedural imaging for detection of left atrial thrombus in patients undergoing surgical ablation is recommended to guide surgical 
strategy, independent of oral anticoagulant use, to prevent peri-procedural ischaemic stroke and thromboembolism.
I
C
Concomitant surgical ablation should be considered in patients undergoing non-mitral valve cardiac surgery and AF suitable for a rhythm 
control strategy to prevent symptoms and recurrence of AF, with shared decision-making supported by an experienced team of 
electrophysiologists and arrhythmia surgeons.
IIa
B
Patient-reported outcome measures—Section 8.4
Evaluating quality of care and identifying opportunities for improved treatment of AF should be considered by practitioners and institutions 
to improve patient experiences.
IIa
B
Acute and chronic coronary syndromes in patients with AF—Section 9.2
Recommendations for AF patients with chronic coronary or vascular disease
Antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary or vascular disease treated with oral 
anticoagulation, due to lack of efficacy and to avoid major bleeding.
III
B
Trigger-induced AF—Section 9.5
Long-term oral anticoagulation should be considered in suitable patients with trigger-induced AF at elevated thromboembolic risk to 
prevent ischaemic stroke and systemic thromboembolism.
IIa
C
Post-operative AF—Section 9.6
Peri-operative amiodarone therapy is recommended where drug therapy is desired to prevent post-operative AF after cardiac surgery.
I
A
Concomitant posterior peri-cardiotomy should be considered in patients undergoing cardiac surgery to prevent post-operative AF.
IIa
B
Patients with embolic stroke of unknown source (ESUS)—Section 9.7
Initiation of oral anticoagulation in ESUS patients without documented AF is not recommended due to lack of efficacy in preventing 
ischaemic stroke and thromboembolism.
III
A
Atrial flutter—Section 9.14
Oral anticoagulation is recommended in patients with atrial flutter at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
B
Screening strategies for AF—Section 10.3
Review of an ECG (12-lead, single, or multiple leads) by a physician is recommended to provide a definite diagnosis of AF and commence 
appropriate management.
I
B
Population-based screening for AF using a prolonged non-invasive ECG-based approach should be considered in individuals aged ≥75 years, 
or ≥65 years with additional CHA2DS2-VA risk factors to ensure earlier detection of AF.
IIa
B
Primary prevention of AF—Section 10.5
Maintaining optimal blood pressure is recommended in the general population to prevent AF, with ACE inhibitors or ARBs as first-line 
therapy.
I
B
Appropriate medical HF therapy is recommended in individuals with HFrEF to prevent AF.
I
B
Maintaining normal weight (BMI 20–25 kg/m2) is recommended for the general population to prevent AF.
I
B
Maintaining an active lifestyle is recommended to prevent AF, with the equivalent of 150–300 min per week of moderate intensity or 75– 
150 min per week of vigorous intensity aerobic physical activity.
I
B
Avoidance of binge drinking and alcohol excess is recommended in the general population to prevent AF.
I
B
Metformin or SGLT2 inhibitors should be considered for individuals needing pharmacological management of diabetes mellitus to prevent 
AF.
IIa
B
Weight reduction should be considered in obese individuals to prevent AF.
IIa
B
© ESC 2024
AAD, antiarrhythmic drugs; ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid stroke 
and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; ARB, angiotensin receptor blocker; BMI, body mass index; CHA2DS2-VA, 
congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 
years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; ESUS, embolic stroke of undetermined source; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LAA, left 
atrial appendage; LVEF, left ventricular ejection fraction; PVI, pulmonary vein isolation; SGLT2, sodium-glucose cotransporter-2; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cOr body mass index ≥35 kg/m2 with obesity-related complications.


<!-- PAGE 12 -->

### Page 12

Table 4 Revised recommendations
Recommendations in 2020 version
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
Section 3.2—Diagnostic criteria for AF
ECG documentation is required to establish the 
diagnosis of AF. A standard 12-lead ECG recording or a 
single-lead ECG tracing of ≥30 s showing heart rhythm 
with no discernible repeating P waves and irregular RR 
intervals (when atrioventricular conduction is not 
impaired) is diagnostic of clinical AF.
I
B
Confirmation by an electrocardiogram (12-lead, 
multiple, or single leads) is recommended to establish 
the diagnosis of clinical AF and commence risk 
stratification and treatment.
I
A
In patients with AF, it is recommended to: 
• Evaluate AF-related symptoms (including fatigue, 
tiredness, exertional shortness of breath, palpitations, 
and chest pain) and quantify the patient symptom 
status using the modified EHRA symptom scale 
before and after initiation of treatment.
• Evaluate AF-related symptoms before and after 
cardioversion of persistent AF to aid rhythm control 
treatment decisions.
I
C
Evaluating the impact of AF-related symptoms is 
recommended before and after major changes in 
treatment to inform shared decision-making and guide 
treatment choices.
I
B
Section 5—[C] Comorbidity and risk factor management
Attention to good BP control is recommended in AF 
patients with hypertension to reduce AF recurrences 
and risk of stroke and bleeding.
I
B
Blood pressure lowering treatment is recommended in 
patients with AF and hypertension to reduce 
recurrence and progression of AF and prevent adverse 
cardiovascular events.
I
B
In obese patients with AF, weight loss together with 
management of other risk factors should be considered 
to reduce AF incidence, AF progression, AF 
recurrences, and symptoms.
IIa
B
Weight loss is recommended as part of comprehensive 
risk factor management in overweight and obese 
individuals with AF to reduce symptoms and AF burden, 
with a target of 10% or more reduction in body weight.
I
B
Physical activity should be considered to help prevent 
AF incidence or recurrence, with the exception of 
excessive endurance exercise, which may promote AF.
IIa
C
A tailored exercise programme is recommended in 
individuals with paroxysmal or persistent AF to improve 
cardiorespiratory fitness and reduce AF recurrence.
I
B
Advice and management to avoid alcohol excess should 
be considered for AF prevention and in AF patients 
considered for OAC therapy.
IIa
B
Reducing alcohol consumption to ≤3 standard drinks 
(≤30 grams of alcohol) per week is recommended as 
part of comprehensive risk factor management to 
reduce AF recurrence.
I
B
Section 6.6—Surgical left atrial appendage occlusion
Surgical occlusion or exclusion of the LAA may be 
considered for stroke prevention in patients with AF 
undergoing cardiac surgery.
IIb
C
Surgical closure of the left atrial appendage is 
recommended as an adjunct to oral anticoagulation in 
patients with AF undergoing cardiac surgery to prevent 
ischaemic stroke and thromboembolism.
I
B
Section 6.7—Bleeding risk
For a formal risk-score-based assessment of bleeding 
risk, the HAS-BLED score should be considered to help 
address modifiable bleeding risk factors, and to identify 
patients at high risk of bleeding (HAS-BLED score ≥3) 
for early and more frequent clinical review and 
follow-up.
IIa
B
Assessment and management of modifiable bleeding 
risk factors is recommended in all patients eligible for 
oral anticoagulation, as part of shared decision-making 
to ensure safety and prevent bleeding.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3325


<!-- PAGE 13 -->

### Page 13

### 3 Definitions and clinical impact

3.1. Definition and classification of AF
Atrial fibrillation is one of the most common heart rhythm disorders. 
A supraventricular arrhythmia with uncoordinated atrial activation, 
AF results in a loss of effective atrial contraction (see 
Supplementary data online for pathophysiology). AF is reflected on 
the surface electrocardiogram (ECG) by the absence of discernible 
and regular P waves, and irregular activation of the ventricles. This re­
sults in no specific pattern to RR intervals, in the absence of an atrio­
ventricular block. The definition of AF by temporal pattern is 
presented in Table 5. It should be noted that these categories reflect 
observed episodes of AF and do not suggest the underlying patho­
physiological process. Some patients may progress consecutively 
through these categories, while others may need periodic reclassifica­
tion due to their individual clinical status. Over time, some patients 
with AF develop atrial and ventricular damage, which can make at­
tempts at rhythm control futile. For this reason, or when patients 
and physicians make a joint decision for rate control, AF is classified 
as permanent (the most common ‘type’ of AF in historical registries).1
Despite many limitations, this task force have retained this temporal 
approach because most trials in patients with AF have used these de­
finitions. Classifying AF by underlying drivers could inform manage­
ment, but the evidence in support of the clinical use of such 
classification is currently lacking.
Several other classifications have been applied to patients with AF, 
many of which have limited evidence to support them. The definition 
of AF is a developing field and ongoing research may allow for 
pathology-based strategies that could facilitate personalized manage­
ment in the future. Table 6 presents some commonly used concepts 
in current clinical practice. Due to the lack of supporting evidence (par­
ticularly for the time periods stated), this task force have edited and up­
dated these definitions by consensus.
Section 7.2—Rhythm control strategies in patients with AF
AF catheter ablation for PVI should/may be considered 
as first-line rhythm control therapy to improve 
symptoms in selected patients with symptomatic: 
• Paroxysmal AF episodes.
IIa
B
Catheter ablation is recommended as a first-line option 
within a shared decision-making rhythm control 
strategy in patients with paroxysmal AF, to reduce 
symptoms, recurrence, and progression of AF.
I
A
Thoracoscopic procedures—including hybrid surgical 
ablation—should be considered in patients who have 
symptomatic paroxysmal or persistent AF refractory to 
AAD therapy and have failed percutaneous AF ablation, 
or with evident risk factors for catheter ablation failure, 
to maintain long-term sinus rhythm. The decision must 
be supported by an experienced team of 
electrophysiologists and surgeons.
IIa
B
Endoscopic and hybrid ablation procedures may be 
considered in patients with symptomatic paroxysmal 
AF refractory to AAD therapy and failed percutaneous 
catheter ablation strategy to prevent symptoms, 
recurrence, and progression of AF, within a shared 
decision-making rhythm control team of 
electrophysiologists and surgeons.
IIb
B
Thoracoscopic procedures—including hybrid surgical 
ablation—may be considered in patients with persistent 
AF with risk factors for recurrence, who remain 
symptomatic during AF despite at least one failed AAD 
and who prefer further rhythm control therapy.
IIb
C
Endoscopic and hybrid ablation procedures should be 
considered in patients with symptomatic persistent AF 
refractory to AAD therapy to prevent symptoms, 
recurrence, and progression of AF, within a shared 
decision-making rhythm control team of 
electrophysiologists and surgeons.
IIa
A
Concomitant AF ablation should be considered in 
patients undergoing cardiac surgery, balancing the 
benefits of freedom from atrial arrhythmias and the risk 
factors for recurrence (left atrial dilatation, years in AF, 
age, renal dysfunction, and other cardiovascular risk 
factors).
IIa
A
Concomitant surgical ablation is recommended in 
patients undergoing mitral valve surgery and AF suitable 
for a rhythm control strategy to prevent symptoms and 
recurrence of AF, with shared decision-making 
supported by an experienced team of 
electrophysiologists and arrhythmia surgeons.
I
A
Section 9.6—Post-operative AF
Long-term OAC therapy to prevent thromboembolic 
events may be considered in patients at risk for stroke 
with post-operative AF after cardiac surgery, 
considering the anticipated net clinical benefit of OAC 
therapy and informed patient preferences.
IIb
B
Long-term oral anticoagulation should be considered in 
patients with post-operative AF after cardiac and 
non-cardiac surgery at elevated thromboembolic risk, 
to prevent ischaemic stroke and thromboembolism.
IIa
B
© ESC 2024
AAD, antiarrhythmic drugs; AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; EHRA, European Heart Rhythm Association; HAS-BLED, Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly; LAA, left atrial appendage; OAC, oral 
anticoagulant; PVI, pulmonary vein isolation; RR, relative risk. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 14 -->

### Page 14

3.2. Diagnostic criteria for AF
In many patients, the diagnosis of AF is straightforward, e.g. typical 
symptoms associated with characteristic features on a standard 
12-lead ECG that indicate the need for AF management. Diagnosis be­
comes more challenging in the context of asymptomatic episodes or AF 
detected on longer-term monitoring devices, particularly those that do 
Table 6 Other clinical concepts relevant to AF
Clinical concept
Definition
Clinical AF
Symptomatic or asymptomatic AF that is 
clearly documented by an ECG (12-lead 
ECG or other ECG devices). The 
minimum duration to establish the 
diagnosis of clinical AF for ambulatory 
ECG is not clear and depends on the 
clinical context. Periods of 30 s or more 
may indicate clinical concern, and trigger 
further monitoring or risk stratification 
for thromboembolism.
Device-detected 
subclinical AF
Device-detected subclinical AF refers to 
asymptomatic episodes of AF detected 
on continuous monitoring devices. These 
devices include implanted cardiac 
electronic devices, for which most atrial 
high-rate episodesa may be AF, as well as 
consumer-based wearable monitors. 
Confirmation is needed by a competent 
professional reviewing intracardiac 
electrograms or an ECG-recorded 
rhythm.5,6 Device-detected subclinical 
AF is a predictor of future clinical AF.7
Continued 
Table 5 Definitions and classifications for the temporal 
pattern of AF
Temporal 
classification
Definition
First-diagnosed AF
AF that has not been diagnosed before, 
regardless of symptom status, temporal pattern, 
or duration.
Paroxysmal AF
AF which terminates spontaneously within 7 
days or with the assistance of an intervention. 
Evidence suggests that most self-terminating 
paroxysms last <48 h.2
Persistent AF
AF episodes which are not self-terminating. 
Many intervention trials have used 7 days as a 
cut-off for defining persistent AF.3,4
Long-standing persistent AF is arbitrarily defined 
as continuous AF of at least 12 months’ duration 
but where rhythm control is still a treatment 
option in selected patients, distinguishing it from 
permanent AF.
Permanent AF
AF for which no further attempts at restoration 
of sinus rhythm are planned, after a shared 
decision between the patient and physician.
© ESC 2024
AF, atrial fibrillation.
AF burden
The overall time spent in AF during a 
clearly specified and reported period of 
monitoring, expressed as a percentage of 
time.
Recent-onset AF
There is accumulating data on the value 
of the term recent-onset AF in 
decision-making for acute 
pharmacological or electrical 
cardioversion of AF. The cut-off time 
interval to define this entity has not yet 
been established.8–10
Trigger-induced AF
New AF episode in close proximity to a 
precipitating and potentially reversible 
factor.11–14
Early AF
The time since diagnosis that qualifies for 
early AF is dissociated from any 
underlying atrial cardiomyopathy and is 
not well defined, broadly ranging from 3 
to 24 months.15–17 The definition of early 
AF also does not necessarily determine 
early timing of intervention.
Self-terminating AF
Paroxysmal AF which terminates 
spontaneously.2 This definition may be of 
value for decisions on acute rhythm 
control taken jointly by the patient and 
healthcare provider.
Non-self-terminating AF
Atrial fibrillation which does not 
terminate spontaneously and, if needed, 
termination can be achieved only with an 
intervention.
Atrial cardiomyopathy
A combination of structural, electrical, or 
functional changes in the atria that leads 
to clinical impact (e.g. progression/ 
recurrence of AF, limited effectiveness of 
AF therapy, and/or development of heart 
failure).18,19 Atrial cardiomyopathy 
includes inflammatory and 
prothrombotic remodelling of the atria, 
neurohormonal activation (thereby 
affecting the ventricles), and fibrosis of 
myocardial tissue.20
© ESC 2024
AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram. 
aAtrial high-rate episodes are defined as episodes generally lasting more than 5 min with an 
atrial lead rate ≥170 b.p.m.,7,21–24 detected by implanted cardiac devices that allow for 
automated continuous monitoring and storage of atrial rhythm. Atrial high-rate episodes 
need to be visually inspected because some may be electrical artefacts or false positives.
ESC Guidelines                                                                                                                                                                                          3327


<!-- PAGE 15 -->

### Page 15

not provide an ECG (see Section 10). To guard against inappropriate 
diagnosis of AF, this task force continues to recommend that ECG 
documentation is required to initiate risk stratification and AF manage­
ment. In current practice, ECG confirmation can include multiple op­
tions: not only where AF persists across a standard 12-lead ECG, but 
also single- and multiple-lead devices that provide an ECG (see 
Supplementary data online, Additional Evidence Table S1). This does 
not include non-ECG wearables and other devices that typically use 
photoplethysmography. Note that many pivotal AF trials required 
two or more ECGs documenting AF, or an established AF diagnosis be­
fore randomization.25–29 The time period of AF required for diagnosis 
on monitoring devices is not clear cut. A standard 12-lead ECG mea­
sures 10 s, while 30 s or more on single-lead or multiple-lead ECG de­
vices has generally been the consensus opinion, albeit with limited 
evidence.
3.3. Symptoms attributable to AF
Symptoms related to episodes of AF are variable and broad, and not 
just typical palpitations (Figure 1). Asymptomatic episodes of AF can 
occur,30 although 90% of patients with AF describe symptoms with 
variable severity.31 Even in symptomatic patients, some episodes of 
AF may remain asymptomatic.32,33 The presence or absence of symp­
toms is not related to incident stroke, systemic embolism, or mortal­
ity.34 However, symptoms do impact on patient quality of life.35,36
Cardiac-specific AF symptoms such as palpitations are less common 
than non-specific symptoms such as fatigue, but they significantly 
impair quality of life.36,37 Although women are often underrepresented 
in clinical trials of AF,38–40 the available literature suggests that 
women with AF appear to be more symptomatic and have poorer 
quality of life.41,42 Patients with AF report a higher burden of anxiety 
and severity of depression (odds ratio [OR], 1.08; 95% confidence 
interval [CI], 1.02–1.15; P = .009) as compared with the general 
population,43,44 with higher prevalence of these symptoms in women 
with AF.45
Assessment of AF-related symptoms should be recorded initially, 
after a change in treatment, or before and after intervention. The 
modified European Heart Rhythm Association score (mEHRA) 
symptom classification (Table 7) is similar to the New York 
Heart Association (NYHA) functional class for heart failure. It cor­
relates with quality of life scores in clinical trials, is associated with 
clinical progress and events, and may be a valuable starting point 
in routine practice to assess the burden and impact of symptoms to­
gether with the patient.46–48 Note that symptoms may also relate to 
associated comorbidities and not just the AF component. The 
patient-related effects of symptoms from AF over time can alterna­
tively be evaluated using patient-reported outcome measures (see 
Section 8.4).
3.4. Diagnostic evaluation of new AF
All patients with AF should be offered a comprehensive diagnostic as­
sessment and review of medical history to identify risk factors and/or 
comorbidities needing active treatment. Table 8 displays the essential 
diagnostic work-up for a patient with AF.
A 12-lead ECG is warranted in all AF patients to confirm rhythm, de­
termine ventricular rate, and look for signs of structural heart disease, 
conduction defects, or ischaemia.56 Blood tests should be carried out 
(kidney function, serum electrolytes, liver function, full blood count, glu­
cose/glycated haemoglobin [HbA1c], and thyroid tests) to detect any 
concomitant conditions that may exacerbate AF or increase the risk 
of bleeding and/or thromboembolism.57,58
Other investigations will depend on individualized assessment and 
the planned treatment strategy.59–65 A transthoracic echocardiogram 
(TTE) should be carried out in the initial work-up, where this will guide 
management decisions, or in patients where there is a change in cardio­
vascular signs or symptoms. The task force recognizes that accessibility 
to TTE might be limited or delayed in the primary care setting, but this 
should not delay initiation of oral anticoagulation (OAC) or other com­
ponents of AF-CARE where indicated.66 Further details on TTE and re­
assessment (e.g. if elevated heart rate limits diagnostic imaging, or 
where there is a change in clinical status) are presented in Section 8.3. 
Additional imaging using different modalities may be required to assist 
with comorbidity and AF-related management (see Supplementary 
data online, Figure S1).
Recommendation Table 1 — Recommendations for the 
diagnosis of AF (see also Evidence Table 1)
Recommendations
Classa
Levelb
Confirmation by an electrocardiogram (12-lead, 
multiple, or single leads) is recommended to establish 
the diagnosis of clinical AF and commence risk 
stratification and treatment.25–29
I
A
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 2 — Recommendations for 
symptom evaluation in patients with AF (see also 
Evidence Table 2)
Recommendations
Classa
Levelb
Evaluating the impact of AF-related symptoms is 
recommended before and after major changes in 
treatment to inform shared decision-making and 
guide treatment choices.17,36,46–55
I
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 3 — Recommendations for 
diagnostic evaluation in patients with new AF (see also 
Evidence Table 3)
Recommendations
Classa
Levelb
A transthoracic echocardiogram is recommended in 
patients with an AF diagnosis where this will guide 
treatment decisions.59,65,67
I
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 16 -->

### Page 16

3.5. Adverse events associated with AF
Atrial fibrillation is associated with a range of serious adverse events 
(Figure 1) (see Supplementary data online, Additional Evidence 
Table S2). Patients with AF also have high rates of hospitalization 
and complications from coexisting medical conditions. The most com­
mon non-fatal outcome in those with AF is heart failure, occurring in 
around half of patients over time. Patients with AF have a four- to five- 
fold increase in the relative risk (RR) of heart failure compared with 
those without AF, as demonstrated in two meta-analyses (RR, 4.62; 
95% CI, 3.13–6.83 and RR, 4.99; 95% CI, 3.0–8.22).68,69 The next 
most common adverse impacts from AF are ischaemic stroke (RR, 
2.3; 95% CI, 1.84–2.94), ischaemic heart disease (RR, 1.61; 95% CI, 
1.38–1.87), and other thromboembolic events.69–71 The latter typic­
ally include arterial thromboembolic events (preferred to the term 
systemic), although venous thromboembolism is also associated 
Patient symptoms
Adverse outcomes
Healthcare and society
A
t r
i a
l
 
fi b
r il l
a t
i o
n
I
m p
a c
t
 
a n
d
 
o u
t c
o m
e s
Palpitations
Shortness of breath
Fatigue
Chest pain
Dizziness
Poor exercise capacity
Fainting (syncope)
Anxiety
Depressed mood
Disordered sleep
Recurrent hospitalization
Heart failure
Ischaemic stroke
Thromboembolism
Cognitive decline and vascular dementia
Depression
Impaired quality of life
Death
Increasing prevalence
High economic cost
Impact on individuals,
families and communities
Doubling of AF
2010 
  2060
Lifetime risk
1 in 5   1 in 3
1–2% of healthcare expenditure
Figure 1 Impacts and outcomes associated with clinical AF. AF, atrial fibrillation.
Table 7 The modified European Heart Rhythm 
Association (mEHRA) symptom classification
Score
Symptoms
Description
1
None
AF does not cause any symptoms
2a
Mild
Normal daily activity not affected by symptoms 
related to AF
2b
Moderate
Normal daily activity not affected by symptoms 
related to AF, but patient troubled by 
symptoms
3
Severe
Normal daily activity affected by symptoms 
related to AF
4
Disabling
Normal daily activity discontinued
© ESC 2024
AF, atrial fibrillation.
ESC Guidelines                                                                                                                                                                                          3329


<!-- PAGE 17 -->

### Page 17

with AF.72,73 Patients with AF also have an increased risk of cognitive 
impairment (adjusted hazard ratio [HR], 1.39; 95% CI, 1.25–1.53)74
and dementia (OR, 1.6; 95% CI, 1.3–2.0).75–77 It should be noted 
that most of the observational studies on adverse events have a mix 
of patients taking and not taking OAC. When carefully controlling 
for the confounding effects of stroke, comorbidities, and OAC, AF ex­
posure was still significantly associated with vascular dementia (HR, 
1.68; 95% CI, 1.33–2.12; P < .001), but not Alzheimer’s disease (HR, 
0.85; 95% CI, 0.70–1.03; P = .09).78
Hospital admission rates due to AF vary widely depending on the 
population studied, and may be skewed by selection bias. In a Dutch 
RCT including first-diagnosed AF patients (mean age 64 years), car­
diovascular hospitalization rates were 7.0% to 9.4% per year.79 An 
Australian study identified 473 501 hospitalizations for AF during 
15 years of follow-up (300 million person-years), with a relative in­
crease in AF hospitalizations of 203% over the study period, in con­
trast to an increase for all hospitalizations of 71%. The age-specific 
incidence of hospital admission increased particularly in the older 
age groups.80
Atrial fibrillation is also associated with increased mortality. In 
2017, AF contributed to over 250 000 deaths globally, with an 
age-standardized mortality rate of 4.0 per 100 000 people (95% un­
certainty interval 3.9–4.2).81 The most frequent cause of death in pa­
tients with AF is heart failure related,70 with complex relationships to 
cardiovascular and non-cardiovascular disease.82 There is up to a 
two-fold increased risk of all-cause mortality (RR, 1.95; 95% CI, 
1.50–2.54),68 and cardiovascular mortality (RR, 2.03; 95% CI, 1.79– 
2.30)69 in AF compared with sinus rhythm. Even in the absence of 
major thromboembolic risk factors, the incidence of death is 15.5 
per 1000 person-years in those with AF exposure, compared 
with 9.4 per 1000 person-years without (adjusted HR, 1.44; 95% CI, 
1.38–1.50; P < .001).78 Patients with OAC-related bleeding have 
higher mortality, including both minor and major bleeding (as 
defined by the International Society on Thrombosis and 
Haemostasis scale).83 Despite OAC, patients with AF remain at high 
residual risk of death, highlighting the importance of attention to con­
comitant disease.84
3.6. Atrial flutter
Atrial flutter (AFL) is the among the most common atrial tachyarrhyth­
mias, with an overall incidence rate of 88 per 100 000 person-years, ris­
ing to 317 per 100 000 person-years in people over 50 years of age.85
Risk factors for AFL and AF are similar, and more than half of all patients 
with AFL will develop AF.85 Observational studies suggest that 
thromboembolic risk is elevated in AFL.86 In direct comparison of 
AFL with AF, some studies suggest a similar risk of stroke and others 
a lower risk in AFL,87–90 possibly due to different comorbidity burdens 
and the impact of confounders such as AFL/AF ablation and anticoagu­
lation (more frequently stopped in AFL).91
4. Patient pathways and 
management of AF
4.1. Patient-centred, multidisciplinary AF 
management
4.1.1. The patient at the heart of care
A patient-centred and integrated approach to AF management means 
working with a model of care that respects the patient’s experience, 
values, needs, and preferences for planning, co-ordination, and delivery 
of care. A central component of this model is the therapeutic relationship 
between the patient and the multidisciplinary team of healthcare profes­
sionals (Figure 2). In patient-centred AF management, patients are seen 
not as passive recipients of health services, but as active participants 
who work as partners alongside healthcare professionals. Patient- 
centred AF management requires integration of all aspects of AF man­
agement. This includes symptom control, lifestyle recommendations, 
psychosocial support, and management of comorbidities, alongside op­
timal medical treatment consisting of pharmacotherapy, cardioversion, 
and interventional or surgical ablation (Table 9). Services should be de­
signed to ensure that all patients have access to an organized model of 
AF management, including tertiary care specialist services when indi­
cated (see Supplementary data online, Table S1, Evidence Table 4 and 
Additional Evidence Table S3). It is equally important to maintain path­
ways for patients to promptly re-engage with specialist services when 
their condition alters.
Table 8 Diagnostic work-up for patients with AF
All patients
Selected patients
• Medical history to determine AF 
pattern, relevant family history, 
and comorbidities, and to assess 
risk factors for thromboembolism 
and bleeding
• Ambulatory ECG monitoring for 
assessing AF burden and 
ventricular rate control
• Exercise ECG to evaluate rate 
control or effects of class IC 
antiarrhythmic drugs
• 12-lead ECG
• Further blood tests for 
investigation of cardiovascular 
disease and refinement of stroke/ 
bleeding risk (e.g. NT-proBNP, 
troponin)
• Assess symptoms and functional 
impairment
• Transoesophageal 
echocardiography for left atrial 
thrombus and valvular disease 
assessment
• Collect generic or AF-specific 
patient-reported outcome 
measures
• Coronary CT, angiography, or 
ischaemia imaging for suspected 
CAD
• Blood tests (full blood count, 
kidney function, serum 
electrolytes, liver function, 
glucose/HbA1c, and thyroid 
function)
• CMR for evaluation of atrial and 
ventricular cardiomyopathies, 
and to plan interventional 
procedures
• Transthoracic echocardiography 
where this will guide AF-CARE 
management decisions
• Brain imaging and cognitive 
function assessment for 
cerebrovascular disease and 
dementia risk
© ESC 2024
AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate 
and rhythm control, [E] Evaluation and dynamic reassessment; CAD, coronary artery 
disease; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed 
tomography angiography; ECG, electrocardiogram; HbA1c, glycated haemoglobin; 
NT-proBNP, N-terminal pro-B-type natriuretic peptide.


<!-- PAGE 18 -->

### Page 18

4.1.2. Education and shared decision-making
Clear advice about the rationale for treatments, the possibility of 
treatment modification, and shared decision-making can help patients 
live with AF (see Supplementary data online, Table S2).92 An open and 
effective relationship between the patient and the healthcare profes­
sional is critical, with shared decision-making found to improve 
outcomes for OAC and arrhythmia management.93,94 In using a 
shared approach, both the clinician and patient are involved in the 
decision-making process (to the extent that the patient prefers). 
Information is shared in both directions. Furthermore, both the 
clinician and the patient express their preferences and discuss the 
options. Of the potential treatment decisions, no treatment is 
also a possibility.95 There are several toolkits available to facilitate 
this, although most are focused on anticoagulation decisions. For ex­
ample, the Shared Decision-Making Toolkit (http://afibguide.com, 
http://afibguide.com/clinician) 
and 
the 
Successful 
Intravenous 
Cardioversion for Atrial Fibrillation (SIC-AF) score have been shown 
to reduce decisional conflict compared with usual care in patients 
with AF.93,94 Patient-support organizations can also make an import­
ant contribution to providing understandable and actionable knowl­
edge about AF and its treatments (e.g. local support groups and 
international charities, such as http://afa-international.org). As AF is a 
chronic or recurrent disease in most patients, education is central 
to empower patients, their families, and caregivers.
Atrial fibrillation
P
a t
i e
n t
-
c e
n t
r e
d
C
A
R
E
Comorbidity and risk factor management
Lifestyle help
Primary care
Cardiology
Internal medicine
Nursing care
Other
Avoid stroke and thromboembolism
Primary care
Cardiology
Neurology
Nursing care
Anticoagulation services e-Health
Reduce symptoms by rate and rhythm control
Evaluation and dynamic reassessment
Primary care
Cardiology
Pharmacy
Nursing
Family/carers e-Health
Primary care
Cardiology
Electrophysiology
Cardiac surgeons e-Health i
n t
e g
r a
t e
d
 
A
F
-
C
A
R
E
Figure 2 Multidisciplinary approach to AF management. Principal caregivers are involved in the community and hospital settings to provide optimal, 
patient-centred care for patients living with AF. AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid stroke and 
thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment.
Table 9 Achieving patient-centred AF management
Components of patient-centred AF management:
• Optimal treatment according to the AF-CARE pathway, which includes:
∘ [C] Comorbidity and risk factor management
∘ [A] Avoid stroke and thromboembolism
∘ [R] Reduce symptoms by rate and rhythm control
∘ [E] Evaluation and dynamic reassessment
• Lifestyle recommendations
• Psychosocial support
• Education and awareness for patients, family members, and caregivers
• Seamless co-ordination between primary care and specialized AF care
How to implement patient-centred AF management:
• Shared decision-making
• Multidisciplinary team approach
• Patient education and empowerment, with emphasis on self-care
• Structured educational programmes for healthcare professionals
• Technology support (e-Health, m-Health, telemedicine)a
© ESC 2024
AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate 
and rhythm control, [E] Evaluation and dynamic reassessment. 
ae-Health refers to healthcare services provided using electronic methods; m-Health, 
refers to healthcare services supported by mobile devices; and telemedicine refers to 
remote diagnosis or treatment supported by telecommunications technology.
ESC Guidelines                                                                                                                                                                                          3331


<!-- PAGE 19 -->

### Page 19

4.1.3. Education of healthcare professionals
Gaps in knowledge and skills across all domains of AF care are consist­
ently described among cardiologists, neurologists, internal medicine 
specialists, emergency physicians, general practitioners, nurses, and al­
lied health practitioners.96–98 Healthcare professionals involved in 
multidisciplinary AF management should have a knowledge of all avail­
able options for diagnosis and treatment.99–101 In the STEEER-AF 
trial,99 real-world adherence to clinical practice guidelines for AF 
across six ESC countries was poor. These findings highlight the critical 
need for appropriate training and education of healthcare 
professionals.102
Specifically targeted education for healthcare professionals can in­
crease knowledge and lead to more appropriate use of OAC for 
prevention of thromboembolism.103 However, educational interventions 
for healthcare providers are often not enough to sustainably impact be­
haviour.104 Other tools may be needed, such as active feedback,103
clinical decision support tools,105 expert consultation,106 or e-Health 
learning.107
4.1.4. Inclusive management of AF
Evidence is growing on differences in AF incidence, prevalence, risk fac­
tors, comorbidities, and outcomes according to gender.108 Women di­
agnosed with AF are generally older, have more hypertension and heart 
failure with preserved ejection fraction (HFpEF), and have less diag­
nosed coronary artery disease (CAD).109 Registry studies have re­
ported differences in outcomes, with higher morbidity and mortality 
in women, although these may be confounded by age and comorbidity 
burden.110–112 Women with AF may be more symptomatic, and report 
a lower quality of life.41,113 It is unclear whether this is related to de­
layed medical assessment in women, or whether there are genuine 
sex differences. Despite a higher symptom load, women are less likely 
to undergo AF ablation than men, even though antiarrhythmic drug 
therapy seems to be associated with more proarrhythmic events in 
women.109 These observations call for more research on gender 
differences in order to prevent disparities and inequality in care. 
Other diversity aspects such as age, race, ethnicity, and transgender 
issues, as well as social determinants (including socioeconomic status, 
disability, education level, health literacy, and rural/urban location) are 
important contributors to inequality that should be actively considered 
to improve patient outcomes.114
4.2. Principles of AF-CARE
The 2024 ESC Guidelines for the management of AF have compiled and 
evolved past approaches to create principles of management to aid im­
plementation of these guidelines, and hence improve patient care and 
outcomes. There is growing evidence that clinical support tools115–118
can aid best-practice management, with the caveat that any tool is a 
guide only, and that all patients require personalized attention. The 
AF-CARE approach covers many established principles in the manage­
ment of AF, but does so in a systematic, time-orientated format with 
four essential treatment pillars (Figure 3; central illustration). Joint man­
agement with each patient forms the starting point of the AF-CARE ap­
proach. Notably, it takes account of the growing evidence base that 
therapies for AF are most effective when associated health conditions 
are addressed. A careful search for these comorbidities and risk factors 
[C] is critical and should be applied in all patients with a diagnosis of AF. 
Avoidance of stroke and thromboembolism [A] in patients with risk 
factors is considered next, focused on appropriate use of anticoagu­
lant therapy. Reducing AF-related symptoms and morbidity by effect­
ive use of heart rate and rhythm control [R] is then applied, which in 
selected patients may also reduce hospitalization or improve progno­
sis. The potential benefit of rhythm control, accompanied by consid­
eration of all risks involved, should be considered in all patients at each 
contact point with healthcare professionals. As AF, and its related co­
morbidities, changes over time, different levels of evaluation [E] and 
re-evaluation are required in each patient, and these approaches 
should be dynamic. Due to the wide variability in response to therapy, 
and the changing pathophysiology of AF as age and comorbidities ad­
vance, reassessment should be built into the standard care pathway to 
prevent adverse outcomes for patients and improve population 
health.
AF-CARE builds upon prior ESC Guidelines, e.g. the five-step 
outcome-focused integrated approach in the 2016 ESC Guidelines for 
the management of AF,119 and the AF Better Care (ABC) pathway in 
the 2020 ESC Guidelines for the diagnosis and management of AF.120
The reorganization into AF-CARE was based on the parallel develop­
ments in new approaches and technologies (in particular for rhythm 
control), with new evidence consistently suggesting that all aspects of 
AF management are more effective when comorbidities and risk factors 
have been considered. This includes management relating to symptom 
benefit, improving prognosis, prevention of thromboembolism, and the 
response to rate and rhythm control strategies. AF-CARE makes expli­
cit the need for individualized evaluation and follow-up in every patient, 
with an active approach that accounts for how patients, their AF, and 
associated comorbidities change over time. The AF-CARE principles 
have been applied to different patient pathways for ease of implemen­
tation into routine clinical care. This includes the management of first- 
diagnosed AF (Figure 4), paroxysmal AF (Figure 5), persistent AF 
(Figure 6), and permanent AF (Figure 7).
Recommendation Table 4 — Recommendations for 
patient-centred care and education (see also Evidence 
Table 4)
Recommendation
Classa
Levelb
Education directed to patients, family members, 
caregivers, and healthcare professionals is 
recommended to optimize shared decision-making, 
facilitating open discussion of both the benefit and 
risk associated with each treatment option.94,103
I
C
Access to patient-centred management according to 
the AF-CARE principles is recommended in all 
patients with AF, regardless of gender, ethnicity, and 
socioeconomic status, to ensure equality in 
healthcare provision and improve outcomes.
I
C
Patient-centred AF management with a 
multidisciplinary approach should be considered in all 
patients with AF to optimize management and 
improve outcomes.79,121–124
IIa
B
© ESC 2024
AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate 
and rhythm control, [E] Evaluation and dynamic reassessment. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 20 -->

### Page 20

C
Comorbidity and risk factor management
Hypertension
Diabetes mellitus
Blood pressure lowering treatment
(Class I)
Patient-centred AF management with a multidisciplinary approach (Class IIa)
Education for patients, families and healthcare professionals (Class I)
Equality in healthcare provision (gender, ethnicity, socioeconomic) (Class I)
Heart failure
Diuretics for congestion
(Class I)
Overweight or obese
Weight loss
(target 10%)a
(Class I)
Obstructive sleep apnoea
Management of OSAa
(Class IIb)
Appropriate HFrEF
medical therapy
(Class I)
Bariatric surgery if rhythm controla
(Class IIb)
SGLT2 inhibitors
(Class 1)
Alcohol
Reduce to 3
drinks per week
(Class I)
 Effective glycaemic controla
(Class I)
Exercise capacity
Tailored exercise programme
(Class I)
Other risk factors/
comorbidities
Identify and manage aggressivelya
(Class I)
A
Avoid stroke and thromboembolism
Risk of thromboembolism
Start oral anticoagulation
(Class I)
Use locally-validated risk score or CHA2DS2-VA
OAC if CHA2DS2-VA
 score = 2 or more
(Class I)
Choice of anticoagulant
Assess 
bleeding risk
OAC if CHA2DS2-VA
score = 1
(Class IIa)
Use DOAC, except mechanical valve or mitral stenosis
(Class I)
Target INR 2.0–3.0;
(Class I)
>70% INR range;
(Class IIa)
or switch to DOAC
(Class I)
Assess and manage all modifiable risk factors for bleeding
(Class I)
Do not use risk scores to withhold anticoagulation
(Class III)
Do not combine antiplatelets and OAC
for stroke prevention
(Class III)
Avoid antiplatelets beyond 12 months in OAC treated
CCS/PVD
(Class III)
Temporal pattern of AF not relevant
(Class III)
Antiplatelet therapy not an alternative
(Class III)
Prevent bleeding
R
Reduce symptoms by rate and rhythm control
E
Evaluation and dynamic reassessment
See patient pathways for:
First-diagnosed AF
Paroxysmal AF
Persistent AF
Permanent AF
Consider:
AF
C A R
E
If  VKA:
Rate control drugs
Ablate and pace
Cardioversion
Catheter ablation
Endoscopic/hybrid ablation Surgical ablation
Antiarrhythmic drugs
Re-evaluate when AF episodes or non-AF admissions
ECG, blood tests,
cardiac imaging,
ambulatory ECG,
other imaging as needed
Assess new and existing risk factors 
and comorbidities
(Class I)
Stratify risk for stroke and thromboembolism
(Class I)
Check impact of AF
symptoms before and after treatment
(Class I)
Assess and manage modifiable bleeding risk factors
(Class I)
Continue OAC
despite rhythm control if risk of thromboembolism
(Class I)
Regular re-evaluation: 6 months after presentation, and then at least annually or based on clinical need
Figure 3 Central illustration. Patient pathway for AF-CARE (see Figures 4, 5, 6, and 7 for the [R] pathways for first-diagnosed, paroxysmal, persistent and 
permanent AF). AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid stroke and thromboembolism, 
[R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; CCS, chronic coronary syndrome; CHA2DS2-VA, congest­
ive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), 
vascular disease, age 65–74 years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; INR, 
international normalized ratio of prothrombin time; OAC, oral anticoagulant; OSA, obstructive sleep apnoea; PVD, peripheral vascular disease; SGLT2, 
sodium-glucose cotransporter-2; VKA, vitamin K antagonist. aAs part of a comprehensive management of cardiometabolic risk factors.
ESC Guidelines                                                                                                                                                                                          3333


<!-- PAGE 21 -->

### Page 21

N
Patient with first-diagnosed AF
Y
Y
N
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Haemodynamically stable
Initial rate control
 (Class I)
Electrical cardioversion
(Class I)
LVEF ≤40%
Beta-blocker, digoxin,
diltiazem or verapamil
 (Class I)
Beta-blocker 
or digoxin
 (Class I)
Combination
 rate control therapy
(Class IIa)
Combination
 rate control therapy
(Class IIa)
Cardioversion of symptomatic 
persistent AF
(Class I)
Wait-and-see if sinus rhythm restores spontaneously <48 h
 (Class IIa)
Figure 4 [R] Pathway for patients with first-diagnosed AF. AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor man­
agement, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; LVEF, 
left ventricular ejection fraction. After following the pathway for first-diagnosed AF, patients with recurrent AF should enter the AF-CARE [R] pathway 
for paroxysmal, persistent, or permanent AF, depending on the type of their AF.


<!-- PAGE 22 -->

### Page 22

Rate control target = resting heart rate <110 b.p.m. (lenient control), 
with stricter control with continuing symptoms
(Class IIa)
Beta-blocker 
or digoxin
(Class I)
Patient with paroxysmal AF
LVEF ≤40%
Beta-blocker, digoxin,
diltiazem or verapamil
 (Class I)
Combination
 rate control therapy
(Class IIa)
Combination
 rate control therapy
(Class IIa)
Amiodarone
(Class I)
Dronedarone, flecainide 
or propafenone
(Class I)
Catheter ablation
 (Class I)
Amiodarone or dronedarone 
(Class I)
Sotalol 
(Class IIb)
HFrEF
(LVEF ≤40%)
Stable HFmrEF
(LVEF 41–49%), 
coronary heart disease, 
valvular heart disease
Absence or minimal heart disease
Sotalol 
(Class IIb)
Recurrence of AF symptoms
Antiarrhythmic drug therapy
Y
N
Shared decision-making on rhythm control
(Class I)
If failed antiarrhythmic drug therapy
If failed catheter ablation
Re-do catheter ablation
(Class IIa)
Surgical/hybrid ablation
(Class IIb)
Antiarrhythmic drug therapy (see above)
Catheter ablationa
 (Class I)
Shared decision-making
(Class I)
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Figure 5 [R] Pathway for patients with paroxysmal AF. AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor manage­
ment, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; b.p.m., 
beats per minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, Heart failure with reduced ejection fraction; LVEF, left ventricular 
ejection fraction. aIn patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve 
prognosis.
ESC Guidelines                                                                                                                                                                                          3335


<!-- PAGE 23 -->

### Page 23

Electrical cardioversion
Rate control target = resting heart rate <110 b.p.m. (lenient control), 
with stricter control with continuing symptoms
(Class IIa)
Beta-blocker or digoxin
(Class I)
Patient with persistent AF
LVEF ≤40%
Combination
 rate control therapy
(Class IIa)
Combination
 rate control therapy
(Class IIa)
Amiodarone
(Class I)
Dronedarone, flecainide 
or propafenone
(Class I)
Amiodarone or dronedarone 
(Class I)
Sotalol 
(Class IIb)
HFrEF
(LVEF ≤40%)
Stable HFmrEF
(LVEF 41–49%), 
coronary heart disease, 
valvular heart disease
Absence
 or minimal heart disease
Sotalol 
(Class IIb)
Recurrence of AF symptoms
Antiarrhythmic drug therapy
Y
N
Shared decision-making on rhythm control
(Class I)
If failed antiarrhythmic drug therapy
If failed catheter ablation
Catheter ablationa
 (Class IIb)
Shared decision-making, considering all rhythm control options
(Class I)
Beta-blocker, digoxin,
diltiazem or verapamil
(Class I)
Catheter ablation
(Class I)
Re-do catheter ablation
Endoscopic hybrid or surgical ablation
Antiarrhythmic drug therapy 
(see above)
Consider rate control 
strategy 
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Haemodynamic instability (Class I)
Part of rhythm control strategy (Class IIa)
Clarify benefit from sinus rhythm (Class IIa)
Endoscopic/
hybrid ablation
(Class IIa)
Figure 6 [R] Pathway for patients with persistent AF. AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor management, 
[A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; b.p.m., beats per 
minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection 
fraction. aIn patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve prognosis.


<!-- PAGE 24 -->

### Page 24

LVEF >40%
Patient with permanent AF
Y
Evaluation and dynamic reassessment
Initiate beta-blocker, 
digoxin, diltiazem or verapamil
 (Class I)
Continue beta-blocker,
digoxin, diltiazem 
or verapamil
 (Class I)
Combination beta-blocker with digoxin, or diltiazem/
verapamil with digoxin;
 avoiding bradycardia
(Class IIa)a
N
Rate control target = resting heart rate <110 b.p.m. (lenient control), with stricter control with continuing symptoms
(Class IIa)
Continue review and follow-up as per
AF-CARE approach
LVEF ≤40%
Continue beta-blocker or digoxin
 (Class I)
Combination beta-blocker with digoxin,
avoiding bradycardia
(Class IIa)
Y
Evaluation and dynamic reassessment
Initiate beta-blocker or digoxin
 (Class I)
Rate control target = resting heart rate  <110 b.p.m.
(lenient control), 
with stricter control 
with continuing symptoms
(Class IIa)
N
Severely symptomatic and
HF hospitalization
Atrioventricular node ablation and CRT
(Class IIa)
Y
Intensify rate control therapy under observation
Evaluation for atrioventricular node ablation in combination with pacemaker
(Class IIa)
N
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Rate control target = resting heart rate  <110 b.p.m.
(lenient control), 
with stricter control 
with continuing symptoms
(Class IIa)
Figure 7 [R] Pathway for patients with permanent AF. AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor manage­
ment, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; b.p.m., 
beats per minute; CRT, cardiac resynchronization therapy; HF, heart failure; LVEF, left ventricular ejection fraction. Permanent AF is a shared decision 
made between the patient and physician that no further attempts at restoration of sinus rhythm are planned. aNote that the combination of beta- 
blockers with diltiazem or verapamil should only be used under specialist advice, and monitored with an ambulatory ECG to check for bradycardia.
ESC Guidelines                                                                                                                                                                                          3337


<!-- PAGE 25 -->

### Page 25

5. [C] Comorbidity and risk factor 
management
A broad array of comorbidities are associated with the recurrence 
and progression of AF. Managing comorbidities is also central to the 
success of other aspects of care for patients with AF, with evidence 
available for hypertension, heart failure, diabetes mellitus, obesity, 
and sleep apnoea, along with lifestyle changes that improve physical 
activity and reduce alcohol intake (see Supplementary data online, 
Additional Evidence Table S4). Identification and treatment of these 
comorbidities and clusters of risk factors form an important part 
of effective AF-CARE (Figure 8), with the evidence outlined in the 
rest of this section highlighting where management can improve 
patient outcomes or prevent AF recurrence. Many of these 
factors (and more) are also associated with incident AF (see 
Section 10).
Focus on key risk factors
Provide information 
without overloading
Suggested approach and targets
Setting individual targets for comorbidities and risk factors
Key targets
Behavioural change
Achievable targets
Identify and actively manage all risk factors and comorbidities
(Class I) 
Blood pressure treatment with target 120–129 mmHg /
70–79 mmHg in most adults (or as low as reasonably achievable)
(Class I) 
Effective glycaemic control with diet/medication(s)
(Class I)
Weight loss programme if overweight /obese, 
with 10% or more weight loss
(Class I) 
Management of obstructive sleep apnoea to minimize apnoeic episodes
(Class IIb)
Tailored exercise programme aiming for regular moderate/vigorous activity
(Class I)
Reduce alcohol consumption to 3 or less standard drinks per week
(Class I) 
Shared decision-making
Hypertension
Sleep apnoea
Heart failure
Diabetes
Obesity
Integrated management
Physical activity
Alcohol intake 
Optimize with diuretics to alleviate congestion appropriate,
medical therapy for reduced LVEF, and SGLT2 inhibitors for all LVEF
(Class I)
Figure 8 Management of key comorbidities to reduce AF recurrence. LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose 
cotransporter-2.


<!-- PAGE 26 -->

### Page 26

5.1. Hypertension
Hypertension in patients with AF is associated with an increased risk of 
stroke, heart failure, major bleeding, and cardiovascular mortality.158–161
The target for treated systolic blood pressure (BP) in most adults is 
120–129 mmHg. Where BP-lowering treatment is poorly tolerated, 
clinically significant frailty exists or the patient’s age is 85 years or 
older, a more lenient target of <140 mmHg is acceptable or ‘as low 
as reasonably achievable’. On-treatment diastolic BP should ideally 
be 70–79 mmHg.162 In an individual participant data meta-analysis of 
22 randomized trials reporting baseline AF, a 5 mmHg reduction in 
systolic BP reduced the risk of major cardiovascular events by 9% 
(HR, 0.91; 95% CI, 0.83–1.00), with identical effect in patients with 
AF or sinus rhythm.129
In individuals with AF, hypertension often coexists with other 
modifiable and non-modifiable risk factors that all contribute to re­
currence of AF, readmission to hospital, and ongoing symptoms after 
rhythm control.163–171 Optimal control of blood pressure should be 
considered an essential component of treating AF and undertaken 
within a strategy of comprehensive risk factor management.126–128
Although the majority of research has focused on clinical outcomes, 
limited comparative data on hypertension medication suggests that 
use of angiotensin-converting enzyme (ACE) inhibitors or angioten­
sin receptor blockers (ARB) may be superior for prevention of recur­
rent AF.172–175
5.2. Heart failure
Heart failure is a key determinant of prognosis in patients with AF, as 
well as an important factor associated with recurrence and progression 
of AF.176,177 During 30 years of follow-up in the Framingham cohort, 
57% of those with new heart failure had concomitant AF, and 37% of 
those with new AF had heart failure.178 Numerous cardiovascular 
and non-cardiovascular conditions impact the development of both 
AF and heart failure, leading to the common pathway of atrial cardio­
myopathy.18 In patients with acute heart failure attending the emer­
gency department, AF is one of the most prevalent triggering factors 
of the episode.179 The development of heart failure in patients with 
AF is associated with a two-fold increase in stroke and thrombo­
embolism,180 even after anticoagulation,181 and 25% higher all-cause 
mortality.178 Prognosis may be affected by left ventricular ejection 
fraction (LVEF), with the rate of death highest with the combination 
of AF and heart failure with reduced ejection fraction (HFrEF) 
(LVEF ≤ 40%), as compared with AF and HFpEF (LVEF ≥ 50%). 
However, rates of stroke and incident heart failure hospitalization 
are similar regardless of LVEF.182 Due to how common concomitant 
AF and heart failure are in clinical practice, strategies to improve out­
comes in these patients are detailed within each component of the 
AF-CARE pathway. However, it is also critical that heart failure itself 
is managed appropriately in patients with AF to prevent avoidable ad­
verse events.
Optimization of heart failure management should follow current 
ESC Guidelines: 2023 Focused Update183 of the 2021 ESC Guidelines 
for the diagnosis and treatment of acute and chronic heart failure.137
Achieving euvolaemia with diuretics is an important first step that not 
only manages the heart failure component, but can also facilitate better 
control of heart rate in AF. For HFrEF, it should be highlighted that 
many older guideline-recommended therapies lack specific evidence 
for benefit in patients with coexisting AF. No trial data are available 
in this context for ACE inhibitors, there are conflicting data on 
ARBs,132,184 and an individual patient-level analysis of RCTs found no 
Recommendation Table 5 — Recommendations for 
comorbidity and risk factor management in AF (see 
also Evidence Table 5)
Recommendation
Classa
Levelb
Identification and management of risk factors and 
comorbidities is recommended as an integral part of 
AF care.39,125–127
I
B
Blood pressure lowering treatment is recommended 
in patients with AF and hypertension to reduce 
recurrence and progression of AF and prevent 
adverse cardiovascular events.126–130
I
B
Diuretics are recommended in patients with AF, HF, 
and congestion to alleviate symptoms and facilitate 
better AF management.
I
C
Appropriate medical therapy for HF is 
recommended in AF patients with HF and impaired 
LVEF to reduce symptoms and/or HF hospitalization 
and prevent AF recurrence.131–137
I
B
Sodium-glucose cotransporter-2 inhibitors are 
recommended for patients with HF and AF 
regardless of left ventricular ejection fraction to 
reduce the risk of HF hospitalization and 
cardiovascular death.136,138–140
I
A
Effective glycaemic control is recommended as part 
of comprehensive risk factor management in 
individuals with diabetes mellitus and AF, to reduce 
burden, recurrence, and progression of AF.
I
C
Weight loss is recommended as part of 
comprehensive risk factor management in 
overweight and obese individuals with AF to reduce 
symptoms and AF burden, with a target of 10% or 
more reduction in body weight.125–128
I
B
A tailored exercise programme is recommended in 
individuals with paroxysmal or persistent AF to 
improve cardiorespiratory fitness and reduce AF 
recurrence.141–146
I
B
Reducing alcohol consumption to ≤3 standard drinks 
(≤30 grams of alcohol) per week is recommended as 
part of comprehensive risk factor management to 
reduce AF recurrence.126,127,147
I
B
Bariatric surgery may be considered in conjunction 
with lifestyle changes and medical management in 
individuals with AF and body mass index ≥40 kg/m2 c 
where a rhythm control strategy is planned, to 
reduce recurrence and progression of AF.
IIb
C
Management of obstructive sleep apnoea may be 
considered as part of a comprehensive management 
of risk factors in individuals with AF to reduce 
recurrence and progression.126–128,148–154
IIb
B
When screening for obstructive sleep apnoea in 
individuals with AF, using only symptom-based 
questionnaires is not recommended.155–157
III
B
© ESC 2024
AF, atrial fibrillation; HF, heart failure; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence. 
cOr body mass index ≥35 kg/m2 with obesity-related complications.
ESC Guidelines                                                                                                                                                                                          3339


<!-- PAGE 27 -->

### Page 27

difference between beta-blockers and placebo for all-cause mortality in 
HFrEF with AF.133 However, these drugs have clear proof of safety and 
there may be other indications for these therapies beyond prognosis, 
including comorbidity management and symptom improvement. 
These and other therapies may also have dual functions, for example, 
beta-blockers or digoxin for rate control of AF, in addition to improving 
heart failure metrics and reducing hospitalization.48,185,186 More recent 
additions to HFrEF management, such as eplerenone, sacubitril- 
valsartan, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, 
had substantial numbers of patients with AF enrolled in RCTs, with 
no evidence that AF status affected their ability to reduce cardiovascu­
lar mortality/heart failure hospitalization.134–136 Cardiac resynchroniza­
tion therapy (CRT) in the context of HFrEF and AF is discussed in detail 
in the 2021 ESC Guidelines on cardiac pacing and cardiac resynchroni­
zation therapy, with an important focus on ensuring effective biventri­
cular pacing (with a low threshold for considering atrioventricular node 
ablation).187 Patients who have heart failure with mildly reduced ejec­
tion fraction (HFmrEF) (LVEF 41%–49%) and AF should generally be 
treated according to guidance for HFrEF,137 albeit with limited evidence 
to date in AF.188–190 For treatment of HFpEF and AF,191 pre-specified 
subgroup data on AF from multiple large trials show that the SGLT2 
inhibitors dapagliflozin, empaglifozin, and sotagliflozin are effective in 
improving prognosis.138–140
Appropriate management of heart failure has the potential to reduce 
recurrence of AF, e.g. by reducing adverse atrial and ventricular myo­
cardial remodelling, but there are limited data for specific therapies. 
In the Routine versus Aggressive upstream rhythm Control for preven­
tion of Early AF in heart failure (RACE 3) trial, combined management 
of mild-to-moderate heart failure with ACE inhibitors/ARBs, mineralo­
corticoid receptor antagonists, statins, and cardiac rehabilitation in­
creased the maintenance of sinus rhythm on ambulatory monitoring 
at 12 months.39 This benefit was not preserved at the 5 year follow-up, 
although this may have been confounded by the lack of ongoing inter­
vention beyond the initial 12 months.192
5.3. Type 2 diabetes mellitus
Diabetes mellitus is present in around 25% of patients with AF.193–195
Patients with both diabetes and AF have a worse prognosis,196 with in­
creased healthcare utilization and excess mortality and cardiovascular 
events. The prevalence and incidence of AF and type 2 diabetes are 
widely increasing, thus making the association of these two conditions 
a public health challenge.195,197 Moreover, diabetes is a major factor in­
fluencing thromboembolic risk.198,199 Following catheter ablation of AF, 
diabetes and higher HbA1c are associated with increased length of stay 
and a greater recurrence of AF.200–203
In cohort studies, the management of diabetes mellitus as part of 
comprehensive risk factor management has been associated with re­
duced AF symptoms, burden, reversal of the type of AF (from persist­
ent to paroxysmal or no AF), and improved maintenance of sinus 
rhythm.126–128 However, robust evidence is limited, and individual 
glucose-lowering medications have had variable effects on AF.204–206
There are emerging data of the use of SGLT2 and glucagon-like 
peptide-1 antagonists in patients with diabetes and AF that may impact 
on treatment choice in the near future. Importantly, diabetes frequently 
coexists with multiple risk factors in patients with AF, and a compre­
hensive approach to management is required. Further details are 
provided in the 2023 ESC Guidelines for the management of cardiovas­
cular disease in patients with diabetes.207
5.4. Obesity
Obesity frequently coexists with other risk factors that have been inde­
pendently associated with the development of AF.208,209 Obesity (body 
mass index [BMI] ≥30 kg/m2) and being overweight (BMI >25 kg/m2) 
are associated with a greater risk of recurrent atrial arrhythmias after 
AF ablation (13% increase for every 5 kg/m2 higher BMI).210–212 In 
the setting of comprehensive risk factor management, weight loss of 
≥10% in overweight and obese individuals with AF has been associated 
with reduced AF symptoms and AF burden in an RCT (aiming for BMI 
<27 kg/m2).125 Cohort studies have also shown a graded response to 
maintenance of sinus rhythm,126 improved ablation outcomes,128 and 
reversal of the type of AF127 commensurate with the degree of weight 
loss and risk factor management. However, in the Supervised Obesity 
Reduction Trial for AF Ablation Patients (SORT-AF) randomized trial 
in AF ablation patients, a sole weight loss intervention that achieved 
4% loss in weight over 12 months did not impact ablation outcomes.213
This is consistent with the findings in LEGACY (Long-Term Effect of 
Goal directed weight management on Atrial Fibrillation Cohort: a 5 
Year follow-up study) that showed that weight loss of ≤3% had no im­
pact on AF recurrence.126 Observational studies have raised the possi­
bility of a point of no return in terms of the benefit of weight loss,214 but 
also the possibility that bariatric surgery can improve symptoms and re­
duce AF recurrence.215–217
5.5. Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) is a highly prevalent condition, particu­
larly in patients with AF.157,218 Optimal screening tools in the AF popu­
lation are still under evaluation, although it may be reasonable to screen 
for OSA in patients where a rhythm control strategy is being pursued. 
Polysomnography or home sleep apnoea testing are suggested in pref­
erence to screening questionnaires.155–157,219 Questionnaires assessing 
daytime sleepiness are poor predictors of moderate-to-severe OSA.155
Which parameter should be used to focus on risk of AF in patients with 
OSA, and to guide OSA treatment in patients with AF, is still 
unclear.220,221
Observational studies have suggested that individuals with OSA not 
treated with continuous positive airway pressure (CPAP) respond 
poorly to treatments for AF, with an increased risk of recurrence 
after cardioversion or ablation.222 Conversely, OSA patients treated 
with CPAP seem to mitigate their propensity toward developing 
AF.148–153,222–224 A small randomized trial of CPAP vs. no therapy de­
monstrated reversal of atrial remodelling in individuals with moderate 
OSA.154 However, other small RCTs have failed to show a benefit of 
CPAP therapy on ablation outcomes225 or post-cardioversion.226
Data on the cardiovascular mortality benefit of CPAP therapy in 
OSA are inconclusive.227–230
5.6. Physical inactivity
Reduced cardiorespiratory fitness frequently coexists with other modi­
fiable risk factors and has been associated with a greater recurrence of 
AF after catheter ablation.141 Better cardiorespiratory fitness has a de­
monstrated inverse relationship to AF burden in both middle-aged and 
elderly people.141 Small RCTs, meta-analyses, and observational


<!-- PAGE 28 -->

### Page 28

cohorts have shown that regular aerobic exercise may also improve 
AF-related symptoms, quality of life, and exercise capacity.142,143
Better cardiorespiratory fitness and a gain in cardiorespiratory fitness 
over time are associated with a greater reduction in AF burden and im­
proved maintenance of sinus rhythm.141–145
5.7. Alcohol excess
Alcohol consumption can increase the risk of adverse events in patients 
with AF, such as thromboembolism, death, or AF-related hospitaliza­
tion.231,232 Alcohol is associated with an increased risk of ischaemic 
stroke in patients with newly diagnosed AF, and alcohol abstinence after 
AF diagnosis can reduce the risk of ischaemic stroke.233 In patients re­
ceiving OAC, alcohol excess is associated with a greater risk of bleed­
ing,234 mediated by poor adherence, alcohol–drug interactions, liver 
disease, and variceal bleeding.
Alcohol consumption is associated with a dose-dependent increase 
in the recurrence of AF after catheter ablation.147,235 In an RCT among 
regular non-binge drinkers with AF, the goal of abstinence led to a sig­
nificant reduction in AF recurrence and burden; alcohol intake was re­
duced from 16.8 to 2.1 standard drinks per week (≤30 grams or 3 
standard drinks of alcohol) in the intervention arm, with 61% attaining 
abstinence.147 In observational data of patients undergoing catheter ab­
lation, reduction of consumption to ≤7 standard drinks (≤70 grams of 
alcohol) per week was associated with improved maintenance of sinus 
rhythm.128,235
6. [A] Avoid stroke and 
thromboembolism
6.1. Initiating oral anticoagulation
Atrial fibrillation is a major risk factor for thromboembolism, irre­
spective of whether it is paroxysmal, persistent, or permanent.236,237
Left untreated, and dependent on other patient-specific factors, the 
risk of ischaemic stroke in AF is increased five-fold, and one in every 
five strokes is associated with AF.238 The default approach should 
therefore be to provide OAC to all eligible patients, except those 
at low risk of incident stroke or thromboembolism. The effectiveness 
of OAC to prevent ischaemic stroke in patients with AF is well estab­
lished.239,240 Antiplatelet drugs alone (aspirin, or aspirin in combin­
ation with clopidogrel) are not recommended for stroke prevention 
in AF.241,242
6.1.1. Decision support for anticoagulation in AF
Tools have been developed to enable easier implementation of OAC 
in patients with clinical AF. The majority of OAC clinical trials have 
used variations of the CHADS2 score to indicate those at risk (with 
points for chronic heart failure, hypertension, age, diabetes, and 2 
points for prior stroke/transient ischaemic attack [TIA]). Although 
most available stroke risk scores are simple and practical, the predict­
ive value of scores is generally modest (see Supplementary data 
online, Table S3).243–245 Classification and discrimination of adverse 
events is relatively poor for all scores and hence the benefit of using 
them to select patients for OAC is unclear. There is also considerable 
variation in the definition of risk factors across countries,246 and a lack 
of evidence from clinical trials on the ability of stroke risk scoring to 
enhance clinical practice.243 This guideline continues to provide a 
Class IA recommendation for the use of OAC in patients at risk of 
thromboembolism. However, in the absence of strong evidence for 
how to apply risk scores in real-world patients, this has been sepa­
rated from the use of any particular risk score. This is also in line 
with regulatory approvals for direct oral anticoagulants (DOACs), 
which do not stipulate risk scores or numerical thresholds.25–28,245
Substantive changes have occurred in the decades since these risk 
scores were developed in regards to population-level risk factor pro­
files, therapies, and targets.198 Historical scores do not take into ac­
count parameters that have been associated with thromboembolism 
in contemporary cohorts, such as cancer, chronic kidney disease 
(CKD), ethnicity, and a range of circulating biomarkers (including tropo­
nin and B-type natriuretic peptide [BNP]). As an example, for CKD 
there is a correlation between decreasing glomerular filtration rate 
and proteinuria with stroke risk,247–250 and cohort data suggest a two- 
fold increased risk of ischaemic stroke and mortality in AF patients with 
CKD vs. without.251 Other factors, such as atrial enlargement, hyperlip­
idaemia, smoking, and obesity, have been identified in specific cohort 
studies as additional risk factors for ischaemic stroke in AF.70,252,253
Biomarkers, such as troponin, natriuretic peptides, growth differenti­
ation factor-15, cystatin C, and interleukin-6, can also indicate residual 
stroke risk among anticoagulated AF patients.254,255 Biomarker-guided 
stroke prevention is currently being evaluated in an ongoing RCT 
(NCT03753490). Until further validation within RCTs is available, this 
task force continues to support using simple clinical classification for im­
plementation of OAC. Clinicians should use tools that have been vali­
dated in their local population and take an individualized approach to 
thromboembolic risk stratification that considers the full range of 
each patient’s specific risk factors. The absolute risk level at which to 
start OAC in individual patients cannot be estimated from population- 
level studies. It will vary depending on how those factors interact with 
other medical issues, and the degree of risk acceptable or tolerated by 
that person. In general, most of the available risk scores have a thresh­
old of 0.6%–1.0% per annum of thromboembolic events for clinical AF 
to warrant OAC prescription.
Across Europe, the most popular risk score is CHA2DS2–VASc, giv­
ing points for congestive heart failure, hypertension, age ≥75 years 
(2 points), diabetes mellitus, prior stroke/TIA/thromboembolism 
(2 points), vascular disease, age 65–74 years and female sex. 
However, implementation has varied in terms of gender. Female sex 
is an age-dependent stroke risk modifier rather than a risk factor per 
se.112,256,257 The inclusion of gender complicates clinical practice both 
for healthcare professionals and patients.258 It also omits individuals 
who identify as non-binary, transgender, or are undergoing sex hor­
mone therapy. Previous guidelines from the ESC (and globally) have 
not actually used CHA2DS2-VASc; instead providing different score le­
vels for women and men with AF to qualify for OAC. Hence, 
CHA2DS2-VA (excluding gender) has effectively been in place 
(Table 10).78 This task force proposes, in the absence of other locally 
validated alternatives, that clinicians and patients should use the 
CHA2DS2-VA score to assist in decisions on OAC therapy (i.e. without 
a criterion for birth sex or gender). Pending further trials in lower risk 
patients (NCT04700826,259 NCT02387229260), OAC are recom­
mended in those with a CHA2DS2-VA score of 2 or more and should 
be considered in those with a CHA2DS2-VA score of 1, following a 
patient-centred and shared care approach. Healthcare professionals 
should take care to assess for other thromboembolic risk factors 
that may also indicate the need for OAC prescription.
ESC Guidelines                                                                                                                                                                                          3341


<!-- PAGE 29 -->

### Page 29

Recommendation Table 6 — Recommendations to 
assess and manage thromboembolic risk in AF (see also 
Evidence Table 6)
Recommendations
Classa
Levelb
Oral anticoagulation is recommended in patients 
with clinical AF at elevated thromboembolic risk to 
prevent ischaemic stroke and 
thromboembolism.239,240
I
A
A CHA2DS2-VA score of 2 or more is recommended 
as an indicator of elevated thromboembolic risk for 
decisions on initiating oral anticoagulation.
I
C
Oral anticoagulation is recommended in all patients 
with AF and hypertrophic cardiomyopathy or 
cardiac amyloidosis, regardless of CHA2DS2-VA 
score, to prevent ischaemic stroke and 
thromboembolism.270–276
I
B
Individualized reassessment of thromboembolic risk 
is recommended at periodic intervals in patients with 
AF to ensure anticoagulation is started in appropriate 
patients.277–280
I
B
Continued 
A CHA2DS2-VA score of 1 should be considered an 
indicator of elevated thromboembolic risk for 
decisions on initiating oral anticoagulation.
IIa
C
Direct oral anticoagulant therapy may be considered 
in patients with asymptomatic device-detected 
subclinical AF and elevated thromboembolic risk to 
prevent ischaemic stroke and thromboembolism, 
excluding patients at high risk of bleeding.281,282
IIb
B
Antiplatelet therapy is not recommended as an 
alternative to anticoagulation in patients with AF to 
prevent ischaemic stroke and 
thromboembolism.242,283
III
A
Using the temporal pattern of clinical AF 
(paroxysmal, persistent, or permanent) is not 
recommended to determine the need for oral 
anticoagulation.284,285
III
B
© ESC 2024
AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 
points), 
diabetes 
mellitus, 
prior 
stroke/transient 
ischaemic 
attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years; DOAC, direct oral 
anticoagulant. 
aClass of recommendation. 
bLevel of evidence.
Table 10 Updated definitions for the CHA2DS2-VA score
CHA2DS2-VA component
Definition and comments
Points 
awardeda
C
Chronic heart failure
Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and 
HFrEF), or the presence of asymptomatic LVEF ≤40%.261–263
1
H
Hypertension
Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive 
treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 
120–129/70–79 mmHg (or keep as low as reasonably achievable).162,264
1
A
Age 75 years or above
Age is an independent determinant of ischaemic stroke risk.265 Age-related risk is a continuum, 
but for reasons of practicality, two points are given for age ≥75 years.
2
D
Diabetes mellitus
Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,266 or treatment 
with glucose lowering therapy.
1
S
Prior stroke, TIA, or arterial 
thromboembolism
Previous thromboembolism is associated with highly elevated risk of recurrence and therefore 
weighted 2 points.
2
V
Vascular disease
Coronary artery disease, including prior myocardial infarction, angina, history of coronary 
revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac 
imaging.267
OR 
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, 
percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on 
imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).268,269
1
A
Age 65–74 years
1 point is given for age between 65 and 74 years.
1
© ESC 2024
BP, blood pressure; CAD, coronary artery disease; CHA2DS2-VA, chronic heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/ 
arterial thromboembolism (2 points), vascular disease, age 65–74 years; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection 
fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease. 
aIn addition to these factors, other markers that modify an individual’s risk for stroke and thromboembolism should be considered, including cancer, chronic kidney disease, ethnicity (black, 
Hispanic, Asian), biomarkers (troponin and BNP), and in specific groups, atrial enlargement, hyperlipidaemia, smoking, and obesity.


<!-- PAGE 30 -->

### Page 30

6.2. Oral anticoagulants
Vitamin K antagonists (VKA), predominantly warfarin but also other 
coumarin and indandione derivatives, have been the principal drugs to 
prevent thromboembolic events in the context of AF. As with any 
anticoagulant, a balance must be reached between preventing thrombo­
embolism and preserving physiological haemostasis, with VKA-associated 
intracranial and other major haemorrhage the most critical limitation for 
acceptance of OAC. The global switch to DOACs as first-line therapy 
has changed this risk–benefit balance, allowing more widespread pre­
scription with no need for routine monitoring (see Supplementary 
data online, Additional Evidence Tables S5–S7). This component of AF 
management may see substantive changes in the coming years, with a 
number of factor XI inhibitors in various stages of clinical evaluation. A 
phase 2 trial of abelacimab in patients with AF has shown lower rates 
of bleeding compared with rivaroxaban286; however, a phase 3 trial of 
asundexian was terminated early due to lack of efficacy against apixaban 
(NCT05643573), despite favourable phase 2 results.287 Regardless of the 
type of OAC prescribed, healthcare teams should be aware of the poten­
tial for interactions with other drugs, foods, and supplements, and in­
corporate this information into the education provided to patients and 
their carers. The list of potential interactions with VKA is broad,288,289
but there are also some common cardiovascular and non-cardiovascular 
drugs that interact with DOACs.290,291 Figure 9 highlights common and 
major interactions to consider for VKAs and DOACs.
Caution if renal function impaired
Vitamin K antagonist oral anticoagulants
Avoid where possible
NSAIDs
Fluconazole
Voriconazole
Fluoxetine
Avoid where possible
Carbamazepine
Phenytoin
Phenobarbital
Rifampicin
Ritonavir
Itraconazole
Ketoconazole  
Avoid where possible
Dronedarone
Carbamazepine
Phenytoin
Rifampicin
Ritonavir
Itraconazole
Ketoconazole
Cyclosporin
Glecaprevir/pibrentasvir
Tacrolimus
Avoid where possible
Carbamazepine
Phenytoin
Phenobarbital
Rifampicin
Ritonavir
Avoid where possible
Dronedarone
Carbamazepine
Phenytoin
Phenobarbital
Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Rifampicin
Ritonavir
Limit consumption
Avoid or reduce apixaban dose if another interacting drug therapy
Avoid if another interacting drug therapy
Avoid or reduce edoxaban dose if another interacting drug therapy
Avoid or reduce edoxaban dose
Reduce warfarin dose
Apixaban
Dabigatran
Edoxaban
Delay timing of drugs and/or adjust dose
Amiodarone
Metronidazole
Sulphonamides
Allopurinol
Fluvastatin
Gemfibrozil
Fluorouracil
Increase warfarin dose
Carbamazepine
Monitor INR carefully
Dronedarone
Statins
Penicillin antibiotics
Macrolide antibiotics
Quinolone antibiotics
Rifampicin
Methotrexate
Ritonavir
Phenytoin
Sodium valproate
Tamoxifen
Chemotherapies
Posaconazole
Voriconazole
Protease inhibitors
Apalutamide
Enzalutamide
Tyrosine kinase inhibitors
Limit consumption
Grapefruit juice
St John’s wort
Limit consumption
Grapefruit juice
St John’s wort
Limit consumption
Grapefruit juice
St John’s wort
Limit consumption
Grapefruit juice
St John’s wort
Amiodarone
Ticagrelor
Verapamil
Quinidine
Clarithromycin
Posaconazole
Dronedarone
Protease inhibitors
Tyrosine kinase inhibitors
Verapamil
Cyclosporin
Clarithromycin
Erythromycin
Fluconazole
Cyclosporin
Itraconazole
Ketoconazole
Erythromycin
Alcohol
Grapefruit/cranberry juice
St John’s wort
Rivaroxaban
Direct oral anticoagulants
Figure 9 Common drug interactions with oral anticoagulants. INR, international normalized ratio of prothrombin time; NSAID, non-steroidal anti- 
inflammatory drug. This figure depicts only common or major interactions and is not an exhaustive list of all potential interactions. Please see the 
European Medicines Agency website or your local formulary for more information.
ESC Guidelines                                                                                                                                                                                          3343


<!-- PAGE 31 -->

### Page 31

6.2.1. Direct oral anticoagulants
The DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) have all 
demonstrated at least non-inferior efficacy compared with warfarin for 
the prevention of thromboembolism, but with the added benefit of a 
50% reduction in intracranial haemorrhage (ICH).25–28 Meta-analyses of 
individual data from 71 683 RCT patients showed that standard, full-dose 
DOAC treatment compared with warfarin reduces the risk of stroke or 
systemic embolism (HR, 0.81; 95% CI, 0.73–0.91), all-cause mortality (HR, 
0.90; 95% CI, 0.85–0.95), and intracranial bleeding (HR, 0.48; 95% CI, 
0.39–0.59), with no significant difference in other major bleeding (HR, 
0.86; 95% CI, 0.73–1.00) and little or no between-trial heterogeneity.292
Post-marketing observational data on the effectiveness and safety of 
dabigatran,313,314 rivaroxaban,315,316 apixaban,317 and edoxaban318 vs. 
warfarin show general consistency with the respective phase 3 RCTs.
For patients undergoing cardioversion, three underpowered trials 
showed non-significantly lower rates of cardiovascular events with 
DOACs compared with warfarin.319–321 In meta-analysis of these 
5203 patients predominantly undergoing electrical cardioversion, the 
composite of stroke, systemic embolism, myocardial infarction (MI), 
and cardiovascular death was significantly lower at 0.42% in 
patients randomized to a DOAC vs. 0.98% in those allocated VKA 
(risk ratio, 0.42; 95% CI, 0.21–0.86; P = .017), with no heterogeneity be­
tween trials and no significant difference in major bleeding.293
Specific patient subgroups show consistent benefit with DOACs vs. 
VKAs. For heart failure, major thromboembolic events were lower in 
DOAC-treated patients vs. warfarin in subgroup analysis of landmark 
RCTs,322 confirmed in large-scale real-world data.323 In a retrospective 
cohort of patients aged over 80 years, DOAC use was associated with a 
lower risk of ischaemic stroke, dementia, mortality, and major bleeding 
than warfarin,324 but this may be confounded by prescription bias.
Direct oral anticoagulants retain their efficacy and safety over VKAs 
in patients with mild-to-moderate CKD (creatinine clearance 
[CrCl] >30 mL/min),325
although specific dosing adjustments 
apply.25–28,326 In Europe, reduced doses of rivaroxaban, apixaban, and 
edoxaban are approved in patients with severe CKD (CrCl 15–29 mL/ 
min), although limited numbers of patients were included in the major 
RCTs against VKA.327 Dabigatran is more dependent on renal elimination 
and so is contraindicated with an estimated glomerular filtration rate 
<30 mL/min/1.73 m2. Small trials have been performed in patients on 
haemodialysis, with two finding no difference between apixaban 2.5 mg 
twice daily and VKA for efficacy or safety outcomes,328,329 and one trial 
showing that rivaroxaban 10 mg led to significantly lower rates of cardiovas­
cular events and major bleeding compared with VKA.330 Careful institution 
and regular follow-up are advised when instituting anticoagulants in any pa­
tient with impaired renal function (See Supplementary data online, 
Additional Evidence Table 8).326
Direct oral anticoagulants as a class should be avoided in specific pa­
tient groups, such as those with mechanical heart valves or 
moderate-to-severe mitral stenosis. In patients with mechanical heart 
valves, an excess of thromboembolic and major bleeding events among 
patients on dabigatran therapy vs. VKA was observed, with an RCT ter­
minated prematurely.331 A trial of apixaban vs. VKA after implantation 
of a mechanical aortic valve was also stopped due to excess thrombo­
embolic events in the apixaban group.332 The restriction on DOAC use 
does not apply to bioprosthetic heart valves (including mitral) or after 
transcatheter aortic valve implantation, where DOACs can be used and 
trial data show non-inferiority for clinical events compared with 
VKAs.304,333,334 With regards to mitral stenosis, the DOAC vs. VKA 
trials excluded patients with moderate-to-severe disease. In 4531 ran­
domized patients with rheumatic heart disease and AF, VKAs led to a 
lower rate of composite cardiovascular events and death than rivarox­
aban, without a higher rate of bleeding.294 Eighty-two per cent of the 
patients included had a mitral valve area ≤2 cm, supporting the restric­
tion of DOAC use in patients with moderate-to-severe mitral stenosis. 
Note that patients with other types of valve disease (mitral regurgita­
tion and others) should preferentially be prescribed a DOAC, and 
the term ‘valvular’ AF is obsolete and should be avoided.
Inappropriate dose reductions for DOACs are frequent in clinical 
practice,311 but need to be avoided as they increase the risk of stroke with­
out decreasing bleeding risk.310 Hence, DOAC therapy should be instituted 
according to the standard full dose as tested in phase 3 RCTs and approved 
by regulators (Table 11). The prescribed dosage should consider the individ­
ual patient’s profile.335 Drug interactions need to be considered in all pa­
tients taking or planned for DOACs (see Figure 9 for common drug 
interactions).336There is insufficient evidence currently to advise on routine 
laboratory testing for DOAC levels. However, in certain situations, meas­
urement of DOAC levels (where available) may be helpful, such as severe 
bleeding, the need for urgent surgery, or thromboembolic events despite 
apparent DOAC compliance.337,338 Patients should always be involved in 
decision-making on anticoagulation,339leading to better alignment with per­
sonal preferences that can help to increase understanding and adherence.
Recommendation Table 7 — Recommendations for 
oral anticoagulation in AF (see also Evidence Table 7)
Recommendations
Classa
Levelb
Direct oral anticoagulants are recommended in 
preference to VKAs to prevent ischaemic stroke and 
thromboembolism, except in patients with 
mechanical heart valves or moderate-to-severe 
mitral stenosis.25–28,292–294
I
A
A target INR of 2.0–3.0 is recommended for patients 
with AF prescribed a VKA for stroke prevention to 
ensure safety and effectiveness.295–298
I
B
Switching to a DOAC is recommended for eligible 
patients that have failed to maintain an adequate time 
in therapeutic range on a VKA (TTR <70%) to 
prevent thromboembolism and intracranial 
haemorrhage.299–303
I
B
Keeping the time in therapeutic range above 70% 
should be considered in patients taking a VKA to 
ensure safety and effectiveness, with INR checks at 
appropriate frequency and patient-directed 
education and counselling.304–308
IIa
A
Maintaining VKA treatment rather than switching to 
a DOAC may be considered in patients aged ≥75 
years on clinically stable therapeutic VKA with 
polypharmacy to prevent excess bleeding risk.309
IIb
B
A reduced dose of DOAC therapy is not 
recommended, unless patients meet DOAC-specific 
criteria,c to prevent underdosing and avoidable 
thromboembolic events.310–312
III
B
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; INR, international normalized ratio 
of prothrombin time; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cSee Table 11.


<!-- PAGE 32 -->

### Page 32

6.2.2. Vitamin K antagonists
Vitamin K antagonist therapy reduces stroke risk by 64% and mortality 
by 26% in patients with AF at elevated thromboembolic risk (mostly 
warfarin in trials, compared with placebo or no treatment).239
Vitamin K antagonists are still used in many patients worldwide, but 
prescriptions have declined sharply since the introduction of 
DOACs.340,341 Vitamin K antagonists are currently the only treatment 
option in AF patients with mechanical heart valves or moderate-to- 
severe mitral valve stenosis.294,331 The use of VKAs is not only limited 
by numerous drug and food interactions (Figure 9), but also a narrow 
therapeutic range. This requires frequent monitoring and dose adjust­
ment according to the prothrombin time expressed as the international 
normalized ratio (INR).342 If the time in therapeutic range (TTR) is 
maintained for long periods (e.g. >70% with INR 2.0–3.0), then VKA 
can be effective for thromboembolic protection with an acceptable 
safety profile.295–297,343 However, VKAs are associated with higher 
rates of intracranial bleeding,299,300 and also higher rates of other types 
of bleeding compared with DOACs.83
In view of the potential safety benefits, switching from VKAs to a 
DOAC is justified where there are concerns about intracranial bleeding 
or for patient-choice reasons, and a switch is recommended where pa­
tients have failed to maintain an adequate TTR (<70%). This depends 
on patients fulfilling eligibility criteria for DOACs and should take into ac­
count other correctable reasons for poor INR control. There is limited 
data on switching OAC in older patients (≥75 years) with polypharmacy 
or other markers of frailty. A recent trial in this patient group premature­
ly stopped for futility showed that switching from VKAs to DOACs led 
to a higher primary outcome rate of major or clinically relevant non- 
major bleeding events compared with continuing with INR-guided 
VKA (17.8 vs. 10.5 per 100 patient-years, driven by non-major bleeds).309
Hence, in such patients who are clinically stable with good TTR, VKAs 
may be continued rather than switching to a DOAC after an open discus­
sion with the patient and shared decision-making.
6.2.3. Clinical vs. device-detected subclinical AF
The known benefit of anticoagulation applies to clinical AF. Two RCTs 
have been published assessing the value of DOAC therapy in device- 
detected subclinical AF. The ARTESiA trial (Apixaban for the 
Reduction of Thromboembolism in Patients With Device-Detected 
Sub-Clinical Atrial Fibrillation) was completed with 4012 patients 
with device-detected subclinical AF and a mean follow-up of 3.5 
years.282 The primary efficacy outcome of stroke or systemic embolism 
was significantly less in those randomized to apixaban compared with 
aspirin (HR, 0.63; 95% CI, 0.45–0.88; P = .007). In the intention-to-treat 
analysis, the primary safety outcome of major bleeding was higher with 
apixaban (HR, 1.36; 95% CI, 1.01–1.82; P = .04). The NOAH trial (Non- 
vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High 
Rate Episodes) was stopped prematurely due to safety concerns and 
futility for the efficacy of edoxaban, and hence provides limited informa­
tion.281 The analysis of 2536 patients with device-detected atrial high- 
rate episodes and a median follow-up of 21 months identified no differ­
ence in a composite of cardiovascular death, stroke, or embolism com­
paring edoxaban and placebo (HR, 0.81; 95% CI, 0.60–1.08; 
P = .15). Those randomized to edoxaban had a higher rate of the 
composite of death or major bleeding than placebo (HR, 1.31; 
95% CI, 1.02–1.67; P = .03). Patients had a low burden of device- 
detected subclinical AF in both trials (median duration 1.5 h and 
Table 11 Recommended doses for direct oral anticoagulant therapy
DOAC
Standard full dose
Criteria for dose reduction
Reduced dose only  
if criteria met
Apixaban
5 mg twice daily
Two out of three needed for dose reduction: 
(i) age ≥80 years 
(ii) body weight ≤60 kg 
(iii) serum creatinine ≥133 mmol/L.
2.5 mg twice daily
Dabigatran
150 mg twice daily
Dose reduction recommended if any apply: 
(i) age ≥80 years 
(ii) receiving concomitant verapamil. 
Dose reduction considered on an individual basis if any apply: 
(i) age 75–80 
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min) 
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux 
(iv) others at increased risk of bleeding.
110 mg twice daily
Edoxaban
60 mg once daily
Dose reduction if any apply: 
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min) 
(ii) body weight ≤60 kg 
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole.
30 mg once daily
Rivaroxaban
20 mg once daily
Creatinine clearance 15–49 mL/min.
15 mg once daily
© ESC 2024
DOAC, direct oral anticoagulant. 
Dose and dose adjustments are taken from the European Medicines Association Summary of Product Characteristics for each DOAC. There may be other patient-specific reasons 
for providing a reduced dose, but, in general, the standard full dose should be used to provide optimal prevention of thromboembolism related to AF. Note that antiplatelet agents 
should be stopped in most patients when commencing a DOAC (see Section 6.3). A number of drug interactions exist with each DOAC and should be taken into consideration 
(see Figure 9).
ESC Guidelines                                                                                                                                                                                          3345


<!-- PAGE 33 -->

### Page 33

2.8 h, respectively), with lower rates of thromboembolism (around 1% 
per patient-year) than would be expected for an equivalent cohort of 
patients with clinical AF and a CHA2DS2-VASc score of 4.
Considering the trade-off between potential benefit and the risk of 
major bleeding, this task force concludes that DOAC therapy may be 
considered in subgroups of patients with asymptomatic device- 
detected subclinical AF who have high estimated stroke risk and an ab­
sence of major bleeding risk factors (see Section 6.7). The duration and 
burden of subclinical AF that could indicate potential benefit from OAC 
remains uncertain.344 Regardless of the initial decision on OAC, pa­
tients with subclinical AF should receive management and follow-up 
for all aspects of AF-CARE as the risk of developing clinical AF is high 
(6%–9% per year).
6.3. Antiplatelet drugs and combinations 
with anticoagulants
Antiplatelet drugs, such as aspirin and clopidogrel, are not an alternative 
to OAC. They should not be used for stroke prevention, and can lead 
to potential harm (especially among elderly patients with AF).345–347 In 
ACTIVE W (Atrial fibrillation Clopidogrel Trial with Irbesartan for 
prevention of Vascular Events), dual antiplatelet therapy (DAPT) with 
aspirin and clopidogrel was less effective than warfarin for the preven­
tion of stroke, systemic embolism, MI, or vascular death (annual risk of 
events 5.6% vs. 3.9%, respectively; P = .0003), with similar rates of 
major bleeding.348 The AVERROES (Apixaban Versus Acetylsalicylic 
Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed 
or Are Unsuitable for Vitamin K Antagonist Treatment) trial demon­
strated a lower rate of stroke or systemic embolism with apixaban 
compared with aspirin (HR, 0.45; 95% CI, 0.32–0.62; P < .001), with 
no significant difference in major bleeding (there were 11 cases of intra­
cranial bleeding with apixaban and 13 with aspirin).242
The combination of OAC with antiplatelet agents (especially aspirin) 
without an adequate indication occurs frequently in clinical practice 
(see Supplementary data online, Additional Evidence Table S9).349,350
Bleeding events are more common when antithrombotic agents are 
combined, and no clear benefit has been observed in terms of preven­
tion of stroke or death.349 In general, combining antiplatelet drugs with 
anticoagulants (DOACs or VKAs) should only occur in selected pa­
tients with acute vascular disease (e.g. acute coronary syndromes; see 
Section 9.2). The combination of low-dose rivaroxaban (2.5 mg) with 
aspirin reduced the risk of stroke in patients with chronic vascular dis­
ease in a subanalysis of the COMPASS (Cardiovascular Outcomes for 
People Using Anticoagulation Strategies) trial,351,352 but this cannot 
be generalized to AF patients because those with an indication for full- 
dose anticoagulants were excluded.
6.4. Residual ischaemic stroke risk despite 
anticoagulation
Although OAC significantly reduces the risk of ischaemic stroke in pa­
tients with AF, there remains a residual risk.252,354 One-third of patients 
with AF presenting with an ischaemic stroke are already on anticoagu­
lation,355 with heterogeneous aetiology.356 This may include non-AF- 
related competing stroke mechanisms (such as large artery and small 
vessel diseases), non-adherence to therapy, an inappropriately low 
dose of anticoagulant, or thromboembolism despite sufficient anticoa­
gulation.357 Laboratory measurement of INR or DOAC levels may con­
tribute to revealing an amenable cause of the stroke. Regardless of 
anticoagulation status, patients with ischaemic stroke are more likely 
to have cardiovascular risk factors.358 Many clinicians managing patients 
with an incident stroke despite taking anticoagulation will be tempted 
to switch their anticoagulant regimen. While there may be some advan­
tage in switching from VKAs to DOACs for protection against future 
recurrent ischaemic or haemorrhagic stroke, this task force does not 
recommend routinely switching from one DOAC to another, or 
from a DOAC to a VKA, since this has no proven efficacy.252,356,359
There may be individual reasons for switching, including potential inter­
actions with new drugs; however, there is no consistent data across 
countries that adherence or efficacy differs between once- and twice- 
daily approaches.360,361 Emerging, but observational evidence suggests 
that switching provides limited reduction in the risk of recurrent ischae­
mic stroke.252,356,359 The alternative strategy of adding antiplatelet 
therapy to OAC may lead to an increased risk of bleeding.356,359
Aside from thorough attention to underlying risk factors and co­
morbidities, the approach to management of patients with a stroke des­
pite OAC remains a distinct challenge.
6.5. Percutaneous left atrial appendage 
occlusion
Percutaneous left atrial appendage occlusion (LAAO) is a device-based 
therapy that aims to prevent ischaemic stroke in patients with AF.362,363
In the VKA era, two RCTs compared warfarin with LAAO using the 
Recommendation Table 9 — Recommendations for 
thromboembolism despite anticoagulation (see also 
Evidence Table 9)
Recommendation
Classa
Levelb
A thorough diagnostic work-up should be 
considered in patients taking an oral anticoagulant 
and presenting with ischaemic stroke or 
thromboembolism to prevent recurrent events, 
including assessment of non-cardioembolic causes, 
vascular risk factors, dosage, and adherence.356,357
IIa
B
Adding antiplatelet treatment to anticoagulation is 
not recommended in patients with AF to prevent 
recurrent embolic stroke.356,359
III
B
Switching from one DOAC to another, or from a 
DOAC to a VKA, without a clear indication is not 
recommended in patients with AF to prevent 
recurrent embolic stroke.252,356,359
III
B
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 8 — Recommendations for 
combining antiplatelet drugs with anticoagulants for 
stroke prevention (see also Evidence Table 8)
Recommendation
Classa
Levelb
Adding antiplatelet treatment to oral anticoagulation 
is not recommended in AF patients for the goal of 
preventing ischaemic stroke or 
thromboembolism.345,347,353
III
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 34 -->

### Page 34

Watchman device. The 5-year pooled outcomes demonstrated a simi­
lar rate of the composite endpoint (cardiovascular or unexplained 
death, systemic embolism, and stroke) between the LAAO and war­
farin arms. Those randomized to LAAO had significantly lower rates 
of haemorrhagic stroke and all-cause death, but also a 71% non- 
significant increase in ischaemic stroke and systemic embolism.364
With DOACs demonstrating similar rates of major bleeding to as­
pirin,242 warfarin in the control arms in these trials is no longer standard 
of care and hence the place of LAAO in current practice is unclear. The 
Amulet occluder is an alternative LAAO device which was non-inferior 
in an RCT to the Watchman device for safety events 
(procedure-related complications, death, or major bleeding) and 
thromboembolism.365 In the PRAGUE-17 trial, 402 AF patients were 
randomized to DOAC or LAAO (Watchman or Amulet), with non- 
inferiority reported for a broad composite primary endpoint of stroke, 
TIA, systemic embolism, cardiovascular death, major or non-major clin­
ically relevant bleeding, and procedure/device-related complica­
tions.366,367 Larger trials368,369 are expected to provide more 
comprehensive data that can add to the current evidence base (see 
Supplementary data online, Additional Evidence Table S10).
Pending further RCTs (see Supplementary data online, Table S4), pa­
tients with a contraindication to all of the OAC options (the four 
DOACs and VKAs) have the most appropriate rationale for LAAO im­
plantation, despite the paradox that the need for post-procedure 
antithrombotic treatment exposes the patient to a bleeding risk that 
may be equivalent to that of DOACs. Regulatory approvals based on 
RCT protocols suggest the need for 45 days of VKA plus aspirin after 
implantation, followed by 6 months of DAPT in patients with no major 
peri-device leaks, and then ongoing aspirin (see Supplementary data 
online, Figure S2).370–372 However, real-world practice is markedly dif­
ferent and also varied. Direct oral anticoagulant administration at full 
or reduced dose has been proposed as a treatment alternative to 
warfarin.373 Observational studies have also supported the use of anti­
platelet therapy without associated increases in device-related throm­
bosis or stroke.374–376 In a propensity-matched comparison of patients 
receiving limited early OAC vs. antiplatelet treatment post-Watchman 
implantation, thromboembolic event rates and bleeding complications 
were similar.377 While waiting for solid RCT data (NCT03445949, 
NCT03568890),378 pertinent decisions on antithrombotic treatment 
are usually made on an individualized basis.379–381 Prevention of recur­
rent stroke, in addition to OAC, is another potential indication for 
LAAO. Only limited data are so far available from registries,382 with on­
going trials expected to provide more insight (NCT03642509, 
NCT05963698).
Left atrial appendage occlusion device implantation is associated 
with procedural risk including stroke, major bleeding, device- 
related thrombus, pericardial effusion, vascular complications, and 
death.362,383–385 Voluntary registries enrolling patients considered 
ineligible 
for 
OAC 
have 
reported 
low 
peri-procedural 
risk,372,376,386,387 although national registries report in-hospital ma­
jor adverse event rates of 9.5% in centres performing 5–15 LAAO 
cases per year, and 5.6% performing 32–211 cases per year 
(P < .001).388 Registries with new-generation devices report a low­
er complication rate compared with RCT data.389,390 Device- 
related thrombi occur with an incidence of 1.7%–7.2% and are 
associated with a higher risk of ischaemic stroke.386,391–397 Their 
detection can be documented as late as 1 year post-implantation 
in one-fifth of patients, thus mandating a late ‘rule-out’ imaging ap­
proach.391 Likewise, follow-up screening for peri-device leaks is 
relevant, as small leaks (0–5 mm) are present in ∼25% and have 
been associated with higher thromboembolic and bleeding events 
during 1 year follow-up in a large observational registry of one par­
ticular device.398
6.6. Surgical left atrial appendage occlusion
Surgical occlusion or exclusion of the left atrial appendage (LAA) can 
contribute to stroke prevention in patients with AF undergoing 
cardiac surgery.399,400 The Left Atrial Appendage Occlusion Study 
(LAAOS III) randomized 4811 patients with AF to undergo or not 
undergo LAAO at the time of cardiac surgery for another indication. 
During a mean of 3.8 years follow-up, ischaemic stroke or systemic em­
bolism occurred in 114 patients (4.8%) in the occlusion group and 168 
(7.0%) in the control arm (HR, 0.67; 95% CI, 0.53–0.85; P = .001).401
The LAAOS III trial did not compare appendage occlusion with anticoa­
gulation (77% of participants continued to receive OAC), and there­
fore, surgical LAA closure should be considered as an adjunct 
therapy to prevent thromboembolism in addition to anticoagulation 
in patients with AF.
There are no RCT data showing a beneficial effect on ischaemic 
stroke or systemic embolism in patients with AF undergoing LAAO 
during endoscopic or hybrid AF ablation. A meta-analysis of RCT and 
observational data showed no differences in stroke prevention or all- 
cause mortality when comparing LAA clipping during thoracoscopic 
AF ablation with percutaneous LAAO and catheter ablation.402
While the percutaneous LAAO/catheter ablation group showed a high­
er acute success rate, it was also associated with a higher risk of haem­
orrhage during the peri-operative period. In an observational study 
evaluating 222 AF patients undergoing LAA closure using a clipping de­
vice as a part of endoscopic or hybrid AF ablation, complete closure 
was achieved in 95% of patients.403 There were no intra-operative 
complications, and freedom from a combined endpoint of ischaemic 
stroke, haemorrhagic stroke, or TIA was 99.1% over 369 patient-years 
of follow-up. Trials evaluating the beneficial effect of surgical LAA clos­
ure in patients undergoing cardiac surgery but without a known history 
of AF are ongoing (NCT03724318, NCT02701062).404
There is a potential advantage for stand-alone epicardial over 
percutaneous LAA closure in patients with a contraindication for 
OAC, as there is no need for post-procedure anticoagulation after epi­
cardial closure. Observational data show that stand-alone LAA closure 
using an epicardial clip is feasible and safe.405 A multidisciplinary team 
approach can facilitate the choice between epicardial or percutaneous 
LAA closure in such patients.406 The majority of safety data and experi­
ence in epicardial LAA closure originate from a single clipping device 
(AtriClip)403,407,408
(see Supplementary data online, Additional 
Evidence Table S11).
Recommendation Table 10 — Recommendations for 
percutaneous left atrial appendage occlusion (see also 
Evidence Table 10)
Recommendation
Classa
Levelb
Percutaneous LAA occlusion may be considered in 
patients with AF and contraindications for long-term 
anticoagulant treatment to prevent ischaemic stroke 
and thromboembolism.372,376,386,387
IIb
C
© ESC 2024
AF, atrial fibrillation; LAA, left atrial appendage. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3347


<!-- PAGE 35 -->

### Page 35

6.7. Bleeding risk
6.7.1. Assessment of bleeding risk
When initiating antithrombotic therapy, modifiable bleeding risk factors 
should be managed to improve safety (Figure 10).414–418 This includes 
strict control of hypertension, advice to reduce excess alcohol intake, 
avoidance of unnecessary antiplatelet or anti-inflammatory agents, 
and attention to OAC therapy (adherence, control of TTR if on 
VKAs, and review of interacting medications). Clinicians should con­
sider the balance between stroke and bleeding risk—as factors for 
both are dynamic and overlapping, they should be re-assessed at 
each review depending on the individual patient.419–421 Bleeding risk 
factors are rarely a reason to withdraw or withhold OAC in eligible 
patients, as the risk of stroke without anticoagulation often outweighs 
the risk of major bleeding.422,423 Patients with non-modifiable risk 
factors should be reviewed more often, and where appropriate, 
a multidisciplinary team approach should be instituted to guide 
management.
Several bleeding risk scores have been developed to account for a 
wide range of clinical factors (see Supplementary data online, 
Table S5 and Additional Evidence Tables S12 and S13).424 Systematic re­
views and validation studies in external cohorts have shown contrasting 
results and only modest predictive ability.244,425–434 This task force 
does not recommend a specific bleeding risk score given the uncer­
tainty in accuracy and potential adverse implications of not providing 
appropriate OAC to those at thromboembolic risk. There are very 
few absolute contraindications to OAC (especially DOAC therapy). 
Whereas primary intracranial tumours435 or an intracerebral bleed re­
lated to cerebral amyloid angiopathy436 are examples where OAC 
should be avoided, many other contraindications are relative or tem­
porary. For example, a DOAC can often be safely initiated or re- 
initiated after acute bleeding has stopped, as long as the source has 
been fully investigated and managed. Co-prescription of proton 
pump inhibitors is common in clinical practice for patients receiving 
OAC that are at high risk of gastrointestinal bleeding. However, the evi­
dence base is limited and not specifically in patients with AF. Whereas 
observational studies have shown potential benefit from proton pump 
inhibitors,437 a large RCT in patients receiving low-dose anticoagulation 
and/or aspirin for stable cardiovascular disease found that pantoprazole 
had no significant impact on upper gastrointestinal bleeding events 
compared with placebo (HR, 0.88; 95% CI, 0.67–1.15).438 Hence, the 
use of gastric protection should be individualized for each patient 
according to the totality of their perceived bleeding risk.
6.7.2. Management of bleeding on anticoagulant 
therapy
General management of bleeding in patients receiving OAC is outlined 
in Figure 11. Cause-specific management is beyond the scope of these 
guidelines, and will depend on the individual circumstances of the pa­
tient and the healthcare environment.447 Assessment of patients with 
active bleeding should include confirmation of the bleeding site, 
bleeding severity, type/dose/timepoint of last anticoagulant intake, 
concomitant use of other antithrombotic agents, and other factors in­
fluencing bleeding risk (renal function, platelet count, and medications 
such as non-steroidal anti-inflammatories). INR testing and information 
on recent results are invaluable for patients taking VKAs. Specific 
coagulation tests for DOACs include diluted thrombin time, ecarin 
clotting time, ecarin chromogenic assay for dabigatran, and chro­
mogenic anti-factor Xa assay for rivaroxaban, apixaban, and edoxa­
ban.447–449 Diagnostic and treatment interventions to identify and 
manage the cause of bleeding (e.g. gastroscopy) should be performed 
promptly.
In cases of minor bleeding, temporary withdrawal of OAC while the 
cause is managed is usually sufficient, noting that the reduction in anti­
coagulant effect is dependent on the INR level for VKAs or the half-life 
of the particular DOAC.
For major bleeding events in patients taking VKAs, administration 
of fresh frozen plasma restores coagulation more rapidly than 
vitamin K, but prothrombin complex concentrates achieve even 
faster blood coagulation with fewer complications, and so are 
preferrable to achieve haemostasis.450 In DOAC-treated patients 
where the last DOAC dose was taken within 2–4 h, charcoal 
administration and/or gastric lavage may reduce further exposure. 
If the patient is taking dabigatran, idarucizumab can fully reverse its anti­
coagulant effect and help to achieve haemostasis within 2–4 h in 
Recommendation Table 12 — Recommendations for 
assessment of bleeding risk (see also Evidence Table 12)
Recommendations
Classa
Levelb
Assessment and management of modifiable bleeding 
risk factors is recommended in all patients eligible for 
oral anticoagulation, as part of shared 
decision-making to ensure safety and prevent 
bleeding.439–444
I
B
Use of bleeding risk scores to decide on starting or 
withdrawing oral anticoagulation is not 
recommended in patients with AF to avoid 
under-use of anticoagulation.431,445,446
III
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 11 — Recommendations for 
surgical left atrial appendage occlusion (see also 
Evidence Table 11)
Recommendations
Classa
Levelb
Surgical closure of the left atrial appendage is 
recommended as an adjunct to oral anticoagulation 
in patients with AF undergoing cardiac surgery to 
prevent ischaemic stroke and 
thromboembolism.400,401,408–412
I
B
Surgical closure of the left atrial appendage should be 
considered as an adjunct to oral anticoagulation in 
patients with AF undergoing endoscopic or hybrid 
AF ablation to prevent ischaemic stroke and 
thromboembolism.402,403
IIa
C
Stand-alone endoscopic surgical closure of the left 
atrial appendage may be considered in patients with 
AF and contraindications for long-term anticoagulant 
treatment to prevent ischaemic stroke and 
thromboembolism.399,405,406,413
IIb
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 36 -->

### Page 36

Hypertension
NSAIDs
Other factors
Optimize blood pressure lowering treatment
(Class I)
Do not use antiplatelet therapy beyond 12 months in stable OAC-treated patients with chronic coronary/vascular disease 
(Class III)
Do not add antiplatelet therapy to OAC to prevent thromboembolic events
(Class III)
or recurrent stroke
(Class III)
Reduce alcohol to <3
standard drinks per week
(Class I)
DOAC instead of  VKA
when antiplatelet treatment is needed
(Class I)
Keep INR 2.0–3.0
(Class I) 
and TTR >70% 
(Class IIa)
Switch to DOAC if eligible and failed to maintain
TTR on VKA
(Class I)
Minimize duration of heparin-bridging therapy
Manage all modifiable bleeding risk factors with shared decision-making
(Class I)
Do not use bleeding risk scores to decide starting or withdrawing OAC
(Class III)
Comprehensive medical history to determine all bleeding risk factors at OAC initiation/follow-up
(Class I)
Review patient more regularly
Work with multidisciplinary team to monitor risk factors
If clear contraindications for OACa, consider left atrial appendage occlusion 
(Class IIb)
Work with multidisciplinary team on each element
Ensure correct OAC dose and monitoring
Manage heart failure and achieve euvolaemia
(Class I)
Effective glycaemic control for patients with diabetes
(Class I)
Antiplatelet drugs
Alcohol intake
Unstable/variable INR
 Offer alternative analgesia or disease-modifying therapy
Re-assess at next interaction with patient
Renal impairment 
Risk of falls
Diabetes mellitus
Congestive heart failure
Reduced platelet count or function
Anaemia
Severe renal impairment, dialysis or renal transplant
Severe hepatic dysfunction or cirrhosis 
Malignancy 
Previous major bleeding
Age
Genetic factors (e.g. CYP2C9 polymorphisms)
Previous stroke
Intracerebral pathology
Cognitive impairment or dementia
Consider drug interactions
Reduce corticosteroid use 
if possible
Offer proton pump inhibitors if high GI bleeding risk
Advise restricting hazardous hobbies/occupations
Address all potentially modifiable bleeding risk factors with shared decision-making
Consider the impact of non-modifiable bleeding risk factors with shared decision-making
Figure 10 Modifying the risk of bleeding associated with OAC. DOAC, direct oral anticoagulant; GI, gastrointestinal; INR, international normalized 
ratio of prothrombin time; NSAID, non-steroidal anti-inflammatory drug; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K 
antagonist. aAbsolute contraindications for OAC therapy are rare, and include primary intracranial tumours and intracerebral bleeds related to amyloid 
angiopathy. In most cases, contraindications may be relative or temporary. Left atrial appendage occlusion can be performed through a percutaneous or 
endoscopic approach.
ESC Guidelines                                                                                                                                                                                          3349


<!-- PAGE 37 -->

### Page 37

Assess haemodynamic status, basic coagulation parameters, blood count and kidney function
Determine dose and time of last OAC and all co-medications
Compress bleeding sites mechanically, if accessible
Patient with active bleeding
DOAC
VKA
Interrupt anticoagulation and perform diagnostic or treatment interventions
(Class I)
Aim to re-initiate anticoagulation in the absence of contraindications or if source of bleeding has been addressed
Assess risk of repeat bleeding
Intensify efforts to modify bleeding risk factors
Discuss benefits and risk of restarting OAC (shared decision-making approach)
Review choice and dose of OAC
Institute close and ongoing monitoring
Management after the bleeding episode
Minor bleeding
Non-lifethreatening major bleeding
Life-threatening or bleeding into a critical site
Delay VKA
until INR <2
Delay DOAC 
for 1–2 doses
(or more depending on recovery)
Interrupt anticoagulation and perform diagnostic or treatment interventions
(Class I)
Minor bleeding
Non-lifethreatening major bleeding
Life-threatening or bleeding into a critical site
Fluid replacement
Blood transfusion
Consider need for vitamin K,
FFP, PCC
Fluid replacement
Blood transfusion
PCC
(Class IIa)
FFP if PCC not available
Replacement of platelets where appropriate
Fluid replacement
Blood transfusion
Consider oral charcoal or gastric lavage if DOAC taken within 2–4
hours
Consider need for PCC
Fluid replacement
Blood transfusion
Specific antidotes
(Class IIa)
PCC if no antidotes available
Replacement of platelets where appropriate
Monitoring of
DOAC levels
Multidisciplinary team approach
Multidisciplinary team approach
Figure 11 Management of oral anticoagulant-related bleeding in patients with AF. DOAC, direct oral anticoagulant; FFP, fresh frozen plasma; INR, 
international normalized ratio of prothrombin time; OAC, oral anticoagulant; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.


<!-- PAGE 38 -->

### Page 38

uncontrolled bleeding.451 Dialysis can also be effective in reducing dabiga­
tran concentration. Andexanet alfa rapidly reverses the activity of factor 
Xa inhibitors (apixaban, edoxaban, rivaroxaban) (see Supplementary data 
online, Additional evidence Table S14). An open-label RCT comparing 
andexanet alfa to usual care in patients presenting with acute ICH within 
6 h of symptom onset was stopped early due to improved control of 
bleeding after 450 patients had been randomized.452 As DOAC-specific 
antidotes are not yet available in all institutions, prothrombin complex 
concentrates are often used in cases of serious bleeding on factor Xa in­
hibitors, with evidence limited to observational studies.453
Due to the complexities of managing bleeding in patients taking 
OAC, it is advisable that each institution develop specific policies involv­
ing a multidisciplinary team that includes cardiologists, haematologists, 
emergency physicians/intensive care specialists, surgeons, and others. 
It is also important to educate patients taking anticoagulants on the 
signs and symptoms of bleeding events and to alert their healthcare 
provider when such events occur.335
The decision to reinstate OAC will be determined by the severity, 
cause, and subsequent management of bleeding, preferably by a multidis­
ciplinary team and with close monitoring. Failure to reinstitute OAC after 
a bleed significantly increases the risk of MI, stroke, and death.454
However, if the cause of severe or life-threatening bleeds cannot be trea­
ted or reversed, the risk of ongoing bleeding may outweigh the benefit of 
thromboembolic protection.335
7. [R] Reduce symptoms by rate 
and rhythm control
Most patients diagnosed with AF will need therapies and/or interven­
tions to control heart rate, revert to sinus rhythm, or maintain sinus 
rhythm to limit symptoms or improve outcomes. While the concept 
of choosing between rate and rhythm control is often discussed, in real­
ity most patients require a combination approach which should be con­
sciously re-evaluated during follow-up. Within a patient-centred and 
shared-management approach, rhythm control should be a consider­
ation in all suitable AF patients, with explicit discussion of benefits 
and risks.
7.1. Management of heart rate in patients 
with AF
Limiting tachycardia is an integral part of AF management and is often 
sufficient to improve AF-related symptoms. Rate control is indicated as 
initial therapy in the acute setting, in combination with rhythm control 
therapies, or as the sole treatment strategy to control heart rate and 
reduce symptoms. Limited evidence exists to inform the best type 
and intensity of rate control treatment.457 The approach to heart 
rate control presented in Figure 7 can be used for all types of AF, includ­
ing paroxysmal, persistent, and permanent AF.
Recommendation Table 14 — Recommendations for 
heart rate control in patients with AF (see also 
Evidence Table 14)
Recommendations
Classa
Levelb
Rate control therapy is recommended in patients 
with AF, as initial therapy in the acute setting, an 
adjunct to rhythm control therapies, or as a sole 
treatment strategy to control heart rate and reduce 
symptoms.458–460
I
B
Beta-blockers, diltiazem, verapamil, or digoxin are 
recommended as first-choice drugs in patients with 
AF and LVEF >40% to control heart rate and reduce 
symptoms.48,461,462
I
B
Beta-blockers and/or digoxin are recommended in 
patients with AF and LVEF ≤40% to control heart 
rate and reduce symptoms.40,185,463–465
I
B
Combination rate control therapy should be 
considered if a single drug does not control 
symptoms or heart rate in patients with AF, 
providing that bradycardia can be avoided, to control 
heart rate and reduce symptoms.
IIa
C
Lenient rate control with a resting heart rate of 
< 110 b.p.m. should be considered as the initial 
target for patients with AF, with stricter control 
reserved for those with continuing AF-related 
symptoms.459,460,466
IIa
B
Atrioventricular node ablation in combination with 
pacemaker implantation should be considered in 
patients unresponsive to, or ineligible for, intensive 
rate and rhythm control therapy to control heart 
rate and reduce symptoms.467–469
IIa
B
Atrioventricular node ablation combined with 
cardiac resynchronization therapy should be 
considered in severely symptomatic patients with 
permanent AF and at least one hospitalization for HF 
to reduce symptoms, physical limitations, recurrent 
HF hospitalization, and mortality.470,471
IIa
B
Intravenous amiodarone, digoxin, esmolol, or 
landiolol may be considered in patients with AF who 
have haemodynamic instability or severely depressed 
LVEF to achieve acute control of heart rate.472,473
IIb
B
© ESC 2024
AF, atrial fibrillation; b.p.m., beats per minute; HF, heart failure; LVEF, left ventricular 
ejection fraction. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 13 — Recommendations for 
management of bleeding in anticoagulated patients 
(see also Evidence Table 13)
Recommendations
Classa
Levelb
Interrupting anticoagulation and performing 
diagnostic or treatment interventions is 
recommended in AF patients with active bleeding 
until the cause of bleeding is identified and resolved.
I
C
Prothrombin complex concentrates should be 
considered in AF patients on VKAs who develop a 
life-threatening bleed, or bleed into a critical site, to 
reverse the antithrombotic effect.450
IIa
C
Specific antidotes should be considered in AF 
patients on a DOAC who develop a life-threatening 
bleed, or bleed into a critical site, to reverse the 
antithrombotic effect.451,455,456
IIa
B
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3351


<!-- PAGE 39 -->

### Page 39

7.1.1. Indications and target heart rate
The optimal heart rate target in AF patients depends on the setting, 
symptom burden, presence of heart failure, and whether rate control 
is combined with a rhythm control strategy. In the RACE II (Rate 
Control Efficacy in Permanent Atrial Fibrillation) RCT of patients 
with permanent AF, lenient rate control (target heart rate <110  [beats 
per minute] b.p.m.) was non-inferior to a strict approach (<80 b.p.m. at 
rest; <110 b.p.m. during exercise; Holter for safety) for a composite of 
clinical events, NYHA class, or hospitalization.186,459 Similar results 
were found in a post-hoc combined analysis from the AFFIRM (Atrial 
Fibrillation Follow-up Investigation of Rhythm Management) and the 
RACE (Rate Control versus Electrical cardioversion) studies.474
Therefore, lenient rate control is an acceptable initial approach, unless 
there are ongoing symptoms or suspicion of tachycardia-induced car­
diomyopathy, where stricter targets may be indicated.
7.1.2. Heart rate control in the acute setting
In acute settings, physicians should always evaluate and manage under­
lying causes for the initiation of AF prior to, or in parallel to, instituting 
acute rate and/or rhythm control. These include treating sepsis, addres­
sing fluid overload, or managing cardiogenic shock. The choice of drug 
(Table 12) will depend on the patient’s characteristics, presence of heart 
failure and LVEF, and haemodynamic profile (Figure 7). In general for 
acute rate control, beta-blockers (for all LVEF) and diltiazem/verapamil 
(for LVEF >40%) are preferred over digoxin because of their more 
rapid onset of action and dose-dependent effects.462,475,476 More se­
lective beta-1 receptor blockers have a better efficacy and safety profile 
than unselective beta-blockers.477 Combination therapy with digoxin 
may be required in acute settings (combination of beta-blockers with 
diltiazem/verapamil should be avoided except in closely monitored 
situations).177,478 In selected patients who are haemodynamically 
unstable or with severely impaired LVEF, intravenous amiodarone, 
landiolol, or digoxin can be used.472,473,479
7.1.3. Long-term heart rate control
Pharmacological rate control can be achieved with beta-blockers, 
diltiazem, verapamil, digoxin, or combination therapy (Table 12) (see 
Supplementary data online, Additional Evidence Table S15).480
The choice of rate control drugs depends on symptoms, comorbid­
ities, and the potential for side effects and interactions. Combination 
therapy of different rate-controlling drugs should be considered only 
when needed to achieve the target heart rate, and careful follow-up 
to avoid bradycardia is advised. Combining beta-blockers with verap­
amil or diltiazem should only be performed in secondary care 
with regular monitoring of heart rate by 24 h ECG to check for 
bradycardia.459 Some antiarrhythmic drugs (AADs) also have rate- 
limiting properties (e.g. amiodarone, sotalol), but they should generally 
be used only for rhythm control. Dronedarone should not be instituted 
for rate control since it increases rates of heart failure, stroke, and 
cardiovascular death in permanent AF.481
Beta-blockers, specifically beta-1 selective adrenoreceptor an­
tagonists, are often first-line rate-controlling agents largely based on 
their acute effect on heart rate and the beneficial effects demonstrated 
in patients with chronic HFrEF. However, the prognostic benefit of 
beta-blockers seen in HFrEF patients with sinus rhythm may not be pre­
sent in patients with AF.133,482
Verapamil and diltiazem are non-dihydropyridine calcium channel 
blockers. They provide rate control461 and have a different adverse effect 
profile, making verapamil or diltiazem useful for those experiencing side 
effects from beta-blockers.483 In a 60 patient crossover RCT, verapamil 
and diltiazem did not lead to the same reduction in exercise capacity as 
seen with beta-blockers, and had a beneficial impact on BNP.480
Digoxin and digitoxin are cardiac glycosides that inhibit the 
sodium–potassium adenosine triphosphatase and augment parasympa­
thetic tone. In RCTs, there is no association between the use of digoxin 
and any increase in all-cause mortality.185,484 Lower doses of digoxin 
may be associated with better prognosis.185 Serum digoxin concentra­
tions can be monitored to avoid toxicity,485 especially in patients at 
higher risk due to older age, renal dysfunction, or use of interacting 
medications. In RATE-AF (RAte control Therapy Evaluation in perman­
ent Atrial Fibrillation), a trial in patients with symptomatic permanent 
AF, there was no difference between low-dose digoxin and bisoprolol 
for patient-reported quality of life outcomes at 6 months. However, 
those randomized to digoxin demonstrated fewer adverse effects, a 
greater improvement in mEHRA and NYHA scores, and a reduction 
in BNP.48 Two ongoing RCTs are addressing digoxin and digitoxin 
use in patients with HFrEF with and without AF (EudraCT- 
2013-005326-38, NCT03783429).486
Table 12 Drugs for rate control in AF
Agenta
Intravenous administration
Usual range for oral maintenance 
dose
Contraindicated
Beta-blockersb
Metoprolol 
tartrate
2.5–5 mg bolus over 2 mins; up to 15 mg 
maximal cumulative dose
25–100 mg twice daily
In case of asthma, non-selective 
beta-blockers should be avoided. 
Contraindicated in acute HF and history of 
severe bronchospasm.
Metoprolol XL 
(succinate)
N/A
50–200 mg once daily
Bisoprolol
N/A
1.25–20 mg once daily
Atenololc
N/A
25–100 mg once daily
Esmolol
500 µg/kg i.v. bolus over 1 min; followed by 
50–300 µg/kg/min
N/A
Landiolol
100 µg/kg i.v. bolus over 1 min; followed by 
10–40 µg/kg/min
N/A
Nebivolol
N/A
2.5–10 mg once daily
Carvedilol
N/A
3.125–50 mg twice daily
Continued


<!-- PAGE 40 -->

### Page 40

Due to its broad extracardiac adverse effect profile, amiodarone is 
reserved as a last option when heart rate cannot be controlled even 
with maximal tolerated combination therapy, or in patients who do not 
qualify for atrioventricular node ablation and pacing. Many of the adverse 
effects from amiodarone have a direct relationship with cumulative dose, 
restricting the long-term value of amiodarone for rate control.487
7.1.4. Atrioventricular node ablation and pacemaker 
implantation
Ablation of the atrioventricular node and pacemaker implantation (‘ablate 
and pace’) can lower and regularize heart rate in patients with AF (see 
Supplementary data online, Additional Evidence Table S16). The procedure 
has a low complication rate and a low long-term mortality risk.468,488 The 
pacemaker should be implanted a few weeks before the atrioventricular 
node ablation, with the initial pacing rate after ablation set at 70– 
90 b.p.m.489,490 This strategy does not worsen LV function,491 and may 
even improve LVEF in selected patients.492,493 The evidence base has typ­
ically included older patients. For younger patients, ablate and pace should 
only be considered if heart rate remains uncontrolled despite consideration 
of other pharmacological and non-pharmacological treatment options. The 
choice of pacing therapy (right ventricular or biventricular pacing) depends 
on patient characteristics, presence of heart failure, and LVEF.187,494
In severely symptomatic patients with permanent AF and at least one 
hospitalization for heart failure, atrioventricular node ablation combined 
with CRT should be considered. In the APAF-CRT (Ablate and Pace for 
Atrial Fibrillation-cardiac resynchronization therapy) trial in a population 
with narrow QRS complexes, atrioventricular node ablation combined 
with CRT was superior to rate control drugs for the primary outcomes 
(all-cause mortality, and death or hospitalization for heart failure), and sec­
ondary outcomes (symptom burden and physical limitation).470,471
Conduction system pacing may become a potentially useful alternate pa­
cing mode when implementing a pace and ablate strategy, once safety and 
efficacy have been confirmed in larger RCTs.495,496 In CRT recipients, the 
presence (or occurrence) of AF is one of the main reasons for suboptimal 
biventricular pacing.187 Improvement of biventricular pacing is indicated 
and can be reached by intensification of rate control drug regimens, atrio­
ventricular node ablation, or rhythm control, depending on patient and AF 
characteristics.187
7.2. Rhythm control strategies in patients 
with AF
7.2.1. General principles and anticoagulation
Rhythm control refers to therapies dedicated to restoring and main­
taining sinus rhythm. These treatments include cardioversion, AADs, 
percutaneous catheter ablation, endoscopic and hybrid ablation, and 
open surgical approaches (see Supplementary data online, Additional 
Evidence Table S17). Rhythm control is never a strategy on its own; in­
stead, it should always be part of the AF-CARE approach.
In patients with acute or worsening haemodynamic instability thought to 
be caused by AF, rapid electrical cardioversion is recommended. For other 
patients, a wait-and-see approach should be considered as an alternative to 
immediate cardioversion (Figure 12). The Rate Control versus Electrical 
Cardioversion Trial 7–Acute Cardioversion versus Wait and See (RACE 
7 ACWAS) trial in patients with recent-onset symptomatic AF without 
haemodynamic compromise showed a wait-and-see approach for spon­
taneous conversion until 48 h after the onset of AF symptoms was non- 
inferior as compared with immediate cardioversion at 4 weeks follow-up.10
Since the publication of landmark trials more than 20 years ago, the 
main reason to consider longer-term rhythm control therapy has been 
the reduction in symptoms from AF.497–500 Older studies have shown 
that the institution of a rhythm control strategy using AADs does not re­
duce mortality and morbidity when compared with a rate control-only 
strategy,497–500 and may increase hospitalization.457 In contrast, multiple 
studies have shown that rhythm control strategies have a positive effect 
on quality of life once sinus rhythm is maintained.501,502 Therefore, in the 
case of uncertainty of the presence of symptoms associated with AF, an 
attempt to restore sinus rhythm is a rational first step. In patients with 
symptoms, patient factors that favour an attempt at rhythm control 
should be considered, including suspected tachycardiomyopathy, a brief 
AF history, non-dilated left atrium, or patient preference.
Rhythm control strategies have significantly evolved due to an increas­
ing experience in the safe use of antiarrhythmic drugs,17 consistent use of 
OAC, improvements in ablation technology,503–509 and identification and 
management of risk factors and comorbidities.39,510,511 In the ATHENA 
trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess 
the Efficacy of Dronedarone 400 mg twice daily for the Prevention of 
Non-dihydropyridine calcium channel antagonists
Verapamil
2.5–10 mg i.v. bolus over 5 min
40 mg twice daily to 480 mg (extended 
release) once daily
Contraindicated if LVEF ≤40%.  
Adapt doses in hepatic and renal 
impairment.
Diltiazem
0.25 mg/kg i.v. bolus over 5 min, then 
5–15 mg/h
60 mg three times daily to 360 mg 
(extended release) once daily
Digitalis glycosides
Digoxin
0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in 
divided doses)
0.0625–0.25 mg once daily
High plasma levels associated with adverse 
events. 
Check renal function before starting 
digoxin and adapt dose in CKD patients.
Digitoxin
0.4–0.6 mg
0.05–0.1 mg once daily
Other
Amiodaroned
300 mg i.v. diluted in 250 mL 5% dextrose over 
30–60 min (preferably via central venous 
cannula), followed by 900–1200 mg i.v. over 24 
h diluted in 500–1000 mL via a central venous 
cannula
200 mg once daily after loading 
Loading: 200 mg three times daily for 4 
weeks, then 200 mg daily or less as 
appropriate (reduce other rate control 
drugs according to heart rate)
Contraindicated in iodine sensitivity. 
Serious potential adverse effects (including 
pulmonary, ophthalmic, hepatic, and 
thyroid). Consider numerous drug 
interactions.
© ESC 2024
AF, atrial fibrillation; CKD, chronic kidney disease; HF, heart failure; i.v., intravenous; min, minutes; N/A, not available or not widely available. Maximum doses have been defined based on the 
summary of product characteristic of each drug. 
aAll rate control drugs are contraindicated in Wolff–Parkinson–White syndrome; also intravenous amiodarone. 
bOther beta-blockers are available but not recommended as specific rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol). 
cNo data on atenolol; should not be used in heart failure with reduced ejection fraction or in pregnancy. 
dLoading regimen may vary; i.v. dosage should be considered when calculating total load.
ESC Guidelines                                                                                                                                                                                          3353


<!-- PAGE 41 -->

### Page 41

N
Cardioversion for atrial fibrillation
Y
Check OAC status as soon as 
possible and proceed to last step 
Pharmacological or electrical cardioversion
(Class IIa)
Decide on continued OAC post-cardioversion
Short-term OAC after cardioversion (4 weeks) for all patients, even if CHA2DS2-VA = 0
(optional if AF onset definitely <24 h and low thromboembolic risk)
Long-term OAC for all patients according to thromboembolic risk assessment
Already on therapeutic OAC
for minimum 3 weeks
Not already on OAC
Wait-and-see approach for spontaneous conversion
(Class IIa)
Initiation of DOAC
(or VKA, LMWH, 
or UFH) for 
unscheduled 
cardioversion as 
soon as possible
(Class IIa)
Therapeutic OAC
for at least 3 weeks before scheduled cardioversion 
(adherence to 
DOACs or 
INR ≥2.0 for VKAs) 
(Class I)
Suitable for wait-and-see approach
(Class IIa)
Cardioversion cannot wait
Haemodynamically stable
Emergency electrical cardioversion
(Class I)
AF onset ≥24 h or unknown
AF onset <24 h
Elective electrical cardioversion,
if needed
Check OAC status
Check current AF
episode duration
Pharmacological or electrical cardioversion
TOE guided cardioversion
(Class I)
Figure 12 Approaches for cardioversion in patients with AF. AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years 
(2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; h, hour; 
LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TOE, transoesophageal echocardiography; UFH, 
unfractionated heparin; VKA, vitamin K antagonist. Flowchart for decision-making on cardioversion of AF depending on clinical presentation, AF onset, 
oral anticoagulation intake, and risk factors for stroke. aSee Section 6.


<!-- PAGE 42 -->

### Page 42

Cardiovascular Hospitalization or Death from Any Cause in Patients with 
Atrial Fibrillation/Atrial Flutter), dronedarone significantly reduced the 
risk of hospitalization due to cardiovascular events or death as compared 
with placebo in patients with paroxysmal or persistent AF.512 The 
CASTLE-AF trial (Catheter Ablation versus Standard Conventional 
Treatment in Patients With Left Ventricle Dysfunction and AF) demon­
strated that a rhythm control strategy with catheter ablation can improve 
mortality and morbidity in selected patients with HFrEF and an implanted 
cardiac device.4 In end-stage HFrEF, the CASTLE-HTx trial (Catheter 
Ablation for Atrial Fibrillation in Patients With End-Stage Heart Failure 
and Eligibility for Heart Transplantation) found, in a single centre, that 
catheter ablation combined with guideline-directed medical therapy sig­
nificantly reduced the composite of death from any cause, implantation 
of left ventricular assist device, or urgent heart transplantation compared 
with medical treatment.513 At the same time, however, the CABANA 
trial (Catheter Ablation versus Anti-arrhythmic Drug Therapy for 
Atrial Fibrillation) could not demonstrate a significant difference in mor­
tality and morbidity between catheter ablation and standard rhythm and/ 
or rate control drugs in symptomatic AF patients older than 64 years, or 
younger than 65 years with risk factors for stroke.3 EAST-AFNET 4 
(Early treatment of Atrial fibrillation for Stroke prevention Trial) re­
ported that implementation of a rhythm control strategy within 1 year 
compared with usual care significantly reduced the risk of cardiovascular 
death, stroke, or hospitalization for heart failure or acute coronary syn­
drome in patients older than 75 years or with cardiovascular condi­
tions.17 Of note, rhythm control was predominantly pursued with 
antiarrhythmic drugs (80% of patients in the intervention arm). Usual 
care consisted of rate control therapy; only when uncontrolled 
AF-related symptoms occurred was rhythm control considered. 
Patients in the EAST-AFNET 4 trial all had cardiovascular risk factors 
but were at an early stage of AF, with more than 50% being in sinus 
rhythm and 30% being asymptomatic at the start of the study.
Based on all of these studies, this task force concludes that implementa­
tion of a rhythm control strategy can be safely instituted and confers ameli­
oration of AF-related symptoms. Beyond control of symptoms, sinus 
rhythm maintenance should also be pursued to reduce morbidity and mor­
tality in selected groups of patients.4,17,502,513,514
Any rhythm control procedure has an inherent risk of thrombo­
embolism. Patients undergoing cardioversion require at least 3 weeks 
of therapeutic anticoagulation (adherence to DOACs or INR >2 if 
VKA) prior to the electrical or pharmacological procedure. In acute set­
tings or when early cardioversion is needed, transoesophageal echocar­
diography (TOE) can be performed to exclude cardiac thrombus prior 
to cardioversion. These approaches have been tested in multiple 
RCTs.319–321 In the case of thrombus detection, therapeutic anticoagu­
lation should be instituted for a minimum of 4 weeks followed by repeat 
TOE to ensure thrombus resolution. When the definite duration of AF 
is less than 48 hours, cardioversion has typically been considered with­
out the need for pre-procedure OAC or TOE for thrombus exclusion. 
However, the ‘definite’ onset of AF is often not known, and observa­
tional data suggest that stroke/thromboembolism risk is lowest within 
a much shorter time period.515–519 This task force reached consensus 
that safety should come first. Cardioversion is not recommended if AF 
duration is longer than 24 hours, unless the patient has already received 
at least 3 weeks of therapeutic anticoagulation or a TOE is performed 
to exclude intracardiac thrombus. Most patients should continue OAC 
for at least 4 weeks post-cardioversion. Only for those without 
thromboembolic risk factors and sinus rhythm restoration within 24 
h of AF onset is post-cardioversion OAC optional. In the presence of 
any thromboembolic risk factors, long-term OAC should be instituted 
irrespective of the rhythm outcome.
Recommendation Table 15 — Recommendations for 
general concepts in rhythm control (see also Evidence 
Table 15)
Recommendations
Classa
Levelb
Electrical cardioversion is recommended in AF patients 
with acute or worsening haemodynamic instability to 
improve immediate patient outcomes.520
I
C
Direct oral anticoagulants are recommended in 
preference to VKAs in eligible patients with AF 
undergoing cardioversion for thromboembolic risk 
reduction.293,319–321,521
I
A
Therapeutic oral anticoagulation for at least 3 weeks 
(adherence to DOACs or INR ≥2.0 for VKAs) is 
recommended before scheduled cardioversion of AF 
and atrial flutter to prevent procedure-related 
thromboembolism.319–321
I
B
Transoesophageal echocardiography is recommended 
if 3 weeks of therapeutic oral anticoagulation has not 
been provided, for exclusion of cardiac thrombus to 
enable early cardioversion.319–321,522
I
B
Oral anticoagulation is recommended to continue 
for at least 4 weeks in all patients after cardioversion 
and long-term in patients with thromboembolic risk 
factor(s) irrespective of whether sinus rhythm is 
achieved, to prevent thromboembolism.239,319,320,523,524
I
B
Cardioversion of AF (either electrical or 
pharmacological) should be considered in 
symptomatic patients with persistent AF as part of a 
rhythm control approach.52,525,526
IIa
B
A wait-and-see approach for spontaneous 
conversion to sinus rhythm within 48 h of AF onset 
should be considered in patients without 
haemodynamic compromise as an alternative to 
immediate cardioversion.10,525
IIa
B
Implementation of a rhythm control strategy should 
be considered within 12 months of diagnosis in 
selected patients with AF at risk of thromboembolic 
events to reduce the risk of cardiovascular death or 
hospitalization.17,527
IIa
B
Initiation of therapeutic anticoagulation should 
be considered as soon as possible in the setting 
of unscheduled cardioversion for AF or atrial 
flutter to prevent procedure-related 
thromboembolism.319–321,528
IIa
B
Repeat transoesophageal echocardiography should be 
considered before cardioversion if thrombus has been 
identified on initial imaging to ensure thrombus 
resolution and prevent peri-procedural 
thromboembolism.529
IIa
C
Early cardioversion is not recommended without 
appropriate anticoagulation or transoesophageal 
echocardiography if AF duration is longer than 24 h, or 
there is scope to wait for spontaneous cardioversion.522
III
C
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; INR, international normalized ratio 
of prothrombin time; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3355


<!-- PAGE 43 -->

### Page 43

7.2.2. Electrical cardioversion
Electrical cardioversion (ECV) can be safely applied in the elective and 
acute setting (see Supplementary data online, Additional Evidence 
Table S18) with sedation by intravenous midazolam, propofol, or 
etomidate.530 Structured and integrated care for patients with acute- 
onset AF at the emergency department is associated with better out­
comes without compromising safety.531 Rates of major adverse clinical 
events after cardioversion are significantly lower with DOACs com­
pared with warfarin.293
Blood pressure monitoring and oximetry should be used routinely. 
Intravenous atropine or isoproterenol, or temporary transcutaneous 
pacing, should be available in case of post-cardioversion bradycardia. 
Biphasic defibrillators are standard because of their superior efficacy 
compared with monophasic defibrillators.532–534 There is no single op­
timal position for electrodes, with a meta-analysis of 10 RCTs showing 
no difference in sinus rhythm restoration comparing anterior-posterior 
with antero-lateral electrode positioning.535 Applying active compres­
sion to the defibrillation pads is associated with lower defibrillation 
thresholds, lower total energy delivery, fewer shocks for successful 
ECV, and higher success rates.536 A randomized trial showed that max­
imum fixed-energy shocks were more effective than low-escalating en­
ergy for ECV.537
Immediate administration of vernakalant,538 or pre-treatment 
for 3–4 days with flecainide,539,540 ibutilide,541,542 propafenone,543 or 
amiodarone544–546 improves the rate of successful ECV and can 
facilitate long-term maintenance of sinus rhythm by preventing 
early recurrent AF.547 A meta-analysis demonstrated that pre- 
treatment with amiodarone (200–800 mg/day for 1–6 weeks pre- 
cardioversion) and post-treatment (200 mg/day) significantly improved 
the restoration and maintenance of sinus rhythm after ECV of AF.546
In some cases of persistent AF there is no clear relationship between 
the arrhythmia and symptoms. In these cases, restoring sinus rhythm by 
ECV might serve to confirm the impact of arrhythmia on symptoms 
and/or on heart failure symptoms and signs. Such an approach might 
be useful to identify truly asymptomatic individuals, to assess the impact 
of AF on LV function in patients with HFrEF, and to distinguish 
AF-related symptoms from heart failure symptoms.
7.2.3. Pharmacological cardioversion
Pharmacological cardioversion to sinus rhythm is an elective procedure 
in haemodynamically stable patients. It is less effective than electrical car­
dioversion for restoration of sinus rhythm,549 with timing of cardiover­
sion being a significant determinant of success.550 There are limited 
contemporary data on the true efficacy of pharmacological cardiover­
sion, which are likely biased by the spontaneous restoration of sinus 
rhythm in 76%–83% of patients with recent-onset AF (10%–18% within 
the first 3 h, 55%–66% within 24 h, and 69% within 48 h).10,119,445,551–555
The choice of a specific drug is based on the type and severity of con­
comitant heart disease (Table 13). A meta-analysis demonstrated that 
intravenous vernakalant and flecainide have the highest conversion rate 
within 4 h, possibly allowing discharge from the emergency department 
and reducing hospital admissions. Intravenous and oral formulations of 
Class IC antiarrhythmics (flecainide more so than propafenone) 
are superior regarding conversion rates within 12 h, while amiodarone 
efficacy is exhibited in a delayed fashion (within 24 h).556
Pharmacological cardioversion does not require fasting, sedation, or an­
aesthesia. Anticoagulation should be started or continued according to a 
formal (re-)assessment of thromboembolic risk.554,557–559
A single self-administered oral dose of flecainide or propafenone 
(pill-in-the-pocket) is effective in symptomatic patients with infre­
quent and recent-onset paroxysmal AF. Safe implementation of this 
strategy requires patient screening to exclude sinus node dysfunction, 
atrioventricular conduction defects, or Brugada syndrome, as well as 
prior in-hospital validation of its efficacy and safety.560 An atrioven­
tricular node-blocking drug should be instituted in patients treated 
with Class IC AADs to avoid 1:1 conduction if the rhythm transforms 
to AFL.561
Recommendation Table 17 — Recommendations for 
pharmacological cardioversion of AF (see also Evidence 
Table 17)
Recommendations
Classa
Levelb
Intravenous flecainide or propafenone is 
recommended when pharmacological cardioversion 
of recent-onset AF is desired, excluding patients with 
severe left ventricular hypertrophy, HFrEF, or 
coronary artery disease.562–566
I
A
Intravenous vernakalant is recommended when 
pharmacological cardioversion of recent-onset AF is 
desired, excluding patients with recent ACS, HFrEF, 
or severe aortic stenosis.562–568
I
A
Intravenous amiodarone is recommended when 
cardioversion of AF in patients with severe left 
ventricular hypertrophy, HFrEF, or coronary artery 
disease is desired, accepting there may be a delay in 
cardioversion.473,569,570
I
A
A single self-administered oral dose of flecainide or 
propafenone (pill-in-the-pocket) should be 
considered for patient-led cardioversion in selected 
patients with infrequent paroxysmal AF, after efficacy 
and safety assessment and excluding those with 
severe left ventricular hypertrophy, HFrEF, or 
coronary artery disease.560,571–573
IIa
B
Pharmacological cardioversion is not recommended 
for patients with sinus node dysfunction, 
atrioventricular conduction disturbances, or 
prolonged QTc (>500 ms), unless risks for 
proarrhythmia and bradycardia have been considered.
III
C
© ESC 2024
ACS, acute coronary syndromes; AF, atrial fibrillation; HFrEF, heart failure with reduced 
ejection fraction. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 16 — Recommendations for 
electrical cardioversion of AF (see also Evidence 
Table 16)
Recommendations
Classa
Levelb
Electrical cardioversion as a diagnostic tool should be 
considered in patients with persistent AF where 
there is uncertainty about the value of sinus rhythm 
restoration on symptoms, or to assess improvement 
in left ventricular function.548
IIa
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

7.2.4. Antiarrhythmic drugs
The aims of long-term rhythm control are to maintain sinus rhythm, im­
prove quality of life, slow the progression of AF, and potentially reduce 
morbidity related to AF episodes (see Supplementary data online, 
Additional Evidence Table S19).17,445,574,575 Antiarrhythmic drugs do 
not eliminate recurrences of AF, but in patients with paroxysmal 
or persistent AF, a recurrence is not equivalent to treatment 
failure if episodes are less frequent, briefer, or less symptomatic. 
Antiarrhythmic drugs also have a role for long-term rhythm control in 
AF patients that are considered ineligible or unwilling to undergo cath­
eter or surgical ablation.
Before starting AAD treatment, reversible triggers should be identified 
and underlying comorbidities treated to reduce the arrhythmogenic sub­
strate, prevent progression of AF, and facilitate maintenance of sinus 
Table 13 Antiarrhythmic drugs for sinus rhythm restoration
Drug
Administration 
route
Initial dosing
Subsequent 
dosing [long- 
term approach]
Acute success 
rate and time 
to sinus 
rhythm
Contraindications and precautions
Flecainide
Oral
200–300 mg
[long-term  
50−150 mg twice 
daily]
50%–60% at 3 h 
and 75%–85% at 
6–8 h (3–8 h)
• Should not be used in patients with severe 
structural or coronary artery disease, Brugada 
syndrome, or severe renal failure (CrCl 
<35 mL/min/1.73 m2).
• Prior documentation of safety and efficacy in 
an inpatient setting is recommended prior to 
pill-in-the-pocket use.
• An AVN-blocking agent should be 
administered to avoid 1:1 conduction if 
transformation to AFL.
• Drug infusion should be discontinued in case 
of QRS widening >25% or bundle branch 
block occurrence.
• Caution is needed in patients with sinus node 
disease and AVN dysfunction.
• Do NOT use for conversion of atrial flutter.
Intravenous
1–2 mg/kg over 
10 min
52%–95%  
(Up to 6 h)
Propafenone
Oral
450–600 mg
[long-term  
150-300 mg three 
times daily]
45%–55% at 3 h, 
69%–78% at 8 h 
(3–8 h)
Intravenous
1.5–2 mg/kg over 
10 min
43%–89%  
(Up to 6 h)
Amiodarone
Intravenous (/oral)
300 mg intravenous 
over 30–60 min
900-1200 mg 
intravenous over 24 
hours (or 200 mg 
oral three times 
daily for 4 weeks). 
[long-term 200 mg 
oral daily]
44% (8–12 h to 
several days)
• May cause phlebitis (use a large peripheral 
vein, avoid i.v. administration >24 h and use 
preferably volumetric pump).
• May cause hypotension, bradycardia/ 
atrioventricular block, QT prolongation.
• Only if no other option in patients with 
hyperthyroidism (risk of thyrotoxicosis).
• Consider the broad range of drug 
interactions.
Ibutilide
Intravenous
1 mg over 10 min 
(0.01 mg/kg if body 
weight <60 kg)
1 mg over 10 min 
(10–20 min after 
the initial dose)
31%–51%  
(30–90 min)  
in AF 
60–75% in AFL 
(60 min)
• Should be used in the setting of a cardiac care 
unit as it may cause QT prolongation and 
torsades de pointes.
• ECG monitoring for at least 4 h after 
administration to detect any proarrhythmic 
effects.
• Should not be used in patients with prolonged 
QT, severe LVH, or low LVEF.
Vernakalant
Intravenous
3 mg/kg over 10 min 
(maximum 339 mg)
2 mg/kg over 10 min 
(10–15 min after 
the initial dose) 
(maximum 226 mg)
50% within 
10 min
• Should not be used in patients with arterial 
hypotension (SBP <100 mmHg), recent ACS 
(within 1 month), NYHA III or IV HF, QT 
prolongation or severe aortic stenosis.
• May cause arterial hypotension, QT 
prolongation, QRS widening, or 
non-sustained ventricular tachycardia.
© ESC 2024
ACS, acute coronary syndromes; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; CrCl, creatinine clearance; ECG, electrocardiogram; HF, heart failure; LVEF, left 
ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; QT, QT interval; SBP, systolic blood pressure. Long-term dosage for maintenance 
of sinus rhythm  is indicated in [square brackets]. Long-term oral dosing for dronedarone is 400 mg twice daily, and for sotalol 80-160 mg twice daily.
ESC Guidelines                                                                                                                                                                                          3357


<!-- PAGE 45 -->

### Page 45

rhythm.39,128 The RACE 3 trial, including patients with early persistent AF 
and mild-to-moderate heart failure (predominantly HFpEF and HFmrEF), 
showed that targeted therapy of underlying conditions improved sinus 
rhythm maintenance at 1 year (75% vs. 63% as compared with standard 
care).39 The selection of an AAD for long-term rhythm control requires 
careful evaluation that takes into account AF type, patient parameters, 
and safety profile.445 It also includes shared decision-making, balancing 
the benefit/risk ratio of AADs in comparison with other strategies. 
Notably, recent evidence has shown that careful institution of AADs 
can be performed safely.17
The long-term effectiveness of AADs is limited. In a meta-analysis of 
59 RCTs, AADs reduced AF recurrences by 20%–50% compared with 
no treatment, placebo, or drugs for rate control.576,577 When one AAD 
fails to reduce AF recurrences, a clinically acceptable response may be 
achieved with another drug, particularly if from a different class.578
Combinations of AADs are not recommended. The data available sug­
gest that AADs do not produce an appreciable effect on mortality or 
other cardiovascular complications with the exception of increased 
mortality signals for sotalol574,579,580 and amiodarone.581 In contrast, 
use of AADs within a rhythm control strategy can be associated with 
reduction of morbidity and mortality in selected patients.582
All AADs may produce serious cardiac (proarrhythmia, negative in­
otropism, hypotension) and extracardiac adverse effects (organ tox­
icity, predominantly amiodarone). Drug safety, rather than efficacy, 
should determine the choice of drug. The risk of proarrhythmia in­
creases in patients with structural heart disease. Suggested doses for 
long-term oral AAD are presented in Table 13.577,583,584
7.2.5. Catheter ablation
Catheter ablation prevents AF recurrences, reduces AF burden, and 
improves quality of life in symptomatic paroxysmal or persistent AF 
where the patient is intolerant or does not respond to AAD.503–509
Multiple RCTs have provided evidence in favour of catheter ablation 
as a first-line approach for rhythm control in patients with paroxysmal 
AF, with a similar risk of adverse events as compared with initial AAD 
treatment (see Supplementary data online, Additional Evidence Table 
S20).15,16,591–594 In contrast, it is not clear whether first-line ablation 
is superior to drug therapy in persistent AF. Catheter ablation may 
also have a role in patients with symptoms due to prolonged pauses 
upon AF termination, where non-randomized data have shown im­
proved symptoms, and avoidance of pacemaker implantation.595–598
Pulmonary vein isolation (PVI) remains the cornerstone of AF cath­
eter ablation,503,508,593,599 but the optimal ablation strategy has not 
been clarified in the non-paroxysmal AF population.600 New technolo­
gies are emerging, such as pulsed field ablation, in which high-amplitude 
electrical pulses are used to ablate the myocardium by electroporation 
with high tissue specificity. In a single-blind RCT of 607 patients, pulsed 
field ablation was non-inferior for efficacy and safety endpoints com­
pared with conventional radiofrequency or cryoballoon ablation.601
Regarding timing of ablation, a small RCT found that delaying catheter 
ablation in patients with paroxysmal or persistent AF by 12 months 
(while on optimized medical therapy) did not impact on arrhythmia- 
free survival compared with ablation within 1 month.602
As with any type of rhythm control, many patients in clinical practice 
will not be suitable for catheter ablation due to factors that reduce the 
likelihood of a positive response, such as left atrial dilatation. Definitive 
evidence that supports the prognostic benefit of catheter ablation is 
needed before this invasive treatment can be considered for truly 
asymptomatic patients. As previously noted, the CABANA trial did 
not confirm a benefit of catheter ablation compared with medical ther­
apy, although high crossover rates and low event rates may have diluted 
the treatment effect.3 Therefore, only highly selected asymptomatic pa­
tients could be candidates for catheter ablation, and only after detailed 
discussion of associated risks and potential benefit of delaying AF pro­
gression.4,603 Randomized trials have shown that AF catheter ablation 
in patients with HFrEF significantly reduces arrhythmia recurrence 
and increases ejection fraction, with improvement in clinical outcomes 
and mortality also observed in selected patients.4,513,514,604–612 Several 
Recommendation Table 18 — Recommendations for 
antiarrhythmic drugs for long-term maintenance of si­
nus rhythm (see also Evidence Table 18)
Recommendations
Classa
Levelb
Amiodarone is recommended in patients with AF 
and HFrEF requiring long-term antiarrhythmic drug 
therapy to prevent recurrence and progression of 
AF, with careful consideration and monitoring for 
extracardiac toxicity.577,585–587
I
A
Dronedarone is recommended in patients with AF 
requiring long-term rhythm control, including those 
with HFmrEF, HFpEF, ischaemic heart disease, or 
valvular disease to prevent recurrence and 
progression of AF.512,577,588,589
I
A
Flecainide or propafenone is recommended in 
patients with AF requiring long-term rhythm control 
to prevent recurrence and progression of AF, 
excluding those with impaired left ventricular systolic 
function, severe left ventricular hypertrophy, or 
coronary artery disease.526,577,585,590
I
A
Concomitant use of a beta-blocker, diltiazem, or 
verapamil should be considered in AF patients 
treated with flecainide or propafenone, to prevent 
1:1 conduction if their rhythm is transformed to atrial 
flutter.
IIa
C
Continued 
Sotalol may be considered in patients with AF 
requiring long-term rhythm control with normal 
LVEF or coronary artery disease to prevent 
recurrence and progression of AF, but requires close 
monitoring of QT interval, serum potassium levels, 
renal function, and other proarrhythmia risk 
factors.585,587
IIb
A
Antiarrhythmic drug therapy is not recommended in 
patients with advanced conduction disturbances 
unless antibradycardia pacing is provided.
III
C
© ESC 2024
AF, atrial fibrillation; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, 
heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

characteristics, including but not limited to AF type, left atrial dilatation, 
and the presence of atrial and/or ventricular fibrosis, could refine pa­
tient selection to maximize outcome benefit from AF catheter ablation 
in patients with HFrEF.604,608,613–617 The prognostic value of catheter 
ablation in patients with HFpEF is less well established than for 
HFrEF.617–626
Recent registries and trials report varying rates of peri-procedural 
serious adverse events associated with catheter ablation (2.9%–7.2%) 
with a very low 30 day mortality rate (<0.1%). Operator experience 
and procedural volume at the ablation centre are critical, since they 
are associated with complication rates and 30 day mortality.627–631
Intermittent rhythm monitoring has typically been used to detect AF 
relapses following catheter ablation. Recent technology developments 
such as smartwatch or smartphone photoplethysmography and wear­
able patches may have an emerging role in post-ablation monitor­
ing.632,633 In addition, implantable loop recorders have been used to 
quantify AF burden before and after ablation as an additional endpoint 
beyond binary AF elimination.634 Management of arrhythmia recur­
rence post-ablation is an informed, shared decision-making process dri­
ven by available options for symptom control. In the post-AF ablation 
context, there is data supporting a role for AAD continuation or re- 
initiation, even for previously ineffective drugs.635 A short-term AAD 
treatment (2–3 months) following ablation reduces early recurrences 
of AF,554,635–639 but does not affect late recurrences636,637,640–642 or 
1 year clinical outcomes.642 Repeat PVI should be offered in patients 
with AF recurrence if symptom improvement was demonstrated after 
the first ablation, with shared decision-making and clear goals of treat­
ment.643–645
7.2.6. Anticoagulation in patients undergoing 
catheter ablation
The presence of left atrial thrombus is a contraindication to catheter- 
based AF ablation due to the risk of thrombus dislodgement leading 
to ischaemic stroke. Patients planned for catheter ablation of AF with 
an increased risk of thromboembolism should be on OAC for at least 
3 full weeks prior to the procedure.554,647
There is a wide range in practice for visualization of intra-atrial 
thrombi prior to catheter ablation, including TOE, intracardiac echo­
cardiography, or delayed phase cardiac computed tomography 
(CT).554,648 The prevalence of left atrial thrombus was 1.3% and 
2.7% in two meta-analyses of observational studies in patients planned 
for catheter ablation of AF on adequate OAC.649,650 The prevalence of 
left atrial thrombus was higher in patients with elevated stroke risk 
scores, and in patients with non-paroxysmal compared with paroxys­
mal AF.650 In addition, several patient subgroups with AF have increased 
risk of ischaemic stroke and intracardiac thrombus even if treated with 
adequate anticoagulation, including those with cardiac amyloidosis, 
rheumatic heart disease, and hypertrophic cardiomyopathy (HCM). 
Cardiac imaging before catheter ablation should be considered in these 
high-risk patient groups regardless of preceding effective OAC. 
Observational studies suggest that patients with a low thromboembolic 
risk profile may be managed without visualization of the LAA,651–653
but no RCTs have been performed (see Supplementary data online, 
Additional Evidence Table S21).
For patients who have been anticoagulated prior to the ablation pro­
cedure it is recommended to avoid interruption of OAC (see 
Supplementary data online, Additional Evidence Table S22).654–656
Patients with interrupted OAC showed an increase in silent stroke de­
tected by brain magnetic resonance imaging (MRI) as compared with 
those with uninterrupted OAC.657–659 In a true uninterrupted 
Recommendation Table 19 — Recommendations for 
catheter ablation of AF (see also Evidence Table 19)
Recommendations
Classa
Levelb
Shared decision-making
Shared decision-making is recommended when 
considering catheter ablation for AF, taking into 
account procedural risks, likely benefits, and risk 
factors for AF recurrence.128,210,503,646
I
C
AF patients resistant or intolerant to antiarrhythmic drug 
therapy
Catheter ablation is recommended in patients with 
paroxysmal or persistent AF resistant or intolerant 
to antiarrhythmic drug therapy to reduce symptoms, 
recurrence, and progression of AF.3,15,503,505,506,508
I
A
First-line rhythm control therapy
Catheter ablation is recommended as a first-line 
option within a shared decision-making rhythm 
control strategy in patients with paroxysmal AF, to 
reduce symptoms, recurrence, and progression of 
AF.16,591–594
I
A
Catheter ablation may be considered as a first-line 
option within a shared decision-making rhythm 
control strategy in selected patients with persistent 
AF to reduce symptoms, recurrence, and 
progression of AF.
IIb
C
Continued 
Patients with heart failure
AF catheter ablation is recommended in patients 
with AF and HFrEF with high probability of 
tachycardia-induced cardiomyopathy to reverse left 
ventricular dysfunction.604,611
I
B
AF catheter ablation should be considered in 
selected AF patients with HFrEF to reduce HF 
hospitalization and prolong survival.4,513,514,604,610,612
IIa
B
Sinus node disease/tachycardia–bradycardia syndrome
AF catheter ablation should be considered in patients 
with AF-related bradycardia or sinus pauses on AF 
termination to improve symptoms and avoid 
pacemaker implantation.595–598
IIa
C
Recurrence after catheter ablation
Repeat AF catheter ablation should be considered in 
patients with AF recurrence after initial catheter 
ablation, provided the patient’s symptoms were 
improved after the initial PVI or after failed initial PVI, 
to reduce symptoms, recurrence, and progression of 
AF.643–645
IIa
B
© ESC 2024
AF, atrial fibrillation; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; 
PVI, pulmonary vein isolation. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3359


<!-- PAGE 47 -->

### Page 47

DOAC strategy for once-daily dosing, a pre-procedural shift to evening 
intake might be considered to mitigate bleeding risk. Randomized trials 
show comparable safety and efficacy with minimally interrupted OAC 
(withholding the morning DOAC dose on the day of the procedure) 
and a totally uninterrupted peri-ablation OAC strategy.655
Anticoagulation with heparin during AF ablation is common 
practice.554 Post-ablation DOACs should be continued as per the 
dosing regimen when haemostasis has been achieved.335,554,647 All 
patients should be kept on an OAC for at least 2 months after an 
AF ablation procedure irrespective of estimated thromboembolic 
risk 
(see 
Supplementary 
data 
online, 
Additional 
Evidence 
Table S23).647 Meta-analyses of observational studies have tried to as­
sess the safety of stopping OAC treatment after catheter ablation for 
AF, but the results have been heterogenous.660–663 Until the comple­
tion of relevant RCTs (e.g. NCT02168829), it is recommended to 
continue OAC therapy post-AF ablation according to the patient’s 
CHA2DS2-VA score and not the perceived success of the ablation 
procedure.554
7.2.7. Endoscopic and hybrid AF ablation
Minimally invasive surgical AF ablation can be performed via a thoraco­
scopic approach or a subxiphoid approach. The term endoscopic cov­
ers both strategies. Hybrid ablation approaches have been developed 
where endoscopic epicardial ablation on the beating heart is performed 
in combination with endocardial catheter ablation, either in a simultan­
eous or sequential procedure. The rationale for combining an endocar­
dial with an epicardial approach is that a more effective transmural 
ablation strategy can be pursued.666,667
For paroxysmal AF, an endoscopic or hybrid ablation approach may 
be considered after a failed percutaneous catheter ablation strat­
egy.668–670 Long-term follow-up of the FAST RCT (mean of 7.0 years), 
which included patients with paroxysmal and persistent AF, found ar­
rhythmia recurrence was common but substantially lower with thor­
acoscopic ablation than catheter ablation: 34/61 patients (56%) 
compared with 55/63 patients (87%), with P < .001 for the compari­
son.669 For persistent AF, endoscopic or hybrid ablation approaches 
are suitable as a first procedure to maintain long-term sinus rhythm 
in selected patients.667–672 A meta-analysis of three RCTs confirmed 
a lower rate of atrial arrhythmia recurrence after thoracoscopic vs. 
catheter ablation (incidence rate ratio, 0.55; 95% CI, 0.38–0.78; 
with no heterogeneity between trials).669 An RCT with 12 month 
follow-up published after the meta-analysis in patients with long- 
standing persistent AF found no difference in arrhythmia freedom 
comparing thoracoscopic with catheter ablation.673 Although overall 
morbidity and mortality of both techniques is low, endoscopic and hy­
brid ablation have higher complication rates than catheter ablation, 
but similar long-term rates of the composite of mortality, MI, or 
stroke.667,669
More recent trials have assessed the efficacy and safety of the hybrid 
epicardial-plus-endocardial approach in persistent AF refractory to 
AAD therapy, including a single-centre RCT670 and two multicentre 
RCTs.671,674 Across these trials, hybrid ablation was consistently super­
ior to catheter ablation alone for maintaining long-term sinus rhythm, 
without significant differences in major adverse events. Notably, these 
studies were typically performed in highly experienced centres (see 
Supplementary data online, Additional Evidence Table S24).
Similar to other rhythm control approaches, this task force recom­
mends that OAC are continued in all patients who have a risk of 
thromboembolism, irrespective of rhythm outcome, and regardless 
of LAA exclusion performed as part of the surgical procedure.
Recommendation Table 21 — Recommendations for 
endoscopic and hybrid AF ablation (see also Evidence 
Table 21)
Recommendations
Classa
Levelb
Continuation of oral anticoagulation is 
recommended in patients with AF at elevated 
thromboembolic risk after concomitant, endoscopic, 
or hybrid AF ablation, independent of rhythm 
outcome or LAA exclusion, to prevent ischaemic 
stroke and thromboembolism.
I
C
Continued 
Recommendation Table 20 — Recommendations for 
anticoagulation in patients undergoing catheter ablation 
(see also Evidence Table 20)
Recommendations
Classa
Levelb
Initiation of oral anticoagulation is recommended at 
least 3 weeks prior to catheter-based ablation in AF 
patients at elevated thromboembolic risk, to prevent 
peri-procedural ischaemic stroke and 
thromboembolism.554,647
I
C
Uninterrupted oral anticoagulation is recommended 
in patients undergoing AF catheter ablation to 
prevent peri-procedural ischaemic stroke and 
thromboembolism.664,665
I
A
Continuation of oral anticoagulation is 
recommended for at least 2 months after AF ablation 
in all patients, irrespective of rhythm outcome or 
CHA2DS2-VA score, to reduce the risk of 
peri-procedural ischaemic stroke and 
thromboembolism.554,663
I
C
Continuation of oral anticoagulation is 
recommended after AF ablation according to the 
patient’s CHA2DS2-VA score, and not the perceived 
success of the ablation procedure, to prevent 
ischaemic stroke and thromboembolism.554
I
C
Cardiac imaging should be considered prior to 
catheter ablation of AF in patients at high risk of 
ischaemic stroke and thromboembolism despite 
taking oral anticoagulation to exclude 
thrombus.649,650
IIa
B
© ESC 2024
AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 
points), 
diabetes 
mellitus, 
prior 
stroke/transient 
ischaemic 
attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

7.2.8. AF ablation during cardiac surgery
Atrial fibrillation is a significant risk factor for early mortality, late mor­
tality, and stroke in patients referred for cardiac surgery.675–677 The 
best validated method of surgical ablation is the Maze procedure, 
consisting of a pattern of transmural lesions including PVI, with 
subsequent modifications using bipolar radiofrequency and/or 
cryothermy ablation with LAA amputation (see Supplementary data 
online, Additional Evidence Table S25).678–681 Education and training, 
close co-operation within a multidisciplinary team, and shared 
decision-making can improve the quality and outcomes of surgical 
ablation.682
A number of RCTs have shown that surgical AF ablation during 
cardiac surgery increases freedom from arrhythmia recur­
rence.683–688 Performing surgical AF ablation, mainly targeting 
those patients needing mitral valve surgery, is not associated with 
increased morbidity or mortality.678,683–685 Observational data, 
including large registries, have supported the potential value of 
surgical AF ablation,689–700 but further RCTs are needed to evaluate 
which patients should be selected, and whether this approach 
contributes to the prevention of stroke, thromboembolism, and 
death.
Data on pacemaker implantation rates after surgical AF ablation 
are variable and are likely influenced by centre experience and the 
patients treated (e.g. underlying sinus node disease). In a systematic 
review of 22 RCTs (1726 patients), permanent pacemaker implant­
ation rates were higher with surgical AF ablation than without con­
comitant AF surgery (6.0% vs. 4.1%; RR, 1.69; 95% CI, 1.12–2.54).701
Observational registry data from contemporary cohorts (2011– 
2020) suggest an overall pacemaker rate post-operatively of 2.1% 
in patients selected for surgical AF ablation, with no discernible 
impact of surgical ablation on the need for a pacemaker, but 
higher rates in those needing multivalve surgery.702 With a safety- 
first approach in mind, imaging is advised during surgical AF ablation 
to exclude thrombus and help to plan the surgical approach 
(e.g. with TOE), regardless of effective pre-procedural anticoagulant 
use.
7.2.9. Atrial tachycardia after pulmonary vein 
isolation
After any ablation for AF, recurrent arrhythmias may manifest as AF, 
but also as atrial tachycardia (AT). Although AT may be perceived as 
a step in the right direction by the treating physician, this view is often 
not shared by the patient because AT can be equally or more symptom­
atic than the original AF. Conventionally, an early arrhythmia recur­
rence post-PVI (whether AT, AF, or flutter) is considered potentially 
transitory.708 Recent trials using continuous implantable loop recorders 
for peri-procedural monitoring have provided insight into the incidence 
and significance of early arrhythmia recurrences, and have confirmed a 
link between early and later recurrence.709 Discussion of management 
options for AT post-ablation should ideally involve a multidisciplinary 
team with experience in interventional management of complex ar­
rhythmias, considering technical challenges, procedural efficacy, and 
safety, in the context of patient preferences.
8. [E] Evaluation and dynamic 
reassessment
The development and progression of AF results from continuous 
interactions between underlying mechanisms (electrical, cellular, 
neurohormonal, and haemodynamic), coupled with a broad range of 
clinical factors and associated comorbidities. Each individual factor 
Endoscopic and hybrid ablation procedures should 
be considered in patients with symptomatic 
persistent AF refractory to AAD therapy to 
prevent symptoms, recurrence, and progression of 
AF, within a shared decision-making rhythm 
control team of electrophysiologists and 
surgeons.667–671,674
IIa
A
Endoscopic and hybrid ablation procedures may 
be considered in patients with symptomatic 
paroxysmal AF refractory to AAD therapy and 
failed percutaneous catheter ablation strategy to 
prevent symptoms, recurrence, and progression of 
AF, within a shared decision-making rhythm 
control team of electrophysiologists and 
surgeons.668,669
IIb
B
© ESC 2024
AAD, antiarrhythmic drugs; AF, atrial fibrillation; LAA, left atrial appendage. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 22 — Recommendations for 
AF ablation during cardiac surgery (see also Evidence 
Table 22)
Recommendations
Classa
Levelb
Concomitant surgical ablation is recommended in 
patients undergoing mitral valve surgery and AF 
suitable for a rhythm control strategy to prevent 
symptoms and recurrence of AF, with shared 
decision-making supported by an experienced team 
of electrophysiologists and arrhythmia surgeons.683– 
685,701
I
A
Intraprocedural imaging for detection of left atrial 
thrombus in patients undergoing surgical ablation is 
recommended to guide surgical strategy, 
independent of oral anticoagulant use, to prevent 
peri-procedural ischaemic stroke and 
thromboembolism.
I
C
Concomitant surgical ablation should be considered 
in patients undergoing non-mitral valve cardiac 
surgery and AF suitable for a rhythm control strategy 
to prevent symptoms and recurrence of AF, with 
shared decision-making supported by an 
experienced team of electrophysiologists and 
arrhythmia surgeons.701,703–707
IIa
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3361


<!-- PAGE 49 -->

### Page 49

has considerable variability over time, affecting its contribution to the 
AF-promoting substrate. The risk profile of each patient is also far 
from static, and requires a dynamic mode of care to ensure optimal 
AF management.710,711 Patients with AF require periodic reassessment 
of therapy based on this changing risk status if we are to improve the 
overall quality of care. Timely attention to modifiable factors and 
underpinning comorbidities has the potential to slow or reverse the 
progression of AF, increase quality of life, and prevent adverse out­
comes such as heart failure, thromboembolism, and major bleeding.
The [E] in AF-CARE encompasses the range of activity needed by 
healthcare professionals and patients to: (i) thoroughly evaluate asso­
ciated comorbidities and risk factors that can guide treatment; and 
(ii) provide the dynamic assessment needed to ensure that treatment 
plans remain suited to that particular patient. This task force recom­
mends an adaptive strategy that not only reacts to changes notified 
by a patient, but also proactively seeks out issues where altering man­
agement could impact on patient wellbeing. Avoidance of unnecessary 
and costly follow-up is also inherent in this framework, with educated 
and empowered patients contributing to identifying the need for access 
to specialist care or an escalation of management. The patient-centred, 
shared decision philosophy is embedded to improve efficiency in mod­
els of care and to address the needs of patients with AF.
Medical history and the results of any tests should be regularly re- 
evaluated to address the dynamic nature of comorbidities and risk fac­
tors.712 This may have impact on therapeutic decisions; e.g. resumption 
of full-dose DOAC therapy after improvement in the patient’s renal 
function. The timing of review of the AF-CARE pathway is patient spe­
cific and should respond to changes in clinical status. In most cases, this 
task force advises re-evaluation 6 months after initial presentation, and 
then at least annually by a healthcare professional in primary or second­
ary care (see Figure 3).
8.1. Implementation of dynamic care
A multidisciplinary-based approach is advocated to improve implemen­
tation of dynamic AF-CARE (see Figure 2); although potentially re­
source intensive, this is preferred to more simplistic or opportunistic 
methods. For example, in a pragmatic trial of 47 333 AF patients iden­
tified through health insurance claims, there was no difference in OAC 
initiation at 1 year in those randomized to a single mailout of patient and 
clinician education, compared with those in the usual care group.713 For 
co-ordination of care there is a core role for cardiologists, general prac­
titioners, specialized nurses, and pharmacists.714 If needed, and depend­
ing on local resources, others may also be involved (cardiac surgeons, 
physiotherapists, neurologists, psychologists, and other allied health 
professionals). It is strongly advocated that one core team member co- 
ordinates care, and that additional team members become involved ac­
cording to the needs of the individual patient throughout their AF 
trajectory.
Several organizational models of integrated care for AF have been 
evaluated, but which components are most useful remains unclear. 
Some models include a multidisciplinary team,715,716 while others are 
nurse-led79,122,124,717 or cardiologist-led.79,122,124,717 Several published 
models used computerized decision support systems or electronic 
health applications.79,122,715,718 Evaluation within RCTs has demon­
strated mixed results due to the variety of methods tested and differ­
ences in regional care. Several studies report significant improvements 
with respect to adherence to anticoagulation, cardiovascular mortality, 
and hospitalization relative to standard of care.121–123 However, the 
RACE 4 (IntegRAted Chronic Care Program at Specialized AF Clinic 
Versus Usual CarE in Patients with Atrial Fibrillation) trial, which in­
cluded 1375 patients, failed to demonstrate superiority of nurse-led 
over usual care.79 New studies of the components and optimal models 
for delivery for integrated care approaches in routine practice are on­
going (ACTRN12616001109493, NCT03924739).
8.2. Improving treatment adherence
Advances in the care of patients with AF can only be effective if appro­
priate tools are available to support the implementation of the treat­
ment regimen.719 A number of factors are related to the optimal 
implementation of care at the level of: (i) the individual patient (culture, 
cognitive impairment, and psychological status); (ii) the treatment 
(complexity, side effects, polypharmacy, impact on daily life, and 
cost); (iii) the healthcare system (access to treatment and multidiscip­
linary approach); and (iv) the healthcare professional (knowledge, 
awareness of guidelines, expertise, and communication skills). A collab­
orative approach to patient care, based upon shared decision-making 
and goals tailored to individual patient needs, is crucial in promoting on­
going patient adherence to the agreed treatment regimen.720 Even 
when treatment seems feasible for the individual, patients often lack ac­
cess to reliable and up-to-date information about risks and benefits of 
various treatment options, and consequently are not empowered to 
engage in their own management. A sense of ownership that promotes 
the achievement of joint goals can be encouraged through the use of 
educational programmes, websites (such as https://afibmatters.org), 
app-based tools, and individually tailored treatment protocols which 
take into account gender, ethnic, socioeconomic, environmental, and 
work factors. In addition, practical tools (e.g. schedules, apps, bro­
chures, reminders, pillboxes) can help to implement treatment in daily 
life.721,722 Regular review by members of the multidisciplinary team en­
ables the evolution of a flexible and responsive management regimen 
that the patient will find easier to follow.
8.3. Cardiac imaging
A TTE is a valuable asset across all four AF-CARE domains when 
there are changes in the clinical status of an individual patient 
(Figure 13).723–725 The key findings to consider from an echocardiogram 
are any structural heart disease (e.g. valvular disease or left ventricular 
hypertrophy), impairment of left ventricular function (systolic and/or 
diastolic to classify heart failure subtype), left atrial dilatation, and right 
heart dysfunction.59,67,726 To counter irregularity when in AF, obtaining 
measurements in cardiac cycles that follow two similar RR intervals can 
improve the value of parameters compared with sequential averaging of 
cardiac cycles.723,727 Contrast TTE or alternative imaging modalities 
may be required where image quality is poor, and quantification of 
left ventricular systolic function is needed for decisions on rate or 
rhythm control. Other cardiac imaging techniques, such as cardiac mag­
netic resonance (CMR), CT, TOE, and nuclear imaging can be valuable 
when: (i) TTE quality is suboptimal for diagnostic purposes; (ii) addition­
al information is needed on structure, substrate, or function; and (iii) to 
support decisions on interventional procedures (see Supplementary 
data online, Figure S1).59,724,725,728 As with TTE, other types of cardiac 
imaging can be challenging in the context of AF irregularity or with rapid 
heart rate, requiring technique-specific modifications when acquiring 
ECG-gated sequences.729–731


<!-- PAGE 50 -->

### Page 50

8.4. Patient-reported outcome measures
Patients with AF have a lower quality of life compared with the general 
population.732 Improvement in quality of life and functional status should 
play a key role in assessing and reassessing treatment decisions (see 
Supplementary data online, Additional Evidence Table S26).36
Patient-reported outcome measures are valuable to measure quality of 
life, functional status, symptoms, and treatment burden for patients 
with AF over time.55,733–735 Patient-reported outcome measures are 
playing an increasing role in clinical trials to assess the success of treat­
ment; however, they remain under-utilized.736,737 They can be divided 
into generic or disease-specific tools, with the latter helping to provide 
insight into AF-related impacts.738 However, multimorbidity can still con­
found the sensitivity of all PROMs, impacting on association with other 
established metrics of treatment performance such as mEHRA symptom 
AF-CARE
pathway
Objective for imaging
To identify comorbidities which are associated with recurrence and progression of AF
To determine stroke risk, choice of anticoagulant drug and ensure safety for cardioversion
To determine optimal choice of rate and rhythm control strategy and likely success of ablation
To detect changes in the patient's heart structure and function which would affect their management plan
C
Comorbidity and risk factor management
R
Reduce symptoms by rate and rhythm control
Avoid stroke and thromboembolism
A
Evaluation and dynamic reassessment
E
Assessment
Left ventricular ejection fraction, 
wall motion abnormalities, diastolic indices, right ventricular function and 
left ventricular hypertrophy to determine subtype and aetiology of heart failure
Detection of valvular disease
Detection of pericardial fluid or pericardial disease
Detection of heart failure for
CHA2DS2-VA score
Transoesophageal echocardiogram for left atrial appendage assessment to exclude thrombus prior to cardioversion
Detection of moderate-severe mitral stenosis to determine choice of anticoagulation
Reassess known valve disease for increase in severity
Reassess left ventricular size and function if there is a change in the patient’s clinical status or symptoms
Left ventricular ejection fraction to determine choice of rate control
Left ventricular size and function to determine choice of rhythm control
Severity of valvular disease to determine choice of rhythm control
Left atrial size and function to determine risk of arrhythmia recurrence following ablation
Example of pathology
Cardiac amyloid
Clot in LAA
Severe LV
impairment
Mixed mitral valve disease
Figure 13 Relevance of echocardiography in the AF-CARE pathway. AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk fac­
tor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; 
CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years; LAA, left atrial appendage; LV, left ventricle.
ESC Guidelines                                                                                                                                                                                          3363


<!-- PAGE 51 -->

### Page 51

class and natriuretic peptides.48 Intervention studies have demonstrated 
an association between improvement in PROM scores and reduction in 
AF burden and symptoms.48,738
Atrial fibrillation-specific questionnaires include the AF 6 (AF6),739
Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT),740 the Atrial 
Fibrillation Quality of Life Questionnaire (AFQLQ),741 the Atrial 
Fibrillation Quality of Life (AF-QoL),742 and the Quality of Life in 
Atrial Fibrillation (QLAF).743 The measurement properties of most of 
these tools lack sufficient validation.49 The International Consortium 
for Health Outcomes Measurement (ICHOM) working group recom­
mends the use of the AFEQT PROM or a symptom questionnaire called 
the Atrial Fibrillation Severity Scale (AFSS) for measuring exercise tol­
erance and the impact of symptoms in AF.744 Through wider use of pa­
tient experience measures, there is an opportunity at the institutional 
level to improve the quality of care delivered to patients with AF.49–55
9. The AF-CARE pathway in specific 
clinical settings
The following sections detail specific clinical settings where approaches 
to AF-CARE may vary. Unless specially discussed, measures for [C] co­
morbidity and risk factor management, [A] avoidance of stroke and 
thromboembolism, [R] rate and rhythm control, and [E] evaluation 
and dynamic reassessment should follow the standard pathways intro­
duced in Section 4.
9.1. AF-CARE in unstable patients
Unstable patients with AF include those with haemodynamic instability 
caused by the arrhythmia or acute cardiac conditions, and severely ill 
patients who develop AF (sepsis, trauma, surgery, and particularly 
cancer-related surgery). Conditions such as sepsis, adrenergic over­
stimulation, and electrolyte disturbances contribute to onset and recur­
rence of AF in these patients. Spontaneous restoration of sinus rhythm 
has been reported in up to 83% during the first 48 h after appropriate 
treatment of the underlying cause.551,745
Emergency electrical cardioversion is still considered the first-choice 
treatment if sinus rhythm is thought to be beneficial, despite the limita­
tion of having a high rate of immediate relapse.746 Amiodarone is a 
second-line option because of its delayed activity; however, it may be 
an appropriate alternative in the acute setting.747,748 In a multicentre co­
hort study carried out in the United Kingdom and the United States of 
America, amiodarone and beta-blockers were similarly effective for 
rate control in intensive care patients, and superior to digoxin and cal­
cium channel blockers.749 The ultra-short acting and highly selective beta- 
blocker landiolol can safely control rapid AF in patients with low ejection 
fraction and acutely decompensated heart failure, with a limited impact 
on myocardial contractility or blood pressure.477,750,751
9.2. AF-CARE in acute and chronic 
coronary syndromes
The incidence of AF in acute coronary syndromes (ACS) ranges from 
2% to 23%.752 The risk of new-onset AF is increased by 60%–77% in 
patients suffering an MI,753 and AF may be associated with an increased 
risk of ST-segment elevation myocardial infarction (STEMI) or 
non-STEMI ACS.754 Overall, 10%–15% of AF patients undergo percu­
taneous intervention (PCI) for CAD.755 In addition, AF is a common 
precipitant for type 2 MI.756 Observational studies show that patients 
with both ACS and AF are less likely to receive appropriate antithrom­
botic therapy757 and more likely to experience adverse outcomes.758
Peri-procedural management of patients with ACS or chronic coronary 
syndromes (CCS) are detailed in the 2023 ESC Guidelines for the man­
agement of acute coronary syndromes and 2024 ESC Guidelines for the 
management of chronic coronary syndromes.759,760
The combination of AF with ACS is the area where use of multiple 
antithrombotic drugs is most frequently indicated, consisting of antiplate­
let agents plus OAC (Figure 14) (see Supplementary data online, 
Additional Evidence Table S27). There is a general trend to decrease the 
duration of DAPT to reduce bleeding; however, this may increase ischae­
mic events and stent thrombosis.761,762 In ACS there is a high risk of pre­
dominantly platelet-driven atherothrombosis and thus of coronary 
ischaemic events. Acute coronary syndromes treated by PCI require 
DAPT for improved short- and long-term prognosis. Therefore, a peri- 
procedural triple antithrombotic regimen including an OAC, aspirin, and 
a P2Y12 inhibitor should be the default strategy for most patients. Major 
thrombotic events vs. major bleeding risk need to be balanced when pre­
scribing antiplatelet therapy and OAC after the acute phase and/or after 
PCI. The combination of OAC (preferably a DOAC) and a P2Y12 inhibi­
tor results in less major bleeding than triple therapy that includes aspirin. 
Clopidogrel is the preferred P2Y12 inhibitor, as the evidence for ticagre­
lor and prasugrel is less clear with higher bleeding risk.763–769 Ongoing 
trials will add to our knowledge about safely combining DOACs with 
antiplatelet agents (NCT04981041, NCT04436978). When using 
VKAs with antiplatelet agents, there is consensus opinion to use an 
INR range of 2.0–2.5 to mitigate excess bleeding risk.
Short–term triple therapy (≤1 week) is recommended for all pa­
tients without diabetes after ACS or PCI. In pooled analyses of 
RCTs, omitting aspirin in patients with ACS undergoing PCI has 
the potential for higher rates of ischaemic/stent thrombosis, without 
impact on incident stroke.761,762,770–772 None of the trials were 
powered for ischaemic events. All patients in AUGUSTUS (an open– 
label, 2 × 2 factorial, randomized controlled clinical trial to evaluate 
the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin pla­
cebo in patients with AF and ACS or PCI) received aspirin plus a P2Y12 
inhibitor for a median time of 6 days.773 At the end of the trial, apixaban 
and a P2Y12 inhibitor without aspirin was the optimal treatment regi­
men for most patients with AF and ACS and/or PCI, irrespective of 
the patient’s baseline bleeding and stroke risk.774,775
Recommendation Table 23 — Recommendations to 
improve patient experience (see also Evidence Table 23)
Recommendations
Classa
Levelb
Evaluating quality of care and identifying 
opportunities for improved treatment of AF should 
be considered by practitioners and institutions to 
improve patient experiences.49–55
IIa
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 52 -->

### Page 52

Prolonged triple therapy up to 1 month after ACS/PCI should 
be considered in patients at high ischaemic risk, e.g. STEMI, 
prior stent thrombosis, complex coronary procedures, and pro­
longed cardiac instability, even though these patients were not 
adequately represented in the RCTs so far available.776 In AF 
patients with ACS or CCS and diabetes mellitus undergoing 
coronary stent implantation, prolonging triple therapy with low- 
dose aspirin, clopidogrel, and an OAC up to 3 months may be 
of benefit if thrombotic risk outweighs bleeding risk in the individ­
ual patient.207
When using VKA in combination with antiplatelet therapy, keep INR 2.0–2.5 and TTR >70%
(Class IIa)
VKA: INR 2.0–3.0
(Class I)
Clopidogrel is the preferred P2Y12i when combining with any OAC
Use the appropriate DOAC dosea.  A reduced dose is not recommended unless the patient meets DOAC-specific criteriaa
(Class III)
DOACs rather than VKA are recommended in eligible patients when combining with antiplatelet therapy
(Class I)
ACS, PCI or CCS
Up to 1 week
1 month
6 months
12 months
CCS
uncomplicated
PCI
CCS high ischaemic riskb
OAC + P2Y12i
+ aspirin
(Class I)
OAC only (Class I)
ACS
undergoing
PCI
OAC + P2Y12i (Class I)
OAC + P2Y12i
+ aspirin 
(Class I)
OAC only (Class I)
OAC + P2Y12i (Class I)
Stable CCS
OAC + P2Y12i
+ aspirin
(Class IIa)
OAC only (Class I)
OAC + P2Y12i (Class I)
ACS high ischaemic riskb
OAC + P2Y12i
+ aspirin
(Class IIa)
OAC only (Class I)
OAC + P2Y12i (Class I)
ACS
medically managed
OAC only
OAC only
OAC + P2Y12i
Figure 14 Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes. ACS, acute coronary syndromes; CCS, chronic 
coronary syndrome; DOAC, direct oral anticoagulant; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; P2Y12i, 
P2Y12-receptor inhibitor antiplatelet agents (clopidogrel, prasugrel, ticagrelor); PCI, percutaneous intervention; TTR, time in therapeutic range; 
VKA, vitamin K antagonist. The flowchart applies to those patients with an indication for oral anticoagulant therapy. aThe full standard dose of 
DOACs should be used unless the patient fulfils dose-reduction criteria (Table 11). When rivaroxaban or dabigatran are used as the DOAC and con­
cerns about bleeding risk prevail over stent thrombosis or ischaemic stroke, the reduced dose should be considered (15 mg and 110 mg respectively; 
Class IIa). bIn patients with diabetes mellitus undergoing coronary stent implantation, prolonging triple antithrombotic therapy for up to 3 months may 
be of value if thrombotic risk outweighs the bleeding risk.
ESC Guidelines                                                                                                                                                                                          3365


<!-- PAGE 53 -->

### Page 53

The evidence for ACS treated without revascularization is 
limited. Six to 12 months of a single antiplatelet agent in addition to a 
long-term DOAC is usually sufficient and can minimize bleeding 
risk.760,764,774 Although there are no head-to-head comparisons be­
tween aspirin and clopidogrel, studies have typically used clopidogrel. 
In patients with stable CCS for more than 12 months, sole 
therapy with a DOAC is sufficient and no additional antiplatelet therapy 
is required.353 In patients at potential risk of gastrointestinal bleeding, 
use of proton pump inhibitors is reasonable during combined 
antithrombotic therapy, although evidence in AF patients is 
limited.437,777–779 Multimorbid patients with ACS or CCS need careful 
assessment of ischaemic risk and management of modifiable bleeding 
risk factors, with a comprehensive work-up to individually adapt 
antithrombotic therapy.
9.3. AF-CARE in vascular disease
Peripheral arterial disease (PAD) is common in patients with AF, ran­
ging from 6.7% to 14% of patients.783,784 Manifest PAD is associated 
with incident AF.785 PAD predicts a higher mortality in patients with 
AF and is an independent predictor of stroke in those not on 
OAC.783,786 Patients with lower extremity artery disease and AF 
also have a higher overall mortality and risk of major cardiac 
events.784,787,788 A public health database of >40 000 patients 
hospitalized for PAD or critical limb ischaemia showed AF to be an 
independent predictor for mortality (HR, 1.46; 95% CI, 1.39–1.52) 
and ischaemic stroke (HR, 1.63; 95% CI, 1.44–1.85) as compared 
with propensity-matched controls.784 Similarly, in patients undergoing 
carotid endarterectomy or stenting, the presence of AF is associated 
with higher mortality (OR, 1.59; 95% CI, 1.11–2.26).789
Anticoagulation alone is usually sufficient in the chronic disease 
phase, with DOACs being the preferred agents despite one RCT sub­
analysis showing a higher risk of bleeding as compared with warfarin.790
In the case of recent endovascular revascularization, a period of com­
bination with single antiplatelet therapy should be considered, weighing 
bleeding and thrombotic risks and keeping the period of combination 
antithrombotic therapy as brief as possible (ranging between 1 month 
for peripheral791 and 90 days for neuro-interventional procedures).792
9.4. AF-CARE in acute stroke or 
intracranial haemorrhage
9.4.1. Management of acute ischaemic stroke
Management of acute stroke in patients with AF is beyond the scope of 
these guidelines. In AF patients presenting with acute ischaemic stroke 
while taking OAC, acute therapy depends on the treatment regimen 
and intensity of OAC. Management should be co-ordinated by a spe­
cialist neurologist team according to relevant guidelines.793
Recommendation Table 24 — Recommendations for 
patients with acute coronary syndromes or undergoing 
percutaneous intervention (see also Evidence Table 24)
Recommendations
Classa
Levelb
General recommendations for patients with AF and an 
indication for concomitant antiplatelet therapy
For combinations with antiplatelet therapy, a DOAC 
is recommended in eligible patients in preference to a 
VKA to mitigate bleeding risk and prevent 
thromboembolism.764,766
I
A
Rivaroxaban 15 mg once daily should be considered 
in preference to rivaroxaban 20 mg once daily when 
combined with antiplatelet therapy in patients where 
concerns about bleeding risk prevail over concerns 
about stent thrombosis or ischaemic stroke.765
IIa
B
Dabigatran 110 mg twice daily should be considered 
in preference to dabigatran 150 mg twice daily when 
combined with antiplatelet therapy in patients where 
concerns about bleeding risk prevail over concerns 
about stent thrombosis or ischaemic stroke.766
IIa
B
Carefully regulated VKA dosing with a target INR of 
2.0–2.5 and TTR >70% should be considered when 
combined with antiplatelet therapy in AF patients to 
mitigate bleeding risk.
IIa
C
Recommendations for AF patients with ACS
Early cessation (≤1 week) of aspirin and continuation 
of an oral anticoagulant (preferably DOAC) with a 
P2Y12 inhibitor (preferably clopidogrel) for up to 12 
months is recommended in AF patients with ACS 
undergoing an uncomplicated PCI to avoid major 
bleeding, if the risk of thrombosis is low or bleeding 
risk is high.764–767
I
A
Triple therapy with aspirin, clopidogrel, and oral 
anticoagulation for longer than 1 week after an ACS 
should be considered in patients with AF when 
ischaemic risk outweighs the bleeding risk, with the 
total duration (≤1 month) decided according to 
assessment of these risks and clear documentation of 
the discharge treatment plan.776
IIa
C
Continued 
Recommendations for AF patients undergoing PCI
After uncomplicated PCI, early cessation (≤1 week) 
of aspirin and continuation of an oral anticoagulant 
and a P2Y12 inhibitor (preferably clopidogrel) for up 
to 6 months is recommended to avoid major 
bleeding, if ischaemic risk is low.763–766,776,780
I
A
Triple therapy with aspirin, clopidogrel, and an oral 
anticoagulant for longer than 1 week should be 
considered after PCI when the risk of stent 
thrombosis outweighs the bleeding risk, with the total 
duration (≤1 month) decided according to 
assessment of these risks and clear documentation.776
IIa
B
Recommendations for AF patients with chronic coronary or 
vascular disease
Antiplatelet therapy beyond 12 months is not 
recommended in stable patients with chronic 
coronary or vascular disease treated with oral 
anticoagulation, due to lack of efficacy and to avoid 
major bleeding.353,781,782
III
B
© ESC 2024
ACS, acute coronary syndromes; AF, atrial fibrillation; DOAC, direct oral anticoagulant; 
INR, international normalized ratio of prothrombin time; PCI, percutaneous 
intervention; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

9.4.2. Introduction or re-introduction of 
anticoagulation after ischaemic stroke
The optimal time for administering OAC in patients with acute cardio­
embolic stroke and AF remains unclear. Randomized control trials have 
been unable to provide any evidence to support the administration of 
anticoagulants or heparin in patients with acute ischaemic stroke within 
48 h from stroke onset. This suggests that low-dose aspirin should be 
administered to all patients during this timeframe.794
Two trials have examined the use of DOAC therapy early after 
stroke, with no difference in clinical outcomes compared with delayed 
DOAC prescription. The ELAN (Early versus Late initiation of direct 
oral Anticoagulants in post-ischaemic stroke patients with atrial 
fibrillatioN) trial randomized 2013 patients with acute ischaemic stroke 
and AF to open-label early use of DOACs (<48 h after minor/moderate 
stroke; day 6–7 after major stroke) vs. later DOAC prescription (day 
3–4 after minor stroke; day 6–7 after moderate stroke; day 12–14 after 
major stroke). There was no significant difference in the composite 
thromboembolic, bleeding, and vascular death outcome at 30 days 
(risk difference early vs. late, −1.18%; 95% CI, −2.84 to 0.47).795 The 
TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic 
Stroke With Atrial Fibrillation) trial, a registry-based, non-inferiority, 
open-label, blinded endpoint trial randomized 888 patients within 
72 h of ischaemic stroke onset to early (≤4 days) or delayed (5–10 days) 
DOAC initiation. Early DOAC use was non-inferior to the delayed 
strategy for the composite of thromboembolism, bleeding and all-cause 
mortality at 90 days (risk difference, −1.79%; 95% CI, −5.31% to 
1.74%).796 Two ongoing trials will provide further guidance on the 
most appropriate timing of DOAC therapy after ischaemic stroke 
(NCT03759938, NCT03021928).
9.4.3. Introduction or re-introduction of 
anticoagulation after haemorrhagic stroke
There is insufficient evidence currently to recommend whether OAC 
should be started or re-started after ICH to protect against the high 
risk of ischaemic stroke in these patients (see Supplementary data 
online, Additional Evidence Table S28). Data from two pilot trials are avail­
able. The APACHE-AF (Apixaban After Anticoagulation-associated 
Intracerebral Haemorrhage in Patients With Atrial Fibrillation) trial 
was a prospective, randomized, open-label trial with masked endpoint as­
sessment; 101 patients who survived 7–90 days after anticoagulation- 
associated ICH were randomized to apixaban or no OAC. During a 
median of 1.9 years follow-up (222 person-years), there was no differ­
ence in non-fatal stroke or vascular death, with an annual event rate of 
12.6% with apixaban and 11.9% with no OAC (adjusted HR, 1.05; 95% 
CI, 0.48–2.31; P = .90).797 SoSTART (Start or STop Anticoagulants 
Randomised Trial) was an open-label RCT in 203 patients with AF after 
symptomatic spontaneous ICH. Starting OAC was not non-inferior to 
avoiding long-term (≥1 year) OAC, with ICH recurrence in 8/101 
(8%) vs. 4/102 (4%) patients (adjusted HR, 2.42; 95% CI, 0.72–8.09). 
Mortality occurred in 22/101 (22%) patients in the OAC group vs. 
11/102 (11%) patients where OAC were avoided.798
Until additional trials report on the clinical challenge of post-ICH an­
ticoagulation (NCT03950076, NCT03996772), an individualized multi­
disciplinary approach is advised led by an expert neurology team.
9.5. AF-CARE for trigger-induced AF
Trigger-induced AF is defined as new AF in the immediate association of a 
precipitating and potentially reversible factor. Also known as ‘secondary’ 
AF, this task force prefer the term trigger-induced as there are almost 
always underlying factors in individual patients that can benefit from full 
consideration of the AF-CARE pathway. The most common precipitant 
unmasking a tendency to AF is acute sepsis, where AF prevalence is 
between 9% and 20% and has been associated with a worse 
prognosis.11–14 The degree of inflammation correlates with the incidence 
of AF,799 which may partly explain the wide variability across studies in 
prevalence, as well as recurrence of AF. Longer-term data suggest that 
AF triggered by sepsis recurs after discharge in between a third to a half 
of patients.12,800–807In addition to other acute triggers which may be causal 
(such as alcohol808,809 and illicit drug use810), numerous conditions are also 
associated with chronic inflammation leading to subacute stimuli for AF 
(Table 14). The specific trigger of an operative procedure is discussed in 
Section 9.6.
After meeting the diagnostic criteria for AF (see Section 3.2), the 
management of trigger-induced AF is recommended to follow the 
AF-CARE principles, with critical consideration of underlying risk factors 
and comorbidities. Based on retrospective and observational data, patients 
with AF and trigger-induced AF seem to carry the same thromboembolic 
risk as patients with primary AF.811,812 In the acute phase of sepsis, patients 
show an unclear risk–benefit profile with anticoagulation therapy.813,814
Prospective studies on anticoagulation in patients with triggered AF epi­
sodes are lacking.802,812,815 Acknowledging that there are no RCTs specif­
ically available in this population to assess trigger-induced AF, long-term 
OAC therapy should be considered in suitable patients with trigger- 
induced AF who are at elevated risk of thromboembolism, starting 
OAC after the acute trigger has been corrected and considering the antici­
pated net clinical benefit and informed patient preferences. As with any de­
cision on OAC, not all patients will be suitable for OAC, depending on 
relative and absolute contraindications and the risk of major bleeding. 
The approach to rate and rhythm control will depend on subsequent re­
currence of AF or any associated symptoms, and re-evaluation should be 
individualized to take account of the often high AF recurrence rate.
Table 14 Non-cardiac conditions associated with 
trigger-induced AF
Acute conditions
Infections (bacterial and viral)
Pericarditis, myocarditis
Emergency conditions (burn injury, severe trauma, shock)
Binge alcohol consumption
Drug use, including methamphetamines, cocaine, opiates, and cannabis
Acute interventions, procedures, and surgery
Endocrine disorders (thyroid, adrenal, pituitary, others)
Chronic conditions with inflammation and enhanced AF 
substrate
Immune-mediated diseases (rheumatoid arthritis, systemic lupus 
erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, 
others)
Obesity
Chronic obstructive airways disease
Obstructive sleep apnoea
Cancer
Fatty liver disease
Stress
Endocrine disorders (see Section 9.10)
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3367


<!-- PAGE 55 -->

### Page 55

9.6. AF-CARE in post-operative patients
Peri-operative AF describes the onset of the arrhythmia during an 
ongoing intervention. Post-operative AF (POAF), defined as new- 
onset AF in the immediate post-operative period, is a common com­
plication with clinical impact that occurs in 30%–50% of patients 
undergoing cardiac surgery,816–818 and in 5%–30% of patients under­
going non-cardiac surgery. Intra- and post-operative changes and 
specific AF triggers (including peri-operative complications) and 
pre-existing AF-related risk factors and comorbidities increase the 
susceptibility to POAF.819 Although POAF episodes may be self- 
terminating, POAF is associated with 4–5 times increase in recurrent 
AF during the next 5 years,820,821 and is a risk factor for stroke, MI, 
heart failure, and death.822–827 Other adverse events associated 
with POAF include haemodynamic instability, prolonged hospital 
stay, infections, renal complications, bleeding, increased in-hospital 
death, and greater healthcare cost.828–830
While multiple strategies to prevent POAF with pre-treatment or acute 
drug treatment have been described, there is a lack of evidence from large 
RCTs. Pre-operative use of propranolol or carvedilol plus N-acetyl 
cysteine in cardiac and non-cardiac surgery is associated with a reduced 
incidence of POAF,831–834 but not major adverse events.835 An umbrella 
review of 89 RCTs from 23 meta-analyses (19 211 patients, but not neces­
sarily in AF) showed no benefit from beta-blockers in cardiac surgery for 
mortality, MI, or stroke. In non-cardiac surgery, beta-blockers were asso­
ciated with reduced rates of MI after surgery (RR range, 0.08–0.92), but 
higher mortality (RR range, 1.03–1.31), and increased risk of stroke (RR 
range, 1.33–7.72).836 Prevention of peri-operative AF can also be achieved 
with amiodarone. In a meta-analyses, amiodarone (oral or intravenous 
[i.v.]) and beta-blockers were equally effective in reducing post-operative 
AF,837 but their combination was better than beta-blockers alone.838
Lower cumulative doses of amiodarone (<3000 mg during the 
loading phase) could be effective, with fewer adverse events.837,839,840
Withdrawal of beta-blockers should be avoided due to increased risk 
of POAF.841 Other treatment strategies (steroids, magnesium, sotalol, 
(bi)atrial pacing, and botulium injection into the epicardial fat pad) lack 
scientific evidence for the prevention of peri-operative AF.842,843
Peri-operative posterior pericardiotomy, due to the reduction of post- 
operative pericardial effusion, showed a significant decrease in POAF 
in patients undergoing cardiac surgery (OR, 0.44; 95% CI, 0.27–0.70; 
P = .0005).844–846 In 3209 patients undergoing non-cardiac thoracic sur­
gery, colchicine did not lead to any significant reduction in AF compared 
with placebo (HR, 0.85; 95% CI, 0.65–1.10; P = .22).847
The evidence for prevention of ischaemic stroke in POAF by OAC 
is limited.822,827 Oral anticoagulant therapy is associated with a high 
bleeding risk soon after cardiac surgery or major non-cardiac inter­
ventions.827 Conversely, meta-analyses of observational cohort stud­
ies suggest a possible protective impact of OAC in POAF for all-cause 
mortality848 and a lower risk of thromboembolic events following car­
diac surgery, accompanied by higher rates of bleeding.849 This task 
force recommends to treat post-operative AF according to the 
AF-CARE pathway as discussed for trigger-induced AF (with the [R] 
pathway the same as for first-diagnosed AF). Ongoing RCTs in cardiac 
surgery (NCT04045665) and non-cardiac surgery (NCT03968393) 
will inform optimal long-term OAC use among patients with POAF. 
While awaiting the results of these trials, this task force recommends 
that after acute bleeding risk has settled, long-term OAC should be 
considered in patients with POAF according to their thromboembolic 
risk factors.
9.7. AF-CARE in embolic stroke of 
unknown source
The term ‘embolic stroke of undetermined source’ (ESUS) was introduced 
to identify non-lacunar strokes whose mechanism is likely to be embolic, 
but the source remains unidentified.856 Of note, these patients have a re­
current risk of stroke of 4%–5% per year.856 The main embolic sources as­
sociated with ESUS are concealed AF, atrial cardiomyopathy, left 
ventricular disease, atherosclerotic plaques, patent foramen ovale (PFO), 
valvular diseases, and cancer. Atrial cardiomyopathy and left ventricular dis­
ease are the most prevalent causes.856 AF is reported to be the underlying 
mechanism in 30% of ESUS patients.857–859 The detection of AF among 
ESUS patients increases the longer cardiac monitoring is provided (see 
Supplementary data online, Additional Evidence Table S29).857,860–864 This 
also holds for the duration of implantable cardiac monitoring, with prob­
ability of AF detection ranging from 2% with 1 week to over 20% by 3 
years.865 In patients with ESUS, factors associated with an increased detec­
tion of AF are increasing age,866,867 left atrial enlargement,866 cortical loca­
tion of stroke,868 large or small vessel disease,863 an increased number of 
Recommendation Table 26 — Recommendations for 
management of post-operative AF (see also Evidence 
Table 26)
Recommendations
Classa
Levelb
Peri-operative amiodarone therapy is recommended 
where drug therapy is desired to prevent 
post-operative AF after cardiac surgery.838,839,850,851
I
A
Concomitant posterior peri-cardiotomy should be 
considered in patients undergoing cardiac surgery to 
prevent post-operative AF.845,846
IIa
B
Long-term oral anticoagulation should be considered 
in patients with post-operative AF after cardiac and 
non-cardiac surgery at elevated thromboembolic 
risk, to prevent ischaemic stroke and 
thromboembolism.811,852–854
IIa
B
Routine use of beta-blockers is not recommended in 
patients undergoing non-cardiac surgery for the 
prevention of post-operative AF.836,855
III
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 25 — Recommendations for 
trigger-induced AF (see also Evidence Table 25)
Recommendation
Classa
Levelb
Long-term oral anticoagulation should be considered 
in suitable patients with trigger-induced AF at 
elevated thromboembolic risk to prevent ischaemic 
stroke and systemic thromboembolism.13,800,806,807,815
IIa
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 56 -->

### Page 56

atrial premature beats per 24 h,868 rhythm irregularity,859 and risk stratifi­
cation scores (such as CHA2DS2-VASc,869
Brown ESUS-AF,870
HAVOC,871 and C2HEST872). This task force recommends prolonged 
monitoring depending on the presence of the above-mentioned risk 
markers.865,873,874
Currently available evidence, including two completed RCTs and one 
stopped for futility, do not support the use of DOACs compared with 
aspirin in patients with acute ESUS without documented AF.875–877
Ongoing trials will provide further guidance (NCT05134454, 
NCT05293080, NCT04371055).
9.8. AF-CARE during pregnancy
Atrial fibrillation is one of the most common arrhythmias during preg­
nancy, with prevalence increasing due to higher maternal age and 
changes in lifestyle, and because more women with congenital heart dis­
ease survive to childbearing age.878–881 Rapid atrioventricular conduc­
tion of AF may have serious haemodynamic consequences for 
mother and foetus. AF during pregnancy is associated with an increased 
risk of death.882 A multidisciplinary approach is essential to prevent ma­
ternal and foetal complications, bringing together gynaecologists, neo­
natologists, anaesthesiologists, and cardiologists experienced in 
maternal medicine.883
Pregnancy is associated with a hypercoagulable state and increased 
thromboembolic risk.884 The same rules for risk assessment of 
thromboembolism should be used as in non-pregnant women, as de­
tailed in the 2018 ESC Guidelines for the management of cardiovascular 
diseases during pregnancy.885 The preferred agents for anticoagulation 
of AF during pregnancy are unfractionated or low molecular weight he­
parins (LMWHs), which do not cross the placenta. Vitamin K antago­
nists should be avoided in the first trimester (risk of miscarriage, 
teratogenicity) and from week 36 onwards (risk of foetal intracranial 
bleeding if early unexpected delivery). Direct oral anticoagulants are 
not recommended during pregnancy due to concerns about safety.886
However, an accidental exposure during pregnancy should not lead to a 
recommendation for termination of the pregnancy.887 Vaginal delivery 
should be advised for most women, but is contraindicated during VKA 
treatment because of the risk of foetal intracranial bleeding.885
Intravenous selective beta-1 receptor blockers are recommended as 
first choice for acute heart rate control of AF.888 This does not include 
atenolol, which can lead to intrauterine growth retardation.889 If beta- 
blockers fail, digoxin and verapamil can be considered for rate control 
(verapamil should be avoided in the first trimester). Rhythm control is 
the preferred strategy during pregnancy. Electrical cardioversion is re­
commended if there is haemodynamic instability, considerable risk to 
mother or foetus, or with concomitant HCM. Electrical cardioversion 
can be performed safely without compromising foetal blood flow, 
and the consequent risk for foetal arrhythmias or pre-term labour is 
low. The foetal heart rate should be closely monitored throughout 
and after cardioversion, which should generally be preceded by anticoa­
gulation.885 In haemodynamically stable women without structural 
heart disease, intravenous ibutilide or flecainide may be considered 
for termination of AF, but experience is limited.890 Catheter ablation 
is normally avoided during pregnancy,883 but is technically feasible with­
out radiation in refractory symptomatic cases with a minimal/zero 
fluoroscopy approach.883
Counselling is important in women of childbearing potential prior to 
pregnancy, highlighting the potential risks of anticoagulation and rate or 
rhythm control drugs (including teratogenic risk, where relevant). 
Contraception and timely switch to safe drugs should be proactively 
discussed.
Recommendation Table 27 — Recommendations for 
patients with embolic stroke of unknown source (see 
also Evidence Table 27)
Recommendations
Classa
Levelb
Prolonged monitoring for AF is recommended in 
patients with ESUS to inform on AF treatment 
decisions.861–863
I
B
Initiation of oral anticoagulation in ESUS patients 
without documented AF is not recommended due to 
lack of efficacy in preventing ischaemic stroke and 
thromboembolism.875,876
III
A
© ESC 2024
AF, atrial fibrillation; ESUS, embolic stroke of undetermined source. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 28 — Recommendations for 
patients with AF during pregnancy (see also Evidence 
Table 28)
Recommendations
Classa
Levelb
Immediate electrical cardioversion is recommended 
in patients with AF during pregnancy and 
haemodynamic instability or pre-excited AF to 
improve maternal and foetal outcomes.885,891–893
I
C
Therapeutic anticoagulation with LMWHs or VKAs 
(except VKAs for the first trimester or beyond 
Week 36) is recommended for pregnant patients 
with AF at elevated thromboembolic risk to prevent 
ischaemic stroke and thromboembolism.885
I
C
Beta-1 selective blockers are recommended for 
heart rate control of AF in pregnancy to reduce 
symptoms and improve maternal and foetal 
outcomes, excluding atenolol.888
I
C
Electrical cardioversion should be considered for 
persistent AF in pregnant women with HCM to 
improve maternal and foetal outcomes.885,894
IIa
C
Digoxin should be considered for heart rate control 
of AF in pregnancy, if beta-blockers are ineffective or 
not tolerated, to reduce symptoms and improve 
maternal and foetal outcomes.885
IIa
C
Intravenous ibutilide or flecainide may be considered 
for termination of AF in stable pregnant patients with 
a structurally normal heart to improve maternal and 
foetal outcomes.895,896
IIb
C
Flecainide or propafenone may be considered for 
longer-term rhythm control in pregnancy, if rate 
controlling drugs are ineffective or not tolerated, to 
reduce symptoms and improve maternal and foetal 
outcomes.885
IIb
C
© ESC 2024
AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy; LMWH, low molecular weight 
heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3369


<!-- PAGE 57 -->

### Page 57

9.9. AF-CARE in congenital heart disease
Survival of patients with congenital heart disease has increased over 
time, but robust data on the management of AF are missing and avail­
able evidence is derived mainly from observational studies. Oral anti­
coagulants are recommended for all patients with AF and intracardiac 
repair, cyanotic congenital heart disease, Fontan palliation, or systemic 
right ventricle irrespective of the individuals’ thromboembolic risk 
factors.897 Patients with AF and other congenital heart diseases should 
follow the general risk stratification for OAC use in AF (i.e. depending 
on the thromboembolic risk or CHA2DS2-VA score). Direct oral 
anticoagulants are contraindicated in patients with mechanical heart 
valves,331 but appear safe in patients with congenital heart dis­
ease,898,899 or those with a valvular bioprosthesis.900,901
Rate control drugs such as selective beta-1 receptor blockers, 
verapamil, diltiazem, and digoxin can be used with caution, with moni­
toring for bradycardia and hypotension. Rhythm control strategies such 
as amiodarone may be effective, but warrant monitoring for bradycar­
dia. When cardioversion is planned, both 3 weeks of OAC and TOE 
should be considered because thrombi are common in patients with 
congenital heart disease and atrial arrhythmias.902,903 Ablation ap­
proaches can be successful in patients with congenital heart disease, 
but AF recurrence rates may be high (see Supplementary data online, 
Additional Evidence Table S30).
In patients with atrial septal defect, closure may be performed be­
fore the fourth decade of life to decrease the risk of AF or AFL.904
Patients with stroke who underwent closure of their PFO may have 
an increased risk of AF,905 but in patients with PFO and AF, PFO clos­
ure is not recommended for stroke prevention. AF surgery or cath­
eter ablation can be considered at the time of closure of the atrial 
septal defect within a multidisciplinary team.906–908 AF catheter 
ablation of late atrial arrhythmias is likely to be effective after surgical 
atrial septal closure.909
9.10. AF-CARE in endocrine disorders
Endocrine dysfunction is closely related to AF, both as the direct action 
of endocrine hormones and as a consequence of treatments for endo­
crine disease. Optimal management of endocrine disorders is therefore 
part of the AF-CARE pathway.910,911
Clinical and subclinical hyperthyroidism, as well as subclinical hypo­
thyroidism, are associated with an increased risk of AF.912,913 Patients 
presenting with new-onset or recurrent AF should be tested for 
thyroid-stimulating hormone (TSH) levels. The risk of AF is enhanced 
in vulnerable patients, including the elderly and those with structural 
atrial diseases,914,915 as well as cancer patients on immune checkpoint 
inhibitors.916,917 In hyperthyroidism, and even in the euthyroid range, 
the risk of AF increases according to the reduction in TSH and elevated 
levels of thyroxine.918,919 Moreover, the risk of stroke is higher in 
patients with hyperthyroidism, which can be mitigated by treating the 
thyroid disorder.920,921 Amiodarone induces thyroid dysfunction in 
15%–20% of treated patients, leading to both hypo- and hyperthyroid­
ism,922,923 which warrants referral to an endocrinologist (see 
Supplementary data online for further details).
Hypercalcaemia may also induce arrhythmias, but the role of primary 
hyperparathyroidism in incident AF is poorly studied. Surgical para­
thyroidectomy has been found to reduce both supraventricular and ven­
tricular premature beats.924–926 Primary aldosteronism is related to an 
increased risk of AF through direct actions and vascular effects,927,928
with a three-fold higher rate of incident AF compared with patients 
with essential hypertension.929 Increases in genetically predicted plasma 
cortisol are associated with greater risk of AF, and patients with adrenal 
incidentalomas with subclinical cortisol secretion have a higher preva­
lence of AF.930,931 Acromegaly may predispose to an increased sub­
strate for AF, with incident AF rates significantly higher than controls 
in long-term follow-up, even after adjusting for AF risk factors.932
The association between type 2 diabetes and AF is discussed in 
Sections 5.3 (AF recurrence) and Section 10.5 (incident AF). In addition 
to insulin-resistance mechanisms typical of type 2 diabetes, the loss of 
insulin signalling has recently been associated with electrical changes 
that can lead to AF. Type 1 diabetes is associated with an increased 
risk of several cardiovascular diseases including AF.933–937
9.11. AF-CARE in inherited 
cardiomyopathies and primary 
arrhythmia syndromes
A higher incidence and prevalence of AF have been described in pa­
tients with inherited cardiomyopathies and primary arrhythmia syn­
dromes.271,938–970 AF can be the presenting or only clinically overt 
feature.969,971–975 AF in these patients is associated with adverse clinical 
outcomes,947,954,959,963,965,976–978 and has important implications on 
management (see Supplementary data online, Additional Evidence 
Table S31). When AF presents at a young age, there should be a careful 
interrogation about family history and a search for underlying 
disease.979
Rhythm control approaches may be challenging in patients with inher­
ited cardiomyopathies and primary arrhythmia syndromes. For example, 
many drugs have a higher risk of adverse events or may be contraindicated 
(e.g. amiodarone and sotalol in congenital long QT syndrome, and Class IC 
AADs in Brugada syndrome) (see Supplementary Data online, Table S6). 
Owing to long-term adverse effects, chronic use of amiodarone is prob­
lematic in these typically young individuals. In patients with an implantable 
cardioverter defibrillator, AF is a common cause of inappropriate 
shocks.959,966,980,981 Programming a single high-rate ventricular fibrillation 
zone ≥210–220 b.p.m. with long detection time is safe,950,953,982 and is 
suggested in patients without documented slow monomorphic ventricu­
lar tachycardia. Implantation of an atrial lead may be considered in the case 
of significant bradycardia with beta-blocker treatment.
Patients with Wolff–Parkinson–White syndrome and AF are at risk 
of fast ventricular rates from rapid conduction of atrial electrical activity 
to the ventricles via the accessory pathway, potentially leading to ven­
tricular fibrillation and sudden death.983,984 Immediate electrical cardi­
oversion is needed for haemodynamically compromised patients with 
Recommendation Table 29 — Recommendations for 
patients with AF and congenital heart disease (see also 
Evidence Table 29)
Recommendation
Classa
Levelb
Oral anticoagulation should be considered in all adult 
congenital heart disease patients with AF/AFL and 
intracardiac repair, cyanosis, Fontan palliation, or 
systemic right ventricle to prevent ischaemic stroke 
and thromboembolism, regardless of other 
thromboembolic risk factors.897
IIa
C
© ESC 2024
AF, atrial fibrillation; AFL, atrial flutter. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 58 -->

### Page 58

pre-excited AF, and atrioventricular node-modulating drugs should be 
avoided.985,986 Pharmacological cardioversion can be attempted using 
ibutilide987 or flecainide, while propafenone should be used with cau­
tion due to effects on the atrioventricular node.988,989 Amiodarone 
should be avoided in pre-excited AF due to its delayed action. 
Further details on inherited cardiomyopathies can be found in the 
9.12. AF-CARE in cancer
All types of cancer show an increased risk of AF, with prevalence vary­
ing from 2% to 28%.991–995 The occurrence of AF may often be related 
to a pre-existing atrial substrate with vulnerability to AF. AF may be an 
indicator of an occult cancer, but also can appear in the context of con­
comitant surgery, chemotherapy, or radiotherapy.916,994,996 Risk of AF 
is dependent on, among other factors, the cancer type and stage,997 and 
is greater in older patients with pre-existing cardiovascular dis­
ease.991,993,994 Some procedures are associated with higher incidence 
of AF, including lung surgery (from 6% to 32%) and non-thoracic sur­
gery such as a colectomy (4%–5%).994
Atrial fibrillation in the context of cancer is associated with a two- 
fold higher risk of systemic thromboembolism and stroke, and six-fold 
increased risk of heart failure.991,994 On the other hand, the coexistence 
of cancer increases the risk of all-cause mortality and major bleeding in 
patients with AF.998 Bleeding in those receiving OAC can also unmask 
the presence of cancer.999
Stroke risk scores may underestimate thromboembolic risk in cancer 
patients.1000 The association between cancer, AF, and ischaemic stroke 
also differs between cancer types. In some types of cancer, the risk of 
bleeding seems to exceed the risk of thromboembolism.998 Risk strati­
fication is therefore complex in this population, and should be per­
formed on an individual basis considering cancer type, stage, 
prognosis, bleeding risk, and other risk factors. These aspects can 
change within a short period of time, requiring dynamic assessment 
and management.
As with non-cancer patients, DOACs in those with cancer have simi­
lar efficacy and better safety compared with VKAs.1001–1010 Low 
molecular weight heparin is a short-term anticoagulation option, mostly 
during some cancer treatments, recent active bleeding, or thrombo­
cytopaenia.1011 Decision-making on AF management, including on 
rhythm control, is best performed within a cardio-oncology multi­
disciplinary team.916,1012 Attention is required on interactions with can­
cer treatments, in particular QT-interval prolongation with AADs.
9.13. AF-CARE in older, multimorbid, or 
frail patients
Atrial fibrillation increases with age, and older patients more frequently 
have multimorbidity and frailty which are associated with worse clinical 
outcomes.1013–1016 Multimorbidity is the coexistence of two or more 
medically diagnosed diseases in the same individual. Frailty is defined 
as a person more vulnerable and less able to respond to a stressor 
or acute event, increasing the risk of adverse outcomes.1016,1017 The 
prevalence of frailty in AF varies due to different methods of assess­
ment from 4.4% to 75.4%, and AF prevalence in the frail population 
ranges from 48.2% to 75.4%.1018 Frailty status is a strong independent 
risk factor for new-onset AF among older adults with hypertension.1019
Atrial fibrillation in frail patients is associated with less use of 
OAC and lower rates of management with a rhythm control 
strategy.1015,1018,1020 Oral anticoagulation initiation in older, frail 
multimorbid AF patients has improved since the introduction of 
DOACs, but is still lower in AF patients at older age (OR, 0.98 per 
year; 95% CI, 0.98–0.98), with dementia (OR, 0.57; 95% CI, 
0.55–0.58), or frailty (OR, 0.74; 95% CI, 0.72–0.76).1021 The value of 
observational data which show potential benefit from OAC (in particu­
lar, DOACs) is limited due to prescription biases.1022–1027 Frail patients 
aged ≥75 years with polypharmacy and stable on a VKA may remain on 
the VKA rather than switching to a DOAC (Section 6.2).309
9.14. AF-CARE in atrial flutter
Due to the association between AFL and thromboembolic outcomes, 
and the frequent development of AF in patients with AFL, the manage­
ment of comorbidities and risk factors in AFL should mirror that for AF 
(see Section 5). Similarly, the approach to prevent thromboembolism in 
AFL includes peri-procedural and long-term OAC (see Section 6). Rate 
control can be difficult to achieve in AFL, despite combination therapy. 
Rhythm control is often the first-line approach,983 with small rando­
mized trials showing that cavo-tricuspid isthmus (CTI) ablation is super­
ior to AADs.1028,1029 Recurrence of AFL is uncommon after achieving 
and confirming bidirectional block in typical CTI-dependent AFL. 
However, the majority of patients (50%–70%) have manifested AF 
during long-term follow-up in observational studies after AFL 
ablation.1030,1031 Hence the necessity for long-term dynamic re- 
evaluation in all patients with AFL in keeping with the AF-CARE 
approach. More detail on the management of AFL and other atrial ar­
rhythmias is described in the 2019 ESC Guidelines for the management of 
patients with supraventricular tachycardia.983
10. Screening and prevention of AF
10.1. Epidemiology of AF
Atrial fibrillation is the most common sustained arrhythmia worldwide, 
with an estimated global prevalence in 2019 of 59.7 million persons 
with AF.1033 Incident cases of AF are doubling every few decades.1034
Future increases are anticipated, in particular in middle-income coun­
tries.1034 In community-based individuals, the prevalence of AF in a 
United States of America cohort was up to 5.9%.1035
The 
age-standardized prevalence and incidence rates have remained con­
stant over time.1033,1036 The increase in overall prevalence is largely at­
tributable to population growth, ageing, and survival from other cardiac 
conditions. In parallel, increases in risk factor burden, better awareness, 
and improved detection of AF have been observed.1037 The lifetime risk 
Recommendation Table 30 — Recommendations for 
prevention of thromboembolism in atrial flutter (see 
also Evidence Table 30)
Recommendation
Classa
Levelb
Oral anticoagulation is recommended in patients 
with atrial flutter at elevated thromboembolic risk to 
prevent ischaemic stroke and 
thromboembolism.86,1032
I
B
© ESC 2024
AF, atrial fibrillation; AFL, atrial flutter. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3371


<!-- PAGE 59 -->

### Page 59

of AF has been estimated to be as high as 1 in 3 for older individuals,1038
with age-standardized incidence rates higher for men than women. 
Populations of European ancestry are typically found to have higher 
AF prevalence, individuals of African ancestry have worse outcomes, 
and other groups may have less access to interventions.1039–1041
Socioeconomic and other factors likely play a role in racial and ethnic 
differences in AF, but studies are also limited due to differences in 
how groups access healthcare. Greater deprivation in socioeconomic 
and living status is associated with higher AF incidence.1042
10.2. Screening tools for AF
In recent years, an abundance of novel devices that can monitor heart 
rhythm have come to the market, including fitness bands and smart­
watches. Although the evidence for clinical effectiveness of digital de­
vices is limited, they may be useful in detecting AF, and their clinical, 
economic, legal, and policy implications merit further investiga­
tion.1043,1044 Devices for AF detection can broadly be divided into those 
that provide an ECG, and those with non-ECG approaches such as 
photoplethysmography (Figure 15 and Table 15).
Diagnostic for AF if diagnosis is confirmed by a physician
(Class I)
Not diagnostic (may be indicative for AF)
No of leads
Tracing
1 or 2
ECG-based methods
Non ECG-based methods
6
>6
Method
Tracing
Pulse palpation
Oscillometry
Contact
Contactless
Contactless
PPG
Smart speaker
Mechanocardiography
Figure 15 Non-invasive diagnostic methods for AF screening. AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; PPG, 
photoplethysmography.


<!-- PAGE 60 -->

### Page 60

Most consumer-based devices use photoplethysmography, and 
several large studies have been performed typically in low-risk indi­
viduals.633,1076,1117,1118 In an RCT of 5551 participants invited by 
their health insurer, smartphone-based photoplethysmography in­
creased the odds of OAC-treated new AF by 2.12 (95% CI, 
1.19–3.76; P = .01) compared with usual care.605 RCTs powered 
for assessment of clinical outcomes are still lacking for consumer- 
based AF screening. Further head-to-head comparisons between 
novel digital devices and those commonly used in healthcare set­
tings are needed to establish their comparative effectiveness in 
the clinical setting and account for different populations and set­
tings.1119 In a systematic review of smartphone-based photo­
plethysmography compared with a reference ECG, unrealistically 
high sensitivity and specificity were noted, likely due to small, low- 
quality studies with a high degree of patient selection bias.1120
Hence, when AF is suggested by a photoplethysmography device 
or any other screening tool, a single-lead or continuous ECG tra­
cing of >30 s or 12-lead ECG showing AF analysed by a physician 
with expertise in ECG rhythm interpretation is recommended to 
establish a definitive diagnosis of AF.1091,1121–1125
The combination of big data and artificial intelligence (AI) is hav­
ing an increasing impact on the field of electrophysiology. 
Algorithms have been created to improve automated AF diagnosis 
and several algorithms to aid diagnostics are being investigated.1046
However, the clinical performance and broad applicability of these 
solutions are not yet known. The use of AI may enable future 
treatment changes to be assessed with dynamic and continuous 
patient-directed monitoring using wearable devices.1126 There are 
still challenges in the field that need clarification, such as data acqui­
sition, model performance, external validity, clinical implementation, 
algorithm interpretation, and confidence, as well as the ethical 
aspects.1127
10.3. Screening strategies for AF
Screening can be performed systematically, with an invitation issued to 
a patient, or opportunistically, at the time of an ad hoc meeting with a 
healthcare professional. Regardless of the mode of invitation, screening 
should be part of a structured programme1128 and is not the same as 
identification of AF during a routine healthcare visit or secondary to ar­
rhythmia symptoms.
Screening can be done at a single timepoint (snapshot of the heart 
rhythm), e.g. using pulse palpation or a 12-lead ECG. Screening can 
also be of an extended duration, i.e. prolonged, using either intermittent 
or continuous monitoring of heart rhythm. Most studies using an oppor­
tunistic strategy have screened for AF at a single timepoint with short 
duration (such as a single timepoint ECG), compared with systematic 
screening studies that have mainly used prolonged (repeated or continu­
ous) rhythm assessment.1129 The optimal screening method will vary de­
pending on the population being studied (Figure 16) (see Supplementary 
data online, Additional Evidence Table S32). More sensitive methods will 
detect more AF but may lead to an increased risk of false positives and 
an increased detection of low burden AF, whereas more specific meth­
ods result in less false positives, at the risk of missing AF.
Invasive monitoring of heart rhythm in high-risk populations ex­
tended for several years has been shown to result in device-detected 
AF prevalence of around 30%, albeit most of whom have a low burden 
of AF.5,857,1130,1131 Pacemaker studies have shown that patients with a 
low burden of device-detected subclinical AF have a lower risk of is­
chaemic stroke.5,24,1131,1132 This has been confirmed in RCTs assessing 
DOAC use in patients with device-detected subclinical AF (see Section 
6.1.1).5,281,282 The burden needed for device-detected subclinical AF to 
translate into stroke risk is not known, and further studies are clearly 
needed.1133,1134 Benefit and cost-effectiveness of screening are dis­
cussed in the Supplementary data online.
Table 15 Tools for AF screening
Tools for AF screening
(i) Pulse palpation1045
(ii) Use of artificial intelligence algorithms to identify patients at risk1046
(iii) ECG-based devices 
(a) Conventional ECG devices 
(1) Classic 12-lead ECG 1047
(2) Holter monitoring (from 24 h to a week or more)1048
(3) Mobile cardiac telemetry (during hospitalization)1049
(4) Handheld devices1050–1052
(5) Wearable patches (up to 14 days)1053–1067
(6) Biotextiles (up to 30 days)1068–1072
(7) Smart devices (30 s)1073–1091
(b) Implantable loop recorders (3–5 years)1092–1099
(iv) Non-ECG-based devices 
(a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)1100–1106
(b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)1107–1110
(c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)1111
(d) Contactless video plethysmography (through video monitoring)1112–1115
(e) Smart speakers (through the identification of abnormal heart rate patterns)1116
© ESC 2024
ECG, electrocardiogram.
ESC Guidelines                                                                                                                                                                                          3373


<!-- PAGE 61 -->

### Page 61

10.3.1. Single timepoint screening ‘snapshot’
Several cluster RCTs in primary care settings have explored whether 
screening performed as a snapshot of the heart rhythm at one time­
point can detect more AF compared with usual care in individuals 
aged ≥65 years.1138–1140 No increased detection of AF was seen in 
groups randomized to single timepoint screening.1138–1140 These find­
ings were confirmed in a meta-analysis of RCTs showing that screening 
as a one-time event did not increase detection of AF compared with 
usual care.1135 Notably, these studies were performed in healthcare 
settings where the detection of AF in the population might be high, 
hence the results might not be generalizable to healthcare settings 
with a lower spontaneous AF detection. There are no RCTs addressing 
clinical outcomes in patients with AF detected by single timepoint 
screening.1123,1135
10.3.2. Prolonged screening
Studies using prolonged screening have shown an increased detection 
of AF leading to initiation of OAC.1129,1135,1141 Two RCTs have inves­
tigated the effect on clinical outcomes in prolonged screening for AF.5,6
In the STROKESTOP trial (Systematic ECG Screening for Atrial 
Fibrillation Among 75 Year Old Subjects in the Region of Stockholm 
Recommendation Table 31 — Recommendations for 
screening for AF (see also Evidence Table 31)
Recommendations
Classa
Levelb
Review of an ECG (12-lead, single, or multiple leads) 
by a physician is recommended to provide a definite 
diagnosis of AF and commence appropriate 
management.1091,1121–1123,1125
I
B
Routine heart rhythm assessment during healthcare 
contact is recommended in all individuals aged ≥65 
years for earlier detection of AF.
I
C
Population-based screening for AF using a prolonged 
non-invasive ECG-based approach should be 
considered in individuals aged ≥75 years, or ≥65 
years with additional CHA2DS2-VA risk factors to 
ensure earlier detection of AF.6,1135–1137
IIa
B
© ESC 2024
AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years 
(2 
points), 
diabetes 
mellitus, 
prior 
stroke/transient 
ischaemic 
attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
Screening approach
Population example
Setting for 
AF detection
Type of screening
Follow
AF-CARE
After thromboembolic event
Patients with embolic stroke of unknown source
Age ≥65 years,
or risk of thromboembolism
Age ≥75 years,
or ≥65 years plus other
CHA2DS2-VA
factors
Initiated after index event
At the time of routine healthcare contact
Structured national or regional screening programmes
Ad-hoc to catch AF
In patients with risk factors
Patient informed about implications of AF
detection
C
Comorbidity and risk factor management
A
Avoid stroke and thromboembolism
R
Reduce symptoms by rate and rhythm control
E
Evaluation and 
dynamic reassessment
Any rhythm check,
confirmed by ECG
Routine heart rhythm assessment
(Class I)
Invasive or non-invasive ECG
Prolonged monitoring
(Class I)
Population-based 
Non-invasive ECG
(Class IIa)
Figure 16 Approaches to screening for AF. AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid 
stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; CHA2DS2-VA, congestive 
heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/TIA/arterial thromboembolism (2 points), vascular disease, age 65– 
74 years; ECG, electrocardiogram. See Figure 15 for non-invasive ECG methods.


<!-- PAGE 62 -->

### Page 62

and Halland, Sweden), 75- and 76-year-olds were randomized to be in­
vited to prolonged screening for AF using single-lead ECGs twice daily 
for 2 weeks, or to standard of care. After a median of 6.9 years there 
was a small reduction in the primary combined endpoint of all-cause 
mortality, stroke, systematic embolism, and severe bleeding in favour 
of prolonged screening (HR, 0.96; 95% CI, 0.92–1.00; P = .045).6 In 
the LOOP (Atrial Fibrillation Detected by Continuous ECG 
Monitoring) trial, individuals at increased risk of stroke were rando­
mized to receive an implantable loop recorder that monitored heart 
rhythm for an average of 3.3 years, or to a control group receiving 
standard of care. Although there was a higher detection of AF 
(31.8%) and subsequent initiation of OAC in the loop recorder 
group compared with standard of care (12.2%), this was not accom­
panied by a difference in the primary outcome of stroke or systemic 
embolism.5 In a meta-analysis of recent RCTs on the outcome of 
stroke, a small but significant benefit was seen in favour of prolonged 
screening (RR, 0.91; 95% CI, 0.84–0.99).1136 This was not repeated 
in a second meta-analysis including older RCTs, where no risk reduc­
tion was seen with regard to mortality or stroke.1135 Notably, both 
these meta-analyses are likely underpowered to assess clinical 
outcomes.
10.4. Factors associated with incident AF
The most common risk predictors for incident (new-onset) AF are 
shown in Table 16. While the factors listed are robustly associated 
with incident AF in observational studies, it is not known whether 
the relationships are causal. Studies using Mendelian randomization 
(genetic proxies for risk factors to estimate causal effects) robustly im­
plicate systolic BP and higher BMI as causal risk factors for incident 
AF.1142
A high degree of interaction occurs between all factors related to AF 
development (see Supplementary data online, Additional Evidence 
Table S33).1038,1039,1143–1145 For ease of clinical application, risk predic­
tion tools have combined various factors, and have recently employed 
machine learning algorithms for prediction.1146,1147 Classical risk scores 
are also available with variable predictive ability and model performance 
(see Supplementary data online, Table S7).1148 Improved outcomes 
when using these risk scores have yet to be demonstrated. Although 
knowledge is rapidly increasing about the genetic basis for AF in 
some patients, the value of genetic screening is limited at the present 
time (see Supplementary data online).
10.5. Primary prevention of AF
Preventing the onset of AF before clinical manifestation has clear 
potential to improve the lives of the general population and reduce 
the considerable health and social care costs associated with 
development of AF. Whereas the [C] in AF-CARE is focused on the 
effective management of risk factors and comorbidities to limit AF 
recurrence and progression, there is also evidence they can be targeted 
to prevent AF. Available data are presented below for hypertension, 
heart failure, type 2 diabetes mellitus, obesity, sleep apnoea syndrome, 
Table 16 Factors associated with incident AF
Demographic factors
Age1149–1151
Male sex1149–1152
European ancestry1149,1150
Lower socioeconomic status1150
Lifestyle behaviours
Smoking/tobacco use1149–1151
Alcohol intake1149,1150
Physical inactivity1149,1150
Vigorous exercise1153–1156
Competitive or athlete-level endurance 
sports1151,1157
Caffeine1158–1160
Continued 
Comorbidities and risk 
factors
Hypertension1149–1151
Heart failure178,1149–1151,1161
Valvular disease1149,1151,1162–1164
Coronary artery disease1149,1151,1161,1165
Peripheral arterial disease785
Congenital heart disease1149,1166
Heart rate, heart rate variability1167,1168
Total cholesterol1149,1150
Low-density lipoprotein cholesterol1150
High-density lipoprotein cholesterol1150
Triglycerides1150
Impaired glucose tolerance,1169–1172diabetes 
mellitus1149–1151,1169
Renal dysfunction/CKD1149–1151,1173,1174
Obesity1149–1151,1175,1176
Body mass index, weight1149–1151
Height1150
Sleep apnoea1149,1151,1177,1178
Chronic obstructive pulmonary disease1179
Subclinical 
atherosclerosis
Coronary artery calcification1149,1151,1180
Carotid IMT and carotid plaque1149,1151,1181,1182
ECG abnormalities
PR interval prolongation1149,1151,1183
Sick sinus syndrome1149,1184,1185
Wolff–Parkinson–White1149,1186
Genetic factors
Family history of AF1149,1151,1187–1190
AF-susceptible loci identified by 
GWAS1149,1151,1191,1192
Short QT syndrome1149
Genetic cardiomyopathies990,1193
Biomarkers
C-reactive protein1150,1151
Fibrinogen1150
Growth differentiation factor-151194
Natriuretic peptides (atrial and B-type)1195–1200
Cardiac troponins1199
Inflammatory biomarkers 1149,1151
Others
Thyroid dysfunction912,1149–1151
Autoimmune diseases1150
Air pollution1149,1201
Sepsis1149,1202
Psychological factors 1203,1204
© ESC 2024
AF, atrial fibrillation; CKD, chronic kidney disease; GWAS, genome-wide association 
studies; HF, heart failure; IMT, intima-media thickness.
ESC Guidelines                                                                                                                                                                                          3375


<!-- PAGE 63 -->

### Page 63

physical activity, and alcohol, although many other risk markers can 
also be targeted. Further information on each factor’s attributable 
risk for AF is provided in the Supplementary data online (see 
Supplementary data online, Evidence Table 32 and additional Evidence 
Tables S34–S39).
10.5.1. Hypertension
Management of hypertension has been associated with a reduction in 
incident AF.1205–1207,1232 In the LIFE (Losartan Intervention for End 
point reduction in hypertension) trial, a 10 mmHg reduction in systolic 
BP was associated with a 17% reduction in incident AF.1207 Secondary 
analysis of RCTs and observational studies suggest that ACE inhibitors 
or ARBs may be superior to beta-blockers, calcium channel blockers, or 
diuretics for the prevention of incident AF.1233–1236
10.5.2. Heart failure
Long-standing established pharmacological treatments for HFrEF have 
been associated with a reduction in incident AF. The use of ACE inhi­
bitors or ARBs in patients with known HFrEF was associated with a 
44% reduction in incidence of AF.1208 Similarly, beta-blockers in 
HFrEF led to a 33% reduction in the odds of incident AF.133
Mineralocorticoid receptor antagonists have also been shown to re­
duce the risk of new-onset AF by 42% in patients with HFrEF.1209
Although there have been variable effects of SGLT2 inhibitors on 
incident AF, several meta-analyses have demonstrated that there is 
an 18%–37% reduction in incident AF.136,1210,1211,1237 However, treat­
ment of HFrEF with sacubitril/valsartan has not yet been shown to con­
fer any adjunctive benefit in reducing new-onset AF when compared 
with ACE inhibitors/ARBs alone.1238 There is some evidence to suggest 
that effective CRT in eligible patients with HFrEF reduces the risk of in­
cident AF.1239 To date, no treatments in HFpEF have been shown to 
reduce incident AF.
10.5.3. Type 2 diabetes mellitus
The integrated care of type 2 diabetes, based on lifestyle and pharma­
cological treatments for comorbidities such as obesity, hypertension, 
and dyslipidaemia, are useful steps in preventing atrial remodelling 
and subsequent AF. Intensive glucose-lowering therapy targeting an 
HbA1c level of <6.0% (<42 mmol/mol) failed to show a protective ef­
fect on incident AF.1240 More than glycaemic control per se, the class of 
glucose-lowering agent may influence the risk of AF.1240 Insulin pro­
motes adipogenesis and cardiac fibrosis, and sulfonylureas have been 
consistently associated with an increased risk of AF.193 Observational 
studies have associated metformin with lower rates of incident 
AF.1224,1225,1241–1243 Various recent studies and meta-analyses point 
to the positive role of SGLT2 inhibitors to reduce the risk of incident 
AF in diabetic and non-diabetic patients.136,1226,1244–1246 Pooled 
data from 22 trials including 52 951 patients with type 2 diabetes and 
heart failure showed that SGLT2 inhibitors compared with placebo 
can significantly reduce the incidence of AF by 18% in studies on dia­
betes, and up to 37% in heart failure with or without type 2 
diabetes.1210,1211
10.5.4. Obesity
Management of weight is important in the prevention of AF. In a large 
population-based cohort study, normal weight was associated with a 
reduced risk of incident AF compared with those who were obese 
(4.7% increase in the risk of incident AF for each 1 kg/m2 increase of 
BMI).208 In the Women’s Health Study, participants who became obese 
had a 41% increased risk of incident AF compared with those who 
maintained their BMI <30 kg/m2.1212 Similarly, observational studies 
in populations using bariatric surgery for weight loss in morbidly obese 
individuals (BMI ≥40 kg/m2) have observed a lower risk of incident 
AF.1227–1231
10.5.5. Sleep apnoea syndrome
Although it would seem rational to optimize sleep habits, to date there 
is no conclusive evidence to support this for the primary prevention of 
AF. The SAVE (Sleep Apnea cardioVascular Endpoints) trial failed to 
demonstrate a difference in clinical outcomes in those randomized to 
CPAP therapy or placebo.230 There was no difference in incident AF, 
albeit the analysis of AF was not based on systematic screening but ra­
ther on clinically documented AF.
10.5.6. Physical activity
Several studies have demonstrated beneficial effects of moderate phys­
ical activity on cardiovascular health.1247 Moderate aerobic exercise 
may also reduce the risk of new-onset AF.1214–1219 It should be noted 
that the incidence of AF appears to be increased among athletes, with a 
meta-analysis of observational studies showing a 2.5-fold increased risk 
of AF compared with non-athlete controls.1248
Recommendation Table 32 — Recommendations for 
primary prevention of AF (see also Evidence Table 32)
Recommendation
Classa
Levelb
Maintaining optimal blood pressure is recommended 
in the general population to prevent AF, with ACE 
inhibitors or ARBs as first-line therapy.1205–1207
I
B
Appropriate medical HF therapy is recommended in 
individuals with HFrEF to prevent AF.133,136,1208–1211
I
B
Maintaining normal weight (BMI 20–25 kg/m2) is 
recommended for the general population to prevent 
AF.208,1212,1213
I
B
Maintaining an active lifestyle is recommended to 
prevent AF, with the equivalent of 150–300 min 
per week of moderate intensity or 75–150 min per 
week of vigorous intensity aerobic physical 
activity.1214–1219
I
B
Avoidance of binge drinking and alcohol excess is 
recommended in the general population to prevent 
AF.1220–1223
I
B
Metformin or SGLT2 inhibitors should be considered 
for individuals needing pharmacological management 
of diabetes mellitus to prevent AF.1210,1211,1224–1226
IIa
B
Weight reduction should be considered in obese 
individuals to prevent AF.1212,1227–1231
IIa
B
© ESC 2024
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor 
blocker; BMI, body mass index; HF, heart failure; HFrEF, heart failure with reduced 
ejection fraction; SGLT2, sodium-glucose cotransporter-2. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 64 -->

### Page 64

10.5.7. Alcohol intake
The premise that reducing alcohol intake can prevent AF is based on 
observational studies linking alcohol to an excess risk of incident AF 
in a dose-dependent manner (see Supplementary data online).1220–1222
In addition, a population cohort study of those with high alcohol con­
sumption (>60 g/day for men and >40 g/day for women) found that ab­
stinence from alcohol was associated with a lower incidence of AF 
compared with patients who continued heavy drinking.1223
11. Key messages
(1) General management: optimal treatment according to the 
AF-CARE pathway, which includes: [C] Comorbidity and risk fac­
tor management; [A] Avoid stroke and thromboembolism; [R] 
Reduce symptoms by rate and rhythm control; and [E] 
Evaluation and dynamic reassessment.
(2) Shared care: patient-centred AF management with joint decision- 
making and a multidisciplinary team.
(3) Equal care: avoid health inequalities based on gender, ethnicity, 
disability, and socioeconomic factors.
(4) Education: for patients, family members, caregivers, and health­
care professionals to aid shared decision-making.
(5) Diagnosis: clinical AF requires confirmation on an ECG device to 
initiate risk stratification and AF management.
(6) Initial evaluation: medical history, assessment of symptoms and 
their impact, blood tests, echocardiography/other imaging, 
patient-reported outcome measures, and risk factors for 
thromboembolism and bleeding.
(7) Comorbidities and risk factors: thorough evaluation and manage­
ment critical to all aspects of care for patients with AF to avoid 
recurrence and progression of AF, improve success of AF treat­
ments, and prevent AF-related adverse outcomes.
(8) Focus on conditions associated with AF: including hypertension, 
heart failure, diabetes mellitus, obesity, obstructive sleep apnoea, 
physical inactivity, and high alcohol intake.
(9) Assessing the risk of thromboembolism: use locally validated risk 
tools or the CHA2DS2-VA score and assessment of other risk fac­
tors, with reassessment at periodic intervals to assist in decisions 
on anticoagulant prescription.
(10) Oral anticoagulants: recommended for all eligible patients, except 
those at low risk of incident stroke or thromboembolism 
(CHA2DS2-VA = 1 anticoagulation should be considered; 
CHA2DS2-VA ≥2 anticoagulation recommended).
(11) Choice of anticoagulant: DOACs (apixaban, dabigatran, edoxa­
ban, and rivaroxaban) are preferred over VKAs (warfarin and 
others), except in patients with mechanical heart valves and mitral 
stenosis.
(12) Dose/range of anticoagulant: use full standard doses for DOACs 
unless the patient meets specific dose-reduction criteria; for 
VKAs, keep INR generally 2.0–3.0, and in range for >70% of the 
time.
(13) Switching anticoagulants: switch from a VKA to DOAC if risk of 
intracranial haemorrhage or poor control of INR levels.
(14) Bleeding risk: modifiable bleeding risk factors should be managed 
to improve safety; bleeding risk scores should not be used to de­
cide on starting or withdrawing anticoagulants.
(15) Antiplatelet therapy: avoid combining anticoagulants and antipla­
telet agents, unless the patient has an acute vascular event or 
needs interim treatment for procedures.
(16) Rate control therapy: use beta-blockers (any ejection fraction), di­
goxin (any ejection fraction), or diltiazem/verapamil (LVEF >40%) 
as initial therapy in the acute setting, an adjunct to rhythm control 
therapies, or as a sole treatment strategy to control heart rate and 
symptoms.
(17) Rhythm control: consider in all suitable AF patients, explicitly dis­
cussing with patients all potential benefits and risks of cardiover­
sion, antiarrhythmic drugs, and catheter or surgical ablation to 
reduce symptoms and morbidity.
(18) Safety first: keep safety and anticoagulation in mind when consid­
ering rhythm control; e.g. delay cardioversion and provide at least 
3 weeks of anticoagulation beforehand if AF duration >24 h, and 
consider toxicity and drug interactions for antiarrhythmic 
therapy.
(19) Cardioversion: use electrical cardioversion in cases of haemo­
dynamic instability; otherwise choose electrical or pharmacologic­
al cardioversion based on patient characteristics and preferences.
(20) Indication for long-term rhythm control: the primary indication 
should be reduction in AF-related symptoms and improvement 
in quality of life; for selected patient groups, sinus rhythm main­
tenance can be pursued to reduce morbidity and mortality.
(21) Success or failure of rhythm control: continue anticoagulation ac­
cording to the patient’s individual risk of thromboembolism, irre­
spective of whether they are in AF or sinus rhythm.
(22) Catheter ablation: consider as second-line option if antiarrhyth­
mic drugs fail to control AF, or first-line option in patients with 
paroxysmal AF.
(23) Endoscopic or hybrid ablation: consider if catheter ablation fails, 
or an alternative to catheter ablation in persistent AF despite anti­
arrhythmic drugs.
(24) Atrial fibrillation ablation during cardiac surgery: perform in cen­
tres with experienced teams, especially for patients undergoing 
mitral valve surgery.
(25) Dynamic evaluation: periodically reassess therapy and give atten­
tion to new modifiable risk factors that could slow/reverse the 
progression of AF, increase quality of life, and prevent adverse 
outcomes.
12. Gaps in evidence
The following bullet list gives the most important gaps in evidence 
where new clinical trials could substantially aid the patient pathway:
Definition and clinical impact of AF 
• Paroxysmal AF is not one entity, and patterns of AF progression and 
regression are highly variable. It is uncertain what the relevance is for 
treatment strategies and management decisions.
• Thirty seconds as definition for clinical AF needs validation and evalu­
ation whether it is related to AF-related outcomes.
• Definition, clinical features, diagnosis, and implementation for treat­
ment choices of atrial cardiomyopathy in patients with AF is 
unsettled.
• Diversity in AF presentation, underlying pathophysiological mechan­
isms, and associated comorbidities is incompletely understood with 
regard to differences in sex, gender, race/ethnicity, socioeconomic 
state, education, and differences between low-, moderate-, and high- 
income countries.
• Personalized risk prediction for AF incidence, AF progression, and as­
sociated outcomes remains challenging.
ESC Guidelines                                                                                                                                                                                          3377


<!-- PAGE 65 -->

### Page 65

• Insights into psychosocial and environmental factors and risk of AF 
and adverse outcomes in AF are understudied.
Patient-centred, multidisciplinary AF management 
• The benefit of additional education directed to patients, to family 
members, and to healthcare professionals in order to optimize 
shared decision-making still needs to be proved.
• Access to patient-centred management according to the AF-CARE 
principles to ensure equality in healthcare provision and improve out­
comes warrants evidence.
• The place of remote monitoring and telemedicine for identification 
and follow-up of patients with AF, or its subgroups is non-established, 
though widely applied.
[C] Comorbidity and risk factor management 
• Methods to achieve consistent and reproducible weight loss in pa­
tients with AF requires substantial improvement. Despite some evi­
dence demonstrating the benefits of weight loss, widespread 
adoption has been limited by the need for reproducible strategies.
• The importance of sleep apnoea syndrome and its treatment on 
AF-related outcomes remains to be elucidated.
[A] Avoid stroke and thromboembolism 
• Data are lacking on how to treat patients with low risk of stroke (with 
a CHA2DS2-VA score of 0 or 1), as these patients were excluded 
from large RCTs.
• Not enough evidence is available for OAC in elderly patients, frail 
polypharmacy patients, those with cognitive impairment/dementia, 
recent bleeding, previous ICH, severe end-stage renal failure, liver im­
pairment, cancer, or severe obesity.
• In elderly patients, routinely switching VKAs to DOACs is associated 
with increased bleeding risk; however, the reasons why this happens 
are unclear.
• The selection of which patients with asymptomatic device-detected 
subclinical AF benefit from OAC therapy needs to be defined.
• There is a lack of evidence whether and when to (re)start anticoagu­
lation after intracranial haemorrhage.
• There is lack of evidence about optimal anticoagulation in patients 
with ischaemic stroke or left atrial thrombus while being treated 
with OAC.
• There is uncertainty about the place of LAA closure and how to man­
age antithrombotic post-procedural management when LAAO is 
performed.
• Balance of thromboembolism and bleeding is unclear in patients with 
AF and incidental cerebral artery aneurysms identified on brain MRI.
[R] Reduce symptoms by rate and rhythm control 
• In some patients, AF can be benign in terms of symptoms and out­
comes. In which patients rhythm control is not needed warrants 
investigation.
• Application of antiarrhythmic drugs has been hampered by poor ef­
fectiveness and side effects; however, new antiarrhythmic drugs are 
needed to increase the therapeutic arsenal for AF patients.
• The amount of AF reduction obtained by rhythm control to improve 
outcomes is unknown.
• Large catheter ablation studies showed no improved outcome of 
patients with AF. Some small studies in specific subpopulations 
have observed an improved outcome. This warrants further inves­
tigation to provide each patient with AF with personalized treat­
ment goals.
• Uncertainty exists on the time of duration of AF and risk of stroke 
when performing a cardioversion.
• The value of diagnostic cardioversion for persistent AF in steering 
management of AF is unknown.
• Decisions on continuation of OAC are completely based on stroke 
risk scores and irrespective of having (episodes) of AF; whether 
this holds for patients undergoing successful catheter ablation is 
uncertain.
• Large variability in ablation strategies and techniques exist for pa­
tients with persistent AF, or after first failed catheter ablation for par­
oxysmal AF. The optimal catheter ablation strategy and techniques, 
however, are unknown.
• Sham-controlled intervention studies are lacking to determine the ef­
fects on AF symptoms, quality of life, and PROMS, accounting for the 
placebo effect that is associated with interventions.
The AF-CARE pathway in specific clinical settings 
• The optimal duration of triple therapy in patients with AF at high risk 
of recurrent coronary events after acute coronary syndrome is 
unclear.
• The role of the coronary vessel involved and whether this should im­
pact on the duration of combined OAC and antiplatelet treatment 
needs further study.
• The role of antiplatelet therapy in patients with AF and peripheral ar­
tery disease on OAC is uncertain.
• The use of DOACs in patients with congenital heart disease, particu­
larly in patients with complex corrected congenital defects, is poorly 
studied.
• Improved risk stratification for stroke in patients with AF and cancer, 
or with post-operative or trigger-induced AF is needed to inform on 
OAC treatment decisions.
Screening and prevention of AF 
• There are a lack of adequately powered randomized controlled stud­
ies on ischaemic stroke rate in patients screened for AF, both in the 
primary prevention setting and in secondary prevention (post- 
stroke), and its cost-effectiveness.
• Population selection that might benefit the most from screening, the 
optimal duration of screening, and the burden of AF that might in­
crease the risk for patients with screening-detected AF are uncertain.
• Evaluation of strategies to support longer-term use of technologies 
for AF detection are awaited.
• The role of photoplethysmography technology for AF screening in an 
effort to assess AF burden and reduce stroke is still unclear.
• How new consumer devices and wearable technology can be used 
for diagnostic and monitoring purposes in routine clinical practice 
needs to be clarified.


<!-- PAGE 66 -->

### Page 66

13. ‘What to do’ and ‘What not to do’ messages from the guidelines
Table 17 lists all Class I and Class III recommendations from the text alongside their level of evidence.
Table 17 ‘What to do’ and ‘what not to do’
Recommendations
Classa
Levelb
Recommendations for the diagnosis of AF
Confirmation by an electrocardiogram (12-lead, multiple, or single leads) is recommended to establish the diagnosis of clinical AF and 
commence risk stratification and treatment.
I
A
Recommendations for symptom evaluation in patients with AF
Evaluating the impact of AF-related symptoms is recommended before and after major changes in treatment to inform shared 
decision-making and guide treatment choices.
I
B
Recommendations for diagnostic evaluation in patients with new AF
A transthoracic echocardiogram is recommended in patients with an AF diagnosis where this will guide treatment decisions.
I
C
Recommendations for patient-centred care and education
Education directed to patients, family members, caregivers, and healthcare professionals is recommended to optimize shared 
decision-making, facilitating open discussion of both the benefit and risk associated with each treatment option.
I
C
Access to patient-centred management according to the AF-CARE principles is recommended in all patients with AF, regardless of gender, 
ethnicity, and socioeconomic status, to ensure equality in healthcare provision and improve outcomes.
I
C
Recommendations for comorbidity and risk factor management in AF
Identification and management of risk factors and comorbidities is recommended as an integral part of AF care.
I
B
Blood pressure lowering treatment is recommended in patients with AF and hypertension to reduce recurrence and progression of AF and 
prevent adverse cardiovascular events.
I
B
Diuretics are recommended in patients with AF, HF, and congestion to alleviate symptoms and facilitate better AF management.
I
C
Appropriate medical therapy for HF is recommended in AF patients with HF and impaired LVEF to reduce symptoms and/or HF 
hospitalization and prevent AF recurrence.
I
B
Sodium-glucose cotransporter-2 inhibitors are recommended for patients with HF and AF regardless of left ventricular ejection fraction to 
reduce the risk of HF hospitalization and cardiovascular death.
I
A
Effective glycaemic control is recommended as part of comprehensive risk factor management in individuals with diabetes mellitus and AF, 
to reduce burden, recurrence, and progression of AF.
I
C
Weight loss is recommended as part of comprehensive risk factor management in overweight and obese individuals with AF to reduce 
symptoms and AF burden, with a target of 10% or more reduction in body weight.
I
B
A tailored exercise programme is recommended in individuals with paroxysmal or persistent AF to improve cardiorespiratory fitness and 
reduce AF recurrence.
I
B
Reducing alcohol consumption to ≤3 standard drinks (≤30 grams of alcohol) per week is recommended as part of comprehensive risk 
factor management to reduce AF recurrence.
I
B
When screening for obstructive sleep apnoea in individuals with AF, using only symptom-based questionnaires is not recommended.
III
B
Recommendations to assess and manage thromboembolic risk in AF
Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
A
A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral 
anticoagulation.
I
C
Oral anticoagulation is recommended in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of 
CHA2DS2-VA score, to prevent ischaemic stroke and thromboembolism.
I
B
Individualized reassessment of thromboembolic risk is recommended at periodic intervals in patients with AF to ensure anticoagulation is 
started in appropriate patients.
I
B
Antiplatelet therapy is not recommended as an alternative to anticoagulation in patients with AF to prevent ischaemic stroke and 
thromboembolism.
III
A
Using the temporal pattern of clinical AF (paroxysmal, persistent, or permanent) is not recommended to determine the need for oral 
anticoagulation.
III
B
Continued 
ESC Guidelines                                                                                                                                                                                          3379


<!-- PAGE 67 -->

### Page 67

Recommendations for oral anticoagulation in AF
Direct oral anticoagulants are recommended in preference to VKAs to prevent ischaemic stroke and thromboembolism, except in patients 
with mechanical heart valves or moderate-to-severe mitral stenosis.
I
A
A target INR of 2.0–3.0 is recommended for patients with AF prescribed a VKA for stroke prevention to ensure safety and effectiveness.
I
B
Switching to a DOAC is recommended for eligible patients that have failed to maintain an adequate time in therapeutic range on a VKA 
(TTR <70%) to prevent thromboembolism and intracranial haemorrhage.
I
B
A reduced dose of DOAC therapy is not recommended, unless patients meet DOAC-specific criteria, to prevent underdosing and 
avoidable thromboembolic events.
III
B
Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention
Adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for the goal of preventing ischaemic stroke or 
thromboembolism.
III
B
Recommendations for thromboembolism despite anticoagulation
Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke.
III
B
Switching from one DOAC to another, or from a DOAC to a VKA, without a clear indication is not recommended in patients with AF to 
prevent recurrent embolic stroke.
III
B
Recommendations for surgical left atrial appendage occlusion
Surgical closure of the left atrial appendage is recommended as an adjunct to oral anticoagulation in patients with AF undergoing cardiac 
surgery to prevent ischaemic stroke and thromboembolism.
I
B
Recommendations for assessment of bleeding risk
Assessment and management of modifiable bleeding risk factors is recommended in all patients eligible for oral anticoagulation, as part of 
shared decision-making to ensure safety and prevent bleeding.
I
B
Use of bleeding risk scores to decide on starting or withdrawing oral anticoagulation is not recommended in patients with AF to avoid 
under-use of anticoagulation.
III
B
Recommendations for management of bleeding in anticoagulated patients
Interrupting anticoagulation and performing diagnostic or treatment interventions is recommended in AF patients with active bleeding until 
the cause of bleeding is identified and resolved.
I
C
Recommendations for heart rate control in patients with AF
Rate control therapy is recommended in patients with AF, as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as 
a sole treatment strategy to control heart rate and reduce symptoms.
I
B
Beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-choice drugs in patients with AF and LVEF >40% to control heart 
rate and reduce symptoms.
I
B
Beta-blockers and/or digoxin are recommended in patients with AF and LVEF ≤40% to control heart rate and reduce symptoms.
I
B
Recommendations for general concepts in rhythm control
Electrical cardioversion is recommended in AF patients with acute or worsening haemodynamic instability to improve immediate patient 
outcomes.
I
C
Direct oral anticoagulants are recommended in preference to VKAs in eligible patients with AF undergoing cardioversion for 
thromboembolic risk reduction.
I
A
Therapeutic oral anticoagulation for at least 3 weeks (adherence to DOACs or INR ≥2.0 for VKAs) is recommended before scheduled 
cardioversion of AF and atrial flutter to prevent procedure-related thromboembolism.
I
B
Transoesophageal echocardiography is recommended if 3 weeks of therapeutic oral anticoagulation has not been provided, for exclusion of 
cardiac thrombus to enable early cardioversion.
I
B
Oral anticoagulation is recommended to continue for at least 4 weeks in all patients after cardioversion and long-term in patients with 
thromboembolic risk factor(s) irrespective of whether sinus rhythm is achieved, to prevent thromboembolism.
I
B
Early cardioversion is not recommended without appropriate anticoagulation or transoesophageal echocardiography if AF duration is 
longer than 24 h, or there is scope to wait for spontaneous cardioversion.
III
C
Recommendations for pharmacological cardioversion of AF
Intravenous flecainide or propafenone is recommended when pharmacological cardioversion of recent-onset AF is desired, excluding 
patients with severe left ventricular hypertrophy, HFrEF, or coronary artery disease.
I
A
Intravenous vernakalant is recommended when pharmacological cardioversion of recent-onset AF is desired, excluding patients with recent 
ACS, HFrEF, or severe aortic stenosis.
I
A
Intravenous amiodarone is recommended when cardioversion of AF in patients with severe left ventricular hypertrophy, HFrEF, or 
coronary artery disease is desired, accepting there may be a delay in cardioversion.
I
A
Pharmacological cardioversion is not recommended for patients with sinus node dysfunction, atrioventricular conduction disturbances, or 
prolonged QTc (>500 ms), unless risks for proarrhythmia and bradycardia have been considered.
III
C
Continued


<!-- PAGE 68 -->

### Page 68

Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm
Amiodarone is recommended in patients with AF and HFrEF requiring long-term antiarrhythmic drug therapy to prevent recurrence and 
progression of AF, with careful consideration and monitoring for extracardiac toxicity.
I
A
Dronedarone is recommended in patients with AF requiring long-term rhythm control, including those with HFmrEF, HFpEF, ischaemic 
heart disease, or valvular disease to prevent recurrence and progression of AF.
I
A
Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression 
of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease.
I
A
Antiarrhythmic drug therapy is not recommended in patients with advanced conduction disturbances unless antibradycardia pacing is 
provided.
III
C
Recommendations for catheter ablation of AF
Shared decision-making
Shared decision-making is recommended when considering catheter ablation for AF, taking into account procedural risks, likely benefits, and 
risk factors for AF recurrence.
I
C
Atrial fibrillation patients resistant or intolerant to antiarrhythmic drug therapy
Catheter ablation is recommended in patients with paroxysmal or persistent AF resistant or intolerant to antiarrhythmic drug therapy to 
reduce symptoms, recurrence, and progression of AF.
I
A
First-line rhythm control therapy
Catheter ablation is recommended as a first-line option within a shared decision-making rhythm control strategy in patients with 
paroxysmal AF, to reduce symptoms, recurrence, and progression of AF.
I
A
Patients with heart failure
Atrial fibrillation catheter ablation is recommended in patients with AF and HFrEF with high probability of tachycardia-induced 
cardiomyopathy to reverse left ventricular dysfunction.
I
B
Recommendations for anticoagulation in patients undergoing catheter ablation
Initiation of oral anticoagulation is recommended at least 3 weeks prior to catheter-based ablation in AF patients at elevated 
thromboembolic risk, to prevent peri-procedural ischaemic stroke and thromboembolism.
I
C
Uninterrupted oral anticoagulation is recommended in patients undergoing AF catheter ablation to prevent peri-procedural ischaemic 
stroke and thromboembolism.
I
A
Continuation of oral anticoagulation is recommended for at least 2 months after AF ablation in all patients, irrespective of rhythm outcome 
or CHA2DS2-VA score, to reduce the risk of peri-procedural ischaemic stroke and thromboembolism.
I
C
Continuation of oral anticoagulation is recommended after AF ablation according to the patient’s CHA2DS2-VA score, and not the 
perceived success of the ablation procedure, to prevent ischaemic stroke and thromboembolism.
I
C
Recommendations for endoscopic and hybrid AF ablation
Continuation of oral anticoagulation is recommended in patients with AF at elevated thromboembolic risk after concomitant, endoscopic, 
or hybrid AF ablation, independent of rhythm outcome or LAA exclusion, to prevent ischaemic stroke and thromboembolism.
I
C
Recommendations for AF ablation during cardiac surgery
Concomitant surgical ablation is recommended in patients undergoing mitral valve surgery and AF suitable for a rhythm control strategy to 
prevent symptoms and recurrence of AF, with shared decision-making supported by an experienced team of electrophysiologists and 
arrhythmia surgeons.
I
A
Intraprocedural imaging for detection of left atrial thrombus in patients undergoing surgical ablation is recommended to guide surgical 
strategy, independent of oral anticoagulant use, to prevent peri-procedural ischaemic stroke and thromboembolism.
I
C
Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention
General recommendations for patients with AF and an indication for concomitant antiplatelet therapy
For combinations with antiplatelet therapy, a DOAC is recommended in eligible patients in preference to a VKA to mitigate bleeding risk 
and prevent thromboembolism.
I
A
Recommendations for AF patients with ACS
Early cessation (≤1 week) of aspirin and continuation of an oral anticoagulant (preferably DOAC) with a P2Y12 inhibitor (preferably 
clopidogrel) for up to 12 months is recommended in AF patients with ACS undergoing an uncomplicated PCI to avoid major bleeding, if the 
risk of thrombosis is low or bleeding risk is high.
I
A
Recommendations for AF patients undergoing PCI
After uncomplicated PCI, early cessation (≤1 week) of aspirin and continuation of an oral anticoagulant and a P2Y12 inhibitor (preferably 
clopidogrel) for up to 6 months is recommended to avoid major bleeding, if ischaemic risk is low.
I
A
Continued 
ESC Guidelines                                                                                                                                                                                          3381


<!-- PAGE 69 -->

### Page 69

### 14 Evidence tables

Evidence tables are available at European Heart Journal online.
15. Data availability statement
No new data were generated or analysed in support of this research.
16. Author information
Author/Task Force Member Affiliations: Michiel Rienstra, 
Department of Cardiology, University of Groningen, University 
Medical Center Groningen, Groningen, Netherlands; Karina 
V. Bunting, Institute of Cardiovascular Sciences, University of 
Birmingham, Birmingham, United Kingdom, Cardiology Department, 
Queen Elizabeth Hospital, University Hospitals Birmingham NHS 
Foundation 
Trust, 
Birmingham, 
United 
Kingdom; 
Ruben 
Casado-Arroyo, Department of Cardiology, H.U.B.-Hôpital 
Erasme, Université Libre de Bruxelles, Brussels, Belgium; Valeria 
Caso, Stroke Unit, Santa della Misericordia Hospital, Perugia, Italy; 
Harry J.G.M. Crijns, Cardiology Maastricht University Medical 
Centre, Maastricht, Netherlands, Cardiology Cardiovascular Research 
Institute Maastricht, Maastricht University, Maastricht, Netherlands; 
Tom J. R. De Potter, Department of Cardiology, OLV Hospital, 
Recommendations for AF patients with chronic coronary or vascular disease
Antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary or vascular disease treated with oral 
anticoagulation, due to lack of efficacy and to avoid major bleeding.
III
B
Recommendations for management of post-operative AF
Peri-operative amiodarone therapy is recommended where drug therapy is desired to prevent post-operative AF after cardiac surgery.
I
A
Routine use of beta-blockers is not recommended in patients undergoing non-cardiac surgery for the prevention of post-operative AF.
III
B
Recommendations for patients with embolic stroke of unknown source
Prolonged monitoring for AF is recommended in patients with ESUS to inform on AF treatment decisions.
I
B
Initiation of oral anticoagulation in ESUS patients without documented AF is not recommended due to lack of efficacy in preventing 
ischaemic stroke and thromboembolism.
III
A
Recommendations for patients with AF during pregnancy
Immediate electrical cardioversion is recommended in patients with AF during pregnancy and haemodynamic instability or pre-excited AF 
to improve maternal and foetal outcomes.
I
C
Therapeutic anticoagulation with LMWHs or VKAs (except VKAs for the first trimester or beyond Week 36) is recommended for pregnant 
patients with AF at elevated thromboembolic risk to prevent ischaemic stroke and thromboembolism.
I
C
Beta-1 selective blockers are recommended for heart rate control of AF in pregnancy to reduce symptoms and improve maternal and foetal 
outcomes, excluding atenolol.
I
C
Recommendations for prevention of thromboembolism in atrial flutter
Oral anticoagulation is recommended in patients with atrial flutter at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
B
Recommendations for screening for AF
Review of an ECG (12-lead, single, or multiple leads) by a physician is recommended to provide a definite diagnosis of AF and commence 
appropriate management.
I
B
Routine heart rhythm assessment during healthcare contact is recommended in all individuals aged ≥65 years for earlier detection of AF.
I
C
Recommendations for primary prevention of AF
Maintaining optimal blood pressure is recommended in the general population to prevent AF, with ACE inhibitors or ARBs as first-line 
therapy.
I
B
Appropriate medical HF therapy is recommended in individuals with HFrEF to prevent AF.
I
B
Maintaining normal weight (BMI 20–25 kg/m2) is recommended for the general population to prevent AF.
I
B
Maintaining an active lifestyle is recommended to prevent AF, with the equivalent of 150–300 min per week of moderate intensity or 75– 
150 min per week of vigorous intensity aerobic physical activity.
I
B
Avoidance of binge drinking and alcohol excess is recommended in the general population to prevent AF.
I
B
© ESC 2024
AAD, antiarrhythmic drugs; ACEi, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk 
factor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; AFL, atrial flutter; ARB, 
angiotensin receptor blocker; BMI, body mass index; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic 
attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; ESUS, embolic stroke of undetermined source; 
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; 
INR, international normalized ratio of prothrombin time; LAA, left atrial appendage; LMWH, low molecular weight heparin; LVEF, left ventricular ejection fraction; PCI, percutaneous 
intervention; SGLT2, sodium-glucose cotransporter-2; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 70 -->

### Page 70

Aalst, Belgium; Jeremy Dwight (United Kingdom), ESC Patient 
Forum, Sophia Antipolis, France; Luigina Guasti, Department of 
Medicine and Surgery, University of Insubria, Varese, Italy, Division of 
Geriatrics and Clinical Gerontology, ASST-Settelaghi, Varese, Italy; 
Thorsten Hanke, Clinic For Cardiac Surgery, Asklepios Klinikum, 
Harburg, Hamburg, Germany; Tiny Jaarsma, Department of 
Cardiology, Linkoping University, Linkoping, Sweden, Julius Center 
for Health Sciences and Primary Care, University Medical Center 
Utrecht, Utrecht, Netherlands; Maddalena Lettino, Department 
for Cardiac, Thoracic and Vascular Diseases, Fondazione IRCCS San 
Gerardo dei Tintori, Monza, Italy; Maja-Lisa Løchen, Deparment 
of Clincal Medicine UiT, The Arctic University of Norway, Tromsø, 
Norway, Department of Cardiology, University Hospital of North 
Norway, Tromsø, Norway; R. Thomas Lumbers, Institute of 
Health Informatics, University College London, London, United 
Kingdom, Saint Bartholomew’s Hospital, Barts Health NHS Trust, 
London, United Kingdom, University College Hospital, University 
College London Hospitals NHS Trust, London, United Kingdom; 
Bart Maesen, Department of Cardiothoracic Surgery, Maastricht 
University Medical Centre+, Maastricht, Netherlands, Cardiovascular 
Research Institute Maastricht, Maastricht University, Maastricht, 
Netherlands; Inge Mølgaard (Denmark), ESC Patient Forum, 
Sophia Antipolis, France; Giuseppe M.C. Rosano, Department of 
Human Sciences and Promotion of Quality of Life, Chair of 
Pharmacology, San Raffaele University of Rome, Rome, Italy, 
Cardiology, 
San 
Raffaele 
Cassino 
Hospital, 
Cassino, 
Italy, 
Cardiovascular Academic Group, St George’s University Medical 
School, London, United Kingdom; Prashanthan Sanders, Centre 
for Heart Rhythm Disorders, University of Adelaide, Adelaide, 
Australia, Department of Cardiology, Royal Adelaide Hospital, 
Adelaide, Australia; Renate B. Schnabel, Cardiology University 
Heart & Vascular Center Hamburg, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany, German Center for 
Cardiovascular Research (DZHK) Partner site Hamburg/Kiel/Lübeck, 
Germany; Piotr Suwalski, Department of Cardiac Surgery and 
Transplantology, National Medical Institute of the Ministry of Interior 
and Administration, Centre of Postgraduate Medical Education, 
Warsaw, Poland; Emma Svennberg, Department of Medicine, 
Karolinska University Hospital Huddinge, Karolinska Institutet, 
Stockholm, Sweden, Department of Cardiology, Karolinska University 
Hospital, Stockholm, Sweden; Juan Tamargo, Pharmacology and 
Toxicology School of Medicine, Universidad Complutense, Madrid, 
Spain; Otilia Tica, Department of Cardiology, Emergency County 
Clinical 
Hospital of 
Bihor, 
Oradea, Romania, 
Institute 
of 
Cardiovascular Sciences, University of Birmingham, Birmingham, 
United Kingdom; Vassil Traykov, Department of Invasive 
Electrophysiology, Acibadem City Clinic Tokuda University Hospital, 
Sofia, Bulgaria; and Stylianos Tzeis, Cardiology Department, Mitera 
Hospital, Athens, Greece.
17. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Nikolaos Dagres (CPG Review 
Co-ordinator) (Germany), Bianca Rocca (CPG Review Co-ordinator) 
(Italy), Syed Ahsan (United Kingdom), Pietro Ameri (Italy), Elena 
Arbelo (Spain), Axel Bauer (Austria), Michael A. Borger (Germany), 
Sergio Buccheri (Sweden), Barbara Casadei (United Kingdom), Ovidiu 
Chioncel (Romania), Dobromir Dobrev (Germany), Laurent Fauchier 
(France), Bruna Gigante (Sweden), Michael Glikson (Israel), Ziad 
Hijazi (Sweden), Gerhard Hindricks (Germany), Daniela Husser 
(Germany), Borja Ibanez (Spain), Stefan James (Sweden), Stefan Kaab 
(Germany), Paulus Kirchhof (Germany), Lars Køber (Denmark), 
Konstantinos C. Koskinas (Switzerland), Thomas Kumler (Denmark), 
Gregory Y.H. Lip (United Kingdom), John Mandrola (United States of 
America), Nikolaus Marx (Germany), John William Mcevoy (Ireland), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Denisa Muraru (Italy), Lis Neubeck (United Kingdom), Jens 
Cosedis Nielsen (Denmark), Jonas Oldgren (Sweden), Maurizio 
Paciaroni (Italy), Agnes A. Pasquet (Belgium), Eva Prescott 
(Denmark), Filip Rega (Belgium), Francisco Javier Rossello (Spain), 
Marcin Rucinski (Poland), Sacha P. Salzberg (Switzerland), Sam 
Schulman (Canada), Philipp Sommer (Germany), Jesper Hastrup 
Svendsen (Denmark), Jurrien M. ten Berg (Netherlands), Hugo Ten 
Cate (Netherlands), Ilonca Vaartjes (Netherlands), Christiaan Jm. 
Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld 
(Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2024 ESC Guidelines for the management of atrial 
fibrillation:
Albania: Albanian Society of Cardiology, Leonard Simoni; Algeria: 
Algerian Society of Cardiology, Brahim Kichou; Armenia: Armenian 
Cardiologists Association, Hamayak S. Sisakian; Austria: Austrian 
Society of Cardiology, Daniel Scherr; Belgium: Belgian Society of 
Cardiology, Frank Cools; Bosnia and Herzegovina: Association of 
Cardiologists of Bosnia and Herzegovina, Elnur Smajić; Bulgaria: 
Bulgarian Society of Cardiology, Tchavdar Shalganov; Croatia: 
Croatian Cardiac Society, Sime Manola; Cyprus: Cyprus Society 
of Cardiology, Panayiotis Avraamides; Czechia: Czech Society of 
Cardiology, Milos Taborsky; Denmark: Danish Society of 
Cardiology, Axel Brandes; Egypt: Egyptian Society of Cardiology, 
Ahmed M. El-Damaty; Estonia: Estonian Society of Cardiology, Priit 
Kampus; Finland: Finnish Cardiac Society, Pekka Raatikainen; 
France: French Society of Cardiology, Rodrigue Garcia; Georgia: 
Georgian Society of Cardiology, Kakhaber Etsadashvili; Germany: 
German Cardiac Society, Lars Eckardt; Greece: Hellenic Society of 
Cardiology, Eleftherios Kallergis; Hungary: Hungarian Society of 
Cardiology, László Gellér; Iceland: Icelandic Society of Cardiology, 
Kristján Guðmundsson; Ireland: Irish Cardiac Society, Jonathan 
Lyne; Israel: Israel Heart Society, Ibrahim Marai; Italy: Italian 
Federation of Cardiology, Furio Colivicchi; Kazakhstan: Association 
of Cardiologists of Kazakhstan, Ayan Suleimenovich Abdrakhmanov; 
Kosovo (Republic of): Kosovo Society of Cardiology, Ibadete 
Bytyci; 
Kyrgyzstan: 
Kyrgyz 
Society 
of 
Cardiology, 
Alina 
Kerimkulova; Latvia: Latvian Society of Cardiology, Kaspars Kupics; 
Lebanon: Lebanese Society of Cardiology, Marwan Refaat; Libya: 
Libyan Cardiac Society, Osama Abdulmajed Bheleel; Lithuania: 
Lithuanian Society of Cardiology, Jūratė Barysienė; Luxembourg: 
Luxembourg Society of Cardiology, Patrick Leitz; Malta: Maltese 
Cardiac Society, Mark A. Sammut; Moldova (Republic of): 
Moldavian Society of Cardiology, Aurel Grosu; Montenegro: 
Montenegro Society of Cardiology, Nikola Pavlovic; Morocco: 
Moroccan 
Society 
of 
Cardiology, 
Abdelhamid 
Moustaghfir; 
Netherlands: Netherlands Society of Cardiology, Sing-Chien Yap; 
North Macedonia: National Society of Cardiology of North 
Macedonia, Jane Taleski; Norway: Norwegian Society of Cardiology, 
Trine Fink; Poland: Polish Cardiac Society, Jaroslaw Kazmierczak; 
Portugal: Portuguese Society of Cardiology, Victor M. Sanfins; 
Romania: Romanian Society of Cardiology, Dragos Cozma; San 
ESC Guidelines                                                                                                                                                                                          3383


<!-- PAGE 71 -->

### Page 71

Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: 
Cardiology Society of Serbia, Dragan V. Kovačević; Slovakia: Slovak 
Society of Cardiology, Peter Hlivak; Slovenia: Slovenian Society of 
Cardiology, Igor Zupan; Spain: Spanish Society of Cardiology, David 
Calvo; Sweden: Swedish Society of Cardiology, Anna Björkenheim; 
Switzerland: Swiss Society of Cardiology, Michael Kühne; Tunisia: 
Tunisian Society of Cardiology and Cardiovascular Surgery, Sana 
Ouali; Turkey: Turkish Society of Cardiology, Sabri Demircan; 
Ukraine: Ukrainian Association of Cardiology, Oleg S. Sychov; 
United Kingdom of Great Britain and Northern Ireland: 
British Cardiovascular Society, Andre Ng; and Uzbekistan: 
Association of Cardiologists of Uzbekistan, Husniddin Kuchkarov.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands). Andrea Sarkozy* (Belgium) *Contributor ei­
ther stepped down or was engaged in only a part of the review process.
18. References
1. Alam M, Bandeali SJ, Shahzad SA, Lakkis N. Real-life global survey evaluating 
patients with atrial fibrillation (REALISE-AF): results of an international observa­
tional registry. Expert Rev Cardiovasc Ther 2012;10:283–91. https://doi.org/10. 
1586/erc.12.8
2. De With RR, Erküner Ö, Rienstra M, Nguyen BO, Körver FWJ, Linz D, et al. Temporal 
patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE 
V. Europace 2020;22:1162–72. https://doi.org/10.1093/europace/euaa123
3. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of 
catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and 
cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical 
trial. JAMA 2019;321:1261–74. https://doi.org/10.1001/jama.2019.0693
4. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. 
Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378: 
417–27. https://doi.org/10.1056/NEJMoa1707855
5. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al. 
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The 
LOOP Study): a randomised controlled trial. Lancet 2021;398:1507–16. https://doi. 
org/10.1016/S0140-6736(21)01698-6
6. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical out­
comes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, 
parallel group, unmasked, randomised controlled trial. Lancet 2021;398:1498–506. 
https://doi.org/10.1016/S0140-6736(21)01637-8
7. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical 
atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120–9. https://doi.org/ 
10.1056/NEJMoa1105575
8. McIntyre WF, Healey JS, Bhatnagar AK, Wang P, Gordon JA, Baranchuk A, et al. 
Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review 
and meta-analysis. Europace 2019;21:1159–66. https://doi.org/10.1093/europace/ 
euz175
9. Bager JE, Martín A, Carbajosa Dalmau J, Simon A, Merino JL, Ritz B, et al. Vernakalant 
for cardioversion of recent-onset atrial fibrillation in the emergency department: 
the SPECTRUM study. Cardiology 2022;147:566–77. https://doi.org/10.1159/000 
526831
10. Pluymaekers N, Dudink E, Luermans J, Meeder JG, Lenderink T, Widdershoven J, et al. 
Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med 2019;380: 
1499–508. https://doi.org/10.1056/NEJMoa1900353
11. Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, et al. Long-term 
outcomes of secondary atrial fibrillation in the community: the Framingham Heart 
Study. Circulation 2015;131:1648–55. https://doi.org/10.1161/CIRCULATIONAHA. 
114.014058
12. Wang EY, Hulme OL, Khurshid S, Weng LC, Choi SH, Walkey AJ, et al. Initial precipi­
tants and recurrence of atrial fibrillation. Circ Arrhythm Electrophysiol 2020;13:e007716. 
https://doi.org/10.1161/CIRCEP.119.007716
13. Corica B, Romiti GF, Basili S, Proietti M. Prevalence of new-onset atrial fibrillation and 
associated outcomes in patients with sepsis: a systematic review and meta-analysis. 
J Pers Med 2022;12:547. https://doi.org/10.3390/jpm12040547
14. Bedford JP, Ferrando-Vivas P, Redfern O, Rajappan K, Harrison DA, Watkinson PJ, 
et al. New-onset atrial fibrillation in intensive care: epidemiology and outcomes. Eur 
Heart J Acute Cardiovasc Care 2022;11:620–8. https://doi.org/10.1093/ehjacc/zuac080
15. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. 
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomat­
ic atrial fibrillation: a randomized trial. JAMA 2005;293:2634–40. https://doi.org/10. 
1001/jama.293.21.2634
16. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. 
Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 
2021;384:305–15. https://doi.org/10.1056/NEJMoa2029980
17. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm- 
control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16. 
https://doi.org/10.1056/NEJMoa2019422
18. Coats AJS, Heymans S, Farmakis D, Anker SD, Backs J, Bauersachs J, et al. Atrial disease 
and heart failure: the common soil hypothesis proposed by the heart failure associ­
ation of the European Society of Cardiology. Eur Heart J 2022:43:863–7. https://doi. 
org/10.1093/eurheartj/ehab834
19. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, et al. Early diag­
nosis and better rhythm management to improve outcomes in patients with atrial fib­
rillation: the 8th AFNET/EHRA consensus conference. Europace 2023;25:6–27. https:// 
doi.org/10.1093/europace/euac062
20. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/ 
APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, character­
ization, and clinical implication. Europace 2016;18:1455–90. https://doi.org/10.1093/ 
europace/euw161
21. Sagris D, Georgiopoulos G, Pateras K, Perlepe K, Korompoki E, Milionis H, et al. Atrial 
high-rate episode duration thresholds and thromboembolic risk: a systematic review 
and meta-analysis. J Am Heart Assoc 2021;10:e022487. https://doi.org/10.1161/JAHA. 
121.022487
22. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH, 
et al. Positive predictive value of device-detected atrial high-rate episodes at different 
rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6. https:// 
doi.org/10.1016/j.hrthm.2012.03.017
23. Miyazawa K, Pastori D, Martin DT, Choucair WK, Halperin JL, Lip GYH. 
Characteristics of patients with atrial high rate episodes detected by implanted defib­
rillator and resynchronization devices. Europace 2022;24:375–83. https://doi.org/10. 
1093/europace/euab186
24. Vitolo M, Imberti JF, Maisano A, Albini A, Bonini N, Valenti AC, et al. Device-detected 
atrial high rate episodes and the risk of stroke/thromboembolism and atrial fibrillation 
incidence: a systematic review and meta-analysis. Eur J Intern Med 2021;92:100–6. 
https://doi.org/10.1016/j.ejim.2021.05.038
25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran 
versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51. 
https://doi.org/10.1056/NEJMoa0905561
26. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. 
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369: 
2093–104. https://doi.org/10.1056/NEJMoa1310907
27. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. 
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 
981–92. https://doi.org/10.1056/NEJMoa1107039
28. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus 
warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91. https://doi. 
org/10.1056/NEJMoa1009638
29. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527–39. 
https://doi.org/10.1161/01.CIR.84.2.527
30. Mannina C, Jin Z, Matsumoto K, Ito K, Biviano A, Elkind MSV, et al. Frequency of cardiac 
arrhythmias in older adults: findings from the subclinical atrial fibrillation and risk of is­
chemic stroke (SAFARIS) study. Int J Cardiol 2021;337:64–70. https://doi.org/10.1016/j. 
ijcard.2021.05.006
31. Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, et al. Gender 
differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 
2017;103:1024–30. https://doi.org/10.1136/heartjnl-2016-310406
32. Simantirakis EN, Papakonstantinou PE, Chlouverakis GI, Kanoupakis EM, Mavrakis HE, 
Kallergis EM, et al. Asymptomatic versus symptomatic episodes in patients with parox­
ysmal atrial fibrillation via long-term monitoring with implantable loop recorders. Int J 
Cardiol 2017;231:125–30. https://doi.org/10.1016/j.ijcard.2016.12.025
33. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, et al. Discerning the in­
cidence of symptomatic and asymptomatic episodes of atrial fibrillation before and 
after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern 
Med 2013;173:149–56. https://doi.org/10.1001/jamainternmed.2013.1561


<!-- PAGE 72 -->

### Page 72

34. Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, Proietti M, et al. 
Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic 
review and meta-analysis of 81,462 patients. J Clin Med 2021;10:3979. https://doi.org/ 
10.3390/jcm10173979
35. Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, et al. Defining 
clinically important difference in the atrial fibrillation effect on quality-of-life score. 
Circ 
Cardiovasc 
Qual 
Outcomes 
2019;12:e005358. 
https://doi.org/10.1161/ 
CIRCOUTCOMES.118.005358
36. Jones J, Stanbury M, Haynes S, Bunting KV, Lobban T, Camm AJ, et al. Importance and 
assessment of quality of life in symptomatic permanent atrial fibrillation: patient focus 
groups from the RATE-AF trial. Cardiology 2020;145:666–75. https://doi.org/10.1159/ 
000511048
37. Abu HO, Wang W, Otabil EM, Saczynski JS, Mehawej J, Mishra A, et al. Perception of 
atrial fibrillation symptoms: impact on quality of life and treatment in older adults. J Am 
Geriatr Soc 2022;70:2805–17. https://doi.org/10.1111/jgs.17954
38. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC; RACE Investigators. 
Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. 
Heart Rhythm 2014;11:939–45. https://doi.org/10.1016/j.hrthm.2014.03.016
39. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, et al. Targeted 
therapy of underlying conditions improves sinus rhythm maintenance in patients with 
persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987–96. 
https://doi.org/10.1093/eurheartj/ehx739
40. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, et al. Digoxin 
in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm 
2014;11:1543–50. https://doi.org/10.1016/j.hrthm.2014.06.007
41. Kloosterman M, Crijns H, Mulder BA, Groenveld HF, Van Veldhuisen DJ, Rienstra M, 
et al. Sex-related differences in risk factors, outcome, and quality of life in patients with 
permanent atrial fibrillation: results from the RACE II study. Europace 2020;22: 
1619–27. https://doi.org/10.1093/europace/euz300
42. Park YJ, Park JW, Yu HT, Kim TH, Uhm JS, Joung B, et al. Sex difference in atrial fibril­
lation recurrence after catheter ablation and antiarrhythmic drugs. Heart 2023;109: 
519–26. https://doi.org/10.1136/heartjnl-2021-320601
43. Kupper N, van den Broek KC, Widdershoven J, Denollet J. Subjectively reported 
symptoms in patients with persistent atrial fibrillation and emotional distress. Front 
Psychol 2013;4:192. https://doi.org/10.3389/fpsyg.2013.00192
44. Schnabel RB, Michal M, Wilde S, Wiltink J, Wild PS, Sinning CR, et al. Depression in 
atrial fibrillation in the general population. PLoS One 2013;8:e79109. https://doi.org/ 
10.1371/journal.pone.0079109
45. Gleason KT, Dennison Himmelfarb CR, Ford DE, Lehmann H, Samuel L, Han HR, et al. 
Association of sex, age and education level with patient reported outcomes in atrial 
fibrillation. BMC Cardiovasc Disord 2019;19:85. https://doi.org/10.1186/s12872-019- 
1059-6
46. Schnabel RB, Pecen L, Rzayeva N, Lucerna M, Purmah Y, Ojeda FM, et al. Symptom 
burden of atrial fibrillation and its relation to interventions and outcome in Europe. 
J Am Heart Assoc 2018;7:e007559. https://doi.org/10.1161/JAHA.117.007559
47. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European 
Heart Rhythm Association symptom classification for atrial fibrillation: validation and 
improvement through a simple modification. Europace 2014;16:965–72. https://doi. 
org/10.1093/europace/eut395
48. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs 
bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: 
the RATE-AF randomized clinical trial. JAMA 2020;324:2497–508. https://doi.org/10. 
1001/jama.2020.23138
49. Kotecha D, Ahmed A, Calvert M, Lencioni M, Terwee CB, Lane DA. Patient-reported 
outcomes for quality of life assessment in atrial fibrillation: a systematic review of 
measurement properties. PLoS One 2016;11:e0165790. https://doi.org/10.1371/ 
journal.pone.0165790
50. Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, Novak P, et al. Relationship of 
quality of life with procedural success of atrial fibrillation (AF) ablation and postablation 
AF burden: substudy of the STAR AF randomized trial. Can J Cardiol 2013;29:1211–7. 
https://doi.org/10.1016/j.cjca.2013.06.006
51. Samuel M, Khairy P, Champagne J, Deyell MW, Macle L, Leong-Sit P, et al. Association 
of atrial fibrillation burden with health-related quality of life after atrial fibrillation ab­
lation: substudy of the cryoballoon vs contact-force atrial fibrillation ablation 
(CIRCA-DOSE) randomized clinical trial. JAMA Cardiol 2021;6:1324–8. https://doi. 
org/10.1001/jamacardio.2021.3063
52. Sandhu RK, Smigorowsky M, Lockwood E, Savu A, Kaul P, McAlister FA. Impact of elec­
trical cardioversion on quality of life for the treatment of atrial fibrillation. Can J Cardiol 
2017;33:450–5. https://doi.org/10.1016/j.cjca.2016.11.013
53. Terricabras M, Mantovan R, Jiang CY, Betts TR, Chen J, Deisenhofer I, et al. Association 
between quality of life and procedural outcome after catheter ablation for atrial fibril­
lation: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2020;3: 
e2025473. https://doi.org/10.1001/jamanetworkopen.2020.25473
54. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, et al. Patient-reported 
outcomes and subsequent management in atrial fibrillation clinical practice: results 
from the Utah mEVAL AF program. J Cardiovasc Electrophysiol 2020;31:3187–95. 
https://doi.org/10.1111/jce.14795
55. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators 
for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494–5. 
https://doi.org/10.1093/europace/euaa253
56. Kvist LM, Vinter N, Urbonaviciene G, Lindholt JS, Diederichsen ACP, Frost L. 
Diagnostic accuracies of screening for atrial fibrillation by cardiac nurses versus radio­
graphers. Open Heart 2019;6:e000942. https://doi.org/10.1136/openhrt-2018-000942
57. Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrilla­
tion: a clinical review. Eur Heart J 2013;34:1475–80. https://doi.org/10.1093/eurheartj/ 
eht024
58. Berg DD, Ruff CT, Morrow DA. Biomarkers for risk assessment in atrial fibrillation. 
Clin Chem 2021;67:87–95. https://doi.org/10.1093/clinchem/hvaa298
59. Tops LF, Schalij MJ, Bax JJ. Imaging and atrial fibrillation: the role of multimodality im­
aging in patient evaluation and management of atrial fibrillation. Eur Heart J 2010;31: 
542–51. https://doi.org/10.1093/eurheartj/ehq005
60. Obeng-Gyimah E, Nazarian S. Advancements in imaging for atrial fibrillation ablation: is 
there a potential to improve procedural outcomes? J Innov Card Rhythm Manag 2020; 
11:4172–8. https://doi.org/10.19102/icrm.2020.110701
61. Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial 
appendage thrombus by cardiac computed tomography in patients with atrial fibrilla­
tion: a meta-analysis. Circ Cardiovasc Imaging 2013;6:185–94. https://doi.org/10.1161/ 
CIRCIMAGING.112.000153
62. Bisbal F, Benito E, Teis A, Alarcón F, Sarrias A, Caixal G, et al. Magnetic resonance 
imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial. 
Circ Arrhythm Electrophysiol 2020;13:e008707. https://doi.org/10.1161/CIRCEP.120. 
008707
63. Khurram IM, Habibi M, Gucuk Ipek E, Chrispin J, Yang E, Fukumoto K, et al. Left atrial 
LGE and arrhythmia recurrence following pulmonary vein isolation for paroxysmal and 
persistent AF. JACC Cardiovasc Imaging 2016;9:142–8. https://doi.org/10.1016/j.jcmg. 
2015.10.015
64. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. 
Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial 
fibrillation catheter ablation: the DECAAF study. JAMA 2014;311:498–506. https:// 
doi.org/10.1001/jama.2014.3
65. Roney CH, Sillett C, Whitaker J, Lemus JAS, Sim I, Kotadia I, et al. Applications of multi­
modality imaging for left atrial catheter ablation. Eur Heart J Cardiovasc Imaging 2021; 
23:31–41. https://doi.org/10.1093/ehjci/jeab205
66. Potter A, Augustine DX, Ingram TE. Referring for echocardiography: when not to test. 
Br J Gen Pract 2021;71:333–4. https://doi.org/10.3399/bjgp21X716441
67. Troughton RW, Asher CR, Klein AL. The role of echocardiography in atrial fibrillation 
and cardioversion. Heart 2003;89:1447–54. https://doi.org/10.1136/heart.89.12.1447
68. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation 
and risks of cardiovascular disease, renal disease, and death: systematic review and 
meta-analysis. BMJ 2016;354:i4482. https://doi.org/10.1136/bmj.i4482
69. Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fib­
rillation and the risk for myocardial infarction, all-cause mortality and heart failure: a 
systematic review and meta-analysis. Eur J Prev Cardiol 2017;24:1555–66. https://doi. 
org/10.1177/2047487317715769
70. Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, et al. 
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF 
registry: rationale for comprehensive management of atrial fibrillation. PLoS One 2018; 
13:e0191592. https://doi.org/10.1371/journal.pone.0191592
71. Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, et al. Two-year 
outcomes of patients with newly diagnosed atrial fibrillation: results from 
GARFIELD-AF. Eur Heart J 2016;37:2882–9. https://doi.org/10.1093/eurheartj/ 
ehw233
72. Hornestam B, Adiels M, Wai Giang K, Hansson PO, Björck L, Rosengren A. Atrial fib­
rillation and risk of venous thromboembolism: a Swedish nationwide registry study. 
Europace 2021;23:1913–21. https://doi.org/10.1093/europace/euab180
73. Lutsey PL, Norby FL, Alonso A, Cushman M, Chen LY, Michos ED, et al. Atrial fibril­
lation and venous thromboembolism: evidence of bidirectionality in the atheroscler­
osis risk in communities study. J Thromb Haemost 2018;16:670–9. https://doi.org/10. 
1111/jth.13974
74. Koh YH, Lew LZW, Franke KB, Elliott AD, Lau DH, Thiyagarajah A, et al. Predictive 
role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 
2.8 million individuals. Europace 2022;24:1229–39. https://doi.org/10.1093/europace/ 
euac003
75. Papanastasiou CA, Theochari CA, Zareifopoulos N, Arfaras-Melainis A, Giannakoulas 
G, Karamitsos TD, et al. Atrial fibrillation is associated with cognitive impairment, all- 
cause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and 
meta-analysis. J Gen Intern Med 2021;36:3122–35. https://doi.org/10.1007/s11606- 
021-06954-8
76. Giannone ME, Filippini T, Whelton PK, Chiari A, Vitolo M, Boriani G, et al. Atrial fib­
rillation and the risk of early-onset dementia: a systematic review and meta-analysis. 
J Am Heart Assoc 2022;11:e025653. https://doi.org/10.1161/JAHA.122.025653
ESC Guidelines                                                                                                                                                                                          3385


<!-- PAGE 73 -->

### Page 73

77. Zuin M, Roncon L, Passaro A, Bosi C, Cervellati C, Zuliani G. Risk of dementia in pa­
tients with atrial fibrillation: short versus long follow-up. A systematic review and 
meta-analysis. Int J Geriatr Psychiatry 2021;36:1488–500. https://doi.org/10.1002/gps. 
5582
78. Mobley AR, Subramanian A, Champsi A, Wang X, Myles P, McGreavy P, et al. 
Thromboembolic events and vascular dementia in patients with atrial fibrillation and 
low apparent stroke risk. Nat Med 2024. https://doi.org/10.1038/s41591-024- 
03049-9.
79. Wijtvliet E, Tieleman RG, van Gelder IC, Pluymaekers N, Rienstra M, Folkeringa RJ, 
et al. Nurse-led vs. usual-care for atrial fibrillation. Eur Heart J 2020;41:634–41. 
https://doi.org/10.1093/eurheartj/ehz666
80. Wong CX, Brooks AG, Lau DH, Leong DP, Sun MT, Sullivan T, et al. Factors associated 
with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol 2012;110: 
1496–9. https://doi.org/10.1016/j.amjcard.2012.07.011
81. Dai H, Zhang Q, Much AA, Maor E, Segev A, Beinart R, et al. Global, regional, and na­
tional prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990– 
2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care 
Clin Outcomes 2021;7:574–82. https://doi.org/10.1093/ehjqcco/qcaa061
82. Țica O, Țica O, Bunting KV, deBono J, Gkoutos GV, Popescu MI, et al. Post-mortem 
examination of high mortality in patients with heart failure and atrial fibrillation. BMC 
Med 2022;20:331. https://doi.org/10.1186/s12916-022-02533-8
83. Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, et al. Bleeding and 
related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results 
from the GARFIELD-AF registry. Blood Adv 2021;5:1081–91. https://doi.org/10.1182/ 
bloodadvances.2020003560
84. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of 
death and predictors of all-cause mortality in anticoagulated patients with nonvalvular 
atrial fibrillation: data from ROCKET AF. J Am Heart Assoc 2016;5:e002197. https://doi. 
org/10.1161/JAHA.115.002197
85. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, et al. Incidence and 
predictors of atrial flutter in the general population. J Am Coll Cardiol 2000;36:2242–6. 
https://doi.org/10.1016/S0735-1097(00)00982-7
86. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, et al. Atrial flut­
ter and thromboembolic risk: a systematic review. Heart 2015;101:1446–55. https:// 
doi.org/10.1136/heartjnl-2015-307550
87. Lelorier P, Humphries KH, Krahn A, Connolly SJ, Talajic M, Green M, et al. Prognostic 
differences between atrial fibrillation and atrial flutter. Am J Cardiol 2004;93:647–9. 
https://doi.org/10.1016/j.amjcard.2003.11.042
88. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial 
flutter. Am J Cardiol 2001;87:346–9, A9. https://doi.org/10.1016/S0002-9149(00) 
01374-6
89. Corrado G, Sgalambro A, Mantero A, Gentile F, Gasparini M, Bufalino R, et al. 
Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana 
di Ecografia Cardiovascolare) multicentre study. Eur Heart J 2001;22:1042–51. 
https://doi.org/10.1053/euhj.2000.2427
90. Lin YS, Chen TH, Chi CC, Lin MS, Tung TH, Liu CH, et al. Different implications of 
heart failure, ischemic stroke, and mortality between nonvalvular atrial fibrillation 
and atrial flutter–a view from a national cohort study. J Am Heart Assoc 2017;6: 
e006406. https://doi.org/10.1161/JAHA.117.006406
91. Giehm-Reese M, Johansen MN, Kronborg MB, Jensen HK, Gerdes C, Kristensen J, et al. 
Discontinuation of oral anticoagulation and risk of stroke and death after ablation for 
typical atrial flutter: a nation-wide Danish cohort study. Int J Cardiol 2021;333:110–6. 
https://doi.org/10.1016/j.ijcard.2021.02.057
92. Gallagher C, Rowett D, Nyfort-Hansen K, Simmons S, Brooks AG, Moss JR, et al. 
Patient-centered educational resources for atrial fibrillation. JACC Clin Electrophysiol 
2019;5:1101–14. https://doi.org/10.1016/j.jacep.2019.08.007
93. Chung MK, Fagerlin A, Wang PJ, Ajayi TB, Allen LA, Baykaner T, et al. Shared decision 
making in cardiac electrophysiology procedures and arrhythmia management. Circ 
Arrhythm 
Electrophysiol 
2021;14:e007958. 
https://doi.org/10.1161/CIRCEP.121. 
007958
94. Wang PJ, Lu Y, Mahaffey KW, Lin A, Morin DP, Sears SF, et al. A randomized clinical 
trial to evaluate an atrial fibrillation stroke prevention shared decision-making pathway. 
J Am Heart Assoc 2022;12:e028562. https://doi.org/10.1161/JAHA.122.028562
95. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared 
decision making in atrial fibrillation: where we are and where we should be going. 
Circulation 
2014;129:704–10. 
https://doi.org/10.1161/CIRCULATIONAHA.113. 
004498
96. Zhang J, Lenarczyk R, Marin F, Malaczynska-Rajpold K, Kosiuk J, Doehner W, et al. The 
interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey 
by the European Heart Rhythm Association (EHRA) scientific initiatives committee, 
the EHRA young electrophysiologists, the Association of Cardiovascular Nursing 
and Allied Professionals, and the European Society of Cardiology council on stroke. 
Europace 2021;23:314–22. https://doi.org/10.1093/europace/euaa358
97. Omoush A, Aloush S, Albashtawy M, Rayan A, Alkhawaldeh A, Eshah N, et al. Nurses’ 
knowledge of anticoagulation therapy for atrial fibrillation patients: effectiveness of an 
educational course. Nurs Forum 2022;57:825–32. https://doi.org/10.1111/nuf.12770
98. Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, et al. Major knowledge 
gaps and system barriers to guideline implementation among European physicians 
treating patients with atrial fibrillation: a European Society of Cardiology international 
educational needs assessment. Europace 2018;20:1919–28. https://doi.org/10.1093/ 
europace/euy039
99. Bunting KV, Van Gelder IC, Kotecha D. STEEER-AF: a cluster-randomized education 
trial from the ESC. Eur Heart J 2020;41:1952–4. https://doi.org/10.1093/eurheartj/ 
ehaa421
100. Tanner FC, Brooks N, Fox KF, Gonçalves L, Kearney P, Michalis L, et al. ESC core cur­
riculum for the cardiologist. Eur Heart J 2020;41:3605–92. https://doi.org/10.1093/ 
eurheartj/ehaa641
101. Astin F, Carroll D, De Geest S, Fernandez-Oliver AL, Holt J, Hinterbuchner L, et al. A 
core curriculum for the continuing professional development of nurses working in car­
diovascular settings: developed by the education committee of the Council on 
Cardiovascular Nursing and Allied Professions (CCNAP) on behalf of the European 
Society of Cardiology. Eur J Cardiovasc Nurs 2015;14:S1–17. https://doi.org/10.1177/ 
1474515115580905
102. Sterlinski M, Bunting KV, Boriani G, Boveda S, Guasch E, Mont L, et al. STEEER-AF Trial 
Team. Design and deployment of the STEEER-AF trial to evaluate and improve guide­
line adherence: a cluster-randomised trial by the European Society of Cardiology and 
European Heart Rhythm Association. Europace 2024:euae178. https://doi.org/ 
10.1093/europace/euae178
103. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, et al. A multifaceted 
intervention to improve treatment with oral anticoagulants in atrial fibrillation 
(IMPACT-AF): an international, cluster-randomised trial. Lancet 2017;390:1737–46. 
https://doi.org/10.1016/S0140-6736(17)32165-7
104. Franchi C, Antoniazzi S, Ardoino I, Proietti M, Marcucci M, Santalucia P, et al. 
Simulation-based education for physicians to increase oral anticoagulants in hospita­
lized elderly patients with atrial fibrillation. Am J Med 2019;132:e634–47. https://doi. 
org/10.1016/j.amjmed.2019.03.052
105. Baicus C, Delcea C, Dima A, Oprisan E, Jurcut C, Dan GA. Influence of decision aids on 
oral anticoagulant prescribing among physicians: a randomised trial. Eur J Clin Invest 
2017;47:649–58. https://doi.org/10.1111/eci.12786
106. Ono F, Akiyama S, Suzuki A, Ikeda Y, Takahashi A, Matsuoka H, et al. Impact of care 
coordination on oral anticoagulant therapy among patients with atrial fibrillation in 
routine clinical practice in Japan: a prospective, observational study. BMC Cardiovasc 
Disord 2019;19:235. https://doi.org/10.1186/s12872-019-1216-y
107. Ferguson C, Hickman LD, Phillips J, Newton PJ, Inglis SC, Lam L, et al. An mHealth 
intervention to improve nurses’ atrial fibrillation and anticoagulation knowledge and 
practice: the EVICOAG study. Eur J Cardiovasc Nurs 2019;18:7–15. https://doi.org/ 
10.1177/1474515118793051
108. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, et al. 
Improved outcomes with European Society of Cardiology guideline-adherent antith­
rombotic treatment in high-risk patients with atrial fibrillation: a report from the 
EORP-AF general pilot registry. Europace 2015;17:1777–86. https://doi.org/10.1093/ 
europace/euv269
109. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa T, 
et al. Sex differences in cardiac arrhythmia: a consensus document of the European 
Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific 
Heart Rhythm Society. Europace 2018;20:1565–1565ao. https://doi.org/10.1093/ 
europace/euy067
110. Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, et al. 
Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular 
atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ 
Open 2017;7:e014579. https://doi.org/10.1136/bmjopen-2016-014579
111. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, et al. Atrial 
fibrillation as risk factor for cardiovascular disease and death in women compared 
with men: systematic review and meta-analysis of cohort studies. BMJ 2016;532: 
h7013. https://doi.org/10.1136/bmj.h7013
112. Tomasdottir M, Friberg L, Hijazi Z, Lindback J, Oldgren J. Risk of ischemic stroke and 
utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation. Clin Cardiol 
2019;42:1003–9. https://doi.org/10.1002/clc.23257
113. Kloosterman M, Chua W, Fabritz L, Al-Khalidi HR, Schotten U, Nielsen JC, et al. Sex 
differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. 
Europace 2020;22:1026–35. https://doi.org/10.1093/europace/euaa015
114. Benjamin EJ, Thomas KL, Go AS, Desvigne-Nickens P, Albert CM, Alonso A, et al. 
Transforming atrial fibrillation research to integrate social determinants of health: a na­
tional heart, lung, and blood institute workshop report. JAMA Cardiol 2023;8:182–91. 
https://doi.org/10.1001/jamacardio.2022.4091
115. Karlsson LO, Nilsson S, Bang M, Nilsson L, Charitakis E, Janzon M. A clinical decision 
support tool for improving adherence to guidelines on anticoagulant therapy in pa­
tients with atrial fibrillation at risk of stroke: a cluster-randomized trial in a Swedish 
primary care setting (the CDS-AF study). PLoS Med 2018;15:e1002528. https://doi. 
org/10.1371/journal.pmed.1002528


<!-- PAGE 74 -->

### Page 74

116. Biersteker TE, Schalij MJ, Treskes RW. Impact of mobile health devices for the detec­
tion of atrial fibrillation: systematic review. JMIR Mhealth Uhealth 2021;9:e26161. 
https://doi.org/10.2196/26161
117. Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. 
Adherence to the ‘atrial fibrillation better care’ pathway in patients with atrial fibrilla­
tion: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 
patients. Thromb Haemost 2022;122:406–14. https://doi.org/10.1055/a-1515-9630
118. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R, et al. 
Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart 
2017;103:1947–53. https://doi.org/10.1136/heartjnl-2016-310952
119. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC 
Guidelines for the management of atrial fibrillation developed in collaboration with 
EACTS. Eur Heart J 2016;37:2893–962. https://doi.org/10.1093/eurheartj/ehw210
120. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col­
laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the 
task force for the diagnosis and management of atrial fibrillation of the European 
Society of Cardiology (ESC) developed with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 
373–498. https://doi.org/10.1093/eurheartj/ehaa612
121. Qvist I, Hendriks JM, Møller DS, Albertsen AE, Mogensen HM, Oddershede GD, et al. 
Effectiveness of structured, hospital-based, nurse-led atrial fibrillation clinics: a com­
parison between a real-world population and a clinical trial population. Open Heart 
2016;3:e000335. https://doi.org/10.1136/openhrt-2015-000335
122. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, et al. Nurse-led care 
vs. usual care for patients with atrial fibrillation: results of a randomized trial of inte­
grated chronic care vs. routine clinical care in ambulatory patients with atrial fibrilla­
tion. Eur Heart J 2012;33:2692–9. https://doi.org/10.1093/eurheartj/ehs071
123. Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, et al. An integrated 
management approach to atrial fibrillation. J Am Heart Assoc 2016;5:e002950. https:// 
doi.org/10.1161/JAHA.115.002950
124. van den Dries CJ, van Doorn S, Rutten FH, Oudega R, van de Leur S, Elvan A, et al. 
Integrated management of atrial fibrillation in primary care: results of the ALL-IN clus­
ter randomized trial. Eur Heart J 2020;41:2836–44. https://doi.org/10.1093/eurheartj/ 
ehaa055
125. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect 
of weight reduction and cardiometabolic risk factor management on symptom burden 
and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 
310:2050–60. https://doi.org/10.1001/jama.2013.280521
126. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. 
Long-term effect of goal-directed weight management in an atrial fibrillation cohort: 
a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:2159–69. https:// 
doi.org/10.1016/j.jacc.2015.03.002
127. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. 
PREVEntion and regReSsive effect of weight-loss and risk factor modification on atrial 
fibrillation: the REVERSE-AF study. Europace 2018;20:1929–35. https://doi.org/10. 
1093/europace/euy117
128. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. 
Aggressive risk factor reduction study for atrial fibrillation and implications for the out­
come of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014;64:2222–31. 
https://doi.org/10.1016/j.jacc.2014.09.028
129. Pinho-Gomes AC, Azevedo L, Copland E, Canoy D, Nazarzadeh M, Ramakrishnan R, 
et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in 
patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med 
2021;18:e1003599. https://doi.org/10.1371/journal.pmed.1003599
130. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif J-C, Greiss I, et al. Effect of aggressive 
blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a 
randomized, open-label clinical trial (SMAC-AF [Substrate Modification with 
Aggressive Blood Pressure Control]). Circulation 2017;135:1788–98. https://doi.org/ 
10.1161/CIRCULATIONAHA.116.026230
131. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC 
guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the 
task force for the diagnosis and treatment of acute and chronic heart failure 2012 of 
the European Society of Cardiology. Developed in collaboration with the Heart Failure 
Association (HFA) of the ESC. Eur Heart J 2012;33:1787–847. https://doi.org/10.1093/ 
eurheartj/ehs104
132. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. 
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left 
ventricular systolic dysfunction: results from the Candesartan in Heart 
failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. 
J Am Coll Cardiol 2006;47:1997–2004. https://doi.org/10.1016/j.jacc.2006.01.060
133. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of 
beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient 
data meta-analysis. Lancet 2014;384:2235–43. https://doi.org/10.1016/S0140- 
6736(14)61373-8
134. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. 
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 
2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492
135. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. 
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 
371:993–1004. https://doi.org/10.1056/NEJMoa1409077
136. Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-glucose co- 
transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of 
randomized controlled trials. J Am Heart Assoc 2021;10:e022222. https://doi.org/10. 
1161/JAHA.121.022222
137. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368
138. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. 
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl 
J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286
139. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in 
heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. 
https://doi.org/10.1056/NEJMoa2107038
140. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in 
patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384: 
117–28. https://doi.org/10.1056/NEJMoa2030183
141. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of 
CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial 
fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 2015;66:985–96. https://doi.org/ 
10.1016/j.jacc.2015.06.488
142. Hegbom F, Stavem K, Sire S, Heldal M, Orning OM, Gjesdal K. Effects of short-term 
exercise training on symptoms and quality of life in patients with chronic atrial fibrilla­
tion. Int J Cardiol 2007;116:86–92. https://doi.org/10.1016/j.ijcard.2006.03.034
143. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized 
study of the effects of exercise training on patients with atrial fibrillation. Am Heart J 
2011;162:1080–7. https://doi.org/10.1016/j.ahj.2011.09.013
144. Malmo V, Nes BM, Amundsen BH, Tjonna AE, Stoylen A, Rossvoll O, et al. Aerobic 
interval training reduces the burden of atrial fibrillation in the short term: a randomized 
trial. Circulation 2016;133:466–73. https://doi.org/10.1161/CIRCULATIONAHA.115. 
018220
145. Oesterle A, Giancaterino S, Van Noord MG, Pellegrini CN, Fan D, Srivatsa UN, et al. 
Effects of supervised exercise training on atrial fibrillation: a meta-analysis of rando­
mized controlled trials. J Cardiopulm Rehabil Prev 2022;42:258–65. https://doi.org/10. 
1097/HCR.0000000000000665
146. Elliott AD, Verdicchio CV, Mahajan R, Middeldorp ME, Gallagher C, Mishima RS, et al. 
An exercise and physical activity program in patients with atrial fibrillation: the 
ACTIVE-AF randomized controlled trial. JACC Clin Electrophysiol 2023;9:455–65. 
https://doi.org/10.1016/j.jacep.2022.12.002
147. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, et al. 
Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 2020;382:20–8. 
https://doi.org/10.1056/NEJMoa1817591
148. Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, et al. Impact of ob­
structive sleep apnea and continuous positive airway pressure therapy on outcomes in 
patients with atrial fibrillation-results from the Outcomes Registry for Better Informed 
Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2015;169:647–654.e2. https:// 
doi.org/10.1016/j.ahj.2014.12.024
149. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K, et al. Treatment of obstructive 
sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am 
Coll Cardiol 2013;62:300–5. https://doi.org/10.1016/j.jacc.2013.03.052
150. Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y, et al. Efficacy of catheter ablation of atrial 
fibrillation in patients with obstructive sleep apnoea with and without continuous posi­
tive airway pressure treatment: a meta-analysis of observational studies. Europace 
2014;16:1309–14. https://doi.org/10.1093/europace/euu066
151. Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y, et al. Concomitant 
obstructive sleep apnea increases the recurrence of atrial fibrillation following radio­
frequency catheter ablation of atrial fibrillation: clinical impact of continuous positive 
airway pressure therapy. Heart Rhythm 2013;10:331–7. https://doi.org/10.1016/j. 
hrthm.2012.11.015
152. Qureshi WT, Nasir UB, Alqalyoobi S, O’Neal WT, Mawri S, Sabbagh S, et al. 
Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation 
in obstructive sleep apnea. Am J Cardiol 2015;116:1767–73. https://doi.org/10.1016/j. 
amjcard.2015.08.046
153. Shukla A, Aizer A, Holmes D, Fowler S, Park DS, Bernstein S, et al. Effect of obstructive 
sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. JACC Clin 
Electrophysiol 2015;1:41–51. https://doi.org/10.1016/j.jacep.2015.02.014
154. Nalliah CJ, Wong GR, Lee G, Voskoboinik A, Kee K, Goldin J, et al. Impact of CPAP on 
the atrial fibrillation substrate in obstructive sleep apnea: the SLEEP-AF study. JACC Clin 
Electrophysiol 2022;8:869–77. https://doi.org/10.1016/j.jacep.2022.04.015
155. Kadhim K, Middeldorp ME, Elliott AD, Jones D, Hendriks JML, Gallagher C, et al. 
Self-reported daytime sleepiness and sleep-disordered breathing in patients with atrial 
ESC Guidelines                                                                                                                                                                                          3387


<!-- PAGE 75 -->

### Page 75

fibrillation: SNOozE-AF. Can J Cardiol 2019;35:1457–64. https://doi.org/10.1016/j.cjca. 
2019.07.627
156. Traaen GM, Overland B, Aakeroy L, Hunt TE, Bendz C, Sande L, et al. Prevalence, risk 
factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation. Int J 
Cardiol Heart Vasc 2020;26:100447. https://doi.org/10.1016/j.ijcha.2019.100447
157. Kadhim K, Middeldorp ME, Elliott AD, Agbaedeng T, Gallagher C, Malik V, et al. 
Prevalence and assessment of sleep-disordered breathing in patients with atrial fibril­
lation: a systematic review and meta-analysis. Can J Cardiol 2021;37:1846–56. https:// 
doi.org/10.1016/j.cjca.2021.09.026
158. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic 
stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibril­
lation cohort study. Eur Heart J 2012;33:1500–10. https://doi.org/10.1093/eurheartj/ 
ehr488
159. Lopes LC, Spencer FA, Neumann I, Ventresca M, Ebrahim S, Zhou Q, et al. Systematic 
review of observational studies assessing bleeding risk in patients with atrial fibrillation 
not using anticoagulants. PLoS One 2014;9:e88131. https://doi.org/10.1371/journal. 
pone.0088131
160. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Lip GY. Predictors and prognos­
tic implications of incident heart failure following the first diagnosis of atrial fibrillation 
in patients with structurally normal hearts: the Belgrade atrial fibrillation study. Eur J 
Heart Fail 2013;15:415–24. https://doi.org/10.1093/eurjhf/hft004
161. Noubiap JJ, Feteh VF, Middeldorp ME, Fitzgerald JL, Thomas G, Kleinig T, et al. A 
meta-analysis of clinical risk factors for stroke in anticoagulant-naive patients with atrial 
fibrillation. Europace 2021;23:1528–38. https://doi.org/10.1093/europace/euab087
162. McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 
sion. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178
163. Santoro F, Di Biase L, Trivedi C, Burkhardt JD, Paoletti Perini A, Sanchez J, et al. Impact 
of uncontrolled hypertension on atrial fibrillation ablation outcome. JACC Clin 
Electrophysiol 2015;1:164–73. https://doi.org/10.1016/j.jacep.2015.04.002
164. Trines SA, Stabile G, Arbelo E, Dagres N, Brugada J, Kautzner J, et al. Influence of risk 
factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Pacing Clin 
Electrophysiol 2019;42:1365–73. https://doi.org/10.1111/pace.13763
165. Shah AN, Mittal S, Sichrovsky TC, Cotiga D, Arshad A, Maleki K, et al. Long-term out­
come following successful pulmonary vein isolation: pattern and prediction of very late 
recurrence. J Cardiovasc Electrophysiol 2008;19:661–7. https://doi.org/10.1111/j.1540- 
8167.2008.01101.x
166. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M, et al. 
Pre-procedural predictors of atrial fibrillation recurrence after circumferential pul­
monary vein ablation. Eur Heart J 2007;28:836–41. https://doi.org/10.1093/eurheartj/ 
ehm027
167. Themistoclakis S, Schweikert RA, Saliba WI, Bonso A, Rossillo A, Bader G, et al. Clinical 
predictors and relationship between early and late atrial tachyarrhythmias after pul­
monary vein antrum isolation. Heart Rhythm 2008;5:679–85. https://doi.org/10.1016/ 
j.hrthm.2008.01.031
168. Letsas KP, Weber R, Burkle G, Mihas CC, Minners J, Kalusche D, et al. Pre-ablative pre­
dictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential 
role of inflammation. Europace 2009;11:158–63. https://doi.org/10.1093/europace/ 
eun309
169. Khaykin Y, Oosthuizen R, Zarnett L, Essebag V, Parkash R, Seabrook C, et al. Clinical 
predictors of arrhythmia recurrences following pulmonary vein antrum isolation for 
atrial fibrillation: predicting arrhythmia recurrence post-PVAI. J Cardiovasc 
Electrophysiol 2011;22:1206–14. https://doi.org/10.1111/j.1540-8167.2011.02108.x
170. Kamioka M, Hijioka N, Matsumoto Y, Nodera M, Kaneshiro T, Suzuki H, et al. 
Uncontrolled blood pressure affects atrial remodeling and adverse clinical outcome 
in paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2018;41:402–10. https://doi. 
org/10.1111/pace.13311
171. Zylla MM, Hochadel M, Andresen D, Brachmann J, Eckardt L, Hoffmann E, et al. 
Ablation of atrial fibrillation in patients with hypertension—an analysis from the 
German ablation registry. J Clin Med 2020;9:1–14. https://doi.org/10.3390/jcm9082402
172. Galzerano D, Di Michele S, Paolisso G, Tuccillo B, Lama D, Carbotta S, et al. A multi­
centre, randomized study of telmisartan versus carvedilol for prevention of atrial fib­
rillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012; 
13:496–503. https://doi.org/10.1177/1470320312443909
173. Du H, Fan J, Ling Z, Woo K, Su L, Chen S, et al. Effect of nifedipine versus telmisartan on 
prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension 2013; 
61:786–92. https://doi.org/10.1161/HYPERTENSIONAHA.111.202309
174. Giannopoulos G, Kossyvakis C, Efremidis M, Katsivas A, Panagopoulou V, Doudoumis 
K, et al. Central sympathetic inhibition to reduce postablation atrial fibrillation recur­
rences in hypertensive patients: a randomized, controlled study. Circulation 2014;130: 
1346–52. https://doi.org/10.1161/CIRCULATIONAHA.114.010999
175. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention 
of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll 
Cardiol 2010;55:2299–307. https://doi.org/10.1016/j.jacc.2010.01.043
176. Blum S, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer JH, et al. Incidence and 
predictors of atrial fibrillation progression. J Am Heart Assoc 2019;8:e012554. https:// 
doi.org/10.1161/JAHA.119.012554
177. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 
2015;36:3250–7. https://doi.org/10.1093/eurheartj/ehv513
178. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. 
Atrial fibrillation begets heart failure and vice versa: temporal associations and differ­
ences in preserved versus reduced ejection fraction. Circulation 2016;133:484–92. 
https://doi.org/10.1161/CIRCULATIONAHA.115.018614
179. Rossello X, Gil V, Escoda R, Jacob J, Aguirre A, Martín-Sánchez FJ, et al. Editor’s choice 
– impact of identifying precipitating factors on 30-day mortality in acute heart failure 
patients. Eur Heart J Acute Cardiovasc Care 2019;8:667–80. https://doi.org/10.1177/ 
2048872619869328
180. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with 
atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern 
Med 1998;158:1316–20. https://doi.org/10.1001/archinte.158.12.1316
181. Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors 
for thromboembolic and bleeding events in anticoagulated patients with atrial fibrilla­
tion: the prospective, multicentre observational PREvention oF thromboembolic 
events—European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open 2019;9: 
e022478. https://doi.org/10.1136/bmjopen-2018-022478
182. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart 
failure due to reduced versus preserved ejection fraction: a systematic review and 
meta-analysis of death and adverse outcomes. Int J Cardiol 2016;203:660–6. https:// 
doi.org/10.1016/j.ijcard.2015.10.220
183. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 
focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure. Eur Heart J 2023;44:3627–39. https://doi.org/10.1093/ 
eurheartj/ehad195
184. ACTIVE I Investigators; Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, et al. 
Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928–38. https:// 
doi.org/10.1056/NEJMoa1008816
185. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of 
digoxin: systematic review and meta-analysis of observational and controlled trial data. 
BMJ 2015;351:h4451. https://doi.org/10.1136/bmj.h4451
186. Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG, 
et al. The effect of rate control on quality of life in patients with permanent atrial fib­
rillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation 
II) study. J Am Coll Cardiol 2011;58:1795–803. https://doi.org/10.1016/j.jacc.2011.06. 
055
187. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427–520. https://doi.org/10.1093/eurheartj/ehab364
188. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of 
ejection fraction on outcomes and efficacy of spironolactone in patients with heart fail­
ure with preserved ejection fraction. Eur Heart J 2016;37:455–62. https://doi.org/10. 
1093/eurheartj/ehv464
189. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid- 
range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan 
across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230–9. https:// 
doi.org/10.1002/ejhf.1149
190. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. 
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection frac­
tion: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 
2018;39:26–35. https://doi.org/10.1093/eurheartj/ehx564
191. Țica O, Khamboo W, Kotecha D. Breaking the cycle of heart failure with preserved 
ejection fraction and atrial fibrillation. Card Fail Rev 2022;8:e32. https://doi.org/10. 
15420/cfr.2022.03
192. Nguyen BO, Crijns H, Tijssen JGP, Geelhoed B, Hobbelt AH, Hemels MEW, et al. 
Long-term outcome of targeted therapy of underlying conditions in patients with early 
persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace 2022; 
24:910–20. https://doi.org/10.1093/europace/euab270
193. Wang A, Green JB, Halperin JL, Piccini JP, Sr. Atrial fibrillation and diabetes mellitus: 
JACC review topic of the week. J Am Coll Cardiol 2019;74:1107–15. https://doi.org/ 
10.1016/j.jacc.2019.07.020
194. Alijla F, Buttia C, Reichlin T, Razvi S, Minder B, Wilhelm M, et al. Association of diabetes 
with atrial fibrillation types: a systematic review and meta-analysis. Cardiovasc Diabetol 
2021;20:230. https://doi.org/10.1186/s12933-021-01423-2
195. Ding WY, Kotalczyk A, Boriani G, Marin F, Blomstrom-Lundqvist C, Potpara TS, et al. 
Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis 
from the ESC-EHRA EORP-AF long-term general registry. Eur J Intern Med 2022; 
103:41–9. https://doi.org/10.1016/j.ejim.2022.04.026
196. Proietti M, Romiti GF, Basili S. The case of diabetes mellitus and atrial fibrillation: 
underlining the importance of non-cardiovascular comorbidities. Eur J Intern Med 
2022;103:38–40. https://doi.org/10.1016/j.ejim.2022.06.017


<!-- PAGE 76 -->

### Page 76

197. Karayiannides S, Norhammar A, Landstedt-Hallin L, Friberg L, Lundman P. Prognostic 
impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe 
hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol 2022;29:1759–69. https:// 
doi.org/10.1093/eurjpc/zwac093
198. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification 
for predicting stroke and thromboembolism in atrial fibrillation using a novel risk 
factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137: 
263–72. https://doi.org/10.1378/chest.09-1584
199. Abdel-Qadir H, Gunn M, Lega IC, Pang A, Austin PC, Singh SM, et al. Association of 
diabetes duration and glycemic control with stroke rate in patients with atrial fibrilla­
tion and diabetes: a population-based cohort study. J Am Heart Assoc 2022;11: 
e023643. https://doi.org/10.1161/JAHA.121.023643
200. Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, et al. Association be­
tween pre-ablation glycemic control and outcomes among patients with diabetes 
undergoing atrial fibrillation ablation. JACC Clin Electrophysiol 2019;5:897–903. https:// 
doi.org/10.1016/j.jacep.2019.05.018
201. D’Souza S, Elshazly MB, Dargham SR, Donnellan E, Asaad N, Hayat S, et al. Atrial fib­
rillation catheter ablation complications in obese and diabetic patients: insights from 
the US nationwide inpatient sample 2005–2013. Clin Cardiol 2021;44:1151–60. 
https://doi.org/10.1002/clc.23667
202. Creta A, Providencia R, Adragao P, de Asmundis C, Chun J, Chierchia G, et al. Impact of 
type-2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation 
(European Observational Multicentre Study). Am J Cardiol 2020;125:901–6. https:// 
doi.org/10.1016/j.amjcard.2019.12.037
203. Wang Z, Wang YJ, Liu ZY, Li Q, Kong YW, Chen YW, et al. Effect of insulin resistance 
on recurrence after radiofrequency catheter ablation in patients with atrial fibrillation. 
Cardiovasc Drugs Ther 2023;37:705–13. https://doi.org/10.1007/s10557-022-07317-z
204. Papazoglou AS, Kartas A, Moysidis DV, Tsagkaris C, Papadakos SP, Bekiaridou A, et al. 
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation. 
Cardiovasc Diabetol 2022;21:39. https://doi.org/10.1186/s12933-022-01473-0
205. Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, et al. 
Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC 
Cardiovasc Disord 2017;17:96. https://doi.org/10.1186/s12872-017-0531-4
206. Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, 
pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab 2019;21: 
210–7. https://doi.org/10.1111/dom.13512
207. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
208. Di Benedetto L, Michels G, Luben R, Khaw KT, Pfister R. Individual and combined im­
pact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the 
EPIC-Norfolk prospective population study. Eur J Prev Cardiol 2018;25:1374–83. 
https://doi.org/10.1177/2047487318782379
209. Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Ostgren CJ, et al. Body 
weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 dia­
betes; an observational study. Cardiovasc Diabetol 2015;14:5. https://doi.org/10.1186/ 
s12933-014-0170-3
210. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, et al. Obesity and 
the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis 
of 626,603 individuals in 51 studies. JACC Clin Electrophysiol 2015;1:139–52. https://doi. 
org/10.1016/j.jacep.2015.04.004
211. Providencia R, Adragao P, de Asmundis C, Chun J, Chierchia G, Defaye P, et al. Impact 
of body mass index on the outcomes of catheter ablation of atrial fibrillation: a 
European observational multicenter study. J Am Heart Assoc 2019;8:e012253. https:// 
doi.org/10.1161/JAHA.119.012253
212. Glover BM, Hong KL, Dagres N, Arbelo E, Laroche C, Riahi S, et al. Impact of body 
mass index on the outcome of catheter ablation of atrial fibrillation. Heart 2019; 
105:244–50. https://doi.org/10.1136/heartjnl-2018-313490
213. Gessler N, Willems S, Steven D, Aberle J, Akbulak RO, Gosau N, et al. Supervised 
obesity reduction trial for AF ablation patients: results from the SORT-AF trial. 
Europace 2021;23:1548–58. https://doi.org/10.1093/europace/euab122
214. Mohanty S, Mohanty P, Natale V, Trivedi C, Gianni C, Burkhardt JD, et al. Impact of 
weight loss on ablation outcome in obese patients with longstanding persistent atrial 
fibrillation. J Cardiovasc Electrophysiol 2018;29:246–53. https://doi.org/10.1111/jce. 
13394
215. Donnellan E, Wazni OM, Kanj M, Elshazly M, Hussein AA, Patel DR, et al. Impact of 
risk-factor modification on arrhythmia recurrence among morbidly obese patients 
undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 2020;31:1979–86. 
https://doi.org/10.1111/jce.14607
216. Donnellan E, Wazni OM, Kanj M, Baranowski B, Cremer P, Harb S, et al. Association 
between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly ob­
ese patients undergoing atrial fibrillation ablation. Europace 2019;21:1476–83. https:// 
doi.org/10.1093/europace/euz183
217. Donnellan E, Wazni O, Kanj M, Hussein A, Baranowski B, Lindsay B, et al. Outcomes of 
atrial fibrillation ablation in morbidly obese patients following bariatric surgery 
compared with a nonobese cohort. Circ Arrhythm Electrophysiol 2019;12:e007598. 
https://doi.org/10.1161/CIRCEP.119.007598
218. Moula AI, Parrini I, Tetta C, Lucà F, Parise G, Rao CM, et al. Obstructive sleep apnea 
and atrial fibrillation. J Clin Med 2022;11:1242. https://doi.org/10.3390/jcm11051242
219. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, et al. Clinical 
practice guideline for diagnostic testing for adult obstructive sleep apnea: an American 
academy of sleep medicine clinical practice guideline. J Clin Sleep Med 2017;13: 
479–504. https://doi.org/10.5664/jcsm.6506
220. Linz D, Brooks AG, Elliott AD, Nalliah CJ, Hendriks JML, Middeldorp ME, et al. 
Variability of sleep apnea severity and risk of atrial fibrillation: the VARIOSA-AF study. 
JACC Clin Electrophysiol 2019;5:692–701. https://doi.org/10.1016/j.jacep.2019.03.005
221. Linz D, Linz B, Dobrev D, Baumert M, Hendriks JM, Pepin JL, et al. Personalized man­
agement of sleep apnea in patients with atrial fibrillation: an interdisciplinary and trans­
lational challenge. Int J Cardiol Heart Vasc 2021;35:100843. https://doi.org/10.1016/j. 
ijcha.2021.100843.
222. Kanagala R, Murali NS, Friedman PA, Ammash NM, Gersh BJ, Ballman KV, et al. 
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003; 
107:2589–94. https://doi.org/10.1161/01.CIR.0000068337.25994.21
223. Abumuamar AM, Newman D, Dorian P, Shapiro CM. Cardiac effects of CPAP treat­
ment in patients with obstructive sleep apnea and atrial fibrillation. J Interv Card 
Electrophysiol 2019;54:289–97. https://doi.org/10.1007/s10840-018-0482-4
224. Mittal S, Golombeck D, Pimienta J. Sleep apnoea and AF: where do we stand? Practical 
advice for clinicians. Arrhythm Electrophysiol Rev 2021;10:140–6. https://doi.org/10. 
15420/aer.2021.05
225. Hunt TE, Traaen GM, Aakeroy L, Bendz C, Overland B, Akre H, et al. Effect of continu­
ous positive airway pressure therapy on recurrence of atrial fibrillation after pulmon­
ary vein isolation in patients with obstructive sleep apnea: a randomized controlled 
trial. Heart Rhythm 2022;19:1433–41. https://doi.org/10.1016/j.hrthm.2022.06.016
226. Caples SM, Mansukhani MP, Friedman PA, Somers VK. The impact of continuous posi­
tive airway pressure treatment on the recurrence of atrial fibrillation post cardiover­
sion: a randomized controlled trial. Int J Cardiol 2019;278:133–6. https://doi.org/10. 
1016/j.ijcard.2018.11.100
227. Labarca G, Dreyse J, Drake L, Jorquera J, Barbe F. Efficacy of continuous positive airway 
pressure (CPAP) in the prevention of cardiovascular events in patients with obstruct­
ive sleep apnea: systematic review and meta-analysis. Sleep Med Rev 2020;52:101312. 
https://doi.org/10.1016/j.smrv.2020.101312
228. Abuzaid AS, Al Ashry HS, Elbadawi A, Ld H, Saad M, Elgendy IY, et al. Meta-analysis of 
cardiovascular outcomes with continuous positive airway pressure therapy in patients 
with obstructive sleep apnea. Am J Cardiol 2017;120:693–9. https://doi.org/10.1016/j. 
amjcard.2017.05.042
229. Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, et al. Association of 
positive airway pressure with cardiovascular events and death in adults with sleep ap­
nea: a systematic review and meta-analysis. JAMA 2017;318:156–66. https://doi.org/10. 
1001/jama.2017.7967
230. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of 
cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919–31. 
https://doi.org/10.1056/NEJMoa1606599
231. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, et al. Alcohol 
intake and prognosis of atrial fibrillation. Heart 2013;99:1093–9. https://doi.org/10. 
1136/heartjnl-2013-304036
232. Lim C, Kim T-H, Yu HT, Lee S-R, Cha M-J, Lee J-M, et al. Effect of alcohol consumption 
on the risk of adverse events in atrial fibrillation: from the COmparison study of Drugs 
for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) 
registry. EP Europace 2021;23:548–56. https://doi.org/10.1093/europace/euaa340
233. Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH. Lower risk of stroke after alcohol 
abstinence in patients with incident atrial fibrillation: a nationwide population-based 
cohort study. Eur Heart J 2021;42:4759–68. https://doi.org/10.1093/eurheartj/ehab315
234. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly 
score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibril­
lation: the Euro Heart Survey. Chest 2010;138:1093–100. https://doi.org/10.1378/ 
chest.10-0134
235. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, et al. Alcohol con­
sumption reduction and clinical outcomes of catheter ablation for atrial fibrillation. Circ 
Arrhythm 
Electrophysiol 
2021;14:e009770. 
https://doi.org/10.1161/CIRCEP.121. 
009770
236. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report 
from the Stockholm cohort of atrial fibrillation. Eur Heart J 2010;31:967–75. https:// 
doi.org/10.1093/eurheartj/ehn599
237. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Pattern of 
atrial fibrillation and risk of outcomes: the Loire valley atrial fibrillation project. Int J 
Cardiol 2013;167:2682–7. https://doi.org/10.1016/j.ijcard.2012.06.118
238. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for 
stroke: the Framingham study. Stroke 1991;22:983–8. https://doi.org/10.1161/01.STR. 
22.8.983
ESC Guidelines                                                                                                                                                                                          3389


<!-- PAGE 77 -->

### Page 77

239. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent 
stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 
857–67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
240. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in pa­
tients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 
955–62. https://doi.org/10.1016/S0140-6736(13)62343-0
241. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit 
from acetylsalicylic acid. Europace 2014;16:631–8. https://doi.org/10.1093/europace/ 
eut333
242. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in 
patients with atrial fibrillation. N Engl J Med 2011;364:806–17. https://doi.org/10.1056/ 
NEJMoa1007432
243. van Doorn S, Rutten FH, O’Flynn CM, Oudega R, Hoes AW, Moons KGM, et al. 
Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial 
fibrillation: a cluster randomised trial in general practice. Int J Cardiol 2018;273:123–9. 
https://doi.org/10.1016/j.ijcard.2018.08.096
244. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting 
thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: 
a systematic review. Thromb Haemost 2018;118:2171–87. https://doi.org/10.1055/s- 
0038-1675400
245. van der Endt VHW, Milders J, de Vries BBLP, Trines SA, Groenwold RHH, Dekkers 
OM, et al. Comprehensive comparison of stroke risk score performance: a systematic 
review and meta-analysis among 6 267 728 patients with atrial fibrillation. Europace 
2022;24:1739–53. https://doi.org/10.1093/europace/euac096
246. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of 
stroke across cohorts of patients with atrial fibrillation. Circulation 2017;135: 
208–19. https://doi.org/10.1161/CIRCULATIONAHA.116.024057
247. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial 
fibrillation. Circ J 2012;76:2289–304. https://doi.org/10.1253/circj.CJ-12-1036
248. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of 
apixaban when compared with warfarin in relation to renal function in patients with 
atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821–30. 
https://doi.org/10.1093/eurheartj/ehs274
249. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of 
stroke and systemic embolism with rivaroxaban compared with warfarin in patients 
with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 
32:2387–94. https://doi.org/10.1093/eurheartj/ehr342
250. Yaghi S, Henninger N, Giles JA, Leon Guerrero C, Mistry E, Liberman AL, et al. 
Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioem­
bolic stroke: the IAC study. J Neurol Neurosurg Psychiatry 2021;92:1062–7. https://doi. 
org/10.1136/jnnp-2021-326166
251. Ocak G, Khairoun M, Khairoun O, Bos WJW, Fu EL, Cramer MJ, et al. Chronic kidney 
disease and atrial fibrillation: a dangerous combination. PLoS One 2022;17:e0266046. 
https://doi.org/10.1371/journal.pone.0266046
252. Seiffge DJ, De Marchis GM, Koga M, Paciaroni M, Wilson D, Cappellari M, et al. 
Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. 
Ann Neurol 2020;87:677–87. https://doi.org/10.1002/ana.25700
253. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, et al. Prognostic 
value of trans-thoracic echocardiography in patients with acute stroke and atrial fibril­
lation: findings from the RAF study. J Neurol 2016;263:231–7. https://doi.org/10.1007/ 
s00415-015-7957-3
254. Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of biomarkers for risk strati­
fication in patients with atrial fibrillation. Clin Chem 2017;63:152–64. https://doi.org/10. 
1373/clinchem.2016.255182
255. Singleton MJ, Yuan Y, Dawood FZ, Howard G, Judd SE, Zakai NA, et al. Multiple blood 
biomarkers and stroke risk in atrial fibrillation: the REGARDS study. J Am Heart Assoc 
2021;10:e020157. https://doi.org/10.1161/JAHA.120.020157
256. Wu VC, Wu M, Aboyans V, Chang SH, Chen SW, Chen MC, et al. Female sex as a risk 
factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart 2020; 
106:534–40. https://doi.org/10.1136/heartjnl-2019-315065
257. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. 
Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. 
J Thromb Haemost 2012;10:1745–51. https://doi.org/10.1111/j.1538-7836.2012. 
04853.x
258. Antonenko K, Paciaroni M, Agnelli G, Falocci N, Becattini C, Marcheselli S, et al. 
Sex-related differences in risk factors, type of treatment received and outcomes in pa­
tients with atrial fibrillation and acute stroke: results from the RAF study (early recur­
rence and cerebral bleeding in patients with acute ischemic stroke and atrial 
fibrillation). Eur Stroke J 2017;2:46–53. https://doi.org/10.1177/2396987316679577
259. Wang X, Mobley AR, Tica O, Okoth K, Ghosh RE, Myles P, et al. Systematic approach 
to outcome assessment from coded electronic healthcare records in the 
DaRe2THINK NHS-embedded randomized trial. Eur Heart J - Dig Health 2022;3: 
426–36. https://doi.org/10.1093/ehjdh/ztac046
260. Rivard L, Khairy P, Talajic M, Tardif JC, Nattel S, Bherer L, et al. Blinded randomized trial 
of anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial 
fibrillation (BRAIN-AF): methods and design. Can J Cardiol 2019;35:1069–77. https:// 
doi.org/10.1016/j.cjca.2019.04.022
261. Chung S, Kim TH, Uhm JS, Cha MJ, Lee JM, Park J, et al. Stroke and systemic embolism 
and other adverse outcomes of heart failure with preserved and reduced ejection frac­
tion in patients with atrial fibrillation (from the COmparison study of Drugs for symp­
tom control and complication prEvention of Atrial Fibrillation [CODE-AF]). Am J 
Cardiol 2020;125:68–75. https://doi.org/10.1016/j.amjcard.2019.09.035
262. Uhm JS, Kim J, Yu HT, Kim TH, Lee SR, Cha MJ, et al. Stroke and systemic embolism in 
patients with atrial fibrillation and heart failure according to heart failure type. ESC 
Heart Fail 2021;8:1582–9. https://doi.org/10.1002/ehf2.13264
263. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al. Left ven­
tricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism 
in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 
2013;6:451–60. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000143
264. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients 
with atrial fibrillation. J Am Coll Cardiol 2018;72:1233–45. https://doi.org/10.1016/j.jacc. 
2018.05.076
265. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk 
in elderly patients aged ≥75 years with atrial fibrillation: the Loire valley atrial fibrilla­
tion project. Stroke 2015;46:143–50. https://doi.org/10.1161/STROKEAHA.114. 
007199
266. American Diabetes Association Professional Practice Committee. 2. Classification and 
diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care 2022; 
45:S17–38. https://doi.org/10.2337/dc22-S002
267. Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, et al. Should the 
presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc 
score in atrial fibrillation? A report from the western Denmark heart registry. 
Thromb Haemost 2018;118:2162–70. https://doi.org/10.1055/s-0038-1675401
268. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. 
Transesophageal echocardiographic correlates of clinical risk of thromboembolism 
in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. 
J Am Coll Cardiol 1998;31:1622–6. https://doi.org/10.1016/S0735-1097(98)00146-6
269. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. 
Transesophageal echocardiography in atrial fibrillation: standards for acquisition and 
interpretation and assessment of interobserver variability. Stroke prevention in atrial 
fibrillation investigators committee on echocardiography. J Am Soc Echocardiogr 1996; 
9:556–66. https://doi.org/10.1016/S0894-7317(96)90127-3
270. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic out­
comes of different anticoagulation strategies for patients with atrial fibrillation in the 
setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation 2019; 
12:2207. https://doi.org/10.4022/jafib.2207
271. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation 
and thromboembolism in patients with hypertrophic cardiomyopathy: systematic re­
view. Heart 2014;100:465–72. https://doi.org/10.1136/heartjnl-2013-304276
272. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. 
Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy 
(HCM risk-CVA). Eur J Heart Fail 2015;17:837–45. https://doi.org/10.1002/ejhf.316
273. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic 
embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail 2022;24: 
1387–96. https://doi.org/10.1002/ejhf.2566
274. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on 
the clinical course of apical hypertrophic cardiomyopathy. Heart 2017;103:1496–501. 
https://doi.org/10.1136/heartjnl-2016-310720
275. Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Clinical profile of 
thromboembolic events in patients with hypertrophic cardiomyopathy in a regional 
Japanese cohort–results from Kochi RYOMA study. Circ J 2019;83:1747–54. https:// 
doi.org/10.1253/circj.CJ-19-0186
276. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with 
atrial fibrillation: a nationwide database study. Aging (Albany NY) 2020;12:24219–27. 
https://doi.org/10.18632/aging.104133
277. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Relationship of aging and 
incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll 
Cardiol 2018;71:122–32. https://doi.org/10.1016/j.jacc.2017.10.085
278. Weijs B, Dudink E, de Vos CB, Limantoro I, Tieleman RG, Pisters R, et al. Idiopathic 
atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year 
follow-up study. Neth Heart J 2019;27:487–97. https://doi.org/10.1007/s12471-019- 
1272-z
279. Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Salahudeen MS, Garrahy E, et al. 
Stroke risk reassessment and oral anticoagulant initiation in primary care patients with 
atrial fibrillation: A ten-year follow-up. Eur J Clin Invest 2021;51:e13489. https://doi.org/ 
10.1111/eci.13489
280. Fauchier L, Bodin A, Bisson A, Herbert J, Spiesser P, Clementy N, et al. Incident co­
morbidities, aging and the risk of stroke in 608,108 patients with atrial fibrillation: a na­
tionwide analysis. J Clin Med 2020;9:1234. https://doi.org/10.3390/jcm9041234


<!-- PAGE 78 -->

### Page 78

281. Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. 
Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J 
Med 2023;389:1167–79. https://doi.org/10.1056/NEJMoa2303062
282. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for 
stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024;390:107–17. 
https://doi.org/10.1056/NEJMoa2310234
283. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral 
anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient 
meta-analysis. JAMA 2002;288:2441–8. https://doi.org/10.1001/jama.288.19.2441
284. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with 
intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke 
prevention in atrial fibrillation investigators. J Am Coll Cardiol 2000;35:183–7. https:// 
doi.org/10.1016/S0735-1097(99)00489-1
285. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, et al. Should we 
abandon the common practice of withholding oral anticoagulation in paroxysmal atrial 
fibrillation? Eur Heart J 2008;29:915–22. https://doi.org/10.1093/eurheartj/ehn101
286. Ruff CT. AZALEA-TIMI 71 Steering Committee. Abelacimab, a novel factor XI/XIa in­
hibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the 
AZALEA-TIMI 71 randomized trial. Circulation 2024;148:e282–317. https://doi.org/ 
10.1161/CIR.0000000000001200
287. Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, et al. Safety of the oral 
factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrilla­
tion (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose- 
finding phase 2 study. Lancet 2022;399:1383–90. https://doi.org/10.1016/S0140- 
6736(22)00456-1
288. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a 
systematic review. Br J Clin Pharmacol 2021;87:352–74. https://doi.org/10.1111/bcp. 
14404
289. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. 
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 
2005;165:1095–106. https://doi.org/10.1001/archinte.165.10.1095
290. Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of dir­
ect oral anticoagulants (DOACs): from pharmacological to clinical practice. 
Pharmaceutics 2022;14:1120. https://doi.org/10.3390/pharmaceutics14061120
291. Mar PL, Gopinathannair R, Gengler BE, Chung MK, Perez A, Dukes J, et al. Drug inter­
actions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol 2022;15:e007956. 
https://doi.org/10.1161/CIRCEP.121.007956
292. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. 
Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient- 
level network meta-analyses of randomized clinical trials with interaction testing by 
age 
and 
sex. 
Circulation 
2022;145:242–55. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.121.056355
293. Kotecha D, Pollack CV, Jr, De Caterina R, Renda G, Kirchhof P. Direct oral anticoagu­
lants halve thromboembolic events after cardioversion of AF compared with warfarin. 
J Am Coll Cardiol 2018;72:1984–6. https://doi.org/10.1016/j.jacc.2018.07.083
294. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, 
et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J 
Med 2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051
295. Halperin JL, Hart RG, Kronmal RA, McBride R. Warfarin versus aspirin for prevention 
of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. 
Lancet 1994;343:687–91. https://doi.org/10.1016/S0140-6736(94)91577-6
296. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, et al. The 
effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial 
fibrillation. 
N 
Engl 
J 
Med 
1990;323:1505–11. 
https://doi.org/10.1056/ 
NEJM199011293232201
297. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. 
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose war­
farin for stroke prevention in atrial fibrillation: second Copenhagen atrial fibrillation, 
aspirin, and anticoagulation study. Arch Intern Med 1998;158:1513–21. https://doi. 
org/10.1001/archinte.158.14.1513
298. Blackshear JL, Halperin JL, Hart RG, Laupacis A. Adjusted-dose warfarin versus low- 
intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: 
stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348: 
633–8. https://doi.org/10.1016/S0140-6736(96)03487-3
299. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of 
the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates 
and its influence on the medical cost avoidance associated with novel oral anticoagu­
lant use–learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb 
Thrombolysis 2014;38:150–9. https://doi.org/10.1007/s11239-013-1048-z
300. Själander S, Sjögren V, Renlund H, Norrving B, Själander A. Dabigatran, rivaroxaban 
and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res 2018;167:113–8. 
https://doi.org/10.1016/j.thromres.2018.05.022
301. van Miert JHA, Kooistra HAM, Veeger N, Westerterp A, Piersma-Wichers M, Meijer 
K. Choosing between continuing vitamin K antagonists (VKA) or switching to a direct 
oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a 
randomised controlled trial (GAInN). Br J Haematol 2019;186:e21–3. https://doi.org/ 
10.1111/bjh.15856
302. Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor 
time in therapeutic range control is associated with adverse clinical outcomes in pa­
tients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF 
registry. J Clin Med 2020;9:1698. https://doi.org/10.3390/jcm9061698
303. Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, et al. Time in 
therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fib­
rillation patients with renal dysfunction. J Am Heart Assoc 2017;6:e004925. https://doi. 
org/10.1161/JAHA.116.004925
304. Cardoso R, Ternes CMP, Justino GB, Fernandes A, Rocha AV, Knijnik L, et al. 
Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bio­
prosthetic valves: a systematic review and meta-analysis. Am J Med 2022;135:228–­
234.e1. https://doi.org/10.1016/j.amjmed.2021.08.026
305. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. 
Anticoagulation control and prediction of adverse events in patients with atrial fibril­
lation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84–91. https://doi. 
org/10.1161/CIRCOUTCOMES.108.796185
306. Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in thera­
peutic range for complication rates in warfarin therapy of patients with atrial fibrilla­
tion: a systematic review and meta-regression analysis. PLoS One 2017;12:e0188482. 
https://doi.org/10.1371/journal.pone.0188482
307. Macaluso GP, Pagani FD, Slaughter MS, Milano CA, Feller ED, Tatooles AJ, et al. Time in 
therapeutic range significantly impacts survival and adverse events in destination therapy 
patients. ASAIO J 2022;68:14–20. https://doi.org/10.1097/MAT.0000000000001572
308. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, et al. Self-monitoring 
of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
Lancet 2012;379:322–34. https://doi.org/10.1016/S0140-6736(11)61294-4
309. Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. 
Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anti­
coagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF rando­
mized controlled trial. Circulation 2024;149:279–89. https://doi.org/10.1161/ 
CIRCULATIONAHA.123.066485
310. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antag­
onist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. 
J Am Coll Cardiol 2017;69:2779–90. https://doi.org/10.1016/j.jacc.2017.03.600
311. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label 
dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the 
ORBIT-AF II registry. J Am Coll Cardiol 2016;68:2597–604. https://doi.org/10.1016/j. 
jacc.2016.09.966
312. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. 
Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation 
and advanced age, low body weight, or high creatinine: a secondary analysis of a ran­
domized clinical trial. JAMA Cardiol 2016;1:673–81. https://doi.org/10.1001/jamacardio. 
2016.1829
313. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibril­
lation. Meta-analysis of observational comparison studies with vitamin K antagonists. 
Thromb Haemost 2016;116:754–63. https://doi.org/10.1160/TH16-03-0203
314. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. 
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial 
fibrillation: global registry on long-term antithrombotic treatment in patients with at­
rial fibrillation (GLORIA-AF) registry. Am Heart J 2018;198:55–63. https://doi.org/10. 
1016/j.ahj.2017.08.018
315. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real- 
world, prospective, observational study of patients treated with rivaroxaban for stroke 
prevention in atrial fibrillation. Eur Heart J 2016;37:1145–53. https://doi.org/10.1093/ 
eurheartj/ehv466
316. Martinez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL, et al. 
XANTUS-EL: a real-world, prospective, observational study of patients treated with 
rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle 
East, Africa and Latin America. Egypt Heart J 2018;70:307–13. https://doi.org/10. 
1016/j.ehj.2018.09.002
317. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. 
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation pa­
tients in “real-world” clinical practice. A propensity-matched analysis of 76,940 pa­
tients. Thromb Haemost 2017;117:1072–82. https://doi.org/10.1160/TH17-01-0068
318. Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian patients with 
atrial fibrillation: effectiveness and safety. J Am Coll Cardiol 2018;72:838–53. https:// 
doi.org/10.1016/j.jacc.2018.05.066
319. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al. 
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur 
Heart J 2014;35:3346–55. https://doi.org/10.1093/eurheartj/ehu367
320. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, et al. Edoxaban 
versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation 
(ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388: 
1995–2003. https://doi.org/10.1016/S0140-6736(16)31474-X
ESC Guidelines                                                                                                                                                                                          3391


<!-- PAGE 79 -->

### Page 79

321. Ezekowitz MD, Pollack CV, Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, et al. 
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation 
scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018;39:2959–71. https:// 
doi.org/10.1093/eurheartj/ehy148
322. Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. 
Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and 
heart failure: a meta-analysis. JACC Heart Fail 2016;4:870–80. https://doi.org/10.1016/ 
j.jchf.2016.07.012
323. von Lueder TG, Atar D, Agewall S, Jensen JK, Hopper I, Kotecha D, et al. All-cause 
mortality and cardiovascular outcomes with non-vitamin K oral anticoagulants versus 
warfarin in patients with heart failure in the food and drug administration adverse 
event reporting system. Am J Ther 2019;26:e671–8. https://doi.org/10.1097/MJT. 
0000000000000883
324. Harrison SL, Buckley BJR, Ritchie LA, Proietti R, Underhill P, Lane DA, et al. Oral antic­
oagulants and outcomes in adults >/=80 years with atrial fibrillation: a global federated 
health network analysis. J Am Geriatr Soc 2022;70:2386–92. https://doi.org/10.1111/jgs. 
17884
325. Malhotra K, Ishfaq MF, Goyal N, Katsanos AH, Parissis J, Alexandrov AW, et al. Oral 
anticoagulation in patients with chronic kidney disease: a systematic review and 
meta-analysis. Neurology 2019;92:e2421–31. https://doi.org/10.1212/WNL.00000000 
00007534
326. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 
European heart rhythm association practical guide on the use of non-vitamin K antag­
onist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39: 
1330–93. https://doi.org/10.1093/eurheartj/ehy136
327. Rhee TM, Lee SR, Choi EK, Oh S, Lip GYH. Efficacy and safety of oral anticoagulants for 
atrial fibrillation patients with chronic kidney disease: a systematic review and 
meta-analysis. Front Cardiovasc Med 2022;9:885548. https://doi.org/10.3389/fcvm. 
2022.885548
328. Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH, Gerß J, et al. A 
randomized controlled trial comparing apixaban with the vitamin K antagonist phen­
procoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. 
Circulation 
2023;147:296–309. 
https://doi.org/10.1161/CIRCULATIONAHA.122. 
062779
329. Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, et al. 
Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized 
controlled 
trial. 
Circulation 
2022;146:1735–45. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.121.054990
330. De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and 
efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial 
fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 2021;32: 
1474–83. https://doi.org/10.1681/ASN.2020111566
331. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. 
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 
369:1206–14. https://doi.org/10.1056/NEJMoa1300615
332. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or 
warfarin in patients with an on-X mechanical aortic valve. NEJM Evid 2023;2: 
EVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067
333. Guimarães HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F, 
et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N 
Engl J Med 2020;383:2117–26. https://doi.org/10.1056/NEJMoa2029603
334. Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs. 
standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur 
Heart J 2022;43:2783–97. https://doi.org/10.1093/eurheartj/ehac242
335. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European 
heart rhythm association practical guide on the use of non-vitamin K antagonist oral 
anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612–76. https:// 
doi.org/10.1093/europace/euab065
336. Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, et al. 
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in pa­
tients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a na­
tionwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023;9:722–30. https:// 
doi.org/10.1093/ehjcvp/pvad070
337. Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, et al. Drug levels 
and bleeding complications in atrial fibrillation patients treated with direct oral antic­
oagulants. J Thromb Haemost 2019;17:1064–72. https://doi.org/10.1111/jth.14457
338. Suwa M, Nohara Y, Morii I, Kino M. Safety and efficacy re-evaluation of edoxaban and 
rivaroxaban dosing with plasma concentration monitoring in non-valvular atrial fibril­
lation: with observations of on-label and off-label dosing. Circ Rep 2023;5:80–9. https:// 
doi.org/10.1253/circrep.CR-22-0076
339. Song D, Zhou J, Fan T, Chang J, Qiu Y, Zhuang Z, et al. Decision aids for shared 
decision-making and appropriate anticoagulation therapy in patients with atrial fibrilla­
tion: a systematic review and meta-analysis. Eur J Cardiovasc Nurs 2022;21:97–106. 
https://doi.org/10.1093/eurjcn/zvab085
340. Vora P, Morgan Stewart H, Russell B, Asiimwe A, Brobert G. Time trends and treat­
ment pathways in prescribing individual oral anticoagulants in patients with nonvalvular 
atrial fibrillation: an observational study of more than three million patients from 
Europe and the United States. Int J Clin Pract 2022;2022:6707985. https://doi.org/10. 
1155/2022/6707985
341. Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide 
trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: 
a systematic review and meta-analysis. Europace 2022;24:887–98. https://doi.org/10. 
1093/europace/euab303
342. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. 
Vitamin K antagonists in heart disease: current status and perspectives (section III). 
Position paper of the ESC working group on thrombosis—task force on anticoagu­
lants in heart disease. Thromb Haemost 2013;110:1087–107. https://doi.org/10.1160/ 
TH13-06-0443
343. Pandey AK, Xu K, Zhang L, Gupta S, Eikelboom J, Cook O, et al. Lower versus standard 
INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized 
controlled trials. Thromb Haemost 2020;120:484–94. https://doi.org/10.1055/s-0039- 
3401823
344. Sanders P, Svennberg E, Diederichsen SZ, Crijns HJGM, Lambiase PD, Boriani G, et al. 
Great debate: device-detected subclinical atrial fibrillation should be treated like clinical at­
rial fibrillation. Eur Heart J 2024;45:2594–603. https://doi.org/10.1093/eurheartj/ehae365
345. ACTIVE Investigators; Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. 
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 
2009;360:2066–78. https://doi.org/10.1056/NEJMoa0901301
346. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus 
aspirin for stroke prevention in an elderly community population with atrial fibrillation 
(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a rando­
mised controlled trial. Lancet 2007;370:493–503. https://doi.org/10.1016/S0140- 
6736(07)61233-1
347. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol 
2011;8:602–6. https://doi.org/10.1038/nrcardio.2011.112
348. ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, 
Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for 
atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for preven­
tion of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 
367:1903–12. https://doi.org/10.1016/S0140-6736(06)68845-4
349. Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, et al. 
Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly 
diagnosed atrial fibrillation. JAMA Netw Open 2020;3:e200107. https://doi.org/10.1001/ 
jamanetworkopen.2020.0107
350. Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, et al. 
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy 
compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur 
Heart J 2018;39:464–73. https://doi.org/10.1093/eurheartj/ehx730
351. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS 
trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin 
in patients with chronic vascular disease. Circulation 2020;142:40–8. https://doi.org/10. 
1161/CIRCULATIONAHA.120.046048
352. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, et al. Stroke out­
comes in the COMPASS trial. Circulation 2019;139:1134–45. https://doi.org/10.1161/ 
CIRCULATIONAHA.118.035864
353. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic ther­
apy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103–13. 
https://doi.org/10.1056/NEJMoa1904143
354. Senoo K, Lip GY, Lane DA, Büller HR, Kotecha D. Residual risk of stroke and death in 
anticoagulated patients according to the type of atrial fibrillation: AMADEUS trial. 
Stroke 2015;46:2523–8. https://doi.org/10.1161/STROKEAHA.115.009487
355. Meinel TR, Branca M, De Marchis GM, Nedeltchev K, Kahles T, Bonati L, et al. Prior 
anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol 
2021;89:42–53. https://doi.org/10.1002/ana.25917
356. Polymeris AA, Meinel TR, Oehler H, Hölscher K, Zietz A, Scheitz JF, et al. Aetiology, 
secondary prevention strategies and outcomes of ischaemic stroke despite oral anti­
coagulant therapy in patients with atrial fibrillation. J Neurol Neurosurg Psychiatry 
2022;93:588–98. https://doi.org/10.1136/jnnp-2021-328391
357. Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S, et al. Causes and risk 
factors of cerebral ischemic events in patients with atrial fibrillation treated with non- 
vitamin K antagonist oral anticoagulants for stroke prevention. Stroke 2019;50: 
2168–74. https://doi.org/10.1161/STROKEAHA.119.025350
358. Purrucker JC, Hölscher K, Kollmer J, Ringleb PA. Etiology of ischemic strokes of pa­
tients with atrial fibrillation and therapy with anticoagulants. J Clin Med 2020;9:2938. 
https://doi.org/10.3390/jcm9092938
359. Paciaroni M, Caso V, Agnelli G, Mosconi MG, Giustozzi M, Seiffge DJ, et al. Recurrent 
ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute 
stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the 
RENO-EXTEND 
study. 
Stroke 
2022;53:2620–7. 
https://doi.org/10.1161/ 
STROKEAHA.121.038239
360. Smits E, Andreotti F, Houben E, Crijns H, Haas S, Spentzouris G, et al. Adherence and 
persistence with once-daily vs twice-daily direct oral anticoagulants among patients


<!-- PAGE 80 -->

### Page 80

with atrial fibrillation: real-world analyses from The Netherlands, Italy and Germany. 
Drugs Real World Outcomes 2022;9:199–209. https://doi.org/10.1007/s40801-021- 
00289-w
361. Polymeris AA, Zietz A, Schaub F, Meya L, Traenka C, Thilemann S, et al. Once versus 
twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrilla­
tion. Eur Stroke J 2022;7:221–9. https://doi.org/10.1177/23969873221099477
362. Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, et al. EHRA/EAPCI 
expert consensus statement on catheter-based left atrial appendage occlusion—an 
update. Europace 2020;22:184. https://doi.org/10.1093/europace/euz258
363. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical pa­
tients with atrial fibrillation. Ann Thorac Surg 1996;61:755–9. https://doi.org/10.1016/ 
0003-4975(95)00887-X
364. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-Year outcomes 
after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am 
Coll Cardiol 2017;70:2964–75. https://doi.org/10.1016/j.jacc.2017.10.021
365. Lakkireddy D, Thaler D, Ellis CR, Swarup V, Sondergaard L, Carroll J, et al. Amplatzer 
amulet left atrial appendage occluder versus watchman device for stroke prophylaxis 
(amulet IDE): a randomized, controlled trial. Circulation 2021;144:1543–52. https://doi. 
org/10.1161/CIRCULATIONAHA.121.057063
366. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left atrial append­
age closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. 
J Am Coll Cardiol 2020;75:3122–35. https://doi.org/10.1016/j.jacc.2020.04.067
367. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. 4-Year outcomes 
after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fib­
rillation. J Am Coll Cardiol 2022;79:1–14. https://doi.org/10.1016/j.jacc.2021.10.023
368. Korsholm K, Damgaard D, Valentin JB, Packer EJS, Odenstedt J, Sinisalo J, et al. Left at­
rial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial 
fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. 
Am Heart J 2022;243:28–38. https://doi.org/10.1016/j.ahj.2021.08.020
369. Huijboom M, Maarse M, Aarnink E, van Dijk V, Swaans M, van der Heijden J, et al. 
COMPARE LAAO: rationale and design of the randomized controlled trial 
“COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard 
of care for atrial fibrillation patients at high stroke risk and ineligible to use oral antic­
oagulation therapy”. Am Heart J 2022;250:45–56. https://doi.org/10.1016/j.ahj.2022.05. 
001
370. Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, et al. 
Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fib­
rillation. J Am Coll Cardiol 2022;79:1785–98. https://doi.org/10.1016/j.jacc.2022.02.047
371. Patti G, Sticchi A, Verolino G, Pasceri V, Vizzi V, Brscic E, et al. Safety and efficacy of 
single versus dual antiplatelet therapy after left atrial appendage occlusion. Am J 
Cardiol 2020;134:83–90. https://doi.org/10.1016/j.amjcard.2020.08.013
372. Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant 
success and safety of left atrial appendage closure with the WATCHMAN device: peri- 
procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465–74. 
https://doi.org/10.1093/eurheartj/ehv730
373. Garg J, Shah S, Shah K, Turagam MK, Tzou W, Natale A, et al. Direct oral anticoagulant 
versus warfarin for watchman left atrial appendage occlusion—systematic review. 
JACC Clin Electrophysiol 2020;6:1735–7. https://doi.org/10.1016/j.jacep.2020.08.020
374. Osman M, Busu T, Osman K, Khan SU, Daniels M, Holmes DR, et al. Short-term anti­
platelet versus anticoagulant therapy after left atrial appendage occlusion: a systematic 
review and meta-analysis. JACC Clin Electrophysiol 2020;6:494–506. https://doi.org/10. 
1016/j.jacep.2019.11.009
375. Hildick-Smith D, Landmesser U, Camm AJ, Diener HC, Paul V, Schmidt B, et al. Left 
atrial appendage occlusion with the Amplatzer Amulet device: full results of the pro­
spective global observational study. Eur Heart J 2020;41:2894–901. https://doi.org/10. 
1093/eurheartj/ehaa169
376. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial 
appendage closure with the Watchman device in patients with a contraindication for 
oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left 
Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551–6. https://doi. 
org/10.1016/j.jacc.2013.03.035
377. Sondergaard L, Wong YH, Reddy VY, Boersma LVA, Bergmann MW, Doshi S, et al. 
Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy 
after left atrial appendage closure with Watchman. JACC Cardiovasc Interv 2019;12: 
1055–63. https://doi.org/10.1016/j.jcin.2019.04.004
378. Flores-Umanzor EJ, Cepas-Guillen PL, Arzamendi D, Cruz-Gonzalez I, Regueiro A, 
Freixa X. Rationale and design of a randomized clinical trial to compare two antithrom­
botic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. 
apixaban (ADALA study). J Interv Card Electrophysiol 2020;59:471–7. https://doi.org/ 
10.1007/s10840-020-00884-x
379. Aminian A, Schmidt B, Mazzone P, Berti S, Fischer S, Montorfano M, et al. Incidence, 
characterization, and clinical impact of device-related thrombus following left atrial ap­
pendage occlusion in the prospective global AMPLATZER amulet observational study. 
JACC Cardiovasc Interv 2019;12:1003–14. https://doi.org/10.1016/j.jcin.2019.02.003
380. Kany S, Metzner A, Lubos E, Kirchhof P. The atrial fibrillation heart team-guiding ther­
apy in left atrial appendage occlusion with increasingly complex patients and little evi­
dence. Eur Heart J 2022;43:1691–2. https://doi.org/10.1093/eurheartj/ehab744
381. Saw J, Holmes DR, Cavalcante JL, Freeman JV, Goldsweig AM, Kavinsky CJ, et al. SCAI/ 
HRS expert consensus statement on transcatheter left atrial appendage closure. Heart 
Rhythm 2023;20:e1–16. https://doi.org/10.1016/j.hrthm.2023.01.007
382. Cruz-González I, González-Ferreiro R, Freixa X, Gafoor S, Shakir S, Omran H, et al. 
Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant 
stroke). Results from the Amplatzer Cardiac Plug registry. Rev Esp Cardiol (Engl Ed) 
2020;73:28–34. https://doi.org/10.1016/j.rec.2019.02.013
383. Willits I, Keltie K, Linker N, de Belder M, Henderson R, Patrick H, et al. Left atrial ap­
pendage occlusion in the UK: prospective registry and data linkage to hospital episode 
statistics. Eur Heart J Qual Care Clin Outcomes 2021;7:468–75. https://doi.org/10.1093/ 
ehjqcco/qcab042
384. Price MJ, Valderrabano M, Zimmerman S, Friedman DJ, Kar S, Curtis JP, et al. 
Periprocedural pericardial effusion complicating transcatheter left atrial appendage oc­
clusion: a report from the NCDR LAAO registry. Circ Cardiovasc Interv 2022;15: 
e011718. https://doi.org/10.1161/CIRCINTERVENTIONS.121.011718
385. Aminian A, De Backer O, Nielsen-Kudsk JE, Mazzone P, Berti S, Fischer S, et al. 
Incidence and clinical impact of major bleeding following left atrial appendage occlu­
sion: insights from the amplatzer amulet observational post-market study. 
EuroIntervention 2021;17:774–82. https://doi.org/10.4244/EIJ-D-20-01309
386. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating real- 
world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN 
left atrial appendage closure technology: final 2–year outcome data of the 
EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm 
Electrophysiol 2019;12:e006841. https://doi.org/10.1161/CIRCEP.118.006841
387. Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage 
occlusion for stroke prevention in atrial fibrillation: multicentre experience with the 
AMPLATZER cardiac plug. EuroIntervention 2016;11:1170–9. https://doi.org/10.4244/ 
EIJY15M01_06
388. Nazir S, Ahuja KR, Kolte D, Isogai T, Michihata N, Saad AM, et al. Association of hos­
pital procedural volume with outcomes of percutaneous left atrial appendage occlu­
sion. JACC Cardiovasc Interv 2021;14:554–61. https://doi.org/10.1016/j.jcin.2020.11.029
389. Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, et al. The 
NCDR left atrial appendage occlusion registry. J Am Coll Cardiol 2020;75:1503–18. 
https://doi.org/10.1016/j.jacc.2019.12.040
390. Cruz-Gonzalez I, Korsholm K, Trejo-Velasco B, Thambo JB, Mazzone P, Rioufol G, 
et al. Procedural and short-term results with the new watchman FLX left atrial append­
age occlusion device. JACC Cardiovasc Interv 2020;13:2732–41. https://doi.org/10.1016/ 
j.jcin.2020.06.056
391. Simard T, Jung RG, Lehenbauer K, Piayda K, Pracon R, Jackson GG, et al. Predictors of 
device-related thrombus following percutaneous left atrial appendage occlusion. J Am 
Coll Cardiol 2021;78:297–313. https://doi.org/10.1016/j.jacc.2021.04.098
392. Simard TJ, Hibbert B, Alkhouli MA, Abraham NS, Holmes DR, Jr. Device-related 
thrombus following left atrial appendage occlusion. EuroIntervention 2022;18: 
224–32. https://doi.org/10.4244/EIJ-D-21-01010
393. Lempereur M, Aminian A, Freixa X, Gafoor S, Kefer J, Tzikas A, et al. Device-associated 
thrombus formation after left atrial appendage occlusion: a systematic review of events 
reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter 
Cardiovasc Interv 2017;90:E111–21. https://doi.org/10.1002/ccd.26903
394. Saw J, Tzikas A, Shakir S, Gafoor S, Omran H, Nielsen-Kudsk JE, et al. Incidence and 
clinical impact of device-associated thrombus and peri-device leak following left atrial 
appendage closure with the amplatzer cardiac plug. JACC Cardiovasc Interv 2017;10: 
391–9. https://doi.org/10.1016/j.jcin.2016.11.029
395. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, et al. Device-related 
thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. 
J Am Coll Cardiol 2018;71:1528–36. https://doi.org/10.1016/j.jacc.2018.01.076
396. Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN, et al. 
Device-related thrombus after left atrial appendage closure: incidence, predictors, 
and outcomes. Circulation 2018;138:874–85. https://doi.org/10.1161/CIRCULATI 
ONAHA.118.035090
397. Kar S, Doshi SK, Sadhu A, Horton R, Osorio J, Ellis C, et al. Primary outcome evaluation 
of a next-generation left atrial appendage closure device: results from the PINNACLE 
FLX trial. Circulation 2021;143:1754–62. https://doi.org/10.1161/CIRCULATIONAHA. 
120.050117
398. Alkhouli M, Du C, Killu A, Simard T, Noseworthy PA, Friedman PA, et al. Clinical im­
pact of residual leaks following left atrial appendage occlusion: insights from the NCDR 
LAAO registry. JACC Clin Electrophysiol 2022;8:766–78. https://doi.org/10.1016/j.jacep. 
2022.03.001
399. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial 
appendage occlusion during cardiac surgery for patients with atrial fibrillation: a 
meta-analysis. Eur J Cardiothorac Surg 2015;47:847–54. https://doi.org/10.1093/ejcts/ 
ezu291
ESC Guidelines                                                                                                                                                                                          3393


<!-- PAGE 81 -->

### Page 81

400. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, et al. Left atrial ap­
pendage occlusion study II (LAAOS II). Can J Cardiol 2013;29:1443–7. https://doi.org/ 
10.1016/j.cjca.2013.06.015
401. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left at­
rial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; 
384:2081–91. https://doi.org/10.1056/NEJMoa2101897
402. Zhang S, Cui Y, Li J, Tian H, Yun Y, Zhou X, et al. Concomitant transcatheter occlusion 
versus thoracoscopic surgical clipping for left atrial appendage in patients undergoing 
ablation for atrial fibrillation: a meta-analysis. Front Cardiovasc Med 2022;9:970847. 
https://doi.org/10.3389/fcvm.2022.970847
403. van Laar C, Verberkmoes NJ, van Es HW, Lewalter T, Dunnington G, Stark S, et al. 
Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis. JACC Clin 
Electrophysiol 2018;4:893–901. https://doi.org/10.1016/j.jacep.2018.03.009
404. Kiviniemi T, Bustamante-Munguira J, Olsson C, Jeppsson A, Halfwerk FR, Hartikainen J, 
et al. A randomized prospective multicenter trial for stroke prevention by prophylactic 
surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic 
valve surgery–LAA-CLOSURE trial protocol. Am Heart J 2021;237:127–34. https://doi. 
org/10.1016/j.ahj.2021.03.014
405. Cartledge R, Suwalski G, Witkowska A, Gottlieb G, Cioci A, Chidiac G, et al. 
Standalone epicardial left atrial appendage exclusion for thromboembolism prevention 
in atrial fibrillation. Interact Cardiovasc Thorac Surg 2022;34:548–55. https://doi.org/10. 
1093/icvts/ivab334
406. Branzoli S, Guarracini F, Marini M, D’Onghia G, Penzo D, Piffer S, et al. Heart team for 
left atrial appendage occlusion: a patient-tailored approach. J Clin Med 2022;11:176. 
https://doi.org/10.3390/jcm11010176
407. Toale C, Fitzmaurice GJ, Eaton D, Lyne J, Redmond KC. Outcomes of left atrial ap­
pendage occlusion using the AtriClip device: a systematic review. Interact Cardiovasc 
Thorac Surg 2019;29:655–62. https://doi.org/10.1093/icvts/ivz156
408. Caliskan E, Sahin A, Yilmaz M, Seifert B, Hinzpeter R, Alkadhi H, et al. Epicardial left 
atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with 
atrial fibrillation undergoing cardiac surgery. Europace 2018;20:e105–14. https://doi. 
org/10.1093/europace/eux211
409. Nso N, Nassar M, Zirkiyeva M, Lakhdar S, Shaukat T, Guzman L, et al. Outcomes of 
cardiac surgery with left atrial appendage occlusion versus no occlusion, direct oral an­
ticoagulants, and vitamin K antagonists: a systematic review with meta-analysis. Int J 
Cardiol Heart Vasc 2022;40:100998. https://doi.org/10.1016/j.ijcha.2022.100998
410. Ibrahim AM, Tandan N, Koester C, Al-Akchar M, Bhandari B, Botchway A, et al. 
Meta-analysis evaluating outcomes of surgical left atrial appendage occlusion during 
cardiac surgery. Am J Cardiol 2019;124:1218–25. https://doi.org/10.1016/j.amjcard. 
2019.07.032
411. Park-Hansen J, Holme SJV, Irmukhamedov A, Carranza CL, Greve AM, Al-Farra G, 
et al. Adding left atrial appendage closure to open heart surgery provides protection 
from ischemic brain injury six years after surgery independently of atrial fibrillation his­
tory: the LAACS randomized study. J Cardiothorac Surg 2018;13:53. https://doi.org/10. 
1186/s13019-018-0740-7
412. Soltesz EG, Dewan KC, Anderson LH, Ferguson MA, Gillinov AM. Improved outcomes 
in CABG patients with atrial fibrillation associated with surgical left atrial appendage 
exclusion. J Card Surg 2021;36:1201–8. https://doi.org/10.1111/jocs.15335
413. Fu M, Qin Z, Zheng S, Li Y, Yang S, Zhao Y, et al. Thoracoscopic left atrial appendage 
occlusion for stroke prevention compared with long-term warfarin therapy in patients 
with nonvalvular atrial fibrillation. Am J Cardiol 2019;123:50–6. https://doi.org/10.1016/ 
j.amjcard.2018.09.025
414. Peterson D, Geison E. Pharmacist interventions to reduce modifiable bleeding risk fac­
tors using HAS-BLED in patients taking warfarin. Fed Pract 2017;34:S16–20.
415. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Incident risk factors and ma­
jor bleeding in patients with atrial fibrillation treated with oral anticoagulants: a com­
parison of baseline, follow-up and Delta HAS-BLED scores with an approach focused 
on modifiable bleeding risk factors. Thromb Haemost 2018;47:768–77. https://doi.org/ 
10.1055/s-0038-1636534
416. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral 
anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 
2003;139:893–900. https://doi.org/10.7326/0003-4819-139-11-200312020-00007
417. Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, et al. Impact of 
modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation an­
ticoagulated with rivaroxaban. J Am Heart Assoc 2020;9:e009530. https://doi.org/10. 
1161/JAHA.118.009530
418. Guo Y, Lane DA, Chen Y, Lip GYH; mAF-App II Trial investigators. Regular bleeding 
risk assessment associated with reduction in bleeding outcomes: the mAFA-II rando­
mized trial. Am J Med 2020;133:1195–1202.e2. https://doi.org/10.1016/j.amjmed.2020. 
03.019
419. Lane DA, Lip GYH. Stroke and bleeding risk stratification in atrial fibrillation: a critical 
appraisal. Eur Heart J Suppl 2020;22:O14–27. https://doi.org/10.1093/eurheartj/ 
suaa178
420. Lip GYH, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the 
use and misuse of bleeding risk scores. J Thromb Haemost 2016;14:1711–4. https://doi. 
org/10.1111/jth.13386
421. Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, et al. Assessment and 
mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position 
paper from the ESC working group on thrombosis, in collaboration with the European 
Heart Rhythm Association, the Association for Acute CardioVascular Care and the 
Asia-Pacific Heart Rhythm Society. Europace 2022;24:1844–71. https://doi.org/10. 
1093/europace/euac020
422. Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, et al. Stroke 
risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment 
among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. 
Curr Med Res Opin 2017;33:631–8. https://doi.org/10.1080/03007995.2016.1275936
423. Hijazi Z, Lindbäck J, Oldgren J, Benz AP, Alexander JH, Connolly SJ, et al. Individual net 
clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk 
scores. Am Heart J 2023;261:55–63. https://doi.org/10.1016/j.ahj.2023.03.012
424. Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, 
biomarkers, clinical history) stroke risk score: a biomarker-based risk score for pre­
dicting stroke in atrial fibrillation. Eur Heart J 2016;37:1582–90. https://doi.org/10. 
1093/eurheartj/ehw054
425. Gao X, Cai X, Yang Y, Zhou Y, Zhu W. Diagnostic accuracy of the HAS-BLED bleeding 
score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review 
and meta-analysis. Front Cardiovasc Med 2021;8:757087. https://doi.org/10.3389/ 
fcvm.2021.757087
426. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major 
bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and 
meta-analysis. Clin Cardiol 2015;38:555–61. https://doi.org/10.1002/clc.22435
427. Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED 
high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients 
with atrial fibrillation: a systematic review and meta-analysis. J Interv Card 
Electrophysiol 2014;40:277–84. https://doi.org/10.1007/s10840-014-9930-y
428. Zeng J, Yu P, Cui W, Wang X, Ma J, Zeng C. Comparison of HAS-BLED with other risk 
models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: 
a PRISMA-compliant article. Medicine (Baltimore) 2020;99:e20782. https://doi.org/10. 
1097/MD.0000000000020782
429. Wang C, Yu Y, Zhu W, Yu J, Lip GYH, Hong K. Comparing the ORBIT and HAS-BLED 
bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and 
meta-analysis. Oncotarget 2017;8:109703–11. https://doi.org/10.18632/oncotarget. 
19858
430. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic 
review and performance analysis of clinical prediction rules. Ann Hematol 2011;90: 
1191–200. https://doi.org/10.1007/s00277-011-1267-3
431. Hilkens NA, Algra A, Greving JP. Predicting major bleeding in ischemic stroke patients 
with atrial fibrillation. Stroke 2017;48:3142–4. https://doi.org/10.1161/STROKEAHA. 
117.019183
432. Dalgaard F, Pieper K, Verheugt F, Camm AJ, Fox KA, Kakkar AK, et al. GARFIELD-AF 
model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nation­
wide validation study. BMJ Open 2019;9:e033283. https://doi.org/10.1136/bmjopen- 
2019-033283
433. Mori N, Sotomi Y, Hirata A, Hirayama A, Sakata Y, Higuchi Y. External validation of the 
ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation pa­
tients using direct oral anticoagulants (Asian Data from the DIRECT Registry). Am J 
Cardiol 2019;124:1044–8. https://doi.org/10.1016/j.amjcard.2019.07.005
434. Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS, et al. 
Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA 
risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleed­
ing in patients with atrial fibrillation. Am J Cardiol 2017;120:1549–56. https://doi.org/10. 
1016/j.amjcard.2017.07.051
435. Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandalà M. ICH in primary or 
metastatic brain cancer patients with or without anticoagulant treatment: a systematic 
review and meta-analysis. Blood Adv 2022;6:4873–83. https://doi.org/10.1182/ 
bloodadvances.2022008086
436. Shoamanesh A. Anticoagulation in patients with cerebral amyloid angiopathy. Lancet 
2023;402:1418–9. https://doi.org/10.1016/S0140-6736(23)02025-1
437. Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association 
of antisecretory drugs with upper gastrointestinal bleeding in patients using oral antic­
oagulants: a systematic review and meta-analysis. Am J Med 2022;135:1231–1243.e8. 
https://doi.org/10.1016/j.amjmed.2022.05.031
438. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. 
Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban 
and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 
2019;157:403–412.e5. https://doi.org/10.1053/j.gastro.2019.04.041
439. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, et al. Factors af­
fecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: ob­
servations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM) study. Am Heart J 2005;149:650–6. https://doi.org/10.1016/j.ahj.2004.11.015
440. Harskamp RE, Lucassen WAM, Lopes RD, Himmelreich JCL, Parati G, Weert H. Risk 
of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial


<!-- PAGE 82 -->

### Page 82

fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol 2022;77: 
191–5. https://doi.org/10.1080/00015385.2021.1882111
441. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagu­
lant and thrombolytic treatment: American College of Chest Physicians evidence- 
based clinical practice guidelines (8th Edition). Chest 2008;133:257s–98s. https://doi. 
org/10.1378/chest.08-0674
442. Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, et al. Relation of the 
HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality 
in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012;5: 
312–8. https://doi.org/10.1161/CIRCEP.111.967000
443. Bouillon K, Bertrand M, Boudali L, Ducimetière P, Dray-Spira R, Zureik M. Short-term 
risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in 
more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient 
care. J Am Heart Assoc 2016;5:e004065. https://doi.org/10.1161/JAHA.116.004065
444. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of out­
comes among patients randomized to warfarin therapy according to anticoagulant 
control: results from SPORTIF III and V. Arch Intern Med 2007;167:239–45. https:// 
doi.org/10.1001/archinte.167.3.239
445. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr, et al. 2014 
AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: ex­
ecutive summary: a report of the American College of Cardiology/American Heart 
Association Task Force on practice guidelines and the Heart Rhythm Society. 
Circulation 2014;130:2071–104. https://doi.org/10.1161/CIR.0000000000000040
446. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of 
thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibril­
lation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. 
Thromb Haemost 2011;106:739–49. https://doi.org/10.1160/TH11-05-0364
447. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 
2020 ACC expert consensus decision pathway on management of bleeding in patients 
on oral anticoagulants: a report of the American College of Cardiology Solution Set 
Oversight Committee. J Am Coll Cardiol 2020;76:594–622. https://doi.org/10.1016/j. 
jacc.2020.04.053
448. Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagu­
lants: selecting the optimal assay based on drug, assay availability, and clinical indication. 
J Thromb Thrombolysis 2016;41:241–7. https://doi.org/10.1007/s11239-015-1282-7
449. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, et al. 
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide 
for clinicians. J Thromb Haemost 2018;16:209–19. https://doi.org/10.1111/jth.13912
450. Milling TJ, Jr, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, et al. Safety of a four- 
factor prothrombin complex concentrate versus plasma for vitamin K antagonist re­
versal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med 2016; 
23:466–75. https://doi.org/10.1111/acem.12911
451. Pollack CV, Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. 
Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 2017;377: 
431–41. https://doi.org/10.1056/NEJMoa1707278
452. Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, et al. 
ANNEXA–I investigators. Andexanet for factor Xa inhibitor–associated acute intra­
cerebral hemorrhage. N Engl J Med 2024;390:1745–55. https://doi.org/10.1056/ 
NEJMoa2313040
453. Milioglou I, Farmakis I, Neudeker M, Hussain Z, Guha A, Giannakoulas G, et al. 
Prothrombin complex concentrate in major bleeding associated with DOACs; an up­
dated systematic review and meta-analysis. J Thromb Thrombolysis 2021;52:1137–50. 
https://doi.org/10.1007/s11239-021-02480-w
454. Meyre PB, Blum S, Hennings E, Aeschbacher S, Reichlin T, Rodondi N, et al. Bleeding 
and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk 
and timing. Eur Heart J 2022;43:4899–908. https://doi.org/10.1093/eurheartj/ehac587
455. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. 
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N 
Engl J Med 2019;380:1326–35. https://doi.org/10.1056/NEJMoa1814051
456. Fanikos J, Murwin D, Gruenenfelder F, Tartakovsky I, França LR, Reilly PA, et al. Global 
use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance pro­
gram. Thromb Haemost 2020;120:27–35. https://doi.org/10.1055/s-0039-1695771
457. Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, et al. A review of rate 
control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ 
Open 2017;7:e015099. https://doi.org/10.1136/bmjopen-2016-015099
458. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict 
versus lenient versus poor rate control among patients with atrial fibrillation and heart 
failure (from the get with the guidelines—heart failure program). Am J Cardiol 2020; 
125:894–900. https://doi.org/10.1016/j.amjcard.2019.12.025
459. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. 
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 
2010;362:1363–73. https://doi.org/10.1056/NEJMoa1001337
460. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A, et al. The 
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: ap­
proaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201–8. https:// 
doi.org/10.1016/j.jacc.2003.11.032
461. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, et al. 
Comparison of four single-drug regimens on ventricular rate and arrhythmia-related 
symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111: 
225–30. https://doi.org/10.1016/j.amjcard.2012.09.020
462. Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, et al. A ran­
domized, double-blind comparison of intravenous diltiazem and digoxin for atrial fib­
rillation after coronary artery bypass surgery. Am Heart J 1998;135:739–47. https://doi. 
org/10.1016/S0002-8703(98)70031-6
463. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or 
in combination with digoxin for the management of atrial fibrillation in patients with 
heart failure? J Am Coll Cardiol 2003;42:1944–51. https://doi.org/10.1016/j.jacc.2003. 
07.020
464. Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical 
heart rate control management. Postgrad Med J 2009;85:303–12. https://doi.org/10. 
1136/pgmj.2008.068908
465. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, et al. Diltiazem 
improves cardiac function and exercise capacity in patients with idiopathic dilated car­
diomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 
1996;94:346–52. https://doi.org/10.1161/01.CIR.94.3.346
466. Andrade JG, Roy D, Wyse DG, Tardif JC, Talajic M, Leduc H, et al. Heart rate and ad­
verse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF 
substudy. Heart Rhythm 2016;13:54–61. https://doi.org/10.1016/j.hrthm.2015.08.028
467. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, et al. The 
Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial 
(AIRCRAFT). J Am Coll Cardiol 2003;41:1697–702. https://doi.org/10.1016/S0735- 
1097(03)00338-3
468. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, et al. Ablate and pace 
strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace 2007;9: 
498–505. https://doi.org/10.1093/europace/eum091
469. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His 
bundle pacing. Europace 2017;19:iv10–6. https://doi.org/10.1093/europace/eux263
470. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A ran­
domized controlled trial of atrioventricular junction ablation and cardiac resynchroni­
zation therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart 
J 2018;39:3999–4008. https://doi.org/10.1093/eurheartj/ehy555
471. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV 
junction ablation and cardiac resynchronization for patients with permanent atrial fib­
rillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021;42:4731–9. 
https://doi.org/10.1093/eurheartj/ehab569
472. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, 
et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial 
tachyarrhythmias. Crit Care Med 2001;29:1149–53. https://doi.org/10.1097/ 
00003246-200106000-00011
473. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of 
recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous 
amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995;16:521–8. 
https://doi.org/10.1093/oxfordjournals.eurheartj.a060945
474. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. 
Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of 
pooled data from the RACE and AFFIRM studies. Europace 2006;8:935–42. https:// 
doi.org/10.1093/europace/eul106
475. Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B, et al. 
Safety and efficiency of calcium channel blockers versus beta-blockers for rate control 
in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg 
Med 2013;20:222–30. https://doi.org/10.1111/acem.12091
476. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intra­
venous amiodarone or digoxin for achieving ventricular rate control in patients with 
acute uncomplicated atrial fibrillation. Crit Care Med 2009;37:2174–9, quiz 2180. 
https://doi.org/10.1097/CCM.0b013e3181a02f56
477. Perrett M, Gohil N, Tica O, Bunting KV, Kotecha D. Efficacy and safety of intravenous 
beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a 
systematic review and meta-analysis of randomised trials. Clin Res Cardiol 2023; 
113:831–41. https://doi.org/10.1007/s00392-023-02295-0
478. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural 
heart 
disease. 
Circulation 
2012;125:945–57. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.111.019935
479. Imamura T, Kinugawa K. Novel rate control strategy with landiolol in patients with car­
diac dysfunction and atrial fibrillation. ESC Heart Fail 2020;7:2208–13. https://doi.org/ 
10.1002/ehf2.12879
480. Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, et al. Calcium 
channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natri­
uretic peptide levels compared with beta-blockers in patients with permanent atrial 
fibrillation. Eur Heart J 2014;35:517–24. https://doi.org/10.1093/eurheartj/eht429
481. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone 
in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268–76. https://doi. 
org/10.1056/NEJMoa1109867
ESC Guidelines                                                                                                                                                                                          3395


<!-- PAGE 83 -->

### Page 83

482. Karwath A, Bunting KV, Gill SK, Tica O, Pendleton S, Aziz F, et al. Redefining beta­
blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a ma­
chine learning cluster analysis. Lancet 2021;398:1427–35. https://doi.org/10.1016/ 
S0140-6736(21)01638-X
483. Koldenhof T, Wijtvliet P, Pluymaekers N, Rienstra M, Folkeringa RJ, Bronzwaer P, et al. 
Rate control drugs differ in the prevention of progression of atrial fibrillation. Europace 
2022;24:384–9. https://doi.org/10.1093/europace/euab191
484. Champsi A, Mitchell C, Tica O, Ziff OJ, Bunting KV, Mobley AR, et al. Digoxin in pa­
tients with heart failure and/or atrial fibrillation: a systematic review and meta-analysis 
of 5.9 million patient years of follow-up. SSRN preprint. 2023. https://doi.org/10.2139/ 
ssrn.4544769.
485. Andrews P, Anseeuw K, Kotecha D, Lapostolle F, Thanacoody R. Diagnosis and prac­
tical management of digoxin toxicity: a narrative review and consensus. Eur J Emerg 
Med 2023;30:395–401. https://doi.org/10.1097/MEJ.0000000000001065
486. Bavendiek U, Berliner D, Dávila LA, Schwab J, Maier L, Philipp SA, et al. Rationale and 
design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with ad­
vanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. 
Eur J Heart Fail 2019;21:676–84. https://doi.org/10.1002/ejhf.1452
487. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute 
heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 
1998;81:594–8. https://doi.org/10.1016/S0002-9149(97)00962-4
488. Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: long term 
survival and predictors of permanent atrial fibrillation. Heart 2003;89:1035–8. https:// 
doi.org/10.1136/heart.89.9.1035
489. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death 
after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin 
Electrophysiol 1997;20:343–8. https://doi.org/10.1111/j.1540-8159.1997.tb06179.x
490. Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF, et al. Effect of pacing 
method on risk of sudden death after atrioventricular node ablation and pacemaker 
implantation in patients with atrial fibrillation. Heart Rhythm 2013;10:696–701. 
https://doi.org/10.1016/j.hrthm.2013.01.021
491. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. 
Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic re­
view. Circ Arrhythm Electrophysiol 2012;5:68–76. https://doi.org/10.1161/CIRCEP.111. 
967810
492. Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic 
elderly patients: pharmacologic therapy versus AV node ablation. Clin Pharmacol 
Ther 2007;81:284–7. https://doi.org/10.1038/sj.clpt.6100062
493. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, et al. Long-term sur­
vival after ablation of the atrioventricular node and implantation of a permanent pace­
maker in patients with atrial fibrillation. N Engl J Med 2001;344:1043–51. https://doi. 
org/10.1056/NEJM200104053441403
494. Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP. Atrioventricular 
nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular 
pacing mode. Eur J Heart Fail 2012;14:661–7. https://doi.org/10.1093/eurjhf/hfs036
495. Huang W, Su L, Wu S. Pacing treatment of atrial fibrillation patients with heart failure: 
His bundle pacing combined with atrioventricular node ablation. Card Electrophysiol 
Clin 2018;10:519–35. https://doi.org/10.1016/j.ccep.2018.05.016
496. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, et al. Benefits of permanent His bundle 
pacing combined with atrioventricular node ablation in atrial fibrillation patients with 
heart failure with both preserved and reduced left ventricular ejection fraction. J Am 
Heart Assoc 2017;6:e005309. https://doi.org/10.1161/JAHA.116.005309
497. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A com­
parison of rate control and rhythm control in patients with recurrent persistent atrial 
fibrillation. N Engl J Med 2002;347:1834–40. https://doi.org/10.1056/NEJMoa021375
498. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A 
comparison of rate control and rhythm control in patients with atrial fibrillation. N 
Engl J Med 2002;347:1825–33. https://doi.org/10.1056/NEJMoa021328
499. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation— 
pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 
2000;356:1789–94. https://doi.org/10.1016/S0140-6736(00)03230-X
500. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus 
rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667–77. 
https://doi.org/10.1056/NEJMoa0708789
501. Blomström-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kennebäck 
G, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in 
patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA 2019; 
321:1059–68. https://doi.org/10.1001/jama.2019.0335
502. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of cath­
eter ablation vs medical therapy on quality of life among patients with atrial fibrillation: 
the CABANA randomized clinical trial. JAMA 2019;321:1275–85. https://doi.org/10. 
1001/jama.2019.0692
503. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison 
of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with 
paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333–40. 
https://doi.org/10.1001/jama.2009.2029
504. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial 
fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic litera­
ture reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349–61. https://doi. 
org/10.1161/CIRCEP.108.824789
505. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation 
versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118: 
2498–505. https://doi.org/10.1161/CIRCULATIONAHA.108.772582
506. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, et al. 
Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results 
of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013;61: 
1713–23. https://doi.org/10.1016/j.jacc.2012.11.064
507. Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, et al. 
Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy 
in the CABANA trial. J Am Coll Cardiol 2020;75:3105–18. https://doi.org/10.1016/j.jacc. 
2020.04.065
508. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A, et al. 
Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a 
multicentre, randomized, controlled trial (SARA study). Eur Heart J 2014;35:501–7. 
https://doi.org/10.1093/eurheartj/eht457
509. Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, et al. 
Five-year outcome of catheter ablation of persistent atrial fibrillation using termination 
of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol 2015;8:18–24. 
https://doi.org/10.1161/CIRCEP.114.001943
510. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. 
Circulation 
2017;136:583–96. 
https://doi.org/10.1161/CIRCULATIONAHA.116. 
023163
511. Sanders P, Elliott AD, Linz D. Upstream targets to treat atrial fibrillation. J Am Coll 
Cardiol 2017;70:2906–8. https://doi.org/10.1016/j.jacc.2017.10.043
512. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. 
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 
2009;360:668–78. https://doi.org/10.1056/NEJMoa0803778
513. Sohns C, Fox H, Marrouche NF, Crijns H, Costard-Jaeckle A, Bergau L, et al. Catheter 
ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389: 
1380–9. https://doi.org/10.1056/NEJMoa2306037
514. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. 
Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients 
with congestive heart failure and an implanted device: results from the AATAC multi­
center randomized trial. Circulation 2016;133:1637–44. https://doi.org/10.1161/ 
CIRCULATIONAHA.115.019406
515. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion 
for acute atrial fibrillation and thromboembolic complications. JAMA 2014;312:647–9. 
https://doi.org/10.1001/jama.2014.3824
516. Garg A, Khunger M, Seicean S, Chung MK, Tchou PJ. Incidence of thromboembolic 
complications within 30 days of electrical cardioversion performed within 48 hours 
of atrial fibrillation onset. JACC Clin Electrophysiol 2016;2:487–94. https://doi.org/10. 
1016/j.jacep.2016.01.018
517. Tampieri A, Cipriano V, Mucci F, Rusconi AM, Lenzi T, Cenni P. Safety of cardioversion 
in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in pa­
tients at low cardioembolic risk. Intern Emerg Med 2018;13:87–93. https://doi.org/10. 
1007/s11739-016-1589-1
518. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, et al. 
Thromboembolic complications after cardioversion of acute atrial fibrillation: the 
FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 2013;62:1187–92. https://doi. 
org/10.1016/j.jacc.2013.04.089
519. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, et al. 
Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current 
cardioversion with and without oral anticoagulant therapy. Europace 2015;17:18–23. 
https://doi.org/10.1093/europace/euu189
520. Bonfanti L, Annovi A, Sanchis-Gomar F, Saccenti C, Meschi T, Ticinesi A, et al. 
Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation 
in the emergency department: a real-world 10-year single center experience. Clin 
Exp Emerg Med 2019;6:64–9. https://doi.org/10.15441/ceem.17.286
521. Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P. Non-vitamin K 
antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of 
atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2018;268:143–8. 
https://doi.org/10.1016/j.ijcard.2018.04.034
522. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al. 
Use of transesophageal echocardiography to guide cardioversion in patients with atrial 
fibrillation. N Engl J Med 2001;344:1411–20. https://doi.org/10.1056/NEJM200105 
103441901
523. Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M. Direct 
oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibril­
lation: an updated meta-analysis. J Thromb Thrombolysis 2018;45:550–6. https://doi.org/ 
10.1007/s11239-018-1622-5
524. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. Analysis of 
cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm


<!-- PAGE 84 -->

### Page 84

Management (AFFIRM) study. Circulation 2004;109:1973–80. https://doi.org/10.1161/ 
01.CIR.0000118472.77237.FA
525. Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martín A, et al. Contemporary 
real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF 
study. Int J Cardiol 2014;172:588–94. https://doi.org/10.1016/j.ijcard.2014.01.099
526. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al. Short-term 
versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation 
(Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. 
Lancet 2012;380:238–46. https://doi.org/10.1016/S0140-6736(12)60570-4
527. Zhu W, Wu Z, Dong Y, Lip GYH, Liu C. Effectiveness of early rhythm control in im­
proving clinical outcomes in patients with atrial fibrillation: a systematic review and 
meta-analysis. BMC Med 2022;20:340. https://doi.org/10.1186/s12916-022-02545-4
528. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, et al. 
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral an­
ticoagulants for prevention of thromboembolic complications in cardioversion of non­
valvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) 
trial. Circulation 2004;109:997–1003. https://doi.org/10.1161/01.CIR.0000120509. 
64740.DC
529. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Left atrial throm­
bus resolution in atrial fibrillation or flutter: results of a prospective study with rivar­
oxaban (X-TRA) and a retrospective observational registry providing baseline data 
(CLOT-AF). Am Heart J 2016;178:126–34. https://doi.org/10.1016/j.ahj.2016.05.007
530. Stiell IG, Eagles D, Nemnom MJ, Brown E, Taljaard M, Archambault PM, et al. Adverse 
events associated with electrical cardioversion in patients with acute atrial fibrillation 
and atrial flutter. Can J Cardiol 2021;37:1775–82. https://doi.org/10.1016/j.cjca.2021.08. 
018
531. Stiell IG, Archambault PM, Morris J, Mercier E, Eagles D, Perry JJ, et al. RAFF-3 Trial: a 
stepped-wedge cluster randomised trial to improve care of acute atrial fibrillation and 
flutter in the emergency department. Can J Cardiol 2021;37:1569–77. https://doi.org/ 
10.1016/j.cjca.2021.06.016
532. Gurevitz OT, Ammash NM, Malouf JF, Chandrasekaran K, Rosales AG, Ballman KV, 
et al. Comparative efficacy of monophasic and biphasic waveforms for transthoracic 
cardioversion of atrial fibrillation and atrial flutter. Am Heart J 2005;149:316–21. 
https://doi.org/10.1016/j.ahj.2004.07.007
533. Mortensen K, Risius T, Schwemer TF, Aydin MA, Köster R, Klemm HU, et al. Biphasic 
versus monophasic shock for external cardioversion of atrial flutter: a prospective, 
randomized trial. Cardiology 2008;111:57–62. https://doi.org/10.1159/000113429
534. Inácio JF, da Rosa Mdos S, Shah J, Rosário J, Vissoci JR, Manica AL, et al. Monophasic and 
biphasic shock for transthoracic conversion of atrial fibrillation: systematic review and 
network meta-analysis. Resuscitation 2016;100:66–75. https://doi.org/10.1016/j. 
resuscitation.2015.12.009
535. Eid M, Abu Jazar D, Medhekar A, Khalife W, Javaid A, Ahsan C, et al. Anterior-posterior 
versus anterior-lateral electrodes position for electrical cardioversion of atrial fibrilla­
tion: a meta-analysis of randomized controlled trials. Int J Cardiol Heart Vasc 2022;43: 
101129. https://doi.org/10.1016/j.ijcha.2022.101129
536. Squara F, Elbaum C, Garret G, Liprandi L, Scarlatti D, Bun SS, et al. Active compression 
versus standard anterior-posterior defibrillation for external cardioversion of atrial fib­
rillation: a prospective randomized study. Heart Rhythm 2021;18:360–5. https://doi. 
org/10.1016/j.hrthm.2020.11.005
537. Schmidt AS, Lauridsen KG, Torp P, Bach LF, Rickers H, Løfgren B. Maximum-fixed en­
ergy shocks for cardioverting atrial fibrillation. Eur Heart J 2020;41:626–31. https://doi. 
org/10.1093/eurheartj/ehz585
538. Müssigbrodt A, John S, Kosiuk J, Richter S, Hindricks G, Bollmann A. 
Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant 
and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after 
failed electrical cardioversion. Europace 2016;18:51–6. https://doi.org/10.1093/ 
europace/euv194
539. Climent VE, Marin F, Mainar L, Gomez-Aldaravi R, Martinez JG, Chorro FJ, et al. Effects 
of pretreatment with intravenous flecainide on efficacy of external cardioversion of 
persistent atrial fibrillation. Pacing Clin Electrophysiol 2004;27:368–72. https://doi.org/ 
10.1111/j.1540-8159.2004.00444.x
540. Tieleman RG, Van Gelder IC, Bosker HA, Kingma T, Wilde AA, Kirchhof CJ, et al. Does 
flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent 
atrial fibrillation? Heart Rhythm 2005;2:223–30. https://doi.org/10.1016/j.hrthm.2004. 
11.014
541. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, et al. Facilitating 
transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J 
Med 1999;340:1849–54. https://doi.org/10.1056/NEJM199906173402401
542. Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial 
flutter and fibrillation. J Am Board Fam Med 2011;24:86–92. https://doi.org/10.3122/ 
jabfm.2011.01.080096
543. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propa­
fenone administration before electrical cardioversion of chronic atrial fibrillation: a 
placebo-controlled study. J Am Coll Cardiol 1996;28:700–6. https://doi.org/10.1016/ 
S0735-1097(96)00230-6
544. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, et al. A randomized 
placebo-controlled trial of pre-treatment and short- or long-term maintenance ther­
apy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur 
Heart J 2004;25:144–50. https://doi.org/10.1016/j.ehj.2003.10.020
545. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the 
efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with 
chronic atrial fibrillation. Eur Heart J 2000;21:66–73. https://doi.org/10.1053/euhj.1999. 
1734
546. Um KJ, McIntyre WF, Healey JS, Mendoza PA, Koziarz A, Amit G, et al. Pre- and post- 
treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a 
systematic review and meta-analysis. Europace 2019;21:856–63. https://doi.org/10. 
1093/europace/euy310
547. Toso E, Iannaccone M, Caponi D, Rotondi F, Santoro A, Gallo C, et al. Does antiar­
rhythmic drugs premedication improve electrical cardioversion success in persistent 
atrial fibrillation? J Electrocardiol 2017;50:294–300. https://doi.org/10.1016/j. 
jelectrocard.2016.12.004
548. Ganapathy AV, Monjazeb S, Ganapathy KS, Shanoon F, Razavi M. “Asymptomatic” per­
sistent or permanent atrial fibrillation: a misnomer in selected patients. Int J Cardiol 
2015;185:112–3. https://doi.org/10.1016/j.ijcard.2015.03.122
549. Voskoboinik A, Kalman E, Plunkett G, Knott J, Moskovitch J, Sanders P, et al. A com­
parison of early versus delayed elective electrical cardioversion for recurrent episodes 
of persistent atrial fibrillation: a multi-center study. Int J Cardiol 2019;284:33–7. https:// 
doi.org/10.1016/j.ijcard.2018.10.068
550. Airaksinen KEJ. Early versus delayed cardioversion: why should we wait? Expert Rev 
Cardiovasc Ther 2020;18:149–54. https://doi.org/10.1080/14779072.2020.1736563
551. Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion 
of atrial fibrillation: current management and treatment options. Drugs 2004;64: 
2741–62. https://doi.org/10.2165/00003495-200464240-00003
552. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al. 
Antiarrhythmic drugs–clinical use and clinical decision making: a consensus document 
from the European Heart Rhythm Association (EHRA) and European Society of 
Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by 
the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and 
International Society of Cardiovascular Pharmacotherapy (ISCP). Europace 2018;20: 
731–732an. https://doi.org/10.1093/europace/eux373
553. Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T. Types and out­
comes of cardioversion in patients admitted to hospital for atrial fibrillation: results of 
the German RHYTHM-AF study. Clin Res Cardiol 2013;102:713–23. https://doi.org/10. 
1007/s00392-013-0586-x
554. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/ 
EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical 
ablation of atrial fibrillation: executive summary. Europace 2018;20:157–208. https:// 
doi.org/10.1093/europace/eux275
555. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spon­
taneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998;31: 
588–92. https://doi.org/10.1016/S0735-1097(97)00534-2
556. Tsiachris D, Doundoulakis I, Pagkalidou E, Kordalis A, Deftereos S, Gatzoulis KA, et al. 
Pharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network 
meta-analysis. Cardiovasc Drugs Ther 2021;35:293–308. https://doi.org/10.1007/ 
s10557-020-07127-1
557. Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE, et al. 
Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the 
FinCV study. Europace 2013;15:1432–5. https://doi.org/10.1093/europace/eut106
558. Brandes A, Crijns H, Rienstra M, Kirchhof P, Grove EL, Pedersen KB, et al. 
Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and prac­
tical guidance for a common procedure. Europace 2020;22:1149–61. https://doi.org/ 
10.1093/europace/euaa057
559. Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, et al. Electrical 
versus pharmacological cardioversion for emergency department patients with acute 
atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet 2020;395:339–49. 
https://doi.org/10.1016/S0140-6736(19)32994-0
560. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment 
of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 
2004;351:2384–91. https://doi.org/10.1056/NEJMoa041233
561. Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A, Louis P. 
Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiar­
rhythmic drugs for atrial tachyarrhythmias. Int J Cardiol 2001;80:7–15. https://doi. 
org/10.1016/S0167-5273(01)00459-4
562. Conde D, Costabel JP, Caro M, Ferro A, Lambardi F, Corrales Barboza A, et al. 
Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J 
Cardiol 2013;168:2423–5. https://doi.org/10.1016/j.ijcard.2013.02.006
563. Markey GC, Salter N, Ryan J. Intravenous flecainide for emergency department man­
agement of acute atrial fibrillation. J Emerg Med 2018;54:320–7. https://doi.org/10. 
1016/j.jemermed.2017.11.016
564. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, 
Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and 
ESC Guidelines                                                                                                                                                                                          3397


<!-- PAGE 85 -->

### Page 85

amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 
2000;86:950–3. https://doi.org/10.1016/S0002-9149(00)01128-0
565. Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, et al. Flecainide 
versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur 
Heart J 2004;25:1318–24. https://doi.org/10.1016/j.ehj.2004.04.030
566. Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide 
vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract 
2005;59:1395–400. https://doi.org/10.1111/j.1368-5031.2005.00705.x
567. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. 
A randomized active-controlled study comparing the efficacy and safety of vernakalant 
to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313–21. 
https://doi.org/10.1016/j.jacc.2010.07.046
568. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Vernakalant 
hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, 
placebo-controlled trial. Circulation 2008;117:1518–25. https://doi.org/10.1161/ 
CIRCULATIONAHA.107.723866
569. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous 
conversion and maintenance of sinus rhythm by amiodarone in patients with heart fail­
ure and atrial fibrillation: observations from the veterans affairs congestive heart failure 
survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans 
Affairs CHF-STAT Investigators. Circulation 1998;98:2574–9. https://doi.org/10.1161/ 
01.cir.98.23.2574
570. Hofmann R, Steinwender C, Kammler J, Kypta A, Wimmer G, Leisch F. Intravenous 
amiodarone bolus for treatment of atrial fibrillation in patients with advanced congest­
ive heart failure or cardiogenic shock. Wien Klin Wochenschr 2004;116:744–9. https:// 
doi.org/10.1007/s00508-004-0264-0
571. Alboni P, Botto GL, Boriani G, Russo G, Pacchioni F, Iori M, et al. Intravenous admin­
istration of flecainide or propafenone in patients with recent-onset atrial fibrillation 
does not predict adverse effects during ‘pill-in-the-pocket’ treatment. Heart 2010; 
96:546–9. https://doi.org/10.1136/hrt.2009.187963
572. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of 
recent-onset atrial fibrillation. J Am Coll Cardiol 2001;37:542–7. https://doi.org/10.1016/ 
S0735-1097(00)01116-5
573. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of 
recent-onset atrial fibrillation. Int J Cardiol 2003;87:121–8. https://doi.org/10.1016/ 
S0167-5273(02)00467-9
574. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, 
et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic 
review. Ann Intern Med 2014;160:760–73. https://doi.org/10.7326/M13-1467
575. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 
Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive 
Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 2020;36: 
1847–948. https://doi.org/10.1016/j.cjca.2020.09.001
576. Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for main­
taining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst 
Rev 2015;3:CD005049. https://doi.org/10.1002/14651858.CD005049.pub4
577. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. 
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. 
Cochrane Database 
Syst Rev 
2019;2019:Cd005049. https://doi.org/10.1002/ 
14651858.CD005049.pub5
578. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiar­
rhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for 
chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335–41. https://doi. 
org/10.1016/0002-9149(91)90828-9
579. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus 
rhythm-control strategies in atrial fibrillation: an updated comprehensive review and 
meta-analysis. Pacing Clin Electrophysiol 2013;36:122–33. https://doi.org/10.1111/j. 
1540-8159.2012.03513.x
580. Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality 
and stroke in atrial fibrillation but better data are needed. Evid Based Med 2014;19: 
222–3. https://doi.org/10.1136/ebmed-2014-110062
581. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative 
efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in pa­
tients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089–95. https://doi.org/10. 
1016/j.jacc.2009.04.085
582. Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns H, et al. Attaining sinus 
rhythm mediates improved outcome with early rhythm control therapy of atrial fibril­
lation: the EAST-AFNET 4 trial. Eur Heart J 2022;43:4127–44. https://doi.org/10.1093/ 
eurheartj/ehac471
583. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment 
comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the 
management of atrial fibrillation. Europace 2011;13:329–45. https://doi.org/10.1093/ 
europace/euq450
584. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysio­
logical mechanisms. Nat Rev Cardiol 2016;13:36–47. https://doi.org/10.1038/nrcardio. 
2015.110
585. Kochiadakis GE, Marketou ME, Igoumenidis NE, Chrysostomakis SI, Mavrakis HE, 
Kaleboubas MD, et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which 
is preferred to maintain normal sinus rhythm? Pacing Clin Electrophysiol 2000;23: 
1883–7. https://doi.org/10.1111/j.1540-8159.2000.tb07044.x
586. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to 
prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation 
Investigators. 
N 
Engl 
J 
Med 
2000;342:913–20. 
https://doi.org/10.1056/ 
NEJM200003303421302
587. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus 
sotalol for atrial fibrillation. N Engl J Med 2005;352:1861–72. https://doi.org/10.1056/ 
NEJMoa041705
588. Ehrlich JR, Look C, Kostev K, Israel CW, Goette A. Impact of dronedarone on the risk 
of myocardial infarction and stroke in atrial fibrillation patients followed in general 
practices in Germany. Int J Cardiol 2019;278:126–32. https://doi.org/10.1016/j.ijcard. 
2018.11.133
589. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for 
maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357: 
987–99. https://doi.org/10.1056/NEJMoa054686
590. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of 
atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997; 
79:418–23. https://doi.org/10.1016/S0002-9149(96)00779-5
591. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ab­
lation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316–24. https://doi. 
org/10.1056/NEJMoa2029554
592. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad 
O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N 
Engl J Med 2012;367:1587–95. https://doi.org/10.1056/NEJMoa1113566
593. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al. 
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal 
atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014;311:692–700. https://doi. 
org/10.1001/jama.2014.467
594. Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, et al. Cryoballoon ab­
lation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fib­
rillation. Europace 2021;23:1033–41. https://doi.org/10.1093/europace/euab029
595. Hocini M, Sanders P, Deisenhofer I, Jais P, Hsu LF, Scavee C, et al. Reverse remodeling 
of sinus node function after catheter ablation of atrial fibrillation in patients with pro­
longed sinus pauses. Circulation 2003;108:1172–5. https://doi.org/10.1161/01.CIR. 
0000090685.13169.07
596. Inada K, Yamane T, Tokutake K, Yokoyama K, Mishima T, Hioki M, et al. The role of 
successful catheter ablation in patients with paroxysmal atrial fibrillation and pro­
longed sinus pauses: outcome during a 5-year follow-up. Europace 2014;16:208–13. 
https://doi.org/10.1093/europace/eut159
597. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, et al. Pacing or ablation: which is 
better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome? 
Pacing Clin Electrophysiol 2014;37:403–11. https://doi.org/10.1111/pace.12340
598. Zhang R, Wang Y, Yang M, Yang Y, Wang Z, Yin X, et al. Risk stratification for atrial 
fibrillation and outcomes in tachycardia-bradycardia syndrome: ablation vs. pacing. 
Front Cardiovasc Med 2021;8:674471. https://doi.org/10.3389/fcvm.2021.674471
599. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Jr, et al. Circumferential 
pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354: 
934–41. https://doi.org/10.1056/NEJMoa050955
600. Yan Huo TG, Schönbauer R, Wójcik M, Fiedler L, Roithinger FX, Martinek M, et al. 
Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation. NEJM 
Evid 2022;1:EVIDoa2200141. https://doi.org/10.1056/EVIDoa2200141.
601. Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field 
or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med 2023; 
389:1660–71. https://doi.org/10.1056/NEJMoa2307291
602. Kalman JM, Al-Kaisey AM, Parameswaran R, Hawson J, Anderson RD, Lim M, et al. 
Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia re­
currences. Eur Heart J 2023;44:2447–54. https://doi.org/10.1093/eurheartj/ehad247
603. Kalman JM, Sanders P, Rosso R, Calkins H. Should we perform catheter ablation for 
asymptomatic atrial fibrillation? Circulation 2017;136:490–9. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.024926
604. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized 
controlled trial of catheter ablation versus medical treatment of atrial fibrillation in 
heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31–8. https:// 
doi.org/10.1161/CIRCEP.113.000806
605. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A ran­
domized trial to assess catheter ablation versus rate control in the management of per­
sistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894–903. https://doi. 
org/10.1016/j.jacc.2013.01.069
606. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, et al. Catheter ablation 
versus best medical therapy in patients with persistent atrial fibrillation and congestive 
heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12: 
e007731. https://doi.org/10.1161/CIRCEP.119.007731


<!-- PAGE 86 -->

### Page 86

607. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, et al. 
Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart 
failure and severe left ventricular systolic dysfunction: a randomised controlled trial. 
Heart 2011;97:740–7. https://doi.org/10.1136/hrt.2010.207340
608. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized 
ablation-based rhythm-control versus rate-control trial in patients with heart failure 
and atrial fibrillation: results from the RAFT-AF trial. Circulation 2022;145: 
1693–704. https://doi.org/10.1161/CIRCULATIONAHA.121.057095
609. Romero J, Gabr M, Alviz I, Briceno D, Diaz JC, Rodriguez D, et al. Improved survival in 
patients with atrial fibrillation and heart failure undergoing catheter ablation compared 
to medical treatment: a systematic review and meta-analysis of randomized controlled 
trials. J Cardiovasc Electrophysiol 2022;33:2356–66. https://doi.org/10.1111/jce.15622
610. Chen S, Purerfellner H, Meyer C, Acou WJ, Schratter A, Ling Z, et al. Rhythm control 
for patients with atrial fibrillation complicated with heart failure in the contemporary 
era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J 
2020;41:2863–73. https://doi.org/10.1093/eurheartj/ehz443
611. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al. 
Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunc­
tion: the CAMERA-MRI study. J Am Coll Cardiol 2017;70:1949–61. https://doi.org/10. 
1016/j.jacc.2017.08.041
612. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, 
et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from 
the 
CABANA 
trial. 
Circulation 
2021;143:1377–90. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.120.050991
613. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, et al. The import­
ance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012;14: 
1030–40. https://doi.org/10.1093/eurjhf/hfs097
614. Sohns C, Zintl K, Zhao Y, Dagher L, Andresen D, Siebels J, et al. Impact of left ventricu­
lar function and heart failure symptoms on outcomes post ablation of atrial fibrillation 
in heart failure: CASTLE-AF trial. Circ Arrhythm Electrophysiol 2020;13:e008461. https:// 
doi.org/10.1161/CIRCEP.120.008461
615. Sugumar H, Prabhu S, Costello B, Chieng D, Azzopardi S, Voskoboinik A, et al. 
Catheter ablation versus medication in atrial fibrillation and systolic dysfunction: late 
outcomes of CAMERA-MRI study. JACC Clin Electrophysiol 2020;6:1721–31. https:// 
doi.org/10.1016/j.jacep.2020.08.019
616. Kirstein B, Neudeck S, Gaspar T, Piorkowski J, Wechselberger S, Kronborg MB, et al. 
Left atrial fibrosis predicts left ventricular ejection fraction response after atrial fibril­
lation ablation in heart failure patients: the fibrosis-HF study. Europace 2020;22: 
1812–21. https://doi.org/10.1093/europace/euaa179
617. Ishiguchi H, Yoshiga Y, Shimizu A, Ueyama T, Fukuda M, Kato T, et al. Long-term events 
following catheter-ablation for atrial fibrillation in heart failure with preserved ejection 
fraction. ESC Heart Fail 2022;9:3505–18. https://doi.org/10.1002/ehf2.14079
618. Gu G, Wu J, Gao X, Liu M, Jin C, Xu Y. Catheter ablation of atrial fibrillation in patients 
with heart failure and preserved ejection fraction: a meta-analysis. Clin Cardiol 2022;45: 
786–93. https://doi.org/10.1002/clc.23841
619. Yamauchi R, Morishima I, Okumura K, Kanzaki Y, Morita Y, Takagi K, et al. Catheter 
ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with pre­
served ejection fraction: feasibility and benefits in functions and B-type natriuretic pep­
tide. Europace 2021;23:1252–61. https://doi.org/10.1093/europace/euaa420
620. Rordorf R, Scazzuso F, Chun KRJ, Khelae SK, Kueffer FJ, Braegelmann KM, et al. 
Cryoballoon ablation for the treatment of atrial fibrillation in patients with concomi­
tant heart failure and either reduced or preserved left ventricular ejection fraction: re­
sults from the Cryo AF global registry. J Am Heart Assoc 2021;10:e021323. https://doi. 
org/10.1161/JAHA.121.021323
621. Cha YM, Wokhlu A, Asirvatham SJ, Shen WK, Friedman PA, Munger TM, et al. Success 
of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a com­
parison to systolic dysfunction and normal ventricular function. Circ Arrhythm 
Electrophysiol 2011;4:724–32. https://doi.org/10.1161/CIRCEP.110.960690
622. Machino-Ohtsuka T, Seo Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M, et al. Efficacy, 
safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart fail­
ure with preserved ejection fraction. J Am Coll Cardiol 2013;62:1857–65. https://doi. 
org/10.1016/j.jacc.2013.07.020
623. Aldaas OM, Lupercio F, Darden D, Mylavarapu PS, Malladi CL, Han FT, et al. 
Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients 
with heart failure with preserved ejection fraction. Am J Cardiol 2021;142:66–73. 
https://doi.org/10.1016/j.amjcard.2020.11.039
624. Black-Maier E, Ren X, Steinberg BA, Green CL, Barnett AS, Rosa NS, et al. Catheter 
ablation of atrial fibrillation in patients with heart failure and preserved ejection frac­
tion. Heart Rhythm 2018;15:651–7. https://doi.org/10.1016/j.hrthm.2017.12.001
625. von Olshausen G, Benson L, Dahlström U, Lund LH, Savarese G, Braunschweig F. 
Catheter ablation for patients with atrial fibrillation and heart failure: insights from 
the Swedish Heart Failure Registry. Eur J Heart Fail 2022;24:1636–46. https://doi.org/ 
10.1002/ejhf.2604
626. Shiraishi Y, Kohsaka S, Ikemura N, Kimura T, Katsumata Y, Tanimoto K, et al. Catheter 
ablation for patients with atrial fibrillation and heart failure with reduced and preserved 
ejection fraction: insights from the KiCS-AF multicentre cohort study. Europace 2023; 
25:83–91. https://doi.org/10.1093/europace/euac108
627. Wu L, Narasimhan B, Ho KS, Zheng Y, Shah AN, Kantharia BK. Safety and complica­
tions of catheter ablation for atrial fibrillation: predictors of complications from an up­
dated analysis the national inpatient database. J Cardiovasc Electrophysiol 2021;32: 
1024–34. https://doi.org/10.1111/jce.14979
628. Tripathi B, Arora S, Kumar V, Abdelrahman M, Lahewala S, Dave M, et al. Temporal 
trends of in-hospital complications associated with catheter ablation of atrial fibrilla­
tion in the United States: an update from nationwide inpatient sample database 
(2011–2014). J Cardiovasc Electrophysiol 2018;29:715–24. https://doi.org/10.1111/jce. 
13471
629. Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H. Incidence of 
complications related to catheter ablation of atrial fibrillation and atrial flutter: a na­
tionwide in-hospital analysis of administrative data for Germany in 2014. Eur Heart J 
2018;39:4020–9. https://doi.org/10.1093/eurheartj/ehy452
630. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital compli­
cations associated with catheter ablation of atrial fibrillation in the United States be­
tween 2000 and 2010: analysis of 93 801 procedures. Circulation 2013;128: 
2104–12. https://doi.org/10.1161/CIRCULATIONAHA.113.003862
631. Cheng EP, Liu CF, Yeo I, Markowitz SM, Thomas G, Ip JE, et al. Risk of mortality follow­
ing catheter ablation of atrial fibrillation. J Am Coll Cardiol 2019;74:2254–64. https://doi. 
org/10.1016/j.jacc.2019.08.1036
632. Gawalko M, Duncker D, Manninger M, van der Velden RMJ, Hermans ANL, Verhaert 
DVM, et al. The European TeleCheck-AF project on remote app-based management 
of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences. 
Europace 2021;23:1003–15. https://doi.org/10.1093/europace/euab050
633. Rizas KD, Freyer L, Sappler N, von Stülpnagel L, Spielbichler P, Krasniqi A, et al. 
Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. 
Nat Med 2022;28:1823–30. https://doi.org/10.1038/s41591-022-01979-w
634. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon 
or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a 
randomized clinical trial. Circulation 2019;140:1779–88. https://doi.org/10.1161/ 
CIRCULATIONAHA.119.042622
635. Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al. 
PulmOnary vein isolation with vs. without continued antiarrhythmic Drug 
trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from 
a multicentre randomized trial. Eur Heart J 2018;39:1429–37. https://doi.org/10. 
1093/eurheartj/ehx666
636. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, et al. Recurrence 
of arrhythmia following short-term oral AMIOdarone after CATheter ablation for at­
rial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT 
trial). Eur Heart J 2014;35:3356–64. https://doi.org/10.1093/eurheartj/ehu354
637. Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, et al. Antiarrhythmics after 
ablation of atrial fibrillation (5A study): six-month follow-up study. Circ Arrhythm 
Electrophysiol 2011;4:11–4. https://doi.org/10.1161/CIRCEP.110.955393
638. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al. Efficacy of anti­
arrhythmic drugs short-term use after catheter ablation for atrial fibrillation 
(EAST-AF) trial. Eur Heart J 2016;37:610–8. https://doi.org/10.1093/eurheartj/ehv501
639. Noseworthy PA, Van Houten HK, Sangaralingham LR, Deshmukh AJ, Kapa S, Mulpuru 
SK, et al. Effect of antiarrhythmic drug initiation on readmission after catheter ablation 
for atrial fibrillation. JACC Clin Electrophysiol 2015;1:238–44. https://doi.org/10.1016/j. 
jacep.2015.04.016
640. Xu X, Alida CT, Yu B. Administration of antiarrhythmic drugs to maintain sinus rhythm 
after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovasc Ther 2015;33: 
242–6. https://doi.org/10.1111/1755-5922.12133
641. Chen W, Liu H, Ling Z, Xu Y, Fan J, Du H, et al. Efficacy of short-term antiarrhythmic 
drugs use after catheter ablation of atrial fibrillation—a systematic review with 
meta-analyses and trial sequential analyses of randomized controlled trials. PLoS One 
2016;11:e0156121. https://doi.org/10.1371/journal.pone.0156121
642. Schleberger R, Metzner A, Kuck KH, Andresen D, Willems S, Hoffmann E, et al. 
Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation–insights 
from the German Ablation Registry. Pharmacol Res Perspect 2021;9:e00880. https:// 
doi.org/10.1002/prp2.880
643. Zhang XD, Gu J, Jiang WF, Zhao L, Zhou L, Wang YL, et al. Optimal rhythm-control 
strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fib­
rillation: a randomized clinical trial. Eur Heart J 2014;35:1327–34. https://doi.org/10. 
1093/eurheartj/ehu017
644. Zhou L, He L, Wang W, Li C, Li S, Tang R, et al. Effect of repeat catheter ablation vs. 
antiarrhythmic drug therapy among patients with recurrent atrial tachycardia/atrial fib­
rillation after atrial fibrillation catheter ablation: data from CHINA-AF registry. 
Europace 2023;25:382–9. https://doi.org/10.1093/europace/euac169
645. Fink T, Metzner A, Willems S, Eckardt L, Ince H, Brachmann J, et al. Procedural success, 
safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: 
results from the German ablation registry. Clin Res Cardiol 2019;108:1354–63. https:// 
doi.org/10.1007/s00392-019-01471-5
ESC Guidelines                                                                                                                                                                                          3399


<!-- PAGE 87 -->

### Page 87

646. Winkle RA, Mead RH, Engel G, Kong MH, Fleming W, Salcedo J, et al. Impact of obesity 
on atrial fibrillation ablation: patient characteristics, long-term outcomes, and compli­
cations. Heart Rhythm 2017;14:819–27. https://doi.org/10.1016/j.hrthm.2017.02.023
647. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan G-A, et al. Antithrombotic 
management in patients undergoing electrophysiological procedures: a European 
Heart Rhythm Association (EHRA) position document endorsed by the ESC 
Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart 
Rhythm Society (APHRS). EP Europace 2015;17:1197–214. https://doi.org/10.1093/ 
europace/euv190
648. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ 
ECAS expert consensus statement on catheter and surgical ablation of atrial fibrilla­
tion: recommendations for patient selection, procedural techniques, patient manage­
ment and follow-up, definitions, endpoints, and research trial design. J Interv Card 
Electrophysiol 2012;33:171–257. https://doi.org/10.1007/s10840-012-9672-7
649. Noubiap JJ, Agbaedeng TA, Ndoadoumgue AL, Nyaga UF, Kengne AP. Atrial thrombus 
detection on transoesophageal echocardiography in patients with atrial fibrillation 
undergoing cardioversion or catheter ablation: a pooled analysis of rates and predic­
tors. J Cardiovasc Electrophysiol 2021;32:2179–88. https://doi.org/10.1111/jce.15082
650. Lurie A, Wang J, Hinnegan KJ, McIntyre WF, Belley-Côté EP, Amit G, et al. Prevalence 
of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 
2021;77:2875–86. https://doi.org/10.1016/j.jacc.2021.04.036
651. Efremidis M, Bazoukis G, Vlachos K, Prappa E, Megarisiotou A, Dragasis S, et al. Safety 
of catheter ablation of atrial fibrillation without pre- or peri-procedural imaging for the 
detection of left atrial thrombus in the era of uninterrupted anticoagulation. J Arrhythm 
2021;37:28–32. https://doi.org/10.1002/joa3.12466
652. Diab M, Wazni OM, Saliba WI, Tarakji KG, Ballout JA, Hutt E, et al. Ablation of atrial 
fibrillation without left atrial appendage imaging in patients treated with direct oral an­
ticoagulants. Circ Arrhythm Electrophysiol 2020;13:e008301. https://doi.org/10.1161/ 
CIRCEP.119.008301
653. Patel K, Natale A, Yang R, Trivedi C, Romero J, Briceno D, et al. Is transesophageal 
echocardiography necessary in patients undergoing ablation of atrial fibrillation on 
an uninterrupted direct oral anticoagulant regimen? Results from a prospective multi­
center registry. Heart Rhythm 2020;17:2093–9. https://doi.org/10.1016/j.hrthm.2020. 
07.017
654. Mao YJ, Wang H, Huang PF. Meta-analysis of the safety and efficacy of using minimally 
interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial 
fibrillation. J Interv Card Electrophysiol 2021;60:407–17. https://doi.org/10.1007/s10840- 
020-00754-6
655. van Vugt SPG, Westra SW, Volleberg R, Hannink G, Nakamura R, de Asmundis C, et al. 
Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non- 
vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation. 
Europace 2021;23:1961–9. https://doi.org/10.1093/europace/euab175
656. Ge Z, Faggioni M, Baber U, Sartori S, Sorrentino S, Farhan S, et al. Safety and efficacy of 
nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrilla­
tion: a systematic review and meta-analysis. Cardiovasc Ther 2018;36:e12457. https:// 
doi.org/10.1111/1755-5922.12457
657. Asad ZUA, Akhtar KH, Jafry AH, Khan MH, Khan MS, Munir MB, et al. Uninterrupted 
versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: 
a systematic review and meta-analysis. J Cardiovasc Electrophysiol 2021;32:1995–2004. 
https://doi.org/10.1111/jce.15043
658. Mao YJ, Wang H, Huang PF. Peri-procedural novel oral anticoagulants dosing strategy 
during atrial fibrillation ablation: a meta-analysis. Pacing Clin Electrophysiol 2020;43: 
1104–14. https://doi.org/10.1111/pace.14040
659. Basu-Ray I, Khanra D, Kupó P, Bunch J, Theus SA, Mukherjee A, et al. Outcomes of 
uninterrupted vs interrupted periprocedural direct oral anticoagulants in atrial fibrilla­
tion ablation: a meta-analysis. J Arrhythm 2021;37:384–93. https://doi.org/10.1002/joa3. 
12507
660. Romero J, Cerrud-Rodriguez RC, Diaz JC, Rodriguez D, Arshad S, Alviz I, et al. Oral 
anticoagulation after catheter ablation of atrial fibrillation and the associated risk of 
thromboembolic events and intracranial hemorrhage: a systematic review and 
meta-analysis. J Cardiovasc Electrophysiol 2019;30:1250–7. https://doi.org/10.1111/jce. 
14052
661. Liu XH, Xu Q, Luo T, Zhang L, Liu HJ. Discontinuation of oral anticoagulation therapy 
after successful atrial fibrillation ablation: a systematic review and meta-analysis of pro­
spective studies. PLoS One 2021;16:e0253709. https://doi.org/10.1371/journal.pone. 
0253709
662. Proietti R, AlTurki A, Di Biase L, China P, Forleo G, Corrado A, et al. Anticoagulation 
after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review and 
meta-analysis. J Cardiovasc Electrophysiol 2019;30:468–78. https://doi.org/10.1111/jce. 
13822
663. Maduray K, Moneruzzaman M, Changwe GJ, Zhong J. Benefits and risks associated with 
long-term oral anticoagulation after successful atrial fibrillation catheter ablation: sys­
tematic review and meta-analysis. Clin Appl Thromb Hemost 2022;28:1076029622 
1118480. https://doi.org/10.1177/10760296221118480
664. Brockmeyer M, Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, et al. 
Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no 
difference in major bleeding and stroke between direct oral anticoagulants and vitamin 
K antagonists in an updated meta-analysis of randomised controlled trials. Acta Cardiol 
2021;76:288–95. https://doi.org/10.1080/00015385.2020.1724689
665. Di Monaco A, Guida P, Vitulano N, Quadrini F, Troisi F, Langialonga T, et al. Catheter 
ablation of atrial fibrillation with uninterrupted anticoagulation: a meta-analysis of six 
randomized controlled trials. J Cardiovasc Med (Hagerstown) 2020;21:483–90. https:// 
doi.org/10.2459/JCM.0000000000000939
666. Maesen B, Luermans J, Bidar E, Chaldoupi SM, Gelsomino S, Maessen JG, et al. A hybrid 
approach to complex arrhythmias. Europace 2021;23:ii28–33. https://doi.org/10.1093/ 
europace/euab027
667. van der Heijden CAJ, Vroomen M, Luermans JG, Vos R, Crijns H, Gelsomino S, et al. 
Hybrid versus catheter ablation in patients with persistent and longstanding persistent 
atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2019;56: 
433–43. https://doi.org/10.1093/ejcts/ezy475
668. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, et al. Atrial 
fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center ran­
domized 
clinical 
trial. 
Circulation 
2012;125:23–30. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.111.074047
669. Castella M, Kotecha D, van Laar C, Wintgens L, Castillo Y, Kelder J, et al. 
Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the 
FAST randomized trial. Europace 2019;21:746–53. https://doi.org/10.1093/europace/ 
euy325
670. van der Heijden CAJ, Weberndörfer V, Vroomen M, Luermans JG, Chaldoupi SM, 
Bidar E, et al. Hybrid ablation versus repeated catheter ablation in persistent atrial fib­
rillation: a randomized controlled trial. JACC Clin Electrophysiol 2023;9:1013–23. https:// 
doi.org/10.1016/j.jacep.2022.12.011
671. DeLurgio DB, Crossen KJ, Gill J, Blauth C, Oza SR, Magnano AR, et al. Hybrid conver­
gent procedure for the treatment of persistent and long-standing persistent atrial fib­
rillation: results of CONVERGE clinical trial. Circ Arrhythm Electrophysiol 2020;13: 
e009288. https://doi.org/10.1161/CIRCEP.120.009288
672. Pokushalov E, Romanov A, Elesin D, Bogachev-Prokophiev A, Losik D, Bairamova S, 
et al. Catheter versus surgical ablation of atrial fibrillation after a failed initial pulmonary 
vein isolation procedure: a randomized controlled trial. J Cardiovasc Electrophysiol 2013; 
24:1338–43. https://doi.org/10.1111/jce.12245
673. Haldar S, Khan HR, Boyalla V, Kralj-Hans I, Jones S, Lord J, et al. Catheter ablation vs. 
thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF 
randomized controlled trial. Eur Heart J 2020;41:4471–80. https://doi.org/10.1093/ 
eurheartj/ehaa658
674. Doll N, Weimar T, Kosior DA, Bulava A, Mokracek A, Mönnig G, et al. Efficacy and 
safety of hybrid epicardial and endocardial ablation versus endocardial ablation in pa­
tients with persistent and longstanding persistent atrial fibrillation: a randomised, con­
trolled trial. EClinicalMedicine 2023;61:102052. https://doi.org/10.1016/j.eclinm.2023. 
102052
675. Malaisrie SC, McCarthy PM, Kruse J, Matsouaka R, Andrei AC, Grau-Sepulveda MV, 
et al. Burden of preoperative atrial fibrillation in patients undergoing coronary artery 
bypass grafting. J Thorac Cardiovasc Surg 2018;155:2358–2367 e1. https://doi.org/10. 
1016/j.jtcvs.2018.01.069
676. Saxena A, Dinh DT, Reid CM, Smith JA, Shardey GC, Newcomb AE. Does preopera­
tive atrial fibrillation portend a poorer prognosis in patients undergoing isolated aortic 
valve replacement? A multicentre Australian study. Can J Cardiol 2013;29:697–703. 
https://doi.org/10.1016/j.cjca.2012.08.016
677. Quader MA, McCarthy PM, Gillinov AM, Alster JM, Cosgrove DM, 3rd, Lytle BW, et al. 
Does preoperative atrial fibrillation reduce survival after coronary artery bypass graft­
ing? Ann Thorac Surg 2004;77:1514–22; discussion 1522–4. https://doi.org/10.1016/j. 
athoracsur.2003.09.069
678. Damiano RJ, Jr, Schwartz FH, Bailey MS, Maniar HS, Munfakh NA, Moon MR, et al. The 
Cox Maze IV procedure: predictors of late recurrence. J Thorac Cardiovasc Surg 2011; 
141:113–21. https://doi.org/10.1016/j.jtcvs.2010.08.067
679. Cox JL, Schuessler RB, Boineau JP. The development of the Maze procedure for the 
treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000;12:2–14. https:// 
doi.org/10.1016/S1043-0679(00)70010-4
680. Melby SJ, Zierer A, Bailey MS, Cox JL, Lawton JS, Munfakh N, et al. A new era in the 
surgical treatment of atrial fibrillation: the impact of ablation technology and lesion 
set on procedural efficacy. Ann Surg 2006;244:583–92. https://doi.org/10.1097/01.sla. 
0000237654.00841.26
681. Badhwar V, Rankin JS, Damiano RJ, Jr, Gillinov AM, Bakaeen FG, Edgerton JR, et al. The 
Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treat­
ment of atrial fibrillation. Ann Thorac Surg 2017;103:329–41. https://doi.org/10.1016/ 
j.athoracsur.2016.10.076
682. Ad N, Henry L, Hunt S, Holmes SD. Impact of clinical presentation and surgeon experi­
ence on the decision to perform surgical ablation. Ann Thorac Surg 2013;96:763–8; dis­
cussion 768–9. https://doi.org/10.1016/j.athoracsur.2013.03.066
683. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for 
atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations 
(Phila) 2010;5:84–96. https://doi.org/10.1177/155698451000500204


<!-- PAGE 88 -->

### Page 88

684. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ab­
lation of atrial fibrillation: a systematic review and meta-analysis of randomized con­
trolled trials. Europace 2018;20:1442–50. https://doi.org/10.1093/europace/eux336
685. Phan K, Xie A, La Meir M, Black D, Yan TD. Surgical ablation for treatment of atrial 
fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled 
trials. Heart 2014;100:722–30. https://doi.org/10.1136/heartjnl-2013-305351
686. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: 
a meta-analysis. J Thorac Cardiovasc Surg 2006;131:1029–35. https://doi.org/10.1016/j. 
jtcvs.2005.10.020
687. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ, Jr, Moskowitz AJ, Voisine P, et al. 
Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; 
372:1399–409. https://doi.org/10.1056/NEJMoa1500528
688. MacGregor RM, Bakir NH, Pedamallu H, Sinn LA, Maniar HS, Melby SJ, et al. Late re­
sults after stand-alone surgical ablation for atrial fibrillation. J Thorac Cardiovasc Surg 
2022;164:1515–1528.e8. https://doi.org/10.1016/j.jtcvs.2021.03.109
689. Musharbash FN, Schill MR, Sinn LA, Schuessler RB, Maniar HS, Moon MR, et al. 
Performance of the Cox-Maze IV procedure is associated with improved long-term 
survival in patients with atrial fibrillation undergoing cardiac surgery. J Thorac 
Cardiovasc Surg 2018;155:159–70. https://doi.org/10.1016/j.jtcvs.2017.09.095
690. Rankin JS, Lerner DJ, Braid-Forbes MJ, McCrea MM, Badhwar V. Surgical ablation of 
atrial fibrillation concomitant to coronary-artery bypass grafting provides cost- 
effective mortality reduction. J Thorac Cardiovasc Surg 2020;160:675–686 e13. 
https://doi.org/10.1016/j.jtcvs.2019.07.131
691. Suwalski P, Kowalewski M, Jasinski M, Staromlynski J, Zembala M, Widenka K, et al. 
Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis 
from the Polish National Registry of Cardiac Surgery Procedures (KROK). J Thorac 
Cardiovasc Surg 2019;157:1007–1018 e4. https://doi.org/10.1016/j.jtcvs.2018.07.099
692. Suwalski P, Kowalewski M, Jasinski M, Staromlynski J, Zembala M, Widenka K, et al. 
Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery. 
Eur J Cardiothorac Surg 2020;57:691–700. https://doi.org/10.1093/ejcts/ezz298
693. Wehbe M, Albert M, Lewalter T, Ouarrak T, Senges J, Hanke T, et al. The German car­
diosurgery atrial fibrillation registry: 1-year follow-up outcomes. Thorac Cardiovasc Surg 
2023;71:255–63. https://doi.org/10.1055/s-0042-1750311
694. Kim HJ, Kim YJ, Kim M, Yoo JS, Kim DH, Park DW, et al. Surgical ablation for atrial 
fibrillation during aortic and mitral valve surgery: a nationwide population-based co­
hort study. J Thorac Cardiovasc Surg 2024;167:981–93. https://doi.org/10.1016/j.jtcvs. 
2022.08.038
695. Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by adding the 
Cox Maze III procedure to aortic valve replacement and coronary artery bypass sur­
gery? J Thorac Cardiovasc Surg 2012;143:936–44. https://doi.org/10.1016/j.jtcvs.2011. 
12.018
696. Maesen B, van der Heijden CAJ, Bidar E, Vos R, Athanasiou T, Maessen JG. 
Patient-reported quality of life after stand-alone and concomitant arrhythmia surgery: 
a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2022;34:339–48. 
https://doi.org/10.1093/icvts/ivab282
697. Osmancik P, Budera P, Talavera D, Hlavicka J, Herman D, Holy J, et al. Five-year out­
comes in cardiac surgery patients with atrial fibrillation undergoing concomitant sur­
gical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 study. 
Heart Rhythm 2019;16:1334–40. https://doi.org/10.1016/j.hrthm.2019.05.001
698. Lee R, Jivan A, Kruse J, McGee EC, Jr, Malaisrie SC, Bernstein R, et al. Late neurologic 
events after surgery for atrial fibrillation: rare but relevant. Ann Thorac Surg 2013;95: 
126–31; discussion 131–2. https://doi.org/10.1016/j.athoracsur.2012.08.048
699. Kowalewski M, Pasierski M, Kołodziejczak M, Litwinowicz R, Kowalówka A, Wańha W, 
et al. Atrial fibrillation ablation improves late survival after concomitant cardiac surgery. 
J Thorac Cardiovasc Surg 2023;166:1656–1668.e8. https://doi.org/10.1016/j.jtcvs.2022. 
04.035
700. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients 
with atrial fibrillation. J Thorac Cardiovasc Surg 1999;118:833–40. https://doi.org/10. 
1016/S0022-5223(99)70052-8
701. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al. 
Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. 
Cochrane Database Syst Rev 2016;8:CD011814. https://doi.org/10.1002/14651858. 
CD011814.pub2
702. Kowalewski M, Pasierski M, Finke J, Kolodziejczak M, Staromlynski J, Litwinowicz R, 
et al. Permanent pacemaker implantation after valve and arrhythmia surgery in patients 
with preoperative atrial fibrillation. Heart Rhythm 2022;19:1442–9. https://doi.org/10. 
1016/j.hrthm.2022.04.007
703. Pokushalov E, Romanov A, Corbucci G, Cherniavsky A, Karaskov A. Benefit of ablation 
of first diagnosed paroxysmal atrial fibrillation during coronary artery bypass grafting: a 
pilot study. Eur J Cardiothorac Surg 2012;41:556–60. https://doi.org/10.1093/ejcts/ 
ezr101
704. Yoo JS, Kim JB, Ro SK, Jung Y, Jung SH, Choo SJ, et al. Impact of concomitant surgical 
atrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J 2014; 
78:1364–71. https://doi.org/10.1253/circj.CJ-13-1533
705. Malaisrie SC, Lee R, Kruse J, Lapin B, Wang EC, Bonow RO, et al. Atrial fibrillation ab­
lation in patients undergoing aortic valve replacement. J Heart Valve Dis 2012;21: 
350–7.
706. Rankin JS, Lerner DJ, Braid-Forbes MJ, Ferguson MA, Badhwar V. One-year mortality 
and costs associated with surgical ablation for atrial fibrillation concomitant to coron­
ary artery bypass grafting. Eur J Cardiothorac Surg 2017;52:471–7. https://doi.org/10. 
1093/ejcts/ezx126
707. Schill MR, Musharbash FN, Hansalia V, Greenberg JW, Melby SJ, Maniar HS, et al. Late 
results of the Cox-Maze IV procedure in patients undergoing coronary artery bypass 
grafting. J Thorac Cardiovasc Surg 2017;153:1087–94. https://doi.org/10.1016/j.jtcvs. 
2016.12.034
708. Gupta D, Ding WY, Calvert P, Williams E, Das M, Tovmassian L, et al. Cryoballoon 
pulmonary vein isolation as first-line treatment for typical atrial flutter. Heart 2023; 
109:364–71. https://doi.org/10.1136/heartjnl-2022-321729
709. Steinberg C, Champagne J, Deyell MW, Dubuc M, Leong-Sit P, Calkins H, et al. 
Prevalence and outcome of early recurrence of atrial tachyarrhythmias in the cryobal­
loon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study. Heart 
Rhythm 2021;18:1463–70. https://doi.org/10.1016/j.hrthm.2021.06.1172
710. Heijman J, Linz D, Schotten U. Dynamics of atrial fibrillation mechanisms and co­
morbidities. Annu Rev Physiol 2021;83:83–106. https://doi.org/10.1146/annurev- 
physiol-031720-085307
711. Fabritz L, Crijns H, Guasch E, Goette A, Hausler KG, Kotecha D, et al. Dynamic risk 
assessment to improve quality of care in patients with atrial fibrillation: the 7th 
AFNET/EHRA consensus conference. Europace 2021;23:329–44. https://doi.org/10. 
1093/europace/euaa279
712. Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk factor management 
in atrial fibrillation. Arrhythm Electrophysiol Rev 2018;7:118–27. https://doi.org/10. 
15420/aer.2018.18.2
713. Pokorney SD, Cocoros N, Al-Khalidi HR, Haynes K, Li S, Al-Khatib SM, et al. Effect of 
mailing educational material to patients with atrial fibrillation and their clinicians on use 
of oral anticoagulants: a randomized clinical trial. JAMA Netw Open 2022;5:e2214321. 
https://doi.org/10.1001/jamanetworkopen.2022.14321
714. Ritchie LA, Penson PE, Akpan A, Lip GYH, Lane DA. Integrated care for atrial fibrilla­
tion management: the role of the pharmacist. Am J Med 2022;135:1410–26. https://doi. 
org/10.1016/j.amjmed.2022.07.014
715. Guo Y, Guo J, Shi X, Yao Y, Sun Y, Xia Y, et al. Mobile health technology-supported 
atrial fibrillation screening and integrated care: a report from the mAFA-II trial long- 
term extension cohort. Eur J Intern Med 2020;82:105–11. https://doi.org/10.1016/j. 
ejim.2020.09.024
716. Yan H, Du YX, Wu FQ, Lu XY, Chen RM, Zhang Y. Effects of nurse-led multidisciplin­
ary team management on cardiovascular hospitalization and quality of life in patients 
with atrial fibrillation: randomized controlled trial. Int J Nurs Stud 2022;127:104159. 
https://doi.org/10.1016/j.ijnurstu.2021.104159
717. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, et al. Standard 
versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent 
admission and prolong survival: pragmatic, multicentre, randomised controlled trial. 
Lancet 2015;385:775–84. https://doi.org/10.1016/S0140-6736(14)61992-9
718. Cox JL, Parkash R, Foster GA, Xie F, MacKillop JH, Ciaccia A, et al. Integrated manage­
ment program advancing community treatment of atrial fibrillation (IMPACT-AF): a 
cluster randomized trial of a computerized clinical decision support tool. Am Heart J 
2020;224:35–46. https://doi.org/10.1016/j.ahj.2020.02.019
719. Sposato LA, Stirling D, Saposnik G. Therapeutic decisions in atrial fibrillation for stroke 
prevention: the role of aversion to ambiguity and physicians’ risk preferences. J Stroke 
Cerebrovasc Dis 2018;27:2088–95. https://doi.org/10.1016/j.jstrokecerebrovasdis. 
2018.03.005
720. Noseworthy PA, Brito JP, Kunneman M, Hargraves IG, Zeballos-Palacios C, Montori 
VM, et al. Shared decision-making in atrial fibrillation: navigating complex issues in part­
nership with the patient. J Interv Card Electrophysiol 2019;56:159–63. https://doi.org/10. 
1007/s10840-018-0465-5
721. Poorcheraghi H, Negarandeh R, Pashaeypoor S, Jorian J. Effect of using a mobile drug 
management application on medication adherence and hospital readmission among 
elderly patients with polypharmacy: a randomized controlled trial. BMC Health Serv 
Res 2023;23:1192. https://doi.org/10.1186/s12913-023-10177-4
722. Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, et al. European 
Society of Cardiology (ESC) Atrial Fibrillation Guidelines Taskforce, the CATCH ME 
consortium, and the European Heart Rhythm Association (EHRA). European 
Society of Cardiology smartphone and tablet applications for patients with atrial fibril­
lation and their health care providers. Europace 2018;20:225–33. https://doi.org/10. 
1093/europace/eux299
723. Bunting KV, Gill SK, Sitch A, Mehta S, O’Connor K, Lip GY, et al. Improving the diag­
nosis of heart failure in patients with atrial fibrillation. Heart 2021;107:902–8. https:// 
doi.org/10.1136/heartjnl-2020-318557
724. Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, et al. EACVI/EHRA expert 
consensus document on the role of multi-modality imaging for the evaluation of pa­
tients with atrial fibrillation. Eur Heart J Cardiovasc Imaging 2016;17:355–83. https:// 
doi.org/10.1093/ehjci/jev354
ESC Guidelines                                                                                                                                                                                          3401


<!-- PAGE 89 -->

### Page 89

725. Bunting KV, O’Connor K, Steeds RP, Kotecha D. Cardiac imaging to assess left ven­
tricular systolic function in atrial fibrillation. Am J Cardiol 2021;139:40–9. https://doi. 
org/10.1016/j.amjcard.2020.10.012
726. Timperley J, Mitchell AR, Becher H. Contrast echocardiography for left ventricular 
opacification. Heart 2003;89:1394–7. https://doi.org/10.1136/heart.89.12.1394
727. Kotecha D, Mohamed M, Shantsila E, Popescu BA, Steeds RP. Is echocardiography valid 
and reproducible in patients with atrial fibrillation? A systematic review. Europace 2017; 
19:1427–38. https://doi.org/10.1093/europace/eux027
728. Quintana RA, Dong T, Vajapey R, Reyaldeen R, Kwon DH, Harb S, et al. Preprocedural 
multimodality imaging in atrial fibrillation. Circ Cardiovasc Imaging 2022;15:e014386. 
https://doi.org/10.1161/CIRCIMAGING.122.014386
729. Laubrock K, von Loesch T, Steinmetz M, Lotz J, Frahm J, Uecker M, et al. Imaging of 
arrhythmia: real-time cardiac magnetic resonance imaging in atrial fibrillation. Eur J 
Radiol Open 2022;9:100404. https://doi.org/10.1016/j.ejro.2022.100404
730. Sciagrà R, Sotgia B, Boni N, Pupi A. Assessment of the influence of atrial fibrillation on 
gated SPECT perfusion data by comparison with simultaneously acquired nongated 
SPECT data. J Nucl Med 2008;49:1283–7. https://doi.org/10.2967/jnumed.108.051797
731. Clayton B, Roobottom C, Morgan-Hughes G. CT coronary angiography in atrial fibril­
lation: a comparison of radiation dose and diagnostic confidence with retrospective 
gating vs prospective gating with systolic acquisition. Br J Radiol 2015;88:20150533. 
https://doi.org/10.1259/bjr.20150533
732. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a 
systematic review. Am J Med 2006;119:448.e1–19. https://doi.org/10.1016/j.amjmed. 
2005.10.057
733. Steinberg BA, Dorian P, Anstrom KJ, Hess R, Mark DB, Noseworthy PA, et al. 
Patient-reported outcomes in atrial fibrillation research: results of a Clinicaltrials.gov analysis. JACC Clin Electrophysiol 2019;5:599–605. https://doi.org/10.1016/j.jacep.2019. 
03.008
734. Potpara TS, Mihajlovic M, Zec N, Marinkovic M, Kovacevic V, Simic J, et al. 
Self-reported treatment burden in patients with atrial fibrillation: quantification, major 
determinants, and implications for integrated holistic management of the arrhythmia. 
Europace 2020;22:1788–97. https://doi.org/10.1093/europace/euaa210
735. Moons P, Norekvål TM, Arbelo E, Borregaard B, Casadei B, Cosyns B, et al. Placing 
patient-reported outcomes at the centre of cardiovascular clinical practice: implica­
tions for quality of care and management. Eur Heart J 2023;44:3405–22. https://doi. 
org/10.1093/eurheartj/ehad514
736. Allan KS, Aves T, Henry S, Banfield L, Victor JC, Dorian P, et al. Health-related quality of 
life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic 
drug therapy: a systematic review and meta-analysis. CJC Open 2020;2:286–95. 
https://doi.org/10.1016/j.cjco.2020.03.013
737. Vanderhout S, Fergusson DA, Cook JA, Taljaard M. Patient-reported outcomes and 
target effect sizes in pragmatic randomized trials in ClinicalTrials.gov: a cross-sectional 
analysis. PLoS Med 2022;19:e1003896. https://doi.org/10.1371/journal.pmed.1003896
738. Steinberg BA, Piccini JP, Sr. Tackling patient-reported outcomes in atrial fibrillation and 
heart failure: identifying disease-specific symptoms? Cardiol Clin 2019;37:139–46. 
https://doi.org/10.1016/j.ccl.2019.01.013
739. Härdén M, Nyström B, Bengtson A, Medin J, Frison L, Edvardsson N. Responsiveness 
of AF6, a new, short, validated, atrial fibrillation-specific questionnaire—symptomatic 
benefit of direct current cardioversion. J Interv Card Electrophysiol 2010;28:185–91. 
https://doi.org/10.1007/s10840-010-9487-3
740. Tailachidis P, Tsimtsiou Z, Galanis P, Theodorou M, Kouvelas D, Athanasakis K. The 
atrial fibrillation effect on QualiTy-of-Life (AFEQT) questionnaire: cultural adaptation 
and validation of the Greek version. Hippokratia 2016;20:264–7.
741. Moreira RS, Bassolli L, Coutinho E, Ferrer P, Bragança ÉO, Carvalho AC, et al. 
Reproducibility and reliability of the quality of life questionnaire in patients with atrial 
fibrillation. Arq Bras Cardiol 2016;106:171–81. https://doi.org/10.5935/abc.20160026
742. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramírez P, Badia X. Validation of the 
AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrilla­
tion. Europace 2010;12:364–70. https://doi.org/10.1093/europace/eup421
743. Braganca EO, Filho BL, Maria VH, Levy D, de Paola AA. Validating a new quality of life 
questionnaire for atrial fibrillation patients. Int J Cardiol 2010;143:391–8. https://doi. 
org/10.1016/j.ijcard.2009.03.087
744. International Consortium for Health Outcomes Measurement. Atrial fibrillation data 
collection reference guide Version 5.0.1. https://connect.ichom.org/wp-content/ 
uploads/2023/02/03-Atrial-Fibrillation-Reference-Guide-2023.5.0.1.pdf.
745. Dan GA, Dan AR, Ivanescu A, Buzea AC. Acute rate control in atrial fibrillation: an ur­
gent need for the clinician. Eur Heart J Suppl 2022;24:D3–D10. https://doi.org/10.1093/ 
eurheartjsupp/suac022
746. Shima N, Miyamoto K, Kato S, Yoshida T, Uchino S; AFTER-ICU study group. Primary 
success of electrical cardioversion for new-onset atrial fibrillation and its association 
with clinical course in non-cardiac critically ill patients: sub-analysis of a multicenter ob­
servational study. J Intensive Care 2021;9:46. https://doi.org/10.1186/s40560-021- 
00562-8
747. Betthauser KD, Gibson GA, Piche SL, Pope HE. Evaluation of amiodarone use for new- 
onset atrial fibrillation in critically ill patients with septic shock. Hosp Pharm 2021;56: 
116–23. https://doi.org/10.1177/0018578719868405
748. Drikite L, Bedford JP, O’Bryan L, Petrinic T, Rajappan K, Doidge J, et al. Treatment 
strategies for new onset atrial fibrillation in patients treated on an intensive care 
unit: a systematic scoping review. Crit Care 2021;25:257. https://doi.org/10.1186/ 
s13054-021-03684-5
749. Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, et al. Comparative 
effectiveness of common treatments for new-onset atrial fibrillation within the ICU: 
accounting for physiological status. J Crit Care 2022;67:149–56. https://doi.org/10. 
1016/j.jcrc.2021.11.005
750. Iwahashi N, Takahashi H, Abe T, Okada K, Akiyama E, Matsuzawa Y, et al. Urgent con­
trol of rapid atrial fibrillation by landiolol in patients with acute decompensated heart 
failure with severely reduced ejection fraction. Circ Rep 2019;1:422–30. https://doi.org/ 
10.1253/circrep.CR-19-0076
751. Unger M, Morelli A, Singer M, Radermacher P, Rehberg S, Trimmel H, et al. Landiolol in 
patients with septic shock resident in an intensive care unit (LANDI-SEP): study proto­
col for a randomized controlled trial. Trials 2018;19:637. https://doi.org/10.1186/ 
s13063-018-3024-6
752. Gonzalez-Pacheco H, Marquez MF, Arias-Mendoza A, Alvarez-Sangabriel A, Eid-Lidt 
G, Gonzalez-Hermosillo A, et al. Clinical features and in-hospital mortality associated 
with different types of atrial fibrillation in patients with acute coronary syndrome with 
and without ST elevation. J Cardiol 2015;66:148–54. https://doi.org/10.1016/j.jjcc.2014. 
11.001
753. Krijthe BP, Leening MJ, Heeringa J, Kors JA, Hofman A, Franco OH, et al. Unrecognized 
myocardial infarction and risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol 
2013;168:1453–7. https://doi.org/10.1016/j.ijcard.2012.12.057
754. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial 
fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014;174:107–14. 
https://doi.org/10.1001/jamainternmed.2013.11912
755. Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of cor­
onary artery disease in patients with atrial fibrillation undergoing first-time coronary 
angiography. PLoS One 2011;6:e24964. https://doi.org/10.1371/journal.pone.0024964
756. Coscia T, Nestelberger T, Boeddinghaus J, Lopez-Ayala P, Koechlin L, Miró Ò, et al. 
Characteristics and outcomes of type 2 myocardial infarction. JAMA Cardiol 2022;7: 
427–34. https://doi.org/10.1001/jamacardio.2022.0043
757. Guimaraes PO, Zakroysky P, Goyal A, Lopes RD, Kaltenbach LA, Wang TY. Usefulness 
of antithrombotic therapy in patients with atrial fibrillation and acute myocardial in­
farction. Am J Cardiol 2019;123:12–8. https://doi.org/10.1016/j.amjcard.2018.09.031
758. Erez A, Goldenberg I, Sabbag A, Nof E, Zahger D, Atar S, et al. Temporal trends and 
outcomes associated with atrial fibrillation observed during acute coronary syndrome: 
real-world data from the Acute Coronary Syndrome Israeli Survey (ACSIS), 2000– 
2013. Clin Cardiol 2017;40:275–80. https://doi.org/10.1002/clc.22654
759. Vrints C, Andreotti F, Koskinas K, Rossell X, Adamo M, Ainslie J, et al. 2024 ESC 
Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 
45:3415–537. https://doi.org/10.1093/eurheartj/ehae177
760. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720–826. https://doi.org/10.1093/eurheartj/ehad191
761. Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, et al. Shortening the 
duration of dual antiplatelet therapy after percutaneous coronary intervention for 
acute coronary syndrome: a systematic review and meta-analysis. Am Heart J 2022; 
251:101–14. https://doi.org/10.1016/j.ahj.2022.05.019
762. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and ef­
ficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fib­
rillation following percutaneous coronary intervention: a systematic review and 
meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical 
trials. Eur Heart J 2019;40:3757–67. https://doi.org/10.1093/eurheartj/ehz732
763. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of 
clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and 
undergoing percutaneous coronary intervention: an open-label, randomised, con­
trolled trial. Lancet 2013;381:1107–15. https://doi.org/10.1016/S0140-6736(12) 
62177-1
764. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic 
therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 
380:1509–24. https://doi.org/10.1056/NEJMoa1817083
765. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. 
Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J 
Med 2016;375:2423–34. https://doi.org/10.1056/NEJMoa1611594
766. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrom­
botic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377: 
1513–24. https://doi.org/10.1056/NEJMoa1708454
767. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. 
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after suc­
cessful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a ran­
domised, open-label, phase 3b trial. Lancet 2019;394:1335–43. https://doi.org/10. 
1016/S0140-6736(19)31872-0
768. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and 
efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing


<!-- PAGE 90 -->

### Page 90

percutaneous coronary intervention: a network meta-analysis of randomized con­
trolled trials. JAMA Cardiol 2019;4:747–55. https://doi.org/10.1001/jamacardio.2019. 
1880
769. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, et al. Dabigatran 
dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention 
in atrial fibrillation patients with or without acute coronary syndrome: a subgroup ana­
lysis from the RE-DUAL PCI trial. Eur Heart J 2019;40:1553–62. https://doi.org/10. 
1093/eurheartj/ehz059
770. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, et al. Revisiting the 
effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation 
and acute coronary syndromes or percutaneous coronary interventions: meta-analysis 
of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. 
Europace 2020;22:33–46. https://doi.org/10.1093/europace/euz259
771. Haller PM, Sulzgruber P, Kaufmann C, Geelhoed B, Tamargo J, Wassmann S, et al. 
Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic 
therapy: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 
2019;5:226–36. https://doi.org/10.1093/ehjcvp/pvz021
772. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal an­
tithrombotic regimens for patients with atrial fibrillation undergoing percutaneous 
coronary intervention: an updated network meta-analysis. JAMA Cardiol 2020;5: 
582–9. https://doi.org/10.1001/jamacardio.2019.6175
773. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An open- 
label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban 
vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and 
acute coronary syndrome and/or percutaneous coronary intervention: rationale and 
design of the AUGUSTUS trial. Am Heart J 2018;200:17–23. https://doi.org/10.1016/ 
j.ahj.2018.03.001
774. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, et al. 
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syn­
drome treated medically or with percutaneous coronary intervention or undergoing 
elective percutaneous coronary intervention: insights from the AUGUSTUS trial. 
Circulation 
2019;140:1921–32. 
https://doi.org/10.1161/CIRCULATIONAHA.119. 
043308
775. Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, et al. 
Antithrombotic therapy in patients with atrial fibrillation after acute coronary syn­
dromes or percutaneous intervention. J Am Coll Cardiol 2022;79:417–27. https://doi. 
org/10.1016/j.jacc.2021.11.035
776. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/ 
benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and 
late after an acute coronary syndrome or percutaneous coronary intervention: insights 
from AUGUSTUS. Circulation 2020;141:1618–27. https://doi.org/10.1161/CIRCULA 
TIONAHA.120.046534
777. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety 
of proton pump inhibitors based on a large, multi-year, randomized trial of patients 
receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–691.e2. https://doi. 
org/10.1053/j.gastro.2019.05.056
778. Jeridi D, Pellat A, Ginestet C, Assaf A, Hallit R, Corre F, et al. The safety of long-term 
proton pump inhibitor use on cardiovascular health: a meta-analysis. J Clin Med 2022; 
11:4096. https://doi.org/10.3390/jcm11144096
779. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastropro­
tectant drugs for the prevention and treatment of peptic ulcer disease and its compli­
cations: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3: 
231–41. https://doi.org/10.1016/S2468-1253(18)30037-2
780. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, et al. Duration 
of triple therapy in patients requiring oral anticoagulation after drug-eluting stent im­
plantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619–29. https://doi.org/ 
10.1016/j.jacc.2015.02.050
781. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. 
Open-label randomized trial comparing oral anticoagulation with and without single 
antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease 
beyond 1 year after coronary stent implantation. Circulation 2019;139:604–16. https:// 
doi.org/10.1161/CIRCULATIONAHA.118.036768
782. Jensen T, Thrane PG, Olesen KKW, Würtz M, Mortensen MB, Gyldenkerne C, et al. 
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention 
in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2023;9:208–19. 
https://doi.org/10.1093/ehjcvp/pvac058
783. Vitalis A, Shantsila A, Proietti M, Vohra RK, Kay M, Olshansky B, et al. Peripheral arterial 
disease in patients with atrial fibrillation: the AFFIRM study. Am J Med 2021;134:514–8. 
https://doi.org/10.1016/j.amjmed.2020.08.026
784. Wasmer K, Unrath M, Köbe J, Malyar NM, Freisinger E, Meyborg M, et al. Atrial fibril­
lation is a risk marker for worse in-hospital and long-term outcome in patients with 
peripheral artery disease. Int J Cardiol 2015;199:223–8. https://doi.org/10.1016/j. 
ijcard.2015.06.094
785. Griffin WF, Salahuddin T, O’Neal WT, Soliman EZ. Peripheral arterial disease is asso­
ciated with an increased risk of atrial fibrillation in the elderly. Europace 2016;18:794–8. 
https://doi.org/10.1093/europace/euv369
786. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, et al. Risk factors and incidence 
of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nation wide 
database 
analysis. 
Atherosclerosis 
2011;217:292–5. 
https://doi.org/10.1016/j. 
atherosclerosis.2011.03.033
787. Su MI, Cheng YC, Huang YC, Liu CW. The impact of atrial fibrillation on one-year mor­
tality in patients with severe lower extremity arterial disease. J Clin Med 2022;11:1936. 
https://doi.org/10.3390/jcm11071936
788. Winkel TA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I, et al. 
Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: 
data from the REduction of Atherothrombosis for Continued Health (REACH) 
Registry. Eur J Vasc Endovasc Surg 2010;40:9–16. https://doi.org/10.1016/j.ejvs.2010. 
03.003
789. Nejim B, Mathlouthi A, Weaver L, Faateh M, Arhuidese I, Malas MB. Safety of carotid 
artery revascularization procedures in patients with atrial fibrillation. J Vasc Surg 2020; 
72:2069–2078.e4. https://doi.org/10.1016/j.jvs.2020.01.074
790. Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, et al. Efficacy 
and safety of rivaroxaban compared with warfarin in patients with peripheral artery 
disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 
2014;35:242–9. https://doi.org/10.1093/eurheartj/eht492
791. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 
ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in col­
laboration with the European Society for Vascular Surgery (ESVS): document covering 
atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper 
and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) 
The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the 
European Society of Cardiology (ESC) and of the European Society for Vascular 
Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/10.1093/eurheartj/ 
ehx095
792. Schirmer CM, Bulsara KR, Al-Mufti F, Haranhalli N, Thibault L, Hetts SW. Antiplatelets 
and antithrombotics in neurointerventional procedures: guideline update. J Neurointerv 
Surg 2023;15:1155–62. https://doi.org/10.1136/jnis-2022-019844
793. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. 
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute 
ischaemic stroke. Eur Stroke J 2021;6:I–LXII. https://doi.org/10.1177/239698732198 
9865
794. Caso V, Masuhr F. A narrative review of nonvitamin K antagonist oral anticoagulant use 
in secondary stroke prevention. J Stroke Cerebrovasc Dis 2019;28:2363–75. https://doi. 
org/10.1016/j.jstrokecerebrovasdis.2019.05.017
795. Fischer U, Koga M, Strbian D, Branca M, Abend S, Trelle S, et al. Early versus later antic­
oagulation for stroke with atrial fibrillation. N Engl J Med 2023;388:2411–21. https:// 
doi.org/10.1056/NEJMoa2303048
796. Oldgren J, Åsberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B. Early versus delayed 
non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in at­
rial fibrillation (TIMING): a registry-based randomized controlled noninferiority study. 
Circulation 
2022;146:1056–66. 
https://doi.org/10.1161/CIRCULATIONAHA.122. 
060666
797. Schreuder F, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, Kerkhoff H, Zock E, 
et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral 
haemorrhage in patients with atrial fibrillation in The Netherlands (APACHE-AF): a 
randomised, open-label, phase 2 trial. Lancet Neurol 2021;20:907–16. https://doi.org/ 
10.1016/S1474-4422(21)00298-2
798. SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spon­
taneous intracranial haemorrhage in the UK: a randomised, open-label, assessor- 
masked, pilot-phase, non-inferiority trial. Lancet Neurol 2021;20:842–53. https://doi. 
org/10.1016/S1474-4422(21)00264-7
799. Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, et al. 
Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill pa­
tients with sepsis. A cohort study. Am J Respir Crit Care Med 2017;195:205–11. 
https://doi.org/10.1164/rccm.201603-0618OC
800. Gundlund A, Olesen JB, Butt JH, Christensen MA, Gislason GH, Torp-Pedersen C, 
et al. One-year outcomes in atrial fibrillation presenting during infections: a nationwide 
registry-based study. Eur Heart J 2020;41:1112–9. https://doi.org/10.1093/eurheartj/ 
ehz873
801. Induruwa I, Hennebry E, Hennebry J, Thakur M, Warburton EA, Khadjooi K. 
Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to rec­
ommend anticoagulation? Eur J Intern Med 2022;98:32–6. https://doi.org/10.1016/j. 
ejim.2021.10.022
802. Ko D, Saleeba C, Sadiq H, Crawford S, Paul T, Shi Q, et al. Secondary precipitants of 
atrial fibrillation and anticoagulation therapy. J Am Heart Assoc 2021;10:e021746. 
https://doi.org/10.1161/JAHA.121.021746
803. Li YG, Borgi M, Lip GY. Atrial fibrillation occurring initially during acute medical illness: 
the heterogeneous nature of disease, outcomes and management strategies. Eur Heart 
J Acute Cardiovasc Care 2018;10:2048872618801763. https://doi.org/10.1177/ 
2048872618801763
804. Lowres N, Hillis GS, Gladman MA, Kol M, Rogers J, Chow V, et al. Self-monitoring for 
recurrence of secondary atrial fibrillation following non-cardiac surgery or acute 
ESC Guidelines                                                                                                                                                                                          3403


<!-- PAGE 91 -->

### Page 91

illness: a pilot study. Int J Cardiol Heart Vasc 2020;29:100566. https://doi.org/10.1016/j. 
ijcha.2020.100566
805. Søgaard M, Skjøth F, Nielsen PB, Smit J, Dalager-Pedersen M, Larsen TB, et al. 
Thromboembolic risk in patients with pneumonia and new-onset atrial fibrillation 
not receiving anticoagulation therapy. JAMA Netw Open 2022;5:e2213945. https:// 
doi.org/10.1001/jamanetworkopen.2022.13945
806. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following devel­
opment of new-onset atrial fibrillation during sepsis. Chest 2014;146:1187–95. https:// 
doi.org/10.1378/chest.14-0003
807. McIntyre WF, Um KJ, Cheung CC, Belley-Côté EP, Dingwall O, Devereaux PJ, et al. 
Atrial fibrillation detected initially during acute medical illness: a systematic review. 
Eur Heart J Acute Cardiovasc Care 2019;8:130–41. https://doi.org/10.1177/ 
2048872618799748
808. Marcus GM, Vittinghoff E, Whitman IR, Joyce S, Yang V, Nah G, et al. Acute consump­
tion of alcohol and discrete atrial fibrillation events. Ann Intern Med 2021;174:1503–9. 
https://doi.org/10.7326/M21-0228
809. Marcus GM, Modrow MF, Schmid CH, Sigona K, Nah G, Yang J, et al. Individualized 
studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical 
trial. JAMA Cardiol 2022;7:167–74. https://doi.org/10.1001/jamacardio.2021.5010
810. Lin AL, Nah G, Tang JJ, Vittinghoff E, Dewland TA, Marcus GM. Cannabis, cocaine, 
methamphetamine, and opiates increase the risk of incident atrial fibrillation. Eur 
Heart J 2022;43:4933–42. https://doi.org/10.1093/eurheartj/ehac558
811. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH, et al. 
Risk of thromboembolism associated with atrial fibrillation following noncardiac sur­
gery. J Am Coll Cardiol 2018;72:2027–36. https://doi.org/10.1016/j.jacc.2018.07.088
812. Gundlund A, Kümler T, Bonde AN, Butt JH, Gislason GH, Torp-Pedersen C, et al. 
Comparative thromboembolic risk in atrial fibrillation with and without a secondary 
precipitant–Danish nationwide cohort study. BMJ Open 2019;9:e028468. https://doi. 
org/10.1136/bmjopen-2018-028468
813. Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice patterns and 
outcomes associated with use of anticoagulation among patients with atrial fibrillation 
during sepsis. JAMA Cardiol 2016;1:682–90. https://doi.org/10.1001/jamacardio.2016. 
2181
814. Darwish OS, Strube S, Nguyen HM, Tanios MA. Challenges of anticoagulation for atrial 
fibrillation in patients with severe sepsis. Ann Pharmacother 2013;47:1266–71. https:// 
doi.org/10.1177/1060028013500938
815. Quon MJ, Behlouli H, Pilote L. Anticoagulant use and risk of ischemic stroke and bleed­
ing in patients with secondary atrial fibrillation associated with acute coronary syn­
dromes, acute pulmonary disease, or sepsis. JACC Clin Electrophysiol 2018;4:386–93. 
https://doi.org/10.1016/j.jacep.2017.08.003
816. Echahidi N, Pibarot P, O’Hara G, Mathieu P. Mechanisms, prevention, and treatment of 
atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008;51:793–801. https://doi. 
org/10.1016/j.jacc.2007.10.043
817. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. Rate 
control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J 
Med 2016;374:1911–21. https://doi.org/10.1056/NEJMoa1602002
818. Gaudino M, Di Franco A, Rong LQ, Piccini J, Mack M. Postoperative atrial fibrillation: 
from mechanisms to treatment. Eur Heart J 2023;44:1020–39. https://doi.org/10.1093/ 
eurheartj/ehad019
819. Kotecha D, Castella M. Is it time to treat post-operative atrial fibrillation just like regu­
lar atrial fibrillation? Eur Heart J 2020;41:652–654a. https://doi.org/10.1093/eurheartj/ 
ehz412
820. Konstantino Y, Zelnik Yovel D, Friger MD, Sahar G, Knyazer B, Amit G. Postoperative 
atrial fibrillation following coronary artery bypass graft surgery predicts long-term at­
rial fibrillation and stroke. Isr Med Assoc J 2016;18:744–8.
821. Lee SH, Kang DR, Uhm JS, Shim J, Sung JH, Kim JY, et al. New-onset atrial fibrillation 
predicts long-term newly developed atrial fibrillation after coronary artery bypass 
graft. Am Heart J 2014;167:593–600.e1. https://doi.org/10.1016/j.ahj.2013.12.010
822. Lin MH, Kamel H, Singer DE, Wu YL, Lee M, Ovbiagele B. Perioperative/postoperative 
atrial fibrillation and risk of subsequent stroke and/or mortality. Stroke 2019;50: 
1364–71. https://doi.org/10.1161/STROKEAHA.118.023921
823. AlTurki A, Marafi M, Proietti R, Cardinale D, Blackwell R, Dorian P, et al. Major adverse 
cardiovascular events associated with postoperative atrial fibrillation after noncardiac 
surgery: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2020;13: 
e007437. https://doi.org/10.1161/CIRCEP.119.007437
824. Goyal P, Kim M, Krishnan U, McCullough SA, Cheung JW, Kim LK, et al. Post-operative 
atrial fibrillation and risk of heart failure hospitalization. Eur Heart J 2022;43:2971–80. 
https://doi.org/10.1093/eurheartj/ehac285
825. Eikelboom R, Sanjanwala R, Le ML, Yamashita MH, Arora RC. Postoperative atrial fib­
rillation after cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg 
2021;111:544–54. https://doi.org/10.1016/j.athoracsur.2020.05.104
826. Benedetto U, Gaudino MF, Dimagli A, Gerry S, Gray A, Lees B, et al. Postoperative 
atrial fibrillation and long-term risk of stroke after isolated coronary artery bypass graft 
surgery. Circulation 2020;142:1320–9. https://doi.org/10.1161/CIRCULATIONAHA. 
120.046940
827. Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, et al. New-onset atrial 
fibrillation after coronary artery bypass grafting and long-term outcome: a population- 
based nationwide study from the SWEDEHEART registry. J Am Heart Assoc 2021;10: 
e017966. https://doi.org/10.1161/JAHA.120.017966
828. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: 
mechanisms, manifestations and management. Nat Rev Cardiol 2019;16:417–36. 
https://doi.org/10.1038/s41569-019-0166-5
829. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. A multicenter risk 
index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720–9. https://doi. 
org/10.1001/jama.291.14.1720
830. Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, et al. Postoperative atrial 
fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 
2004;43:742–8. https://doi.org/10.1016/j.jacc.2003.11.023
831. Cardinale D, Sandri MT, Colombo A, Salvatici M, Tedeschi I, Bacchiani G, et al. 
Prevention of atrial fibrillation in high-risk patients undergoing lung cancer surgery: 
the PRESAGE trial. Ann Surg 2016;264:244–51. https://doi.org/10.1097/SLA. 
0000000000001626
832. Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, et al. Randomized 
clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and post­
operative complications after oesophagectomy for cancer. Br J Surg 2017;104:1003–9. 
https://doi.org/10.1002/bjs.10548
833. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, et al. Interventions 
for preventing post-operative atrial fibrillation in patients undergoing heart surgery. 
Cochrane Database Syst Rev 2013;1:CD003611. https://doi.org/10.1002/14651858. 
CD003611.pub3
834. Ozaydin M, Icli A, Yucel H, Akcay S, Peker O, Erdogan D, et al. Metoprolol vs. carvedilol 
or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, 
double-blind, placebo-controlled study. Eur Heart J 2013;34:597–604. https://doi.org/ 
10.1093/eurheartj/ehs423
835. O’Neal JB, Billings F, Liu X, Shotwell MS, Liang Y, Shah AS, et al. Effect of preoperative 
beta-blocker use on outcomes following cardiac surgery. Am J Cardiol 2017;120: 
1293–7. https://doi.org/10.1016/j.amjcard.2017.07.012
836. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, et al. Beta-blocker 
efficacy across different cardiovascular indications: an umbrella review and 
meta-analytic assessment. BMC Med 2020;18:103. https://doi.org/10.1186/s12916- 
020-01564-3
837. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, et al. A ran­
domized trial evaluating amiodarone for prevention of atrial fibrillation after pulmon­
ary resection. Ann Thorac Surg 2009;88:886–93; discussion 894–5. https://doi.org/10. 
1016/j.athoracsur.2009.04.074
838. Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, et al. A comparison between 
oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: 
the pilot Study of Prevention of Postoperative Atrial Fibrillation (SPPAF), a rando­
mized, placebo-controlled trial. Am Heart J 2004;147:636–43. https://doi.org/10. 
1016/j.ahj.2003.10.041
839. Buckley MS, Nolan PE, Jr, Slack MK, Tisdale JE, Hilleman DE, Copeland JG. Amiodarone 
prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response 
and timing of initiation. Pharmacotherapy 2007;27:360–8. https://doi.org/10.1592/phco. 
27.3.360
840. Riber LP, Christensen TD, Jensen HK, Hoejsgaard A, Pilegaard HK. Amiodarone signifi­
cantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. Ann 
Thorac Surg 2012;94:339–44; discussion 345–6. https://doi.org/10.1016/j.athoracsur. 
2011.12.096
841. Couffignal C, Amour J, Ait-Hamou N, Cholley B, Fellahi JL, Duval X, et al. Timing of 
β-blocker reintroduction and the occurrence of postoperative atrial fibrillation after 
cardiac surgery: a prospective cohort study. Anesthesiology 2020;132:267–79. 
https://doi.org/10.1097/ALN.0000000000003064
842. Piccini JP, Ahlsson A, Dorian P, Gillinov MA, Kowey PR, Mack MJ, et al. Design and ra­
tionale of a phase 2 study of NeurOtoxin (Botulinum Toxin Type A) for the 
PreVention of post-operative atrial fibrillation—the NOVA study. Am Heart J 2022; 
245:51–9. https://doi.org/10.1016/j.ahj.2021.10.114
843. O’Brien B, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, et al. Society of 
Cardiovascular 
Anesthesiologists/European 
Association 
of 
Cardiothoracic 
Anaesthetists Practice Advisory for the management of perioperative atrial fibrillation 
in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2019;33:12–26. 
https://doi.org/10.1053/j.jvca.2018.09.039
844. Gaudino M, Sanna T, Ballman KV, Robinson NB, Hameed I, Audisio K, et al. Posterior 
left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an 
adaptive, single-centre, single-blind, randomised, controlled trial. Lancet 2021;398: 
2075–83. https://doi.org/10.1016/S0140-6736(21)02490-9
845. Abdelaziz A, Hafez AH, Elaraby A, Roshdy MR, Abdelaziz M, Eltobgy MA, et al. 
Posterior pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: 
a systematic review and meta-analysis of 25 randomised controlled trials. 
EuroIntervention 2023;19:e305–17. https://doi.org/10.4244/EIJ-D-22-00948
846. Soletti GJ, Perezgrovas-Olaria R, Harik L, Rahouma M, Dimagli A, Alzghari T, et al. 
Effect of posterior pericardiotomy in cardiac surgery: a systematic review and


<!-- PAGE 92 -->

### Page 92

meta-analysis of randomized controlled trials. Front Cardiovasc Med 2022;9:1090102. 
https://doi.org/10.3389/fcvm.2022.1090102
847. Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, et al. Effect of col­
chicine on perioperative atrial fibrillation and myocardial injury after non-cardiac sur­
gery in patients undergoing major thoracic surgery (COP-AF): an international 
randomised trial. Lancet 2023;402:1627–35. https://doi.org/10.1016/S0140-6736(23) 
01689-6
848. Fragão-Marques M, Teixeira F, Mancio J, Seixas N, Rocha-Neves J, Falcão-Pires I, et al. 
Impact of oral anticoagulation therapy on postoperative atrial fibrillation outcomes: a 
systematic review and meta-analysis. Thromb J 2021;19:89. https://doi.org/10.1186/ 
s12959-021-00342-2
849. Neves IA, Magalhães A, Lima da Silva G, Almeida AG, Borges M, Costa J, et al. 
Anticoagulation therapy in patients with post-operative atrial fibrillation: systematic 
review with meta-analysis. Vascul Pharmacol 2022;142:106929. https://doi.org/10. 
1016/j.vph.2021.106929
850. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al. Preoperative 
amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 
1997;337:1785–91. https://doi.org/10.1056/NEJM199712183372501
851. Yagdi T, Nalbantgil S, Ayik F, Apaydin A, Islamoglu F, Posacioglu H, et al. Amiodarone 
reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac 
Cardiovasc Surg 2003;125:1420–5. https://doi.org/10.1016/S0022-5223(02)73292-3
852. Butt JH, Xian Y, Peterson ED, Olsen PS, Rorth R, Gundlund A, et al. Long-term 
thromboembolic risk in patients with postoperative atrial fibrillation after coronary ar­
tery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol 
2018;3:417–24. https://doi.org/10.1001/jamacardio.2018.0405
853. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al. 
Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014; 
312:616–22. https://doi.org/10.1001/jama.2014.9143
854. Horwich P, Buth KJ, Legare JF. New onset postoperative atrial fibrillation is associated 
with a long-term risk for stroke and death following cardiac surgery. J Card Surg 2013; 
28:8–13. https://doi.org/10.1111/jocs.12033
855. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release 
metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a ran­
domised controlled trial. Lancet 2008;371:1839–47. https://doi.org/10.1016/S0140- 
6736(08)60601-7
856. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic 
strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 
2014;13:429–38. https://doi.org/10.1016/S1474-4422(13)70310-7
857. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. 
Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370: 
2478–86. https://doi.org/10.1056/NEJMoa1313600
858. Rubiera M, Aires A, Antonenko K, Lémeret S, Nolte CH, Putaala J, et al. European 
Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after 
stroke or transient ischaemic attack of undetermined origin. Eur Stroke J 2022;7:VI. 
https://doi.org/10.1177/23969873221099478
859. von Falkenhausen AS, Feil K, Sinner MF, Schönecker S, Müller J, Wischmann J, et al. 
Atrial fibrillation risk assessment after embolic stroke of undetermined source. Ann 
Neurol 2023;93:479–88. https://doi.org/10.1002/ana.26545
860. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in 
patients with cryptogenic stroke. N Engl J Med 2014;370:2467–77. https://doi.org/10. 
1056/NEJMoa1311376
861. Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. 
Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke 
(Find-AF(RANDOMISED)): an open-label randomised controlled trial. Lancet Neurol 
2017;16:282–90. https://doi.org/10.1016/S1474-4422(17)30002-9
862. Buck BH, Hill MD, Quinn FR, Butcher KS, Menon BK, Gulamhusein S, et al. Effect of 
implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation 
detection in patients with ischemic stroke: the PER DIEM randomized clinical trial. 
JAMA 2021;325:2160–8. https://doi.org/10.1001/jama.2021.6128
863. Bernstein RA, Kamel H, Granger CB, Piccini JP, Sethi PP, Katz JM, et al. Effect of long- 
term continuous cardiac monitoring vs usual care on detection of atrial fibrillation in 
patients with stroke attributed to large- or small-vessel disease: the STROKE-AF ran­
domized clinical trial. JAMA 2021;325:2169–77. https://doi.org/10.1001/jama.2021. 
6470
864. Tsivgoulis G, Katsanos AH, Köhrmann M, Caso V, Perren F, Palaiodimou L, et al. 
Duration of implantable cardiac monitoring and detection of atrial fibrillation in ische­
mic stroke patients: a systematic review and meta-analysis. J Stroke 2019;21:302–11. 
https://doi.org/10.5853/jos.2019.01067
865. Sagris D, Harrison SL, Buckley BJR, Ntaios G, Lip GYH. Long-term cardiac monitoring 
after embolic stroke of undetermined source: search longer, look harder. Am J Med 
2022;135:e311–7. https://doi.org/10.1016/j.amjmed.2022.04.030
866. Liantinioti C, Palaiodimou L, Tympas K, Parissis J, Theodorou A, Ikonomidis I, et al. 
Potential utility of neurosonology in paroxysmal atrial fibrillation detection in patients 
with cryptogenic stroke. J Clin Med 2019;8:2002. https://doi.org/10.3390/jcm8112002
867. Tsivgoulis G, Katsanos AH, Grory BM, Köhrmann M, Ricci BA, Tsioufis K, et al. 
Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients 
with cryptogenic cerebral ischemia. Stroke 2019;50:2175–80. https://doi.org/10. 
1161/STROKEAHA.119.025169
868. Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messé SR, et al. Predictors of finding 
occult atrial fibrillation after cryptogenic stroke. Stroke 2015;46:1210–5. https://doi. 
org/10.1161/STROKEAHA.114.007763
869. Lip GY, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor 
(CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? Yes: even 1 stroke 
risk factor confers a real risk of stroke. Circulation 2016;133:1498–503; discussion 
1503. https://doi.org/10.1161/CIRCULATIONAHA.115.016713
870. Ricci B, Chang AD, Hemendinger M, Dakay K, Cutting S, Burton T, et al. A simple score 
that predicts paroxysmal atrial fibrillation on outpatient cardiac monitoring after em­
bolic stroke of unknown source. J Stroke Cerebrovasc Dis 2018;27:1692–6. https://doi. 
org/10.1016/j.jstrokecerebrovasdis.2018.01.028
871. Kwong C, Ling AY, Crawford MH, Zhao SX, Shah NH. A clinical score for predicting 
atrial fibrillation in patients with cryptogenic stroke or transient ischemic attack. 
Cardiology 2017;138:133–40. https://doi.org/10.1159/000476030
872. Li YG, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, et al. C(2) HEST 
score and prediction of incident atrial fibrillation in poststroke patients: a French na­
tionwide study. J Am Heart Assoc 2019;8:e012546. https://doi.org/10.1161/JAHA.119. 
012546
873. Haeusler KG, Gröschel K, Köhrmann M, Anker SD, Brachmann J, Böhm M, et al. Expert 
opinion paper on atrial fibrillation detection after ischemic stroke. Clin Res Cardiol 
2018;107:871–80. https://doi.org/10.1007/s00392-018-1256-9
874. Dilaveris PE, Antoniou CK, Caiani EG, Casado-Arroyo R, Climent A, Cluitmans M, 
et al. ESC working group on e-cardiology position paper: accuracy and reliability of 
electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic 
stroke patients: in collaboration with the Council on Stroke, the European Heart 
Rhythm Association, and the Digital Health Committee. Eur Heart J Digit Health 
2022;3:341–58. https://doi.org/10.1093/ehjdh/ztac026
875. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. 
Dabigatran for prevention of stroke after embolic stroke of undetermined source. 
N Engl J Med 2019;380:1906–17. https://doi.org/10.1056/NEJMoa1813959
876. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. 
Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N 
Engl J Med 2018;378:2191–201. https://doi.org/10.1056/NEJMoa1802686
877. Poli S, Meissner C, Baezner HJ, Kraft A, Hillenbrand F, Hobohm C, et al. Apixaban for 
treatment of embolic stroke of undetermined source (ATTICUS) randomized trial— 
update of patient characteristics and study timeline after interim analysis. Eur Heart J 
2021;42:ehab724.2070. https://doi.org/10.1093/eurheartj/ehab724.2070
878. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, et al. Burden of ar­
rhythmia in pregnancy. Circulation 2017;135:619–21. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.026681
879. Lee MS, Chen W, Zhang Z, Duan L, Ng A, Spencer HT, et al. Atrial fibrillation and atrial 
flutter in pregnant women—a population-based study. J Am Heart Assoc 2016;5: 
e003182. https://doi.org/10.1161/JAHA.115.003182
880. Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, et al. 
Arrhythmias in pregnancy. JACC Clin Electrophysiol 2022;8:120–35. https://doi.org/10. 
1016/j.jacep.2021.10.004
881. Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR, et al. Atrial 
fibrillation or flutter during pregnancy in patients with structural heart disease: data 
from the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin 
Electrophysiol 2015;1:284–92. https://doi.org/10.1016/j.jacep.2015.04.013
882. Chokesuwattanaskul R, Thongprayoon C, Bathini T, O’Corragain OA, Sharma K, 
Prechawat S, et al. Incidence of atrial fibrillation in pregnancy and clinical significance: 
a meta-analysis. Adv Med Sci 2019;64:415–22. https://doi.org/10.1016/j.advms.2019. 
07.003
883. Tamirisa KP, Dye C, Bond RM, Hollier LM, Marinescu K, Vaseghi M, et al. Arrhythmias 
and heart failure in pregnancy: a dialogue on multidisciplinary collaboration. J Cardiovasc 
Dev Dis 2022;9:199. https://doi.org/10.3390/jcdd9070199
884. Al Bahhawi T, Aqeeli A, Harrison SL, Lane DA, Skjøth F, Buchan I, et al. 
Pregnancy-related complications and incidence of atrial fibrillation: a systematic re­
view. J Clin Med 2023;12:1316. https://doi.org/10.3390/jcm12041316
885. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis­
eases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/ 
eurheartj/ehy340
886. Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy—a 
systematic review. J Perinat Med 2022;50:457–61. https://doi.org/10.1515/jpm-2021- 
0457
887. Ueberham L, Hindricks G. Anticoagulation in special patient populations with atrial fib­
rillation. Herz 2021;46:323–8. https://doi.org/10.1007/s00059-021-05042-1
888. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, et al. 
β-Blocker use in pregnancy and the risk for congenital malformations: an international 
cohort study. Ann Intern Med 2018;169:665–73. https://doi.org/10.7326/M18-0338
889. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. 
BMJ 1990;301:587–9. https://doi.org/10.1136/bmj.301.6752.587
ESC Guidelines                                                                                                                                                                                          3405


<!-- PAGE 93 -->

### Page 93

890. Ramlakhan KP, Kauling RM, Schenkelaars N, Segers D, Yap SC, Post MC, et al. 
Supraventricular arrhythmia in pregnancy. Heart 2022;108:1674–81. https://doi.org/ 
10.1136/heartjnl-2021-320451
891. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, et al. European 
Heart Rhythm Association (EHRA) consensus document on the management of su­
praventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific 
Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion 
Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J 2017;19:465–511. https://doi. 
org/10.1093/europace/euw301
892. Moore JS, Teefey P, Rao K, Berlowitz MS, Chae SH, Yankowitz J. Maternal arrhythmia: 
a case report and review of the literature. Obstet Gynecol Surv 2012;67:298–312. 
https://doi.org/10.1097/OGX.0b013e318253a76e
893. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal 
haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–9. https://doi.org/10. 
1016/j.ejogrb.2005.11.021
894. European Heart Rhythm Association; European Association for Cardio-Thoracic 
Surgery; Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the manage­
ment of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of 
the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429. https:// 
doi.org/10.1093/eurheartj/ehq278
895. Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fib­
rillation during pregnancy. J Cardiovasc Electrophysiol 2007;18:545–7. https://doi.org/ 
10.1111/j.1540-8167.2006.00752.x
896. Georgiopoulos G, Tsiachris D, Kordalis A, Kontogiannis C, Spartalis M, Pietri P, et al. 
Pharmacotherapeutic strategies for atrial fibrillation in pregnancy. Expert Opin 
Pharmacother 2019;20:1625–36. https://doi.org/10.1080/14656566.2019.1621290
897. Jensen AS, Idorn L, Nørager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults 
with congenital heart disease: the who, the when and the how? Heart 2015;101: 
424–9. https://doi.org/10.1136/heartjnl-2014-305576
898. Pujol C, Niesert AC, Engelhardt A, Schoen P, Kusmenkov E, Pittrow D, et al. 
Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J 
Cardiol 2016;117:450–5. https://doi.org/10.1016/j.amjcard.2015.10.062
899. Yang H, Bouma BJ, Dimopoulos K, Khairy P, Ladouceur M, Niwa K, et al. Non-vitamin K 
antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they 
safe in congenital heart disease? Results of a worldwide study. Int J Cardiol 2020; 
299:123–30. https://doi.org/10.1016/j.ijcard.2019.06.014
900. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoa­
gulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol 
2017;69:1363–71. https://doi.org/10.1016/j.jacc.2016.12.038
901. Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral antic­
oagulants in patients with atrial fibrillation and valvular heart disease: systematic review 
and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2018;4:111–8. https://doi.org/ 
10.1093/ehjcvp/pvx028
902. Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman PA, et al. 
Outcome of direct current cardioversion for atrial arrhythmias in adults with congeni­
tal heart disease. Int J Cardiol 2012;154:270–4. https://doi.org/10.1016/j.ijcard.2010.09. 
028
903. Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial throm­
bi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. 
J Am Coll Cardiol 1994;24:1365–70. https://doi.org/10.1016/0735-1097(94)90121-X
904. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, 
et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure long- 
term after surgical ASD closure at young age. A prospective follow-up study of 21–33 
years. Eur Heart J 2003;24:190–7. https://doi.org/10.1016/S0195-668X(02)00383-4
905. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent 
foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 
2017;377:1011–21. https://doi.org/10.1056/NEJMoa1705915
906. Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and 
the Cox-Maze procedure in congenital heart disease. Congenit Heart Dis 2013;8:434–9. 
https://doi.org/10.1111/chd.12031
907. Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y. Maze procedure 
for atrial fibrillation associated with atrial septal defect. Circulation 1998;98:II399–402.
908. Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the Maze procedure for atrial 
fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg 2013;46: 
98–103. https://doi.org/10.5090/kjtcs.2013.46.2.98
909. Sherwin ED, Triedman JK, Walsh EP. Update on interventional electrophysiology in 
congenital heart disease: evolving solutions for complex hearts. Circ Arrhythm 
Electrophysiol 2013;6:1032–40. https://doi.org/10.1161/CIRCEP.113.000313
910. Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. J Intensive 
Care Med 2015;30:131–40. https://doi.org/10.1177/0885066613498053
911. Y-Hassan S, Falhammar H. Cardiovascular manifestations and complications of pheo­
chromocytomas and paragangliomas. J Clin Med 2020;9:2435. https://doi.org/10.3390/ 
jcm9082435
912. Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, et al. Thyroid 
function within the normal range, subclinical hypothyroidism, and the risk of atrial 
fibrillation. Circulation 2017;136:2100–16. https://doi.org/10.1161/CIRCULATIONAHA. 
117.028753
913. Huang M, Yang S, Ge G, Zhi H, Wang L. Effects of thyroid dysfunction and the thyroid- 
stimulating hormone levels on the risk of atrial fibrillation: a systematic review and 
dose-response meta-analysis from cohort studies. Endocr Pract 2022;28:822–31. 
https://doi.org/10.1016/j.eprac.2022.05.008
914. Shin DG, Kang MK, Han D, Choi S, Cho JR, Lee N. Enlarged left atrium and decreased 
left atrial strain are associated with atrial fibrillation in patients with hyperthyroidism 
irrespective of conventional risk factors. Int J Cardiovasc Imaging 2022;38:613–20. 
https://doi.org/10.1007/s10554-021-02450-6
915. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum 
thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N 
Engl J Med 1994;331:1249–52. https://doi.org/10.1056/NEJM199411103311901
916. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
917. El Sabbagh R, Azar NS, Eid AA, Azar ST. Thyroid dysfunctions due to immune check­
point inhibitors: a review. Int J Gen Med 2020;13:1003–9. https://doi.org/10.2147/IJGM. 
S261433
918. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. 
Association between serum free thyroxine concentration and atrial fibrillation. Arch 
Intern Med 2007;167:928–34. https://doi.org/10.1001/archinte.167.9.928
919. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, et al. The spec­
trum of thyroid disease and risk of new onset atrial fibrillation: a large population co­
hort study. BMJ 2012;345:e7895. https://doi.org/10.1136/bmj.e7895
920. Kim K, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Increased risk of ischemic stroke 
and systemic embolism in hyperthyroidism-related atrial fibrillation: a nationwide co­
hort study. Am Heart J 2021;242:123–31. https://doi.org/10.1016/j.ahj.2021.08.018
921. Zhang J, Bisson A, Fauchier G, Bodin A, Herbert J, Ducluzeau PH, et al. Yearly incidence 
of stroke and bleeding in atrial fibrillation with concomitant hyperthyroidism: a nation­
al discharge database study. J Clin Med 2022;11:1342. https://doi.org/10.3390/ 
jcm11051342
922. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump 
M. 2018 European Thyroid Association (ETA) guidelines for the management of 
amiodarone-associated thyroid dysfunction. Eur Thyroid J 2018;7:55–66. https://doi. 
org/10.1159/000486957
923. Cappellani D, Papini P, Di Certo AM, Morganti R, Urbani C, Manetti L, et al. Duration 
of exposure to thyrotoxicosis increases mortality of compromised AIT patients: the 
role of early thyroidectomy. J Clin Endocrinol Metab 2020;105:dgaa464. https://doi. 
org/10.1210/clinem/dgaa464
924. Trevisan C, Piovesan F, Lucato P, Zanforlini BM, De Rui M, Maggi S, et al. 
Parathormone, vitamin D and the risk of atrial fibrillation in older adults: a prospective 
study. Nutr Metab Cardiovasc Dis 2019;29:939–45. https://doi.org/10.1016/j.numecd. 
2019.05.064
925. Pepe J, Cipriani C, Curione M, Biamonte F, Colangelo L, Danese V, et al. Reduction of 
arrhythmias in primary hyperparathyroidism, by parathyroidectomy, evaluated with 
24-h ECG monitoring. Eur J Endocrinol 2018;179:117–24. https://doi.org/10.1530/ 
EJE-17-0948
926. Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular mani­
festations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 2017; 
177:R297–308. https://doi.org/10.1530/EJE-17-0485
927. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. 
Cardiovascular events and target organ damage in primary aldosteronism compared 
with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes 
Endocrinol 2018;6:41–50. https://doi.org/10.1016/S2213-8587(17)30319-4
928. Bollati M, Lopez C, Bioletto F, Ponzetto F, Ghigo E, Maccario M, et al. Atrial fibrillation 
and aortic ectasia as complications of primary aldosteronism: focus on pathophysio­
logical aspects. Int J Mol Sci 2022;23:2111. https://doi.org/10.3390/ijms23042111
929. Kim KJ, Hong N, Yu MH, Lee H, Lee S, Lim JS, et al. Time-dependent risk of atrial 
fibrillation in patients with primary aldosteronism after medical or surgical treatment 
initiation. Hypertension 2021;77:1964–73. https://doi.org/10.1161/HYPERTENSIONA 
HA.120.16909
930. Larsson SC, Lee WH, Burgess S, Allara E. Plasma cortisol and risk of atrial fibrillation: a 
Mendelian randomization study. J Clin Endocrinol Metab 2021;106:e2521–6. https://doi. 
org/10.1210/clinem/dgab219
931. Di Dalmazi G, Vicennati V, Pizzi C, Mosconi C, Tucci L, Balacchi C, et al. Prevalence and 
incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: a long-term 
study. J Clin Endocrinol Metab 2020;105:dgaa270. https://doi.org/10.1210/clinem/ 
dgaa270
932. Hong S, Kim KS, Han K, Park CY. Acromegaly and cardiovascular outcomes: a cohort 
study. Eur Heart J 2022;43:1491–9. https://doi.org/10.1093/eurheartj/ehab822
933. Polina I, Jansen HJ, Li T, Moghtadaei M, Bohne LJ, Liu Y, et al. Loss of insulin signaling 
may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes.


<!-- PAGE 94 -->

### Page 94

Proc Natl Acad Sci USA 2020;117:7990–8000. https://doi.org/10.1073/pnas.19148 
53117
934. Lee YB, Han K, Kim B, Lee SE, Jun JE, Ahn J, et al. Risk of early mortality and cardiovas­
cular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. 
Cardiovasc Diabetol 2019;18:157. https://doi.org/10.1186/s12933-019-0953-7
935. Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age, 
type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a 
nationwide analysis. Cardiovasc Diabetol 2021;20:24. https://doi.org/10.1186/s12933- 
021-01216-7
936. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. 
Risk of atrial fibrillation in people with type 1 diabetes compared with matched con­
trols from the general population: a prospective case-control study. Lancet Diabetes 
Endocrinol 2017;5:799–807. https://doi.org/10.1016/S2213-8587(17)30262-0
937. Cai X, Li J, Cai W, Chen C, Ma J, Xie Z, et al. Meta-analysis of type 1 diabetes mellitus 
and risk of cardiovascular disease. J Diabetes Complications 2021;35:107833. https://doi. 
org/10.1016/j.jdiacomp.2020.107833
938. Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J, et al. Atrial ar­
rhythmias in long-QT syndrome under daily life conditions: a nested case control 
study. J Cardiovasc Electrophysiol 2009;20:401–7. https://doi.org/10.1111/j.1540-8167. 
2008.01339.x
939. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of 
early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008;5: 
704–9. https://doi.org/10.1016/j.hrthm.2008.02.007
940. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, et al. Short QT syn­
drome: a familial cause of sudden death. Circulation 2003;108:965–70. https://doi.org/ 
10.1161/01.CIR.0000085071.28695.C4
941. Borggrefe M, Wolpert C, Antzelevitch C, Veltmann C, Giustetto C, Gaita F, et al. Short 
QT syndrome genotype-phenotype correlations. J Electrocardiol 2005;38:75–80. 
https://doi.org/10.1016/j.jelectrocard.2005.06.009
942. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P, et al. Short 
QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 
2006;27:2440–7. https://doi.org/10.1093/eurheartj/ehl185
943. Bordachar P, Reuter S, Garrigue S, Cai X, Hocini M, Jais P, et al. Incidence, clinical im­
plications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004; 
25:879–84. https://doi.org/10.1016/j.ehj.2004.01.004
944. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 
2008;51:1149–53. https://doi.org/10.1016/j.jacc.2007.10.062
945. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, et al. Long-term 
follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011;58:587–95. 
https://doi.org/10.1016/j.jacc.2011.03.038
946. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic 
criteria. J Am Coll Cardiol 2011;57:802–12. https://doi.org/10.1016/j.jacc.2010.09.048
947. Kusano KF, Taniyama M, Nakamura K, Miura D, Banba K, Nagase S, et al. Atrial fibril­
lation in patients with Brugada syndrome relationships of gene mutation, electrophysi­
ology, and clinical backgrounds. J Am Coll Cardiol 2008;51:1169–75. https://doi.org/10. 
1016/j.jacc.2007.10.060
948. Rodriguez-Manero M, Namdar M, Sarkozy A, Casado-Arroyo R, Ricciardi D, de 
Asmundis C, et al. Prevalence, clinical characteristics and management of atrial fibrilla­
tion in patients with Brugada syndrome. Am J Cardiol 2013;111:362–7. https://doi.org/ 
10.1016/j.amjcard.2012.10.012
949. Choi YJ, Choi EK, Han KD, Jung JH, Park J, Lee E, et al. Temporal trends of the preva­
lence and incidence of atrial fibrillation and stroke among Asian patients with hyper­
trophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 2018; 
273:130–5. https://doi.org/10.1016/j.ijcard.2018.08.038
950. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, Gomez-Juanatey A, 
et al. Patients with Brugada syndrome and implanted cardioverter-defibrillators: long- 
term follow-up. J Am Coll Cardiol 2017;70:1991–2002. https://doi.org/10.1016/j.jacc. 
2017.08.029
951. Klopotowski M, Kwapiszewska A, Kukula K, Jamiolkowski J, Dabrowski M, Derejko P, 
et al. Clinical and echocardiographic parameters as risk factors for atrial fibrillation in 
patients with hypertrophic cardiomyopathy. Clin Cardiol 2018;41:1336–40. https://doi. 
org/10.1002/clc.23050
952. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, et al. Occurrence and 
natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomy­
opathy. Am J Cardiol 2017;119:1862–5. https://doi.org/10.1016/j.amjcard.2017.02.040
953. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, et al. Outcome after 
implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multi­
center study-part 2. Circulation 2013;128:1739–47. https://doi.org/10.1161/ 
CIRCULATIONAHA.113.001941
954. Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in 
hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large 
high-risk population. J Am Heart Assoc 2014;3:e001002. https://doi.org/10.1161/JAHA. 
114.001002
955. Sumitomo N, Sakurada H, Taniguchi K, Matsumura M, Abe O, Miyashita M, et al. 
Association of atrial arrhythmia and sinus node dysfunction in patients with 
catecholaminergic polymorphic ventricular tachycardia. Circ J 2007;71:1606–9. 
https://doi.org/10.1253/circj.71.1606
956. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, et al. Arrhythmia character­
ization and long-term outcomes in catecholaminergic polymorphic ventricular tachy­
cardia. Heart Rhythm 2011;8:864–71. https://doi.org/10.1016/j.hrthm.2011.01.048
957. van Velzen HG, Theuns DA, Yap SC, Michels M, Schinkel AF. Incidence of device- 
detected atrial fibrillation and long-term outcomes in patients with hypertrophic car­
diomyopathy. Am J Cardiol 2017;119:100–5. https://doi.org/10.1016/j.amjcard.2016.08. 
092
958. Bourfiss M, Te Riele AS, Mast TP, Cramer MJ, Van Der Heijden J, Van Veen TAB, et al. 
Influence of genotype on structural atrial abnormalities and atrial fibrillation or flutter 
in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc 
Electrophysiol 2016;27:1420–8. https://doi.org/10.1111/jce.13094
959. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele AS, et al. Prevalence of 
atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart 
Rhythm 2013;10:1661–8. https://doi.org/10.1016/j.hrthm.2013.08.032
960. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic 
right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 
2010;106:720–2. https://doi.org/10.1016/j.amjcard.2010.04.031
961. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/ 
C cardiomyopathy: young onset, high penetrance, and frequent need for heart trans­
plantation. Eur Heart J 2018;39:853–60. https://doi.org/10.1093/eurheartj/ehx596
962. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, et al. 
Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. 
J Am Coll Cardiol 2016;68:2299–307. https://doi.org/10.1016/j.jacc.2016.08.058
963. Mussigbrodt A, Knopp H, Efimova E, Weber A, Bertagnolli L, Hilbert S, et al. 
Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dyspla­
sia/cardiomyopathy associate with long-term outcome after catheter ablation of ven­
tricular tachycardias. Europace 2018;20:1182–7. https://doi.org/10.1093/europace/ 
eux179
964. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term out­
come and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52: 
1250–60. https://doi.org/10.1016/j.jacc.2008.06.044
965. Saguner AM, Ganahl S, Kraus A, Baldinger SH, Medeiros-Domingo A, Saguner AR, et al. 
Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dys­
plasia. Circ J 2014;78:2854–61. https://doi.org/10.1253/circj.CJ-14-0474
966. Tonet JL, Castro-Miranda R, Iwa T, Poulain F, Frank R, Fontaine GH. Frequency of su­
praventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J 
Cardiol 1991;67:1153. https://doi.org/10.1016/0002-9149(91)90886-P
967. van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast 
JF, et al. Gender-specific differences in major cardiac events and mortality in lamin A/C 
mutation carriers. Eur J Heart Fail 2013;15:376–84. https://doi.org/10.1093/eurjhf/ 
hfs191
968. Aras D, Tufekcioglu O, Ergun K, Ozeke O, Yildiz A, Topaloglu S, et al. Clinical features 
of isolated ventricular noncompaction in adults long-term clinical course, echocardio­
graphic properties, and predictors of left ventricular failure. J Card Fail 2006;12: 
726–33. https://doi.org/10.1016/j.cardfail.2006.08.002
969. Li S, Zhang C, Liu N, Bai H, Hou C, Wang J, et al. Genotype-positive status is associated 
with poor prognoses in patients with left ventricular noncompaction cardiomyopathy. 
J Am Heart Assoc 2018;7:e009910. https://doi.org/10.1161/JAHA.118.009910
970. Stollberger C, Blazek G, Winkler-Dworak M, Finsterer J. Atrial fibrillation in left ven­
tricular noncompaction with and without neuromuscular disorders is associated 
with a poor prognosis. Int J Cardiol 2009;133:41–5. https://doi.org/10.1016/j.ijcard. 
2007.11.099
971. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense muta­
tions in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and 
conduction-system disease. N Engl J Med 1999;341:1715–24. https://doi.org/10.1056/ 
NEJM199912023412302
972. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation 
caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005;16:394–6. https://doi. 
org/10.1046/j.1540-8167.2005.40621.x
973. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, et al. High prevalence of 
long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial 
fibrillation. 
Circ 
Cardiovasc 
Genet 
2012;5:450–9. 
https://doi.org/10.1161/ 
CIRCGENETICS.111.962597
974. Pappone C, Radinovic A, Manguso F, Vicedomini G, Sala S, Sacco FM, et al. New-onset 
atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence 
and clinical significance. Eur Heart J 2009;30:2985–92. https://doi.org/10.1093/ 
eurheartj/ehp326
975. Peters S. Atrial arrhythmias in arrhythmogenic cardiomyopathy: at the beginning or at 
the end of the disease story? Circ J 2015;79:446. https://doi.org/10.1253/circj.CJ-14- 
1193
976. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical profile 
and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 
2017;136:2420–36. https://doi.org/10.1161/CIRCULATIONAHA.117.029267
ESC Guidelines                                                                                                                                                                                          3407


<!-- PAGE 95 -->

### Page 95

977. Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al. 
Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of ar­
rhythmic risk. J Am Coll Cardiol 2016;68:2540–50. https://doi.org/10.1016/j.jacc.2016. 
09.951
978. Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E, et al. Atrial 
fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, 
management, and correlation with prognosis. Heart Rhythm 2014;11:259–65. https:// 
doi.org/10.1016/j.hrthm.2013.10.043
979. Beckmann BM, Holinski-Feder E, Walter MC, Haserück N, Reithmann C, Hinterseer 
M, et al. Laminopathy presenting as familial atrial fibrillation. Int J Cardiol 2010;145: 
394–6. https://doi.org/10.1016/j.ijcard.2010.04.024
980. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecho­
laminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. 
J Cardiovasc Electrophysiol 2008;19:1319–21. https://doi.org/10.1111/j.1540-8167. 
2008.01211.x
981. Sugiyasu A, Oginosawa Y, Nogami A, Hata Y. A case with catecholaminergic poly­
morphic ventricular tachycardia unmasked after successful ablation of atrial tachycar­
dias from pulmonary veins. Pacing Clin Electrophysiol 2009;32:e21–4. https://doi.org/10. 
1111/j.1540-8159.2009.02519.x
982. Veltmann C, Kuschyk J, Schimpf R, Streitner F, Schoene N, Borggrefe M, et al. 
Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res 
Cardiol 2010;99:37–44. https://doi.org/10.1007/s00392-009-0075-4
983. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al. 2019 
ESC Guidelines for the management of patients with supraventricular tachycardia. The 
Task Force for the management of patients with supraventricular tachycardia of the 
European Society of Cardiology (ESC). Eur Heart J 2020;41:655–720. https://doi.org/ 
10.1093/eurheartj/ehz467
984. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fib­
rillation in the Wolff–Parkinson–White syndrome. N Engl J Med 1979;301:1080–5. 
https://doi.org/10.1056/NEJM197911153012003
985. Morady F, DiCarlo LA, Jr, Baerman JM, De Buitleir M. Effect of propranolol on ven­
tricular rate during atrial fibrillation in the Wolff–Parkinson–White syndrome. 
Pacing Clin Electrophysiol 1987;10:492–6. https://doi.org/10.1111/j.1540-8159.1987. 
tb04511.x
986. Sellers TD, Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. 
Analysis during atrial fibrillation. Circulation 1977;56:260–7. https://doi.org/10.1161/ 
01.CIR.56.2.260
987. Glatter KA, Dorostkar PC, Yang Y, Lee RJ, Van Hare GF, Keung E, et al. 
Electrophysiological effects of ibutilide in patients with accessory pathways. 
Circulation 2001;104:1933–9. https://doi.org/10.1161/hc4101.097538
988. Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in 
Wolff–Parkinson–White syndrome: electrophysiologic findings and long-term follow- 
up. J Am Coll Cardiol 1987;9:1357–63. https://doi.org/10.1016/S0735-1097(87)80478-3
989. Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodar­
one for rate control in Wolff–Parkinson–White and atrial fibrillation. Intern Emerg Med 
2010;5:421–6. https://doi.org/10.1007/s11739-010-0385-6
990. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 
44:3503–626. https://doi.org/10.1093/eurheartj/ehad194
991. Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, et al. Incident thromboembolism 
and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J 
Cardiol 2013;165:355–7. https://doi.org/10.1016/j.ijcard.2012.08.036
992. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. 
Anticoagulation strategies in patients with cancer: JACC review topic of the week. 
J Am Coll Cardiol 2019;73:1336–49. https://doi.org/10.1016/j.jacc.2019.01.017
993. Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, et al. Atrial fibril­
lation in patients with active malignancy and use of anticoagulants: under-prescription 
but no adverse impact on all-cause mortality. Eur J Intern Med 2019;59:27–33. https:// 
doi.org/10.1016/j.ejim.2018.10.012
994. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in 
cancer. J Am Coll Cardiol 2014;63:945–53. https://doi.org/10.1016/j.jacc.2013.11.026
995. Yun JP, Choi EK, Han KD, Park SH, Jung JH, Ahn HJ, et al. Risk of atrial fibrillation ac­
cording to cancer type: a nationwide population-based study. JACC CardioOncol 2021;3: 
221–32. https://doi.org/10.1016/j.jaccao.2021.03.006
996. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of 
anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigi­
lance database. Eur Heart J Cardiovasc Pharmacother 2021;7:312–20. https://doi.org/10. 
1093/ehjcvp/pvaa037
997. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al. Incidence, 
risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-medicare ana­
lysis. Eur Heart J 2022;43:300–12. https://doi.org/10.1093/eurheartj/ehab745
998. Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, et al. 
Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients 
with and without cancer: a nationwide cohort study. Cancer 2021;127:2122–9. 
https://doi.org/10.1002/cncr.33470
999. Aspberg S, Yu L, Gigante B, Smedby KE, Singer DE. Risk of ischemic stroke and major 
bleeding in patients with atrial fibrillation and cancer. J Stroke Cerebrovasc Dis 2020;29: 
104560. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104560
1000. D’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, et al. 
CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients 
with atrial fibrillation and recent cancer. Eur J Prev Cardiol 2018;25:651–8. https:// 
doi.org/10.1177/2047487318759858
1001. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al. 
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fib­
rillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care 
Clin Outcomes 2019;5:145–52. https://doi.org/10.1093/ehjqcco/qcy040
1002. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy 
and safety of apixaban versus warfarin in patients with atrial fibrillation and a history 
of cancer: insights from the ARISTOTLE trial. Am J Med 2017;130:1440–8.e1. https:// 
doi.org/10.1016/j.amjmed.2017.06.026
1003. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efficacy and safety 
of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the 
ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2018;7:e008987. https://doi.org/10. 
1161/JAHA.118.008987
1004. Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al. Superior 
safety of direct oral anticoagulants compared to warfarin in patients with atrial fibril­
lation and underlying cancer: a national veterans affairs database study. J Geriatr 
Cardiol 2019;16:706–9. https://doi.org/10.11909/j.issn.1671-5411.2019.09.006
1005. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative 
effectiveness of direct oral anticoagulants and warfarin in patients with cancer and 
atrial fibrillation. Blood Adv 2018;2:200–9. https://doi.org/10.1182/bloodadvances. 
2017010694
1006. Mariani MV, Magnocavallo M, Straito M, Piro A, Severino P, Iannucci G, et al. Direct 
oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and 
cancer a meta-analysis. J Thromb Thrombolysis 2021;51:419–29. https://doi.org/10. 
1007/s11239-020-02304-3
1007. Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al. 
Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation pa­
tients with active cancer. JACC CardioOncol 2021;3:411–24. https://doi.org/10.1016/j. 
jaccao.2021.06.004
1008. Lin YS, Kuan FC, Chao TF, Wu M, Chen SW, Chen MC, et al. Mortality associated 
with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: dabi­
gatran versus rivaroxaban. Cancer Med 2021;10:7079–88. https://doi.org/10.1002/ 
cam4.4241
1009. Atterman A, Asplund K, Friberg L, Engdahl J. Use of oral anticoagulants after ischae­
mic stroke in patients with atrial fibrillation and cancer. J Intern Med 2020;288: 
457–68. https://doi.org/10.1111/joim.13092
1010. Atterman A, Friberg L, Asplund K, Engdahl J. Net benefit of oral anticoagulants in pa­
tients with atrial fibrillation and active cancer: a nationwide cohort study. Europace 
2020;22:58–65. https://doi.org/10.1093/europace/euz306
1011. Falanga A, Leader A, Ambaglio C, Bagoly Z, Castaman G, Elalamy I, et al. EHA guide­
lines on management of antithrombotic treatments in thrombocytopenic patients 
with cancer. Hemasphere 2022;6:e750. https://doi.org/10.1097/HS9.00000000000 
00750
1012. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, 
et al. Cardio-oncology services: rationale, organization, and implementation. Eur 
Heart J 2019;40:1756–63. https://doi.org/10.1093/eurheartj/ehy453
1013. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in car­
diology: definition, assessment and clinical implications for general cardiology. A con­
sensus document of the Council for Cardiology Practice (CCP), Association for 
Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and 
Allied Professions (ACNAP), European Association of Preventive Cardiology 
(EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart 
Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology 
(CCO), Working Group (WG) aorta and peripheral vascular diseases, WG e-cardi­
ology, WG thrombosis, of the European Society of Cardiology, European Primary 
Care Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi. 
org/10.1093/eurjpc/zwaa167
1014. Proietti M, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, et al. Impact of clinical 
phenotypes on management and outcomes in European atrial fibrillation patients: a 
report from the ESC-EHRA EURObservational Research Programme in AF 
(EORP-AF) general long-term registry. BMC Med 2021;19:256. https://doi.org/10. 
1186/s12916-021-02120-3
1015. Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, et al. Epidemiology 
and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022;51: 
afac192. https://doi.org/10.1093/ageing/afac192
1016. Savelieva I, Fumagalli S, Kenny RA, Anker S, Benetos A, Boriani G, et al. EHRA expert 
consensus document on the management of arrhythmias in frailty syndrome, en­
dorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society 
(APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia


<!-- PAGE 96 -->

### Page 96

Society of Southern Africa (CASSA). Europace 2023;25:1249–76. https://doi.org/10. 
1093/europace/euac123
1017. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 
2013;381:752–62. https://doi.org/10.1016/S0140-6736(12)62167-9
1018. Villani ER, Tummolo AM, Palmer K, Gravina EM, Vetrano DL, Bernabei R, et al. Frailty 
and atrial fibrillation: a systematic review. Eur J Intern Med 2018;56:33–8. https://doi. 
org/10.1016/j.ejim.2018.04.018
1019. Hang F, Chen J, Wang Z, Yan J, Wu Y. Association between the frailty and new-onset 
atrial fibrillation/flutter among elderly hypertensive patients. Front Cardiovasc Med 
2022;9:881946. https://doi.org/10.3389/fcvm.2022.881946
1020. Steinberg BA, Holmes DN, Ezekowitz MD, Fonarow GC, Kowey PR, Mahaffey KW, 
et al. Rate versus rhythm control for management of atrial fibrillation in clinical prac­
tice: results from the Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation (ORBIT-AF) registry. Am Heart J 2013;165:622–9. https://doi.org/10. 
1016/j.ahj.2012.12.019
1021. Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, et al. Trends in use of oral 
anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010–2020. 
JAMA Netw Open 2022;5:e2242964. https://doi.org/10.1001/jamanetworkopen. 
2022.42964
1022. Bul M, Shaikh F, McDonagh J, Ferguson C. Frailty and oral anticoagulant prescription 
in adults with atrial fibrillation: a systematic review. Aging Med (Milton) 2023;6: 
195–206. https://doi.org/10.1002/agm2.12214
1023. Hu J, Zhou Y, Cai Z. Outcome of novel oral anticoagulant versus warfarin in frail eld­
erly patients with atrial fibrillation: a systematic review and meta-analysis of retro­
spective studies. Acta Clin Belg 2023;78:367–77. https://doi.org/10.1080/17843286. 
2023.2179908
1024. Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. 
warfarin in patients with atrial fibrillation and frailty: a systematic review and 
meta-analysis. Front Cardiovasc Med 2022;9:907197. https://doi.org/10.3389/fcvm. 
2022.907197
1025. Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. Impact of frailty 
on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants 
(NOACs) in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 
Qual Care Clin Outcomes 2024;10:55–65. https://doi.org/10.1093/ehjqcco/qcad019
1026. Kim D, Yang PS, Sung JH, Jang E, Yu HT, Kim TH, et al. Effectiveness and safety of an­
ticoagulation therapy in frail patients with atrial fibrillation. Stroke 2022;53:1873–82. 
https://doi.org/10.1161/STROKEAHA.121.036757
1027. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very 
elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018; 
138:37–47. https://doi.org/10.1161/CIRCULATIONAHA.117.031658
1028. Da Costa A, Thévenin J, Roche F, Romeyer-Bouchard C, Abdellaoui L, Messier M, 
et al. Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on 
atrial flutter, a multicentric prospective randomized study comparing amiodarone 
and radiofrequency ablation after the first episode of symptomatic atrial flutter. 
Circulation 2006;114:1676–81. https://doi.org/10.1161/CIRCULATIONAHA.106. 
638395
1029. Natale A, Newby KH, Pisano E, Leonelli F, Fanelli R, Potenza D, et al. Prospective ran­
domized comparison of antiarrhythmic therapy versus first-line radiofrequency abla­
tion in patients with atrial flutter. J Am Coll Cardiol 2000;35:1898–904. https://doi.org/ 
10.1016/S0735-1097(00)00635-5
1030. Chinitz JS, Gerstenfeld EP, Marchlinski FE, Callans DJ. Atrial fibrillation is common 
after ablation of isolated atrial flutter during long-term follow-up. Heart Rhythm 
2007;4:1029–33. https://doi.org/10.1016/j.hrthm.2007.04.002
1031. De Bortoli A, Shi LB, Ohm OJ, Hoff PI, Schuster P, Solheim E, et al. Incidence and clin­
ical predictors of subsequent atrial fibrillation requiring additional ablation after cavo­
tricuspid isthmus ablation for typical atrial flutter. Scand Cardiovasc J 2017;51:123–8. 
https://doi.org/10.1080/14017431.2017.1304570
1032. Rahman F, Wang N, Yin X, Ellinor PT, Lubitz SA, LeLorier PA, et al. Atrial flutter: clin­
ical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm 
2016;13:233–40. https://doi.org/10.1016/j.hrthm.2015.07.031
1033. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. 
Global burden of cardiovascular diseases and risk factors, 1990–2019: update from 
the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. https://doi.org/10. 
1016/j.jacc.2020.11.010
1034. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an 
increasing epidemic and public health challenge. Int J Stroke 2021;16:217–21. 
https://doi.org/10.1177/1747493019897870
1035. Alonso A, Alam AB, Kamel H, Subbian V, Qian J, Boerwinkle E, et al. Epidemiology of 
atrial fibrillation in the all of US research program. PLoS One 2022;17:e0265498. 
https://doi.org/10.1371/journal.pone.0265498
1036. Ghelani KP, Chen LY, Norby FL, Soliman EZ, Koton S, Alonso A. Thirty-year trends in 
the incidence of atrial fibrillation: the ARIC study. J Am Heart Assoc 2022;11:e023583. 
https://doi.org/10.1161/JAHA.121.023583
1037. Williams BA, Chamberlain AM, Blankenship JC, Hylek EM, Voyce S. Trends in atrial 
fibrillation incidence rates within an integrated health care delivery system, 2006 to 
2018. JAMA Netw Open 2020;3:e2014874. https://doi.org/10.1001/jamanetwork 
open.2020.14874
1038. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I, et al. Sex 
differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality 
in community cohorts: results from the BiomarCaRE consortium (Biomarker for 
Cardiovascular Risk Assessment in Europe). Circulation 2017;136:1588–97. https:// 
doi.org/10.1161/CIRCULATIONAHA.117.028981
1039. Rodriguez CJ, Soliman EZ, Alonso A, Swett K, Okin PM, Goff DC, Jr, et al. Atrial fib­
rillation incidence and risk factors in relation to race-ethnicity and the population at­
tributable fraction of atrial fibrillation risk factors: the multi-ethnic study of 
atherosclerosis. Ann Epidemiol 2015;25:71–6, 76.e1. https://doi.org/10.1016/j. 
annepidem.2014.11.024
1040. Ugowe FE, Jackson LR, 2nd, Thomas KL. Racial and ethnic differences in the preva­
lence, management, and outcomes in patients with atrial fibrillation: a systematic re­
view. Heart Rhythm 2018;15:1337–45. https://doi.org/10.1016/j.hrthm.2018.05.019
1041. Volgman AS, Bairey Merz CN, Benjamin EJ, Curtis AB, Fang MC, Lindley KJ, et al. Sex 
and race/ethnicity differences in atrial fibrillation. J Am Coll Cardiol 2019;74:2812–5. 
https://doi.org/10.1016/j.jacc.2019.09.045
1042. Chung SC, Sofat R, Acosta-Mena D, Taylor JA, Lambiase PD, Casas JP, et al. Atrial 
fibrillation epidemiology, disparity and healthcare contacts: a population-wide study 
of 5.6 million individuals. Lancet Reg Health Eur 2021;7:100157. https://doi.org/10. 
1016/j.lanepe.2021.100157
1043. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, et al. How to use 
digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace 
2022;24:979–1005. https://doi.org/10.1093/europace/euac038
1044. Spatz ES, Ginsburg GS, Rumsfeld JS, Turakhia MP. Wearable digital health technolo­
gies for monitoring in cardiovascular medicine. N Engl J Med 2024;390:346–56. 
https://doi.org/10.1056/NEJMra2301903
1045. Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation? 
A systematic review. J Fam Pract 2006;55:130–4.
1046. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, 
et al. An artificial intelligence-enabled ECG algorithm for the identification of patients 
with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome predic­
tion. Lancet 2019;394:861–7. https://doi.org/10.1016/S0140-6736(19)31721-0
1047. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised 
controlled trial and cost-effectiveness study of systematic screening (targeted and to­
tal population screening) versus routine practice for the detection of atrial fibrillation 
in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii–iv, ix-x, 
1–74. https://doi.org/10.3310/hta9400
1048. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, et al. Improved detec­
tion of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic 
stroke: a prospective multicenter cohort study. Stroke 2013;44:3357–64. https:// 
doi.org/10.1161/STROKEAHA.113.001884
1049. Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, et al. Continuous 
stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiog­
raphy for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012;43: 
2689–94. https://doi.org/10.1161/STROKEAHA.112.654954
1050. Doliwa PS, Frykman V, Rosenqvist M. Short-term ECG for out of hospital detection 
of silent atrial fibrillation episodes. Scand Cardiovasc J 2009;43:163–8. https://doi.org/ 
10.1080/14017430802593435
1051. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, et al. Validation 
and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 
2014;16:1291–5. https://doi.org/10.1093/europace/euu057
1052. Kearley K, Selwood M, Van den Bruel A, Thompson M, Mant D, Hobbs FR, et al. 
Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy 
study comparing single-lead ECG and modified BP monitors. BMJ Open 2014;4: 
e004565. https://doi.org/10.1136/bmjopen-2013-004565
1053. Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, et al. Comparison 
of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic 
monitoring. Am J Med 2014;127:95.e11–7. https://doi.org/10.1016/j.amjmed.2013.10. 
003
1054. Turakhia MP, Hoang DD, Zimetbaum P, Miller JD, Froelicher VF, Kumar UN, et al. 
Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol 
2013;112:520–4. https://doi.org/10.1016/j.amjcard.2013.04.017
1055. Rosenberg MA, Samuel M, Thosani A, Zimetbaum PJ. Use of a noninvasive continu­
ous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin 
Electrophysiol 2013;36:328–33. https://doi.org/10.1111/pace.12053
1056. Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, et al. Feasibility of 
extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation 
in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation 
(STUDY-AF). Clin Cardiol 2015;38:285–92. https://doi.org/10.1002/clc.22387
1057. Rooney MR, Soliman EZ, Lutsey PL, Norby FL, Loehr LR, Mosley TH, et al. Prevalence 
and characteristics of subclinical atrial fibrillation in a community-dwelling elderly 
population: the ARIC study. Circ Arrhythm Electrophysiol 2019;12:e007390. https:// 
doi.org/10.1161/CIRCEP.119.007390
ESC Guidelines                                                                                                                                                                                          3409


<!-- PAGE 97 -->

### Page 97

1058. Stehlik J, Schmalfuss C, Bozkurt B, Nativi-Nicolau J, Wohlfahrt P, Wegerich S, et al. 
Continuous wearable monitoring analytics predict heart failure hospitalization: the 
LINK-HF multicenter study. Circ Heart Fail 2020;13:e006513. https://doi.org/10. 
1161/CIRCHEARTFAILURE.119.006513
1059. Ganne C, Talkad SN, Srinivas D, Somanna S. Ruptured blebs and racing hearts: auto­
nomic cardiac changes in neurosurgeons during microsurgical clipping of aneurysms. 
Br J Neurosurg 2016;30:450–2. https://doi.org/10.3109/02688697.2016.1159656
1060. Smith WM, Riddell F, Madon M, Gleva MJ. Comparison of diagnostic value using a 
small, single channel, P-wave centric sternal ECG monitoring patch with a standard 
3-lead Holter system over 24 hours. Am Heart J 2017;185:67–73. https://doi.org/ 
10.1016/j.ahj.2016.11.006
1061. Olson JA, Fouts AM, Padanilam BJ, Prystowsky EN. Utility of mobile cardiac out­
patient telemetry for the diagnosis of palpitations, presyncope, syncope, and the as­
sessment of therapy efficacy. J Cardiovasc Electrophysiol 2007;18:473–7. https://doi. 
org/10.1111/j.1540-8167.2007.00779.x
1062. Derkac WM, Finkelmeier JR, Horgan DJ, Hutchinson MD. Diagnostic yield of asymp­
tomatic arrhythmias detected by mobile cardiac outpatient telemetry and autotrigger 
looping event cardiac monitors. J Cardiovasc Electrophysiol 2017;28:1475–8. https:// 
doi.org/10.1111/jce.13342
1063. Teplitzky BA, McRoberts M, Ghanbari H. Deep learning for comprehensive ECG an­
notation. Heart Rhythm 2020;17:881–8. https://doi.org/10.1016/j.hrthm.2020.02.015
1064. Jeon E, Oh K, Kwon S, Son H, Yun Y, Jung ES, et al. A lightweight deep learning model 
for fast electrocardiographic beats classification with a wearable cardiac monitor: de­
velopment and validation study. JMIR Med Inform 2020;8:e17037. https://doi.org/10. 
2196/17037
1065. Breteler MJMM, Huizinga E, van Loon K, Leenen LPH, Dohmen DAJ, Kalkman CJ, et al. 
Reliability of wireless monitoring using a wearable patch sensor in high-risk surgical 
patients at a step-down unit in The Netherlands: a clinical validation study. BMJ 
Open 2018;8:e020162. https://doi.org/10.1136/bmjopen-2017-020162
1066. Hopkins L, Stacey B, Robinson DBT, James OP, Brown C, Egan RJ, et al. 
Consumer-grade biosensor validation for examining stress in healthcare profes­
sionals. Physiol Rep 2020;8:e14454. https://doi.org/10.14814/phy2.14454
1067. Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect 
of a home-based wearable continuous ECG monitoring patch on detection of undiag­
nosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA 2018;320: 
146–55. https://doi.org/10.1001/jama.2018.8102
1068. Elliot CA, Hamlin MJ, Lizamore CA. Validity and reliability of the hexoskin wearable 
biometric vest during maximal aerobic power testing in elite cyclists. J Strength Cond 
Res 2019;33:1437–44. https://doi.org/10.1519/JSC.0000000000002005
1069. Eysenck W, Freemantle N, Sulke N. A randomized trial evaluating the accuracy of AF 
detection by four external ambulatory ECG monitors compared to permanent pace­
maker AF detection. J Interv Card Electrophysiol 2020;57:361–9. https://doi.org/10. 
1007/s10840-019-00515-0
1070. Fabregat-Andres O, Munoz-Macho A, Adell-Beltran G, Ibanez-Catala X, Macia A, 
Facila L. Evaluation of a new shirt-based electrocardiogram device for cardiac screen­
ing in soccer players: comparative study with treadmill ergospirometry. Cardiol Res 
2014;5:101–7. https://doi.org/10.14740/cr333w
1071. Feito Y, Moriarty TA, Mangine G, Monahan J. The use of a smart-textile garment dur­
ing high-intensity functional training: a pilot study. J Sports Med Phys Fitness 2019;59: 
947–54. https://doi.org/10.23736/S0022-4707.18.08689-9
1072. Pagola J, Juega J, Francisco-Pascual J, Moya A, Sanchis M, Bustamante A, et al. Yield of 
atrial fibrillation detection with textile wearable Holter from the acute phase of 
stroke: pilot study of crypto-AF registry. Int J Cardiol 2018;251:45–50. https://doi. 
org/10.1016/j.ijcard.2017.10.063
1073. Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, et al. iphone ECG 
application for community screening to detect silent atrial fibrillation: a novel technol­
ogy to prevent stroke. Int J Cardiol 2013;165:193–4. https://doi.org/10.1016/j.ijcard. 
2013.01.220
1074. Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, et al. 
Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol 
2018;71:2381–8. https://doi.org/10.1016/j.jacc.2018.03.003
1075. Lubitz SA, Faranesh AZ, Atlas SJ, McManus DD, Singer DE, Pagoto S, et al. Rationale 
and design of a large population study to validate software for the assessment of atrial 
fibrillation from data acquired by a consumer tracker or smartwatch: the Fitbit heart 
study. Am Heart J 2021;238:16–26. https://doi.org/10.1016/j.ahj.2021.04.003
1076. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale 
assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 2019;381: 
1909–17. https://doi.org/10.1056/NEJMoa1901183
1077. Saghir N, Aggarwal A, Soneji N, Valencia V, Rodgers G, Kurian T. A comparison of 
manual electrocardiographic interval and waveform analysis in lead 1 of 12-lead 
ECG and apple watch ECG: a validation study. Cardiovasc Digit Health J 2020;1: 
30–6. https://doi.org/10.1016/j.cvdhj.2020.07.002
1078. Seshadri DR, Bittel B, Browsky D, Houghtaling P, Drummond CK, Desai MY, et al. 
Accuracy of apple watch for detection of atrial fibrillation. Circulation 2020;141: 
702–3. https://doi.org/10.1161/CIRCULATIONAHA.119.044126
1079. Zhang H, Zhang J, Li HB, Chen YX, Yang B, Guo YT, et al. Validation of single centre 
pre-mobile atrial fibrillation apps for continuous monitoring of atrial fibrillation in a 
real-world setting: pilot cohort study. J Med Internet Res 2019;21:e14909. https:// 
doi.org/10.2196/14909
1080. Fan YY, Li YG, Li J, Cheng WK, Shan ZL, Wang YT, et al. Diagnostic performance of a 
smart device with photoplethysmography technology for atrial fibrillation detection: 
pilot study (Pre-mAFA II registry). JMIR Mhealth Uhealth 2019;7:e11437. https://doi. 
org/10.2196/11437
1081. Brito R, Mondouagne LP, Stettler C, Combescure C, Burri H. Automatic atrial fibril­
lation and flutter detection by a handheld ECG recorder, and utility of sequential fin­
ger and precordial recordings. J Electrocardiol 2018;51:1135–40. https://doi.org/10. 
1016/j.jelectrocard.2018.10.093
1082. Desteghe L, Raymaekers Z, Lutin M, Vijgen J, Dilling-Boer D, Koopman P, et al. 
Performance of handheld electrocardiogram devices to detect atrial fibrillation in a 
cardiology and geriatric ward setting. Europace 2017;19:29–39. https://doi.org/10. 
1093/europace/euw025
1083. Nigolian A, Dayal N, Nigolian H, Stettler C, Burri H. Diagnostic accuracy of multi-lead 
ECGs obtained using a pocket-sized bipolar handheld event recorder. J Electrocardiol 
2018;51:278–81. https://doi.org/10.1016/j.jelectrocard.2017.11.004
1084. Magnusson P, Lyren A, Mattsson G. Diagnostic yield of chest and thumb ECG after 
cryptogenic stroke, Transient ECG Assessment in Stroke Evaluation (TEASE): an ob­
servational trial. BMJ Open 2020;10:e037573. https://doi.org/10.1136/bmjopen-2020- 
037573
1085. Carnlöf C, Schenck-Gustafsson K, Jensen-Urstad M, Insulander P. Instant electrocar­
diogram feedback with a new digital technique reduces symptoms caused by palpita­
tions and increases health-related quality of life (the RedHeart study). Eur J Cardiovasc 
Nurs 2021;20:402–10. https://doi.org/10.1093/eurjcn/zvaa031
1086. Haverkamp HT, Fosse SO, Schuster P. Accuracy and usability of single-lead ECG from 
smartphones—a clinical study. Indian Pacing Electrophysiol J 2019;19:145–9. https:// 
doi.org/10.1016/j.ipej.2019.02.006
1087. Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, et al. Screening for 
cardiac contractile dysfunction using an artificial intelligence-enabled electrocardio­
gram. Nat Med 2019;25:70–4. https://doi.org/10.1038/s41591-018-0240-2
1088. Bekker CL, Noordergraaf F, Teerenstra S, Pop G, van den Bemt BJF. Diagnostic ac­
curacy of a single-lead portable ECG device for measuring QTc prolongation. Ann 
Noninvasive Electrocardiol 2020;25:e12683. https://doi.org/10.1111/anec.12683
1089. Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, et al. 
Prospective, multicentre validation of a simple, patient-operated electrocardiograph­
ic system for the detection of arrhythmias and electrocardiographic changes. 
Europace 2009;11:1362–8. https://doi.org/10.1093/europace/eup262
1090. Guan J, Wang A, Song W, Obore N, He P, Fan S, et al. Screening for arrhythmia with 
the new portable single-lead electrocardiographic device (SnapECG): an application 
study in community-based elderly population in Nanjing, China. Aging Clin Exp Res 
2021;33:133–40. https://doi.org/10.1007/s40520-020-01512-4
1091. Svennberg E, Stridh M, Engdahl J, Al-Khalili F, Friberg L, Frykman V, et al. Safe auto­
matic one-lead electrocardiogram analysis in screening for atrial fibrillation. 
Europace 2017;19:1449–53. https://doi.org/10.1093/europace/euw286
1092. Musat DL, Milstein N, Mittal S. Implantable loop recorders for cryptogenic stroke 
(plus real-world atrial fibrillation detection rate with implantable loop recorders). 
Card Electrophysiol Clin 2018;10:111–8. https://doi.org/10.1016/j.ccep.2017.11.011
1093. Sakhi R, Theuns D, Szili-Torok T, Yap SC. Insertable cardiac monitors: current indica­
tions and devices. Expert Rev Med Devices 2019;16:45–55. https://doi.org/10.1080/ 
17434440.2018.1557046
1094. Tomson TT, Passman R. The reveal LINQ insertable cardiac monitor. Expert Rev Med 
Devices 2015;12:7–18. https://doi.org/10.1586/17434440.2014.953059
1095. Ciconte G, Saviano M, Giannelli L, Calovic Z, Baldi M, Ciaccio C, et al. Atrial fibrillation 
detection using a novel three-vector cardiac implantable monitor: the atrial fibrilla­
tion detect study. Europace 2017;19:1101–8. https://doi.org/10.1093/europace/ 
euw181
1096. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, et al. 
Performance of a new leadless implantable cardiac monitor in detecting and quanti­
fying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3: 
141–7. https://doi.org/10.1161/CIRCEP.109.877852
1097. Mittal S, Rogers J, Sarkar S, Koehler J, Warman EN, Tomson TT, et al. Real-world per­
formance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac 
monitor. Heart Rhythm 2016;13:1624–30. https://doi.org/10.1016/j.hrthm.2016.05. 
010
1098. Nölker G, Mayer J, Boldt LH, Seidl K VVAND, Massa T, Kollum M, et al. Performance 
of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT 
AF study. J Cardiovasc Electrophysiol 2016;27:1403–10. https://doi.org/10.1111/jce. 
13089
1099. Sanders P, Pürerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, et al. 
Performance of a new atrial fibrillation detection algorithm in a miniaturized insert­
able cardiac monitor: results from the reveal LINQ usability study. Heart Rhythm 
2016;13:1425–30. https://doi.org/10.1016/j.hrthm.2016.03.005


<!-- PAGE 98 -->

### Page 98

1100. Chan PH, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, et al. Diagnostic per­
formance of a smartphone-based photoplethysmographic application for atrial fibril­
lation screening in a primary care setting. J Am Heart Assoc 2016;5:e003428. https:// 
doi.org/10.1161/JAHA.116.003428
1101. Mc MD, Chong JW, Soni A, Saczynski JS, Esa N, Napolitano C, et al. PULSE-SMART: 
pulse-based arrhythmia discrimination using a novel smartphone application. 
J Cardiovasc Electrophysiol 2016;27:51–7. https://doi.org/10.1111/jce.12842
1102. Proesmans T, Mortelmans C, Van Haelst R, Verbrugge F, Vandervoort P, Vaes B. 
Mobile phone-based use of the photoplethysmography technique to detect atrial fib­
rillation in primary care: diagnostic accuracy study of the FibriCheck app. JMIR 
Mhealth Uhealth 2019;7:e12284. https://doi.org/10.2196/12284
1103. Rozen G, Vaid J, Hosseini SM, Kaadan MI, Rafael A, Roka A, et al. Diagnostic accuracy 
of a novel mobile phone application for the detection and monitoring of atrial fibril­
lation. Am J Cardiol 2018;121:1187–91. https://doi.org/10.1016/j.amjcard.2018.01.035
1104. O’Sullivan JW, Grigg S, Crawford W, Turakhia MP, Perez M, Ingelsson E, et al. 
Accuracy of smartphone camera applications for detecting atrial fibrillation: a system­
atic review and meta-analysis. JAMA Netw Open 2020;3:e202064. https://doi.org/10. 
1001/jamanetworkopen.2020.2064
1105. Koenig N, Seeck A, Eckstein J, Mainka A, Huebner T, Voss A, et al. Validation of a new 
heart rate measurement algorithm for fingertip recording of video signals with smart­
phones. Telemed J E Health 2016;22:631–6. https://doi.org/10.1089/tmj.2015.0212
1106. Krivoshei L, Weber S, Burkard T, Maseli A, Brasier N, Kühne M, et al. Smart detection 
of atrial fibrillation†. Europace 2017;19:753–7. https://doi.org/10.1093/europace/ 
euw125
1107. Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial fibrillation using a 
modified microlife blood pressure monitor. Am J Hypertens 2009;22:848–52. 
https://doi.org/10.1038/ajh.2009.98
1108. Chen Y, Lei L, Wang JG. Atrial fibrillation screening during automated blood pressure 
measurement—comment on “diagnostic accuracy of new algorithm to detect atrial 
fibrillation in a home blood pressure monitor”. J Clin Hypertens (Greenwich) 2017;19: 
1148–51. https://doi.org/10.1111/jch.13081
1109. Kane SA, Blake JR, McArdle FJ, Langley P, Sims AJ. Opportunistic detection of atrial 
fibrillation using blood pressure monitors: a systematic review. Open Heart 2016;3: 
e000362. https://doi.org/10.1136/openhrt-2015-000362
1110. Kario K. Evidence and perspectives on the 24-hour management of hypertension: 
hemodynamic biomarker-initiated ‘anticipation medicine’ for zero cardiovascular 
event. Prog Cardiovasc Dis 2016;59:262–81. https://doi.org/10.1016/j.pcad.2016.04. 
001
1111. Jaakkola J, Jaakkola S, Lahdenoja O, Hurnanen T, Koivisto T, Pänkäälä M, et al. Mobile 
phone detection of atrial fibrillation with mechanocardiography: the MODE-AF study 
(mobile phone detection of atrial fibrillation). Circulation 2018;137:1524–7. https:// 
doi.org/10.1161/CIRCULATIONAHA.117.032804
1112. Couderc JP, Kyal S, Mestha LK, Xu B, Peterson DR, Xia X, et al. Detection of atrial 
fibrillation using contactless facial video monitoring. Heart Rhythm 2015;12: 
195–201. https://doi.org/10.1016/j.hrthm.2014.08.035
1113. Yan BP, Lai WHS, Chan CKY, Au ACK, Freedman B, Poh YC, et al. High-throughput, 
contact-free detection of atrial fibrillation from video with deep learning. JAMA Cardiol 
2020;5:105–7. https://doi.org/10.1001/jamacardio.2019.4004
1114. Yan BP, Lai WHS, Chan CKY, Chan SC, Chan LH, Lam KM, et al. Contact-free screen­
ing of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic 
signals. J Am Heart Assoc 2018;7:e008585. https://doi.org/10.1161/JAHA.118.008585
1115. Tsouri GR, Li Z. On the benefits of alternative color spaces for noncontact heart rate 
measurements using standard red-green-blue cameras. J Biomed Opt 2015;20: 
048002. https://doi.org/10.1117/1.JBO.20.4.048002
1116. Chan J, Rea T, Gollakota S, Sunshine JE. Contactless cardiac arrest detection using 
smart devices. NPJ Digit Med 2019;2:52. https://doi.org/10.1038/s41746-019-0128-7
1117. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile photoplethysmographic 
technology to detect atrial fibrillation. J Am Coll Cardiol 2019;74:2365–75. https://doi. 
org/10.1016/j.jacc.2019.08.019
1118. Lubitz SA, Faranesh AZ, Selvaggi C, Atlas SJ, McManus DD, Singer DE, et al. Detection 
of atrial fibrillation in a large population using wearable devices: the Fitbit heart study. 
Circulation 2022;146:1415–24. https://doi.org/10.1161/CIRCULATIONAHA.122. 
060291
1119. Lopez Perales CR, Van Spall HGC, Maeda S, Jimenez A, Laţcu DG, Milman A, et al. 
Mobile health applications for the detection of atrial fibrillation: a systematic review. 
Europace 2021;23:11–28. https://doi.org/10.1093/europace/euaa139
1120. Gill S, Bunting KV, Sartini C, Cardoso VR, Ghoreishi N, Uh HW, et al. Smartphone 
detection of atrial fibrillation using photoplethysmography: a systematic review and 
meta-analysis. 
Heart 
2022;108:1600–7. 
https://doi.org/10.1136/heartjnl-2021- 
320417
1121. Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, et al. Accuracy of 
diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and 
interpretative diagnostic software: analysis of data from screening for atrial fibrillation 
in the elderly (SAFE) trial. BMJ 2007;335:380. https://doi.org/10.1136/bmj.39227. 
551713.AE
1122. Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment 
of remote heart rhythm sampling using the AliveCor heart monitor to screen for at­
rial fibrillation: the REHEARSE-AF study. Circulation 2017;136:1784–94. https://doi. 
org/10.1161/CIRCULATIONAHA.117.030583
1123. Duarte R, Stainthorpe A, Greenhalgh J, Richardson M, Nevitt S, Mahon J, et al. Lead-I 
ECG for detecting atrial fibrillation in patients with an irregular pulse using single time 
point testing: a systematic review and economic evaluation. Health Technol Assess 
2020;24:1–164. https://doi.org/10.3310/hta24030
1124. Mannhart D, Lischer M, Knecht S, du Fay de Lavallaz J, Strebel I, Serban T, et al. Clinical 
validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: 
BASEL wearable study. JACC Clin Electrophysiol 2023;9:232–42. https://doi.org/10. 
1016/j.jacep.2022.09.011
1125. Paul Nordin A, Carnlöf C, Insulander P, Mohammad Ali A, Jensen-Urstad M, Saluveer 
O, et al. Validation of diagnostic accuracy of a handheld, smartphone-based rhythm 
recording device. Expert Rev Med Devices 2023;20:55–61. https://doi.org/10.1080/ 
17434440.2023.2171290
1126. Gill SK, Barsky A, Guan X, Bunting KV, Karwath A, Tica O, et al. Consumer wearable 
devices to evaluate dynamic heart rate with digoxin versus beta-blockers: the 
RATE-AF randomised trial. Nat Med 2024;30:2030–2036. https://doi.org/10.1038/ 
s41591-024-03094-4.
1127. Kahwati LC, Asher GN, Kadro ZO, Keen S, Ali R, Coker-Schwimmer E, et al. 
Screening for atrial fibrillation: updated evidence report and systematic review for 
the US preventive services task force. JAMA 2022;327:368–83. https://doi.org/10. 
1001/jama.2021.21811
1128. Strong K, Wald N, Miller A, Alwan A. Current concepts in screening for noncommu­
nicable disease: World Health Organization Consultation Group Report on method­
ology of noncommunicable disease screening. J Med Screen 2005;12:12–9. https://doi. 
org/10.1258/0969141053279086
1129. Whitfield R, Ascenção R, da Silva GL, Almeida AG, Pinto FJ, Caldeira D. Screening 
strategies for atrial fibrillation in the elderly population: a systematic review and net­
work meta-analysis. Clin Res Cardiol 2023;112:705–15. https://doi.org/10.1007/ 
s00392-022-02117-9
1130. Proietti M, Romiti GF, Vitolo M, Borgi M, Rocco AD, Farcomeni A, et al. Epidemiology 
of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a 
systematic review and meta-regression. Eur J Intern Med 2022;103:84–94. https://doi. 
org/10.1016/j.ejim.2022.06.023
1131. Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ, et al. Subclinical atrial 
fibrillation in older patients. Circulation 2017;136:1276–83. https://doi.org/10.1161/ 
CIRCULATIONAHA.117.028845
1132. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR, et al. Duration of 
device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur 
Heart J 2017;38:1339–44. https://doi.org/10.1093/eurheartj/ehx042
1133. Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, Al-Khalili F, Friberg L, Frykman 
V, et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natri­
uretic peptide: the STROKESTOP II study. Europace 2020;22:24–32. https://doi.org/ 
10.1093/europace/euz255
1134. Williams K, Modi RN, Dymond A, Hoare S, Powell A, Burt J, et al. Cluster randomised 
controlled trial of screening for atrial fibrillation in people aged 70 years and over to 
reduce stroke: protocol for the pilot study for the SAFER trial. BMJ Open 2022;12: 
e065066. https://doi.org/10.1136/bmjopen-2022-065066
1135. Elbadawi A, Sedhom R, Gad M, Hamed M, Elwagdy A, Barakat AF, et al. Screening for 
atrial fibrillation in the elderly: a network meta-analysis of randomized trials. Eur J 
Intern Med 2022;105:38–45. https://doi.org/10.1016/j.ejim.2022.07.015
1136. McIntyre WF, Diederichsen SZ, Freedman B, Schnabel RB, Svennberg E, Healey JS. 
Screening for atrial fibrillation to prevent stroke: a meta-analysis. Eur Heart J Open 
2022;2:oeac044. https://doi.org/10.1093/ehjopen/oeac044
1137. Lyth J, Svennberg E, Bernfort L, Aronsson M, Frykman V, Al-Khalili F, et al. 
Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP 
study. Eur Heart J 2023;44:196–204. https://doi.org/10.1093/eurheartj/ehac547
1138. Lubitz SA, Atlas SJ, Ashburner JM, Lipsanopoulos ATT, Borowsky LH, Guan W, et al. 
Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF rando­
mized controlled trial. Circulation 2022;145:946–54. https://doi.org/10.1161/ 
CIRCULATIONAHA.121.057014
1139. Uittenbogaart SB, Verbiest-van Gurp N, Lucassen WAM, Winkens B, Nielen M, 
Erkens PMG, et al. Opportunistic screening versus usual care for detection of atrial 
fibrillation in primary care: cluster randomised controlled trial. BMJ 2020;370: 
m3208. https://doi.org/10.1136/bmj.m3208
1140. Kaasenbrood F, Hollander M, de Bruijn SH, Dolmans CP, Tieleman RG, Hoes AW, 
et al. Opportunistic screening versus usual care for diagnosing atrial fibrillation in gen­
eral practice: a cluster randomised controlled trial. Br J Gen Pract 2020;70:e427–33. 
https://doi.org/10.3399/bjgp20X708161
1141. Petryszyn P, Niewinski P, Staniak A, Piotrowski P, Well A, Well M, et al. Effectiveness 
of screening for atrial fibrillation and its determinants. A meta-analysis. PLoS One 
2019;14:e0213198. https://doi.org/10.1371/journal.pone.0213198
ESC Guidelines                                                                                                                                                                                          3411


<!-- PAGE 99 -->

### Page 99

### 1142 Wang Q, Richardson TG, Sanderson E, Tudball MJ, Ala-Korpela M, Davey Smith G,

et al. A phenome-wide bidirectional Mendelian randomization analysis of atrial fibril­
lation. Int J Epidemiol 2022;51:1153–66. https://doi.org/10.1093/ije/dyac041
1143. Siddiqi HK, Vinayagamoorthy M, Gencer B, Ng C, Pester J, Cook NR, et al. Sex differ­
ences in atrial fibrillation risk: the VITAL rhythm study. JAMA Cardiol 2022;7:1027–35. 
https://doi.org/10.1001/jamacardio.2022.2825
1144. Lu Z, Aribas E, Geurts S, Roeters van Lennep JE, Ikram MA, Bos MM, et al. Association 
between sex-specific risk factors and risk of new-onset atrial fibrillation among wo­
men. JAMA Netw Open 2022;5:e2229716. https://doi.org/10.1001/jamanetworkopen. 
2022.29716
1145. Wong GR, Nalliah CJ, Lee G, Voskoboinik A, Chieng D, Prabhu S, et al. Sex-related 
differences in atrial remodeling in patients with atrial fibrillation: relationship to abla­
tion outcomes. Circ Arrhythm Electrophysiol 2022;15:e009925. https://doi.org/10. 
1161/CIRCEP.121.009925
1146. Mokgokong R, Schnabel R, Witt H, Miller R, Lee TC. Performance of an electronic 
health record-based predictive model to identify patients with atrial fibrillation across 
countries. PLoS One 2022;17:e0269867. https://doi.org/10.1371/journal.pone. 
0269867
1147. Schnabel RB, Witt H, Walker J, Ludwig M, Geelhoed B, Kossack N, et al. Machine 
learning-based identification of risk-factor signatures for undiagnosed atrial fibrillation 
in primary prevention and post-stroke in clinical practice. Eur Heart J Qual Care Clin 
Outcomes 2022;9:16–23. https://doi.org/10.1093/ehjqcco/qcac013
1148. Himmelreich JCL, Veelers L, Lucassen WAM, Schnabel RB, Rienstra M, van Weert H, 
et al. Prediction models for atrial fibrillation applicable in the community: a systematic 
review and meta-analysis. Europace 2020;22:684–94. https://doi.org/10.1093/ 
europace/euaa005
1149. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. 
Heart disease and stroke statistics—2019 update: a report from the American Heart 
Association. Circulation 2019;139:e56–528. https://doi.org/10.1161/CIR.000000000 
0000659
1150. Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, et al. Are cardio­
vascular risk factors also associated with the incidence of atrial fibrillation? A system­
atic review and field synopsis of 23 factors in 32 population-based cohorts of 20 
million participants. Thromb Haemost 2017;117:837–50. https://doi.org/10.1160/ 
TH16-11-0825
1151. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, et al. Comprehensive risk 
reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic op­
tions—a report from the 3rd Atrial Fibrillation Competence NETwork/European 
Heart Rhythm Association consensus conference. Europace 2012;14:8–27. https:// 
doi.org/10.1093/europace/eur241
1152. Lu Z, Tilly MJ, Geurts S, Aribas E, Roeters van Lennep J, de Groot NMS, et al. 
Sex-specific anthropometric and blood pressure trajectories and risk of incident atrial 
fibrillation: the Rotterdam study. Eur J Prev Cardiol 2022;29:1744–55. https://doi.org/ 
10.1093/eurjpc/zwac083
1153. Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE. A systematic review of the 
health benefits of exercise rehabilitation in persons living with atrial fibrillation. Can J 
Cardiol 2013;29:483–91. https://doi.org/10.1016/j.cjca.2012.07.003
1154. Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K, et al. Risk of 
arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 
2013;34:3624–31. https://doi.org/10.1093/eurheartj/eht188
1155. Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA, et al. 
Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the 
Henry Ford exercise testing (FIT) project. Circulation 2015;131:1827–34. https:// 
doi.org/10.1161/CIRCULATIONAHA.114.014833
1156. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and inci­
dence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2014; 
177:467–76. https://doi.org/10.1016/j.ijcard.2014.09.104
1157. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the gen­
eral population? A systematic review and meta-analysis. Europace 2009;11:1156–9. 
https://doi.org/10.1093/europace/eup197
1158. Cheng M, Hu Z, Lu X, Huang J, Gu D. Caffeine intake and atrial fibrillation incidence: 
dose response meta-analysis of prospective cohort studies. Can J Cardiol 2014;30: 
448–54. https://doi.org/10.1016/j.cjca.2013.12.026
1159. Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine con­
sumption and incident atrial fibrillation in women. Am J Clin Nutr 2010;92:509–14. 
https://doi.org/10.3945/ajcn.2010.29627
1160. Shen J, Johnson VM, Sullivan LM, Jacques PF, Magnani JW, Lubitz SA, et al. Dietary fac­
tors and incident atrial fibrillation: the Framingham heart study. Am J Clin Nutr 2011; 
93:261–6. https://doi.org/10.3945/ajcn.110.001305
1161. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year 
trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the 
Framingham heart study: a cohort study. Lancet 2015;386:154–62. https://doi.org/ 
10.1016/S0140-6736(14)61774-8
1162. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence 
of atrial fibrillation in elderly subjects (the cardiovascular health study). Am J Cardiol 
1994;74:236–41. https://doi.org/10.1016/0002-9149(94)90363-8
1163. Lip GYH, Collet JP, de Caterina R, Fauchier L, Lane DA, Larsen TB, et al. 
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: ex­
ecutive summary of a joint consensus document from the European Heart Rhythm 
Association (EHRA) and European Society of Cardiology Working Group on 
Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, 
Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society 
(HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA 
Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y 
Electrofisiologia (SOLEACE). Thromb Haemost 2017;117:2215–36. https://doi.org/ 
10.1160/TH-17-10-0709
1164. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent 
risk factors for atrial fibrillation in a population-based cohort. The Framingham heart 
study. JAMA 1994;271:840–4. https://doi.org/10.1001/jama.1994.03510350050036
1165. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. 
Patients with atrial fibrillation and coronary artery disease—double trouble. Adv 
Med Sci 2018;63:30–5. https://doi.org/10.1016/j.advms.2017.06.005
1166. Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S. Arrhythmias in 
adults with congenital heart disease: what are risk factors for specific arrhythmias? 
Pacing Clin Electrophysiol 2017;40:353–61. https://doi.org/10.1111/pace.12983
1167. Siland JE, Geelhoed B, Roselli C, Wang B, Lin HJ, Weiss S, et al. Resting heart rate and 
incident atrial fibrillation: a stratified Mendelian randomization in the AFGen consor­
tium. PLoS One 2022;17:e0268768. https://doi.org/10.1371/journal.pone.0268768
1168. Geurts S, Tilly MJ, Arshi B, Stricker BHC, Kors JA, Deckers JW, et al. Heart rate vari­
ability and atrial fibrillation in the general population: a longitudinal and Mendelian 
randomization study. Clin Res Cardiol 2023;112:747–58. https://doi.org/10.1007/ 
s00392-022-02072-5
1169. Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood 
glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of co­
hort studies. J Diabetes Complications 2018;32:501–11. https://doi.org/10.1016/j. 
jdiacomp.2018.02.004
1170. Nakanishi K, Daimon M, Fujiu K, Iwama K, Yoshida Y, Hirose K, et al. Prevalence of 
glucose metabolism disorders and its association with left atrial remodelling before 
and after catheter ablation in patients with atrial fibrillation. Europace 2023;25: 
euad119. https://doi.org/10.1093/europace/euad119
1171. Kim J, Kim D, Jang E, Kim D, You SC, Yu HT, et al. Associations of high-normal blood 
pressure and impaired fasting glucose with atrial fibrillation. Heart 2023;109:929–35. 
https://doi.org/10.1136/heartjnl-2022-322094
1172. Lee SS, Ae Kong K, Kim D, Lim YM, Yang PS, Yi JE, et al. Clinical implication of an im­
paired fasting glucose and prehypertension related to new onset atrial fibrillation in a 
healthy Asian population without underlying disease: a nationwide cohort study in 
Korea. Eur Heart J 2017;38:2599–607. https://doi.org/10.1093/eurheartj/ehx316
1173. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kid­
ney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis 
Risk in Communities (ARIC) study. Circulation 2011;123:2946–53. https://doi.org/ 
10.1161/CIRCULATIONAHA.111.020982
1174. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, et al. eGFR and al­
buminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson 
heart study, the multi-ethnic study of atherosclerosis, and the cardiovascular health 
study. Clin J Am Soc Nephrol 2017;12:1386–98. https://doi.org/10.2215/CJN. 
01860217
1175. Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with 
incident atrial fibrillation independent of gender: a meta-analysis. J Cardiovasc 
Electrophysiol 2018;29:725–32. https://doi.org/10.1111/jce.13458
1176. Aune D, Sen A, Schlesinger S, Norat T, Janszky I, Romundstad P, et al. Body mass in­
dex, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review 
and dose-response meta-analysis of prospective studies. Eur J Epidemiol 2017;32: 
181–92. https://doi.org/10.1007/s10654-017-0232-4
1177. May AM, Blackwell T, Stone PH, Stone KL, Cawthon PM, Sauer WH, et al. Central 
sleep-disordered breathing predicts incident atrial fibrillation in older men. Am J 
Respir Crit Care Med 2016;193:783–91. https://doi.org/10.1164/rccm.201508- 
1523OC
1178. Tung P, Levitzky YS, Wang R, Weng J, Quan SF, Gottlieb DJ, et al. Obstructive and 
central sleep apnea and the risk of incident atrial fibrillation in a community cohort 
of men and women. J Am Heart Assoc 2017;6:e004500. https://doi.org/10.1161/ 
JAHA.116.004500
1179. Desai R, Patel U, Singh S, Bhuva R, Fong HK, Nunna P, et al. The burden and impact of 
arrhythmia in chronic obstructive pulmonary disease: insights from the national in­
patient sample. Int J Cardiol 2019;281:49–55. https://doi.org/10.1016/j.ijcard.2019. 
01.074
1180. O’Neal WT, Efird JT, Qureshi WT, Yeboah J, Alonso A, Heckbert SR, et al. Coronary 
artery calcium progression and atrial fibrillation: the multi-ethnic study of athero­
sclerosis. Circ Cardiovasc Imaging 2015;8:e003786. https://doi.org/10.1161/ 
CIRCIMAGING.115.003786
1181. Chen LY, Leening MJ, Norby FL, Roetker NS, Hofman A, Franco OH, et al. Carotid 
intima-media thickness and arterial stiffness and the risk of atrial fibrillation: the 
Atherosclerosis Risk in Communities (ARIC) study, Multi-Ethnic Study of


<!-- PAGE 100 -->

### Page 100

Atherosclerosis (MESA), and the Rotterdam study. J Am Heart Assoc 2016;5:e002907. 
https://doi.org/10.1161/JAHA.115.002907
1182. Geurts S, Brunborg C, Papageorgiou G, Ikram MA, Kavousi M. Subclinical measures of 
peripheral atherosclerosis and the risk of new-onset atrial fibrillation in the general 
population: the Rotterdam study. J Am Heart Assoc 2022;11:e023967. https://doi. 
org/10.1161/JAHA.121.023967
1183. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. 
Long-term outcomes in individuals with prolonged PR interval or first-degree atrio­
ventricular block. JAMA 2009;301:2571–7. https://doi.org/10.1001/jama.2009.888
1184. Alonso A, Jensen PN, Lopez FL, Chen LY, Psaty BM, Folsom AR, et al. Association of 
sick sinus syndrome with incident cardiovascular disease and mortality: the athero­
sclerosis risk in communities study and cardiovascular health study. PLoS One 2014; 
9:e109662. https://doi.org/10.1371/journal.pone.0109662
1185. Bodin A, Bisson A, Gaborit C, Herbert J, Clementy N, Babuty D, et al. Ischemic stroke 
in patients with sinus node disease, atrial fibrillation, and other cardiac conditions. 
Stroke 2020;51:1674–81. https://doi.org/10.1161/STROKEAHA.120.029048
1186. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, et al. Long-term nat­
ural history of adult Wolff–Parkinson–White syndrome patients treated with and 
without catheter ablation. Circ Arrhythm Electrophysiol 2015;8:1465–71. https://doi. 
org/10.1161/CIRCEP.115.003013
1187. Chang SH, Kuo CF, Chou IJ, See LC, Yu KH, Luo SF, et al. Association of a family his­
tory of atrial fibrillation with incidence and outcomes of atrial fibrillation: a 
population-based family cohort study. JAMA Cardiol 2017;2:863–70. https://doi.org/ 
10.1001/jamacardio.2017.1855
1188. Fox CS, Parise H, D’Agostino RB, Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, et al. 
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 
2004;291:2851–5. https://doi.org/10.1001/jama.291.23.2851
1189. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, et al. Association be­
tween familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010; 
304:2263–9. https://doi.org/10.1001/jama.2010.1690
1190. Zoller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of atrial fibrillation/at­
rial flutter in multiplex families: a nationwide family study in Sweden. J Am Heart Assoc 
2013;2:e003384. https://doi.org/10.1161/JAHA.112.003384
1191. Ko D, Benson MD, Ngo D, Yang Q, Larson MG, Wang TJ, et al. Proteomics profiling 
and risk of new-onset atrial fibrillation: Framingham heart study. J Am Heart Assoc 
2019;8:e010976. https://doi.org/10.1161/JAHA.118.010976
1192. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide 
polygenic scores for common diseases identify individuals with risk equivalent to 
monogenic mutations. Nat Genet 2018;50:1219–24. https://doi.org/10.1038/ 
s41588-018-0183-z
1193. Buckley BJR, Harrison SL, Gupta D, Fazio-Eynullayeva E, Underhill P, Lip GYH. Atrial 
fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from 
real-world data. J Am Heart Assoc 2021;10:e021970. https://doi.org/10.1161/JAHA. 
121.021970
1194. Chen M, Ding N, Mok Y, Mathews L, Hoogeveen RC, Ballantyne CM, et al. Growth 
differentiation factor 15 and the subsequent risk of atrial fibrillation: the atheroscler­
osis risk in communities study. Clin Chem 2022;68:1084–93. https://doi.org/10.1093/ 
clinchem/hvac096
1195. Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, et al. Data-driven 
discovery and validation of circulating blood-based biomarkers associated with preva­
lent atrial fibrillation. Eur Heart J 2019;40:1268–76. https://doi.org/10.1093/eurheartj/ 
ehy815
1196. Brady PF, Chua W, Nehaj F, Connolly DL, Khashaba A, Purmah YJV, et al. Interactions 
between atrial fibrillation and natriuretic peptide in predicting heart failure hospital­
ization or cardiovascular death. J Am Heart Assoc 2022;11:e022833. https://doi.org/10. 
1161/JAHA.121.022833
1197. Werhahn SM, Becker C, Mende M, Haarmann H, Nolte K, Laufs U, et al. NT-proBNP 
as a marker for atrial fibrillation and heart failure in four observational outpatient 
trials. ESC Heart Fail 2022;9:100–9. https://doi.org/10.1002/ehf2.13703
1198. Geelhoed B, Börschel CS, Niiranen T, Palosaari T, Havulinna AS, Fouodo CJK, et al. 
Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: 
a Mendelian randomization study in the FINRISK cohort. Europace 2020;22:1463–9. 
https://doi.org/10.1093/europace/euaa158
1199. Toprak B, Brandt S, Brederecke J, Gianfagna F, Vishram-Nielsen JKK, Ojeda FM, et al. 
Exploring the incremental utility of circulating biomarkers for robust risk prediction 
of incident atrial fibrillation in European cohorts using regressions and modern ma­
chine learning methods. Europace 2023;25:812–9. https://doi.org/10.1093/ 
europace/euac260
1200. Benz AP, Hijazi Z, Lindbäck J, Connolly SJ, Eikelboom JW, Oldgren J, et al. 
Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fib­
rillation not receiving oral anticoagulation. Circulation 2021;143:1863–73. https:// 
doi.org/10.1161/CIRCULATIONAHA.120.053100
1201. Monrad M, Sajadieh A, Christensen JS, Ketzel M, Raaschou-Nielsen O, Tjonneland A, 
et al. Long-term exposure to traffic-related air pollution and risk of incident atrial fib­
rillation: a cohort study. Environ Health Perspect 2017;125:422–7. https://doi.org/10. 
1289/EHP392
1202. Walkey AJ, Greiner MA, Heckbert SR, Jensen PN, Piccini JP, Sinner MF, et al. Atrial 
fibrillation among medicare beneficiaries hospitalized with sepsis: incidence and risk 
factors. Am Heart J 2013;165:949–955.e3. https://doi.org/10.1016/j.ahj.2013.03.020
1203. Svensson T, Kitlinski M, Engstrom G, Melander O. Psychological stress and risk of in­
cident atrial fibrillation in men and women with known atrial fibrillation genetic risk 
scores. Sci Rep 2017;7:42613. https://doi.org/10.1038/srep42613
1204. Eaker ED, Sullivan LM, Kelly-Hayes M, D’Agostino RB, Sr, Benjamin EJ. Anger and hos­
tility predict the development of atrial fibrillation in men in the Framingham offspring 
study. Circulation 2004;109:1267–71. https://doi.org/10.1161/01.CIR.0000118535. 
15205.8F
1205. Chen LY, Bigger JT, Hickey KT, Chen H, Lopez-Jimenez C, Banerji MA, et al. Effect of 
intensive blood pressure lowering on incident atrial fibrillation and P-wave indices in 
the ACCORD blood pressure trial. Am J Hypertens 2016;29:1276–82. https://doi.org/ 
10.1093/ajh/hpv172
1206. Soliman EZ, Rahman AF, Zhang ZM, Rodriguez CJ, Chang TI, Bates JT, et al. Effect of 
intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension 2020; 
75:1491–6. https://doi.org/10.1161/HYPERTENSIONAHA.120.14766
1207. Larstorp ACK, Stokke IM, Kjeldsen SE, Hecht Olsen M, Okin PM, Devereux RB, et al. 
Antihypertensive therapy prevents new-onset atrial fibrillation in patients with iso­
lated systolic hypertension: the LIFE study. Blood Press 2019;28:317–26. https://doi. 
org/10.1080/08037051.2019.1633905
1208. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention 
of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin re­
ceptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832–9. https://doi.org/10. 
1016/j.jacc.2004.11.070
1209. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al. 
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the 
EMPHASIS-HF (eplerenone in mild patients hospitalization and SurvIval study in heart 
failure) study. J Am Coll Cardiol 2012;59:1598–603. https://doi.org/10.1016/j.jacc.2011. 
11.063
1210. Wang M, Zhang Y, Wang Z, Liu D, Mao S, Liang B. The effectiveness of SGLT2 inhibi­
tor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes 
mellitus/heart failure: a systematic review and meta-analysis. J Thorac Dis 2022;14: 
1620–37. https://doi.org/10.21037/jtd-22-550
1211. Yin Z, Zheng H, Guo Z. Effect of sodium-glucose co-transporter protein 2 inhibitors 
on arrhythmia in heart failure patients with or without type 2 diabetes: a 
meta-analysis of randomized controlled trials. Front Cardiovasc Med 2022;9:902923. 
https://doi.org/10.3389/fcvm.2022.902923
1212. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, et al. The long- 
and short-term impact of elevated body mass index on the risk of new atrial fibrilla­
tion the WHS (Women’s Health Study). J Am Coll Cardiol 2010;55:2319–27. https:// 
doi.org/10.1016/j.jacc.2010.02.029
1213. Chan YH, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH. The impact of weight 
loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mel­
litus treated with sodium-glucose cotransporter 2 inhibitor. Cardiovasc Diabetol 2021; 
20:93. https://doi.org/10.1186/s12933-021-01285-8
1214. Mishima RS, Verdicchio CV, Noubiap JJ, Ariyaratnam JP, Gallagher C, Jones D, et al. 
Self-reported physical activity and atrial fibrillation risk: a systematic review and 
meta-analysis. Heart Rhythm 2021;18:520–8. https://doi.org/10.1016/j.hrthm.2020. 
12.017
1215. Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, et al. 
Association between physical activity and risk of incident arrhythmias in 402 406 in­
dividuals: evidence from the UK Biobank cohort. Eur Heart J 2020;41:1479–86. 
https://doi.org/10.1093/eurheartj/ehz897
1216. Jin MN, Yang PS, Song C, Yu HT, Kim TH, Uhm JS, et al. Physical activity and risk of 
atrial fibrillation: a nationwide cohort study in general population. Sci Rep 2019;9: 
13270. https://doi.org/10.1038/s41598-019-49686-w
1217. Khurshid S, Weng LC, Al-Alusi MA, Halford JL, Haimovich JS, Benjamin EJ, et al. 
Accelerometer-derived physical activity and risk of atrial fibrillation. Eur Heart J 
2021;42:2472–83. https://doi.org/10.1093/eurheartj/ehab250
1218. Tikkanen E, Gustafsson S, Ingelsson E. Associations of fitness, physical activity, 
strength, and genetic risk with cardiovascular disease: longitudinal analyses in the 
UK biobank study. Circulation 2018;137:2583–91. https://doi.org/10.1161/ 
CIRCULATIONAHA.117.032432
1219. Morseth B, Graff-Iversen S, Jacobsen BK, Jørgensen L, Nyrnes A, Thelle DS, et al. 
Physical activity, resting heart rate, and atrial fibrillation: the Tromsø study. Eur 
Heart J 2016;37:2307–13. https://doi.org/10.1093/eurheartj/ehw059
1220. Csengeri D, Sprünker NA, Di Castelnuovo A, Niiranen T, Vishram-Nielsen JK, 
Costanzo S, et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrilla­
tion and adverse outcomes. Eur Heart J 2021;42:1170–7. https://doi.org/10.1093/ 
eurheartj/ehaa953
1221. Gallagher C, Hendriks JML, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, et al. 
Alcohol and incident atrial fibrillation – a systematic review and meta-analysis. Int J 
Cardiol 2017;246:46–52. https://doi.org/10.1016/j.ijcard.2017.05.133
ESC Guidelines                                                                                                                                                                                          3413


<!-- PAGE 101 -->

### Page 101

1222. Tu SJ, Gallagher C, Elliott AD, Linz D, Pitman BM, Hendriks JML, et al. Risk thresholds 
for total and beverage-specific alcohol consumption and incident atrial fibrillation. 
JACC Clin Electrophysiol 2021;7:1561–9. https://doi.org/10.1016/j.jacep.2021.05.013
1223. Lee JW, Roh SY, Yoon WS, Kim J, Jo E, Bae DH, et al. Changes in alcohol consumption 
habits and risk of atrial fibrillation: a nationwide population-based study. Eur J Prev 
Cardiol 2024;31:49–58. https://doi.org/10.1093/eurjpc/zwad270
1224. Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin 
with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a 
population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13: 
123. https://doi.org/10.1186/s12933-014-0123-x
1225. Tseng CH. Metformin use is associated with a lower incidence of hospitalization for 
atrial fibrillation in patients with type 2 diabetes mellitus. Front Med (Lausanne) 2021; 
7:592901. https://doi.org/10.3389/fmed.2020.592901
1226. Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 
2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. 
Cardiovasc Diabetol 2020;19:130. https://doi.org/10.1186/s12933-020-01105-5
1227. Srivatsa UN, Malhotra P, Zhang XJ, Beri N, Xing G, Brunson A, et al. Bariatric surgery 
to aLleviate OCcurrence of atrial fibrillation hospitalization—BLOC-AF. Heart 
Rhythm O2 2020;1:96–102. https://doi.org/10.1016/j.hroo.2020.04.004
1228. Hoskuldsdottir G, Sattar N, Miftaraj M, Naslund I, Ottosson J, Franzen S, et al. 
Potential effects of bariatric surgery on the incidence of heart failure and atrial fibril­
lation in patients with type 2 diabetes mellitus and obesity and on mortality in patients 
with preexisting heart failure: a nationwide, matched, observational cohort study. 
J Am Heart Assoc 2021;10:e019323. https://doi.org/10.1161/JAHA.120.019323
1229. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Sharma K, Watthanasuntorn K, 
Lertjitbanjong P, et al. Incident atrial fibrillation in patients undergoing bariatric sur­
gery: a systematic review and meta-analysis. Intern Med J 2020;50:810–7. https:// 
doi.org/10.1111/imj.14436
1230. Lynch KT, Mehaffey JH, Hawkins RB, Hassinger TE, Hallowell PT, Kirby JL. Bariatric 
surgery reduces incidence of atrial fibrillation: a propensity score-matched analysis. 
Surg Obes Relat Dis 2019;15:279–85. https://doi.org/10.1016/j.soard.2018.11.021
1231. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K. Bariatric surgery 
and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 
2016;68:2497–504. https://doi.org/10.1016/j.jacc.2016.09.940
1232. Okin PM, Hille DA, Larstorp AC, Wachtell K, Kjeldsen SE, Dahlöf B, et al. Effect 
of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in 
hypertensive patients. Hypertension 2015;66:368–73. https://doi.org/10.1161/ 
HYPERTENSIONAHA.115.05728
1233. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin 
II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke com­
pared to atenolol: the Losartan Intervention for End point reduction in hypertension 
(LIFE) study. J Am Coll Cardiol 2005;45:712–9. https://doi.org/10.1016/j.jacc.2004.10. 
068
1234. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, et al. Reduced 
incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the 
VALUE trial. J Hypertens 2008;26:403–11. https://doi.org/10.1097/HJH.0b013e 
3282f35c67
1235. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident at­
rial fibrillation in patients who receive antihypertensive drugs: a nested case-control 
study. Ann Intern Med 2010;152:78–84. https://doi.org/10.7326/0003-4819-152-2- 
201001190-00005
1236. Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, et al. 
Pharmacologic prevention of incident atrial fibrillation: long-term results from the 
ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack 
trial). Circ Arrhythm Electrophysiol 2017;10:e005463. https://doi.org/10.1161/ 
CIRCEP.117.005463
1237. Butt JH, Docherty KF, Jhund PS, de Boer RA, Böhm M, Desai AS, et al. Dapagliflozin 
and atrial fibrillation in heart failure with reduced ejection fraction: insights from 
DAPA-HF. Eur J Heart Fail 2022;24:513–25. https://doi.org/10.1002/ejhf.2381
1238. Liu X, Liu H, Wang L, Zhang L, Xu Q. Role of sacubitril-valsartan in the prevention of 
atrial fibrillation occurrence in patients with heart failure: a systematic review and 
meta-analysis of randomized controlled trials. PLOS ONE 2022;17:e0263131. 
https://doi.org/10.1371/journal.pone.0263131
1239. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy 
an antiarrhythmic therapy for atrial fibrillation? A systematic review and 
meta-analysis. Curr Cardiol Rep 2013;15:330. https://doi.org/10.1007/s11886-012- 
0330-6
1240. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of in­
tensive glycemic control on the incidence of atrial fibrillation and associated cardio­
vascular outcomes in patients with type 2 diabetes mellitus (from the action to 
control cardiovascular risk in diabetes study). Am J Cardiol 2014;114:1217–22. 
https://doi.org/10.1016/j.amjcard.2014.07.045
1241. Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of met­
formin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc 
Diabetol 2020;19:198. https://doi.org/10.1186/s12933-020-01176-4
1242. Chang CY, Yeh YH, Chan YH, Liu JR, Chang SH, Lee HF, et al. Dipeptidyl peptidase-4 
inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a na­
tionwide cohort study in Taiwan. Cardiovasc Diabetol 2017;16:159. https://doi.org/10. 
1186/s12933-017-0640-5
1243. Ostropolets A, Elias PA, Reyes MV, Wan EY, Pajvani UB, Hripcsak G, et al. Metformin 
is associated with a lower risk of atrial fibrillation and ventricular arrhythmias com­
pared with sulfonylureas: an observational study. Circ Arrhythm Electrophysiol 2021; 
14:e009115. https://doi.org/10.1161/CIRCEP.120.009115
1244. Proietti R, Lip GYH. Sodium-glucose cotransporter 2 inhibitors: an additional man­
agement option for patients with atrial fibrillation? Diabetes Obes Metab 2022;24: 
1897–900. https://doi.org/10.1111/dom.14818
1245. Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A new hope: sodium- 
glucose cotransporter-2 inhibition to prevent atrial fibrillation. J Cardiovasc Dev Dis 
2022;9:236. https://doi.org/10.3390/jcdd9080236
1246. Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, et al. Comparison of 
sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on 
the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a 
propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther 2023;37: 
561–9. https://doi.org/10.1007/s10557-022-07319-x
1247. Elliott AD, Maatman B, Emery MS, Sanders P. The role of exercise in atrial fibrillation 
prevention and promotion: finding optimal ranges for health. Heart Rhythm 2017;14: 
1713–20. https://doi.org/10.1016/j.hrthm.2017.07.001
1248. Newman W, Parry-Williams G, Wiles J, Edwards J, Hulbert S, Kipourou K, et al. Risk 
of atrial fibrillation in athletes: a systematic review and meta-analysis. Br J Sports Med 
2021;55:1233–8. https://doi.org/10.1136/bjsports-2021-103994

<!-- 2024_Chronic_Coronary_Syndromes.md -->

# ESC Guidelines: Chronic Coronary Syndromes (2024)

**Source**: `2024_Chronic_Coronary_Syndromes.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 123

---

## Table of Contents

- [2024 ESC Guidelines for the management of chronic coronary syndromes](#2024-esc-guidelines-for-the-management-of-chronic-) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. Evolving pathophysiological concepts of chronic coronary syndromes](#21-evolving-pathophysiological-concepts-of-chronic) *(p. 9)*
    - [2.2. Chronic coronary syndromes: clinical presentations (Figure 1)](#22-chronic-coronary-syndromes:-clinical-presentati) *(p. 10)*
    - [2.3. Changing epidemiology and management strategies](#23-changing-epidemiology-and-management-strategies) *(p. 10)*
    - [2.4. What is new](#24-what-is-new) *(p. 12)*
  - [3. Stepwise approach to the initial management of individuals with suspected chronic coronary syndrome](#3-stepwise-approach-to-the-initial-management-of-i) *(p. 19)*
    - [3.1. STEP 1: General clinical examination](#31-step-1:-general-clinical-examination) *(p. 19)*
      - [3.1.1. History, differential diagnosis, and physical examination](#311-history,-differential-diagnosis,-and-physical-) *(p. 19)*
      - [3.1.2. Basic testing: 12-lead electrocardiogram and biochemistry](#312-basic-testing:-12-lead-electrocardiogram-and-b) *(p. 22)*
        - [3.1.2.1. Electrocardiogram](#3121-electrocardiogram) *(p. 22)*
        - [3.1.2.2. Biochemical tests](#3122-biochemical-tests) *(p. 23)*
    - [3.2. STEP 2: Further evaluation](#32-step-2:-further-evaluation) *(p. 23)*
      - [3.2.1. Pre-test clinical likelihood of obstructive atherosclerotic coronary artery disease](#321-pre-test-clinical-likelihood-of-obstructive-at) *(p. 23)*
      - [3.2.2. Transthoracic echocardiography and cardiac magnetic resonance at rest](#322-transthoracic-echocardiography-and-cardiac-mag) *(p. 26)*
      - [3.2.3. Exercise electrocardiogram testing](#323-exercise-electrocardiogram-testing) *(p. 26)*
      - [3.2.4. Chest X-ray](#324-chest-x-ray) *(p. 27)*
      - [3.2.5. Ambulatory electrocardiogram monitoring](#325-ambulatory-electrocardiogram-monitoring) *(p. 27)*
    - [3.3. STEP 3: Confirming the diagnosis](#33-step-3:-confirming-the-diagnosis) *(p. 27)*
      - [3.3.1. Anatomical imaging: coronary computed tomography angiography](#331-anatomical-imaging:-coronary-computed-tomograp) *(p. 27)*
        - [3.3.1.1. Computed tomography perfusion imaging](#3311-computed-tomography-perfusion-imaging) *(p. 27)*
        - [3.3.1.2. Prognosis, plaque features, and opportunity to improve outcomes](#3312-prognosis,-plaque-features,-and-opportunity-t) *(p. 28)*
        - [3.3.1.3. Recognized pre-requisites for coronary computed tomography angiography](#3313-recognized-pre-requisites-for-coronary-comput) *(p. 28)*
      - [3.3.2. Functional imaging](#332-functional-imaging) *(p. 28)*
        - [3.3.2.1. Stress echocardiography](#3321-stress-echocardiography) *(p. 28)*
        - [3.3.2.2. Myocardial perfusion scintigraphy—single-photon emission computed tomography](#3322-myocardial-perfusion-scintigraphy—single-phot) *(p. 29)*
        - [3.3.2.3. Positron emission tomography-computed tomography](#3323-positron-emission-tomography-computed-tomogra) *(p. 30)*
        - [3.3.2.4. Cardiac magnetic resonance imaging](#3324-cardiac-magnetic-resonance-imaging) *(p. 30)*
        - [3.3.2.5. Non-invasive testing for microvascular dysfunction](#3325-non-invasive-testing-for-microvascular-dysfun) *(p. 31)*
      - [3.3.3. Invasive tests](#333-invasive-tests) *(p. 31)*
        - [3.3.3.1. Invasive coronary angiography](#3331-invasive-coronary-angiography) *(p. 31)*
        - [3.3.3.2. Functional assessment of epicardial stenosis severity to guide coronary revascularization](#3332-functional-assessment-of-epicardial-stenosis-) *(p. 32)*
        - [3.3.3.3. Assessment of microvascular dysfunction](#3333-assessment-of-microvascular-dysfunction) *(p. 33)*
        - [3.3.3.4. Testing for coronary vasospasm](#3334-testing-for-coronary-vasospasm) *(p. 33)*
      - [3.3.4. Diagnostic algorithm and selection of appropriate tests](#334-diagnostic-algorithm-and-selection-of-appropri) *(p. 34)*
      - [3.3.5. Adverse-event risk assessment](#335-adverse-event-risk-assessment) *(p. 39)*
    - [3.4. STEP 4: Initial therapy](#34-step-4:-initial-therapy) *(p. 40)*
  - [4. Guideline-directed therapy](#4-guideline-directed-therapy) *(p. 41)*
    - [4.1. Patient education, lifestyle optimization for risk-factor control, and exercise therapy](#41-patient-education,-lifestyle-optimization-for-r) *(p. 41)*
      - [4.1.1. Patient education](#411-patient-education) *(p. 41)*
      - [4.1.2. Key lifestyle interventions for risk-factor control](#412-key-lifestyle-interventions-for-risk-factor-co) *(p. 41)*
        - [4.1.2.1. Smoking and substance abuse](#4121-smoking-and-substance-abuse) *(p. 42)*
        - [4.1.2.2. Weight management](#4122-weight-management) *(p. 42)*
        - [4.1.2.3. Diet and alcohol](#4123-diet-and-alcohol) *(p. 42)*
        - [4.1.2.4. Mental health](#4124-mental-health) *(p. 42)*
        - [4.1.2.5. Physical activity and sedentary behaviour](#4125-physical-activity-and-sedentary-behaviour) *(p. 42)*
      - [4.1.3. Exercise therapy](#413-exercise-therapy) *(p. 43)*
    - [4.2. Antianginal/anti-ischaemic medication](#42-antianginal/anti-ischaemic-medication) *(p. 43)*
      - [4.2.1. General strategy](#421-general-strategy) *(p. 43)*
      - [4.2.2. Beta blockers](#422-beta-blockers) *(p. 44)*
      - [4.2.3. Combination therapy](#423-combination-therapy) *(p. 45)*
    - [4.3. Medical therapy for event prevention](#43-medical-therapy-for-event-prevention) *(p. 46)*
      - [4.3.1. Antithrombotic drugs](#431-antithrombotic-drugs) *(p. 46)*
        - [4.3.1.1. Antiplatelet drugs](#4311-antiplatelet-drugs) *(p. 46)*
          - [4.3.1.1.1. Aspirin monotherapy](#43111-aspirin-monotherapy) *(p. 46)*
          - [4.3.1.1.2. Oral P2Y12 inhibitor monotherapy](#43112-oral-p2y12-inhibitor-monotherapy) *(p. 46)*
          - [4.3.1.1.2.1. Clopidogrel monotherapy](#431121-clopidogrel-monotherapy) *(p. 46)*
          - [4.3.1.1.2.2. Ticagrelor monotherapy](#431122-ticagrelor-monotherapy) *(p. 46)*
          - [4.3.1.1.3. Dual antiplatelet therapy post-percutaneous coronary intervention](#43113-dual-antiplatelet-therapy-post-percutaneous-) *(p. 48)*
          - [4.3.1.1.4. Extended intensified antithrombotic therapy](#43114-extended-intensified-antithrombotic-therapy) *(p. 48)*
          - [4.3.1.1.5. Genotype- and phenotype-guided dual antiplatelet therapy](#43115-genotype--and-phenotype-guided-dual-antiplat) *(p. 49)*
        - [4.3.1.2. Anticoagulant therapy](#4312-anticoagulant-therapy) *(p. 50)*
          - [4.3.1.2.1. Monotherapy with oral anticoagulant](#43121-monotherapy-with-oral-anticoagulant) *(p. 50)*
          - [4.3.1.2.2. Combination of anticoagulant and antiplatelet therapy after percutaneous coronary intervention in chronic coronary syndrome patients with AF or other indication for oral anticoagulant](#43122-combination-of-anticoagulant-and-antiplatele) *(p. 50)*
        - [4.3.1.3. Coronary artery bypass grafting and antithrombotic therapy](#4313-coronary-artery-bypass-grafting-and-antithrom) *(p. 51)*
        - [4.3.1.4. Proton pump inhibitors](#4314-proton-pump-inhibitors) *(p. 51)*
      - [4.3.2. Lipid-lowering drugs](#432-lipid-lowering-drugs) *(p. 53)*
      - [4.3.3. Renin–angiotensin–aldosterone blockers/angiotensin receptor neprilysin inhibitor](#433-renin–angiotensin–aldosterone-blockers/angiote) *(p. 53)*
      - [4.3.4. Sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists](#434-sodium–glucose-cotransporter-2-inhibitors-and-) *(p. 54)*
      - [4.3.5. Anti-inflammatory agents for event prevention](#435-anti-inflammatory-agents-for-event-prevention) *(p. 54)*
    - [4.4. Revascularization for chronic coronary syndromes](#44-revascularization-for-chronic-coronary-syndrome) *(p. 55)*
      - [4.4.1. Appropriate indication for myocardial revascularization](#441-appropriate-indication-for-myocardial-revascul) *(p. 55)*
      - [4.4.2. Additional considerations on reduced systolic left ventricular function: myocardial viability, revascularization, and its modality](#442-additional-considerations-on-reduced-systolic-) *(p. 56)*
      - [4.4.3. Additional considerations—complete vs. partial revascularization](#443-additional-considerations—complete-vs-partial-) *(p. 57)*
      - [4.4.4. Assessment of clinical risk and anatomical complexity](#444-assessment-of-clinical-risk-and-anatomical-com) *(p. 57)*
      - [4.4.5. Choice of myocardial revascularization modality](#445-choice-of-myocardial-revascularization-modalit) *(p. 58)*
        - [4.4.5.1. Patients with single- or two-vessel coronary artery disease](#4451-patients-with-single--or-two-vessel-coronary-) *(p. 58)*
        - [4.4.5.2. Patients with unprotected left main coronary artery disease](#4452-patients-with-unprotected-left-main-coronary-) *(p. 58)*
        - [4.4.5.3. Patients with multivessel coronary artery disease](#4453-patients-with-multivessel-coronary-artery-dis) *(p. 60)*
        - [4.4.5.4. Impact of coronary pressure guidance on multivessel coronary artery disease patients undergoing percutaneous coronary intervention](#4454-impact-of-coronary-pressure-guidance-on-multi) *(p. 60)*
        - [4.4.5.5. Virtual percutaneous coronary intervention: combination of coronary pressure mapping with coronary anatomy for percutaneous coronary intervention planning](#4455-virtual-percutaneous-coronary-intervention:-c) *(p. 60)*
        - [4.4.5.6. Impact of intracoronary imaging guidance on multivessel coronary artery disease patients undergoing percutaneous coronary intervention](#4456-impact-of-intracoronary-imaging-guidance-on-m) *(p. 60)*
        - [4.4.5.7. Hybrid revascularization in multivessel coronary artery disease patients](#4457-hybrid-revascularization-in-multivessel-coron) *(p. 61)*
      - [4.4.6. Patient–physician shared decision-making to perform and select revascularization modality](#446-patient–physician-shared-decision-making-to-pe) *(p. 61)*
      - [4.4.7. Institutional protocols, clinical pathways, and quality of care](#447-institutional-protocols,-clinical-pathways,-an) *(p. 61)*
  - [5. Optimal assessment and treatment of specific groups](#5-optimal-assessment-and-treatment-of-specific-gro) *(p. 64)*
    - [5.1. Coronary artery disease and heart failure](#51-coronary-artery-disease-and-heart-failure) *(p. 64)*
    - [5.2. Angina/ischaemia with non-obstructive coronary arteries](#52-angina/ischaemia-with-non-obstructive-coronary-) *(p. 65)*
      - [5.2.1. Definition](#521-definition) *(p. 65)*
      - [5.2.2. Angina/ischaemia with non-obstructive coronary arteries endotypes](#522-angina/ischaemia-with-non-obstructive-coronary) *(p. 65)*
        - [5.2.2.1. Microvascular angina](#5221-microvascular-angina) *(p. 66)*
        - [5.2.2.2. Epicardial vasospastic angina](#5222-epicardial-vasospastic-angina) *(p. 67)*
      - [5.2.3. Clinical presentations](#523-clinical-presentations) *(p. 67)*
      - [5.2.4. Short- and long-term prognosis](#524-short--and-long-term-prognosis) *(p. 67)*
      - [5.2.5. Diagnosis](#525-diagnosis) *(p. 67)*
        - [5.2.5.1. Non-invasive diagnosis](#5251-non-invasive-diagnosis) *(p. 67)*
        - [5.2.5.2. Invasive coronary functional testing](#5252-invasive-coronary-functional-testing) *(p. 67)*
          - [5.2.5.2.1. Basic coronary functional testing](#52521-basic-coronary-functional-testing) *(p. 67)*
          - [5.2.5.2.2. Coronary vasomotor testing](#52522-coronary-vasomotor-testing) *(p. 67)*
      - [5.2.6. Management of angina/ischaemia with non-obstructive coronary arteries](#526-management-of-angina/ischaemia-with-non-obstru) *(p. 69)*
    - [5.3. Other specific patient groups](#53-other-specific-patient-groups) *(p. 71)*
      - [5.3.1. Older adults](#531-older-adults) *(p. 71)*
      - [5.3.2. Sex differences in chronic coronary syndromes](#532-sex-differences-in-chronic-coronary-syndromes) *(p. 71)*
      - [5.3.3. High bleeding-risk patients](#533-high-bleeding-risk-patients) *(p. 72)*
      - [5.3.4. Inflammatory rheumatic diseases](#534-inflammatory-rheumatic-diseases) *(p. 72)*
      - [5.3.5. Hypertension](#535-hypertension) *(p. 72)*
      - [5.3.6. Atrial fibrillation](#536-atrial-fibrillation) *(p. 72)*
      - [5.3.7. Valvular heart disease](#537-valvular-heart-disease) *(p. 72)*
      - [5.3.8. Chronic kidney disease](#538-chronic-kidney-disease) *(p. 73)*
      - [5.3.9. Cancer](#539-cancer) *(p. 73)*
      - [5.3.10. Optimal treatment of patients with human immunodeficiency virus](#5310-optimal-treatment-of-patients-with-human-immu) *(p. 73)*
      - [5.3.11. Socially and geographically diverse groups](#5311-socially-and-geographically-diverse-groups) *(p. 73)*
    - [5.4. Screening for coronary artery disease in asymptomatic individuals](#54-screening-for-coronary-artery-disease-in-asympt) *(p. 74)*
  - [6. Long-term follow-up and care](#6-long-term-follow-up-and-care) *(p. 75)*
    - [6.1. Voice of the patient](#61-voice-of-the-patient) *(p. 75)*
      - [6.1.1. Communication](#611-communication) *(p. 75)*
      - [6.1.2. Depression and anxiety](#612-depression-and-anxiety) *(p. 75)*
    - [6.2. Adherence and persistence](#62-adherence-and-persistence) *(p. 75)*
      - [6.2.1. Adherence to healthy lifestyle behaviours](#621-adherence-to-healthy-lifestyle-behaviours) *(p. 75)*
        - [6.2.1.1. Why behavioural changes are difficult](#6211-why-behavioural-changes-are-difficult) *(p. 75)*
        - [6.2.1.2. How to change behaviour and support healthy lifestyles](#6212-how-to-change-behaviour-and-support-healthy-l) *(p. 76)*
        - [6.2.1.3. Digital and mHealth](#6213-digital-and-mhealth) *(p. 77)*
        - [6.2.1.4. How to assess adherence](#6214-how-to-assess-adherence) *(p. 78)*
      - [6.2.2. Adherence to medical therapy](#622-adherence-to-medical-therapy) *(p. 78)*
        - [6.2.2.1. Strategies to improve medication adherence](#6221-strategies-to-improve-medication-adherence) *(p. 78)*
        - [6.2.2.2. mHealth strategies for medication adherence](#6222-mhealth-strategies-for-medication-adherence) *(p. 78)*
    - [6.3. Diagnosis of disease progression](#63-diagnosis-of-disease-progression) *(p. 78)*
      - [6.3.1. Risk factors for recurrent coronary artery disease events](#631-risk-factors-for-recurrent-coronary-artery-dis) *(p. 79)*
      - [6.3.2. Organization of long-term follow-up](#632-organization-of-long-term-follow-up) *(p. 79)*
      - [6.3.3. Non-invasive diagnostic testing](#633-non-invasive-diagnostic-testing) *(p. 80)*
    - [6.4. Treatment of myocardial revascularization failure](#64-treatment-of-myocardial-revascularization-failu) *(p. 81)*
      - [6.4.1. Percutaneous coronary intervention failure](#641-percutaneous-coronary-intervention-failure) *(p. 81)*
      - [6.4.2. Managing graft failure after coronary artery bypass grafting](#642-managing-graft-failure-after-coronary-artery-b) *(p. 81)*
    - [6.5. Recurrent or refractory angina/ischaemia](#65-recurrent-or-refractory-angina/ischaemia) *(p. 82)*
    - [6.6. Treatment of disease complications](#66-treatment-of-disease-complications) *(p. 83)*
  - [7. Key messages](#7-key-messages) *(p. 83)*
  - [8. Gaps in evidence](#8-gaps-in-evidence) *(p. 84)*
  - [9. ‘What to do’ and ‘What not to do’ messages from the guidelines](#9-‘what-to-do’-and-‘what-not-to-do’-messages-from-) *(p. 85)*
  - [10. Evidence tables](#10-evidence-tables) *(p. 91)*
  - [11. Data availability statement](#11-data-availability-statement) *(p. 91)*
  - [12. Author information](#12-author-information) *(p. 91)*
  - [Appendix](#appendix) *(p. 92)*
  - [14. References](#14-references) *(p. 93)*
  - [14. References](#14-references) *(p. 93)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management 
of chronic coronary syndromes
Developed by the task force for the management of chronic 
coronary syndromes of the European Society of Cardiology (ESC)
Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)
Authors/Task Force Members: Christiaan Vrints  *†, (Chairperson) (Belgium), 
Felicita Andreotti  *†, (Chairperson) (Italy), Konstantinos C. Koskinas‡, 
(Task Force Co-ordinator) (Switzerland), Xavier Rossello  
‡, (Task Force 
Co-ordinator) (Spain), Marianna Adamo  
(Italy), James Ainslie (United Kingdom), 
Adrian Paul Banning  
(United Kingdom), Andrzej Budaj  
(Poland), 
Ronny R. Buechel  
(Switzerland), Giovanni Alfonso Chiariello  
(Italy), 
Alaide Chieffo  
(Italy), Ruxandra Maria Christodorescu  
(Romania), 
Christi Deaton  
(United Kingdom), Torsten Doenst  
1 (Germany), 
Hywel W. Jones (United Kingdom), Vijay Kunadian  
(United Kingdom), 
Julinda Mehilli  
(Germany), Milan Milojevic  
1 (Serbia), Jan J. Piek  
(Netherlands), Francesca Pugliese  
(United Kingdom), Andrea Rubboli  
(Italy), 
Anne Grete Semb  
(Norway), Roxy Senior  
(United Kingdom), 
Jurrien M. ten Berg  
(Netherlands), Eric Van Belle  
(France), 
Emeline M. Van Craenenbroeck  
(Belgium), Rafael Vidal-Perez  
(Spain), 
Simon Winther  
(Denmark), and ESC Scientific Document Group      
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
* Corresponding authors: Christiaan Vrints, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium, and Research Group Cardiovascular Diseases, GENCOR, University 
of Antwerp, Antwerp, Belgium. Tel: +32 3 8213571, E-mail: christiaan.vrints@uantwerpen.be; and Felicita Andreotti, Cardiovascular Science Department, Fondazione Policlinico Universitario 
Gemelli IRCCS, Rome, Italy, and Cardio-Thoracic Department, Catholic University Medical School, Rome, Italy. Tel: +39-06-30154187, E-mail: felicita.andreotti@unicatt.it.  
† The two Chairpersons contributed equally to the document and are joint first authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the Association European Association for Cardio-Thoracic Surgery (EACTS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice.
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Coronary Pathophysiology and Microcirculation, Thrombosis.
Patient Forum  
https://doi.org/10.1093/eurheartj/ehae177
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Michael Borger, (CPG Review Co-ordinator) (Germany), Ingibjörg J. Gudmundsdóttir, 
(CPG Review Co-ordinator) (Iceland), Juhani Knuuti, (CPG Review Co-ordinator) (Finland), Ingo Ahrens 
(Germany), Michael Böhm (Germany), Sergio Buccheri (Italy), Davide Capodanno (Italy), Evald Høj Christiansen 
(Denmark), Jean-Philippe Collet¶ (France), Kenneth Dickstein (Norway), Christian Eek (Norway), Volkmar Falk 
(Germany), Peter A. Henriksen (United Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), Sasko Kedev 
(Macedonia), Lars Køber (Denmark), Martha Kyriakou (Cyprus), Emma F. Magavern (United Kingdom), 
Angela McInerney (Ireland), John William McEvoy (United Kingdom), Caius Ovidiu Mersha (Romania), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), 
Franz-Josef Neumann (Germany), Jens Cosedis Nielsen (Denmark), Pasquale Paolisso (Italy), Valeria Paradies 
(Netherlands), Agnes A. Pasquet (Belgium), Massimo Piepoli (Italy), Eva Prescott (Denmark), Amina Rakisheva 
(Kazakhstan), Bianca Rocca (Italy), Marc Ruel (Canada), Sigrid Sandner (Austria), Antti Saraste (Finland), 
Karolina Szummer (Sweden), Ilonca Vaartjes (Netherlands), William Wijns (Ireland), Stephan Windecker 
(Switzerland), Adam Witkowsky (Poland), Marija Zdrakovic (Serbia), and Katja Zeppenfeld (Netherlands)
¶ Professor Jean-Philippe Collet sadly passed away during the development of these guidelines. Professor Collet’s 
contribution to these guidelines was, as always, highly valued.
All experts involved in the development of these guidelines have submitted declarations of interest, which are 
reported in a supplementary document to the guidelines. See the European Heart Journal online or https://www. 
escardio.org/Guidelines for supplementary documents as well as evidence tables.
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and 
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, 
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant 
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged 
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do 
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated 
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s 
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC 
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational 
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written 
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of 
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Antianginal therapy • Antithrombotic therapy • Atherosclerosis • Clinical likelihood • Chronic 
coronary syndromes • Coronary artery disease • Diagnostic testing/algorithm • Heart team • Lipid-lowering therapy 
• Microvascular disease • Myocardial ischaemia • Myocardial revascularization • Outcomes • PROMS/PREMS • 
Shared decision-making • Stable angina • Vasospasm


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble .............................................................................................................. 3422
2. Introduction ....................................................................................................... 3423
2.1. Evolving pathophysiological concepts of chronic coronary 
syndromes ..........................................................................................................
3423
2.2. Chronic coronary syndromes: clinical presentations 
(Figure 1) .............................................................................................................
3424
2.3. Changing epidemiology and management strategies ..............
3424
2.4. What is new .............................................................................................
3426
3. Stepwise approach to the initial management of individuals with 
suspected chronic coronary syndrome ....................................................... 3433
3.1. STEP 1: General clinical examination .............................................
3433
3.1.1. History, differential diagnosis, and physical examination
3433
3.1.2. Basic testing: 12-lead electrocardiogram and 
biochemistry .................................................................................................. 3436
3.1.2.1. Electrocardiogram .................................................................
3436
3.1.2.2. Biochemical tests ....................................................................
3437
3.2. STEP 2: Further evaluation .................................................................
3437
3.2.1. Pre-test clinical likelihood of obstructive atherosclerotic 
coronary artery disease ............................................................................ 3437
3.2.2. Transthoracic echocardiography and cardiac magnetic 
resonance at rest ........................................................................................ 3440
3.2.3. Exercise electrocardiogram testing ......................................... 3440
3.2.4. Chest X-ray ....................................................................................... 3441
3.2.5. Ambulatory electrocardiogram monitoring ........................ 3441
3.3. STEP 3: Confirming the diagnosis ...................................................
3441
3.3.1. Anatomical imaging: coronary computed tomography 
angiography .................................................................................................... 3441
3.3.1.1. Computed tomography perfusion imaging .................
3441
3.3.1.2. Prognosis, plaque features, and opportunity to 
improve outcomes ................................................................................
3442
3.3.1.3. Recognized pre-requisites for coronary computed 
tomography angiography ....................................................................
3442
3.3.2. Functional imaging .......................................................................... 3442
3.3.2.1. Stress echocardiography .....................................................
3442
3.3.2.2. Myocardial perfusion scintigraphy—single-photon 
emission computed tomography ....................................................
3443
3.3.2.3. Positron emission tomography-computed 
tomography ..............................................................................................
3444
3.3.2.4. Cardiac magnetic resonance imaging .............................
3444
3.3.2.5. Non-invasive testing for microvascular dysfunction
3445
3.3.3. Invasive tests ..................................................................................... 3445
3.3.3.1. Invasive coronary angiography .........................................
3445
3.3.3.2. Functional assessment of epicardial stenosis severity 
to guide coronary revascularization ...............................................
3446
3.3.3.3. Assessment of microvascular dysfunction ...................
3447
3.3.3.4. Testing for coronary vasospasm .....................................
3447
3.3.4. Diagnostic algorithm and selection of appropriate tests
3448
3.3.5. Adverse-event risk assessment ................................................. 3453
3.4. STEP 4: Initial therapy ..........................................................................
3454
4. Guideline-directed therapy .......................................................................... 3455
4.1. Patient education, lifestyle optimization for risk-factor 
control, and exercise therapy ....................................................................
3455
4.1.1. Patient education ............................................................................ 3455
4.1.2. Key lifestyle interventions for risk-factor control ............ 3455
4.1.2.1. Smoking and substance abuse ..........................................
3456
4.1.2.2. Weight management ............................................................
3456
4.1.2.3. Diet and alcohol .....................................................................
3456
4.1.2.4. Mental health ...........................................................................
3456
4.1.2.5. Physical activity and sedentary behaviour ....................
3456
4.1.3. Exercise therapy .............................................................................. 3457
4.2. Antianginal/anti-ischaemic medication ...........................................
3457
4.2.1. General strategy .............................................................................. 3457
4.2.2. Beta blockers .................................................................................... 3458
4.2.3. Combination therapy .................................................................... 3459
4.3. Medical therapy for event prevention ...........................................
3460
4.3.1. Antithrombotic drugs ................................................................... 3460
4.3.1.1. Antiplatelet drugs ...................................................................
3460
4.3.1.1.1. Aspirin monotherapy ...................................................
3460
4.3.1.1.2. Oral P2Y12 inhibitor monotherapy .......................
3460
4.3.1.1.2.1. Clopidogrel monotherapy .................................
3460
4.3.1.1.2.2. Ticagrelor monotherapy ....................................
3460
4.3.1.1.3. Dual antiplatelet therapy post-percutaneous 
coronary intervention .....................................................................
3462
4.3.1.1.4. Extended intensified antithrombotic therapy ...
3462
4.3.1.1.5. Genotype- and phenotype-guided dual 
antiplatelet therapy ..........................................................................
3463
4.3.1.2. Anticoagulant therapy ..........................................................
3464
4.3.1.2.1. Monotherapy with oral anticoagulant ..................
3464
4.3.1.2.2. Combination of anticoagulant and antiplatelet 
therapy after percutaneous coronary intervention in 
chronic coronary syndrome patients with AF or other 
indication for oral anticoagulant .................................................
3464
4.3.1.3. Coronary artery bypass grafting and antithrombotic 
therapy ........................................................................................................
3465
4.3.1.4. Proton pump inhibitors .......................................................
3465
4.3.2. Lipid-lowering drugs ...................................................................... 3467
4.3.3. Renin–angiotensin–aldosterone blockers/angiotensin 
receptor neprilysin inhibitor .................................................................. 3467
4.3.4. Sodium–glucose cotransporter 2 inhibitors and glucagon- 
like peptide-1 receptor agonists ........................................................... 3468
4.3.5. Anti-inflammatory agents for event prevention ................ 3468
4.4. Revascularization for chronic coronary syndromes ................
3469
4.4.1. Appropriate indication for myocardial revascularization
3469
4.4.2. Additional considerations on reduced systolic left 
ventricular function: myocardial viability, revascularization, and 
its modality .................................................................................................... 3470
4.4.3. Additional considerations—complete vs. partial 
revascularization .......................................................................................... 3471
4.4.4. Assessment of clinical risk and anatomical complexity .. 3471
4.4.5. Choice of myocardial revascularization modality ............. 3472
4.4.5.1. Patients with single- or two-vessel coronary artery 
disease .........................................................................................................
3472
4.4.5.2. Patients with unprotected left main coronary artery 
disease .........................................................................................................
3472
4.4.5.3. Patients with multivessel coronary artery disease ...
3474
4.4.5.4. Impact of coronary pressure guidance on multivessel 
coronary artery disease patients undergoing percutaneous 
coronary intervention ..........................................................................
3474
4.4.5.5. Virtual percutaneous coronary intervention: 
combination of coronary pressure mapping with coronary 
anatomy for percutaneous coronary intervention planning
3474
4.4.5.6. Impact of intracoronary imaging guidance on 
multivessel coronary artery disease patients undergoing 
percutaneous coronary intervention .............................................
3474
4.4.5.7. Hybrid revascularization in multivessel coronary 
artery disease patients .........................................................................


<!-- PAGE 4 -->

### Page 4

4.4.6. Patient–physician shared decision-making to perform and 
select revascularization modality .......................................................... 3475
4.4.7. Institutional protocols, clinical pathways, and quality of 
care .................................................................................................................... 3475
5. Optimal assessment and treatment of specific groups ................... 3478
5.1. Coronary artery disease and heart failure ..................................
3478
5.2. Angina/ischaemia with non-obstructive coronary arteries ...
3479
5.2.1. Definition ........................................................................................... 3479
5.2.2. Angina/ischaemia with non-obstructive coronary arteries 
endotypes ....................................................................................................... 3479
5.2.2.1. Microvascular angina .............................................................
3480
5.2.2.2. Epicardial vasospastic angina .............................................
3481
5.2.3. Clinical presentations .................................................................... 3481
5.2.4. Short- and long-term prognosis ............................................... 3481
5.2.5. Diagnosis ............................................................................................ 3481
5.2.5.1. Non-invasive diagnosis .........................................................
3481
5.2.5.2. Invasive coronary functional testing ...............................
3481
5.2.5.2.1. Basic coronary functional testing ............................
3481
5.2.5.2.2. Coronary vasomotor testing ....................................
3481
5.2.6. Management of angina/ischaemia with non-obstructive 
coronary arteries ........................................................................................ 3483
5.3. Other specific patient groups ...........................................................
3485
5.3.1. Older adults ...................................................................................... 3485
5.3.2. Sex differences in chronic coronary syndromes ............... 3485
5.3.3. High bleeding-risk patients ......................................................... 3486
5.3.4. Inflammatory rheumatic diseases ............................................. 3486
5.3.5. Hypertension .................................................................................... 3486
5.3.6. Atrial fibrillation ............................................................................... 3486
5.3.7. Valvular heart disease ................................................................... 3486
5.3.8. Chronic kidney disease ................................................................. 3487
5.3.9. Cancer ................................................................................................. 3487
5.3.10. Optimal treatment of patients with human 
immunodeficiency virus ............................................................................ 3487
5.3.11. Socially and geographically diverse groups ........................ 3487
5.4. Screening for coronary artery disease in asymptomatic 
individuals ...........................................................................................................
3488
6. Long-term follow-up and care ................................................................... 3489
6.1. Voice of the patient ..............................................................................
3489
6.1.1. Communication ............................................................................... 3489
6.1.2. Depression and anxiety ............................................................... 3489
6.2. Adherence and persistence ...............................................................
3489
6.2.1. Adherence to healthy lifestyle behaviours ........................... 3489
6.2.1.1. Why behavioural changes are difficult ..........................
3489
6.2.1.2. How to change behaviour and support healthy 
lifestyles ......................................................................................................
3490
6.2.1.3. Digital and mHealth ..............................................................
3491
6.2.1.4. How to assess adherence ..................................................
3492
6.2.2. Adherence to medical therapy ................................................. 3492
6.2.2.1. Strategies to improve medication adherence ............
3492
6.2.2.2. mHealth strategies for medication adherence ..........
3492
6.3. Diagnosis of disease progression .....................................................
3492
6.3.1. Risk factors for recurrent coronary artery disease 
events ............................................................................................................... 3493
6.3.2. Organization of long-term follow-up ..................................... 3493
6.3.3. Non-invasive diagnostic testing ................................................. 3494
6.4. Treatment of myocardial revascularization failure ...................
3495
6.4.1. Percutaneous coronary intervention failure ....................... 3495
6.4.2. Managing graft failure after coronary artery bypass 
grafting ............................................................................................................. 3495
6.5. Recurrent or refractory angina/ischaemia ...................................
3496
6.6. Treatment of disease complications ..............................................
3497
7. Key messages ..................................................................................................... 3497
8. Gaps in evidence .............................................................................................. 3498
9. ‘What to do’ and ‘What not to do’ messages from the guidelines
3499
10. Evidence tables ............................................................................................... 3505
11. Data availability statement ......................................................................... 3505
12. Author information ...................................................................................... 3505
13. Appendix ........................................................................................................... 3506
14. References ........................................................................................................ 3507
Tables of Recommendations
Recommendation Table 1 — Recommendations for history taking, 
risk factor assessment, and resting electrocardiogram in individuals 
with suspected chronic coronary syndrome (see also Evidence 
Table 1) ...............................................................................................................................
3436
Recommendation Table 2 — Recommendations for basic 
biochemistry in the initial diagnostic management of individuals 
with suspected chronic coronary syndrome (see also Evidence 
Table 2) ...............................................................................................................................
3437
Recommendation Table 3 — Recommendations for estimating, 
adjusting and reclassifying the likelihood of obstructive 
atherosclerotic coronary artery disease in the initial diagnostic 
management of individuals with suspected chronic coronary 
syndrome (see also Evidence Table 3) ......................................................... 3438
Recommendation Table 4 — Recommendations for resting 
transthoracic ultrasound and cardiac magnetic resonance imaging in 
the initial diagnostic management of individuals with suspected 
chronic coronary syndrome (see also Evidence Table 4) ................... 3440
Recommendation Table 5 — Recommendations for exercise ECG 
in the initial diagnostic management of individuals with suspected 
chronic coronary syndrome (see also Evidence Table 5) ................... 3441
Recommendation Table 6 — Recommendations for chest X-ray in 
the initial diagnostic management of individuals with suspected 
chronic coronary syndrome (see also Evidence Table 6) ................... 3441
Recommendation Table 7 — Recommendations for ambulatory ECG 
monitoring in the initial diagnostic management of individuals with 
suspected chronic coronary syndrome (see also Evidence Table 7) .
3441
Recommendation Table 8 — Recommendations for non-invasive 
anatomical imaging tests in the initial diagnostic management of 
individuals with suspected chronic coronary syndrome—coronary 
computed tomography angiography, if available, and supported by 
local expertise (see also Evidence Table 8) ............................................... 3442
Recommendation Table 9 — Recommendations for non-invasive 
tests in the initial diagnostic management of individuals with suspected 
chronic coronary syndrome—stress echocardiography, if available, 
and supported by local expertise (see also Evidence Table 9) ..............
3443
Recommendation Table 10 — Recommendations for non-invasive 
functional myocardial imaging tests in the initial diagnostic 
management of individuals with suspected chronic coronary 
syndrome—resting and stress single-photon emission computed 
tomography/positron emission tomography—cardiac magnetic 
resonance imaging, if available, and supported by local expertise (see 
also Evidence Table 10) ...................................................................................... 3444
Recommendation Table 11 — Recommendations for invasive 
coronary angiography in the diagnostic management of individuals 
with suspected chronic coronary syndrome (see also Evidence 
Table 11) ................................................................................................................... 3446
Recommendation Table 12 — Recommendations for functional 
assessment of epicardial artery stenosis severity during invasive


<!-- PAGE 5 -->

### Page 5

coronary angiography to guide revascularization (see also Evidence 
Table 12) ................................................................................................................... 3447
Recommendation Table 13 — Recommendations for selection of 
initial diagnostic tests in individuals with suspected chronic coronary 
syndrome (see also Evidence Table 13) ...................................................... 3453
Recommendation Table 14 — Recommendations for definition of 
high risk of adverse events (see also Evidence Table 14) .................... 3454
Recommendation Table 15 — Recommendations for cardiovascular 
risk reduction, lifestyle changes, and exercise interventions in 
patients with established chronic coronary syndrome (see also 
Evidence Table 15) ............................................................................................... 3457
Recommendation Table 16 — Recommendations for antianginal 
drugs in patients with chronic coronary syndrome (see also Evidence 
Table 16) ................................................................................................................... 3459
Recommendation Table 17 — Recommendations for 
antithrombotic therapy in patients with chronic coronary syndrome 
(see also Evidence Table 17) ............................................................................ 3465
Recommendation Table 18 — Recommendations for lipid-lowering 
drugs in patients with chronic coronary syndrome (see also Evidence 
Table 18) ................................................................................................................... 3467
Recommendation Table 19 — Recommendations for sodium– 
glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 
receptor agonists in patients with chronic coronary syndrome (see 
also Evidence Table 19) ...................................................................................... 3468
Recommendation Table 20 — Recommendations for 
anti-inflammatory drugs in patients with chronic coronary syndrome 
(see also Evidence Table 20) ............................................................................ 3469
Recommendation Table 21 — Recommendations for 
angiotensin-converting enzyme inhibitors in patients with chronic 
coronary syndrome (see also Evidence Table 21) ................................. 3469
Recommendation Table 22 — Recommendations for 
revascularization in patients with chronic coronary syndrome (see 
also Evidence Table 22) ...................................................................................... 3476
Recommendation Table 23 — Recommendations for mode of 
revascularization in patients with chronic coronary syndrome (see 
also Evidence Table 23) ...................................................................................... 3477
Recommendation Table 24 — Recommendations for management 
of chronic coronary syndrome patients with chronic heart failure 
(see also Evidence Table 24) ............................................................................ 3478
Recommendation Table 25 — Recommendations for diagnosis and 
management of patients with angina/ischaemia with non-obstructive 
coronary arteries (see also Evidence Table 25) ........................................ 3485
Recommendation Table 26 — Recommendations for older, female, 
high bleeding risk, comorbid, and socially/geographically diverse 
patients (see also Evidence Table 26) ........................................................... 3488
Recommendation Table 27 — Recommendations for screening for 
coronary artery disease in asymptomatic individuals (see also 
Evidence Table 27) ............................................................................................... 3488
Recommendation Table 28 — Recommendations for adherence to 
medical therapy and lifestyle changes (see also Evidence Table 28)
3492
Recommendation Table 29 — Recommendations for diagnosis of 
disease progression in patients with established chronic coronary 
syndrome (see also Evidence Table 29) ...................................................... 3495
Recommendation Table 30 — Recommendations for treatment of 
revascularization failure (see also Evidence Table 30) .......................... 3496
Recommendation Table 31 — Recommendations for recurrent or 
refractory angina/ischaemia (see also Evidence Table 31) .................. 3496
List of tables
Table 1 Classes of recommendations .......................................................... 3422
Table 2 Levels of evidence ................................................................................ 3423
Table 3 New major recommendations in 2024 ...................................... 3426
Table 4 Revised recommendations ............................................................... 3430
Table 5 Grading of effort angina severity according to the Canadian 
Cardiovascular Society ........................................................................................ 3436
Table 6 Overview of non-invasive tests used for first-line testing in 
individuals with suspected chronic coronary syndrome ...................... 3451
Table 7 Practical advice on lifestyle counselling and interventions . 3455
Table 8 Options for extended intensified antithrombotic therapy
3464
Table 9 Summary of trial-based evidence for the comparison of 
percutaneous coronary intervention and coronary artery bypass 
grafting in patients with left main coronary artery disease ................ 3473
Table 10 ‘What to do’ and ‘What not to do’ .......................................... 3499
List of figures
Figure 1 (Central Illustration) Clinical presentations of chronic 
coronary syndrome and mechanisms of myocardial ischaemia ........ 3425
Figure 2 Stepwise approach to the initial management of individuals 
with suspected chronic coronary syndrome ............................................ 3434
Figure 3 Main CCS symptoms: angina and exertional dyspnoea ..... 3435
Figure 4 Estimation of the clinical likelihood of obstructive coronary 
artery disease .......................................................................................................... 3439
Figure 5 Adjustment and reclassification of the estimated clinical 
likelihood of obstructive coronary artery disease .................................. 3448
Figure 6 Appropriate first-line testing in symptomatic individuals 
with suspected chronic coronary syndrome ............................................ 3449
Figure 7 Initial management of symptomatic individuals with 
suspected chronic coronary syndrome ....................................................... 3450
Figure 8 Ruling in and ruling out functionally significant obstructive 
coronary artery disease by sequential anatomical (coronary 
computed tomography angiography) and functional (dobutamine 
stress echocardiography) testing.a ................................................................. 3452
Figure 9 Possible combinations of antianginal drugs .............................. 3458
Figure 10 Antithrombotic drugs for chronic coronary syndromes: 
pharmacological targets ...................................................................................... 3461
Figure 11 Antithrombotic treatment in chronic coronary syndrome 
patients undergoing percutaneous coronary intervention ................. 3463
Figure 12 Prevalence of disease characteristics in patients with 
ANOCA/INOCA referred for invasive coronary functional testing
3480
Figure 13 Diagnostic algorithm for patients with angina/ischaemia 
with non-obstructive coronary arteries ...................................................... 3482
Figure 14 Spasm provocation and functional testing protocol ......... 3483
Figure 15 Treatment of angina/ischaemia with non-obstructive 
coronary arteries .................................................................................................. 3484
Figure 16 Actions on the five dimensions of adherence to therapy
3490
Figure 17 Strategies for long-term adherence to a healthy lifestyle
3491
Figure 18 Approach for the follow-up of patients with established 
chronic coronary syndrome ............................................................................. 3494
Abbreviations and acronyms
99mTc
Technetium-99m
ACE-I
Angiotensin-converting enzyme inhibitor
Ach
Acetylcholine
ACS
Acute coronary syndrome(s)
AF
Atrial fibrillation
AKI
Acute kidney injury
ALPHEUS
Assessment of Loading with the P2Y12 Inhibitor 
Ticagrelor or Clopidogrel to Halt Ischemic 
Events in Patients Undergoing Elective Coronary 
Stenting
ANOCA
Angina with non-obstructive coronary arteries
ARB
Angiotensin receptor blocker
ESC Guidelines                                                                                                                                                                                          3419


<!-- PAGE 6 -->

### Page 6

ARC-HBR
Academic Research Consortium for High 
Bleeding Risk
ARNI
Angiotensin receptor neprilysin inhibitor
ART
Antiretroviral therapy
ASCVD
Atherosclerotic cardiovascular disease
ASE
American Society of Echocardiography
AUGUSTUS
Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety of 
Apixaban versus Vitamin K Antagonist and 
Aspirin versus Aspirin Placebo in Patients with 
Atrial Fibrillation and Acute Coronary Syndrome 
or Percutaneous Coronary Intervention
BARC
Bleeding Academic Research Consortium b.i.d.
bis in die (twice daily)
BMI
Body mass index
BP
Blood pressure b.p.m.
Beats per minute
CABG
Coronary artery bypass grafting
CAC
Coronary artery calcification
CACS
Coronary artery calcium score
CACS-CL
CACS + risk-factor-weighted clinical likelihood 
(RF-CL) model
CAD
Coronary artery disease
CANTOS
Canakinumab Antiinflammatory Thrombosis 
Outcome Study
CAPRIE
Clopidogrel versus Aspirin in Patients at Risk of 
Ischaemic Events
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome(s)
CCTA
Coronary computed tomography angiography
CFC
Coronary flow capacity
CFR
Coronary flow reserve
CFVR
Coronary flow velocity reserve
CHA2DS2-VASc
Congestive heart failure or left ventricular 
dysfunction, hypertension, age ≥75 (doubled), 
diabetes, stroke (doubled), vascular disease, age 
65–74, sex category (female)
CI
Confidence interval
CKD
Chronic kidney disease
CMD
Coronary microvascular dysfunction
CMR
Cardiac magnetic resonance
COLCOT
Colchicine Cardiovascular Outcomes Trial
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COURAGE
Clinical Outcomes Utilizing Revascularization 
and Aggressive Drug Evaluation
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CVD
Cardiovascular disease
CYP2C19
Cytochrome P450 2C19
CYP3A4
Cytochrome P450 3A4
CZT
Cadmium–zinc–telluride
DAPT
Dual antiplatelet therapy
DEFINE GPS
Distal Evaluation of Functional Performance with 
Intravascular Sensors to Assess the Narrowing 
Effect: Guided Physiologic Stenting
DES
Drug-eluting stent
DEFINE-FLAIR
Functional Lesion Assessment of Intermediate 
Stenosis to Guide Revascularisation
DHP
Dihydropyridine
DM
Diabetes mellitus
DOAC
Direct oral anticoagulant dPR
Diastolic pressure ratio
DSE
Dobutamine stress echocardiography
EACTS
European Association for Cardio-Thoracic Surgery
EACVI
European Association of Cardiovascular Imaging
ECG
Electrocardiogram
EF
Ejection fraction eGFR
Estimated glomerular filtration rate
EMA
European Medicines Agency
ESC
European Society of Cardiology
EXCEL
Evaluation of XIENCE versus Coronary Artery 
Bypass Surgery for Effectiveness of Left Main 
Revascularization
FAME
Fractional Flow Reserve versus Angiography for 
Multivessel Evaluation
FFR
Fractional flow reserve
FFR-CT
Coronary computed tomography 
angiography-derived fractional flow reserve
FREEDOM
Strategies for Multivessel Revascularization in 
Patients with Diabetes
GDMT
Guideline-directed medical therapy
GI
Gastrointestinal
GIP
Glucose-dependent insulinotropic polypeptide
GLOBAL 
LEADERS
Ticagrelor plus aspirin for 1 month, followed by 
ticagrelor monotherapy for 23 months vs. aspirin 
plus clopidogrel or ticagrelor for 12 months, 
followed by aspirin monotherapy for 12 months 
after implantation of a drug-eluting stent (DES): 
a multicentre, open-label, randomized 
superiority trial
GLP-1
Glucagon-like peptide-1
GUSTO
Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Arteries
HbA1c
Glycated haemoglobin
HBR
High bleeding risk
HDL-C
High-density lipoprotein cholesterol
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HIV
Human immunodeficiency virus
HMR
Hyperaemic myocardial velocity resistance
HOST-EXAM
Harmonizing Optimal Strategy for Treatment of 
Coronary Artery Stenosis-EXtended 
Antiplatelet Monotherapy
HR
Hazard ratio hs-CRP
High-sensitivity C-reactive protein
HSR
Hyperaemic stenosis resistance i.c.
Intracoronary i.v.
Intravenous
ICA
Invasive coronary angiography
ICD
Implantable cardioverter defibrillator
ICFT
Invasive coronary functional testing iFR
Instantaneous wave-free ratio iFR- 
SWEDEHEART
Instantaneous Wave-free Ratio versus Fractional 
Flow Reserve in Patients with Stable Angina 
Pectoris or Acute Coronary Syndrome
ILIAS
Inclusive Invasive Physiological Assessment in 
Angina Syndromes
IMR
Index of microcirculatory resistance
INOCA
Ischaemia with non-obstructive coronary arteries
INR
International normalized ratio
IQR
Interquartile range


<!-- PAGE 7 -->

### Page 7

ISCHEMIA
Initial Invasive or Conservative Strategy for 
Stable Coronary Disease (trial)
ISR
In-stent restenosis
ISTH
International Society on Thrombosis and 
Haemostasis
IVUS
Intravascular ultrasound
LAD
Left anterior descending
LBBB
Left bundle branch block
LDL-C
Low-density lipoprotein cholesterol
LGE
Late gadolinium enhancement
LIMA
Left internal mammary artery
LITA
Left internal thoracic artery
LMCA
Left main coronary artery
LMCAD
Left main coronary artery disease
LODOCO2
LOw-DOse COlchicine 2
LOE
Level of evidence
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MACCE
Major adverse cardiac or cerebrovascular events
MACE
Major adverse cardiovascular events
MASTER-DAPT
Management of High Bleeding Risk Patients Post 
Bioresorbable Polymer Coated Stent Implantation 
with an Abbreviated versus Standard DAPT Regimen
MBF
Myocardial blood flow
MCE
Myocardial contrast echocardiography
MCS
Mechanical circulatory support
MFR
Myocardial flow reserve mHealth
Mobile device-based healthcare
MI
Myocardial infarction
MIDCAB
Minimally invasive direct coronary artery bypass
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging
MRR
Microvascular resistance reserve
MVA
Microvascular angina
MVD
Multivessel disease
NNH
Number needed to harm
NNT
Number needed to treat to prevent an adverse event
NOBLE
Nordic–Baltic–British Left Main 
Revascularisation Study
NSTEMI
Non-ST-segment elevation myocardial infarction
NTG
Nitroglycerine
NYHA
New York Heart Association
OAC
Oral anticoagulant
OCT
Optical coherence tomography
OR
Odds ratio
ORBITA
Objective Randomised Blinded Investigation with 
optimal medical Therapy of Angioplasty in stable 
angina
ORBITA-COSMIC
Coronary Sinus Reducer Objective Impact on 
Symptoms, MRI Ischaemia and Microvascular 
Resistance
PAD
Peripheral artery disease
PAR
Protease-activated receptor
PARR-2
F-18-Fluorodeoxyglucose Positron Emission 
Tomography Imaging-Assisted Management of 
Patients with Severe Left Ventricular 
Dysfunction and Suspected Coronary Disease: a 
Randomized, Controlled Trial
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
Pd/Pa
Distal coronary pressure to aortic pressure ratio
PDE-5
Phosphodiesterase-5
PEGASUS-TIMI 
54
Prevention of Cardiovascular Events in Patients 
with Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of 
Aspirin Thrombolysis In Myocardial Infarction
PESA
Progression of Early Subclinical Atherosclerosis
PET
Positron emission tomography
PRECISE-DAPT
PREdicting bleeding Complications In 
patients undergoing Stent implantation 
and subsEquent Dual AntiPlatelet Therapy
PRECOMBAT
Randomized Trial of Stents versus Bypass 
Surgery for Left Main Coronary Artery Disease 
(trial)
PRIZE
Precision Medicine with Zibotentan in 
Microvascular Angina
PROM
Patient-reported outcome measure
PROMISE
Prospective Multicenter Imaging Study for 
Evaluation of Chest Pain
PTP
Pre-test probability
QFR
Quantitative flow ratio
QoL
Quality of life
R3F
French FFR Registry
RAAS
Renin–angiotensin–aldosterone system
RCT
Randomized controlled trial
REVIVED-BCIS2
Percutaneous Revascularization for Ischemic Left 
Ventricular Dysfunction
RF-CL
Risk-factor-weighted clinical likelihood
RFR
Relative flow reserve
RIPCORD
Routine Pressure Wire Assessment Influence 
Management Strategy at Coronary Angiography 
for Diagnosis of Chest Pain trial
RR
Relative risk
RWTA
Regional systolic wall-thickening abnormalities
SAPT
Single antiplatelet therapy
SCORE2
Systematic Coronary Risk Estimation 2
SCORE2-OP
Systematic Coronary Risk Estimation 2–Older 
Persons
SCOT-HEART
Scottish Computed Tomography of the Heart
SELECT
Semaglutide Effects on Cardiovascular 
Outcomes in People With Overweight or 
Obesity
SGLT2
Sodium–glucose cotransporter 2
SLE
Systemic lupus erythematosus
SPECT
Single-photon emission computed  
tomography
STEMI
ST-segment elevation myocardial infarction
STICH
Surgical Treatment for Ischemic Heart Failure
STS-PROM
Society of Thoracic Surgeons Predicted Risk of 
Mortality
SURMOUNT
Efficacy and Safety of Tirzepatide Once Weekly 
in Participants Without Type 2 Diabetes Who 
Have Obesity or Are Overweight With Weight- 
Related Comorbidities: A Randomized, Double- 
Blind, Placebo-Controlled Trial
SYNTAX
SYNergy between PCI with TAXUS and Cardiac 
Surgery
THEMIS
The Effect of Ticagrelor on Health Outcomes  
in diabEtes Mellitus patients Intervention Study
TID
Transient ischaemic dilatation
TIMI
Thrombolysis In Myocardial Infarction
Tx
Thromboxane
ESC Guidelines                                                                                                                                                                                          3421


<!-- PAGE 8 -->

### Page 8

TWILIGHT
Ticagrelor with Aspirin or Alone in High-Risk 
Patients after Coronary Intervention vFFR
Vessel fractional flow reserve
VKA
Vitamin K antagonist
VSA
Vasospastic angina
VTE
Venous thrombo-embolism
WARRIOR
Women’s IschemiA Trial to Reduce Events 
in Non-ObstRuctIve CORonary Artery Disease
WOMEN
What is the Optimal Method for Ischemia 
Evaluation of Women
X-ECG
Exercise ECG testing
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals, and the European Society of 
Cardiology (ESC) makes its guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription and to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated when warranted by new evidence. ESC 
Policies and Procedures for formulating and issuing ESC Guidelines can 
be found on the ESC website (https://www.escardio.org/Guidelines/ 
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Gui 
delines). These guidelines update and replace the previous version from 
2019 and partly replace the myocardial revascularization guidelines 
from 2018.
The Members of this task force were selected by the ESC to include 
professionals involved in the medical care of patients with this path­
ology, as well as patient representatives and methodologists. The selec­
tion procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
and inclusion, notably with respect to gender and country of origin. 
The task force performed a critical review and evaluation of the pub­
lished literature on diagnostic and therapeutic approaches including as­
sessment of the risk–benefit ratio. The strength of every 
recommendation and the level of evidence supporting them were 
weighed and scored according to predefined scales as outlined in 
Tables 1 and 2 below. Patient-reported outcome measures (PROMs) 
and patient-reported experience measures (PREMs) were also evalu­
ated as the basis for recommendations and/or discussion in these guide­
lines. The task force followed ESC voting procedures and all approved 
recommendations were subject to a vote and achieved at least 75% 
agreement among voting members. Members of the task force with de­
clared interests on specific topics were asked to abstain from voting on 
related recommendations.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules, 
which can be found on the ESC website (http://www.escardio.org/ 
guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. Funding for the development 
of ESC Guidelines is derived entirely from the ESC with no involvement 
of the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2024


<!-- PAGE 9 -->

### Page 9

for the approval process. In addition to review by the CPG Committee, 
ESC Guidelines undergo multiple rounds of double-blind peer review 
by external experts, including members from across the whole of the 
ESC region, all National Cardiac Societies of the ESC and from relevant 
ESC Subspecialty Communities. After appropriate revisions, the 
guidelines are signed off by all the experts in the task force. The finalized 
document is signed off by the CPG Committee for publication in the 
ESC Guidelines are based on analyses of published evidence, chiefly 
on clinical trials and meta-analyses of trials, but potentially including 
other types of studies. Evidence tables summarizing key information 
from relevant studies are generated early in the guideline development 
process to facilitate the formulation of recommendations, to enhance 
comprehension of recommendations after publication, and reinforce 
transparency in the guideline development process. The tables are pub­
lished in their own section of the ESC Guidelines and are specifically 
related to the recommendation tables.
Off-label use of medication may be presented in these guidelines if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
The 2019 ESC (European Society of Cardiology) Guidelines for the 
diagnosis and management of chronic coronary syndromes introduced 
the term chronic coronary syndromes (CCS)1 to describe the clinical 
presentations of coronary artery disease (CAD) during stable periods, 
particularly those preceding or following an acute coronary syndrome 
(ACS). CAD was defined as the pathological process characterized by 
atherosclerotic plaque accumulation in the epicardial arteries, whether 
obstructive or non-obstructive. Based on expanded pathophysiological 
concepts, a new, more comprehensive definition of CCS is introduced: 
‘CCS are a range of clinical presentations or syndromes that 
arise due to structural and/or functional alterations related to 
chronic diseases of the coronary arteries and/or microcircula­
tion. These alterations can lead to transient, reversible, myocar­
dial demand vs. blood supply mismatch resulting in 
hypoperfusion (ischaemia), usually (but not always) provoked 
by exertion, emotion or other stress, and may manifest as angina, 
other chest discomfort, or dyspnoea, or be asymptomatic. 
Although stable for long periods, chronic coronary diseases 
are frequently progressive and may destabilize at any moment 
with the development of an ACS.’
Of note, ‘disease’ refers to the underlying coronary pathology, and ‘syn­
drome’ refers to the clinical presentation.
2.1. Evolving pathophysiological concepts 
of chronic coronary syndromes
Our understanding of the pathophysiology of CCS is transitioning from 
a simple to a more complex and dynamic model. Older concepts 
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3423


<!-- PAGE 10 -->

### Page 10

considered a fixed, focal, flow-limiting atherosclerotic stenosis of a large 
or medium coronary artery as a sine qua non for inducible myocardial 
ischaemia and ischaemic chest pain (angina pectoris). Current concepts 
have broadened to embrace structural and functional abnormalities in 
both the macro- and microvascular compartments of the coronary tree 
that may lead to transient myocardial ischaemia. At the macrovascular 
level, not only fixed, flow-limiting stenoses but also diffuse atheroscler­
otic lesions without identifiable luminal narrowing may cause ischaemia 
under stress;2,3 structural abnormalities such as myocardial bridging4
and congenital arterial anomalies5 or dynamic epicardial vasospasm 
may be responsible for transient ischaemia. At the microvascular level, 
coronary microvascular dysfunction (CMD) is increasingly acknowl­
edged as a prevalent factor characterizing the entire spectrum of 
CCS;6 functional and structural microcirculatory abnormalities may 
cause angina and ischaemia even in patients with non-obstructive 
disease of the large or medium coronary arteries [angina with 
non-obstructive coronary arteries (ANOCA); ischaemia with non- 
obstructive coronary arteries (INOCA)].6 Finally, systemic or extracor­
onary conditions, such as anaemia, tachycardia, blood pressure (BP) 
changes, myocardial hypertrophy, and fibrosis, may contribute to the 
complex pathophysiology of non-acute myocardial ischaemia.7
The risk factors that predispose to the development of epicardial 
coronary atherosclerosis also promote endothelial dysfunction and ab­
normal vasomotion in the entire coronary tree, including the arterioles 
that regulate coronary flow and resistance,8–10 and adversely affect 
myocardial capillaries,6,11–14 leading to their rarefaction. Potential con­
sequences include a lack of flow-mediated vasodilation in the epicardial 
conductive arteries9 and macro- and microcirculatory vasoconstric­
tion.15
Of note, different mechanisms of ischaemia may act 
concomitantly.
2.2. Chronic coronary syndromes: clinical 
presentations (Figure 1)
In clinical practice, the following, not entirely exclusive, CCS patients 
seek outpatient medical attention: (i) the symptomatic patient with re­
producible stress-induced angina or ischaemia with epicardial obstruct­
ive CAD; (ii) the patient with angina or ischaemia caused by epicardial 
vasomotor abnormalities or functional/structural microvascular altera­
tions in the absence of epicardial obstructive CAD (ANOCA/INOCA); 
(iii) the non-acute patient post-ACS or after a revascularization; 
(iv) the non-acute patient with heart failure (HF) of ischaemic or 
cardiometabolic origin. A further growing category (v) are the 
asymptomatic individuals in whom epicardial CAD is detected during 
an imaging test for refining cardiovascular risk assessment,16 screening 
for personal or professional purposes, or as an incidental finding for an­
other indication.17 Patients may experience a variable and unpredict­
able course, transitioning between different types of CCS and ACS 
presentations throughout their lifetime.
The clinical presentations of CCS are not always specific for the 
mechanism causing myocardial ischaemia; thus, symptoms of 
dysfunctional microvascular angina (MVA) may overlap with those of 
vasospastic or even obstructive large–medium artery angina. 
Furthermore, it is important to note that CCS doesn’t always present 
as classical angina pectoris and symptoms may vary depending on age 
and sex. Sex-stratified analyses indicate that women with suspected 
angina are usually older and have a heavier cardiovascular risk 
factor burden, more frequent comorbidities, non-anginal symptoms 
such as dyspnoea and fatigue, and greater prevalence of MVA than 
men.18–21
2.3. Changing epidemiology and 
management strategies
Contemporary primary prevention,16 including lifestyle changes and 
guideline-directed medical therapy (GDMT), has led to a decline of 
the age-standardized prevalence22,23 of obstructive epicardial coronary 
atherosclerosis in patients with suspected CCS.24–28 As a consequence, 
the diagnostic and prognostic risk prediction models applied in the past 
to identify obstructive epicardial CAD in patients with suspected angina 
pectoris have required updating and refinement.27,29,30 Initial use of 
coronary computed tomography angiography (CCTA)31,32 for detect­
ing and assessing epicardial coronary atherosclerosis is increasingly 
being adopted since it has shown similar performance to non-invasive 
stress testing for detecting segmental myocardial ischaemia.33–35
Invasive coronary angiography (ICA), classically used to detect anatom­
ically significant stenoses, has expanded to become a functional test36
that includes refined haemodynamic assessment of epicardial stenoses, 
provocative testing for the detection of epicardial or microvascular 
spasm,37–40 and a functional assessment of CMD.41–43 Moreover, there 
is a growing interest in non-invasive imaging methods such as stress 
positron emission tomography (PET)44,45 or stress magnetic resonance 
imaging (MRI),46 which allow accurate assessment of the coronary 
microcirculation in a quantitative manner.
Medical therapy for CCS patients, including antithrombotic strat­
egies, anti-inflammatory drugs, statins and new lipid-lowering, meta­
bolic, and anti-obesity agents, has significantly improved survival 
after conservative treatment, making it harder to demonstrate the 
benefits of early invasive therapy.47 However, revascularization can 
still benefit patients with obstructive CAD at high risk of adverse 
events, not only for symptom relief48–52 but also to prevent spontan­
eous myocardial infarction (MI) and cardiac death and, in some 
groups, to improve overall survival53–56 during long-term follow-up. 
Recently, revascularization through percutaneous coronary interven­
tion (PCI) was shown to provide more angina relief than a placebo 
procedure in patients with stable angina and evidence of ischaemia, 
on minimal or no antianginal therapy, confirming the beneficial effects 
of revascularization.52
The present guidelines deal with the assessment and diagnostic algo­
rithm in patients with symptoms suspected of CCS (Section 3) and their 
treatment (Section 4), special subgroups of CCS patients (Section 5) and 
finally, long-term follow-up and care (Section 6).


<!-- PAGE 11 -->

### Page 11

Asymptomatic with abnormal coronary anatomical or functional test
Angina or equivalent with no obstructive CAD
(ANOCA/INOCA)
Stabilized phase after ACS, PCI, or CABG
Stress-induced angina, or equivalent, 
with obstructive CAD
A
B
LV dysfunction or heart failure of ischaemic origin
Structural
Epicardial
Microvascular
Main mechanisms of myocardial ischaemia in chronic coronary syndromes 
Functional
Structural
Functional
Atherosclerosis
(focal or diffuse)
Stabilized intramural haematoma
Myocardial 
bridge
Coronary aneurysm
Impaired vasodilation
Increased vasoconstriction
Epicardial vasospasm
Inward arteriolar remodelling
Capillary rarefaction
Intravascular plugging
Perivascular fibrosis or infiltration
Extramural compression
(myocardial hypertrophy,
increased LVEDP)
Clinical spectrum 
of suspected, or 
confirmed, 
chronic coronary 
syndromes 
Autonomic dysregulation
Endothelial dysfunction and/or
VSMC hyperreactivity
Autonomic dysregulation
Endothelial dysfunction and/or
VSMC hyperreactivity
Figure 1 (Central Illustration) Clinical presentations of chronic coronary syndrome and mechanisms of myocardial ischaemia. ACS, acute coronary 
syndrome; ANOCA, angina with non-obstructive coronary arteries; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, 
chronic coronary syndrome; INOCA, ischaemia with non-obstructive coronary arteries; LV, left ventricular; LVEDP, left ventricular end-diastolic pres­
sure; PCI, percutaneous coronary intervention; VSMC, vascular smooth muscle cell.
ESC Guidelines                                                                                                                                                                                          3425


<!-- PAGE 12 -->

### Page 12

2.4. What is new
The 2024 Guidelines contain a number of new and revised recommendations, which are summarized in Tables 3 and 4, respectively.
Table 3 New major recommendations in 2024
Recommendations
Classa
Levelb
History taking and risk factor assessment and resting electrocardiogram in individuals with suspected chronic coronary syndrome— 
Section 3
In individuals reporting symptoms of suspected myocardial ischaemic origin, a detailed assessment of cardiovascular risk factors, medical 
history, and symptom characteristics (including onset, duration, type, location, triggers, relieving factors, time of day) is recommended.
I
C
Symptoms like chest pain triggered by emotional stress; dyspnoea or dizziness on exertion; pain in the arms, jaw, neck, or upper back; or 
fatigue should be considered as potential angina equivalents.
IIa
B
Basic biochemistry in the initial diagnostic management of individuals with suspected chronic coronary syndrome—Section 3
• Additionally, high-sensitivity C-reactive protein and/or fibrinogen plasma levels should be considered.
IIa
B
Likelihood of obstructive atherosclerotic coronary artery disease in the initial diagnostic management of individuals with suspected 
chronic coronary syndrome—Section 3
It is recommended to estimate the pre-test likelihood of obstructive epicardial CAD using the Risk Factor-weighted Clinical Likelihood 
model.
I
B
It is recommended to use additional clinical data (e.g. examination of peripheral arteries, resting ECG, resting echocardiography, presence of 
vascular calcifications on previously performed imaging tests) to adjust the estimate yielded by the Risk Factor-weighted Clinical Likelihood 
model.
I
C
In individuals with a very low (≤5%) pre-test likelihood of obstructive CAD, deferral of further diagnostic tests should be considered.
IIa
B
In individuals with a low (>5%–15%) pre-test likelihood of obstructive CAD, CACS should be considered to reclassify subjects and to 
identify more individuals with very low (≤5%) CACS-weighted clinical likelihood.
IIa
B
In individuals with an initially low (>5%–15%) likelihood of obstructive CAD, exercise ECG and detection of atherosclerotic disease in 
non-coronary arteries may be considered to adjust the pre-test likelihood estimate.
IIb
C
Ambulatory electrocardiogram in the initial diagnostic management of individuals with suspected chronic coronary syndrome—Section 3
Ambulatory ECG monitoring should be considered in subjects with suspected vasospastic angina.
IIa
B
Non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected obstructive coronary artery 
disease—coronary computed tomography angiography, if available and supported by local expertise—Section 3
In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to 
diagnose obstructive CAD and to estimate the risk of MACE.
I
A
Non-invasive tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome—stress 
echocardiography, if available and supported by local expertise—Section 3
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress echocardiography is 
recommended to diagnose myocardial ischaemia and to estimate the risk of MACE.
I
B
During stress echocardiography, when two or more contiguous myocardial segments are not visualized, it is recommended to use 
commercially available intravenous ultrasound contrast agents (microbubbles) to improve diagnostic accuracy.
I
B
During stress echocardiography, myocardial perfusion using commercially available intravenous ultrasound contrast agents (microbubbles) 
is recommended to improve diagnostic accuracy and to refine risk stratification beyond wall motion.
I
B
During stress echocardiography, Doppler left anterior descending coronary artery flow reserve may be considered to improve risk 
stratification beyond wall motion and to assess microvascular function.
IIb
B
Non-invasive functional myocardial imaging tests in the initial diagnostic management of individuals with suspected chronic coronary 
syndrome—resting and stress single-photon emission computed tomography/positron emission tomography—cardiac magnetic 
resonance imaging, if available and supported by local expertise—Section 3
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, SPECT or, preferably, PET 
myocardial perfusion imaging is recommended to:  
• diagnose and quantify myocardial ischaemia and/or scar;
• estimate the risk of MACE;
• quantify myocardial blood flow (PET).
I
B
In patients selected for PET or SPECT myocardial perfusion imaging, it is recommended to measure CACS from unenhanced chest CT 
imaging (used for attenuation correction) to improve detection of both non-obstructive and obstructive CAD.
I
B
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, CMR perfusion imaging is 
recommended to diagnose and quantify myocardial ischaemia and/or scar and estimate the risk of MACE.
I
B
Continued


<!-- PAGE 13 -->

### Page 13

Indications for invasive coronary angiography in individuals with suspected obstructive coronary artery disease—Section 3
When ICA is indicated, radial artery access is recommended as the preferred access site.
I
A
When ICA is indicated, it is recommended to have coronary pressure assessment available and to use it to evaluate the functional severity of 
intermediate non-left main stem stenoses prior to revascularization.
I
A
In individuals with de novo symptoms highly suggestive of obstructive CAD that occur at a low level of exercise, ICA with a view towards 
revascularization is recommended as first diagnostic test after clinical assessment by a cardiologist.
I
C
Functional assessment of epicardial artery stenosis severity during invasive coronary angiography—Section 3
During ICA, selective assessment of functional severity of intermediate diameter stenoses is recommended to guide the decision to revascularize, using the 
following techniques:
• FFR/iFR (significant ≤0.8 or ≤0.89, respectively);
I
A
• QFR (significant ≤0.8).
I
B
In addition:
• CFR/HSR/CFC should be considered as a complementary investigation;
IIa
B
• resting invasive measurement of Pd/Pa, dPR, RFR, or angiography-derived vessel FFR may be considered as alternative parameters.
IIb
C
Systematic and routine wire-based coronary pressure assessment of all coronary vessels is not recommended.
III
A
Selection of individual diagnostic tests in individuals with suspected chronic coronary syndrome—Section 3
To rule out obstructive CAD in individuals with low or moderate (>5%–50%) pre-test likelihood, CCTA is recommended as the preferred 
diagnostic modality.
I
B
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD if functional imaging for 
myocardial ischaemia is not diagnostic.
I
B
Invasive coronary angiography with the availability of invasive functional assessments is recommended to confirm or exclude the diagnosis of 
obstructive CAD or ANOCA/INOCA in individuals with an uncertain diagnosis on non-invasive testing.
I
B
In patients with a known intermediate coronary artery stenosis in a proximal or mid coronary segment on CCTA, CT-based FFR may be 
considered.
IIb
B
Definition of high risk of adverse events
An initial stratification of risk of adverse events is recommended based on basic clinical assessment (e.g. age, ECG, anginal threshold, 
diabetes, CKD, LVEF).
I
B
The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events: 
• exercise ECG: 
⚬Duke Treadmill Score < −10;
• stress SPECT or PET perfusion imaging: 
⚬area of ischaemia ≥10% of the LV myocardium;
• stress echocardiography: 
⚬≥3 of 16 segments with stress-induced hypokinesia or akinesia;
• stress CMR: 
⚬≥2 of 16 segments with stress perfusion defects or
⚬≥3 dobutamine-induced dysfunctional segments;
• CCTA: 
⚬left main disease with ≥50% stenosis,
⚬three-vessel disease with ≥70 stenosis, or
⚬two-vessel disease with ≥70% stenosis, including the proximal LAD or
⚬one-vessel disease of the proximal LAD with ≥70% stenosis and FFR-CT ≤0.8
I
B
Cardiovascular risk, lifestyle changes, and exercise interventions in patients with established chronic coronary syndrome—Section 4
An informed discussion on CVD risk and treatment benefits tailored to individual patient needs is recommended.
I
C
Multidisciplinary behavioural approaches to help patients achieve healthy lifestyles, in addition to appropriate pharmacological management, 
are recommended.
I
A
Aerobic physical activity of at least 150–300 min per week of moderate intensity or 75–150 min per week of vigorous intensity and 
reduction in sedentary time are recommended.
I
B
Home-based cardiac rehabilitation and mobile health interventions should be considered to increase patients’ long-term adherence to 
healthy behaviours, and to reduce hospitalizations or cardiac events.
IIa
B
Antianginal drugs in patients with chronic coronary syndrome—Section 4
It is recommended to tailor the selection of antianginal drugs to the patient’s characteristics, comorbidities, concomitant medications, 
treatment tolerability, and underlying pathophysiology of angina, also considering local drug availability and cost.
I
C
Ivabradine should be considered as add-on antianginal therapy in patients with left ventricular systolic dysfunction (LVEF <40%) and 
inadequate control of symptoms, or as part of initial treatment in properly selected patients.
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3427


<!-- PAGE 14 -->

### Page 14

Ivabradine is not recommended as add-on therapy in patients with CCS, LVEF >40%, and no clinical heart failure.
III
B
Combination of ivabradine with non-DHP-CCB or other strong CYP3A4 inhibitors is not recommended.
III
B
Antithrombotic therapy in patients with chronic coronary syndrome—Section 4
Long-term antithrombotic therapy in patients with chronic coronary syndrome and no clear indication for oral anticoagulation
In CCS patients with a prior MI or PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin monotherapy.
I
A
After CABG, aspirin 75–100 mg daily is recommended lifelong.
I
A
In CCS patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is 
recommended lifelong.
I
B
Lipid-lowering drugs in patients with chronic coronary syndrome—Section 4
Lipid-lowering treatment with an LDL-C goal of <1.4 mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C vs. baseline is recommended.
I
A
For patients who are statin intolerant and do not achieve their goal on ezetimibe, combination with bempedoic acid is recommended.
I
B
For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with bempedoic acid should 
be considered.
IIa
C
Sodium–glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 receptor agonists in patients with chronic coronary 
syndrome—Section 4
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and CCS to reduce CV events, independent of baseline 
or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
The GLP-1 receptor agonist semaglutide should be considered in CCS patients without diabetes, but with overweight or obesity 
(BMI ≥27 kg/m2), to reduce CV mortality, MI, or stroke.
IIa
B
Anti-inflammatory drugs in patients with chronic coronary syndrome—Section 4
In CCS patients with atherosclerotic CAD, low-dose colchicine (0.5 mg daily) should be considered to reduce myocardial infarction, stroke, 
and need for revascularization.
IIa
A
Revascularization in patients with chronic coronary syndrome—Section 4
Informed and shared decisions
For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of 
recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, 
non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient 
outcomes and quality of life.
I
C
It is recommended that the decision for revascularization and its modality be patient-centred, considering when possible patient 
preferences, health literacy, cultural circumstances, and social support.
I
C
Revascularization to improve outcomes
In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, 
preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life 
expectancy, individual risk-to-benefit ratio, and patient perspectives.
I
C
Assessment of procedural risks and post-procedural outcomes
Intracoronary imaging guidance by IVUS or OCT is recommended for performing PCI on anatomically complex lesions, in particular left 
main stem, true bifurcations and long lesions.
I
A
Intracoronary pressure measurement (FFR or iFR) or computation (QFR):
• is recommended to guide lesion selection for intervention in patients with multivessel disease;
I
A
• should be considered at the end of the procedure to identify patients at high risk of persistent angina and subsequent clinical events;
IIa
B
• may be considered at the end of the procedure to identify lesions potentially amenable to treatment with additional PCI.
IIb
B
Choice of revascularization modality
It is recommended that physicians select the most appropriate revascularization modality based on patient profile, coronary anatomy, 
procedural factors, LVEF, patient preferences and outcome expectations.
I
C
Mode of revascularization in patients with chronic coronary syndrome
Left main disease
In CCS patients at low surgical risk with significant left main coronary stenosis, CABG:
• is recommended over medical therapy alone to improve survival;
I
A
• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and 
repeat revascularization.
I
A
In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and non- 
inferior survival.
I
A
Continued


<!-- PAGE 15 -->

### Page 15

Management of chronic coronary syndrome patients with chronic heart failure—Section 5
In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by 
CABG, taking into account the risk-to-benefit ratio of the procedures.
I
B
In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or 
functional imaging is recommended.
I
C
In patients with HFpEF with angina or equivalent symptoms and normal or non-obstructive epicardial coronary arteries, PET or CMR 
perfusion or invasive functional coronary testing should be considered to detect or rule out coronary microvascular dysfunction.
IIa
B
In selected patients with HFrEF undergoing high-risk PCI for complex CAD, the use of a microaxial flow pump may be considered in 
experienced centres.
IIb
C
It is recommended that CCS patients with heart failure be enrolled in a multidisciplinary heart failure management programme to reduce 
the risk of heart failure hospitalization and to improve survival.
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of heart failure 
hospitalization and death.
I
B
Diagnosis and management of patients with angina/ischaemia with non-obstructive coronary arteries—Section 5
Management of ANOCA/INOCA
In symptomatic patients with ANOCA/INOCA, medical therapy based on coronary functional test results should be considered to improve 
symptoms and quality of life.
IIa
A
For the management of endothelial dysfunction, ACE-I should be considered for symptom control.
IIa
B
For the management of microvascular angina associated with reduced coronary/myocardial blood flow reserve, beta-blockers should be 
considered for symptom control.
IIa
B
For the treatment of isolated vasospastic angina: 
• calcium channel blockers are recommended to control symptoms and to prevent ischaemia and potentially fatal complications;
I
A
• nitrates should be considered to prevent recurrent episodes.
IIa
B
In patients with evidence of overlapping endotypes, combination therapy with nitrates, calcium channel blockers, and other vasodilators may 
be considered.
IIb
B
Older, female, high bleeding risk, comorbid, and socially/geographically diverse patients—Section 5
Similar guideline-directed cardiovascular preventive therapy is recommended in women and men.
I
C
Bleeding risk assessment is recommended using the PRECISE-DAPT score, the qualitative ARC-HBR tool or other, validated methods.
I
B
Attention to interaction between antiretroviral treatment and statins is recommended in patients with HIV.
I
B
Socioeconomic, geographical, and under-investigated groups
Continued targeted efforts are recommended: 
• to increase delivery of safe and effective cardiac care to all CCS patients, especially those of lower socioeconomic classes, and
• to enhance inclusion in future clinical trials of geographical, social, or other groups that are currently underrepresented.
I
C
Screening for coronary artery disease in asymptomatic individuals—Section 5
When coronary artery calcification findings are available from previous chest CT scans, using these findings to enhance risk stratification and 
guide treatment of modifiable risk factors should be considered.
IIa
C
Coronary artery calcium scoring (CACS) may be considered to improve risk classification around treatment decision thresholds.
IIb
C
Adherence to medical therapy and lifestyle changes—Section 6
Mobile health interventions (e.g. using text messages, apps, wearable devices) are recommended to improve patient adherence to healthy 
lifestyles and medical therapy.
I
A
Behavioural interventions are recommended to improve adherence.
I
B
Simplifying medication regimens (e.g. using fixed-dose drug combinations) is recommended to increase patient adherence to medications.
I
B
Multiprofessional and family involvement is recommended to promote adherence, in addition to patient education and involvement.
I
C
Recurrent or refractory angina/ischaemia
In patients with refractory angina leading to poor quality of life and with documented or suspected ANOCA/INOCA, invasive coronary functional 
testing is recommended to define ANOCA/INOCA endotypes and appropriate treatment, considering patient choices and preferences.
I
B
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ANOCA, angina with non-obstructive coronary arteries; ARB, angiotensin receptor blocker; ARC-HBR, Academic Research Consortium for High 
Bleeding Risk; BMI, body mass index; CABG, coronary artery bypass grafting; CACS, coronary artery calcium score; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic 
coronary syndrome; CCTA, coronary computed tomography angiography; CFC, coronary flow capacity; CFR, coronary flow reserve; CKD, chronic kidney disease; CMR, cardiac magnetic 
resonance; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular disease; CYP3A4, cytochrome P450 3A4; DHP, dihydropyridine; dPR, diastolic pressure ratio; ECG, 
electrocardiogram; FFR, fractional flow reserve; FFR-CT, coronary computed tomography angiography-derived fractional flow reserve; GLP-1, glucagon-like peptide-1; HbA1c, glycated 
haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HIV, human immunodeficiency virus; HSR, hyperaemic 
stenosis resistance; ICA, invasive coronary angiography; iFR, instantaneous wave-free ratio; INOCA, ischaemia with non-obstructive coronary arteries; IVUS, intravascular ultrasound; LAD, left 
anterior descending; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; MCS, mechanical 
circulatory support; MI, myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; Pd/Pa, distal coronary pressure to aortic pressure ratio; PET, 
positron emission tomography; PRECISE-DAPT, PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy; QFR, quantitative 
flow ratio; RFR, relative flow reserve; SGLT2, sodium–glucose cotransporter 2; SPECT, single-photon emission computed tomography; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3429


<!-- PAGE 16 -->

### Page 16

Table 4 Revised recommendations
Recommendations in 2019 version
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
Recommendations for antianginal drugs in patients with chronic coronary syndrome—Section 4
Nicorandil, ranolazine, ivabradine, or trimetazidine 
should be considered as a second-line treatment to 
reduce angina frequency and improve exercise 
tolerance in subjects who cannot tolerate, have 
contraindications to, or whose symptoms are not 
adequately controlled by beta-blockers, CCBs, and 
long-acting nitrates.
IIa
B
Long-acting nitrates or ranolazine should be considered 
as add-on therapy in patients with inadequate control of 
symptoms while on treatment with beta-blockers and/ 
or CCBs, or as part of initial treatment in properly 
selected patients.
IIa
B
In selected patients, the combination of a beta-blocker 
or a CCB with second-line drugs (ranolazine, nicorandil, 
ivabradine, and trimetazidine) may be considered for 
first-line treatment according to heart rate, blood 
pressure, and tolerance.
IIb
B
Nicorandil or trimetazidine may be considered as 
add-on therapy in patients with inadequate control of 
symptoms while on treatment with beta-blockers and/ 
or CCBs, or as part of initial treatment in properly 
selected patients.
IIb
B
Antithrombotic therapy in patients with chronic coronary syndrome—Section 4
Aspirin 75–100 mg daily is recommended in patients 
with a previous MI or revascularization.
I
A
In CCS patients with a prior MI or remote PCI, aspirin 
75–100 mg daily is recommended lifelong after an initial 
period of DAPT.
I
A
Clopidogrel 75 mg daily is recommended as an 
alternative to aspirin in patients with aspirin intolerance.
I
B
In CCS patients with a prior MI or remote PCI, 
clopidogrel 75 mg daily is recommended as a safe and 
effective alternative to aspirin monotherapy.
I
A
Clopidogrel 75 mg daily may be considered in 
preference to aspirin in symptomatic and asymptomatic 
patients with either PAD or a history of ischaemic 
stroke or transient ischaemic attack.
IIb
B
Aspirin 75–100 mg daily may be considered in patients 
without a history of MI or revascularization, but with 
definitive evidence of CAD on imaging.
IIb
C
In patients without prior MI or revascularization but with 
evidence of significant obstructive CAD, aspirin 75–100 
mg daily is recommended lifelong.
I
B
Antithrombotic therapy post-percutaneous coronary intervention in patients with chronic coronary syndrome and no indication for 
oral anticoagulation—Section 4
Aspirin 75–100 mg daily is recommended following 
stenting.
I
A
In CCS patients with no indication for oral 
anticoagulation, DAPT consisting of aspirin 75–100 mg 
and clopidogrel 75 mg daily for up to 6 months is 
recommended as the default antithrombotic strategy 
after PCI-stenting.
I
A
Clopidogrel 75 mg daily following appropriate loading 
(e.g. 600 mg or >5 days of maintenance therapy) is 
recommended, in addition to aspirin, for 6 months 
following coronary stenting, irrespective of stent type, 
unless a shorter durations (1–3 months) is indicated due 
to risk of occurrence of life-threatening bleeding.
I
A
Clopidogrel 75 mg daily following appropriate loading 
(e.g. 600 mg or >5 days of maintenance therapy) may be 
considered for 1 month in patients with very high risk of 
life-threatening bleeding.
IIb
C
In patients at high bleeding risk but not at high ischaemic 
risk, it is recommended to discontinue DAPT 1–3 
months after PCI and continue single antiplatelet 
therapy.
I
A
Clopidogrel 75 mg daily following appropriate loading 
(e.g. 600 mg or >5 days of maintenance therapy) should 
be considered for 3 months in patients with a higher risk 
of life-threatening bleeding.
IIa
A
Stopping DAPT after 1–3 months from PCI-stenting 
may be considered in patients who are not at high 
bleeding risk nor at high risk of ischaemic events.
IIb
B
Continued


<!-- PAGE 17 -->

### Page 17

Long-term antithrombotic therapy in patients with chronic coronary syndrome and an indication for oral anticoagulation—Section 4
When oral anticoagulation is initiated in a patient with 
AF who is eligible for a NOAC, a NOAC is 
recommended in preference to a VKA.
I
A
In CCS patients with a long-term indication for OAC, an 
AF-therapeutic-dose of VKA alone or, preferably, of 
DOAC alone (unless contraindicated) is recommended 
lifelong.
I
B
Long-term OAC therapy (NOAC or VKA with time in 
therapeutic range >70%) is recommended in patients 
with AF and a CHA2DS2-VASc score ≥2 in males and 
≥3 in females.
I
A
Long-term OAC therapy (NOAC or VKA with time in 
therapeutic range >70%) should be considered in 
patients with AF and a CHA2DS2-VASc score of 1 in 
males and 2 in females.
IIa
B
Aspirin 75–100 mg daily (or clopidogrel 75 mg daily) 
may be considered in addition to long-term OAC 
therapy in patients with AF, history of MI, and at high 
risk of recurrent ischaemic events who do not have a 
high bleeding risk.
IIb
B
Antithrombotic therapy post-percutaneous coronary intervention in chronic coronary syndrome patients and an indication for oral 
anticoagulation—Section 4
After uncomplicated PCI, early cessation (≤1 week) of 
aspirin and continuation of dual therapy with an OAC 
and clopidogrel should be considered if the risk of stent 
thrombosis is low, or if concerns about bleeding risk 
prevail over concerns about the risk of stent 
thrombosis, irrespective of the type of stent used.
IIa
B
After uncomplicated PCI in CCS patients with 
concomitant indication for OAC: 
• early cessation of aspirin (≤1 week);
• followed by continuation of OAC and clopidogrel: 
⚬up to 6 months in patients not at high ischaemic 
risk or
⚬up to 12 months in patients at high ischaemic risk;
• followed by OAC alone; is recommended.
I
A
Triple therapy with aspirin, clopidogrel, and an OAC for 
≥1 month should be considered when the risk of stent 
thrombosis outweighs the bleeding risk, with the total 
duration (≤6 months) decided according to assessment 
of these risks and clearly specified at hospital discharge.
IIa
C
Continuation of aspirin up to 1 month after PCI, in 
addition to OAC and clopidogrel, should be considered 
in patients at high thrombotic risk or with anatomical/ 
procedural characteristics judged to outweigh the 
bleeding risk.
IIa
B
Recommendations for lipid-lowering drugs in patients with chronic coronary syndrome—Section 4
Statins are recommended in all patients with CCS.
I
A
A high-intensity statin up to the highest tolerated dose 
to reach the LDL-C goals is recommended for all 
patients with CCS.
I
A
Diagnosis and management of patients with angina/ischaemia with non-obstructive coronary arteries—Section 5
Guidewire-based CFR and/or microcirculatory 
resistance measurements should be considered in 
patients with persistent symptoms, but coronary 
arteries that are either angiographically normal or have 
moderate stenoses with preserved iwFR/FFR.
IIa
B
In persistently symptomatic patients despite medical 
treatment with suspected ANOCA/INOCA (i.e. anginal 
symptoms with normal coronary arteries or 
non-obstructive lesions at non-invasive imaging, or 
intermediate stenoses with normal FFR/iFR at coronary 
arteriography) and poor quality of life, invasive coronary 
functional testing is recommended to identify 
potentially treatable endotypes and to improve 
symptoms and quality of life, considering patient choices 
and preferences.
I
B
Intracoronary acetylcholine with ECG monitoring may 
be considered during angiography, if coronary arteries 
are either angiographically normal or have moderate 
stenoses with preserved iwFR/FFR, to assess 
microvascular vasospasm.
IIb
B
Diagnostic tests for vasospastic angina—Section 5
Ambulatory ST-segment monitoring should be 
considered to identify ST-segment deviation in the 
absence of increased heart rate.
IIa
C
In individuals with suspected vasospastic angina and 
frequent symptoms, ambulatory ST-segment 
monitoring should be considered to identify 
ST-segment deviation during angina.
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3431


<!-- PAGE 18 -->

### Page 18

Screening for coronary artery disease in asymptomatic individuals—Section 5
Total risk estimation using a risk-estimation system such 
as SCORE is recommended for asymptomatic adults 
>40 years of age without evidence of CVD, diabetes, 
CKD, or familial hypercholesterolaemia.
I
C
Opportunistic screening of healthy individuals for 
cardiovascular risk factors and to estimate risk of future 
cardiovascular events using scoring systems, e.g. 
SCORE2 and SCORE2-OP, is recommended to detect 
individuals at high risk and guide treatment decisions.
I
C
Diagnosis of disease progression in patients with established chronic coronary syndrome—Section 6
Risk stratification is recommended in patients with new 
or worsening symptom levels, preferably using stress 
imaging or, alternatively, exercise stress ECG.
I
B
Risk stratification is recommended in patients with new 
or worsening symptoms, preferably using stress 
imaging.
I
C
2018 ESC/EACTS Guidelines on myocardial 
revascularization
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
Recommendations for revascularization in patients with chronic coronary syndrome—Section 4
Revascularization to improve outcomes
In CCS patients with LV ejection fraction ≤35%
In patients with one- or two-vessel disease, PCI should 
be considered as an alternative to CABG when 
complete revascularization can be achieved.
IIa
C
In selected CCS patients with functionally significant 
MVD and LVEF ≤35% who are at high surgical risk or 
not operable, PCI may be considered as an alternative 
to CABG.
IIb
B
In patients with three-vessel disease, PCI should be 
considered based on the evaluation by the Heart Team 
of the patient’s coronary anatomy, the expected 
completeness of revascularization, diabetes status, and 
comorbidities.
IIa
C
Anatomically and clinically based recommendations for revascularization in chronic coronary syndrome—Section 4
Left main disease
Left main disease with low SYNTAX score (0–22), PCI.
I
A
In CCS patients with significant left main coronary 
stenosis of low complexity (SYNTAX score ≤22), in 
whom PCI can provide equivalent completeness of 
revascularization to that of CABG, PCI is recommended 
as an alternative to CABG, given its lower invasiveness 
and non-inferior survival.
I
A
Left main disease with intermediate SYNTAX score 
(23–32), PCI.
IIa
A
In CCS patients with significant left main coronary 
stenosis of intermediate complexity (SYNTAX score 
23–32), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI 
should be considered, given its lower invasiveness and 
non-inferior survival.
IIa
A
Left main with multivessel disease
For left main disease with high SYNTAX score (≥33), 
PCI.
III
B
In CCS patients at high surgical risk, PCI may be 
considered over medical therapy alone.
IIb
B
Multivessel disease and diabetes
For CCS patients with diabetes and three-vessel disease 
with low SYNTAX score 0–22, PCI.
IIb
A
In CCS patients at very high surgical risk, PCI should be 
considered over medical therapy alone to reduce 
symptoms and adverse outcomes.
IIa
B
For CCS patients with diabetes and three-vessel disease 
with intermediate or high SYNTAX score (>22), PCI.
III
A
Single- or double-vessel disease involving the proximal LAD
For one or two-vessel disease with proximal LAD 
stenosis, CABG, or PCI are recommended.
I
A
In CCS patients with significant single- or double-vessel 
disease involving the proximal LAD and insufficient 
response to guideline-directed medical therapy, CABG 
or PCI is recommended over medical therapy alone to 
improve symptoms and outcomes.
I
A
In CCS patients with complex significant single- or 
double-vessel disease involving the proximal LAD, less 
amenable to PCI, and insufficient response to 
guideline-directed medical therapy, CABG is 
recommended over PCI to improve symptoms and 
reduce revascularization rates.
I
B
Continued


<!-- PAGE 19 -->

### Page 19

### 3 Stepwise approach to the initial

management of individuals with 
suspected chronic coronary 
syndrome
Managing individuals with suspected CCS involves four steps (Figure 2): 
STEP 1. The first step is a general clinical evaluation that focuses on as­
sessing symptoms and signs of CCS, differentiating non-cardiac 
causes of chest pain and ruling out ACS. This initial clinical evaluation 
requires recording a 12-lead resting electrocardiogram (ECG), basic 
blood tests, and in selected individuals, chest X-ray imaging and pul­
monary function testing. This evaluation can be done by the general 
practitioner.
STEP 2. The second step is a further cardiac examination, including 
echocardiography at rest to rule out left ventricular (LV) dysfunc­
tion and valvular heart disease. After that, it is recommended to es­
timate the clinical likelihood of obstructive CAD to guide deferral or 
referral to further non-invasive and invasive testing.
STEP 3. The third step involves diagnostic testing to establish the diag­
nosis of CCS and determine the patient’s risk of future events.
STEP 4. The final step includes lifestyle and risk-factor modification 
combined with disease-modifying medications. A combination of 
antianginal medications is frequently needed, and coronary revascu­
larization is considered if symptoms are refractory to medical treat­
ment or if high-risk CAD is present. If symptoms persist after 
obstructive CAD is ruled out, coronary microvascular disease and 
vasospasm should be considered.
3.1. STEP 1: General clinical examination
3.1.1. History, differential diagnosis, and physical 
examination
Careful and detailed history taking is the initial step in diagnostic man­
agement for all clinical scenarios within the spectrum of CCS. Although 
chest pain or discomfort (Figure 3) is the most cardinal symptom of 
CCS, it must be emphasized that many patients do not present with 
characteristic anginal symptoms and that the symptomatology may 
vary with age, sex, race, socioeconomic class, and geographical location. 
In contemporary studies, only 10% to 25% of patients with suspected 
CCS present with angina with classic aggravating and relieving factors, 
while 57% to 78% have symptoms less characteristic of angina and 
10% to 15% have dyspnoea on exertion.33,57
While older studies suggested that women were more likely to ex­
perience less characteristic chest pain symptoms,58 recent data show 
that anginal chest pain is equally prevalent in both men and women, al­
beit with slightly different characteristics.59 Symptoms were classified as 
non-characteristic angina in over two-thirds of the patients of both 
sexes.21,60 Of note, the absence of anginal symptoms does not preclude 
CCS, as it may be absent in patients with diabetes with autonomic neur­
opathy or in elderly patients with a very sedentary lifestyle despite very 
severe obstructive CAD. Of course, chest pain is not always angina (i.e. 
of ischaemic origin), since it can be related to non-coronary (e.g. peri­
carditis) or non-cardiovascular conditions.61,62
Anginal pain symptoms have been traditionally classified as “typical, 
atypical, or non-anginal/non-cardiac” based on the location of the 
pain, as well as precipitating and relieving factors. Although angina 
that meets all three characteristics, with retrosternal chest discomfort 
provoked by exertion or emotional stress and relieved by rest or nitro­
glycerine, is highly suggestive of ischaemia caused by obstructive CAD, 
these characteristics are rarely all present when ischaemia is caused by 
microvascular dysfunction and vasospasm. Furthermore, patients with 
“typical” vs. “atypical” angina included in the PRECISE study had similar 
1-year outcomes,57 highlighting the limited prognostic value of symp­
tom classification on typicality of angina used in obstructive CAD pre­
diction models. Because this terminology to describe anginal symptoms 
no longer aligns with current concepts of CCS, it should be replaced 
by a detailed description of symptoms (Figure 3). It is important to 
thoroughly evaluate chest pain, including an objective exclusion of myo­
cardial ischaemia caused by obstructive CAD, microvascular disease, 
and/or coronary vasospasm, before classifying it as non-cardiac.
Single- or double-vessel disease not involving the proximal LAD
For one or two-vessel disease without proximal LAD 
stenosis PCI is recommended.
I
C
In symptomatic CCS patients with single- or 
double-vessel disease not involving the proximal LAD 
and with insufficient response to guideline-directed 
medical therapy, PCI is recommended to improve 
symptoms.
I
B
For one or two-vessel disease without proximal LAD 
stenosis, CABG may be considered.
IIb
C
In symptomatic CCS patients with single- or 
double-vessel disease not involving the proximal LAD 
and with insufficient response to guideline-directed 
medical therapy, not amenable to revascularization by 
PCI, CABG may be considered to improve symptoms.
IIb
C
© ESC 2024
AF, atrial fibrillation; ANOCA, angina with non-obstructive coronary arteries; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, 
chronic coronary syndrome; CFR, coronary flow reserve; CHA2DS2-VASc, congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke 
(doubled), vascular disease, age 65–74, sex category (female); CKD, chronic kidney disease; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DOAC, direct oral 
anticoagulant; EACTS, European Association for Cardio-Thoracic Surgery; ECG, electrocardiogram; ESC, European Society of Cardiology; FFR, fractional flow reserve; iFR(iwFR), 
instantaneous wave-free ratio; INOCA, ischaemia with non-obstructive coronary arteries; LAD, left anterior descending; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; MVD, multivessel disease; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PAD, 
peripheral artery disease; PCI, percutaneous coronary intervention; SCORE2, Systematic Coronary Risk Estimation 2; SCORE-OP, Systematic Coronary Risk Estimation 2–Older 
Persons; SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3433


<!-- PAGE 20 -->

### Page 20

Step 1
Step 2
Step 3
Step 4
History, 
symptoms,
physical examination
Resting ECG. Biochemistry
Pulmonary function testa
Chest X-raya
Initial evaluation
Non-cardiac reason for symptoms identified:
treat underlying cause
Unstable cardiac symptoms with angina,
heart failure or arrhythmia: 
acute assessment by the ED
Assess clinical likelihood of obstructive CAD
Echocardiography at rest
Exercise ECGa
Further evaluation
Very low clinical likelihood of obstructive CAD (≤5%):
consider deferring further testingb
Severe comorbidities or low quality of life: consider no further testing and treat medically
Further non-invasive 
testing recommended 
based on clinical likelihood, 
availability,
local expertise, patient 
characteristics and 
preferenceb
Confirming diagnosis and estimating event-risk
CCTA: obstructive CAD?
Revascularization if:
high risk of adverse events
GDMT fails to relieve 
symptoms
Treatment
Invasive angiography if:
Very high clinical likelihood (>85%)
Suspicion of high-risk obstructive CAD
Severe myocardial ischaemia
Revascularization
To reduce symptoms
To improve prognosis in patients with obstructive CAD who are at high risk of adverse events
Antianginal medical treatment
Lifestyle and risk factor 
modification
To improve prognosis
Disease-modifying medical treatment
To improve prognosis
Functional imaging: myocardial ischaemia?
Selective second-line imaging to increase post-test likelihood
To reduce symptoms
In individuals with low and moderate (>5–50%)
clinical likelihood
In individuals with moderate and high (>15–85%) 
clinical likelihood
Consider ANOCA/INOCA
Figure 2 Stepwise approach to the initial management of individuals with suspected chronic coronary syndrome. ANOCA, angina with non- 
obstructive coronary arteries; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; 
ECG, electrocardiogram; ED, emergency department; GDMT, guideline-directed medical therapy; INOCA, ischaemia with non-obstructive coronary 
arteries. aIn selected patients. bConsider also coronary spasm or microvascular dysfunction.


<!-- PAGE 21 -->

### Page 21

The Canadian Cardiovascular Society classification is still widely used 
as a grading system for effort-induced angina to quantify the threshold 
at which symptoms occur with physical activities (Table 5). Importantly, 
the severity of symptoms is not well associated with the severity of ob­
structive CAD and appears to differ by sex. Women have more fre­
quent angina, independent of less extensive epicardial CAD, and less 
severe myocardial ischaemia than men.63 Angina at rest is not always 
indicative of severe, fixed obstructive CAD, as it may also occur in pa­
tients with transient epicardial or microvascular coronary vasospasm.
It is essential to document coronary risk factors during history taking, 
as they may be modifiable and will be used for the pre-test likelihood 
estimation of obstructive CAD. Smoking cessation counselling starts 
with a quantitative assessment of prior and current tobacco use to 
make the risk factor more evident to the patient. In addition, detailed 
family history looking for premature cardiovascular disease (CVD) or 
sudden cardiac death should always be obtained. If available, cholesterol 
levels help define familial hypercholesterolaemia.64 It is also essential 
to assess the presence of comorbidities that affect the likelihood of 
CAD and overall survival. Because of their high prevalence in CCS 
patients, diabetes, chronic obstructive pulmonary disease, kidney dis­
ease, and peripheral and cerebral vascular disease are particularly 
relevant.
Quality
Chest discomfort
Dyspnoea
Location and size
Decreasing likelihood of CCS
Increasing likelihood of CCS
Strangling
Constricting
Squeezing
Pressure
Heaviness
Retrosternal
Extending to left arm, or to jugular or intrascapular region
“Fist”-size
Burning
Sharp
Tearing - Ripping
Pleuritic
Aching
Right
Shifting
Large area or fine spot
Duration
Short: up to 5–10 min if triggered by physical exertion or emotion
Lasting
Trigger
On effort
More frequent in cold weather, strong winds or after a heavy meal
Emotional distress (anxiety, anger,
excitation or nightmare)
On deep inspiration or when coughing
When pressing on ribs or sternum
Relief
Subsiding within 1–5 min after effort discontinuation
Relief accelerated by sublingual nitroglycerin
Quality
Difficulty catching breath
Difficulty to exhale
With wheezing
Trigger
On effort
Both at rest and on effort
While coughing
Slowly subsiding at rest or after inhalation of bronchodilators
Relief
Rapidly subsiding after effort discontinuation
Symptom characteristics
At rest
By antacids, drinking milk
Figure 3 Main CCS symptoms: angina and exertional dyspnoea. CCS, chronic coronary syndrome.
ESC Guidelines                                                                                                                                                                                          3435


<!-- PAGE 22 -->

### Page 22

Recent-onset anginal symptoms with changing frequency or intensity 
should raise the suspicion that a coronary atherosclerotic plaque may 
be destabilizing. In these patients, the diagnostic algorithm recom­
mended by the 2023 ESC Guidelines for the management of patients 
with acute coronary syndromes should be used to rule out an acute 
event.65
When investigating suspected CCS, it is important to perform a 
thorough physical examination that includes BP measurement and 
body mass index (BMI) calculation, to assess the presence of anaemia, 
hypertension, valvular heart disease, LV hypertrophy, or arrhythmias. It 
is also recommended to search for evidence of non-coronary vascular 
disease, which may be asymptomatic (palpation of peripheral pulses; 
auscultation of carotid and femoral arteries), and signs of other co­
morbid conditions, such as thyroid disease, renal disease, or diabetes. 
This should be used in the context of other clinical information, such 
as the presence of cough or stinging pain, making CCS less likely. 
One should also try to reproduce the symptoms by palpation and 
test the effect of sublingual nitroglycerine to classify the symptoms.
3.1.2. Basic testing: 12-lead electrocardiogram and 
biochemistry
Basic testing in individuals with suspected CCS includes a 12-lead ECG, 
standard laboratory tests, resting echocardiography, and, in selected 
patients, a chest X-ray, and a pulmonary function test if dyspnoea is 
the main symptom. Such tests can be done on an outpatient basis.
3.1.2.1. Electrocardiogram
The paradigm of diagnosing myocardial ischaemia has, for almost a cen­
tury, been based on detecting repolarization abnormalities, mainly in 
the form of ST-segment depressions or T wave abnormalities. Thus, 
the resting 12-lead ECG remains an indispensable component of the ini­
tial evaluation of a patient with chest pain.67
A normal resting ECG is frequently recorded after an anginal attack. 
However, even in the absence of repolarization abnormalities, the ECG 
at rest may suggest CCS indirectly, through signs of previous MI (patho­
logical Q or R waves) or conduction abnormalities [mainly left bundle 
branch block (LBBB) and impaired atrioventricular conduction]. Atrial 
fibrillation (AF) is not rarely associated with CCS.68 ST-segment de­
pression during supraventricular tachyarrhythmias, however, is not a 
strong predictor of obstructive CAD.69–72
The ECG can be crucial for diagnosing transient myocardial ischae­
mia by recording dynamic ST-segment changes during ongoing angina. 
Vasospastic angina (VSA) should be suspected when observing typical 
transient ST-segment elevations or depressions with U-wave changes 
during an angina attack at rest.73
Long-term ambulatory ECG monitoring can be considered in se­
lected patients to detect ischaemia during anginal episodes unrelated 
to physical activities. ECG changes suggesting ischaemia on ambulatory 
ECG monitoring are frequent in women but do not correlate with find­
ings during stress testing.74 Ambulatory ECG monitoring may also re­
veal ‘silent’ ischaemia in patients with CCS, but therapeutic strategies 
targeting it have not demonstrated clear survival benefits.75,76
Table 5 Grading of effort angina severity according to 
the Canadian Cardiovascular Society
Grade
Description of angina severity66
I
Angina only with 
strenuous exertion
Presence of angina during strenuous, 
rapid, or prolonged ordinary activity 
(walking or climbing the stairs)
II
Angina with 
moderate exertion
Slight limitation of ordinary activities 
when they are performed rapidly, after 
meals, in the cold, in the wind, under 
emotional stress, or during the first 
few hours after waking up, but also 
walking uphill, climbing more than one 
flight of ordinary stairs at a normal 
pace, and in normal conditions
III
Angina with mild 
exertion
Having difficulties walking one or two 
blocks or climbing one flight of stairs at 
a normal pace and conditions
IV
Angina at rest
No exertion is needed to trigger angina
© ESC 2024
Recommendation Table 1 — Recommendations for his­
tory taking, risk factor assessment, and resting electro­
cardiogram in individuals with suspected chronic 
coronary syndrome (see also Evidence Table 1)
Recommendations
Classa
Levelb
History taking and risk factor assessment
In individuals reporting symptoms of suspected 
myocardial ischaemic origin, a detailed assessment of 
cardiovascular risk factors, medical history, and 
symptom characteristics (including onset, duration, 
type, location, triggers, relieving factors, time of day) 
is recommended.
I
C
Symptoms like chest pain triggered by emotional 
stress; dyspnoea or dizziness on exertion; pain in the 
arms, jaw, neck, or upper back; or fatigue should be 
considered as potential angina 
equivalents.18,33,57,59,77
IIa
B
Resting ECG
If clinical or ECG assessment suggests ACS rather 
than CCS, immediate referral to the emergency 
department and/or repeated measurement of blood 
troponin, preferably using high-sensitivity or 
ultrasensitive assays, to rule out acute myocardial 
injury, is recommended.78,79
I
B
A resting 12-lead ECG is recommended in all 
individuals reporting chest pain (unless an obvious 
non-cardiac cause is identified), particularly during, or 
immediately after, an episode suggestive of 
myocardial ischaemia.
I
C
Using ST-segment deviations during supraventricular 
tachyarrhythmias, particularly during re-entrant 
atrioventricular tachycardias, per se, as reliable 
evidence of obstructive CAD, is not 
recommended.80–84
III
B
© ESC 2024
ACS, acute coronary syndrome; CAD, coronary artery disease; CCS, chronic coronary 
syndrome; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 23 -->

### Page 23

3.1.2.2. Biochemical tests
Laboratory blood tests identify potential causes of ischaemia (e.g. se­
vere anaemia, hyperthyroidism), cardiovascular risk factors (e.g. lipids, 
fasting glucose), and yield prognostic information (e.g. renal disease, in­
flammation). When fasting plasma glucose and glycated haemoglobin 
(HbA1c) are both inconclusive, an additional oral glucose tolerance 
test is useful.85,86
A lipid profile, including total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), and triglycerides, allowing calculation of low- 
density lipoprotein cholesterol (LDL-C), is necessary in every person 
with suspected CCS to refine his/her risk profile and guide treat­
ment.16,64 Fasting values are needed to characterize severe dyslipidae­
mia or follow-up hypertriglyceridaemia,64
but not in other 
situations.87 Elevated lipoprotein(a) is a marker of cardiovascular risk, 
particularly early-onset atherosclerotic disease;88
lipoprotein(a)- 
lowering strategies are currently being investigated in phase 3 cardiovas­
cular outcomes trials.89–91 Given that circulating lipoprotein(a) levels are 
genetically determined and do not fluctuate substantially over a life­
time,89,91 a single measure is sufficient in persons with suspected CCS.92
Renal dysfunction increases the likelihood of CAD and has a negative 
impact on prognosis.93–95 Glomerular filtration rate (GFR) also impacts 
renally cleared drugs. It is reasonable to also measure uric acid levels, as 
hyperuricaemia is frequent, and may affect renal function.
If there is a clinical suspicion of CAD instability, biochemical markers 
of myocardial injury—such as troponin T or troponin I—should be 
measured, preferably using high-sensitivity assays, and management 
should follow the 2023 ESC Guidelines for the management of patients 
with acute coronary syndromes.65 If high-sensitivity assays are em­
ployed, low troponin levels can be detected in many patients with stable 
angina. Increased troponin levels are associated with adverse out­
comes,96–100 and small studies have indicated a possible incremental va­
lue in diagnosing obstructive CAD,101–104 but larger trials are needed to 
verify the utility of systematic assessment in individuals suspected of 
CCS. While multiple biomarkers may be useful for prognostication, 
they do not yet have a role in diagnosing obstructive CAD, but some 
promising results have been published.105–108 Measuring NT-proBNP 
helps confirm or exclude suspected HF.
Markers of inflammation such as C-reactive protein109–113 and 
fibrinogen114–118 are predictors of an individual’s risk of CAD and can 
predict cardiovascular event risk in CCS patients,99,111 but their value 
is limited beyond traditional risk factors.111 However, in patients taking 
contemporary statins, high-sensitivity C-reactive protein (hs-CRP) was 
a stronger predictor for future cardiovascular events and death than 
LDL-C.119,120 These patients may benefit from additional LDL-C reduc­
tion through adjunctive lipid-lowering therapies, such as ezetimibe, 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition,121
inclisiran, and bempedoic acid.122–124 Elevated hs-CRP levels in patients 
taking statins and PCSK9 inhibitors may indicate residual inflammatory 
risk that could be further reduced through inflammation modula­
tion.119,125,126 Experimental inhibition of interleukin-6, a pivotal factor 
in atherothrombosis, resulted in a marked parallel reduction of 
C-reactive protein and fibrinogen in patients with chronic kidney dis­
ease (CKD) and high cardiovascular risk.127
3.2. STEP 2: Further evaluation
3.2.1. Pre-test clinical likelihood of obstructive 
atherosclerotic coronary artery disease
The diagnosis of CCS is based on interpreting the individual’s symp­
toms, balancing the impact of age, sex, risk factors, and comorbidities 
on the likelihood that CCS is present, and choosing the most appropri­
ate diagnostic test to confirm the clinically suspected diagnosis. To aid 
diagnosis, prediction tables for obstructive CAD can be used that inte­
grate these clinical factors and provide guidance on selecting diagnostic 
tests based on their capacities to rule in and rule out obstructive 
atherosclerotic CAD. Importantly, these models do not include the prob­
ability of ANOCA/INOCA, which always needs to be considered if 
symptoms persist after deferral of further testing or diagnostic testing 
that excludes obstructive CAD.
The tables used to estimate the likelihood of obstructive CAD as 
confirmed by ICA were initially based on the Diamond–Forrester ap­
proach, which considered sex, age, and angina symptoms.25
However, these tables have had to be updated several times owing 
to the declining prevalence of obstructive CAD at invasive angiography 
in contemporary Western cohorts.26,29 The overestimation of ob­
structive CAD prevalence has limited the utility of these tables in clinical 
routine and in accurately estimating the post-test likelihood of ob­
structive CAD by diagnostic imaging methods.1,29,30
The 2019 ESC Guidelines for the diagnosis and management of CCS 
introduced the concept of clinical likelihood as a more comprehensive 
and individualized assessment of the probability of obstructive CAD.1
Compared with a basic pre-test probability model, incorporation of 
risk factors in the basic pre-test likelihood model (based on age, sex, and 
Recommendation Table 2 — Recommendations for ba­
sic biochemistry in the initial diagnostic management of in­
dividuals with suspected chronic coronary syndrome (see 
also Evidence Table 2)
Recommendations
Classa
Levelb
The following blood tests are recommended in all 
individuals to refine risk stratification, diagnose 
comorbidities, and guide treatment:
• lipid profile including LDL-C;64,128
I
A
• full blood count (including haemoglobin);129–133
I
B
• creatinine with estimation of renal function;134
I
B
• glycaemic status with HbA1c and/or fasting plasma 
glucose.16,86,135,136
I
B
In patients with suspected CCS, it is recommended 
to assess thyroid function at least once.137,138
I
B
Additionally, hs-CRP and/or fibrinogen plasma levels 
should be considered.109–118,121,125
IIa
B
© ESC 2024
CCS, chronic coronary syndrome; HbA1c, glycated haemoglobin; hs-CRP, high-sensitivity 
C-reactive protein; LDL-C, low-density lipoprotein cholesterol. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3437


<!-- PAGE 24 -->

### Page 24

symptoms) leads to improved prediction of obstructive CAD, down- 
classifies more individuals to very low and low likelihood of disease, 
and maintains high calibration.30,139,140 The Risk-Factor-weighted 
Clinical Likelihood (RF-CL) model includes sex, age, angina symptoms, 
and number of risk factors without losing diagnostic accuracy com­
pared with more advanced models requiring computed calculation 
(Figure 4).139,141,142 The RF-CL model increases three-fold the number 
of subjects categorized as at very low (≤5%) likelihood of obstructive 
CAD compared with the ESC pretest probability (ESC-PTP) model 
(38% vs. 12%),139 while predicting annualized event rates of MI and 
death of 0.5%, 1.1%, and 2.1% for individuals having very low, low, 
and moderate likelihood of obstructive CAD, respectively.143
Individual adjustment of the likelihood may be necessary for indivi­
duals with severe single risk factors or comorbidities associated with 
an increased prevalence of obstructive CAD, which are not reflected 
in the RF-CL model, e.g. familial hypercholesterolaemia, severe kidney 
dysfunction, rheumatic/inflammatory diseases, and peripheral artery 
disease (PAD).
Exercise ECG testing may modify the likelihood of obstructive CAD 
and can be used in patients with low (>5%–15%) clinical likelihood, in 
whom a negative test allows reclassification to the very low (≤5%) clin­
ical likelihood group with a favourable prognosis.144 However, CCTA 
as a first-line diagnostic test can give more accurate information and 
has been associated with fewer angina symptoms during follow-up 
than a strategy with exercise ECG as the first investigation.145–148 In 
addition, more adverse events were observed in randomized trials 
with an exercise ECG than with a CCTA-based diagnostic strat­
egy.34,146 However, exercise ECG remains clinically useful for reprodu­
cing anginal symptoms, which have a prognostic value.149,150
In contrast to exercise ECG, visualization of calcified atherosclerotic 
plaque in the coronary artery significantly impacts the clinical likelihood 
of atherosclerotic obstructive CAD. Coronary artery calcification 
(CAC) can be measured using the coronary artery calcium score 
(CACS), which is derived from an ECG-gated non-contrast-enhanced 
computed tomography (CT) scan. Alternatively, the presence of 
CAC can be evaluated qualitatively by visually inspecting the coronary 
arteries on a previous non-cardiac chest CT scan, if available. The ab­
sence of CAC (CACS = 0) has a very high negative predictive value 
(>95%) for obstructive CAD.151 Of note, in younger patients, obstruct­
ive CAD is rare, but when present, a higher percentage (58% of those 
younger than 40 years) have a CACS of 0 compared with older patients 
with obstructive CAD (9% among those aged 60 to 69 years).152
Small, randomized studies have shown that further testing can safely 
be deferred in patients without CAC, without increased event rates 
during follow-up.146,153 Finally, in a larger prospective observational 
study, absence of CAC alone was sufficient to define a low-risk 
group with no need for further testing with improved accuracy com­
pared with basic clinical prediction models.154 The combination of 
CACS with the RF-CL model [CACS + RF-CL (the Coronary Artery 
Calcium Score-Weighted Clinical Likelihood—CACS-CL)] showed 
the strongest potential to effectively defer cardiac testing compared 
with other clinical prediction models or CACS alone (adjustment of 
the estimation of the clinical likelihood of obstructive CAD).139,154
With the CACS-CL model, substantially more individuals (54%) com­
pared with the RF-CL model (38%) were categorized as having a very 
low clinical likelihood of obstructive CAD in the external validation co­
horts.139 Finally, the CACS-CL model was superior to other clinical 
prediction models in predicting MI and death during follow-up.143
Detection of atherosclerotic disease in non-coronary arteries with 
ultrasound or CT scans of, e.g. the aorta, and the carotid or femoral ar­
teries, may increase the clinical likelihood of obstructive CAD,155–158
and the risk for future CVD events.159,160 However, how accurately 
the detection of non-coronary atherosclerotic disease impacts the like­
lihood estimation of obstructive CAD needs further investigation.
In general, individuals with a very low (≤5%) likelihood of obstructive 
CAD do not require further diagnostic testing unless symptoms persist 
and non-cardiac causes have been excluded. In patients with a low 
(>5%–15%) likelihood of obstructive CAD, the benefit of diagnostic 
testing is uncertain but may be performed if symptoms are limiting 
and require clarification. Patients with moderate (>15%–50%), high 
(>50%–85%), and very high (>85%) likelihood of obstructive CAD 
are encouraged to undergo further diagnostic testing.
By using pre-test likelihood estimates and diagnostic imaging-test 
positive and negative likelihood ratios, it is possible to calculate the 
post-test probability of obstructive CAD. Hence, pre-test likelihood es­
timation is useful to guide non-invasive diagnostic test strategies for de­
tecting obstructive CAD (Section 3.3.4).
Recommendation Table 3 — Recommendations for 
estimating, adjusting and reclassifying the likelihood of 
obstructive atherosclerotic coronary artery disease in 
the initial diagnostic management of individuals with sus­
pected chronic coronary syndrome (see also Evidence 
Table 3)
Recommendations
Classa
Levelb
It is recommended to estimate the pre-test 
likelihood of obstructive epicardial CAD using the 
Risk Factor-weighted Clinical Likelihood 
model.139,140,142,143,161,162
I
B
It is recommended to use additional clinical data (e.g. 
examination of peripheral arteries, resting ECG, 
resting echocardiography, presence of vascular 
calcifications on previously performed imaging tests) 
to adjust the estimate yielded by the Risk 
Factor-weighted Clinical Likelihood model.163
I
C
In individuals with a very low (≤5%) pre-test likelihood 
of obstructive CAD, deferral of further diagnostic 
tests should be considered.139,164
IIa
B
In individuals with a low (>5%–15%) pre-test 
likelihood of obstructive CAD, CACS should be 
considered to reclassify subjects and to identify more 
individuals with very low (≤5%) CACS-weighted 
clinical likelihood.139,143,165
IIa
B
In individuals with an initially low (>5%–15%) 
likelihood of obstructive CAD, exercise ECG and 
detection of atherosclerotic disease in non-coronary 
arteries may be considered to adjust the pre-test 
likelihood estimate.144,166
IIb
C
© ESC 2024
CACS, coronary artery calcium score; CAD, coronary artery disease; ECG, 
electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

1
2
3
Chest pain characteristics
Type and location
Constricting discomfort located retrosternally or in neck, jaw, shoulder or arm (I point)
Aggravated by
Physical or emotional stress (1 point)
Main symptom either:
Relieved by
Rest or nitrates within 5 min (1 point)
Symptom score
Shortness of breath and/or trouble catching breath aggravated by physical exertion (2 points)
Dyspnoea characteristics
Symptom score
Symptom score (0–3 points)
Estimate the Risk Factor-weighted Clinical Likelihood (RF-CL)
of obstructive CAD 
Number of risk factors for CAD (0–5): 
Family history, smoking, dyslipidaemia, hypertension and diabetes
Age 30–39
Very low
Low
Moderate
Age 40–49
Age 50–59
Age 60–69
Age 70–80
Clinical likelihood:
0–1 point
2 points
3 points
Number of risk factors
4
7
11
0
1
2
2
4
7
1
2
5
1
1
3
0–1 2–3 4–5
Women
15 19 24
1
2
5
8
12 17
4
7
12
2
4
8
0–1 2–3 4–5
Men
6
10 16
0
1
3
3
6
11
2
3
7
1
2
5
0–1 2–3 4–5
Women
22 27 34
2
4
8
12 17 25
6
11 17
3
6
12
0–1 2–3 4–5
Men
16 19 23
2
5
10
10 14 19
6
10 15
4
7
12
0–1 2–3 4–5
Women
44 44 45
9
14 22
32 35 39
21 27 33
14 20 27
0–1 2–3 4–5
Men
Chest pain
(0–3 points)
Dyspnoea
(2 points)
or
Figure 4 Estimation of the clinical likelihood of obstructive coronary artery disease. CAD, coronary artery disease; RF-CL, risk factor-weighted clinical 
likelihood. Data derived from Winther et al.139 The symptom score replaces the previous, potentially misleading terminology, that defined presence of 
three chest pain characteristics as ‘typical’ angina (here = 3 points), two of three characteristics as ‘atypical’ angina (here = 2 points), and no or one 
characteristic as ‘non-cardiac/non-anginal’ (here = 0–1 point). Family history of CAD is defined as 1 or more first-degree relatives with early signs 
of CAD (men <55 and women <65 years of age); smoking, as current or past smoker; dyslipidaemia, hypertension, and diabetes, as present at the 
time of diagnosis. Values in the lower panel are the clinical likelihood estimates expressed as %.
ESC Guidelines                                                                                                                                                                                          3439


<!-- PAGE 26 -->

### Page 26

3.2.2. Transthoracic echocardiography and cardiac 
magnetic resonance at rest
An echocardiographic study will provide important information about car­
diac function and anatomy. Patients with CCS have often preserved left 
ventricular ejection fraction (LVEF).167 A decreased LV function and/or 
regional wall motion abnormalities may increase the suspicion of ischaemic 
myocardial damage,167 and a pattern of LV dysfunction following the 
anatomical perfusion territory of the coronary arteries is typical in patients 
who have already had an MI.168,169 The detection of regional wall motion 
abnormalities can be challenging by visual assessment, and detection of 
early systolic lengthening, decreased systolic shortening, or post-systolic 
shortening by strain imaging techniques,170–172 or new parameters such 
as global myocardial work,173 may be helpful in individuals with apparently 
normal LV function but with clinical suspicion of CCS. Diastolic LV dysfunc­
tion has been reported to be an early sign of ischaemic myocardial dysfunc­
tion and may also be indicative of microvascular dysfunction.174,175
Echocardiography can help in detecting alternative causes of chest 
pain (e.g. pericarditis) and in diagnosing valvular heart diseases, ischae­
mic HF, and most cardiomyopathies,176 though these diseases may co- 
exist with obstructive CAD. The use of an echocardiographic contrast 
agent can be helpful in patients with poor acoustic windows.177
Cardiac magnetic resonance (CMR) is an alternative in patients with 
suspected CAD when the echocardiogram (having used ultrasound 
contrast agent) is inconclusive.178 Cardiac magnetic resonance can as­
sess global and regional function,179 and the use of late gadolinium en­
hancement (LGE) CMR can reveal a typical pattern of scarred 
myocardium in patients who have already experienced an MI.180
Moreover, CMR provides information on myocardial ischaemia 
through the evaluation of stress-induced perfusion defects.181
The strongest predictor of long-term survival is systolic LV function. 
Hence, risk stratification through the assessment of systolic LV function 
is useful in all symptomatic individuals with suspected CCS. Mortality 
increases as LVEF declines.182 Management of patients with either an­
gina or HF symptoms, with reduced LVEF ≤40% or mildly reduced 
LVEF 41%–49%, is described in Section 4.
3.2.3. Exercise electrocardiogram testing
Exercise ECG testing is low cost, does not use ionizing radiation, is 
widely accessible, and remains an alternative for diagnostic testing de­
pending on local resources and individual characteristics.
The classical exercise ECG, involving graded exercise until the occur­
rence of fatigue, limiting chest pain or discomfort, significant ischaemic 
ECG changes, arrhythmias, excessive hypertension, a BP drop or after 
reaching 85% of the maximal predicted heart rate, has been the main­
stay of the examination techniques used in clinical cardiology for asses­
sing individuals with suspected CCS. Exercise ECG testing has a lower 
diagnostic performance of obstructive CAD compared with modern 
functional imaging and CCTA,148 which, therefore, should be preferred 
as a first-line test in subjects with suspected CCS. Several clinical trials 
have confirmed that a strategy based on anatomical34,146,187,188 or func­
tional imaging189 simplifies the diagnosis, enables the targeting of pre­
ventive therapies and interventions, and potentially reduces the risk 
of MI compared with usual care based on exercise ECG. In addition, 
two randomized trials showed that patients reported fewer anginal 
complaints during follow-up when randomized to CCTA as an index 
investigation for stable chest pain compared with exercise ECG.145,146
Although the Scottish Computed Tomography of the Heart 
(SCOT-HEART) trial favoured CCTA as first-line test in CCS, a post 
hoc analysis suggested that abnormal results of exercise ECG remain 
a specific indicator of obstructive CAD, and are associated with future 
coronary revascularization and risk of MI.188 Exercise ECG testing with 
clearly abnormal results was most predictive for these outcomes; how­
ever, in a large proportion of individuals who underwent exercise ECG, 
particularly those with normal or inconclusive results, there was still a 
significant amount of unrecognized non-obstructive and obstructive 
CAD, which can be detected by additional CCTA imaging.188 In the 
WOMEN trial (What is the Optimal Method for Ischemia Evaluation 
of Women), including low-risk symptomatic women, exercise ECG 
was equally effective compared with exercise myocardial perfusion 
scintigraphy, with a similar 2-year incidence of major adverse cardiovas­
cular events (MACE), defined as CAD death, or hospitalization for an 
ACS or HF, while providing significant diagnostic cost savings.190
Individuals exercising >10 metabolic equivalents with a negative exer­
cise ECG and a low-risk Duke Treadmill Score have a good prognosis 
with limited need for downstream testing and revascularization.166,191
Patients with marked ischaemia at a low workload and a high-risk 
Duke Treadmill Score may benefit from further anatomical or function­
al testing. In regions with limited access to functional imaging or CCTA, 
or in individuals with a low (>5%–15%) pre-test likelihood of obstruct­
ive CAD,144 exercise ECG remains, therefore, useful for risk stratifica­
tion and prognostication.144 Particularly, in subjects with a low (>5%– 
15%) likelihood of obstructive CAD, a negative exercise ECG may help 
to down-classify patients into the very low likelihood (<5%) class, in 
whom further testing can be deferred.144
An exercise ECG is of no diagnostic value in patients with ECG ab­
normalities at rest that prevent interpretation of the ST-segment 
changes during stress (i.e. LBBB, paced rhythm, Wolff−Parkinson 
−White syndrome, ≥0.1 mV ST-segment depression on resting ECG, 
or treatment with digitalis). In patients with known CAD, exercise 
ECG may be considered in selected patients to complement their clin­
ical evaluation for assessing symptoms, ST-segment changes, exercise 
tolerance, arrhythmias, BP response, and event risk.
In summary, due to its low sensitivity (58%) and specificity (62%), ex­
ercise ECG testing has low diagnostic performance for the diagnosis of 
obstructive CAD148 and should mainly be used for risk stratification.
Recommendation Table 4 — Recommendations for 
resting transthoracic ultrasound and cardiac magnetic 
resonance imaging in the initial diagnostic management 
of individuals with suspected chronic coronary syn­
drome (see also Evidence Table 4)
Recommendations
Classa
Levelb
A resting transthoracic echocardiogram is 
recommended: 
to measure LVEF, volumes and diastolic function; 
• identify regional wall motion abnormalities;
• identify non-coronary cardiac disease (e.g. 
hypertrophy, cardiomyopathy, valve disease, 
pericardial effusion);
• assess right ventricular function and estimate 
systolic pulmonary artery pressure;
to refine risk stratification and guide 
treatment.167,183,184
I
B
CMR, if available, may be considered as an alternative 
imaging test in individuals with inconclusive 
echocardiographic evaluation.185,186
IIb
C
© ESC 2024
CMR, cardiac magnetic resonance; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

3.2.4. Chest X-ray
Chest X-ray is commonly utilized in the evaluation of patients experi­
encing chest pain. However, in the context of CCS, it does not yield 
specific information for accurate diagnosis or risk stratification. The 
test may provide assistance in assessing patients with suspected HF. 
Additionally, chest X-ray may prove beneficial in diagnosing pulmonary 
conditions that often co-exist with CAD, or in ruling out other poten­
tial causes of chest pain.
3.2.5. Ambulatory electrocardiogram monitoring
Ambulatory ECG monitoring can assist in evaluating patients with chest 
pain and palpitations. It can also help in detecting and evaluating silent 
myocardial ischaemia, as well as suspected VSA.192–194
3.3. STEP 3: Confirming the diagnosis
3.3.1. Anatomical imaging: coronary computed 
tomography angiography
Through the intravenous (i.v.) injection of contrast agent, CCTA allows 
direct anatomical visualization of the coronary artery lumen and wall. 
CCTA offers a practical, non-invasive test, with proven diagnostic per­
formance in detecting obstructive coronary artery stenoses when com­
pared with ICA.32,148
Obstructive coronary stenoses have typically been defined using 
visual thresholds of either 50% or 70% diameter reduction. It is 
accepted that not all anatomical stenoses above such thresholds, es­
pecially those of moderate (50%–69%) stenosis severity, are haemo­
dynamically or functionally significant195 or induce myocardial 
ischaemia.196 Depending on the clinical context, it may be necessary 
to complement CCTA with functional data either from non-invasive 
imaging techniques or from invasive angiography with fractional 
flow reserve (FFR) (see Section 3.3.3.2), when the haemodynamic con­
sequence of a stenosis is deemed questionable for management 
options.
While several earlier trials (publication date during or before 2016) 
reported a higher rate of downstream ICA in patients receiving CCTA 
compared with functional imaging,197 this was no longer observed in 
more recent trials (publication date after 2016). Moreover, increased 
downstream use of invasive procedures was linked to non-adherence 
to guideline recommendations as these procedures were used signifi­
cantly less when the guidelines were adopted.198
Coronary computed tomography angiography-derived fractional 
flow reserve (FFR-CT) can complement CCTA by providing values 
of model-based computational FFR along the coronary tree. 
FFR-CT has shown good agreement with invasive FFR,199 and has clin­
ical utility by reducing the number of unnecessary ICA procedures.200
However, in patients with severe disease at CCTA, FFR-CT has less 
impact on patient management.201 FFR-CT does not require pharma­
cological stress, additional contrast agent injection, or radiation ex­
posure. FFR-CT, however, is not ubiquitous and depends on image 
quality. Nevertheless, the rejection rate is reported to be quite low 
in real-world data with newest-generation scanners.202–204
3.3.1.1. Computed tomography perfusion imaging
Computed tomography perfusion imaging, performed under pharma­
cological stress, has been validated against several reference stan­
dards, including single-photon computed tomography (SPECT) and 
Recommendation Table 5 — Recommendations for 
exercise ECG in the initial diagnostic management of in­
dividuals with suspected chronic coronary syndrome 
(see also Evidence Table 5)
Recommendations
Classa
Levelb
Exercise ECG is recommended in selected patientsc 
for the assessment of exercise tolerance, symptoms, 
arrhythmias, BP response, and event risk.
I
C
Exercise ECG may be considered as an alternative 
test to rule in and rule out CAD when non-invasive 
imaging tests are unavailable.148,166,188,190,191
IIb
B
An exercise ECG may be considered to refine risk 
stratification and treatment.188
IIb
B
In individuals with a low (>5%–15%) pre-test 
likelihood of obstructive CAD, an exercise ECG may 
be considered to identify patients in whom further 
testing can be deferred.144
IIb
C
Exercise ECG is not recommended for diagnostic 
purposes in patients with ≥0.1 mV ST-segment 
depression on resting ECG, left bundle branch block 
or who are being treated with digitalis.
III
C
In individuals with a low or moderate (>5%–50%) 
pre-test likelihood of obstructive CAD, an exercise 
ECG is not recommended to rule out CAD if CCTA 
or functional imaging tests are available.148
III
C
© ESC 2024
BP, blood pressure; CAD, coronary artery disease; CCTA, coronary computed 
tomography angiography; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence. 
cWhen this information will have an impact on diagnostic strategy or management.
Recommendation Table 6 — Recommendations for 
chest X-ray in the initial diagnostic management of indi­
viduals with suspected chronic coronary syndrome (see 
also Evidence Table 6)
Recommendations
Classa
Levelb
A chest X-ray should be considered for individuals with: 
• signs and symptoms suggestive of heart failure;
• suspected acute pulmonary disease;
• suspected aortic, non-coronary cardiac, or other 
thoracic causes of chest pain.
IIa
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 7 — Recommendations for am­
bulatory ECG monitoring in the initial diagnostic manage­
ment of individuals with suspected chronic coronary 
syndrome (see also Evidence Table 7)
Recommendations
Classa
Levelb
Ambulatory ECG monitoring is recommended in 
subjects with chest pain and suspected arrhythmias.
I
C
Ambulatory ECG monitoring should be considered 
in subjects with suspected vasospastic angina.192–194
IIa
B
© ESC 2024
ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3441


<!-- PAGE 28 -->

### Page 28

invasive FFR. It has shown adequate diagnostic performance in se­
lected cohorts,205,206 and a potential to reduce the number of un­
necessary downstream invasive angiography procedures, when 
compared with functional tests (mostly symptom-limited exercise 
ECG).153 While CT perfusion imaging could complement CCTA dur­
ing the same visit, this technique requires the administration of a 
pharmacological stressor, contrast agent, and further patient irradi­
ation. Imaging techniques and analysis methods are not yet widely 
standardized (e.g. static and dynamic imaging techniques, visual and 
quantitative assessment).207–209
3.3.1.2. Prognosis, plaque features, and opportunity to improve 
outcomes
The SCOT-HEART trial demonstrated a small but significant decrease 
of the combined endpoint of cardiovascular death or non-fatal MI 
(from 3.9% to 2.3% during 5-year follow-up) in patients in whom 
CCTA was performed in addition to routine testing (exercise 
ECG).34 In a post hoc analysis of this trial, CCTA features (low- 
attenuation plaque, positive remodelling, spotty calcifications, and 
napkin-ring sign) conferred an increased risk of death or non-fatal 
MI, although these plaque features were not independent of 
CACS.210 Systematically evaluating adverse plaque features by 
CCTA can be challenging due to technical limitations (spatial reso­
lution) and patient characteristics (calcifications).
A network meta-analysis of randomized trials suggested that diag­
nostic testing with CCTA was associated with clinical outcomes similar 
to those with functional imaging in patients with suspected stable 
CAD.197 In another pairwise meta-analysis, CCTA showed a lower 
rate of MI compared with functional testing, but the absolute per 
cent risk difference was small (0.4%).211
In the available randomized trials comparing CCTA and functional 
testing (all testing a diagnostic strategy),33,210,212 test reporting and pa­
tient management variability could in part help explain the improved 
outcomes observed in the CCTA arm of SCOT-HEART. In this trial, 
CCTA findings, including non-obstructive atherosclerosis, emphasized 
the need to trigger the start or intensification of medical treatment. 
Increased standardization in reporting CCTA to encompass key plaque 
features (accepting inherent limitations) will be warranted to systemat­
ically harvest prognostic information and help fine-tune risk manage­
ment strategies.213
3.3.1.3. Recognized pre-requisites for coronary computed 
tomography angiography
Generally, a slow and regular heart rate, and compliance with breath- 
holding instructions are necessary to achieve good image quality. 
This includes suitability to receive pre-medication (typically oral or 
i.v. beta-blockers) when needed. Kidney function and allergy to con­
trast agents should be assessed prior to referral. Temporal and spatial 
resolution remain technical limitations and can hinder precision in 
adjudicating coronary stenosis severity. This is most problematic in 
older patients with heavily calcified coronary arteries, in whom func­
tional testing may be more appropriate than CCTA. Contemporary 
CT technology (64-slice technology or above) and a well-trained 
imaging team can help mitigate these limitations and must be consid­
ered a pre-requisite for CCTA.
3.3.2. Functional imaging
3.3.2.1. Stress echocardiography
Stress echocardiography is used to detect myocardial ischaemia by 
assessing regional systolic wall-thickening abnormalities (RWTA) 
during stress. It relies on inducing myocardial ischaemia by increasing 
myocardial oxygen demand beyond the myocardial blood supply. 
Because ischaemia starts in the subendocardium, which contributes 
to more than 50% of systolic myocardial wall thickening, stress testing 
will precipitate wall-thickening abnormalities in the perfusion territory 
of narrowed coronary arteries. Stress modalities used to increase myo­
cardial oxygen demand are exercise (treadmill or bicycle), or i.v. admin­
istration of dobutamine, or vasodilators (adenosine, dipyridamole, 
regadenoson) combined with atropine (to increase heart rate ad­
equately—a major determinant of oxygen demand). Stress echocardi­
ography using demand stress has provided diagnostic accuracy and 
risk-stratification capabilities similar to those obtained with other con­
temporary functional imaging testing modalities.148,223 The advantages 
of stress echocardiography are that it is widely available, low-cost, can 
be performed and interpreted at the bedside, rapid, free of ionizing ra­
diation, and can be repeated without safety concerns.224–227 Although 
stress echocardiography is operator-dependent, which may comprom­
ise reproducibility, the technique is within reach of every cardiology 
department or office. Compromised image quality, especially in obese 
and chronic obstructive pulmonary disease subjects, is a significant 
Recommendation Table 8 — Recommendations for 
non-invasive anatomical imaging tests in the initial 
diagnostic management of individuals with suspected 
chronic coronary syndrome—coronary computed tom­
ography angiography, if available, and supported by local 
expertise (see also Evidence Table 8)
Recommendations
Classa
Levelb
In individuals with suspected CCS and low or 
moderate (>5%–50%) pre-test likelihood of 
obstructive CAD, CCTA is recommended to 
diagnose obstructive CAD and to estimate the risk of 
MACE.33,34,145,212,214–221
I
A
CCTA is recommended in individuals with low or 
moderate (>5%–50%) pre-test likelihood of 
obstructive CAD to refine diagnosis if another 
non-invasive test is non-diagnostic.222
I
B
CCTA is not recommended in patients with severe 
renal failure (eGFR <30 mL/min/1.73 m2), 
decompensated heart failure, extensive coronary 
calcification, fast irregular heart rate, severe obesity, 
inability to cooperate with breath-hold commands, 
or any other conditions that can make obtaining 
good imaging quality unlikely.
III
C
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary 
computed tomography angiography; eGFR, estimated glomerular filtration rate; MACE, 
major adverse cardiovascular events. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 29 -->

### Page 29

limitation. RWTA may not occur if the myocardial oxygen demand in­
crease is inadequate or if the induced perfusion abnormalities are not 
large enough (<10% of the myocardium), such as in mild atherosclerot­
ic CAD or single-vessel obstructive CAD.228 As stress echocardiog­
raphy relies on RWTA as a marker of ischaemia, it may 
under-estimate ischaemia in patients with microvascular disease not af­
fecting the subendocardium as in ANOCA/INOCA.36
Ultrasound contrast agents considerably enhance the quality of diag­
nostic images obtained during stress echocardiography. These micro­
bubbles, consisting of stable gas and shells about the size and 
rheology of red blood cells, can pass through the pulmonary microcir­
culation and induce a dense opacification of the left heart chambers. 
The enhanced image quality and endocardial border definition by using 
ultrasound contrast agents markedly improve the accuracy of stress 
echocardiography.229,230 Ultrasound contrast agents may be required 
in individuals with obesity and chronic obstructive pulmonary disease 
and must be used in all cases if it is evident at baseline that all segments 
may not be visible during stress. Passage of ultrasound contrast agents 
through the myocardium allows assessment of myocardial perfusion 
simultaneously with regional wall motion, improving the sensitivity of 
stress echocardiography (better detection of single-vessel and micro­
vascular disease) and risk stratification beyond RWTA.231–235 The 
use of ultrasound contrast agents during stress echocardiography for 
assessing regional and global LV function is strongly recommended by 
the European Association of Cardiovascular Imaging (EACVI) and the 
American Society of Echocardiography (ASE) guidelines—both class I 
indications. Similarly, myocardial perfusion assessment has received a 
class I recommendation by the EACVI and a class IIa recommendation 
by the ASE.177,236 Ultrasound contrast agents are generally safe, but 
rare cases of anaphylactic reactions have been reported.237
Measurement of the coronary flow velocity reserve (CFVR) based 
on Doppler flow velocity recordings at rest and during stress in the 
left anterior descending (LAD) artery, and assessment of lung conges­
tion through the visualization of B-lines on lung ultrasound, can easily be 
added to routine stress echocardiography procedures. In a prospective 
observational multicentre study, a reduced CFVR was often accompan­
ied by RWTA, abnormal LV contractile reserve, and pulmonary conges­
tion during stress, and showed independent value over RWTA in 
predicting an adverse outcome.238 The inclusion of these additional 
parameters in routine stress echocardiography procedures provides in­
sights on coronary microcirculatory dysfunction.
Finally, carotid ultrasound may be performed in the same session with 
stress echocardiography to assess extracoronary atherosclerosis; while 
this does not add value for confirming a CCS diagnosis per se, it provides 
incremental prognostic value beyond myocardial ischaemia.239,240
3.3.2.2. Myocardial perfusion scintigraphy—single-photon emission 
computed tomography
Myocardial perfusion SPECT imaging relies on the myocardial uptake and 
retention of a radiopharmaceutical. Technetium-99m (99mTc)-based 
tracers are the most commonly used radiopharmaceuticals, whereas 
Thallium 201 (201Tl) should be avoided as it is associated with higher ra­
diation exposure. Myocardial perfusion SPECT produces images of re­
gional myocardial tracer retention, which reflects relative regional 
myocardial blood flow (MBF). Myocardial hypoperfusion is characterized 
by relative reduced radionuclide tracer uptake and retention during vaso­
dilatation or stress, compared with the uptake and retention at rest. The 
inherent need for a normally perfused myocardial reference territory al­
lowing for visualization of the myocardium with relative hypoperfusion 
constitutes the main limitation of SPECT (and stress CMR), particularly 
in multivessel CAD. Coronary calcium scoring from non-contrast- 
enhanced CT, acquired for attenuation correction, as well as transient 
ischaemic dilatation (TID) and reduced post-stress ejection fraction 
(EF) are important non-perfusion predictors of severe obstructive CAD.
Ischaemia can be demonstrated by physical exercise or through the 
administration of pharmacological stressors (e.g. dobutamine) or 
vasodilators 
(e.g. 
dipyridamole, 
adenosine, 
or 
regadenoson). 
Pharmacological agents are indicated in patients who cannot exercise ad­
equately or may be used as an alternative or an adjunct to exercise stress. 
The possibility to use physical exercise and/or different pharmacological 
stressors in combination with the wide-spread availability of the technique 
and the lack of absolute contraindications contributes to the high versa­
tility and applicability of myocardial perfusion SPECT in clinical routine.
SPECT myocardial perfusion imaging is associated with good accur­
acy for the detection of flow-limiting coronary lesions,148,256–258 and 
has been shown to provide prognostic information223,259 and to im­
prove patient management in a randomized controlled trial (RCT).178
Newer-generation SPECT cameras based on cadmium–zinc–telluride 
(CZT) semiconductor detector technology enable a substantial reduction 
in radiation dose exposure and acquisition time, as well as an increased 
diagnostic accuracy260 and absolute quantification of MBF. Hence, its diag­
nostic performance for multivessel CAD has improved substantially.261
Recommendation Table 9 — Recommendations for 
non-invasive tests in the initial diagnostic management 
of individuals with suspected chronic coronary syndrome 
—stress echocardiography, if available, and supported by 
local expertise (see also Evidence Table 9)
Recommendations
Classa
Levelb
In individuals with suspected CCS and moderate or 
high (>15%–85%) pre-test likelihood of obstructive 
CAD, stress echocardiography is recommended to 
diagnose myocardial ischaemia and to estimate the 
risk of MACE.33,241–246
I
B
Continued 
During stress echocardiography, when two or more 
contiguous myocardial segments are not visualized, it 
is recommended to use commercially available 
intravenous ultrasound contrast agents 
(microbubbles) to improve diagnostic 
accuracy.177,229,236,247,248
I
B
During stress echocardiography, myocardial 
perfusion using commercially available intravenous 
ultrasound contrast agents (microbubbles) is 
recommended to improve diagnostic accuracy and 
to refine risk stratification beyond wall 
motion.177,230,232,236,249–254
I
B
During stress echocardiography, Doppler left 
anterior descending coronary artery flow reserve 
may be considered to improve risk stratification 
beyond wall motion and to assess microvascular 
function.177,238,255
IIb
B
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome; MACE, major adverse 
cardiovascular events. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3443


<!-- PAGE 30 -->

### Page 30

However, non-obstructive coronary atherosclerosis not linked with is­
chaemia remains undetected by functional testing in general.
If available, assessment of myocardial perfusion using SPECT is recom­
mended in patients with suspected CCS with moderate or high pre-test 
likelihood of obstructive CAD (15%–85%) or known CCS. Importantly, if 
non-contrast-enhanced CT for attenuation correction is acquired, this al­
lows for additional CAC scoring, providing important information for risk 
stratification even in the absence of flow-limiting coronary lesions.
3.3.2.3. Positron emission tomography-computed tomography
Similarly to myocardial perfusion SPECT imaging, PET also relies on 
radiopharmaceuticals. Contrary to SPECT, however, the radionuclides 
commonly used (i.e. 13N-ammonia, 15O-water, and 82Rubidium) are 
short-lived, with half-lives in the range of minutes, requiring production 
of these radionuclides ad hoc for every investigation. As attenuation 
correction is mandatory, PET is routinely performed in combination 
with non-contrast-enhanced CT. Scans are performed during both 
rest and infusion of pharmacological stressors (e.g. dobutamine) or va­
sodilators (e.g. dipyridamole, adenosine, or regadenoson).
While myocardial perfusion PET-CT produces retention images de­
picting relative differences in regional MBF similar to those from SPECT 
—albeit with superior image quality and at much lower radiation dose 
exposure—the unique strength of PET-CT imaging is its ability to pro­
vide robust absolute quantitative measures of MBF. Measuring MBF 
with cardiac PET does not increase radiation or imaging time. Several 
measurements of MBF can be routinely obtained, including MBF during 
hyperaemia, MBF at rest, the MBF reserve, and the relative MBF reserve, 
and confer added diagnostic and prognostic value beyond relative per­
fusion assessment.262,263
Quantitative measures of MBF offer the ability to assess individuals 
with known or suspected diffusely impaired MBF, e.g. with multivessel 
CAD, or microvascular dysfunction.45,264 In general, PET-CT myocar­
dial perfusion imaging is associated with high accuracy for detecting 
flow-limiting coronary lesions,148,258,265 and has been shown to provide 
prognostic information.223,262,263 In several head-to-head comparisons, 
PET-CT myocardial perfusion imaging outperformed other functional 
imaging modalities.257,266–269 However, whether the superiority in diag­
nostic accuracy leads to improved clinical effectiveness and post-test 
management remains to be elucidated.270 In a large retrospective study, 
a low MBF reserve measured by PET independently predicted mortality 
and helped identify patients with a survival benefit from early revascu­
larization with PCI or coronary artery bypass grafting (CABG) beyond 
the extent of myocardial ischaemia.271
Limitations of PET-CT arise from its limited availability compared with 
other imaging modalities. Furthermore, methodological heterogeneity 
exists, particularly regarding thresholds for abnormality of quantitative 
measurements. Finally, physical exercise is challenging to perform.
If available, assessment of myocardial perfusion using PET-CT is par­
ticularly recommended in obese patients (due to the high photon en­
ergy), in young patients (due to the low radiation dose exposure), 
and in those with known or suspected diffusely impaired MBF, e.g. those 
with multivessel CAD or microvascular dysfunction.264 Notably, the 
mandatory non-contrast-enhanced CT for attenuation correction al­
lows for additional CAC scoring, providing essential information for 
risk stratification even in the absence of flow-limiting coronary lesions.
3.3.2.4. Cardiac magnetic resonance imaging
Aside from providing highly accurate and reproducible assessments of 
overall cardiac anatomy, cardiac volumes, function, and tissue charac­
terization, CMR also offers the ability to assess myocardial perfusion, 
which relies on the first-pass myocardial perfusion of gadolinium-based 
contrast agents.
Recently, CMR methods using various parameters for quantitative MBF 
assessment have been introduced. However, the diagnostic performance 
of these parameters varies extensively among studies, and standardized 
protocols and software are lacking.272 Therefore, visual assessment of 
perfusion defects is currently used in clinical practice. Myocardial 
perfusion imaging by stress CMR combines high spatial resolution with 
the absence of ionizing radiation. This has been shown to provide high 
diagnostic accuracy in detecting flow-limiting coronary lesions,148,257,258
prognostic value,223,273–275 and improving patient management.178,276
Pharmacological vasodilators (e.g. adenosine or regadenoson) or stres­
sors (e.g. dobutamine) are commonly applied, as physical exercise is chal­
lenging to perform. In conjunction with a dobutamine infusion, wall 
motion abnormalities induced by ischaemia can also be detected.277 Of 
note, and as for all non-invasive imaging modalities used for assessing myo­
cardial perfusion, incorporating all available imaging and non-imaging in­
formation as part of an integrative approach is mandatory. For CMR, a 
multiparametric protocol, including LV function and assessment of LGE 
along with myocardial perfusion, increases the ability to rule in or rule 
out obstructive CAD in suspected CCS.278
Coronary magnetic resonance angiography allows non-invasive visu­
alization of the coronary arteries.279 However, CMR angiography re­
mains primarily a research tool due to limitations arising from long 
imaging times, low spatial resolution, and operator dependency. 
General limitations of CMR for myocardial perfusion arise from its lim­
ited availability, the claustrophobia experienced by patients, duration of 
image acquisition,280 and possible contraindications to CMR [e.g. non- 
conditional pacemakers and implantable cardioverter defibrillators 
(ICDs)] or to gadolinium-based contrast agents (e.g. renal failure due 
to the potential risk of nephrogenic systemic fibrosis). Finally, and con­
trary to SPECT/CT or PET-CT, stress CMR does not currently provide 
information on presence or absence of coronary calcifications.
If available, and if no contraindications are met, stress CMR is recom­
mended as an option in patients with suspected CCS with moderate or 
high (>15%–85%) pre-test likelihood of obstructive CAD or known 
CCS, particularly if additional information on cardiac function and tissue 
characterization is warranted.
Recommendation Table 10 — Recommendations for 
non-invasive functional myocardial imaging tests in the 
initial diagnostic management of individuals with 
suspected chronic coronary syndrome—resting and 
stress single-photon emission computed tomography/ 
positron 
emission 
tomography—cardiac 
magnetic 
resonance imaging, if available, and supported by local 
expertise (see also Evidence Table 10)
Recommendations
Classa
Levelb
In individuals with suspected CCS and moderate or 
high (>15%–85%) pre-test likelihood of obstructive 
CAD, stress SPECT or, preferably, PET myocardial 
perfusion imaging is recommended to: 
• diagnose and quantify myocardial ischaemia and/or 
scar;
• estimate the risk of MACE;
• quantify myocardial blood flow 
(PET).33,44,223,257,263,268,270,271,281–288
I
B
Continued


<!-- PAGE 31 -->

### Page 31

3.3.2.5. Non-invasive testing for microvascular dysfunction
Angina/ischaemia with non-obstructive coronary arteries (ANOCA/ 
INOCA) may be caused by transient and/or sustained impairments in 
the supply–demand of myocardial perfusion. Functional disorders leading 
to ANOCA/INOCA (e.g. MVA and VSA) are more common in women 
than in men.298,299 A recent meta-analysis reported an overall prevalence 
of MVA of 41% and VSA of 40% in selected patients without obstructive 
CAD.299 However, the true prevalence in unselected patient populations 
with suspected CCS remains unclear. Patients with ANOCA/INOCA 
have increased morbility/mortality,300,301 impaired quality of life (QoL), 
and weigh on health resource utilization. Early, accurate, and preferably 
non-invasive diagnosis is, therefore, of importance.
The possibility of a microcirculatory origin of angina should be con­
sidered in individuals with symptoms suggestive of myocardial ischaemia 
and coronary arteries that are either normal or with non-obstructive 
lesions on CCTA or ICA. Several measurements that rely on quantify­
ing blood flow through the coronary circulation are used to describe 
the function of the microvasculature to identify cases of MVA. 
Among the non-invasive imaging modalities, transthoracic Doppler 
echocardiography has been used as a non-invasive means to measure 
coronary blood flow but is limited to the assessment of the LAD artery 
and is affected by high inter- and intra-operator variability.302,303
Furthermore, this modality cannot distinguish between impairment of 
coronary flow caused by epicardial CAD or coronary microcirculatory 
dysfunction.
A more direct and accurate microvascular function assessment is 
based on MBF measurement. This is commonly achieved by PET-CT 
myocardial perfusion imaging.299 PET allows for the quantification of 
MBF (expressed as millilitres per minute per gram of myocardium) 
and myocardial flow reserve (MFR). The latter reflects the magnitude 
of the increase in MBF that can be achieved by maximal coronary vaso­
dilation conferred by vasodilators, such as adenosine or regadenoson. 
Since the microvasculature primarily determines vascular resistance, 
MFR measures the ability of the microvasculature to respond to a 
stimulus and therefore represents small vessel function. An MFR of 
less than 2.0 (2.5 for non-obstructive CAD) is often considered abnor­
mal for PET.304 Of note, however, no definitive references are available 
across imaging modalities due to the moderate correlation among dif­
ferent MBF estimates.264
Recently, quantitative CMR has been proposed as an emerging tech­
nique for the assessment of microvascular dysfunction through MBF 
quantification but is currently limited to experienced centres.275
Quantitative myocardial perfusion can also be achieved by myocardial 
contrast echocardiography (MCE) through destruction–reperfusion 
imaging and analysis of the time–intensity curves from different regions 
of interest in the myocardium.231,233–235 Of note, MCE assesses capil­
lary blood flow, and capillaries comprise 90% of the microvasculature. 
Measuring MBF at rest and during hyperaemia allows calculation of MBF 
reserve, which is associated with severity of coronary stenoses in pa­
tients with stable angina. In a meta-analysis, MBF reserve had high accur­
acy for predicting flow-limiting CAD.231 However, in the absence of 
obstructive CAD, reduced MBF reserve by MCE depicts microcircula­
tory abnormalities. Transthoracic Doppler evaluation of the LAD ar­
tery is also used to assess coronary flow reserve (CFR) during stress 
hyperaemia and has prognostic value.238,255,305,306
In contrast, the diagnosis of VSA ideally relies on the results of provo­
cation tests in the catheterization laboratory through selective intracor­
onary acetylcholine (Ach) infusion (see Section 5.2.5.2).
It is important to note that there is only a modest correlation be­
tween the values of MBF reserve measured by different techniques 
and modalities.269,305,307
3.3.3. Invasive tests
Invasive coronary angiography has undergone significant advancements 
over time. It is no longer just an angiographic technique that provides ana­
tomical information about the presence of coronary atherosclerosis and 
luminal obstructions of the epicardial coronary arteries. It can also deter­
mine the functional consequences of these obstructions on coronary 
blood flow [FFR and instantaneous wave-free ratio (iFR)] by direct meas­
urement of the coronary BP49,308–311 or by calculating the coronary 
pressure drop across a stenosis based on two or more angiographic 
projections.312 Furthermore, new technologies allow measurement of 
CFR and microvascular resistance, and protocols have been introduced 
for testing the presence of coronary vasospasm.36,39
3.3.3.1. Invasive coronary angiography
Invasive coronary angiography with available coronary pressure 
assessment49,308–311,313 is indicated in patients with a very high 
(>85%) clinical likelihood of obstructive CAD,1 in particular those 
with severe symptoms refractory to antianginal treatment, or charac­
teristic angina or dyspnoea at a low level of exercise1,47 or left ventricle 
dysfunction suggesting extensive obstructive CAD.47,182,314,315
Invasive coronary angiography/coronary pressure assessment is also 
indicated if non-invasive assessment suggests high event risk—e.g. 
CCTA shows ≥50% left main stenosis, or ≥70% proximal LAD stenosis 
with single or two-vessel CAD, or ≥70% proximal three-vessel 
CAD56,182,316,317—or when any stress test shows moderate to severe 
inducible ischaemia316 or when symptoms are highly suggestive for ob­
structive CAD. In all the above situations, ICA/coronary pressure as­
sessment is performed for additional risk stratification318–320 and to 
determine a potential revascularization approach (see Section 
4.4).49,308,309,313
Invasive coronary angiography/coronary pressure assessment may 
also be indicated to confirm or exclude the diagnosis of obstructive 
CAD in patients with uncertain results on non-invasive testing.316
Given the frequent mismatch between the angiographic and haemo­
dynamic severities of coronary stenoses, coronary pressure assessment 
should be readily available to complement ICA investigation for clinical 
decision-making.321–326
In patients selected for PET or SPECT myocardial 
perfusion imaging, it is recommended to measure 
CACS from unenhanced chest CT imaging (used for 
attenuation correction) to improve detection of 
both non-obstructive and obstructive CAD.289–293
I
B
In individuals with suspected CCS and moderate 
or high (>15%–85%) pre-test likelihood of 
obstructive CAD, stress CMR perfusion imaging is 
recommended to diagnose and quantify myocardial 
ischaemia and/or scar and estimate the risk of 
MACE.148,273,276,278,294–297
I
B
© ESC 2024
CACS, coronary artery calcium score; CAD, coronary artery disease; CCS, chronic 
coronary syndrome; CMR, cardiac magnetic resonance; CT, computed tomography; 
MACE, major adverse cardiovascular events; PET, positron emission tomography; 
SPECT, single-photon emission computed tomography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3445


<!-- PAGE 32 -->

### Page 32

In patients with suspected ANOCA/INOCA and an ICA/coronary 
pressure assessment disclosing no significant epicardial CAD, additional 
invasive investigations including index of microcirculatory resistance 
(IMR), CFR and, if necessary, invasive vasoreactivity testing using Ach 
(or ergonovine)36 as part of a complete ‘invasive coronary functional 
testing’ (ICFT) can be performed.
Performing ICA is not exempt from potential complications. Given 
that femoral diagnostic catheterization has been associated with a 
0.5%–2.0% composite rate of major complications, mainly bleeding re­
quiring blood transfusions,327 radial access is now the standard access 
when possible. Radial access has been associated with reduced mortal­
ity and reduced major bleeding while allowing rapid ambulation.327 Still, 
the composite ICA rate of death, MI, or stroke through radial access is 
of the order of 0.1%–0.2%.327 The decision to perform ICA should bal­
ance benefits and risks, as well as potential therapeutic consequences, 
of the investigation that should be part of the process of shared clinical 
decision-making. Patients should be adequately informed of these as­
pects ahead of the procedure.
3.3.3.2. Functional assessment of epicardial stenosis severity to 
guide coronary revascularization
When non-invasive stress tests are inconclusive or not performed, identi­
fying the artery responsible for ischaemia during ICA can be challenging, 
especially in cases with multivessel CAD or coronary stenoses of inter­
mediate severity (typically around 40%–90% for non-left main stem sten­
oses or 40%–70% for left main stem stenoses by visual estimate). In such 
cases, recording wire-based intracoronary pressure during maximal hyper­
aemia to calculate FFR or at rest to measure iFR is recommended to im­
prove risk assessment and clinical decision-making and to reduce clinical 
events.318–320 This has been confirmed by large clinical outcome studies 
such as FAME 1,308 FAME 2,49 DEFINE-FLAIR (Functional Lesion 
Assessment of Intermediate Stenosis to Guide Revascularisation),310
iFR-SWEDEHEART (Instantaneous Wave-free Ratio versus Fractional 
Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary 
Syndrome),311 R3F (French FFR Registry),313 and RIPCORD (Routine 
Pressure Wire Assessment Influence Management Strategy at Coronary 
Angiography for Diagnosis of Chest Pain trial).309 Haemodynamic rele­
vance, as defined by FFR of ≤0.80, or iFR of ≤0.89, correlates poorly 
with diameter stenosis by visual assessment. In the PRIME-FFR [Insights 
From the POST-IT (Portuguese Study on the Evaluation of FFR-Guided 
Treatment of Coronary Disease) and R3F Integrated Multicenter 
Registries—Implementation of FFR (Fractional Flow Reserve) in Routine 
Practice]322 and FAME (Fractional Flow Reserve versus Angiography for 
Multivessel Evaluation) study,195 31% of the 40%–49% stenoses were 
haemodynamically significant while only 35% of the 50%–70% stenoses 
were haemodynamically relevant, and of the 71%–90% stenoses, 20% 
were not. Only an estimated diameter stenosis of >90% predicted haemo­
dynamic relevance with high accuracy (96% correct classification). The 
discordance between angiographical and functional assessment of cor­
onary stenosis severity varies with age, presence of CMD and lesion- 
specific factors.338,339 Lesions in the left main or proximal LAD are 
more likely to result in a significant FFR, as they supply a larger myocar­
dial mass than those in smaller arteries. As a result, the optimal angio­
graphic cut-off value for functionally non-significant stenosis is 43% for 
the left main and 55% for small vessels.339 This implies that the thresh­
old for functional assessment for larger arteries should be set at 40% 
diameter stenosis.
Large management studies showed that integration of FFR to ICA is 
associated with treatment reclassification in 30%–50% of cases in the 
R3F, POST-IT, RIPCORD, and DEFINE-REAL studies.309,313,340,341
Subsequently, many other non-hyperaemic pressure parameters 
were introduced [distal coronary pressure to aortic pressure ratio 
(Pd/Pa), diastolic pressure ratio (dPR), relative flow reserve (RFR)], 
with good correlation with FFR or iFR, but without available clinical out­
come data. It is interesting to note that both separate and pooled ana­
lyses of the patients included in those studies reveal that ‘FFR/iFR-based 
reclassification’ does not have any significant effect on the number of 
patients recommended for revascularization.342
Meta-analyses of the 5-year outcome of patients managed with iFR 
and FFR as part of the randomized DEFINE-FLAIR and DEFINE- 
SWEDEHEART studies have reported a 2% absolute increase in all-cause 
mortality in those managed with iFR.343,344 This was not associated with 
any unplanned revascularization or non-fatal MI rate increase.343,344
Although it was initially hypothesized that this mortality excess could be 
related to a higher proportion of ‘inappropriate’ revascularization deferral 
with iFR compared with FFR (50% vs. 45%),343 it is reassuring that 
iFR-based deferral is as safe as FFR-based deferral up to 5 years.345
In patients with multivessel CAD, systematic FFR measurement of all 
epicardial vessels has been proposed to select appropriate therapy, but 
Recommendation Table 11 — Recommendations for 
invasive coronary angiography in the diagnostic manage­
ment of individuals with suspected chronic coronary 
syndrome (see also Evidence Table 11)
Recommendations
Classa
Levelb
When ICA is indicated, radial artery access is 
recommended as the preferred access site.327–330
I
A
When ICA is indicated, it is recommended to have 
coronary pressure assessment available and to use it 
to evaluate the functional severity of intermediate 
non-left main stem stenosesc prior to 
revascularization.49,195,308,313,321,322,325,331–333
I
A
Invasive coronary angiography is recommended to 
diagnose obstructive CAD in individuals with a very 
high (>85%) clinical likelihood of disease, severe 
symptoms refractory to guideline-directed medical 
therapy, angina at a low level of exercise, and/or high 
event risk.
I
C
In individuals with de novo symptoms highly 
suggestive of obstructive CAD that occur at a low 
level of exercise, ICA with a view towards 
revascularization is recommended as first diagnostic 
test after clinical assessment by a cardiologist.
I
C
When ICA is indicated, measurement of FFR/iFR 
should be considered to evaluate the functional 
severity of intermediate left main stem stenosesc 
prior to revascularization.331,334,335
IIa
A
When ICA is indicated, IVUS should be considered to 
evaluate the severity of intermediate stenoses of left 
main stemc prior to revascularization.336,337
IIa
B
© ESC 2024
CAD, coronary artery disease; FFR, fractional flow reserve; ICA, invasive coronary 
angiography; iFR, instantaneous wave-free ratio; IVUS, intravascular ultrasound. 
aClass of recommendation. 
bLevel of evidence. 
cTypically 40%–90% for non–left main stem stenoses and 40%–70% for left main stem 
stenoses by visual estimate. For ICA in the diagnostic management of individuals with 
suspected ANOCA/INOCA, see Section 5.3. (Specific groups).


<!-- PAGE 33 -->

### Page 33

recent studies (RIPCORD2 and FUTURE) did not demonstrate any clinical 
outcome improvement compared with angiography alone.346,347
Therefore, intracoronary pressure measurement in patients with multi­
vessel CAD should only be performed on intermediate lesions.
Several recent studies using either FFR or iFR suggest that the pattern 
of pressure drop along the coronary artery (focal vs. progressive) re­
corded during a pullback is important to select patients who will benefit 
more from PCI.2,348–352 Longitudinal functional vessel interrogation can 
therefore be helpful in patients with serial lesions or diffuse CAD.
New 3D angiographically derived wireless coronary pressure para­
meters, such as quantitative flow ratio (QFR) or vessel fractional flow 
reserve (vFFR), are at different stages of clinical investigation325,353,354
(NCT03729739) and have important features that may help to increase 
the use of coronary pressure measurement during ICA significantly. 
These technologies have indeed the unique advantage of providing 
both distal coronary pressure measures and a coronary pressure 
map along the coronary vessel without requiring the use of any pres­
sure wire. The lack of benefits shown in some recent FFR trials demon­
strates that it is not sufficient to validate such new coronary pressure 
indexes against FFR alone to demonstrate their clinical value, and it is 
important to also show benefit in a direct comparative trial vs. angiog­
raphy. In that context, the results of the FAVOR III China study355 are 
important, demonstrating an improved clinical outcome in the 
QFR-guided group compared with the angiography-guided group, 
driven by fewer MIs and ischaemia-driven revascularizations.
The combined measurements of pressure and flow (measured by 
Doppler or thermodilution) may further reduce the number of inter­
ventions. Patients with lesions and concordant normal FFR and CFR 
have an excellent prognosis. Patients with lesions and discordant results 
between FFR and CFR have a similar prognosis to that of patients with 
lesions and concordant abnormal FFR and CFR, treated with PCI. 
Lesions with an abnormal FFR but normal CFR pertain to a good clinical 
outcome up to 5 years of follow-up if left untreated.356–358 Moreover, 
hyperaemic stenosis resistance (HSR), by measuring the pressure gra­
dient across a lesion divided by flow, is an excellent index for both 
diagnostic and prognostic purposes.359,360 The recently introduced 
continuous thermodilution technique for measuring absolute coronary 
flow presents an alternative method for determining CFR. Additionally, 
this method allows for evaluation of the microvascular resistance 
reserve (MRR), a novel index for assessing coronary microvascular 
function.361–364
Coronary flow capacity (CFC) integrates hyperaemic flow and CFR 
and is useful for both diagnostic purposes as well as the evaluation of 
the result after PCI.365–368
Intravascular imaging techniques [e.g. intravascular ultrasound (IVUS) 
or optical coherence tomography (OCT)] have demonstrated good 
diagnostic accuracy in predicting FFR, especially in stenoses located in 
the left main stem.369,370 They are reasonable options to assess left 
main stenosis severity and prognosis; increasing left main plaque burden 
was associated with long-term all-cause and cardiac mortality in pa­
tients not undergoing revascularization.371
While coronary pressure thresholds, specifically 0.80 for FFR and 
0.89 for iFR, are crucial in aiding clinical decision-making, particularly 
in the case of deferring revascularization when FFR/iFR exceeds the is­
chaemic threshold,310,372 they must be considered alongside other 
parameters. These include a careful assessment of the patient’s symp­
toms and the results of non-invasive stress testing to determine the 
need for revascularization.
3.3.3.3. Assessment of microvascular dysfunction
Detailed discussion of microvascular dysfunction by invasive coronary 
functional testing is provided in Section 5.2.5.2. After nitroglycerine, ad­
enosine is administered to assess endothelium-independent vasodila­
tion [CFR, IMR, and hyperaemic myocardial velocity resistance 
(HMR)]. Coronary flow reserve can be calculated using bolus thermo­
dilution (as baseline transit time divided by hyperaemic transit time) or 
continuous thermodilution (as the ratio of hyperaemic and resting abso­
lute coronary flow), or Doppler flow velocity (hyperaemic flow velocity 
divided by baseline flow velocity).307,378,379 The IMR is calculated as the 
product of distal coronary pressure at maximal hyperaemia multiplied 
by the hyperaemic mean transit time. Increased IMR (≥25 U) indicates 
microvascular dysfunction.380,381 It is important to note that continuous 
thermodilution-derived measurements have shown higher reproducibil­
ity than similar measurements derived from bolus thermodilution.382
Angiography-derived index of coronary microcirculatory resistance 
(angio-IMR) allows microcirculation assessment without using intracor­
onary wires.383
3.3.3.4. Testing for coronary vasospasm
Vasoreactivity testing explores endothelium-dependent mechanisms of 
CMD and epicardial and microvascular vasomotor tone disorders.36,73,384
The most established approach for coronary vasoreactivity testing 
is by intracoronary infusion of Ach, although other substances like 
ergonovine have been proposed.384,385 The methodology is described 
in detail in Section 5.2.5.2.2.
Recommendation Table 12 — Recommendations for 
functional assessment of epicardial artery stenosis 
severity during invasive coronary angiography to guide 
revascularization (see also Evidence Table 12)
Recommendations
Classa
Levelb
During ICA, selective assessment of functional severity of intermediatec 
diameter stenoses is recommended to guide the decision to revascularize, 
using the following techniques:
• FFR/iFR (significant ≤0.8 or ≤0.89, 
respectively);49,308,310,311,313,321–323,332,373
I
A
• QFR (significant ≤0.8).325,355,374,375
I
B
In addition:
• CFR/HSR/CFC should be considered as a 
complementary investigation;359,360,366–368,376
IIa
B
• resting invasive measurement of Pd/Pa, dPR, RFR, 
or angiography-derived vessel FFR may be 
considered as alternative parameters.353,377
IIb
C
Systematic and routine wire-based coronary 
pressure assessment of all coronary vessels is not 
recommended.346,347
III
A
© ESC 2024
CFC, coronary flow capacity; CFR, coronary flow reserve; dPR, diastolic pressure ratio; 
FFR, fractional flow reserve; HSR, hyperaemic stenosis resistance; ICA, invasive coronary 
angiography; iFR, instantaneous wave-free ratio; Pd/Pa, distal coronary pressure to aortic 
pressure ratio; QFR, quantitative flow ratio; RFR, relative flow reserve. 
aClass of recommendation. 
bLevel of evidence. 
cTypically around 40%–90% for non-left main stem or 40%–70% for left main stem by visual 
estimate.
ESC Guidelines                                                                                                                                                                                          3447


<!-- PAGE 34 -->

### Page 34

3.3.4. Diagnostic algorithm and selection of 
appropriate tests
After estimation of the pre-test likelihood of obstructive epicardial 
CAD based on the RF-CL model (Figure 4 and Figure 5),139 further diag­
nostic testing is dependent on the clinical scenario, general condition, 
QoL, presence of comorbidities, local availability and expertise for dif­
ferent diagnostic techniques, and importantly patient expectations and 
preferences (Figure 6; Table 6).
In patients with severe comorbidities or severe frailty or very low 
QoL that all contribute to a limited life expectancy, in whom revascu­
larization is judged to be futile, the diagnosis of CCS can be made clin­
ically, and managed with medical therapy and lifestyle changes alone. If 
CCS diagnosis is uncertain in such patients, establishing a diagnosis using 
non-invasive functional imaging for myocardial ischaemia before treat­
ment is reasonable.
Individual adjustment of the clinical likelihood should always be con­
sidered based on the clinical CCS scenario including ECG and echocar­
diography findings (Figure 5, Section 2). Further diagnostic testing can be 
deferred in patients with a very low (≤5%) likelihood of obstructive 
CAD. Based on the CACS-CL model, in patients with a low 
(>5%–15%) likelihood of obstructive CAD, CACS can be considered 
to re-estimate the likelihood of obstructive CAD.139,165,141,154
Further diagnostic testing can also be deferred in patients reclassified 
based on CACS from a low to a very low (<5%) likelihood of 
Risk Factor-weighted Clinical Likelihood  (RF-CL)
Symptom score
Age 30–39
Very low
Low
Moderate
Age 40–49
Age 50–59
Age 60–69
Age 70–80
Clinical likelihood:
0–1 point
2 points
3 points
Number of risk factors
4
7
11
0
1
2
2
4
7
1
2
5
1
1
3
0–1 2–3 4–5
Women
15 19 24
1
2
5
8
12 17
4
7
12
2
4
8
0–1 2–3 4–5
Men
6
10 16
0
1
3
3
6
11
2
3
7
1
2
5
0–1 2–3 4–5
Women
22 27 34
2
4
8
12 17 25
6
11 17
3
6
12
0–1 2–3 4–5
Men
16 19 23
2
5
10
10 14 19
6
10 15
4
7
12
0–1 2–3 4–5
Women
44 44 45
9
14 22
32 35 39
21 27 33
14 20 27
0–1 2–3 4–5
Men
Resting ECG changes (Q-wave or ST-segment/T-wave changes)
LV dysfunction (severe or segmental)
Exercise ECG with abnormal findings
Ventricular arrhythmia
Coronary calcification on pre-existing chest CT
Peripheral artery disease
0
0
1
5
10
15
20
30
50
70
85
100
CACS 1000
CACS 400–999
CACS 100–399
CACS 10–99
CACS 1–9
CACS 0
Coronary artery calcium score (CACS)-weighted clinical likelihood of obstructive CAD (%)
Risk Factor-Weighted Clinical Likelihood of obstructive CAD (%)
10
20
30
40
50
60
70
80
1
2
3
Consider reclassification of low RF-CL (>5–15%) using
CACS to identify very low (5%) CACS-CL
(Class I)
(Class IIa)
Adjust clinical likelihood based on abnormal clinical findings
(Class I)
Figure 5 Adjustment and reclassification of the estimated clinical likelihood of obstructive coronary artery disease. CACS, coronary artery calcium 
score; CACS-CL, coronary artery calcium score + RF-CL model; CAD, coronary artery disease; CT, computed tomography; ECG, electrocardiogram; 
LV, left ventricular; RF-CL, risk factor-weighted clinical likelihood.


<!-- PAGE 35 -->

### Page 35

obstructive CAD (Figure 5).143 Conversely, if CACS is high and there 
are clinical findings indicating that the RF-CL model may be under- 
estimating the likelihood of obstructive CAD, further diagnostic testing 
should be selected based on the adjusted clinical likelihood and coron­
ary calcium burden. It is important to note that patients with a very low 
and low (≤15%) likelihood of obstructive CAD constitute approxi­
mately 85% of individuals with de novo symptoms suspected of 
CCS.27,30,139 Most can be treated conservatively without the need 
for further testing as they have no stenoses or non-obstructive CAD 
with a very low incidence of events during long-term follow-up.27,139,143
Individuals with a moderate or high (>15%–85%) likelihood of 
obstructive CAD should be referred for non-invasive anatomical or 
functional imaging to establish the diagnosis and assess the risk for 
future cardiac events. There is growing support for using CCTA as a 
first-line test in the group with a low or moderate (15%–50%) likeli­
hood.27,31,32,139,386 Given the low prevalence of CAD in this group of 
patients and its high negative predictive value, CCTA is the most effect­
ive diagnostic method to rule out obstructive CAD. Moreover, besides 
its strength in ruling out CAD, CCTA offers direct visualization of 
non-obstructive CAD, which may trigger intensification of preventive 
measures. The use of CCTA as a first-line test is supported by large, 
randomized trials showing equivalence in health outcomes with func­
tional testing33 and even superiority compared with usual care using ex­
ercise ECG.34
In patients with a very high (≥85%) clinical likelihood of obstructive 
CAD, symptoms unresponsive to medical therapy, or angina at a low 
level of exercise, and an initial clinical evaluation (including echocardio­
gram and, in selected patients, exercise ECG) that indicates a high event 
risk, proceeding directly to ICA without further diagnostic testing is a 
reasonable option. Under such circumstances, the indication for revas­
cularization of stenoses with a diameter reduction of <90% should be 
guided by coronary pressure assessment (Figure 6; Table 6).
Clinical likelihood of 
obstructive CADa
Very high
Appropriate first-line test for suspected CCS
>85%
High
>50–85%
Moderate
>15–50%
Low
>5–15%
Very low
Invasive coronary angiography
Functional imaging
PET/SPECT
CMR
Stress ECHO
OR
Functional imaging
CCTA
CCTA
Adjust the clinical likelihood
OR
Defer further testing
5%
PET/SPECT
CMR
Stress ECHO
Figure 6 Appropriate first-line testing in symptomatic individuals with suspected chronic coronary syndrome. CAD, coronary artery disease; CACS- 
CL, coronary artery calcium score + RF-CL model; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac 
magnetic resonance; ECHO, echocardiography; PET, positron emission tomography; RF-CL, risk factor-weighted clinical likelihood; SPECT, single-photon 
emission computed tomography. aThe clinical likelihood of obstructive CAD should be estimated based on the RF-CL model (Figure 4). Individual adjust­
ment of the RF-CL values is in some cases needed based on abnormal clinical finding (Figure 5) or highly suspicious symptoms. Beyond the CACS-CL no 
methods are validated to give accurate adjusted values to the RF-CL and the adjusted values is therefore based on clinical judgment.
ESC Guidelines                                                                                                                                                                                          3449


<!-- PAGE 36 -->

### Page 36

Functional imaging should be selected as a first line test if information 
on myocardial ischaemia, viability, or microvascular disease is desired. 
Tests for detecting ischaemia have better rule-in power compared 
with CCTA and therefore should be selected if there is a moderate- 
high (>15-85%) likelihood of obstructive CAD. Moreover, functional 
imaging tests overcome the limitations of CCTA in certain groups (old­
er patients with more extensive coronary calcifications, AF, and other 
situations with an irregular or fast heart rate, renal insufficiency, or io­
dinated contrast allergy), and avoid exposure to ionizing radiation in 
young individuals and in those suspected of ANOCA/INOCA (Figure 7).
Anatomical imaging by CCTA
preferable if:
Low or moderate pre-test likelihood of obstructive CAD
Information on CAD (also non-obstructive) desired
Individual characteristics suggest high image quality
Invasive coronary angiography with FFR/iFR preferable if:
Very high pre-test likelihood of obstructive CAD
Low-threshold angina or equivalent
Findings suggestive of poor prognosis: e.g. severe
LV dysfunction, ventricular arrhythmia, or hypotension during exercise
Functional imaging by stress echo,
SPECT, PET or CMR preferable if:
Moderate or high pre-test likelihood of obstructive CAD
Information on myocardial ischaemia,
viability or microvascular disease desired
Individual with suspected CCS: pre-test likelihood of obstructive CAD?
CCTA
Functional imaging
Lifestyle and risk factor modification
Disease-modifying and antianginal treatment
Selective sequential testing
Severe ischaemia
High-risk
CADa
Refractory symptoms
Obstructive epicardial CAD
Consider revascularization
No obstructive CAD
Consider ICFT: ANOCA/INOCA?
Invasive investigation
Figure 7 Initial management of symptomatic individuals with suspected chronic coronary syndrome. ANOCA, angina with non-obstructive coronary 
arteries; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac mag­
netic resonance; Echo, echocardiography; FFR, fractional flow reserve; ICFT, invasive coronary functional testing; iFR, instantaneous wave-free ratio; 
INOCA, ischaemia with non-obstructed coronary arteries; LV, left ventricular; PET, positron emission tomography; SPECT, single-photon emission 
computed tomography. Consider local availability and expertise, and individual characteristics when choosing non-invasive testing. Table 6 offers 
tips for selecting the first-line test in people with suspected CCS. aHigh–risk CAD: obstructive CAD at high risk of adverse events by CCTA: ≥50% 
stenosis of the left main stem; three–vessel disease with severe stenoses (≥70% diameter stenosis); single- or two–vessel disease including the proximal 
LAD with severe stenoses. Consider functional imaging or invasive investigation.


<!-- PAGE 37 -->

### Page 37

The discussion about which modality to use as a first-line test has 
been heavily focused on the detection of obstructive epicardial sten­
oses, neglecting the relatively high prevalence of non-obstructive cor­
onary disease and ANOCA/INOCA, especially in female patients. 
The current rationale behind choosing a first-line test should be to as­
sess the anatomical severity and functional consequences of coronary 
disease, whether obstructive or not. In this regard, PET-CT should 
be more frequently considered and its availability increased as it 
combines calcium scoring with accurate operator-independent 
detection of myocardial ischaemia and CMD with a low irradiation 
dose.45
Individuals in the moderate likelihood group, except older men with all 
three CCS symptom characteristics, will have a likelihood of obstructive 
CAD around 20%. In these, anatomical and functional testing will each re­
sult in an intermediate positive predictive value with eventually many false 
positives, especially with CCTA  easily overestimating stenosis severity. 
Sequential testing (i.e. functional testing after CCTA, or vice versa) will 
therefore be needed in many individuals to establish an accurate diagnosis 
of obstructive, ischaemia-inducing CAD  (Figure 8). Sequential or combined 
anatomical and functional testing is also useful for the non-invasive diagnosis 
of ANOCA/INOCA.41 Moreover, combined testing, e.g. combining CCTA 
and PET, may result in improved prognostication of CCS patients.387
Table 6 Overview of non-invasive tests used for first-line testing in individuals with suspected chronic coronary 
syndrome
Main imaging target(s) in 
CCS
Requirements
Limitations
Anatomical imaging
CCTA
Atherosclerosis (obstructive and 
non-obstructive) in epicardial 
coronary arteries
Iodinated contrast 
Radiation 
Premedication: 
• Beta-blockers or ivabradine for heart rate control
• Nitroglycerine for adequate vasodilation
Severely impaired kidney functiona 
Documented allergy to iodinated contrast 
Tachyarrhythmia refractory to 
beta-blockade 
Irradiation (especially young women)
SPECT/CT 
PET/CT
Atherosclerosis coronary artery 
calcium score
Radiation
Irradiation (especially young women)
Functional imaging
Stress Echo
LVEF and volumes
Poor Echo windows
Wall motion abnormalities 
Myocardial perfusion 
Coronary velocity flow reserve
Performed with exercise, dobutamine and vasodilators 
Echo contrast to improve image quality and assess 
perfusion
Poor Echo windows 
Contraindications to stressor
CMR
LVEF and volumes
Non-CMR-compatible metal devices 
Severe claustrophobia
MI (scar)
Paramagnetic contrast
Non-CMR-compatible metal devices 
Severe claustrophobia 
Haemodialysis
Ischaemia/blood flow
Vasodilator stress + paramagnetic contrast
Non-CMR-compatible metal devices 
Severe claustrophobia 
Contraindications to stressor 
Haemodialysis
Wall motion abnormalities
Inotropic stress (dobutamine)
Non-CMR-compatible metal devices 
Severe claustrophobia 
Contraindication to stressor
SPECT
LVEF and volumes 
Ischaemia/viability
Vasodilator or exercise stress 
Radioactive tracer
Contraindication to stressor 
Irradiation (especially young women)
PET
LVEF 
Ischaemia/blood flow 
Viability
Vasodilator stress 
Radioactive tracer (13N-ammonia, 15O-water, 82Rb)
Contraindication to stressor 
Irradiation (especially young women)
© ESC 2024
CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; CT, computed tomography; Echo, echocardiography; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; PET, positron emission tomography; SPECT, single-photon emission computed tomography. 
aPreventive measures are recommended for patients with eGFR <30 mL/min/1.73 m2.389
ESC Guidelines                                                                                                                                                                                          3451


<!-- PAGE 38 -->

### Page 38

100
80
60
40
20
0
0
20
40
60
80
100
Pre-test likelihood (%)
Post-test likelihood (%)
DSE +
CCTA +
CCTA -
DSE -
A
B
C
Figure 8 Ruling in and ruling out functionally significant obstructive coronary artery disease by sequential anatomical (coronary computed tomog­
raphy angiography) and functional (dobutamine stress echocardiography) testing.a CAD, coronary artery disease; CCTA, coronary computed tomog­
raphy angiography; DSE; dobutamine stress echocardiography; ECG, electrocardiogram; FFR, fractional flow reserve. The curves display the post-test 
likelihood of obstructive CAD for a positive (+) and a negative (−) test result for CCTA and DSE, as the pre-test likelihood of obstructive CAD in­
creases. The post-test likelihoods were calculated using the likelihood ratios taken from recent meta-analyses.148,388 aBased on invasive FFR measure­
ment or diameter stenosis of ≥70%.   
• A 70-year-old woman with four coronary risk factors and exertional dyspnoea has a pre-test likelihood of 16% (A). A normal CCTA almost com­
pletely rules out obstructive CAD with a very low negative post-test likelihood (2%).  
• A 55-year-old man with two coronary risk factors and all three anginal symptom characteristics has a pre-test likelihood of 27% (B). An abnormal 
CCTA brings the post-test likelihood to 40%, insufficient to rule in obstructive CAD. Sequential testing with DSE performed after CCTA brings the 
post-test likelihood to 82%. A normal CCTA effectively rules out obstructive CAD.  
• A 69-year-old man with four coronary risk factors and all three anginal symptom characteristics has an adjusted pre-test likelihood of 60% (C) (ad­
justment based on abnormalities on the resting ECG and on symptoms during exercise). A positive DSE alone has a high post-test likelihood 
(± 90%). A negative DSE is associated with a 32% post-test likelihood. Sequential testing by CCTA would allow ruling out obstructive CAD 
(<5% post-test likelihood).


<!-- PAGE 39 -->

### Page 39

After confirmation of diagnosis with the first line of testing, all patients 
should receive lifestyle and risk-factor modification recommendations, 
and disease-modifying and antianginal therapy should be prescribed. 
The ISCHEMIA trial (Initial Invasive or Conservative Strategy for Stable 
Coronary Disease)47 showed that an early revascularization strategy 
did not yield a short-term survival benefit in patients without left main 
disease nor reduced LVEF and with moderate-severe ischaemia at 
non-invasive testing, suggesting that most such patients should initially 
be treated conservatively with optimized GDMT. Patients can be re­
ferred for ICA if CCTA detects a ≥50% stenosis of the left main stem, 
three-vessel or two-vessel disease including the proximal LAD artery 
with ≥70% stenosis, or if functional imaging shows moderate or severe 
ischaemia encompassing an extensive perfusion territory.
For patients with obstructive CAD and refractory symptoms despite 
optimized GDMT, a referral for ICA may be considered to improve 
symptoms through revascularization. Optimization of medical therapy 
by combining two or more antianginal drugs can safely be obtained over 
6 weeks in almost all patients and should be awaited before referral to 
ICA.402,403 It is worth noting that in the Objective Randomised Blinded 
Investigation with optimal medical Therapy of Angioplasty in stable an­
gina (ORBITA) trial, PCI did not provide short-term advantages com­
pared with GDMT in terms of reducing anginal frequency or physical 
limitations.402 In the CLARIFY registry, anginal symptoms resolved in 
many CCS patients over time without requiring revascularization or 
changes in antianginal therapy.404
Combined anatomical and functional imaging before ICA facilitates 
its planning by orientating the invasive cardiologist to perform, in the 
same session, haemodynamic assessment of coronary stenoses and 
ICFT to detect microvascular disease or vasospasm in individuals sus­
pected of ANOCA/INOCA, performing these tests in a single session 
rather than in staged procedures.
3.3.5. Adverse-event risk assessment
Chronic coronary syndromes can be complicated by cardiovascular 
death, ischaemic and haemorrhagic events, HF, arrhythmic events, the 
development of valvular heart disease, and other comorbidities, which 
are further discussed in the Supplementary data, available at European 
Heart Journal online. It is recommended that all patients with newly diag­
nosed obstructive CAD or myocardial ischaemia undergo an adverse- 
risk event assessment to identify those at high risk of adverse outcomes 
who could benefit from revascularization beyond symptom relief. Based 
on large registries and historical RCTs, a high event risk has been defined 
as a cardiac mortality rate of >3% per year, intermediate event risk as 
between ≥1% and ≤3% per year, and low event risk as <1% per year.405
Adverse-event risk stratification is usually based on the same clinical, 
non-invasive and invasive investigations used to diagnose obstructive 
CAD (see Table 14).
Clinical history, physical examination, 12-lead ECG and laboratory 
tests can provide important prognostic information. Assessment of 
risk factors such as advanced age, diabetes mellitus (DM), or renal fail­
ure allows the identification of patients at high risk of events.406–408 Left 
ventricular function is the strongest predictor of long-term survival; a 
patient with an LVEF of <50% is already at high risk for all-cause and 
cardiovascular death.409,410
Although the diagnostic value of an exercise ECG is limited, the oc­
currence of ST-segment depression at a low workload combined with 
exertional symptoms (angina or dyspnoea), low exercise capacity, com­
plex ventricular ectopy, or other arrhythmias and abnormal BP re­
sponse are markers of a high risk of cardiac mortality.411–414
High plaque burden and coronary stenoses are well-known prognostic 
markers. The ISCHEMIA trial using a cut-off of 70% stenosis on CCTA317
confirms the very old observations of the Coronary Artery Surgery 
Study182 that the prognosis of obstructive CAD-related CCS is mainly 
determined by the number of >70% obstructed coronary arteries or 
by the presence of a left main stenosis (using for the latter a cut-off of 
>50% diameter stenosis on coronary angiography).317 More recently, 
the classical paradigm that the severity of stenoses and the number of dis­
eased vessels are the main determinants of prognosis has been challenged 
by post hoc analyses of the SCOT-HEART trial and other CCTA-based 
Recommendation Table 13 — Recommendations for 
selection of initial diagnostic tests in individuals with sus­
pected chronic coronary syndrome (see also Evidence 
Table 13)
Recommendations
Classa
Levelb
Selection of non-invasive testing
It is recommended to select the initial non-invasive 
diagnostic test based on pre-test likelihood of 
obstructive CAD, other patient characteristics that 
influence the performance of non-invasive tests,c and 
local expertise and availability.29,148
I
C
In symptomatic patients in whom the pre-test 
likelihood of obstructive CAD by clinical assessment 
is >5%, CCTA or non-invasive functional imaging for 
myocardial ischaemia is recommended as the initial 
diagnostic test.33,148,178,187,189,211,212,219,222,390
I
B
To rule out obstructive CAD in individuals with low 
or moderate (>5%–50%) pre-test likelihood, CCTA 
is recommended as the preferred diagnostic 
modality.29,148
I
B
CCTA is recommended in individuals with low or 
moderate (>5%–50%) pre-test likelihood of 
obstructive CAD if functional imaging for myocardial 
ischaemia is not diagnostic.391
I
B
Functional imaging for myocardial ischaemia is 
recommended if CCTA has shown CAD of 
uncertain functional significance or is not 
diagnostic.392–394
I
B
In patients with a known intermediate coronary 
artery stenosisd in a proximal or mid coronary 
segment on CCTA, CT-based FFR may be 
considered.395–401
IIb
B
Subsequent invasive testing
Invasive coronary angiography with the availability of 
invasive functional assessments is recommended to 
confirm or exclude the diagnosis of obstructive CAD 
or ANOCA/INOCA in individuals with an uncertain 
diagnosis on non-invasive testing.36,49,308,384
I
B
© ESC 2024
ANOCA, angina with non-obstructive coronary arteries; CAD, coronary artery disease; 
CCTA, coronary computed tomography angiography; CT, computed tomography; FFR, 
fractional flow reserve; INOCA, ischaemia with non-obstructive coronary arteries. 
aClass of recommendation. 
bLevel of evidence. 
cCharacteristics determining ability to exercise, likelihood of good image quality, expected 
radiation exposure, and risks or contraindications. 
dTypically around 40%–90% by visual estimate.
ESC Guidelines                                                                                                                                                                                          3453


<!-- PAGE 40 -->

### Page 40

registries showing that plaque burden and presence of adverse plaque 
characteristics, especially low-attenuation plaque, are the strongest pre­
dictors of fatal and non-fatal MI above the classical risk factors, including 
stenosis severity.210,415–417 These findings emphasize a major advantage 
of anatomical imaging by CCTA as an initial test in selected patients, al­
lowing the assessment of severity and extent of obstructive CAD as 
well as coronary plaque characteristics.
Regarding the prognostic impact of inducible myocardial ischaemia 
by functional stress imaging, the evidence remains conflicting. While 
there are extensive data from large observational studies315,418–425
consistently demonstrating a robust prognostic value conferred by 
the extent of inducible ischaemia as detected by functional imaging 
(e.g. ≥3/16 abnormal segments at stress echocardiography, ≥10% LV 
ischaemia at nuclear or magnetic resonance perfusion imaging, or de­
creased hyperaemic flow or flow reserve at quantitative PET imaging), 
post hoc analyses of the randomized COURAGE426,427
and 
ISCHEMIA317 trials showed that only CAD severity, but not ischaemia 
severity, was independently predictive of long-term mortality and MI 
risk. These discrepancies may be explained by selection and entry biases 
between registries and RCTs.428 Registries typically report on all- 
comer populations with suspected CCS referred for diagnostic testing 
and/or revascularization, representing the real-life scenario. RCTs usu­
ally include only a very selected group of patients, and the external ap­
plicability of their findings is always open for debate. As COURAGE and 
ISCHEMIA selectively included only patients with functionally moderate 
or severe myocardial ischaemia but without any information on CAD 
anatomical severity, it becomes harder to demonstrate a prognostic ef­
fect of myocardial ischaemia, and the anatomical burden becomes the 
prominent prognostic factor. The PROMISE (Prospective Multicenter 
Imaging Study for Evaluation of Chest Pain) trial, which included pa­
tients more representative of an all-comer population, demonstrated 
that CCTA, mainly by detecting non-obstructive CAD, outperformed 
functional testing in predicting outcomes, emphasizing the prognostic 
significance of imaging coronary atherosclerosis beyond myocardial is­
chaemia.208 However, adding the Framingham Risk Score to the func­
tional test result improved its prognostic value, making the difference 
with anatomical testing insignificant. Both modalities are thus equivalent 
for detecting CCS symptoms and predicting outcomes when consider­
ing risk factors.
Besides imaging coronary atherosclerosis, the additional benefit of ICA 
is the ability to perform intracoronary pressure measurements. While 
FFR of ≤0.8 and iFR of ≤0.89 have been associated with a higher risk of 
vessel-related cardiovascular events, it is important to remember that a 
lower FFR/iFR reflects more profound ischaemia in the vessel territory 
and is associated with a progressive and proportional increase in 
risk.318,319 A similar observation has been made with FFR-CT.401 It has 
also been shown that for any given FFR value, a more proximal lesion is 
associated with more extensive ischaemia and an increased risk of a clinical 
event.429In addition, global FFR, summing the coronary pressure collected 
in each of the three main coronary vessel territories as a single patient- 
related index (normal value of global FFR = 1 + 1 + 1 = 3), can appreciate 
overall cardiovascular risk; patients with a borderline FFR but with a global 
FFR of <2.72 showed a significantly increased risk compared with higher 
global-FFR patients.430,431 One of the main limitations of such a global in­
tegrative approach based on invasive coronary pressure is that it requires 
advancing a pressure wire in each of the three coronary arteries, which is 
not often performed341 and is not recommended as a routine, based on 
the RIPCORD2347 and FUTURE results.346 Recent methods using 3-di­
mensional image reconstruction and computational fluid dynamics enable 
FFR estimation with CCTA432 or with ’wire-less’ invasive coronary 
angiography.433,434 This allows a less invasive, easier and more accurate 
global FFR calculation, provided imaging is of sufficiently good 
quality.369–371
In summary, when assessing event risk, clinicians should choose an 
integrative approach, considering risk factors, comorbidities, LV dys­
function, the severity of myocardial ischaemia, the number of function­
ally significantly stenotic coronary arteries, and the coronary plaque 
burden and characteristics, as all of these are likely interrelated factors 
that affect overall prognosis.
3.4. STEP 4: Initial therapy
Initial therapy frequently starts during the diagnostic process. In indivi­
duals with a high suspicion of CCS, sublingual nitroglycerine is frequent­
ly prescribed to treat anginal pain symptoms. Rapid relief within 1 or 2 
Recommendation Table 14 — Recommendations for 
definition of high risk of adverse events (see also 
Evidence Table 14)
Recommendations
Classa
Levelb
An initial stratification of risk of adverse events is 
recommended based on basic clinical assessment 
(e.g. age, ECG, anginal threshold, diabetes, CKD, 
LVEF).406–408
I
B
The use of one or more of the following test results is 
recommended to identify individuals at high risk of 
adverse events:405
• exercise ECG: 
⚬Duke Treadmill Score < −10;191
• stress SPECT or PET perfusion imaging: 
⚬area of ischaemia ≥10% of the LV 
myocardium;287,315,422,423,435
• stress echocardiography: 
⚬≥3 of 16 segments with stress-induced 
hypokinesia or akinesia;435
• stress CMR: 
⚬≥2 of 16 segments with stress perfusion defects 
or ≥3 dobutamine-induced dysfunctional 
segments;435
• CCTA: 
⚬left main disease with ≥50% stenosis, three-vessel 
disease with ≥70 stenosis, or two-vessel disease 
with ≥70% stenosis, including the proximal LAD 
or317one-vessel disease of the proximal LAD with 
≥70% stenosis and FFR-CT ≤0.8.
I
B
In individuals at high risk of adverse events (regardless 
of symptoms), ICA—complemented by invasive 
coronary pressure (FFR/iFR) when appropriate—is 
recommended, with the aim of refining risk 
stratification and improving symptoms and 
cardiovascular outcomes by revascularization.318,319
I
A
© ESC 2024
CCTA, coronary computed tomography angiography; CKD, chronic kidney disease; CMR, 
cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; FFR, 
fractional flow reserve; FFR-CT, CCTA-derived FFR; ICA, invasive coronary angiography; 
iFR, instantaneous wave-free ratio; LAD, left anterior descending; LV, left ventricular; 
LVEF, left ventricular ejection fraction; PET, positron emission tomography; SPECT, 
single-photon emission computed tomography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 41 -->

### Page 41

min of chest discomfort after sublingual nitroglycerine increases the 
likelihood of CCS. Patients may be advised to refrain from strenuous 
physical activities before the diagnostic process is completed and 
should be instructed what to do if prolonged anginal chest pain indica­
tive of acute MI arises.
Guideline-directed management and therapy are started during or 
after the diagnostic process is concluded. The main goals of treating 
CCS are to improve both QoL and life expectancy. This involves vari­
ous interventions to reduce the risk of (i) cardiac mortality, (ii) non-fatal 
ischaemic events, (iii) progression of epicardial and/or microvascular 
chronic coronary disease, and (iv) symptoms and limitations caused 
by CCS. When deciding on treatment options, it is important to con­
sider patient preferences, possible complications of procedures or 
medications, and healthcare costs. In shared decision-making with pa­
tients, clinicians should clearly explain that certain treatments can alle­
viate symptoms, while others can reduce the likelihood of ischaemic 
events.
4. Guideline-directed therapy
4.1. Patient education, lifestyle 
optimization for risk-factor control, 
and exercise therapy
4.1.1. Patient education
In CCS patients, education on risk factors and symptom management is 
associated with improvements in knowledge, self-care, and patient 
empowerment, and may improve health-related QoL.436 In addition, 
education can facilitate long-term adherence to lifestyle interven­
tions.437,438 Educational programmes—either alone or as a core compo­
nent of multidisciplinary care management programmes—promote 
patients’ awareness of their condition and the rationale for lifestyle inter­
ventions. However, awareness of CVD risk factors through education 
alone might be insufficient for adoption of healthy behaviour.439
Therefore, self-care programmes are needed to enable patients to have 
a major role in coping with their condition and accepting their prescribed 
treatment.440,441 Elements in patient education include (modifiable) risk 
factors in relation to individual cardiovascular risk, since risk perception 
is an integral part of many major health behaviour theories, ultimately 
leading to modification of human habits.441,442
Information on benefits of risk-factor control on recurrence risk, dis­
ease progression, complications, and overall survival should be dis­
cussed. The format, time horizon, and outcome used for risk 
estimation influence patient perceptions and should be considered 
when designing risk communication tools.443–445
Lifelong education for patient-centred information and problem- 
based learning is superior to home-sent information in improving risk- 
factor control in the long term.438,444 Refer to Section 6.2.1 for further 
guidance on patient education.
4.1.2. Key lifestyle interventions for risk-factor 
control
Reducing CVD risk at the individual level begins with effective informa­
tion on risk and anticipated risk reduction by treatment. Risk algorithms 
are available for use in clinical practice by means of interactive tools on­
line. The use of the Smart risk score (U-prevent.com) is suggested by 
the European Association of Preventive Cardiology for risk estimation 
in patients with previous CVD.446 Ideally, patients are made aware of 
their individual risks and the potential benefit of prevention treatments 
and then actively engaged in managing their disease. Treatment goals 
are communicated using a patient-centred approach (Table 7).
Table 7 Practical advice on lifestyle counselling and 
interventions
Topic
Recommendation and treatment goals in 
patients with established CCS
Lifestyle counselling
Immunization
• Vaccination against influenza, pneumococcal 
disease and other widespread infections, e.g. 
COVID-19
Sleep quality
• Treat sleep-related breathing disorders
Sexual activity
• Males and females: low risk for stable patients 
who are not symptomatic at low-to-moderate 
activity levels
• Males: PDE-5 inhibitors are generally safe, not 
to be taken in combination with nitrate 
medications because of risk of severe 
hypotension
Psychosocial aspects
• Avoid psychosocial stress
• Treat depression and anxiety by psychological 
or pharmacological interventions
Environment/pollution
• Avoid passive smoking
• Reduce environmental noise
• Avoid exposure to air pollution
Lifestyle interventions for risk-factor control
Smoking and 
substance abuse
• Use pharmacological and behavioural 
strategies to assist in smoking cessation
• Avoid e-cigarettes
• Abstain from substance abuse
Obesity and being 
overweight
• Obtain and maintain a healthy weight (BMI 
18.5–25 kg/m2)
• Reduce weight through recommended energy 
intake and increased physical activity and 
through pharmacological/surgical 
interventions in selected patients
Hyperlipidaemia
• Ultimate LDL-C goal of <1.4 mmol/L (55 mg/ 
dL) and a ≥50% reduction in LDL-C vs. 
baseline is recommended
Diabetes
• HbA1c < 7.0% (53 mmol/mol)
Arterial hypertension
• SBP 120–129 mmHg, provided the 
antihypertensive treatment is well tolerated
Diet and alcohol 
consumption
• Limit alcohol consumption to <100 g/week
• Diet high in vegetables, fruit, and wholegrains 
(Mediterranean diet)
• Limit saturated fat to <10% of total calorie 
intake
Physical activity and 
exercise
• 30–60 min moderate activity, >5 days/week
• Reduce sedentary time and engage in at least 
light activity throughout the day
© ESC 2024
BMI, body mass index; CCS, chronic coronary syndrome; COVID-19, coronavirus disease 
2019; HbA1c, glycated haemoglobin; LDL-C, low-density lipoprotein cholesterol; PDE-5, 
phosphodiesterase-5; SBP, systolic blood pressure.
ESC Guidelines                                                                                                                                                                                          3455


<!-- PAGE 42 -->

### Page 42

4.1.2.1. Smoking and substance abuse
Smoking cessation in CCS patients improves prognosis, with a reported 
36% risk reduction of premature death in those who quit compared 
with those who continue to smoke.447 Measures to promote smoking ces­
sation include brief advice, counselling and behavioural interventions, and 
pharmacological therapy.448,449 Patients should also avoid passive smoking.
Drug support to assist in smoking cessation should be considered in 
all smokers who are ready to undertake this action. Nicotine- 
replacement therapy, bupropion, or varenicline are effective,450,451
and are not linked to an increase in MACE.452
The use of electronic cigarettes (e-cigarettes), as an alternative to con­
ventional cigarettes, should be discouraged because they are not harm- 
free.453 Newer devices deliver higher nicotine contents, and e-cigarettes 
emit other constituents, such as carbonyls, and fine and ultrafine particu­
lates.454 Evidence from several studies indicates that acute inhalation of 
e-cigarettes leads to negative changes in vascular endothelial func­
tion.453,454 E-cigarettes should only be considered to aid tobacco cessa­
tion alongside a formal tobacco cessation programme.453,455,456
Various substances, including cocaine, opioids, and marihuana can 
have adverse effects on the cardiovascular system and have a potential 
for drug–drug interactions with cardiovascular medication.457–459
Single-question screening for unhealthy drug use has been validated 
in primary care and can identify individuals requiring counselling on ad­
verse cardiovascular effects.460
4.1.2.2. Weight management
In a population-based study, lifetime risk of incident CVD, and cardiovas­
cular morbidity and mortality, were higher in those who were overweight 
or obese compared with those with a normal BMI (18.5–24.9 kg/m2).461
Compared with normal BMI, among middle-aged men and women, 
competing hazard ratios (HR) for incident CVD were 1.21 [95% 
confidence interval (CI), 1.14–1.28] and 1.32 (95% CI, 1.24–1.40), respect­
ively, for overweight (BMI of 25.0–29.9 kg/m2), 1.67 (95% CI, 1.55–1.79) 
and 1.85 (95% CI, 1.72–1.99) for obesity (BMI of 30.0–39.9 kg/m2), 
and 3.14 (95% CI, 2.48–3.97) and 2.53 (95% CI, 2.20–2.91) for mor­
bid obesity (BMI of ≥40.0 kg/m2). Obesity was associated with a 
shorter overall lifespan, and being overweight was associated with 
developing CVD at an earlier age.461 In subjects with CAD, intention­
al weight loss is associated with a significantly lower risk of adverse 
clinical outcomes,462 and has beneficial effects on risk-factor control 
and QoL.463 Healthy diets with energy intake limited to the amount 
needed to obtain and maintain a healthy weight (BMI of 18.5–25 kg/m2), 
and combined with increasing physical activity, are recommended for 
weight management.16 If weight targets are not reached, pharmaco­
logical treatment with glucagon-like peptide-1 (GLP-1) receptor ago­
nists may be considered for further weight reduction (Section 4.3.4). 
In patients without diabetes, the STEP8 trial showed a significant reduc­
tion in weight after 68 weeks with either semaglutide (mean weight 
change of −15.8%; 95% CI, −17.6% to −13.9%) or liraglutide (mean 
weight change of −6.4%; 95% CI, −8.2% to −4.6%) compared with pla­
cebo (−1.9%; 95% CI, −4.0% to 0.2%).464 The double-blind, placebo- 
controlled Semaglutide Effects on Cardiovascular Outcomes in 
People with Overweight or Obesity (SELECT) trial showed a significant 
reduction in the incidence of cardiovascular death, MI, or stroke (HR 
0.80; 95% CI, 0.72–0.90) in patients with pre-existing CVD who 
were overweight or obese, but without diabetes, treated with weekly 
subcutaneous semaglutide.465
The SURMOUNT-1 (Efficacy and Safety of Tirzepatide Once Weekly 
in Participants Without Type 2 Diabetes Who Have Obesity or Are 
Overweight With Weight- Related Comorbidities: A Randomized, 
Double-Blind, Placebo-Controlled Trial) trial showed a dose-dependent 
weight-loss benefit (mean weight change of up to −20.9%; 95% CI, 
−21.8% to −19.9%) with tirzepatide, a combined glucose-dependent in­
sulinotropic polypeptide (GIP) and GLP-1 receptor agonist, compared 
with placebo in obese adults without diabetes over 72 weeks,466 a dose 
effect that was confirmed in the SURMOUNT-2 trial.467 Bariatric surgery 
in severe obesity appears to be a safe and effective intervention for further 
weight loss in CCS patients.468
Cardiac rehabilitation programmes should include weight-loss inter­
ventions to reach a healthy weight as a specific component. The incre­
mental value of telehealth interventions and pharmacological 
interventions need full consideration in secondary prevention.469
4.1.2.3. Diet and alcohol
Dietary habits influence cardiovascular risk, mainly through risk factors 
such as lipids, BP, body weight, and DM. It is recommended to adopt a 
Mediterranean or similar diet to lower the risk of CVD, as described in 
the 2021 ESC Guidelines on cardiovascular disease prevention in clinical 
practice.16 If alcohol is consumed, it should be limited to <100 g/week 
or 15 g/day, since alcohol intake of >100 g/week is associated with higher 
all-cause and other CVD mortality in large individual-data meta-analyses.470
A recent genetic analysis showed that the causal association between 
light-to-moderate levels of alcohol intake and lower cardiovascular risk is 
possibly mediated by confounding lifestyle factors, therefore questioning 
the previously observed cardioprotective role of light alcohol use.471
4.1.2.4. Mental health
Psychosocial stress, depression, and anxiety are associated with worse 
cardiovascular outcomes, and make it difficult for patients to make posi­
tive changes to their lifestyles or adhere to a therapeutic regimen. 
Therefore, assessment for psychosocial risk factors is recommended 
in secondary prevention.16 Clinical trials have shown that psychological 
(e.g. counselling and/or cognitive behavioural therapy) and pharmaco­
logical interventions have a beneficial effect on depression, anxiety, 
and stress, with some evidence of a reduction in cardiac mortality 
and events compared with placebo (see Section 6.1.2).472
4.1.2.5. Physical activity and sedentary behaviour
Physical activity reduces the risk of many adverse health outcomes and risk 
factors in all ages and both sexes. There is an inverse relationship between 
moderate-to-vigorous physical activity and all-cause mortality, cardiovascu­
lar mortality, and atherosclerotic cardiovascular disease (ASCVD).473 The 
reduction in risk continues across the full range of physical activity volumes, 
and the slope of risk decline is steepest for the least active individuals.474
Adults are recommended to perform at least 150–300 min per week of 
moderate-intensity physical activity, or 75–150 min of vigorous-intensity 
physical activity, or an equivalent combination of both, spread throughout 
the week.473 Additional benefits are gained with even more physical activ­
ity.475 Practising physical activity should still be encouraged in individuals un­
able to meet the minimum. In sedentary individuals, a gradual increase in 
activity level is recommended.476 Physical activity can be incorporated flex­
ibly, either daily or limited to specific days. Activity patterns limited to 1–2 
sessions per week but meeting recommended levels of physical activity 
have been shown to reduce all-cause mortality (HR 0.66; 95% CI, 0.62– 
0.72), CVD mortality (HR 0.60; 95% CI, 0.52–0.69), and cancer mortality 
(HR 0.83; 95% CI, 0.73–0.94) when compared with inactive partici­
pants.477 Physical activity accumulated in bouts of even <10 min is asso­
ciated with favourable outcomes, including mortality.478
High levels of time spent sedentary is associated with an increased 
risk for several major chronic diseases and mortality.479 For physically


<!-- PAGE 43 -->

### Page 43

inactive adults, light-intensity physical activity, even as little as 15 min a 
day, is likely to produce benefits.479
4.1.3. Exercise therapy
Exercise training, either alone or in the context of multidisciplinary, 
exercise-based cardiac rehabilitation, leads to reduction in hospitaliza­
tions, adverse cardiovascular events, mortality rates, and improved 
CVD risk profile in patients with ASCVD.480–483 Therefore, exercise 
is a therapy that should be offered to every CCS patient in the setting 
of secondary disease prevention.16
Exercise training should be individually prescribed according to the 
FITT (frequency, intensity, time, type) model for aerobic and resistance 
training.484
For aerobic training (walking, jogging, cycling, swimming, etc.), an ex­
ercise frequency of at least 3 days/week, preferably 6–7 days/week, at 
moderate or moderate-to-high intensity is recommended. Relative in­
tensity is determined based on an individual’s maximum (peak) effort, 
e.g. percentage of cardiorespiratory fitness (%VO2 max), percentage 
of maximum (peak) heart rate (%HRmax) or ventilatory thresholds 
(VT1 and VT2).485 To date, there is insufficient evidence to promote 
high-intensity interval training over moderate-intensity continuous 
training; nevertheless, optimizing total energy expenditure (either by 
increasing intensity or total exercise volume) is related to greater 
favourable changes in cardiovascular risk and physical fitness.486
Moderate-intensity continuous training is the most feasible and cost- 
effective aerobic training modality for patients with CCS. 
High-intensity interval training can be prescribed in selected patients 
for specific targets of intervention (e.g. to increase VO2 peak).485
Resistance exercise in addition to aerobic training is associated with 
lower risks of total cardiovascular events and all-cause mortality.16 The 
suggested prescription is one to three sets of 8–12 repetitions, at the 
intensity of 6%–80% of the individual’s one-repetition maximum, at a 
frequency of at least 2 days per week, using a variety of 8–10 different 
exercises involving each major muscle group.16,484
Exercise is contraindicated in patients with refractory/unstable angina 
and other high-risk cardiovascular conditions (e.g. high-grade arrhyth­
mias, decompensated HF, severe aortic dilatation, active thrombo- 
embolic disease). In non-cardiac unstable conditions (e.g. active infection, 
uncontrolled diabetes, end-stage cancer, chronic obstructive pulmonary 
disease exacerbation), exercise is contraindicated. Maintenance of the 
prescribed exercise regimen is crucial. According to a meta-regression 
analysis, no single exercise component predicts mortality outcomes, 
whereas the largest reductions in total and cardiovascular mortality 
were seen in post-cardiac rehabilitation patients with the highest adher­
ence rate.487 In addition, continuation of the exercise therapy (Phase III 
cardiac rehabilitation) is recommended as it will result in increased/main­
tained functional capacity, QoL, and physical activity levels.488
Sharing decision-making and offering a personalized prescription, 
based on the patient’s preferences (self-selected training) and abilities 
(age, concomitant diseases, leisure and working habits, logistical re­
straints), is recommended to increase long-term adherence.489 In add­
ition, smartphone applications490 and wearable activity trackers491 may 
assist in long-term adherence to physical activity goals and exercise 
therapy (see Section 6.2.1.3).492
Home-based cardiac rehabilitation with or without telemonitoring 
may increase participation and be as effective as centre-based cardiac 
rehabilitation.493 Telehealth interventions are more effective than no 
intervention and may also complement conventional cardiac rehabilita­
tion.494,495 Also, mobile device-based healthcare (mHealth) delivery 
through smartphones may be as effective as traditional centre-based 
cardiac 
rehabilitation, 
showing 
significant 
improvements 
in 
health-related QoL.496
Small, single-centre studies on exercise training in patients with 
INOCA show that it is feasible and improves cardiorespiratory function 
and QoL.497 Larger trials are needed to determine the optimal rehabili­
tation protocols and define its long-term benefits.
4.2. Antianginal/anti-ischaemic medication
4.2.1. General strategy
In patients with CCS, antianginal medical therapy aims to control symp­
toms while ensuring acceptable tolerability and patient adherence. 
Several factors should be considered for the selection of antianginal 
medical therapy. First, there is no robust evidence from direct compar­
isons that some antianginal drugs are more effective than others for im­
proving symptoms.504,505 There have been no large randomized trials 
comparing head-to-head the historically first approved antianginal 
medications [i.e. beta-blockers or calcium channel blockers (CCBs)] 
vs. newer anti-ischaemic drugs (ivabradine, nicorandil, ranolazine, 
trimetazidine);504,506 the latter have been tested in smaller trials assessing 
non-inferiority compared with beta-blockers507 or CCBs,508 or in a lar­
ger trial as add-on therapy with a background of beta-blockers and/or 
CCBs.508,509 Moreover, there is no evidence that any antianginal medi­
cation may improve long-term cardiovascular outcomes, except beta- 
blockers if administered within 1 year after an acute MI.510 Second, 
many patients require a combination of anti-ischaemic drugs to ad­
equately control symptoms.511 It remains unclear whether upfront 
combination therapy with two antianginal drugs is preferable to mono­
therapy, or which combinations of antianginal classes may be better 
Recommendation Table 15 — Recommendations for 
cardiovascular risk reduction, lifestyle changes, and ex­
ercise interventions in patients with established chronic 
coronary syndrome (see also Evidence Table 15)
Recommendations
Classa
Levelb
An informed discussion on CVD risk and treatment 
benefits tailored to individual patient needs is 
recommended.16
I
C
Multidisciplinary behavioural approaches to help 
patients achieve healthy lifestyles, in addition to 
appropriate pharmacological management, are 
recommended.484,498–503
I
A
A multidisciplinary exercise-based programme to 
improve cardiovascular risk profile and reduce 
cardiovascular mortality is recommended.480–482
I
A
Aerobic physical activity of at least 150–300 min per 
week of moderate intensity or 75–150 min per week 
of vigorous intensity and reduction in sedentary time 
are recommended.16,473,478,479
I
B
Home-based cardiac rehabilitation and mobile health 
interventions should be considered to increase 
patients’ long-term adherence to healthy behaviours, 
and to reduce hospitalizations or cardiac 
events.480,493,494
IIa
B
© ESC 2024
CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3457


<!-- PAGE 44 -->

### Page 44

than others for improving angina symptoms. Third, in any given patient, 
myocardial ischaemia and angina symptoms may be caused by various 
underlying pathophysiological mechanisms, alone or in combin­
ation;6,512 these may include obstruction of epicardial coronary arter­
ies, vasospasm, and endothelial/microvascular dysfunction. Based on 
their mechanisms of action, different classes of antianginal drugs may 
be preferable (as initial therapy or as part of combination therapy) 
for patients with myocardial ischaemia of predominantly obstructive, 
vasospastic, or microvascular origin.513
The current empirical paradigm for the selection of antianginal med­
ical therapy has consisted of a hierarchical, stepwise approach including 
first-line (beta-blockers, CCBs) and second-line drugs (long-acting ni­
trates, nicorandil, ranolazine, ivabradine, trimetazidine).1,514 This task 
force reinforces the concept that medical therapy for symptom control 
in CCS should be tailored to each patient’s haemodynamic profile (BP, 
heart rate), comorbidities (particularly presence of HF), concomitant 
medications with potential drug interactions, and preferences, also tak­
ing into account the pathophysiological basis of myocardial ischaemia in 
each patient, as well as local availability of different drugs.515,516 For 
many patients with CCS, initial drug therapy should include a beta- 
blocker and/or a CCB. Other antianginal drugs (long-acting nitrates, 
ivabradine, nicorandil, ranolazine, trimetazidine) can be added on top 
of a beta-blocker and/or a CCB, or as a part of initial combination ther­
apy in appropriately selected patients (Figure 9).
Regardless of the initial strategy, response to initial antianginal therapy 
should be reassessed, and treatment should be adapted if adequate an­
gina control is not achieved or if the initial treatment is poorly tolerated.
A review of the antianginal agents that can be used in the medical 
treatment of CCS can be found in the Supplementary data.
4.2.2. Beta blockers
Beta-blockers can be used for symptomatic relief of angina, or to im­
prove prognosis in some patients with CCS. If used for antianginal pur­
poses, the aim should be to lower resting heart rate to 55–60 beats per 
minute (b.p.m.).517,518
Beyond improving symptoms, the clinical benefit of beta-blockers in 
patients with CAD without prior MI and with normal LVEF is largely un­
known in the absence of evidence from RCTs. The main findings of 
some observational studies addressing this issue are summarized in 
the Supplementary data.
The clinical benefit of beta-blockers in post-ACS patients with reduced 
LVEF is supported by solid evidence.519–521 However, there are no large 
RCTs supporting the prescription of beta-blockers after uncomplicated 
ACS in patients with LVEF >40%.522 The evidence provided by 
Useful combinations 
Possible combinations 
Drugs with similar effects 
Not recommended 
Beta-blockers
DihydropyridineCCB
Diltiazem
Verapamil
Trimetazidine
Ranolazine
Ivabradine
Nitrates
Nicorandil
Obstructive CAD
Microvascular dysfunction
Arterial hypertension
Atrial fibrillation
HFrEF
Obstructive CAD
Vasospastic angina
Arterial hypertension
COPD
Peripheral arterial disease
Type I diabetes mellitus
Obstructive CAD
Vasospastic angina
Atrial fibrillation
Obstructive CAD
Microvascular dysfunction
Obstructive CAD
Microvascular dysfunction
Obstructive CAD
Vasospastic angina
May be indicated in 
specific situations
HCM
Sick sinus syndrome
Sick sinus syndrome
HFrEF
Sick sinus syndrome
HFrEF
HFrEF
HFrEF
Contraindicated
Indicated unless there are specific contraindications
Figure 9 Possible combinations of antianginal drugs. CAD, coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pul­
monary disease; HCM, hypertrophic cardiomyopathy; HFrEF, heart failure with reduced ejection fraction. The schematic shows useful combinations 
(green lines), combinations that are not recommended (red lines), possible combinations (solid blue lines), and drugs with similar effects (blue dashed 
lines), which can be combined in selected indications: HFrEF (ivabradine and beta-blocker), atrial fibrillation (diltiazem/verapamil and beta-blocker), 
vasospastic angina (dihydropyridine CCB and nitrates). Modified from Davies et al.555.


<!-- PAGE 45 -->

### Page 45

observational studies and meta-analyses is conflicting (some suggest an as­
sociation between beta-blockers and better clinical outcomes, whereas 
others show a lack of association).521,523–526 There have been only two 
open-label trials testing the efficacy of beta blockers in post-MI patients 
(NCT03278509 and NCT01155635), though both trials were under­
powered to yield solid conclusions.527 To further elucidate the benefit 
of beta-blockers in this clinical scenario, three European pragmatic, pro­
spective, large-scale RCTs recruiting post-ACS patients with preserved 
LVEF to receive beta-blockers or control treatment are currently under­
way.522,528–530
The duration of beta-blocker therapy, in the long run, is a matter of 
debate, particularly in patients with prior MI and preserved LVEF.531
Evidence from RCTs assessing beta-blockers rarely goes beyond a 
few years of follow-up, but patients are often given continuous treat­
ment up to old age.531 Observational data are also conflicting in this re­
gard. One study has suggested that the clinical benefit of beta-blockers 
might be restricted to the first year after the index event, showing that 
their discontinuation at 1 year was not associated with higher 5-year 
mortality.532 In contrast, a Swedish study starting the follow-up 1 
year after the ACS episode has shown a lack of association between 
the use of beta-blockers and a composite of all-cause mortality, MI, un­
scheduled revascularization, or hospitalization for HF.533 Another study 
has shown that the discontinuation of beta-blockers beyond 1 year 
after acute MI was associated with an increased risk of a composite 
of death or readmission for ACS, but not of all-cause mortality.534
The impact of beta-blocker withdrawal 6–12 months after uncompli­
cated ACS in patients with LVEF ≥40% is being tested in two large-scale 
RCTs (NCT03498066, NCT04769362.535
4.2.3. Combination therapy
The aim of antianginal medications is to ensure adequate relief of angina 
symptoms in patients with CCS, in part independently of their effect or 
lack of effect on MACE. Initiation of monotherapy, with subsequent es­
calation to a combination of antianginal drugs in the case of inadequate 
relief of symptoms, is a reasonable approach. In this context, the empir­
ical approach of starting with a beta-blocker can be recommended in 
many patients with CCS, unless there are contraindications or other 
drugs are more suitable instead of beta-blockers (e.g. patients with 
low heart rate and/or BP). If a combination of antianginal drugs is re­
quired, the selection of the most appropriate drugs should be individua­
lized and determined by the haemodynamic profile, comorbidities, and 
tolerability. The combination of a beta-blocker with a dihydropyridine 
CCB is appropriate for most patients, whereas the addition of other 
antianginal drugs (long-acting nitrates, ranolazine, nicorandil, trimetazi­
dine, or ivabradine in patients with LV systolic dysfunction) can be con­
sidered when treatment with a beta-blocker and/or CCB is 
contraindicated or poorly tolerated, or when angina symptoms are in­
adequately controlled.
The following points should additionally be kept in mind: (i) beta- 
blockers are not indicated in the presence of sick sinus syndrome or 
Recommendation Table 16 — Recommendations for 
antianginal drugs in patients with chronic coronary syn­
drome (see also Evidence Table 16)
Recommendations
Classa
Levelb
General strategy
It is recommended to tailor the selection of 
antianginal drugs to the patient’s characteristics, 
comorbidities, concomitant medications, treatment 
tolerability, and underlying pathophysiology of angina, 
also considering local drug availability and cost.
I
C
Selection of antianginal medication
Short-acting nitrates are recommended for 
immediate relief of angina.536,537
I
B
Initial treatment with beta-blockers and/or CCBs to 
control heart rate and symptoms is recommended 
for most patients with CCS.c 518,538
I
B
If anginal symptoms are not successfully controlled 
by initial treatment with a beta-blocker or a CCB 
alone, the combination of a beta-blocker and a 
DHP-CCB should be considered, unless 
contraindicated.505,538,539
IIa
B
Long-acting nitrates or ranolazine should be 
considered as add-on therapy in patients with 
inadequate control of symptoms while on treatment 
with beta-blockers and/or CCBs, or as part of initial 
treatment in properly selected patients.d 513,540
IIa
B
Continued 
When long-acting nitrates are prescribed, a 
nitrate-free or low-nitrate interval should be 
considered to reduce tolerance.540
IIa
B
Ivabradine should be considered as add-on 
antianginal therapy in patients with left ventricular 
systolic dysfunction (LVEF <40%) and inadequate 
control of symptoms, or as part of initial treatment in 
properly selected patients.541,542
IIa
B
Nicorandil or trimetazidine may be considered as 
add-on therapy in patients with inadequate control 
of symptoms while on treatment with beta-blockers 
and/or CCBs, or as part of initial treatment in 
properly selected patients.543–550
IIb
B
Ivabradine is not recommended as add-on therapy in 
patients with CCS, LVEF >40%, and no clinical heart 
failure.509
III
B
Combination of ivabradine with non-DHP-CCB or 
other strong CYP3A4 inhibitors is not 
recommended.551
III
B
Nitrates are not recommended in patients with 
hypertrophic cardiomyopathy or in 
co-administration with phosphodiesterase 
inhibitors.552,553
III
B
© ESC 2024
CCB, calcium channel blocker; CCS, chronic coronary syndrome; CYP3A4, cytochrome 
P450 3A4; DHP, dihydropyridine; DM, diabetes mellitus; LVEF, left ventricular ejection 
fraction. 
aClass of recommendation. 
bLevel of evidence. 
cThese drugs may require caution or may be contraindicated in certain patients with low BP 
(beta-blockers and DHP-CCB), DM (beta-blockers), atrioventricular conduction disorders 
(beta-blockers 
and 
non-DHP-CCB), 
chronic 
obstructive 
pulmonary 
disease 
(non-cardioselective beta-blockers). 
dConsideration for initial therapy: ivabradine, nicorandil, long-acting nitrates, ranolazine, or 
trimetazidine for patients with intolerance or contraindications to beta-blockers and/or 
CCBs; ranolazine and trimetazidine for patients with microvascular angina; nicorandil or 
nitrates for patients with coronary artery spasm. The drugs are listed in alphabetical order.
ESC Guidelines                                                                                                                                                                                          3459


<!-- PAGE 46 -->

### Page 46

atrioventricular conduction disorders,554 and should be used with 
caution in patients with PAD and chronic obstructive pulmonary dis­
ease; (ii) CCBs require caution in patients with heart failure with re­
duced ejection fraction (HFrEF);526 (iii) ivabradine should not be 
combined with non-dihydropyridine CCBs (verapamil or diltiazem); 
and (iv) ranolazine and trimetazidine are reasonable options as part 
of antianginal combination therapy in patients with low heart rate 
and/or BP.
4.3. Medical therapy for event prevention
Prevention of coronary ischaemic events is based on lowering the risk 
of coronary artery occlusion and consequent ACS. Medical event- 
preventing 
therapies 
include 
antithrombotic, 
lipid-lowering, 
anti-RAAS (renin–angiotensin–aldosterone system), anti-inflammatory, 
and metabolic-acting agents.
4.3.1. Antithrombotic drugs
The standard antithrombotic treatment of patients with epicardial ath­
erosclerotic CAD is single antiplatelet therapy (SAPT), typically with as­
pirin. In patients with ACS or post-PCI, standard treatment is dual 
antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor, 
for a duration of 12 months after ACS (with or without PCI)65 or 
6 months after CCS-PCI.1,556 Thus, in ACS or CCS-PCI patients, 
DAPT is usually replaced by SAPT at some point. Several recent trials 
have investigated shortened DAPT durations and P2Y12 inhibitor 
monotherapy post-PCI to reduce the risk of bleeding. On the other 
hand, in CCS patients with persistently high ischaemic risk and low 
bleeding risk, extended intensified antithrombotic therapy should be 
considered. Ultimately, the choice and duration of antithrombotic regi­
mens largely depend on the delicate balance between each individual’s 
ischaemic and bleeding risks.
The mechanisms of action of the most commonly used antithrombo­
tic drugs in CCS patients are depicted in Figure 10.
4.3.1.1. Antiplatelet drugs
For details on antiplatelet drugs, please see Supplementary data, 
Table S1.
4.3.1.1.1. Aspirin monotherapy. Low-dose aspirin (75–100 mg once 
daily) is the traditional drug of choice in patients with CCS, with or 
without prior MI.557,558 In an individual-patient data meta-analysis of 
secondary prevention trials (43 000 patient-years), aspirin vs. no aspirin 
significantly reduced the combined risk of non-fatal MI, non-fatal ischae­
mic stroke, or death from vascular causes [from 8.2% to 6.7% per year 
(P < .0001), with relative risk (RR) reductions of 31%, 22%, and 9%, re­
spectively], translating into 15 fewer fatal and non-fatal serious vascular 
events for every 1000 patients treated for 1 year.558 Aspirin allocation 
increased major gastrointestinal (GI) and extracranial bleeds, from 
0.07% to 0.10% per year (P < .0001), with a non-significant increase 
in haemorrhagic stroke but reductions of about a fifth in total stroke 
(from 2.54% to 2.08% per year, P = .002) and in coronary events 
(from 5.3% to 4.3% per year, P < .0001).
Thus, for secondary prevention, the reduction of ischaemic events 
with aspirin outweighs serious bleeding events.557,558 There is no evi­
dence of different aspirin effects in women and men.558,559 Daily aspirin 
doses of 75–100 mg seem to be as effective as higher doses for long- 
term treatments.558–561
4.3.1.1.2. Oral P2Y12 inhibitor monotherapy.
4.3.1.1.2.1. 
Clopidogrel 
monotherapy. In 
addition 
to 
the 
cyclooxygenase-I pathway inhibited by aspirin, the platelet P2Y12 recep­
tor also plays a pivotal role in arterial thrombus formation and is the 
target for three oral platelet inhibitors: clopidogrel, prasugrel, and 
ticagrelor. The relative efficacy and safety of clopidogrel compared 
with aspirin for secondary prevention in CCS patients has been tested 
in multiple randomized trials that, taken together, have involved over 
29 000 patient-years.562,563
In an overall population of 19 185 patients with either previous MI 
(within 35 days), stroke (within 6 months), or PAD, followed for a 
mean of 1.9 years, the CAPRIE trial (Clopidogrel versus Aspirin in 
Patients at Risk of Ischaemic Events) demonstrated a small benefit in is­
chaemic events (RR reduction of 8.7%) with clopidogrel 75 mg/day vs. 
aspirin 325 mg/day.564
In the recent, open-label, South Korean, non-inferiority HOST-EXAM 
(Harmonizing Optimal Strategy for Treatment of Coronary Artery 
Stenosis-EXtended Antiplatelet Monotherapy) trial, clopidogrel was 
compared with low-dose aspirin in 5530 patients after 6–18 months of 
uneventful DAPT post-PCI (72% initial ACS, 28% initial CCS).565
Relative to aspirin, clopidogrel reduced the composite of all-cause death, 
non-fatal MI, readmission attributable to ACS, stroke, and BARC 
(Bleeding Academic Research Consortium) ≥3 bleeding from 7.7% to 
5.7% at the end of the 2-year follow-up; the results were maintained 
at 5.8 years, in a post hoc, per-protocol, post-trial analysis.566
A very recent individual patient-level meta-analysis examined seven 
trials involving 24 325 patients (including recent ACS, post-CABG, or 
initial CCS patients) randomized to either aspirin monotherapy 
(12 147 patients) or P2Y12 inhibitor monotherapy [clopidogrel in 7545 
(62.0%), ticagrelor in 4633 (38.0%)] and followed for 6–36 months.562
P2Y12 inhibitors reduced the combined ischaemic outcome of cardio­
vascular death, MI, and stroke compared with aspirin (in doses of 100 
or 325 mg daily), mainly through reduction of infarction. The risk of ma­
jor bleeding was similar, whereas GI bleeding and haemorrhagic stroke 
occurred less frequently with a P2Y12 inhibitor. The treatment effect 
was consistent across pre-specified subgroups (ACS or CCS) and 
type of P2Y12 inhibitor.562
The above overall evidence supports clopidogrel monotherapy as an 
effective and safe alternative to aspirin monotherapy for long-term sec­
ondary prevention in patients with CCS.
4.3.1.1.2.2. Ticagrelor monotherapy. Since ticagrelor compared with 
clopidogrel is more effective and displays less variable platelet inhib­
ition,567,568 although with greater bleeding potential,569 ticagrelor 
monotherapy has been compared with aspirin monotherapy for sec­
ondary prevention in CCS patients treated with PCI.
The RCT GLOBAL LEADERS trial [Ticagrelor plus aspirin for 
1 month, followed by ticagrelor monotherapy for 23 months vs. as­
pirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin 
monotherapy for 12 months after implantation of a drug-eluting stent 
(DES): a multicentre, open-label, randomized superiority trial]570 of 
15 968 patients (53% with initial CCS) did not show superiority of 
ticagrelor monotherapy vs. standard of care in terms of survival or 
new Q-wave MI.570 A pre-specified GLOBAL LEADERS ancillary ana­
lysis of independently adjudicated outcomes in 7585 patients reported 
non-inferiority for ischaemic events and no difference in BARC major 
bleeding between the two strategies.571 A post hoc landmark analysis 
of the GLOBAL LEADERS trial, conducted in 11 121 uneventful patients 
at 1 year (53% CCS from trial onset, 47% transitioning to CCS from


<!-- PAGE 47 -->

### Page 47

ACS), showed reduced ischaemic events, but increased BARC 3 and 5 
major bleeding, during ticagrelor monotherapy compared with aspirin 
monotherapy from 1 to 2 years after PCI.572
The double-blind, non-inferiority TWILIGHT trial, conducted in 7119 
patients [35% CCS, 65% NSTE (non-ST-segment elevation)-ACS] 
undergoing high-risk PCI (defined as multivessel, stenting of >30 mm, 
thrombotic, two-stent bifurcation, left main, proximal LAD, or 
atherectomy-treated calcified lesions) and uneventfully receiving 
3 months of ticagrelor-based DAPT after PCI, showed that ticagrelor 
monotherapy 90 mg b.i.d. (twice daily) compared with ticagrelor- 
based DAPT for an additional 12 months significantly reduced the 
primary endpoint of clinically relevant bleeds (BARC 2, 3, and 5, or 
BARC 3 and 5), with no significant increase in the composite of any 
death, MI, or stroke (3.9% in both groups).573
P
P
Clopidogrel
Aspirin
Vorapaxar
Ticagrelor
Prasugrel
Cangrelor
Rivaroxaban
Apixaban
Edoxaban
UFH
Enoxaparin
Eptifibatide
Tirofiban
Dabigatran
VKA
Bivalirudin
Argatroban
Fondaparinux
GP IIb/IIIa
GP IIb/IIIa
PAR I
PAR 4
TxA2
P2Y12 receptor
Thromboxane receptor
ADP
Plaque rupture or plaque erosion
TF:FVIIa coagulation
Platelet rolling and adhesion
Platelet activation
Platelet aggregation
Fibrinogen
Fibrinogen
Fibrin
FXa
Thrombin
Thrombin
Fibrin network
Platelet fibrin thrombus
Figure 10 Antithrombotic drugs for chronic coronary syndromes: pharmacological targets. ADP, adenosine diphosphate; FVIIa, activated factor VII; 
FXa, activated factor X; GP, glycoprotein; PAR, protease-activated receptor; TF, tissue factor; TxA2, thromboxane A2; UFH, unfractionated heparin; 
VKA, vitamin K antagonist. Orally administered drugs are shown on a blue background, parenterally administered ones on red. Aspirin prevents TxA2 
formation by acetylating platelet cyclooxygenase-1.
ESC Guidelines                                                                                                                                                                                          3461


<!-- PAGE 48 -->

### Page 48

The above trial data570–573 and meta-analytical data562,563,574 suggest 
that ticagrelor monotherapy may be an option for selected CCS or sta­
bilized post-ACS patients treated with PCI. However, the overall evi­
dence is weaker than for other recommended antithrombotic 
strategies. Moreover, the optimal timing and duration (longest tested 
duration 23 months) are unclear. Only the 90 mg b.i.d. regimen has 
been tested as monotherapy.573,575 Data on prasugrel monotherapy 
for CCS patients are limited to a single-armed, open-label study with 
3 months of follow-up.576
In summary, for long-term secondary prevention in CCS patients 
without an indication for oral anticoagulant (OAC), aspirin or, as an al­
ternative, clopidogrel monotherapy are generally recommended. In se­
lected patients at high ischaemic risk without high bleeding risk (HBR), 
ticagrelor monotherapy may be considered [at the time of writing 
not contemplated by the European Medicines Agency (EMA) (https:// 
www.ema.europa.eu/en/medicines/human/EPAR/brilique)] with a low­
er level of evidence than for aspirin or clopidogrel (Figure 11). Details 
on the pharmacology of antiplatelet drugs567,577–582 and on the rando­
mized evidence (including trial limitations) can be found in the 
Supplementary data, Table S1 and in the evidence tables.
4.3.1.1.3. Dual antiplatelet therapy post-percutaneous coronary 
intervention. After PCI for CCS, DAPT consisting of aspirin and clopido­
grel is recommended to reduce the risk of stent thrombosis and MI com­
pared with aspirin alone.556 With few exceptions, there is no reason to 
replace clopidogrel with ticagrelor, based on the ALPHEUS 
(Assessment of Loading with the P2Y12 Inhibitor Ticagrelor or 
Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective 
Coronary Stenting) trial results demonstrating, in 1883 patients followed 
for 30 days, that ticagrelor did not significantly reduce PCI-related MI or 
major myocardial injury, while minor bleeding was significantly increased 
compared with clopidogrel.583
In the THEMIS trial (The Effect of Ticagrelor on Health Outcomes in 
diabEtes Mellitus patients Intervention Study) of 19 220 CCS patients aged 
≥50 years, with type 2 DM and no previous MI or stroke (58% with prior 
PCI), ticagrelor plus low-dose aspirin marginally reduced ischaemic events 
compared with placebo plus aspirin at a median follow-up of 40 months, 
but increased major bleeding, including intracranial haemorrhage.584
A default DAPT duration of 6 months is recommended for CCS pa­
tients undergoing PCI.556 However, multiple RCTs have investigated 
shorter DAPT durations (1 or 3 months) to decrease the risk of 
bleeding.570,573,585–588 The combined evidence indeed shows a decrease 
in—mostly minor—bleeding, without an increase in ischaemic events, in­
dicating that a shorter duration of DAPT of 1–3 months post-PCI may 
benefit CCS patients who are not at high ischaemic risk or who are at HBR.
This concept was tested in the MASTER-DAPT trial (Management of 
High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent 
Implantation with an Abbreviated versus Standard DAPT Regimen), 
randomizing 4579 PCI patients (∼50% CCS) with HBR, after 1-month 
uneventful DAPT, to immediate DAPT discontinuation or to DAPT 
continuation for at least 2 additional months.587 After 335 days, the trial 
demonstrated that discontinuation was non-inferior for ischaemic 
events compared with standard duration of DAPT, but major and clin­
ically relevant non-major bleeding was reduced.587
A meta-analysis, including 11 RCTs and 9006 patients (42% CCS) at 
HBR [defined by a PREdicting bleeding Complications In patients 
undergoing Stent implantation and subsEquent Dual AntiPlatelet 
Therapy (PRECISE-DAPT) score of >25 or by Academic Research 
Consortium for High Bleeding Risk (ARC-HBR) criteria, listed in 
Supplementary data, Table S2]589–591 showed at 12 months of follow-up 
that an abbreviated DAPT of 1–3 months reduced both major bleeding 
and ischaemic events, as well as cardiovascular mortality, compared with 
standard DAPT, irrespective of CCS or ACS presentation.591
The overall data indicate that, in CCS patients with HBR, DAPT dis­
continuation 1–3 months after PCI is recommended, while in patients 
without HBR, DAPT duration may be reduced only in the absence of 
high ischaemic risk (Figure 11). For patients at high ischaemic risk with­
out HBR, see below.
4.3.1.1.4. Extended intensified antithrombotic therapy. In patients at 
high ischaemic risk without HBR, there are three options for intensifying 
antithrombotic therapy to prevent ischaemic events, albeit at the cost of 
increased bleeding: (i) continue DAPT, consisting of aspirin and clopido­
grel or of aspirin and prasugrel after PCI, based on the results of the 
DAPT Study;592 (ii) add ticagrelor to aspirin in post-MI patients, based 
on the PEGASUS-TIMI (Prevention of Cardiovascular Events in 
Patients with Prior Heart Attack Using Ticagrelor Compared to 
Placebo on a Background of Aspirin - Thrombolysis In Myocardial 
Infarction) 54 trial;593 or (iii) add very low-dose rivaroxaban to aspirin 
in CCS patients, based on the COMPASS trial (Cardiovascular 
Outcomes for People Using Anticoagulant Strategies).594
The randomized DAPT Study demonstrated, in patients at 1-year 
post-PCI, that an additional 18 months of DAPT reduced ischaemic 
events compared with aspirin alone, but moderate and severe GUSTO 
(Global Utilization of Streptokinase and Tissue Plasminogen Activator 
for Occluded Arteries) or BARC bleeding rates were higher, and all- 
cause death tended to be increased.592 Of note, in the DAPT Study, first- 
generation DES were used with an increased risk of stent thrombosis.
The PEGASUS-TIMI 54 trial showed that in aspirin-treated patients 
with a history of MI 1–3 years previously and at least one high-risk char­
acteristic (i.e. aged >65 years, DM, second MI, multivessel CAD, or 
CKD), ticagrelor (90 or 60 mg b.i.d.) vs. placebo reduced ischaemic 
events at 3 years, while it increased TIMI (Thrombolysis In Myocardial 
Infarction) major, but not fatal, bleeding.593 The 60 mg dose was safer 
and better tolerated than the 90 mg dose584,593 and therefore approved. 
The subgroups of patients with (compared with those without) DM, 
multivessel CAD, and PAD benefited more from ticagrelor.595–597
The COMPASS trial demonstrated that the combination of aspirin 
plus rivaroxaban 2.5 mg b.i.d., but not rivaroxaban 5.0 mg b.i.d. mono­
therapy, reduced ischaemic events, but increased modified-ISTH 
(International Society on Thrombosis and Haemostasis) major bleeding, 
compared with aspirin alone in patients with stable atherosclerotic 
disease (mostly CAD, with additional risk conditions if younger than 
65 years).594 There was no significant difference in intracranial or fatal 
bleeding between the two treatment arms, and death rates were lower 
in the aspirin plus rivaroxaban 2.5 mg b.i.d. group. Subgroups of patients 
with (compared with those without) DM, PAD, mild CKD, and active 
smoking habit benefited more from aspirin plus rivaroxaban.594,598
Patient eligibility for extended intensified antithrombotic therapy 
must be defined taking into account individual patient characteristics 
(see Supplementary data, Table S2), as well as study inclusion and exclu­
sion criteria. The different options are described in Table 8.
In summary, in high ischaemic risk CCS patients without HBR, either 
aspirin plus ticagrelor 60 mg b.i.d. or aspirin plus rivaroxaban 2.5 mg 
b.i.d. should be considered, based on patient characteristics 
(Figure 11). DAPT prolongation with clopidogrel or prasugrel may 
also be an option, although the evidence for this choice suffers limita­
tions. In patients with extended intensified antithrombotic therapy, re- 
evaluation of bleeding and ischaemic risk at regular intervals is essential. 
Randomized evidence beyond study follow-up times is unavailable.


<!-- PAGE 49 -->

### Page 49

4.3.1.1.5. Genotype- and phenotype-guided dual antiplatelet 
therapy. There is high laboratory interindividual variability in patients 
treated with clopidogrel, with patients who carry a cytochrome 
P450 2C19 (CYP2C19) loss-of-function allele having less platelet 
inhibition and a higher risk of ischaemic events post-PCI compared 
with non-carriers.599,600 In ST-segment elevation myocardial infarction 
(STEMI) patients, early de-escalation from aspirin plus ticagrelor or as­
pirin plus prasugrel to aspirin plus clopidogrel based on genotyping or 
platelet function testing was non-inferior for net adverse clinical events 
(ischaemic endpoints and bleeding combined) compared with routine 
Patients with CCS without indication for OAC undergoing PCI
Assess bleeding risk
Non-high bleeding risk
High bleeding risk
Default
Non-high ischaemic risk
High ischaemic risk
Default
1 month
3 months
6 months
Long term
A
A
C
C
A
C
A
C
A
R
A
A
P
A
C
T
T
P
A
C
6 mo. DAPT
(Class I)
A
C
1–3 mo. DAPT
(Class I)
(Class I)
1–3 mo. DAPT
(Class IIb)
OR
A
C
(Class I)
OR
A
C
(Class I)
OR
OR
OR
OR
1–6 mo. DAPTa
(Class IIb)
(Class IIa)
R
(Class IIb)
Aspirin 100 mg o.d.
T
Clopidogrel 75 mg o.d.
Ticagrelor 90 mg b.i.d.
Prasugrel 10 mg o.d.b
Rivaroxaban 2.5 mg b.i.d.
T
Ticagrelor 60 mg b.i.d.
A
T
A
P
OR
6 mo. DAPT
(Class I)
Figure 11 Antithrombotic treatment in chronic coronary syndrome patients undergoing percutaneous coronary intervention. ARC-HBR, Academic 
Research Consortium for High Bleeding Risk; b.i.d., bis in die (twice daily); CCS, chronic coronary syndrome; CYP2C19, cytochrome P450 2C19; DAPT, dual 
antiplatelet therapy; mo., months; OAC, oral anticoagulant; o.d., once daily; PCI, percutaneous coronary intervention; PRECISE-DAPT, PREdicting bleeding 
Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy.  aIn CCS patients undergoing high-thrombotic risk stent­
ing (e.g. complex left main stem, 2-stent bifurcation, suboptimal stenting result, prior stent thrombosis, previously known CYP2C19*2/*3 polymorphisms), 
prasugrel or ticagrelor (in addition to aspirin) may be considered instead of clopidogrel for the first month, and up to 3-6 months. bPrasugrel 5 mg o.d. for 
patients aged ≥75 years or with a body weight <60 kg. Bleeding risk criteria according to PRECISE-DAPT or ARC-HBR.
ESC Guidelines                                                                                                                                                                                          3463


<!-- PAGE 50 -->

### Page 50

treatment with ticagrelor or prasugrel.601,602 In patients with CCS, 
current evidence does not support the routine use of genotype or plate­
let function testing.602–607 However, in patients undergoing high-risk PCI 
who are known carriers of a CYP2C19 loss-of-function allele, replacing 
aspirin plus clopidogrel with aspirin plus ticagrelor or prasugrel is a rea­
sonable option.600,607,608
4.3.1.2. Anticoagulant therapy
4.3.1.2.1. Monotherapy with oral anticoagulant. Historical rando­
mized data from patients with recent MI not undergoing PCI, followed 
for up to 4 years, showed that OAC monotherapy with a vitamin K 
antagonist (VKA) targeted to an international normalized ratio (INR) 
of about 3.0–4.0 was at least as effective as low-dose aspirin in prevent­
ing MACE, but with a significant increase in major bleeding.609,610
Moreover, given the obsoletely high INR target and the cumbersome 
management, VKA has not gained popularity for secondary prevention 
in patients with CCS. Successful introduction of the direct oral 
anticoagulants (DOACs) for stroke prevention in AF and for preven­
tion and treatment of venous thrombo-embolism (VTE) has renewed 
the interest in OAC for patients with CAD. The COMPASS trial in 
CCS and/or PAD patients at high ischaemic risk, however, reported 
no significant ischaemic benefit of rivaroxaban monotherapy 5 mg twice 
daily over aspirin alone, with a significantly higher incidence of 
modified-ISTH major bleeding, although not of fatal bleeding.594
Thus, in CCS patients without a concomitant long-term indication 
for OAC, OAC monotherapy with either VKA or rivaroxaban (the 
only DOAC currently tested in this context) is not recommended. 
OAC may be considered, however, when antiplatelet agents are not 
tolerated, if the risk of bleeding is not high,594,611 or in CCS patients 
with a concomitant long-term indication for OAC (see below).
4.3.1.2.2. Combination of anticoagulant and antiplatelet therapy 
after percutaneous coronary intervention in chronic coronary 
syndrome patients with AF or other indication for oral anticoagu­
lant. Approximately one in five patients with AF need to undergo 
PCI, with a theoretical indication for both OAC for stroke prevention 
(for which DOACs are preferred to VKA) and DAPT for stent throm­
bosis and MI prevention, leading to triple antithrombotic therapy.612,613
The combination of an OAC plus DAPT, however, leads to an in­
creased bleeding risk, and major bleeding is associated with earlier mor­
tality and should therefore be avoided when possible.614 In this setting, 
the results of five RCTs have shown that double compared with triple 
antithrombotic therapy reduced major or clinically relevant non-major 
bleeding, without a significant increase of ischaemic events, leading to 
the recommended use of double antithrombotic therapy (OAC plus 
P2Y12 receptor inhibitor, mostly clopidogrel) after a 1–4 week 
period of triple antithrombotic therapy in CCS patients with AF under­
going PCI.615–620
The AUGUSTUS trial (Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety of Apixaban versus 
Vitamin K Antagonist and Aspirin versus Aspirin Placebo in Patients 
with AF and Acute Coronary Syndrome or Percutaneous Coronary 
Intervention) additionally demonstrated that the DOAC apixaban re­
duced major or clinically relevant non-major bleeding compared with 
VKA, independently of a double or triple antithrombotic regimen.619
The AUGUSTUS trial and several meta-analyses demonstrated that as­
pirin compared with placebo reduced stent thrombosis events, which 
occurred mainly during the first 30 days after PCI and not thereafter, 
while increasing bleeding risk.620–622
Thus, based on the combined evidence, double antithrombotic ther­
apy with a DOAC and clopidogrel for up to 12 months should be stand­
ard care for CCS patients with AF undergoing PCI, with additional 
aspirin only for a limited initial period (from during PCI up to a max­
imum of 30 days in patients at high ischaemic risk). In patients with 
the highest bleeding risk, clopidogrel discontinuation at 6 (or even 3) 
months post-PCI and continuation of OAC alone may be considered 
when ischaemic risk is not high [Class IIb/level of evidence (LOE) C]. 
Ticagrelor or prasugrel should generally not be used as part of triple an­
tithrombotic therapy, while ticagrelor, and possibly prasugrel (although 
specific data are not available), may be considered as part of double 
Table 8 Options for extended intensified antithrombotic therapy
Drug
Dose
Clinical setting
NNT (ischaemic 
outcomes)
NNH (bleeding outcomes)
Co-administered with aspirin 100 mg o.d.
Rivaroxaban (COMPASS 
trial; vs. placebo)
2.5 mg b.i.d.
Patients with CAD or symptomatic 
PAD at high risk of ischaemic events
77
84 
(modified-ISTH major bleeding)
Co-administered with low-dose aspirin 75–162 mg o.d.
Clopidogrel, (6505/9961 of 
DAPT trial; vs. placebo)
75 mg/day
Post MI in patients who have 
tolerated DAPT for 1 year (25% ACS, 
22% previous MI)
63
105 
(moderate and severe GUSTO 
bleeds, or BARC 2, 3, and 5 
bleeds)
Prasugrel, (3456/9961 of 
DAPT trial; vs. placebo)
10 mg/day (5 mg/day if 
body weight <60 kg or 
age ≥75 years)
Post PCI for MI in patients who have 
tolerated DAPT for 1 year
63
105 
(as above)
Ticagrelor (PEGASUS-TIMI 
54; vs. placebo)
60/90 mg b.i.d.
Post-MI in patients who have 
tolerated DAPT for 1 year
84
81 
(TIMI major bleeds)
© ESC 2024
ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium; b.i.d., bis in die (twice daily); CAD, coronary artery disease; DAPT, dual antiplatelet therapy; GUSTO, 
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; 
NNH, number needed to cause a harmful event; NNT, number needed to treat to prevent an adverse event; o.d., once daily; PAD, peripheral artery disease; PCI, percutaneous 
coronary intervention; TIMI, Thrombolysis In Myocardial Infarction. Drugs (in addition to aspirin 75–100 mg/day) for extended DAPT options are listed in alphabetical order. For 
definitions of highly/moderately increased ischaemic and bleeding risk see Supplementary data, Tables S2 and S3. NNT refers to the primary ischaemic endpoints and NNH refers to the 
key safety endpoints of the respective trials. NNT and NNH from the DAPT trial are pooled numbers for clopidogrel and prasugrel.


<!-- PAGE 51 -->

### Page 51

antithrombotic therapy when there is a very high risk of stent throm­
bosis and a low bleeding risk.619,623,624
After a 6- to 12-month period of double antithrombotic therapy, in 
most AF-PCI CCS patients, OAC alone is preferred over continuation 
of double antithrombotic therapy.625,626 An open-label randomized trial, 
conducted in 2236 Japanese AF patients who had undergone PCI (71% of 
patients) or CABG (11% of patients) >1 year before or had known CAD 
not requiring revascularization, compared rivaroxaban monotherapy (15 
or 10 mg once daily based on creatinine clearance) with rivaroxaban plus 
SAPT (mostly aspirin).627 At a median follow-up of 23 months, the occur­
rence of ISTH major bleeding and of all-cause deaths were each signifi­
cantly lower with rivaroxaban monotherapy, whereas MACE 
occurrence did not differ significantly in the two treatment arms.627
Whether the above considerations remain valid when the indication 
for OAC is other than AF, e.g. mechanical heart valves (where 
DOACs are not indicated) or VTE, is uncertain given limited available evi­
dence. In the absence of data regarding the efficacy for MACE prevention 
of rivaroxaban 10 mg once daily and apixaban 2.5 mg twice daily, which 
should be used for extended OAC after the first 6 months of therapeutic 
anticoagulation in patients with VTE,628 it is recommended to resume full 
doses of these anticoagulants in case of concomitant CCS.
4.3.1.3. Coronary artery bypass grafting and antithrombotic therapy
Low-dose aspirin is recommended lifelong in patients undergoing 
CABG.629,630 Aspirin should be continued until the day of CABG and 
restarted as soon as there is no concern over bleeding, possibly within 
24 h of CABG.631,632 In general, other antithrombotic drugs should be 
stopped at intervals related to their duration of action (prasugrel 
stopped ≥7 days before; clopidogrel ≥5 days before; ticagrelor 
≥3 days before; and rivaroxaban, apixaban, edoxaban, and dabigatran 
1–2 days before, depending on drug and renal function).633,634
Although not consistent, there is evidence that DAPT with a P2Y12 re­
ceptor inhibitor compared with aspirin monotherapy provides higher 
graft patency rates after CABG.635,636,637 A meta-analysis of four 
RCTs, involving 1316 patients (with 3079 grafts) followed for 3 to 12 
months after CABG, reported superior vein graft patency with 
ticagrelor-based DAPT vs. aspirin alone, but with increased rates of 
BARC 2–5 (but not BARC 3–5) bleeds, and no significant differences 
in cardiovascular death, or the composite of cardiovascular death, 
MI, and stroke, or the composite of all-cause death, MI, stroke, and 
revascularization.635 Therefore, in patients undergoing CABG for CCS, 
DAPT is not routinely indicated; however, it may be considered in se­
lected cases at increased risk of graft occlusion who are not at high bleed­
ing risk (defined in Supplementary data, Tables S2 and S3).
Transient new-onset AF is common 2 to 3 days after CABG, occur­
ring in approximately one-third of patients.638 AF after CABG is asso­
ciated with a higher stroke risk,639 which is, however, lower than that 
with AF unrelated to surgery.640 The impact of early OAC initiation 
on patient outcomes remains unclear.641,642 In a Danish cohort study, 
early OAC initiation was associated with a lower risk of thrombo- 
embolic events,641 while in a Swedish cohort study, OAC was asso­
ciated with no reduction of thrombo-embolic complications but an 
increased risk of major bleeding.642
Decisions on OAC should consider thrombo-embolic and bleeding 
risks, timing, and duration of post-operative AF. Longer AF durations 
and delayed-onset post-CABG have higher risks. We refer to the 
dations for OAC in this context. It is unknown whether, in such pa­
tients, the combination of aspirin and OAC may be more effective 
compared with OAC alone in preventing ischaemic events post-CABG.
4.3.1.4. Proton pump inhibitors
Antithrombotic therapy may provoke GI bleeding, especially in patients at 
increased risk, such as the elderly, those with a history of GI bleeding or 
peptic disease, high alcohol consumption, chronic use of steroids or non- 
steroidal anti-inflammatory drugs (NSAIDs), or receiving a combination of 
antithrombotic drugs.643–645 In patients on various types of antithrombo­
tic therapy, proton pump inhibitors may be effective in reducing the risk of 
GI bleeding, in particular from gastroduodenal lesions.646–648 In general, 
gastric protection with proton pump inhibitors is recommended in pa­
tients at increased risk of GI bleeding for as long as any antithrombotic 
therapy is administered.65,86 Because the proton pump inhibitors omepra­
zole and esomeprazole inhibit CYP2C19, when administered with clopi­
dogrel, they reduce exposure to clopidogrel’s active metabolite; while 
their use is discouraged in combination with clopidogrel, univocal effects 
of these combinations on the risk of ischaemic events or stent thrombosis 
have not been demonstrated (https://www.ema.europa.eu/en/medicines/ 
human/EPAR/plavix).643,646 Of note, proton pump inhibitors do not in­
crease MACE vs. placebo in patients with CVD.646
Recommendation Table 17 — Recommendations for antithrombotic therapy in patients with chronic coronary syn­
drome (see also Evidence Table 17)
Recommendations
Classa
Levelb
Long-term antithrombotic therapy in patients with chronic coronary syndrome and no clear indication for oral anticoagulation
In CCS patients with a prior MI or remote PCI, aspirin 75–100 mg daily is recommended lifelong after an initial period of DAPT.558,559
I
A
In CCS patients with a prior MI or remote PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin 
monotherapy.562,564–566,649
I
A
After CABG, aspirin 75–100 mg daily is recommended lifelong.558,559,629
I
A
In patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is recommended 
lifelong.557–559
I
B
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients at enhanced 
ischaemic riskc and without high bleeding riskd (options and definitions in Table 8 and in the Supplementary data online, Tables S2 and S3).592–594
IIa
A
In CCS or stabilized post-ACS patients who underwent PCI and were initially treated with ticagrelor-based DAPT, who remain at high 
ischaemic risk and are not at high bleeding risk, ticagrelor monotherapy 90 mg b.i.d. may be considered as an alternative to dual or other 
single antiplatelet therapy.563,570–573
IIb
C
Continued 
ESC Guidelines                                                                                                                                                                                          3465


<!-- PAGE 52 -->

### Page 52

Antithrombotic therapy post-percutaneous coronary intervention in patients with chronic coronary syndrome and no indication for 
oral anticoagulation
In CCS patients with no indication for oral anticoagulation, DAPT consisting of aspirin 75–100 mg and clopidogrel 75 mg daily for up to 6 
months is recommended as the default antithrombotic strategy after PCI-stenting.650–654
I
A
In patients at high bleeding riskd but not at high ischaemic risk,c it is recommended to discontinue DAPT 1–3 months after PCI and to 
continue with single antiplatelet therapy.587,591
I
A
Stopping DAPT after 1–3 months from PCI-stenting may be considered in patients who are not at high bleeding risk nor at high risk of 
ischaemic events.588,655–657,c,d
IIb
B
In CCS patients undergoing high-thrombotic risk stenting (e.g. complex left main stem, 2-stent bifurcation, suboptimal stenting result, prior 
stent thrombosis, previously known CYP2C19 *2/*3 polymorphisms), prasugrel or ticagrelor (in addition to aspirin) may be considered 
instead of clopidogrel, for the first month, and up to 3–6 months.
IIb
C
Long-term antithrombotic therapy in patients with chronic coronary syndrome and an indication for oral anticoagulation
In CCS patients with a long-term indication for OAC, an AF therapeutic dose of VKA alone or, preferably, of DOAC alone (unless 
contraindicated) is recommended lifelong.609,627
I
B
Antithrombotic therapy post-percutaneous coronary intervention in chronic coronary syndrome patients with an indication for oral 
anticoagulation
In patients with an indication for OAC who undergo PCI, initial low-dose aspirin once daily is recommended (loading dose when not on 
maintenance dose) in addition to OAC and clopidogrel.
I
C
In patients who are eligible for OAC, DOAC (unless contraindicated) is recommended in preference to VKA.619,658
I
A
After uncomplicated PCI in CCS patients with concomitant indication for OAC: 
• early cessation of aspirin (≤1 week);
• followed by continuation of OAC and clopidogrel: 
⚬up to 6 months in patients not at high ischaemic risk;c or
⚬up to 12 months in patients at high ischaemic risk;c
• followed by OAC alone;
is recommended.616–619,622,627,659
I
A
Continuation of aspirin up to 1 month after PCI, in addition to OAC and clopidogrel, should be considered in patients at high ischaemic riskc 
or with anatomical/procedural characteristics judged to outweigh the bleeding risk.620–622,e
IIa
B
When concerns about high bleeding risk prevail over concerns about stent thrombosis or ischaemic stroke: 
rivaroxaban 15 mg daily should be considered in preference to rivaroxaban 20 mg daily for the duration of concomitant antiplatelet therapy;616
IIa
B
dabigatran 110 mg twice daily should be considered in preference to dabigatran 150 mg twice daily for the duration of concomitant 
antiplatelet therapy.617
IIa
B
In patients with an indication for VKA in combination with single or dual antiplatelet therapy, targeting VKA intensity to an INR in the lower 
part of the recommended range and to a time in therapeutic range >70% should be considered.615,660–663
IIa
B
The use of ticagrelor or prasugrel is generally not recommended as part of triple antithrombotic therapy with aspirin and an OAC.
III
C
Antithrombotic therapy post-coronary artery bypass grafting
It is recommended to initiate aspirin post-operatively as soon as there is no concern over bleeding.629,630
I
B
DAPT may be considered after CABG in selected patients at greater risk of graft occlusionf and at low risk of bleeding.635
IIb
B
Use of proton pump inhibitors
A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined 
antithrombotic therapy (antiplatelet therapy and/or OAC).646–648,664
I
A
A proton pump inhibitor should be considered when a single antithrombotic (antiplatelet or anticoagulant) drug is used, considering the 
gastrointestinal bleeding risk of the individual patient.646,665–668
IIa
A
© ESC 2024
ACS, acute coronary syndrome; AF, atrial fibrillation; ARC-HBR, Academic Research Consortium for High Bleeding Risk; b.i.d., bis in die (twice daily); CABG, coronary artery bypass grafting; 
CAD, coronary artery disease; CCS, chronic coronary syndrome; CKD, chronic kidney disease; CYP2C19, cytochrome P450 2C19; DAPT, dual antiplatelet therapy; DOAC, direct oral 
anticoagulant; INR, international normalized ratio; LAD, left anterior descending; MI, myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; 
PRECISE-DAPT, PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cEnhanced thrombotic/ischaemic risk criteria for extended treatment with a second antithrombotic agent (Supplementary data, Table S3). Thrombotic risk encompasses (i) the risk of 
thrombosis occurring, and (ii) the risk of death should a thrombotic event occur, both of which relate to anatomical, procedural, and clinical characteristics. Thrombotic/ischaemic risk 
factors for CCS (that may also apply to CABG) patients include stenting of left main stem, proximal LAD, or last remaining patent artery; suboptimal stent deployment; stent length of 
>60 mm; diabetes mellitus; CKD; bifurcation with two stents implanted; treatment of chronic total occlusion; and previous stent thrombosis on adequate antithrombotic therapy. 
dBleeding-risk criteria according to PRECISE-DAPT or ARC-HBR (Supplementary data, Table S2). 
eAnatomical/procedural thrombotic risk characteristics: stenting of left main, proximal LAD, or last remaining patent artery; suboptimal stent deployment; stent length of >60 mm; bifurcation 
with two stents implanted; treatment of chronic total occlusions. 
fFor example, stentectomy, endarterectomy, poor venous graft quality.


<!-- PAGE 53 -->

### Page 53

4.3.2. Lipid-lowering drugs
Evidence from genetic, epidemiological, and randomized clinical 
studies has established the key causal role of LDL-C and other 
apo-B-containing lipoproteins in the development of atherosclerotic 
disease.669 In patients with established ASCVD, lowering of LDL-C le­
vels reduces the risk of recurrent MACE.128,670,671 Elevated lipid levels 
should be managed according to the 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias64 and the 2021 ESC Guidelines on car­
diovascular disease prevention in clinical practice.16
Because patients with CCS are considered at very high cardiovascular 
risk, the treatment goal is to lower LDL-C levels to <1.4 mmol/L 
(<55 mg/dL) and achieve a reduction by at least 50% from baseline. 
For patients who experience a second vascular event within 2 years 
while taking maximum tolerated statin-based therapy, an even lower 
LDL-C goal of <1.0 mmol/L (40 mg/dL) may be considered.
In addition to exercise, diet, and weight control, which favourably af­
fect blood lipid levels and are recommended for all patients with CCS 
(see Section 5.1), pharmacological treatment with a maximally tolerated 
dose of a potent statin is the first-line therapy recommended for all 
CCS patients.128,670,671 In a landmark meta-analysis involving patients 
with and without ASCVD, statin treatment was shown to reduce the 
risk of major vascular events by 22%, all-cause mortality by 10%, and 
mortality due to coronary heart disease by 20% per 1.0 mmol/L of 
achieved reduction in LDL-C levels.670 High-intensity statin treatment 
(i.e. atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) reduces 
LDL-C levels by 45%–50% on average, although interindividual variabil­
ity exists.672 Statins should not be given when pregnancy is planned, 
during pregnancy, or during the breastfeeding period.64
In many patients with CCS, statin therapy alone will not suffice to 
achieve the recommended LDL-C goals;673 hence, a combination of 
lipid-lowering drug therapy is required. In a trial of patients with recent 
ACS, the combination of statin with ezetimibe resulted in additional re­
duction of LDL-C levels by 20%–25% compared with simvastatin 
monotherapy. This LDL-C reduction translated into a modest reduc­
tion of a composite endpoint involving fatal and non-fatal events 
(6.4% RR reduction, 2.0% absolute risk reduction).674 Ezetimibe should 
be used as second-line therapy when the treatment goal is not achieved 
with maximally tolerated statin therapy, or as first-line therapy in the 
case of intolerance to any statin regimen. Proprotein convertase subti­
lisin/kexin type 9 inhibitors (alirocumab or evolocumab), administered 
subcutaneously every 2 or 4 weeks, lower LDL-C levels by 60% when 
added to statin therapy.675 In cardiovascular outcomes trials, these 
monoclonal antibodies resulted in significant reduction of non-fatal car­
diovascular events, with no impact on cardiovascular mortality.675,676
Their favourable safety profile was recently confirmed for longer 
follow-up (median 5 years) in open-label extension studies of the out­
comes trials.677 The high cost of PCSK9 inhibitors is still a limitation for 
broader implementation.
Bempedoic acid is an oral cholesterol synthesis inhibitor that lowers 
LDL-C by approximately 18% in monotherapy and 38% when com­
bined with ezetimibe.678,679 In a recent cardiovascular outcomes trial 
including statin-intolerant patients, bempedoic acid significantly re­
duced MACE.680 Inclisiran, a small interfering ribonucleic acid molecule, 
is administered subcutaneously every 3–6 months and reduces LDL-C 
by approximately 50% either in combination with statin or without sta­
tin therapy.681 A cardiovascular outcomes trials for inclisiran is current­
ly underway (ClinicalTrials.gov identifier: NCT03705234).
In patients scheduled to undergo elective PCI, pre-treatment with a 
high-dose statin in statin-naïve patients or loading with high-dose statin 
in statin-treated patients has been shown to reduce the risk of 
periprocedural events.682 Routine pre-treatment or loading (in the 
context of pre-existing statin treatment) with a high-dose statin can 
be considered in patients with CCS undergoing PCI.
4.3.3. Renin–angiotensin–aldosterone blockers/ 
angiotensin receptor neprilysin inhibitor
Modulation of the RAAS and the neprilysin inhibitor sacubitril in com­
bination with a RAS blocker has proved beneficial in patients with HF 
post-MI and in patients with hypertension. In these clinical syndromes, 
RAAS inhibition has greatly improved morbidity and mortality. 
Angiotensin-converting enzyme inhibitors (ACE-Is) can reduce mortal­
ity, MI, stroke, and HF among patients with LV dysfunction,683–685 pre­
vious vascular disease,686–688 and high-risk DM.689 These data bring 
strong evidence to recommend ACE-Is [or angiotensin receptor block­
ers (ARBs) in cases of intolerance] for the treatment of patients with 
CCS with co-existing hypertension, LVEF ≤40%, DM, or CKD, unless 
contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.). In 
trials that include patients with mildly reduced and preserved LV func­
tion >40%, the effect of ACE-Is to reduce all-cause death, cardiovascu­
lar death, non-fatal MI, stroke, or HF in patients with atherosclerosis is 
not uniform.686,687,690 A meta-analysis, including 24 trials and 61 961 
patients, documented that, in CCS patients without HF, RAAS inhibi­
tors reduced cardiovascular events and death only when compared 
Recommendation Table 18 — Recommendations for 
lipid-lowering drugs in patients with chronic coronary 
syndrome (see also Evidence Table 18)
Recommendations
Classa
Levelb
Lipid-lowering treatment with an LDL-C goal of <1.4 
mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C 
vs. baseline is recommended.64,670,671
I
A
A high-intensity statin up to the highest tolerated 
dose to reach the LDL-C goals is recommended for 
all patients with CCS.670,671
I
A
If a patient’s goal is not achieved with the maximum 
tolerated dose of statin, combination with ezetimibe 
is recommended.674
I
B
For patients who are statin intolerant and do not 
achieve their goal on ezetimibe, combination with 
bempedoic acid is recommended.680
I
B
For patients who do not achieve their goal on a 
maximum tolerated dose of statin and ezetimibe, 
combination with a PCSK9 inhibitor is 
recommended.675,676
I
A
For patients who do not achieve their goal on a 
maximum tolerated dose of statin and ezetimibe, 
combination with bempedoic acid should be 
considered.
IIa
C
For patients with a recurrent atherothrombotic 
event (not necessarily of the same type as the first 
event) while taking maximally tolerated statin 
therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) 
may be considered.675,676
IIb
B
© ESC 2024
CCS, chronic coronary syndrome; LDL-C, low-density lipoprotein cholesterol; PCSK9, 
proprotein convertase subtilisin/kexin type 9. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3467


<!-- PAGE 54 -->

### Page 54

with placebo, but not when compared with active control treat­
ment.691 For this reason ACE-I therapy in CCS patients without HF 
or high cardiovascular risk is not generally recommended, unless re­
quired to meet BP targets. However, a new observational study 
showed that ACE-I/ARB therapy was associated with significant long- 
term survival benefit in patients post-PCI for STEMI/non-ST-segment 
elevation myocardial infarction (NSTEMI). This survival benefit is appar­
ent in patients with both preserved and reduced LV function. These 
findings provide contemporary evidence to support the use of these 
agents in coronary patients who underwent PCI for STEMI/NSTEMI, ir­
respective of their baseline LV function.692
Sacubitril/valsartan contains an ARB and a prodrug of neprilysin 
inhibitor, which inhibits the degradation of endogenous natriuretic pep­
tides. In patients with LVEF ≤35% (of ischaemic aetiology in 60%), 
sacubitril/valsartan proved to reduce HF hospitalization and cardiovas­
cular death compared with ACE-I.693 Moreover, sacubitril/valsartan 
may decrease myocardial ischaemia because of its effect in reducing 
LV wall stress and improving coronary circulation. The risk of coronary 
events using sacubitril/valsartan compared with ACE-I was also signifi­
cantly reduced on post-hoc analyses.694
4.3.4. Sodium–glucose cotransporter 2 inhibitors and 
glucagon-like peptide-1 receptor agonists
Sodium–glucose cotransporter 2 (SGLT2) inhibitors and GLP-1 recep­
tor agonists were initially intended as glucose-lowering medications for 
patients with type 2 DM; however, a growing body of evidence has es­
tablished that these drugs lower ASCVD risk and confer cardiovascular 
benefits beyond their glucose-lowering potential.688,695–697 Among pa­
tients with DM, SGLT2 inhibitor use was associated with a reduced risk 
of MACE, especially in patients with established ASCVD.698 The exact 
mechanism(s) by which SGLT2 inhibitors improve CVD outcomes re­
main largely unknown, but several hypotheses have been pro­
posed.695,696,699–702 The benefits of SGLT2 inhibitors may relate 
more to cardiorenal haemodynamic effects than to atherosclerosis16
The cardiovascular benefits of GLP-1 receptor agonists is driven by re­
duced risk of ASCVD-related events.703 Overall, the results of cardio­
vascular outcome trials of SGLT2 inhibitors and GLP-1 receptor 
agonists support their recommendation as first-line treatment for all 
patients with type 2 DM and ASCVD including CCS, independently 
of decisions about glycaemic management (Recommendation Table 19).
In patients with HF with reduced (HFrEF) or preserved EF (HFpEF), 
dapagliflozin and empagliflozin lowered the risk of worsening HF or car­
diovascular death in the presence or absence of type 2 DM.704–707
Recent results indicate benefits of SGLT2 inhibitors on hospitalization 
for HF and cardiovascular death in patients at high cardiovascular risk, ir­
respective of HF history.708 Recommendations for the use of SGLT2 in­
hibitors in patients with diabetes and patients with HF are detailed in the 
tients with diabetes86 and the 2021 ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure526 and its 2023 Focused 
Update. 709 Recommendations on the use of these medications in pa­
tients with HF are given in Section 4.3.4 and Recommendation Table 24.
In patients with pre-existing CVD, the SELECT trial assessed the ef­
fect of weekly subcutaneous administration of the GLP-1 receptor 
agonist semaglutide at a dose of 2.4 mg on MACE reduction in over­
weight or obese adults without type 2 DM. The trial involved 17 604 
patients with established CVD and a BMI ≥27 kg/m2. Patients lost a 
mean of 9.4% of body weight over the first 2 years with semaglutide 
vs. 0.88% with placebo. The primary cardiovascular endpoint—a 
composite of death from cardiovascular causes, non-fatal MI, or non- 
fatal stroke—was reduced significantly, with an HR of 0.80 (95% CI, 
0.72–0.90; P < .001).465
4.3.5. Anti-inflammatory agents for event prevention
Four large double-blind trials have compared the effects of anti- 
inflammatory agents vs. placebo in patients with atherothrombotic 
CAD. The Canakinumab Antiinflammatory Thrombosis Outcome 
Study (CANTOS) tested three doses of the anti-interleukin-1-beta 
monoclonal antibody canakinumab against placebo in over 10 000 pa­
tients with previous MI and plasma C-reactive protein ≥2 mg/L.712
The highest dose (300 mg every 3 months) reduced plasma 
interleukin-6 and C-reactive protein and the combined endpoint of car­
diovascular death, non-fatal MI, and non-fatal stroke over a mean of 
3.7 years: 3.90 vs. 4.50 events per 100 person-years (HR 0.86; 95% 
CI, 0.75–0.99; P = .031). The other doses did not provide favourable re­
sults. Despite efficacy, the drug was not developed further for this indi­
cation because of the risk of fatal infections and high costs.
Low-dose methotrexate (target dose 15–20 mg once weekly) did not 
reduce the composite of cardiovascular death, non-fatal MI, non-fatal 
stroke, or unstable angina-driven revascularization in 4786 patients 
with previous MI or multivessel coronary atherosclerosis and additional 
DM or metabolic syndrome.713 The trial was stopped early (median 
2.3 year follow-up) for futility.
The COLCOT (Colchicine Cardiovascular Outcomes Trial) tested 
low-dose colchicine (0.5 mg daily) vs. placebo in 4745 patients with re­
cent MI (<30 days) regardless of C-reactive protein values.714 During a 
median of 2.3 years, the composite of cardiovascular death, resuscitated 
Recommendation Table 19 — Recommendations for 
sodium–glucose cotransporter 2 inhibitors and/or 
glucagon-like peptide-1 receptor agonists in patients 
with chronic coronary syndrome (see also Evidence 
Table 19)
Recommendations
Classa
Levelb
CCS patients with type 2 diabetes
SGLT2 inhibitors with proven CV benefitc are 
recommended in patients with T2DM and CCS to 
reduce CV events, independent of baseline or target 
HbA1c and independent of concomitant 
glucose-lowering medication.86,688,695,697,700
I
A
GLP-1 receptor agonists with proven CV benefitd 
are recommended in patients with T2DM and CCS 
to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant 
glucose-lowering medication.710,711
I
A
CCS patients without type 2 diabetes
The GLP-1 receptor agonist semaglutide should be 
considered in overweight  (BMI ≥27 kg/m2) or obese 
CCS patients without diabetes to reduce CV 
mortality, MI, or stroke.465
IIa
B
© ESC 2024
BMI, body mass index; CCS, chronic coronary syndrome; CV, cardiovascular; GLP-1, 
glucagon-like peptide-1; HbA1c, glycated haemoglobin; MI, myocardial infarction; SGLT2, 
sodium–glucose cotransporter 2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cCanaglifozin, dapagliflozin, empagliflozin, sotagliflozin (listed in alphabetical order). 
dDulaglutide, efpeglenatide, liraglutide, semaglutide (listed in alphabetical order).


<!-- PAGE 55 -->

### Page 55

cardiac arrest, non-fatal MI, non-fatal stroke, or unstable angina-driven 
revascularization occurred in 5.5% on colchicine vs. 7.1% on placebo 
(HR 0.77; 95% CI, 0.61–0.96; P = .02). Colchicine had favourable effects 
on each outcome component. All-cause mortality did not differ (43 vs. 44 
events). Diarrhoea was reported in 9.7% vs. 8.9% (statistically non- 
significant); pneumonia, although not frequent, was recorded more often 
with colchicine than placebo (0.9% vs. 0.4%; P = .03).
The LODOCO2 trial (Low-Dose Colchicine 2) randomized 5500 
patients with atherosclerotic CAD who had been stable for at least 
6 months to low-dose colchicine (0.5 mg daily) or placebo for a median 
of 2.4 years.715 The primary endpoint (cardiovascular death, spontan­
eous MI, ischaemic stroke, or ischaemia-driven revascularization) oc­
curred in 6.8% on colchicine vs. 9.6% on placebo (HR 0.69; 95% CI, 
0.57–0.83; P < .001). The main secondary endpoint (cardiovascular 
death, non-fatal MI, or non-fatal stroke) was reduced by 28% (4.2% 
on colchicine vs. 5.7% on placebo; HR 0.72; 95% CI, 0.57–0.92; 
P = .007). There were no significant differences in rates of pneumonia 
or GI disorders. The incidence of non-cardiovascular death was nomin­
ally higher, but not statistically significant (0.7 vs. 0.5 events per 100 
person-years; HR 1.51; 95% CI, 0.99–2.31).
A recent meta-analysis including over 12 000 patients with athero­
thrombotic CAD716 has estimated the treatment effects of colchicine 
vs. placebo for individual outcome components. Significantly lower risks 
were found for MI (RR, 0.76; 95% CI, 0.61–0.96), stroke (RR, 0.48; 95% 
CI, 0.30–0.77) and unstable angina-driven revascularization (RR, 0.61; 
95% CI, 0.42–0.89), with no significant difference for cardiovascular 
death (RR, 0.73; 95% CI, 0.45–1.21), all-cause death (RR, 1.01; 95% 
CI, 0.71–1.43), or GI events (provided colchicine daily dose did not ex­
ceed 0.5 mg; RR, 1.02; 95% CI, 0.92–1.14).
4.4. Revascularization for chronic coronary 
syndromes
Invasive treatment of CAD with either CABG or PCI is historically de­
scribed under the term revascularization. Although both procedures in­
crease CFC365,366 and prevent myocardial ischaemia during exercise or 
emotional stress, they do not heal coronary atherosclerosis. 
Revascularization by both modalities improves angina-related health 
status.50,52,717 Randomized and meta-analytical evidence supports a 
survival benefit above medical therapy for CABG in patients with left 
main disease,718–721 as well as three-vessel disease,722 particularly in pa­
tients with LV dysfunction.719,723,724 Most of this evidence was obtained 
prior to the introduction of disease-modifying therapies such as ACE-Is/ 
ARBs and statins. Meta-analytical evidence suggests a potential benefit 
of PCI on cardiovascular survival,55,725,726 which, similarly to CABG, ap­
pears to be related to the prevention of MI.55,727 In general, among sur­
gically eligible patients with multivessel disease, CABG is superior to 
PCI and to medical therapy, particularly in those with diabetes and high­
er coronary complexity.727,728 Recent evidence has generated contro­
versy on (i) the value of routine early revascularization compared with 
optimal medical therapy alone,47,56,314,729 (ii) the value of PCI vs. CABG 
for complex CAD,326,730 and (iii) the value of ischaemia testing for 
decision-making in revascularization.315,317,726 At the same time, ad­
vances in interventional technologies and medications have expanded 
the application of PCI to more complex forms of CAD.731
4.4.1. Appropriate indication for myocardial 
revascularization
In CAD patients with moderate or severe inducible ischaemia but no 
left main disease nor LVEF of <35%, the largest-to-date ISCHEMIA trial, 
up to 5 years, did not show significant benefit of an initial invasive strat­
egy over an initial conservative strategy for the primary endpoint of is­
chaemic cardiovascular events or death from any cause,47 triggering 
discussion about the role of initial angiography followed by revascular­
ization when feasible, in this type of CCS patients, once optimal medical 
therapy has been established. The CLARIFY registry found that many 
CCS patients with angina experience a resolution of symptoms over 
time, often without changes in treatment or revascularization, and ex­
perience good outcomes.404 While these findings suggest that this type 
of CCS patients should initially receive conservative medical manage­
ment, it is worth noting that patients who were randomly assigned 
to the invasive strategy in the ISCHEMIA trial experienced significantly 
lower rates of spontaneous MI and greater improvement in 
angina-related health status compared with those assigned to the con­
servative strategy.47,50 Furthermore, the ORBITA 2 trial demonstrated 
that patients with stable angina, who were receiving minimal or no anti­
anginal medication and had objective evidence of ischaemia, experi­
enced a lower angina symptom score following PCI treatment 
compared with a placebo procedure, indicating a better health status 
with respect to angina.52 Although initial conservative medical manage­
ment of CCS patients is generally preferred, symptom improvement by 
revascularization should therefore not be neglected if patients remain 
symptomatic despite antianginal treatment.
After publication of the ISCHEMIA trial results, several meta- 
analyses have reported similar overall survival and inevitably higher 
rates of procedural MI with routine revascularization, while confirming 
consistently greater freedom from spontaneous MI, unstable angina, 
and anginal symptoms after revascularization compared with GDMT 
alone.732–734 Of note, these meta-analyses showed some differences 
in methodology, in selected trials, and follow-up duration. 
Recommendation Table 20 — Recommendations for 
anti-inflammatory drugs in patients with chronic coron­
ary syndrome (see also Evidence Table 20)
Recommendation
Classa
Levelb
In CCS patients with atherosclerotic CAD, low-dose 
colchicine (0.5 mg daily) should be considered to 
reduce myocardial infarction, stroke, and need for 
revascularization.714–716
IIa
A
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 21 — Recommendations for 
angiotensin-converting enzyme inhibitors in patients 
with chronic coronary syndrome (see also Evidence 
Table 21)
Recommendations
Classa
Levelb
In CCS patients, ACE-Is (or ARBs) are 
recommended in the presence of specific 
comorbidities, such as hypertension, diabetes, or 
heart failure.683–685
I
A
ACE-Is should be considered in CCS patients at very 
high risk of cardiovascular events.686,687,690,691
IIa
A
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCS, 
chronic coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3469


<!-- PAGE 56 -->

### Page 56

Furthermore, the importance of ‘any myocardial infarction’ as an end­
point is complicated by a debate over the prognostic importance of 
procedural infarctions as well as how various MI definitions affect the 
prediction of long-term outcomes735,736 A more recent meta-analysis 
of RCTs that included the longest available follow-up showed that add­
ing revascularization to GDMT reduced cardiac mortality compared 
with GDMT alone. The cardiac survival benefit improved with the dur­
ation of follow-up and was linearly related to a lower rate of spontan­
eous MI.55
In ISCHEMIA, patients randomized to initial medical therapy alone had 
significantly more spontaneous MIs during the 5-year follow-up, which 
were associated with subsequent cardiovascular death.737 An early inva­
sive strategy was associated with lower long-term risks of cardiovascular 
events, mainly spontaneous MIs, compared with a conservative strategy, 
at the cost of a higher risk of procedural MIs.738
Extended follow-up of the ISCHEMIA trial population up to 7 years 
(ISCHEMIA-EXTEND) revealed a significant 2.2% absolute decrease in 
cardiovascular mortality (adjusted HR 0.78; 95% CI, 0.63–0.96) favour­
ing the initial invasive strategy.56 The benefit was most marked in pa­
tients with multivessel CAD (≥70% diameter stenosis on CCTA; 
adjusted HR 0.68; 95% CI, 0.48–0.97) but was offset by a significant 
1.2% absolute increase in non-cardiac mortality, without a significant 
difference (absolute decrease of −0.7%) in all-cause mortality.56 In a re­
cent meta-analysis of 18 trials, on the other hand, non-cardiac mortality 
did not differ significantly by initial invasive or conservative strategy in 
CCS patients with preserved or slightly impaired LVEF.739 In a post 
hoc analysis of the ISCHEMIA trial, CAD severity was associated with 
a higher risk of all-cause death, MI, and the primary endpoint of the 
trial.317 This effect appeared to be most noticeable in patients with mul­
tivessel disease and/or proximal LAD stenosis (≥70% diameter stenosis 
on CCTA).
4.4.2. Additional considerations on reduced systolic 
left ventricular function: myocardial viability, 
revascularization, and its modality
Ischaemic cardiomyopathy is the leading cause of HFrEF, and new ischae­
mic events are the main drivers of worsening LV function, strongly im­
pacting long-term survival.740 Ischaemic HFrEF is characterized by 
irreversibly damaged and scarred myocardium alternating with ‘viable’ 
myocardium that may be dysfunctional owing to repetitive ischaemic epi­
sodes (stunning) or chronic hypoperfusion (hibernation).741 According 
to classical concepts, revascularization combined with GDMT synergis­
tically improves systolic LV function and overall prognosis in patients 
with ischaemic HFrEF by restoring sufficient perfusion to dysfunctional 
yet viable myocardial segments and preventing new ischaemic events.742
However, it carries increased periprocedural risk, especially in patients 
with severe LV dysfunction (LVEF ≤ 35%). A meta-analysis of 26 obser­
vational studies, including 4119 patients, showed that CABG can be per­
formed with acceptable operative mortality (5.4%; 95% CI, 4.5%–6.4%) 
and 5-year actuarial survival (75%) in patients with severe LV dysfunction 
(mean pre-operative EF of 24.7%).743
In the 1990s, observational studies reported improved survival after 
revascularization in patients with severe CAD, significant LV dysfunc­
tion, and evidence of myocardial viability on imaging tests.744 The 
PARR-2 trial (PET and Recovery Following Revascularization) rando­
mized 430 patients with suspected ischaemic cardiomyopathy to an 
F-18-fluorodeoxyglucose PET-assisted strategy or standard care. 
While there was a non-significant trend towards lower risk of cardiac 
events at 1 year with PET assistance,745 the 5-year follow-up showed 
no overall reduction in cardiac events.746 However, significant benefits 
were observed when adhering to PET recommendations (after exclud­
ing 25% protocol violations).746 Post hoc analyses and substudies con­
firmed the positive outcomes of a PET-guided strategy.747,748
The Surgical Treatment for Ischemic Heart Failure (STICH) trial ran­
domized 1212 patients with CAD without left main diseases eligible 
for CABG and LVEF ≤35% to receive either CABG and GDMT, or 
GDMT alone. The trial failed to achieve its primary endpoint of all-cause 
mortality at a median follow-up of 4 years (HR with CABG, 0.86; 95% CI, 
0.72–1.04; P = .12).53 However, at a median follow-up of 9.8 years, both 
all-cause and cardiovascular mortality were significantly reduced with 
CABG compared with GDMT alone (from 66.1% to 58.9%; HR 0.84; 
95% CI, 0.73–0.97; P = .02; and from 49.3% to 40.5%; HR 0.79; 95% 
CI, 0.66–0.93; P = .006, respectively).54 The reduction of cardiovascular 
mortality by CABG was greater in patients with three-vessel disease54
and the reduction of all-cause mortality was greater in younger patients, 
in whom cardiovascular deaths accounted for a larger proportion of 
deaths vs. older patients (P = .004 for interaction).749 Viability was as­
sessed by SPECT, dobutamine echocardiography, or both in 50% of 
STICH patients (298 randomized to CABG and 303 randomized to 
GDMT alone).750 There were no significant interactions between pres­
ence or absence of myocardial viability and improved LV function or 
long-term survival benefit for CABG above GDMT.747,748,750
There have been no RCTs directly comparing CABG and PCI in pa­
tients with ischaemic HF. A meta-analysis of 21 studies, mostly obser­
vational except three including STICH, published between 1983 and 
2016, supported CABG and PCI on a background of GDMT in appro­
priate patients with multivessel disease and LV systolic dysfunction; re­
vascularization with either CABG or PCI improved long-term survival 
compared with GDMT, but compared with PCI, CABG provided a sur­
vival benefit and a lower risk of MI or repeat revascularization, with a 
slightly higher incidence of stroke.751
PCI is increasingly used over CABG for treating patients with ischaemic 
HF and multivessel disease, as shown by two large registries.752,753 While 
these registries suggest that CABG is associated with a lower risk of long- 
term all-cause and cardiovascular mortality and lower MACE compared 
with PCI in patients with CAD and LVEF ≤35%,752,753 it is important to 
interpret these observational studies with great caution, given significant 
differences in baseline characteristics, including age, history of previous MI, 
severity of CAD, and completeness of revascularization.754 For the com­
parison of CABG with PCI in managing ischaemic HF with severely im­
paired LV dysfunction and multivessel CAD, the results of ongoing trials 
(NCT05427370 and NCT05329285) are awaited.
The Percutaneous Revascularization for Ischemic Left Ventricular 
Dysfunction (REVIVED-BCIS2) trial randomized 700 patients with im­
paired LV function (EF ≤ 35%), extensive CAD amenable to PCI, and 
evidence of myocardial viability in at least four dysfunctional myocardial 
segments to a strategy of PCI plus GDMT or GDMT alone.729 After a 
3.4-year follow-up, PCI showed no significant reduction in the compos­
ite primary endpoint of all-cause death or HF rehospitalization (HR 
0.99; 95% CI, 0.78–1.27; P = .96). Patients treated by PCI showed slight 
and temporary improvements in their symptoms and no incremental 
improvement of overall LV function compared with GDMT.
A pre-specified secondary analysis of REVIVED-BCIS2, conducted in 
87% of patients, failed to establish significant correlations between via­
bility extent (assessed by CMR or dobutamine stress echocardiog­
raphy) and outcomes, thereby challenging the traditional concept of 
myocardial hibernation, which can be reversed by revascularization.755
However, the analysis did find that larger amounts of non-viable myo­
cardium were linked to an increased risk of the primary outcome,


<!-- PAGE 57 -->

### Page 57

regardless of whether PCI was performed, suggesting that viability as­
sessment may be useful for risk stratification.
The two main RCTs, STICH and REVIVED-BCIS2, differ in various 
aspects. The REVIVED-BCIS2 trial patients were, on average, 10 years 
older than those in the STICH trial, had a less frequent history of MI 
(50% vs. 78%) and were more likely to be angina-free at baseline 
(67% vs. 36%). REVIVED-BCIS2 included fewer patients with three- 
vessel disease (38% vs. 60%). Additionally, patients in REVIVED- 
BCIS2 received more modern HF therapy and were more commonly 
treated with an ICD/CRT (cardiac resynchronization therapy) 
(21%/53% vs. 2%/19%). Finally, the duration of follow-up was shorter 
compared with the STICH trials. All these factors may have contributed 
to the absence of any PCI effect on survival.
In conclusion, the heterogeneous designs of the above studies, the 
statistical underpower of subgroup analyses, the heterogeneous meth­
ods of viability assessments (e.g. based on metabolism, contractile re­
serve, or scar extent) and variable quantification (dichotomous vs. 
continuous) leave many open questions on how viability should be de­
fined,756 and when and why it should be assessed in ischaemic HFrEF 
patients. For instance, the classical binary definition of myocardial viabil­
ity may benefit from more contemporary paradigms and from greater 
focus on anatomic alignment between viable myocardial regions and 
feasible revascularization of corresponding perfusing arteries.741
Moreover, therapeutic aims should go beyond enhancing local and 
overall LV function to include safeguarding against new ischaemic 
events727 and their ensuing possibly lethal arrhythmias. Therefore, an 
integrative approach, including highly specialized imaging, HF, arrhyth­
mia, and revascularization specialists, is needed for optimal patient man­
agement and improved outcomes.
4.4.3. Additional considerations—complete vs. partial 
revascularization
Complete revascularization treating all vessels and lesions causing is­
chaemia is preferable to incomplete revascularization.757 However, 
various factors may influence the implementation of complete revascu­
larization, including clinical setting, comorbidities, anatomical and pro­
cedural features, advanced age, or frailty.758,759
Furthermore, 
whether the focus of complete revascularization should be anatomical 
or functional is still unclear. In the PCI group of the SYNTAX (SYNergy 
Between PCI with TAXUS and Cardiac Surgery) trial, a higher residual 
SYNTAX score, indicating incomplete anatomical revascularization, 
was associated with a higher mortality rate.760 However, the outcomes 
of anatomically incomplete but functionally complete revascularization 
by PCI were superior to those of anatomically complete revasculariza­
tion.49,308,761 Of note, recent studies suggest that significant levels of re­
sidual ischaemia can persist despite good angiographic results after 
complex coronary stenting.
Individual reports suggest that incomplete revascularization is asso­
ciated with increased mortality compared with complete revasculariza­
tion.762 In addition, unintended incomplete revascularization appears to 
be a surrogate marker of anatomic complexity and comorbidities, pre­
disposing to more rapid native CAD progression.760,763 An important 
predictor of anatomical incomplete revascularization by PCI is the pres­
ence of chronic total occlusion. Randomized trials have shown im­
provements of angina and QoL with PCI for chronic total occlusion 
lesions,764,765 but failed to show any reduction of mortality risk and 
MI rates.764–767
Among patients with high-risk multivessel CAD, incomplete anatom­
ical revascularization is reported more frequently among those treated 
with PCI compared with those treated with CABG. The rate ranges 
from 32% to 56% for PCI and 30% to 37% for CABG.759,762,768
However, interpreting these data is challenging due to several factors. 
Firstly, there is no uniform definition of complete revascularization.769,770
Secondly, although completeness of revascularization with PCI can be 
evaluated immediately after the procedure, many patients require staged 
procedures to achieve complete revascularization. Thirdly, within the 
first year after CABG, 20% to 40% of patients may experience asymp­
tomatic graft failure as determined by CCTA.771–773 Therefore, selecting 
a revascularization modality cannot be based solely on completeness of 
revascularization but rather should be determined through shared 
decision-making and a risk–benefit assessment.
4.4.4. Assessment of clinical risk and anatomical 
complexity
While both CABG and PCI have shown continuous technical improve­
ments and better clinical outcomes over time,774,775 the potential benefit 
of revascularization must be carefully evaluated against the procedural 
risk. The Society of Thoracic Surgeons Predicted Risk of Mortality 
(STS-PROM) risk model has proved to be more effective than the 
EuroSCORE II risk model in predicting peri-operative mortality and com­
plications in CABG patients due to its continuous calibration.776 It has 
also shown satisfactory discrimination for all-cause death at 30 days in pa­
tients undergoing CABG, allowing differentiation of high (>8%) and inter­
mediate (4% to 8%) from low (<4%) surgical mortality risk. Although 
primarily designed for surgical risk assessment, the STS-PROM score 
can also be used to evaluate the risk of revascularization through PCI 
in patients with multivessel disease, as recent studies326 have shown simi­
lar mortality rates between PCI and CABG. However, in patients with 
left main coronary artery disease (LMCAD) participating in the EXCEL 
trial (Evaluation of XIENCE versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization), the STS risk models 
were effective in predicting outcomes for CABG but not for PCI regard­
ing peri-operative mortality and renal failure.777 Interestingly, the STS 
stroke risk model was more successful in predicting outcomes for PCI 
compared with CABG. More accurate risk prediction tools are needed 
to precisely estimate adverse events following LMCAD revascularization 
through both CABG and PCI. Other clinical factors, such as frailty or liver 
cirrhosis,778,779 have been found to increase post-operative mortality and 
should be taken into consideration during the decision-making 
process.780
The SYNTAX score was prospectively developed as an angiographic 
stratification tool to quantify the complexity of coronary lesions in pa­
tients with left main coronary artery (LMCA) or multivessel CAD and 
aid clinicians in deciding the most appropriate revascularization proced­
ure during Heart Team discussions.781 However, there are limitations 
to the SYNTAX score. Firstly, it is a time-consuming score requiring 
a detailed angiographic evaluation of each lesion. Secondly, there is con­
siderable inter-observer variability in its calculation, with a poor correl­
ation between core lab and operator-calculated SYNTAX score being 
reported.779 Thirdly, it is an anatomical score that quantifies obstruc­
tion but not plaque burden. Fourthly, it does not take physiological 
and clinical variables into account.782 Machine learning may streamline 
this process, generating prognostic information that is superior to clin­
ical risk scores783 and relevant to clinical decision-making.
The SYNTAX II score was developed by combining clinical and ana­
tomic features to better guide decision-making between CABG and PCI 
than the anatomical SYNTAX score.784,785 Although the usefulness of 
the SYNTAX II score was demonstrated in several studies,785–787 it 
ESC Guidelines                                                                                                                                                                                          3471


<!-- PAGE 58 -->

### Page 58

overestimated 4-year all-cause mortality in the EXCEL trial.788 The up­
dated version, SYNTAX score II 2020, using the SYNTAX Extended 
Survival (SYNTAXES) data and external validation in the population 
of the FREEDOM, BEST, and PRECOMBAT trials,789 showed modest 
discrimination for predicting 5-year MACE (c-index for PCI and 
CABG of 0.62 and 0.67, respectively) and acceptable discrimination 
for predicting 10-year mortality. Another validation study indicated 
that the score displayed acceptable discrimination for all-cause mortal­
ity at 5 years in a Japanese cohort with LMCAD and/or multivessel 
CAD,787 but external validation in a prospective setting is lacking.783
The British Cardiovascular Intervention Society myocardial jeopardy 
score (BCIS-JS) is an alternative to the SYNTAX score, enabling the as­
sessment of the severity and extent of CAD. It has been proven effect­
ive in predicting mortality after PCI and assessing the completeness of 
revascularization,790 but it is not as commonly used as the SYNTAX 
score.
4.4.5. Choice of myocardial revascularization 
modality
Both myocardial revascularization modalities—PCI and CABG—can 
achieve excellent outcomes, although through different mechanisms, 
in appropriately selected patients when GDMT alone fails.
4.4.5.1. Patients with single- or two-vessel coronary artery disease
Randomized evidence and subgroup analyses of trials enrolling a broad­
er spectrum of CAD patients showed similar performance of PCI and 
CABG in patients with one- or two-vessel CAD, with or without the 
involvement of the proximal LAD in terms of death, stroke, or 
MI.791–797 In patients with complex LAD lesions, the need for late re­
peat revascularization is higher after PCI than CABG,797 but CABG is 
a more invasive procedure with inherent risks, longer hospital stay 
and healing.758
4.4.5.2. Patients with unprotected left main coronary artery disease
Over the past two decades, several trials have compared PCI and 
CABG in patients with multivessel CAD, with or without unprotected 
LMCAD326,728,730,798–801 (Table 9). The patients who were included in 
these trials had to meet the eligibility criteria for both CABG or PCI at 
an acceptable risk level, and their coronary anatomy had to allow com­
plete revascularization through both procedures. However, due to the 
strict inclusion criteria, only a small percentage of eligible patients (ran­
ging from 6% to 40%) were enrolled in these trials.798,801 The strict in­
clusion criteria resulted in enrolling a relatively young population with a 
lower burden of comorbidities (mean age <66 years).728,730,798,801
Meta-analyses of RCTs have shown that the risk of death is similar for 
both CABG and PCI for LMCAD, even for patients with a high 
SYNTAX score, up to 5–10 years after the intervention. However, 
the risk of stroke is higher with CABG, while the risk of spontaneous 
MI is higher with PCI.728,730,800,802–804 In the individual-patient data 
meta-analysis of four randomized trials,730 mortality over 5 years was 
not statistically different between patients treated with PCI or with 
CABG [11.2% vs. 10.2%; HR 1.10 (95% CI, 0.91–1.32); P = .33; absolute 
risk difference of 0.9%]. A similar treatment effect was observed for 
10-year mortality [22.4% vs. 20.4%; HR 1.10 (95% CI, 0.93–1.29); 
P = .25; absolute risk difference 2.0%]. Spontaneous MI was lower in 
the CABG arm [6.2% vs. 2.6%; HR 2.35 (95% CI, 1.71–3.23); 
P < .0001; absolute risk difference 3.5%], while the results of periproce­
dural MI differed according to whether the analysis used the protocol 
definition or the universal definition of MI (available for only two 
studies). Stroke was not statistically different overall [2.7% vs. 3.1%; 
HR 0.84 (95% CI, 0.59–1.21); P = .36; absolute risk difference of 
−0.4%]. However, in a pre-specified analysis of the first 12 months of 
follow-up, stroke was lower after PCI than after CABG [0.6% vs. 
1.6%; HR 0.37 (95% CI, 0.19–0.69); P = .002; absolute risk difference 
of −1.0%].782 Subgroup analysis based on the SYNTAX score and 
the number of additionally involved coronary vessels revealed no differ­
ence in all-cause mortality between CABG and PCI for SYNTAX score 
≤32 or LMCA stenosis with 0/1 vessel disease. However, a trend for 
higher all-cause mortality was noted with PCI for SYNTAX score 
>32 (HR 1.30; 95% CI, 0.92–1.84) and/or LMCA stenosis with 2/3 ves­
sel disease (HR 1.25; 95% CI, 0.97–1.60).782 Of note, the LMCA sten­
osis involved distal bifurcation in 75% of the patients, and the absence of 
a bifurcation lesion had no impact on mortality.730 True bifurcation left 
main lesions (defined as Medina type 1,1,1 or 0,1,1 both main vessel and 
side vessel >50% narrowed with reference diameters ≥2.75 mm),805
which frequently require 2-stent techniques, have worse clinical out­
comes than non-bifurcation lesions.806–808 Despite excellent results 
after LMCA bifurcation stenting on angiography, 13% of patients still 
experience residual ischaemia in turn associated with higher long- 
term cardiovascular mortality.809 Using intracoronary imaging guidance 
to optimize stent expansion and prevent side-branch jailing may im­
prove outcomes after PCI of bifurcation LMCA lesions.810
Operator experience may significantly affect the outcomes after 
interventional procedures. A single-centre study from China found 
that operators with a higher volume of procedures performed 
(>15 per year) had better outcomes for unprotected LMCA PCI.811
An analysis of the outcome data from the British Cardiovascular 
Intervention Society’s national PCI database on 6724 patients who under­
went PCI for unprotected LMCA between 2012 and 2014 revealed that 
the volume of procedures performed by the operator plays a significant 
role in determining the outcome after PCI of unprotected LMCA.812
Although high-volume operators undertook PCIs on patients with greater 
comorbid burden and CAD complexity compared with low-volume op­
erators, 12-month survival was lower in high-volume operators [odds 
ratio (OR) 0.54; 95% CI, 0.39–0.73]. A close association between oper­
ator volume and superior 12-month survival was observed (P < .001).
A 2022 Joint ESC/EACTS (European Association for Cardio- 
Thoracic Surgery) task force recently reviewed the 2018 guideline 
recommendations on the revascularization of LMCAD in low-risk 
surgical patients with suitable anatomy for PCI or CABG.782 The 
review was mainly based on the recent individual-patient data 
meta-analysis730 of the long-term outcomes after CABG or PCI for 
LMCAD from four randomized clinical trials that included 4394 pa­
tients between March 2005 and January 2015. The review confirmed 
that for stable CCS patients with left main stem disease requiring re­
vascularization, both treatment options are clinically reasonable based 
on patient preference, expertise availability, and local operator vo­
lumes. It was proposed that revascularization with CABG be the re­
commended option, with suggested class I and LOE A, while PCI be 
overall recommended with a suggested class IIa and LOE A. The pre­
sent guidelines confirm that, among patients suitable for both revascu­
larization modalities, CABG is recommended as the overall preferred 
revascularization mode over PCI, given the lower risk of spontaneous 
MI and repeat revascularization.730,782 The present guidelines also ac­
knowledge that in patients with significant LMCA stenosis of low com­
plexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recom­
mended as an alternative to CABG, given its lower invasiveness and 
non-inferior survival.718,728,730,802,813


<!-- PAGE 59 -->

### Page 59

Table 9 Summary of trial-based evidence for the comparison of percutaneous coronary intervention and coronary artery bypass grafting in patients with left 
main coronary artery disease
Study
Study population
Primary endpoint
Follow-up
Findings
PRECOMBAT 
(non-inferiority)814
600 patients with newly diagnosed LMCAD who 
had stable angina, unstable angina, silent ischaemia, 
or non-ST-segment elevation MI
All-cause death, MI, stroke, or 
ischaemia-driven target vessel 
revascularization
2 years
1-year follow-up: 
8.7% and 6.7% primary endpoints for PCI and CABG, respectively, 
absolute risk difference 2% (95% CI, –1.6% to 5.6%), P = .01 for 
non-inferiority 
2-year follow-up: 
12.2% and 8.1% primary endpoints for PCI and CABG, respectively, 
HR 1.50 (95% CI, 0.90–2.52), P = .12
PRECOMBAT 
(extended follow-up)815
5 years
17.5% and 14.3% primary endpoints for PCI and CABG, respectively, 
HR 1.27 (95% CI, 0.84–1.90), P = .26
PRECOMBAT 
(extended follow-up)816
11.3 years 
(median)
29.8% and 24.7% primary endpoints for PCI and CABG, respectively, 
HR 1.25 (95% CI, 0.93–1.69)
SYNTAX817
1800 patients with de novo three-vessel (n = 1095) 
and LMCAD (n = 795)
All-cause death, stroke, MI, and 
repeat revascularization
1 year
For the LMCAD group: 15.8% and 13.7% primary endpoints for PCI 
and CABG, respectively; P = .44
SYNTAX818
3 years
For the LMCAD group: 26.8% and 22.3%, primary endpoints for PCI 
and CABG, respectively; P = .20
SYNTAX813
5 years
For the LMCAD group: 36.9% and 31.0% primary endpoints for PCI 
and CABG, respectively, HR 1.25 (95% CI, 0.93–1.69), P = .12
SYNTAX (extended 
follow-up)795
All-cause death
10 years
For the LMCAD group: 27% and 28% primary endpoints for PCI and 
CABG, respectively, HR 0.92 (95% CI, 0.69–1.22)
NOBLE (non-inferiority 
hypothesis)819
1201 patients with LMCAD who had stable angina 
pectoris, unstable angina pectoris, or 
non-ST-segment elevation myocardial infarction
All-cause death, non-procedural MI, 
any repeat coronary 
revascularization, or stroke
3.1 years 
(mean)
28% and 18% primary endpoints for PCI and CABG, HR 1.51 (95% 
CI, 1.13–2.00), P = .004 for superiority
NOBLE (extended 
follow-up)820
4.9 years 
(median)
28% and 19% primary endpoints for PCI and CABG, HR 1.58 (95% 
CI, 1.24–2.01), P < .001 for superiority
EXCEL (non-inferiority 
hypothesis)821
1905 patients with LMCAD of low or intermediate 
anatomical complexity (SYNTAX score ≤ 32)
All-cause death, stroke, or MI
3 years 
(median)
15.4% and 14.7% primary endpoints for PCI and CABG, absolute risk 
difference 0.7% (upper 97.5% confidence limit: 4%), P = .02 for 
non-inferiority; HR 1.00 (95% CI, 0.79–1.26), P = .98 for superiority
EXCEL (extended 
follow-up)822
5 years
22.0% and 19.2% primary endpoints for PCI and CABG, absolute risk 
difference 2.8% (95% CI, −0.9 to 6.5), P = .13; OR 1.19 (95% CI, 
0.95–1.50)
© ESC 2024
CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; LMCAD, left main coronary artery disease; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
ESC Guidelines                                                                                                                                                                                          3473


<!-- PAGE 60 -->

### Page 60

4.4.5.3. Patients with multivessel coronary artery disease
The SYNTAX and SYNTAXES randomized trials, comparing PCI and 
CABG for multivessel CAD with or without unprotected LMCAD, re­
ported differences in terms of survival and freedom from cardiovascular 
events dependent on SYNTAX score.795,798,823 The recently published 
10-year follow-up results of the SYNTAX trial (SYNTAXES trial) re­
ported similar all-cause death rates with both revascularization modal­
ities,795 while there was significantly higher mortality in patients with 
SYNTAX scores ≥33 who were randomized for PCI (HR 1.41; 95% 
CI, 1.05–1.89).795 A significant 5-year mortality gap between PCI and 
CABG has been reported among patients with complex multivessel 
CAD in the presence of DM (15.7% after PCI vs. 10.7% after CABG; 
HR 1.44; 95% CI, 1.20–1.77; P = .0001).728
In the FREEDOM trial (Strategies for Multivessel Revascularization in 
Patients with Diabetes), 1900 patients with diabetes and multivessel 
disease without LMCAD were randomized to CABG vs. PCI (using 
first-generation DES). Long-term results at a median follow-up dur­
ation of 3.8 years [interquartile range (IQR) 2.5–4.9 years] showed 
higher all-cause mortality in the PCI group vs. CABG group (24.3% 
vs. 18.3%; P = .01).801 Out of all the centres that participated in the 
study, only 25 agreed to participate in the FREEDOM extended follow- 
up, and therefore, only 49.6% of patients in the study were followed up 
for up to 8 years thus limiting statistical power. The all-cause mortality 
rate among the FREEDOM follow-up patients was not significantly dif­
ferent between those who underwent PCI and CABG procedures 
(23.7% vs. 18.7%; HR 1.32; 95% CI, 0.97–1.79; P = .076). In multivariable 
analysis, a significant interaction emerged between patient age and long- 
term survival benefit of CABG surgery. Patients younger than the 
median age at study entry (63.3 years) preferentially derived benefit 
from CABG; mortality among patients ≤63.3 years old was 20.7% 
(PCI) vs. 10.2% (CABG); mortality among patients >63.3 years old 
was 26.3% vs. 27.6% (P = .01 for interaction).824
4.4.5.4. Impact of coronary pressure guidance on multivessel coronary 
artery disease patients undergoing percutaneous coronary intervention
Consistently higher rates of repeat revascularizations following PCI 
compared with CABG have been shown in clinical trials involving multi­
vessel CAD patients, with significant impacts on outcomes.825 With the 
use of modern DESs, the rate of repeat revascularization after PCI has 
declined.725,795,802,820 FFR guidance during PCI leads to lower revascu­
larization rates compared with angiography-guided PCI, with fewer 
stents placed in the FFR group.826
In the FAME 3 trial, 1500 patients with three-vessel CAD not involv­
ing the LMCA were randomly assigned to PCI with second-generation 
DESs (durable polymer zotarolimus-eluting stents) guided by FFR, or to 
CABG.326 At 1-year follow-up, the incidence of the composite primary 
endpoint, MACCE [major adverse cardiac (death from any cause, MI, 
stroke, or repeat revascularization) or cerebrovascular events], was 
10.6% among patients assigned to FFR-guided PCI and 6.9% among 
patients assigned to CABG surgery (HR 1.5; 95% CI, 1.1–2.2), findings 
that were not consistent with non-inferiority (P = .35 for non- 
inferiority).326 At 3-year follow-up, there still was a significantly higher 
rate of MACCE for PCI than for CABG (18.6% vs. 12.5%; HR 1.5; 95% 
CI, 1.2–2.0; P = .002), consistent with the 1-year follow-up results. 
However, there was no difference in the incidence of the composite 
of death, MI, or stroke after FFR-guided PCI compared with CABG 
(12.0% vs. 9.2%; HR 1.3; 95% CI, 0.98–1.83; P = .07). The rates of death 
(4.1% vs. 3.9%; HR 1.0; 95% CI, 0.6–1.7; P = .88) and stroke (1.6% vs. 
2.0%; HR 0.8; 95% CI, 0.4–1.7; P = .56) were not different, while MI 
again occurred more frequently after PCI (7.0% vs. 4.2%; HR 1.7; 
95% CI, 1.1–2.7; P = .02).827 Repeat revascularization was also more 
frequent after PCI (11.1% vs. 5.9%; HR 1.9; 95% CI, 1.3–2.7; 
P = .001). Of note, after both PCI and CABG, event rates were lower 
(about half for mortality) than in the SYNTAX cohort of patients with 
three-vessel CAD. There was a narrower difference for MI rates be­
tween the two modalities, probably owing to procedural advances 
with PCI and CABG and improvements in GDMT. In patients with 
less complex CAD (SYNTAX score ≤22), outcomes were as favour­
able as after CABG.
4.4.5.5. Virtual percutaneous coronary intervention: combination of 
coronary pressure mapping with coronary anatomy for percutaneous 
coronary intervention planning
There is increasing evidence on the impact of post-PCI FFR/iFR/QFR on 
outcomes after PCI.828–833 A quarter of these patients have residual is­
chaemia (FFR < 0.80 or iFR ≤ 0.89) after angiographically successful 
PCI, with circa 80% of cases attributable to focal lesions not identified 
by angiography alone.830 One randomized trial reported that post-PCI 
iFR/FFR can be improved by additional intracoronary intervention, in­
cluding post-dilatation or additional stent implantation, but remains 
≤0.80 in 18% of cases.829 Preliminary results demonstrate that the 
combination of invasive coronary pressure mapping by iFR pullback 
or QFR mapping superimposed on the anatomical information of 
ICA accurately predict the post-PCI coronary pressure for any combin­
ation of stent location and stent length, as part of a ‘virtual PCI’ ap­
proach,348,834 and allows modification of the procedural planning in 
about 30% of cases.835 The AQVA (Angio-based Quantitative Flow 
Ratio Virtual PCI Versus Conventional Angio-guided PCI in the 
Achievement of an Optimal Post-PCI QFR) trial (n = 300) demonstrated 
that a strategy of QFR/ICA-based virtual PCI was associated with a higher 
rate of post-PCI QFR ≥0.90 compared with angiography-based PCI 
(93.4% vs. 84.9%, P = .009).836 The DEFINE GPS trial (NCT04451044) 
is currently investigating the clinical benefit of pre-procedural coronary 
pressure mapping with iFR pullback and ‘virtual PCI’ to clarify this issue 
further and improve post-PCI clinical outcomes.
Virtual PCI can be conducted by combining anatomical information 
from CCTA with that of FFR-CT. FFR-CT/CCTA-based virtual PCI has 
two theoretical advantages over ICA-based virtual PCI: (i) it does not re­
quire invasive investigation, and (ii) it provides information on vessel wall/ 
plaque composition.837 FFR-CT/CCTA-based virtual PCI has been 
shown to accurately predict post-PCI FFR838 and to modify PCI proced­
ural planning in 31% of lesions and 45% of patients.839 The Precise 
Procedural and PCI Plan (P4) trial (NCT05253677) is currently investi­
gating the clinical benefit of iFR-based virtual PCI to clarify this issue fur­
ther and improve post-PCI clinical outcomes.
4.4.5.6. Impact of intracoronary imaging guidance on multivessel 
coronary artery disease patients undergoing percutaneous coronary 
intervention
Three large randomized trials have recently investigated the clinical 
benefit of intracoronary imaging during ‘complex’ PCI. One trial, 
RENOVATE-COMPLEX PCI,840 mainly investigated the benefit of 
IVUS (74% IVUS, 26% OCT), while the two others, OCTOBER810
and ILUMIEN IV,841 investigated the benefit of OCT. Importantly, 
while OCTOBER (true bifurcation lesions) and RENOVATE- 
COMPLEX PCI (including true bifurcation lesions, long lesions,


<!-- PAGE 61 -->

### Page 61

chronic total occlusion lesions) focused on ‘anatomically’ complex le­
sions, ILUMIEN IV made the choice to define ‘complexity’ by the clin­
ical context (DM and STEMI/NSTEMI) and/or by the anatomical 
characteristics of the lesions.
In RENOVATE-COMPLEX PCI, intravascular imaging-guided PCI led 
to a lower risk of a composite of death from a cardiac cause, target 
vessel-related MI, or clinically driven target-vessel revascularization 
than angiography-guided PCI by 2 years (7.7% vs. 12.3%; HR 0.64; 
95% CI, 0.45–0.89; P = .008).840
In OCTOBER, OCT-guided PCI led to a lower risk of a composite of 
death from a cardiac cause, target-lesion MI, or ischaemia-driven 
target-lesion revascularization than angiography-guided PCI by 2 years 
(10.1% vs. 14.1%; HR 0.70; 95% CI, 0.50–0.98; P = .035).810 In ILUMIEN 
IV, OCT-guided PCI failed to decrease the rate of the primary efficacy 
endpoint of target-vessel failure, defined as death from cardiac causes, 
target-vessel MI, or ischaemia-driven target-vessel revascularization 
(7.4% vs. 8.2%; HR 0.90; 95% CI, 0.67–1.19; P = .45), while the incidence 
of definite/probable stent thrombosis was significantly reduced by OCT 
guidance vs. angiography guidance (0.5% vs. 1.4%; HR 0.36; 95% CI, 
0.14–0.91; P = .02).841
4.4.5.7. Hybrid revascularization in multivessel coronary artery 
disease patients
Arterial grafting with left internal mammary artery (LIMA) to the LAD 
system and multiple arterial grafting reduces the risk of graft occlusion, 
thus increasing the longevity of revascularization efficacy after 
CABG.842,843 Hybrid revascularization of multivessel CAD with minim­
ally invasive direct coronary artery bypass (MIDCAB)-LAD plus PCI of 
the remaining arteries may represent an alternative option. Hybrid off- 
pump revascularization seems a suitable option for patients at moder­
ate-to-high risk for surgery by avoiding the use of cardiopulmonary by­
pass. Despite this attractive concept, the frequency of hybrid 
revascularizations remains extremely modest, with about 0.1% of sur­
gical revascularizations.844 Few data are available comparing hybrid re­
vascularization vs. conventional CABG or PCI. Large registry data 
report higher rates of bleeding, renal failure, MI, and HF with hybrid re­
vascularization compared with PCI alone,844 while a very small rando­
mized trial reported similar clinical outcomes at long-term 
follow-up.845 It seems challenging to perform larger RCTs to investigate 
this question. The recent National Heart, Lung, and Blood 
Institute-funded Hybrid Trial (Hybrid Coronary Revascularization 
Trial; NCT03089398) was prematurely discontinued due to slow en­
rolment, with only 200 patients in 5 years.
4.4.6. Patient–physician shared decision-making to 
perform and select revascularization modality
Shared decision-making between patients and healthcare professionals, 
based on patient-centred care, is considered a paramount process in 
defining the appropriate therapeutic pathway. Essential aspects of 
shared decision-making are: a complete and accurate explanation of 
the disease; presentation and description of therapeutic options; dis­
cussion of potential risks, benefits, and impact on QoL for each proced­
ure; considering patient preferences and goals; and carefully explaining 
each step of the post-procedural course and follow-up. Poor shared 
decision-making is associated with worse physical and mental out­
comes, lower adherence to therapy, and an increased number of emer­
gency department visits.846–848 Shared decision-making and family 
meetings involving relatives increase patient trust in the physicians, 
with greater adherence to therapeutic decisions. Shared decision- 
making and patient medical education, considering the patient’s charac­
teristics, mental status, cultural beliefs, and educational level, are there­
fore associated with increased patient knowledge and better QoL and 
with lower levels of anxiety and depression.849–851
Using lay language and discussion with patients and relatives of short- 
term procedure-related and long-term risks and benefits—such as sur­
vival, relief of angina, QoL, the potential need for late reintervention, 
the need for prevention measures, and uncertainties associated with 
different treatment strategies—are of great importance. Although cur­
rent recommendations are primarily based on the ability of treatments 
to reduce adverse events, including improved survival, there is growing 
interest in PROMs.852 Patients are not only interested in knowing how 
recommended treatment impacts prognosis but also their QoL in the 
way they perceive it.853 The patient’s right to decline the treatment op­
tion recommended by the Heart Team must be respected. Patient re­
fusal of a recommended treatment should be acknowledged in a 
written document after the patient has received the necessary informa­
tion. In this case, the Heart Team may offer the patient an alternative 
treatment option.
The multidisciplinary Heart Team, on site or with partner institutions 
(Hub-Spoke institutions)—comprising clinical or non-invasive cardiolo­
gists, cardiac surgeons and interventional cardiologists, as well as anaes­
thetists or other specialists and healthcare professionals, if deemed 
necessary—should provide a balanced multidisciplinary decision- 
making process.
Transparency in informed consent is critical, particularly when treat­
ment options are debated. Complex cases, such as patients with CAD 
of high anatomic complexity and significant non-cardiac comorbidities, 
should be discussed in the Heart Team, taking into consideration other 
characteristics not always included in traditional databases, such as 
frailty. Heart Team/guideline discordance is common in complex 
CAD patients undergoing revascularization, especially in elderly pa­
tients, those with complex coronary disease, and those treated at cen­
tres without cardiac surgery service. These patients have a higher risk of 
mid-term mortality.854
In all cases, it is necessary to allow sufficient time to assess all available 
information and clearly explain and discuss the findings with each patient. 
The rationale for a decision and consensus on the optimal revasculariza­
tion treatment should be documented on the patient’s chart. While the 
Heart Team decision is mainly driven by long-term survival benefits with 
a certain modality of revascularization, patient’s preferences must be 
respected.853,855,856
4.4.7. Institutional protocols, clinical pathways, and 
quality of care
Institutional protocols, developed by the Heart Team and aligned with 
the current guidelines, should delineate specific anatomical and func­
tional criteria of disease complexity and specific clinical subsets of pa­
tient’ risk for cardiac surgery or intervention that may or may not be 
treated ad hoc. These protocols should be incorporated into clinical 
pathways, with regular meetings to assess the applied indications for 
myocardial revascularization and monitor the safety and effectiveness 
of the procedures, ensuring the quality of delivered patient care. 
Collaborative protocols are necessary when cardiac surgery isn’t avail­
able on site, and remote Heart Team meetings should be established.
ESC Guidelines                                                                                                                                                                                          3475


<!-- PAGE 62 -->

### Page 62

Recommendation Table 22 — Recommendations for revascularization in patients with chronic coronary syndrome (see 
also Evidence Table 22)
Recommendations
Classa
Levelb
Informed and shared decisions
It is recommended that patients scheduled for percutaneous or surgical revascularization receive complete information about the benefits, 
risks, therapeutic consequences, and alternatives to revascularization, as part of shared clinical decision-making.847,848,857
I
C
For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of 
recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, 
non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient 
outcomes and quality of life.
I
C
It is recommended to communicate the proposal of the Heart Team in a balanced way using language that the patient can understand.
I
C
It is recommended that the decision for revascularization and its modality be patient-centred, considering patient preferences, health 
literacy, cultural circumstances, and social support.849–851
I
C
It is recommended that the Heart Team (on site or with a partner institution) develop institutional protocols to implement the appropriate 
revascularization strategy in accordance with current guidelines.855,856,858
I
C
Revascularization to improve outcomes
In chronic coronary syndrome patients with left ventricular ejection fraction >35%
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant left main stem stenosis to improve survival.718,719,859,860
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant three-vessel disease to improve long-term survival and to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.55,56,317,732–734
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant single- or two-vessel disease involving the proximal LAD, to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.55,56,317,719,732–734
I
B
In chronic coronary syndrome patients with left ventricular ejection fraction ≤35%
In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, 
preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life 
expectancy, individual risk-to-benefit ratio, and patient perspectives.
I
C
In surgically eligible CCS patients with multivessel CAD and LVEF ≤35%, myocardial revascularization with CABG is recommended over 
medical therapy alone to improve long-term survival.53,54,749,861
I
B
In selected CCS patients with functionally significant MVD and LVEF ≤35% who are at high surgical risk or not operable, PCI may be 
considered as an alternative to CABG.526,729
IIb
B
Revascularization to improve symptoms
In CCS patients with persistent angina or anginal equivalent, despite guideline-directed medical treatment, myocardial revascularization of 
functionally significant obstructive CAD is recommended to improve symptoms.50,321,402,732,734,757
I
A
Assessment of procedural risks and post-procedural outcomes
In patients with complex CAD in whom revascularization is being considered, it is recommended to assess procedural risks and 
post-procedural outcomes to guide shared clinical decision-making.
I
C
Calculation of the STS score is recommended to estimate in-hospital morbidity and 30-day mortality after CABG.777,862–864
I
B
In patients with multivessel obstructive CAD, calculation of the SYNTAX score is recommended to assess the anatomical complexity of 
disease.786,865
I
B
Intracoronary imaging guidance by IVUS or OCT is recommended when performing PCI on anatomically complex lesions, in particular left 
main stem, true bifurcations, and long lesions.866,337,810,840,841
I
A
Intracoronary pressure measurement (FFR or iFR) or computation (QFR) :
• is recommended to guide lesion selection for intervention in patients with multivessel disease; 308,826,866,867
I
A
• should be considered at the end of the procedure to identify patients at high risk of persistent angina and subsequent clinical 
events;828,830,831,868
IIa
B
• may be considered at the end of the procedure to identify lesions potentially amenable to treatment with additional PCI.350,829,831
IIb
B
Continued


<!-- PAGE 63 -->

### Page 63

Choice of revascularization modality
It is recommended that physicians select the most appropriate revascularization modality based on patient profile,c coronary anatomy,d 
procedural factors,e LVEF, preferences, and outcome expectations.719,725,728,792–795,801,816,820,822,859,869
I
C
© ESC 2024
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, chronic coronary syndrome; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; IVUS, intravascular 
ultrasound; LAD, left anterior descending; LV, left ventricular; LVEF, left ventricular ejection fraction; MVD, multivessel disease; OCT, optical coherence tomography; PCI, percutaneous 
coronary intervention; QFR, quantitative flow ratio; STS, Society of Thoracic Surgeons; SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery. 
aClass of recommendation. 
bLevel of evidence. 
cAge, frailty, cognitive status, diabetes, and any other comorbidities. 
dMultivessel disease with/out left main stem involvement, high anatomical complexity, and likelihood of revascularization completeness. 
eLocal expertise and outcomes, surgical and interventional risk.
Recommendation Table 23 — Recommendations for mode of revascularization in patients with chronic coronary syn­
drome (see also Evidence Table 23)
Anatomically and clinically based recommendations for revascularization in CCS
Classa
Levelb
Left main disease
In CCS patients at low surgical riskc with significant left main coronary stenosis, CABG:
• is recommended over medical therapy alone to improve survival;719
I
A
• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and 
repeat revascularization.728,730,782
I
A
In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and 
non-inferior survival. 718,728,730,802,813
I
A
In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), in whom PCI can provide 
equivalent completeness of revascularization to that of CABG, PCI should be considered, given its lower invasiveness and non-inferior 
survival.718,728,730,802,805,809,813,820,822
IIa
A
Left main with multivessel diseased
In CCS patients at low surgical risk with suitable anatomy, CABG is recommended over medical therapy alone to improve survival.718,719,870
I
A
In CCS patients at high surgical risk, PCI may be considered over medical therapy alone.728,813
IIb
B
Multivessel diseased and diabetes
In CCS patients with significant multivessel disease and diabetes, with insufficient response to guideline-directed medical therapy, CABG is 
recommended over medical therapy alone and over PCI to improve symptoms and outcomes.801,824,871–874
I
A
In CCS patients at very high surgical risk, PCI should be considered over medical therapy alone to reduce symptoms and adverse 
outcomes.55,874
IIa
B
Three-vessel disease, without diabetes
In CCS patients with significant three-vessel disease, preserved LVEF, no diabetes, and insufficient response to guideline-directed medical 
therapy, CABG is recommended over medical therapy alone to improve symptoms, survival, and other outcomes.719,722,875
I
A
In CCS patients with preserved LVEF, no diabetes, insufficient response to guideline-directed medical therapy, and significant three-vessel 
disease of low-to-intermediate anatomic complexity in whom PCI can provide similar completeness of revascularization to that of CABG, 
PCI is recommended, given its lower invasiveness, and generally non-inferior survival.326,728,795,798,876
I
A
Single- or double-vessel disease involving the proximal LAD
In CCS patients with significant single- or double-vessel disease involving the proximal LAD and insufficient response to guideline-directed 
medical therapy, CABG or PCI is recommended over medical therapy alone to improve symptoms and outcomes.52,321,719,791,792
I
A
In CCS patients with complex significant single- or double-vessel disease involving the proximal LAD, less amenable to PCI, and insufficient 
response to guideline-directed medical therapy, CABG is recommended to improve symptoms and reduce revascularization rates.877–879
I
B
Single- or double-vessel disease not involving the proximal LAD
In symptomatic CCS patients with significant single- or double-vessel disease not involving the proximal LAD and with insufficient response 
to guideline-directed medical therapy, PCI is recommended to improve symptoms.50,321,732
I
B
In symptomatic CCS patients with significant single- or double-vessel disease not involving the proximal LAD and with insufficient response 
to guideline-directed medical therapy, not amenable to revascularization by PCI, CABG may be considered to improve symptoms.
IIb
C
© ESC 2024
CABG, coronary artery bypass grafting; CCS, chronic coronary syndrome; LAD, left anterior descending; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; 
SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery. 
aClass of recommendation. 
bLevel of evidence. 
cFor example: absence of previous cardiac surgery, or severe morbidities, or frailty, or immobility precluding CABG. 
dMultivessel disease is defined as the involvement of at least two main coronary arteries.
ESC Guidelines                                                                                                                                                                                          3477


<!-- PAGE 64 -->

### Page 64

### 5 Optimal assessment and

treatment of specific groups
5.1. Coronary artery disease and heart 
failure
About half of acute and chronic HF patients have an ischaemic aeti­
ology.880,881 Over the last decades, the proportion of ischaemic 
HFrEF has decreased while that of HFpEF, defined according to the 
chronic heart failure,526 has increased.882 The evaluation of inducible is­
chaemia is important in patients with HF, given the high prevalence of 
CAD.883–885 Moreover, patients with HFpEF may present MVA due to 
CMD.886 Indeed, CMD was observed in up to 75% of patients with 
HFpEF and was associated with worse diastolic relaxation velocities, 
as well as higher filling pressures, and an increased risk of adverse 
events.883–885,887–890 Clinical assessment alone may under-estimate 
the proportion of patients with obstructive or non-obstructive CAD, 
which can be found in up to 81% of HFpEF patients.887
Under-estimation of obstructive CAD leads to failure in identifying 
those patients who may benefit from revascularization. Conversely, 
in ANOCA patients with preserved LV function, a CFR of <2 was in­
dependently associated with diastolic dysfunction and future MACE, es­
pecially HFpEF events.891 This suggests that CMD and myocardial 
stiffness may contribute to HFpEF pathophysiology.892 In HFpEF pa­
tients, functional imaging should, therefore, be considered to detect 
CMD and epicardial CAD.
Exercise or pharmacological stress echocardiography can be used 
for the assessment of inducible ischaemia and can also help in the dif­
ferential diagnosis of HFpEF.893,894 Stress SPECT or PET can also be 
used for the detection of inducible ischaemia. Non-invasive stress 
testing can be difficult in patients with HF because of possible exer­
cise intolerance. CCTA is recommended in patients with HF with a 
low-to-intermediate pre-test likelihood of obstructive CAD and 
those with equivocal non-invasive stress tests, provided there is no 
contraindication to contrast administration.894–898 In HFpEF pa­
tients, perfusion PET should be considered for the detection of 
CMD.891 In patients with HFrEF and moderate-to-severe inducible 
myocardial ischaemia, surgical revascularization improved long-term 
survival.54,315 The results of the REVIVED-BCIS2 trial seem to 
contradict these findings, as PCI did not reduce mortality or HF hos­
pitalization in patients with severe LV systolic dysfunction (LVEF ≤  
35%) receiving optimal medical therapy.729 The same trial also re­
vealed that viability testing did not offer any prognostic benefit.755
The role of myocardial revascularization and viability testing is further 
addressed in Section 4.4.2.
In HF patients with anginal (or equivalent) symptoms, despite opti­
mized GDMT, CCTA or ICA is recommended to confirm the diagnosis 
of obstructive CAD and its severity.
Over the past three decades, several landmark clinical trials have pro­
vided robust evidence on the prognostic benefit of pharmacological 
therapies in patients with HFrEF. In these patients, four drug classes 
[ACE-Is or angiotensin receptor neprilysin inhibitors (ARNIs),891 beta- 
blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 
inhibitors] are recommended for outcome improvement regardless 
of HF aetiology and comorbidities, including CAD.526
In patients with HFrEF, an ARB is recommended in patients who do 
not tolerate ACE-Is or ARNIs. Also, ivabradine should be considered in 
addition to the four pillars. It can be used as an alternative to beta- 
blockers, when contraindicated or not tolerated, or as additional 
antianginal therapy in patients with sinus rhythm and heart rate of 
>70 b.p.m.899 Other antianginal drugs (e.g. amlodipine, felodipine, ni­
corandil, trimetazidine, ranolazine, and nitrates) are effective for im­
proving symptoms in patients with HFrEF.546,900–902 Diltiazem and 
verapamil increase HF-related events in patients with HFrEF and are 
contraindicated.526 In patients with LVEF ≤35% of ischaemic aetiology, 
an ICD is strongly recommended for primary prevention; in those with 
LVEF ≤35% and QRS >130 ms, CRT needs to be considered.526
Further details regarding the management of patients with HFrEF are 
reported in the 2021 ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure.526
In patients with HFpEF, in addition to diuretics for treating conges­
tion, SGLT2 inhibitors are now recommended for outcome improve­
ment.709 Additionally, beta-blockers, long-acting nitrates, CCBs, 
ivabradine, ranolazine, trimetazidine, nicorandil, and their combinations 
should be considered in patients with HFpEF and CAD for angina relief, 
but without foreseen benefits on HF and coronary endpoints. 
Low-dose rivaroxaban may be considered in patients with CAD and 
HF, LVEF of >40%, and sinus rhythm when at high risk of stroke and 
with low haemorrhagic risk.526,903,904
Evidence and recommendations for myocardial revascularization in 
patients with HF are reported in Section 4.4.2. Notably, patients with 
advanced HF may be candidates for LV assistance devices and/or heart 
transplantation.526
During of high-risk PCI for complex CAD905 in patients with HFrEF, 
mechanical cardiac support, such as the microaxial flow pump, may min­
imize the risk of severe complications and provide haemodynamic stabil­
ity, facilitating the achievement of complete revascularization.906,907
Recommendation Table 24 — Recommendations for management of chronic coronary syndrome patients with chronic 
heart failure (see also Evidence Table 24)
Recommendations
Classa
Levelb
Managing CCS in heart failure patients
In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by 
CABG, taking into account the risk-to-benefit ratio of the procedures.54,729,749,908
I
B
In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or 
functional imaging is recommended.887
I
C
In HF patients with LVEF >35% and suspected CCS with very high (>85%) pre-test likelihood of obstructive CAD, ICA (with FFR, iFR, or 
QFR when needed) is recommended.887
I
C
Continued


<!-- PAGE 65 -->

### Page 65

5.2. Angina/ischaemia with 
non-obstructive coronary arteries
5.2.1. Definition
A large proportion of patients undergoing coronary angiography be­
cause of angina do not have obstructive epicardial coronary arteries 
(ANOCA). In these patients, the prevalence of demonstrable ischaemia 
(INOCA) varies, depending on the stress test performed, between 10% 
and 30% (Figure 12).926–928 Angina/ischaemia with non-obstructive cor­
onary arteries is more frequent among women (approximately 50% to 
70%) than in men (30% to 50%) referred for ICA.7,929 The mismatch 
between blood supply and myocardial oxygen demands leading to an­
gina and ischaemia in ANOCA/INOCA may be caused by CMD and/ 
or epicardial coronary artery spasm.36 However, these conditions are 
rarely correctly diagnosed, and, therefore, no tailored therapy is pre­
scribed for these patients. As a consequence, these patients continue 
to experience recurrent angina with poor QoL, leading to repeated 
hospitalizations, unnecessary repeat coronary angiography, and adverse 
cardiovascular outcomes in the short and long term.36
5.2.2. Angina/ischaemia with non-obstructive 
coronary arteries endotypes
Invasive functional coronary testing using Ach and adenosine in indivi­
duals suspected of CCS and with non-obstructive coronary arteries en­
ables the differentiation of the following endotypes: (i) endothelial 
dysfunction; (ii) impaired vasodilation (low coronary flow reserve and/ 
or high microvascular resistance); (iii) epicardial vasospastic angina; 
(iv) microvascular vasospastic angina; (v) endotype combinations; (vi) 
equivocal response, i.e. angina without fulfilling any endotype criteria.37,38
The prevalence of ANOCA and INOCA in relation to the presence of 
the endotypes is shown in Figure 12. Angina with non-obstructive cor­
onary arteries occurs in up to 70% of the patients undergoing ICA, of 
whom 25% have documented ischaemia (INOCA). Among the patients 
who are tested with Ach, 80% show endothelial dysfunction, 60% have 
MVA/VSA, and 50% have an impaired CFR and/or high microvascular 
resistance.38,927,930,931 This emphasizes the importance of testing not 
only patients with INOCA but also all patients with ANOCA to deter­
mine the final endotype so that appropriate treatment can be initiated.
In patients with HFpEF with persistent angina or equivalent symptoms and normal or non-obstructive epicardial coronary arteries, PET 
or CMR perfusion or invasive coronary functional testing should be considered to detect or rule out coronary microvascular 
dysfunction.883–885,887–889
IIa
B
In selected patients with HFrEF undergoing high-risk PCI for complex CAD, the use of a microaxial flow pump may be considered in 
experienced centres.905–907
IIb
C
Managing heart failure in CCS patients
It is recommended that CCS patients with HF be enrolled in a multidisciplinary HF management programme to reduce the risk of HF 
hospitalization and to improve survival.526,909–911
I
A
An ACE-I, an MRA, an SGLT2 inhibitor (dapagliflozin or empagliflozin), and, in stable conditions, a beta-blocker are recommended for CCS 
patients with HFrEF to reduce the risk of HF hospitalization and death.526,704,705,912,913
I
A
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with Heart Failure with mildly reduced Ejection Fraction 
(HFmrEF) or HFpEF to reduce the risk of HF hospitalization or cardiovascular death.706,707
I
A
An ARB is recommended in symptomatic patients with CCS and HFrEF unable to tolerate an ACE-I or ARNI to reduce the risk of HF 
hospitalization and cardiovascular death.914
I
B
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of HF 
hospitalization and of cardiovascular and all-cause death.693
I
B
Diuretics are recommended in CCS patients with HF and signs and/or symptoms of congestion to alleviate symptoms, improve exercise 
capacity, and reduce HF hospitalizations.915
I
B
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of 
ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimized medical treatment, 
provided they are expected to survive substantially longer than 1 year with good functional status.526,916
I
A
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular 
arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of 
reversible causes or unless the ventricular arrhythmia has occurred <48 h after an MI. 917–920
I
A
CRT is recommended for CCS patients with symptomatic HF, sinus rhythm, LVEF ≤35% despite GDMT, and a QRS duration ≥150 ms with 
an LBBB QRS morphology to improve symptoms and survival and to reduce morbidity.526,921,922
I
A
CRT rather than right ventricular pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an 
indication for ventricular pacing for high-degree AV block in order to reduce morbidity. This includes patients with AF. 923–925
I
A
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic 
resonance; CRT, cardiac resynchronization therapy; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved 
ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICA, invasive coronary angiography; ICD, implantable cardioverter defibrillator; iFR, instantaneous wave-free ratio; 
LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; PET, positron emission tomography; SGLT2, sodium–glucose cotransporter 2. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3479


<!-- PAGE 66 -->

### Page 66

5.2.2.1. Microvascular angina
Microvascular angina is the clinical manifestation of myocardial ischaemia 
caused by structural or functional changes in the coronary microvascula­
ture (leading to impaired CFR and/or reduced microcirculatory conduct­
ance) and/or abnormal vasoconstriction of coronary arterioles (causing 
dynamic arteriolar obstruction).932,933 Both vascular dysfunction me­
chanisms may co-exist and contribute to MVA.
The prevalence of MVA was 26% in a study of patients with 
non-obstructive CAD who had a CFVR below 2 when assessed by 
transthoracic Doppler echocardiography.934 Studies assessing CMD in­
vasively or by PET with different cut-offs have found that 39% to 54% 
had CMD.935,936 The threshold for CMD varies between studies and 
depending on the techniques used (PET, CMR, thermodilution, or 
Doppler); the threshold is a CFR of <2.0–2.5.36,39 A thermodilution 
CFR of <2.0 has low sensitivity for identifying CMD, but using the 
same threshold as for Doppler (<2.5) results in reasonable diagnostic 
accuracy.937
Smoking, age, diabetes, hypertension, and dyslipidaemia are associated 
with CMD.934,935,938 Other studies have shown that diabetes was un­
common among patients with angina and non-obstructive CAD, while 
hypertension and dyslipidaemia were relatively more prevalent.939,940
Inflammatory conditions such as systemic lupus erythematosus (SLE) 
and rheumatoid arthritis appear to be associated with MVA and are 
not infrequently encountered in patients with angina.941 Inflammatory 
diseases occur more often in women after menopause than in men, 
which may contribute to the sex differences in MVA.942–944 Last, but 
not least, there is increasing evidence that psychosocial stress is involved 
in coronary vasomotor disorders.945,946
Obstructive CAD
Coronary risk 
factors
Detectable demand ischaemia
INOCA
ANOCA
50–70%
30–50%
Ischaemiaª
Abnormal vasodilation
(CFR <2.5)
Vasospasm on Ach
Endothelial dysfunction
Non-obstructive or no apparent CAD
30–50%
50–70%
25%
50%
60%
80%
Figure 12 Prevalence of disease characteristics in patients with ANOCA/INOCA referred for invasive coronary functional testing. Ach, acetylcholine; 
ANOCA, angina with non-obstructive coronary arteries; CFR, coronary flow reserve; i.c., intracoronary; INOCA, ischaemia with non-obstructive cor­
onary arteries. In the ILIAS (Inclusive Invasive Physiological Assessment in Angina Syndromes) registry,927 ANOCA is present in up to 70% of patients 
referred for invasive coronary angiography and functional testing. Endothelial dysfunction is present in 80% and an acetylcholine test is positive in 60% of 
these patients. An impaired CFR (≤2.5), measured by i.c. Doppler guidewires, is present in 50%, while ischaemia (INOCA) is documented by non- 
invasive functional testing in only 25% of ANOCA patients. The prevalence of coronary vasospasm can vary in different studies depending on dose 
of acetylcholine and test protocol. aPrevalence of ischaemia by non-invasive functional testing increases from non-obstructive to obstructive CAD.


<!-- PAGE 67 -->

### Page 67

5.2.2.2. Epicardial vasospastic angina
Vasospastic angina is the clinical manifestation of myocardial ischaemia 
caused by abnormal vasoconstriction of one or more epicardial coron­
ary arteries leading to a dynamic coronary obstruction. Standardized 
diagnostic criteria for VSA have been defined.73 Microvascular angina 
and epicardial VSA can co-exist, which is associated with a worse prog­
nosis.947 Concomitant endothelial dysfunction is prevalent in most pa­
tients with INOCA with inducible coronary artery spasm and/or 
impaired adenosine-mediated vasodilation.38,948
The Japanese population has a higher prevalence of coronary vaso­
spasm than Western populations. In addition, the frequencies of mul­
tiple coronary spasms (≥2 spastic arteries) by provocative testing in 
Japanese (24.3%) and Taiwanese populations (19.3%) are markedly 
higher than those in Caucasians (7.5%).949–951
5.2.3. Clinical presentations
Angina/ischaemia with non-obstructive coronary arteries is associated 
with a wide variation in its clinical presentation, and symptom burden 
may vary over time. Failure to diagnose epicardial obstructive CAD in 
a patient with documented ischaemia should stimulate a subsequent 
search pathway to elucidate ANOCA/INOCA endotypes.
5.2.4. Short- and long-term prognosis
Symptoms of angina/ischaemia with non-obstructive coronary arteries 
are associated with adverse physical, mental, and social health.952
Angina/ischaemia with non-obstructive coronary arteries is associated 
with poor QoL, higher risk of disability, and a higher incidence of ad­
verse events, including mortality, morbidity, healthcare costs, recurrent 
hospital readmissions and repeat coronary angiograms.300,953–958 The 
incidence of all-cause death and non-fatal MI in patients with non- 
obstructive atherosclerosis was higher than in those with angiographi­
cally normal epicardial vessels.298,959–961 Proven myocardial ischaemia 
by stress echocardiography or nuclear imaging was associated with a 
higher incidence of events compared with ischaemia detected by exer­
cise electrocardiographic stress testing.958 There is a two- to four-fold 
higher risk of adverse cardiovascular outcomes in patients with MVA 
diagnosed by PET or transthoracic echocardiography and a two-fold 
higher risk in patients with epicardial endothelial-dependent dysfunc­
tion.300,962 Microvascular angina due to impaired CFR was associated 
with increased major adverse cardiac events and target-vessel failure 
rates over a 5-year follow-up period.931 Vasospastic angina is associated 
with major adverse events, including sudden cardiac death, acute MI, 
and syncope.963 In a group of ANOCA/INOCA patients, abnormal 
non-invasive testing did not allow the identification of patients with a 
higher risk of long-term cardiovascular events. However, adding intra­
coronary physiological assessment to non-invasive information allowed 
the identification of patient subgroups with up to a four-fold difference 
in long-term cardiovascular events.357
5.2.5. Diagnosis
The presence of myocardial ischaemia on functional imaging without 
obstructive CAD on CCTA or ICA should always raise the clinical sus­
picion of ANOCA/INOCA. The diagnosis of ANOCA/INOCA is exclu­
sively based on invasive functional evaluation of the coronary 
microcirculation, given that no technique allows direct visualization of 
the coronary microcirculation in vivo in humans. Several non-invasive 
and invasive tests have been established to assess the coronary micro­
vascular function (Figure 13).6,41,964,965
5.2.5.1. Non-invasive diagnosis
Non-invasive tests (stress echocardiography, PET, perfusion CCTA, and 
CMR) allow diagnosing ANOCA/INOCA by measuring the CFR.41
These techniques have an excellent negative predictive value, but the 
positive predictive value is an issue for most, as obstructive CAD needs 
to be ruled out before the diagnosis of CMD can be made. Only hybrid 
techniques such as CCTA with perfusion and PET-CT offer combined 
imaging of the epicardial coronary arteries and functional testing of the 
coronary microcirculation in a single test.6,964
5.2.5.2. Invasive coronary functional testing
Invasive coronary functional testing consists of a comprehensive 
evaluation of the coronary circulation in a single procedure by combin­
ing angiography, direct invasive assessment of the coronary haemo­
dynamics by intracoronary pressure and flow measurement either by 
thermodilution (bolus/continuous) or Doppler techniques, and 
pharmacological vasomotor testing. Recently, a standardized protocol 
has been proposed.36
5.2.5.2.1. Basic coronary functional testing. Intracoronary pressure 
and flow measurements allow assessment of the haemodynamic signifi­
cance of focal or diffuse coronary lesions by measuring FFR or iFR (see 
Section 3.3.3.2) and of microcirculatory function by measuring CFR and 
IMR, HMR, or MRR361,961 (see Section 3.3.3.3). Coronary microvascular 
dysfunction is characterized by decreased CFR and increased microvascu­
lar vascular resistance (IMR, HMR, MRR). Decreased CFR can be due to 
structural or functional microvascular dysfunction.926,966 Functional CMD 
is characterized by increased resting flow linked to enhanced nitric oxide 
synthase (NOS) activity, whereas patients with structural CMD have 
endothelial dysfunction, leading to a reduced increase of coronary blood 
flow during exercise.926,966
A Doppler-derived CFR of <2.5 in non-obstructive CAD indicates 
an abnormal microcirculatory response corresponding to a 
thermodilution-derived CFR of <2.5.361,926,937,961 Of note, in assessing 
coronary microvascular function, continuous thermodilution showed 
significantly less variability than bolus thermodilution on repeated mea­
surements.382 An increased IMR (≥25) indicates microvascular dysfunc­
tion.380,381 For the Doppler-derived HMR, a value of >2.5 mmHg/cm/s 
indicates augmented microvascular resistance.42 Recently, MRR has 
been considered abnormal for values <2.7.364,967 Doppler flow analysis 
allows assessment of the flow-recovery time after Ach administration 
as a sign of myocardial ischaemia, which is helpful in the diagnosis of pa­
tients with equivocal test results.968
5.2.5.2.2. Coronary vasomotor testing. Epicardial and microvascular 
endothelium-dependent vasodilation and vasospasm are tested by in­
tracoronary bolus administration or graded infusion of Ach, first at a 
low dose/grade to assess endothelial dysfunction at the microvascular 
or epicardial level, and after that at a higher dose/grade to eventually in­
duce microvascular or/and epicardial coronary vasospasm. The LAD ar­
tery is usually preferred as the pre-specified target vessel reflecting its 
subtended myocardial mass and coronary dominance. The left circum­
flex coronary artery is also tested if Ach is administered in the LMCA. 
Additional studies in the right coronary artery may be appropriate if the 
initial tests are negative and clinical suspicion is high. As Ach exerts a 
cholinergic effect on the atrioventricular node, significant bradycardia 
may ensue if infused especially in the right coronary artery or a domin­
ant left circumflex coronary artery. Bradycardia can be prevented by se­
lective infusion in the LAD, prophylactic ventricular pacing, or reduction 
of the concentration infused or of the injected dose. If necessary, the 
ESC Guidelines                                                                                                                                                                                          3481


<!-- PAGE 68 -->

### Page 68

bradycardia effect of Ach can be antagonized by atropine. The effect of 
Ach is short in contrast to the prolonged effect of ergonovine, which 
was previously used for the provocation of coronary vasospasm.969
The diagnosis of MVA and VSA due to microvascular or macrovascular 
vasospasm is made according to established criteria.41,73,932 The test is 
considered positive for macrovascular spasm if symptoms occur, 
accompanied by ischaemic ECG changes and an angiographic ≥90% re­
duction of the coronary lumen. If the lumen reduction is <90%, the diag­
nosis of microvascular spasm is made. The vasospastic effect of Ach is 
rapidly transient and can, if needed, be reversed by intracoronary admin­
istration of nitroglycerine, which also allows assessment of 
endothelium-independent epicardial coronary vasodilation. The safety 
CCS likely
ANOCA/INOCA
Initial clinical evaluation
History including risk factors
Exclude non-cardiac symptoms
Physical exam
ECG
Functional imaging 
(PET, MRI, stress echo, SPECT)
Coronary microvascular dysfunction and/or
Myocardial ischaemia and
Further cardiac evaluation
Treat for ANOCA-INOCA and evaluate symptoms
Invasive coronary functional testing if persisting symptoms
Sequential testing (in any order):
FFR, iFR: distal pressure drop ~ focal or diffuse epicardial atherosclerosis?
Anatomical imaging (CCTA)
Endotheliumindependent
Endotheliumdependent
Adenosine
CFR <2.5
IMR >25
HMR >2.5
Ach
Low dose
2–20 µg i.c.
Abnormal vasodilation?
Epicardial
Microvascular
Ach
High dose
100–200 µg i.c.
Ach
High dose
100–200 µg i.c.
Abnormal vasoconstriction?
No apparent or non-obstructive CAD
[Obstructive CAD    GDMT ± ICA]
Figure 13 Diagnostic algorithm for patients with angina/ischaemia with non-obstructive coronary arteries. Ach, acetylcholine; ANOCA, angina with 
non-obstructive coronary arteries; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiog­
raphy; CFR, coronary flow reserve; ECG, electrocardiogram; echo, echocardiography; FFR, fractional flow reserve; GDMT, guideline-directed medical 
therapy; HMR, hyperaemic myocardial velocity resistance; i.c., intracoronary; ICA, invasive coronary angiography; iFR, instantaneous-wave free ratio; 
IMR, index of microcirculatory resistance; INOCA, ischaemia with non-obstructive coronary arteries; MRI, magnetic resonance imaging; PET, positron 
emission tomography; SPECT, single-photon emission  computed tomography.


<!-- PAGE 69 -->

### Page 69

of coronary vasospasm provocation testing with increasing intracoronary 
Ach boluses of up to a maximum of 200 μg has been repeatedly re­
ported.37,970,971 In a small study, testing coronary vasospasm using this al­
gorithm was also safe in patients with a recent ACS.972
At the end of the procedure, microcirculatory vasomotor response 
to i.v. administration of the endothelium-independent vasodilator ad­
enosine973 is assessed and CFR, IMR, HMR, or MRR are measured. In 
patients with contraindications to the use of adenosine, papaverine 
can be used974 but precautionary measures need to be taken given 
the risk of inducing polymorphic ventricular tachycardia.975,976
Different protocols have been applied in clinical practice. Figure 14
shows an example of a standardized and stepwise algorithm for ICFT 
that may be adopted in the cardiac catheterization laboratory for diag­
nosing vasospasm. Informed consent should be obtained, mentioning 
unlicensed, parenteral use of Ach, and administration performed by 
an experienced interventional cardiologist.
5.2.6. Management of angina/ischaemia with 
non-obstructive coronary arteries
Management should be patient-centred with a patient-oriented multi­
disciplinary care approach.977 Figure 15 provides an algorithm for the 
therapeutic management of ANOCA/INOCA. In all patients with es­
tablished ANOCA/INOCA due to the frequent presence of coronary 
atherosclerosis and endothelial dysfunction, tailored counselling on life­
style factors is warranted to address risk factors, reduce symptoms, and 
improve QoL and prognosis. Management of traditional CVD risk fac­
tors, hypertension, dyslipidaemia, smoking, and diabetes should be as 
per clinical practice guidelines recommendations.
Treatment of anginal symptoms in patients with ANOCA/INOCA is 
challenging as the patients represent a heterogeneous group and rando­
mized trials are lacking. A small study showed that a stratified antianginal 
therapy algorithm based on coronary functional testing resulted in im­
proved angina symptoms and QoL compared with a control group 
treated with standard therapy.978 In patients with MVA and reduced 
CFR and/or increased IMR (which may reflect arteriolar remodelling), 
beta-blockers, CCBs, ranolazine, and ACE-Is are used.979 In these pa­
tients, anti-ischaemic therapy with amlodipine or ranolazine resulted 
in a significant improvement in exercise time.980 In patients with either 
epicardial or microvascular spasm following Ach testing, calcium an­
tagonists should be considered as first-line therapy. In patients with se­
vere VSA, it may be necessary to administer unusually high dosages of 
calcium antagonist (2 × 200 mg diltiazem daily or higher up to 960 mg 
daily) or even a combination of non-dihydropyridine (such as diltiazem) 
with dihydropyridine calcium blockers (such as amlodipine). Of note, a 
small study using either oral diltiazem or placebo up to 360 mg/day in 
CMD for 6 weeks did not substantially improve symptoms or QoL, 
but diltiazem therapy did reduce the prevalence of epicardial spasm.981
Nicorandil, a combinatorial vasodilator agent acting via nitrate- and 
potassium-channel activation, may be an effective alternative, although 
side effects are frequent.982 First-line therapy can also be combined 
Ach 2 µga i.c. 
over 60 s
Ach 20 µga i.c.
over 60 s
Ach 100 µga i.c.
over 60 s
Ach 200 µga i.c. 
over 60 s
Adenosine
200 µg i.c.b
Continuous Doppler flow monitoring,12-lead ECG and symptom monitoring
Ach testing performed after at least 24 hours of washout from CCB and nitrates
Repeat angiogram after each dose
NTG
200 µg i.c. 
Final angiogram
Baseline angiogram
CFR / MR
Ach- and adenosine-based vasoreactivity protocol 
Figure 14 Spasm provocation and functional testing protocol. Ach, acetylcholine; CCB, calcium channel blocker; CFR, coronary flow reserve; ECG, 
electrocardiogram; i.c., intracoronary; i.v., intravenous; MR, microvascular resistance; NTG, nitroglycerine. i.c. bolus injections of Ach over 60s to assess: 
(i) endothelial-dependent vasodilation using low-dose Ach (2–20 µg), and (ii) endothelial dysfunction and vasoconstriction using high-dose Ach 
(100–200 µg). This is followed by i.c. administration of nitroglycerine (200 µg) to revert vasospasm. Endothelial-independent vasodilation is assessed 
by i.c. adenosine (200 µg) or i.v. infusion to determine CFR and IMR. Coronary flow can be continuously monitored if i.c. Doppler guidewires are used. 
aThe incremental administration of Ach is stopped whenever a coronary vasospasm is induced. bi.v. adenosine can also be used.
ESC Guidelines                                                                                                                                                                                          3483


<!-- PAGE 70 -->

### Page 70

with ranolazine, an antianginal agent that improves myocyte relaxation 
and ventricular compliance by decreasing sodium and calcium over­
load.983 Spinal cord stimulation is an option for patients who remain re­
fractory after medical therapy.984
There are currently several studies evaluating therapies specific to 
ANOCA/INOCA. The Women’s IschemiA Trial to Reduce Events in 
Non-ObstRuctIve 
CORonary 
Artery 
Disease 
(WARRIOR, 
NCT03417388) is currently enrolling subjects in a multicentre, 
prospective, randomized, blinded outcome evaluation to assess inten­
sive statin and ACE-I/ARB therapy (ischaemia-intensive medical ther­
apy) vs. usual care on MACE in symptomatic women with ANOCA. 
The Precision Medicine with Zibotentan in Microvascular Angina 
(PRIZE) trial holds future promise (NCT04097314). Zibotentan is an 
oral, endothelin A receptor antagonist that may provide benefit by 
opposing the reported vasoconstrictor response of coronary micro­
vessels to endothelin.
Endothelial dysfunction and co-existing atherosclerosis
Nutrition
Exercise
Coping with stress
Hypertension
Dyslipidaemia
Diabetes mellitus
2
3
Weight management
Smoking cessation
Consider statins and ACEi
Abnormal vasodilation
Microvascular
Abnormal vasoconstriction
Microvascular
Epicardial
1
Medical treatment based on pathophysiological endotypes
Lifestyle
Risk factors
Treatment of ANOCA/INOCA
CCB
Nitrates
Nicorandil
CCB
2nd CCB
Nitrates
Beta-blocker
CCB
Ranolazine
Trimetazidine
Ivabradine
Figure 15 Treatment of angina/ischaemia with non-obstructive coronary arteries. ACE-I, angiotensin-converting enzyme inhibitor; ANOCA, angina 
with non-obstructive coronary arteries; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; INOCA, ischaemia with non-obstructive 
coronary arteries. Treatment of ANOCA/INOCA patients includes lifestyle modification, management of cardiovascular risk factors, and antianginal 
treatment according to underlying endotypes. Note: endotypes frequently overlap, requiring combined medical therapy.


<!-- PAGE 71 -->

### Page 71

5.3. Other specific patient groups
5.3.1. Older adults
Between 2015 and 2050, the proportion of the world’s population 
aged >60 years is set to nearly double to 22%. Ageing predisposes 
patients to a high incidence and prevalence of CAD, in both men 
and women. Typically, in the context of CVD, older patients are de­
fined as those ≥75 years of age;1 it should be noted, however, that 
such age cut-offs are relatively arbitrary, and biological age influences 
this threshold in clinical practice. Clinical characteristics of the older 
adult population are heterogeneous, with frailty, comorbidity, cogni­
tive function, and health-related QoL playing important roles in guid­
ing clinical care and as predictors of adverse outcomes.1001–1005
Older patients often present with symptoms other than angina, 
which may delay the diagnosis of CCS.1004
Ageing is often accompanied by both comorbidities and frailty, and 
consequently leads to potentially excessive polypharmacy.531 In mak­
ing treatment decisions, clinicians should take into account the lim­
ited external validity of RCTs for older adults.36 Older people are 
often underrepresented in RCTs as a consequence of exclusion cri­
teria and under-recruitment,531,1006,1007 though they have been 
shown to have a higher underlying risk for cardiovascular out­
comes.1008 The treatment of CCS in older adults is complicated by 
a higher vulnerability to complications for both conservative and in­
vasive strategies, such as bleeding, renal failure, and neurological im­
pairments, all of which require special attention. The use of DES, 
compared with bare-metal stents, in combination with a short dur­
ation of DAPT, is associated with significant safety and efficacy ben­
efits in older adults.1009 Frailty is of utmost importance in the clinical 
decision-making.1010
5.3.2. Sex differences in chronic coronary syndromes
Ischaemic heart disease is the leading cause of mortality for women, yet 
they have been historically underrepresented in RCTs.1011–1013
Differences in symptom presentation, in the accuracy of diagnostic tests 
for obstructive CAD, and other factors that lead to differential triage, 
evaluation, or early treatment of women with myocardial ischaemia 
Recommendation Table 25 — Recommendations for 
diagnosis and management of patients with angina/ 
ischaemia with non-obstructive coronary arteries (see 
also Evidence Table 25)
Recommendations
Classa
Levelb
Diagnosis of ANOCA/INOCA endotypes
In persistently symptomatic patients despite 
medical treatment with suspected ANOCA/ 
INOCA (i.e. anginal symptoms with normal 
coronary arteries or non-obstructive lesions at 
non-invasive imaging, or intermediate stenoses with 
normal FFR/iFR at coronary arteriography) and 
poor quality of life, invasive coronary functional 
testing is recommended to identify potentially 
treatable endotypes and to improve symptoms and 
quality of life, considering patient choices and 
preferences.36,37,298,930,939,985
I
B
In persistently symptomatic patients with 
documented or suspected ANOCA/INOCA, 
transthoracic Doppler of the LAD, stress 
echocardiography, CMR, and PET may be 
considered for the non-invasive assessment 
of coronary/myocardial flow reserve.44,231,233– 
235,300,986,987
IIb
B
Diagnostic tests for vasospastic angina
In individuals with suspected vasospastic angina, a 
resting 12-lead ECG recording during angina is 
recommended.
I
C
In patients with suspected vasospastic angina and 
repetitive episodes of rest angina associated with 
ST-segment changes that resolve with nitrates and/or 
calcium antagonists, invasive coronary functional 
testing is recommended to confirm the diagnosis and 
to determine the severity of underlying 
atherosclerotic disease.
I
C
In individuals with suspected vasospastic angina and 
frequent symptoms, ambulatory ST-segment 
monitoring should be considered to identify 
ST-segment deviation during angina.192–194
IIa
B
Management of ANOCA/INOCA
In symptomatic patients with ANOCA/INOCA, 
medical therapy based on coronary functional test 
results should be considered to improve symptoms 
and quality of life.298,977
IIa
A
For the management of endothelial dysfunction, 
ACE-I should be considered for symptom 
control.988
IIa
B
For the management of microvascular angina 
associated with reduced coronary/myocardial blood 
flow reserve, antianginal medications aiming at 
preventing demand myocardial ischaemia should be 
considered for symptom control.989,990
IIa
B
Continued 
For the treatment of isolated vasospastic angina
Calcium channel blockers are recommended to 
control symptoms and to prevent ischaemia and 
potentially fatal complications.991–996
I
A
Nitrates should be considered to prevent recurrent 
episodes.993,997,998
IIa
B
For the treatment of overlapping endotypes
In patients with evidence of overlapping endotypes, 
combination therapy with nitrates, calcium channel 
blockers, and other vasodilators may be 
considered.999,1000
IIb
B
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ANOCA, angina with non-obstructive 
coronary arteries; CMR, cardiac magnetic resonance; ECG, electrocardiogram; FFR, 
fractional flow reserve; iFR, instantaneous wave-free ratio; INOCA, ischaemia with 
non-obstructive coronary arteries; LAD, left anterior descending; PET, positron emission 
tomography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3485


<!-- PAGE 72 -->

### Page 72

compared with men could contribute to unfavourable outcomes. There 
are also risk factors that are unique to women.1014,1015 Not only prema­
ture menopause,1016 but also hypertensive disorders of pregnancy, 
pre-term delivery, gestational diabetes, small-for-gestational-age delivery, 
placental abruption, and pregnancy loss are predictors of subsequent 
CVD.1017 Also, the association between low socioeconomic status and 
increased cardiovascular risk seems stronger in women.1018 In addition, 
higher levels of residential segregation are associated with incident 
CVD and obesity among black women.1019
Women are less likely to be referred for diagnostic testing and are 
under-treated for essential secondary prevention therapies.1020
Compared with men, women have a shorter survival after PCI1021
and CABG.1022 In a large-scale, individual-patient data pooled analysis 
of contemporary PCI trials with early and new-generation DES, women 
had a higher risk of MACE and ischaemia-driven target-lesion revascu­
larization compared with men at 5 years following PCI.1021 However, 
the excess risk after PCI among women can be primarily explained 
by a greater burden of cardiovascular risk factors and comorbid condi­
tions.1023 Nevertheless, in a population undergoing contemporary PCI, 
women and men had similar risks of death or new Q-wave MI at 2 years, 
but women faced a higher risk of bleeding and haemorrhagic stroke 
compared with men.1024
Women with signs and symptoms suggestive of cardiac ischaemia 
should be investigated carefully. The same guideline-recommended car­
diovascular preventive therapy should be provided to women and 
men.1025 Hormone replacement therapy in post-menopausal women 
does not reduce the risk of ischaemic myocardial disease1015 and it 
may come at the cost of other health risks,1026 which should be dis­
cussed with the patient.
5.3.3. High bleeding-risk patients
An HBR is increasingly present in many CCS patients referred for cor­
onary revascularization. The ARC-HBR consortium provided a consist­
ent definition of HBR for patients undergoing PCI. Patients are 
considered at HBR if at least one major or two minor criteria are 
met.590 In the context of PCI in HBR patients, short duration of 
DAPT (1–3 months) and PCI with a DES was beneficial in many recent 
studies.1009,1027–1032
5.3.4. Inflammatory rheumatic diseases
Patients with inflammatory rheumatic diseases have an increased risk of 
CVD compared with the general population.1033,1034 Accumulating evi­
dence has shown elevated cardiovascular morbidity and mortality in 
other rheumatic and musculoskeletal diseases, including gout, vasculitis, 
systemic sclerosis, myositis, mixed connective tissue disease, Sjögren 
syndrome, SLE, and the antiphospholipid syndrome.1035–1044
Some of these patient categories have two- to three-fold higher pre­
valences of asymptomatic ASCVD compared with the general popula­
tion,1045–1051 which is linked to ASCVD outcomes.1049,1052–1054 Thus, 
identification of ASCVD such as carotid artery plaque(s) may be consid­
ered in ASCVD and CAD risk evaluation.1050,1055–1057
In patients with inflammatory rheumatic diseases and CCS, CVD 
preventive medications such as lipid-lowering medications and antihy­
pertensive treatment should be used as in the general popula­
tion.1058–1062
5.3.5. Hypertension
Blood pressure lowering has been associated with favourable cardio­
vascular outcomes in patients regardless of the presence of CAD.1063
Due to concerns of a possible J-curve relationship between achieved 
BP and cardiovascular outcomes in patients with CAD, previous guide­
lines did not recommend a target BP of <120/70 mmHg. In line with the 
2024 ESC Hypertension Guidelines1064, the present guidelines recom­
mend that treated systolic BP values in most CCS patients be targeted 
to 120–129 mmHg, provided the treatment is well tolerated. In cases 
where on-treatment systolic BP is at or below target (120–129 
mmHg) but diastolic BP is not at target (≥80 mmHg), intensifying 
BP-lowering treatment to achieve an on-treatment diastolic BP of 
70–79 mmHg may be considered to reduce CVD risk.1065 More leni­
ent targets (e.g. 140/90 mmHg) can be considered in older patients 
(≥85 years of age) or patients with pre-treatment symptomatic 
orthostatic hypotension. In hypertensive patients with a history of 
MI, beta-blockers and RAS blockers are first-line treatments. In 
patients with symptomatic angina, beta-blockers and/or CCBs can 
be useful.1065
5.3.6. Atrial fibrillation
Diagnostic assessment of CAD (CCTA and non-invasive tests) may be 
difficult in AF with a high ventricular rate. In patients with CAD and AF, 
rhythm or rate control strategies may help improve symptoms of myo­
cardial ischaemia. Amiodarone or dronedarone are drugs of choice for 
rhythm control, as an alternative to catheter ablation, in patients with 
CAD and AF. Sotalol may also be considered. Beta-blockers, diltiazem, 
verapamil, or digoxin can be used for rate control depending on the 
LVEF.613 After PCI, combined anticoagulant and antiplatelet therapies 
are needed. Recommendations on post-PCI antithrombotic therapy 
in patients with AF and indication for OAC are detailed in Section 
4.3.1.2.2 and Recommendation Table 17.613,621,659 Surgical ablation of 
AF during isolated CABG seems to be safe and effective in improving 
long-term outcomes.1066 Concomitant surgical closure of the left atrial 
appendage is recommended as an adjunct to oral anticoagulation in 
patients with AF undergoing cardiac surgery (e.g. CABG) to prevent is­
chaemic stroke and thrombo-embolism (see the ESC 2024 Guidelines 
for the management of Atrial Fibrillation).1067
5.3.7. Valvular heart disease
In patients with valvular heart disease with a risk for associated CAD 
who require surgery or in whom a decision of a percutaneous or sur­
gical approach is still pending, ICA or CCTA is recommended to deter­
mine the need for coronary revascularization.1068 Evidence of CAD in 
patients with valvular heart disease can drive to a surgical instead of a 
percutaneous treatment of valvular heart disease. Invasive coronary 
angiography is recommended in patients with secondary mitral regur­
gitation as this condition is frequently due to ischaemic LV dysfunc­
tion.1068 Routine stress testing to detect CAD associated with severe 
symptomatic valvular heart disease is not recommended because of 
low diagnostic value and potential risk. The usefulness of FFR or iFR 
in patients with valvular heart disease is not well established, and cau­
tion is warranted in interpreting these measurements, especially in 
the presence of aortic stenosis.1068 Beta-blockers need to be used 
with caution in patients with aortic valve disease. Coronary artery by­
pass grafting is recommended in patients with a primary indication for 
aortic/mitral/tricuspid valve surgery and significant coronary stenosis. 
Percutaneous coronary intervention should be considered in patients 
with a primary indication of transcatheter aortic valve implantation 
or transcatheter mitral valve intervention and coronary artery diameter 
stenosis of >70% in proximal segments.1068


<!-- PAGE 73 -->

### Page 73

5.3.8. Chronic kidney disease
Chronic kidney disease increases the risk of CAD progression and is as­
sociated with high mortality rates due to cardiovascular causes.1069,1070
Patients with CKD have a higher burden of atherosclerosis and more 
advanced plaque features.1070 Despite the higher prevalence of disease, 
non-invasive diagnostic testing is often less accurate, and guidance re­
lated to the use of pharmacological and interventional therapy is limited 
due to inconsistent definitions of CKD and underrepresentation of 
CKD patients in clinical trials.1070–1072
Careful assessment of the risk-to-benefit ratio is needed in patients 
with CKD before considering ICA, CCTA, or non-invasive tests requir­
ing nephrotoxic agents.1073 Pre-existing CKD is the primary patient- 
related risk factor for the development of acute kidney injury (AKI), 
whereas DM increases the susceptibility to develop AKI. The most im­
portant measures to prevent AKI are using the lowest necessary total 
dose of low-osmolality or iso-osmolality contrast medium and suffi­
cient pre- and post-hydration.1073
CKD raises the risks associated with both CABG and PCI.316 The 
ISCHEMIA-CKD trial included patients with advanced CKD [estimated 
glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 or dialysis] 
and CCS with moderate or severe myocardial ischaemia detected by 
stress test. An invasive strategy of ICA and PCI was not superior to con­
servative management in reducing the primary endpoint of death or 
non-fatal MI.1074
In a propensity score-matched analysis involving 5920 CKD patients 
(2960 pairs), PCI utilizing second-generation DES displayed a reduced 
risk of death, stroke, and repeat revascularization at 30 days when com­
pared with CABG.1075 However, PCI was associated with a higher risk 
of repeat revascularization over the long term. Conversely, among pa­
tients on dialysis, the findings favoured CABG over PCI. Additionally, a 
meta-analysis of 11 registries revealed lower rates of death, MI, and re­
peat revascularization with CABG in contrast to PCI among patients 
with eGFR of <60 mL/min/1.73 m².1076 Nevertheless, there is a notable 
absence of large RCTs comparing revascularization modalities among 
CKD patients.
5.3.9. Cancer
Several cancer treatments are associated with an increased risk of CCS. 
Spontaneous bleeding in ACS and CCS patients has been associated 
with subsequent cancer diagnosis.1077 A prompt evaluation of bleeding 
may be useful to enable an early detection of cancer. The management 
of CCS is similar in patients with and without cancer. However, deci­
sions regarding coronary revascularization should be undertaken by a 
multidisciplinary team. The approach should be individualized and based 
on life expectancy, additional comorbidities such as thrombocyto­
paenia, increased thrombosis, or bleeding risk, and potential interac­
tions between drugs used in CCS management and anticancer 
therapy.1078,1079
5.3.10. Optimal treatment of patients with human 
immunodeficiency virus
Patients with human immunodeficiency virus (HIV) have longer life expect­
ancy than before due to effective antiretroviral therapy (ART), but are 
twice as likely to develop CVD compared with the general population.1080
The long-term CVD outcomes in patients with HIV may change, given the 
relatively recent epidemiological transition of HIV to a chronic disease. 
Dyslipidaemia is a common condition in patients with HIV, whether trea­
ted or untreated with ART.1081 The treatment of dyslipidaemia in patients 
with HIV includes both non-pharmacological and pharmacological options. 
Special attention to the impact of polypharmacy, drug interactions be­
tween ART and lipid-lowering medications, and close monitoring for ad­
verse events is critical to successfully managing dyslipidaemia and risk of 
CVD in patients with HIV. Hepatic cytochrome P450 3A4 (CYP3A4) me­
tabolizes many statins; many ARTs are also metabolized by CYP3A4 and, 
thus, may have interactions with statins. Simvastatin and lovastatin are con­
traindicated with protease inhibitors; atorvastatin has less of a CYP3A4 
interaction; pravastatin, fluvastatin, pitavastatin and rosuvastatin are not 
or minimally metabolized through CYP3A4.1082,1083 Ezetimibe has no in­
teractions with CYP3A4 or ART.1081
A clinical trial investigating the impact of PCSK9 inhibitor therapy on 
lipids, inflammatory markers, and subclinical ASCVD (including non- 
calcified plaque and arterial inflammation) in HIV is currently being con­
ducted [EPIC-HIV study (Effect of PCSK9 Inhibition on Cardiovascular 
Risk in Treated HIV Infection), NCT03207945]. Future studies are 
needed to evaluate the impact of PCSK9 inhibition on clinical events 
in HIV.
5.3.11. Socially and geographically diverse groups
A lower socioeconomic status has implications of increased CVD mor­
tality1084 and poorer CVD risk factor profiles.1085 A multicohort study 
of 1.7 million adults followed up for any cause of death for an average of 
13 years found that low socioeconomic status was associated with a 
2.1-year reduction in life expectancy between the ages 40 and 85 
years.1086 Education level, occupation, household income, health, dis­
ability, and living conditions also contribute to socioeconomic status. 
There were different rates of decline in mortality from CVD in 
Europe between the most and the least deprived.1087 It has been pro­
posed that on this basis, CVD could become a disease prevalently of the 
lower socioeconomic groups by the mid-2020s.1088
Black patients with diabetes have a higher hospitalization burden 
with a concomitant disparity in comorbid presentation and outcome 
compared with other patients with diabetes.1089 South Asian ethnicity, 
even after adjustment for traditional risk factors, is associated with an 
increased risk of coronary heart disease outcomes. This risk was great­
er than other studied racial/ethnic groups and second only to diabetes 
in coronary heart disease risk prediction.1090
Within a large prospective study, South Asian individuals had a 
substantially higher risk of ASCVD than individuals of European 
ancestry.1091 South Asians have a more diffuse pattern with multives­
sel involvement. However, less is known about other morphological 
characteristics, such as atherosclerotic plaque composition and 
coronary diameter in South Asian populations. Despite a similar cor­
onary calcification burden, higher non-calcified plaque contribution, 
elevated thrombosis, and inflammatory markers likely contribute to 
the disease pattern. Although the current evidence on the role of cor­
onary vessel size remains inconsistent, smaller diameters in South 
Asians could play a potential role in the higher disease prevalence.1092
Individuals of South Asian descent have a high prevalence of CYP2C19 
loss-of-function alleles (poor metabolizers: 13% vs. 2.4% in European 
populations),1093 which are associated with reduced efficacy of 
clopidogrel.
ESC Guidelines                                                                                                                                                                                          3487


<!-- PAGE 74 -->

### Page 74

5.4. Screening for coronary artery disease 
in asymptomatic individuals
Presence of asymptomatic atherosclerotic CAD is common in the gen­
eral population.1097–1100 In the Swedish Cardiopulmonary Bioimage 
Study, CCTA was performed in randomly selected individuals from 
the general population.1097 In the 25 182 individuals without known 
CAD, atherosclerotic plaque was present in 42% of participants. 
Plaque was more common in older individuals and in males (males 
50–54 vs. 60–64 years old: 41% vs. 69%, and females 50–54 vs. 
60–64 years old: 19% vs. 40%). Obstructive coronary stenosis was pre­
sent in 5% of participants. In the PESA study (Progression of Early 
Subclinical Atherosclerosis), 63% of asymptomatic middle-aged partici­
pants had subclinical atherosclerosis,157 although most of them were 
categorized as low-risk individuals by several risk scores.142
The risk of adverse events in asymptomatic subjects can be estimated 
using the European risk-estimation system [Systematic Coronary Risk 
Estimation 2 (SCORE2)], described in the 2021 ESC Guidelines on car­
diovascular disease prevention in clinical practice.16,1101 Systematic 
screening of risk factors cannot be strongly recommended in the general 
population as it did not affect CVD outcomes.1102 However, when pa­
tients are seen for other reasons, opportunistic screening is effective at 
increasing detection rates of CVD risk factors, such as high BP or lipids. 
Hence, opportunistic screening is recommended, although its beneficial 
effect on clinical outcomes remains uncertain.1103
Information on CAC can be used to guide risk-factor management, and 
initiate lipid-lowering and antithrombotic treatment in patients with esti­
mated future risk around treatment decision thresholds.1104 To date, two 
randomized screening studies have indicated that statin therapy impacts 
outcomes when guided by CACS in younger patients with high 
CACS.1105,1106 Coronary artery calcium score could potentially guide 
not only risk-factor management but also primary prophylaxis with as­
pirin, but randomized studies are lacking.1107 Importantly, opportunistic 
screening of the burden of calcified atherosclerotic CAD can be accurate­
ly accessed with non-ECG-gated chest CT performed for other rea­
sons.17,1108 Reporting the visual interpretation of the coronary plaque 
burden according to a simple score with four categories (none, mild, 
moderate, severe) is recommended.1108–1110 However, there is no 
current evidence to support further diagnostic imaging in asymptomatic 
individuals on the basis of presence of calcified plaque alone.
Carotid ultrasound,1111 aortic pulse wave velocity, arterial augmen­
tation index, and ankle–brachial index are other modalities to improve 
the prediction of future CVD events. However, evidence is less exten­
sive for these modalities compared with CACS.
Recommendation Table 26 — Recommendations for 
older, female, high bleeding risk, comorbid, and socially/ 
geographically diverse patients (see also Evidence 
Table 26)
Recommendations
Classa
Levelb
Older adults
In older adults (≥75 years), particular attention to 
drug side effects, intolerance, drug–drug interactions, 
overdosing, and procedural complications is 
recommended.
I
C
In older, as in younger, individuals, diagnostic and 
revascularization decisions based on symptoms, 
extent of ischaemia, frailty, life expectancy, 
comorbidities, and patient preferences are 
recommended.
I
C
Sex
Similar guideline-directed cardiovascular preventive 
therapy is recommended in women and men.
I
C
Systemic post-menopausal hormone therapy is not 
recommended in women with CCS, given the lack of 
cardiovascular benefit and an increased risk of 
thrombo-embolic complications.1026,1094,1095
III
A
High bleeding risk
Bleeding risk assessment is recommended using the 
PRECISE-DAPT score, the qualitative ARC-HBR tool 
or other, validated methods.589,590
I
B
HIV
Attention to interaction between antiretroviral 
treatment and statins is recommended in patients 
with HIV.1096
I
B
Socioeconomic, geographical, and under-investigated groups
Continued targeted efforts are recommended: 
• to increase delivery of safe and effective cardiac 
care to all CCS patients, especially those of lower 
socioeconomic classes; and
• to enhance inclusion in future clinical trials of 
geographical, social, or other groups that are 
currently underrepresented.
I
C
© ESC 2024
ARC-HBR, Academic Research Consortium for High Bleeding Risk; CCS, chronic coronary 
syndrome; HIV, human immunodeficiency virus; PRECISE-DAPT, PREdicting bleeding 
Complications In patients undergoing Stent implantation and subsEquent Dual 
AntiPlatelet Therapy. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 27 — Recommendations for 
screening for coronary artery disease in asymptomatic 
individuals (see also Evidence Table 27)
Recommendations
Classa
Levelb
Opportunistic screening of healthy individuals for 
cardiovascular risk factors and to estimate the risk of 
future cardiovascular events using scoring systems, 
e.g. SCORE2 and SCORE-OP, is recommended to 
detect individuals at high risk and guide treatment 
decisions.16,1101,1112
I
C
When coronary artery calcification findings are 
available from previous chest CT scans, using these 
findings to enhance risk stratification and guide 
treatment of modifiable risk factors should be 
considered.17,1108–1110
IIa
C
CACS may be considered to improve risk classification 
around treatment decision thresholds.1104–1106
IIb
C
An ultrasound of the carotid arteries may be 
considered as an alternative when CACS is 
unavailable or not feasible to detect atherosclerotic 
disease and to improve risk classification around 
treatment decision thresholds.1111
IIb
B
© ESC 2024
CACS, coronary artery calcium scoring; CT, computed tomography; SCORE2, Systematic 
Coronary Risk Estimation 2; SCORE-OP, Systematic Coronary Risk Estimation 2–Older 
Persons. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 75 -->

### Page 75

### 6 Long-term follow-up and care

6.1. Voice of the patient
A diagnosis of CCS can have an impact on self-identity, lifestyle, employ­
ment, and cause anxiety, depression, and burdensome treatment. 
Patients are experts in their own conditions, and their voices and pre­
ferences are integral to decisions about treatment. Health outcomes 
improve with better patient involvement, and shared decision-making 
is central to future patient care.1113
6.1.1. Communication
Communication is essential to support patients’ understanding, adher­
ence, and engagement in decision-making.1114 Good communication 
requires providing information at an appropriate level, active listening, 
assessing patient understanding, and determining patient perspectives 
and priorities. A meta-analysis summarizing a total of 127 studies of 
communication training concluded that patients were 19% more likely 
to be non-adherent when physicians had poor communication, and 
12% more likely to be non-adherent when their physicians had not 
received communication training.1115 Communication and shared 
decision-making can be particularly challenging when patients have co­
morbidities, low health literacy, language differences, cognitive impair­
ment, depression, or anxiety, and when evidence for treatment is less 
robust.
Patient reported outcome measures can be useful to improve as­
sessment and communication of symptoms, function, and QoL, and 
can highlight problems that may not have been previously discussed. 
Under- and overestimation of symptoms can lead to a lack of or in­
appropriate treatment.1116,1117 The routine use of PROMs in clinical 
practice is hampered by the challenge of interpretation of scores and 
their integration into routine clinical processes.1116
Although quality of communication can be improved through train­
ing, meta-analyses have not found evidence of significant impact on out­
comes such as physical or mental health, satisfaction, QoL, or specific 
risk factors in patients with cancer, diabetes, and hyperten­
sion.1115,1118,1119 Structured tools and a flexible range of resources (in­
cluding videos, workbooks, and health-literacy materials) that provide 
individualized information and decision aids can be adjuncts to better 
communication and shared decision-making.443 A systematic review 
of 17 RCTs of tools to support decision-making in severe illness con­
cluded that they improved patient knowledge and readiness to make 
decisions.1120
Communicating the risk of future CVD events and how risk can be 
lowered through lifestyle and medications is best presented using visual 
or imaging approaches, natural frequencies rather than percentages, 
and positive framing (focusing on risk-reduction benefits).1121–1125
Relative risk reduction is more persuasive than either absolute risk re­
duction or the number needed to treat.1122 The use of risk prediction 
estimates may have an impact on individuals’ health when their informa­
tion (i.e. predicted risk stratification) changes individuals’ behaviour, 
self-management decisions, and even treatment decisions.446 This en­
ables patients to gain insights into their cardiovascular prognosis and 
to empower them to take part in the decision-making process.1126
This approach may increase self-motivation for therapy adherence 
and lifestyle changes, including changes in nutrition, physical activity, 
relaxation training, weight management, and participation in smoking 
cessation programmes for resistant smokers.446 Previous unsuccessful 
attempts to change to a healthy lifestyle or take guideline- 
recommended treatment can be addressed to set realistic goals.446
Communication should be clear regarding symptoms, even if not car­
diac. Patients with CCS experiencing non-cardiac chest pain experience 
uncertainty about the cause and actions to take. A multidisciplinary ap­
proach and evaluation of non-cardiac aetiology with an appropriate re­
ferral are advocated to ensure that appropriate treatment is 
initiated.1127,1128
6.1.2. Depression and anxiety
Depression is common (15%–20% prevalence) in CVD, and associated 
with poor adherence and worse outcomes, including MACE and pre­
mature death.1129 Coronary microvascular dysfunction (prevalent in 
INOCA) is linked with psychological stress and depression.946
Unfortunately, depression and psychological stress are often unrecog­
nized due to a lack of systematic screening using validated tools.1129 For 
anxiety, a recent meta-analysis involving 16 studies reported a preva­
lence in post-MI between 5.5% and 58%, and a 27% greater risk of 
poor clinical outcomes in anxious patients compared with those with­
out anxiety.1130 In contrast, in a 15-year follow-up of 1109 patients with 
CCS moderate anxiety did not increase the risk of cardiovascular 
events compared with low anxiety levels. Patients on a high but de­
creasing anxiety trajectory had an HR of 1.72 (95% CI, 1.11–2.68) for 
cardiovascular events.1131 Treatment of psychosocial factors, depres­
sion, and anxiety with pharmacotherapy, psychotherapy, and/or exer­
cise can improve symptoms and QoL in some patients, and there is 
some evidence for improvement in cardiac outcomes.472,1132–1134
Stepped care (initial therapy based on patient preferences) and a com­
bination of therapies may be more efficacious.1129,1135 First-line treat­
ment with selective serotonin reuptake inhibitors (recommended in 
CCS) or non-pharmacological interventions and a multidisciplinary col­
laborative approach are recommended.1129
6.2. Adherence and persistence
Earlier analyses reported that adherence to long-term therapies in 
chronic conditions in Western countries averaged 50% and was lower 
in developing countries.1136 Pooled prevalence of non-adherence from 
a recent meta-analysis of eight studies (n = 3904 patients with multimor­
bidity) was 42.63% (95% CI, 34%–51%).1137 Data from the ESC-EORP 
EUROASPIRE V registry indicate that many CCS patients still have un­
healthy lifestyles in terms of smoking, diet, and sedentary behaviour.1138
Poor adherence and persistence (duration of time in which medications 
and healthy behaviours are continued) have a profound effect on effect­
ive management, patient safety, and outcomes. The World Health 
Organization (WHO) advocates training in adherence for healthcare 
professionals, a multidisciplinary approach, support rather than blame, 
tailored interventions based on illness-related demands for each patient, 
and viewing adherence as a dynamic process.1136
The five dimensions of adherence are patient, disease, provider, ther­
apy, and healthcare system (Figure 16).1139 Therefore, identifying pa­
tients at risk of non-adherence, addressing all five dimensions, 
developing a multidisciplinary pathway to support sustained adherence, 
and a follow-up strategy are essential steps.1139
6.2.1. Adherence to healthy lifestyle behaviours
Different strategies may help improve long-term adherence to a 
healthy lifestyle (Figure 17).
6.2.1.1. Why behavioural changes are difficult
Making changes to unhealthy lifestyles and controlling risk factors can 
be a daunting task as these are usually longstanding habits and patterns 
ESC Guidelines                                                                                                                                                                                          3489


<!-- PAGE 76 -->

### Page 76

of behaviour. Habits and environmental cues primarily govern beha­
viours, so education and information alone are seldom enough.1140
Factors such as psychological state and low health literacy (associated 
with depression and worse behavioural risk factors) also impact the 
ability to make changes.1141,1142
6.2.1.2. How to change behaviour and support healthy lifestyles
A multidisciplinary approach and behavioural counselling can improve 
adherence. A systematic review and meta-analysis of 12 RCTs of 
nurse-led patient-centred interventions for secondary prevention 
found greater adherence to smoking cessation and physical activity, 
and better control of total cholesterol (with medication titration), 
but no improvements in dietary habits, BP, blood glucose, or sur­
vival.1143 A systematic review of behavioural counselling found that 
medium- to high-contact counselling resulted in 20% lower risk of 
CVD events, lower BP, and decreased LDL-C and adiposity in adults 
with CVD risk factors.1144 Incorporating cardiovascular visual images 
into risk-factor discussions is effective in reducing subsequent 10-year 
risk assessment and individual risk factors.445
Actions on the five dimensions of adherence to therapy
Disease
Be aware of low adherence predictors
Consider graded therapy in multimorbidity
Prevent frequent change in therapy
(especially in multimorbidity)
Health care provider
Provide correct,
timely and sufficient information
Improve communication skills
Optimize the patient’s perception of risk
Prevent clinical inertia
Patient
Provide additional psychosocial support in distress,
depression and anxiety
Optimize health literacy
Empower the 
patient. 
Increase the patient's self-efficacy
Therapy
Prefer poly-pill treatment
Intensify/increase use of mHealth and e-Health
Consider complexity and workload for 
patient
Healthcare system
Make access to care easy, rapid,
efficient and affordable
Implement community-based programs/
interventions
Encourage social media coverage to assist therapeutic adherence
Involve informal caregivers
Shared-decision making
Structured tools (PROMs and clinical processes)
Improved outcomes
Figure 16 Actions on the five dimensions of adherence to therapy. e-Health, healthcare services provided electronically; mHealth, mobile device- 
based healthcare; PROMs, patient-reported outcome measures. Adapted from Pedretti et al.1139.


<!-- PAGE 77 -->

### Page 77

Lifestyle changes also impact relatives, partners, and friends, so they 
should be involved in patient support.1139 Physical activity can be incor­
porated flexibly, either daily, or limited to specific days. Activity pat­
terns limited to 1–2 sessions per week but meeting recommended 
levels of physical activity have been shown to reduce or postpone 
all-cause, CVD, and cancer mortality risk.477 Importantly, maintaining 
changed behaviour over time is a challenge. Some trials have shown 
an impact of lifestyle intervention on cardiovascular health and behav­
ioural metrics, which became attenuated in the long term as the inten­
sity of the intervention declined.1145
6.2.1.3. Digital and mHealth
Behavioural change and habit formation can be facilitated through tech­
nology such as wearable devices, the internet, and smartphones. In 27 
studies including 5165 patients with CAD or cerebrovascular disease, 
text messaging and smartphone apps resulted in a greater ability to 
reach BP targets and exercise goals, less anxiety, and increased aware­
ness of diet and exercise compared with control.1146 Nevertheless, 
there was no significant difference in smoking cessation, LDL-C, and 
hospital readmissions.1146 Digital interventions mainly stimulate healthy 
behavioural factors but are less effective in reducing unhealthy behav­
ioural factors (smoking, alcohol intake, sedentary behaviour, and un­
healthy diet) and clinical outcomes.1146,1147
The use of wearable devices has significantly increased physical activ­
ity and decreased waist circumference, systolic BP, and LDL-C among 
individuals with chronic conditions including CVD.491 Younger age 
has been associated with a higher increase in physical activity, and 
CVD has been associated with a lower increase. Wearable activity 
trackers have shown effectiveness, but the effect was greater when 
ealthy diet
H
xercise
E
chieve normal weight
A
eave smoking
L
ake control of cholesterol and blood pressure
T
andle alcohol consumption
H
ield to stress management
Y
Supporting adherence
Good communication,
structured tools and visual images
Multidisciplinary behavioural interventions mHealth and telehealth
Fixed dose combination pills and simplified medication regimens
PROMs and feedback
Cardiovascular risk reduction
Figure 17 Strategies for long-term adherence to a healthy lifestyle. mHealth, mobile device-based healthcare; PROMs, patient-reported outcome 
measures.
ESC Guidelines                                                                                                                                                                                          3491


<!-- PAGE 78 -->

### Page 78

combined with other behaviour-change strategies.491 A systematic re­
view of CCS patients that used activity trackers combined with feed­
back by healthcare professionals (most also giving lifestyle education) 
showed a significant increase in peak VO2 in studies using an acceler­
ometer (but not a pedometer) compared with non-users. The overall 
effect across studies reduced MACE and improved QoL.1148 Similarly, 
smartphone and tablet computer apps have been shown to increase 
physical activity (minutes per week or steps per day) among people 
with CVD (1543 participants, most of them with CCS). This effect 
was largest in small studies focused on physical activity only, partici­
pants ≥60 years old, and duration of up to 3 months.1149
Adherence to the apps was 20% to 85% and tended to wane over 
time. Of note, the implementation of digital and mHealth should 
not be at odds with a less digital-oriented care for those unfamiliar 
with new technologies (e.g. elderly people).
6.2.1.4. How to assess adherence
Addressing lifestyle behaviour and medication adherence in a non- 
judgemental way at clinical encounters is important to identify barriers 
and offer tailored solutions to promote healthier actions. The encoun­
ter can be useful to review patient self-monitoring records (digital or 
written), accelerometer data, and diaries, or validated questionnaires 
on physical activity.
6.2.2. Adherence to medical therapy
Guideline-directed medications are key to the effective management of 
CCS and prevention of subsequent cardiovascular events, but depend­
ent on patient adherence and persistence with treatment. Despite ro­
bust evidence of benefits in terms of mortality and morbidity,1150
adherence remains suboptimal.1151 Although adherence is usually high­
er in RCTs, approximately 28% of CCS patients in the ISCHEMIA trial 
were non-adherent to prescribed medications at baseline.1152
Non-adherence was associated with significantly worse health status 
regardless of randomization to the conservative or invasive strat­
egy.1152 Medication adherence can be intentional or unintentional, 
and can be adversely affected by polypharmacy, complex drug regi­
mens, high cost, and side effects.
6.2.2.1. Strategies to improve medication adherence
Improving adherence to medications has proved challenging.1153 One 
systematic review and meta-analysis (771 studies to 2015) found that 
interventions that were behaviourally focused, e.g. linking medication- 
taking to existing habits, were more effective than those that were 
cognitively focused.1154 A systematic review of 17 trials of adherence 
for secondary CVD prevention found that a short message service, a 
fixed-dose combination pill, and a community health worker-based 
intervention (one trial each) increased adherence compared with 
usual care.1155 Behavioural and mixed behavioural/educational inter­
ventions improved adherence in older adults with multiple medica­
tions (low-quality evidence), with little evidence for educational-only 
interventions.1156 Drug reminder packaging—i.e. incorporating the 
date and time for the medication to be taken in a package (pre-filled 
containers)—can act as a prompt, with some evidence that it in­
creases pills taken and improves diastolic BP and HbA1c levels.1157
Treating depression is important, as depression was associated with 
reduced adequate and optimal adherence to recommended medica­
tions 12 months post-PCI in an analysis of 124 443 patients.1158
Simplifying medication regimens using fixed-dose polypills has been 
shown to increase adherence.1159–1162 The SECURE trial demon­
strated that patients 6 months post-MI randomized to a polypill con­
taining aspirin, ramipril, and atorvastatin had significantly lower MACE 
and were more likely to have high adherence at 6 and 24 months com­
pared with the usual care group.1163
6.2.2.2. mHealth strategies for medication adherence
A review of mobile phone text messaging found promising, if limited, 
evidence that such messaging could improve medication adherence 
up to 12 months after acute coronary events.1164 Similarly, another re­
view of 24 studies of text messages and/or apps found robust evidence 
for adherence to pharmacological therapy.1146 A pilot trial of 135 
non-adherent patients with hypertension and/or diabetes randomized 
patients to a highly tailored digital intervention (text messages and 
interactive voice response) or usual care for 12 weeks. Medication 
adherence was significantly improved in the intervention group, along 
with improvements in systolic BP and HbA1c, compared with the con­
trol group.1165
6.3. Diagnosis of disease progression
Long-term follow-up of patients with CCS who have either established 
CAD (prior acute MI, revascularization, known CAD) or non- 
obstructive CAD includes surveillance for disease progression. 
However, current literature is sparse regarding mode, frequency, and 
duration. Follow-up of patients is based on their clinical condition, 
which includes cardiovascular risk factors, residual symptoms, cardiac 
complications [such as post-infarction LV remodelling and dysfunction, 
associated mitral regurgitation (mostly functional), known HF, signifi­
cant arrhythmias], and non-cardiac comorbidities like PAD, stroke, 
and renal dysfunction.
The main goal of follow-up is to determine the patient’s risk of 
developing new cardiac events through risk stratification and to 
identify symptoms suggestive of CAD progression. A second goal is 
Recommendation Table 28 — Recommendations for 
adherence to medical therapy and lifestyle changes 
(see also Evidence Table 28)
Recommendations
Classa
Levelb
Mobile health interventions (e.g. using text messages, 
apps, wearable devices) are recommended to 
improve patient adherence to healthy lifestyles and 
medical therapy.491,1148,1149,1154,1156,1164
I
A
Behavioural interventions are recommended to 
improve adherence.491,1140,1144
I
B
Simplifying medication regimens (e.g. using 
fixed-dose drug combinations) is recommended to 
increase patient adherence to 
medications.1139,1163,1166
I
B
Multiprofessional and family involvement is 
recommended to promote adherence, in addition to 
patient education and involvement.1139
I
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 79 -->

### Page 79

to promptly diagnose and manage extracoronary complications, such as 
the onset of HF, arrhythmias, and valvular dysfunction. Additionally, 
during long-term follow-up, antianginal and disease-modifying medica­
tion should be optimized and adjusted based on the development of co­
morbidities. The potential benefits vs. bleeding risks of antithrombotic 
drugs should be considered and evaluated over time.
Although assessing the anginal status is traditionally considered the 
cornerstone of clinical follow-up, it is worth noting that angina resolves 
in 40% of CCS patients at 1 year with further annual decreases, most 
often without revascularization or adaptation of antianginal therapy.404
In contrast to patients with resolving symptoms, those with persistent 
or recurrent angina are at higher risk of cardiovascular death or MI.404
The worse prognosis of persisting angina, however, was only observed 
in patients with a previous MI.408
6.3.1. Risk factors for recurrent coronary artery 
disease events
Patients with established ASCVD are at high risk of recurrent events 
and different risk factors have been identified. The REACH registry de­
monstrated that, in addition to the traditional risk factors, the burden of 
disease, lack of treatment, and geographical location are all related to an 
increased risk of cardiovascular morbidity and mortality in CCS patients 
and validated a risk score that allows estimation of the risk for 
MACE.1167 Using data from stabilized CCS patients from 27 
European countries included in the EUROASPIRE IV and V surveys, a 
new risk model with an online risk calculator to predict recurrent 
CVD events in patients under the age of 75 years was developed and 
externally validated in the SWEDEHEART registry.1168,1169 This model 
indicated that the risk of recurrent MACE is mainly driven by comorbid­
ities including diabetes, renal insufficiency, and dyslipidaemia, but also 
symptoms of depression and anxiety. A study of patients with estab­
lished CAD from the UK Biobank confirmed the value of classical risk 
factors, lifestyle, and sociodemographic factors in predicting recurrent 
MACE.1170 In addition, it was found that high genetic predisposition to 
CAD, low HDL-C, and younger age at first ACS event most strongly 
predicted the recurrence risk. A polygenic risk score, when added to 
the Framingham score, improved predictions of events in a large popu­
lation in the USA.1171 Although the prediction of recurrent MACE has 
been refined, it must be emphasized that the predictive power of the 
different risk factors is weak and that a significant part of recurrent 
MACE in CCS patients remains unexplained. Furthermore, the models 
do not incorporate information on LV function, HF, concomitant valvu­
lar disease, atherosclerotic disease burden in other vascular beds, or the 
severity of existing CAD.1172 While risk factors for recurrent cardiac 
events have been established, no clinical studies have tested predefined 
clinical pathways for long-term follow-up of various types of CCS pa­
tients. As a result, the long-term clinical follow-up of CCS patients is 
primarily empirical, based on good clinical judgement, and on the 
same criteria used in the initial diagnostic process to define high risk 
of adverse events (Section 3.3.5 and Figure 18).
6.3.2. Organization of long-term follow-up
When scheduling long-term follow-up for CCS patients with recurring 
or worsening angina, it is important to consider factors such as patient 
type, the presence of risk factors, availability of diagnostic techniques, 
and cost-effectiveness following regional or national healthcare policies. 
Different CCS phenotypes may develop or recur during long-term 
follow-up, altering the follow-up needed over time. The intervals and 
examination methods during long-term follow-up may vary based on 
the CCS phenotype, coronary atherosclerotic burden, presence of 
CMD, and severity of ischaemic LV dysfunction.
A stepwise approach based on risk assessment can be followed, like 
that applied for diagnosing and treating individuals with suspected CCS.
Step 1: This involves an annual clinical evaluation, by a general prac­
titioner or a cardiologist, encompassing symptom evaluation, medica­
tion review, physical examination, a resting 12-lead ECG, and blood 
tests for lipid profile, renal function, glycaemic status, and full blood 
count. The ECG should be scrutinized for heart rate, rhythm, evidence 
of silent ischaemia/infarction, and evaluation of PR, QRS, and QT inter­
vals. Any new symptoms suggestive of ACS, especially with ECG 
changes, warrant adherence to the 2023 ESC Guidelines for the man­
agement of patients with acute coronary syndromes. 65 Current med­
ical therapy and lifestyle measures for risk-factor control can be 
maintained or optimized for asymptomatic patients.
Step 2: If CCS patients develop new or worsening angina or HF 
symptoms, arrhythmias or ECG changes, further cardiac evaluation is 
crucial, especially if symptoms persist despite optimized GDMT. 
Recurrent CAD event risk should be assessed based on symptoms, 
progression 
of 
risk 
factors, 
and 
resting 
ECG 
changes. 
Echocardiography may be performed to assess LV function, cardiac di­
mensions, and valvular abnormalities. Exercise ECG testing may be con­
sidered to confirm symptoms and evaluate functional capacity if it alters 
patient management. However, routine functional testing is not recom­
mended for asymptomatic post-PCI patients, as it has not been shown 
to improve outcomes compared with standard care after 2 years.1173
Step 3: CCS patients with persistent symptoms at low exercise levels 
despite optimized GDMT or unexpectedly reduced LV function, espe­
cially with regional contraction abnormalities, need further cardiac test­
ing to detect the progression of CAD and assess the event risk.
For patients with known non-obstructive CAD, CCTA can help 
detect new obstructive stenoses, evaluate atherosclerotic disease pro­
gression, and identify high-risk plaque features, while functional imaging 
is reasonable for detecting myocardial ischaemia and guiding further 
management. In patients with ANOCA/INOCA and stratified medical 
therapy, CCTA can be useful to detect new or progressing CAD.
For patients with obstructive CAD or previous cardiac events, non- 
invasive functional imaging is the preferred method to detect and quan­
tify myocardial ischaemia and/or scar. However, in patients with severe­
ly limiting angina and known severe ischaemia on functional testing or 
high-risk CAD on CCTA, direct referral to ICA for revascularization 
is preferred due to the very high risk of recurrent CAD events. 
Although CCTA can detect CABG graft patency and exclude in-stent 
restenosis (ISR) in broad lumen arteries, functional imaging is preferred 
for assessing patients with prior revascularization because of the high 
frequency of extensive CAD in these patients.1174–1176
Step 4: In all patients with recurrent or worsening anginal symptoms, 
lifestyle modifications, risk-factor management, and GDMT should be 
intensified before considering further interventions. For patients with 
significant inducible myocardial ischaemia or high-risk CAD, and persist­
ent anginal symptoms despite lifestyle modifications and intensified 
GDMT, repeat coronary revascularization may be necessary to alleviate 
symptoms and improve prognosis. For patients with prior CABG ex­
periencing stable symptoms, it’s important to optimize GDMT when­
ever possible. If frequent angina persists despite GDMT optimization, 
ICA or CCTA can assist in guiding treatment decisions.1177–1179
When symptoms are uncertain, functional testing may help clarify the 
presence and extent of myocardial ischaemia.
ESC Guidelines                                                                                                                                                                                          3493


<!-- PAGE 80 -->

### Page 80

6.3.3. Non-invasive diagnostic testing
All non-invasive diagnostic testing, including CCTA, stress SPECT, 
or PET myocardial perfusion imaging, stress echocardiography, 
and stress CMR have been shown to provide prognostic informa­
tion in patients with established CAD.296,1180,1181 Anatomical im­
aging with CCTA has the advantage of providing information on 
left main disease and graft patency. Stress imaging provides informa­
tion on the degree of ischaemia, which helps guide an appropriate 
management plan. For example, symptomatic patients with 
moderate-to-severe myocardial ischaemia despite GDMT will usu­
ally undergo additional revascularization. In patients with known 
ANOCA/INOCA, non-invasive imaging with stress SPECT or PET 
myocardial perfusion imaging, stress CMR, or stress echocardiog­
raphy remain first-line investigations, although the diagnostic yield 
may be low;927 however, the current standard remains invasive cor­
onary functional testing.
4
5
6
1
Symptom severity and frequency?
More frequent follow-up or new diagnostic or therapeutic action needed?
3
Extent and severity of known CAD?
Consider:
LV-function? Other heart diseases?
(e.g.  AF, valve disease, RV dysfunction)
Age and gender
Prior ACS, PCI or CABG
Risk factors for CAD
Comorbidities (e.g. CKD, PAD)
Recurrent or new CAD event?
Treatment compliance and lifestyle
Genetic predisposition
Inflammatory markers
Psychosocial factors
2
ECG changes?
Figure 18 Approach for the follow-up of patients with established chronic coronary syndrome. ACS, acute coronary syndrome; AF, atrial fibrillation; 
CABG, coronary aortic bypass grafting; CAD, coronary artery disease; CCS, chronic coronary syndrome; CKD, chronic kidney disease; ECG, electro­
cardiogram; LV, left ventricle; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RV, right ventricle.


<!-- PAGE 81 -->

### Page 81

6.4. Treatment of myocardial 
revascularization failure
One in five revascularized patients needs a repeat revascularization 
within the first 5 years after myocardial revascularization, with higher 
risk after PCI compared with CABG.1182 Revascularization failure can 
manifest either shortly after the initial procedure (within 30 days) or la­
ter on, and recurring symptoms may result from either restenosis of 
the treated coronary segment or the failure of bypass grafts,772 along­
side the progression of underlying native CAD.1183,1184 Published evi­
dence 
regarding 
diagnosis 
and 
management 
of 
myocardial 
revascularization failure has been summarized in the 2020 EAPCI 
(European Association of Percutaneous Cardiovascular Interventions) 
Expert Consensus Paper.1182
6.4.1. Percutaneous coronary intervention failure
Stent thrombosis and ISR are the most frequent reasons for PCI failure. 
Stent thrombosis occurs infrequently and is multifactorial. Anatomical 
and mechanical factors, as well as lack of adherence or hyporesponsive­
ness to antiplatelet treatment, are frequently the reasons behind 
this.1182,1185 The majority of patients with stent thrombosis present 
with ACS and should be treated according to the 2023 ESC 
Guidelines for the management of patients with acute coronary syn­
dromes.65 Urgent ICA to confirm diagnosis and treatment is indicated. 
After restoration of coronary flow, intracoronary imaging to identify 
mechanical failure should be performed. Repeated DES implantation 
is indicated in case of stent fracture or collapse and residual edge dissec­
tions, while high-pressure non-compliant balloon dilation is indicated in 
case of stent under-expansion or malapposition.
In-stent restenosis results as a response to vessel wall injury 
(neointimal hyperplasia) or neoatherosclerosis in the stented segment 
of the coronary artery. Although significantly less frequent than after 
bare-metal stent implantation, the incidence of clinical in-DES restenosis 
is up to 10% within the first 10 years after DES implantation1182 and re­
mains the most frequent cause of PCI failure. The clinical presentation 
of ISR is mostly CCS, with 20% ACS, and the remaining asymptomatic. 
The indication to treat ISR is like that for native CAD. Radiological stent 
enhancement and intracoronary imaging are encouraged to determine 
the ISR mechanism. PCI treatment of ISR should be focused on the 
stenotic segment. Lesion preparation (ultra-high pressure balloon dila­
tion, intravascular lithotripsy, rotation atherectomy) and correction of 
mechanical issues are required.1182 Thereafter, drug-coated balloon 
angioplasty or DES implantation is necessary.1186,1187 Drug-eluting bal­
loon angioplasty and repeat stenting with DES were equally effective 
and safe in treating bare-metal ISR, but drug-coated balloon angioplasty 
was less effective than repeat paclitaxel DES implantation in treating 
DES ISR.1186 However, at 10-year follow-up there was no difference 
in clinical endpoints between drug-coated balloon angioplasty and 
DES implantation, whereas both were more effective than balloon 
angioplasty 
in 
preventing 
target-lesion 
revascularization.1187
Everolimus DES was associated with better long-term outcomes than 
drug-coated balloons.1188
6.4.2. Managing graft failure after coronary artery 
bypass grafting
A variety of reasons have the potential to adversely affect bypass graft 
patency.1189 These include technical (quality of graft material, surgical 
precision) and pathophysiological aspects (competitive flow, activity 
of the coagulation system, disease progression, etc.). Technical aspects 
and competitive flow are thought to influence early graft failure, while 
disease progression and graft degeneration affect long-term 
patency.1182,1189
The majority of graft occlusions are clinically silent.1189 If symptoms 
occur, prompt diagnostic workup (including ECG, assessment of bio­
markers, and possibly repeat coronary angiography) is warranted to 
limit or prevent potential damage from graft occlusion.316 Acute 
CABG graft failure (<1 month after surgery) is observed in approxi­
mately 12% of grafts mostly due to technical problems.1190 Late failure 
of saphenous vein grafts occurs in up to 50% at 10 years, with vein graft 
occlusion rates in up to 27% within 1 year after surgery. 771,1191
The decision for optimal treatment (conservative, CABG revision/ 
redo CABG or PCI of the native vessel or of the failed graft) should 
be made individually considering haemodynamic stability, technical 
Recommendation Table 29 — Recommendations for 
diagnosis of disease progression in patients with estab­
lished chronic coronary syndrome (see also Evidence 
Table 29)
Recommendations
Classa
Levelb
Asymptomatic patients with established chronic coronary 
syndromes
Regardless of symptoms, periodic visits (e.g. annual) 
to a general practitioner or cardiovascular healthcare 
professional are recommended to evaluate 
cardiovascular risk factor control and to assess 
changes in risk status, disease status, and 
comorbidities that may require lifestyle, medical, or 
procedural interventions.
I
C
Symptomatic patients with established chronic coronary 
syndromes
Reassessment of CAD status is recommended in 
patients with deteriorating LV systolic function that 
cannot be attributed to a reversible cause (e.g. 
longstanding tachycardia or myocarditis).
I
C
Risk stratification is recommended in patients with 
new or worsening symptoms, preferably using stress 
imaging.
I
C
In patients with symptoms refractory to medical 
treatment or at high risk of adverse events, invasive 
coronary angiography (with FFR/iFR when necessary) 
is recommended for risk stratification and for 
possible revascularization aimed at improving 
symptoms and prognosis.
I
C
In CCS patients with symptoms refractory to medical 
treatment, and who have had previous coronary 
revascularization, CCTA should be considered to 
evaluate bypass graft or stent patency (for stents ≥3 
mm).1174–1176
IIa
B
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary 
computed tomography angiography; FFR, fractional flow reserve; iFR, instantaneous 
wave-free ratio; LV, left ventricular; QFR, quantitative flow ratio. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3495


<!-- PAGE 82 -->

### Page 82

reasons for graft failure, and ability to treat native CAD. PCI is the first 
choice over redo CABG for late graft failure, with PCI of the native ves­
sel rather than PCI of the graft. 772,1182,1192,1193
If re-operation is required, the surgical risk is generally in­
creased.1182,1192 If acute re-operation is required, acute ischaemia is 
generally present, and adhesions and the presence of patent grafts in­
crease the complexity of the procedure. It is, therefore, important to 
weigh this risk against the expected benefit. Since a patent left internal 
thoracic artery (LITA) to the LAD confers the largest part of CABG 
prognostic potential,1189,1194 redo CABG is primarily recommended 
in patients with indications for CABG and occluded LITA or if the 
LITA was not used during the first operation.772
6.5. Recurrent or refractory  
angina/ischaemia
An ageing population and an increased survival rate in patients with 
CAD due to improvements in anti-ischaemic medical therapy and cor­
onary revascularization have led to a growing number of patients with 
severe and diffuse CAD not amenable to further revascularization pro­
cedures. Despite the use of antianginal drugs and/or PCI or CABG, the 
proportion of patients with CAD who have daily or weekly angina 
ranges from 2% to 24%.555
Refractory angina is defined as long-lasting symptoms (for >3 months) 
due to established reversible ischaemia: (i) in the presence of ob­
structive CAD, which cannot be controlled by escalating medical ther­
apy with additional antianginal drugs, bypass grafting, or PCI including 
recanalization of chronic total coronary occlusion; or (ii) due to 
ANOCA/INOCA. In the case of ANOCA/INOCA, further investiga­
tions are required to define the different endotypes (Section 4.4.2) and 
appropriate treatment (Section 6.3) before diagnosing refractory 
angina.36
The QoL of patients with refractory angina is poor, with frequent 
hospitalization and a high level of resource utilization.555 Once conven­
tional anti-ischaemic targets have been exhausted, novel therapies can 
be ranked by mechanism of action, promotion of collateral growth, 
transmural redistribution of blood flow, and neuromodulation of the 
cardiac pain syndrome.
Considering the chronic nature of the disease and according to risk– 
benefit assessments, among the currently available options, the most 
promising and easily implementable in everyday clinical practice are en­
hanced external counterpulsation and the coronary sinus reducer de­
vice,555 after all medical therapy and mechanical revascularization 
options have been exhausted (see Sections 4.2 and 4.4). Enhanced ex­
ternal counterpulsation has been shown to ameliorate refractory an­
gina in several trials.1198
The coronary sinus reducer consists of controlled coronary sinus 
narrowing with the implantation of a large stainless-steel device to in­
crease coronary sinus pressure and improve perfusion in the LAD ter­
ritory.1199 In a recent meta-analysis including eight registries and one 
RCT, in a total of 846 patients with refractory angina, use of a coronary 
sinus reducer led to improvement of ≥1 CCS class in 76% (95% CI, 
73%–80%) of patients and an improvement of ≥2 CCS class in 40% 
(95% CI, 35%–46%) of patients.1200 The Coronary Sinus Reducer 
Objective Impact on Symptoms, MRI Ischaemia and Microvascular 
Resistance (ORBITA-COSMIC) trial, a small proof-of-concept RCT, 
found no evidence that implantation of a coronary sinus reducer im­
proved transmural myocardial perfusion, but it was associated with im­
proved angina symptoms compared with placebo. 1201
There are several ongoing RCTs evaluating the use of coronary 
sinus reducer in ANOCA/INOCA, such as COronary SInus Reducer 
for the Treatment of Refractory Microvascular Angina (COSIMA; 
NCT04606459), and the Efficacy of the COronary SInus Reducer in 
Patients with Refractory Angina II (COSIRA-II; NCT05102019).
A variety of new pharmacological approaches is becoming available 
and includes angiogenetic therapies with vascular endothelial growth 
factors and fibroblast growth factors, as well as stem cell therapy 
with intramyocardial delivery of CD34+ cells.1202,1203 However, further 
RCTs are needed to validate the feasibility of such therapeutic 
strategies.
To date, the main limitations of reported experiences with all novel 
therapeutic options regard the small number of treated patients and 
the duration of follow-up. Larger sham-controlled RCTs are required 
to define the role of each treatment modality for specific subgroups, 
and ultimately to aim at the best possible personalized treatment algo­
rithm, based on aetiology stratification, and escalation of available thera­
peutic modalities.
Recommendation Table 30 — Recommendations for 
treatment 
of 
revascularization 
failure 
(see 
also 
Evidence Table 30)
Recommendations
Classa
Levelb
DES is recommended over drug-coated balloons for 
treatment of in-DES restenosis.1186–1188
I
A
LIMA is indicated as the conduit of choice for redo 
CABG in patients in whom the LIMA was not used 
previously.1195
I
B
Redo CABG should be considered for patients 
without a patent LIMA graft to the LAD. 842,1192,1196
IIa
B
PCI of the bypassed native artery should be 
considered over PCI of the bypass graft.1197
IIa
B
© ESC 2024
CABG, coronary artery bypass grafting; DES, drug-eluting stent; LAD, left anterior 
descending; LIMA, left internal mammary artery; PCI, percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 31 — Recommendations for 
recurrent or refractory angina/ischaemia (see also 
Evidence Table 31)
Recommendations
Classa
Levelb
In patients with refractory angina leading to poor 
quality of life and with documented or suspected 
ANOCA/INOCA, invasive coronary functional 
testing is recommended to define ANOCA/INOCA 
endotypes and appropriate treatment, considering 
patient choices and preferences.36,37,298,930,939,985
I
B
In patients with debilitating angina and obstructive 
CAD refractory to optimal medical and 
revascularization strategies, a reducer device for 
coronary sinus constriction may be considered to 
improve symptoms, in experienced centres.1199– 
1201,1204
IIb
B
© ESC 2024
ANOCA, angina with non-obstructive coronary arteries; CAD, coronary artery disease; 
INOCA, ischaemia with non-obstructive coronary arteries. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 83 -->

### Page 83

6.6. Treatment of disease complications
Patients with CCS who develop LV dysfunction may experience ad­
vanced HF, malignant arrhythmias and secondary valvular heart disease 
(i.e. mitral and tricuspid regurgitation).
Prior MI and ischaemic aetiology are negative prognostic markers in 
patients with advanced HF,1205 as well as in those with secondary mitral 
regurgitation.1206 Specific treatments need to be considered in these 
patients regardless of HF aetiology (i.e. ischaemic).526 Advanced HF 
treatments include: high diuretic doses; a combination of diuretics 
and renal replacement therapy to treat congestion; inotropic and vaso­
pressor agents to reduce hypoperfusion; and mechanical circulatory 
support in selected patients with severe symptoms or exercise intoler­
ance, despite optimal medical therapies, and without right ventricular 
dysfunction. Heart transplantation is recommended for patients with 
advanced HF, refractory to medical/device therapy, and who do not 
have absolute contraindications. Early evaluation for mechanical circu­
latory supports or heart transplantation is currently suggested also in 
patients with mild symptoms [i.e. New York Heart Association 
(NYHA) class II] and high-risk profile (i.e. LVEF of <20%, recurrent 
HF events, hypotension, intolerance to medical therapy, worsening or­
gan failure, ventricular arrhythmias/ICD shock).526
An ICD is recommended in patients with ischaemic cardiomyopathy 
and LVEF of <35% or who have recovered from ventricular arrhyth­
mias.526 Frequent, symptomatic ventricular arrhythmias in ICD recipi­
ents should be treated medically with either beta-blockers or 
amiodarone. In patients with CCS who develop ventricular fibrillation 
or polymorphic ventricular tachycardia, assessment for myocardial is­
chaemia should be performed without delay. In patients with CAD in 
whom sustained monomorphic ventricular tachycardia recurs while 
on amiodarone treatment, catheter ablation is recommended over 
the escalation of antiarrhythmic drugs.1207 Percutaneous treatment 
of secondary mitral regurgitation in patients with advanced HF may 
be considered to improve symptoms.526 Treatment of secondary tri­
cuspid regurgitation in advanced stages of disease was, until recently, 
supported by limited evidence.1208 Percutaneous tricuspid transcath­
eter edge-to-edge repair was found to reduce significantly severe tri­
cuspid regurgitation and was associated with improvements in QoL 
at 1 year.1209
7. Key messages
• Symptoms of myocardial ischaemia due to obstructive atherosclerot­
ic CAD overlap with those of CMD or vasospasm.
• Similar guideline-directed cardiovascular preventive therapy is re­
commended in women and men in spite of the sex differences in 
the clinical presentation.
• Inclusion of risk factors to classic pre-test likelihood models of ob­
structive atherosclerotic CAD improves the identification of patients 
with very low (≤5%) pre-test likelihood of obstructive CAD in whom 
deferral of diagnostic testing should be considered.
• CACS is a reliable ‘simple’ test to modify the pre-test likelihood of 
atherosclerotic obstructive CAD.
• First-line diagnostic testing of suspected CCS should be done by non- 
invasive anatomic or functional imaging.
• Selection of the initial non-invasive diagnostic test should be based on 
the pre-test likelihood of obstructive CAD, other patient character­
istics that influence the performance of non-invasive tests, and local 
expertise and availability.
• CCTA is preferred to rule out obstructive CAD and detect non- 
obstructive CAD.
• Functional imaging is preferred to correlate symptoms to myocardial 
ischaemia, estimate myocardial viability, and guide decisions on cor­
onary revascularization.
• PET is preferred for absolute MBF measurements, but CMR perfu­
sion studies may offer an alternative.
• Selective second-line cardiac imaging with functional testing in pa­
tients with abnormal CCTA and CCTA after abnormal functional 
testing may improve patient selection for ICA.
• ICA is recommended to diagnose obstructive CAD in individuals 
with a very high pre- or post-test likelihood of disease, severe symp­
toms refractory to GDMT, angina at a low level of exercise, and/or 
high event risk.
• When ICA is indicated, it is recommended to evaluate the functional 
severity of ‘intermediate’ stenoses by invasive functional testing (FFR, 
iFR) before revascularization.
• Computed FFR based on the 3D reconstruction of ICA is emerging as 
a valuable alternative to wire-based coronary pressure to evaluate 
the functional severity of ‘intermediate’ stenoses.
• The use of imaging guidance is now recommended when performing 
complex PCI.
• A single antiplatelet agent, aspirin or clopidogrel, is generally recom­
mended long term in CCS patients with obstructive atherosclerotic 
CAD.
• For high thrombotic-risk CCS patients, long-term therapy with two 
antithrombotic agents is reasonable, as long as bleeding risk is not 
high.
• For CCS patients with sinus rhythm, DAPT is recommended at the 
time of PCI and for 1 to 6 month(s), according to high or low bleeding 
risk, respectively.
• For CCS patients requiring OAC and undergoing PCI, OAC and 
DAPT (aspirin and clopidogrel) for 1 to 4 weeks, followed by 
OAC and clopidogrel for up to 6 months in patients not at high is­
chaemic risk and up to 12 months in patients at high ischaemic risk, 
followed by OAC alone should be considered.
• In CCS patients with functionally significant multivessel CAD, current 
evidence indicates benefit of myocardial revascularization over 
GDMT alone for symptom improvement, prevention of spontaneous 
MI, and reduction of cardiovascular mortality at long follow-up.
• Among CCS patients with normal LV function and no significant left 
main or proximal LAD lesions, current evidence indicates that myo­
cardial revascularization over GDMT alone does not prolong overall 
survival.
• Among CCS patients with reduced LV function and ischaemic cardio­
myopathy, current evidence indicates that surgical revascularization 
compared with GDMT alone prolongs overall survival at very long 
follow-up.
• Among patients with complex multivessel CAD without LMCAD, 
particularly in the presence of diabetes, who are clinically and ana­
tomically suitable for both revascularization modalities, current evi­
dence indicates longer overall survival after CABG than PCI.
• Among patients who are clinically and anatomically suitable for both 
revascularization modalities, a greater need for repeat revasculariza­
tion after PCI than surgery, independently of multivessel CAD ana­
tomical severity, has been consistently reported with current 
surgical and stent technology.
• Lifestyle and risk-factor modification combined with disease- 
modifying and antianginal medications are cornerstones in the man­
agement of CCS.
ESC Guidelines                                                                                                                                                                                          3497


<!-- PAGE 84 -->

### Page 84

• Shared decision-making between patients and healthcare profes­
sionals, based on patient-centred care, is paramount in defining the 
appropriate therapeutic pathway for CCS patients. Patient education 
is key to improve risk-factor control in the long term.
• The relatively high prevalence of ANOCA/INOCA and its associated 
MACE rate warrants improvement in the diagnosis and treatment of 
affected patients.
• Persistently symptomatic patients with suspected ANOCA/INOCA 
who do not respond to GDMT should undergo invasive coronary 
functional testing to determine underlying endotypes.
• Characterization of endotypes is important to guide appropriate 
medical therapy for ANOCA/INOCA patients.
• Research on effective methods to support specific healthy lifestyle 
behaviours, and sustain medication and healthy lifestyle adherence 
over time, is needed.
• More research is needed on improving the implementation of health- 
promoting policies and practices in the workplace setting.
8. Gaps in evidence
• It remains unclear if screening for subclinical obstructive CAD in the 
general population is useful.1106,1210 Further large-scale studies are 
needed to investigate the prognostic benefit of screening and treating 
asymptomatic CCS in the general population, preferably involving dif­
ferent geographical regions. Optimal screening options remain to be 
determined for specific groups at high risk (e.g. asymptomatic indivi­
duals with diagnosed diabetes for longer than 10 years).
• Most studies assessing diagnostic strategies in individuals with symp­
toms suspected of CCS were performed in populations with a mod­
erate (>15%–50%) pre-test clinical likelihood of obstructive CAD. 
Further studies are needed to determine the optimal and most cost- 
effective diagnostic strategy in individuals with a low (>5%–15%) pre- 
test clinical likelihood of obstructive CAD.
• The current diagnosis of ANOCA/INOCA and its different endo­
types is mainly determined by invasive coronary functional testing.36
Further research is needed to refine and assess non-invasive diagnos­
tic imaging modalities for CMD. Currently available and new 
non-invasive imaging modalities should be calibrated against invasive 
testing, allowing the use of their measurements interchangeably.
• The role of antithrombotic therapy in CCS patients with ANOCA/ 
INOCA remains to be established.
• Because of how evidence has accrued over time, there is no clear evi­
dence about the existence of first- and second-line antianginal ther­
apy. It is unclear whether long-acting nitrates, ranolazine, nicorandil, 
ivabradine, trimetazidine, or any of their combinations improve an­
ginal symptoms more than beta-blockers or CCBs.
• The optimal type and duration of DAPT is still uncertain in some sub­
sets of patients (e.g. patients with prior revascularization who might 
benefit from shorter or longer DAPT strategies).
• The long-term benefit of beta-blocker therapy in post-MI patients 
without reduced EF remains to be elucidated.
• In view of the reported positive impact of low-dose colchicine in pa­
tients with CCS in reducing MI, stroke, and revascularization, future 
studies should identify whether certain patient subgroups (e.g. those 
with elevated biomarker levels) might derive even greater clinical 
benefit from this treatment.
• A post hoc analysis of ISCHEMIA detected a graded association 
between the severity of obstructive CAD assessed by CCTA 
and all-cause mortality and acute MI during follow-up.317 There 
is a need for randomized data comparing contemporary medical 
treatment against early revascularization plus medical therapy in 
subsets of patients with an increased risk for death or MI as de­
termined by the post hoc analysis. Moreover, because the benefit 
of an invasive strategy with respect to cardiac mortality was 
shown in a meta-analysis of chronologically heterogeneous trials, 
including several conducted more than two decades ago, the im­
pact of early revascularization plus GDMT vs. contemporary 
GDMT on all-cause and cardiac mortality in patients with CCS 
should ideally be tested in a well-designed, adequately powered 
randomized trial.
• Some meta-analyses have reported a reduction in cardiac mortality 
without a reduction in all-cause mortality. There is a need to clarify 
the impact of revascularization in CCS patients on cardiovascular 
and non-cardiovascular mortality.
• Complete revascularization of multivessel CAD by PCI can be 
achieved as a single procedure (index PCI) or as staged PCI. In the 
setting of CCS, the value of staged PCI and the optimal interval be­
tween interventions needs to be evaluated.
• Whether CABG surgery and PCI are comparable among patients 
with ischaemic cardiomyopathy and HFrEF in the modern era of 
HF treatment needs to be evaluated.
• Various imaging techniques, such as low-dose DSE, CMR, and PET/ 
CT, can identify hibernating myocardium with the potential for func­
tional recovery after revascularization.1211 Further randomized trials 
with contemporary, well-defined modalities and strict adherence to 
protocol are needed to clarify the clinical benefits (if any) of viability 
testing.
• Residual ischaemia post-PCI, as determined by FFR/iFR, reflects re­
maining atherosclerotic lesions and/or suboptimal PCI results, but 
also persistent or worsening microvascular dysfunction. Whether 
post-PCI FFR/iFR is a ‘modifiable’ risk factor remains to be proved.
• Among patients suitable for off-pump CABG with complex multives­
sel CAD but no LMCAD, the impact of hybrid revascularization on 
outcomes, including peri-operative complications other than 
MACE, needs more extensive investigation. Data on the optimal 
time interval between MIDCAB-LIMA and PCI are lacking.
• Whether the decision process based on a multidisciplinary Heart 
Team leads to better outcomes than standard institutional practice 
remains to be investigated.
• The medical therapy of ANOCA/INOCA is largely empirical. 
Therefore, prospective randomized clinical trials are needed to de­
termine the efficacy of antianginal treatments in improving symptoms 
and outcomes for the different endotypes.
• Research on effective methods to support healthy lifestyle beha­
viours, and sustain medication and healthy lifestyle adherence over 
time, is needed. In addition, more research is needed on improving 
the implementation of health-promoting policies and practices in 
the workplace setting.
• There is a need for further evidence on the effectiveness of neuro­
modulation, spinal cord stimulation, therapeutic angiogenesis, and 
coronary sinus occlusion in patients who suffer from refractory 
angina, 
despite 
guideline-directed 
medical 
treatment 
and 
revascularization.


<!-- PAGE 85 -->

### Page 85

Table 10 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for history taking, risk factor assessment, and resting electrocardiogram in individuals with suspected chronic 
coronary syndrome
In individuals reporting symptoms of suspected myocardial ischaemic origin, a detailed assessment of cardiovascular risk factors, medical 
history, and symptom characteristics (including onset, duration, type, location, triggers, relieving factors, time of day) is recommended.
I
C
If clinical or ECG assessment suggests ACS rather than CCS, immediate referral to the emergency department and/or repeated 
measurement of blood troponin, preferably using high-sensitivity or ultrasensitive assays, to rule out acute myocardial injury is 
recommended.
I
B
A resting 12-lead ECG is recommended in all individuals reporting chest pain (unless an obvious non-cardiac cause is identified), particularly 
during, or immediately after, an episode suggestive of myocardial ischaemia.
I
C
Using ST-segment deviations during supraventricular tachyarrhythmias, particularly during re-entrant atrioventricular tachycardias, per se, 
as reliable evidence of obstructive CAD, is not recommended.
III
B
Recommendations for basic biochemistry in the initial diagnostic management of individuals with suspected chronic coronary syndrome
The following blood tests are recommended in all individuals to refine risk stratification, diagnose comorbidities, and guide treatment:
• lipid profile including LDL-C;
I
A
• full blood count (including haemoglobin);
I
B
• creatinine with estimation of renal function;
I
B
• glycaemic status with HbA1c and/or fasting plasma glucose.
I
B
In patients with suspected CCS, it is recommended to assess thyroid function at least once.
I
B
Recommendations for estimating, adjusting and reclassifying the likelihood of obstructive atherosclerotic coronary artery disease in the 
initial diagnostic management of individuals with suspected chronic coronary syndrome
It is recommended to estimate the pre-test likelihood of obstructive epicardial CAD using the Risk Factor-weighted Clinical Likelihood 
model.
I
B
It is recommended to use additional clinical data (e.g. examination of peripheral arteries, resting ECG, resting echocardiography, presence of 
vascular calcifications on previously performed imaging tests) to adjust the estimate yielded by the Risk Factor-weighted Clinical Likelihood 
model.
I
C
Recommendations for resting transthoracic ultrasound and cardiac magnetic resonance imaging in the initial diagnostic management of 
individuals with suspected chronic coronary syndrome
A resting transthoracic echocardiogram is recommended: 
• to measure LVEF, volumes and diastolic function;
• identify regional wall motion abnormalities;
• identify non-coronary cardiac disease (e.g. hypertrophy, cardiomyopathy, valve disease, pericardial effusion);
• assess right ventricular function and estimate systolic pulmonary artery pressure;
to refine risk stratification and guide treatment.
I
B
Recommendations for the use of exercise ECG in the initial diagnostic management of individuals with suspected chronic coronary 
syndrome
Exercise ECG is recommended in selected patients for the assessment of exercise tolerance, symptoms, arrhythmias, BP response, and 
event risk.
I
C
Exercise ECG is not recommended for diagnostic purposes in patients with ≥0.1 mV ST-segment depression on resting ECG, left bundle 
branch block or who are being treated with digitalis.
III
C
In individuals with a low or moderate (>5–50%) pre-test likelihood of obstructive CAD, an exercise ECG is not recommended to rule out 
CAD if CCTA or functional imaging tests are available.
III
C
Recommendations for ambulatory ECG monitoring in the initial diagnostic management of individuals with suspected chronic coronary 
syndrome
Ambulatory ECG monitoring is recommended in subjects with chest pain and suspected arrhythmias.
I
C
Continued 
9. ‘What to do’ and ‘What not to do’ messages from the guidelines
Table 10 lists all Class I and Class III recommendations from the text alongside their level of evidence.
ESC Guidelines                                                                                                                                                                                          3499


<!-- PAGE 86 -->

### Page 86

Recommendations for non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected chronic 
coronary syndrome—coronary computed tomography angiography, if available, and supported by local expertise
In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to 
diagnose obstructive CAD and to estimate the risk of MACE.
I
A
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood to refine diagnosis if another non-invasive test is 
non-diagnostic.
I
B
CCTA is not recommended in patients with severe renal failure (eGFR <30 mL/min/1.73 m2), decompensated heart failure, extensive 
coronary calcification, fast irregular heart rate, severe obesity, inability to cooperate with breath-hold commands, or any other conditions 
that can make obtaining good imaging quality unlikely.
III
C
Recommendations for non-invasive tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome 
—stress echocardiography, if available, and supported by local expertise
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress echocardiography is 
recommended to diagnose myocardial ischaemia and to estimate the risk of MACE.
I
B
During stress echocardiography, when two or more contiguous myocardial segments are not visualized, it is recommended to use 
commercially available intravenous ultrasound contrast agents (microbubbles) to improve diagnostic accuracy.
I
B
During stress echocardiography, myocardial perfusion using commercially available intravenous ultrasound contrast agents (microbubbles) 
is recommended to improve diagnostic accuracy and to refine risk stratification beyond wall motion.
I
B
Recommendations for non-invasive functional myocardial imaging tests in the initial diagnostic management of individuals with 
suspected chronic coronary syndrome—resting and stress single-photon emission computed tomography/positron emission 
tomography—cardiac magnetic resonance imaging, if available, and supported by local expertise
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress SPECT or, preferably, 
PET myocardial perfusion imaging is recommended to: 
• diagnose and quantify myocardial ischaemia and/or scar;
• estimate the risk of MACE;
• quantify myocardial blood flow (PET).
I
B
In patients selected for PET or SPECT myocardial perfusion imaging, it is recommended to measure CACS from unenhanced chest CT 
imaging (used for attenuation correction) to improve detection of both non-obstructive and obstructive CAD.
I
B
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, CMR perfusion imaging is 
recommended to diagnose and quantify myocardial ischaemia and/or scar and estimate the risk of MACE.
I
B
Recommendations for invasive coronary angiography in individuals with suspected obstructive coronary artery disease
When ICA is indicated, radial artery access is recommended as the preferred access site.
I
A
When ICA is indicated, it is recommended to have coronary pressure assessment available and to use it to evaluate the functional severity of 
intermediate non-left main stem stenoses prior to revascularization.
I
A
Invasive coronary angiography is recommended to diagnose CAD in individuals with a very high (>85%) clinical likelihood of disease, severe 
symptoms refractory to guideline-directed medical therapy, angina at a low level of exercise, and/or high event risk.
I
C
In individuals with de novo symptoms highly suggestive of obstructive CAD that occur at a low level of exercise, ICA with a view towards 
revascularization is recommended as first diagnostic test after clinical assessment by a cardiologist.
I
C
Recommendations for functional assessment of epicardial artery stenosis severity during invasive coronary angiography to guide 
revascularization
During ICA, selective assessment of functional severity of intermediate diameter stenoses is recommended to guide the decision to 
revascularize, using the following tools:
• FFR/iFR (significant ≤0.8 or ≤0.89, respectively);
I
A
• QFR (significant ≤0.8).
I
B
Systematic and routine wire-based coronary pressure assessment of all coronary vessels is not recommended.
III
A
Recommendations for selection of initial diagnostic tests in individuals with suspected chronic coronary syndrome
It is recommended to select the initial non-invasive diagnostic test based on pre-test likelihood of obstructive CAD, other patient 
characteristics that influence the performance of non-invasive tests, and local expertise and availability.
I
C
In symptomatic patients in whom the pre-test likelihood of obstructive CAD by clinical assessment is >5%, CCTA or non-invasive functional 
imaging for myocardial ischaemia is recommended as the initial diagnostic test.
I
B
To rule out obstructive CAD in individuals with low or moderate (>5%–50%) pre-test likelihood, CCTA is recommended as the preferred 
diagnostic modality.
I
B
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood if functional imaging for myocardial ischaemia is 
not diagnostic.
I
B
Continued


<!-- PAGE 87 -->

### Page 87

Functional imaging for myocardial ischaemia is recommended if CCTA has shown CAD of uncertain functional significance or is not 
diagnostic.
I
B
Invasive coronary angiography with the availability of invasive functional assessments is recommended to confirm or exclude the diagnosis of 
obstructive CAD or ANOCA/INOCA in individuals with an uncertain diagnosis on non-invasive testing.
I
B
Recommendations for definition of high risk of adverse events
An initial stratification of risk of adverse events is recommended based on basic clinical assessment (e.g. age, ECG, anginal threshold, 
diabetes, CKD, LVEF).
I
B
The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events: 
• Exercise ECG: 
⚬Duke Treadmill Score < −10;
• stress SPECT or PET perfusion imaging: 
⚬Area of ischaemia ≥10% of the LV myocardium;
• Stress echocardiography: 
⚬≥3 of 16 segments with stress-induced hypokinesia or akinesia;
• stress CMR: 
⚬≥2 of 16 segments with stress perfusion defects or ≥3 dobutamine-induced dysfunctional segments;
• CCTA: 
⚬left main disease with ≥50% stenosis, three-vessel disease with ≥70 stenosis, or two-vessel disease with ≥70% stenosis, including the 
proximal LAD or one-vessel disease of the proximal LAD with ≥70% stenosis and FFR-CT ≤0.8.
I
B
In individuals at high risk of adverse events (regardless of symptoms), ICA—complemented by invasive functional measures (FFR/iFR) when 
appropriate—is recommended, with the aim of refining risk stratification and improving symptoms and cardiovascular outcomes by 
revascularization.
I
A
Recommendations for cardiovascular risk reduction, lifestyle changes, and exercise interventions in patients with established chronic 
coronary syndrome
An informed discussion on CVD risk and treatment benefits tailored to individual patient needs is recommended.
I
C
Multidisciplinary behavioural approaches to help patients achieve healthy lifestyles, in addition to appropriate pharmacological management, 
are recommended.
I
A
A multidisciplinary exercise-based programme to improve cardiovascular risk profile and reduce cardiovascular mortality is recommended.
I
A
Aerobic physical activity of at least 150–300 min per week of moderate intensity or 75–150 min per week of vigorous intensity and 
reduction in sedentary time are recommended.
I
B
Recommendations for antianginal drugs in patients with chronic coronary syndrome
It is recommended to tailor the selection of antianginal drugs to the patient’s characteristics, comorbidities, concomitant medications, 
treatment tolerability, and underlying pathophysiology of angina, also considering local drug availability and cost.
I
C
Short-acting nitrates are recommended for immediate relief of angina.
I
B
Initial treatment with beta-blockers and/or CCBs to control heart rate and symptoms is recommended for most patients with CCS.
I
B
Ivabradine is not recommended as add-on therapy in patients with CCS, LVEF >40%, and no clinical heart failure.
III
B
Combination of ivabradine with non-DHP-CCB or other strong CYP3A4 inhibitors is not recommended.
III
B
Nitrates are not recommended in patients with hypertrophic cardiomyopathy or in co-administration with phosphodiesterase inhibitors.
III
B
Recommendations for antithrombotic therapy in patients with chronic coronary syndrome
In CCS patients with a prior MI or remote PCI, aspirin 75–100 mg daily is recommended lifelong after an initial period of DAPT.
I
A
In CCS patients with a prior MI or remote PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin 
monotherapy.
I
A
After CABG, aspirin 75–100 mg daily is recommended lifelong.
I
A
In patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is recommended 
lifelong.
I
B
In CCS patients with no indication for oral anticoagulation, DAPT consisting of aspirin 75–100 mg and clopidogrel 75 mg daily for up to 6 
months is recommended as the default antithrombotic strategy after PCI-stenting.
I
A
In patients at high bleeding risk, but not at high ischaemic risk, it is recommended to discontinue DAPT 1–3 months after PCI and to 
continue with single antiplatelet therapy.
I
A
In CCS patients with a long-term indication for OAC, an AF therapeutic dose of VKA alone or, preferably, of DOAC alone (unless 
contraindicated) is recommended lifelong.
I
B
In patients with an indication for OAC who undergo PCI, initial low-dose aspirin once daily is recommended (loading dose when not on 
maintenance dose) in addition to OAC and clopidogrel.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3501


<!-- PAGE 88 -->

### Page 88

In patients who are eligible for OAC, DOAC (unless contraindicated) is recommended in preference to VKA.
I
A
After uncomplicated PCI in CCS patients with concomitant indication for OAC: 
• early cessation of aspirin (≤1 week);
• followed by continuation of OAC and clopidogrel: 
⚬up to 6 months in patients not at high ischaemic risk; or
⚬up to 12 months in patients at high ischaemic risk;
• followed by OAC alone;
is recommended.
I
A
The use of ticagrelor or prasugrel is generally not recommended as part of triple antithrombotic therapy with aspirin and an OAC.
III
C
It is recommended to initiate aspirin post-operatively as soon as there is no concern over bleeding.
I
B
A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined 
antithrombotic therapy (antiplatelet therapy and/or OAC).
I
A
Recommendations for lipid-lowering drugs in patients with chronic coronary syndrome
Lipid-lowering treatment with an LDL-C goal of <1.4 mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C vs. baseline is recommended.
I
A
A high-intensity statin up to the highest tolerated dose to reach the LDL-C goals is recommended for all patients with CCS.
I
A
If a patient’s goal is not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended.
I
B
For patients who are statin intolerant and do not achieve their goal on ezetimibe, combination with bempedoic acid is recommended.
I
B
For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with a PCSK9 inhibitor is 
recommended.
I
A
Recommendations for sodium–glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 receptor agonists in patients with 
chronic coronary syndrome
CCS patients with type 2 diabetes
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and CCS to reduce CV events, independent of baseline 
or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
GLP-1 receptor agonists with proven CV benefit are recommended in patients with T2DM and CCS to reduce CV events, independent of 
baseline or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
Recommendations for angiotensin-converting enzyme inhibitors in patients with chronic coronary syndrome
In CCS patients, ACE-Is (or ARBs) are recommended in the presence of specific comorbidities, such as hypertension, diabetes, or heart 
failure.
I
A
Recommendations for revascularization in patients with chronic coronary syndrome
It is recommended that patients scheduled for percutaneous or surgical revascularization receive complete information about the benefits, 
risks, therapeutic consequences, and alternatives to revascularization, as part of shared clinical decision-making.
I
C
For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of 
recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, 
non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient 
outcomes and quality of life.
I
C
It is recommended to communicate the proposal of the Heart Team in a very balanced way and in a language that the patient can 
understand.
I
C
It is recommended that the decision for revascularization and its modality be patient-centred, considering patient preferences, health 
literacy, cultural circumstances, and social support.
I
C
It is recommended that the Heart Team (on site or with a partner institution) develop institutional protocols to implement the appropriate 
revascularization strategy in accordance with current guidelines.
I
C
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant left main stem stenosis to improve survival.
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant three-vessel disease to improve long-term survival and to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant single- or two-vessel disease involving the proximal LAD, to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.
I
B
In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, 
preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life 
expectancy, individual risk-to-benefit ratio, and patient perspectives.
I
C
Continued


<!-- PAGE 89 -->

### Page 89

In surgically eligible CCS patients with multivessel CAD and LVEF ≤35%, myocardial revascularization with CABG is recommended over 
medical therapy alone to improve long-term survival.
I
B
In CCS patients with persistent angina or anginal equivalent, despite guideline-directed medical treatment, myocardial revascularization of 
functionally significant obstructive CAD is recommended to improve symptoms.
I
A
In patients with complex CAD in whom revascularization is being considered, it is recommended to assess procedural risks and 
post-procedural outcomes to guide shared clinical decision-making.
I
C
Calculation of the STS score is recommended to estimate in-hospital morbidity and 30-day mortality after CABG.
I
B
In patients with multivessel obstructive CAD, calculation of the SYNTAX score is recommended to assess the anatomical complexity of 
disease.
I
B
Intracoronary imaging guidance by IVUS or OCT is recommended when performing PCI on anatomically complex lesions, in particular left 
main stem, true bifurcations, and long lesions.
I
A
Intracoronary pressure measurement (FFR or iFR) or computation (QFR) is recommended to guide lesion selection for intervention in 
patients with multivessel disease.
I
A
It is recommended that physicians select the most appropriate revascularization modality based on patient profile, coronary anatomy, 
procedural factors, LVEF, preferences, and outcome expectations.
I
C
Recommendations for mode of revascularization in patients with chronic coronary syndrome
Left main disease
In CCS patients at low surgical risk with significant left main coronary stenosis, CABG: 
• is recommended over medical therapy alone to improve survival
I
A
• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and 
repeat revascularization
I
A
In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and 
non-inferior survival.
I
A
Left main with multivessel disease
In CCS patients at low surgical risk with suitable anatomy, CABG is recommended over medical therapy alone to improve survival.
I
A
Multivessel disease and diabetes
In CCS patients with significant multivessel disease and diabetes, with insufficient response to guideline-directed medical therapy, CABG is 
recommended over medical therapy alone and over PCI to improve symptoms and outcomes.
I
A
Three-vessel disease, without diabetes
In CCS patients with significant three-vessel disease, preserved LVEF, no diabetes, and insufficient response to guideline-directed medical 
therapy, CABG is recommended over medical therapy alone to improve symptoms, survival, and other outcomes.
I
A
In CCS patients with preserved LVEF, no diabetes, insufficient response to guideline-directed medical therapy, and significant three-vessel 
disease of low-to-intermediate anatomic complexity in whom PCI can provide similar completeness of revascularization to that of CABG, 
PCI is recommended, given its lower invasiveness, and generally non-inferior survival.
I
A
Single- or double-vessel disease involving the proximal LAD
In CCS patients with significant single- or double-vessel disease involving the proximal LAD and insufficient response to guideline-directed 
medical therapy, CABG or PCI is recommended over medical therapy alone to improve symptoms and outcomes.
I
A
In CCS patients with complex significant single- or double-vessel disease involving the proximal LAD, less amenable to PCI, and insufficient 
response to guideline-directed medical therapy, CABG is recommended over PCI to improve symptoms and reduce revascularization rates.
I
B
Single- or double-vessel disease not involving the proximal LAD
In symptomatic CCS patients with single- or double-vessel disease not involving the proximal LAD and with insufficient response to 
guideline-directed medical therapy, PCI is recommended to improve symptoms.
I
B
Recommendations for management of chronic coronary syndrome patients with chronic heart failure
Managing CCS in heart failure patients
In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by 
CABG, taking into account the risk-to-benefit ratio of the procedures.
I
B
In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or 
functional imaging is recommended.
I
C
In HF patients with LVEF >35% and suspected CCS with very high (>85%) pre-test likelihood of obstructive CAD, ICA (with FFR, iFR, or 
QFR when needed) is recommended.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3503


<!-- PAGE 90 -->

### Page 90

Managing heart failure in CCS patients
It is recommended that CCS patients with HF be enrolled in a multidisciplinary HF management programme to reduce the risk of HF 
hospitalization and to improve survival.
I
A
An ACE-I, an MRA, an SGLT2 inhibitor (dapagliflozin or empagliflozin), and, in stable conditions, a beta-blocker are recommended for CCS 
patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HF with mildly reduced ejection fraction (HFmrEF) or 
HFpEF to reduce the risk of HF hospitalization or cardiovascular death.
I
A
An ARB is recommended in symptomatic patients with CCS and HFrEF unable to tolerate an ACE-I or ARNI to reduce the risk of HF 
hospitalization and cardiovascular death.
I
B
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of HF 
hospitalization and death.
I
B
Diuretics are recommended in CCS patients with HF and signs and/or symptoms of congestion to alleviate symptoms, improve exercise 
capacity, and reduce HF hospitalizations.
I
B
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of 
ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimized GDMT, provided 
they are expected to survive substantially longer than 1 year with good functional status.
I
A
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular 
arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of 
reversible causes or unless the ventricular arrhythmia has occurred <48 h after an MI.
I
A
CRT is recommended for CCS patients with symptomatic HF, sinus rhythm, LVEF ≤35% despite GDMT, and a QRS duration ≥150 ms with 
an LBBB QRS morphology to improve symptoms and survival and to reduce morbidity.
I
A
CRT rather than right ventricular pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an 
indication for ventricular pacing for high-degree AV block in order to reduce morbidity. This includes patients with AF.
I
A
Recommendations for diagnosis and management of patients with angina with non-obstructive coronary arteries/ischaemia with 
non-obstructive coronary arteries
In persistently symptomatic patients despite medical treatment with suspected ANOCA/INOCA (i.e. anginal symptoms with normal 
coronary arteries or non-obstructive lesions at non-invasive imaging, or intermediate stenoses with normal FFR/iFR at coronary 
arteriography) and poor quality of life, invasive coronary functional testing is recommended to identify potentially treatable endotypes and 
to improve symptoms and quality of life, considering patient choices and preferences.
I
B
In individuals with suspected vasospastic angina, a resting 12-lead ECG recording during angina is recommended.
I
C
In patients with suspected vasospastic angina and repetitive episodes of rest angina associated with ST-segment changes that resolve with 
nitrates and/or calcium antagonists, invasive functional angiography is recommended to confirm the diagnosis and to determine the severity 
of underlying atherosclerotic disease.
I
C
For the treatment of isolated vasospastic angina: 
• calcium channel blockers are recommended to control symptoms and to prevent ischaemia and potentially fatal complications.
I
A
Recommendations for older, female, high bleeding risk, comorbid, and socially/geographically diverse patients
In older adults (≥75 years), particular attention to drug side effects, intolerance, drug–drug interactions, overdosing, and procedural 
complications is recommended.
I
C
In older, as in younger, individuals, diagnostic and revascularization decisions based on symptoms, extent of ischaemia, frailty, life expectancy, 
comorbidities, and patient preferences are recommended.
I
C
Similar guideline-directed cardiovascular preventive therapy is recommended in women and men.
I
C
Systemic post-menopausal hormone therapy is not recommended in women with CCS, given the lack of cardiovascular benefit and an 
increased risk of thrombo-embolic complications.
III
A
Bleeding risk assessment is recommended using the PRECISE-DAPT score, the qualitative ARC-HBR tool or other, validated method.
I
B
Attention to interaction between antiretroviral treatment and statins is recommended in patients with HIV.
I
B
Continued targeted efforts are recommended: 
• to increase delivery of safe and effective cardiac care to all CCS patients, especially those of lower socioeconomic classes; and
• to enhance inclusion in future clinical trials of geographical, social, or other groups that are currently underrepresented.
I
C
Recommendations for screening for coronary artery disease in asymptomatic individuals
Opportunistic screening of healthy individuals for cardiovascular risk factors and to estimate the risk of future cardiovascular events using 
scoring systems, e.g. SCORE2 and SCORE-OP, is recommended to detect individuals at high risk and guide treatment decisions.
I
C
Continued


<!-- PAGE 91 -->

### Page 91

### 10 Evidence tables

Evidence tables are available at European Heart Journal online.
11. Data availability statement
No new data were generated or analysed in support of this research.
12. Author information
Author/task force Member Affiliations: Konstantinos 
C. Koskinas, Department of Cardiology, Bern University Hospital— 
INSELSPITAL, University of Bern, Bern, Switzerland; Xavier 
Rossello, Cardiology Department Hospital Universitari Son Espases, 
Palma de Mallorca, Spain, Health Research Institute of the Balearic 
Islands (IdISBa), Universitat de les Illes Balears (UIB), Palma de 
Mallorca, Spain, and Clinical Research Department, Centro Nacional 
de 
Investigaciones 
Cardiovasculares 
(CNIC), 
Madrid, 
Spain; 
Marianna Adamo, Department of Medical and Surgical Specialties, 
Radiological Sciences and Public Health, Institute of Cardiology, ASST 
Spedali Civili di Brescia and University of Brescia, Brescia, Italy; 
James Ainslie, ESC Patient Forum, Sophia Antipolis, France; 
Adrian Paul Banning, Oxford Heart Centre, Oxford University 
Hospitals, Oxford, United Kingdom; Andrzej Budaj, Department 
of Cardiology, Centre of Postgraduate Medical Education, Warsaw, 
Poland; Ronny R. Buechel, Department of Nuclear Medicine, 
Cardiac Imaging, University and University Hospital Zurich, Zurich, 
Switzerland; Giovanni Alfonso Chiariello, Department of 
Cardiovascular 
Sciences, 
Fondazione 
Policlinico 
Universitario 
Agostino Gemelli IRCCS, Rome, Italy, and Università Cattolica del 
Sacro Cuore, Rome, Italy; Alaide Chieffo, Vita Salute San Raffaele 
University, Milan, Italy, and Interventional Cardiology Unit, IRCCS San 
Raffaele Scientific Institute, Milan, Italy; Ruxandra Maria 
Christodorescu, Department V Internal Medicine, University of 
Medicine and Pharmacy V Babes, Timisoara, Romania, and Research 
Recommendations for adherence to medical therapy and lifestyle changes
Mobile health interventions (e.g. using text messages, apps, wearable devices) are recommended to improve patient adherence to healthy 
lifestyles and medical therapy.
I
A
Behavioural interventions are recommended to improve adherence.
I
B
Simplifying medication regimens (e.g. using fixed-dose drug combinations) is recommended to increase patient adherence to medications.
I
B
Multiprofessional and family involvement is recommended to promote adherence, in addition to patient education and involvement.
I
C
Recommendations for diagnosis of disease progression in patients with established chronic coronary syndrome
Regardless of symptoms, periodic visits (e.g. annual) to a general practitioner or cardiovascular healthcare professional are recommended to 
evaluate cardiovascular risk factor control and to assess changes in risk status, disease status, and comorbidities that may require lifestyle, 
medical, or procedural interventions.
I
C
Reassessment of CAD status is recommended in patients with deteriorating LV systolic function that cannot be attributed to a reversible 
cause (e.g. longstanding tachycardia or myocarditis).
I
C
Risk stratification is recommended in patients with new or worsening symptoms, preferably using stress imaging.
I
C
In patients with symptoms refractory to medical treatment or at high risk of adverse events, invasive coronary angiography (with FFR/iFR 
when necessary) is recommended for risk stratification and for possible revascularization aimed at improving symptoms and prognosis.
I
C
Recommendations for treatment of revascularization failure
DES is recommended over drug-coated balloons for treatment of in-DES restenosis.
I
A
LIMA is indicated as the conduit of choice for redo CABG in patients in whom the LIMA was not used previously.
I
B
Recommendations for recurrent or refractory angina/ischaemia
In patients with refractory angina leading to poor quality of life and with documented or suspected ANOCA/INOCA, invasive coronary 
function testing is recommended to define ANOCA/INOCA endotypes and appropriate treatment, considering patient choices and 
preferences.
I
B
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ANOCA, angina with non-obstructive coronary arteries; ARB, angiotensin receptor 
blocker; ARC-HBR, Academic Research Consortium for High Bleeding; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; BP, blood pressure; CABG, coronary artery 
bypass grafting; CACS, coronary artery calcium score; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic coronary syndrome; CCTA, coronary computed 
tomography angiography; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CT, computed tomography; CV, cardiovascular; 
CVD, cardiovascular disease; CYP3A4, cytochrome P450 3A4; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DHP, dihydropyridine; DOAC, direct oral anticoagulant; ECG, 
electrocardiogram; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; FFR-CT, coronary computed tomography angiography-derived fractional flow reserve; 
GDMT, guideline-directed medical therapy; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
heart failure with reduced ejection fraction; HIV, human immunodeficiency virus; ICA, invasive coronary angiography; ICD, implantable cardioverter defibrillator; iFR, instantaneous 
wave-free ratio; INOCA, ischaemia with non-obstructive coronary arteries; IVUS, intravascular ultrasound; LAD, left anterior descending; LBBB, left bundle branch block; LDL-C, 
low-density lipoprotein cholesterol; LIMA, left internal mammary artery; LV, left ventricular; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; MI, 
myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OAC, oral anticoagulant; OCT, optical coherence tomography; PCI, 
percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; PET, positron emission tomography; PRECISE-DAPT, PREdicting bleeding Complications In 
patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy; QFR, quantitative flow ratio; SCORE2, Systematic Coronary Risk Estimation 2; SCORE-OP, 
Systematic Coronary Risk Estimation 2–Older Persons; SGLT2, sodium–glucose cotransporter 2; SPECT, single-photon emission computed tomography; STS, Society of Thoracic 
Surgeons; SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery; T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3505


<!-- PAGE 92 -->

### Page 92

Center, Institute of Cardiovascular Diseases, Timisoara, Romania; 
Christi Deaton, Public Health and Primary Care, Cambridge 
University School of Clinical Medicine, Cambridge, United Kingdom; 
Torsten 
Doenst, 
Department 
of 
cardiothoracic 
surgery, 
Friedrich-Schiller-University Jena, university hospital, Jena, Germany; 
Hywel W. Jones, ESC Patient Forum, Sophia Antipolis, France; Vijay 
Kunadian, Translational and Clinical Research Institute, Faculty of 
Medical Sciences, Newcastle University and Cardiothoracic Centre, 
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation 
Trust, Newcastle upon Tyne, United Kingdom; Julinda Mehilli, 
Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany, 
and 
Klinikum 
der 
Universität 
München 
Ludwig-Maximilians 
University, Munich, Germany; Milan Milojevic, Department of 
Cardiac 
Surgery 
and 
Cardiovascular 
Research, 
Dedinje 
Cardiovascular Institute, Belgrade, Serbia; Jan J. Piek, Heart Center, 
Department of Clinical and Experimental Cardiology, Amsterdam 
Cardiovascular 
Sciences, 
Amsterdam 
UMC, 
University 
of 
Amsterdam, Amsterdam, Netherlands; Francesca Pugliese, 
Centre for Advanced Cardiovascular Imaging, The William Harvey 
Research Institute, Queen Mary University of London, London, 
United Kingdom, Barts Health NHS Trust, London, United Kingdom, 
and Heart Vascular and Thoracic Institute, Cleveland Clinic London, 
London, United Kingdom; Andrea Rubboli, Department of 
Emergency, Internal Medicine, and Cardiology, Division of Cardiology, 
S. Maria delle Croci Hospital, Ravenna, Italy; Anne Grete Semb, 
Preventive cardio-rheuma clinic, Diakonhjemmet Hospital, Oslo, 
Norway, and REMEDY Centre Diakonhjemmet Hospital, Oslo, 
Norway; Roxy Senior, Cardiology Royal Brompton Hospital and 
Imperial College London, London, United Kingdom, and Cardiology, 
Northwick Park Hospital, Harrow, United Kingdom; Jurrien M. ten 
Berg, Cardiology, St Antonius Hospital, Nieuwegein, Netherlands, 
and Cardiology, Maastricht University Medical Centre, Maastricht, 
Netherlands; Eric van Belle, Cardiology, Institut Cour Poumon— 
CHU de Lille, Lille, France, and Equipe 2, INSERM U 1011, Lille, 
France; Emeline M. Van Craenenbroeck, Cardiology department, 
Antwerp University Hospital, Edegem, Belgium, and GENCOR, 
University of Antwerp, Antwerp, Belgium; Rafael Vidal-Perez, 
Cardiology, 
Cardiac 
Imaging 
Unit, 
Complexo 
Hospitalario 
Universitario de A Coruña (CHUAC), A Coruña, Spain, and Centro 
de 
Investigación 
Biomédica 
en 
Red 
de 
Enfermedades 
Cardiovasculares (CIBERCV), Madrid, Spain; and Simon Winther, 
Department of cardiology, Gødstrup hospital, Herning, Denmark, 
and Institute of clinical medicine, Aarhus university, Aarhus, Denmark.
13. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document 
Reviewers: 
Michael 
Borger 
(CPG 
Review 
Co-ordinator) (Germany); Ingibjörg J. Gudmundsdóttir (CPG Review 
Co-ordinator) (Iceland); Juhani Knuuti (CPG Review Co-ordinator) 
(Finland); Ingo Ahrens (Germany); Michael Böhm (Germany); Davide 
Capodanno (Italy); Evald Høj Christiansen (Denmark); Jean-Philippe 
Collet¶ (France); Kenneth Dickstein (Norway); Christian Eek 
(Norway); Volkmar Falk (Germany); Peter A. Henriksen (United 
Kingdom); Borja Ibanez (Spain); Stefan James (Sweden); Sasko Kedev 
(Macedonia); Lars Køber (Denmark); Martha Kyriakou (Cyprus); 
Emma F. Magavern (United Kingdom); Angela McInerney (Ireland); 
John William McEvoy (United Kingdom); Caius Ovidiu Mersha 
(Romania); Borislava Mihaylova (United Kingdom); Richard Mindham 
(United Kingdom); Lis Neubeck (United Kingdom); Franz-Josef 
Neumann (Germany); Jens Cosedis Nielsen (Denmark); Pasquale 
Paolisso (Italy); Valeria Paradies (Netherlands); Agnes A. Pasquet 
(Belgium); Massimo Piepoli (Italy); Eva Prescott (Denmark); Amina 
Rakisheva (Kazakhstan); Bianca Rocca (Italy); Marc Ruel (Canada); 
Sigrid Sandner (Austria); Antti Saraste (Finland); Karolina Szummer 
(Sweden); Ilonca Vaartjes (Netherlands); William Wijns (Ireland); 
Stephan Windecker (Switzerland); Adam Witkowsky (Poland); Marija 
Zdrakovic (Serbia); and Katja Zeppenfeld (Netherlands).
¶Professor Jean-Philippe Collet sadly passed away during the development 
of these guidelines. Professor Collet’s contribution to these guidelines was, as 
always, highly valued.
ESC National Cardiac Societies actively involved in the review 
process of the 2024 ESC Guidelines on the management of chronic 
coronary syndromes:
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: 
Algerian Society of Cardiology, Mohamed Abed Bouraghda; 
Armenia: 
Armenian 
Cardiologists 
Association, 
Hamlet 
G. Hayrapetyan; Austria: Austrian Society of Cardiology, Sebastian 
J. Reinstadler; Azerbaijan: Azerbaijan Society of Cardiology, Ogtay 
Musayev; Belgium: Belgian Society of Cardiology, Michel De Pauw; 
Bosnia and Herzegovina: Association of Cardiologists of Bosnia 
and Herzegovina, Zumreta Kušljugić; Bulgaria: Bulgarian Society of 
Cardiology, Valeri Gelev; Croatia: Croatian Cardiac Society, Bosko 
Skoric; Cyprus: Cyprus Society of Cardiology, Maria Karakyriou; 
Czechia: Czech Society of Cardiology, Tomas Kovarnik; Denmark: 
Danish Society of Cardiology, Lene H. Nielsen; Egypt: Egyptian 
Society of Cardiology, Islam Sh. Abdel-Aziz; Estonia: Estonian 
Society of Cardiology, Tiia Ainla; Finland: Finnish Cardiac Society, 
Pekka Porela; France: French Society of Cardiology, Hakim 
Benamer; Georgia: Georgian Society of Cardiology, Kakha Nadaraia; 
Germany: German Cardiac Society, Gert Richardt; Greece: 
Hellenic Society of Cardiology, Michail I. Papafaklis; Hungary: 
Hungarian Society of Cardiology, Dávid Becker; Iceland: Icelandic 
Society of Cardiology, Ingibjörg J. Gudmundsdóttir; Israel: Israel 
Heart Society, Arik Wolak; Italy: Italian Federation of Cardiology, 
Carmine Riccio; Kazakhstan: Association of Cardiologists of 
Kazakhstan, Bekbolat Kulzhanovich Zholdin; Kosovo (Republic 
of): Kosovo Society of Cardiology, Shpend Elezi; Kyrgyzstan: 
Kyrgyz Society of Cardiology, Saamay Abilova; Latvia: Latvian 
Society of Cardiology, Iveta Mintale; Lebanon: Lebanese Society of 
Cardiology, Bachir Allam; Lithuania: Lithuanian Society of 
Cardiology, Jolita Badarienė; Luxembourg: Luxembourg Society 
of Cardiology, Bruno Pereira; Malta: Maltese Cardiac Society, Philip 
Dingli; Moldova (Republic of): Moldavian Society of Cardiology, 
Valeriu Revenco; Montenegro: Montenegro Society of Cardiology, 
Nebojsa Bulatovic; Morocco: Moroccan Society of Cardiology, El 
Ghali Mohamed Benouna; Netherlands: Netherlands Society of 
Cardiology, Admir Dedic; North Macedonia: National Society of 
Cardiology of North Macedonia, Irena Mitevska; Norway: 
Norwegian Society of Cardiology, Kristin Angel; Poland: Polish 
Cardiac Society, Krzysztof Bryniarski; Portugal: Portuguese Society 
of Cardiology, André Miguel Coimbra Luz; Romania: Romanian 
Society of Cardiology, Bogdan Alexandru Popescu; San Marino: San 
Marino Society of Cardiology, Luca Bertelli; Serbia: Cardiology 
Society of Serbia, Branko Dušan Beleslin; Slovakia: Slovak Society of 
Cardiology, Martin Hudec; Slovenia: Slovenian Society of 
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology, 
Román Freixa-Pamias; Sweden: Swedish Society of Cardiology,


<!-- PAGE 93 -->

### Page 93

Anna Holm; Switzerland: Swiss Society of Cardiology, Raban Jeger; 
Syrian Arab Republic: Syrian Cardiovascular Association, Mhd 
Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology and 
Cardiovascular Surgery, Rania Hammami; Türkiye: Turkish Society 
of Cardiology, Vedat Aytekin; Ukraine: Ukrainian Association of 
Cardiology, Elena G. Nesukay; United Kingdom: British 
Cardiovascular Society, Neil Swanson; and Uzbekistan: Association 
of Cardiologists of Uzbekistan, Aleksandr Borisovich Shek.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), Katja 
Zeppenfeld (Netherlands), and Alexia Rossi§ (Italy).
§Contributor either stepped down or was engaged in only a part of the 
review process.
14. References
1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur 
Heart J 2020;41:407–77. https://doi.org/10.1093/eurheartj/ehz425
2. Collet C, Sonck J, Vandeloo B, Mizukami T, Roosens B, Lochy S, et al. Measurement of 
hyperemic pullback pressure gradients to characterize patterns of coronary athero­
sclerosis. J Am Coll Cardiol 2019;74:1772–84. https://doi.org/10.1016/j.jacc.2019.07.072
3. Scarsini R, Fezzi S, Leone AM, De Maria GL, Pighi M, Marcoli M, et al. Functional pat­
terns of coronary disease: diffuse, focal, and serial lesions. JACC Cardiovasc Interv 2022; 
15:2174–91. https://doi.org/10.1016/j.jcin.2022.07.015
4. Sternheim D, Power DA, Samtani R, Kini A, Fuster V, Sharma S. Myocardial bridging: 
diagnosis, functional assessment, and management: JACC state-of-the-art review. J Am 
Coll Cardiol 2021;78:2196–212. https://doi.org/10.1016/j.jacc.2021.09.859
5. Gentile F, Castiglione V, De Caterina R. Coronary artery anomalies. Circulation 2021; 
144:983–96. https://doi.org/10.1161/CIRCULATIONAHA.121.055347
6. Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, et al. Coronary 
microvascular dysfunction across the spectrum of cardiovascular diseases: JACC 
state-of-the-art review. J Am Coll Cardiol 2021;78:1352–71. https://doi.org/10.1016/j. 
jacc.2021.07.042
7. Marzilli M, Crea F, Morrone D, Bonow RO, Brown DL, Camici PG, et al. Myocardial 
ischemia: from disease to syndrome. Int J Cardiol 2020;314:32–5. https://doi.org/10. 
1016/j.ijcard.2020.04.074
8. Gutierrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernandez-Aviles F. 
Endothelial dysfunction over the course of coronary artery disease. Eur Heart J 
2013;34:3175–81. https://doi.org/10.1093/eurheartj/eht351
9. Allaqaband H, Gutterman DD, Kadlec AO. Physiological consequences of coronary 
arteriolar dysfunction and its influence on cardiovascular disease. Physiology 
(Bethesda) 2018;33:338–47. https://doi.org/10.1152/physiol.00019.2018
10. Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, 
et al. Endothelial function in cardiovascular medicine: a consensus paper of the 
European Society of Cardiology Working Groups on Atherosclerosis and Vascular 
Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and 
Microcirculation, and Thrombosis. Cardiovasc Res 2021;117:29–42. https://doi.org/ 
10.1093/cvr/cvaa085
11. Trask AJ, Katz PS, Kelly AP, Galantowicz ML, Cismowski MJ, West TA, et al. Dynamic 
micro- and macrovascular remodeling in coronary circulation of obese Ossabaw pigs 
with metabolic syndrome. J Appl Physiol 2012;113:1128–40. https://doi.org/10.1152/ 
japplphysiol.00604.2012
12. Campbell DJ, Somaratne JB, Prior DL, Yii M, Kenny JF, Newcomb AE, et al. Obesity is 
associated with lower coronary microvascular density. PLoS One 2013;8:e81798. 
https://doi.org/10.1371/journal.pone.0081798
13. Hinkel R, Howe A, Renner S, Ng J, Lee S, Klett K, et al. Diabetes mellitus-induced 
microvascular destabilization in the myocardium. J Am Coll Cardiol 2017;69:131–43. 
https://doi.org/10.1016/j.jacc.2016.10.058
14. Bajaj Navkaranbir S, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. 
Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am 
Coll Cardiol 2018;72:707–17. https://doi.org/10.1016/j.jacc.2018.05.049
15. Seitz A, Martínez Pereyra V, Sechtem U, Ong P. Update on coronary artery spasm 
2022—a narrative review. Int J Cardiol 2022;359:1–6. https://doi.org/10.1016/j.ijcard. 
2022.04.011
16. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
17. Sandhu AT, Rodriguez F, Ngo S, Patel BN, Mastrodicasa D, Eng D, et al. Incidental cor­
onary artery calcium: opportunistic screening of previous nongated chest computed 
tomography scans to improve statin rates (NOTIFY-1 project). Circulation 2023; 
147:703–14. https://doi.org/10.1161/CIRCULATIONAHA.122.062746
18. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al. Insights from the 
NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: 
gender differences in presentation, diagnosis, and outcome with regard to gender- 
based pathophysiology of atherosclerosis and macrovascular and microvascular cor­
onary disease. J Am Coll Cardiol 2006;47:S21–9. https://doi.org/10.1016/j.jacc.2004. 
12.084
19. Andreotti F, Marchese N. Women and coronary disease. Heart 2008;94:108–16. 
https://doi.org/10.1136/hrt.2005.072769
20. Ferrari R, Abergel H, Ford I, Fox KM, Greenlaw N, Steg PG, et al. Gender- and 
age-related differences in clinical presentation and management of outpatients with 
stable coronary artery disease. Int J Cardiol 2013;167:2938–43. https://doi.org/10. 
1016/j.ijcard.2012.08.013
21. Mehta PK, Bess C, Elias-Smale S, Vaccarino V, Quyyumi A, Pepine CJ, et al. Gender in 
cardiovascular medicine: chest pain and coronary artery disease. Eur Heart J 2019;40: 
3819–26. https://doi.org/10.1093/eurheartj/ehz784
22. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due 
to prevention versus treatment: public health versus clinical care. Annu Rev Public 
Health 2011;32:5–22. https://doi.org/10.1146/annurev-publhealth-031210-101211
23. Safiri S, Karamzad N, Singh K, Carson-Chahhoud K, Adams C, Nejadghaderi SA, et al. 
Burden of ischemic heart disease and its attributable risk factors in 204 countries and 
territories, 1990–2019. Eur J Prev Cardiol 2022;29:420–31. https://doi.org/10.1093/ 
eurjpc/zwab213
24. Andreotti F, Crea F, Sechtem U. Diagnoses and outcomes in patients with suspected 
angina: what are they trying to tell us? Eur Heart J 2019;40:1436–9. https://doi.org/10. 
1093/eurheartj/ehz032
25. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of 
coronary-artery disease. N Engl J Med 1979;300:1350–8. https://doi.org/10.1056/ 
NEJM197906143002402
26. Genders TS, Steyerberg EW, Alkadhi H, Leschka S, Desbiolles L, Nieman K, et al. A 
clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, 
and extension. Eur Heart J 2011;32:1316–30. https://doi.org/10.1093/eurheartj/ehr014
27. Reeh J, Therming CB, Heitmann M, Højberg S, Sørum C, Bech J, et al. Prediction of ob­
structive coronary artery disease and prognosis in patients with suspected stable an­
gina. Eur Heart J 2019;40:1426–35. https://doi.org/10.1093/eurheartj/ehy806
28. Gerber Y, Gibbons RJ, Weston SA, Fabbri M, Herrmann J, Manemann SM, et al. 
Coronary disease surveillance in the community: angiography and revascularization. 
J Am Heart Assoc 2020;9:e015231. https://doi.org/10.1161/jaha.119.015231
29. Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, et al. Impact of 
a decreasing pre-test probability on the performance of diagnostic tests for coronary 
artery disease. Eur Heart J Cardiovasc Imaging 2019;20:1198–207. https://doi.org/10. 
1093/ehjci/jez054
30. Winther S, Schmidt SE, Rasmussen LD, Juárez Orozco LE, Steffensen FH, Bøtker HE, 
et al. Validation of the European Society of Cardiology pre-test probability model for 
obstructive coronary artery disease. Eur Heart J 2021;42:1401–11. https://doi.org/10. 
1093/eurheartj/ehaa755
31. Serruys PW, Hara H, Garg S, Kawashima H, Nørgaard BL, Dweck MR, et al. Coronary 
computed tomographic angiography for complete assessment of coronary artery dis­
ease: JACC state-of-the-art review. J Am Coll Cardiol 2021;78:713–36. https://doi.org/10. 
1016/j.jacc.2021.06.019
32. Serruys WP, Kotoku N, Nørgaard LB, Garg S, Nieman K, Dweck MR, et al. Computed 
tomographic angiography in coronary artery disease. EuroIntervention 2023;18: 
e1307–27. https://doi.org/10.4244/EIJ-D-22-00776
33. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al. 
Outcomes of anatomical versus functional testing for coronary artery disease. 
N Engl J Med 2015;372:1291–300. https://doi.org/10.1056/NEJMoa1415516
34. SCOT-HEART Investigators; Newby DE, Adamson PD, Berry C, Boon NA, Dweck 
MR, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl 
J Med 2018;379:924–33. https://doi.org/10.1056/NEJMoa1805971
35. Mezquita AJV, Biavati F, Falk V, Alkadhi H, Hajhosseiny R, Maurovich-Horvat P, et al. 
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: 
a consensus statement from the Quantitative Cardiovascular Imaging Study Group. 
Nat Rev Cardiol 2023;20:696–714. https://doi.org/10.1038/s41569-023-00880-4
ESC Guidelines                                                                                                                                                                                          3507


<!-- PAGE 94 -->

### Page 94

36. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI 
expert consensus document on ischaemia with non-obstructive coronary arteries in 
collaboration with European Society of Cardiology Working Group on Coronary 
Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders 
International Study Group. Eur Heart J 2020;41:3504–20. https://doi.org/10.1093/ 
eurheartj/ehaa503
37. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, et al. Clinical use­
fulness, angiographic characteristics, and safety evaluation of intracoronary acetylcho­
line provocation testing among 921 consecutive white patients with unobstructed 
coronary 
arteries. 
Circulation 
2014;129:1723–30. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.113.004096
38. Feenstra RGT, Boerhout CKM, Woudstra J, Vink CEM, Wittekoek ME, de Waard GA, 
et al. Presence of coronary endothelial dysfunction, coronary vasospasm, and 
adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstruc­
tive coronary arteries. Circ Cardiovasc Interv 2022;15:e012017. https://doi.org/10.1161/ 
circinterventions.122.012017
39. Samuels BA, Shah SM, Widmer RJ, Kobayashi Y, Miner SES, Taqueti VR, et al. 
Comprehensive management of ANOCA, Part 1—definition, patient population, 
and diagnosis: JACC state-of-the-art review. J Am Coll Cardiol 2023;82:1245–63. 
https://doi.org/10.1016/j.jacc.2023.06.043
40. Smilowitz NR, Prasad M, Widmer RJ, Toleva O, Quesada O, Sutton NR, et al. 
Comprehensive management of ANOCA, Part 2—program development, treatment, 
and research initiatives: JACC state-of-the-art review. J Am Coll Cardiol 2023;82: 
1264–79. https://doi.org/10.1016/j.jacc.2023.06.044
41. Ong P, Safdar B, Seitz A, Hubert A, Beltrame JF, Prescott E. Diagnosis of coronary 
microvascular dysfunction in the clinic. Cardiovasc Res 2020;116:841–55. https://doi. 
org/10.1093/cvr/cvz339
42. Feenstra RGT, Seitz A, Boerhout CKM, de Winter RJ, Ong P, Beijk MAM, et al. 
Reference values for intracoronary Doppler flow velocity-derived hyperaemic micro­
vascular resistance index. Int J Cardiol 2023;371:16–20. https://doi.org/10.1016/j.ijcard. 
2022.09.054
43. Jansen TPJ, Konst RE, Elias-Smale SE, van den Oord SC, Ong P, de Vos AMJ, et al. 
Assessing microvascular dysfunction in angina with unobstructed coronary arteries: 
JACC review topic of the week. J Am Coll Cardiol 2021;78:1471–9. https://doi.org/10. 
1016/j.jacc.2021.08.028
44. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global 
coronary flow reserve is associated with adverse cardiovascular events independently 
of luminal angiographic severity and modifies the effect of early revascularization. 
Circulation 
2015;131:19–27. 
https://doi.org/10.1161/CIRCULATIONAHA.114. 
011939
45. Schindler TH, Fearon WF, Pelletier-Galarneau M, Ambrosio G, Sechtem U, Ruddy TD, 
et al. PET for detection and reporting coronary microvascular dysfunction. JACC 
Cardiovasc Imaging 2023;16:536–48. https://doi.org/10.1016/j.jcmg.2022.12.015
46. Ong P, Seitz A. Advances in risk stratification of patients with coronary microvascular 
dysfunction: usefulness of stress perfusion CMR. JACC Cardiovasc Imaging 2021;14: 
612–4. https://doi.org/10.1016/j.jcmg.2020.09.036
47. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial 
invasive or conservative strategy for stable coronary disease. New Engl J Med 2020; 
382:1395–407. https://doi.org/10.1056/NEJMoa1915922
48. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal 
medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 
356:1503–16. https://doi.org/10.1056/NEJMoa070829
49. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional 
flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J 
Med 2012;367:991–1001. https://doi.org/10.1056/NEJMoa1205361
50. Spertus JA, Jones PG, Maron DJ, O’Brien SM, Reynolds HR, Rosenberg Y, et al. 
Health-status outcomes with invasive or conservative care in coronary disease. 
N Engl J Med 2020;382:1408–19. https://doi.org/10.1056/NEJMoa1916370
51. Creber RM, Dimagli A, Spadaccio C, Myers A, Moscarelli M, Demetres M, et al. Effect 
of coronary artery bypass grafting on quality of life: a meta-analysis of randomized 
trials. Eur Heart J Qual Care Clin Outcomes 2022;8:259–68. https://doi.org/10.1093/ 
ehjqcco/qcab075
52. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, et al. A 
placebo-controlled trial of percutaneous coronary intervention for stable angina. New 
Engl J Med 2023;389:2319–30. https://doi.org/10.1056/NEJMoa2310610
53. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery 
bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364: 
1607–16. https://doi.org/10.1056/NEJMoa1100356
54. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery 
bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374: 
1511–20. https://doi.org/10.1056/NEJMoa1602001
55. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, et al. Cardiac 
mortality in patients randomised to elective coronary revascularisation plus medical 
therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J 
2021;42:4638–51. https://doi.org/10.1093/eurheartj/ehab246
56. Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O’Brien SM, et al. Survival 
after invasive or conservative management of stable coronary disease. Circulation 2023; 
147:8–19. https://doi.org/10.1161/CIRCULATIONAHA.122.062714
57. Douglas PS, Nanna MG, Kelsey MD, Yow E, Mark DB, Patel MR, et al. Comparison of 
an initial risk-based testing strategy vs usual testing in stable symptomatic patients with 
suspected coronary artery disease: the PRECISE randomized clinical trial. JAMA 
Cardiology 2023;8:904–14. https://doi.org/10.1001/jamacardio.2023.2595
58. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. New Engl J Med 1996; 
334:1311–5. https://doi.org/10.1056/nejm199605163342007
59. Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, et al. Sex differences in 
demographics, risk factors, presentation, and noninvasive testing in stable outpatients 
with suspected coronary artery disease: insights from the PROMISE trial. JACC 
Cardiovasc Imaging 2016;9:337–46. https://doi.org/10.1016/j.jcmg.2016.02.001
60. Garcia M, Mulvagh SL, Bairey Merz CN, Buring JE, Manson JE. Cardiovascular disease in 
women: clinical perspectives. Circ Res 2016;118:1273–93. https://doi.org/10.1161/ 
CIRCRESAHA.116.307547
61. Stepinska J, Lettino M, Ahrens I, Bueno H, Garcia-Castrillo L, Khoury A, et al. Diagnosis 
and risk stratification of chest pain patients in the emergency department: focus on 
acute coronary syndromes. A position paper of the Acute Cardiovascular Care 
Association. Eur Heart J Acute Cardiovasc Care 2020;9:76–89. https://doi.org/10.1177/ 
2048872619885346
62. Hoorweg BB, Willemsen RT, Cleef LE, Boogaerts T, Buntinx F, Glatz JFC, et al. 
Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. 
Heart 2017;103:1727–32. https://doi.org/10.1136/heartjnl-2016-310905
63. Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, et al. Association 
of sex with severity of coronary artery disease, ischemia, and symptom burden in pa­
tients with moderate or severe ischemia: secondary analysis of the ISCHEMIA rando­
mized clinical trial. JAMA Cardiol 2020;5:773–86. https://doi.org/10.1001/jamacardio. 
2020.0822
64. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce 
cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ 
ehz455
65. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of patients with acute coronary syndromes. Eur 
Heart J 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191
66. Campeau L. Letter: grading of angina pectoris. Circulation 1976;54:522–3. https://doi. 
org/10.1161/circ.54.3.947585
67. Fiol-Sala M, Birnbaum J, Nikus K, Bayés de Luna A. Electrocardiography in Ischemic Heart 
Disease. Hoboken, NJ: Wiley Blackwell, 2019.
68. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial 
fibrillation: the Framingham study. Am Heart J 1983;106:389–96. https://doi.org/10. 
1016/0002-8703(83)90208-9
69. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation 2003;108:1263–77. 
https://doi.org/10.1161/01.CIR.0000088001.59265.EE
70. Androulakis A, Aznaouridis KA, Aggeli CJ, Roussakis GN, Michaelides AP, Kartalis AN, 
et al. Transient ST-segment depression during paroxysms of atrial fibrillation in other­
wise normal individuals: relation with underlying coronary artery disease. J Am Coll 
Cardiol 2007;50:1909–11. https://doi.org/10.1016/j.jacc.2007.08.005
71. Guo Y, Zhang L, Wang C, Zhao Y, Chen W, Gao M, et al. Medical treatment and long- 
term outcome of chronic atrial fibrillation in the aged with chest distress: a retrospect­
ive analysis versus sinus rhythm. Clin Interv Aging 2011;6:193–8. https://doi.org/10.2147/ 
CIA.S21775
72. Nucifora G, Schuijf JD, van Werkhoven JM, Trines SA, Kajander S, Tops LF, et al. 
Relationship between obstructive coronary artery disease and abnormal stress testing 
in patients with paroxysmal or persistent atrial fibrillation. Int J Cardiovasc Imaging 2011; 
27:777–85. https://doi.org/10.1007/s10554-010-9725-x
73. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, et al. International stand­
ardization of diagnostic criteria for vasospastic angina. Eur Heart J 2017;38:2565–8. 
https://doi.org/10.1093/eurheartj/ehv351
74. Forslund L, Hjemdahl P, Held C, Björkander I, Eriksson SV, Rehnqvist N. Ischaemia dur­
ing exercise and ambulatory monitoring in patients with stable angina pectoris and 
healthy controls. Gender differences and relationships to catecholamines. Eur Heart 
J 1998;19:578–87. https://doi.org/10.1053/euhj.1997.0819
75. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, et al. 
Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes 
of patients randomized to initial strategies of medical therapy versus revascularization. 
Circulation 1997;95:2037–43. https://doi.org/10.1161/01.cir.95.8.2037
76. Stone PH, Chaitman BR, Forman S, Andrews TC, Bittner V, Bourassa MG, et al. 
Prognostic significance of myocardial ischemia detected by ambulatory electrocardiog­
raphy, exercise treadmill testing, and electrocardiogram at rest to predict cardiac 
events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J 
Cardiol 1997;80:1395–401. https://doi.org/10.1016/s0002-9149(97)00706-6
77. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from 
the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: 
gender differences in traditional and novel risk factors, symptom evaluation, and


<!-- PAGE 95 -->

### Page 95

gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47:S4–20. https://doi. 
org/10.1016/j.jacc.2005.01.072
78. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diag­
nosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 
361:858–67. https://doi.org/10.1056/NEJMoa0900428
79. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in 
early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868–77. https:// 
doi.org/10.1056/NEJMoa0903515
80. Nelson SD, Kou WH, Annesley T, de Buitleir M, Morady F. Significance of ST segment 
depression during paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1988;12: 
383–7. https://doi.org/10.1016/0735-1097(88)90410-x
81. Imrie JR, Yee R, Klein GJ, Sharma AD. Incidence and clinical significance of ST segment 
depression in supraventricular tachycardia. Can J Cardiol 1990;6:323–6. https://doi.org/ 
10.1016/j.amjmed.2017.01.002
82. Riva SI, Della Bella P, Fassini G, Carbucicchio C, Tondo C. Value of analysis of ST seg­
ment changes during tachycardia in determining type of narrow QRS complex tachy­
cardia. J Am Coll Cardiol 1996;27:1480–5. https://doi.org/10.1016/0735-1097(96) 
00013-7
83. Rivera S, De La Paz Ricapito M, Conde D, Verdu M, Roux J, Paredes F. The retrograde 
P-wave theory: explaining ST segment depression in supraventricular tachycardia by 
retrograde AV node conduction. Pacing Clin Electrophysiol 2014;37:1100–5. https:// 
doi.org/10.1111/pace.12394
84. Mercik J, Radziejewska J, Pach K, Zawadzki G, Zyśko D, Gajek J, et al. ST-segment de­
pression in atrioventricular nodal reentrant tachycardia: important finding or just an 
artifact? 
Medicine 
(Baltimore) 
2022;101:e31806. 
https://doi.org/10.1097/md. 
0000000000031806
85. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab­
oration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular 
diseases of the European Society of Cardiology (ESC) and the European Association 
for the Study of Diabetes (EASD). Eur Heart J 2019;41:255–323. https://doi.org/10. 
1093/eurheartj/ehz486
86. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes: de­
veloped by the task force on the management of cardiovascular disease in patients with 
diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:4043–140. 
https://doi.org/10.1093/eurheartj/ehad192
87. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is 
not routinely required for determination of a lipid profile: clinical and laboratory im­
plications including flagging at desirable concentration cut-points—a joint consensus 
statement from the European Atherosclerosis Society and European Federation of 
Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016;37:1944–58. https:// 
doi.org/10.1093/eurheartj/ehw152
88. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and 
improved cardiovascular risk prediction. J Am Coll Cardiol 2013;61:1146–56. https://doi. 
org/10.1016/j.jacc.2012.12.023
89. Rossello X. Lifetime risk estimation in atherosclerotic cardiovascular disease: where 
inflammation meets lipoprotein(a). J Am Coll Cardiol 2021;78:1095–6. https://doi.org/ 
10.1016/j.jacc.2021.07.035
90. Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML. Lipoprotein(a) 
and secondary prevention of atherothrombotic events: a critical appraisal. J Clin Lipidol 
2018;12:1358–66. https://doi.org/10.1016/j.jacl.2018.08.012
91. Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical trial design for 
lipoprotein(a)-lowering therapies: JACC focus seminar 2/3. J Am Coll Cardiol 2023;81: 
1633–45. https://doi.org/10.1016/j.jacc.2023.02.033
92. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. 
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a 
European Atherosclerosis Society consensus statement. Eur Heart J 2022;43: 
3925–46. https://doi.org/10.1093/eurheartj/ehac361
93. Lopes NH, da Silva Paulitsch F, Pereira A, Garzillo CL, Ferreira JF, Stolf N, et al. Mild 
chronic kidney dysfunction and treatment strategies for stable coronary artery disease. 
J Thorac Cardiovasc Surg 2009;137:1443–9. https://doi.org/10.1016/j.jtcvs.2008.11.028
94. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. 
Chronic kidney disease and risk of major cardiovascular disease and non-vascular mor­
tality: prospective population based cohort study. BMJ 2010;341:c4986. https://doi. 
org/10.1136/bmj.c4986
95. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, et al. Associations of esti­
mated glomerular filtration rate and albuminuria with mortality and renal failure by sex: 
a meta-analysis. BMJ 2013;346:f324. https://doi.org/10.1136/bmj.f324
96. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A 
sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 
361:2538–47. https://doi.org/10.1056/NEJMoa0805299
97. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association 
of troponin T detected with a highly sensitive assay and cardiac structure and mortality 
risk in the general population. JAMA 2010;304:2503–12. https://doi.org/10.1001/jama. 
2010.1768
98. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltytė Benth J, et al. 
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients 
with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240–9. https://doi.org/ 
10.1016/j.jacc.2012.12.026
99. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, et al. 
Circulating biomarkers for predicting cardiovascular disease risk; a systematic review 
and comprehensive overview of meta-analyses. PLoS One 2013;8:e62080. https://doi. 
org/10.1371/journal.pone.0062080
100. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL, et al. Troponin 
and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015; 
373:610–20. https://doi.org/10.1056/NEJMoa1415921
101. Laufer EM, Mingels AM, Winkens MH, Joosen IAPG, Schellings MWM, Leiner T, et al. 
The extent of coronary atherosclerosis is associated with increasing circulating levels 
of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol 2010;30:1269–75. 
https://doi.org/10.1161/ATVBAHA.109.200394
102. Madsen DM, Diederichsen ACP, Hosbond SE, Gerke O, Mickley H. Diagnostic and 
prognostic value of a careful symptom evaluation and high sensitive troponin in pa­
tients with suspected stable angina pectoris without prior cardiovascular disease. 
Atherosclerosis 2017;258:131–7. https://doi.org/10.1016/j.atherosclerosis.2016.11.030
103. Adamson PD, Hunter A, Madsen DM, Shah ASV, McAllister DA, Pawade TA, et al. 
High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in pa­
tients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes 2018;11:e004227. 
https://doi.org/10.1161/circoutcomes.117.004227
104. Januzzi JL Jr, Suchindran S, Coles A, Ferencik M, Patel MR, Hoffmann U, et al. 
High-sensitivity troponin I and coronary computed tomography in symptomatic out­
patients with suspected cad: insights from the PROMISE trial. JACC Cardiovasc Imaging 
2019;12:1047–55. https://doi.org/10.1016/j.jcmg.2018.01.021
105. Vavassori C, Cipriani E, Colombo GI. Circulating microRNAs as novel biomarkers in 
risk assessment and prognosis of coronary artery disease. Eur Cardiol 2022;17:e06. 
https://doi.org/10.15420/ecr.2021.47
106. Hoogeveen RM, Pereira JPB, Nurmohamed NS, Zampoleri V, Bom MJ, Baragetti A, 
et al. Improved cardiovascular risk prediction using targeted plasma proteomics in pri­
mary prevention. Eur Heart J 2020;41:3998–4007. https://doi.org/10.1093/eurheartj/ 
ehaa648
107. Ibrahim NE, Januzzi JL Jr, Magaret CA, Gaggin HK, Rhyne RF, Gandhi PU, et al. A clinical 
and biomarker scoring system to predict the presence of obstructive coronary artery 
disease. J Am Coll Cardiol 2017;69:1147–56. https://doi.org/10.1016/j.jacc.2016.12.021
108. Hilvo M, Meikle PJ, Pedersen ER, Tell GS, Dhar I, Brenner H, et al. Development and 
validation of a ceramide- and phospholipid-based cardiovascular risk estimation score 
for coronary artery disease patients. Eur Heart J 2020;41:371–80. https://doi.org/10. 
1093/eurheartj/ehz387
109. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 
342:836–43. https://doi.org/10.1056/nejm200003233421202
110. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive 
protein and other circulating markers of inflammation in the prediction of coronary 
heart disease. N Engl J Med 2004;350:1387–97. https://doi.org/10.1056/ 
NEJMoa032804
111. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al. Impact of 
C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable 
angina pectoris: the AtheroGene study. Eur Heart J 2006;27:2962–8. https://doi.org/10. 
1093/eurheartj/ehl362
112. Jia RF, Li L, Li H, Cao X-J, Ruan Y, Meng S, et al. Meta-analysis of C-reactive protein and 
risk of angina pectoris. Am J Cardiol 2020;125:1039–45. https://doi.org/10.1016/j. 
amjcard.2020.01.005
113. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, 
and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 
336:973–9. https://doi.org/10.1056/nejm199704033361401
114. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and 
the risk of myocardial infarction or sudden death in patients with angina pectoris. 
European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study 
Group. N Engl J Med 1995;332:635–41. https://doi.org/10.1056/nejm1995030933 
21003
115. De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, et al. High fibrino­
gen level is an independent predictor of presence and extent of coronary artery dis­
ease among Italian population. J Thromb Thrombolysis 2011;31:458–63. https://doi. 
org/10.1007/s11239-010-0531-z
116. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, et al. Relation of fibrinogen 
level with cardiovascular events in patients with coronary artery disease. Am J Cardiol 
2013;111:804–10. https://doi.org/10.1016/j.amjcard.2012.11.060
117. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovas­
cular disease: the Framingham study. JAMA 1987;258:1183–6. https://doi.org/10. 
1001/jama.1987.03400090067035
118. Appiah D, Schreiner PJ, MacLehose RF, Folsom AR. Association of plasma γ′ fibrinogen 
with incident cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) 
ESC Guidelines                                                                                                                                                                                          3509


<!-- PAGE 96 -->

### Page 96

study. Arterioscler Thromb Vasc Biol 2015;35:2700–6. https://doi.org/10.1161/atvbaha. 
115.306284
119. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, et al. 
Inflammation and cholesterol as predictors of cardiovascular events among patients 
receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 
2023;401:1293–301. https://doi.org/10.1016/S0140-6736(23)00215-5
120. Ridker PM, Lei L, Louie MJ, Haddad T, Nicholls SJ, Lincoff AM, et al. Inflammation and 
cholesterol as predictors of cardiovascular events among 13 970 contemporary high- 
risk patients with statin intolerance. Circulation 2024;149:28–35. https://doi.org/10. 
1161/CIRCULATIONAHA.123.066213
121. Bohula EA, Giugliano RP, Leiter LA, Verma S, Park J-G, Sever PS, et al. Inflammatory 
and cholesterol risk in the FOURIER trial. Circulation 2018;138:131–40. https://doi. 
org/10.1161/circulationaha.118.034032
122. Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur 
Heart J 2022;43:3198–208. https://doi.org/10.1093/eurheartj/ehab841
123. Byrne P, Demasi M, Jones M, Smith SM, O’Brien KK, DuBroff R. Evaluating the associ­
ation between low-density lipoprotein cholesterol reduction and relative and absolute 
effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med 
2022;182:474–81. https://doi.org/10.1001/jamainternmed.2022.0134
124. Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction 
of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1/4. J Am Coll Cardiol 
2021;77:1564–75. https://doi.org/10.1016/j.jacc.2020.11.079
125. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment 
with PCSK9 inhibition and statin therapy. Circulation 2018;138:141–9. https://doi.org/ 
10.1161/CIRCULATIONAHA.118.034645
126. Waksman R, Merdler I, Case BC, Waksman O, Porto I. Targeting inflammation in ath­
erosclerosis: overview, strategy and directions. EuroIntervention 2024;20:32–44. 
https://doi.org/10.4244/EIJ-D-23-00606
127. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. 
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a 
double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021;397: 
2060–9. https://doi.org/10.1016/S0140-6736(21)00520-1
128. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. 
Association between lowering LDL-C and cardiovascular risk reduction among differ­
ent therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316: 
1289–97. https://doi.org/10.1001/jama.2016.13985
129. Arant CB, Wessel TR, Olson MB, Bairey Merz CN, Sopko G, Rogers WJ, et al. 
Hemoglobin level is an independent predictor for adverse cardiovascular outcomes 
in women undergoing evaluation for chest pain: results from the National Heart, 
Lung, and Blood Institute Women’s Ischemia Syndrome Evaluation Study. J Am Coll 
Cardiol 2004;43:2009–14. https://doi.org/10.1016/j.jacc.2004.01.038
130. da Silveira AD, Ribeiro RA, Rossini AP, Stella SF, Ritta HAR, Stein R, et al. Association of 
anemia with clinical outcomes in stable coronary artery disease. Coron Artery Dis 2008; 
19:21–6. https://doi.org/10.1097/MCA.0b013e3282f27c0a
131. Muzzarelli S, Pfisterer M; Time Investigators. Anemia as independent predictor of ma­
jor events in elderly patients with chronic angina. Am Heart J 2006;152:991–6. https:// 
doi.org/10.1016/j.ahj.2006.06.014
132. Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif J-C, Tendera M, et al. Hemoglobin and 
change in hemoglobin status predict mortality, cardiovascular events, and bleeding in 
stable coronary artery disease. Am J Med 2017;130:720–30. https://doi.org/10.1016/ 
j.amjmed.2017.01.002
133. Asif A, Wei J, Lauzon M, Sopko G, Reis SE, Handberg E, et al. Anemia and long-term 
cardiovascular outcomes in women with suspected ischemia—the Women’s Ischemia 
Syndrome Evaluation (WISE). Am Heart J Plus Cardiol Res Pract 2021;10:100059. https:// 
doi.org/10.1016/j.ahjo.2021.100059
134. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of 
coronary heart disease in general populations: new prospective study and systematic 
review. PLoS Med 2007;4:e270. https://doi.org/10.1371/journal.pmed.0040270
135. Bartnik M, Ryden L, Malmberg K, Ohrvik J, Pyorala K, Standl E, et al. Oral glucose tol­
erance test is needed for appropriate classification of glucose regulation in patients 
with coronary artery disease: a report from the Euro Heart Survey on Diabetes and 
the Heart. Heart 2007;93:72–7. https://doi.org/10.1136/hrt.2005.086975
136. Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Sundvall J, et al. Screening 
for dysglycaemia in patients with coronary artery disease as reflected by fasting glu­
cose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a sur­
vey from the European Society of Cardiology. Eur Heart J 2015;36:1171–7. https://doi. 
org/10.1093/eurheartj/ehv008
137. Corona G, Croce L, Sparano C, Petrone L, Sforza A, Maggi M, et al. Thyroid and heart, 
a clinically relevant relationship. J Endocrinol Invest 2021;44:2535–44. https://doi.org/10. 
1007/s40618-021-01590-9
138. Sohn SY, Lee E, Lee MK, Lee JH. The association of overt and subclinical hyperthyroid­
ism with the risk of cardiovascular events and cardiovascular mortality: meta-analysis 
and systematic review of cohort studies. Endocrinol Metab (Seoul) 2020;35:786–800. 
https://doi.org/10.3803/EnM.2020.728
139. Winther S, Schmidt SE, Mayrhofer T, Bøtker HE, Hoffmann U, Douglas PS, et al. 
Incorporating coronary calcification into pre-test assessment of the likelihood of 
coronary artery disease. J Am Coll Cardiol 2020;76:2421–32. https://doi.org/10.1016/j. 
jacc.2020.09.585
140. Genders TS, Steyerberg EW, Hunink MG, Nieman K, Galema TW, Mollet NR, et al. 
Prediction model to estimate presence of coronary artery disease: retrospective 
pooled analysis of existing cohorts. BMJ 2012;344:e3485. https://doi.org/10.1136/ 
bmj.e3485
141. Zhou J, Zhao J, Li Z, Cong H, Wang C, Zhang H, et al. Coronary calcification improves 
the estimation for clinical likelihood of obstructive coronary artery disease and avoids 
unnecessary testing in patients with borderline pretest probability. Eur J Prev Cardiol 
2022;29:e105–7. https://doi.org/10.1093/eurjpc/zwab036
142. Winther S, Murphy T, Schmidt SE, Bax JJ, Wijns W, Knuuti J, et al. Performance of the 
American 
Heart 
Association/American 
College 
of 
Cardiology 
guideline- 
recommended pretest probability model for the diagnosis of obstructive coronary 
artery disease. J Am Heart Assoc 2022:e027260. https://doi.org/10.1161/JAHA.122. 
027260
143. Winther S, Schmidt SE, Foldyna B, Mayrhofer T, Rasmussen LD, Dahl JN, et al. 
Coronary calcium scoring improves risk prediction in patients with suspected ob­
structive coronary artery disease. J Am Coll Cardiol 2022;80:1965–77. https://doi.org/ 
10.1016/j.jacc.2022.08.805
144. Rasmussen LD, Schmidt SE, Knuuti J, Newby DE, Singh T, Nieman K, et al. Exercise 
electrocardiography for pre-test assessment of the likelihood of coronary artery dis­
ease. Heart 2023;110:263–70. https://doi.org/10.1136/heartjnl-2023-322970
145. McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, Trinick TR, et al. A comparison 
of cardiac computerized tomography and exercise stress electrocardiogram test for 
the investigation of stable chest pain: the clinical results of the CAPP randomized pro­
spective trial. Eur Heart J Cardiovasc Imaging 2015;16:441–8. https://doi.org/10.1093/ 
ehjci/jeu284
146. Lubbers M, Dedic A, Coenen A, Galema T, Akkerhuis J, Bruning T, et al. Calcium im­
aging and selective computed tomography angiography in comparison to functional 
testing for suspected coronary artery disease: the multicentre, randomized 
CRESCENT trial. Eur Heart J 2016;37:1232–43. https://doi.org/10.1093/eurheartj/ 
ehv700
147. Banerjee A, Newman DR, Van den Bruel A, Heneghan C. Diagnostic accuracy of ex­
ercise stress testing for coronary artery disease: a systematic review and meta-analysis 
of prospective studies. Int J Clin Pract 2012;66:477–92. https://doi.org/10.1111/j.1742- 
1241.2012.02900.x
148. Knuuti J, Ballo H, Juarez-Orozco LE, Saraste A, Kolh P, Rutjes AWS, et al. The perform­
ance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in 
patients with stable angina: a meta-analysis focused on post-test disease probability. 
Eur Heart J 2018;39:3322–30. https://doi.org/10.1093/eurheartj/ehy267
149. Cole JP, Ellestad MH. Significance of chest pain during treadmill exercise: correlation 
with coronary events. Am J Cardiol 1978;41:227–32. https://doi.org/10.1016/0002- 
9149(78)90161-3
150. Lindow T, Ekström M, Brudin L, Carlén A, Elmberg V, Hedman K. Typical angina during 
exercise stress testing improves the prediction of future acute coronary syndrome. 
Clin Physiol Funct Imaging 2021;41:281–91. https://doi.org/10.1111/cpf.12695
151. Agha AM, Pacor J, Grandhi GR, Mszar R, Khan SU, Parikh R, et al. The prognostic value 
of CAC zero among individuals presenting with chest pain. JACC Cardiovasc Imaging 
2022;15:1745–57. https://doi.org/10.1016/j.jcmg.2022.03.031
152. Mortensen MB, Gaur S, Frimmer A, Bøtker HE, Sørensen HT, Kragholm KH, et al. 
Association of age with the diagnostic value of coronary artery calcium score for ruling 
out coronary stenosis in symptomatic patients. JAMA Cardiol 2022;7:36–44. https://doi. 
org/10.1001/jamacardio.2021.4406
153. Lubbers M, Coenen A, Kofflard M, Bruning T, Kietselaer B, Galema T, et al. 
Comprehensive cardiac CT with myocardial perfusion imaging versus functional test­
ing in suspected coronary artery disease: the multicenter, randomized CRESCENT-II 
trial. JACC Cardiovasc Imaging 2018;11:1625–36. https://doi.org/10.1016/j.jcmg.2017. 
10.010
154. Zhou J, Li C, Cong H, Duan L, Wang H, Wang C, et al. Comparison of different inves­
tigation strategies to defer cardiac testing in patients with stable chest pain. JACC 
Cardiovasc Imaging 2022;15:91–104. https://doi.org/10.1016/j.jcmg.2021.08.022
155. Heald CL, Fowkes FG, Murray GD, Price JF. Risk of mortality and cardiovascular dis­
ease associated with the ankle-brachial index: systematic review. Atherosclerosis 
2006;189:61–9. https://doi.org/10.1016/j.atherosclerosis.2006.03.011
156. Molnár S, Kerényi L, Ritter MA, Magyar MT, Ida Y, Szöllősi Z, et al. Correlations be­
tween the atherosclerotic changes of femoral, carotid and coronary arteries: a post 
mortem study. J Neurol Sci 2009;287:241–5. https://doi.org/10.1016/j.jns.2009.06.001
157. Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, Ibañez B, López-Melgar B, 
Laclaustra M, et al. Prevalence, vascular distribution, and multiterritorial extent of sub­
clinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early 
Subclinical Atherosclerosis) study. Circulation 2015;131:2104–13. https://doi.org/10. 
1161/CIRCULATIONAHA.114.014310
158. Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, 
Jiménez-Borreguero LJ, et al. Femoral and carotid subclinical atherosclerosis associ­
ation with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol 
2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056


<!-- PAGE 97 -->

### Page 97

159. Gepner AD, Young R, Delaney JA, Budoff MJ, Polak JF, Blaha MJ, et al. Comparison of 
carotid plaque score and coronary artery calcium score for predicting cardiovascular 
disease events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2017;6: 
e005179. https://doi.org/10.1161/jaha.116.005179
160. Colledanchise KN, Mantella LE, Hétu MF, Liblik K, Abunassar JG, Johri AM. Femoral 
plaque burden by ultrasound is a better indicator of significant coronary artery disease 
over ankle brachial index. Int J Cardiovasc Imaging 2021;37:2965–73. https://doi.org/10. 
1007/s10554-021-02334-9
161. Bjerking LH, Winther S, Hansen KW, Galatius S, Böttcher M, Prescott E. Prediction 
models as gatekeepers for diagnostic testing in angina patients with suspected chronic 
coronary syndrome. Eur Heart J Qual Care Clin Outcomes 2022;8:630–9. https://doi.org/ 
10.1093/ehjqcco/qcac025
162. Rasmussen LD, Karim SR, Westra J, et al. Clinical likelihood prediction of 
hemodynamically obstructive coronary artery disease in patients with stable chest 
pain. JACC Cardiovasc Imaging 2024; In press. https://doi.org/10.1016/j.jcmg.2024.04. 
015
163. Winther S, Nissen L, Westra J, Schmidt SE, Bouteldja N, Knudsen LL, et al. Pre-test 
probability prediction in patients with a low to intermediate probability of coronary 
artery disease: a prospective study with a fractional flow reserve endpoint. Eur 
Heart J Cardiovasc Imaging 2019;20:1208–18. https://doi.org/10.1093/ehjci/jez058
164. Winther S, Schmidt Samuel E, Knuuti J, Bøttcher M. Comparison of pretest probability 
models of obstructive coronary artery disease. JACC Cardiovasc Imaging 2022;15: 
173–5. https://doi.org/10.1016/j.jcmg.2021.11.019
165. Brix GS, Rasmussen LD, Rohde PD, Schmidt SE, Nyegaard M, Douglas PS, et al. 
Calcium scoring improves clinical management in patients with low clinical likelihood 
of coronary artery disease. JACC Cardiovasc Imaging 2024;17:625–39. https://doi.org/ 
10.1016/j.jcmg.2023.11.008
166. Christman MP, Bittencourt MS, Hulten E, Saksena E, Hainer J, Skali H, et al. Yield of 
downstream tests after exercise treadmill testing: a prospective cohort study. J Am 
Coll Cardiol 2014;63:1264–74. https://doi.org/10.1016/j.jacc.2013.11.052
167. Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F, et al. Predicting 
prognosis in stable angina—results from the Euro heart survey of stable angina: pro­
spective observational study. BMJ 2006;332:262–7. https://doi.org/10.1136/bmj. 
38695.605440.AE
168. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. 
Standardized myocardial segmentation and nomenclature for tomographic imaging 
of the heart. A statement for healthcare professionals from the Cardiac Imaging 
Committee of the Council on Clinical Cardiology of the American Heart 
Association. Circulation 2002;105:539–42. https://doi.org/10.1161/hc0402.102975
169. Eek C, Grenne B, Brunvand H, Aakhus S, Endresen K, Hol PK, et al. Strain echocardi­
ography and wall motion score index predicts final infarct size in patients with 
non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging 2010;3: 
187–94. https://doi.org/10.1161/CIRCIMAGING.109.910521
170. Smedsrud MK, Sarvari S, Haugaa KH, Gjesdal O, Ørn S, Aaberge L, et al. Duration of 
myocardial early systolic lengthening predicts the presence of significant coronary ar­
tery disease. J Am Coll Cardiol 2012;60:1086–93. https://doi.org/10.1016/j.jacc.2012.06. 
022
171. Biering-Sorensen T, Hoffmann S, Mogelvang R, Zeeberg Iversen A, Galatius S, 
Fritz-Hansen T, et al. Myocardial strain analysis by 2-dimensional speckle tracking echo­
cardiography improves diagnostics of coronary artery stenosis in stable angina pec­
toris. Circ Cardiovasc Imaging 2014;7:58–65. https://doi.org/10.1161/CIRCIMAGING. 
113.000989
172. Smedsrud MK, Gravning J, Omland T, Eek C, Mørkrid L, Skulstad H, et al. Sensitive car­
diac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery 
disease: correlation with left ventricular function as assessed by myocardial strain. Int J 
Cardiovasc Imaging 2015;31:967–73. https://doi.org/10.1007/s10554-015-0646-6
173. Edwards NFA, Scalia GM, Shiino K, Sabapathy S, Anderson B, Chamberlain R, et al. 
Global myocardial work is superior to global longitudinal strain to predict significant 
coronary artery disease in patients with normal left ventricular function and wall mo­
tion. J Am Soc Echocardiogr 2019;32:947–57. https://doi.org/10.1016/j.echo.2019.02. 
014
174. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowl­
edge. J Am Coll Cardiol 2009;54:1561–75. https://doi.org/10.1016/j.jacc.2009.04.098
175. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. 
Standardization of adult transthoracic echocardiography reporting in agreement 
with recent chamber quantification, diastolic function, and heart valve disease recom­
mendations: an expert consensus document of the European Association of 
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–10. https://doi. 
org/10.1093/ehjci/jex244
176. Steeds RP, Garbi M, Cardim N, Kasprzak JD, Sade E, Nihoyannopoulos P, et al. EACVI 
appropriateness criteria for the use of transthoracic echocardiography in adults: a re­
port of literature and current practice review. Eur Heart J Cardiovasc Imaging 2017;18: 
1191–204. https://doi.org/10.1093/ehjci/jew333
177. Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, et al. Clinical 
practice of contrast echocardiography: recommendation by the European Association 
of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 2017;18: 
1205–1205af. https://doi.org/10.1093/ehjci/jex182
178. Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, et al. 
Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scin­
tigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the 
CE-MARC 2 randomized clinical trial. JAMA 2016;316:1051–60. https://doi.org/10. 
1001/jama.2016.12680
179. Motwani M, Swoboda PP, Plein S, Greenwood JP. Role of cardiovascular magnetic res­
onance in the management of patients with stable coronary artery disease. Heart 2018; 
104:888–94. https://doi.org/10.1136/heartjnl-2017-311658
180. Kim RJ, Wu E, Rafael A, Chen E-L, Parker MA, Simonetti O, et al. The use of 
contrast-enhanced magnetic resonance imaging to identify reversible myocardial dys­
function. N Engl J Med 2000;343:1445–53. https://doi.org/10.1056/NEJM2000111 
63432003
181. Gómez-Revelles S, Rossello X, Díaz-Villanueva J, López-Lima I, Sciarresi E, Estofán M, 
et al. Prognostic value of a new semiquantitative score system for adenosine stress 
myocardial perfusion by CMR. Eur Radiol 2019;29:2263–71. https://doi.org/10.1007/ 
s00330-018-5774-7
182. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR, Chaitman BR, et al. Long-term 
survival of medically treated patients in the Coronary Artery Surgery Study (CASS) 
registry. Circulation 1994;90:2645–57. https://doi.org/10.1161/01.cir.90.6.2645
183. Daly C, Norrie J, Murdoch DL, Ford I, Dargie HJ, Fox K, et al. The value of routine non- 
invasive tests to predict clinical outcome in stable angina. Eur Heart J 2003;24:532–40. 
https://doi.org/10.1016/s0195-668x(02)00820-5
184. Vitarelli A, Tiukinhoy S, Di Luzio S, Zampino M, Gheorghiade M. The role of echocar­
diography in the diagnosis and management of heart failure. Heart Fail Rev 2003;8: 
181–9. https://doi.org/10.1023/a:1023001104207
185. Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European 
Association of Cardiovascular Imaging expert consensus paper: a comprehensive re­
view of cardiovascular magnetic resonance normal values of cardiac chamber size 
and aortic root in adults and recommendations for grading severity. Eur Heart J 
Cardiovasc Imaging 2019;20:1321–31. https://doi.org/10.1093/ehjci/jez232
186. Hoffmann R, von Bardeleben S, Kasprzak JD, Borges AC, ten Cate F, Firschke C, et al. 
Analysis of regional left ventricular function by cineventriculography, cardiac magnetic 
resonance imaging, and unenhanced and contrast-enhanced echocardiography: a mul­
ticenter comparison of methods. J Am Coll Cardiol 2006;47:121–8. https://doi.org/10. 
1016/j.jacc.2005.10.012
187. Williams MC, Hunter A, Shah ASV, Assi V, Lewis S, Smith J, et al. Use of coronary com­
puted tomographic angiography to guide management of patients with coronary dis­
ease. J Am Coll Cardiol 2016;67:1759–68. https://doi.org/10.1016/j.jacc.2016.02.026
188. Singh T, Bing R, Dweck MR, van Beek EJR, Mills NL, Williams MC, et al. Exercise elec­
trocardiography and computed tomography coronary angiography for patients with 
suspected stable angina pectoris: a post hoc analysis of the randomized 
SCOT-HEART trial. JAMA Cardiol 2020;5:920–8. https://doi.org/10.1001/jamacardio. 
2020.1567
189. Zacharias K, Ahmed A, Shah BN, Gurunathan S, Young G, Acosta D, et al. Relative clin­
ical and economic impact of exercise echocardiography vs. exercise electrocardiog­
raphy, as first line investigation in patients without known coronary artery disease 
and new stable angina: a randomized prospective study. Eur Heart J Cardiovasc 
Imaging 2017;18:195–202. https://doi.org/10.1093/ehjci/jew049
190. Shaw LJ, Mieres JH, Hendel RH, Boden WE, Gulati M, Veledar E, et al. Comparative 
effectiveness of exercise electrocardiography with or without myocardial perfusion 
single photon emission computed tomography in women with suspected coronary ar­
tery disease: results from the What Is the Optimal Method for Ischemia Evaluation in 
Women (WOMEN) trial. Circulation 2011;124:1239–49. https://doi.org/10.1161/ 
CIRCULATIONAHA.111.029660
191. Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value 
of a treadmill exercise score in outpatients with suspected coronary artery disease. 
N Engl J Med 1991;325:849–53. https://doi.org/10.1056/NEJM199109193251204
192. Araki H, Koiwaya Y, Nakagaki O, Nakamura M. Diurnal distribution of ST-segment ele­
vation and related arrhythmias in patients with variant angina: a study by ambulatory 
ECG monitoring. Circulation 1983;67:995–1000. https://doi.org/10.1161/01.cir.67.5. 
995
193. Onaka H, Hirota Y, Shimada S, Kita Y, Sakai Y, Kawakami Y, et al. Clinical observation of 
spontaneous anginal attacks and multivessel spasm in variant angina pectoris with nor­
mal coronary arteries: evaluation by 24-hour 12-lead electrocardiography with com­
puter analysis. J Am Coll Cardiol 1996;27:38–44. https://doi.org/10.1016/0735-1097(95) 
00423-8
194. Beijk MA, Vlastra WV, Delewi R, van de Hoef TP, Boekholdt SM, Sjauw KD, et al. 
Myocardial infarction with non-obstructive coronary arteries: a focus on vasospastic 
angina. Neth Heart J 2019;27:237–45. https://doi.org/10.1007/s12471-019-1232-7
195. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. 
Angiographic versus functional severity of coronary artery stenoses in the FAME study 
fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 
2010;55:2816–21. https://doi.org/10.1016/j.jacc.2009.11.096
ESC Guidelines                                                                                                                                                                                          3511


<!-- PAGE 98 -->

### Page 98

196. Schuijf JD, Wijns W, Jukema JW, Atsma DE, de Roos A, Lamb HJ, et al. Relationship 
between noninvasive coronary angiography with multi-slice computed tomography 
and myocardial perfusion imaging. J Am Coll Cardiol 2006;48:2508–14. https://doi.org/ 
10.1016/j.jacc.2006.05.080
197. Siontis GC, Mavridis D, Greenwood JP, Coles B, Nikolakopoulou A, Jüni P, et al. 
Outcomes of non-invasive diagnostic modalities for the detection of coronary artery 
disease: network meta-analysis of diagnostic randomised controlled trials. BMJ 2018; 
360:k504. https://doi.org/10.1136/bmj.k504
198. Neglia D, Liga R, Gimelli A, Podlesnikar T, Cvijić M, Pontone G, et al. Use of cardiac 
imaging in chronic coronary syndromes: the EURECA Imaging registry. Eur Heart J 
2023;44:142–58. https://doi.org/10.1093/eurheartj/ehac640
199. Celeng C, Leiner T, Maurovich-Horvat P, Merkely B, de Jong P, Dankbaar JW, et al. 
Anatomical and functional computed tomography for diagnosing hemodynamically sig­
nificant coronary artery disease: a meta-analysis. JACC Cardiovasc Imaging 2019;12: 
1316–25. https://doi.org/10.1016/j.jcmg.2018.07.022
200. Curzen N, Nicholas Z, Stuart B, Wilding S, Hill K, Shambrook J, et al. Fractional flow 
reserve derived from computed tomography coronary angiography in the assessment 
and management of stable chest pain: the FORECAST randomized trial. Eur Heart J 
2021;42:3844–52. https://doi.org/10.1093/eurheartj/ehab444
201. Mickley H, Veien KT, Gerke O, Lambrechtsen J, Rohold A, Steffensen FH, et al. 
Diagnostic and clinical value of FFR(CT) in stable chest pain patients with extensive 
coronary calcification: the FACC study. JACC Cardiovasc Imaging 2022;15:1046–58. 
https://doi.org/10.1016/j.jcmg.2021.12.010
202. Nørgaard BL, Terkelsen CJ, Mathiassen ON, Grove EL, Bøtker HE, Parner E, et al. 
Coronary CT angiographic and flow reserve-guided management of patients with 
stable ischemic heart disease. J Am Coll Cardiol 2018;72:2123–34. https://doi.org/10. 
1016/j.jacc.2018.07.043
203. Pontone G, Weir-McCall JR, Baggiano A, Del Torto A, Fusini L, Guglielmo M, et al. 
Determinants of rejection rate for coronary CT angiography fractional flow reserve 
analysis. Radiology 2019;292:597–605. https://doi.org/10.1148/radiol.2019182673
204. Andreini D, Belmonte M, Penicka M, Van Hoe L, Mileva N, Paolisso P, et al. Impact of 
coronary CT image quality on the accuracy of the FFR(CT) planner. Eur Radiol 2023; 
34:2677–88. https://doi.org/10.1007/s00330-023-10228-8
205. Rochitte CE, George RT, Chen MY, Arbab-Zadeh A, Dewey M, Miller JM, et al. 
Computed tomography angiography and perfusion to assess coronary artery stenosis 
causing perfusion defects by single photon emission computed tomography: the 
CORE320 study. Eur Heart J 2014;35:1120–30. https://doi.org/10.1093/eurheartj/ 
eht488
206. Nous FMA, Geisler T, Kruk MBP, Alkadhi H, Kitagawa K, Vliegenthart R, et al. Dynamic 
myocardial perfusion CT for the detection of hemodynamically significant coronary ar­
tery disease. JACC Cardiovasc Imaging 2022;15:75–87. https://doi.org/10.1016/j.jcmg. 
2021.07.021
207. Rossi A, Merkus D, Klotz E, Mollet N, de Feyter PJ, Krestin GP. Stress myocardial per­
fusion: imaging with multidetector CT. Radiology 2014;270:25–46. https://doi.org/10. 
1148/radiol.13112739
208. Hoffmann U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, et al. 
Prognostic value of noninvasive cardiovascular testing in patients with stable chest 
pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for 
Evaluation of Chest Pain). Circulation 2017;135:2320–32. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.024360
209. Adamson PD, Williams MC, Dweck MR, Mills NL, Boon NA, Daghem M, et al. Guiding 
therapy by coronary CT angiography improves outcomes in patients with stable chest 
pain. J Am Coll Cardiol 2019;74:2058–70. https://doi.org/10.1016/j.jacc.2019.07.085
210. Williams MC, Moss AJ, Dweck M, Adamson PD, Alam S, Hunter A, et al. Coronary 
artery plaque characteristics associated with adverse outcomes in the 
SCOT-HEART study. J Am Coll Cardiol 2019;73:291–301. https://doi.org/10.1016/j. 
jacc.2018.10.066
211. Foy AJ, Dhruva SS, Peterson B, Mandrola JM, Morgan DJ, Redberg RF. Coronary com­
puted tomography angiography vs functional stress testing for patients with suspected 
coronary artery disease: a systematic review and meta-analysis. JAMA Intern Med 2017; 
177:1623–31. https://doi.org/10.1001/jamainternmed.2017.4772
212. SCOT-HEART Investigators. CT coronary angiography in patients with suspected an­
gina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, 
multicentre trial. Lancet 2015;385:2383–91. https://doi.org/10.1016/S0140-6736(15) 
60291-4
213. Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, et al. 
CAD-RADS 2.0—2022 Coronary Artery Disease—Reporting and Data System an ex­
pert consensus document of the Society of Cardiovascular Computed Tomography 
(SCCT), the American College of Cardiology (ACC), the American College of 
Radiology (ACR) and the North America Society of Cardiovascular Imaging 
(NASCI). J Cardiovasc Comput Tomogr 2022;16:536–57. https://doi.org/10.1016/j.jcct. 
2022.07.002
214. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CAG, et al. 
Diagnostic accuracy of 64-slice computed tomography coronary angiography: a pro­
spective, multicenter, multivendor study. J Am Coll Cardiol 2008;52:2135–44. https:// 
doi.org/10.1016/j.jacc.2008.08.058
215. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et al. 
Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 
2008;359:2324–36. https://doi.org/10.1056/NEJMoa0806576
216. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic per­
formance of 64-multidetector row coronary computed tomographic angiography for 
evaluation of coronary artery stenosis in individuals without known coronary artery 
disease: results from the prospective multicenter ACCURACY (Assessment by 
Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive 
Coronary Angiography) trial. J Am Coll Cardiol 2008;52:1724–32. https://doi.org/10. 
1016/j.jacc.2008.07.031
217. Min JK, Koduru S, Dunning AM, Cole JH, Hines JL, Greenwell D, et al. Coronary CT 
angiography versus myocardial perfusion imaging for near-term quality of life, cost 
and radiation exposure: a prospective multicenter randomized pilot trial. 
J Cardiovasc Comput Tomogr 2012;6:274–83. https://doi.org/10.1016/j.jcct.2012.06.002
218. Douglas PS, Pontone G, Hlatky MA, Patel MR, Norgaard BL, Byrne RA, et al. Clinical 
outcomes of fractional flow reserve by computed tomographic angiography-guided 
diagnostic strategies vs. usual care in patients with suspected coronary artery disease: 
the prospective longitudinal trial of FFRCT: outcome and resource impacts study. Eur 
Heart J 2015;36:3359–67. https://doi.org/10.1093/eurheartj/ehv444
219. Dewey M, Rief M, Martus P, Kendziora B, Feger S, Dreger H, et al. Evaluation of com­
puted tomography in patients with atypical angina or chest pain clinically referred for 
invasive coronary angiography: randomised controlled trial. BMJ 2016;355:i5441. 
https://doi.org/10.1136/bmj.i5441
220. Chang HJ, Lin FY, Gebow D, An HY, Andreini D, Bathina R, et al. Selective referral using 
CCTA versus direct referral for individuals referred to invasive coronary angiography 
for suspected CAD: a randomized, controlled, open-label trial. JACC Cardiovasc Imaging 
2019;12:1303–12. https://doi.org/10.1016/j.jcmg.2018.09.018
221. Sharma A, Coles A, Sekaran NK, Pagidipati NJ, Lu MT, Mark DB, et al. Stress testing 
versus CT angiography in patients with diabetes and suspected coronary artery dis­
ease. J Am Coll Cardiol 2019;73:893–902. https://doi.org/10.1016/j.jacc.2018.11.056
222. The Discharge Trial Group; Maurovich-Horvat P, Bosserdt M, Kofoed KF, Rieckmann 
N, Benedek T, et al. CT or invasive coronary angiography in stable chest pain. N Engl J 
Med 2022;386:1591–602. https://doi.org/10.1056/NEJMoa2200963
223. Smulders MW, Jaarsma C, Nelemans PJ, Bekkers SCAM, Bucerius J, Leiner T, et al. 
Comparison of the prognostic value of negative non-invasive cardiac investigations 
in patients with suspected or known coronary artery disease-a meta-analysis. Eur 
Heart J Cardiovasc Imaging 2017;18:980–7. https://doi.org/10.1093/ehjci/jex014
224. Picano E, Mathias W Jr, Pingitore A, Bigi R, Previtali M. Safety and tolerability of 
dobutamine-atropine stress echocardiography: a prospective, multicentre study. 
Echo Dobutamine International Cooperative Study Group. Lancet 1994;344: 
1190–2. https://doi.org/10.1016/s0140-6736(94)90508-8
225. Varga A, Garcia MA, Picano E. Safety of stress echocardiography (from the 
International Stress Echo Complication Registry). Am J Cardiol 2006;98:541–3. 
https://doi.org/10.1016/j.amjcard.2006.02.064
226. Lorenzoni V, Bellelli S, Caselli C, Knuuti J, Underwood SR, Neglia D, et al. 
Cost-effectiveness analysis of stand-alone or combined non-invasive imaging tests 
for the diagnosis of stable coronary artery disease: results from the EVINCI study. 
Eur J Health Econ 2019;20:1437–49. https://doi.org/10.1007/s10198-019-01096-5
227. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, et al. 
Guidelines for performance, interpretation, and application of stress echocardiog­
raphy in ischemic heart disease: from the American Society of Echocardiography. 
J Am Soc Echocardiogr 2020;33:1–41.e8. https://doi.org/10.1016/j.echo.2019.07.001
228. Marwick TH. Stress echocardiography. Heart 2003;89:113–8. https://doi.org/10.1136/ 
heart.89.1.113
229. Plana JC, Mikati IA, Dokainish H, Lakkis N, Abukhalil J, Davis R, et al. A randomized 
cross-over study for evaluation of the effect of image optimization with contrast on 
the diagnostic accuracy of dobutamine echocardiography in coronary artery disease 
The OPTIMIZE Trial. JACC Cardiovasc Imaging 2008;1:145–52. https://doi.org/10. 
1016/j.jcmg.2007.10.014
230. Qian L, Xie F, Xu D, Porter TR. Long-term prognostic value of stress myocardial per­
fusion echocardiography in patients with coronary artery disease: a meta-analysis. Eur 
Heart J Cardiovasc Imaging 2021;22:553–62. https://doi.org/10.1093/ehjci/jeaa026
231. Abdelmoneim SS, Dhoble A, Bernier M, Erwin PJ, Korosoglou G, Senior R, et al. 
Quantitative myocardial contrast echocardiography during pharmacological stress 
for diagnosis of coronary artery disease: a systematic review and meta-analysis of diag­
nostic accuracy studies. Eur J Echocardiogr 2009;10:813–25. https://doi.org/10.1093/ 
ejechocard/jep084
232. Porter TR, Smith LM, Wu J, Thomas D, Haas JT, Mathers DH, et al. Patient outcome 
following 2 different stress imaging approaches: a prospective randomized compari­
son. J Am Coll Cardiol 2013;61:2446–55. https://doi.org/10.1016/j.jacc.2013.04.019
233. Rinkevich D, Belcik T, Gupta NC, Cannard E, Alkayed NJ, Kaul S. Coronary autoregu­
lation is abnormal in syndrome X: insights using myocardial contrast echocardiography. 
J Am Soc Echocardiogr 2013;26:290–6. https://doi.org/10.1016/j.echo.2012.12.008
234. Kutty S, Bisselou Moukagna KS, Craft M, Shostrom V, Xie F, Porter TR. Clinical out­
come of patients with inducible capillary blood flow abnormalities during demand


<!-- PAGE 99 -->

### Page 99

stress in the presence or absence of angiographic coronary disease. Circ Cardiovasc 
Imaging 2018;11:e007483. https://doi.org/10.1161/CIRCIMAGING.117.007483
235. Taqui S, Ferencik M, Davidson BP, Belcik JT, Moccetti F, Layoun M, et al. Coronary 
microvascular dysfunction by myocardial contrast echocardiography in nonelderly pa­
tients referred for computed tomographic coronary angiography. J Am Soc 
Echocardiogr 2019;32:817–25. https://doi.org/10.1016/j.echo.2019.03.001
236. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical 
applications of ultrasonic enhancing agents in echocardiography: 2018 American 
Society of Echocardiography Guidelines update. J Am Soc Echocardiogr 2018;31: 
241–74. https://doi.org/10.1016/j.echo.2017.11.013
237. Hu C, Feng Y, Huang P, Jin J. Adverse reactions after the use of SonoVue contrast 
agent: characteristics and nursing care experience. Medicine 2019;98:e17745. https:// 
doi.org/10.1097/md.0000000000017745
238. Ciampi Q, Zagatina A, Cortigiani L, Gaibazzi N, Borguezan Daros C, Zhuravskaya N, 
et al. Functional, anatomical, and prognostic correlates of coronary flow velocity re­
serve during stress echocardiography. J Am Coll Cardiol 2019;74:2278–91. https://doi. 
org/10.1016/j.jacc.2019.08.1046
239. Ahmadvazir S, Shah BN, Zacharias K, Senior R. Incremental prognostic value of stress 
echocardiography with carotid ultrasound for suspected CAD. JACC Cardiovasc 
Imaging 2018;11:173–80. https://doi.org/10.1016/j.jcmg.2016.12.020
240. Ahmadvazir S, Pradhan J, Khattar RS, Senior R. Long-term prognostic value of simul­
taneous assessment of atherosclerosis and ischemia in patients with suspected angina: 
implications for routine use of carotid ultrasound during stress echocardiography. J Am 
Soc Echocardiogr 2020;33:559–69. https://doi.org/10.1016/j.echo.2019.11.019
241. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or ex­
ercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 
280:913–20. https://doi.org/10.1001/jama.280.10.913
242. Marwick TH, Case C, Vasey C, Allen S, Short L, Thomas JD. Prediction of mortality by 
exercise echocardiography: a strategy for combination with the Duke treadmill score. 
Circulation 2001;103:2566–71. https://doi.org/10.1161/01.cir.103.21.2566
243. Shaw LJ, Vasey C, Sawada S, Rimmerman C, Marwick TH. Impact of gender on risk 
stratification by exercise and dobutamine stress echocardiography: long-term mortal­
ity in 4234 women and 6898 men. Eur Heart J 2005;26:447–56. https://doi.org/10. 
1093/eurheartj/ehi102
244. Gurunathan S, Zacharias K, Akhtar M, Ahmed A, Mehta V, Karogiannis N, et al. 
Cost-effectiveness of a management strategy based on exercise echocardiography ver­
sus exercise electrocardiography in patients presenting with suspected angina during 
long term follow up: a randomized study. Int J Cardiol 2018;259:1–7. https://doi.org/ 
10.1016/j.ijcard.2018.01.112
245. Vamvakidou A, Danylenko O, Pradhan J, Kelshiker M, Jones T, Whiteside D, et al. 
Relative 
clinical 
value 
of 
coronary 
computed 
tomography 
and 
stress 
echocardiography-guided management of stable chest pain patients: a propensity- 
matched analysis. Eur Heart J Cardiovasc Imaging 2020;22:1473–81. https://doi.org/10. 
1093/ehjci/jeaa303
246. Woodward W, Dockerill C, McCourt A, Upton R, O’Driscoll J, Balkhausen K, et al. 
Real-world performance and accuracy of stress echocardiography: the EVAREST ob­
servational multi-centre study. Eur Heart J Cardiovasc Imaging 2022;23:689–98. https:// 
doi.org/10.1093/ehjci/jeab092
247. Senior R, Andersson O, Caidahl K, Carlens P, Herregods MC, Jenni R, et al. Enhanced 
left ventricular endocardial border delineation with an intravenous injection of 
SonoVue, a new echocardiographic contrast agent: a European multicenter study. 
Echocardiography 
2000;17:705–11. 
https://doi.org/10.1111/j.1540-8175.2000. 
tb01223.x
248. Edvardsen T, Asch FM, Davidson B, Delgado V, DeMaria A, Dilsizian V, et al. 
Non-invasive imaging in coronary syndromes: recommendations of the European 
Association 
of 
Cardiovascular 
Imaging 
and 
the 
American 
Society 
of 
Echocardiography, in collaboration with the American Society of Nuclear 
Cardiology, Society of Cardiovascular Computed Tomography, and Society for 
Cardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging 2022;23:e6–33. 
https://doi.org/10.1093/ehjci/jeab244
249. Tsutsui JM, Elhendy A, Anderson JR, Xie F, McGrain AC, Porter TR. Prognostic value of 
dobutamine stress myocardial contrast perfusion echocardiography. Circulation 2005; 
112:1444–50. https://doi.org/10.1161/circulationaha.105.537134
250. Jeetley P, Hickman M, Kamp O, Lang RM, Thomas JD, Vannan MA, et al. Myocardial 
contrast echocardiography for the detection of coronary artery stenosis: a prospect­
ive multicenter study in comparison with single-photon emission computed tomog­
raphy. J Am Coll Cardiol 2006;47:141–5. https://doi.org/10.1016/j.jacc.2005.08.054
251. Dolan MS, Gala SS, Dodla S, Abdelmoneim SS, Xie F, Cloutier D, et al. Safety and ef­
ficacy of commercially available ultrasound contrast agents for rest and stress echocar­
diography a multicenter experience. J Am Coll Cardiol 2009;53:32–8. https://doi.org/10. 
1016/j.jacc.2008.08.066
252. Gaibazzi N, Reverberi C, Lorenzoni V, Molinaro S, Porter TR. Prognostic value of high- 
dose dipyridamole stress myocardial contrast perfusion echocardiography. Circulation 
2012;126:1217–24. https://doi.org/10.1161/circulationaha.112.110031
253. Gaibazzi N, Rigo F, Lorenzoni V, Molinaro S, Bartolomucci F, Reverberi C, et al. 
Comparative prediction of cardiac events by wall motion, wall motion plus coronary 
flow reserve, or myocardial perfusion analysis: a multicenter study of contrast stress 
echocardiography. JACC Cardiovasc Imaging 2013;6:1–12. https://doi.org/10.1016/j. 
jcmg.2012.08.009
254. Senior R, Moreo A, Gaibazzi N, Agati L, Tiemann K, Shivalkar B, et al. Comparison of 
sulfur hexafluoride microbubble (SonoVue)-enhanced myocardial contrast echocardi­
ography with gated single-photon emission computed tomography for detection of 
significant coronary artery disease: a large European multicenter study. J Am Coll 
Cardiol 2013;62:1353–61. https://doi.org/10.1016/j.jacc.2013.04.082
255. Schroder J, Prescott E. Doppler echocardiography assessment of coronary micro­
vascular function in patients with angina and no obstructive coronary artery disease. 
Front Cardiovasc Med 2021;8:723542. https://doi.org/10.3389/fcvm.2021.723542
256. Yang Z, Zheng H, Zhou T, Yang L-F, Hu X-F, Peng Z-H, et al. Diagnostic performance 
of myocardial perfusion imaging with SPECT, CT and MR compared to fractional flow 
reserve as reference standard. Int J Cardiol 2015;190:103–5. https://doi.org/10.1016/j. 
ijcard.2015.04.091
257. Takx RA, Blomberg BA, El Aidi H, Habets J, de Jong PA, Nagel E, et al. Diagnostic ac­
curacy of stress myocardial perfusion imaging compared to invasive coronary angiog­
raphy with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging 2015;8: 
e002666. https://doi.org/10.1161/circimaging.114.002666
258. Dai N, Zhang X, Zhang Y, Hou L, Li W, Fan B, et al. Enhanced diagnostic utility achieved 
by myocardial blood analysis: a meta-analysis of noninvasive cardiac imaging in the de­
tection of functional coronary artery disease. Int J Cardiol 2016;221:665–73. https://doi. 
org/10.1016/j.ijcard.2016.07.031
259. Mowatt G, Brazzelli M, Gemmell H, Hillis GS, Metcalfe M, Vale L, et al. Systematic re­
view of the prognostic effectiveness of SPECT myocardial perfusion scintigraphy in pa­
tients with suspected or known coronary artery disease and following myocardial 
infarction. Nucl Med Commun 2005;26:217–29. https://doi.org/10.1097/00006231- 
200503000-00006
260. Cantoni V, Green R, Acampa W, Zampella E, Assante R, Nappi C, et al. Diagnostic per­
formance of myocardial perfusion imaging with conventional and CZT single-photon 
emission computed tomography in detecting coronary artery disease: a meta-analysis. 
J Nucl Cardiol 2021;28:698–715. https://doi.org/10.1007/s12350-019-01747-3
261. Panjer M, Dobrolinska M, Wagenaar NRL, Slart R. Diagnostic accuracy of dynamic 
CZT-SPECT in coronary artery disease. A systematic review and meta-analysis. 
J Nucl Cardiol 2022;29:1686–97. https://doi.org/10.1007/s12350-021-02721-8
262. Juárez-Orozco LE, Tio RA, Alexanderson E, Dweck M, Vliegenthart R, El Moumni M, 
et al. Quantitative myocardial perfusion evaluation with positron emission tomography 
and the risk of cardiovascular events in patients with coronary artery disease: a system­
atic review of prognostic studies. Eur Heart J Cardiovasc Imaging 2018;19:1179–87. 
https://doi.org/10.1093/ehjci/jex331
263. Green R, Cantoni V, Acampa W, Assante R, Zampella E, Nappi C, et al. Prognostic va­
lue of coronary flow reserve in patients with suspected or known coronary artery dis­
ease referred to PET myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol 2021; 
28:904–18. https://doi.org/10.1007/s12350-019-02000-7
264. Groepenhoff F, Klaassen RGM, Valstar GB, Bots SH, Onland-Moret NC, Den Ruijter 
HM, et al. Evaluation of non-invasive imaging parameters in coronary microvascular 
disease: a systematic review. BMC Med Imaging 2021;21:5. https://doi.org/10.1186/ 
s12880-020-00535-7
265. Yang K, Yu SQ, Lu MJ, Zhao SH. Comparison of diagnostic accuracy of stress myocar­
dial perfusion imaging for detecting hemodynamically significant coronary artery dis­
ease between cardiac magnetic resonance and nuclear medical imaging: a 
meta-analysis. Int J Cardiol 2019;293:278–85. https://doi.org/10.1016/j.ijcard.2019.06. 
054
266. Mc Ardle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 
PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstruct­
ive coronary disease?: a systematic review and meta-analysis. J Am Coll Cardiol 2012;60: 
1828–37. https://doi.org/10.1016/j.jacc.2012.07.038
267. Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accur­
acy of cardiac positron emission tomography versus single photon emission computed 
tomography for coronary artery disease: a bivariate meta-analysis. Circ Cardiovasc 
Imaging 2012;5:700–7. https://doi.org/10.1161/circimaging.112.978270
268. Danad I, Raijmakers PG, Driessen RS, Leipsic J, Raju R, Naoum C, et al. Comparison of 
coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic 
heart disease determined by fractional flow reserve. JAMA Cardiol 2017;2:1100–7. 
https://doi.org/10.1001/jamacardio.2017.2471
269. Rasmussen LD, Winther S, Eftekhari A, Karim SR, Westra J, Isaksen C, et al. 
Second-line myocardial perfusion imaging to detect obstructive stenosis: head-to-head 
comparison of CMR and PET. JACC Cardiovasc Imaging 2023;16:642–55. https://doi. 
org/10.1016/j.jcmg.2022.11.015
270. Patel KK, Al Badarin F, Chan PS, Spertus JA, Courter S, Kennedy KF, et al. Randomized 
comparison of clinical effectiveness of pharmacologic SPECT and PET MPI in symp­
tomatic CAD patients. JACC Cardiovasc Imaging 2019;12:1821–31. https://doi.org/10. 
1016/j.jcmg.2019.04.020
271. Patel KK, Spertus JA, Chan PS, Sperry BW, Al Badarin F, Kennedy KF, et al. Myocardial 
blood flow reserve assessed by positron emission tomography myocardial perfusion 
ESC Guidelines                                                                                                                                                                                          3513


<!-- PAGE 100 -->

### Page 100

imaging identifies patients with a survival benefit from early revascularization. Eur Heart 
J 2020;41:759–68. https://doi.org/10.1093/eurheartj/ehz389
272. van Dijk R, van Assen M, Vliegenthart R, de Bock GH, van der Harst P, Oudkerk M. 
Diagnostic performance of semi-quantitative and quantitative stress CMR perfusion 
analysis: a meta-analysis. J Cardiovasc Magn Reson 2017;19:92. https://doi.org/10. 
1186/s12968-017-0393-z
273. Gargiulo P, Dellegrottaglie S, Bruzzese D, Savarese G, Scala O, Ruggiero D, et al. The 
prognostic value of normal stress cardiac magnetic resonance in patients with known 
or suspected coronary artery disease: a meta-analysis. Circ Cardiovasc Imaging 2013;6: 
574–82. https://doi.org/10.1161/circimaging.113.000035
274. Iwata K, Nakagawa S, Ogasawara K. The prognostic value of normal stress cardiovas­
cular magnetic resonance imaging. J Comput Assist Tomogr 2014;38:36–43. https://doi. 
org/10.1097/RCT.0b013e3182a474a0
275. Ricci F, Khanji MY, Bisaccia G, Cipriani A, Di Cesare A, Ceriello L, et al. Diagnostic and 
prognostic value of stress cardiovascular magnetic resonance imaging in patients with 
known or suspected coronary artery disease: a systematic review and meta-analysis. 
JAMA Cardiol 2023;8:662–73. https://doi.org/10.1001/jamacardio.2023.1290
276. Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, et al. 
Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl 
J Med 2019;380:2418–28. https://doi.org/10.1056/NEJMoa1716734
277. Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, et al. Noninvasive diag­
nosis of ischemia-induced wall motion abnormalities with the use of high-dose dobu­
tamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 
1999;99:763–70. https://doi.org/10.1161/01.cir.99.6.763
278. Ripley DP, Motwani M, Brown JM, Nixon J, Everett CC, Bijsterveld P, et al. Individual 
component analysis of the multi-parametric cardiovascular magnetic resonance proto­
col in the CE-MARC trial. J Cardiovasc Magn Reson 2015;17:59. https://doi.org/10.1186/ 
s12968-015-0169-2
279. Di Leo G, Fisci E, Secchi F, Alì M, Ambrogi F, Sconfienza LM, et al. Diagnostic accuracy 
of magnetic resonance angiography for detection of coronary artery disease: a system­
atic review and meta-analysis. Eur Radiol 2016;26:3706–18. https://doi.org/10.1007/ 
s00330-015-4134-0
280. Feger S, Rief M, Zimmermann E, Richter F, Roehle R, Dewey M, et al. Patient satisfac­
tion with coronary CT angiography, myocardial CT perfusion, myocardial perfusion 
MRI, SPECT myocardial perfusion imaging and conventional coronary angiography. 
Eur Radiol 2015;25:2115–24. https://doi.org/10.1007/s00330-015-3604-8
281. Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, et al. 
Baseline stress myocardial perfusion imaging results and outcomes in patients with 
stable ischemic heart disease randomized to optimal medical therapy with or without 
percutaneous coronary intervention. Am Heart J 2012;164:243–50. https://doi.org/10. 
1016/j.ahj.2012.05.018
282. Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. 
Prognostic value of stress myocardial perfusion positron emission tomography: results 
from a multicenter observational registry. J Am Coll Cardiol 2013;61:176–84. https://doi. 
org/10.1016/j.jacc.2012.09.043
283. Kay J, Dorbala S, Goyal A, Fazel R, Di Carli MF, Einstein AJ, et al. Influence of sex on risk 
stratification with stress myocardial perfusion Rb-82 positron emission tomography: 
results from the PET (Positron Emission Tomography) Prognosis Multicenter 
Registry. J Am Coll Cardiol 2013;62:1866–76. https://doi.org/10.1016/j.jacc.2013.06.017
284. Uretsky S, Rozanski A. Long-term outcomes following a normal stress myocardial per­
fusion scan. J Nucl Cardiol 2013;20:715–8. https://doi.org/10.1007/s12350-013-9769-0
285. Rozanski A, Gransar H, Min JK, Hayes SW, Friedman JD, Thomson LEJ, et al. Long-term 
mortality following normal exercise myocardial perfusion SPECT according to coron­
ary disease risk factors. J Nucl Cardiol 2014;21:341–50. https://doi.org/10.1007/s12350- 
013-9830-z
286. Zellweger MJ, Fahrni G, Ritter M, Jeger RV, Wild D, Buser P, et al. Prognostic value of 
“routine” cardiac stress imaging 5 years after percutaneous coronary intervention: the 
prospective long-term observational BASKET (Basel Stent Kosteneffektivitats Trial) 
LATE IMAGING study. JACC Cardiovasc Interv 2014;7:615–21. https://doi.org/10. 
1016/j.jcin.2014.01.161
287. Patel KK, Spertus JA, Arnold SV, Chan PS, Kennedy KF, Jones PG, et al. Ischemia on PET 
MPI may identify patients with improvement in angina and health status post- 
revascularization. J Am Coll Cardiol 2019;74:1734–6. https://doi.org/10.1016/j.jacc. 
2019.06.074
288. Bom MJ, van Diemen PA, Driessen RS, Everaars H, Schumacher SP, Wijmenga J-T, et al. 
Prognostic value of [15O]H2O positron emission tomography-derived global and re­
gional myocardial perfusion. Eur Heart J Cardiovasc Imaging 2020;21:777–86. https:// 
doi.org/10.1093/ehjci/jez258
289. Schepis T, Gaemperli O, Koepfli P, Namdar M, Valenta I, Scheffel H, et al. Added value 
of coronary artery calcium score as an adjunct to gated SPECT for the evaluation of 
coronary artery disease in an intermediate-risk population. J Nucl Med 2007;48: 
1424–30. https://doi.org/10.2967/jnumed.107.040758
290. Schenker MP, Dorbala S, Hong EC, Rybicki FJ, Hachamovitch R, Kwong RY, et al. 
Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients 
with intermediate likelihood of coronary artery disease: a combined positron emission 
tomography/computed tomography study. Circulation 2008;117:1693–700. https:// 
doi.org/10.1161/CIRCULATIONAHA.107.717512
291. Chang SM, Nabi F, Xu J, Peterson LE, Achari A, Pratt CM, et al. The coronary artery 
calcium score and stress myocardial perfusion imaging provide independent and com­
plementary prediction of cardiac risk. J Am Coll Cardiol 2009;54:1872–82. https://doi. 
org/10.1016/j.jacc.2009.05.071
292. Ghadri JR, Pazhenkottil AP, Nkoulou RN, Goetti R, Buechel RR, Husmann L, et al. Very 
high coronary calcium score unmasks obstructive coronary artery disease in patients 
with normal SPECT MPI. Heart 2011;97:998–1003. https://doi.org/10.1136/hrt.2010. 
217281
293. Brodov Y, Gransar H, Dey D, Shalev A, Germano G, Friedman JD, et al. Combined 
quantitative assessment of myocardial perfusion and coronary artery calcium score 
by hybrid 82Rb PET/CT improves detection of coronary artery disease. J Nucl Med 
2015;56:1345–50. https://doi.org/10.2967/jnumed.114.153429
294. Hamon M, Fau G, Nee G, Ehtisham J, Morello R, Hamon M. Meta-analysis of the diag­
nostic performance of stress perfusion cardiovascular magnetic resonance for detec­
tion of coronary artery disease. J Cardiovasc Magn Reson 2010;12:29. https://doi.org/10. 
1186/1532-429X-12-29
295. Jiang B, Cai W, Lv X, Liu H. Diagnostic performance and clinical utility of myocardial 
perfusion MRI for coronary artery disease with fractional flow reserve as the standard 
reference: a meta-analysis. Heart Lung Circ 2016;25:1031–8. https://doi.org/10.1016/j. 
hlc.2016.02.018
296. Heitner JF, Kim RJ, Kim HW, Klem I, Shah DJ, Debs D, et al. Prognostic value of vaso­
dilator stress cardiac magnetic resonance imaging: a multicenter study with 48 000 
patient-years of follow-up. JAMA Cardiol 2019;4:256–64. https://doi.org/10.1001/ 
jamacardio.2019.0035
297. Arai AE, Schulz-Menger J, Shah DJ, Han Y, Bandettini WP, Abraham A, et al. Stress per­
fusion cardiac magnetic resonance vs SPECT imaging for detection of coronary artery 
disease. J Am Coll Cardiol 2023;82:1828–38. https://doi.org/10.1016/j.jacc.2023.08.046
298. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified 
medical therapy using invasive coronary function testing in angina: the CorMicA trial. 
J Am Coll Cardiol 2018;72:2841–55. https://doi.org/10.1016/j.jacc.2018.09.006
299. Mileva N, Nagumo S, Mizukami T, Sonck J, Berry C, Gallinoro E, et al. Prevalence of 
coronary microvascular disease and coronary vasospasm in patients with nonobstruc­
tive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc 
2022;11:e023207. https://doi.org/10.1161/JAHA.121.023207
300. Brainin P, Frestad D, Prescott E. The prognostic value of coronary endothelial and 
microvascular dysfunction in subjects with normal or non-obstructive coronary artery 
disease: a systematic review and meta-analysis. Int J Cardiol 2018;254:1–9. https://doi. 
org/10.1016/j.ijcard.2017.10.052
301. Gdowski MA, Murthy VL, Doering M, Monroy-Gonzalez AG, Slart R, Brown DL. 
Association of isolated coronary microvascular dysfunction with mortality and major 
adverse cardiac events: a systematic review and meta-analysis of aggregate data. J Am 
Heart Assoc 2020;9:e014954. https://doi.org/10.1161/JAHA.119.014954
302. Hozumi T, Yoshida K, Ogata Y, Akasaka T, Asami Y, Takagi T, et al. Noninvasive assess­
ment of significant left anterior descending coronary artery stenosis by coronary flow 
velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998; 
97:1557–62. https://doi.org/10.1161/01.CIR.97.16.1557
303. Sicari R, Rigo F, Cortigiani L, Gherardi S, Galderisi M, Picano E. Additive prognostic va­
lue of coronary flow reserve in patients with chest pain syndrome and normal or near- 
normal coronary arteries. Am J Cardiol 2009;103:626–31. https://doi.org/10.1016/j. 
amjcard.2008.10.033
304. Taqueti VR, Everett BM, Murthy VL, Gaber M, Foster CR, Hainer J, et al. Interaction of 
impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular 
outcomes in patients without overt coronary artery disease. Circulation 2015;131: 
528–35. https://doi.org/10.1161/CIRCULATIONAHA.114.009716
305. Michelsen MM, Mygind ND, Pena A, Olsen RH, Christensen TE, Ghotbi AA, et al. 
Transthoracic Doppler echocardiography compared with positron emission tomog­
raphy for assessment of coronary microvascular dysfunction: the iPOWER study. Int 
J Cardiol 2017;228:435–43. https://doi.org/10.1016/j.ijcard.2016.11.004
306. Cortigiani L, Ciampi Q, Lombardo A, Rigo F, Bovenzi F, Picano E, et al. Age- and 
gender-specific prognostic cutoff values of coronary flow velocity reserve in vasodila­
tor stress echocardiography. J Am Soc Echocardiogr 2019;32:1307–17. https://doi.org/ 
10.1016/j.echo.2019.05.020
307. Everaars H, de Waard GA, Driessen RS, Danad I, van de Ven PM, Raijmakers PG, et al. 
Doppler flow velocity and thermodilution to assess coronary flow reserve: a 
head-to-head comparison with [15O]H2O PET. JACC Cardiovasc Interv 2018;11: 
2044–54. https://doi.org/10.1016/j.jcin.2018.07.011
308. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van ’t Veer M, et al. Fractional 
flow reserve versus angiography for guiding percutaneous coronary intervention. 
N Engl J Med 2009;360:213–24. https://doi.org/10.1056/NEJMoa0807611
309. Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, et al. Does routine 
pressure wire assessment influence management strategy at coronary angiography for 
diagnosis of chest pain? The RIPCORD study. Circ Cardiovasc Interv 2014;7:248–55. 
https://doi.org/10.1161/CIRCINTERVENTIONS.113.000978


<!-- PAGE 101 -->

### Page 101

310. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, et al. Use of the instant­
aneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 2017;376: 
1824–34. https://doi.org/10.1056/NEJMoa1700445
311. Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen 
L, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. 
N Engl J Med 2017;376:1813–23. https://doi.org/10.1056/NEJMoa1616540
312. Faria D, Hennessey B, Shabbir A, Mejía-Rentería H, Wang L, Lee JM, et al. Functional 
coronary angiography for the assessment of the epicardial vessels and the microcircu­
lation. EuroIntervention 2023;19:203–21. https://doi.org/10.4244/EIJ-D-22-00969
313. Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, et al. Outcome im­
pact of coronary revascularization strategy reclassification with fractional flow reserve 
at time of diagnostic angiography: insights from a large French multicenter fractional 
flow reserve registry. Circulation 2014;129:173–85. https://doi.org/10.1161/ 
CIRCULATIONAHA.113.006646
314. Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Piña IL, et al. Initial 
invasive versus conservative management of stable ischemic heart disease in patients 
with a history of heart failure or left ventricular dysfunction. Circulation 2020;142: 
1725–35. https://doi.org/10.1161/CIRCULATIONAHA.120.050304
315. Rozanski A, Miller RJH, Gransar H, Han D, Slomka P, Dey D, et al. Benefit of early re­
vascularization based on inducible ischemia and left ventricular ejection fraction. J Am 
Coll Cardiol 2022;80:202–15. https://doi.org/10.1016/j.jacc.2022.04.052
316. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 
ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165. 
https://doi.org/10.1093/eurheartj/ehy394
317. Reynolds HR, Shaw LJ, Min JK, Page CB, Berman DS, Chaitman BR, et al. Outcomes in 
the ISCHEMIA trial based on coronary artery disease and ischemia severity. Circulation 
2021;144:1024–38. https://doi.org/10.1161/CIRCULATIONAHA.120.049755
318. Johnson NP, Toth GG, Lai D, Zhu H, Açar G, Agostoni P, et al. Prognostic value of 
fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll 
Cardiol 2014;64:1641–54. https://doi.org/10.1016/j.jacc.2014.07.973
319. Barbato E, Toth GG, Johnson NP, Pijls NHJ, Fearon WF, Tonino PAL, et al. A prospect­
ive natural history study of coronary atherosclerosis using fractional flow reserve. J Am 
Coll Cardiol 2016;68:2247–55. https://doi.org/10.1016/j.jacc.2016.08.055
320. Ciccarelli G, Barbato E, Toth GG, Gahl B, Xaplanteris P, Fournier S, et al. Angiography 
versus hemodynamics to predict the natural history of coronary stenoses. Circulation 
2018;137:1475–85. https://doi.org/10.1161/CIRCULATIONAHA.117.028782
321. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al. Fractional flow 
reserve-guided PCI for stable coronary artery disease. N Engl J Med 2014;371: 
1208–17. https://doi.org/10.1056/NEJMoa1408758
322. Van Belle E, Baptista SB, Raposo L, Henderson J, Rioufol G, Santos L, et al. Impact of 
routine fractional flow reserve on management decision and 1-year clinical outcome of 
patients with acute coronary syndromes: PRIME-FFR (Insights from the POST-IT 
[Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary 
Disease] and R3F [French FFR Registry] integrated multicenter registries—implemen­
tation of FFR [Fractional Flow Reserve] in routine practice). Circ Cardiovasc Interv 2017; 
10:e004296. https://doi.org/10.1161/circinterventions.116.004296
323. Escaned J, Ryan N, Mejía-Rentería H, Cook CM, Dehbi H-M, Alegria-Barrero E, et al. 
Safety of the deferral of coronary revascularization on the basis of instantaneous wave- 
free ratio and fractional flow reserve measurements in stable coronary artery disease 
and acute coronary syndromes. JACC Cardiovasc Interv 2018;11:1437–49. https://doi. 
org/10.1016/j.jcin.2018.05.029
324. Elguindy M, Stables R, Nicholas Z, Kemp I, Curzen N. Design and rationale of the 
RIPCORD 2 Trial (does routine pressure wire assessment influence management 
strategy at coronary angiography for diagnosis of chest pain?): a randomized controlled 
trial to compare routine pressure wire assessment with conventional angiography in 
the management of patients with coronary artery disease. Circ Cardiovasc Qual 
Outcomes 2018;11:e004191. https://doi.org/10.1161/circoutcomes.117.004191
325. Xu B, Tu S, Song L, Jin Z, Yu B, Fu G, et al. Angiographic quantitative flow ratio-guided 
coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled 
trial. Lancet 2021;398:2149–59. https://doi.org/10.1016/s0140-6736(21)02248-0
326. Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, 
et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery. 
N Engl J Med 2022;386:128–37. https://doi.org/10.1056/NEJMoa2112299
327. Gargiulo G, Giacoppo D, Jolly SS, Cairns J, Le May M, Bernat I, et al. Effects on mortality 
and major bleeding of radial versus femoral artery access for coronary angiography or 
percutaneous coronary intervention: meta-analysis of individual patient data from 7 
multicenter randomized clinical trials. Circulation 2022;146:1329–43. https://doi.org/ 
10.1161/CIRCULATIONAHA.122.061527
328. Ferrante G, Rao SV, Juni P, Da Costa BR, Reimers B, Condorelli G, et al. Radial versus 
femoral access for coronary interventions across the entire spectrum of patients with 
coronary artery disease: a meta-analysis of randomized trials. JACC Cardiovasc Interv 
2016;9:1419–34. https://doi.org/10.1016/j.jcin.2016.04.014
329. Kolkailah AA, Alreshq RS, Muhammed AM, Zahran ME, Anas El-Wegoud M, Nabhan 
AF. Transradial versus transfemoral approach for diagnostic coronary angiography and 
percutaneous coronary intervention in people with coronary artery disease. Cochrane 
Database Syst Rev 2018;4:CD012318. https://doi.org/10.1002/14651858.CD012318. 
pub2
330. Chiarito M, Cao D, Nicolas J, Roumeliotis A, Power D, Chandiramani R, et al. Radial 
versus femoral access for coronary interventions: an updated systematic review and 
meta-analysis of randomized trials. Catheter Cardiovasc Interv 2021;97:1387–96. 
https://doi.org/10.1002/ccd.29486
331. Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis G, Sarno G, et al. Long-term 
clinical outcome after fractional flow reserve-guided treatment in patients with angio­
graphically equivocal left main coronary artery stenosis. Circulation 2009;120:1505–12. 
https://doi.org/10.1161/CIRCULATIONAHA.109.850073
332. Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, Albertsson P, et al. 
Deferral vs. performance of percutaneous coronary intervention of functionally non- 
significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J 2015; 
36:3182–8. https://doi.org/10.1093/eurheartj/ehv452
333. Warisawa T, Cook CM, Rajkumar C, Howard JP, Seligman H, Ahmad Y, et al. Safety of 
revascularization deferral of left main stenosis based on instantaneous wave-free ratio 
evaluation. JACC Cardiovasc Interv 2020;13:1655–64. https://doi.org/10.1016/j.jcin.2020. 
02.035
334. Mallidi J, Atreya AR, Cook J, Garb J, Jeremias A, Klein LW, et al. Long-term outcomes 
following fractional flow reserve-guided treatment of angiographically ambiguous left 
main coronary artery disease: a meta-analysis of prospective cohort studies. Catheter 
Cardiovasc Interv 2015;86:12–8. https://doi.org/10.1002/ccd.25894
335. Modi BN, van de Hoef TP, Piek JJ, Perera D. Physiological assessment of left main cor­
onary artery disease. EuroIntervention 2017;13:820–7. https://doi.org/10.4244/eij-d-17- 
00135
336. Cerrato E, Echavarria-Pinto M, D’Ascenzo F, Gonzalo N, Quadri G, Quirós A, et al. 
Safety of intermediate left main stenosis revascularization deferral based on fractional 
flow reserve and intravascular ultrasound: a systematic review and meta-regression in­
cluding 908 deferred left main stenosis from 12 studies. Int J Cardiol 2018;271:42–8. 
https://doi.org/10.1016/j.ijcard.2018.04.032
337. Stone GW, Christiansen EH, Ali ZA, Andreasen LN, Maehara A, Ahmad Y, et al. 
Intravascular imaging-guided coronary drug-eluting stent implantation: an updated net­
work meta-analysis. Lancet 2024;403:824–37. https://doi.org/10.1016/S0140- 
6736(23)02454-6
338. Park S-J, Kang S-J, Ahn J-M, Shim EB, Kim Y-T, Yun S-C, et al. Visual-functional mis­
match between coronary angiography and fractional flow reserve. JACC Cardiovasc 
Interv 2012;5:1029–36. https://doi.org/10.1016/j.jcin.2012.07.007
339. Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, et al. Evolving con­
cepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. 
Eur Heart J 2014;35:2831–8. https://doi.org/10.1093/eurheartj/ehu094
340. Baptista SB, Raposo L, Santos L, Ramos R, Calé R, Jorge E, et al. Impact of routine frac­
tional flow reserve evaluation during coronary angiography on management strategy 
and clinical outcome: one-year results of the POST-IT. Circ Cardiovasc Interv 2016;9: 
e003288. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003288
341. Van Belle E, Gil R, Klauss V, Balghith M, Meuwissen M, Clerc J, et al. Impact of routine 
invasive physiology at time of angiography in patients with multivessel coronary artery 
disease on reclassification of revascularization strategy: results from the DEFINE REAL 
study. JACC Cardiovasc Interv 2018;11:354–65. https://doi.org/10.1016/j.jcin.2017.11. 
030
342. Van Belle E, Dupouy P, Rioufol G. Routine fractional flow reserve combined to diag­
nostic coronary angiography as a one-stop procedure: episode 3. Circ Cardiovasc Interv 
2016;9:e004137. https://doi.org/10.1161/CIRCINTERVENTIONS.116.004137
343. Eftekhari A, Holck EN, Westra J, Olsen NT, Bruun NH, Jensen LO, et al. Instantaneous 
wave free ratio vs. fractional flow reserve and 5-year mortality: iFR SWEDEHEART 
and DEFINE FLAIR. Eur Heart J 2023;44:4376–84. https://doi.org/10.1093/eurheartj/ 
ehad582
344. Berry C, McClure JD, Oldroyd KG. Coronary revascularization guided by instantan­
eous wave-free ratio compared to fractional flow reserve: pooled 5-year mortality 
in the DEFINE-FLAIR and iFR-SWEDEHEART trials. Eur Heart J 2023;44:4388–90. 
https://doi.org/10.1093/eurheartj/ehad552
345. Berntorp K, Rylance R, Yndigegn T, Koul S, Fröbert O, Christiansen EH, et al. Clinical 
outcome of revascularization deferral with instantaneous wave-free ratio and fraction­
al flow reserve: a 5-year follow-up substudy from the iFR-SWEDEHEART Trial. J Am 
Heart Assoc 2023;12:e028423. https://doi.org/10.1161/jaha.122.028423
346. Rioufol G, Derimay F, Roubille F, Perret T, Motreff P, Angoulvant D, et al. Fractional 
flow reserve to guide treatment of patients with multivessel coronary artery disease. 
J Am Coll Cardiol 2021;78:1875–85. https://doi.org/10.1016/j.jacc.2021.08.061
347. Stables RH, Mullen LJ, Elguindy M, Nicholas Z, Aboul-Enien YH, Kemp I, et al. Routine 
pressure wire assessment versus conventional angiography in the management of pa­
tients with coronary artery disease: the RIPCORD 2 trial. Circulation 2022;146: 
687–98. https://doi.org/10.1161/circulationaha.121.057793
348. Nijjer SS, Sen S, Petraco R, Escaned J, Echavarria-Pinto M, Broyd C, et al. 
Pre-angioplasty instantaneous wave-free ratio pullback provides virtual intervention 
and predicts hemodynamic outcome for serial lesions and diffuse coronary artery dis­
ease. JACC Cardiovasc Interv 2014;7:1386–96. https://doi.org/10.1016/j.jcin.2014.06.015
ESC Guidelines                                                                                                                                                                                          3515


<!-- PAGE 102 -->

### Page 102

349. Kikuta Y, Cook CM, Sharp ASP, Salinas P, Kawase Y, Shiono Y, et al. Pre-angioplasty 
instantaneous wave-free ratio pullback predicts hemodynamic outcome in humans 
with coronary artery disease. JACC Cardiovasc Interv 2018;11:757–67. https://doi.org/ 
10.1016/j.jcin.2018.03.005
350. Jeremias A, Davies JE, Maehara A, Matsumura M, Schneider J, Tang K, et al. Blinded 
physiological assessment of residual ischemia after successful angiographic percutan­
eous coronary intervention: the DEFINE PCI study. JACC Cardiovasc Interv 2019;12: 
1991–2001. https://doi.org/10.1016/j.jcin.2019.05.054
351. Lee SH, Shin D, Lee JM, Lefieux A, Molony D, Choi KH, et al. Automated algorithm 
using pre-intervention fractional flow reserve pullback curve to predict post- 
intervention physiological results. JACC Cardiovasc Interv 2020;13:2670–84. https:// 
doi.org/10.1016/j.jcin.2020.06.062
352. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Kikuchi J, et al. Comparisons of 
nonhyperemic pressure ratios: predicting functional results of coronary revasculariza­
tion using longitudinal vessel interrogation. JACC Cardiovasc Interv 2020;13:2688–98. 
https://doi.org/10.1016/j.jcin.2020.06.060
353. Masdjedi K, Tanaka N, Van Belle E, Porouchani S, Linke A, Woitek FW, et al. Vessel 
fractional flow reserve (vFFR) for the assessment of stenosis severity: the FAST II 
study. EuroIntervention 2022;17:1498–505. https://doi.org/10.4244/eij-d-21-00471
354. Scoccia A, Byrne RA, Banning AP, Landmesser U, Van Belle E, Amat-Santos IJ, et al. 
Fractional flow reserve or 3D-quantitative-coronary-angiography based vessel-FFR 
guided revascularization. Rationale and study design of the prospective randomized 
fast III trial. Am Heart J 2023;260:1–8. https://doi.org/10.1016/j.ahj.2023.02.003
355. Song L, Xu B, Tu S, Guan C, Jin Z, Yu B, et al. 2-Year outcomes of angiographic quan­
titative flow ratio-guided coronary interventions. J Am Coll Cardiol 2022;80:2089–101. 
https://doi.org/10.1016/j.jacc.2022.09.007
356. Johnson NP, Matsuo H, Nakayama M, Eftekhari A, Kakuta T, Tanaka N, et al. Combined 
pressure and flow measurements to guide treatment of coronary stenoses. JACC 
Cardiovasc Interv 2021;14:1904–13. https://doi.org/10.1016/j.jcin.2021.07.041
357. van de Hoef TP, Lee JM, Boerhout CKM, de Waard GA, Jung J-H, Lee SH, et al. 
Combined assessment of FFR and CFR for decision making in coronary revasculariza­
tion: from the multicenter international ILIAS registry. JACC Cardiovasc Interv 2022;15: 
1047–56. https://doi.org/10.1016/j.jcin.2022.03.016
358. van de Hoef TP, Stegehuis VE, Madera-Cambero MI, van Royen N, van der Hoeven 
NW, de Waard GA, et al. Impact of core laboratory assessment on treatment deci­
sions and clinical outcomes using combined fractional flow reserve and coronary 
flow reserve measurements—DEFINE-FLOW core laboratory sub-study. Int J 
Cardiol 2023;377:9–16. https://doi.org/10.1016/j.ijcard.2023.01.009
359. Meuwissen M, Siebes M, Chamuleau SA, van Eck-Smit BLF, Koch KT, de Winter RJ, 
et al. Hyperemic stenosis resistance index for evaluation of functional coronary lesion 
severity. Circulation 2002;106:441–6. https://doi.org/10.1161/01.cir.0000023041. 
26199.29
360. Boerhout CKM, Echavarria-Pinto M, de Waard GA, et al. Impact of hyperemic stenosis 
resistance (HSR) on long-term outcomes of stable angina. Eurointervention 2024;20: 
e699–706. https://doi.org/10.4244/EIJ-D-23-00713
361. De Bruyne B, Pijls NHJ, Gallinoro E, Candreva A, Fournier S, Keulards DCJ, et al. 
Microvascular resistance reserve for assessment of coronary microvascular function: 
JACC technology corner. J Am Coll Cardiol 2021;78:1541–9. https://doi.org/10.1016/j. 
jacc.2021.08.017
362. Candreva A, Gallinoro E, Fernandez Peregrina E, Sonck J, Keulards DCJ, van‘t Veer M, 
et al. Automation of intracoronary continuous thermodilution for absolute coronary 
flow and microvascular resistance measurements. Catheter Cardiovasc Interv 2022;100: 
199–206. https://doi.org/10.1002/ccd.30244
363. De Bruyne B, Belmonte M, Jabbour JR, Curzen N. Invasive functional testing in the cath 
lab as a routine investigation in INOCA: pros and cons. EuroIntervention 2023;19:23–5. 
https://doi.org/10.4244/EIJ-E-23-00008
364. de Vos A, Jansen TPJ, van ’t Veer M, Dimitriu-Leen A, Konst RE, Elias-Smale S, et al. 
Microvascular resistance reserve to assess microvascular dysfunction in ANOCA pa­
tients. JACC Cardiovasc Interv 2023;16:470–81. https://doi.org/10.1016/j.jcin.2022.12. 
012
365. Johnson NP, Gould KL. Integrating noninvasive absolute flow, coronary flow reserve, 
and ischemic thresholds into a comprehensive map of physiological severity. JACC 
Cardiovasc Imaging 2012;5:430–40. https://doi.org/10.1016/j.jcmg.2011.12.014
366. van de Hoef TP, Echavarria-Pinto M, van Lavieren MA, Meuwissen M, Serruys PWJC, 
Tijssen JGP, et al. Diagnostic and prognostic implications of coronary flow capacity: a 
comprehensive cross-modality physiological concept in ischemic heart disease. JACC 
Cardiovasc Interv 2015;8:1670–80. https://doi.org/10.1016/j.jcin.2015.05.032
367. Murai T, Stegehuis VE, van de Hoef TP, Wijntjens GWM, Hoshino M, Kanaji Y, et al. 
Coronary flow capacity to identify stenosis associated with coronary flow improve­
ment after revascularization: a combined analysis from DEFINE FLOW and IDEAL. 
J Am Heart Assoc 2020;9:e016130. https://doi.org/10.1161/JAHA.120.016130
368. de Winter RW, Jukema RA, van Diemen PA, Schumacher SP, Driessen RS, Stuijfzand 
WJ, et al. The impact of coronary revascularization on vessel-specific coronary flow 
capacity and long-term outcomes: a serial [15O]H2O positron emission tomography 
perfusion imaging study. Eur Heart J Cardiovasc Imaging 2022;23:743–52. https://doi. 
org/10.1093/ehjci/jeab263
369. Park SJ, Ahn JM, Kang SJ, Yoon S-H, Koo B-K, Lee J-Y, et al. Intravascular ultrasound- 
derived minimal lumen area criteria for functionally significant left main coronary ar­
tery stenosis. JACC Cardiovasc Interv 2014;7:868–74. https://doi.org/10.1016/j.jcin. 
2014.02.015
370. Ziedses des Plantes AC, Scoccia A, Gijsen F, van Soest G, Daemen J. Intravascular 
imaging-derived physiology-basic principles and clinical application. Interv Cardiol Clin 
2023;12:83–94. https://doi.org/10.1016/j.iccl.2022.09.008
371. Noguchi M, Gkargkoulas F, Matsumura M, Kotinkaduwa LN, Hu X, Usui E, et al. Impact 
of nonobstructive left main coronary artery atherosclerosis on long-term mortality. 
JACC Cardiovasc Interv 2022;15:2206–17. https://doi.org/10.1016/j.jcin.2022.08.024
372. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech J-W, van’t Veer M, 
et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 
5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007;49:2105–11. https://doi. 
org/10.1016/j.jacc.2007.01.087
373. Van Belle E, Cosenza A, Baptista SB, Vincent F, Henderson J, Santos L, et al. Usefulness 
of routine fractional flow reserve for clinical management of coronary artery disease in 
patients with diabetes. JAMA Cardiol 2020;5:272–81. https://doi.org/10.1001/ 
jamacardio.2019.5097
374. Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, et al. Diagnostic accuracy of angiography- 
based quantitative flow ratio measurements for online assessment of coronary sten­
osis. J Am Coll Cardiol 2017;70:3077–87. https://doi.org/10.1016/j.jacc.2017.10.035
375. Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, et al. 
Diagnostic performance of in-procedure angiography-derived quantitative flow re­
serve compared to pressure-derived fractional flow reserve: the FAVOR II 
Europe-Japan study. J Am Heart Assoc 2018;7:e009603. https://doi.org/10.1161/ 
JAHA.118.009603
376. Johnson NP, Gould KL, De Bruyne B. Autoregulation of coronary blood supply in re­
sponse to demand: JACC review topic of the week. J Am Coll Cardiol 2021;77:2335–45. 
https://doi.org/10.1016/j.jacc.2021.03.293
377. Masdjedi K, van Zandvoort LJC, Balbi MM, Gijsen FJH, Ligthart JMR, Rutten MCM, et al. 
Validation of a three-dimensional quantitative coronary angiography-based software 
to calculate fractional flow reserve: the FAST study. EuroIntervention 2020;16:591–9. 
https://doi.org/10.4244/eij-d-19-00466
378. Pijls NH, De Bruyne B, Smith L, Aarnoudse W, Barbato E, Bartunek J, et al. Coronary 
thermodilution to assess flow reserve: validation in humans. Circulation 2002;105: 
2482–6. https://doi.org/10.1161/01.cir.0000017199.09457.3d
379. Barbato E, Aarnoudse W, Aengevaeren WR, Werner G, Klauss V, Bojara W, et al. 
Validation of coronary flow reserve measurements by thermodilution in clinical prac­
tice. Eur Heart J 2004;25:219–23. https://doi.org/10.1016/j.ehj.2003.11.009
380. Fearon WF, Balsam LB, Farouque HM, Robbins RC, Fitzgerald PJ, Yock PG, et al. Novel 
index for invasively assessing the coronary microcirculation. Circulation 2003;107: 
3129–32. https://doi.org/10.1161/01.Cir.0000080700.98607.D1
381. Fearon WF, Kobayashi Y. Invasive assessment of the coronary microvasculature: the 
index of microcirculatory resistance. Circ Cardiovasc Interv 2017;10:e005361. https:// 
doi.org/10.1161/circinterventions.117.005361
382. Gallinoro E, Bertolone DT, Fernandez-Peregrina E, Paolisso P, Bermpeis K, Esposito G, 
et al. Reproducibility of bolus versus continuous thermodilution for assessment of cor­
onary microvascular function in patients with ANOCA. EuroIntervention 2023;19: 
e155–66. https://doi.org/10.4244/eij-d-22-00772
383. Mejía-Rentería H, Wang L, Chipayo-Gonzales D, van de Hoef TP, Travieso A, Espejo 
C, et al. Angiography-derived assessment of coronary microcirculatory resistance in 
patients with suspected myocardial ischaemia and non-obstructive coronary arteries. 
EuroIntervention 2023;18:e1348–56. https://doi.org/10.4244/EIJ-D-22-00579
384. Ford TJ, Ong P, Sechtem U, Beltrame J, Camici PG, Crea F, et al. Assessment of vascular 
dysfunction in patients without obstructive coronary artery disease: why, how, and 
when. JACC Cardiovasc Interv 2020;13:1847–64. https://doi.org/10.1016/j.jcin.2020.05. 
052
385. Radico F, Cicchitti V, Zimarino M, De Caterina R. Angina pectoris and myocardial is­
chemia in the absence of obstructive coronary artery disease: practical considerations 
for diagnostic tests. JACC Cardiovasc Interv 2014;7:453–63. https://doi.org/10.1016/j. 
jcin.2014.01.157
386. Boerhout CKM, Feenstra RGT, Somsen GA, Appelman Y, Ong P, Beijk MAM, et al. 
Coronary computed tomographic angiography as gatekeeper for new-onset stable an­
gina. Neth Heart J 2021;29:551–6. https://doi.org/10.1007/s12471-021-01639-7
387. Jukema R, Maaniitty T, van Diemen P, Berkhof H, Raijmakers PG, Sprengers R, et al. 
Warranty period of coronary computed tomography angiography and [15O]H2O 
positron emission tomography in symptomatic patients. Eur Heart J Cardiovasc 
Imaging 2022;24:304–11. https://doi.org/10.1093/ehjci/jeac258
388. Haberkorn SM, Haberkorn SI, Bonner F, Kelm M, Hopkin G, Petersen SE. Vasodilator 
myocardial perfusion cardiac magnetic resonance imaging is superior to dobutamine 
stress echocardiography in the detection of relevant coronary artery stenosis: a sys­
tematic review and meta-analysis on their diagnostic accuracy. Front Cardiovasc Med 
2021;8:630846. https://doi.org/10.3389/fcvm.2021.630846
389. van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin M-F, Bertolotto M, et al. 
Post-contrast acute kidney injury—Part 1: definition, clinical features, incidence, role 
of contrast medium and risk factors : recommendations for updated ESUR Contrast


<!-- PAGE 103 -->

### Page 103

Medium Safety Committee guidelines. Eur Radiol 2018;28:2845–55. https://doi.org/10. 
1007/s00330-017-5246-5
390. Bittencourt MS, Hulten EA, Murthy VL, Cheezum M, Rochitte CE, Carli MFD, et al. 
Clinical outcomes after evaluation of stable chest pain by coronary computed tomo­
graphic angiography versus usual care: a meta-analysis. Circ Cardiovasc Imaging 2016;9: 
e004419. https://doi.org/10.1161/CIRCIMAGING.115.004419
391. Reis JF, Ramos RB, Marques H, Daniel PM, Aguiar SR, Morais LA, et al. Cardiac com­
puted tomographic angiography after abnormal ischemia test as a gatekeeper to inva­
sive coronary angiography. Int J Cardiovasc Imaging 2022;38:883–93. https://doi.org/10. 
1007/s10554-021-02426-6
392. Maaniitty T, Stenstrom I, Bax JJ, Uusitalo V, Ukkonen H, Kajander S, et al. Prognostic 
value of coronary CT angiography with selective PET perfusion imaging in coronary 
artery disease. JACC Cardiovasc Imaging 2017;10:1361–70. https://doi.org/10.1016/j. 
jcmg.2016.10.025
393. Pezel T, Hovasse T, Lefevre T, Sanguineti F, Unterseeh T, Champagne S, et al. 
Prognostic value of stress CMR in symptomatic patients with coronary stenosis on 
CCTA. JACC Cardiovasc Imaging 2022;15:1408–22. https://doi.org/10.1016/j.jcmg. 
2022.03.008
394. Winther S, Andersen IT, Gormsen LC, Steffensen FH, Nielsen LH, Grove EL, et al. 
Prognostic value of myocardial perfusion imaging after first-line coronary computed 
tomography angiography: a multi-center cohort study. J Cardiovasc Comput Tomogr 
2022;16:34–40. https://doi.org/10.1016/j.jcct.2021.08.001
395. Min JK, Leipsic J, Pencina MJ, Berman DS, Koo B-K, van Mieghem C, et al. Diagnostic 
accuracy of fractional flow reserve from anatomic CT angiography. JAMA 2012;308: 
1237–45. https://doi.org/10.1001/2012.jama.11274
396. Douglas PS, De Bruyne B, Pontone G, Patel MR, Norgaard BL, Byrne RA, et al. 1-Year 
outcomes of FFRCT-guided care in patients with suspected coronary disease: the 
PLATFORM study. J Am Coll Cardiol 2016;68:435–45. https://doi.org/10.1016/j.jacc. 
2016.05.057
397. Fairbairn TA, Nieman K, Akasaka T, Nørgaard BL, Berman DS, Raff G, et al. Real-world 
clinical utility and impact on clinical decision-making of coronary computed tomog­
raphy angiography-derived fractional flow reserve: lessons from the ADVANCE regis­
try. Eur Heart J 2018;39:3701–11. https://doi.org/10.1093/eurheartj/ehy530
398. Andreini D, Modolo R, Katagiri Y, Mushtaq S, Sonck J, Collet C, et al. Impact of frac­
tional flow reserve derived from coronary computed tomography angiography on 
heart team treatment decision-making in patients with multivessel coronary artery dis­
ease: insights from the SYNTAX III REVOLUTION trial. Circ Cardiovasc Interv 2019;12: 
e007607. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007607
399. Patel MR, Norgaard BL, Fairbairn TA, Nieman K, Akasaka T, Berman DS, et al. 1-year 
impact on medical practice and clinical outcomes of FFR(CT): the ADVANCE registry. 
JACC Cardiovasc Imaging 2020;13:97–105. https://doi.org/10.1016/j.jcmg.2019.03.003
400. Riedl KA, Jensen JM, Ko BS, Leipsic J, Grove EL, Mathiassen ON, et al. Coronary CT 
angiography derived FFR in patients with left main disease. Int J Cardiovasc Imaging 
2021;37:3299–308. https://doi.org/10.1007/s10554-021-02371-4
401. Nørgaard BL, Gaur S, Fairbairn TA, Douglas PS, Jensen JM, Patel MR, et al. Prognostic 
value of coronary computed tomography angiographic derived fractional flow reserve: 
a systematic review and meta-analysis. Heart 2022;108:194–202. https://doi.org/10. 
1136/heartjnl-2021-319773
402. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous cor­
onary intervention in stable angina (ORBITA): a double-blind, randomised controlled 
trial. Lancet 2018;391:31–40. https://doi.org/10.1016/S0140-6736(17)32714-9
403. Foley M, Rajkumar CA, Shun-Shin M, Ganesananthan S, Seligman H, Howard J, et al. 
Achieving optimal medical therapy: insights from the ORBITA trial. J Am Heart Assoc 
2021;10:e017381. https://doi.org/10.1161/JAHA.120.017381
404. Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif J-C, et al. International ob­
servational analysis of evolution and outcomes of chronic stable angina: the multi­
national CLARIFY study. Circulation 2021;144:512–23. https://doi.org/10.1161/ 
CIRCULATIONAHA.121.054567
405. Task Force Members; Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, 
et al. 2013 ESC Guidelines on the management of stable coronary artery disease: the 
Task Force on the management of stable coronary artery disease of the European 
Society of Cardiology. Eur Heart J 2013;34:2949–3003. https://doi.org/10.1093/ 
eurheartj/eht296
406. Rapsomaniki E, Shah A, Perel P, Denaxas S, George J, Nicholas O, et al. Prognostic 
models for stable coronary artery disease based on electronic health record cohort 
of 102 023 patients. Eur Heart J 2014;35:844–52. https://doi.org/10.1093/eurheartj/ 
eht533
407. Barbero U, D’Ascenzo F, Nijhoff F, Moretti C, Biondi-Zoccai G, Mennuni M, et al. 
Assessing risk in patients with stable coronary disease: when should we intensify 
care and follow-up? Results from a meta-analysis of observational studies of the 
COURAGE and FAME era. Scientifica (Cairo) 2016;2016:3769152. https://doi.org/10. 
1155/2016/3769152
408. Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, et al. Long-term outcomes 
of chronic coronary syndrome worldwide: insights from the international CLARIFY 
registry. Eur Heart J 2020;41:347–56. https://doi.org/10.1093/eurheartj/ehz660
409. Liu Y, Song J, Wang W, Zhang K, Qi Y, Yang J, et al. Association of ejection fraction with 
mortality and cardiovascular events in patients with coronary artery disease. ESC Heart 
Fail 2022;9:3461–8. https://doi.org/10.1002/ehf2.14063
410. Thuijs D, Milojevic M, Stone GW, Puskas JD, Serruys PW, Sabik JF, et al. Impact of left 
ventricular ejection fraction on clinical outcomes after left main coronary artery revas­
cularization: results from the randomized EXCEL trial. Eur J Heart Fail 2020;22:871–9. 
https://doi.org/10.1002/ejhf.1681
411. Abidov A, Rozanski A, Hachamovitch R, Hayes SW, Aboul-Enein F, Cohen I, et al. 
Prognostic significance of dyspnea in patients referred for cardiac stress testing. 
N Engl J Med 2005;353:1889–98. https://doi.org/10.1056/NEJMoa042741
412. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and 
mortality among men referred for exercise testing. N Engl J Med 2002;346:793–801. 
https://doi.org/10.1056/NEJMoa011858
413. Sipilä K, Tikkakoski A, Alanko S, Haarala A, Hernesniemi J, Lyytikäinen L-P, et al. 
Combination of low blood pressure response, low exercise capacity and slow heart 
rate recovery during an exercise test significantly increases mortality risk. Ann Med 
2019;51:390–6. https://doi.org/10.1080/07853890.2019.1684550
414. Salokari E, Laukkanen JA, Lehtimaki T, Kurl S, Kunutsor S, Zaccardi F, et al. The Duke 
treadmill score with bicycle ergometer: exercise capacity is the most important pre­
dictor of cardiovascular mortality. Eur J Prev Cardiol 2019;26:199–207. https://doi. 
org/10.1177/2047487318804618
415. Williams MC, Kwiecinski J, Doris M, McElhinney P, D’Souza MS, Cadet S, et al. 
Low-attenuation noncalcified plaque on coronary computed tomography angiography 
predicts myocardial infarction: results from the multicenter SCOT-HEART trial 
(Scottish Computed Tomography of the HEART). Circulation 2020;141:1452–62. 
https://doi.org/10.1161/CIRCULATIONAHA.119.044720
416. Mortensen MB, Dzaye O, Steffensen FH, Bøtker HE, Jensen JM, Rønnow Sand NP, et al. 
Impact of plaque burden versus stenosis on ischemic events in patients with coronary 
atherosclerosis. J Am Coll Cardiol 2020;76:2803–13. https://doi.org/10.1016/j.jacc.2020. 
10.021
417. van Rosendael AR, Bax AM, Smit JM, van den Hoogen IJ, Ma X, Al’Aref S, et al. Clinical 
risk factors and atherosclerotic plaque extent to define risk for major events in pa­
tients without obstructive coronary artery disease: the long-term coronary computed 
tomography angiography CONFIRM registry. Eur Heart J Cardiovasc Imaging 2020;21: 
479–88. https://doi.org/10.1093/ehjci/jez322
418. Sharir T, Germano G, Kang X, Lewin HC, Miranda R, Cohen I, et al. Prediction of myo­
cardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk 
stratification by the amount of stress-induced ischemia and the poststress ejection 
fraction. J Nucl Med 2001;42:831–7.
419. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LEJ, Friedman JD, et al. 
Impact of ischaemia and scar on the therapeutic benefit derived from myocardial re­
vascularization vs. medical therapy among patients undergoing stress-rest myocardial 
perfusion scintigraphy. Eur Heart J 2011;32:1012–24. https://doi.org/10.1093/ 
eurheartj/ehq500
420. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M. Prognostic value of stress 
cardiac magnetic resonance imaging in patients with known or suspected coronary ar­
tery disease: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62:826–38. 
https://doi.org/10.1016/j.jacc.2013.03.080
421. Patel KK, Spertus JA, Chan PS, Sperry BW, Thompson RC, Al Badarin F, et al. Extent of 
myocardial ischemia on positron emission tomography and survival benefit with early 
revascularization. J Am Coll Cardiol 2019;74:1645–54. https://doi.org/10.1016/j.jacc. 
2019.07.055
422. Azadani PN, Miller RJH, Sharir T, Diniz MA, Hu L-H, Otaki Y, et al. Impact of early re­
vascularization on major adverse cardiovascular events in relation to automatically 
quantified ischemia. JACC Cardiovasc Imaging 2021;14:644–53. https://doi.org/10. 
1016/j.jcmg.2020.05.039
423. Sharir T, Hollander I, Hemo B, Tsamir J, Yefremov N, Bojko A, et al. Survival benefit of 
coronary revascularization after myocardial perfusion SPECT: the role of ischemia. 
J Nucl Cardiol 2021;28:1676–87. https://doi.org/10.1007/s12350-019-01932-4
424. Ciampi Q, Zagatina A, Cortigiani L, Wierzbowska-Drabik K, Kasprzak JD, Haberka M, 
et al. Prognostic value of stress echocardiography assessed by the ABCDE protocol. 
Eur Heart J 2021;42:3869–78. https://doi.org/10.1093/eurheartj/ehab493
425. Picano E, Pierard L, Peteiro J, Djordjevic-Dikic A, Sade LE, Cortigiani L, et al. The clinical 
use of stress echocardiography in chronic coronary syndromes and beyond coronary 
artery disease: a clinical consensus statement from the European Association of 
Cardiovascular Imaging of the ESC. Eur Heart J Cardiovasc Imaging 2023;25:e65–90. 
https://doi.org/10.1093/ehjci/jead250
426. Mancini GBJ, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, et al. Predicting 
outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation): coronary anatomy versus ischemia. JACC Cardiovasc 
Interv 2014;7:195–201. https://doi.org/10.1016/j.jcin.2013.10.017
427. Weintraub WS, Hartigan PM, Mancini GBJ, Teo KK, Maron DJ, Spertus JA, et al. Effect 
of coronary anatomy and myocardial ischemia on long-term survival in patients with 
stable ischemic heart disease. Circ Cardiovasc Qual Outcomes 2019;12:e005079. 
https://doi.org/10.1161/circoutcomes.118.005079
ESC Guidelines                                                                                                                                                                                          3517


<!-- PAGE 104 -->

### Page 104

428. Al-Mallah MH, Dilsizian V. The impact of revascularization on mortality: a debate on 
patient selection bias vs entry bias. J Am Coll Cardiol 2022;80:216–8. https://doi.org/ 
10.1016/j.jacc.2022.04.051
429. Adjedj J, De Bruyne B, Floré V, Di Gioia G, Ferrara A, Pellicano M, et al. Significance of 
intermediate values of fractional flow reserve in patients with coronary artery disease. 
Circulation 2016;133:502–8. https://doi.org/10.1161/circulationaha.115.018747
430. Fournier S, Collet C, Xaplanteris P, Zimmermann FM, Toth GG, Tonino PAL, et al. 
Global fractional flow reserve value predicts 5-year outcomes in patients with coron­
ary atherosclerosis but without ischemia. J Am Heart Assoc 2020;9:e017729. https://doi. 
org/10.1161/jaha.120.017729
431. Lee JM, Koo BK, Shin ES, Nam C-W, Doh J-H, Hwang D, et al. Clinical implications of 
three-vessel fractional flow reserve measurement in patients with coronary artery dis­
ease. Eur Heart J 2018;39:945–51. https://doi.org/10.1093/eurheartj/ehx458
432. Collet C, Miyazaki Y, Ryan N, Asano T, Tenekecioglu E, Sonck J, et al. Fractional flow 
reserve derived from computed tomographic angiography in patients with multivessel 
CAD. J Am Coll Cardiol 2018;71:2756–69. https://doi.org/10.1016/j.jacc.2018.02.053
433. Asano T, Katagiri Y, Chang CC, Kogame N, Chichareon P, Takahashi K, et al. 
Angiography-derived fractional flow reserve in the SYNTAX II trial: feasibility, diagnos­
tic performance of quantitative flow ratio, and clinical prognostic value of functional 
SYNTAX score derived from quantitative flow ratio in patients with 3-vessel disease. 
JACC Cardiovasc Interv 2019;12:259–70. https://doi.org/10.1016/j.jcin.2018.09.023
434. Zhang R, Song C, Guan C, Liu Q, Wang C, Xie L, et al. Prognostic value of quantitative 
flow ratio based functional SYNTAX score in patients with left main or multivessel 
coronary artery disease. Circ Cardiovasc Interv 2020;13:e009155. https://doi.org/10. 
1161/circinterventions.120.009155
435. Shaw LJ, Berman DS, Picard MH, Friedrich MG, Kwong RY, Stone GW, et al. 
Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiog­
raphy, and magnetic resonance imaging. JACC Cardiovasc Imaging 2014;7:593–604. 
https://doi.org/10.1016/j.jcmg.2013.10.021
436. Anderson L, Brown JP, Clark AM, Dalal H, Rossau HKK, Bridges C, et al. Patient edu­
cation in the management of coronary heart disease. Cochrane Database Syst Rev 2017; 
6:CD008895. https://doi.org/10.1002/14651858.CD008895.pub3
437. Collado-Mateo D, Lavin-Perez AM, Penacoba C, Del Coso J, Leyton-Román M, 
Luque-Casado A, et al. Key factors associated with adherence to physical exercise 
in patients with chronic diseases and older adults: an umbrella review. Int J Environ 
Res Public Health 2021;18:2023. https://doi.org/10.3390/ijerph18042023
438. Kohler AK, Jaarsma T, Tingstrom P, Nilsson S. The effect of problem-based learning 
after coronary heart disease—a randomised study in primary health care 
(COR-PRIM). BMC Cardiovasc Disord 2020;20:370. https://doi.org/10.1186/s12872- 
020-01647-2
439. Alzaman N, Wartak SA, Friderici J, Rothberg MB. Effect of patients’ awareness of CVD 
risk factors on health-related behaviors. South Med J 2013;106:606–9. https://doi.org/ 
10.1097/SMJ.0000000000000013
440. Riegel B, Jaarsma T, Stromberg A. A middle-range theory of self-care of chronic illness. 
ANS Adv Nurs Sci 2012;35:194–204. https://doi.org/10.1097/ANS.0b013e318261b1ba
441. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for 
the clinician. Heart 2019;105:881–8. https://doi.org/10.1136/heartjnl-2016-310750
442. Sheeran P, Harris PR, Epton T. Does heightening risk appraisals change people’s inten­
tions and behavior? A meta-analysis of experimental studies. Psychol Bull 2014;140: 
511–43. https://doi.org/10.1037/a0033065
443. Zwack CC, Smith C, Poulsen V, Raffoul N, Redfern J. Information needs and commu­
nication strategies for people with coronary heart disease: a scoping review. Int J 
Environ Res Public Health 2023;20:1723. https://doi.org/10.3390/ijerph20031723
444. Navar AM, Wang TY, Mi X, Robinson JG, Virani SS, Roger VL, et al. Influence of car­
diovascular risk communication tools and presentation formats on patient perceptions 
and preferences. JAMA Cardiol 2018;3:1192–9. https://doi.org/10.1001/jamacardio. 
2018.3680
445. Whitmore K, Zhou Z, Chapman N, Huynh Q, Magnussen CG, Sharman JE, et al. Impact 
of patient visualization of cardiovascular images on modification of cardiovascular risk 
factors: systematic review and meta-analysis. JACC Cardiovasc Imaging 2023;16: 
1069–81. https://doi.org/10.1016/j.jcmg.2023.03.007
446. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, 
Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention: 
a report from the ESC Prevention of CVD Programme led by the European 
Association of Preventive Cardiology (EAPC) in collaboration with the Acute 
Cardiovascular Care Association (ACCA) and the Association of Cardiovascular 
Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol 2019;26:1534–44. 
https://doi.org/10.1177/2047487319846715
447. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary 
heart disease. Cochrane Database Syst Rev 2004:CD003041. https://doi.org/10.1002/ 
14651858.CD003041.pub2
448. Barth J, Jacob T, Daha I, Critchley JA. Psychosocial interventions for smoking cessation 
in patients with coronary heart disease. Cochrane Database Syst Rev 2015;7: 
CD006886. https://doi.org/10.1002/14651858.CD006886.pub2
449. Prochaska JJ, Benowitz NL. The past, present, and future of nicotine addiction therapy. 
Annu Rev Med 2016;67:467–86. https://doi.org/10.1146/annurev-med-111314-033712
450. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety 
of smoking cessation interventions in patients with cardiovascular disease: a network 
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: 
e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458
451. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different 
doses, durations and modes of delivery of nicotine replacement therapy for smoking 
cessation. Cochrane Database Syst Rev 2019;4:CD013308. https://doi.org/10.1002/ 
14651858.CD013308
452. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated 
with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 
2014;129:28–41. https://doi.org/10.1161/CIRCULATIONAHA.113.003961
453. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al. 
Electronic cigarettes and health with special focus on cardiovascular effects: position 
paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev 
Cardiol 2020;28:1552–66. https://doi.org/10.1177/2047487320941993
454. Qasim H, Karim ZA, Rivera JO, Khasawneh FT, Alshbool FZ. Impact of electronic ci­
garettes on the cardiovascular system. J Am Heart Assoc 2017;6:e006353. https://doi. 
org/10.1161/JAHA.117.006353
455. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. 
Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;10: 
CD010216. https://doi.org/10.1002/14651858.CD010216.pub4
456. Abu Jad AA, Ravanavena A, Ravindra C, Igweonu-Nwakile EO, Ali S, Paul S, et al. 
Adverse effects of cannabinoids and tobacco consumption on the cardiovascular sys­
tem: a systematic review. Cureus 2022;14:e29208. https://doi.org/10.7759/cureus. 
29208
457. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 
2010;122:2558–69. https://doi.org/10.1161/CIRCULATIONAHA.110.940569
458. Singleton JH, Abner EL, Akpunonu PD, Kucharska-Newton AM. Association of nona­
cute opioid use and cardiovascular diseases: a scoping review of the literature. J Am 
Heart Assoc 2021;10:e021260. https://doi.org/10.1161/JAHA.121.021260
459. DeFilippis EM, Bajaj NS, Singh A, Malloy R, Givertz MM, Blankstein R, et al. Marijuana 
use in patients with cardiovascular disease: JACC review topic of the week. J Am Coll 
Cardiol 2020;75:320–32. https://doi.org/10.1016/j.jacc.2019.11.025
460. McNeely J, Cleland CM, Strauss SM, Palamar JJ, Rotrosen J, Saitz R. Validation of self- 
administered single-item screening questions (SISQS) for unhealthy alcohol and drug 
use in primary care patients. J Gen Intern Med 2015;30:1757–64. https://doi.org/10. 
1007/s11606-015-3391-6
461. Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body 
mass index with lifetime risk of cardiovascular disease and compression of morbidity. 
JAMA Cardiol 2018;3:280–7. https://doi.org/10.1001/jamacardio.2018.0022
462. Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, et al. 
The prognostic importance of weight loss in coronary artery disease: a systematic re­
view and meta-analysis. Mayo Clin Proc 2014;89:1368–77. https://doi.org/10.1016/j. 
mayocp.2014.04.033
463. Strelitz J, Lawlor ER, Wu Y, Estlin A, Nandakumar G, Ahern AL, et al. Association be­
tween weight change and incidence of cardiovascular disease events and mortality 
among adults with type 2 diabetes: a systematic review of observational studies and 
behavioural intervention trials. Diabetologia 2022;65:424–39. https://doi.org/10.1007/ 
s00125-021-05605-1
464. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of 
weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with 
overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 
2022;327:138–50. https://doi.org/10.1001/jama.2021.23619
465. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. 
Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 
2023;389:2221–32. https://doi.org/10.1056/NEJMoa2307563
466. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. 
Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387: 
205–16. https://doi.org/10.1056/NEJMoa2206038
467. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. 
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes 
(SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 
3 trial. Lancet 2023;402:613–26. https://doi.org/10.1016/S0140-6736(23)01200-X
468. Lopez-Jimenez F, Bhatia S, Collazo-Clavell ML, Sarr MG, Somers VK. Safety and efficacy 
of bariatric surgery in patients with coronary artery disease. Mayo Clin Proc 2005;80: 
1157–62. https://doi.org/10.4065/80.9.1157
469. De Bacquer D, Jennings CS, Mirrakhimov E, Lovic D, Bruthans J, De Smedt D, et al. 
Potential for optimizing management of obesity in the secondary prevention of coron­
ary heart disease. Eur Heart J Qual Care Clin Outcomes 2022;8:568–76. https://doi.org/ 
10.1093/ehjqcco/qcab043
470. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk 
thresholds for alcohol consumption: combined analysis of individual-participant data 
for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513–23. 
https://doi.org/10.1016/S0140-6736(18)30134-X


<!-- PAGE 105 -->

### Page 105

471. Biddinger KJ, Emdin CA, Haas ME, Wang M, Hindy G, Ellinor PT, et al. Association of 
habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open 2022;5: 
e223849. https://doi.org/10.1001/jamanetworkopen.2022.3849
472. Tully PJ, Ang SY, Lee EJ, Bendig E, Bauereiß N, Bengel J, et al. Psychological and pharma­
cological interventions for depression in patients with coronary artery disease. 
Cochrane Database Syst Rev 2021;12:CD008012. https://doi.org/10.1002/14651858. 
CD008012.pub4
473. Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, et al. Physical 
activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci 
Sports Exerc 2019;51:1270–81. https://doi.org/10.1249/MSS.0000000000001939
474. Hupin D, Roche F, Gremeaux V, Chatard J-C, Oriol M, Gaspoz J-M, et al. Even a low- 
dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged 
≥60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:1262–7. 
https://doi.org/10.1136/bjsports-2014-094306
475. Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan K, et al. 
Leisure time physical activity and mortality: a detailed pooled analysis of the 
dose-response relationship. JAMA Intern Med 2015;175:959–67. https://doi.org/10. 
1001/jamainternmed.2015.0533
476. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health 
Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports 
Med 2020;54:1451–62. https://doi.org/10.1136/bjsports-2020-102955
477. O’Donovan G, Lee IM, Hamer M, Stamatakis E. Association of “weekend warrior” and 
other leisure time physical activity patterns with risks for all-cause, cardiovascular dis­
ease, and cancer mortality. JAMA Intern Med 2017;177:335–42. https://doi.org/10. 
1001/jamainternmed.2016.8014
478. Jakicic JM, Kraus WE, Powell KE, Campbell WW, Janz KF, Troiano RP, et al. Association 
between bout duration of physical activity and health: systematic review. Med Sci Sports 
Exerc 2019;51:1213–9. https://doi.org/10.1249/MSS.0000000000001933
479. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. 
Dose-response associations between accelerometry measured physical activity and 
sedentary time and all cause mortality: systematic review and harmonised 
meta-analysis. BMJ 2019;366:l4570. https://doi.org/10.1136/bmj.l4570
480. Anderson L, Thompson DR, Oldridge N, Zwisler A-D, Rees K, Martin N, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2016;1:CD001800. https://doi.org/10.1002/14651858.CD001800.pub3
481. Santiago de Araujo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of cardiac rehabili­
tation dose on mortality and morbidity: a systematic review and meta-regression ana­
lysis. Mayo Clin Proc 2017;92:1644–59. https://doi.org/10.1016/j.mayocp.2017.07.019
482. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf M-I, Hackbusch M, et al. 
Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease pa­
tients treated according to contemporary evidence based medicine: update of the 
Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol 2020;27: 
1756–74. https://doi.org/10.1177/2047487320905719
483. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler A-D, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2021;11:CD001800. https://doi.org/10.1002/14651858.CD001800.pub4
484. Ambrosetti M, Abreu A, Corra U, Davos CH, Hansen D, Frederix I, et al. Secondary 
prevention through comprehensive cardiovascular rehabilitation: from knowledge to 
implementation. 2020 update. A position paper from the Secondary Prevention and 
Rehabilitation Section of the European Association of Preventive Cardiology. Eur J 
Prev Cardiol 2020;28:460–95. https://doi.org/10.1177/2047487320913379
485. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise 
intensity assessment and prescription in cardiovascular rehabilitation and beyond: why 
and how: a position statement from the Secondary Prevention and Rehabilitation 
Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 
2022;29:230–45. https://doi.org/10.1093/eurjpc/zwab007
486. Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, et al. 
Exercise prescription in patients with different combinations of cardiovascular disease 
risk factors: a consensus statement from the EXPERT working group. Sports Med 2018; 
48:1781–97. https://doi.org/10.1007/s40279-018-0930-4
487. Abell B, Glasziou P, Hoffmann T. The contribution of individual exercise training com­
ponents to clinical outcomes in randomised controlled trials of cardiac rehabilitation: a 
systematic review and meta-regression. Sports Med Open 2017;3:19. https://doi.org/10. 
1186/s40798-017-0086-z
488. Sanchez-Delgado JC, Camargo Sepulveda DC, Cardona Zapata A, Franco Pico MY, 
Santos Blanco LM, Jácome Hortúa AM, et al. The effects of maintenance cardiac re­
habilitation: a systematic review. J Cardiopulm Rehabil Prev 2020;40:224–44. https:// 
doi.org/10.1097/HCR.0000000000000520
489. Piepoli MF, Corra U, Dendale P, Frederix I, Prescott E, Schmid JP, et al. Challenges in 
secondary prevention after acute myocardial infarction: a call for action. Eur J Prev 
Cardiol 2016;23:1994–2006. https://doi.org/10.1177/2047487316663873
490. Gomes-Neto M, Duraes AR, Reis H, Neves VR, Martinez BP, Carvalho VO. 
High-intensity interval training versus moderate-intensity continuous training on exer­
cise capacity and quality of life in patients with coronary artery disease: a systematic 
review and meta-analysis. Eur J Prev Cardiol 2017;24:1696–707. https://doi.org/10. 
1177/2047487317728370
491. Franssen WMA, Franssen G, Spaas J, Solmi F, Eijnde BO. Can consumer wearable ac­
tivity tracker-based interventions improve physical activity and cardiometabolic health 
in patients with chronic diseases? A systematic review and meta-analysis of randomised 
controlled trials. Int J Behav Nutr Phys Act 2020;17:57. https://doi.org/10.1186/s12966- 
020-00955-2
492. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to 
promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst Rev 2019; 
2:CD007131. https://doi.org/10.1002/14651858.CD007131.pub4
493. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, et al. Home-based versus 
centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017;6:CD007130. 
https://doi.org/10.1002/14651858.CD007130.pub4
494. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, et al. Telehealth in­
terventions for the secondary prevention of coronary heart disease: a systematic re­
view and meta-analysis. Eur J Cardiovasc Nurs 2019;18:260–71. https://doi.org/10.1177/ 
1474515119826510
495. Cruz-Cobo C, Bernal-Jimenez MA, Vazquez-Garcia R, Santi-Cano MJ. Effectiveness of 
mHealth interventions in the control of lifestyle and cardiovascular risk factors in pa­
tients after a coronary event: systematic review and meta-analysis. JMIR Mhealth 
Uhealth 2022;10:e39593. https://doi.org/10.2196/39593
496. Hamilton SJ, Mills B, Birch EM, Thompson SC. Smartphones in the secondary preven­
tion of cardiovascular disease: a systematic review. BMC Cardiovasc Disord 2018;1:25. 
https://doi.org/10.1186/s12872-018-0764-x
497. Kissel CK, Nikoletou D. Cardiac rehabilitation and exercise prescription in symptom­
atic patients with non-obstructive coronary artery disease—a systematic review. Curr 
Treat Options Cardiovasc Med 2018;20:78. https://doi.org/10.1007/s11936-018-0667-2
498. Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, et al. Peak aer­
obic capacity predicts prognosis in patients with coronary heart disease. Am Heart J 
2008;156:292–300. https://doi.org/10.1016/j.ahj.2008.03.017
499. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in 
patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. 
https://doi.org/10.1001/jama.290.1.86
500. Held C, Hadziosmanovic N, Aylward PE, Hagström E, Hochman JS, Stewart RAH, et al. 
Body mass index and association with cardiovascular outcomes in patients with stable 
coronary heart disease—a STABILITY substudy. J Am Heart Assoc 2022;11:e023667. 
https://doi.org/10.1161/JAHA.121.023667
501. Stewart RA, Wallentin L, Benatar J, Danchin N, Hagström E, Held C, et al. Dietary pat­
terns and the risk of major adverse cardiovascular events in a global study of high-risk 
patients with stable coronary heart disease. Eur Heart J 2016;37:1993–2001. https:// 
doi.org/10.1093/eurheartj/ehw125
502. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, 
et al. Physical activity and mortality in patients with stable coronary heart disease. J Am 
Coll Cardiol 2017;70:1689–700. https://doi.org/10.1016/j.jacc.2017.08.017
503. Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein 
AH, et al. Interventions to promote physical activity and dietary lifestyle changes for 
cardiovascular risk factor reduction in adults: a scientific statement from the 
American Heart Association. Circulation 2010;122:406–41. https://doi.org/10.1161/ 
CIR.0b013e3181e8edf1
504. Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, et al. Anti-anginal drugs- 
beliefs and evidence: systematic review covering 50 years of medical treatment. Eur 
Heart J 2019;40:190–4. https://doi.org/10.1093/eurheartj/ehy504
505. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as 
add-on therapy in patients with stable angina: a systematic review and meta-analysis. 
Eur J Prev Cardiol 2015;22:837–48. https://doi.org/10.1177/2047487314533217
506. Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ, et al. Anti-anginal drugs: 
systematic review and clinical implications. Int J Cardiol 2019;283:55–63. https://doi. 
org/10.1016/j.ijcard.2018.12.008
507. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of 
ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic 
stable angina. Eur Heart J 2005;26:2529–36. https://doi.org/10.1093/eurheartj/ehi586
508. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine 
compared with amlodipine in patients with stable effort angina pectoris: a 3-month 
randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393–405. 
https://doi.org/10.2165/00003495-200767030-00005
509. Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R, et al. Ivabradine in stable cor­
onary artery disease without clinical heart failure. N Engl J Med 2014;371:1091–9. 
https://doi.org/10.1056/NEJMoa1406430
510. Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, et al. Beta-blockers, cal­
cium antagonists, and mortality in stable coronary artery disease: an international co­
hort study. Eur Heart J 2019;40:1399–407. https://doi.org/10.1093/eurheartj/ehy811
511. Steg PG, Greenlaw N, Tendera M, Tardif J-C, Ferrari R, Al-Zaibag M, et al. Prevalence 
of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in 
outpatients with stable coronary artery disease: data from the International 
Observational CLARIFY Registry. JAMA Intern Med 2014;174:1651–9. https://doi. 
org/10.1001/jamainternmed.2014.3773
512. Ford TJ, Berry C. Angina: contemporary diagnosis and management. Heart 2020;106: 
387–98. https://doi.org/10.1136/heartjnl-2018-314661
ESC Guidelines                                                                                                                                                                                          3519


<!-- PAGE 106 -->

### Page 106

513. Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, et al. Expert consensus 
document: a ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol 
2018;15:120–32. https://doi.org/10.1038/nrcardio.2017.131
514. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/ 
AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of 
patients with stable ischemic heart disease: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines, and the American College of Physicians, American Association for 
Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for 
Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
J Am Coll Cardiol 2012;60:e44–164. https://doi.org/10.1016/j.jacc.2012.07.013
515. Manolis AJ, Boden WE, Collins P, Dechend R, Kallistratos MS, Lopez Sendon J, et al. 
State of the art approach to managing angina and ischemia: tailoring treatment to 
the evidence. Eur J Intern Med 2021;92:40–7. https://doi.org/10.1016/j.ejim.2021.08. 
003
516. Bertero E, Heusch G, Munzel T, Maack C. A pathophysiological compass to personal­
ize antianginal drug treatment. Nat Rev Cardiol 2021;18:838–52. https://doi.org/10. 
1038/s41569-021-00573-w
517. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart-rate 
profile during exercise as a predictor of sudden death. N Engl J Med 2005;352:1951–8. 
https://doi.org/10.1056/NEJMoa043012
518. Shu DF, Dong BR, Lin XF, Wu TX, Liu GJ. Long-term beta blockers for stable angina: 
systematic review and meta-analysis. Eur J Prev Cardiol 2012;19:330–41. https://doi.org/ 
10.1177/1741826711409325
519. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial in­
farction: systematic review and meta regression analysis. BMJ 1999;318:1730–7. 
https://doi.org/10.1136/bmj.318.7200.1730
520. Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Role of beta- 
blockers in cardiovascular disease in 2019. Rev Esp Cardiol (Engl Ed) 2019;72: 
844–52. https://doi.org/10.1016/j.rec.2019.04.014
521. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of 
oral beta-blocker treatment on mortality in contemporary post-myocardial infarction 
patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 
2019;5:12–20. https://doi.org/10.1093/ehjcvp/pvy034
522. Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, 
Sánchez PL, et al. Rationale and design of the pragmatic clinical trial tREatment with 
Beta-blockers after myOcardial infarction withOut reduced ejection fracTion 
(REBOOT). Eur Heart J Cardiovasc Pharmacother 2022;8:291–301. https://doi.org/10. 
1093/ehjcvp/pvab060
523. Raposeiras-Roubín S, Abu-Assi E, Redondo-Diéguez A, González-Ferreiro R, 
López-López A, Bouzas-Cruz N, et al. Prognostic benefit of beta-blockers after acute 
coronary syndrome with preserved systolic function. Still relevant today? Rev Esp 
Cardiol (Engl Ed) 2015;68:585–91. https://doi.org/10.1016/j.rec.2014.07.028
524. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β-Blockers and 
mortality after acute myocardial infarction in patients without heart failure or ventricu­
lar dysfunction. J Am Coll Cardiol 2017;69:2710–20. https://doi.org/10.1016/j.jacc.2017. 
03.578
525. Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, et al. Long-term β-blocker therapy and 
clinical outcomes after acute myocardial infarction in patients without heart failure: na­
tionwide cohort study. Eur Heart J 2020;41:3521–9. https://doi.org/10.1093/eurheartj/ 
ehaa376
526. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: de­
veloped by the Task Force for the diagnosis and treatment of acute and chronic heart 
failure of the European Society of Cardiology (ESC) With the special contribution of 
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–726. https:// 
doi.org/10.1093/eurheartj/ehab368
527. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term 
use of carvedilol in patients with ST-segment elevation myocardial infarction treated 
with primary percutaneous coronary intervention. PLoS One 2018;13:e0199347. 
https://doi.org/10.1371/journal.pone.0199347
528. Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, et al. 
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients 
without reduced left ventricular ejection fraction (BETAMI): rationale and design of 
a prospective, randomized, open, blinded end point study. Am Heart J 2019;208: 
37–46. https://doi.org/10.1016/j.ahj.2018.10.005
529. Kristensen AMD, Bovin A, Zwisler AD, Cerquira C, Torp-Pedersen C, Bøtker HE, et al. 
Design and rationale of the Danish trial of beta-blocker treatment after myocardial in­
farction without reduced ejection fraction: study protocol for a randomized con­
trolled trial. Trials 2020;21:415. https://doi.org/10.1186/s13063-020-4214-6
530. Yndigegn T, Lindahl B, Alfredsson J, Benatar J, Brandin L, Erlinge D, et al. Design and 
rationale of randomized evaluation of decreased usage of beta-blockers after acute 
myocardial infarction (REDUCE-AMI). Eur Heart J Cardiovasc Pharmacother 2023;9: 
192–7. https://doi.org/10.1093/ehjcvp/pvac070
531. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for 
research and for patient care. J Am Coll Cardiol 2015;66:1273–85. https://doi.org/10. 
1016/j.jacc.2015.07.018
532. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β Blockers and 
mortality after myocardial infarction in patients without heart failure: multicentre pro­
spective cohort study. BMJ 2016;354:i4801. https://doi.org/10.1136/bmj.i4801
533. Ishak D, Aktaa S, Lindhagen L, Alfredsson J, Dondo TB, Held C, et al. Association of 
beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. 
Heart 2023;109:1159–65. https://doi.org/10.1136/heartjnl-2022-322115
534. Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation 
of beta-blockers in patients without heart failure optimally treated after acute myocar­
dial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual 
Outcomes 2018;11:e004356. https://doi.org/10.1161/CIRCOUTCOMES.117.004356
535. Zeitouni M, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet J-P, et al. Do patients 
need lifelong β-blockers after an uncomplicated myocardial infarction? Am J Cardiovasc 
Drugs 2019;19:431–8. https://doi.org/10.1007/s40256-019-00338-4
536. van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, et al. Which 
drug to choose for stable angina pectoris: a comparative study between bisoprolol and 
nitrates. Int J Cardiol 1995;47:217–23. https://doi.org/10.1016/0167-5273(94)02194-n
537. Ueberbacher HJ, Patyna WD, Krepp P, Puespoek J, Neuhaus R, Hilbich K, et al. 
[Randomized, 
double-blind 
comparison 
of 
isosorbide-5-mononitrate 
and 
delayed-action nifedipine in patients with stable exertional angina. Multicenter Study 
Group]. Schweiz Med Wochenschr 1991;121:1836–40.
538. Davies RF, Habibi H, Klinke WP, Dessain P, Nadeau C, Phaneuf DC, et al. Effect of am­
lodipine, atenolol and their combination on myocardial ischemia during treadmill ex­
ercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia 
Study (CASIS) Investigators. J Am Coll Cardiol 1995;25:619–25. https://doi.org/10. 
1016/0735-1097(94)00436-t
539. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined 
antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. 
Coron Artery Dis 2002;13:427–36. https://doi.org/10.1097/00019501-200212000- 
00008
540. Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable angina: a systematic 
review and meta-analysis of randomized clinical trials. Int J Cardiol 2011;146:4–12. 
https://doi.org/10.1016/j.ijcard.2010.05.019
541. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Heart rate as a prog­
nostic risk factor in patients with coronary artery disease and left-ventricular systolic 
dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 
2008;372:817–21. https://doi.org/10.1016/s0140-6736(08)61171-x
542. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between 
ivabradine treatment and cardiovascular outcomes in patients with stable coronary ar­
tery disease and left ventricular systolic dysfunction with limiting angina: a subgroup 
analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30: 
2337–45. https://doi.org/10.1093/eurheartj/ehp358
543. Jiang J, Li Y, Zhou Y, Li X, Li H, Tang B, et al. Oral nicorandil reduces ischemic attacks in 
patients with stable angina: a prospective, multicenter, open-label, randomized, con­
trolled study. Int J Cardiol 2016;224:183–7. https://doi.org/10.1016/j.ijcard.2016.08.305
544. Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, et al. Effects of nicorandil 
on cardiovascular events in patients with coronary artery disease in the Japanese 
Coronary Artery Disease (JCAD) study. Circ J 2010;74:503–9. https://doi.org/10. 
1253/circj.cj-09-0649
545. Zhu WL, Shan YD, Guo JX, Wei J-P, Yang X-C, Li T-D, et al. Double-blind, multicenter, 
active-controlled, randomized clinical trial to assess the safety and efficacy of orally ad­
ministered nicorandil in patients with stable angina pectoris in China. Circ J 2007;71: 
826–33. https://doi.org/10.1253/circj.71.826
546. IONA study group. Effect of nicorandil on coronary events in patients with stable an­
gina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359: 
1269–75. https://doi.org/10.1016/s0140-6736(02)08265-x
547. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, et al. A 
double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. 
Cardiovasc Drugs Ther 1993;7:119–23. https://doi.org/10.1007/BF00878320
548. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with 
isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, 
double-blind, randomized studies with stable coronary heart disease patients. 
J Cardiovasc Pharmacol 1992;20 Suppl 3:S74–81. https://doi.org/10.1097/00005344- 
199206203-00013
549. Zhao Y, Peng L, Luo Y, Li S, Zheng Z, Dong R, et al. Trimetazidine improves exercise 
tolerance in patients with ischemic heart disease: a meta-analysis. Herz 2016;41: 
514–22. https://doi.org/10.1007/s00059-015-4392-2
550. Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable 
angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol 2014;177: 
780–5. https://doi.org/10.1016/j.ijcard.2014.10.149
551. Beltrame JF. Ivabradine and the SIGNIFY conundrum. Eur Heart J 2015;36:3297–9. 
https://doi.org/10.1093/eurheartj/ehv368
552. Dittrich H, Henneke KH, Pohlmann M, Pongratz G, Bachmann K. Provocation of left 
ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy.


<!-- PAGE 107 -->

### Page 107

Comparison of orthostasis testing and nitrate application. Int J Card Imaging 1996;12: 
249–55. https://doi.org/10.1007/BF01797738
553. Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with 
hypertrophic cardiomyopathy. N Engl J Med 1999;341:700–1. https://doi.org/10.1056/ 
NEJM199908263410916
554. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427–520. https://doi.org/10.1093/eurheartj/ehab364
555. Davies A, Fox K, Galassi AR, Banai S, Ylä-Herttuala S, Lüscher TF. Management of re­
fractory angina: an update. Eur Heart J 2021;42:269–83. https://doi.org/10.1093/ 
eurheartj/ehaa820
556. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC fo­
cused update on dual antiplatelet therapy in coronary artery disease developed in col­
laboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery 
disease of the European Society of Cardiology (ESC) and of the European Association 
for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60. https://doi.org/10. 
1093/eurheartj/ehx419
557. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. 
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients 
with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial 
(SAPAT) Group. Lancet 1992;340:1421–5. https://doi.org/10.1016/0140-6736(92) 
92619-q
558. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C, Blackwell L, Collins R, 
Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vas­
cular disease: collaborative meta-analysis of individual participant data from rando­
mised trials. Lancet 2009;373:1849–60. https://doi.org/10.1016/s0140-6736(09) 
60503-1
559. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. BMJ 2002;324:71–86. https://doi.org/10.1136/bmj.324.7329.71
560. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the pre­
vention of atherothrombosis. N Engl J Med 2005;353:2373–83. https://doi.org/10. 
1056/NEJMra052717
561. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative 
effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021;384: 
1981–90. https://doi.org/10.1056/NEJMoa2102137
562. Gragnano F, Cao D, Pirondini L, Franzone A, Kim H-S, von Scheidt M, et al. P2Y12 in­
hibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll 
Cardiol 2023;82:89–105. https://doi.org/10.1016/j.jacc.2023.04.051
563. Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C, et al. Monotherapy 
with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established 
atherosclerosis: a systematic review and meta-analysis. Lancet 2020;395:1487–95. 
https://doi.org/10.1016/S0140-6736(20)30315-9
564. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin 
in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39. https://doi. 
org/10.1016/s0140-6736(96)09457-3
565. Koo BK, Kang J, Park KW, Rhee T-M, Yang H-M, Won K-B, et al. Aspirin versus clo­
pidogrel for chronic maintenance monotherapy after percutaneous coronary inter­
vention 
(HOST-EXAM): an 
investigator-initiated, prospective, 
randomised, 
open-label, multicentre trial. Lancet 2021;397:2487–96. https://doi.org/10.1016/ 
S0140-6736(21)01063-1
566. Kang J, Park KW, Lee H, Hwang D, Yang H-M, Rha S-W, et al. Aspirin versus clopido­
grel for long-term maintenance monotherapy after percutaneous coronary interven­
tion: the HOST-EXAM Extended study. Circulation 2023;147:108–17. https://doi.org/ 
10.1161/circulationaha.122.062770
567. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized 
double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of tica­
grelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ 
OFFSET 
study. 
Circulation 
2009;120:2577–85. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.109.912550
568. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of 
ticagrelor compared with clopidogrel on platelet function in patients with acute cor­
onary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET 
substudy. J Am Coll Cardiol 2010;56:1456–62. https://doi.org/10.1016/j.jacc.2010.03. 
100
569. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor 
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 
1045–57. https://doi.org/10.1056/NEJMoa0904327
570. Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin 
for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopi­
dogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months 
after implantation of a drug-eluting stent: a multicentre, open-label, randomised super­
iority trial. Lancet 2018;392:940–9. https://doi.org/10.1016/S0140-6736(18)31858-0
571. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, et al. ticagre­
lor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary 
stenting. J Am Coll Cardiol 2019;74:2223–34. https://doi.org/10.1016/j.jacc.2019.08. 
1038
572. Ono M, Hara H, Kawashima H, Gao C, Wang R, Wykrzykowska JJ, et al. Ticagrelor 
monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary 
intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention 
2022;18:e377–88. https://doi.org/10.4244/EIJ-D-21-00870
573. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor 
with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381: 
2032–42. https://doi.org/10.1056/NEJMoa1908419
574. O’Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discon­
tinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary 
intervention: a systematic review and meta-analysis. Circulation 2020;142:538–45. 
https://doi.org/10.1161/CIRCULATIONAHA.120.046251
575. Vranckx P, Valgimigli M, Windecker S, Steg P, Hamm C, Jüni P, et al. Long-term tica­
grelor monotherapy versus standard dual antiplatelet therapy followed by aspirin 
monotherapy in patients undergoing biolimus-eluting stent implantation: rationale 
and design of the GLOBAL LEADERS trial. EuroIntervention 2016;12:1239–45. 
https://doi.org/10.4244/EIJY15M11_07
576. Kogame N, Guimaraes PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, et al. 
Aspirin-free prasugrel monotherapy following coronary artery stenting in patients 
with stable CAD: the ASET Pilot study. JACC Cardiovasc Interv 2020;13:2251–62. 
https://doi.org/10.1016/j.jcin.2020.06.023
577. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 
genetic polymorphisms and the response to prasugrel: relationship to pharmacoki­
netic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553–60. 
https://doi.org/10.1161/circulationaha.109.851949
578. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. 
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or with­
out a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374: 
989–97. https://doi.org/10.1016/S0140-6736(09)61525-7
579. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and ex­
cretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514–21. 
https://doi.org/10.1124/dmd.110.032250
580. Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Beyond efficacy: pharma­
cokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin 
Pharmacother 2011;12:1285–95. https://doi.org/10.1517/14656566.2011.550573
581. Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, et al. Consensus and 
update on the definition of on-treatment platelet reactivity to adenosine diphosphate 
associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–73. https://doi. 
org/10.1016/j.jacc.2013.07.101
582. Parker WA, Storey RF. Antithrombotic therapy for patients with chronic coronary 
syndromes. Heart 2021;107:925–33. https://doi.org/10.1136/heartjnl-2020-316914
583. Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger J-G, et al. Ticagrelor versus 
clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, 
open-label, phase 3b trial. Lancet 2020;396:1737–44. https://doi.org/10.1016/S0140- 
6736(20)32236-4
584. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in pa­
tients with stable coronary disease and diabetes. N Engl J Med 2019;381:1309–20. 
https://doi.org/10.1056/NEJMoa1908077
585. Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor 
monotherapy vs dual antiplatelet therapy on cardiovascular events in patients under­
going percutaneous coronary intervention: the SMART-CHOICE randomized clinical 
trial. JAMA 2019;321:2428–37. https://doi.org/10.1001/jama.2019.8146
586. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 
1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplate­
let therapy on cardiovascular and bleeding events in patients receiving PCI: the 
STOPDAPT-2 randomized clinical trial. JAMA 2019;321:2414–27. https://doi.org/10. 
1001/jama.2019.8145
587. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy 
after PCI in patients at high bleeding risk. N Engl J Med 2021;385:1643–55. https://doi. 
org/10.1056/NEJMoa2108749
588. Hong SJ, Kim JS, Hong SJ, Lim D-S, Lee S-Y, Yun KH, et al. 1-Month dual-antiplatelet 
therapy followed by aspirin monotherapy after polymer-free drug-coated stent im­
plantation: one-month DAPT trial. JACC Cardiovasc Interv 2021;14:1801–11. https:// 
doi.org/10.1016/j.jcin.2021.06.003
589. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and valid­
ation of the predicting bleeding complications in patients undergoing stent implant­
ation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled 
analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025–34. 
https://doi.org/10.1016/S0140-6736(17)30397-5
590. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining 
high bleeding risk in patients undergoing percutaneous coronary intervention: a con­
sensus document from the Academic Research Consortium for High Bleeding Risk. Eur 
Heart J 2019;40:2632–53. https://doi.org/10.1093/eurheartj/ehz372
591. Costa F, Montalto C, Branca M, Hong S-J, Watanabe H, Franzone A, et al. Dual anti­
platelet therapy duration after percutaneous coronary intervention in high bleeding 
ESC Guidelines                                                                                                                                                                                          3521


<!-- PAGE 108 -->

### Page 108

risk: a meta-analysis of randomized trials. Eur Heart J 2023;44:954–68. https://doi.org/ 
10.1093/eurheartj/ehac706
592. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve 
or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 
371:2155–66. https://doi.org/10.1056/NEJMoa1409312
593. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of 
ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372: 
1791–800. https://doi.org/10.1056/NEJMoa1500857
594. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. 
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 
2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118
595. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in 
ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in 
PEGASUS-TIMI 54. J Am Coll Cardiol 2016;67:2732–40. https://doi.org/10.1016/j.jacc. 
2016.03.529
596. Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, et al. Ticagrelor for pre­
vention of ischemic events after myocardial infarction in patients with peripheral artery 
disease. J Am Coll Cardiol 2016;67:2719–28. https://doi.org/10.1016/j.jacc.2016.03.524
597. Bansilal S, Bonaca MP, Cornel JH, Storey RF, Bhatt DL, Steg PG, et al. Ticagrelor for 
secondary prevention of atherothrombotic events in patients with multivessel coron­
ary disease. J Am Coll Cardiol 2018;71:489–96. https://doi.org/10.1016/j.jacc.2017.11. 
050
598. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban 
with or without aspirin in patients with stable peripheral or carotid artery disease: an 
international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391: 
219–29. https://doi.org/10.1016/S0140-6736(17)32409-1
599. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function 
CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with 
clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821–30. https:// 
doi.org/10.1001/jama.2010.1543
600. Pereira NL, Rihal C, Lennon R, Marcus G, Shrivastava S, Bell MR, et al. Effect of 
CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a 
meta-analysis. JACC Cardiovasc Interv 2021;14:739–50. https://doi.org/10.1016/j.jcin. 
2021.01.024
601. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided 
de-escalation of antiplatelet treatment in patients with acute coronary syndrome 
undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, 
open-label, multicentre trial. Lancet 2017;390:1747–57. https://doi.org/10.1016/ 
S0140-6736(17)32155-4
602. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der 
Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. 
N Engl J Med 2019;381:1621–31. https://doi.org/10.1056/NEJMoa1907096
603. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet 
reactivity and cardiovascular outcomes after percutaneous coronary intervention: a 
time-dependent analysis of the Gauging Responsiveness with A VerifyNow P2Y12 as­
say: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132–7. 
https://doi.org/10.1161/circulationaha.111.029165
604. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, et al. Dual-antiplatelet 
treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): 
a randomised trial. Lancet 2014;384:1577–85. https://doi.org/10.1016/s0140-6736(14) 
60612-7
605. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al. 
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented 
for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, ran­
domised controlled superiority trial. Lancet 2016;388:2015–22. https://doi.org/10. 
1016/s0140-6736(16)31323-x
606. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. A randomised 
trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients 
undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet 
Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes 
(TROPICAL-ACS) Trial. Thromb Haemost 2017;117:188–95. https://doi.org/10.1160/ 
th16-07-0557
607. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of 
genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy 
on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI 
randomized clinical trial. JAMA 2020;324:761–71. https://doi.org/10.1001/jama.2020. 
12443
608. Ingraham BS, Farkouh ME, Lennon RJ, So D, Goodman SG, Geller N, et al. 
Genetic-guided oral P2Y12 inhibitor selection and cumulative ischemic events after 
percutaneous coronary intervention. JACC Cardiovasc Interv 2023;16:816–25. https:// 
doi.org/10.1016/j.jcin.2023.01.356
609. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both 
after myocardial infarction. N Engl J Med 2002;347:969–74. https://doi.org/10.1056/ 
NEJMoa020496
610. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE; Antithrombotics in the 
Secondary Preventionof Events in Coronary Thrombosis-2 (ASPECT-2) Research 
Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): 
a randomised controlled trial. Lancet 2002;360:109–13. https://doi.org/10.1016/ 
S0140-6736(02)09409-6
611. Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term 
oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the 
Sixty Plus Reinfarction Study Research Group. Lancet 1980;2:989–94. https://doi.org/ 
10.1016/S0140-6736(80)92154-6
612. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. 
Risk of bleeding in patients with acute myocardial infarction treated with different 
combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retro­
spective analysis of nationwide registry data. Lancet 2009;374:1967–74. https://doi. 
org/10.1016/S0140-6736(09)61751-7
613. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col­
laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the 
Task Force for the diagnosis and management of atrial fibrillation of the European 
Society of Cardiology (ESC) Developed with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 
373–498. https://doi.org/10.1093/eurheartj/ehaa612
614. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. 
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary 
syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event 
Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 
2017;38:804–10. https://doi.org/10.1093/eurheartj/ehw525
615. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJGL, Herrman J-P, et al. 
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy 
and undergoing percutaneous coronary intervention: an open-label, randomised, con­
trolled trial. Lancet 2013;381:1107–15. https://doi.org/10.1016/S0140-6736(12) 
62177-1
616. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. 
Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J 
Med 2016;375:2423–34. https://doi.org/10.1056/NEJMoa1611594
617. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrom­
botic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377: 
1513–24. https://doi.org/10.1056/NEJMoa1708454
618. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. 
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after suc­
cessful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a ran­
domised, open-label, phase 3b trial. Lancet 2019;394:1335–43. https://doi.org/10. 
1016/S0140-6736(19)31872-0
619. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic 
therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 
380:1509–24. https://doi.org/10.1056/NEJMoa1817083
620. Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses 
with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic 
therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous cor­
onary intervention/acute coronary syndrome patients. Europace 2020;22:538–46. 
https://doi.org/10.1093/europace/euz345
621. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and ef­
ficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fib­
rillation following percutaneous coronary intervention: a systematic review and 
meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical 
trials. Eur Heart J 2019;40:3757–67. https://doi.org/10.1093/eurheartj/ehz732
622. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/ 
benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and 
late after an acute coronary syndrome or percutaneous coronary intervention: insights 
from 
AUGUSTUS. 
Circulation 
2020;141:1618–27. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.120.046534
623. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, et al. 2018 Joint 
European consensus document on the management of antithrombotic therapy in atrial 
fibrillation patients presenting with acute coronary syndrome and/or undergoing per­
cutaneous cardiovascular interventions: a joint consensus document of the European 
Heart Rhythm Association (EHRA), European Society of Cardiology Working Group 
on Thrombosis, European Association of Percutaneous Cardiovascular Interventions 
(EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the 
Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin 
America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of 
Southern Africa (CASSA). Europace 2019;21:192–3. https://doi.org/10.1093/ 
europace/euy174
624. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, et al. Dabigatran 
dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention 
in atrial fibrillation patients with or without acute coronary syndrome: a subgroup ana­
lysis from the RE-DUAL PCI trial. Eur Heart J 2019;40:1553–62. https://doi.org/10. 
1093/eurheartj/ehz059


<!-- PAGE 109 -->

### Page 109

625. Rubboli A. Oral anticoagulation alone for concomitant stable coronary artery disease 
and atrial fibrillation: a definitive strategy? Int J Cardiol 2018;264:95–6. https://doi.org/ 
10.1016/j.ijcard.2018.04.023
626. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Outcomes of anticoa­
gulated patients with atrial fibrillation treated with or without antiplatelet therapy—a 
pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON regis­
tries. Int J Cardiol 2018;270:160–6. https://doi.org/10.1016/j.ijcard.2018.06.098
627. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic ther­
apy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103–13. 
https://doi.org/10.1056/NEJMoa1904143
628. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 
developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 
2020;41:543–603. https://doi.org/10.1093/eurheartj/ehz405
629. Bjorklund E, Nielsen SJ, Hansson EC, Karlsson M, Wallinder A, Martinsson A, et al. 
Secondary prevention medications after coronary artery bypass grafting and long-term 
survival: a population-based longitudinal study from the SWEDEHEART registry. Eur 
Heart J 2020;41:1653–61. https://doi.org/10.1093/eurheartj/ehz714
630. Mangano DT. Multicenter Study of Perioperative Ischemia Research Group. Aspirin 
and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309–17. 
https://doi.org/10.1056/NEJMoa020798
631. Sousa-Uva M, Storey R, Huber K, Falk V, Leite-Moreira AF, Amour J, et al. Expert pos­
ition paper on the management of antiplatelet therapy in patients undergoing coronary 
artery bypass graft surgery. Eur Heart J 2014;35:1510–4. https://doi.org/10.1093/ 
eurheartj/ehu158
632. Sousa-Uva M, Head SJ, Milojevic M, Collet J-P, Landoni G, Castella M, et al. 2017 
EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J 
Cardiothorac Surg 2018;53:5–33. https://doi.org/10.1093/ejcts/ezx314
633. Shaw JR, Li N, Vanassche T, Coppens M, Spyropoulos AC, Syed S, et al. Predictors of 
preprocedural direct oral anticoagulant levels in patients having an elective surgery or 
procedure. 
Blood 
Adv 
2020;4:3520–7. 
https://doi.org/10.1182/bloodadvances. 
2020002335
634. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European 
Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral 
anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612–76. https://doi. 
org/10.1093/europace/euab065
635. Sandner S, Redfors B, Angiolillo DJ, Audisio K, Fremes SE, Janssen PWA, et al. 
Association of dual antiplatelet therapy with ticagrelor with vein graft failure after cor­
onary artery bypass graft surgery: a systematic review and meta-analysis. JAMA 2022; 
328:554–62. https://doi.org/10.1001/jama.2022.11966
636. Kulik A, Le May MR, Voisine P, Tardif J-C, DeLarochelliere R, Naidoo S, et al. Aspirin 
plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopido­
grel after surgery for coronary artery disease (CASCADE) trial. Circulation 2010;122: 
2680–7. https://doi.org/10.1161/CIRCULATIONAHA.110.978007
637. Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, et al. Effect of ticagrelor plus aspirin, 
ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary 
artery bypass grafting: a randomized clinical trial. JAMA 2018;319:1677–86. https://doi. 
org/10.1001/jama.2018.3197
638. Filardo G, Damiano RJ Jr, Ailawadi G, Thourani VH, Pollock BD, Sass DM, et al. 
Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft 
surgery. Heart 2018;104:985–92. https://doi.org/10.1136/heartjnl-2017-312150
639. Benedetto U, Gaudino MF, Dimagli A, Gerry S, Gray A, Lees B, et al. Postoperative 
atrial fibrillation and long-term risk of stroke after isolated coronary artery bypass graft 
surgery. Circulation 2020;142:1320–9. https://doi.org/10.1161/CIRCULATIONAHA. 
120.046940
640. Taha A, Nielsen SJ, Franzen S, Rezk M, Ahlsson A, Friberg L, et al. Stroke risk stratifi­
cation in patients with postoperative atrial fibrillation after coronary artery bypass 
grafting. J Am Heart Assoc 2022;11:e024703. https://doi.org/10.1161/JAHA.121.024703
641. Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, et al. Long-term 
thromboembolic risk in patients with postoperative atrial fibrillation after coronary ar­
tery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol 
2018;3:417–24. https://doi.org/10.1001/jamacardio.2018.0405
642. Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, et al. New-onset atrial 
fibrillation after coronary artery bypass grafting and long-term outcome: a population- 
based nationwide study from the SWEDEHEART registry. J Am Heart Assoc 2021;10: 
e017966. https://doi.org/10.1161/JAHA.120.017966
643. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ 
ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton 
pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 
2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet 
therapy and NSAID use: a report of the American College of Cardiology Foundation 
Task Force on Expert Consensus Documents. Circulation 2010;122:2619–33. https:// 
doi.org/10.1161/CIR.0b013e318202f701
644. Abraham NS, Noseworthy PA, Inselman J, Herrin J, Yao X, Sangaralingham LR, et al. 
Risk of gastrointestinal bleeding increases with combinations of antithrombotic agents 
and patient age. Clin Gastroenterol Hepatol 2020;18:337–46.e19. https://doi.org/10. 
1016/j.cgh.2019.05.017
645. Li L, Geraghty OC, Mehta Z, Rothwell PM, on behalf of the Oxford Vascular Study. 
Age-specific risks, severity, time course, and outcome of bleeding on long-term anti­
platelet treatment after vascular events: a population-based cohort study. Lancet 
2017;390:490–9. https://doi.org/10.1016/S0140-6736(17)30770-5
646. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety 
of proton pump inhibitors based on a large, multi-year, randomized trial of patients 
receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–91.e2. https://doi. 
org/10.1053/j.gastro.2019.05.056
647. Ahn HJ, Lee SR, Choi EK, Rhee TM, Kwon S, Oh S, et al. Protective effect of 
proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral antic­
oagulants: a systematic review and meta-analysis. Br J Clin Pharmacol 2022;88:4676–87. 
https://doi.org/10.1111/bcp.15478
648. Shang YS, Zhong PY, Ma Y, Bai N, Niu Y, Wang Z-L. Efficacy and safety of proton pump 
inhibitors in patients with coronary artery diseases receiving oral antiplatelet agents 
and/or anticoagulants: a systematic review and meta-analysis. J Cardiovasc Pharmacol 
2022;80:1–12. https://doi.org/10.1097/fjc.0000000000001284
649. Lin Y, Cai Z, Dong S, Liu H, Pang X, Chen Q, et al. Comparative efficacy and safety of 
antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes 
after percutaneous coronary intervention: a network meta-analysis of randomized 
controlled trials. Front Pharmacol 2022;13:992376. https://doi.org/10.3389/fphar. 
2022.992376
650. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- ver­
sus long-term duration of dual-antiplatelet therapy after coronary stenting: a rando­
mized multicenter trial. Circulation 2012;125:2015–26. https://doi.org/10.1161/ 
CIRCULATIONAHA.111.071589
651. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 
12-month dual antiplatelet therapy after implantation of drug-eluting stents: the 
Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting 
(EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–13. https:// 
doi.org/10.1161/CIRCULATIONAHA.111.059022
652. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, et al. 
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of 
clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252–63. https:// 
doi.org/10.1093/eurheartj/ehu523
653. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, et al. Six versus 12 months of dual anti­
platelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: 
randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv 2016;9:e003145. 
https://doi.org/10.1161/CIRCINTERVENTIONS.115.003145
654. Hong SJ, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, et al. 6-Month versus 12-month 
dual-antiplatelet therapy following long everolimus-eluting stent implantation: the 
IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 2016;9:1438–46. https:// 
doi.org/10.1016/j.jcin.2016.04.036
655. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for dis­
continuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy 
of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent im­
plantation). J Am Coll Cardiol 2012;60:1340–8. https://doi.org/10.1016/j.jacc.2012.06. 
043
656. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs 
twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the 
OPTIMIZE randomized trial. JAMA 2013;310:2510–22. https://doi.org/10.1001/jama. 
2013.282183
657. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y12 inhibitor 
monotherapy or dual antiplatelet therapy after coronary revascularisation: individual 
patient level meta-analysis of randomised controlled trials. BMJ 2021;373:n1332. 
https://doi.org/10.1136/bmj.n1332
658. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in pa­
tients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 
955–62. https://doi.org/10.1016/S0140-6736(13)62343-0
659. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, et al. Revisiting the 
effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation 
and acute coronary syndromes or percutaneous coronary interventions: meta-analysis 
of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. 
Europace 2020;22:33–46. https://doi.org/10.1093/europace/euz259
660. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy 
and safety of dabigatran compared with warfarin at different levels of international 
normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the 
RE-LY trial. Lancet 2010;376:975–83. https://doi.org/10.1016/S0140-6736(10) 
61194-4
661. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, et al. Duration 
of triple therapy in patients requiring oral anticoagulation after drug-eluting stent im­
plantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619–29. https://doi.org/ 
10.1016/j.jacc.2015.02.050
ESC Guidelines                                                                                                                                                                                          3523


<!-- PAGE 110 -->

### Page 110

662. Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, et al. Time 
in therapeutic range and major adverse outcomes in atrial fibrillation patients under­
going percutaneous coronary intervention: the Atrial Fibrillation Undergoing 
Coronary Artery Stenting (AFCAS) registry. Am Heart J 2017;190:86–93. https://doi. 
org/10.1016/j.ahj.2017.05.016
663. McDowell TY, Lawrence J, Florian J, Southworth MR, Grant S, Stockbridge N. 
Relationship between international normalized ratio and outcomes in modern trials 
with warfarin controls. Pharmacotherapy 2018;38:899–906. https://doi.org/10.1002/ 
phar.2161
664. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel 
with or without omeprazole in coronary artery disease. N Engl J Med 2010;363: 
1909–17. https://doi.org/10.1056/NEJMoa1007964
665. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. 
Risk of upper gastrointestinal ulcer bleeding associated with selective 
cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory 
drugs, aspirin and combinations. Gut 2006;55:1731–8. https://doi.org/10.1136/gut. 
2005.080754
666. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastropro­
tectant drugs for the prevention and treatment of peptic ulcer disease and its compli­
cations: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3: 
231–41. https://doi.org/10.1016/S2468-1253(18)30037-2
667. Cea Soriano L, Fowkes FGR, Allum AM, Johansson S, Garcia Rodriguez LA. Predictors 
of bleeding in patients with symptomatic peripheral artery disease: a cohort study 
using the health improvement network in the United Kingdom. Thromb Haemost 
2018;118:1101–12. https://doi.org/10.1055/s-0038-1646923
668. Han Y, Liao Z, Li Y, Zhao X, Ma S, Bao D, et al. Magnetically controlled capsule endos­
copy for assessment of antiplatelet therapy-induced gastrointestinal injury. J Am Coll 
Cardiol 2022;79:116–28. https://doi.org/10.1016/j.jacc.2021.10.028
669. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. 
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence 
from genetic, epidemiologic, and clinical studies. A consensus statement from the 
European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459–72. 
https://doi.org/10.1093/eurheartj/ehx144
670. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, 
Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering 
of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised 
trials. Lancet 2010;376:1670–81. https://doi.org/10.1016/s0140-6736(10)61350-5
671. Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey 
M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among 
men and women: meta-analysis of individual data from 174 000 participants in 27 ran­
domised trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/s0140-6736(14) 
61368-4
672. Ridker PM, Mora S, Rose L; Jupiter Trial Study Group. Percent reduction in LDL chol­
esterol following high-intensity statin therapy: potential implications for guidelines and 
for the prescription of emerging lipid-lowering agents. Eur Heart J 2016;37:1373–9. 
https://doi.org/10.1093/eurheartj/ehw046
673. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross- 
sectional observational study of lipid-modifying therapy use in secondary and primary 
care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279–89. https://doi.org/10.1093/ 
eurjpc/zwaa047
674. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. 
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 
2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489
675. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. 
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J 
Med 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664
676. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and 
cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379: 
2097–107. https://doi.org/10.1056/NEJMoa1801174
677. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. 
Long-term evolocumab in patients with established atherosclerotic cardiovascular dis­
ease. Circulation 2022;146:1109–19. https://doi.org/10.1161/CIRCULATIONAHA. 
122.061620
678. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic 
acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia 
and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 
2020;27:593–603. https://doi.org/10.1177/2047487319864671
679. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and 
efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380: 
1022–32. https://doi.org/10.1056/NEJMoa1803917
680. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic 
acid and cardiovascular outcomes in statin-intolerant patients. New Engl J Med 2023; 
388:1353–64. https://doi.org/10.1056/NEJMoa2215024
681. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of 
inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507–19. 
https://doi.org/10.1056/NEJMoa1912387
682. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, et al. Clinical benefit of 
statin pretreatment in patients undergoing percutaneous coronary intervention: a col­
laborative patient-level meta-analysis of 13 randomized studies. Circulation 2011;123: 
1622–32. https://doi.org/10.1161/CIRCULATIONAHA.110.002451
683. SOLVD Investigators; Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril 
on survival in patients with reduced left ventricular ejection fractions and congestive 
heart 
failure. 
N 
Engl 
J 
Med 
1991;325:293–302. 
https://doi.org/10.1056/ 
NEJM199108013250501
684. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of cap­
topril on mortality and morbidity in patients with left ventricular dysfunction after 
myocardial infarction — results of the survival and ventricular enlargement trial. 
The SAVE Investigators. N Engl J Med 1992;327:669–77. https://doi.org/10.1056/ 
NEJM199209033271001
685. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term 
ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a 
systematic overview of data from individual patients. ACE-Inhibitor Myocardial 
Infarction Collaborative Group. Lancet 2000;355:1575–81. https://doi.org/10.1016/ 
s0140-6736(00)02212-1
686. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, 
Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, 
on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53. https:// 
doi.org/10.1056/NEJM200001203420301
687. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable cor­
onary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascu­
lar events among patients with stable coronary artery disease: randomised, 
double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 
2003;362:782–8. https://doi.org/10.1016/s0140-6736(03)14286-9
688. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi. 
org/10.1056/NEJMoa1812389
689. Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B, 
Woodward M, et al. Effects of a fixed combination of perindopril and indapamide 
on macrovascular and microvascular outcomes in patients with type 2 diabetes melli­
tus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–40. 
https://doi.org/10.1016/S0140-6736(07)61303-8
690. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. 
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J 
Med 2004;351:2058–68. https://doi.org/10.1056/NEJMoa042739
691. Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin 
system inhibitors for patients with stable coronary artery disease without heart failure: 
systematic review and meta-analysis of randomized trials. BMJ 2017;356:j4. https://doi. 
org/10.1136/bmj.j4
692. Prosser HC, Peck KY, Dinh D, Roberts L, Chandrasekhar J, Brennan A, et al. Role of 
renin-angiotensin system antagonists on long-term mortality post-percutaneous cor­
onary intervention in reduced and preserved ejection fraction. Clin Res Cardiol 2022; 
111:776–86. https://doi.org/10.1007/s00392-021-01985-x
693. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. 
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 
371:993–1004. https://doi.org/10.1056/NEJMoa1409077
694. Mogensen UM, Kober L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, et al. The ef­
fects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J 
2017;188:35–41. https://doi.org/10.1016/j.ahj.2017.02.034
695. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 
2117–28. https://doi.org/10.1056/NEJMoa1504720
696. Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, et al. 
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular 
Assessment Study–Renal (CANVAS-R): a randomized, placebo-controlled trial. 
Diabetes Obes Metab 2017;19:387–93. https://doi.org/10.1111/dom.12829
697. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. 
Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 
383:1425–35. https://doi.org/10.1056/NEJMoa2004967
698. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. 
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients 
with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–58. https://doi.org/10. 
1001/jamacardio.2020.4511
699. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial car­
diorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. 
Diabetes Care 2016;39:1115–22. https://doi.org/10.2337/dc16-0542
700. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. 
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 
2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925
701. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. 
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of 
Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 2018;61: 
722–6. https://doi.org/10.1007/s00125-017-4509-7


<!-- PAGE 111 -->

### Page 111

702. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co- 
transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 2020; 
5:632–44. https://doi.org/10.1016/j.jacbts.2020.02.004
703. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa­
tients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular 
outcome trials. Lancet Diabetes Endocrinol 2019;7:776–85. https://doi.org/10.1016/ 
S2213-8587(19)30249-9
704. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. 
Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 
2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
705. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular 
and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 
1413–24. https://doi.org/10.1056/NEJMoa2022190
706. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in 
heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. 
https://doi.org/10.1056/NEJMoa2107038
707. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. 
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl 
J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286
708. Razuk V, Chiarito M, Cao D, Nicolas J, Pivato CA, Camaj A, et al. SGLT-2 inhibitors and 
cardiovascular outcomes in patients with and without a history of heart failure: a sys­
tematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2022;8:557–67. 
https://doi.org/10.1093/ehjcvp/pvac001
709. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 
Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure: developed by the task force for the diagnosis and treatment 
of acute and chronic heart failure of the European Society of Cardiology (ESC) wth the 
special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 
2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195
710. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, 
et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. 
N Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269
711. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa­
tients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. 
Lancet Diabetes Endocrinol 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21) 
00203-5
712. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. 
Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J 
Med 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914
713. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. 
Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 
2019;380:752–62. https://doi.org/10.1056/NEJMoa1809798
714. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and 
safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381: 
2497–505. https://doi.org/10.1056/NEJMoa1912388
715. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine 
in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47. https://doi. 
org/10.1056/NEJMoa2021372
716. Andreis A, Imazio M, Piroli F, Avondo S, Casula M, Paneva E, et al. Efficacy and safety of 
colchicine for the prevention of major cardiovascular and cerebrovascular events in 
patients with coronary artery disease: a systematic review and meta-analysis on 12  
869 patients. Eur J Prev Cardiol 2022;28:1916–25. https://doi.org/10.1093/eurjpc/ 
zwab045
717. Abdallah MS, Wang K, Magnuson EA, Osnabrugge RL, Kappetein AP, Morice MC, et al. 
Quality of life after surgery or DES in patients with 3-vessel or left main disease. J Am 
Coll Cardiol 2017;69:2039–50. https://doi.org/10.1016/j.jacc.2017.02.031
718. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SLT; American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. Bayesian 
methods affirm the use of percutaneous coronary intervention to improve survival in 
patients with unprotected left main coronary artery disease. Circulation 2013;127: 
2177–85. https://doi.org/10.1161/CIRCULATIONAHA.112.000646
719. Yusuf S, Zucker D, Passamani E, Peduzzi P, Takaro T, Fisher LD, et al. Effect of coron­
ary artery bypass graft surgery on survival: overview of 10-year results from rando­
mised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. 
Lancet 1994;344:563–70. https://doi.org/10.1016/s0140-6736(94)91963-1
720. Takaro T, Peduzzi P, Detre KM, Hultgren HN, Murphy ML, van der Bel-Kahn J, et al. 
Survival in subgroups of patients with left main coronary artery disease. Veterans 
Administration Cooperative Study of surgery for coronary arterial occlusive disease. 
Circulation 1982;66:14–22. https://doi.org/10.1161/01.cir.66.1.14
721. Talano JV, Scanlon PJ, Meadows WR, Kahn M, Pifarre R, Gunnar RM. Influence of sur­
gery on survival in 145 patients with left main coronary artery disease. Circulation 1975; 
52:I105–111.
722. European Coronary Surgery Study Group. Long-term results of prospective rando­
mised study of coronary artery bypass surgery in stable angina pectoris. European 
Coronary Surgery Study Group. Lancet 1982;320:1173–80. https://doi.org/10.1016/ 
S0140-6736(82)91200-4
723. Coronary artery surgery study (CASS). A randomized trial of coronary artery bypass 
surgery. Survival data. Circulation 1983;68:939–50. https://doi.org/10.1161/01.CIR.68. 
5.939
724. Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. 
Eleven-year survival in the Veterans Administration randomized trial of coronary by­
pass surgery for stable angina. New Engl J Med 1984;311:1333–9. https://doi.org/10. 
1056/nejm198411223112102
725. Windecker S, Stortecky S, Stefanini GG, daCosta BR, Rutjes AW, Di Nisio M, et al. 
Revascularisation versus medical treatment in patients with stable coronary artery dis­
ease: network meta-analysis. BMJ 2014;348:g3859. https://doi.org/10.1136/bmj.g3859
726. Miller RJH, Bonow RO, Gransar H, Park R, Slomka PJ, Friedman JD, et al. Percutaneous 
or surgical revascularization is associated with survival benefit in stable coronary artery 
disease. Eur Heart J Cardiovasc Imaging 2020;21:961–70. https://doi.org/10.1093/ehjci/ 
jeaa083
727. Doenst T, Bonow RO, Bhatt DL, Falk V, Gaudino M. Improving terminology to de­
scribe coronary artery procedures: JACC review topic of the week. J Am Coll Cardiol 
2021;78:180–8. https://doi.org/10.1016/j.jacc.2021.05.010
728. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality 
after coronary artery bypass grafting versus percutaneous coronary intervention with 
stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 
2018;391:939–48. https://doi.org/10.1016/s0140-6736(18)30423-9
729. Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. 
Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J 
Med 2022;387:1351–60. https://doi.org/10.1056/NEJMoa2206606
730. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, et al. 
Percutaneous coronary intervention with drug-eluting stents versus coronary artery 
bypass grafting in left main coronary artery disease: an individual patient data 
meta-analysis. Lancet 2021;398:2247–57. https://doi.org/10.1016/s0140-6736(21) 
02334-5
731. Serruys PW, Ono M, Garg S, Hara H, Kawashima H, Pompilio G, et al. Percutaneous 
coronary revascularization: JACC historical breakthroughs in perspective. J Am Coll 
Cardiol 2021;78:384–407. https://doi.org/10.1016/j.jacc.2021.05.024
732. Bangalore S, Maron David J, Stone Gregg W, Hochman Judith S. Routine revasculariza­
tion versus initial medical therapy for stable ischemic heart disease. Circulation 2020; 
142:841–57. https://doi.org/10.1161/CIRCULATIONAHA.120.048194
733. Soares A, Boden WE, Hueb W, Brooks MM, Vlachos HEA, O’Fee K, et al. Death and 
myocardial infarction following initial revascularization versus optimal medical therapy 
in chronic coronary syndromes with myocardial ischemia: a systematic review and 
meta-analysis of contemporary randomized controlled trials. J Am Heart Assoc 2021; 
10:e019114. https://doi.org/10.1161/JAHA.120.019114
734. Kumar A, Doshi R, Khan SU, Shariff M, Baby J, Majmundar M, et al. Revascularization or 
optimal medical therapy for stable ischemic heart disease: a Bayesian meta-analysis of 
contemporary trials. Cardiovasc Revasc Med 2022;40:42–7. https://doi.org/10.1016/j. 
carrev.2021.12.005
735. Wang HY, Xu B, Dou K, Guan C, Song L, Huang Y, et al. Implications of periprocedural 
myocardial biomarker elevations and commonly used MI definitions after left main PCI. 
JACC Cardiovasc Interv 2021;14:1623–34. https://doi.org/10.1016/j.jcin.2021.05.006
736. Bulluck H, Paradies V, Barbato E, Baumbach A, Bøtker HE, Capodanno D, et al. 
Prognostically relevant periprocedural myocardial injury and infarction associated 
with percutaneous coronary interventions: a Consensus Document of the ESC 
Working Group on Cellular Biology of the Heart and European Association of 
Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2021;42:2630–42. 
https://doi.org/10.1093/eurheartj/ehab271
737. Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, et al. 
Myocardial infarction in the ISCHEMIA Trial: impact of different definitions on inci­
dence, prognosis, and treatment comparisons. Circulation 2021;143:790–804. 
https://doi.org/10.1161/circulationaha.120.047987
738. Redfors B, Stone GW, Alexander JH, Bates ER, Bhatt DL, Biondi-Zoccai G, et al. 
Outcomes according to coronary revascularization modality in the ISCHEMIA trial. 
J Am Coll Cardiol 2024;83:549–58. https://doi.org/10.1016/j.jacc.2023.11.002
739. Navarese EP, Lansky AJ, Farkouh ME, Grzelakowska K, Bonaca MP, Gorog DA, et al. 
Effects of elective coronary revascularization vs medical therapy alone on noncardiac 
mortality: a meta-analysis. JACC Cardiovasc Interv 2023;16:1144–56. https://doi.org/10. 
1016/j.jcin.2023.02.030
740. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ische­
mic heart disease in patients with heart failure and preserved, midrange, and reduced 
ejection fraction: a nationwide cohort study. Circ Heart Fail 2017;10:e003875. https:// 
doi.org/10.1161/circheartfailure.117.003875
741. Panza JA, Chrzanowski L, Bonow RO. Myocardial viability assessment before surgical 
revascularization in ischemic cardiomyopathy: JACC review topic of the week. J Am Coll 
Cardiol 2021;78:1068–77. https://doi.org/10.1016/j.jacc.2021.07.004
742. Rahimtoola SH, Dilsizian V, Kramer CM, Marwick TH, Vanoverschelde JL. Chronic is­
chemic left ventricular dysfunction: from pathophysiology to imaging and its 
ESC Guidelines                                                                                                                                                                                          3525


<!-- PAGE 112 -->

### Page 112

integration into clinical practice. JACC Cardiovasc Imaging 2008;1:536–55. https://doi. 
org/10.1016/j.jcmg.2008.05.009
743. Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ven­
tricular dysfunction: a meta-analysis of observational studies. Eur J Heart Fail 2011;13: 
773–84. https://doi.org/10.1093/eurjhf/hfr037
744. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and im­
pact of revascularization on prognosis in patients with coronary artery disease and left 
ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151–8. https://doi. 
org/10.1016/s0735-1097(02)01726-6
745. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. 
F-18-fluorodeoxyglucose positron emission tomography imaging-assisted manage­
ment of patients with severe left ventricular dysfunction and suspected coronary dis­
ease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002–12. 
https://doi.org/10.1016/j.jacc.2007.09.006
746. Mc Ardle B, Shukla T, Nichol G, deKemp RA, Bernick J, Guo A, et al. Long-term follow- 
up of outcomes with F-18-fluorodeoxyglucose positron emission tomography 
imaging-assisted management of patients with severe left ventricular dysfunction sec­
ondary to coronary disease. Circ Cardiovasc Imaging 2016;9:e004331. https://doi.org/ 
10.1161/circimaging.115.004331
747. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing 
benefit from revascularization is associated with increasing amounts of myocardial hi­
bernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009;2:1060–8. 
https://doi.org/10.1016/j.jcmg.2009.02.017
748. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. 
Identification of therapeutic benefit from revascularization in patients with left ven­
tricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ 
Cardiovasc Imaging 2013;6:363–72. https://doi.org/10.1161/circimaging.112.000138
749. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al. Ten-year outcomes 
after coronary artery bypass grafting according to age in patients with heart failure and 
left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH 
Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016;134:1314–24. 
https://doi.org/10.1161/CIRCULATIONAHA.116.024800
750. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial via­
bility and long-term outcomes in ischemic cardiomyopathy. N Engl J Med 2019;381: 
739–48. https://doi.org/10.1056/NEJMoa1807365
751. Wolff G, Dimitroulis D, Andreotti F, Kołodziejczak M, Jung C, Scicchitano P, et al. 
Survival benefits of invasive versus conservative strategies in heart failure in patients 
with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ 
Heart Fail 2017;10:e003255. https://doi.org/10.1161/circheartfailure.116.003255
752. Sun LY, Gaudino M, Chen RJ, Bader Eddeen A, Ruel M. Long-term outcomes in pa­
tients with severely reduced left ventricular ejection fraction undergoing percutaneous 
coronary intervention vs coronary artery bypass grafting. JAMA Cardiol 2020;5:631–41. 
https://doi.org/10.1001/jamacardio.2020.0239
753. Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S, et al. Long-term mortality 
in patients with ischaemic heart failure revascularized with coronary artery bypass 
grafting or percutaneous coronary intervention: insights from the Swedish 
Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2021;42: 
2657–64. https://doi.org/10.1093/eurheartj/ehab273
754. Ono M, Garg S, Onuma Y, Serruys PW. Coronary artery bypass grafting versus per­
cutaneous coronary intervention in ischaemic heart failure. Can reliable treatment de­
cisions in high-risk patients be based on non-randomized data? Eur Heart J 2021;42: 
2665–9. https://doi.org/10.1093/eurheartj/ehab349
755. Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, et al. Viability and 
outcomes with revascularization or medical therapy in ischemic ventricular dysfunc­
tion: a prespecified secondary analysis of the REVIVED-BCIS2 trial. JAMA Cardiol 
2023;8:1154–61. https://doi.org/10.1001/jamacardio.2023.3803
756. Ryan M, Morgan H, Chiribiri A, Nagel E, Cleland J, Perera D. Myocardial viability testing: 
all STICHed up, or about to be REVIVED? Eur Heart J 2022;43:118–26. https://doi.org/ 
10.1093/eurheartj/ehab729
757. Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, et al. Optimal 
medical therapy with or without percutaneous coronary intervention to reduce ische­
mic burden: results from the Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 
117:1283–91. https://doi.org/10.1161/circulationaha.107.743963
758. Gaudino M, Andreotti F, Kimura T. Current concepts in coronary artery revascularisa­
tion. Lancet 2023;401:1611–28. https://doi.org/10.1016/S0140-6736(23)00459-2
759. Kim T, Kang DY, Kim S, Lee JH, Kim AR, Lee YJ, et al. Impact of complete or incomplete 
revascularization for left main coronary disease: the extended PRECOMBAT study. 
JACC Asia 2023;3:65–74. https://doi.org/10.1016/j.jacasi.2022.10.007
760. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, et al. 
Quantification of incomplete revascularization and its association with five-year mor­
tality in the synergy between percutaneous coronary intervention with taxus and car­
diac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 
2013;128:141–51. https://doi.org/10.1161/CIRCULATIONAHA.113.001803
761. Gallinoro E, Paolisso P, Di Gioia G, Bermpeis K, Fernandez-Peregrina E, Candreva A, 
et al. Deferral of coronary revascularization in patients with reduced ejection fraction 
based on physiological assessment: impact on long-term survival. J Am Heart Assoc 
2022;11:e026656. https://doi.org/10.1161/JAHA.122.026656
762. Ahn JM, Park DW, Lee CW, Chang M, Cavalcante R, Sotomi Y, et al. Comparison of 
stenting versus bypass surgery according to the completeness of revascularization in 
severe coronary artery disease: patient-level pooled analysis of the SYNTAX, 
PRECOMBAT, and BEST trials. JACC Cardiovasc Interv 2017;10:1415–24. https://doi. 
org/10.1016/j.jcin.2017.04.037
763. Girerd N, Magne J, Rabilloud M, Charbonneau E, Mohamadi S, Pibarot P, et al. The im­
pact of complete revascularization on long-term survival is strongly dependent on age. 
Ann Thorac Surg 2012;94:1166–72. https://doi.org/10.1016/j.athoracsur.2012.05.023
764. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A 
randomized multicentre trial to compare revascularization with optimal medical ther­
apy for the treatment of chronic total coronary occlusions. Eur Heart J 2018;39: 
2484–93. https://doi.org/10.1093/eurheartj/ehy220
765. Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized trial evaluating 
percutaneous coronary intervention for the treatment of chronic total occlusion. 
Circulation 
2019;139:1674–83. 
https://doi.org/10.1161/CIRCULATIONAHA.118. 
031313
766. Simsek B, Kostantinis S, Karacsonyi J, Alaswad K, Megaly M, Karmpaliotis D, et al. A 
systematic review and meta-analysis of clinical outcomes of patients undergoing 
chronic total occlusion percutaneous coronary intervention. J Invasive Cardiol 2022; 
34:E763–75.
767. Werner GS, Hildick-Smith D, Martin Yuste V, Boudou N, Sianos G, Gelev V, et al. 
Three-year outcomes of a randomized multicentre trial comparing revascularization 
and optimal medical therapy for chronic total coronary occlusions (EuroCTO). 
EuroIntervention 2023;19:571–9. https://doi.org/10.4244/eij-d-23-00312
768. Takahashi K, Serruys PW, Gao C, Ono M, Wang R, Thuijs DJFM, et al. Ten-year all- 
cause death according to completeness of revascularization in patients with three- 
vessel disease or left main coronary artery disease: insights from the SYNTAX 
Extended survival study. Circulation 2021;144:96–109. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.046289
769. Leviner DB, Torregrossa G, Puskas JD. Incomplete revascularization: what the surgeon 
needs to know. Ann Cardiothorac Surg 2018;7:463–9. https://doi.org/10.21037/acs. 
2018.06.07
770. Gaba P, Gersh BJ, Ali ZA, Moses JW, Stone GW. Complete versus incomplete coron­
ary revascularization: definitions, assessment and outcomes. Nat Rev Cardiol 2021;18: 
155–68. https://doi.org/10.1038/s41569-020-00457-5
771. Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA, et al. Rivaroxaban, aspirin, 
or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. 
J Am Coll Cardiol 2019;73:121–30. https://doi.org/10.1016/j.jacc.2018.10.048
772. Xenogiannis I, Zenati M, Bhatt DL, Rao SV, Rodés-Cabau J, Goldman S, et al. 
Saphenous vein graft failure: from pathophysiology to prevention and treatment strat­
egies. Circulation 2021;144:728–45. https://doi.org/10.1161/CIRCULATIONAHA.120. 
052163
773. Han Z, Zhang G, Chen Y. Early asymptomatic graft failure in coronary artery bypass 
grafting: a study based on computed tomography angiography analysis. J Cardiothorac 
Surg 2023;18:98. https://doi.org/10.1186/s13019-023-02199-0
774. Head SJ, Borgermann J, Osnabrugge RL, Kieser TM, Falk V, Taggart DP, et al. Coronary 
artery bypass grafting: Part 2—optimizing outcomes and future prospects. Eur Heart J 
2013;34:2873–86. https://doi.org/10.1093/eurheartj/eht284
775. Stone GW. Multivessel PCI on its 40th anniversary: finally a match for CABG? Eur 
Heart J 2017;38:3135–8. https://doi.org/10.1093/eurheartj/ehx528
776. Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, et al. 
Performance of EuroSCORE II in a large US database: implications for transcatheter 
aortic valve implantation. Eur J Cardiothorac Surg 2014;46:400–8; discussion 408. 
https://doi.org/10.1093/ejcts/ezu033
777. Thuijs D, Habib RH, Head SJ, Puskas JD, Taggart DP, Stone GW, et al. Prognostic per­
formance of the Society of Thoracic Surgeons risk score in patients with left main cor­
onary artery disease undergoing revascularisation: a post hoc analysis of the EXCEL 
trial. EuroIntervention 2020;16:36–43. https://doi.org/10.4244/EIJ-D-19-00417
778. Reichart D, Rosato S, Nammas W, Onorati F, Dalén M, Castro L, et al. Clinical frailty 
scale and outcome after coronary artery bypass grafting. Eur J Cardiothorac Surg 2018; 
54:1102–9. https://doi.org/10.1093/ejcts/ezy222
779. Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD, et al. 
Prognostic value of site SYNTAX score and rationale for combining anatomic and clin­
ical factors in decision making: insights from the SYNTAX trial. J Am Coll Cardiol 2014; 
64:423–32. https://doi.org/10.1016/j.jacc.2014.05.022
780. Bonaros N, Van Craenenbroeck E. A good operation is not enough, when it comes to 
frail patients. Eur J Cardiothorac Surg 2023;64:ezad205. https://doi.org/10.1093/ejcts/ 
ezad205
781. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The 
SYNTAX score: an angiographic tool grading the complexity of coronary artery dis­
ease. EuroIntervention 2005;1:219–27.
782. Byrne RA, Fremes S, Capodanno D, Czerny M, Doenst T, Emberson JR, et al. 2022 
Joint ESC/EACTS review of the 2018 guideline recommendations on the revasculari­
zation of left main coronary artery disease in patients at low surgical risk and anatomy


<!-- PAGE 113 -->

### Page 113

suitable for PCI or CABG. Eur Heart J 2023;44:4310–20. https://doi.org/10.1093/ 
eurheartj/ehad476
783. Calburean PA, Grebenisan P, Nistor IA, Pal K, Vacariu V, Drincal RK, et al. Prediction of 
3-year all-cause and cardiovascular cause mortality in a prospective percutaneous cor­
onary intervention registry: machine learning model outperforms conventional clinical 
risk scores. Atherosclerosis 2022;350:33–40. https://doi.org/10.1016/j.atherosclerosis. 
2022.03.028
784. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. 
Anatomical and clinical characteristics to guide decision making between coronary ar­
tery bypass surgery and percutaneous coronary intervention for individual patients: 
development and validation of SYNTAX score II. Lancet 2013;381:639–50. https:// 
doi.org/10.1016/s0140-6736(13)60108-7
785. Escaned J, Collet C, Ryan N, Luigi De Maria G, Walsh S, Sabate M, et al. Clinical out­
comes of state-of-the-art percutaneous coronary revascularization in patients with de 
novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J 2017;38: 
3124–34. https://doi.org/10.1093/eurheartj/ehx512
786. Cavalcante R, Sotomi Y, Mancone M, Whan Lee C, Ahn JM, Onuma Y, et al. Impact of 
the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: 
a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST 
trials. Eur Heart J 2017;38:1969–77. https://doi.org/10.1093/eurheartj/ehx138
787. Hara H, Shiomi H, van Klaveren D, Kent DM, Steyerberg EW, Garg S, et al. External 
validation of the SYNTAX score II 2020. J Am Coll Cardiol 2021;78:1227–38. https:// 
doi.org/10.1016/j.jacc.2021.07.027
788. Modolo R, Chichareon P, van Klaveren D, Dressler O, Zhang Y, Sabik JF, et al. Impact of 
non-respect of SYNTAX score II recommendation for surgery in patients with left 
main coronary artery disease treated by percutaneous coronary intervention: an 
EXCEL substudy. Eur J Cardiothorac Surg 2020;57:676–83. https://doi.org/10.1093/ 
ejcts/ezz274
789. Takahashi K, Serruys PW, Fuster V, Farkouh ME, Spertus JA, Cohen DJ, et al. 
Redevelopment and validation of the SYNTAX score II to individualise decision making 
between percutaneous and surgical revascularisation in patients with complex coron­
ary artery disease: secondary analysis of the multicentre randomised controlled 
SYNTAXES trial with external cohort validation. Lancet 2020;396:1399–412. 
https://doi.org/10.1016/S0140-6736(20)32114-0
790. De Silva K, Morton G, Sicard P, Chong E, Indermuehle A, Clapp B, et al. Prognostic 
utility of BCIS myocardial jeopardy score for classification of coronary disease burden 
and completeness of revascularization. Am J Cardiol 2013;111:172–7. https://doi.org/ 
10.1016/j.amjcard.2012.09.012
791. Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, et al. Isolated 
disease of the proximal left anterior descending artery comparing the effectiveness of 
percutaneous coronary interventions and coronary artery bypass surgery. JACC 
Cardiovasc Interv 2008;1:483–91. https://doi.org/10.1016/j.jcin.2008.07.001
792. Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, et al. 
Randomized comparison of minimally invasive direct coronary artery bypass surgery 
versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary 
artery stenosis. J Am Coll Cardiol 2009;53:2324–31. https://doi.org/10.1016/j.jacc.2009. 
03.032
793. Blazek S, Holzhey D, Jungert C, Borger MA, Fuernau G, Desch S, et al. Comparison of 
bare-metal stenting with minimally invasive bypass surgery for stenosis of the left an­
terior descending coronary artery: 10-year follow-up of a randomized trial. JACC 
Cardiovasc Interv 2013;6:20–6. https://doi.org/10.1016/j.jcin.2012.09.008
794. Blazek S, Rossbach C, Borger MA, Fuernau G, Desch S, Eitel I, et al. Comparison of 
sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the 
left anterior descending coronary artery: 7-year follow-up of a randomized trial. 
JACC Cardiovasc Interv 2015;8:30–8. https://doi.org/10.1016/j.jcin.2014.08.006
795. Thuijs D, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, et al. 
Percutaneous coronary intervention versus coronary artery bypass grafting in patients 
with three-vessel or left main coronary artery disease: 10-year follow-up of the multi­
centre randomised controlled SYNTAX trial. Lancet 2019;394:1325–34. https://doi. 
org/10.1016/s0140-6736(19)31997-x
796. Gianoli M, de Jong AR, Jacob KA, Namba HF, van der Kaaij NP, van der Harst P, et al. 
Minimally invasive surgery or stenting for left anterior descending artery disease— 
meta-analysis. Int J Cardiol Heart Vasc 2022;40:101046. https://doi.org/10.1016/j.ijcha. 
2022.101046
797. Patel NC, Hemli JM, Seetharam K, Singh VP, Scheinerman SJ, Pirelli L, et al. Minimally 
invasive coronary bypass versus percutaneous coronary intervention for isolated com­
plex stenosis of the left anterior descending coronary artery. J Thorac Cardiovasc Surg 
2022;163:1839–46.e1. https://doi.org/10.1016/j.jtcvs.2020.04.171
798. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. 
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe 
coronary artery disease. N Engl J Med 2009;360:961–72. https://doi.org/10.1056/ 
NEJMoa0804626
799. Giacoppo D, Colleran R, Cassese S, Frangieh AH, Wiebe J, Joner M, et al. Percutaneous 
coronary intervention vs coronary artery bypass grafting in patients with left main cor­
onary artery stenosis: a systematic review and meta-analysis. JAMA Cardiol 2017;2: 
1079–88. https://doi.org/10.1001/jamacardio.2017.2895
800. Palmerini T, Serruys P, Kappetein AP, Genereux P, Riva DD, Reggiani LB, et al. Clinical 
outcomes with percutaneous coronary revascularization vs coronary artery bypass 
grafting surgery in patients with unprotected left main coronary artery disease: a 
meta-analysis of 6 randomized trials and 4,686 patients. Am Heart J 2017;190: 
54–63. https://doi.org/10.1016/j.ahj.2017.05.005
801. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for 
multivessel revascularization in patients with diabetes. N Engl J Med 2012;367: 
2375–84. https://doi.org/10.1056/NEJMoa1211585
802. Ahmad Y, Howard JP, Arnold AD, Cook CM, Prasad M, Ali ZA, et al. Mortality after 
drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery dis­
ease: a meta-analysis of randomized controlled trials. Eur Heart J 2020;41:3228–35. 
https://doi.org/10.1093/eurheartj/ehaa135
803. Kuno T, Ueyama H, Rao SV, Cohen MG, Tamis-Holland JE, Thompson C, et al. 
Percutaneous coronary intervention or coronary artery bypass graft surgery for left 
main coronary artery disease: a meta-analysis of randomized trials. Am Heart J 2020; 
227:9–10. https://doi.org/10.1016/j.ahj.2020.06.001
804. D’Ascenzo F, De Filippo O, Elia E, Doronzo MP, Omedè P, Montefusco A, et al. 
Percutaneous vs. surgical revascularization for patients with unprotected left main 
stenosis: a meta-analysis of 5-year follow-up randomized controlled trials. Eur Heart 
J Qual Care Clin Outcomes 2021;7:476–85. https://doi.org/10.1093/ehjqcco/qcaa041
805. Hildick-Smith D, Egred M, Banning A, Brunel P, Ferenc M, Hovasse T, et al. The 
European bifurcation club Left Main Coronary Stent study: a randomized comparison 
of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). Eur Heart J 
2021;42:3829–39. https://doi.org/10.1093/eurheartj/ehab283
806. Kandzari DE, Gershlick AH, Serruys PW, Leon MB, Morice MC, Simonton CA, et al. 
Outcomes among patients undergoing distal left main percutaneous coronary inter­
vention. 
Circ 
Cardiovasc 
Interv 
2018;11:e007007. 
https://doi.org/10.1161/ 
CIRCINTERVENTIONS.118.007007
807. Choi KH, Song YB, Lee JM, Park TK, Yang JH, Hahn JY, et al. Prognostic effects of treat­
ment strategies for left main versus non-left main bifurcation percutaneous coronary 
intervention with current-generation drug-eluting stent. Circ Cardiovasc Interv 2020;13: 
e008543. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008543
808. Ninomiya K, Serruys PW, Garg S, Gao C, Masuda S, Lunardi M, et al. Predicted and 
observed mortality at 10 years in patients with bifurcation lesions in the SYNTAX trial. 
JACC Cardiovasc Interv 2022;15:1231–42. https://doi.org/10.1016/j.jcin.2022.04.025
809. Wang HY, Zhang R, Dou K, Huang Y, Xie L, Qiao Z, et al. Left main bifurcation stent­
ing: impact of residual ischaemia on cardiovascular mortality. Eur Heart J 2023;44: 
4324–36. https://doi.org/10.1093/eurheartj/ehad318
810. Holm NR, Andreasen LN, Neghabat O, Laanmets P, Kumsars I, Bennett J, et al. OCT or 
angiography guidance for PCI in complex bifurcation lesions. N Engl J Med 2023;389: 
1477–87. https://doi.org/10.1056/NEJMoa2307770
811. Xu B, Redfors B, Yang Y, Qiao S, Wu Y, Chen J, et al. Impact of operator experience 
and volume on outcomes after left main coronary artery percutaneous coronary inter­
vention. JACC Cardiovasc Interv 2016;9:2086–93. https://doi.org/10.1016/j.jcin.2016.08. 
011
812. Kinnaird T, Gallagher S, Anderson R, Sharp A, Farooq V, Ludman P, et al. Are higher 
operator volumes for unprotected left main stem percutaneous coronary intervention 
associated with improved patient outcomes? A survival analysis of 6724 procedures 
from the British Cardiovascular Intervention Society National Database. Circ 
Cardiovasc Interv 2020;13:e008782. https://doi.org/10.1161/CIRCINTERVENTIONS. 
119.008782
813. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. 
Five-year outcomes in patients with left main disease treated with either percutaneous 
coronary intervention or coronary artery bypass grafting in the Synergy Between 
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery Trial. 
Circulation 
2014;129:2388–94. 
https://doi.org/10.1161/CIRCULATIONAHA.113. 
006689
814. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents 
versus bypass surgery for left main coronary artery disease. N Engl J Med 2011;364: 
1718–27. https://doi.org/10.1056/NEJMoa1100452
815. Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, et al. Randomized trial of stents 
versus bypass surgery for left main coronary artery disease: 5-year outcomes of the 
PRECOMBAT study. J Am Coll Cardiol 2015;65:2198–206. https://doi.org/10.1016/j. 
jacc.2015.03.033
816. Park DW, Ahn JM, Park H, Yun SC, Kang DY, Lee PH, et al. Ten-year outcomes after 
drug-eluting stents versus coronary artery bypass grafting for left main coronary dis­
ease: extended follow-up of the PRECOMBAT trial. Circulation 2020;141:1437–46. 
https://doi.org/10.1161/CIRCULATIONAHA.120.046039
817. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stå hle E, Colombo A, et al. 
Outcomes in patients with de novo left main disease treated with either percutaneous 
coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft 
treatment in the Synergy Between Percutaneous Coronary Intervention with 
TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010;121:2645–53. https:// 
doi.org/10.1161/circulationaha.109.899211
818. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Ståhle E, et al. 
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment 
ESC Guidelines                                                                                                                                                                                          3527


<!-- PAGE 114 -->

### Page 114

of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur 
Heart J 2011;32:2125–34. https://doi.org/10.1093/eurheartj/ehr213
819. Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IBA, et al. 
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treat­
ment of unprotected left main stenosis (NOBLE): a prospective, randomised, open- 
label, non-inferiority trial. Lancet 2016;388:2743–52. https://doi.org/10.1016/S0140- 
6736(16)32052-9
820. Holm NR, Makikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, et al. 
Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treat­
ment of unprotected left main stenosis: updated 5-year outcomes from the rando­
mised, non-inferiority NOBLE trial. Lancet 2020;395:191–9. https://doi.org/10.1016/ 
S0140-6736(19)32972-1
821. Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, et al. 
Everolimus-eluting stents or bypass surgery for left main coronary artery disease. 
N Engl J Med 2016;375:2223–35. https://doi.org/10.1056/NEJMoa1610227
822. Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, et al. Five-year out­
comes after PCI or CABG for left main coronary disease. N Engl J Med 2019;381: 
1820–30. https://doi.org/10.1056/NEJMoa1909406
823. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. 
Coronary artery bypass graft surgery versus percutaneous coronary intervention in 
patients with three-vessel disease and left main coronary disease: 5-year follow-up 
of the randomised, clinical SYNTAX trial. Lancet 2013;381:629–38. https://doi.org/ 
10.1016/S0140-6736(13)60141-5
824. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-term 
survival following multivessel revascularization in patients with diabetes: the 
FREEDOM follow-on study. J Am Coll Cardiol 2019;73:629–38. https://doi.org/10. 
1016/j.jacc.2018.11.001
825. Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC, et al. Incidence, 
characteristics, predictors, and outcomes of repeat revascularization after percutan­
eous coronary intervention and coronary artery bypass grafting: the SYNTAX trial 
at 5 years. JACC Cardiovasc Interv 2016;9:2493–507. https://doi.org/10.1016/j.jcin. 
2016.09.044
826. van Nunen LX, Zimmermann FM, Tonino PA, Barbato E, Baumbach A, Engstrøm T, 
et al. Fractional flow reserve versus angiography for guidance of PCI in patients with 
multivessel coronary artery disease (FAME): 5-year follow-up of a randomised con­
trolled trial. Lancet 2015;386:1853–60. https://doi.org/10.1016/S0140-6736(15) 
00057-4
827. Zimmermann FM, Ding VY, Pijls NHJ, Piroth Z, van Straten AHM, Szekely L, et al. 
Fractional flow reserve-guided pci or coronary bypass surgery for 3-vessel coronary 
artery disease: 3-year follow-up of the FAME 3 trial. Circulation 2023;148:950–8. 
https://doi.org/10.1161/CIRCULATIONAHA.123.065770
828. Piroth Z, Otsuki H, Zimmermann FM, Ferenci T, Keulards DCJ, Yeung AC, et al. 
Prognostic value of measuring fractional flow reserve after percutaneous coronary 
intervention in patients with complex coronary artery disease: insights from the 
FAME 3 trial. Circ Cardiovasc Interv 2022;15:884–91. https://doi.org/10.1161/ 
CIRCINTERVENTIONS.122.012542
829. Collison D, Didagelos M, Aetesam-Ur-Rahman M, Copt S, McDade R, McCartney P, 
et al. Post-stenting fractional flow reserve vs coronary angiography for optimization 
of percutaneous coronary intervention (TARGET-FFR). Eur Heart J 2021;42: 
4656–68. https://doi.org/10.1093/eurheartj/ehab449
830. Patel MR, Jeremias A, Maehara A, Matsumura M, Zhang Z, Schneider J, et al. 1-Year 
outcomes of blinded physiological assessment of residual ischemia after successful 
PCI: DEFINE PCI trial. JACC Cardiovasc Interv 2022;15:52–61. https://doi.org/10. 
1016/j.jcin.2021.09.042
831. Hwang D, Koo BK, Zhang J, Park J, Yang S, Kim M, et al. Prognostic implications of frac­
tional flow reserve after coronary stenting: a systematic review and meta-analysis. 
JAMA Netw Open 2022;5:e2232842. https://doi.org/10.1001/jamanetworkopen.2022. 
32842
832. Collet C, Johnson Nils P, Mizukami T, Fearon WF, Berry C, Sonck J, et al. Impact of 
post-PCI FFR stratified by coronary artery. JACC Cardiovasc Interv 2023;16: 
2396–408. https://doi.org/10.1016/j.jcin.2023.08.018
833. Dai N, Yuan S, Dou K, Zhang R, Hu N, He J, et al. Prognostic implications of prestent 
pullback pressure gradient and poststent quantitative flow ratio in patients undergoing 
percutaneous coronary intervention. J Am Heart Assoc 2022;11:e024903. https://doi. 
org/10.1161/JAHA.121.024903
834. Dai N, Tang X, Chen Z, Huang D, Duan S, Qian J, et al. Pre-stenting angiography-FFR 
based physiological map provides virtual intervention and predicts physiological and 
clinical outcomes. Catheter Cardiovasc Interv 2023;101:1053–61. https://doi.org/10. 
1002/ccd.30635
835. Kikuta Y, Cook CM, Sharp ASP, Salinas P, Kawase Y, Shiono Y, et al. Pre-angioplasty 
instantaneous wave-free ratio pullback predicts hemodynamic outcome in humans 
with coronary artery disease: primary results of the international multicenter iFR 
GRADIENT registry. JACC Cardiovasc Interv 2018;11:757–67. https://doi.org/10.1016/ 
j.jcin.2018.03.005
836. Biscaglia S, Verardi FM, Tebaldi M, Guiducci V, Caglioni S, Campana R, et al. QFR-based 
virtual PCI or conventional angiography to guide PCI: the AQVA trial. JACC Cardiovasc 
Interv 2023;16:783–94. https://doi.org/10.1016/j.jcin.2022.10.054
837. Bouisset F, Ohashi H, Andreini D, Collet C. (September 19, 2023) Role of coronary 
computed tomography angiography to optimise percutaneous coronary intervention 
outcomes. Heart 2024;110:1056–1062
838. Sonck J, Nagumo S, Norgaard BL, Otake H, Ko B, Zhang J, et al. Clinical validation of a 
virtual planner for coronary interventions based on coronary CT angiography. JACC 
Cardiovasc Imaging 2022;15:1242–55. doi: doi:10.1016/j.jcmg.2022.02.003
839. Van Belle E, Raposo L, Bravo Baptista S, Vincent F, Porouchani S, Cosenza A, et al. 
Impact of an interactive CT/FFR(CT) interventional planner on coronary artery dis­
ease management decision making. JACC Cardiovasc Imaging 2021;14:1068–70. 
https://doi.org/10.1016/j.jcmg.2020.09.040
840. Lee JM, Choi KH, Song YB, Lee JY, Lee SJ, Lee SY, et al. Intravascular imaging-guided or 
angiography-guided complex PCI. N Engl J Med 2023;388:1668–79. https://doi.org/10. 
1056/NEJMoa2216607
841. Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, et al. 
Optical coherence tomography-guided versus angiography-guided PCI. N Engl J Med 
2023;389:1466–76. https://doi.org/10.1056/NEJMoa2305861
842. Sabik JF III, Blackstone EH, Gillinov AM, Banbury MK, Smedira NG, Lytle BW. Influence 
of patient characteristics and arterial grafts on freedom from coronary reoperation. 
J Thorac Cardiovasc Surg 2006;131:90–8. https://doi.org/10.1016/j.jtcvs.2005.05.024
843. Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkhart HM, et al. Multiple arterial 
grafts improve late survival of patients undergoing coronary artery bypass graft sur­
gery: analysis of 8622 patients with multivessel disease. Circulation 2012;126: 
1023–30. https://doi.org/10.1161/CIRCULATIONAHA.111.084624
844. Lowenstern A, Wu J, Bradley SM, Fanaroff AC, Tcheng JE, Wang TY. Current land­
scape of hybrid revascularization: a report from the NCDR CathPCI Registry. Am 
Heart J 2019;215:167–77. https://doi.org/10.1016/j.ahj.2019.06.014
845. Ganyukov VI, Kochergin NA, Shilov AA, Tarasov RS, Skupien J, Kozyrin KA, et al. 
Randomized clinical trial of surgical versus percutaneous versus hybrid multivessel cor­
onary revascularization: 3 years’ follow-up. JACC Cardiovasc Interv 2021;14:1163–5. 
https://doi.org/10.1016/j.jcin.2021.02.037
846. Makoul G, Clayman ML. An integrative model of shared decision making in medical en­
counters. Patient Educ Couns 2006;60:301–12. https://doi.org/10.1016/j.pec.2005.06. 
010
847. Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients’ preferences 
matter. BMJ 2012;345:e6572. https://doi.org/10.1136/bmj.e6572
848. Hughes TM, Merath K, Chen Q, Sun S, Palmer E, Idrees JJ, et al. Association of shared 
decision-making on patient-reported health outcomes and healthcare utilization. Am J 
Surg 2018;216:7–12. https://doi.org/10.1016/j.amjsurg.2018.01.011
849. Nuis RJ, Jadoon A, van Dalen BM, Dulfer K, Snelder SM, Yazdi MT, et al. Patient per­
spectives on left main stem revascularization strategies, the OPINION-2 study. 
J Cardiol 2021;77:271–8. https://doi.org/10.1016/j.jjcc.2020.09.009
850. Oudkerk Pool MD, Hooglugt JQ, Schijven MP, Mulder BJM, Bouma BJ, de Winter RJ, 
et al. Review of digitalized patient education in cardiology: a future ahead? Cardiology 
2021;146:263–71. https://doi.org/10.1159/000512778
851. Lincoln TE, Buddadhumaruk P, Arnold RM, Scheunemann LP, Ernecoff NC, Chang 
CCH, et al. Association between shared decision-making during family meetings and 
surrogates’ trust in their ICU physician. Chest 2023;163:1214–24. https://doi.org/10. 
1016/j.chest.2022.10.028
852. Ayton DR, Barker AL, Peeters G, Berkovic DE, Lefkovits J, Brennan A, et al. Exploring 
patient-reported outcomes following percutaneous coronary intervention: a qualita­
tive study. Health Expect 2018;21:457–65. https://doi.org/10.1111/hex.12636
853. Kipp R, Lehman J, Israel J, Edwards N, Becker T, Raval AN. Patient preferences for cor­
onary artery bypass graft surgery or percutaneous intervention in multivessel coronary 
artery disease. Catheter Cardiovasc Interv 2013;82:212–8. https://doi.org/10.1002/ccd. 
24399
854. Witberg G, Segev A, Barac YD, Raanani E, Assali A, Finkelstein A, et al. Heart team/ 
guidelines discordance is associated with increased mortality: data from a national sur­
vey of revascularization in patients with complex coronary artery disease. Circ 
Cardiovasc Interv 2021;14:e009686. https://doi.org/10.1161/circinterventions.120. 
009686
855. Patterson T, McConkey HZR, Ahmed-Jushuf F, Moschonas K, Nguyen H, Karamasis 
GV, et al. Long-term outcomes following heart team revascularization recommenda­
tions in complex coronary artery disease. J Am Heart Assoc 2019;8:e011279. https://doi. 
org/10.1161/jaha.118.011279
856. Jonik S, Marchel M, Huczek Z, Kochman J, Wilimski R, Kuśmierczyk M, et al. An indi­
vidualized approach of multidisciplinary heart team for myocardial revascularization 
and valvular heart disease—state of art. J Pers Med 2022;12:705. https://doi.org/10. 
3390/jpm12050705
857. McKeown L, Hong YA, Kreps GL, Xue H. Trends and differences in perceptions of 
patient-centered communication among adults in the US. Patient Educ Couns 2023; 
106:128–34. https://doi.org/10.1016/j.pec.2022.10.010
858. Tsang MB, Schwalm JD, Gandhi S, Sibbald MG, Gafni A, Mercuri M, et al. Comparison of 
heart team vs interventional cardiologist recommendations for the treatment of


<!-- PAGE 115 -->

### Page 115

patients with multivessel coronary artery disease. JAMA Netw Open 2020;3:e2012749. 
https://doi.org/10.1001/jamanetworkopen.2020.12749
859. Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, et al. Long-term 
survival in 11,661 patients with multivessel coronary artery disease in the era of stent­
ing: a report from the Alberta Provincial Project for Outcome Assessment in 
Coronary Heart Disease (APPROACH) investigators. Am Heart J 2001;142:119–26. 
https://doi.org/10.1067/mhj.2001.116072
860. Lee PH, Ahn JM, Chang M, Baek S, Yoon SH, Kang SJ, et al. Left main coronary artery 
disease: secular trends in patient characteristics, treatments, and outcomes. J Am Coll 
Cardiol 2016;68:1233–46. https://doi.org/10.1016/j.jacc.2016.05.089
861. Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, Favaloro RR, et al. Extent of cor­
onary and myocardial disease and benefit from surgical revascularization in ischemic LV 
dysfunction [Corrected]. J Am Coll Cardiol 2014;64:553–61. https://doi.org/10.1016/j. 
jacc.2014.04.064
862. Sullivan PG, Wallach JD, Ioannidis JP. Meta-analysis comparing established risk predic­
tion models (EuroSCORE II, STS Score, and ACEF Score) for perioperative mortality 
during cardiac surgery. Am J Cardiol 2016;118:1574–82. https://doi.org/10.1016/j. 
amjcard.2016.08.024
863. Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of 
EuroSCORE II, original EuroSCORE, and the Society of Thoracic Surgeons Risk 
Score in cardiac surgery patients. Ann Thorac Surg 2016;102:573–9. https://doi.org/ 
10.1016/j.athoracsur.2016.01.105
864. Sinha S, Dimagli A, Dixon L, Gaudino M, Caputo M, Vohra HA, et al. Systematic review 
and meta-analysis of mortality risk prediction models in adult cardiac surgery. Interact 
Cardiovasc Thorac Surg 2021;33:673–86. https://doi.org/10.1093/icvts/ivab151
865. Scudeler TL, Farkouh ME, Hueb W, Rezende PC, Campolina AG, Martins EB, et al. 
Coronary atherosclerotic burden assessed by SYNTAX scores and outcomes in sur­
gical, percutaneous or medical strategies: a retrospective cohort study. BMJ Open 
2022;12:e062378. https://doi.org/10.1136/bmjopen-2022-062378
866. Kuno T, Kiyohara Y, Maehara A, Ueyama HA, Kampaktsis PN, Takagi H, et al. 
Comparison of intravascular imaging, functional, or angiographically guided coronary 
intervention. J Am Coll Cardiol 2023;82:2167–76. https://doi.org/10.1016/j.jacc.2023. 
09.823
867. Chen H, Hong L, Xi G, Wang H, Hu J, Liu Q, et al. Prognostic value of quantitative flow 
ratio in patients with coronary heart disease after percutaneous coronary intervention 
therapy: a meta-analysis. Front Cardiovasc Med 2023;10:1164290. https://doi.org/10. 
3389/fcvm.2023.1164290
868. Agarwal SK, Kasula S, Hacioglu Y, Ahmed Z, Uretsky BF, Hakeem A. Utilizing post- 
intervention fractional flow reserve to optimize acute results and the relationship to 
long-term outcomes. JACC Cardiovasc Interv 2016;9:1022–31. https://doi.org/10.1016/ 
j.jcin.2016.01.046
869. Milojevic M, Serruys PW, Sabik JF, Kandzari DE, Schampaert E, van Boven AJ, et al. 
Bypass surgery or stenting for left main coronary artery disease in patients with dia­
betes. J Am Coll Cardiol 2019;73:1616–28. https://doi.org/10.1016/j.jacc.2019.01.037
870. Gaudino M, Audisio K, Hueb WA, Stone GW, Farkouh ME, Di Franco A, et al. 
Coronary artery bypass grafting versus medical therapy in patients with stable coron­
ary artery disease: an individual patient data pooled meta-analysis of randomized trials. 
J Thorac Cardiovasc Surg 2024;167:1022–32.e14. https://doi.org/10.1016/j.jtcvs.2022. 
06.003
871. Bari 2D Study Group; Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A 
randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J 
Med 2009;360:2503–15. https://doi.org/10.1056/NEJMoa0805796
872. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, et al. Long-term outcome of 
stents versus bypass surgery in diabetic and nondiabetic patients with multivessel or 
left main coronary artery disease: a pooled analysis of 5775 individual patient data. 
Circ Cardiovasc Interv 2012;5:467–75. https://doi.org/10.1161/circinterventions.112. 
969915
873. Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, et al. Percutaneous cor­
onary intervention versus coronary bypass surgery in United States veterans with dia­
betes. J Am Coll Cardiol 2013;61:808–16. https://doi.org/10.1016/j.jacc.2012.11.044
874. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, et al. 
Treatment of complex coronary artery disease in patients with diabetes: 5-year results 
comparing outcomes of bypass surgery and percutaneous coronary intervention in the 
SYNTAX trial. Eur J Cardiothorac Surg 2013;43:1006–13. https://doi.org/10.1093/ejcts/ 
ezt017
875. Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al. Randomized, con­
trolled trial of coronary artery bypass surgery versus percutaneous coronary interven­
tion in patients with multivessel coronary artery disease: six-year follow-up from the 
Stent or Surgery Trial (SoS). Circulation 2008;118:381–8. https://doi.org/10.1161/ 
circulationaha.107.739144
876. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting 
stents or bypass surgery for coronary disease. N Engl J Med 2015;372:1204–12. https:// 
doi.org/10.1056/NEJMoa1415447
877. Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, et al. The 
Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of 
medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior 
descending artery stenoses. J Am Coll Cardiol 1995;26:1600–5. https://doi.org/10.1016/ 
0735-1097(95)00384-3
878. Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, et al. Meta-analysis of minimally 
invasive internal thoracic artery bypass versus percutaneous revascularisation for iso­
lated lesions of the left anterior descending artery. BMJ 2007;334:617. https://doi.org/ 
10.1136/bmj.39106.476215.BE
879. Deppe A-C, Liakopoulos OJ, Kuhn EW, Slottosch I, Scherner M, Choi YH, et al. 
Minimally invasive direct coronary bypass grafting versus percutaneous coronary inter­
vention for single-vessel disease: a meta-analysis of 2885 patients. Eur J Cardiothorac 
Surg 2015;47:397–406. https://doi.org/10.1093/ejcts/ezu285
880. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. 
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 
1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18: 
613–25. https://doi.org/10.1002/ejhf.566
881. Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, et al. Coronary 
artery disease as the cause of incident heart failure in the population. Eur Heart J 
2001;22:228–36. https://doi.org/10.1053/euhj.2000.2289
882. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J 
Heart Fail 2020;22:1342–56. https://doi.org/10.1002/ejhf.1858
883. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and corre­
lates of coronary microvascular dysfunction in heart failure with preserved ejection 
fraction: PROMIS-HFpEF. Eur Heart J 2018;39:3439–50. https://doi.org/10.1093/ 
eurheartj/ehy531
884. Yang JH, Obokata M, Reddy YNV, Redfield MM, Lerman A, Borlaug BA. 
Endothelium-dependent and independent coronary microvascular dysfunction in pa­
tients with heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22: 
432–41. https://doi.org/10.1002/ejhf.1671
885. Sinha A, Rahman H, Webb A, Shah AM, Perera D. Untangling the pathophysiologic link 
between coronary microvascular dysfunction and heart failure with preserved ejection 
fraction. Eur Heart J 2021;42:4431–41. https://doi.org/10.1093/eurheartj/ehab653
886. Crea F, Bairey Merz CN, Beltrame JF, Kaski JC, Ogawa H, Ong P, et al. The parallel tales 
of microvascular angina and heart failure with preserved ejection fraction: a paradigm 
shift. Eur Heart J 2017;38:473–7. https://doi.org/10.1093/eurheartj/ehw461
887. Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. 
Prevalence of coronary artery disease and coronary microvascular dysfunction in pa­
tients with heart failure with preserved ejection fraction. JAMA Cardiol 2021;6: 
1130–43. https://doi.org/10.1001/jamacardio.2021.1825
888. Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin G, Singh A, et al. 
Prevalence and prognostic significance of microvascular dysfunction in heart failure 
with preserved ejection fraction. JACC Cardiovasc Imaging 2022;15:1001–11. https:// 
doi.org/10.1016/j.jcmg.2021.11.022
889. Lin X, Wu G, Wang S, Huang J. The prevalence of coronary microvascular dysfunction 
(CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review 
and meta-analysis. Heart Fail Rev 2024;29:405–16. https://doi.org/10.1007/s10741- 
023-10362-x
890. Paolisso P, Gallinoro E, Belmonte M, Bertolone DT, Bermpeis K, De Colle C, et al. 
Coronary microvascular dysfunction in patients with heart failure: characterization 
of patterns in HFrEF versus HFpEF. Circ Heart Fail 2023;17:e010805. https://doi.org/ 
10.1161/circheartfailure.123.010805
891. Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. 
Coronary microvascular dysfunction and future risk of heart failure with preserved 
ejection fraction. Eur Heart J 2018;39:840–9. https://doi.org/10.1093/eurheartj/ehx721
892. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection frac­
tion: comorbidities drive myocardial dysfunction and remodeling through coronary 
microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–71. https:// 
doi.org/10.1016/j.jacc.2013.02.092
893. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, 
et al. Stress echocardiography expert consensus statement—executive summary: 
European Association of Echocardiography (EAE) (a registered branch of the ESC). 
Eur Heart J 2009;30:278–89. https://doi.org/10.1093/eurheartj/ehn492
894. Garbi M, McDonagh T, Cosyns B, Bucciarelli-Ducci C, Edvardsen T, Kitsiou A, et al. 
Appropriateness criteria for cardiovascular imaging use in heart failure: report of litera­
ture review. Eur Heart J Cardiovasc Imaging 2015;16:147–53. https://doi.org/10.1093/ 
ehjci/jeu299
895. Ghostine S, Caussin C, Habis M, Habib Y, Clement C, Sigal-Cinqualbre A, et al. 
Non-invasive diagnosis of ischaemic heart failure using 64-slice computed tomography. 
Eur Heart J 2008;29:2133–40. https://doi.org/10.1093/eurheartj/ehn072
896. Andreini D, Pontone G, Bartorelli AL, Agostoni P, Mushtaq S, Bertella E, et al. 
Sixty-four-slice multidetector computed tomography: an accurate imaging modality 
for the evaluation of coronary arteries in dilated cardiomyopathy of unknown etiology. 
Circ Cardiovasc Imaging 2009;2:199–205. https://doi.org/10.1161/circimaging.108. 
822809
897. van den Boogert TPW, Claessen B, van Randen A, van Schuppen J, Boekholdt SM, Beijk 
MAM, et al. Implementation of CT coronary angiography as an alternative to invasive 
coronary angiography in the diagnostic work-up of non-coronary cardiac surgery, 
ESC Guidelines                                                                                                                                                                                          3529


<!-- PAGE 116 -->

### Page 116

cardiomyopathy, heart failure and ventricular arrhythmias. J Clin Med 2021;10:2374. 
https://doi.org/10.3390/jcm10112374
898. Chow BJW, Coyle D, Hossain A, Laine M, Hanninen H, Ukkonen H, et al. Computed 
tomography coronary angiography for patients with heart failure (CTA-HF): a rando­
mized controlled trial (IMAGE-HF 1C). Eur Heart J Cardiovasc Imaging 2021;22: 
1083–90. https://doi.org/10.1093/ehjci/jeaa109
899. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for 
patients with stable coronary artery disease and left-ventricular systolic dysfunction 
(BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 
372:807–16. https://doi.org/10.1016/S0140-6736(08)61170-8
900. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine im­
proves left ventricular function and quality of life in elderly patients with coronary ar­
tery disease. Eur Heart J 2004;25:1814–21. https://doi.org/10.1016/j.ehj.2004.06.034
901. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros 
JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the 
randomized, double-blind, placebo-controlled MERLIN-TIMI (metabolic efficiency 
with ranolazine for less ischemia in non-ST-segment elevation acute coronary syn­
dromes) 36 trial. J Am Coll Cardiol 2009;53:1510–6. https://doi.org/10.1016/j.jacc. 
2009.01.037
902. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the cal­
cium antagonist felodipine as supplementary vasodilator therapy in patients with 
chronic heart failure treated with enalapril. Circulation 1997;96:856–63. https://doi. 
org/10.1161/01.CIR.96.3.856
903. Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, et al. 
Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary 
or peripheral artery disease. Circulation 2019;140:529–37. https://doi.org/10.1161/ 
circulationaha.119.039609
904. Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, et al. A com­
prehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic at­
tack in patients with heart failure, coronary artery disease, and sinus rhythm: the 
COMMANDER HF trial. Eur Heart J 2019;40:3593–602. https://doi.org/10.1093/ 
eurheartj/ehz427
905. Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, et al. Joint 
EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. 
Eur Heart J Acute Cardiovasc Care 2021;10:570–83. https://doi.org/10.1093/ehjacc/ 
zuab015
906. O’Neill WW, Kleiman NS, Moses J, Henriques JPS, Dixon S, Massaro J, et al. A pro­
spective, randomized clinical trial of hemodynamic support with Impella 2.5 versus 
intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary 
intervention: the PROTECT II study. Circulation 2012;126:1717–27. https://doi.org/ 
10.1161/CIRCULATIONAHA.112.098194
907. O’Neill WW, Anderson M, Burkhoff D, Grines CL, Kapur NK, Lansky AJ, et al. 
Improved outcomes in patients with severely depressed LVEF undergoing percutan­
eous coronary intervention with contemporary practices. Am Heart J 2022;248: 
139–49. https://doi.org/10.1016/j.ahj.2022.02.006
908. Morgan H, Ryan M, Briceno N, Modi B, Rahman H, Arnold S, et al. Coronary jeopardy 
score predicts ischemic etiology in patients with left ventricular systolic dysfunction. 
J Invasive Cardiol 2022;34:E683–5.
909. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of ex­
ercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual 
participant meta-analysis. J Am Coll Cardiol 2019;73:1430–43. https://doi.org/10.1016/ 
j.jacc.2018.12.072
910. Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, 
et al. Effect of endurance exercise training on endothelial function and arterial stiffness 
in older patients with heart failure and preserved ejection fraction: a randomized, con­
trolled, single-blind trial. J Am Coll Cardiol 2013;62:584–92. https://doi.org/10.1016/j. 
jacc.2013.04.033
911. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect 
of caloric restriction or aerobic exercise training on peak oxygen consumption and 
quality of life in obese older patients with heart failure with preserved ejection fraction: 
a randomized clinical trial. JAMA 2016;315:36–46. https://doi.org/10.1001/jama.2015. 
17346
912. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects 
of candesartan on mortality and morbidity in patients with chronic heart failure: the 
CHARM-Overall programme. Lancet 2003;362:759–66. https://doi.org/10.1016/ 
s0140-6736(03)14282-1
913. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. 
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, 
left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906. https://doi. 
org/10.1056/NEJMoa032292
914. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of 
candesartan in patients with chronic heart failure and reduced left-ventricular systolic 
function 
intolerant 
to 
angiotensin-converting-enzyme 
inhibitors: 
the 
CHARM-Alternative trial. Lancet 2003;362:772–6. https://doi.org/10.1016/S0140- 
6736(03)14284-5
915. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence 
supporting the role of diuretics in heart failure: a meta analysis of randomised con­
trolled trials. Int J Cardiol 2002;82:149–58. https://doi.org/10.1016/s0167-5273(01) 
00600-3
916. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic im­
plantation of a defibrillator in patients with myocardial infarction and reduced ejection 
fraction. N Engl J Med 2002;346:877–83. https://doi.org/10.1056/NEJMoa013474
917. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison 
of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated 
from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–84. https://doi. 
org/10.1056/NEJM199711273372202
918. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. 
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. 
AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. 
Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart 
J 2000;21:2071–8. https://doi.org/10.1053/euhj.2000.2476
919. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic 
drug therapy with implantable defibrillators in patients resuscitated from cardiac ar­
rest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748–54. 
https://doi.org/10.1161/01.cir.102.7.748
920. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 
352:225–37. https://doi.org/10.1056/NEJMoa043399
921. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. 
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl 
J Med 2009;361:1329–38. https://doi.org/10.1056/NEJMoa0906431
922. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, et al. An 
individual patient meta-analysis of five randomized trials assessing the effects of cardiac 
resynchronization therapy on morbidity and mortality in patients with symptomatic 
heart failure. Eur Heart J 2013;34:3547–56. https://doi.org/10.1093/eurheartj/eht290
923. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, et al. Cardiac re­
synchronization therapy in patients undergoing atrioventricular junction ablation for 
permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:2420–9. https:// 
doi.org/10.1093/eurheartj/ehr162
924. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrio­
ventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. 
Europace 2012;14:1490–7. https://doi.org/10.1093/europace/eus193
925. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular 
pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368: 
1585–93. https://doi.org/10.1056/NEJMoa1210356
926. Rahman H, Ryan M, Lumley M, Modi B, McConkey H, Ellis H, et al. Coronary micro­
vascular dysfunction is associated with myocardial ischemia and abnormal coronary 
perfusion during exercise. Circulation 2019;140:1805–16. https://doi.org/10.1161/ 
circulationaha.119.041595
927. Lee SH, Shin D, Lee JM, van de Hoef TP, Hong D, Choi KH, et al. Clinical relevance of 
ischemia with nonobstructive coronary arteries according to coronary microvascular 
dysfunction. J Am Heart Assoc 2022;11:e025171. https://doi.org/10.1161/JAHA.121. 
025171
928. Reynolds HR, Diaz A, Cyr DD, Shaw LJ, Mancini GBJ, Leipsic J, et al. Ischemia with non­
obstructive coronary arteries: insights from the ISCHEMIA trial. JACC Cardiovasc 
Imaging 2023;16:63–74. https://doi.org/10.1016/j.jcmg.2022.06.015
929. Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK, et al. 
Stable angina pectoris with no obstructive coronary artery disease is associated 
with increased risks of major adverse cardiovascular events. Eur Heart J 2012;33: 
734–44. https://doi.org/10.1093/eurheartj/ehr331
930. Aziz A, Hansen HS, Sechtem U, Prescott E, Ong P. Sex-related differences in vaso­
motor function in patients with angina and unobstructed coronary arteries. J Am 
Coll Cardiol 2017;70:2349–58. https://doi.org/10.1016/j.jacc.2017.09.016
931. Boerhout CKM, de Waard GA, Lee JM, Mejia-Renteria H, Lee SH, Jung JH, et al. 
Prognostic value of structural and functional coronary microvascular dysfunction in pa­
tients with non-obstructive coronary artery disease; from the multicentre internation­
al ILIAS registry. EuroIntervention 2022;18:719–28. https://doi.org/10.4244/eij-d-22- 
00043
932. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, et al. International 
standardization of diagnostic criteria for microvascular angina. Int J Cardiol 2018;250: 
16–20. https://doi.org/10.1016/j.ijcard.2017.08.068
933. Mejia-Renteria H, van der Hoeven N, van de Hoef TP, Heemelaar J, Ryan N, Lerman A, 
et al. Targeting the dominant mechanism of coronary microvascular dysfunction with 
intracoronary physiology tests. Int J Cardiovasc Imaging 2017;33:1041–59. https://doi. 
org/10.1007/s10554-017-1136-9
934. Mygind ND, Michelsen MM, Pena A, Frestad D, Dose N, Aziz A, et al. Coronary micro­
vascular function and cardiovascular risk factors in women with angina pectoris and no 
obstructive coronary artery disease: the iPOWER study. J Am Heart Assoc 2016;5: 
e003064. https://doi.org/10.1161/JAHA.115.003064
935. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, et al. Coronary 
microvascular reactivity to adenosine predicts adverse outcome in women evaluated


<!-- PAGE 117 -->

### Page 117

for suspected ischemia results from the National Heart, Lung and Blood Institute WISE 
(Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825–32. 
https://doi.org/10.1016/j.jacc.2010.01.054
936. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al. Effects of sex on 
coronary microvascular dysfunction and cardiac outcomes. Circulation 2014;129: 
2518–27. https://doi.org/10.1161/CIRCULATIONAHA.113.008507
937. Demir OM, Boerhout CKM, de Waard GA, van de Hoef TP, Patel N, Beijk MAM, et al. 
Comparison of doppler flow velocity and thermodilution derived indexes of coronary 
physiology. JACC Cardiovasc Interv 2022;15:1060–70. https://doi.org/10.1016/j.jcin. 
2022.03.015
938. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs 
endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92: 
1094–100. https://doi.org/10.1161/01.CIR.92.5.1094
939. Sara JD, Widmer RJ, Matsuzawa Y, Lennon RJ, Lerman LO, Lerman A. Prevalence of 
coronary microvascular dysfunction among patients with chest pain and nonobstruc­
tive coronary artery disease. JACC Cardiovasc Interv 2015;8:1445–53. https://doi.org/10. 
1016/j.jcin.2015.06.017
940. Chhabra L, Kowlgi NG. Low incidence of diabetes mellitus in coronary microvascular 
dysfunction: an intriguing association. JACC Cardiovasc Interv 2016;9:395–6. https://doi. 
org/10.1016/j.jcin.2015.11.017
941. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, et al. Myocardial 
ischemia in the absence of obstructive coronary artery disease in systemic lupus ery­
thematosus. JACC Cardiovasc Imaging 2011;4:27–33. https://doi.org/10.1016/j.jcmg. 
2010.09.019
942. Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular 
dysfunction in cardiac syndrome X patients without conventional risk factors for cor­
onary artery disease. JACC Cardiovasc Imaging 2013;6:660–7. https://doi.org/10.1016/j. 
jcmg.2012.12.011
943. Fairweather D. Sex differences in inflammation during atherosclerosis. Clin Med 
Insights Cardiol 2014;8:49–59. https://doi.org/10.4137/CMC.S17068
944. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic in­
flammation and coronary microvascular dysfunction in patients without risk factors for 
coronary artery disease. Eur Heart J 2009;30:1837–43. https://doi.org/10.1093/ 
eurheartj/ehp205
945. Konst RE, Elias-Smale SE, Lier A, Bode C, Maas AH. Different cardiovascular risk fac­
tors and psychosocial burden in symptomatic women with and without obstructive 
coronary artery disease. Eur J Prev Cardiol 2019;26:657–9. https://doi.org/10.1177/ 
2047487318814298
946. van der Meer RE, Maas AH. The role of mental stress in ischaemia with no obstructive 
coronary artery disease and coronary vasomotor disorders. Eur Cardiol 2021;16:e37. 
https://doi.org/10.15420/ecr.2021.20
947. Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Ikeda S, et al. Coronary functional ab­
normalities in patients with angina and nonobstructive coronary artery disease. J Am 
Coll Cardiol 2019;74:2350–60. https://doi.org/10.1016/j.jacc.2019.08.1056
948. Vrints CJ, Bult H, Hitter E, Herman AG, Snoeck JP. Impaired endothelium-dependent 
cholinergic coronary vasodilation in patients with angina and normal coronary arterio­
grams. J Am Coll Cardiol 1992;19:21–31. https://doi.org/10.1016/0735-1097(92)90046- 
p
949. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor 
reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999; 
33:1442–52. https://doi.org/10.1016/s0735-1097(99)00073-x
950. Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, et al. Frequency of pro­
voked coronary spasms in patients undergoing coronary arteriography using a spasm 
provocation test via intracoronary administration of ergonovine. Angiology 2004;55: 
403–11. https://doi.org/10.1177/000331970405500407
951. Hung MY, Hsu KH, Hung MJ, Cheng CW, Cherng WJ. Interactions among gender, age, 
hypertension and C-reactive protein in coronary vasospasm. Eur J Clin Invest 2010;40: 
1094–103. https://doi.org/10.1111/j.1365-2362.2010.02360.x
952. Gulati M, Khan N, George M, Berry C, Chieffo A, Camici PG, et al. Ischemia with no 
obstructive coronary artery disease (INOCA): a patient self-report quality of life sur­
vey from INOCA international. Int J Cardiol 2023;371:28–39. https://doi.org/10.1016/j. 
ijcard.2022.09.047
953. Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, et al. The economic burden of 
angina in women with suspected ischemic heart disease: results from the National 
Institutes of Health–National Heart, Lung, and Blood Institute–sponsored Women’s 
Ischemia Syndrome Evaluation. Circulation 2006;114:894–904. https://doi.org/10. 
1161/circulationaha.105.609990
954. Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, et al. Impact of eth­
nicity and gender differences on angiographic coronary artery disease prevalence and 
in-hospital mortality in the American College of Cardiology–National Cardiovascular 
Data 
Registry. 
Circulation 
2008;117:1787–801. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.107.726562
955. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. 
Adverse cardiovascular outcomes in women with nonobstructive coronary artery dis­
ease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St 
James Women Take Heart Project. Arch Intern Med 2009;169:843–50. https://doi. 
org/10.1001/archinternmed.2009.50
956. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, et al. Age- and sex- 
related differences in all-cause mortality risk based on coronary computed tomog­
raphy angiography findings results from the International Multicenter CONFIRM (cor­
onary CT angiography evaluation for clinical outcomes: an international multicenter 
registry) of 23,854 patients without known coronary artery disease. J Am Coll 
Cardiol 2011;58:849–60. https://doi.org/10.1016/j.jacc.2011.02.074
957. Jespersen L, Abildstrom SZ, Hvelplund A, Madsen JK, Galatius S, Pedersen F, et al. 
Burden of hospital admission and repeat angiography in angina pectoris patients 
with and without coronary artery disease: a registry-based cohort study. PLoS One 
2014;9:e93170. https://doi.org/10.1371/journal.pone.0093170
958. Radico F, Zimarino M, Fulgenzi F, Ricci F, Di Nicola M, Jespersen L, et al. Determinants 
of long-term clinical outcomes in patients with angina but without obstructive coron­
ary artery disease: a systematic review and meta-analysis. Eur Heart J 2018;39: 
2135–46. https://doi.org/10.1093/eurheartj/ehy185
959. Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. 
Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 
2014;312:1754–63. https://doi.org/10.1001/jama.2014.14681
960. Kelshiker MA, Seligman H, Howard JP, Rahman H, Foley M, Nowbar AN, et al. 
Coronary flow reserve and cardiovascular outcomes: a systematic review and 
meta-analysis. Eur Heart J 2022;43:1582–93. https://doi.org/10.1093/eurheartj/ 
ehab775
961. Boerhout CKM, Lee JM, de Waard GA, Mejia-Renteria H, Lee SH, Jung JH, et al. 
Microvascular resistance reserve: diagnostic and prognostic performance in the 
ILIAS registry. Eur Heart J 2023;44:2862–9. https://doi.org/10.1093/eurheartj/ehad378
962. Zhou W, Lee Jonan Chun Y, Leung Siu T, Lai A, Lee TF, Chiang JB, et al. Long-term 
prognosis of patients with coronary microvascular disease using stress perfusion car­
diac magnetic resonance. JACC Cardiovasc Imaging 2021;14:602–11. https://doi.org/10. 
1016/j.jcmg.2020.09.034
963. Lanza GA, Sestito A, Sgueglia GA, Infusino F, Manolfi M, Crea F, et al. Current clinical 
features, diagnostic assessment and prognostic determinants of patients with variant 
angina. Int J Cardiol 2007;118:41–7. https://doi.org/10.1016/j.ijcard.2006.06.016
964. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and 
therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:2625–41. 
https://doi.org/10.1016/j.jacc.2018.09.042
965. Sidik NP, Stanley B, Sykes R, Morrow AJ, Bradley CP, McDermott M, et al. Invasive en­
dotyping in patients with angina and no obstructive coronary artery disease: a rando­
mized 
controlled 
trial. 
Circulation 
2024;149:7–23. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.123.064751
966. Rahman H, Demir OM, Khan F, Ryan M, Ellis H, Mills MT, et al. Physiological stratifica­
tion of patients with angina due to coronary microvascular dysfunction. J Am Coll 
Cardiol 2020;75:2538–49. https://doi.org/10.1016/j.jacc.2020.03.051
967. Belmonte M, Pijls NHJ, Bertolone DT, Bertolone DT, Keulards DCJ, Viscusi MM, et al. 
Measuring absolute coronary flow and microvascular resistance by thermodilution. 
J Am Coll Cardiol 2024;83:699–709. https://doi.org/10.1016/j.jacc.2023.12.014
968. Feenstra RGT, Woudstra J, Bijloo I, Vink CEM, Boerhout CKM, de Waard GA, et al. 
Post-spastic flow recovery time to document vasospasm induced ischemia during 
acetylcholine provocation testing. Int J Cardiol Heart Vasc 2023;47:101220. https:// 
doi.org/10.1016/j.ijcha.2023.101220
969. Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, et al. Induction of coron­
ary artery spasm by two pharmacological agents: comparison between intracoronary 
injection of acetylcholine and ergonovine. Coron Artery Dis 2003;14:451–7. https://doi. 
org/10.1097/00019501-200309000-00006
970. Montone RA, Rinaldi R, Del Buono MG, Gurgoglione F, La Vecchia G, Russo M, et al. 
Safety and prognostic relevance of acetylcholine testing in patients with stable myocar­
dial ischaemia or myocardial infarction and non-obstructive coronary arteries. 
EuroIntervention 2022;18:e666–76. https://doi.org/10.4244/eij-d-21-00971
971. Takahashi T, Samuels BA, Li W, Parikh MA, Wei J, Moses JW, et al. Safety of provoca­
tive testing with intracoronary acetylcholine and implications for standard protocols. 
J Am Coll Cardiol 2022;79:2367–78. https://doi.org/10.1016/j.jacc.2022.03.385
972. Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Cammà G, et al. Patients 
with acute myocardial infarction and non-obstructive coronary arteries: safety and 
prognostic relevance of invasive coronary provocative tests. Eur Heart J 2018;39: 
91–8. https://doi.org/10.1093/eurheartj/ehx667
973. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacol­
ogy, and clinical applications. JACC Cardiovasc Interv 2014;7:581–91. https://doi.org/ 
10.1016/j.jcin.2014.02.009
974. Mizukami T, Sonck J, Gallinoro E, Kodeboina M, Canvedra A, Nagumo S, et al. Duration 
of hyperemia with intracoronary administration of papaverine. J Am Heart Assoc 2021; 
10:e018562. https://doi.org/10.1161/JAHA.120.018562
975. Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T. Ventricular arrhythmia due 
to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory re­
serve. Cathet Cardiovasc Diagn 1990;19:229–36. https://doi.org/10.1002/ccd.


<!-- PAGE 118 -->

### Page 118

976. Nakayama M, Tanaka N, Sakoda K, Hokama Y, Hoshino K, Kimura Y, et al. 
Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve 
study of patients with moderate coronary artery disease—analysis of ECG data. Circ J 
2015;79:530–6. https://doi.org/10.1253/circj.CJ-14-1118
977. Beltrame JF, Tavella R, Jones D, Zeitz C. Management of ischaemia with non- 
obstructive coronary arteries (INOCA). BMJ 2021;375:e060602. https://doi.org/10. 
1136/bmj-2021-060602
978. Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al. 1-Year out­
comes of angina management guided by invasive coronary function testing 
(CorMicA). JACC Cardiovasc Interv 2020;13:33–45. https://doi.org/10.1016/j.jcin.2019. 
11.001
979. Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of ischemic heart disease. Circulation 
2018;138:1463–80. https://doi.org/10.1161/CIRCULATIONAHA.118.031373
980. Sinha A, Rahman H, Douiri A, Demir OM, De Silva K, Clapp B, et al. ChaMP-CMD: a 
phenotype-blinded, randomized controlled, cross-over trial. Circulation 2024;149: 
36–47. https://doi.org/10.1161/CIRCULATIONAHA.123.066680
981. Jansen TPJ, Konst RE, de Vos A, Paradies V, Teerenstra S, van den Oord SCH, et al. 
Efficacy of diltiazem to improve coronary vasomotor dysfunction in ANOCA: the 
EDIT-CMD randomized clinical trial. JACC Cardiovasc Imaging 2022;15:1473–84. 
https://doi.org/10.1016/j.jcmg.2022.03.012
982. Guarini G, Huqi A, Morrone D, Capozza P, Todiere G, Marzilli M. Pharmacological ap­
proaches to coronary microvascular dysfunction. Pharmacol Ther 2014;144:283–302. 
https://doi.org/10.1016/j.pharmthera.2014.06.008
983. Cattaneo M, Porretta AP, Gallino A. Ranolazine: drug overview and possible role in 
primary microvascular angina management. Int J Cardiol 2015;181:376–81. https:// 
doi.org/10.1016/j.ijcard.2014.12.055
984. Imran TF, Malapero R, Qavi AH, Hasan Z, de la Torre B, Patel YR, et al. Efficacy of spinal 
cord stimulation as an adjunct therapy for chronic refractory angina pectoris. Int J 
Cardiol 2017;227:535–42. https://doi.org/10.1016/j.ijcard.2016.10.105
985. Lee BK, Lim HS, Fearon WF, Yong AS, Yamada R, Tanaka S, et al. Invasive evaluation of 
patients with angina in the absence of obstructive coronary artery disease. Circulation 
2015;131:1054–60. https://doi.org/10.1161/CIRCULATIONAHA.114.012636
986. Shufelt CL, Thomson LE, Goykhman P, Agarwal M, Mehta PK, Sedlak T, et al. Cardiac 
magnetic resonance imaging myocardial perfusion reserve index assessment in women 
with microvascular coronary dysfunction and reference controls. Cardiovasc Diagn Ther 
2013;3:153–60. https://doi.org/10.3978/j.issn.2223-3652.2013.08.02
987. Echavarria-Pinto M, Escaned J, Macias E, Medina M, Gonzalo N, Petraco R, et al. 
Disturbed coronary hemodynamics in vessels with intermediate stenoses evaluated 
with fractional flow reserve: a combined analysis of epicardial and microcirculatory in­
volvement in ischemic heart disease. Circulation 2013;128:2557–66. https://doi.org/10. 
1161/CIRCULATIONAHA.112.001345
988. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme 
inhibition on exercise-induced angina and ST segment depression in patients with 
microvascular angina. J Am Coll Cardiol 1994;23:652–7. https://doi.org/10.1016/0735- 
1097(94)90750-1
989. Erdamar H, Sen N, Tavil Y, Yazc HU, Turfan M, Poyraz F, et al. The effect of nebivolol 
treatment on oxidative stress and antioxidant status in patients with cardiac 
syndrome-X. Coron Artery Dis 2009;20:238–44. https://doi.org/10.1097/mca. 
0b013e32830936bb
990. Kayaalti F, Kalay N, Basar E, Mavili E, Duran M, Ozdogru I, et al. Effects of nebivolol 
therapy on endothelial functions in cardiac syndrome X. Heart Vessels 2010;25: 
92–6. https://doi.org/10.1007/s00380-009-1170-1
991. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, et al. Nifedipine 
therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med 1980; 
302:1269–73. https://doi.org/10.1056/nejm198006053022301
992. Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for 
Prinzmetal’s variant angina. N Engl J Med 1981;304:862–6. https://doi.org/10.1056/ 
nejm198104093041502
993. Ginsburg R, Lamb IH, Schroeder JS, Hu M, Harrison DC. Randomized double-blind 
comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris 
due to coronary artery spasm. Am Heart J 1982;103:44–8. https://doi.org/10.1016/ 
0002-8703(82)90527-0
994. Pesola A, Lauro A, Gallo R, Madeo A, Cosentino G. Efficacy of diltiazem in variant an­
gina. Results of a double-blind crossover study in CCU by Holter monitoring. The pos­
sible occurrence of a withdrawal syndrome. G Ital Cardiol 1987;17:329–39.
995. Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, et al. Randomized 
placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 
Group. J Am Coll Cardiol 1993;21:1365–70. https://doi.org/10.1016/0735–1097(93) 
90310-w
996. Oikawa Y, Matsuno S, Yajima J, Nakamura M, Ono T, Ishiwata S, et al. Effects of treat­
ment with once-daily nifedipine CR and twice-daily benidipine on prevention of symp­
tomatic attacks in patients with coronary spastic angina pectoris—Adalat Trial vs 
Coniel in Tokyo against Coronary Spastic Angina (ATTACK CSA). J Cardiol 2010; 
55:238–47. https://doi.org/10.1016/j.jjcc.2009.11.005
997. Aschermann M, Bultas J, Karetová D, Kölbel F, Kozáková M, Simper D. Randomized 
double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pec­
toris. Am J Cardiol 1990;65:J46–9. https://doi.org/10.1016/0002-9149(90)91312-t
998. Seitz A, Feenstra R, Konst RE, Martínez Pereyra V, Beck S, Beijk MAM, et al. 
Acetylcholine rechallenge: a first step toward tailored treatment in patients with cor­
onary artery spasm. JACC Cardiovasc Interv 2022;15:65–75. https://doi.org/10.1016/j. 
jcin.2021.10.003
999. Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, et al. Prognostic 
effects of calcium channel blockers in patients with vasospastic angina—a 
meta-analysis. Circ J 2010;74:1943–50. https://doi.org/10.1253/circj.cj-10-0292
1000. Winniford MD, Gabliani G, Johnson SM, Mauritson DR, Fulton KL, Hillis LD. 
Concomitant calcium antagonist plus isosorbide dinitrate therapy for markedly active 
variant angina. Am Heart J 1984;108:1269–73. https://doi.org/10.1016/0002-8703(84) 
90752-x
1001. Gu SZ, Beska B, Chan D, Neely D, Batty JA, Adams-Hall J, et al. Cognitive decline in 
older patients with non-ST elevation acute coronary syndrome. J Am Heart Assoc 
2019;8:e011218. https://doi.org/10.1161/jaha.118.011218
1002. Beska B, Coakley D, MacGowan G, Adams-Hall J, Wilkinson C, Kunadian V. Frailty 
and quality of life after invasive management for non-ST elevation acute coronary 
syndrome. Heart 2022;108:203–11. https://doi.org/10.1136/heartjnl-2021-319064
1003. Beska B, Mills GB, Ratcovich H, Wilkinson C, Damluji AA, Kunadian V. Impact of mul­
timorbidity on long-term outcomes in older adults with non-ST elevation acute cor­
onary syndrome in the North East of England: a multi-centre cohort study of patients 
undergoing invasive care. BMJ Open 2022;12:e061830. https://doi.org/10.1136/ 
bmjopen-2022-061830
1004. Mills GB, Ratcovich H, Adams-Hall J, Beska B, Kirkup E, Raharjo DE, et al. Is the con­
temporary care of the older persons with acute coronary syndrome evidence-based? 
Eur Heart J Open 2022;2:oeab044. https://doi.org/10.1093/ehjopen/oeab044
1005. Ratcovich H, Beska B, Mills G, Holmvang L, Adams-Hall J, Stevenson H, et al. Five-year 
clinical outcomes in patients with frailty aged ≥75 years with non-ST elevation acute 
coronary syndrome undergoing invasive management. Eur Heart J Open 2022;2: 
oeac035. https://doi.org/10.1093/ehjopen/oeac035
1006. Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular re­
search: observational analysis of the ICON-1 study. Open Heart 2016;3:e000436. 
https://doi.org/10.1136/openhrt-2016-000436
1007. Mas-Llado C, Gonzalez-Del-Hoyo M, Siquier-Padilla J, Blaya-Peña L, Coughlan JJ, 
García de la Villa B, et al. Representativeness in randomised clinical trials supporting 
acute coronary syndrome guidelines. Eur Heart J Qual Care Clin Outcomes 2023;9: 
796–805. https://doi.org/10.1093/ehjqcco/qcad007
1008. Rossello X, Ferreira JP, Caimari F, Lamiral Z, Sharma A, Mehta C, et al. Influence of 
sex, age and race on coronary and heart failure events in patients with diabetes 
and post-acute coronary syndrome. Clin Res Cardiol 2021;110:1612–24. https://doi. 
org/10.1007/s00392-021-01859-2
1009. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents 
in elderly patients with coronary artery disease (SENIOR): a randomised single-blind 
trial. Lancet 2018;391:41–50. https://doi.org/10.1016/S0140-6736(17)32713-7
1010. Chung K, Wilkinson C, Veerasamy M, Kunadian V. Frailty scores and their utility in 
older patients with cardiovascular disease. Interv Cardiol 2021;16:e05. https://doi. 
org/10.15420/icr.2020.18
1011. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The 
Lancet women and cardiovascular disease Commission: reducing the global burden by 
2030. Lancet 2021;397:2385–438. https://doi.org/10.1016/s0140-6736(21)00684-x
1012. Gaudino M, Di Franco A, Cao D, Giustino G, Bairey Merz CN, Fremes SE, et al. 
Sex-related outcomes of medical, percutaneous, and surgical interventions for cor­
onary artery disease: JACC focus seminar 3/7. J Am Coll Cardiol 2022;79:1407–25. 
https://doi.org/10.1016/j.jacc.2021.07.066
1013. Jackson J, Alkhalil M, Ratcovich H, Wilkinson C, Mehran R, Kunadian V. Evidence base 
for the management of women with non-ST elevation acute coronary syndrome. 
Heart 2022;108:1682–9. https://doi.org/10.1136/heartjnl-2021-320533
1014. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future car­
diovascular risk among women: a review. J Am Coll Cardiol 2014;63:1815–22. https:// 
doi.org/10.1016/j.jacc.2014.02.529
1015. Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, et al. 
Cardiovascular health after menopause transition, pregnancy disorders, and other gy­
naecologic conditions: a consensus document from European cardiologists, gynaecol­
ogists, and endocrinologists. Eur Heart J 2021;42:967–84. https://doi.org/10.1093/ 
eurheartj/ehaa1044
1016. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, et al. Age at natural 
menopause and risk of incident cardiovascular disease: a pooled analysis of individual 
patient data. Lancet Public Health 2019;4:e553–64. https://doi.org/10.1016/s2468- 
2667(19)30155-0
1017. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, et al. 
Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities 
for cardiovascular disease prevention in women: a scientific statement from the 
American Heart Association. Circulation 2021;143:e902–16. https://doi.org/10. 
1161/cir.0000000000000961


<!-- PAGE 119 -->

### Page 119

1018. Rossello X, Mas-Lladó C, Pocock S, Vicent L, van de Werf F, Chin CT, et al. Sex dif­
ferences in mortality after an acute coronary syndrome increase with lower country 
wealth and higher income inequality. Rev Esp Cardiol (Engl Ed) 2022;75:392–400. 
https://doi.org/10.1016/j.rec.2021.05.006
1019. Sims M, Kershaw KN, Breathett K, Jackson EA, Lewis LM, Mujahid MS, et al. 
Importance of housing and cardiovascular health and well-being: a scientific state­
ment from the American Heart Association. Circ Cardiovasc Qual Outcomes 2020; 
13:e000089. https://doi.org/10.1161/hcq.0000000000000089
1020. Wilkinson C, Bebb O, Dondo TB, Munyombwe T, Casadei B, Clarke S, et al. Sex dif­
ferences in quality indicator attainment for myocardial infarction: a nationwide co­
hort study. Heart 2019;105:516–23. https://doi.org/10.1136/heartjnl-2018-313959
1021. Kosmidou I, Leon MB, Zhang Y, Serruys PW, von Birgelen C, Smits PC, et al. 
Long-term outcomes in women and men following percutaneous coronary interven­
tion. J Am Coll Cardiol 2020;75:1631–40. https://doi.org/10.1016/j.jacc.2020.01.056
1022. Angraal S, Khera R, Wang Y, Lu Y, Jean R, Dreyer RP, et al. Sex and race differences in 
the utilization and outcomes of coronary artery bypass grafting among medicare 
beneficiaries, 1999–2014. J Am Heart Assoc 2018;7:e009014. https://doi.org/10. 
1161/JAHA.118.009014
1023. Sarma AA, Braunwald E, Cannon CP, Guo J, Im KA, Antman EM, et al. Outcomes of 
women compared with men after non-ST-segment elevation acute coronary syn­
dromes. J Am Coll Cardiol 2019;74:3013–22. https://doi.org/10.1016/j.jacc.2019.09. 
065
1024. Chichareon P, Modolo R, Kerkmeijer L, Tomaniak M, Kogame N, Takahashi K, et al. 
Association of sex with outcomes in patients undergoing percutaneous coronary 
intervention: a subgroup analysis of the GLOBAL LEADERS randomized clinical trial. 
JAMA Cardiol 2020;5:21–9. https://doi.org/10.1001/jamacardio.2019.4296
1025. Ratcovich H, Alkhalil M, Beska B, Holmvang L, Lawless M, Gede Dennis Sukadana I, 
et al. Sex differences in long-term outcomes in older adults undergoing invasive treat­
ment for non-ST elevation acute coronary syndrome: an ICON-1 sub-study. Int J 
Cardiol Heart Vasc 2022;42:101118. https://doi.org/10.1016/j.ijcha.2022.101118
1026. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, 
et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: 
principal results from the Women’s Health Initiative randomized controlled trial. 
JAMA 2002;288:321–33. https://doi.org/10.1001/jama.288.3.321
1027. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free 
drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015; 
373:2038–47. https://doi.org/10.1056/NEJMoa1503943
1028. Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, et al. 
Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J 
Med 2020;382:1208–18. https://doi.org/10.1056/NEJMoa1910021
1029. Angiolillo DJ, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, et al. Impact of age on 
the safety and efficacy of ticagrelor monotherapy in patients undergoing PCI. JACC 
Cardiovasc Interv 2021;14:1434–46. https://doi.org/10.1016/j.jcin.2021.04.043
1030. Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, et al. Ticagrelor monother­
apy in patients at high bleeding risk undergoing percutaneous coronary intervention: 
TWILIGHT-HBR. Eur Heart J 2021;42:4624–34. https://doi.org/10.1093/eurheartj/ 
ehab702
1031. Mehran R, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, et al. 3- or 1-Month 
DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implant­
ation. JACC Cardiovasc Interv 2021;14:1870–83. https://doi.org/10.1016/j.jcin.2021.07. 
016
1032. Valgimigli M, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, et al. Duration of dual 
antiplatelet therapy for patients at high bleeding risk undergoing PCI. J Am Coll Cardiol 
2021;78:2060–72. https://doi.org/10.1016/j.jacc.2021.08.074
1033. Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. 
Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: 
symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus 
erythematosus. Autoimmun Rev 2022;21:102925. https://doi.org/10.1016/j.autrev. 
2021.102925
1034. Kerola AM, Kazemi A, Rollefstad S, Lillegraven S, Sexton J, Wibetoe G, et al. All-cause 
and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spon­
dyloarthritis: a nationwide registry study. Rheumatology (Oxford) 2022;61:4656–66. 
https://doi.org/10.1093/rheumatology/keac210
1035. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic 
stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up 
study from Sweden. BMC Neurol 2012;12:41. https://doi.org/10.1186/1471–2377-12- 
41
1036. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in 
patients hospitalized for immune-mediated diseases: a nationwide follow-up study 
from Sweden. PLoS One 2012;7:e33442. https://doi.org/10.1371/journal.pone. 
0033442
1037. Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction 
among patients with gout: a nationwide population-based study. Rheumatology 
(Oxford) 2013;52:111–7. https://doi.org/10.1093/rheumatology/kes169
1038. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, 
et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year 
period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74: 
1011–8. https://doi.org/10.1136/annrheumdis-2013-204838
1039. Alenghat FJ. The prevalence of atherosclerosis in those with inflammatory connective 
tissue disease by race, age, and traditional risk factors. Sci Rep 2016;6:20303. https:// 
doi.org/10.1038/srep20303
1040. Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and 
children with systemic lupus erythematosus: a systematic review and Bayesian 
meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017;76:2009–16. 
https://doi.org/10.1136/annrheumdis-2017-211663
1041. Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. 
Mortality causes and trends associated with giant cell arteritis: analysis of the 
French national death certificate database (1980–2011). Rheumatology (Oxford) 
2018;57:1047–55. https://doi.org/10.1093/rheumatology/key028
1042. Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, et al. 
Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: 
a meta-analysis of observational studies. Rheumatology (Oxford) 2018;57:555–62. 
https://doi.org/10.1093/rheumatology/kex338
1043. Houben E, Mendel A, van der Heijden JW, Simsek S, Bax WA, Carette S, et al. 
Prevalence and management of cardiovascular risk factors in ANCA-associated vas­
culitis. 
Rheumatology 
(Oxford) 
2019;58:2333–5. 
https://doi.org/10.1093/ 
rheumatology/kez229
1044. Cen X, Feng S, Wei S, Yan L, Sun L. Systemic sclerosis and risk of cardiovascular dis­
ease: a PRISMA-compliant systemic review and meta-analysis of cohort studies. 
Medicine (Baltimore) 2020;99:e23009. https://doi.org/10.1097/md.000000000002 
3009
1045. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased 
coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease dur­
ation and cardiovascular risk factors. Arthritis Rheum 2005;52:3045–53. https://doi. 
org/10.1002/art.21288
1046. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical 
carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 
144:249–56. https://doi.org/10.7326/0003-4819-144-4-200602210-00006
1047. Kobayashi H, Giles JT, Polak JF, Blumenthal RS, Leffell MS, Szklo M, et al. Increased 
prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. 
J Rheumatol 2010;37:730–9. https://doi.org/10.3899/jrheum.090670
1048. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC, et al. Longitudinal pre­
dictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis 
Rheum 2011;63:3216–25. https://doi.org/10.1002/art.30542
1049. Ajeganova S, de Faire U, Jogestrand T, Frostegård J, Hafström I. Carotid atheroscler­
osis, disease measures, oxidized low-density lipoproteins, and atheroprotective nat­
ural antibodies for cardiovascular disease in early rheumatoid arthritis—an inception 
cohort study. J Rheumatol 2012;39:1146–54. https://doi.org/10.3899/jrheum.111334
1050. Lucke M, Messner W, Kim ES, Husni ME. The impact of identifying carotid plaque on 
addressing cardiovascular risk in psoriatic arthritis. Arthritis Res Ther 2016;18:178. 
https://doi.org/10.1186/s13075-016-1074-2
1051. Fischer K, Przepiera-Będzak H, Brzosko I, Sawicki M, Walecka A, Brzosko M. 
Anti-phosphatidylethanolamine and anti-phosphatidylserine antibodies—association 
with renal involvement, atherosclerosis, cardiovascular manifestations, Raynaud phe­
nomenon and disease activity in Polish patients with systemic lupus erythematosus. 
Biomolecules 2022;12:1328. https://doi.org/10.3390/biom12101328
1052. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media 
thickness predicts the development of cardiovascular events in patients with rheuma­
toid arthritis. Semin Arthritis Rheum 2009;38:366–71. https://doi.org/10.1016/j. 
semarthrit.2008.01.012
1053. Evans MR, Escalante A, Battafarano DF, Freeman GL, O’Leary DH, del Rincón I. 
Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid 
arthritis. Arthritis Rheum 2011;63:1211–20. https://doi.org/10.1002/art.30265
1054. Lam SHM, Cheng IT, Li EK, Wong P, Lee J, Yip RML, et al. DAPSA, carotid plaque and 
cardiovascular events in psoriatic arthritis: a longitudinal study. Ann Rheum Dis 2020; 
79:1320–6. https://doi.org/10.1136/annrheumdis-2020-217595
1055. Gupta A, Kesavabhotla K, Baradaran H, Kamel H, Pandya A, Giambrone AE, et al. 
Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic re­
view and meta-analysis. Stroke 2015;46:91–7. https://doi.org/10.1161/strokeaha.114. 
006091
1056. Semb AG, Ikdahl E, Hisdal J, Olsen IC, Rollefstad S. Exploring cardiovascular disease 
risk evaluation in patients with inflammatory joint diseases. Int J Cardiol 2016;223: 
331–6. https://doi.org/10.1016/j.ijcard.2016.08.129
1057. Galarza-Delgado DA, Azpiri-Lopez JR, Colunga-Pedraza IJ, Guajardo-Jauregui N, 
Rodriguez-Romero AB, Lugo-Perez S, et al. Cardiovascular risk reclassification ac­
cording to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arth­
ritis patients. Clin Rheumatol 2022;41:1413–20. https://doi.org/10.1007/s10067-021- 
06002-0
1058. Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, et al. Effect of in­
tensive lipid-lowering therapy on cardiovascular outcome in patients with and those 
without inflammatory joint disease. Arthritis Rheum 2012;64:2836–46. https://doi.org/ 
10.1002/art.34524
ESC Guidelines                                                                                                                                                                                          3533


<!-- PAGE 120 -->

### Page 120

1059. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR 
recommendations for cardiovascular disease risk management in patients with 
rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 up­
date. Ann Rheum Dis 2017;76:17–28. https://doi.org/10.1136/annrheumdis-2016- 
209775
1060. Xie W, Huang H, Xiao S, Yang X, Zhang Z. Effect of statin use on cardiovascular 
events and all-cause mortality in immune-mediated inflammatory diseases: a system­
atic review and meta-analysis involving 148,722 participants. Pharmacol Res 2020;160: 
105057. https://doi.org/10.1016/j.phrs.2020.105057
1061. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recom­
mendations for cardiovascular risk management in rheumatic and musculoskeletal 
diseases, including systemic lupus erythematosus and antiphospholipid syndrome. 
Ann Rheum Dis 2022;81:768–79. https://doi.org/10.1136/annrheumdis-2021-221733
1062. Rahmadi AR, Pranata R, Raffaello WM, Yonas E, Ramadhian MP, Natadikarta MRR, 
et al. The effect of statin on major adverse cardiovascular events and mortality in pa­
tients with rheumatoid arthritis—a systematic review and meta-analysis. Eur Rev Med 
Pharmacol Sci 2022;26:3171–8. https://doi.org/10.26355/eurrev_202205_28734
1063. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood 
pressure lowering for prevention of cardiovascular disease and death: a systematic 
review and meta-analysis. Lancet 2016;387:957–67. https://doi.org/10.1016/S0140- 
6736(15)01225-8
1064. McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 
ESC Guidelines for the management of elevated blood pressure and hypertension. 
Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178
1065. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ 
ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39: 
3021–104. https://doi.org/10.1093/eurheartj/ehy339
1066. Suwalski P, Kowalewski M, Jasiński M, Staromłyński J, Zembala M, Widenka K, et al. 
Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery. 
Eur J Cardiothorac Surg 2020;57:691–700. https://doi.org/10.1093/ejcts/ezz298
1067. Van Gelder IC, Kotecha D, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, et al. 
https://doi.org/10.1093/eurheartj/ehae176
1068. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ 
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 
561–632. https://doi.org/10.1093/eurheartj/ehab395
1069. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause 
of death in patients with reduced kidney function. J Am Soc Nephrol 2015;26:2504–11. 
https://doi.org/10.1681/asn.2014070714
1070. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. 
Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. 
J Am Coll Cardiol 2019;74:1823–38. https://doi.org/10.1016/j.jacc.2019.08.1017
1071. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, et al. 
Representation of patients with kidney disease in trials of cardiovascular interven­
tions: an updated systematic review. JAMA Intern Med 2016;176:121–4. https://doi. 
org/10.1001/jamainternmed.2015.6102
1072. Morales J, Handelsman Y. Cardiovascular outcomes in patients with diabetes and kid­
ney disease: JACC review topic of the week. J Am Coll Cardiol 2023;82:161–70. https:// 
doi.org/10.1016/j.jacc.2023.04.052
1073. Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl 
J Med 2019;380:2146–55. https://doi.org/10.1056/NEJMra1805256
1074. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management 
of coronary disease in patients with advanced kidney disease. N Engl J Med 2020;382: 
1608–18. https://doi.org/10.1056/NEJMoa1915925
1075. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Revascularization in 
patients with multivessel coronary artery disease and chronic kidney disease: 
everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll 
Cardiol 2015;66:1209–20. https://doi.org/10.1016/j.jacc.2015.06.1334
1076. Wang Y, Zhu S, Gao P, Zhang Q. Comparison of coronary artery bypass grafting and 
drug-eluting stents in patients with chronic kidney disease and multivessel disease: a 
meta-analysis. Eur J Intern Med 2017;43:28–35. https://doi.org/10.1016/j.ejim.2017.04. 
002
1077. Raposeiras-Roubin S, Abu-Assi E, Munoz-Pousa I, Rossello X, Cespón-Fernández M, 
Melendo Viu M, et al. Usefulness of bleeding after acute coronary syndromes for un­
masking silent cancer. Am J Cardiol 2020;125:1801–8. https://doi.org/10.1016/j. 
amjcard.2020.03.023
1078. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, 
et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
1079. Falanga A, Leader A, Ambaglio C, Bagoly Z, Castaman G, Elalamy I, et al. EHA guide­
lines on management of antithrombotic treatments in thrombocytopenic patients 
with cancer. Hemasphere 2022;6:e750. https://doi.org/10.1097/hs9.000000000000 
0750
1080. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of ath­
erosclerotic cardiovascular disease in people living with HIV: systematic review and 
meta-analysis. Circulation 2018;138:1100–12. https://doi.org/10.1161/circulationaha. 
117.033369
1081. Lee D. HIV: how to manage dyslipidaemia in HIV. Drugs Context 2022;11:2021-8-7. 
https://doi.org/10.7573/dic.2021-8-7
1082. Dekkers CC, Westerink J, Hoepelman AIM, Arends JE. Overcoming obstacles in 
lipid-lowering therapy in patients with HIV—a systematic review of current evidence. 
AIDS Rev 2018;20:205–19. https://doi.org/10.24875/AIDSRev.18000016
1083. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. 
Characteristics, prevention, and management of cardiovascular disease in people liv­
ing with HIV: a scientific statement from the American Heart Association. Circulation 
2019;140:e98–124. https://doi.org/10.1161/cir.0000000000000695
1084. Foster HME, Celis-Morales CA, Nicholl BI, Petermann-Rocha F, Pell JP, Gill JMR, et al. 
The effect of socioeconomic deprivation on the association between an extended 
measurement of unhealthy lifestyle factors and health outcomes: a prospective ana­
lysis of the UK Biobank cohort. Lancet Public Health 2018;3:e576–85. https://doi.org/ 
10.1016/s2468-2667(18)30200-7
1085. Floud S, Balkwill A, Moser K, Reeves GK, Green J, Beral V, et al. The role of 
health-related behavioural factors in accounting for inequalities in coronary heart dis­
ease risk by education and area deprivation: prospective study of 1.2 million UK wo­
men. BMC Med 2016;14:145. https://doi.org/10.1186/s12916-016-0687-2
1086. Stringhini S, Carmeli C, Jokela M, Avendaño M, Muennig P, Guida F, et al. 
Socioeconomic status and the 25 × 25 risk factors as determinants of premature 
mortality: a multicohort study and meta-analysis of 1·7 million men and women. 
Lancet 2017;389:1229–37. https://doi.org/10.1016/s0140-6736(16)32380-7
1087. Di Girolamo C, Nusselder WJ, Bopp M, Brønnum-Hansen H, Costa G, Kovács K, 
et al. Progress in reducing inequalities in cardiovascular disease mortality in Europe. 
Heart 2020;106:40–9. https://doi.org/10.1136/heartjnl-2019-315129
1088. Leyland AH, Dundas R. Declining cardiovascular mortality masks unpalatable inequal­
ities. Heart 2020;106:6–7. https://doi.org/10.1136/heartjnl-2019-315708
1089. Sidhu GS, Ward C, Ferdinand KC. Racial disparity in atherosclerotic cardiovascular 
disease in hospitalized patients with diabetes 2005–2015: potential warning signs 
for future U.S. public health. Am J Prev Cardiol 2020;4:100095. https://doi.org/10. 
1016/j.ajpc.2020.100095
1090. Pursnani S, Merchant M. South Asian ethnicity as a risk factor for coronary heart dis­
ease. Atherosclerosis 2020;315:126–30. https://doi.org/10.1016/j.atherosclerosis. 
2020.10.007
1091. Patel AP, Wang M, Kartoun U, Ng K, Khera AV. Quantifying and understanding the 
higher risk of atherosclerotic cardiovascular disease among South Asian individuals: 
results from the UK Biobank Prospective Cohort Study. Circulation 2021;144: 
410–22. https://doi.org/10.1161/circulationaha.120.052430
1092. Hosseini F, Malhi N, Sellers SL, Khan N, Li CK, Taylor CM, et al. The morphology of 
coronary artery disease in South Asians vs white Caucasians and its implications. Can J 
Cardiol 2022;38:1570–9. https://doi.org/10.1016/j.cjca.2022.05.005
1093. Magavern EF, Jacobs B, Warren H, Finocchiaro G, Finer S, van Heel DA, et al. 
CYP2C19 genotype prevalence and association with recurrent myocardial infarction 
in British-South Asians treated with clopidogrel. JACC Adv 2023;2:100573. https://doi. 
org/10.1016/j.jacadv.2023.100573
1094. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects 
of hormone replacement therapy. Lancet 2002;360:942–4. https://doi.org/10.1016/ 
s0140-6736(02)11032-4
1095. Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. 
Hormone therapy for preventing cardiovascular disease in post-menopausal women. 
Cochrane Database Syst Rev 2015;3:CD002229. https://doi.org/10.1002/14651858. 
CD002229.pub4
1096. Gili S, Grosso Marra W, D’Ascenzo F, Lonni E, Calcagno A, Cannillo M, et al. 
Comparative safety and efficacy of statins for primary prevention in human immuno­
deficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J 
2016;37:3600–9. https://doi.org/10.1093/eurheartj/ehv734
1097. Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, et al. 
Prevalence of subclinical coronary artery atherosclerosis in the general population. 
Circulation 2021;144:916–29. https://doi.org/10.1161/circulationaha.121.055340
1098. Nasir K, Cainzos-Achirica M, Valero-Elizondo J, Ali SS, Havistin R, Lakshman S, et al. 
Coronary atherosclerosis in an asymptomatic U.S. population: Miami Heart Study at 
Baptist Health South Florida. JACC Cardiovasc Imaging 2022;15:1604–18. https://doi. 
org/10.1016/j.jcmg.2022.03.010
1099. Baber U, Mehran R, Sartori S, Schoos MM, Sillesen H, Muntendam P, et al. Prevalence, 
impact, and predictive value of detecting subclinical coronary and carotid atheroscler­
osis in asymptomatic adults: the BioImage study. J Am Coll Cardiol 2015;65:1065–74. 
https://doi.org/10.1016/j.jacc.2015.01.017
1100. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary 
artery calcium by race, gender, and age: results from the Multi-Ethnic Study of 
Atherosclerosis (MESA). Circulation 2006;113:30–7. https://doi.org/10.1161/ 
circulationaha.105.580696


<!-- PAGE 121 -->

### Page 121

1101. SCORE2 working group, ESC Cardiovascular risk collaboration. SCORE2 risk predic­
tion algorithms: new models to estimate 10-year risk of cardiovascular disease in 
Europe. Eur Heart J 2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309
1102. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing 
morbidity and mortality from disease. Cochrane Database Syst Rev 2019;1:CD009009. 
https://doi.org/10.1002/14651858.CD009009.pub3
1103. Si S, Moss JR, Sullivan TR, Newton SS, Stocks NP. Effectiveness of general practice- 
based health checks: a systematic review and meta-analysis. Br J Gen Pract 2014;64: 
e47–53. https://doi.org/10.3399/bjgp14X676456
1104. Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification 
for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a 
systematic review. Heart 2012;98:177–184. https://doi.org/10.1136/heartjnl-2011- 
300747
1105. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic 
adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin 
E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005;46: 
166–72. https://doi.org/10.1016/j.jacc.2005.02.089
1106. Lindholt JS, Sogaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. 
Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. 
N Engl J Med 2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681
1107. Ajufo E, Ayers CR, Vigen R, Joshi PH, Rohatgi A, de Lemos JA, et al. Value of coronary 
artery calcium scanning in association with the net benefit of aspirin in primary pre­
vention of atherosclerotic cardiovascular disease. JAMA Cardiol 2021;6:179–87. 
https://doi.org/10.1001/jamacardio.2020.4939
1108. Chiles C, Duan F, Gladish GW, Ravenel JG, Baginski SG, Snyder BS, et al. Association 
of coronary artery calcification and mortality in the National Lung Screening Trial: a 
comparison of three scoring methods. Radiology 2015;276:82–90. https://doi.org/10. 
1148/radiol.15142062
1109. Hecht HS, Cronin P, Blaha MJ, Budoff MJ, Kazerooni EA, Narula J, et al. 2016 SCCT/ 
STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest 
CT scans: a report of the Society of Cardiovascular Computed Tomography and 
Society of Thoracic Radiology. J Cardiovasc Comput Tomogr 2017;11:74–84. https:// 
doi.org/10.1016/j.jcct.2016.11.003
1110. Williams MC, Abbas A, Tirr E, Alam S, Nicol E, Shambrook J, et al. Reporting inciden­
tal coronary, aortic valve and cardiac calcification on non-gated thoracic computed 
tomography, a consensus statement from the BSCI/BSCCT and BSTI. Br J Radiol 
2021;94:20200894. https://doi.org/10.1259/bjr.20200894
1111. Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thick­
ness and carotid plaque burden predict future cardiovascular events in asymptomatic 
adult Americans. Eur Heart J Cardiovasc Imaging 2018;19:1042–50. https://doi.org/10. 
1093/ehjci/jex239
1112. SCORE2-OP working group, ESC Cardiovascular risk collaboration. SCORE2-OP 
risk prediction algorithms: estimating incident cardiovascular event risk in older per­
sons in four geographical risk regions. Eur Heart J 2021;42:2455–67. https://doi.org/ 
10.1093/eurheartj/ehab312
1113. Backman WD, Levine SA, Wenger NK, Harold JG. Shared decision-making for older 
adults with cardiovascular disease. Clin Cardiol 2020;43:196–204. https://doi.org/10. 
1002/clc.23267
1114. Street RL Jr, Makoul G, Arora NK, Epstein RM. How does communication heal? 
Pathways linking clinician–patient communication to health outcomes. Patient Educ 
Couns 2009;74:295–301. https://doi.org/10.1016/j.pec.2008.11.015
1115. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to 
treatment: a meta-analysis. Med Care 2009;47:826–34. https://doi.org/10.1097/ 
MLR.0b013e31819a5acc
1116. Thomas M, Jones PG, Arnold SV, Spertus JA. Interpretation of the Seattle angina 
questionnaire as an outcome measure in clinical trials and clinical care: a review. 
JAMA Cardiol 2021;6:593–9. https://doi.org/10.1001/jamacardio.2020.7478
1117. Saxon JT, Chan PS, Tran AT, Angraal S, Jones PG, Grantham JA, et al. Comparison of 
patient-reported vs physician-estimated angina in patients undergoing elective and 
urgent percutaneous coronary intervention. JAMA Netw Open 2020;3:e207406. 
https://doi.org/10.1001/jamanetworkopen.2020.7406
1118. Moore PM, Rivera Mercado S, Grez Artigues M, Lawrie TA. Communication skills 
training for healthcare professionals working with people who have cancer. 
Cochrane Database Syst Rev 2013;3:CD003751. https://doi.org/10.1002/14651858. 
CD003751.pub3
1119. Yao M, Zhou XY, Xu ZJ, Lehman R, Haroon S, Jackson D, et al. The impact of training 
healthcare professionals’ communication skills on the clinical care of diabetes and 
hypertension: a systematic review and meta-analysis. BMC Fam Pract 2021;22:152. 
https://doi.org/10.1186/s12875-021-01504-x
1120. Austin CA, Mohottige D, Sudore RL, Smith AK, Hanson LC. Tools to promote shared 
decision making in serious illness: a systematic review. JAMA Intern Med 2015;175: 
1213–21. https://doi.org/10.1001/jamainternmed.2015.1679
1121. Hoffrage U, Lindsey S, Hertwig R, Gigerenzer G. Communicating statistical informa­
tion. Science 2000;290:2261–2. https://doi.org/10.1126/science.290.5500.2261
1122. Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, et al. Using alternative 
statistical formats for presenting risks and risk reductions. Cochrane Database Syst Rev 
2011;3:CD006776. https://doi.org/10.1002/14651858.CD006776.pub2
1123. Navar AM, Stone NJ, Martin SS. What to say and how to say it: effective communi­
cation for cardiovascular disease prevention. Curr Opin Cardiol 2016;31:537–44. 
https://doi.org/10.1097/hco.0000000000000322
1124. French DP, Cameron E, Benton JS, Deaton C, Harvie M. Can communicating perso­
nalised disease risk promote healthy behaviour change? A systematic review of sys­
tematic reviews. Ann Behav Med 2017;51:718–29. https://doi.org/10.1007/s12160- 
017-9895-z
1125. Schulberg SD, Ferry AV, Jin K, Marshall L, Neubeck L, Strachan FE, et al. 
Cardiovascular risk communication strategies in primary prevention. A systematic re­
view with narrative synthesis. J Adv Nurs 2022;78:3116–40. https://doi.org/10.1111/ 
jan.15327
1126. Hedberg B, Malm D, Karlsson JE, Arestedt K, Brostrom A. Factors associated with 
confidence in decision making and satisfaction with risk communication among pa­
tients with atrial fibrillation. Eur J Cardiovasc Nurs 2018;17:446–55. https://doi.org/ 
10.1177/1474515117741891
1127. Frieling T. Non-cardiac chest pain. Visc Med 2018;34:92–6. https://doi.org/10.1159/ 
000486440
1128. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 
AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diag­
nosis of chest pain: a report of the American College of Cardiology/American 
Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll 
Cardiol 2021;78:e187–285. https://doi.org/10.1016/j.jacc.2021.07.053
1129. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and man­
agement of depression in patients with cardiovascular disease: JACC state-of-the-art 
review. J Am Coll Cardiol 2019;73:1827–45. https://doi.org/10.1016/j.jacc.2019.01.041
1130. Wen Y, Yang Y, Shen J, Luo S. Anxiety and prognosis of patients with myocardial in­
farction: a meta-analysis. Clin Cardiol 2021;44:761–70. https://doi.org/10.1002/clc. 
23605
1131. Peter RS, Meyer ML, Mons U, Schöttker B, Keller F, Schmucker R, et al. Long-term 
trajectories of anxiety and depression in patients with stable coronary heart disease 
and risk of subsequent cardiovascular events. Depress Anxiety 2020;37:784–92. 
https://doi.org/10.1002/da.23011
1132. Fernandes N, Prada L, Rosa MM, Ferreira JJ, Costa J, Pinto FJ, et al. The impact of SSRIs 
on mortality and cardiovascular events in patients with coronary artery disease and 
depression: systematic review and meta-analysis. Clin Res Cardiol 2021;110:183–93. 
https://doi.org/10.1007/s00392-020-01697-8
1133. Parker EL, Banfield M, Fassnacht DB, Hatfield T, Kyrios M. Contemporary treatment 
of anxiety in primary care: a systematic review and meta-analysis of outcomes in 
countries with universal healthcare. BMC Fam Pract 2021;22:92. https://doi.org/10. 
1186/s12875-021-01445-5
1134. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svärdsudd K. Randomized con­
trolled trial of cognitive behavioral therapy vs standard treatment to prevent recur­
rent cardiovascular events in patients with coronary heart disease: Secondary 
Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 
2011;171:134–40. https://doi.org/10.1001/archinternmed.2010.510
1135. Doyle F, Freedland KE, Carney RM, de Jonge P, Dickens C, Pedersen SS, et al. Hybrid 
systematic review and network meta-analysis of randomized controlled trials of in­
terventions for depressive symptoms in patients with coronary artery disease. 
Psychosom Med 2021;83:423–31. https://doi.org/10.1097/psy.0000000000000944
1136. World Health Organization. Adherence to Long-Term Therapies: Evidence for 
Action. 2003. https://iris.who.int/handle/10665/42682
1137. Foley L, Larkin J, Lombard-Vance R, Murphy AW, Hynes L, Galvin E, et al. Prevalence 
and predictors of medication non-adherence among people living with multimorbid­
ity: a systematic review and meta-analysis. BMJ Open 2021;11:e044987. https://doi. 
org/10.1136/bmjopen-2020-044987
1138. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle 
and impact on cardiovascular risk factor control in coronary patients across 27 coun­
tries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V 
registry. Eur J Prev Cardiol 2019;26:824–35. https://doi.org/10.1177/2047487318 
825350
1139. Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, et al. How to 
optimize the adherence to a guideline-directed medical therapy in the secondary pre­
vention of cardiovascular diseases: a clinical consensus statement from the European 
Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2023;30:149–66. 
https://doi.org/10.1093/eurjpc/zwac204
1140. Gardner B, Lally P, Wardle J. Making health habitual: the psychology of ‘habit- 
formation’ and general practice. Br J Gen Pract 2012;62:664–6. https://doi.org/10. 
3399/bjgp12X659466
1141. Brørs G, Dalen H, Allore H, Deaton C, Fridlund B, Osborne RH, et al. Health literacy 
and risk factors for coronary artery disease (from the CONCARDPCI study). Am J 
Cardiol 2022;179:22–30. https://doi.org/10.1016/j.amjcard.2022.06.016
1142. Jennings CS, Astin F, Prescott E, Hansen T, Gale Chris P, De Bacquer D. Illness per­
ceptions and health literacy are strongly associated with health-related quality of life, 
ESC Guidelines                                                                                                                                                                                          3535


<!-- PAGE 122 -->

### Page 122

anxiety and depression in patients with coronary heart disease: results from the 
EUROASPIRE V cross-sectional survey. Eur J Cardiovasc Nurs 2023;22:719–29. 
https://doi.org/10.1093/eurjcn/zvac105
1143. Chiang CY, Choi KC, Ho KM, Yu SF. Effectiveness of nurse-led patient-centered care 
behavioral risk modification on secondary prevention of coronary heart disease: a 
systematic review. Int J Nurs Stud 2018;84:28–39. https://doi.org/10.1016/j.ijnurstu. 
2018.04.012
1144. O’Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to 
promote a healthy diet and physical activity for cardiovascular disease prevention in 
adults with cardiovascular risk factors: updated evidence report and systematic re­
view for the US Preventive Services Task Force. JAMA 2020;324:2076–94. https:// 
doi.org/10.1001/jama.2020.17108
1145. Garcia-Lunar I, van der Ploeg HP, Fernandez Alvira JM, van Nassau F, Castellano 
Vázquez JM, van der Beek AJ, et al. Effects of a comprehensive lifestyle intervention 
on cardiovascular health: the TANSNIP-PESA trial. Eur Heart J 2022;43:3732–45. 
https://doi.org/10.1093/eurheartj/ehac378
1146. Gandhi S, Chen S, Hong L, Sun K, Gong E, Li C, et al. Effect of mobile health interven­
tions on the secondary prevention of cardiovascular disease: systematic review and 
meta-analysis. Can J Cardiol 2017;33:219–31. https://doi.org/10.1016/j.cjca.2016.08. 
017
1147. Akinosun AS, Polson R, Diaz-Skeete Y, De Kock JH, Carragher L, Leslie S, et al. Digital 
technology interventions for risk factor modification in patients with cardiovascular 
disease: systematic review and meta-analysis. JMIR Mhealth Uhealth 2021;9:e21061. 
https://doi.org/10.2196/21061
1148. Kaihara T, Intan-Goey V, Scherrenberg M, Falter M, Frederix I, Dendale P. Impact of 
activity trackers on secondary prevention in patients with coronary artery disease: a 
systematic review and meta-analysis. Eur J Prev Cardiol 2022;29:1047–56. https://doi. 
org/10.1093/eurjpc/zwab146
1149. Patterson K, Davey R, Keegan R, Freene N. Smartphone applications for physical ac­
tivity and sedentary behaviour change in people with cardiovascular disease: a sys­
tematic review and meta-analysis. PLoS One 2021;16:e0258460. https://doi.org/10. 
1371/journal.pone.0258460
1150. Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication adherence on clinical 
outcomes of coronary artery disease: a meta-analysis. Eur J Prev Cardiol 2017;24: 
962–70. https://doi.org/10.1177/2047487317695628
1151. Sanfélix-Gimeno G, Peiró S, Ferreros I, Pérez-Vicente R, Librero J, Catalá-López F, 
et al. Adherence to evidence-based therapies after acute coronary syndrome: a 
retrospective population-based cohort study linking hospital, outpatient, and phar­
macy health information systems in Valencia, Spain. J Manag Care Pharm 2013;19: 
247–57. https://doi.org/10.18553/jmcp.2013.19.3.247
1152. Garcia RA, Spertus JA, Benton MC, Jones PG, Mark DB, Newman JD, et al. 
Association of medication adherence with health outcomes in the ISCHEMIA trial. 
J Am Coll Cardiol 2022;80:755–65. https://doi.org/10.1016/j.jacc.2022.05.045
1153. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. 
Interventions for enhancing medication adherence. Cochrane Database Syst Rev 
2014;2014:CD000011. https://doi.org/10.1002/14651858.CD000011.pub4
1154. Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: 
systematic review and meta-analysis. Prev Med 2017;99:269–76. https://doi.org/10. 
1016/j.ypmed.2017.03.008
1155. Fuller RH, Perel P, Navarro-Ruan T, Nieuwlaat R, Haynes RB, Huffman MD. 
Improving medication adherence in patients with cardiovascular disease: a systematic 
review. Heart 2018;104:1238–43. https://doi.org/10.1136/heartjnl-2017-312571
1156. Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J. Interventions for improving 
medication-taking ability and adherence in older adults prescribed multiple medica­
tions. Cochrane Database Syst Rev 2020;5:CD012419. https://doi.org/10.1002/ 
14651858.CD012419.pub2
1157. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving 
adherence to self-administered long-term medications. Cochrane Database Syst Rev 
2011;9:CD005025. https://doi.org/10.1002/14651858.CD005025.pub3
1158. Lapa ME, Swabe GM, Rollman BL, Muldoon MF, Thurston RC, Magnani JW. 
Assessment of depression and adherence to guideline-directed medical therapies fol­
lowing percutaneous coronary intervention. JAMA Netw Open 2022;5:e2246317. 
https://doi.org/10.1001/jamanetworkopen.2022.46317
1159. Schmieder RE, Wassmann S, Predel HG, Weisser B, Blettenberg J, Gillessen A, et al. 
Improved persistence to medication, decreased cardiovascular events and reduced 
all-cause mortality in hypertensive patients with use of single-pill combinations: re­
sults from the START-study. Hypertension 2023;80:1127–35. https://doi.org/10. 
1161/HYPERTENSIONAHA.122.20810
1160. Simon ST, Kini V, Levy AE, Ho PM. Medication adherence in cardiovascular medicine. 
BMJ 2021;374:n1493. https://doi.org/10.1136/bmj.n1493
1161. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed- 
dose combination strategy on adherence and risk factors in patients with or at high 
risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918–29. https:// 
doi.org/10.1001/jama.2013.277064
1162. Jeong SM, Kim S, Wook Shin D, Han K, Hyun Park S, Hyuk Kim S, et al. Persistence 
and adherence to antihypertensive drugs in newly treated hypertensive patients 
according to initial prescription. Eur J Prev Cardiol 2021;28:e1–4. https://doi.org/10. 
1177/2047487319900326
1163. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. 
Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 
967–77. https://doi.org/10.1056/NEJMoa2208275
1164. Adler AJ, Martin N, Mariani J, Tajer CD, Owolabi OO, Free C, et al. Mobile phone text 
messaging to improve medication adherence in secondary prevention of cardiovas­
cular disease. Cochrane Database Syst Rev 2017;4:CD011851. https://doi.org/10. 
1002/14651858.CD011851.pub2
1165. Kassavou A, Mirzaei V, Brimicombe J, Edwards S, Massou E, Prevost AT, et al. A highly 
tailored text and voice messaging intervention to improve medication adherence in 
patients with either or both hypertension and type 2 diabetes in a UK primary care 
setting: feasibility randomized controlled trial of clinical effectiveness. J Med Internet 
Res 2020;22:e16629. https://doi.org/10.2196/16629
1166. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A 
polypill strategy to improve adherence: results from the FOCUS project. J Am Coll 
Cardiol 2014;64:2071–82. https://doi.org/10.1016/j.jacc.2014.08.021
1167. Wilson PW, D’Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, et al. An inter­
national model to predict recurrent cardiovascular disease. Am J Med 2012;125: 
695–703.e1. https://doi.org/10.1016/j.amjmed.2012.01.014
1168. De Bacquer D, Ueda P, Reiner Z, De Sutter J, De Smedt D, Lovic D, et al. Prediction 
of recurrent event in patients with coronary heart disease: the EUROASPIRE risk 
model. Eur J Prev Cardiol 2022;29:328–39. https://doi.org/10.1093/eurjpc/zwaa128
1169. De Bacquer D, Ueda P, Reiner Z, De Sutter J, De Smedt D, Lovic D, et al. EUROASPIRE 
Risk Calculator. https://www.calconic.com/calculator-widgets/euroaspire-risk-factor-% 
20calculator/5f6223fab75b14001e1f3c67?layouts=true
1170. Cho SMJ, Koyama S, Honigberg MC, Surakka I, Haidermota S, Ganesh S, et al. Genetic, 
sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery dis­
ease events: a population-based cohort study. Eur Heart J 2023;44:3456–65. https:// 
doi.org/10.1093/eurheartj/ehad380
1171. Iribarren C, Lu M, Jorgenson E, Martínez M, Lluis-Ganella C, Subirana I, et al. Clinical 
utility of multimarker genetic risk scores for prediction of incident coronary heart 
disease: a cohort study among over 51 000 individuals of European ancestry. Circ 
Cardiovasc Genet 2016;9:531–40. https://doi.org/10.1161/CIRCGENETICS.116. 
001522
1172. Weintraub WS, Boden WE. Can we measurably improve the prediction of recurrent 
coronary artery disease events? Eur Heart J 2023;44:3466–8. https://doi.org/10.1093/ 
eurheartj/ehad464
1173. Park D-W, Kang D-Y, Ahn J-M, Yun S-C, Yoon Y-H, Hur S-H, et al. Routine functional 
testing or standard care in high-risk patients after PCI. New Engl J Med 2022;387: 
905–15. https://doi.org/10.1056/NEJMoa2208335
1174. Chan M, Ridley L, Dunn DJ, Tian DH, Liou K, Ozdirik J, et al. A systematic review and 
meta-analysis of multidetector computed tomography in the assessment of coronary 
artery bypass grafts. Int J Cardiol 2016;221:898–905. https://doi.org/10.1016/j.ijcard. 
2016.06.264
1175. Li Y, Yu M, Li W, Lu Z, Wei M, Zhang J. Third generation dual-source CT enables 
accurate diagnosis of coronary restenosis in all size stents with low radiation dose 
and preserved image quality. Eur Radiol 2018;28:2647–54. https://doi.org/10.1007/ 
s00330-017-5256-3
1176. Mansour HH, Alajerami YS, Abushab KM, Quffa KM. The diagnostic accuracy of cor­
onary computed tomography angiography in patients with and without previous cor­
onary interventions. J Med Imaging Radiat Sci 2022;53:81–6. https://doi.org/10.1016/j. 
jmir.2021.10.005
1177. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary by­
pass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to 
survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28: 
616–26. https://doi.org/10.1016/0735-1097(96)00206-9
1178. Barbero U, Iannaccone M, d’Ascenzo F, Barbero C, Mohamed A, Annone U, et al. 64 
Slice-coronary computed tomography sensitivity and specificity in the evaluation of 
coronary artery bypass graft stenosis: a meta-analysis. Int J Cardiol 2016;216:52–7. 
https://doi.org/10.1016/j.ijcard.2016.04.156
1179. de Winter RW, Rahman MS, van Diemen PA, Schumacher SP, Jukema RA, Somsen 
YBO, et al. Diagnostic and management strategies in patients with late recurrent an­
gina after coronary artery bypass grafting. Curr Cardiol Rep 2022;24:1309–25. https:// 
doi.org/10.1007/s11886-022-01746-w
1180. Zellweger MJ, Hachamovitch R, Kang X, Hayes SW, Friedman JD, Germano G, et al. 
Threshold, incidence, and predictors of prognostically high-risk silent ischemia in 
asymptomatic patients without prior diagnosis of coronary artery disease. J Nucl 
Cardiol 2009;16:193–200. https://doi.org/10.1007/s12350-008-9016-2
1181. Al-Lamee RK, Shun-Shin MJ, Howard JP, Nowbar AN, Rajkumar C, Thompson D, 
et al. Dobutamine stress echocardiography ischemia as a predictor of the placebo- 
controlled efficacy of percutaneous coronary intervention in stable coronary artery 
disease: the stress echocardiography-stratified analysis of ORBITA. Circulation 2019; 
140:1971–80. https://doi.org/10.1161/CIRCULATIONAHA.119.042918
1182. Stefanini GG, Alfonso F, Barbato E, Byrne R, Capodanno D, Colleran R, et al. 
Management of myocardial revascularisation failure: an expert consensus document


<!-- PAGE 123 -->

### Page 123

of the EAPCI. EuroIntervention 2020;16:e875–90. https://doi.org/10.4244/eij-d-20- 
00487
1183. Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S, Zanchin T, et al. The 
association between in-stent neoatherosclerosis and native coronary artery disease 
progression: a long-term angiographic and optical coherence tomography cohort 
study. Eur Heart J 2015;36:2167–76. https://doi.org/10.1093/eurheartj/ehv227
1184. Pereg D, Fefer P, Samuel M, Wolff R, Czarnecki A, Deb S, et al. Native coronary ar­
tery patency after coronary artery bypass surgery. JACC Cardiovasc Interv 2014;7: 
761–7. https://doi.org/10.1016/j.jcin.2014.01.164
1185. Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, et al. Optical 
coherence tomography findings in patients with coronary stent thrombosis: a report 
of the PRESTIGE consortium (prevention of late stent thrombosis by an interdiscip­
linary global European effort). Circulation 2017;136:1007–21. https://doi.org/10.1161/ 
circulationaha.117.026788
1186. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. 
Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients 
with coronary stent restenosis. J Am Coll Cardiol 2020;75:2664–78. https://doi.org/ 
10.1016/j.jacc.2020.04.006
1187. Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. 
Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or 
drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J 2023; 
44:1343–57. https://doi.org/10.1093/eurheartj/ehad026
1188. Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, et al. 
Drug-eluting balloons versus everolimus-eluting stents for in-stent restenosis: a 
meta-analysis of randomized trials. Cardiovasc Revasc Med 2019;20:612–8. https:// 
doi.org/10.1016/j.carrev.2018.08.010
1189. Doenst T, Sousa-Uva M. How to deal with nonsevere stenoses in coronary artery 
bypass grafting—a critical perspective on competitive flow and surgical precision. 
Curr Opin Cardiol 2022;37:468–73. https://doi.org/10.1097/hco.0000000000000993
1190. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, et al. 
Routine intraoperative completion angiography after coronary artery bypass grafting 
and 1-stop hybrid revascularization results from a fully integrated hybrid catheteriza­
tion laboratory/operating room. J Am Coll Cardiol 2009;53:232–41. https://doi.org/10. 
1016/j.jacc.2008.10.011
1191. Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, et al. 
Saphenous vein grafts with multiple versus single distal targets in patients undergoing 
coronary artery bypass surgery: one-year graft failure and five-year outcomes from 
the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. 
Circulation 2011;124:280–8. https://doi.org/10.1161/circulationaha.110.991299
1192. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, et al. Percutaneous 
coronary intervention versus repeat bypass surgery for patients with medically re­
fractory myocardial ischemia: AWESOME randomized trial and registry experience 
with post-CABG patients. J Am Coll Cardiol 2002;40:1951–4. https://doi.org/10. 
1016/s0735-1097(02)02560-3
1193. Xenogiannis I, Tajti P, Hall AB, Alaswad K, Rinfret S, Nicholson W, et al. Update on 
cardiac catheterization in patients with prior coronary artery bypass graft surgery. 
JACC Cardiovasc Interv 2019;12:1635–49. https://doi.org/10.1016/j.jcin.2019.04.051
1194. Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI and 
CABG for treating stable coronary artery disease: JACC review topic of the week. 
J Am Coll Cardiol 2019;73:964–76. https://doi.org/10.1016/j.jacc.2018.11.053
1195. Sabik JF 3rd, Raza S, Blackstone EH, Houghtaling PL, Lytle BW. Value of internal thor­
acic artery grafting to the left anterior descending coronary artery at coronary reo­
peration. J Am Coll Cardiol 2013;61:302–10. https://doi.org/10.1016/j.jacc.2012.09.045
1196. Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascu­
larization method and long-term outcome of percutaneous coronary intervention or 
repeat coronary bypass surgery in patients with multivessel coronary disease and 
previous coronary bypass surgery. Eur Heart J 2006;27:413–8. https://doi.org/10. 
1093/eurheartj/ehi646
1197. Brilakis ES, O’Donnell CI, Penny W, Armstrong EJ, Tsai T, Maddox TM, et al. 
Percutaneous coronary intervention in native coronary arteries versus bypass grafts 
in patients with prior coronary artery bypass graft surgery: insights from the Veterans 
Affairs clinical assessment, reporting, and tracking program. JACC Cardiovasc Interv 
2016;9:884–93. https://doi.org/10.1016/j.jcin.2016.01.034
1198. Caceres J, Atal P, Arora R, Yee D. Enhanced external counterpulsation: a unique 
treatment for the “No-Option” refractory angina patient. J Clin Pharm Ther 2021; 
46:295–303. https://doi.org/10.1111/jcpt.13330
1199. Verheye S, Jolicoeur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, et al. Efficacy of 
a device to narrow the coronary sinus in refractory angina. N Engl J Med 2015;372: 
519–27. https://doi.org/10.1056/NEJMoa1402556
1200. Hochstadt A, Itach T, Merdler I, Ghantous E, Ziv-Baran T, Leshno M, et al. 
Effectiveness of coronary sinus reducer for treatment of refractory angina: a 
meta-analysis. Can J Cardiol 2022;38:376–83. https://doi.org/10.1016/j.cjca.2021.12. 
009
1201. Foley MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, Chotai S, Pathimagaraj RH, 
et al. Coronary sinus reducer for the treatment of refractory angina 
(ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet 2024;403: 
1543–53. https://doi.org/10.1016/s0140-6736(24)00256-3
1202. Velagapudi P, Turagam M, Kolte D, Khera S, Hyder O, Gordon P, et al. 
Intramyocardial autologous CD34+ cell therapy for refractory angina: a meta-analysis 
of randomized controlled trials. Cardiovasc Revasc Med 2019;20:215–9. https://doi. 
org/10.1016/j.carrev.2018.05.018
1203. Jones DA, Weeraman D, Colicchia M, Hussain MA, Veerapen D, Andiapen M, et al. 
The impact of cell therapy on cardiovascular outcomes in patients with refractory 
angina. Circ Res 2019;124:1786–95. https://doi.org/10.1161/circresaha.118.314118
1204. Giannini F, Baldetti L, Konigstein M, Rosseel L, Ruparelia N, Gallone G, et al. Safety 
and efficacy of the reducer: a multi-center clinical registry—REDUCE study. Int J 
Cardiol 2018;269:40–4. https://doi.org/10.1016/j.ijcard.2018.06.116
1205. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. 
Advanced heart failure: a position statement of the Heart Failure Association of 
the European Society of Cardiology. Eur J Heart Fail 2018;20:1505–35. https://doi. 
org/10.1002/ejhf.1236
1206. Adamo M, Grasso C, Capodanno D, Rubbio AP, Scandura S, Giannini C, et al. 
Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: in­
sights from the multicenter GRASP-IT registry. Am Heart J 2019;217:32–41. 
https://doi.org/10.1016/j.ahj.2019.06.015
1207. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias and the 
prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126. https://doi.org/ 
10.1093/eurheartj/ehac262
1208. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treat­
ment for tricuspid valve disease. EuroIntervention 2021;17:791–808. https://doi.org/ 
10.4244/eij-d-21-00695
1209. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter 
repair for patients with tricuspid regurgitation. New Engl J Med 2023;388:1833–42. 
https://doi.org/10.1056/NEJMoa2300525
1210. Sogaard R, Diederichsen ACP, Rasmussen LM, Lambrechtsen J, Steffensen FH, Frost 
L, et al. Cost effectiveness of population screening vs. no screening for cardiovascular 
disease: the Danish Cardiovascular Screening trial (DANCAVAS). Eur Heart J 2022; 
43:4392–402. https://doi.org/10.1093/eurheartj/ehac488
1211. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating 
myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007;32:375–410. 
https://doi.org/10.1016/j.cpcardiol.2007.04.001
ESC Guidelines                                                                                                                                                                                          3537

<!-- 2024_Hypertension.md -->

# ESC Guidelines: Hypertension (2024)

**Source**: `2024_Hypertension.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 107

---

## Table of Contents

- [2024 ESC Guidelines for the management of elevated blood pressure and hypertension](#2024-esc-guidelines-for-the-management-of-elevated) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. Pathophysiology of elevated blood pressure and hypertension](#3-pathophysiology-of-elevated-blood-pressure-and-h) *(p. 17)*
  - [4. Clinical consequences of elevated blood pressure and hypertension](#4-clinical-consequences-of-elevated-blood-pressure) *(p. 17)*
  - [5. Measuring blood pressure](#5-measuring-blood-pressure) *(p. 18)*
    - [5.1. Introduction and pertinent definitions](#51-introduction-and-pertinent-definitions) *(p. 18)*
    - [5.2. Practical recommendations for measuring blood pressure](#52-practical-recommendations-for-measuring-blood-p) *(p. 19)*
      - [5.2.1. Clinical validation of equipment for measuring blood pressure](#521-clinical-validation-of-equipment-for-measuring) *(p. 19)*
      - [5.2.2. Office blood pressure measurement](#522-office-blood-pressure-measurement) *(p. 19)*
      - [5.2.3. Home blood pressure measurement](#523-home-blood-pressure-measurement) *(p. 20)*
      - [5.2.4. Ambulatory blood pressure measurement](#524-ambulatory-blood-pressure-measurement) *(p. 22)*
      - [5.2.5. Comparison of home and ambulatory blood pressure monitoring](#525-comparison-of-home-and-ambulatory-blood-pressu) *(p. 23)*
    - [5.3. What is the best method for measuring blood pressure to diagnose hypertension?](#53-what-is-the-best-method-for-measuring-blood-pre) *(p. 23)*
      - [5.3.1. Blood pressure measurement for hypertension screening](#531-blood-pressure-measurement-for-hypertension-sc) *(p. 23)*
      - [5.3.2. Blood pressure measurement for diagnosing hypertension](#532-blood-pressure-measurement-for-diagnosing-hype) *(p. 23)*
    - [5.4. What is the best method for measuring blood pressure for long-term management of hypertension?](#54-what-is-the-best-method-for-measuring-blood-pre) *(p. 23)*
      - [5.4.1. Home monitoring](#541-home-monitoring) *(p. 23)*
      - [5.4.2. Ambulatory monitoring](#542-ambulatory-monitoring) *(p. 23)*
    - [5.5. Measuring blood pressure in selected groups](#55-measuring-blood-pressure-in-selected-groups) *(p. 24)*
      - [5.5.1. Pregnancy](#551-pregnancy) *(p. 24)*
      - [5.5.2. Atrial fibrillation](#552-atrial-fibrillation) *(p. 24)*
      - [5.5.3. Orthostatic hypotension](#553-orthostatic-hypotension) *(p. 24)*
    - [5.6. Novel methods of measuring blood pressure](#56-novel-methods-of-measuring-blood-pressure) *(p. 24)*
  - [6. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment](#6-definition-and-classification-of-elevated-blood-) *(p. 25)*
    - [6.1. Definition and classification of elevated blood pressure and hypertension](#61-definition-and-classification-of-elevated-blood) *(p. 25)*
    - [6.2. Principles of a risk-based approach for managing blood pressure and preventing cardiovascular disease](#62-principles-of-a-risk-based-approach-for-managin) *(p. 25)*
      - [6.2.1. Role of cardiovascular disease risk assessment](#621-role-of-cardiovascular-disease-risk-assessment) *(p. 25)*
    - [6.3. Predicting cardiovascular disease risk](#63-predicting-cardiovascular-disease-risk) *(p. 26)*
      - [6.3.1. 10-year cardiovascular disease risk-prediction models](#631-10-year-cardiovascular-disease-risk-prediction) *(p. 27)*
    - [6.4. Refining cardiovascular disease risk estimation beyond risk models](#64-refining-cardiovascular-disease-risk-estimation) *(p. 28)*
      - [6.4.1. Sex-specific non-traditional cardiovascular disease risk modifiers](#641-sex-specific-non-traditional-cardiovascular-di) *(p. 28)*
      - [6.4.2. Non-traditional cardiovascular disease risk modifiers shared by men and women](#642-non-traditional-cardiovascular-disease-risk-mo) *(p. 29)*
      - [6.4.3. Additional risk decision tests](#643-additional-risk-decision-tests) *(p. 30)*
    - [6.5. Summary of the cardiovascular disease risk stratification approach for allocating blood pressure treatment](#65-summary-of-the-cardiovascular-disease-risk-stra) *(p. 30)*
  - [7. Diagnosing hypertension and investigating underlying causes](#7-diagnosing-hypertension-and-investigating-underl) *(p. 32)*
    - [7.1. Screening for hypertension](#71-screening-for-hypertension) *(p. 32)*
    - [7.2. Confirming the diagnosis of hypertension](#72-confirming-the-diagnosis-of-hypertension) *(p. 32)*
    - [7.3. Communicating the diagnosis](#73-communicating-the-diagnosis) *(p. 33)*
    - [7.4. Baseline assessment and diagnostic approach](#74-baseline-assessment-and-diagnostic-approach) *(p. 33)*
      - [7.4.1. Medical history, medication history, and physical examination](#741-medical-history,-medication-history,-and-physi) *(p. 33)*
      - [7.4.2. Drug adherence and persistence with treatment](#742-drug-adherence-and-persistence-with-treatment) *(p. 34)*
      - [7.4.3. Routine and optional tests](#743-routine-and-optional-tests) *(p. 34)*
        - [7.4.3.1. The kidneys](#7431-the-kidneys) *(p. 36)*
        - [7.4.3.2. The heart](#7432-the-heart) *(p. 36)*
        - [7.4.3.3. The arteries](#7433-the-arteries) *(p. 37)*
      - [7.4.4. Genetic testing](#744-genetic-testing) *(p. 37)*
    - [7.5. Resistant hypertension: definition and diagnosis](#75-resistant-hypertension:-definition-and-diagnosi) *(p. 37)*
    - [7.6. Secondary hypertension: when to screen/further investigations](#76-secondary-hypertension:-when-to-screen/further-) *(p. 39)*
      - [7.6.1. General considerations](#761-general-considerations) *(p. 39)*
      - [7.6.2. Primary aldosteronism](#762-primary-aldosteronism) *(p. 39)*
      - [7.6.3. Renovascular hypertension](#763-renovascular-hypertension) *(p. 40)*
      - [7.6.4. Obstructive sleep apnoea syndrome](#764-obstructive-sleep-apnoea-syndrome) *(p. 40)*
      - [7.6.5. Phaeochromocytoma/paraganglioma](#765-phaeochromocytoma/paraganglioma) *(p. 43)*
  - [8. Preventing and treating elevated blood pressure and hypertension](#8-preventing-and-treating-elevated-blood-pressure-) *(p. 43)*
    - [8.1. Prevention strategies in early life](#81-prevention-strategies-in-early-life) *(p. 43)*
    - [8.2. Non-pharmacological interventions](#82-non-pharmacological-interventions) *(p. 43)*
      - [8.2.1. Dietary sodium and potassium intake](#821-dietary-sodium-and-potassium-intake) *(p. 43)*
        - [8.2.1.1. Sodium](#8211-sodium) *(p. 43)*
        - [8.2.1.2. Potassium](#8212-potassium) *(p. 44)*
      - [8.2.2. Physical activity and exercise](#822-physical-activity-and-exercise) *(p. 45)*
      - [8.2.3. Weight reduction and diet](#823-weight-reduction-and-diet) *(p. 46)*
      - [8.2.4. Alcohol, coffee, and soft drinks](#824-alcohol,-coffee,-and-soft-drinks) *(p. 46)*
      - [8.2.5. Smoking](#825-smoking) *(p. 46)*
    - [8.3. Pharmacological interventions](#83-pharmacological-interventions) *(p. 47)*
      - [8.3.1. Treatment strategy to reduce adverse cardiovascular disease outcomes](#831-treatment-strategy-to-reduce-adverse-cardiovas) *(p. 47)*
      - [8.3.2. Drug classes with evidence on clinical outcomes in the target population](#832-drug-classes-with-evidence-on-clinical-outcome) *(p. 47)*
      - [8.3.3. New therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension](#833-new-therapies-with-blood-pressure-lowering-pro) *(p. 48)*
      - [8.3.4. Drug combinations and up-titrating strategies](#834-drug-combinations-and-up-titrating-strategies) *(p. 48)*
      - [8.3.5. A practical algorithm for intensive, effective, and tolerable blood pressure lowering with drug therapy, including considerations around single-pill combinations](#835-a-practical-algorithm-for-intensive,-effective) *(p. 48)*
      - [8.3.6. Timing of blood pressure-lowering drug treatment](#836-timing-of-blood-pressure-lowering-drug-treatme) *(p. 51)*
    - [8.4. Selecting patients for pharmacological blood pressure-lowering treatment](#84-selecting-patients-for-pharmacological-blood-pr) *(p. 51)*
    - [8.5. Intensity of blood pressure-lowering therapy and ideal treatment targets](#85-intensity-of-blood-pressure-lowering-therapy-an) *(p. 53)*
      - [8.5.1. Expected degree of blood pressure reduction with approved drugs](#851-expected-degree-of-blood-pressure-reduction-wi) *(p. 53)*
      - [8.5.2. The ideal target of blood pressure-lowering treatment](#852-the-ideal-target-of-blood-pressure-lowering-tr) *(p. 53)*
      - [8.5.3. Personalizing treatment strategies](#853-personalizing-treatment-strategies) *(p. 54)*
      - [8.5.4. Duration and monitoring of drug therapy](#854-duration-and-monitoring-of-drug-therapy) *(p. 55)*
    - [8.6. Device-based blood pressure lowering](#86-device-based-blood-pressure-lowering) *(p. 55)*
      - [8.6.1. Catheter-based renal denervation](#861-catheter-based-renal-denervation) *(p. 55)*
      - [8.6.2. Other devices](#862-other-devices) *(p. 57)*
    - [8.7. Unintended and potentially harmful consequences of blood pressure lowering and implications for treatment targets](#87-unintended-and-potentially-harmful-consequences) *(p. 57)*
      - [8.7.1. Adverse effects of blood pressure-lowering medications](#871-adverse-effects-of-blood-pressure-lowering-med) *(p. 57)*
        - [8.7.1.1. Symptomatic adverse effects](#8711-symptomatic-adverse-effects) *(p. 57)*
        - [8.7.1.2. Renal effects](#8712-renal-effects) *(p. 57)*
        - [8.7.1.3. Erectile dysfunction](#8713-erectile-dysfunction) *(p. 57)*
      - [8.7.2. Pill burden and non-adherence](#872-pill-burden-and-non-adherence) *(p. 57)*
      - [8.7.3. Potentially harmful consequences of blood pressure lowering for frail older people](#873-potentially-harmful-consequences-of-blood-pres) *(p. 57)*
      - [8.7.4. Clinical inertia in blood pressure lowering](#874-clinical-inertia-in-blood-pressure-lowering) *(p. 57)*
  - [9. Managing specific patient groups or circumstances](#9-managing-specific-patient-groups-or-circumstance) *(p. 58)*
    - [9.1. Young adulthood (18–40 years)](#91-young-adulthood-(18–40 years)) *(p. 58)*
      - [9.1.1. Definition and epidemiology](#911-definition-and-epidemiology) *(p. 58)*
      - [9.1.2. Secondary hypertension in young adulthood](#912-secondary-hypertension-in-young-adulthood) *(p. 58)*
      - [9.1.3. Measurement and management of blood pressure in young adults](#913-measurement-and-management-of-blood-pressure-i) *(p. 58)*
    - [9.2. Pregnancy](#92-pregnancy) *(p. 58)*
      - [9.2.1. Definition and epidemiology](#921-definition-and-epidemiology) *(p. 58)*
      - [9.2.2. Classifying hypertension in pregnancy](#922-classifying-hypertension-in-pregnancy) *(p. 58)*
      - [9.2.3. Measuring blood pressure in pregnancy](#923-measuring-blood-pressure-in-pregnancy) *(p. 59)*
      - [9.2.4. Investigating hypertension in pregnancy](#924-investigating-hypertension-in-pregnancy) *(p. 59)*
      - [9.2.5. Preventing hypertension and pre-eclampsia](#925-preventing-hypertension-and-pre-eclampsia) *(p. 59)*
      - [9.2.6. Treatment initiation and blood pressure targets](#926-treatment-initiation-and-blood-pressure-target) *(p. 59)*
      - [9.2.7. Managing mild hypertension in pregnancy (office blood pressure 140–159/90–109 mmHg)](#927-managing-mild-hypertension-in-pregnancy-(offic) *(p. 59)*
      - [9.2.8. Managing severe hypertension in pregnancy (≫160/110 mmHg)](#928-managing-severe-hypertension-in-pregnancy-(≫16) *(p. 60)*
      - [9.2.9. Managing blood pressure post-partum](#929-managing-blood-pressure-post-partum) *(p. 60)*
      - [9.2.10. Risk of recurrence of hypertensive disorders in a subsequent pregnancy](#9210-risk-of-recurrence-of-hypertensive-disorders-) *(p. 60)*
    - [9.3. Very old age (≧85 years), frailty, multimorbidity, and polypharmacy](#93-very-old-age-(≧85 years),-frailty,-multimorbidi) *(p. 60)*
      - [9.3.1. Definition of frailty](#931-definition-of-frailty) *(p. 60)*
      - [9.3.2. Randomized controlled trials of blood pressure lowering in frail older patients](#932-randomized-controlled-trials-of-blood-pressure) *(p. 61)*
      - [9.3.3. Starting blood pressure-lowering treatment in very old or frail patients](#933-starting-blood-pressure-lowering-treatment-in-) *(p. 62)*
      - [9.3.4. Maintaining blood pressure lowering in very old or frail patients](#934-maintaining-blood-pressure-lowering-in-very-ol) *(p. 62)*
    - [9.4. Isolated systolic and diastolic hypertension](#94-isolated-systolic-and-diastolic-hypertension) *(p. 62)*
      - [9.4.1. Definition of isolated systolic hypertension](#941-definition-of-isolated-systolic-hypertension) *(p. 62)*
      - [9.4.2. Isolated systolic hypertension, risk factors, and ageing](#942-isolated-systolic-hypertension,-risk-factors,-) *(p. 62)*
      - [9.4.3. Isolated systolic hypertension in young adults](#943-isolated-systolic-hypertension-in-young-adults) *(p. 63)*
      - [9.4.4. Isolated diastolic hypertension](#944-isolated-diastolic-hypertension) *(p. 63)*
    - [9.5. Orthostatic hypotension with supine hypertension](#95-orthostatic-hypotension-with-supine-hypertensio) *(p. 63)*
    - [9.6. Diabetes](#96-diabetes) *(p. 64)*
      - [9.6.1. Diabetes and elevated blood pressure/hypertension](#961-diabetes-and-elevated-blood-pressure/hypertens) *(p. 64)*
      - [9.6.2. J-shaped curve of blood pressure and risk of cardiovascular disease in patients with diabetes](#962-j-shaped-curve-of-blood-pressure-and-risk-of-c) *(p. 64)*
      - [9.6.3. Managing blood pressure in diabetes](#963-managing-blood-pressure-in-diabetes) *(p. 64)*
    - [9.7. Chronic kidney disease](#97-chronic-kidney-disease) *(p. 64)*
      - [9.7.1. Relationship between hypertension and chronic kidney disease](#971-relationship-between-hypertension-and-chronic-) *(p. 64)*
      - [9.7.2. Blood pressure lowering in chronic kidney disease](#972-blood-pressure-lowering-in-chronic-kidney-dise) *(p. 65)*
      - [9.7.3. Managing blood pressure in chronic kidney disease](#973-managing-blood-pressure-in-chronic-kidney-dise) *(p. 65)*
      - [9.7.4. Blood pressure targets in chronic kidney disease](#974-blood-pressure-targets-in-chronic-kidney-disea) *(p. 65)*
    - [9.8. Cardiac disease](#98-cardiac-disease) *(p. 65)*
      - [9.8.1. Blood pressure thresholds and targets in patients with cardiac disease](#981-blood-pressure-thresholds-and-targets-in-patie) *(p. 65)*
      - [9.8.2. Coronary artery disease with particular reference to the blood pressure J-curve](#982-coronary-artery-disease-with-particular-refere) *(p. 66)*
      - [9.8.3. Valvular heart disease](#983-valvular-heart-disease) *(p. 66)*
      - [9.8.4. Heart failure](#984-heart-failure) *(p. 66)*
      - [9.8.5. Heart rhythm disease (including AF)](#985-heart-rhythm-disease-(including-af)) *(p. 67)*
    - [9.9. Chronic cerebrovascular disease and/or cognitive impairment](#99-chronic-cerebrovascular-disease-and/or-cogniti) *(p. 67)*
      - [9.9.1. Role of hypertension in chronic cerebrovascular disease](#991-role-of-hypertension-in-chronic-cerebrovascula) *(p. 67)*
      - [9.9.2. Treatment in patients with history of prior stroke or transient ischaemic attack](#992-treatment-in-patients-with-history-of-prior-st) *(p. 67)*
      - [9.9.3. Treatment in patients with chronic cerebrovascular disease and cognitive impairment](#993-treatment-in-patients-with-chronic-cerebrovasc) *(p. 67)*
    - [9.10. Aortopathy](#910-aortopathy) *(p. 68)*
      - [9.10.1. Coarctation of the aorta](#9101-coarctation-of-the-aorta) *(p. 68)*
      - [9.10.2. Bicuspid aortic valve-related aortopathy](#9102-bicuspid-aortic-valve-related-aortopathy) *(p. 68)*
      - [9.10.3. Preventing aortic dilation and dissection in high-risk patients](#9103-preventing-aortic-dilation-and-dissection-in-) *(p. 68)*
    - [9.11. Different ethnic groups](#911-different-ethnic-groups) *(p. 68)*
    - [9.12. Nocturnal hypertension](#912-nocturnal-hypertension) *(p. 68)*
      - [9.12.1. Definition](#9121-definition) *(p. 68)*
      - [9.12.2. Epidemiology](#9122-epidemiology) *(p. 69)*
      - [9.12.3. Night-time blood pressure as a cardiovascular disease risk factor](#9123-night-time-blood-pressure-as-a-cardiovascular) *(p. 69)*
      - [9.12.4. Treatment of nocturnal hypertension](#9124-treatment-of-nocturnal-hypertension) *(p. 69)*
    - [9.13. Resistant hypertension](#913-resistant-hypertension) *(p. 69)*
      - [9.13.1. Definition of resistant hypertension](#9131-definition-of-resistant-hypertension) *(p. 69)*
      - [9.13.2. Non-pharmacological interventions](#9132-non-pharmacological-interventions) *(p. 69)*
      - [9.13.3. Pharmacological interventions](#9133-pharmacological-interventions) *(p. 69)*
      - [9.13.4. Devices for blood pressure lowering](#9134-devices-for-blood-pressure-lowering) *(p. 70)*
    - [9.14. Management of specific causes of secondary hypertension](#914-management-of-specific-causes-of-secondary-hyp) *(p. 71)*
      - [9.14.1. General considerations](#9141-general-considerations) *(p. 71)*
      - [9.14.2. Primary aldosteronism](#9142-primary-aldosteronism) *(p. 71)*
      - [9.14.3. Renovascular hypertension](#9143-renovascular-hypertension) *(p. 71)*
      - [9.14.4. Phaeochromocytoma/paraganglioma](#9144-phaeochromocytoma/paraganglioma) *(p. 72)*
      - [9.14.5. Obstructive sleep apnoea syndrome](#9145-obstructive-sleep-apnoea-syndrome) *(p. 72)*
      - [9.14.6. Drug-induced hypertension](#9146-drug-induced-hypertension) *(p. 72)*
        - [9.14.6.1. Anticancer drug-induced hypertension](#91461-anticancer-drug-induced-hypertension) *(p. 72)*
      - [9.14.7. Other forms of secondary hypertension](#9147-other-forms-of-secondary-hypertension) *(p. 72)*
  - [10. Acute and short-term lowering of blood pressure](#10-acute-and-short-term-lowering-of-blood-pressure) *(p. 72)*
    - [10.1. Acute blood pressure management in hypertensive emergencies](#101-acute-blood-pressure-management-in-hypertensiv) *(p. 72)*
      - [10.1.1. Definition and characteristics of hypertensive emergencies](#1011-definition-and-characteristics-of-hypertensiv) *(p. 72)*
      - [10.1.2. Acute management of hypertensive emergencies](#1012-acute-management-of-hypertensive-emergencies) *(p. 73)*
      - [10.1.3. Prognosis and follow-up](#1013-prognosis-and-follow-up) *(p. 73)*
    - [10.2. Acute blood pressure management in acute intracerebral haemorrhage](#102-acute-blood-pressure-management-in-acute-intra) *(p. 73)*
    - [10.3. Acute blood pressure management in acute ischaemic stroke](#103-acute-blood-pressure-management-in-acute-ischa) *(p. 73)*
    - [10.4. Acute blood pressure management in pre-eclampsia and severe hypertension in pregnancy](#104-acute-blood-pressure-management-in-pre-eclamps) *(p. 74)*
      - [10.4.1. Pre-eclampsia](#1041-pre-eclampsia) *(p. 74)*
      - [10.4.2. Severe acute hypertension in pregnancy](#1042-severe-acute-hypertension-in-pregnancy) *(p. 74)*
    - [10.5. Peri-operative acute management of elevated blood pressure](#105-peri-operative-acute-management-of-elevated-bl) *(p. 74)*
      - [10.5.1. Blood pressure-lowering drugs in the peri-operative phase](#1051-blood-pressure-lowering-drugs-in-the-peri-ope) *(p. 74)*
  - [11. Patient-centred care in hypertension](#11-patient-centred-care-in-hypertension) *(p. 75)*
    - [11.1. Definition](#111-definition) *(p. 75)*
    - [11.2. Communicating consequences of treatment](#112-communicating-consequences-of-treatment) *(p. 75)*
    - [11.3. Self-measuring and monitoring](#113-self-measuring-and-monitoring) *(p. 76)*
    - [11.4. Facilitating medication adherence and persistence](#114-facilitating-medication-adherence-and-persiste) *(p. 76)*
    - [11.5. Multidisciplinary management](#115-multidisciplinary-management) *(p. 76)*
  - [12. Key messages](#12-key-messages) *(p. 77)*
  - [13. Gaps in the evidence](#13-gaps-in-the-evidence) *(p. 78)*
  - [14. ‘What to do’ and ‘what not to do’ messages from the guidelines](#14-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 78)*
  - [15. Evidence tables](#15-evidence-tables) *(p. 82)*
  - [16. Data availability statement](#16-data-availability-statement) *(p. 82)*
  - [17. Author information](#17-author-information) *(p. 82)*
  - [Appendix](#appendix) *(p. 82)*
  - [19. References](#19-references) *(p. 83)*
  - [19. References](#19-references) *(p. 83)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management of 
elevated blood pressure and hypertension
Developed by the task force on the management of elevated blood pressure and 
hypertension of the European Society of Cardiology (ESC) and endorsed by the 
European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)
Authors/Task Force Members: John William McEvoy  *†, (Chairperson) (Ireland), 
Cian P. McCarthy  
‡, (Task Force Co-ordinator) (United States of America), 
Rosa Maria Bruno  
‡, (Task Force Co-ordinator) (France), Sofie Brouwers  
(Belgium), Michelle D. Canavan  
(Ireland), Claudio Ceconi  
(Italy), 
Ruxandra Maria Christodorescu  
(Romania), Stella S. Daskalopoulou  
(Canada), 
Charles J. Ferro  
1 (United Kingdom), Eva Gerdts  
(Norway), Henner Hanssen  
(Switzerland), Julie Harris (United Kingdom), Lucas Lauder  
(Switzerland/Germany), Richard J. McManus  
(United Kingdom), Gerard J. Molloy  
(Ireland), Kazem Rahimi  
(United Kingdom), Vera Regitz-Zagrosek (Germany), 
Gian Paolo Rossi  
2 (Italy), Else Charlotte Sandset  
3 (Norway), Bart Scheenaerts 
(Belgium), Jan A. Staessen  
(Belgium), Izabella Uchmanowicz  
(Poland), 
Maurizio Volterrani  
(Italy), Rhian M. Touyz  *†, (Chairperson) (Canada), 
and ESC Scientific Document Group
*  Corresponding authors: John William McEvoy, Department of Cardiology, University of Galway School of Medicine, Galway, Ireland, and National Institute for Prevention and 
Cardiovascular Health, Galway, Ireland. Tel: +353 91 544310, E-mail: johnwilliam.mcevoy@universityofgalway.ie; and Rhian M. Touyz, Department of Medicine, McGill University, 
Montreal, Canada, Department of Family Medicine, McGill University, Montreal, Canada, and the Research Institute of the McGill University Health Centre, McGill University, Montreal, 
Canada. Tel: +1 514 934 1934 ext 71608, E-mail: Rhian.touyz@mcgill.ca
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1Representing the European Renal Association (ERA), 2Representing the European Society of Endocrinology (ESE), 3Representing the European Stroke Organisation (ESO), 4Representing the 
European Geriatric Medicine Society (EuGMS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous 
Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension, Council on Stroke.
Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, E-Cardiology.
Patient Forum
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guide­
lines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines 
fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC 
Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health 
condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full 
and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating 
to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of 
the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com
https://doi.org/10.1093/eurheartj/ehae178
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Ana Abreu, (CPG Review Co-ordinator) (Portugal), Michael Hecht Olsen, (CPG Review 
Co-ordinator) (Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United Kingdom), Lia Evi Bang 
(Denmark), Jesper Nørgaard Bech (Denmark), Michael A. Borger (Germany), Pierre Boutouyrie (France), 
Luís Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), Maria Carmen De Pablo Zarzosa (Spain), 
Christian Delles (United Kingdom), Maria Manuela Fiuza (Portugal), Rahima Gabulova (Azerbaijan), 
Bjørn Olav Haugen (Norway), Christian Heiss (United Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), 
Vikas Kapil (United Kingdom), Meral Kayikçioglu (Turkey), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), Emanuela Teresa Locati (Italy), Sharon MacDonald (United Kingdom), Anastasia S. Mihailidou 
(Australia), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), 
Martin Bodtker Mortensen (Denmark), Sandor Nardai (Hungary), Lis Neubeck (United Kingdom), 
Jens Cosedis Nielsen (Denmark), Peter M. Nilsson (Sweden), Agnes A. Pasquet (Belgium), Mónica Mendes Pedro 
(Portugal), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Ernst Rietzschel (Belgium), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Jean-Paul Schmid (Switzerland), Eduard Shantsila (United Kingdom), 
Isabella Sudano (Switzerland), Ana Teresa Timóteo (Portugal), Georgios Tsivgoulis3 (Greece), Andrea Ungar4 
(Italy), Ilonca Vaartjes (Netherlands), Frank Visseren (Netherlands), Heinz Voeller (Germany), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), Maria-Christina Zennaro2 (France), 
and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest, 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or 
www.escardio.org/Guidelines for supplementary documents, as well as evidence tables.
Click here to access the corresponding ESC CardioMed chapters.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Blood pressure • Hypertension • Hypertension-mediated organ damage • Blood pressure measurement 
• Ambulatory blood pressure monitoring • Home blood pressure monitoring • Antihypertensive medication • 
Hypertension treatment • Hypertension targets • Secondary hypertension • Cardiovascular disease risk estimation • 
Cardiovascular disease prevention • Resistant hypertension • Hypertension screening
Table of contents
1. Preamble .............................................................................................................. 3918
2. Introduction ....................................................................................................... 3919
2.1. What is new .............................................................................................
3920
3. Pathophysiology of elevated blood pressure and hypertension .. 3928
4. Clinical consequences of elevated blood pressure  
and hypertension ................................................................................................... 3928
5. Measuring blood pressure ............................................................................ 3929
5.1. Introduction and pertinent definitions ..........................................
3929
5.2. Practical recommendations for measuring blood pressure .
3930
5.2.1. Clinical validation of equipment for measuring blood 
pressure .......................................................................................................... 3930
5.2.2. Office blood pressure measurement ..................................... 3930
5.2.3. Home blood pressure measurement ..................................... 3931
5.2.4. Ambulatory blood pressure measurement ......................... 3933
5.2.5. Comparison of home and ambulatory blood pressure 
monitoring ...................................................................................................... 3934
5.3. What is the best method for measuring blood pressure to 
diagnose hypertension? ................................................................................
3934
5.3.1. Blood pressure measurement for hypertension 
screening ......................................................................................................... 3934
5.3.2. Blood pressure measurement for diagnosing 
hypertension ................................................................................................. 3934
5.4. What is the best method for measuring blood pressure for 
long-term management of hypertension? ............................................
3934
5.4.1. Home monitoring ........................................................................... 3934
5.4.2. Ambulatory monitoring ............................................................... 3934
5.5. Measuring blood pressure in selected groups ...........................
3935
5.5.1. Pregnancy ........................................................................................... 3935
5.5.2. Atrial fibrillation ............................................................................... 3935
5.5.3. Orthostatic hypotension ............................................................. 3935
5.6. Novel methods of measuring blood pressure ...........................
3935
6. Definition and classification of elevated blood pressure and 
hypertension, and cardiovascular disease risk assessment .................. 3936
6.1. Definition and classification of elevated blood pressure and 
hypertension .....................................................................................................
3936
6.2. Principles of a risk-based approach for managing blood 
pressure and preventing cardiovascular disease ................................
3936
6.2.1. Role of cardiovascular disease risk assessment ................. 3936
6.3. Predicting cardiovascular disease risk ............................................
3937
6.3.1. 10-year cardiovascular disease risk-prediction models .. 3938
6.4. Refining cardiovascular disease risk estimation beyond risk 
models .................................................................................................................


<!-- PAGE 3 -->

### Page 3

6.4.1. Sex-specific non-traditional cardiovascular disease risk 
modifiers ......................................................................................................... 3939
6.4.2. Non-traditional cardiovascular disease risk modifiers 
shared by men and women .................................................................... 3940
6.4.3. Additional risk decision tests ..................................................... 3941
6.5. Summary of the cardiovascular disease risk stratification 
approach for allocating blood pressure treatment ..........................
3941
7. Diagnosing hypertension and investigating underlying causes ...... 3943
7.1. Screening for hypertension ................................................................
3943
7.2. Confirming the diagnosis of hypertension ..................................
3943
7.3. Communicating the diagnosis ...........................................................
3944
7.4. Baseline assessment and diagnostic approach ...........................
3944
7.4.1. Medical history, medication history, and physical 
examination ................................................................................................... 3944
7.4.2. Drug adherence and persistence with treatment ............ 3945
7.4.3. Routine and optional tests .......................................................... 3945
7.4.3.1. The kidneys ...............................................................................
3947
7.4.3.2. The heart ...................................................................................
3947
7.4.3.3. The arteries ..............................................................................
3948
7.4.4. Genetic testing ................................................................................. 3948
7.5. Resistant hypertension: definition and diagnosis ......................
3948
7.6. Secondary hypertension: when to screen/further 
investigations .....................................................................................................
3950
7.6.1. General considerations ................................................................ 3950
7.6.2. Primary aldosteronism ................................................................. 3950
7.6.3. Renovascular hypertension ........................................................ 3951
7.6.4. Obstructive sleep apnoea syndrome ..................................... 3951
7.6.5. Phaeochromocytoma/paraganglioma ..................................... 3954
8. Preventing and treating elevated blood pressure and 
hypertension ........................................................................................................... 3954
8.1. Prevention strategies in early life .....................................................
3954
8.2. Non-pharmacological interventions ...............................................
3954
8.2.1. Dietary sodium and potassium intake ................................... 3954
8.2.1.1. Sodium ........................................................................................
3954
8.2.1.2. Potassium ...................................................................................
3955
8.2.2. Physical activity and exercise ..................................................... 3956
8.2.3. Weight reduction and diet ......................................................... 3957
8.2.4. Alcohol, coffee, and soft drinks ................................................ 3957
8.2.5. Smoking ............................................................................................... 3957
8.3. Pharmacological interventions ..........................................................
3958
8.3.1. Treatment strategy to reduce adverse cardiovascular 
disease outcomes ........................................................................................ 3958
8.3.2. Drug classes with evidence on clinical outcomes in the 
target population ......................................................................................... 3958
8.3.3. New therapies with blood pressure-lowering properties 
that await supportive evidence from cardiovascular outcomes 
trials prior to guideline endorsement and routine use in 
hypertension ................................................................................................. 3959
8.3.4. Drug combinations and up-titrating strategies .................. 3959
8.3.5. A practical algorithm for intensive, effective, and tolerable 
blood pressure lowering with drug therapy, including 
considerations around single-pill combinations ............................. 3959
8.3.6. Timing of blood pressure-lowering drug treatment ....... 3962
8.4. Selecting patients for pharmacological blood pressure- 
lowering treatment ........................................................................................
3962
8.5. Intensity of blood pressure-lowering therapy and ideal 
treatment targets ............................................................................................
3964
8.5.1. Expected degree of blood pressure reduction with 
approved drugs ............................................................................................ 3964
8.5.2. The ideal target of blood pressure-lowering treatment
3964
8.5.3. Personalizing treatment strategies .......................................... 3965
8.5.4. Duration and monitoring of drug therapy ........................... 3966
8.6. Device-based blood pressure lowering ........................................
3966
8.6.1. Catheter-based renal denervation .......................................... 3966
8.6.2. Other devices ................................................................................... 3968
8.7. Unintended and potentially harmful consequences of blood 
pressure lowering and implications for treatment targets ...........
3968
8.7.1. Adverse effects of blood pressure-lowering medications
3968
8.7.1.1. Symptomatic adverse effects ............................................
3968
8.7.1.2. Renal effects .............................................................................
3968
8.7.1.3. Erectile dysfunction ...............................................................
3968
8.7.2. Pill burden and non-adherence ................................................. 3968
8.7.3. Potentially harmful consequences of blood pressure 
lowering for frail older people .............................................................. 3968
8.7.4. Clinical inertia in blood pressure lowering .......................... 3968
9. Managing specific patient groups or circumstances .......................... 3969
9.1. Young adulthood (18–40 years) ......................................................
3969
9.1.1. Definition and epidemiology ...................................................... 3969
9.1.2. Secondary hypertension in young adulthood ..................... 3969
9.1.3. Measurement and management of blood pressure in 
young adults .................................................................................................. 3969
9.2. Pregnancy ...................................................................................................
3969
9.2.1. Definition and epidemiology ...................................................... 3969
9.2.2. Classifying hypertension in pregnancy ................................... 3969
9.2.3. Measuring blood pressure in pregnancy ............................... 3970
9.2.4. Investigating hypertension in pregnancy ............................... 3970
9.2.5. Preventing hypertension and pre-eclampsia ....................... 3970
9.2.6. Treatment initiation and blood pressure targets .............. 3970
9.2.7. Managing mild hypertension in pregnancy (office blood 
pressure 140–159/90–109 mmHg) ..................................................... 3970
9.2.8. Managing severe hypertension in pregnancy (>160/110  
mmHg) ............................................................................................................. 3971
9.2.9. Managing blood pressure post-partum ................................. 3971
9.2.10. Risk of recurrence of hypertensive disorders in a 
subsequent pregnancy .............................................................................. 3971
9.3. Very old age (≥85 years), frailty, multimorbidity, and 
polypharmacy ....................................................................................................
3971
9.3.1. Definition of frailty ......................................................................... 3971
9.3.2. Randomized controlled trials of blood pressure lowering 
in frail older patients .................................................................................. 3972
9.3.3. Starting blood pressure-lowering treatment in very old or 
frail patients ................................................................................................... 3973
9.3.4. Maintaining blood pressure lowering in very old or frail 
patients ............................................................................................................ 3973
9.4. Isolated systolic and diastolic hypertension ................................
3973
9.4.1. Definition of isolated systolic hypertension ........................ 3973
9.4.2. Isolated systolic hypertension, risk factors, and ageing .. 3973
9.4.3. Isolated systolic hypertension in young adults ................... 3974
9.4.4. Isolated diastolic hypertension .................................................. 3974
9.5. Orthostatic hypotension with supine hypertension ...............
3974


<!-- PAGE 4 -->

### Page 4

9.6. Diabetes .....................................................................................................
3975
9.6.1. Diabetes and elevated blood pressure/hypertension ..... 3975
9.6.2. J-shaped curve of blood pressure and risk of 
cardiovascular disease in patients with diabetes ........................... 3975
9.6.3. Managing blood pressure in diabetes ..................................... 3975
9.7. Chronic kidney disease ........................................................................
3975
9.7.1. Relationship between hypertension and chronic kidney 
disease .............................................................................................................. 3975
9.7.2. Blood pressure lowering in chronic kidney disease ......... 3976
9.7.3. Managing blood pressure in chronic kidney disease ........ 3976
9.7.4. Blood pressure targets in chronic kidney disease ............ 3976
9.8. Cardiac disease ........................................................................................
3976
9.8.1. Blood pressure thresholds and targets in patients with 
cardiac disease .............................................................................................. 3976
9.8.2. Coronary artery disease with particular reference to the 
blood pressure J-curve ............................................................................. 3977
9.8.3. Valvular heart disease ................................................................... 3977
9.8.4. Heart failure ...................................................................................... 3977
9.8.5. Heart rhythm disease (including AF) ...................................... 3978
9.9. Chronic cerebrovascular disease  
and/or cognitive impairment ......................................................................
3978
9.9.1. Role of hypertension in chronic cerebrovascular disease
3978
9.9.2. Treatment in patients with history of prior stroke or 
transient ischaemic attack ....................................................................... 3978
9.9.3. Treatment in patients with chronic cerebrovascular 
disease and cognitive impairment ........................................................ 3978
9.10. Aortopathy .............................................................................................
3979
9.10.1. Coarctation of the aorta ........................................................... 3979
9.10.2. Bicuspid aortic valve-related aortopathy ........................... 3979
9.10.3. Preventing aortic dilation and dissection in high-risk 
patients ............................................................................................................ 3979
9.11. Different ethnic groups .....................................................................
3979
9.12. Nocturnal hypertension ....................................................................
3979
9.12.1. Definition ......................................................................................... 3979
9.12.2. Epidemiology .................................................................................. 3980
9.12.3. Night-time blood pressure as a cardiovascular disease 
risk factor ....................................................................................................... 3980
9.12.4. Treatment of nocturnal hypertension ................................ 3980
9.13. Resistant hypertension ......................................................................
3980
9.13.1. Definition of resistant hypertension .................................... 3980
9.13.2. Non-pharmacological interventions ..................................... 3980
9.13.3. Pharmacological interventions ................................................ 3980
9.13.4. Devices for blood pressure lowering .................................. 3981
9.14. Management of specific causes of secondary hypertension
3982
9.14.1. General considerations .............................................................. 3982
9.14.2. Primary aldosteronism ............................................................... 3982
9.14.3. Renovascular hypertension ...................................................... 3982
9.14.4. Phaeochromocytoma/paraganglioma .................................. 3983
9.14.5. Obstructive sleep apnoea syndrome ................................... 3983
9.14.6. Drug-induced hypertension ..................................................... 3983
9.14.6.1. Anticancer drug-induced hypertension ......................
3983
9.14.7. Other forms of secondary hypertension ........................... 3983
10. Acute and short-term lowering of blood pressure ........................ 3983
10.1. Acute blood pressure management in hypertensive 
emergencies .......................................................................................................
3983
10.1.1. Definition and characteristics of hypertensive 
emergencies ................................................................................................... 3983
10.1.2. Acute management of hypertensive emergencies ......... 3984
10.1.3. Prognosis and follow-up ........................................................... 3984
10.2. Acute blood pressure management in acute intracerebral 
haemorrhage .....................................................................................................
3984
10.3. Acute blood pressure management in acute ischaemic 
stroke ...................................................................................................................
3984
10.4. Acute blood pressure management in pre-eclampsia and 
severe hypertension in pregnancy ...........................................................
3985
10.4.1. Pre-eclampsia ................................................................................. 3985
10.4.2. Severe acute hypertension in pregnancy ........................... 3985
10.5. Peri-operative acute management of elevated blood 
pressure ..............................................................................................................
3985
10.5.1. Blood pressure-lowering drugs in the peri-operative 
phase ................................................................................................................ 3985
11. Patient-centred care in hypertension ................................................... 3986
11.1. Definition ................................................................................................
3986
11.2. Communicating consequences of treatment ..........................
3986
11.3. Self-measuring and monitoring ......................................................
3987
11.4. Facilitating medication adherence and persistence ...............
3987
11.5. Multidisciplinary management ........................................................
3987
12. Key messages .................................................................................................. 3988
13. Gaps in the evidence ................................................................................... 3989
14. ‘What to do’ and ‘what not to do’ messages from the guidelines
3989
15. Evidence tables ............................................................................................... 3993
16. Data availability statement ......................................................................... 3993
17. Author information ...................................................................................... 3993
18. Appendix ........................................................................................................... 3993
19. References ........................................................................................................ 3994
Tables of Recommendations
Recommendation Table 1 — Recommendations for measuring 
blood pressure (see Evidence Tables 1–8) ................................................ 3935
Recommendation Table 2 — Recommendations for categorizing 
blood pressure (see Evidence Table 9) ....................................................... 3936
Recommendation Table 3 — Recommendations for assessing 
cardiovascular disease risk among individuals with elevated blood 
pressure (office systolic blood pressure 120–139 mmHg or diastolic 
blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11) .... 3939
Recommendation Table 4 — Recommendations for refining 
cardiovascular disease risk (see Evidence Tables 12–14) .................... 3941
Recommendation Table 5 — Recommendations for blood pressure 
screening (see Evidence Table 15) ................................................................ 3943
Recommendation Table 6 — Recommendations for confirming 
hypertension diagnosis ........................................................................................ 3943
Recommendation Table 7 — Recommendations for assessing 
adherence and persistence with treatment  (see Evidence Table 16)
3945
Recommendation Table 8 — Recommendations for assessing renal 
hypertension-mediated organ damage ........................................................ 3947
Recommendation Table 9 — Recommendations for assessing 
cardiac hypertension-mediated organ damage ........................................ 3947
Recommendation Table 10 — Recommendations for assessing 
vascular hypertension-mediated organ damage (see Evidence 
Table 17) ................................................................................................................... 3948
Recommendation Table 11 — Recommendations for genetic testing 
in hypertension management .......................................................................... 3948
Recommendation Table 12 — Recommendations for resistant 
hypertension work-up (see Evidence Table 18) ...................................... 3950
ESC Guidelines                                                                                                                                                                                          3915


<!-- PAGE 5 -->

### Page 5

Recommendation Table 13 — Recommendations for screening for 
secondary hypertension (see Evidence Tables 19 and 20) ................. 3954
Recommendation Table 14 — Recommendations for screening for 
hypertension in children and adolescents (see Evidence Table 21)
3954
Recommendation Table 15 — Recommendations for 
non-pharmacological treatment of blood pressure and cardiovascular 
risk reduction (see Evidence Tables 22–26) .................................................
3958
Recommendation Table 16 — Recommendations for 
pharmacological treatment of hypertension (see Evidence Tables 27, 
28, and 29) ............................................................................................................... 3962
Recommendation Table 17 — Recommendations for initiating 
blood pressure-lowering treatment (see Evidence Tables 30–32) . 3963
Recommendation Table 18 — Recommendations for blood 
pressure targets with treatment (see Evidence Table 34) .................. 3966
Recommendation Table 19 — Recommendations for follow-up in 
patients with treated hypertension (see Evidence Table 33) ............ 3966
Recommendation Table 20 — Recommendations for device-based 
treatment of hypertension (see Evidence Table 35) ............................. 3967
Recommendation Table 21 — Recommendations for managing 
hypertension in young adults (see Evidence Tables 36 and 37) ....... 3969
Recommendation Table 22 — Recommendations for managing 
hypertension in pregnancy (see Evidence Tables 38–40) ................... 3971
Recommendation Table 23 — Recommendations for managing 
hypertension in patients who are very old or frail (see Evidence 
Table 41) ................................................................................................................... 3973
Recommendation Table 24 — Recommendations for managing 
hypertension in patients with orthostatic hypotension ....................... 3975
Recommendation Table 25 — Recommendations for managing 
hypertension in patients with diabetes ........................................................ 3975
Recommendation Table 26 — Recommendations for managing 
hypertension in patients with chronic kidney disease ........................... 3976
Recommendation Table 27 — Recommendations for managing 
hypertension in patients with cardiac disease .......................................... 3978
Recommendation Table 28 — Recommendations for managing 
hypertension in patients with chronic cerebrovascular disease and 
cognitive impairment ........................................................................................... 3979
Recommendation Table 29 — Recommendations for managing 
hypertension in different ethnic groups ...................................................... 3979
Recommendation Table 30 — Recommendations for treating 
resistant hypertension (see Evidence Tables 42 and 43) .................... 3981
Recommendation Table 31 — Recommendations for managing 
hypertension in patients with renovascular hypertension (see 
Evidence Tables 44 and 45) .............................................................................. 3982
Recommendation Table 32 — Recommendations for acutely 
managing blood pressure in patients with intracerebral haemorrhage 
or acute ischaemic stroke ................................................................................. 3984
Recommendation Table 33 — Recommendations for acutely 
managing blood pressure in patients with severe hypertension in 
pregnancy and pre-eclampsia (see Evidence Table 46) ........................ 3985
Recommendation Table 34 — Recommendations for 
communicating consequences of treatment (see Evidence 
Table 47) ................................................................................................................... 3987
Recommendation Table 35 — Recommendations for self-measuring 
and monitoring blood pressure (see Evidence Table 48) ................... 3987
Recommendation Table 36 — Recommendations for multi/ 
interdisciplinary blood pressure management (see Evidence 
Table 49) ................................................................................................................... 3987
List of tables
Table 1 Classes of recommendations .......................................................... 3918
Table 2 Levels of evidence ................................................................................ 3919
Table 3 New recommendations .................................................................... 3920
Table 4 Revised recommendations ............................................................... 3923
Table 5 Comparison of office, home, and ambulatory blood pressure 
measurement thresholds for elevated blood pressure and 
hypertension .....................................................................................................................
3933
Table 6 Comparison of ambulatory and home blood pressure 
monitoring ..................................................................................................................
3934
Table 7 Key illness representations and treatment beliefs: how these 
apply to communicating a hypertension diagnosis to the patient 
(note that gender influences these representations) ............................ 3945
Table 8 Routine tests recommended in the initial work-up of a 
patient with elevated blood pressure or hypertension ........................ 3946
Table 9 Optional tests that may be used as clinically indicated in the initial 
work-up of a patient with elevated blood pressure or hypertension to 
assess hypertension-mediated organ damage or established 
cardiovascular disease ...................................................................................................... 3947
Table 10 Current definition of resistant hypertension ........................ 3950
Table 11 Conditions found to cause pseudo-resistance or resistance 
to blood pressure-lowering treatment ........................................................ 3950
Table 12 Drugs and conditions that affect aldosterone, renin, and 
aldosterone-to-renin ratio ................................................................................ 3951
Table 13 Optional tests that should be used to screen for secondary 
hypertension in the presence of suggestive signs, symptoms, or 
medical history ....................................................................................................... 3952
Table 14 Initiation of blood pressure-lowering treatment based on 
confirmed blood pressure category and cardiovascular disease risk
3963
Table 15 What to do and what not to do ................................................ 3989
List of figures
Figure 1 Pathophysiology of elevated blood pressure and 
hypertension ........................................................................................................... 3928
Figure 2 Persistently elevated blood pressure and hypertension lead to 
hypertension-mediated organ damage and cardiovascular disease .....
3929
Figure 3 Summary of office blood pressure measurement ................ 3931
Figure 4 Summary of home blood pressure measurement ................ 3932
Figure 5 Summary of ambulatory blood pressure measurement .... 3933
Figure 6 Blood pressure categories .............................................................. 3937
Figure 7 Sufficiently high cardiovascular risk conditions that warrant 
blood pressure-lowering treatment among adults with elevated 
blood pressure ....................................................................................................... 3938
Figure 8 Cardiovascular disease risk modifiers to consider for 
up-classification of risk ........................................................................................ 3940
Figure 9 Summary of cardiovascular disease risk-stratification 
approach for blood pressure treatment in adults with elevated 
blood pressure ....................................................................................................... 3942
Figure 10 Protocol for confirming hypertension diagnosis ................. 3944
Figure 11 Definitions, assessments, and potential interventions for 
the three phases of adherence to BP-lowering medications ............. 3946
Figure 12 Tests and criteria for defining hypertension-mediated 
organ damage and considerations for their use in clinical practice
3949
Figure 13 Summary of primary aldosteronism as a common form of 
secondary hypertension ..................................................................................... 3952


<!-- PAGE 6 -->

### Page 6

Figure 14 Summary of renovascular disease as a common form of 
secondary hypertension ..................................................................................... 3953
Figure 15 Summary of obstructive sleep apnoea as a common form 
of secondary hypertension ............................................................................... 3953
Figure 16 Physical activity according to different types of exercise 
and reduction of blood pressure and overall cardiovascular disease 
risk ............................................................................................................................... 3955
Figure 17 Effects of main lifestyle factors on blood pressure and 
cardiovascular risk reduction ........................................................................... 3956
Figure 18 Practical algorithm for pharmacological blood pressure 
lowering .................................................................................................................... 3960
Figure 19 Central Illustration ........................................................................... 3961
Figure 20 Systolic blood pressure categories and treatment target 
range ........................................................................................................................... 3965
Figure 21 Frailty assessment in the management of blood pressure
3972
Figure 22 Management of resistant hypertension .................................. 3981
Figure 23 Patient-centred care ....................................................................... 3986
Figure 24 The five dimensions of adherence (WHO, 2003) applied 
to hypertension ..................................................................................................... 3988
Abbreviations and acronyms
ABI
Ankle–brachial index
ABPM
Ambulatory blood pressure monitoring
ACCORD
Action to Control Cardiovascular Risk in Diabetes
ACE
Angiotensin-converting enzyme
ACR
Albumin:creatinine ratio
AF
Atrial fibrillation
AHI
Apnoea–hypopnoea index
ALARA
As low as reasonably achievable
ALLHAT
Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack
AOBP
Automated office blood pressure (measurement)
ARB
Angiotensin receptor blocker
ARNi
Angiotensin receptor-neprilysin inhibitor
ARR
Aldosterone-to-renin ratio
ASCVD
Atherosclerotic cardiovascular disease
BMI
Body mass index
BP
Blood pressure
BSA
Body surface area
CAC
Coronary artery calcium
CAD
Coronary artery disease
CCB
Calcium channel blocker
CHAP
Chronic Hypertension and Pregnancy
CI
Confidence interval
CKD
Chronic kidney disease
CKD-EPI
Chronic Kidney Disease Epidemiology 
Collaboration
COVID-19
Coronavirus disease 2019
CPAP
Continuous positive airway pressure
CPG
Clinical Practice Guidelines
CT
Computed tomography
CVD
Cardiovascular disease
DASH
Dietary Approaches to Stop Hypertension
DBP
Diastolic blood pressure
DECIDE-Salt
Diet, ExerCIse and carDiovascular hEalth–Salt
EACTS
European Association for Cardio-Thoracic Surgery
ECG
Electrocardiogram eGFR
Estimated glomerular filtration rate
EPIC
European Prospective Investigation into Cancer 
and Nutrition
ESC
European Society of Cardiology
ESH
European Society of Hypertension
ESPRIT
Effects of intensive Systolic blood Pressure lowering 
treatment in reducing RIsk of vascular evenTs
FMD-RVH
Fibromuscular dysplasia-induced renovascular 
hypertension
GFR
Glomerular filtration rate
GLP-1
Glucagon-like peptide-1
GP
General practitioner
HbA1c
Glycated haemoglobin
HBPM
Home blood pressure monitoring
HDL
High-density lipoprotein
HFpEF
Heart failure with preserved ejection fraction
HF(m)rEF
Heart failure with (mildly) reduced ejection 
fraction
HIV
Human immunodeficiency virus
HMOD
Hypertension-mediated organ damage i.m.
Intramuscular i.v.
Intravenous
KDIGO
Kidney Disease: Improving Global Outcomes
LA
Left atrial
LDL
Low-density lipoprotein
LV
Left ventricular
LVH
Left ventricular hypertrophy
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging
NNT
Number needed to treat
NT-proBNP
N-terminal pro-brain natriuretic peptide
OSAS
Obstructive sleep apnoea syndrome
PPGL
Phaeochromocytoma/paraganglioma
PREOP-ACEI
Prospective Randomized Evaluation of Preoperative 
Angiotensin-Converting Enzyme Inhibition
PREMs
Patient-Reported Experience Measures
PROMS
Patient-Reported Outcome Measures
PTRA
Percutaneous transluminal renal angioplasty
PWV
Pulse wave velocity
RAAS
Renin-angiotensin-aldosterone system
RADIANCE-HTN
A Study of the Recor Medical Paradise System in 
Clinical Hypertension
RAS
Renin–angiotensin system
RCT
Randomized controlled trial
RVH
Renovascular hypertension
RWT
Relative wall thickness
SBP
Systolic blood pressure
SCORE2
Systematic COronary Risk Evaluation 2
SCORE2-OP
Systematic COronary Risk Evaluation 2–Older 
Persons
SGLT2
Sodium–glucose co-transporter 2
SNP
Single-nucleotide polymorphism
SNS
Sympathetic nervous system
SPC
Single-pill combination
SPRINT
Systolic Blood Pressure Intervention Trial
SSaSS
Salt Substitute and Stroke Study
STEP
Strategy of Blood Pressure Intervention in Elderly 
Hypertensive Patients
STEP-1
Semaglutide Treatment Effect in People with 
Obesity
ESC Guidelines                                                                                                                                                                                          3917


<!-- PAGE 7 -->

### Page 7

TIA
Transient ischaemic attack
TRIUMPH
Treating Resistant Hypertension Using Lifestyle 
Modification to Promote Health
TSH
Thyroid-stimulating hormone
WHO
World Health Organization
WML
White matter lesion
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription and to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given topic 
and are regularly updated when warranted by new evidence. ESC Policies 
and Procedures for formulating and issuing ESC Guidelines can be 
found on the ESC website (https://www.escardio.org/Guidelines/Clinical- 
Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). 
This guideline version updates and replaces the previous version 
from 2018.
The Members of this task force were selected by the ESC to include 
professionals involved in the medical care of patients with this path­
ology, as well as patient representatives and methodologists. The se­
lection procedure included an open call for authors and aimed to 
include members from across the whole of the ESC region and 
from relevant ESC Subspecialty Communities. Consideration was gi­
ven to diversity and inclusion, notably with respect to gender and 
country of origin. The task force performed a critical review and 
evaluation of the published literature on diagnostic and therapeutic 
approaches including assessment of the risk-benefit ratio. The strength 
of every recommendation and the level of evidence supporting them 
were weighed and scored according to predefined scales as outlined in 
Tables 1 and 2 below. Patient-Reported Outcome Measures (PROMs) 
and Patient-Reported Experience Measures (PREMs) were also evaluated 
as the basis for recommendations and/or discussion in these guidelines. 
The task force followed ESC voting procedures and all approved recom­
mendations were subject to a vote and achieved at least 75% agreement 
among voting members. Members of the task force with declared inter­
ests on specific topics were asked to abstain from voting on related 
recommendations.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules, 
which can be found on the ESC website (http://www.escardio.org/ 
guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. Funding for the development 
of ESC Guidelines is derived entirely from the ESC with no involvement 
of the healthcare industry.
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2024


<!-- PAGE 8 -->

### Page 8

The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. In addition to review by the CPG 
Committee, ESC Guidelines undergo multiple rounds of double-blind 
peer review by external experts, including members from across the 
whole of the ESC region, all National Cardiac Societies of the ESC 
and from relevant ESC Subspecialty Communities. After appropriate 
revisions, the guidelines are signed off by all the experts in the task 
force. The finalized document is signed off by the CPG Committee 
for publication in the European Heart Journal.
ESC Guidelines are based on analyses of published evidence, chiefly 
on clinical trials and meta-analyses of trials, but potentially including 
other types of studies. Evidence tables summarizing key information 
from relevant studies are generated early in the guideline development 
process to facilitate the formulation of recommendations, to enhance 
comprehension of recommendations after publication, and reinforce 
transparency in the guidelines development process. The tables are 
published in their own section of ESC Guidelines and reference specific 
recommendation tables.
Off-label use of medication may be presented in these guidelines if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent;
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
This 2024 document updates the 2018 ESC/European Society of 
Hypertension (ESH) Guidelines on the management of arterial hyper­
tension.1 While the current document builds on prior guidelines, it 
also incorporates important updates and new recommendations based 
on current evidence. For example: 
(1) The title has changed from ‘Guidelines on the management of ar­
terial hypertension’ to ‘Guidelines on the management of elevated 
blood pressure and hypertension’. This is based on evidence that 
the risk for cardiovascular disease (CVD) attributable to blood 
pressure (BP) is on a continuous exposure scale, not a binary scale 
of normotension vs. hypertension.2,3 Updated evidence also in­
creasingly demonstrates the benefit on CVD outcomes of 
BP-lowering medications among persons with high CVD risk and 
BP levels that are elevated but that do not meet traditional thresh­
olds used to define hypertension. The term ‘arterial’ is removed 
from the title of the 2024 Guidelines, as arterial hypertension can 
also occur in the pulmonary arteries, which is not a focus here.
(2) The 2024 Guidelines continue to define hypertension as office sys­
tolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. However, a 
new BP category called ‘Elevated BP’ is introduced. Elevated BP is 
defined as an office systolic BP of 120–139 mmHg or diastolic BP 
of 70–89 mmHg.
(3) A major, evidence-based change in the 2024 Guidelines is the rec­
ommendation to pursue a target systolic BP of 120–129 mmHg 
among adults receiving BP-lowering medications. There are several 
important caveats to this recommendation, including: (i) the re­
quirement that treatment to this BP target is well tolerated by 
the patient, (ii) the fact that more lenient BP targets can be consid­
ered in persons with symptomatic orthostatic hypotension, those 
aged 85 years or over, or those with moderate-to-severe frailty 
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3919


<!-- PAGE 9 -->

### Page 9

or limited life expectancy, and (iii) a strong emphasis on 
out-of-office BP measurement to confirm the systolic BP target 
of 120–129 mmHg is achieved. For those selected individual cases 
where a target systolic BP of 120–129 mmHg is not pursued, either 
due to intolerance or the existence of conditions that favour a 
more lenient BP target, we recommend targeting a BP that is as 
low as reasonably achievable. Personalized clinical decision-making 
and shared decisions with the patient are also emphasized.
(4) Another important change in the 2024 Guidelines compared with 
earlier versions is the increased focus on evidence related to fatal 
and non-fatal CVD outcomes rather than surrogate outcomes such 
as BP lowering alone. Except for lifestyle interventions and low-risk 
non-pharmacological interventions aimed at implementation or care 
delivery, the current guidelines require that, for a Class I recommen­
dation to be made for a drug or procedural intervention, the evidence 
must show benefit on CVD outcomes and not only BP lowering.
(5) The task force comprised of a balanced representation of males 
and females.
(6) The present guidelines consider sex and gender as an integral com­
ponent throughout the document, rather than in a separate section 
at the end. In this document, sex is the biological condition of being 
female or male from conception, based on genes, and gender is the 
socio-cultural dimension of being a woman or a man in a given soci­
ety, based on gender roles, gender norms, gender identity, and gen­
der relations valid in the respective society at a given timepoint.4,5
(7) The 2024 Guidelines are written to make them more ‘user friendly’. 
Input from general practitioners (GPs) was obtained in this regard, 
and one task force member is a GP. Given the ageing population in 
Europe, there was also a focus on tailoring treatment with respect to 
frailty and into older age, which is addressed in multiple sections. 
Moreover, patient input and their lived experiences are considered 
throughout. We also now include evidence tables in the 
Supplementary section to provide improved transparency regarding 
our recommendations. As appropriate, readers who wish to seek add­
itional details and information are referred to the Supplementary data 
online and to the 
ESC CardioMed.6
(8) The task force recognized that a major challenge in guideline usage 
is poor implementation. This likely contributes to suboptimal con­
trol of hypertension.7–9 To address this, a dedicated section on im­
plementation is included in the Supplementary data online. 
Moreover, through a new initiative, we include information from 
national societies following a survey on guideline implementation 
completed during the national society peer review of the guidelines 
document. It is hoped this information may help inform national so­
cieties about potential barriers to implementation.
2.1. What is new
These 2024 Guidelines contain a number of new and revised recom­
mendations, which are summarized in Tables 3 and 4, respectively.
Table 3 New recommendations
Recommendations
Classa
Levelb
5. Measuring blood pressure
It is recommended to measure BP using a validated and calibrated device, to enforce the correct measurement technique, and to apply a 
consistent approach to BP measurement for each patient.
I
B
Out-of-office BP measurement is recommended for diagnostic purposes, particularly because it can detect both white-coat hypertension 
and masked hypertension. Where out-of-office measurements are not logistically and/or economically feasible, then it is recommended that 
the diagnosis be confirmed with a repeat office BP measurement using the correct standardized measurement technique.
I
B
Most automated oscillometric monitors have not been validated for BP measurement in AF; BP measurement should be considered using a 
manual auscultatory method in these circumstances, where possible.
IIa
C
An assessment for orthostatic hypotension (≥20 systolic BP and/or ≥10 diastolic BP mmHg drop at 1 and/or 3 min after standing) should be 
considered at least at the initial diagnosis of elevated BP or hypertension and thereafter if suggestive symptoms arise. This should be 
performed after the patient is first lying or sitting for 5 min.
IIa
C
6. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment
It is recommended to use a risk-based approach in the treatment of elevated BP, and individuals with moderate or severe CKD, established 
CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia are considered at increased risk for CVD events.
I
B
It is recommended that, irrespective of age, individuals with elevated BP and a SCORE2 or SCORE2-OP CVD risk of ≥10% be considered at 
increased risk for CVD for the purposes of risk-based management of their elevated BP.
I
B
SCORE2-Diabetes should be considered to estimate CVD risk among type 2 diabetes mellitus patients with elevated BP, particularly if they 
are <60 years of age.
IIa
B
History of pregnancy complications (gestational diabetes, gestational hypertension, pre-term delivery, pre-eclampsia, one or more 
stillbirths, and recurrent miscarriage) are sex-specific risk modifiers that should be considered to up-classify individuals with elevated BP and 
borderline increased 10-year CVD risk (5% to <10% risk).
IIa
B
High-risk ethnicity (e.g. South Asian), family history of premature onset atherosclerotic CVD, socio-economic deprivation, auto-immune 
inflammatory disorders, HIV, and severe mental illness are risk modifiers shared by both sexes that should be considered to up-classify 
individuals with elevated BP and borderline increased 10-year CVD risk (5% to <10% risk).
IIa
B
After assessing 10-year predicted CVD risk and non-traditional CVD risk modifiers, if a risk-based BP-lowering treatment decision remains 
uncertain for individuals with elevated BP, measuring CAC score, carotid or femoral plaque using ultrasound, high-sensitivity cardiac troponin 
or B-type natriuretic peptide biomarkers, or arterial stiffness using pulse wave velocity, may be considered to improve risk stratification 
among patients with borderline increased 10-year CVD risk (5% to <10% risk) after shared decision-making and considering costs.
IIb
B
Continued


<!-- PAGE 10 -->

### Page 10

### 7 Diagnosing hypertension and investigating underlying causes

Opportunistic screening for elevated BP and hypertension should be considered: 
• At least every 3 years for adults aged <40 years.
• At least annually for adults aged ≥40 years.
IIa
C
In individuals with elevated BP who do not currently meet risk thresholds for BP-lowering treatment, a repeat BP measurement and risk 
assessment within 1 year should be considered.
IIa
C
Other forms of screening for hypertension (i.e. systematic screening, self-screening, and non-physician screening) may be considered, 
depending on their feasibility in different countries and healthcare systems.
IIb
B
In individuals with increased CVD risk where their screening office BP is 120–139/70–89 mmHg, it is recommended to measure BP out of 
office, using ABPM and/or HBPM or, if not logistically feasible, make repeated office BP measurements on more than one visit.
I
B
Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should be 
considered in the clinical work-up of patients with apparent resistant hypertension, if resources allow.
IIa
B
If moderate-to-severe CKD is diagnosed, it is recommended to repeat measurements of serum creatinine, eGFR, and urine ACR at 
least annually.
I
C
Coronary artery calcium scoring may be considered in patients with elevated BP or hypertension when it is likely to change patient management.
IIb
B
Patients with resistant hypertension should be considered for referral to clinical centres with expertise in hypertension management for 
further testing.
IIa
B
It is recommended that patients with hypertension presenting with suggestive signs, symptoms, or medical history of secondary 
hypertension are appropriately screened for secondary hypertension.
I
B
Screening for primary aldosteronism by renin and aldosterone measurements should be considered in all adults with confirmed 
hypertension (BP ≥ 140/90 mmHg).
IIa
B
8. Preventing and treating elevated blood pressure
Opportunistic screening with office BP measurements to monitor development of BP during late childhood and adolescence, especially 
if one or both parents have hypertension, should be considered to better predict development of adult hypertension and associated 
CVD risk.
IIa
B
It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy 
intake. It is also recommended to discourage consumption of sugar-sweetened beverages, such as soft drinks and fruit juices, starting 
at young age.
I
B
In patients with hypertension without moderate-to-advanced CKD and with high daily sodium intake, an increase of potassium intake by 
0.5–1.0 g/day—for example through sodium substitution with potassium-enriched salt (comprising 75% sodium chloride and 25% 
potassium chloride) or through diets rich in fruits and vegetables—should be considered.
IIa
A
In patients with CKD or taking potassium-sparing medication, such as some diuretics, ACE inhibitors, ARBs, or spironolactone, monitoring 
serum levels of potassium should be considered if dietary potassium is being increased.
IIa
C
It is recommended to take medications at the most convenient time of day for the patient, to establish a habitual pattern of medication 
taking to improve adherence.
I
B
In adults with elevated BP and low/medium CVD risk (<10% over 10 years), BP lowering with lifestyle measures is recommended and can 
reduce the risk of CVD.
I
B
In adults with elevated BP and sufficiently high CVD risk, after 3 months of lifestyle intervention, BP lowering with pharmacological 
treatment is recommended for those with confirmed BP ≥130/80 mmHg to reduce CVD risk.
I
A
It is recommended that in hypertensive patients with confirmed BP ≥140/90 mmHg, irrespective of CVD risk, lifestyle measures and 
pharmacological BP-lowering treatment is initiated promptly to reduce CVD risk.
I
A
It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.
I
A
Because the benefit in reducing CVD outcomes is uncertain in these settings, and noting that close monitoring of treatment tolerance is 
advised, BP-lowering treatment should only be considered from ≥140/90 mmHg (office) among persons meeting the following criteria: 
• pre-treatment symptomatic orthostatic hypotension;
• age ≥85 years;
• clinically significant moderate-to-severe frailty;
• and/or limited predicted lifespan (<3 years).
IIa
B
In cases where BP-lowering treatment is poorly tolerated and achieving a target systolic of 120–129 mmHg is not possible, it is 
recommended to target a systolic BP level that is ‘as low as reasonably achievable’ (ALARA principle).
I
A
Once BP is controlled and stable under BP-lowering therapy, at least a yearly follow-up for BP and other CVD risk factors should 
be considered.
IIa
C
Continued
ESC Guidelines                                                                                                                                                                                          3921


<!-- PAGE 11 -->

### Page 11

### 9 Managing specific patient groups or circumstances

Young adults
Comprehensive screening for the main causes of secondary hypertension is recommended in adults diagnosed with hypertension before 
the age of 40 years, except for obese young adults where it is recommended to start with an obstructive sleep apnoea evaluation.
I
B
Since SCORE2 has not been validated for individuals <40 years, screening for HMOD may be considered in such young individuals with 
elevated BP without other increased CVD risk conditions to identify additional individuals for possible medical treatment.
IIb
B
Hypertension in pregnancy
In consultation with an obstetrician, low- to moderate-intensity exercise is recommended in all pregnant women without contraindications 
to reduce the risk of gestational hypertension and pre-eclampsia.
I
B
HBPM and ABPM should be considered to exclude white-coat and masked hypertension, which are more common in pregnancy.
IIa
C
Older and frail patients
It is recommended that treatment of elevated BP and hypertension among older patients aged <85 years who are not moderately to 
severely frail follows the same guidelines as for younger people, provided BP-lowering treatment is well tolerated.
I
A
When initiating BP-lowering treatment for patients aged ≥85 years, and/or with moderate-to-severe frailty (at any age), long-acting 
dihydropyridine CCBs or RAS inhibitors should be considered, followed, if necessary, by a low-dose diuretic if tolerated, but preferably not 
a beta-blocker (unless compelling indications exist) or an alpha-blocker.
IIa
B
As the safety and efficacy of BP treatment is less certain in individuals with moderate or severe frailty, clinicians should consider screening 
older adults for frailty using validated clinical tests; frail patients’ health priorities and a shared-decision approach should be considered when 
deciding on BP treatments and targets.
IIa
C
If BP drops with progressing frailty, deprescription of BP-lowering medications (and other drugs that can reduce BP, such as sedatives and 
prostate-specific alpha-blockers) may be considered.
IIb
C
Hypertension and orthostatic hypotension
Before starting or intensifying BP-lowering medication, it is recommended to test for orthostatic hypotension, by first having the patient sit 
or lie for 5 min and then measuring BP 1 and/or 3 min after standing.
I
B
It is recommended to pursue non-pharmacological approaches as the first-line treatment of orthostatic hypotension among persons with 
supine hypertension. For such patients, it is also recommended to switch BP-lowering medications that worsen orthostatic hypotension to 
an alternative BP-lowering therapy and not to simply de-intensify therapy.
I
A
Chronic kidney disease
In hypertensive patients with CKD and eGFR >20 mL/min/1.73 m2, SGLT2 inhibitors are recommended to improve outcomes in the 
context of their modest BP-lowering properties.
I
A
Other conditions
BP-lowering drug treatment is recommended for people with pre-diabetes or obesity when confirmed office BP is ≥140/90 mmHg or when 
office BP is 130–139/80–89 mmHg and the patient is at predicted 10-year risk of CVD ≥10% or with high-risk conditions, despite a 
maximum of 3 months of lifestyle therapy.
I
A
In patients with a history of aortic valve stenosis and/or regurgitation who require BP-lowering treatment, RAS blockers should be 
considered as part of that treatment.
IIa
C
In patients with a history of moderate-to-severe mitral valve regurgitation who require BP-lowering treatment, RAS blockers should be 
considered as part of that treatment.
IIa
C
Renovascular hypertension
Renal artery angioplasty without stenting should be considered for patients with hypertension and haemodynamically significant renal artery 
stenosis due to fibromuscular dysplasia.
IIa
C
Renal artery angioplasty and stenting may be considered in patients with haemodynamically significant, atherosclerotic, renal artery stenosis 
(stenosis of 70%–99%, or 50%–69% with post-stenotic dilatation and/or significant trans-stenotic pressure gradient) with: 
• Recurrent heart failure, unstable angina, or sudden-onset flash pulmonary oedema despite maximally tolerated medical therapy;
• Resistant hypertension;
• Hypertension with unexplained unilaterally small kidney or CKD;
• Bilateral renal artery stenosis or unilateral renal artery stenosis in a solitary viable kidney.
IIb
C
Renal artery angioplasty is not recommended in patients without confirmed haemodynamically significant renal artery stenosis.
III
A
10. Acute and short-term lowering of blood pressure
In patients with intracerebral haemorrhage presenting with systolic BP ≥220 mmHg, acute reduction in systolic BP >70 mmHg from initial 
levels within 1 h of commencing treatment is not recommended.
III
B
Continued


<!-- PAGE 12 -->

### Page 12

### 11 Patient-centred care in hypertension

An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended as part of hypertension 
management.
I
C
Motivational interviewing should be considered for patients with hypertension at hospitals and community health centres to assist patients 
in controlling their BP and to enhance treatment adherence.
IIa
B
Physician–patient web communications are an effective tool that should be considered in primary care, including reporting on home BP 
readings.
IIa
C
Home BP measurement for managing hypertension by using self-monitored BP is recommended to achieve better BP control.
I
B
Self-measurement, when properly performed, is recommended due to positive effects on the acceptance of a diagnosis of hypertension, 
patient empowerment, and adherence to treatment.
I
C
Enhanced self-monitoring of BP using a device paired with a connected smartphone application may be considered, though evidence to date 
suggests that this may be no more effective than standard self-monitoring.
IIb
B
Multidisciplinary approaches in the management of patients with elevated BP and hypertension, including appropriate and safe task-shifting 
away from physicians are recommended to improve BP control.
I
A
© ESC 2024
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio (urine); AF, atrial fibrillation; ALARA, as low as reasonably achievable; 
ARB, angiotensin receptor blocker; BP, blood pressure; CAC, coronary artery calcium; CCB, calcium channel blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, 
estimated glomerular filtration rate; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeficiency virus; HMOD, 
hypertension-mediated organ damage; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, 
Systematic COronary Risk Evaluation 2–Older Persons; SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence.
Table 4 Revised recommendations
Recommendations in 2018 version
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
6. Definition and classification of elevated blood pressure and hypertension
It is recommended that BP be classified as optimal, 
normal, high–normal, or grades 1–3 hypertension, 
according to office BP.
I
C
It is recommended that BP be categorized as 
non-elevated BP, elevated BP, and hypertension to aid 
treatment decisions.
I
B
CV risk assessment with the SCORE system is 
recommended for hypertensive patients who are not 
already at high or very high risk due to established CVD, 
renal disease, or diabetes, a markedly elevated single 
risk factor (e.g. cholesterol), or hypertensive LVH.
I
B
SCORE2 is recommended for assessing 10-year risk of 
fatal and non-fatal CVD among individuals aged 40–69 
years with elevated BP who are not already considered 
at increased risk due to moderate or severe CKD, 
established CVD, HMOD, diabetes mellitus, or familial 
hypercholesterolaemia.
I
B
SCORE2-OP is recommended for assessing the 
10-year risk of fatal and non-fatal CVD among 
individuals aged ≥70 years with elevated BP who are 
not already considered at increased risk due to 
moderate or severe CKD, established CVD, HMOD, 
diabetes mellitus, or familial hypercholesterolaemia.
I
B
7. Diagnosing hypertension and investigating underlying causes
It is recommended that the diagnosis of hypertension 
should be based on: 
• Repeated office BP measurements on more than one 
visit, except when hypertension is severe (e.g. grade 3 
and especially in high-risk patients). At each visit, three 
BP measurements should be recorded, 1–2 min apart, 
and additional measurements should be performed if 
the first two readings differ by >10 mmHg. The 
patient’s BP is the average of the last two BP readings. 
Or
• Out-of-office BP measurement with ABPM and/or 
HBPM, provided that these measurements are 
logistically and economically feasible.
I
C
Where screening office BP is 140–159/90–99 mmHg, it is 
recommended that the diagnosis of hypertension should 
be based on out-of-office BP measurement with ABPM 
and/or HBPM. If these measurements are not logistically 
or economically feasible, then diagnosis can be made on 
repeated office BP measurements on more than one visit.
I
B
Where screening office BP is ≥160/100 mmHg: 
• It is recommended that BP 160–179/100–109 mmHg 
be confirmed as soon as possible (e.g. within 1 
month) preferably by either home or ambulatory BP 
measurements.
• It is recommended when BP ≥180/110 mmHg that 
hypertensive emergency be excluded.
I
C
Continued
ESC Guidelines                                                                                                                                                                                          3923


<!-- PAGE 13 -->

### Page 13

Echocardiography is recommended  in hypertensive 
patients when there are ECG abnormalities  or signs or 
symptoms of LV dysfunction.
I
B
Echocardiography is recommended in patients with 
hypertension and ECG abnormalities, or signs or 
symptoms of cardiac disease.
I
B
Echocardiography may be considered when the 
detection of LVH may influence treatment decisions.
IIb
B
Echocardiography may be considered in patients with 
elevated BP, particularly when it is likely to change 
patient management.
IIb
B
Ultrasound examination of the carotid arteries may be 
considered for the detection of asymptomatic 
atherosclerotic plaques or carotid stenosis in patients 
with documented vascular disease elsewhere.
IIb
B
Ultrasound examination of the carotid or femoral 
arteries for detecting plaque may be considered in 
patients with elevated BP or hypertension when it is 
likely to change patient management.
IIb
B
Measurement of PWV may be considered for 
measuring arterial stiffness.
IIb
B
Measurement of PWV may be considered in patients 
with elevated BP or hypertension when it is likely to 
change patient management.
IIb
B
8. Preventing and treating elevated blood pressure
Regular aerobic exercise (e.g. at least 30 min of 
moderate dynamic exercise on 5–7 days/week) is 
recommended.
I
A
Moderate intensity aerobic exercise of ≥150 min/week 
(≥30 min, 5–7 days/week) or alternatively 75 min of 
vigorous intensity aerobic exercise per week over 3 
days are recommended and should be complemented 
with low- or moderate-intensity dynamic or isometric 
resistance training (2–3 times/week) to reduce BP and 
CVD risk.
I
A
Body-weight control is indicated to avoid obesity (BMI 
>30 kg/m2 or waist circumference >102 cm in men and 
>88 cm in women), as is aiming at healthy BMI (about 
20–25 kg/m2) and waist circumference values (<94 cm in 
men and <80 cm in women) to reduce BP and CV risk.
I
A
It is recommended to aim for a stable and healthy BMI 
(20–25 kg/m2) and waist circumference values (<94 cm 
in men and <80 cm in women) to reduce BP and CVD 
risk.
I
A
Increased consumption of vegetables, fresh fruits, fish, 
nuts, and unsaturated fatty acids (olive oil); low 
consumption of red meat; and consumption of low-fat 
dairy products are recommended.
I
A
Adopting a healthy and balanced diet, such as the 
Mediterranean or DASH diets, is recommended to help 
reduce BP and CVD risk.
I
A
It is recommended to restrict alcohol consumption to: 
• Less than 14 units/week for men.
• Less than 8 units/week for women.
I
A
Men and women are recommended to drink less 
alcohol than the upper limit, which is about 100 g/week 
of pure alcohol. How this translates into number of 
drinks depends on portion size (the standards of which 
differ per country), but most drinks contain 8–14 g of 
alcohol per drink. Preferably, it is recommended to 
avoid alcohol to achieve the best health outcomes.
I
B
Among all anti-hypertensive drugs, ACE inhibitors, 
ARBs, beta-blockers, CCBs, and diuretics (thiazides and 
thiazide-like drugs, such as chlorthalidone and 
indapamide) have demonstrated effective reduction of 
BP and CV events in RCTs, and thus are indicated as the 
basis of anti-hypertensive treatment strategies.
I
A
Among all BP-lowering drugs, ACE inhibitors, ARBs, 
dihydropyridine CCBs, and diuretics (thiazides and 
thiazide-like drugs such as chlorthalidone and 
indapamide) have demonstrated the most effective 
reduction of BP and CVD events, and are therefore 
recommended as first-line treatments to lower BP.
I
A
It is recommended that if BP is not controlled with a 
three-drug combination, treatment should be 
increased by the addition of spironolactone or, if not 
tolerated, other diuretics such as amiloride or higher 
doses of other diuretics, a beta-blocker, or an 
alpha-blocker.
I
B
If BP is not controlled with a three-drug combination 
and in whom spironolactone is not effective or 
tolerated, treatment with eplerenone instead of 
spironolactone, or the addition of a beta-blocker if not 
already indicated and, next, a centrally acting 
BP-lowering medication, an alpha-blocker, hydralazine, 
or a potassium-sparing diuretic should be considered.
IIa
B
8. Preventing and treating elevated blood pressure (blood pressure targets)
It is recommended that the first objective of treatment 
should be to lower BP to <140/90 mmHg in all patients 
and, provided that the treatment is well tolerated, 
treated BP values should be targeted to 130/80 mmHg 
or lower in most patients.
I
A
To reduce CVD risk, it is recommended that treated 
systolic BP values in most adults be targeted to 120– 
129 mmHg, provided the treatment is well tolerated.
I
A
Continued


<!-- PAGE 14 -->

### Page 14

A diastolic BP target of <80 mmHg should be 
considered for all hypertensive patients, independent of 
the level of risk and comorbidities.
IIa
B
In cases where on-treatment systolic BP is at or below 
target (120–129 mmHg) but diastolic BP is not at target 
(≥80 mmHg), intensifying BP-lowering treatment to 
achieve an on-treatment diastolic BP of 70–79 mmHg 
may be considered to reduce CVD risk.
IIb
C
In older patients (aged ≥65 years) receiving 
BP-lowering drugs: 
• It is recommended that systolic BP should be 
targeted to a BP range of 130–139 mmHg.
I
A
Because the CVD benefit of an on-treatment systolic BP 
target of 120–129 mmHg may not generalize to the 
following specific settings, personalized and more lenient 
systolic BP targets (e.g. <140 mmHg): should be 
considered among patients meeting the following criteria: 
• pre-treatment, symptomatic, orthostatic 
hypotension;
• and/or age ≥85 years.
IIa
C
Because the CVD benefit of an on-treatment systolic BP 
target of 120–129 mmHg may not generalize to the 
following specific settings, personalized and more lenient 
BP targets (e.g. <140/90 mmHg) may be considered 
among patients meeting the following criteria: 
• clinically significant, moderate to severe frailty at any 
age;
• and/or limited predicted lifespan (<3 years).
IIb
C
8. Preventing and treating elevated blood pressure (renal denervation)
Use of device-based therapies is not recommended for 
the routine treatment of hypertension, unless in the 
context of clinical studies and RCTs, until further 
evidence regarding their safety and efficacy becomes 
available.
III
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation may 
be considered for resistant hypertension patients who 
have BP that is uncontrolled despite a three 
BP-lowering drug combination (including a thiazide or 
thiazide-like diuretic), and who express a preference to 
undergo renal denervation after a shared risk-benefit 
discussion and multidisciplinary assessment.
IIb
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation may 
be considered for patients with both increased CVD 
risk and uncontrolled hypertension on fewer than three 
drugs, if they express a preference to undergo renal 
denervation after a shared risk-benefit discussion and 
multidisciplinary assessment.
IIb
A
Due to a lack of adequately powered outcomes trials 
demonstrating its safety and CVD benefits, renal 
denervation is not recommended as a first-line 
BP-lowering intervention for hypertension.
III
C
Renal denervation is not recommended for treating 
hypertension in patients with moderately to severely 
impaired renal function (eGFR <40 mL/min/1.73 m2) or 
secondary causes of hypertension, until further 
evidence becomes available.
III
C
9.1. Managing specific patient groups or circumstances
Hypertension in pregnancy
In women with gestational hypertension, pre-existing 
hypertension superimposed by gestational 
hypertension, or with hypertension and subclinical 
organ damage or symptoms, initiation of drug 
treatment is recommended when systolic BP is  
≥140 mmHg or diastolic BP ≥90 mmHg.
I
C
In women with gestational hypertension, starting drug 
treatment is recommended for those with confirmed 
systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3925


<!-- PAGE 15 -->

### Page 15

In all other cases, initiation of drug treatment is 
recommended when systolic BP is ≥150 mmHg or 
diastolic BP is ≥95 mmHg.
I
C
In pregnant women with chronic hypertension, starting 
drug treatment is recommended for those with 
confirmed office systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg.
I
B
In women with chronic and gestational hypertension, it 
is recommended to lower BP below 140/90 mmHg but 
not below 80 mmHg for diastolic BP.
I
C
Systolic BP ≥170 mmHg or diastolic BP ≥110 mmHg in 
a pregnant woman is an emergency, and admission to 
hospital is recommended.
I
C
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in 
pregnancy can indicate an emergency, and immediate 
hospitalization should be considered.
IIa
C
Diabetes
Antihypertensive drug treatment is recommended for 
people with diabetes when office BP is ≥140/90 mmHg.
I
A
In most adults with elevated BP and diabetes, after a 
maximum of 3 months of lifestyle intervention, BP 
lowering with pharmacological treatment is 
recommended for those with confirmed office BP 
≥130/80 mmHg to reduce CVD risk.
I
A
In people with diabetes receiving BP-lowering 
drugs it is recommended: 
• To target SBP to 130 mmHg and <130 mmHg if 
tolerated, but not <120 mmHg.
• In older people (aged ≥65 years aged), to target to an 
SBP range of 130–139 mmHg.
I
A
In persons with diabetes who are receiving BP-lowering 
drugs, it is recommended to target systolic BP to 120– 
129 mmHg, if tolerated.
I
A
Chronic kidney disease
In patients with diabetic or non-diabetic CKD, it is 
recommended that an office BP ≥140/90 mmHg be 
treated with lifestyle advice and BP-lowering 
medication. 
I
A
In patients with diabetic or non-diabetic 
moderate-to-severe CKD and confirmed BP ≥130/80  
mmHg, lifestyle optimization and BP-lowering 
medication are recommended to reduce CVD risk, 
provided such treatment is well tolerated.
I
A
In patients with diabetic or non-diabetic CKD:
In adults with moderate-to-severe CKD who are 
receiving BP-lowering drugs and who have eGFR >30  
mL/min/1.73 m2, it is recommended to target systolic 
BP to 120–129 mmHg, if tolerated. Individualized BP 
targets are recommended for those with lower eGFR 
or renal transplantation.
I
A
• It is recommended to lower systolic BP to a range of 
130–139 mmHg.
I
A
• Individualized treatment should be considered 
according to its tolerability and impact on renal 
function and electrolytes.
IIa
C
RAS blockers are more effective at reducing 
albuminuria than other antihypertensive agents, and are 
recommended as part of the treatment strategy in 
hypertensive patients in the presence of 
microalbuminuria or proteinuria.
I
A
ACE inhibitors or ARBs are more effective at reducing 
albuminuria than other BP-lowering agents and should 
be considered as part of the treatment strategy for 
patients with hypertension and microalbuminuria or 
proteinuria.
IIa
B
Heart failure
In patients with HFrEF, it is recommended that 
BP-lowering treatment comprises an ACE inhibitor or 
ARB, a beta-blocker and diuretic and/or MRA if 
required.
I
A
In patients with symptomatic HFrEF/HFmrEF, the 
following treatments with BP-lowering effects are 
recommended to improve outcomes: ACE inhibitors 
(or ARBs if ACE inhibitors are not tolerated) or ARNi, 
beta-blocker, MRA, and SGLT2 inhibitors.
I
A
In patients with HFpEF, because no specific drug has 
proven its superiority, all major agents can be used.
I
C
In hypertensive patients with symptomatic HFpEF, 
SGLT2 inhibitors are recommended to improve 
outcomes in the context of their modest BP-lowering 
properties.
I
A
In patients with symptomatic HFpEF who have BP 
above target, ARBs and/or MRAs may be considered to 
reduce heart failure hospitalizations and reduce BP.
IIb
B
Continued


<!-- PAGE 16 -->

### Page 16

Stroke
In all hypertensive patients with ischaemic stroke or 
TIA, an SBP target range of 120–130 mmHg should be 
considered.
IIa
B
In patients with confirmed BP ≥130/80 mmHg with a 
history of TIA or stroke a systolic BP target of 120–129  
mmHg is recommended to reduce CVD outcomes, 
provided treatment is tolerated.
I
A
Different ethnic groups
In black patients, initial antihypertensive treatment 
should include a diuretic or a CCB, either in 
combination or with a RAS blocker.
I
B
In black patients from Sub-Saharan Africa who require 
BP-lowering treatment, combination therapy including 
a CCB combined with either a thiazide diuretic or a 
RAS blocker should be considered.
IIa
B
Resistant hypertension
Recommended treatment of resistant hypertension is: 
• Reinforcement of lifestyle measures, especially 
sodium restriction.
• Addition of low-dose spironolactone to existing 
treatment.
• Or the addition of further diuretic therapy if 
intolerant to spironolactone, with either eplerenone, 
amiloride, a higher dose thiazide/thiazide-like 
diuretic, or a loop diuretic.
• Or the addition of bisoprolol or doxazosin.
I
B
In patients with resistant hypertension and 
uncontrolled BP despite use of first-line BP-lowering 
therapies, the addition of spironolactone to existing 
treatment should be considered.
IIa
B
In patients with resistant hypertension in whom 
spironolactone is not effective or tolerated, treatment 
with eplerenone instead of spironolactone, or the 
addition of a beta-blocker if not already indicated, and, 
next, a centrally acting BP-lowering medication, an 
alpha-blocker, or hydralazine, or a potassium-sparing 
diuretic should be considered.
IIa
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation may 
be considered for resistant hypertension patients who 
have BP that is uncontrolled despite a three 
BP-lowering drug combination, and who express a 
preference to undergo renal denervation after a shared 
risk-benefit discussion and multidisciplinary assessment.
IIb
B
10. Acute and short-term management of blood pressure
In patients with acute intracerebral haemorrhage:
In patients with intracerebral haemorrhage, immediate 
BP lowering (within 6 h of symptom onset) should be 
considered to a systolic target 140–160 mmHg to 
prevent haematoma expansion and improve functional 
outcome.
IIa
A
• Immediate BP lowering is not recommended for 
patients with systolic BP <220 mmHg.
III
A
• In patients with systolic BP ≥220 mmHg, careful 
acute BP lowering with i.v. therapy to <180 mmHg 
should be considered.
IIa
B
In hypertensive patients with an acute cerebrovascular event, anti-hypertensive 
treatment is recommended:
For patients with ischaemic stroke or TIA and an 
indication for blood pressure lowering, it is 
recommended that BP lowering therapy be 
commenced before hospital discharge.
I
B
• Immediately for TIA.
I
A
• After several days in ischaemic stroke.
I
A
In severe hypertension, drug treatment with i.v. 
labetalol, oral methyldopa, or nifedipine is 
recommended.
I
C
In severe hypertension in pregnancy, drug treatment 
with i.v. labetalol, oral methyldopa, or oral nifedipine is 
recommended. Intravenous hydralazine is a second-line 
option.
I
C
© ESC 2024
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio (urine); ARB, angiotensin receptor blocker; ARNi, angiotensin 
receptor–neprilysin inhibitor; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; 
DASH, Dietary Approaches to Stop Hypertension; eGFR, estimated glomerular filtration rate; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection 
fraction; HF(m)rEF, heart failure with (mildly) reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMOD, hypertension-mediated organ damage; i.v., 
intravenous; LVH, left ventricular hypertrophy; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; RCT, randomized controlled trial; SBP, systolic blood 
pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons; SGLT2, sodium–glucose co-transporter 2; TIA, 
transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3927


<!-- PAGE 17 -->

### Page 17

### 3 Pathophysiology of elevated

blood pressure and hypertension
Persistently high BP in systemic arteries is the hallmark of hypertension, 
which is the most important modifiable risk factor for all-cause 
and CVD morbidity and mortality globally.2 Most patients with 
hypertension have essential or primary hypertension, where the exact 
cause remains unknown, while an estimated 10% have secondary 
hypertension, with an identifiable cause (notably some studies indicate 
that the prevalence of secondary hypertension may be substantially 
higher, with modern systematic screening).10
The pathophysiology of hypertension involves complex interactions 
between environmental and behavioural factors, genes, hormonal net­
works, and multiple organ systems (renal, cardiovascular, and central 
nervous system11) (Figure 1). In addition, vascular and immune 
mechanisms are involved.12 Dysregulation of these processes leads to 
hypertension, which if uncontrolled, can lead to hypertension-mediated 
organ damage (HMOD) and adverse CVD outcomes.
Details on the pathophysiological processes, molecular mechanisms, 
and environmental and psychosocial elements that underlie hypertension 
are provided in the Supplementary text (Supplementary data online).
4. Clinical consequences of 
elevated blood pressure  
and hypertension
Longstanding hypertension causes organ damage and ultimately leads 
to cardiovascular, cerebrovascular, and clinical renal disease, which 
are all major contributors to the global burden of chronic disease 
Physical activity
Sedentary behaviour
Sleep quality/quantity
Dietary patterns
Sodium and potassium intake
Obesity
Alcohol consumption
Drugs or substances that increase BP
Geopolitical status
Noise pollution
Air pollution
Climate
Salt sensitivity
Pressure- natriuresis
RAAS
Renal ischaemia
RAAS
Endothelin system
Sex hormones
Endothelial dysfunction
Small artery remodelling
Large artery stiﬀness         
Biological sex
BP-associated SNPs
Monogenic forms of hypertension
Epigenetic and foetal programming
Stress
Low socio-economic status
Social deprivation
Healthcare access
Gender identity, roles and norms
Gender-based violence
Discrimination
B
e h
a vi o
u ra l 
fa ct o
rs
G
e n
et ic
 f a
ct o
rs
S
o ci o
-e c
o n
o m
ic
 a n
d 
p sy c
h o
s o
ci al
 f a
ct o
rs
E
n vi r
o n
m e
n ta l 
fa ct o
rs
H
o r
m o
n a
l 
m e
c h
a n
i s
m s
R
e n
a l 
m e
c h
a n
i s
m s
N
e u
r a
l 
m e
c h
a n
i s
m s
V
a s
c u
l a
r
 
m e
c h
a n
i s
m s
Autonomic nervous system
(SNS/PNS)
Baroreceptor reﬂex
Figure 1 Pathophysiology of elevated blood pressure and hypertension. BP, blood pressure; PNS, parasympathetic nervous system; RAAS, 
renin-angiotensin-aldosterone system; SNP, single-nucleotide polymorphism; SNS, sympathetic nervous system. Complex interplay between genes, 
environmental, and behavioural factors, organs, physiological systems, and neurohumoral processes contribute to BP regulation. Dysfunction of these 
processes leads to hypertension. The contribution of these factors to elevated BP and hypertension may differ among males and females.


<!-- PAGE 18 -->

### Page 18

(Figure 2).2,13–22 Organs adversely affected by elevated BP and hyper­
tension include the heart, brain, kidneys, eyes, and vessels (macrocir­
culation and microcirculation in organs with low resistance, such as 
the brain or kidney23), which undergo structural and functional 
changes. Although factors besides BP can contribute to these changes 
(i.e. dyslipidaemia, hyperglycaemia), we use the term ‘hypertension- 
mediated organ damage’ to indicate the presence of subclinical 
complications of hypertension that indicate high risk for subsequent 
clinical events. HMOD may have different profiles in men and women; 
for instance, left ventricular hypertrophy (LVH) and left atrial dilatation 
are more frequent in women.24–28
Evidence of HMOD usually indicates long-standing elevated BP and/ 
or hypertension and confers incremental prognostic information re­
garding CVD risk in all BP categories.29–31 Unless treated, HMOD 
can progress from asymptomatic to symptomatic, ultimately resulting 
in overt CVD events.31
The pathophysiological mechanisms underlying HMOD in the heart, 
brain, kidneys, vessels, and eyes are detailed in the Supplementary text
(Supplementary data online). The clinical consequences of HMOD, es­
pecially cerebrovascular disease (stroke and cognitive decline), kidney 
disease (acute and chronic), and heart disease [heart failure, atrial fibril­
lation (AF), ischaemic heart disease, and valvular disease] are also dis­
cussed in the Supplementary text (Supplementary data online). In 
addition, the Supplement highlights the impact of different measures 
of BP on CVD risk, including systolic BP, diastolic BP, pulse pressure, 
and BP variability.22,32–36
5. Measuring blood pressure
5.1. Introduction and pertinent definitions
This section reviews practical aspects of BP measurement, including 
technique and clinical validation of devices. It also reviews the evi­
dence for the most appropriate BP measurement methods when 
screening populations for hypertension, diagnosing hypertension, 
and managing patients receiving BP-lowering interventions. The cur­
rent guidelines promote use of out-of-office measurement for 
diagnosis and ongoing management of hypertension, reflecting in­
creasing evidence for the stronger relationship of home and ambula­
tory monitoring with outcomes, the ability to detect white-coat 
and masked hypertension, new BP treatment targets as low as 
120–129 mmHg systolic (Table 5), and evidence supporting enabling 
patient involvement and shared decision-making.
Definitions:
Systolic BP: arterial BP during systole (maximum arterial 
pulsatile pressure). This is measured using an auscultatory device at 
the onset of the first Korotkoff sound. Oscillometric devices esti­
mate systole using an algorithm that imputes from mean arterial 
pressure.37
Diastolic BP: arterial BP during diastole (minimum arterial pulsatile 
pressure). This is measured using an auscultatory device at the time of 
complete disappearance of the Korotkoff sounds (fifth sound). If there 
is no disappearance of sounds (no fifth sound) then the fourth 
See footnote for information on sex-differences
White matter lesions
Silent microinfarcts
Microbleeds
Brain atrophy 
Cognitive impairment
Vascular dementia
Ischaemic stroke
Cerebral haemorrhage
Brain
Microvascular remodelling
Hypertensive retinopathy
Eye
Atherosclerosis
Vascular calcification
Arterial stiffness
Large and medium arteries
Endothelial dysfunction
   Vasoreactivity
Vascular remodelling
Fibrosis and inflammation
   Peripheral vascular resistance 
Microcirculation
LVH
LA and LV dilatation
AF
Obstructive and non-obstructive CAD 
Myocardial Infarction 
Diastolic and/or systolic 
heart failure
Heart
Kidney
Glomerular arteriolar hypertension
Glomerulosclerosis
Albuminuria/Proteinuria
  GFR
Figure 2 Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease. AF, atrial 
fibrillation; CAD, coronary artery disease; GFR, glomerular filtration rate; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy. See the 
supplementary data online for detailed information on sex differences.  
ESC Guidelines                                                                                                                                                                                          3929


<!-- PAGE 19 -->

### Page 19

Korotkoff sound (muffling) is used to estimate diastolic BP. 
Oscillometric devices estimate diastole using an algorithm that 
imputes from mean arterial pressure.37
Inter-arm difference: systolic BP difference of >10 mmHg when 
BP is measured sequentially in each arm.38
Postural/orthostatic hypotension: decrement of ≥20 mmHg 
in systolic BP and/or ≥10 mmHg in diastolic BP when BP is measured 
in the standing position at 1 and/or 3 min after standing following a 
5-min period in the sitting or lying position.
White-coat hypertension: BP that is above the threshold for 
diagnosing hypertension in the office but below the threshold in home/ 
ambulatory settings, e.g. ≥140/90 mmHg in office but <135/85 mmHg 
at home/ambulatory daytime (or 24-h BP < 130/80 mmHg).
Masked hypertension: BP that is below the hypertension 
diagnostic threshold in the office but above the hypertension diagnostic 
threshold in home/ambulatory settings, e.g. <140/90 mmHg in clinic 
but ≥135/85 mmHg at home/ambulatory daytime (or 24-h BP 
≥130/80 mmHg).
Office BP: also known as clinic BP. The two terms are interchange­
able. This guidelines document uses ‘office BP’ preferentially. Of note, 
office BP can be measured manually or using an automated device. In 
addition, automated office BP (AOBP) can be conducted in a setting at­
tended by a healthcare professional or in an unattended fashion. Finally, 
not all office BP measurements are equal, with some facilities using a 
standardized method (which is recommended and outlined below) 
and others unfortunately using suboptimal approaches to office BP 
measurement.
Home BP measurement (HBPM): an out-of-office approach 
to measuring BP when the patient measures their own BP at home 
using a validated monitor (usually an upper-arm oscillometric cuff 
device).
Ambulatory BP measurement (ABPM): an out-of-office BP 
measurement that uses a fully automated oscillometric device, usually 
for a 24-h period, and measures BP at set intervals.
5.2. Practical recommendations for 
measuring blood pressure
5.2.1. Clinical validation of equipment for measuring 
blood pressure
A prerequisite of BP measurement is that it must be undertaken 
using a device that has been clinically validated and confirmed to 
be accurate. Of the commercially available oscillometric BP meas­
urement devices, as few as 6% have been adequately tested.39–41
National and international organizations provide lists of validated monitors 
(e.g. www.stridebp.org, www.validatebp.org).
Since the 2018 ESC/ESH Guidelines on the management of arter­
ial hypertension, three arbiters of device accuracy (the Association 
for the Advancement of Medical Instrumentation, the ESH, and the 
International Organization for Standardization) have published a 
universal standard for validating devices for measuring BP.42 This 
standard will likely become widely adopted. Validation standards 
and methodology need to be developed and implemented for novel 
BP measurement devices that are non-occlusive and ‘cuffless’.43,44
5.2.2. Office blood pressure measurement
All BP measurements can be influenced by circumstances of measure­
ment, including position, ambient temperature, the technique of meas­
urement, accuracy of equipment, and physical condition of the 
patient.45 For BP measurements in the office, we recommend following 
a standardized method (Figure 3).
Patient preparation: BP should be measured with the patient 
seated comfortably after 5 min of rest. Patients should avoid exercising 
and stimulants (caffeine, tobacco) for at least 30 min before measure­
ment. The patient’s bladder should be emptied if needed.46 Patients 
should be seated with their legs unfolded and their back supported at 
the time of measurement. The arm should be supported (to avoid iso­
metric exercise-induced increases in BP). Clothing at the location of the 
cuff placement should be removed; rolling up of shirt sleeves should be 
avoided as this can result in a tourniquet effect.
BP measurement technique: auscultatory or oscillometric 
techniques can be used to measure BP non-invasively. The manual aus­
cultatory approach is the traditional method of measuring systolic and 
diastolic BP at the brachial artery site using a stethoscope. In contrast, 
oscillometric devices compute mean arterial BP using the oscillation 
amplitude with cuff deflation (or inflation) and then estimate systolic 
and diastolic BP. Oscillometric devices can be semi-automated (taking 
one reading per activation) or fully automated (obtaining multiple read­
ings before averaging them). Oscillometric devices are not typically va­
lidated for use in AF, and the manual auscultatory method is preferred 
in these circumstances when feasible.47–49
BP cuff selection and positioning: an appropriately sized cuff 
should be used, as an under-sized or over-sized cuff will artificially 
elevate or reduce BP, respectively.50 The bladder length should be 
75%–100% and the width 35%–50% of the arm circumference. The 
arm circumference can be measured at the mid-point of the olecranon 
and the acromion but many cuffs include sizing indicators. The cuff 
should be positioned on the patient’s upper arm at the level of the heart 
with the lower edge of the cuff a few centimetres above the antecubital 
fossa. The stethoscope should not be placed under the cuff. In those 
with significant obesity where a correctly fitting upper arm cuff is not 
available, measurement at the lower arm or wrist can be considered 
as an alternative.51
BP measurement by manual auscultation: three BP mea­
surements should be taken, each 1–2 min apart, and additional mea­
surements only if the readings differ by >10 mmHg (e.g. this may 
occur with arrhythmias or white-coat effects). The BP recorded should 
be the average of the last two BP readings.
BP measurement using AOBP measurement: as noted 
above, AOBP using oscillometric devices may be obtained with (at­
tended) or without (unattended) clinicians or staff present. Clear evi­
dence regarding superiority of unattended vs. attended AOBP in 
managing BP to reduce rates of CVD is lacking; however, because BP 
readings may differ for unattended vs. attended measurements,52 we 
advise that a consistent approach be used depending on local resource 
and preference. AOBP monitors typically make three or six readings at 
1-min intervals and provide an average. AOBP correlates more closely 
with mean ABPM than with the manual auscultatory technique and may 
reduce measurement error and white-coat effects.53
Inter-arm BP difference: at the initial visit, BP should be measured 
in both arms to detect an inter-arm difference. Though devices allowing 
simultaneous measurement in both arms exist, sequential arm measure­
ment is considered sufficiently reliable.54,55 Measurement in the contra­
lateral arm should be undertaken once the three measurements in the 
index arm have been taken, and if a difference is detected, further meas­
urement in the original arm is indicated to ensure the difference is con­
sistent. If systolic BP differs by >10 mmHg between arms, subsequent 
measurements are obtained using the arm with the higher BP value. 
Significant inter-arm BP differences may reflect arterial stenosis or


<!-- PAGE 20 -->

### Page 20

coarctation of the aorta, which may require investigation. Also, of note, in 
some patients one arm is preferred to the other for routine BP measure­
ment (e.g. to avoid measurement of BP in an arm with an arteriovenous 
fistula or an arm where axillary lymph node dissection has occurred).
Postural/orthostatic hypotension: patients should be as­
sessed for orthostatic hypotension at the initial visit and if concerning 
symptoms arise. After 5 min of rest in the sitting or lying position, BP 
should be measured at 1 min and/or 3 min after standing, with a thresh­
old for orthostatic hypotension of ≥20/10 mmHg (systolic BP/diastolic 
BP) drop. Measurement after lying may be more sensitive for detecting 
orthostatic hypotension and may better predict falls but may be less 
feasible than measurement after sitting in clinical practice.56
Pulse assessment: heart rate should be recorded at the initial visit 
and arrhythmia excluded.
5.2.3. Home blood pressure measurement
HBPM is an out-of-office approach to measuring BP when the patient 
measures their own BP at home using a validated monitor (usually an 
upper-arm oscillometric cuff device).57,58 A consistent approach to 
>10
mmHg
1
2
3
4
5
6
7
8
Office blood pressure measurement
Measure after 5 min seated comfortably in a 
quiet environment
Use a validated device 
with an appropriate cuff 
size based on arm circumference
Place the BP cuff at the level 
of the heart with the patient's 
back and arm supported
Assess for orthostatic 
hypotension at Ist visit and 
thereafter by symptoms
Measure BP three times 
(1–2 min apart) and 
average the last 2 readings
Record heart rate and exclude arrhythmia 
by pulse palpation
Measure BP in both 
arms at the Ist visit to 
detect between arm 
differences
Obtain further measurements if the 
readings differ by 
>10 mmHg
90
62
Figure 3 Summary of office blood pressure measurement. BP, blood pressure.  
ESC Guidelines                                                                                                                                                                                          3931


<!-- PAGE 21 -->

### Page 21

HBPM should be used (Figure 4). Patients should be counselled to fol­
low the same preparation steps as used in clinics, which are outlined 
in Section 5.2.2. Two measurements should be taken at each measure­
ment session, performed 1–2 min apart. Measurements should be 
made twice a day (morning and evening) at the same time for a min­
imum of 3 days and up to 7 days.59 At the end of the measurement per­
iod, all readings are averaged. If the average after 3 days is close to the 
treatment threshold, then measurement should continue for the full 7  
days. Patients should be informed to keep a record of their home BP 
values and to ask their healthcare provider that the device accuracy 
be intermittently checked. Devices older than 4 years may be inaccur­
ate and, if inaccurate, should be replaced.60
An average HBPM of ≥135/85 mmHg (equivalent to an office BP of 
≥140/90 mmHg) should be used to diagnose hypertension and an aver­
age systolic BP of 120–134 mmHg or diastolic BP of 70–84 mmHg 
should be used to diagnose elevated BP. Of note, we use the same low­
er BP threshold (120/70 mmHg) for both office and HBPM in defining 
elevated BP.61
3
Home-based blood pressure measurement
1
Use a validated BP 
device
2
Measure BP in a quiet room 
after 5 min of rest with arm 
and back supported
Obtain two readings on each occasion,
1–2 min apart
4
Obtain readings twice a day 
(morninga and evening) for 
at least 3 and ideally 7 days average HBPM
≥135/85 mmHg
Hypertension:
5
Record and average all 
readings and present 
results to clinician
Figure 4 Summary of home blood pressure measurement. BP, blood pressure; HBPM, home blood pressure measurement. aMorning HBPM readings 
should be obtained before breakfast and before intake of medication but not immediately after awakening.


<!-- PAGE 22 -->

### Page 22

5.2.4. Ambulatory blood pressure measurement
ABPM (summarized in Figure 5) is an out-of-office BP measurement 
that uses a fully automated device, usually for a 24-h period. The 
devices measure BP by the oscillometric method and are pro­
grammed to measure BP at set intervals. Readings are usually 
obtained at 15–30 min intervals during the day (typically 7 a.m. to 
11 p.m.) and 30–60 min intervals at night (typically 11 p.m. to 
7 a.m.). The software usually provides average BP measurements 
for daytime, night-time, and 24 h. A minimum of 70% useable BP 
recordings is required for a valid measurement session, typically 
numbering ≥27 measurements over 24 h. Preferably, seven noctur­
nal readings should also be obtained.62 However, emerging data in­
dicate that ≥8/≥4 wake/sleep readings may be adequate if more 
cannot be obtained.63 Prior to using mean ABPM values (either 
24 h, daytime, or night-time) the raw BP values at each measurement 
should be reviewed for possible outlier or erroneous values. A diary 
should record activities (e.g. meals and exercise) and sleep time to 
assist interpretation. The diagnostic thresholds for elevated BP and 
hypertension using ABPM, and comparison with office BP and 
HBPM, are provided in Table 5.61,64
1
2
3
4
Ambulatory blood pressure measurement
Use a validated BP 
device
Device usually records BP at 
15–30 min intervals during the 
day and 30–60 min at night
A minimum of 70%
usable BP recordings is required
A diary of the patient's activities, 
intake of medications and sleep 
time should be completed
ABPM ≥130/80 mmHg over 24 h or
≥135/85 mmHg for the daytime average or
≥120/70 mmHg for the night-time average
Hypertension:
Figure 5 Summary of ambulatory blood pressure measurement. ABPM, ambulatory blood pressure measurement; BP, blood pressure.  
Table 5 Comparison of office, home, and ambulatory blood pressure measurement thresholds for elevated blood 
pressure and hypertension
Office BP 
(mmHg)a
Home BP 
(mmHg)
Daytime ABPM 
(mmHg)
24 h ABPM 
(mmHg)
Night-time 
ABPM (mmHg)
Reference
Non-elevated BP
<120/70
<120/70
<120/70
<115/65
<110/60
Elevated BP
120/70–<140/90
120/70–<135/85
120/70–<135/85
115/65–<130/80
110/60–<120/70
Hypertension
≥140/90
≥135/85
≥135/85
≥130/80
≥120/70
© ESC 2024
ABPM, ambulatory blood pressure monitoring; BP, blood pressure. 
aThe BP thresholds provided assume that a standardized approach to office BP measurement is performed (Figure 3). However, evidence indicates that office BP measurement in routine 
clinical settings is often not done using a standardized approach and, in this case, the routine office BP value may be 5–10 mmHg higher than it would have been if measured using the 
recommended standardized approach.65,66
ESC Guidelines                                                                                                                                                                                          3933


<!-- PAGE 23 -->

### Page 23

5.2.5. Comparison of home and ambulatory blood 
pressure monitoring
There is overlap between home and ambulatory monitoring in terms of 
differentiating between hypertensive phenotypes. However, around 
15% of people will have diagnostic disagreement, of whom approximately 
50% will represent clinically significant differences of >5 mmHg.67 The ad­
vantages and disadvantages of home and ambulatory monitoring are out­
lined in Table 6.
5.3. What is the best method for 
measuring blood pressure to diagnose 
hypertension?
5.3.1. Blood pressure measurement for hypertension 
screening
Opportunistic screening is typically performed using office BP measure­
ment and is key in detecting possible hypertension. However, a single 
screening office BP alone does not typically have sufficient diagnostic 
test performance to establish a diagnosis, especially for BP values close 
to diagnostic thresholds. Therefore, a single screening office BP re­
quires some form of repeat BP assessment to confirm a diagnosis (pref­
erably out-of-office or repeat office if out-of-office is not available). 
Relatedly, the BP threshold for acting on a screening office BP by con­
ducting repeat BP assessments should also be lower than the office BP 
threshold used for diagnosing hypertension. This latter consideration is 
particularly relevant in the presence of increased CVD risk or markers 
of HMOD. Also of note, populations where masked hypertension is 
more prevalent include men, those who smoke, those with excessive 
alcohol intake, or those with diabetes or obesity.68,69 While a screening 
office BP of >160/100 mmHg is almost always consistent with a diagno­
sis of hypertension, a small proportion of patients will have extreme 
white-coat effects that motivate prompt repeat BP assessment.68
Hypertension screening approaches are discussed further in Section 7.1.
5.3.2. Blood pressure measurement for diagnosing 
hypertension
After detecting high BP in the office, subsequent BP measurement 
for diagnosing hypertension depends on the clinical circumstances. 
Office BP has lower specificity than ABPM for detecting hypertension, 
so diagnosis based on office BP alone is less desirable unless resources 
do not allow out-of-office measurements.70 For screening BP of 
160–179 mmHg systolic or 100–109 mmHg diastolic, prompt confirm­
ation (within 1 month) using either office or out-of-office methods is 
recommended, as delays in treatment are associated with increased 
CVD event rates.71 For BP of ≥180/110 mmHg, assessment for hyper­
tensive emergency is recommended. In the setting of hypertensive 
emergency, immediately commencing BP-lowering treatment is recom­
mended, otherwise, prompt confirmation (preferably within a week) 
can be considered prior to commencing treatment (Sections 7 and 10).
For screening BP of 140–159/90–99 mmHg, out-of-office BP should be 
measured to confirm the diagnosis.72 When treatment of elevated BP is 
being considered (e.g. 120–139/70–89 mmHg) for individuals with high 
risk CVD conditions or sufficiently high 10-year predicted CVD risk, 
out-of-office BP measurement is recommended, both to confirm BP 
and to assess for masked hypertension. Out-of-office measurements 
may also be helpful for individuals with office BP of 130–139/85–89  
mmHg to diagnose masked hypertension. Further details on the diag­
nostic evaluation of hypertension are provided in Section 7.2.
5.4. What is the best method for 
measuring blood pressure for long-term 
management of hypertension?
While repeat office measurement of BP remains the commonest ap­
proach to long-term management of hypertension, several lines of in­
vestigation support augmenting office BP measurements with 
out-of-office assessment.
5.4.1. Home monitoring
There are over 50 trials of different self-monitoring-based interventions.73
Self-monitoring is associated with lower mean systolic BP at 12 months 
[−3.2 mmHg; 95% confidence interval (CI) −4.9 to −1.6 mmHg].74
Furthermore, there are known benefits of telemonitoring, digital interven­
tions, and mobile health in managing BP.75–78 Self-monitoring is also likely 
to be cost-effective.79 Unfortunately, in clinical practice, some patients 
may not provide reliable information on their home BP, and both their de­
vice and measurement technique need to be checked.
5.4.2. Ambulatory monitoring
ABPM provides a reference BP measurement but repeat ABPM testing 
is sometimes not practical due to resource constraints and, uncom­
monly, low patient acceptability.80 There is a paucity of data on treat­
ment guided by ABPM vs. that of office or HBPM measurements. A 
trial of treatment guided by HBPM vs. clinic and ambulatory monitoring 
found equivalence in BP control and HMOD.81 Other studies reported 
a non-significant trend to worse BP control with ambulatory vs. office 
BP monitoring, though the ambulatory group also received fewer 
Table 6 Comparison of ambulatory and home blood 
pressure monitoring
Ambulatory monitoring 
Advantages 
• Can identify white-coat and masked hypertension
• Measurement in real-life settings and during usual activities
• Stronger prognostic evidence
• Night-time readings
• Abundant information from a single investigation, including short-term 
diurnal BP variability
• Additional BP phenotyping (e.g. nocturnal dipping status)
Disadvantages 
• Relatively expensive and sometimes limited availability
• Can be uncomfortable and affect sleep
Home monitoring 
Advantages 
• Identify white-coat and masked hypertension
• Cheap and widely available
• Measurement at home, which may be more relaxed than at doctor’s office
• Patient engagement in BP measurement and telemedicine potential
• Easily repeated and used over longer periods to assess day-to-day BP 
variability
Disadvantages 
• Only static BP at rest is typically available
• Potential for measurement error due to improper measurement 
technique or unvalidated or poorly calibrated device
• Nocturnal readings not usually possible
© ESC 2024
BP, blood pressure.


<!-- PAGE 24 -->

### Page 24

medications.82 Potential advantages of ABPM over HBPM include diag­
nosing nocturnal hypertension or symptomatic transient hypotension 
or hypertension with exertion. As such, ABPM and HBPM should be 
considered complementary and additive, rather than competing ap­
proaches to long-term BP management.83
5.5. Measuring blood pressure in selected 
groups
5.5.1. Pregnancy
Monitoring BP during pregnancy is typically done at antenatal visits, 
which vary dependent on trimester (with increasing frequency to­
wards term). BP tends to reach a nadir at 20–30 weeks of pregnancy 
before increasing towards term at 40 weeks.84 Only a small number 
of automated oscillometric BP monitors have been adequately vali­
dated in pregnancy and several have failed, usually due to providing 
BP values that are erroneously high.85 Auscultatory measurement 
with sphygmomanometry is consequently the clinical standard in 
pregnancy.85 Self-monitoring at home is not yet proven to be effect­
ive in gestational hypertension.86,87 While norms for BP during 
pregnancy remain unclear, the 2022 Chronic Hypertension and 
Pregnancy (CHAP) trial indicated benefit of targeting clinic BP below 
140/90 mmHg.88 Consideration of secondary causes of hyperten­
sion is important in young women with gestational hypertension. 
Further details are provided in Section 9.2 and the 2018 ESC 
Guideline for the management of cardiovascular disease during 
pregnancy.89
5.5.2. Atrial fibrillation
Hypertension is a risk factor for AF.90,91 Oscillometric BP monitors 
are not always accurate in the presence of AF, due to the greater 
variability of BP beat to beat, so multiple auscultatory measurements 
are recommended.48,92,93 Some oscillometric BP monitors include 
an algorithm for detecting AF, but an electrocardiogram (ECG) is still 
required to confirm the diagnosis.49,94
5.5.3. Orthostatic hypotension
Postural or orthostatic hypotension is common,95,96 present in ap­
proximately 10% of all hypertensive adults and up to 50% of older 
institutionalized adults.97,98 Orthostatic hypotension is defined as 
a BP drop of ≥20/10 mmHg 1 and/or 3 min after standing following 
a 5-min period in the seated or lying position.99–101 Diagnosis is 
made in the office. Routine ABPM is not currently suitable for for­
mally assessing orthostatic hypotension,102 though it may help in 
some cases, particularly when accompanied by a patient symptom 
diary.103
5.6. Novel methods of measuring blood 
pressure
New methods to measure BP are under development. Continuous of­
fice and out-of-office BP recordings and ABPM and HBPM have been 
developed that derive beat-to-beat, reading-to-reading, and day-to-day 
BP variability. However, there is no agreement on the optimum ap­
proach to measuring variability, and there is no trial evidence that redu­
cing BP variability specifically can reduce CVD events.104 Other 
emerging technologies include wearable, wrist-based BP measurement 
devices, devices evaluating central BP, and cuffless devices implementing 
plethysmographic or other technologies.105,106 However, there is at 
present insufficient scientific consensus on the accuracy standards 
and validation procedures that these cuffless devices must comply 
with prior to commercialization.43,44,107–109
In view of these issues, none of these cuffless measurement modal­
ities are currently recommended for routine clinical use.
Recommendation Table 1 — Recommendations for 
measuring blood pressure (see Evidence Tables 1–8)
Recommendations
Classa
Levelb
It is recommended to measure BP using a validated 
and calibrated device, to enforce the correct 
measurement technique, and to apply a consistent 
approach to BP measurement for each patient.41,42
I
B
All adult patients (≥18 years) are recommended to 
have their office and/or out-of-office BP measured 
on an opportunistic basis and recorded in their 
medical file, and be told what their current BP is.
I
C
Out-of-office BP measurement is recommended for 
diagnostic purposes, particularly because it can 
detect both white-coat hypertension and masked 
hypertension. Where out-of-office measurements 
are not logistically and/or economically feasible, then 
it is recommended that the diagnosis be confirmed 
with a repeat office BP measurement using the 
correct standardized measurement technique.70
I
B
It is recommended that office BP should be measured 
in both arms at least at the first visit, because a 
between-arm systolic BP difference of >10 mmHg is 
associated with an increased CVD risk and may 
indicate arterial stenosis.55,110
I
B
If a between-arm difference of >10 mmHg in systolic 
BP is recorded, then it is recommended that all 
subsequent BP readings use the arm with the higher 
BP reading.110
I
B
Out-of-office BP measurement is recommended for 
ongoing management to quantify the effects of 
treatment and guide BP-lowering medication 
titration, and/or identify possible causes of side 
effects (e.g. symptomatic hypotension). Where 
out-of-office measurements are not logistically and/ 
or economically feasible, then ongoing management 
is recommended to be based on repeated office BP 
measurements using the correct standardized 
measurement technique.74,111,112
I
B
It is recommended that all patients undergoing 
BP measurement also undergo pulse palpation 
at rest to determine heart rate and arrhythmias 
such as AF.113
I
C
Most automated oscillometric monitors have 
not been validated for BP measurement in AF; 
BP measurement should be considered using 
a manual auscultatory method in these 
circumstances where possible.47–49
IIa
C
Continued
ESC Guidelines                                                                                                                                                                                          3935


<!-- PAGE 25 -->

### Page 25

### 6 Definition and classification of

elevated blood pressure and 
hypertension, and cardiovascular 
disease risk assessment
6.1. Definition and classification of 
elevated blood pressure and hypertension
Epidemiological studies demonstrate a continuous and log-linear asso­
ciation between BP and adverse CVD outcomes.22,32,33,114,115 Starting 
at levels as low as 90 mmHg systolic, the higher the BP the higher the 
relative risk of CVD including atherosclerosis.32,114 These observational 
data are complemented by randomized clinical trials (RCTs),116 which 
have provided experimental evidence regarding the BP range for which 
BP lowering with treatment is proven to reduce CVD events. Of note, 
some studies suggest a stronger relative risk for CVD for a given BP 
among females compared with males.117,118
A healthy lifestyle should be encouraged for all adults to prevent an 
increase in BP and development of hypertension.119,120 To aid pharma­
cological treatment decisions, the 2024 ESC Guidelines recommend a 
simplified categorization of adults according to their BP (Figure 6). In 
compiling this categorization, priority was given to evidence from ran­
domized trials over observational data. However, it is important to re­
iterate that the risk of CVD attributable to BP is continuous and that 
interpreting randomized trial data is an iterative process involving an 
element of subjectivity. As such, no categorization of BP can be consid­
ered immutable or flawless.
The 2024 Guidelines define hypertension as a confirmed office sys­
tolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. For this diagnosis 
to be made, confirmation is recommended with out-of-office measure­
ments (HBPM or ABPM) or at least one repeat office measurement at a 
subsequent visit, as detailed in Section 5 and Section 7.2. This definition is 
based on several factors. First, meta-analyses of randomized trials pro­
vide evidence among all adults and across various settings for the bene­
fit of BP-lowering therapy among patients with BP above this 
threshold.116,121,122 Second, most adults with BP above this threshold 
are at increased CVD risk, typically with 10-year risk estimates of 
≥10% for fatal and non-fatal CVD events.123–125 The higher the pa­
tient’s baseline absolute risk for CVD, the greater the net benefit 
from BP-lowering treatment and, at the population level, the lower 
the estimated number needed to treat (NNT).126–128 Third, this 
more traditional BP threshold for hypertension is already widely used 
by policymakers to define a disease state, and maintaining this BP 
threshold to define hypertension (vs. lowering it) does not require 
most adults to be labelled with what is widely considered a disease.129
Here, we introduce a new BP category called ‘elevated BP’, which 
is defined as an office systolic BP of 120–139 mmHg or diastolic BP 
of 70–89 mmHg. Within this BP range, the efficacy of BP-lowering ther­
apy has been established in meta-analyses of RCTs,116 but average CVD 
risk in the elevated BP group is not sufficiently high to merit drug treat­
ment in all patients.123,124,130 Pharmacological treatment initiation is, 
however, suggested for a subgroup of patients within this BP range 
who are at increased global risk of CVD as identified by the risk strati­
fication approach outlined in Sections 6.3, 6.4, and 8.
Non-elevated BP is defined as a systolic BP of <120 mmHg and a dia­
stolic BP of <70 mmHg. Fewer individuals within this BP range are at 
increased risk of CVD,124 and evidence for CVD benefit with 
BP-lowering pharmacological treatment is lacking due to an absence 
of trials. We use the term ‘non-elevated BP’ to define this BP category 
in recognition that these are treatment categories and not prognostic 
categories. Because the relative risk for CVD starts to increase at BP 
below this threshold (even as low as 90 mmHg systolic BP), particularly 
among women,117,118 we avoid terms like ‘normal BP’, ‘optimal BP’, or 
‘normotension’ in defining this category.
6.2. Principles of a risk-based approach for 
managing blood pressure and preventing 
cardiovascular disease
In the context of BP-lowering interventions, randomized trials demon­
strate a consistent relative risk reduction in adverse CVD outcomes 
per unit reduction in BP.131,139 However, many medical interventions in­
cur costs and have side effects. Therefore, guidance is needed on select­
ing patients most likely to benefit from BP-lowering treatment. This is 
especially true among adults with elevated BP (office systolic BP of 
120–139 mmHg and/or diastolic BP of 70–89 mmHg). Practical aspects 
for implementing a risk-based approach are further discussed in Section 8.
6.2.1. Role of cardiovascular disease risk assessment
The risk of adverse CVD outcomes increases log-linearly with constant 
increments in systolic BP and diastolic BP.22,32,33,114,140 Concurrently, at 
higher BP, there is clustering of additional CVD risk factors.141,142
Consequently, many patients with hypertension will have an estimated 
10-year risk for CVD events of ≥10%,116,121,122 which, for the purposes 
of these guidelines, is considered sufficiently high risk to merit consid­
eration of BP-lowering treatment in the setting of elevated BP.143
Using BP thresholds for hypertension alone for allocating treatment 
would lead to under-treatment of many high-risk patients.144,145,115
A substantial proportion of excess CVD events attributable to BP oc­
cur in patients with BP levels below the traditional threshold for 
An assessment for orthostatic hypotension (≥20 
systolic BP and/or ≥10 diastolic BP mmHg drop at 1 
and/or 3 min after standing) should be considered at 
least at the initial diagnosis of elevated BP or 
hypertension and thereafter if suggestive symptoms 
arise. This should be performed after the patient is 
first lying or sitting for 5 min.
IIa
C
Other BP measures and indices (pulse pressure, BP 
variability, exercise BP) may be considered to 
provide additional clinical information on CVD risk in 
some circumstances.
IIb
C
© ESC 2024
AF, atrial fibrillation; BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 2 — Recommendations for 
categorizing blood pressure (see Evidence Table 9)
Recommendation
Classa
Levelb
It is recommended that BP be categorized as 
non-elevated BP, elevated BP, and hypertension to 
aid treatment decisions.116,121,122,131–138
I
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 26 -->

### Page 26

hypertension diagnosis. As the efficacy of BP lowering on preventing 
CVD events extends down to a systolic BP of 120 mmHg and a diastolic 
BP of 70 mmHg,116,135,136,146 patients with elevated BP and increased 
CVD risk can also derive benefit from BP-lowering treatment.124,145
The heterogeneity in CVD risk among adults with elevated BP is lar­
ger than in those with hypertension, as such patients tend to be young­
er, and their absolute CVD risk depends more on the prevalence of 
concomitant CVD risk factors.123,147 Consequently, formally estimating 
the patient’s CVD risk, encapsulating demographics and other CVD risk 
factors, is recommended to guide BP-lowering treatment decisions 
among patients with elevated BP.148–151
6.3. Predicting cardiovascular disease risk
Certain conditions on their own are associated with sufficient CVD risk 
such that patients with elevated BP alongside these conditions can be 
considered for BP-lowering therapy (Figure 7). These include moderate 
or severe chronic kidney disease (CKD),152 established clinical CVD (cor­
onary heart disease, cerebrovascular disease, peripheral arterial disease, 
or heart failure)153–158 concomitant HMOD (see Figure 7; Section 7; 
Supplementary data online, Table S1),31,159 diabetes mellitus, and familial 
hypercholesterolaemia (probable or definite).160–163 Regarding diabetes, 
some adults aged <60 years with type 2 diabetes and elevated BP have 
10-year CVD risk of <10%. Accordingly, the diabetes-specific 
Non-elevated blood pressure
Office BP
SBP <120 mmHg and
DBP <70 mmHg
HBPM
SBP <120 mmHg and
DBP <70 mmHg
ABPM
Daytime SBP <120 mmHg and
Daytime DBP <70 mmHg
Elevated blood pressure
Office BP
SBP 120–139 mmHg or
DBP 70–89 mmHg
HBPM
SBP 120–134 mmHg or
DBP 70–84 mmHg
ABPM
Daytime SBP 120–134 mmHg or
Daytime DBP 70–84 mmHg
Hypertension
Office BP
SBP ≥140 mmHg or
DBP ≥90 mmHg
HBPM
SBP ≥135 mmHg or
DBP ≥85 mmHg
ABPM
Daytime SBP ≥135 mmHg or 
Daytime DBP ≥85 mmHg
Insufficient evidence confirming the efficacy and safety of BP
pharmacological treatment
Risk stratify to identify individuals with high cardiovascular risk for BP
pharmacological treatment
Cardiovascular risk is sufficiently high to merit
BP pharmacological treatment initiation
Blood pressure classification
The diagnosis of hypertension and elevated BP requires confirmation using out-of-office measurements  (HBPM or ABPM) or at least one additional subsequent office measurement
Figure 6 Blood pressure categories. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home 
blood pressure monitoring; SBP, systolic blood pressure. We note that the respective non-daytime ABPM thresholds for elevated BP and hypertension 
diagnosis are listed in Section 5 (Table 5).  
ESC Guidelines                                                                                                                                                                                          3937


<!-- PAGE 27 -->

### Page 27

Systematic COronary Risk Evaluation 2 (SCORE2)-Diabetes risk- 
prediction model should be considered to confirm CVD risk is sufficient­
ly high (≥10%) among individuals with type 2 diabetes mellitus who are 
aged <60 years.164
In the absence of these sufficiently high-risk conditions, risk-prediction 
models (SCORE2 and SCORE-OP) have been developed in the general 
population to predict 10-year risk of CVD.165,166 In adults with elevated 
BP without the above sufficiently high-risk conditions, risk-prediction 
models are recommended to inform BP-lowering treatment decisions. 
Risk-prediction models are more accurate than clinical judgment or tally­
ing of individual risk factors.167–169
6.3.1. 10-year cardiovascular disease risk-prediction 
models
Prediction models differ in their input variables, predicted endpoints 
(outputs), and populations in which they were derived and validated. 
We endorse the use of SCORE2 for individuals aged 40–69 years 
and SCORE2–Older Persons (SCORE2-OP) for individuals aged 
≥70 years for predicting 10-year global risk of fatal and non-fatal 
CVD events (stroke or myocardial infarction).165,166 The management 
of adults aged <40 years is discussed in Section 9.1. The SCORE2 and 
SCORE2-OP models are preferred over other 10-year risk-prediction 
models, as they predict both fatal and non-fatal CVD events, have 
been validated and recalibrated to European populations, and because 
SCORE2-OP is adjusted for the competing risk of non-cardiovascular 
mortality. Calculating SCORE2 or SCORE2-OP is recommended for 
individuals with elevated BP who are not already at sufficiently high 
CVD risk due to established CVD, moderate or severe CKD, prob­
able or definite familial hypercholesterolaemia, diabetes mellitus, or 
HMOD.165,166,170
For the purpose of BP-lowering treatment decisions, individuals with 
elevated BP and a predicted 10-year CVD risk of ≥10% by SCORE2 or 
SCORE2-OP are considered in these guidelines to be sufficiently high 
risk, with details on the choice of lifestyle or drugs to facilitate 
BP-lowering treatment in this setting provided in Section 8.171,172 A 
number of considerations influenced our choice to recommend a single 
risk threshold of ≥10%, vs. the alternative option of using age-specific 
risk thresholds, such as those provided in the 2021 ESC Guidelines 
on cardiovascular disease prevention in clinical practice.170 For ex­
ample, contemporary data indicate the heightened importance of BP 
control in older adults due to their higher absolute CVD risk (resulting 
in a lower NNT) and concomitantly to reduce age-dependent adverse 
outcomes attributable to increased BP, such as dementia. Recent 
treat-to-target trials (testing systolic BP targets of approximately 
120 mmHg) used a single CVD risk inclusion threshold and were also 
Moderate or severe
CKD
eGFR <60 mL/min/1.73 m2 or albuminuria ≥30 mg/g (≥3 mg/mmol)
Familial hypercholesterolaemia
Probable or definite familial hypercholesterolaemia
Diabetes mellitus
Type 1 and type 2 diabetes mellitusc
Established clinical cardiovascular disease
Atherosclerotic cardiovascular diseasea
Heart failure
Other forms of hypertensionmediated organ damage
Cardiacb
Vascularb
Figure 7 Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure. 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. aCoronary heart disease, cerebrovascular disease, peripheral arterial disease. 
bSee Section 7. cSCORE2-Diabetes should be considered to identify lower-risk individuals (<10% 10-year CVD risk), who may not require BP-lowering 
medication, particularly in individuals <60 years.


<!-- PAGE 28 -->

### Page 28

enriched with older adults.135,136,146 In addition, the average CVD event 
rate in the control arm of a landmark meta-analysis showing the bene­
fits of more intensive BP-lowering treatment was approximately 
equivalent to a 10% 10-year risk.116 Finally, the task force, which in­
cluded patient members, felt that age-specific risk thresholds could re­
sult in BP treatment decisions being made solely based on age, which is 
difficult to support scientifically or otherwise. To try to avoid any con­
fusion with the 2021 ESC Guidelines on cardiovascular disease preven­
tion in clinical practice, we use the terms ‘sufficiently high risk’ or 
‘increased risk’ to describe a person with 10-year CVD risk of ≥10% 
(rather than the terms ‘high risk’ or ‘very high risk’).
6.4. Refining cardiovascular disease risk 
estimation beyond risk models
The SCORE2 and SCORE2-OP risk-prediction models incorporate 
traditional risk factors such as age, sex, systolic BP, cholesterol values, 
and smoking status to predict 10-year risk of CVD.165,166 However, 
they do not include ‘non-traditional’ CVD risk factors (detailed below 
and hereafter termed ’risk modifiers’). Non-traditional CVD risk 
modifiers can improve the predictive performance (i.e. discrimin­
ation) of other CVD risk-prediction models, and may also apply to 
SCORE2 or SCORE2-OP.173 For example, among individuals with 
elevated BP and borderline increased 10-year predicted CVD risk 
by SCORE2 or SCORE2-OP (estimates of 5% to <10%), these non- 
traditional CVD risk modifiers may help up-classify the patient’s risk 
and thereby prompt BP-lowering treatment (Figure 8).
6.4.1. Sex-specific non-traditional cardiovascular 
disease risk modifiers
Sex differences in the distribution of traditional and non-traditional 
CVD risk factors have been documented among patients with 
hypertension.174 Although sex itself is included as an input variable 
in the SCORE2 and SCORE2-OP, and though these models were 
derived separately in men and women, some sex-specific, non- 
traditional risk modifiers were not included, and their associated 
impact on CVD risk may not be fully captured by SCORE2, 
SCORE2-OP, or SCORE2-Diabetes.
The relationship between BP and overall CVD risk is similar in 
both sexes, though some studies even suggest a stronger relative 
risk for CVD for a given BP level among females compared with 
males.117 Female-specific, non-traditional CVD risk modifiers often 
arise at specific times throughout the life course, especially during 
pregnancy and the peri-partum period. Women with a history of 
hypertensive disorders of pregnancy, including gestational hyperten­
sion and pre-eclampsia, have a two-fold higher long-term risk of 
CVD vs. women without these pregnancy conditions.175–177 The 
relative long-term CVD risk associated with hypertensive disorders 
of pregnancy may also be higher in younger vs. older pregnant wo­
men.178,179 Most, but not all, of the excess CVD risk associated 
with hypertensive disorders of pregnancy is captured by convention­
al CVD risk factors.176,178 Gestational diabetes is independently as­
sociated with an approximately two-fold increase in the long-term 
relative risk of CVD events.180 Other complications such as pre- 
term delivery, recurrent miscarriage, and one or more stillbirths 
are associated with a 40% relative increase in long-term CVD 
risk.181–185 Accordingly, a history of specific pregnancy complica­
tions, including gestational hypertension, pre-eclampsia, gestational 
diabetes, pre-term delivery, one or more stillbirths, and recurrent 
miscarriage, can be considered as non-traditional CVD risk modi­
fiers to up-classify women with elevated BP and borderline increased 
10-year predicted CVD risk (5% to <10%) to sufficiently high risk, 
thereby influencing the risk-based management of their elevated BP.
Evidence whether other female-specific conditions (infertility, poly­
cystic ovary syndrome, and premature menopause) and male-specific 
conditions (androgenic alopecia and erectile dysfunction) improve pre­
diction of CVD sufficiently to inform risk-based BP-lowering treatment 
decisions is inconclusive at present.
Recommendation Table 3 — Recommendations for 
assessing cardiovascular disease risk among individuals 
with elevated blood pressure (office systolic blood 
pressure 120–139 mmHg or diastolic blood pressure 
70–89 mmHg) (see Evidence Tables 10 and 11)
Recommendations
Classa
Levelb
It is recommended to use a risk-based approach in 
the treatment of elevated BP, and individuals with 
moderate or severe CKD, established CVD, HMOD, 
diabetes mellitus, or familial hypercholesterolaemia 
are considered at increased risk for CVD 
events.31,153–159,161–163,172
I
B
SCORE2 is recommended for assessing 10-year risk 
of fatal and non-fatal CVD among individuals aged 
40–69 years with elevated BP who are not already 
considered at increased risk due to moderate or 
severe CKD, established CVD, HMOD, diabetes 
mellitus, or familial hypercholesterolaemia.143,165,172
I
B
SCORE2-OP is recommended for assessing the 
10-year risk of fatal and non-fatal CVD among 
individuals aged ≥70 years with elevated BP who are 
not already considered at increased risk due to 
moderate or severe CKD, established CVD, HMOD, 
diabetes mellitus, or familial 
hypercholesterolaemia.143,166,172
I
B
It is recommended that, irrespective of age, 
individuals with elevated BP and a SCORE2 or 
SCORE2-OP CVD risk of ≥10% be considered at 
increased risk for CVD for the purposes of 
risk-based management of their elevated 
BP.143,165,166,172
I
B
SCORE2-Diabetes should be considered to estimate 
CVD risk among type 2 diabetes mellitus patients 
with elevated BP, particularly if they are <60 years of 
age.164
IIa
B
© ESC 2024
BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; HMOD, 
hypertension-mediated organ damage; SCORE2, Systematic COronary Risk Evaluation 2; 
SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. 
Established CVD: coronary artery disease, cerebrovascular disease, peripheral arterial 
disease, or heart failure. For details on HMOD see Section 7. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3939


<!-- PAGE 29 -->

### Page 29

6.4.2. Non-traditional cardiovascular disease risk 
modifiers shared by men and women
In addition to sex-specific risk modifiers, several other non-traditional 
risk factors are associated with an increased risk of CVD, but few 
have been shown to improve risk prediction or discrimination beyond 
traditional CVD risk factors.
We advise considering high-CVD-risk race/ethnicity (e.g. South 
Asian),186–188 family history of premature onset atherosclerotic 
CVD (CVD event in males aged <55 years and/or females <65  
years),189,190 socio-economic deprivation,191 inflammatory condi­
tions (e.g. systemic lupus erythematosus, rheumatoid arthritis, 
and psoriasis affecting 10% or more of body surface area or requir­
ing systemic therapy),192–202 HIV,203–205 and severe mental illness 
(major depressive disorder, bipolar disorder, and schizophre­
nia)206–208 as shared non-traditional risk modifiers to up-classify 
the risk of individuals with a borderline increased 10-year pre­
dicted risk using SCORE2/SCORE2-OP (5% to <10%) to sufficient­
ly high CVD risk.
Sex-specific modifiers
 (Class IIa) 
Shared modifiers
(Class IIa) 
High-risk ethnicity
Gestational hypertension
Gestational diabetes
Pre-eclampsia
Pre-term delivery
One or more stillbirth
Recurrent miscarriage
Family history of 
premature onset ASCVD
Socio-economic deprivation
Auto-immune inflammatory diseases
Severe mental illness
Risk modifiers
HIV
Figure 8 Cardiovascular disease risk modifiers to consider for up-classification of risk. ASCVD, atherosclerotic cardiovascular disease; HIV, human 
immunodeficiency virus.


<!-- PAGE 30 -->

### Page 30

6.4.3. Additional risk decision tests
Coronary artery calcium (CAC) scoring improves CVD risk prediction 
and reclassifies risk when added to conventional CVD risk factor-based 
estimation models.209,210 A CAC score of >100 Agatston units or 
≥75th percentile for age, sex, and ethnicity favours up-classification 
of CVD risk.127 Internal or external carotid plaque may also improve 
CVD risk prediction.211 Similarly, femoral artery plaque detection 
may improve CVD risk prediction.212–214 Arterial stiffness, as assessed 
by pulse wave velocity (PWV), is associated with increased risk of CVD 
events and improves CVD risk stratification.215–218 Common arterial 
stiffness thresholds for increased risk include carotid–femoral PWV 
of >10 m/s and brachial–ankle PWV of >14 m/s. After assessing 
10-year predicted CVD risk and non-traditional risk factors, if a risk- 
based treatment decision remains uncertain for patients with elevated 
BP, it is reasonable to measure a CAC score or, alternatively, carotid or 
femoral plaque, or arterial stiffness; most especially after shared 
decision-making with the patient and after considering cost (see 
Section 7 for more details on these tests). There is also evidence that 
elevated cardiac biomarker levels (specifically high-sensitivity cardiac 
troponin and B-type natriuretic peptide/N-terminus B-type natriuretic 
peptide) are significant and effective risk modifiers,219,220 with further 
supportive data from hypertensive participants.159,221,222 Of note, 
these cardiac biomarkers can be considered markers of HMOD 
(Section 7); however, we focus on them in this risk modifier section be­
cause they may be elevated due to other reasons besides high BP (such 
as atherosclerosis or heart rhythm disease).
6.5. Summary of the cardiovascular disease 
risk stratification approach for allocating 
blood pressure treatment
Measured BP combined with 10-year CVD risk-prediction models and 
non-traditional risk modifiers should be used for stratifying risk when allo­
cating BP-lowering treatment for persons with elevated BP (Figure 9). It is 
important to stress here that patients with confirmed hypertension are re­
commended to receive BP-lowering treatment and no further risk strati­
fication is needed.
For patients with elevated BP, the presence of diabetes, familial 
hypercholesterolaemia, established CVD (defined as prior acute or 
chronic coronary syndrome, cerebrovascular disease, symptomatic 
peripheral arterial disease, or heart failure), moderate or severe 
CKD, or HMOD confers increased CVD risk. One caveat is that, spe­
cifically for individuals with elevated BP and type 2 diabetes mellitus only 
aged <60 years, SCORE2-Diabetes should be considered to identify 
lower CVD risk individuals (<10% over 10 years).
Otherwise, for patients without these high-risk conditions, 10-year risk 
of CVD should be calculated using SCORE2 (if aged 40–69 years) and 
SCORE2-OP (if aged ≥70 years). Patients with elevated BP and a 
10-year predicted risk of CVD events ≥10% are considered sufficiently 
high risk to warrant BP-lowering treatment (either by lifestyle or drug 
treatment, see Section 8). For patients with elevated BP and borderline in­
creased predicted CVD risk by SCORE2/SCORE2-OP (5% to <10% over 
10 years), up-classification of risk may be considered in the presence of 
sex-specific or shared non-traditional risk modifiers. After considering 
sex-specific and shared non-traditional risk modifiers, if a risk-based 
BP-lowering treatment decision remains uncertain, it may be reasonable 
to measure CAC score, carotid or femoral plaque, high-sensitivity cardiac 
troponin or B-type natriuretic peptide biomarkers, or arterial stiffness.
Risk stratification for patients with non-elevated BP (systolic BP of 
<120 mmHg and diastolic BP of <70 mmHg) is not required for the 
purpose of allocating BP-lowering treatment, as the safety and efficacy 
of commencing BP-lowering treatment below this threshold is uncer­
tain. Risk assessment may nonetheless be needed in this setting when 
considering other prevention therapies (e.g. lipid lowering).
Recommendation Table 4 — Recommendations for 
refining cardiovascular disease risk (see Evidence 
Tables 12–14)
Recommendation
Classa
Levelb
History of pregnancy complications (gestational 
diabetes, gestational hypertension, pre-term 
delivery, pre-eclampsia, one or more stillbirths, 
and recurrent miscarriage) are sex-specific risk 
modifiers that should be considered to up-classify 
individuals with elevated BP and borderline 
increased 10-year CVD risk (5% to <10% risk). 
183,184,223,224
IIa
B
High-risk ethnicity (e.g. South Asian), family history of 
premature onset atherosclerotic CVD, 
socio-economic deprivation, auto-immune 
inflammatory disorders, HIV, and severe mental 
illness are risk modifiers shared by both sexes that 
should be considered to up-classify individuals with 
elevated BP and borderline increased 10-year CVD 
risk (5% to <10% risk). 186–191,193,198,202,204,208
IIa
B
Continued
After assessing 10-year predicted CVD risk and 
non-traditional CVD risk modifiers, if a risk-based 
BP-lowering treatment decision remains uncertain for 
individuals with elevated BP, measuring CAC score, 
carotid or femoral plaque using ultrasound, 
high-sensitivity cardiac troponin or B-type natriuretic 
peptide biomarkers, or arterial stiffness using pulse wave 
velocity, may be considered to improve risk stratification 
among patients with borderline increased 10-year CVD 
risk (5% to <10% risk) after shared decision-making and 
considering costs.209–211,215,218,225,226
IIb
B
© ESC 2024
BP, blood pressure; CAC, coronary artery calcium; CVD, cardiovascular disease; HIV, 
human immunodeficiency virus. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3941


<!-- PAGE 31 -->

### Page 31

Patient with elevated BPa office SBP 120–139 mmHg or
DBP 70–89 mmHg
Y
Established CVD,
moderate/severe CKD,
HMOD, DM, or FH
(Class I)
N
Calculate 
SCORE2 or SCORE2-OP
(Class I)
Patient with
T2DM (only)
and
<60 years old
10-year predicted CVD risk
Any of the following:
Gestational diabetes
Gestational hypertension
Pre-eclampsia
Pre-term delivery
One or more still births
Recurrent miscarriage
N
Consider shared risk modifiers
(Class IIa)
Any of the following:
High-risk ethnicity
Family history of premature onset ASCVD
Socio-economic deprivation
Auto-immune diseases
Severe mental illness
HIV
N
If still uncertain, shared decision-making informed by risk tools
(Class IIb)
Any of the following meeting abnormal criteria:
CAC score
Carotid or femoral plaque
High-sensitivity cardiac troponin
NT-proBNP
Pulse wave velocity
Lifestyle measures to reduce BP
(Class I)
Reassess risk/BP
one year later
(Class IIa)
N
Lifestyle measures to reduce BP
(Class I)
After 3 months of lifestyle measures, pharmacological treatment for patients with
≥130/80 mmHg 
(Class I)
Y
N
Y
Y
Calculate
SCORE2- Diabetes
(Class IIa)
Y
 <5%
5% – <10%
≥10% 
Consider sex-specific risk modifiers
(Class IIa)
aExercise caution when considering treating persons with elevated
BP and;
Moderate-to-severe frailty
Symptomatic orthostatic hypotension
Age ≥85 years
Figure 9 Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure. ASCVD, 
atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CKD, chronic kidney disease; CVD, cardiovascular disease; 
DBP, diastolic blood pressure; DM, diabetes mellitus; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ damage; NT-proBNP, 
N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic 
COronary Risk Evaluation 2–Older Persons.


<!-- PAGE 32 -->

### Page 32

### 7 Diagnosing hypertension and

investigating underlying causes
7.1. Screening for hypertension
Hypertension is predominantly an asymptomatic condition that is typ­
ically detected by systematic or opportunistic screening in a healthcare 
setting. Systematic screening refers to any process where individuals 
are identified and invited to a healthcare setting solely to measure their 
BP and CVD risk profile. Opportunistic screening refers to BP being 
measured when the patient presents to a healthcare setting for any rea­
son, such as a routine check-up or the treatment of an acute or chronic 
condition. Self-screening and non-physician screening are also increas­
ingly used.227–230
Few data are available on the effectiveness of different hypertension 
screening strategies to reduce the morbidity and mortality associated 
with hypertension.231–233 More evidence is needed before systematic 
screening programmes with BP measurement can be recommended 
in all adults to reduce CVD events.231
Opportunistic BP screening in a primary care setting appears effect­
ive, with an estimated 90% of all adults aged >40 years in the UK having 
a BP check within a 5-year time period,234 though these findings may 
not extrapolate to other countries. When patients provide HBPM re­
cordings, these can also be used as part of an opportunistic screening 
programme (see Section 5.2).235
Despite ongoing uncertainty about the effect of hypertension 
screening programmes on CVD outcomes, many studies have de­
monstrated that screening (mostly opportunistic screening) in­
creases hypertension detection, and that the benefits of screening 
likely outweigh harms.70 Global initiatives to raise BP awareness, 
such as the May Measurement Month,228 or targeted initiatives, 
such as the barbershop health outreach programmes,229 are success­
ful examples of BP screening campaigns.
Screening for hypertension, like for global CVD risk assessment, 
should be intermittently repeated, e.g. every 3 years. Considering 
the rate of progression to hypertension in European population 
samples,236 it is reasonable to measure BP at least every 3 years 
in the case of non-elevated BP and low–moderate CVD risk (i.e. in­
dividuals aged <40 years). More frequent BP checks (i.e. yearly) 
should be considered in individuals 40 years or older and individuals 
with elevated BP not currently meeting indications for treatment170
(Figure 10).
7.2. Confirming the diagnosis of 
hypertension
As noted in Section 5, assessment at a single visit by office BP has lower 
specificity compared with ABPM for diagnosing hypertension.70,238–241
Accordingly, a protocol for confirming the diagnosis of hypertension is 
proposed (Figure 10), with out-of-office BP measurement as the 
preferred method for confirming cases of elevated BP or hypertension. 
For initial screening systolic BP of >160 mmHg and/or diastolic 
BP of >100 mmHg, a prompt re-evaluation (within days to weeks but 
not >1 month) preferably with ABPM or HBPM is advisable.71
BP of >180/110 mmHg at screening requires exclusion of 
hypertensive emergencies, which should be managed as appropriate 
(see 242 and Section 10) with prompt treatment. For individuals with 
BP of >180/110 mmHg at screening but without hypertensive emer­
gency, prompt confirmation (preferably within a week) can be consid­
ered prior to commencing treatment.
Recommendation Table 5 — Recommendations for 
blood pressure screening (see Evidence Table 15)
Recommendation
Classa
Levelb
Opportunistic screening for elevated BP and 
hypertension should be considered at least every 3 
years for adults aged <40 years.236,237
IIa
C
Opportunistic screening for elevated BP and 
hypertension should be considered at least annually 
for adults aged ≥40 years.231,237
IIa
C
In individuals with elevated BP who do not currently 
meet risk thresholds for BP-lowering treatment, a 
repeat BP measurement and risk assessment within 1 
year should be considered.
IIa
C
Continued
Other forms of screening for hypertension (i.e. 
systematic screening, self-screening, and 
non-physician screening) may be considered, 
depending on their feasibility in different countries 
and healthcare systems.231–233
IIb
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 6 — Recommendations for 
confirming hypertension diagnosis
Recommendations
Classa
Levelb
In individuals with increased CVD risk where their 
screening office BP is 120–139/70–89 mmHg, it is 
recommended to measure BP out of office, using 
ABPM and/or HBPM or, if not logistically feasible, by 
making repeated office BP measurements on more 
than one visit.70,238–241
I
B
Where screening office BP is 140–159/90–99 mmHg, 
it is recommended that the diagnosis of 
hypertension should be based on out-of-office BP 
measurement with ABPM and/or HBPM. If these 
measurements are not logistically or economically 
feasible, then diagnosis can be made on repeated 
office BP measurements on more than one 
visit.70,238–241
I
B
Where screening office BP is ≥160/100 mmHg: 
• It is recommended that BP 160–179/100–109  
mmHg be confirmed as soon as possible (e.g. 
within 1 month) preferably by either home or 
ambulatory BP measurements;
• It is recommended when BP ≥180/110 mmHg that 
hypertensive emergency be excluded.
I
C
© ESC 2024
ABPM, ambulatory blood pressure measurement; BP, blood pressure; CVD, cardiovascular 
disease; HBPM, home blood pressure measurement. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3943


<!-- PAGE 33 -->

### Page 33

7.3. Communicating the diagnosis
Behavioural responses to health-related threats are strongly influ­
enced by five core themes (termed ‘illness representations’), which 
are identity, timeline, cause, consequences, and control/cure.243,244
These illness representations form the basis of how patients under­
stand a diagnosis, and can influence their responses after being diag­
nosed with hypertension.243 This conceptual framework can help 
guide the clinical communication of a diagnosis of hypertension. 
For example, patients’ understanding of the chronic nature of hyper­
tension (i.e. timeline theme) is key for ensuring long-term engage­
ment with medical treatment.245 Prior to commencing treatment, 
it is helpful to understand the extent to which patients believe that 
medications are necessary and ascertain if they have concerns.246
The core illness representations and beliefs about medicines for clin­
icians to consider are included in Table 7.
The 2021 ESC Guidelines on cardiovascular disease prevention in 
clinical practice recommend “an informed discussion about CVD risk 
and treatment benefits—tailored to the needs of a patient” as part 
of a diagnosis communication in hypertension.170 This can be facilitated 
using an interdisciplinary healthcare-provided approach (see Section 11) 
and by visual information or other more accessible material that might 
optimally communicate hypertension-related risk.128 Visualizing risk by 
medical imaging to motivate risk-reducing behaviour changes may also 
be beneficial.247
7.4. Baseline assessment and diagnostic 
approach
7.4.1. Medical history, medication history, and 
physical examination
The purpose of clinical evaluation is to diagnose hypertension, delineate 
factors potentially contributing to hypertension, identify other CVD 
risk factors, define relevant comorbidities, screen for potential second­
ary causes of hypertension (where indicated), and establish whether 
N
Y
N
Y
Screening for hypertension by office BP
High CVD risk conditions or
SCORE2/SCORE2-OP ≥10%
or
SCORE2/SCORE2-OP 5% – <10% 
+ risk modifiers
 ≥40 years? 
Non-elevated BP
<120/70
mmHg
Elevated BP
120–139/70–89
mmHg
Hypertension
140–159/90–99
mmHg
Hypertension
160–179/100–109
mmHg
Hypertension
≥180/110
mmHg
Opportunistic
BP screening at least every
3 years
(Class IIa)
Opportunistic
BP screening at least every year
(Class IIa)
Evaluate for hypertensive emergency
(Class I)
Confirm BP
preferably with either home or ambulatory
BP measurements
(Class I)
Confirm BP promptly preferably with either home or ambulatory
BP measurements
(Class I)
Figure 10 Protocol for confirming hypertension diagnosis. BP, blood pressure; CVD, cardiovascular disease; SCORE2, Systematic COronary Risk 
Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons.


<!-- PAGE 34 -->

### Page 34

there is evidence of HMOD or existing cardiac, cerebrovascular, or re­
nal disease.
Details on medical history and physical examination steps are sum­
marized in the supplement (see Supplementary data online, Tables S2 
and S3), as well as drugs or substances that may increase BP (see 
Supplementary data online, Table S4).
7.4.2. Drug adherence and persistence with 
treatment
Adherence is defined as the extent to which a patient’s behaviour, e.g. 
with respect to taking medication, coincides with agreed recommenda­
tions from a healthcare provider. Persistence represents the amount of 
time from initiation to discontinuation of therapy.248 Adherence to med­
ical therapies is especially suboptimal in asymptomatic conditions such as 
hypertension.249–254 Non-adherence to BP-lowering therapy correlates 
with a higher risk of CVD events.255,256 Objective methods to assess ad­
herence, such as detecting prescribed drugs in blood or urine samples and 
directly observed treatment (witnessed pill intake during ABPM), have de­
monstrated their potential usefulness, particularly in the setting of appar­
ently resistant hypertension.257 However, all methods for testing drug 
adherence have limitations.
Non-adherence to BP-lowering therapy depends on many factors 
(Figure 11).253 Effective patient–physician communication is crucial to im­
prove adherence.258,259 Single-pill combinations improve persistence in 
BP-lowering treatment and are associated with lower all-cause mortality.260
7.4.3. Routine and optional tests
Routine tests include laboratory and clinical tests to detect increased CVD 
risk and relevant comorbidities (e.g. hyperlipidaemia and diabetes) (Table 8).
Optional tests should be considered in the initial assessment if they 
are likely to change patient management, with the main rationale being 
to improve CVD risk stratification.170 As highlighted in Section 6, for 
adults with elevated BP who also have a 10-year estimated CVD risk 
of 5% to <10%, optional tests including those for HMOD may be con­
sidered if up-classification of risk on the basis of an abnormal test result 
could prompt initiation of BP-lowering therapy.31,170 Evidence of sub­
clinical microvascular neurodegeneration and/or lacunar brain disease 
due to small-vessel pathology may also indicate HMOD.264
Table 7 Key illness representations and treatment beliefs: how these apply to communicating a hypertension diagnosis 
to the patient (note that gender influences these representations)
Illness 
representation
Example patient question
Application to a hypertension diagnosis conversation
Identity
What is the disease/illness label and the 
related symptoms?
The condition where your systolic BP is ≥140 and/or diastolic  
BP ≥90 mmHg is called hypertension. We classify systolic BP 120–139 or diastolic  
BP 70–89 mmHg as elevated BP. For most people, this has no noticeable signs or 
symptoms, therefore, we need to monitor your BP to assess how medications and 
behavioural changes are working.
Control
Is the illness controllable through medical 
intervention or behavioural change?
Hypertension can usually be controlled with medication and behavioural changes such as 
dietary changes and regular physical activity. For some people we need to try a few 
different options before we get BP under control.
Timeline
Is this an acute or chronic problem?
This is a serious long-term or chronic condition condition that will require long-term 
management. This means that it may need to be managed throughout life.
Consequences
What are the physical and psychosocial 
consequences?
If hypertension is not controlled, then there is a risk of a serious acute cardiovascular 
disease event such as a stroke or heart attack; however, if it is managed through the right 
medical intervention and behavioural changes, then this risk can be reduced and the 
condition will have less consequences for your life.
Causes
What caused the condition?
Multiple factors contribute to someone developing hypertension. These include both 
non-modifiable factors (e.g. genetics and age) and modifiable factors (e.g. diet, weight, 
and physical activity). We are best focusing on those things that we can control to 
reduce your BP.
Treatment beliefs
Example patient question
Application to a hypertension diagnosis communication
Necessity
To what extent is treatment necessary?
Taking BP-lowering medication every day is necessary to keep your BP under control and 
to help prevent a more serious health problem developing. Do you think that these 
medicines will help you?
Concerns
To what extent does treatment cause 
concern?
Some patients have concerns about taking daily medications throughout their life, e.g. 
about side effects. Do you have any concerns about taking your BP medications every day?
© ESC 2024
BP, blood pressure.
Recommendation Table 7 — Recommendations for 
assessing adherence and persistence with treatment 
(see Evidence Table 16)
Recommendation
Classa
Levelb
Objective evaluation of adherence (either directly 
observed treatment or detecting prescribed drugs in 
blood or urine samples) should be considered in the 
clinical work-up of patients with apparent resistant 
hypertension, if resources allow.261–263
IIa
B
© ESC 2024
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3945


<!-- PAGE 35 -->

### Page 35

While the role of optional tests for HMOD (Table 9) in the man­
agement of elevated BP is emphasized in these guidelines, we also 
note that these tests may help to optimize treatment in hyperten­
sive adults with BP of >140/90 mmHg who are prescribed 
BP-lowering therapy (e.g. by facilitating patient adherence and 
overcoming clinician inertia in achieving an intensive BP treatment 
target of as low as 120 mmHg systolic). The role of visualizing 
HMOD in helping motivate risk-reducing changes in patients and 
overcome physician inertia has been tested in interventional trials 
(Section 7.3).247,265–267
Non-adherence definition
Assessment
Intervention
Non-adherence definition
Assessments
Intervention
1
2
3
Patient does not initiate medication
Prescription fill data and self-report
Communicate benefits/safety of medication; alleviate fear of side effects/harm; discuss practicalities
Patient does not take medication as prescribed
Prescription refill data; self-report; electronic monitoring; 
chemical adherence testing (blood/urine)
Reminders; encourage habit formation; simplify drug regimen
Patient discontinues medication
Prescription refill data; self-report; electronic monitoring;
chemical adherence testing (blood/urine)
Motivational counseling on benefits/safety of medication; 
discuss side effects; medication reconciliation; review practical aspects (cost and ease of access to medication)
Non-adherence definition
Assessment
Intervention
Initiation
Implementation
Persistence
Figure 11 Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications.  
Table 8 Routine tests recommended in the initial work-up of a patient with elevated blood pressure or hypertension
Routine test
Clinical utility
Fasting blood glucose (and HbA1c if fasting blood glucose is 
elevated)
Assessing CVD risk and comorbidities
Serum lipids: total cholesterol, LDL cholesterol, HDL and 
non-HDL cholesterol, triglycerides
Assessing CVD risk
Blood sodium and potassium, haemoglobin and/or haematocrit, 
calcium, and TSH
Screening secondary hypertension (primary aldosteronism, Cushing’s disease, 
polycythaemia, hyperparathyroidism, and hyperthyroidism)
Blood creatinine and eGFR; urinalysis and urinary 
albumin-to-creatinine ratio
Assessing CVD risk and HMOD 
Guiding treatment choice 
Screening secondary hypertension (renoparenchymal and renovascular)
12-lead ECG
Assessing HMOD (left atrial enlargement, left ventricular hypertrophy) 
Assessing irregular pulse and other comorbidities (AF, previous acute myocardial infarction)
© ESC 2024
AF, atrial fibrillation; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HMOD, 
hypertension-mediated organ damage; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.


<!-- PAGE 36 -->

### Page 36

HMOD assessment is also an important way to identify young adults 
<40 years old who have increased CVD risk, since 10-year estimated 
CVD risk by SCORE2 cannot be calculated in this age group (see 
Section 8.1). More details on diagnostic thresholds for HMOD by the 
various assessment options, including important sex differences, are 
provided in Supplementary data online, Tables S1 and S5 and Figure 12.
Finally, some individuals may be at heightened risk for CVD events 
when cardiac and vascular HMOD measurements like LVH and 
increased PWV do not regress over time with appropriate treatment 
and BP control.14,268–271
Investigations aimed at screening for secondary hypertension are 
additional optional tests and are detailed in Section 7.6. Of note, patients 
with an incidental adrenal nodule or nodules (typically detected on im­
aging of the abdomen done for other clinical reasons) warrant screen­
ing for elevated BP and hypertension. Those with adrenal 
incidentalomas and hypertension warrant a basic work-up for second­
ary hypertension to include screening for primary aldosteronism, 
Cushing’s syndrome and phaeochromocytoma.
7.4.3.1. The kidneys
CKD is defined as abnormalities of kidney structure or function, pre­
sent for at least 3 months with implications for health.272 Renal function 
is evaluated initially using serum creatinine and an estimated glomerular 
filtration rate (eGFR) equation (preferably race-free CKD-EPI) and typ­
ically for proteinuria.273 Our definition of moderate-to-severe CKD re­
quires an eGFR of <60 mL/min/1.73 m2 or albuminuria of ≥30 mg/g 
(≥3 mg/mmol). Intensive BP control in patients with CKD reduces rates 
of CVD events.274,275 CKD can influence the choice of BP-lowering 
treatment (Sections 8 and 9), as well as newer drugs for cardiovascular 
prevention, such as sodium–glucose co-transporter 2 (SGLT2) inhibi­
tors and finerenone.
We recommend repeat measurement of eGFR and urine albumin: 
creatinine ratio (ACR) at least annually if clinically significant CKD is di­
agnosed. Renal ultrasound and Doppler examination to evaluate causes 
of CKD and to exclude renoparenchymal and renovascular hyperten­
sion (RVH) should also be considered.276,277
7.4.3.2. The heart
A 12-lead ECG is a part of the initial routine work-up for all patients with 
hypertension and should be repeated whenever patients present with an 
irregular pulse or cardiac symptoms. The ECG should be analysed for 
LVH (Supplementary data online, Table S1) and AF.31,278–282
Echocardiography is recommended in patients with hypertension 
when the ECG is abnormal, murmurs are detected, or there are cardiac 
symptoms. A full, standardized, two-dimensional echocardiogram should 
be performed, preferably with tissue Doppler and strain assessment. 
Echocardiography can be considered for all patients with newly diag­
nosed hypertension, if local resources and reimbursement policies allow. 
Over 5 years of follow-up, subclinical left ventricular diastolic dysfunction 
predicts the incidence of CVD.283–285 In addition, LVH detected by echo­
cardiography predicts total and cardiovascular mortality and CVD events 
in the general population,286,287 including in young adults.26,268,288,289
Data on the associations with CVD of other metrics for detecting 
HMOD in the heart are also available.26,268,290 Since cardiac size and func­
tion differ by sex, sex-specific thresholds for detecting HMOD in the 
heart are used to avoid under-diagnosis in women.25,174,291
Table 9 Optional tests that may be used as clinically indi­
cated in the initial work-up of a patient with elevated blood 
pressure or hypertension to assess hypertension-mediated 
organ damage or established cardiovascular disease
Optional test
Clinical utility
Echocardiography
Assessing HMOD (hypertensive heart 
disease) 
Assessing established CVD (previous 
acute myocardial infarction, heart 
failure) 
Assessing thoracic aorta dilation
CAC by cardiac CT or carotid or 
femoral artery ultrasound imaging
Assessing HMOD (atherosclerotic 
plaque)
Large artery stiffness (carotid– 
femoral or brachial–ankle PWV)
Assessing HMOD (arterial stiffness)
High-sensitivity cardiac troponin 
and/or NT-proBNP
Assessing HMOD
Ankle–brachial index
Assessing established CVD 
(lower-extremity arterial disease)
Abdominal ultrasound
Assessing established CVD 
(abdominal aneurysm)
Fundoscopy
Assessing HMOD (hypertensive 
retinopathy) 
Diagnosing hypertensive emergency/ 
malignant hypertension 
(haemorrhages and exudates, 
papilloedema)
© ESC 2024
CAC, coronary artery calcium; CT, computed tomography; CVD, cardiovascular disease; 
HMOD, hypertension-mediated organ damage; NT-proBNP, N-terminal pro-brain 
natriuretic peptide; PWV, pulse wave velocity.
Recommendation Table 8 — Recommendations for 
assessing renal hypertension-mediated organ damage
Recommendation
Classa
Levelb
It is recommended to measure serum creatinine, 
eGFR, and urine ACR in all patients with 
hypertension.170,273
I
A
If moderate-to-severe CKD is diagnosed, it is 
recommended to repeat measurements of serum 
creatinine, eGFR, and urine ACR at least annually.276
I
C
Renal ultrasound and Doppler examination should 
be considered in hypertensive patients with CKD to 
assess kidney structure and determine causes of 
CKD and to exclude renoparenchymal and 
renovascular hypertension.276,277 CT or magnetic 
resonance renal angiography are alternative testing 
options.
IIa
C
© ESC 2024
ACR, albumin:creatinine ratio; CKD, chronic kidney disease; CT, computed tomography; 
eGFR, estimated glomerular filtration rate. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 9 — Recommendations for 
assessing cardiac hypertension-mediated organ damage
Recommendation
Classa
Levelb
A 12-lead ECG is recommended for all patients with 
hypertension.31,281
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3947


<!-- PAGE 37 -->

### Page 37

7.4.3.3. The arteries
Cardiac computed tomography (CT) may be used to measure CAC 
and, if intravascular contrast is administered, fully visualize coronary 
artery disease to improve risk stratification.211,293 As noted in 
Section 6, CAC scoring can reclassify CVD risk upwards or down­
wards in addition to conventional risk factors.127,170,211,233,294
Carotid ultrasound detects presence or absence of carotid plaque 
(wall thickness ≥ 1.5 mm) and stenosis. Presence of plaque in the ca­
rotid or femoral arteries improves risk prediction for CVD events in 
asymptomatic patients on top of conventional risk-factor assess­
ment.211,247,265,267,295,296 Systematic use of intima media thickness 
does not appear to consistently improve prediction of future CVD 
events.297 Arterial stiffness is measured as carotid–femoral PWV or 
brachial–ankle PWV, and can contribute to predictive value and risk 
reclassification.28,31,215,216 PWV is currently used mostly for research 
purposes or in specialist referral centres. Checking for inter-arm BP 
difference may identify a subclavian stenosis as vascular HMOD.38
Other tests assessing the vasculature [such as abdominal ultrasound 
or ankle–brachial index (ABI)] should also be considered in patients 
with hypertension, when specific cardiovascular complications (ab­
dominal aneurysm, peripheral artery disease) are clinically suspected. 
Finally, microvascular HMOD can be assessed by fundoscopy. A sim­
plified classification has been proposed and validated.298 In hyperten­
sive individuals, the presence of mild or moderate hypertensive 
retinopathy is associated with an increased risk of CVD events.299
Fundoscopy is recommended also in hypertensive diabetic patients 
and in the work-up of malignant hypertension and hypertensive 
emergencies.
7.4.4. Genetic testing
Hypertension is considered a complex polygenic disorder, because 
many genes or gene combinations influence BP.300,301 However, some 
well-defined phenotypes relating to single-gene mutations (i.e. mono­
genic forms of hypertension) have been identified (see Supplementary 
data online, Table S6). These are rare, but knowledge of the genetic 
defect may allow targeted treatment of the proband and also proper 
management of the patient’s siblings.302,303 As such, genetic testing 
should be considered only for those with a high prior probability of hav­
ing a monogenic condition and such patients should be referred to spe­
cialized centres. In most patients with elevated BP or hypertension, 
routine genetic testing is not recommended. Family history and a pedi­
gree analysis can help to find a heritable pattern of hypertension or 
hypotension.304
7.5. Resistant hypertension: definition and 
diagnosis
Despite availability and use of multiple BP-lowering medications, 
many patients worldwide have uncontrolled hypertension.306–308
Considering this, societies have introduced the term ‘drug-resistant 
hypertension’, or ‘treatment-resistant hypertension’, or ‘resistant 
hypertension’,309 which has been reported in 10%–20% of patients 
with hypertension.310,311
Resistant hypertension is not a disease per se. Compared with 
treated patients who achieve BP control, patients with resistant 
hypertension (by any definition) have a worse prognosis: risk of 
myocardial infarction, stroke, end-stage renal disease, and death 
in these adults may be two- to six-fold higher.309 Secondary causes 
of hypertension are also more likely in the presence of resistant 
hypertension.312
All resistant hypertension definitions require a diuretic in the prescribed 
multiple-drug regimen, because excess salt intake and salt and water reten­
tion are key players in resistance to BP-lowering treatments (Table 10).309
Echocardiography is recommended in patients with 
hypertension and ECG abnormalities, or signs or 
symptoms of cardiac disease.14,31,292
I
B
Echocardiography may be considered in patients 
with elevated BP, particularly when it is likely to 
change patient management.31,291
IIb
B
© ESC 2024
BP, blood pressure; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 10 — Recommendations for 
assessing vascular hypertension-mediated organ dam­
age (see Evidence Table 17)
Recommendations
Classa
Levelb
Fundoscopy is recommended if BP >180/110 mmHg 
in the work-up of hypertensive emergency and 
malignant hypertension, as well as in hypertensive 
patients with diabetes.
I
C
Fundoscopy for detecting hypertensive retinopathy 
may be considered in patients with elevated BP or 
hypertension.299
IIb
B
Ultrasound examination of the carotid or femoral 
arteries for detecting plaque may be considered in 
patients with elevated BP or hypertension when it is 
likely to change patient management.211
IIb
B
Continued
Coronary artery calcium scoring may be considered 
in patients with elevated BP or hypertension when it 
is likely to change patient management.127,211
IIb
B
Measurement of PWV may be considered in patients 
with elevated BP or hypertension when it is likely to 
change patient management.28,31,215,216
IIb
B
© ESC 2024
BP, blood pressure; PWV, pulse wave velocity. 
aClass of recommendation. 
bLevel of recommendation.
Recommendation Table 11 — Recommendations for 
genetic testing in hypertension management
Recommendations
Classa
Levelb
Genetic testing should be considered in specialist 
centres for patients suspected to have rare 
monogenic causes of secondary hypertension or for 
those with phaeochromocytoma/ 
paraganglioma.302,305
IIa
B
Routine genetic testing for hypertension is not 
recommended.
III
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 38 -->

### Page 38

Coronary artery calcium score
>100 Agatston units
Carotid-femoral PWV >10 m/s
Brachial-ankle PWV >14 m/s
Plaque (focal wall thickening >1.5 mm)
Cornell voltage: SV3+RaVL>28 mm (men) 
SV3+RaVL>20 mm (women)
RaVL ≥11 mm
Sokolow–Lyon: SV1+RV5 >35 mm
Cardiac CT
Pulse wave velocity
Carotid or femoral ultrasound
Cardiac biomarkers
Echocardiography
ECG
eGFR
ACR
Moderate-to-severe kidney disease
LVH
LVH
Diastolic dysfunction
LV mass/height2.7(g/m2.7):
>50 (men)
>47 (women)
LV mass/BSA(g/m2): 
>115 (men)
>95 (women)
RWT ≥0.43
LV concentric geometry:
LA volume/height2 (mL/m2): >18.5 (men)
>16.5 (women)
LA volume index (mL/m2): 34
e’ <7cm; E/e’ >14
hs-cTnT or I >99th percentile upper reference limit
NT-proBNP >125 pg/mL if age <75 years or >450 pg/mL if ≥75 years eGFR <60 mL/min/1.73 m2 irrespective of albuminuria
Albuminuria ≥30 mg/g irrespective of eGFR
Assistance overcoming patient and physician inertia
Individuals <40
years old with elevated blood pressure
Uncertain situations
(i.e. BP or risk close to thresholds,
masked or white-coat hypertension,
non-traditional
CVD risk factors)
Individuals with elevated BP with
SCORE2/SCORE2-OP
risk of 5–<10%
Support decision to start or intensify BPlowering treatment for:
Why measure?
How to diagnose HMOD?
What to measure?
Which organ?
Kidney
Heart
Arteries
Figure 12 Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice. ACR, albumin: 
creatinine ratio; BP, blood pressure; BSA, body surface area; CT, computed tomography; CVD, cardiovascular disease; ECG, electrocardiogram; 
eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrial; 
LV, left ventricular; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RWT, relative 
wall thickness; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. More details 
and references can be found in the Supplementary data online, Tables S1 and S5.  
ESC Guidelines                                                                                                                                                                                          3949


<!-- PAGE 39 -->

### Page 39

In addition, excluding pseudo-resistance is a prerequisite. Specifically, 
pseudo-resistance indicates poor adherence to BP-lowering treatment, 
which should be verified by careful questioning of the patient in the first 
instance (Section 7.4.3).257 In addition, white-coat hypertension must be 
excluded.263 Contributors to pseudo-resistance are listed in Table 11. 
Objective evaluation of adherence (either directly observed treatment 
or detecting prescribed drugs in blood or urine samples) should also 
be considered, if resources allow.
The work-up of patients presumed to have resistant hypertension is 
complex and often requires technologies that are not available to 
GPs.257,309 Accordingly, we recommend these patients are referred 
to specialized centres.
7.6. Secondary hypertension: when to 
screen/further investigations
7.6.1. General considerations
Secondary hypertension is more prevalent than previously thought 
(Figures 13–15).312–317 Depending on the definition used and the 
cohort studied, the prevalence of secondary hypertension is 10%–35% in 
all hypertensive patients318,319 and up to 50% of patients with resistant 
hypertension (though the latter prevalence estimate included persons 
with eGFR < 40 mL/min/1.73 m2).312 Primary aldosteronism is a 
common cause,315,320 with, e.g. a high prevalence of hyperaldosteron­
ism (up to 12%) observed in patients with BP of >180/110 mmHg.316
Despite these numbers, screening rates for primary aldosteronism, 
even in high-risk groups such as those with resistant hypertension321
and hypokalaemia,322 are low (around 2% and 4% of eligible patients, 
respectively). In most healthcare systems, GPs are typically the ‘gate­
keeper’ of access to specialized care and should be involved in screen­
ing patients for common causes of secondary hypertension, especially 
sleep apnoea and primary aldosteronism (Supplementary data online, 
Tables S2 and S3). Primary aldosteronism is associated with an increased 
risk of CVD events, which may be partly independent of BP.323,324
7.6.2. Primary aldosteronism
Though spontaneous or diuretic-induced hypokalaemia are strongly 
suggestive of primary aldosteronism, a history of hypokalaemia is 
not present in most patients diagnosed with this condition. The 
aldosterone-to-renin ratio (ARR) is thus recommended for primary 
aldosteronism screening (see Figure 13).325 This test can easily be done 
in treatment-naïve patients, though it is far more common for the 
ARR test to be considered when patients are already being treated for 
elevated BP or hypertension. This is relevant because ARR can be influ­
enced by the drugs being taken at the time of testing. Accordingly, there 
are 2 approaches to screen for aldosteronism among patients who are 
already undergoing treatment for elevated BP or hypertension: 
• The first is to conduct ARR testing in treated patients with an indication 
for aldosteronism screening as efficiently as possible and without chan­
ging or stopping their baseline BP-lowering medications, simply to facili­
tate such testing. The ARR result then needs to be interpreted in the 
context of the specific medication(s) the patient is taking. Advantages 
of this approach include reducing barriers to screening and no change 
in medication in these patients, many of whom do not have BP con­
trolled and in whom further deterioration in their BP control by stop­
ping or changing medication may increase risk of CVD. Disadvantages 
include the interpretation of the ARR result, which depends on the spe­
cific medications taken at the time of testing.326 Input from a hyperten­
sion specialist or endocrinologist may be necessary.
Recommendation Table 12 — Recommendations for 
resistant hypertension work-up (see Evidence Table 18)
Recommendation
Classa
Levelb
Patients with resistant hypertension should be 
considered for referral to clinical centres with expertise 
in hypertension management for further testing.309,312
IIa
B
© ESC 2024
aClass of recommendation. 
bLevel of evidence.
Table 10 Current definition of resistant hypertension
Definition of resistant hypertension
Hypertension is defined as resistant when a treatment strategy including 
appropriate lifestyle measures and treatment with maximum or maximally 
tolerated doses of a diuretic (thiazide or thiazide-like), a RAS blocker, and a 
calcium channel blocker fail to lower office systolic and diastolic BP values to 
<140 mmHg and/or <90 mmHg, respectively. These uncontrolled BP values 
must be confirmed by out-of-office BP measurements (HBPM or ABPM— 
Section 5.1 for relevant BP thresholds).
Key considerations
• Resistant hypertension is not a disease, but an indicator that should be 
used to identify patients at high risk for CVD, in which secondary 
hypertension is also frequent;
• Pseudo-resistant hypertension must be excluded, including that caused by 
non-adherence to treatment;
• In patients with decreased eGFR (i.e. <30 mL/min/1.73 m2) an adequately 
up-titrated loop diuretic is necessary to define resistant hypertension;
• Patients with suspected resistant hypertension should be referred to 
specialized centres;
• These ESC Guidelines do not include the terms ‘controlled resistant 
hypertension’ (BP at target but requiring ≥4 medications) or ‘refractory 
hypertension’ (BP not at target despite ≥5 medications).
© ESC 2024
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular 
disease; eGFR, estimated glomerular filtration rate; HBPM, home blood pressure 
monitoring; RAS, renin–angiotensin system.
Table 11 Conditions found to cause pseudo-resistance 
or resistance to blood pressure-lowering treatment
Causes of pseudo-resistant hypertension
Poor adherence to and persistence with treatment 
White-coat phenomenon 
Poor BP measurement method 
Marked brachial artery calcification (Osler phenomenon) 
Clinician inertia (inadequate doses, inappropriate combinations of 
BP-lowering drugs) 
Munchausen syndrome (rare)
Causes of resistant hypertension
Behavioural factors 
Overweight/obesity 
Physical inactivity 
Excess daily dietary sodium 
Excess habitual alcohol consumption
Use of drugs or substances that may increase BP 
See Supplementary data online, Table S4
Undetected secondary hypertension 
See Table 13
© ESC 2024
BP, blood pressure.


<!-- PAGE 40 -->

### Page 40

• To reliably estimate renin and aldosterone status (and therefore 
ARR), and to facilitate a ‘clean’ screen for aldosteronism, a second 
approach is to discontinue drugs that affect these variables when­
ever feasible before ARR testing (Table 12). Such interfering drugs 
include, beta-blockers, centrally acting drugs (e.g., clonidine and 
alpha-methyldopa) renin-angiotensin system (RAS) blockers and 
diuretics.326 Long-acting calcium channel blockers (CCBs), either di­
hydropyridine or non-dihydropyridine, and alpha-receptor antago­
nists do not interfere with the ARR and can be used instead of 
interfering medications before ARR testing. Should drugs that do 
not interfere with the ARR be contraindicated or insufficient to con­
trol BP, centrally acting sympatholytic drugs can also then be used, but 
at the risk of slightly more false positives (by renin suppression). 
Furthermore, when mineralocorticoid receptor antagonists (MRAs) 
cannot be stopped for safety reasons (i.e. severe hypokalaemia or se­
vere hypertension among patients with severe hyperaldosteronism), 
recent evidence suggests that the accuracy of ARR testing under 
this treatment is only marginally impacted, particularly in the presence 
of florid primary aldosteronism.327
Assessing sodium intake (preferably 24 h urinary sodium, or sodium- 
to-creatinine ratio in the morning urine sample) is also important for 
interpreting the ARR, as is time in menstrual cycle for females. ARR 
cut-offs vary depending on unit of measurement and by local labora­
tory. For detailed information, readers are referred to the latest pri­
mary aldosteronism guidelines.328,329
7.6.3. Renovascular hypertension
Renovascular hypertension (RVH) defines a condition where renal 
artery occlusion or stenosis decreases renal perfusion pressure to 
a level that activates the renin–angiotensin–aldosterone system 
(RAAS), thereby raising BP. Major causes are atherosclerosis and 
fibromuscular dysplasia (Figure 14 and Supplementary data online, 
Tables S1 and S2). Atherosclerosis is the most common form of 
RVH, especially in older adults.318 Fibromuscular dysplasia is a sys­
temic non-atherosclerotic vascular disease involving medium-sized 
muscular arteries. When renal arteries are involved, fibromuscular 
dysplasia may induce RVH (FMD-RVH), especially in children and 
younger women.330–332
Though not highly sensitive, very elevated renin levels raise the sus­
picion for RVH. The work-up of RVH (Table 13) is based on imaging 
tests, such as renal artery Doppler ultrasound, with bilateral assessment 
of renal arterial resistive index, or abdominal CT angiography, or mag­
netic resonance imaging (MRI), in line with current ESC Guidelines on 
the diagnosis and treatment of peripheral arterial diseases,277 which 
will be updated in 2024. Of note, bystander renal artery stenosis may 
be present in patients with essential hypertension, without causing sec­
ondary hypertension due to RVH. Since fibromuscular dysplasia is a sys­
temic disease, CT or MRI angiography from head to pelvis is 
recommended in patients with FMD-RVH.277,332
7.6.4. Obstructive sleep apnoea syndrome
Obstructive sleep apnoea syndrome (OSAS) is prevalent in hyperten­
sion and particularly in resistant hypertension, with studies indicating 
that up to 60% of patients with resistant hypertension have features 
of OSAS.314 OSAS should be suspected in patients with hypertension 
and suggestive symptoms (see Supplementary data online, Table S2), 
in all patients with resistant hypertension, and in patients with non- 
dipping or reverse-dipping pattern at 24 h BP monitoring, especially if 
obese (Figure 15). Using validated questionnaires may help identify pa­
tients at high risk of OSAS.333 Lack of suggestive symptoms does not 
rule out OSAS. A simplified polysomnogram confirms the diagnosis [ap­
noea–hypopnoea index (AHI) > 5] and can quantify the severity of 
OSAS (mild: AHI < 15; moderate: AHI of 15–30; severe: AHI > 30).334
Table 12 Drugs and conditions that affect aldosterone, renin, and aldosterone-to-renin ratio
Factor
Effect on plasma aldosterone levels
Effect on renin levels
Effect on ARR
Serum potassium status
Hypokalaemia
↓
→↑
↓ (FN)
Potassium loading
↑
→↓
↑
Sodium restriction
↑
↑↑
↓ (FN)
Sodium loading
↓
↓↓
↑ (FP)
Drugs
Beta-adrenergic blockers
↓
↓↓
↑ (FP)
Calcium channel blockers (DHPs)
→↓
→↑
→↓ (FN with short-acting DHPs)
ACE inhibitors
↓
↑↑
↓ (FN)
ARBs
↓
↑↑
↓ (FN)
Potassium-sparing diuretics
↑
↑↑
↓ (FN)
Potassium-wasting diuretics
→↑
↑↑
↓ (FN)
Alpha-2 agonists (clonidine, methyldopa)
↓
↓↓
↑ (FP)
NSAIDs
↓
↓↓
↑ (FP)
Steroids
↓
→↓
↑ (FP)
Contraceptive agents (drospirenone)
↑
↑
↑ (FP)
© ESC 2024
↑, raised; ↓, lowered; →, no effect; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARR, aldosterone-to-renin ratio; DHPs, dihydropyridines; FN, false negative; FP, 
false positive; NSAID, non-steroidal anti-inflammatory drug.
ESC Guidelines                                                                                                                                                                                          3951


<!-- PAGE 41 -->

### Page 41

Primary aldosteronism
Mostly asymptomatic
Spontaneous or diureticprovoked hypokalaemia
AF 
Disproportionate HMOD
Muscle weakness and tetany
Family history of primary aldosteronism, early onset hypertension and/or stroke
Adrenal incidentaloma
Signs and symptoms
Diagnosis
Pathophysiology
Treatment
Aldosterone-renin ratio (ARR)
Confirmatory tests (e.g. saline suppression test)
Adrenal vein sampling or functional imaging
Genetic testing
Aldosterone-producing adenoma
Familial forms due to germline mutations
Bilateral hyperplasia
Medical: mineralocorticoid receptor antagonists
Surgical: unilateral adrenalectomy
Figure 13 Summary of primary aldosteronism as a common form of secondary hypertension. AF, atrial fibrillation; HMOD, hypertension-mediated 
organ damage.  
Table 13 Optional tests that should be used to screen for secondary hypertension in the presence of suggestive signs, 
symptoms, or medical history
Cause of secondary 
hypertension
Screening test
Primary aldosteronism
Aldosterone-to-renin ratio 
Helpful information can also be provided by reviewing prior potassium levels (hypokalaemia increases the likelihood of 
coexistent primary hyperaldosteronism)
Renovascular hypertension
Renal doppler ultrasound 
Abdominal CT angiogram or MRI
Phaeochromocytoma/paraganglioma
24 h urinary and/or plasma metanephrine and normetanephrine
Obstructive sleep apnoea syndrome
Overnight ambulatory polysomnography
Renal parenchymal disease
Plasma creatinine, sodium, and potassium 
eGFR 
Urine dipstick for blood and protein 
Urinary albumin-to-creatinine ratio 
Renal ultrasound
Cushing’s syndrome
24 h urinary free cortisol 
Low-dose dexamethasone suppression test
Thyroid disease (hyper- or 
hypothyroidism)
TSH
Hyperparathyroidism
Parathyroid hormone 
Calcium and phosphate
Coarctation of the aorta
Echocardiogram 
Aortic CT angiogram
© ESC 2024
CT, computed tomography; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; TSH, thyroid-stimulating hormone.


<!-- PAGE 42 -->

### Page 42

Restless/intermittent sleep,
recurrent awakenings daytime sleepiness, fatigue,
impaired concentration
Increased neck circumference
Apnoea, snoring
Obesity
Signs and symptoms
Atrial fibrillation
Non-dipping or reverse dipping pattern 24 h ABPM
Obstructive sleep apnoea
Pathophysiology
Intermittent upper airway obstruction during sleep
Overnight ambulatory polysomnography
Diagnosis
Treatment
Weight loss
CPAP
Mandibular advancement devices
Figure 15 Summary of obstructive sleep apnoea as a common form of secondary hypertension. AF, atrial fibrillation; ABPM, ambulatory blood pres­
sure monitor; CPAP, continuous positive airway pressure.  
Renovascular hypertension
Migraine, pulsatile tinnitus (FMD)
Pulmonary oedema (bilateral)
Multisite atherosclerosis
Unexplained small kidney or kidney asymmetry
Age <40 years (FMD)
Signs and symptoms
Pathophysiology
Diagnosis
Treatment
Significant renal artery stenosis:
Atherosclerosis
Fibromuscular dysplasia
Rare causes
Renal doppler ultrasound
Abdominal CT-Angio or MRI
Vascular bruits
Arterial dissections and/or aneurysms (FMD)
Medical: optimal CV
risk management
Interventional: renal angioplasty without (FMD) or with stenting (atherosclerosis)
Acute    eGFR after RAS blocker
GFR, albuminuria,    renin
Age >60 years with acute change in BP or flash pulmonary oedema
(atherosclerosis)
Figure 14 Summary of renovascular disease as a common form of secondary hypertension. CT-Angio, computed tomography angiography; 
CV, cardiovascular; FMD, fibromuscular dysplasia; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; RAS, renin–angiotensin system.  
ESC Guidelines                                                                                                                                                                                          3953


<!-- PAGE 43 -->

### Page 43

7.6.5. Phaeochromocytoma/paraganglioma
Phaeochromocytomas/paragangliomas (PPGLs) are a rare form of sec­
ondary hypertension characterized by a highly heterogeneous clinical 
presentation.335,336 PPGLs are usually discovered incidentally.337
A PPGL should be suspected in the presence of signs and symptoms of 
catecholamine excess or in syndromic PPGL, in patients with a family his­
tory of PPGL, and in carriers of a germline mutation in one of the 
PPGL-causing genes.338 Since normetanephrine and metanephrine are se­
creted constitutively, as opposed to the highly variable nature of catechol­
amine secretion, they are preferred as screening tests for PPGL (Table 13).
8. Preventing and treating elevated 
blood pressure and hypertension
The ultimate goal of preventing and treating elevated BP and hyperten­
sion is to reduce CVD, to improve quality of life, and to prevent prema­
ture death. Crucially, besides BP, other CVD risk factors need to be 
comprehensively addressed (e.g. smoking, glucose, dyslipidaemia) as de­
tailed in the 2021 ESC Guidelines on cardiovascular disease prevention 
in clinical practice.170 Indeed, it is worth emphasizing that, when com­
bined, these CVD risk factors have multiplicative (not additive) effects 
on CVD risk.340
8.1. Prevention strategies in early life
Detailed information on this topic is provided in the Supplementary data 
online. High BP tracks from childhood to adulthood.341,342 Hypertension 
in childhood was redefined in a 2022 ESC Consensus Document.343
8.2. Non-pharmacological interventions
A major underlying contributor to elevated BP and hypertension in the 
general adult population is unhealthy lifestyle, with severe consequences 
for all-cause and CVD mortality. As such, we give lifestyle interventions to 
reduce BP a special status in our recommendations throughout these 
guidelines (Figures 16 and 17). This is reflected by a modified approach 
to the class of recommendations for lifestyle interventions compared 
with medical interventions (pharmacological or procedural). Given the 
salutary benefits of healthy lifestyle on a range of outcomes that extend 
well beyond BP-lowering effects,347 including broad mental and physical 
health benefits, we do not require lifestyle interventions to have RCT evi­
dence for efficacy in reducing CVD events through BP lowering to achieve 
a Class I recommendation. In deciding to give lifestyle interventions this 
status, the task force also recognizes that: (i) lifestyle interventions are 
less likely to be subjected to clinical outcomes trials (e.g. due to funding 
limitations and lack of interest from industry), and (ii) the risks of adverse 
effects and toxicity relating to healthy lifestyle interventions are low. In 
contrast, in these guidelines, to achieve a Class I recommendation (irre­
spective of level of evidence) there needs to be evidence that medical in­
terventions that reduce BP also decrease CVD events by BP lowering.
8.2.1. Dietary sodium and potassium intake
8.2.1.1. Sodium
Reducing dietary salt (sodium chloride) intake in individuals with high 
baseline intake lowers CVD event rates.348 Extensive observational stud­
ies have reported dose–response associations between high dietary so­
dium intake and CVD events.349–351 The potential impact of salt 
reduction on population health is significant, particularly in countries 
where the population’s average salt intake is high. Pooled data from long- 
term follow-up salt-reduction trials demonstrate that reducing salt by 
2.5 g/day is associated with an approximately 20% reduction in CVD 
events at the population level.349
The health benefits of salt reduction are likely mediated, largely, by 
BP-lowering effects.352–354 An almost linear relationship has been de­
scribed in a dose–response meta-analysis between sodium intake ran­
ging from 0.4 to 7.6 g/day and reduction of systolic and diastolic BP is 
independent of baseline BP.355,356 Women appear to be, on average, 
more sodium sensitive than men,357 and may have greater outcome 
benefits when receiving comparable sodium-restricted diets.358 Trial 
evidence for the BP-lowering benefits of salt reduction extend down 
to daily sodium intakes of <1.5 g/day.356,358–361
The task force acknowledges that the observational data linking so­
dium intake to CVD outcomes are mixed and that some studies have 
not found a link between salt intake and CVD.362,363 In addition, a po­
tential J-curve exists between sodium intake and CVD events (where­
by some analyses suggest that sodium reduction to very low levels 
could be harmful).363,364 While there are differences of opinion, the 
task force agreed that, on balance, (i) observational J-curve data are 
often due to reverse causality or confounding,114,348,365,366 (ii) the re­
lationship between dietary sodium and stroke is typically linear in 
shape, without any J-curve, (iii) if the J-curve were causal, the adverse 
effect of very low sodium on CVD would have to be mediated by some 
harmful mechanism that overcomes the expected benefit mediated by 
BP lowering (which is unlikely), and (iv) estimation of sodium intake 
using spot-urine sodium testing (which was commonly done in studies 
reporting a J-curve) may not be as valid as other methods.367 For ex­
ample, most (but not all)362 reports measuring 24 h urine sodium ex­
cretion (a surrogate measure of sodium intake) have not reported a 
J-curve association with CVD.350,364 Furthermore the causal evidence 
demonstrating reduced CVD with sodium restriction (using potassium- 
enriched salt substitutes) in the Salt Substitute and Stroke Study (SSaSS) 
Recommendation Table 13 — Recommendations for 
screening for secondary hypertension (see Evidence 
Tables 19 and 20)
Recommendations
Classa
Levelb
It is recommended that patients with hypertension 
presenting with suggestive signs, symptoms or medical 
history of secondary hypertension are appropriately 
screened for secondary hypertension.312,314,315,323,339
I
B
Screening for primary aldosteronism by renin 
and aldosterone measurements should be 
considered in all adults with confirmed 
hypertension (BP ≥140/90 mmHg).313,316,323,339
IIa
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 14 — Recommendations for 
screening for hypertension in children and adolescents 
(see Evidence Table 21)
Recommendation
Classa
Levelb
Opportunistic screening with office BP 
measurements to monitor development of BP during 
late childhood and adolescence, especially if one or 
both parents have hypertension, should be 
considered to better predict development of adult 
hypertension and associated CVD risk.344–346
IIa
B
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

and Diet, ExerCIse and carDiovascular hEalth-Salt  (DECIDE-Salt) trials 
was compelling,348,368 even though sodium restriction in these trials 
was not below 2 g/day.
It is recommended to restrict total dietary sodium intake to ap­
proximately 2 g/day or less (equivalent to approximately 5 g or about 
a teaspoon of salt per day). This includes added salt and salt already 
contained in food. While the feasibility of this sodium target can be 
debated, the evidence for the benefits of this sodium target among 
patients with elevated BP or hypertension is sufficient, particularly 
in terms of lowering BP. The optimal sodium intake in the general 
population with non-elevated BP is less clear (noting also that 
the BP-lowering effect of salt reduction among patients with 
non-elevated BP appears lower).353,354 A more feasible compromise 
in the general population might be a target sodium intake range of 2– 
4 g/day.369,370 It needs to be emphasized that large parts of daily so­
dium intake occur by means of sodium consumption contained in 
processed foods.
8.2.1.2. Potassium
Optimal dietary potassium intake, e.g. by consuming diets rich in fruits and 
vegetables, has BP-lowering effects and may be associated with lower 
CVD risk.348,364,368,371–373The association between potassium intake, systol­
ic BP, and CVD events may be sex-specific, being stronger in women.374 The 
World Health Organization (WHO) recommends over 3.5 g/day (∼90  
mmol/day) of dietary potassium.375 Excessive potassium supplementation 
should, however, be avoided374and CKD guidelines recommend dietary po­
tassium restriction to <2.4 g/day in persons with advanced CKD (see 
Supplementary data online).376
A lower urinary sodium-to-potassium ratio (Na+/K+ ratio; a surro­
gate for reduced dietary sodium intake complemented by increased po­
tassium intake) has been associated with a greater reduction in systolic 
and diastolic BP than with a higher ratio.348,377
In patients with hypertension and high dietary sodium, increased dietary 
intake of potassium (in addition to lower dietary sodium) should be con­
sidered.348,350,378In patients with persistently high sodium intake (>5 g/day) 
Aerobic exercise training
At least 150 min/week moderateintensity or 75 min/week vigorous intensity: brisk walking, jogging,
cycling, swimming
(Class I)
Isometric resistance exercise training:
Low-to-moderate-intensity
(3 sets of 1–2 min contraction:
hand-grip, plank, wall sit)
Dynamic resistance exercise training:
Large muscle groups, low-tomoderate-intensity (2–3 sets with
10–15 reps.: squat, push-ups, sit-up)
Increase daily physical activity
(steps/day, take stairs, walk/cycle)
Avoid sedentary lifestyle
BP
Reduction
CV Risk
Reduction
Dynamic or isometric resistance training to complement aerobic exercise training 
2–3 times/week
(Class I)
Figure 16 Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk. Priority is 
given to aerobic exercise training (green). BP, blood pressure; CVD, cardiovascular disease.  
ESC Guidelines                                                                                                                                                                                          3955


<!-- PAGE 45 -->

### Page 45

and without moderate-to-advanced CKD, particularly women, an increase 
in potassium intake by 0.5–1.0 g/day may be considered to achieve a fa­
vourable Na+/K+ ratio of 1.5–2.0 and to reduce CVD risk. Potassium sup­
plementation can be achieved by substituting sodium using potassium 
enriched salts (75% sodium chloride and 25% potassium chloride)368,379,380
or by increasing dietary potassium intake [e.g. a 125 g (medium) banana 
contains about 450 mg potassium, or unsalted boiled spinach (840 mg/ 
cup) or mashed avocado (710 mg/cup)]. In patients with CKD and/or 
those taking potassium-sparing medication, such as some diuretics, 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs) or spironolactone, serum levels of potassium should be 
monitored (noting that phlebotomy recommendations to avoid spuriously 
high potassium results should be followed).
8.2.2. Physical activity and exercise
In a systematic review and meta-analyses, aerobic (endurance) exercise 
was suggested as the first-line exercise therapy for reducing BP in pa­
tients with elevated BP and hypertension vs. alternative forms of exercise, 
such as dynamic or isometric resistance training.381 In patients with 
hypertension, regular aerobic exercise substantially lowers systolic BP 
by up to 7–8 mmHg and diastolic BP by up to 4–5 mmHg.381,382 For non- 
white patients with hypertension, dynamic resistance training elicits BP 
reductions that appear comparable to aerobic exercise.383 Isometric re­
sistance training also achieves clinically relevant BP reductions in patients 
with hypertension, but results are inconsistent and more data from more 
high-quality intervention trials are required (see Supplementary data 
online).381,384,385 With respect to mode and intensity of aerobic exercise, 
Increase physical activity
Increase potassium intake
Optimize weight management and diet
No smoking
Reduce alcohol intake
Reduce table salt
(sodium chloride) intake
BP
Reduction
CV Risk
Reduction
Figure 17 Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction. BP, blood pressure; CV, cardiovascular. Smoking ces­
sation reduces overall cardiovascular risk but not BP (long arrow). Salt reduction reduces BP and (for persons with high baseline intake) reduces car­
diovascular risk. Increased potassium intake and higher physical activity, as well as optimized weight management, reduce BP and are associated with 
lower overall cardiovascular risk (short arrows).


<!-- PAGE 46 -->

### Page 46

high-intensity interval training elicits comparable BP reductions to mod­
erate continuous exercise, with high-intensity interval training achieving 
greater improvement in physical fitness.386
In patients with known hypertension, engaging in physical activity is 
associated with reduced CVD mortality risk vs. sedentary patients 
with hypertension.387
An exaggerated BP response to exercise may yield diagnostic merits for 
predicting incident hypertension and CVD. In a meta-analysis, an exagger­
ated BP response to exercise was associated with an increased risk for 
masked hypertension.388 The risk of coronary heart disease also increases 
with higher systolic BP during exercise, independent of systolic BP at rest.389
Prior recommendations for at least 150 min/week of moderate inten­
sity aerobic exercise (≥30 min, 5–7 days/week) can be maintained.1,390
Alternatively, 75 min of vigorous-intensity exercise per week over 3 days 
may be performed, with additional benefits derived by achieving 300 min 
of moderate-intensity or 150 min of vigorous-intensity aerobic physical 
activity per week.390,391 As acute aerobic exercise induces intensity- 
dependent short-term reductions in ambulatory BP after exercise, patients 
with elevated BP and hypertension may benefit from daily exercise to im­
prove their 24 h BP profile and avoid BP peaks on sedentary days.392
Aerobic exercise should be complemented by low- or moderate-intensity 
resistance training (2–3 times per week), e.g. dynamic resistance, starting at 
2–3 sets of 10–15 repetitions at 40%–60% of one-repetition maximum393
or isometric resistance training with three sets of 1–2 min contractions, 
such as hand-grip, plank, or wall sit (Figure 16).381,394
In uncontrolled hypertension at rest, high-intensity exercise should 
be applied with caution, with resting systolic BP of >200 mmHg and dia­
stolic BP of >110 mmHg indicating relative contraindications.395 Age, 
sex, gender,396 ethnicity, and comorbidities, as well as individual prefer­
ences, should be considered for individual exercise prescription. 
Detailed information on exercise prescription in terms of frequency, in­
tensity, time (duration) and type and progression are available in the 
with cardiovascular disease,390 which include recommendations for 
pre-participation screening and cardiopulmonary exercise testing.390
8.2.3. Weight reduction and diet
Visceral obesity is common and associated with incident hyperten­
sion.397,398 An average weight loss of 5 kg has been associated with 
an average systolic and diastolic BP reduction of 4.4 and 3.6 mmHg, re­
spectively.399 Data show that, starting at an index body mass index 
(BMI) of 40 kg/m2, a median weight loss of 13% is associated with a 
22% lower risk for hypertension.400,401 Maintaining even moderate 
weight loss of 5%–10% of initial body weight can improve not only 
BP, but also glucose and lipid metabolism, and potentially reduce pre­
mature all-cause mortality.402–404 However, achieving long-term effects 
in patients with hypertension via weight loss is challenging and the mag­
nitude of these effects remains unclear.405,406 Weight stabilization dur­
ing middle-age appears to be an important and attainable goal to 
prevent obesity-related increase in BP later in life.407
Evidence-based diets, such as the Mediterranean diet and the Dietary 
Approaches to Stop Hypertension (DASH) diet, are established inter­
ventions in patients with hypertension to reduce their BP and CVD 
risk.408,409 Additional information on healthy dietary patterns is pro­
vided in the 2021 ESC Guidelines on cardiovascular disease prevention 
in clinical practice and Supplementary data online.170
In combination with weight-loss and exercise interventions410 and 
low sodium intake,411 the DASH diet has added effect on BP reduc­
tion.412 Pharmacological treatment of obesity with orlistat achieved a 
slight reduction of 2.6 mmHg in systolic BP.413 The greatest 
BP-lowering effects of weight-loss medications may be achieved with 
the glucagon-like peptide 1 (GLP-1) receptor agonists.414–416 For ex­
ample, in the Semaglutide Treatment Effect in People with Obesity 
(STEP-1) trial, the GLP-1 analogue semaglutide resulted in a mean 
weight reduction of 12.4% and a 5.1 mmHg reduction in systolic BP.415
8.2.4. Alcohol, coffee, and soft drinks
In a 2020 Cochrane review, the short-term effects of alcohol on BP were 
dose dependent; low-dose alcohol (<14 g) did not affect BP within 6 h, 
medium-dose (14–28 g) decreased both systolic and diastolic BP, and high- 
dose alcohol (>30 g) first decreased BP up to 12 h and then increased BP 
following >13 h of consumption by 3.7 mmHg systolic and 2.4 mmHg dia­
stolic.417 The trials in this Cochrane review included small numbers of wo­
men. In the longer term, no evidence has been found for a protective effect 
of chronic alcohol consumption on hypertension, for either sex. In con­
trast, even low-dose alcohol consumption (10 g/day) increases chronic 
risk of hypertension by 14% in men, but not in women.418 As per the 
tice, men and women are recommended to stay within the upper limit of 
drinking alcoholic beverages (100 g/week of pure alcohol). Defining num­
ber of drinks depends on portion size, the standards of which differ per 
country, but translates to 8–14 g/drink.170 Emerging data indicate it is likely 
healthiest to avoid all alcohol, where possible.419
Coffee intake is not associated with a higher risk of hypertension in 
the general population; in fact, higher coffee consumption may be asso­
ciated with a lower risk for incident hypertension.420 Data regarding the 
association between tea drinking and CVD are inconclusive, though 
mechanistic trials have suggested benefits on BP lowering.421 In con­
trast, energy drinks with high concentrations of ingredients such as 
taurine and caffeine increase BP and may lead to acute or chronic car­
diovascular complications in young adults.422–424
Consuming two or more servings per day of sugar-sweetened bev­
erages was associated with a 35% higher risk of coronary artery disease 
in women in the Nurses’ Health Study.425 In the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort, both sugar- and 
artificially sweetened soft drinks were associated with higher all-cause 
mortality.426 In children and adolescents, sugar-sweetened beverages 
increased systolic BP and the risk for incident hypertension.427 It is re­
commended to restrict free sugar consumption, in particular 
sugar-sweetened beverages, to a maximum of 10% of energy intake.
8.2.5. Smoking
To stop smoking is arguably the most effective measure in preventing 
major CVD events at the individual level, likely through improved vas­
cular health.428–431 Estimated health benefits will be even more sub­
stantial looking at all-cause morbidity and mortality, e.g. including 
smoking cessation for cancer prevention.
The effects of electronic cigarettes (e-cigarettes) on BP remain un­
clear and to date there are no robust outcomes data. However, grow­
ing evidence suggests that e-cigarettes can increase BP (see 
Supplementary data online).432,433
Among adults, smoking affects ambulatory BP by raising daily BP,434 but 
effects of chronic smoking on office BP appear to be small.435 Smoking ces­
sation advice helps, but more intensive interventions are superior.436,437 As 
recommended by previous ESC Guidelines, smoking cessation is recom­
mended to reduce CVD risk and improve non-CVD health.1,170
ESC Guidelines                                                                                                                                                                                          3957


<!-- PAGE 47 -->

### Page 47

8.3. Pharmacological interventions
8.3.1. Treatment strategy to reduce adverse 
cardiovascular disease outcomes
The main goal of reducing BP is to prevent adverse CVD outcomes. The 
relative risk reduction afforded by a fixed degree of BP reduction is largely 
independent of pre-treatment BP.116 There is a clear relationship be­
tween the intensity of BP lowering and the relative and absolute reduction 
in risk of CVD events for all adults, regardless of age (at least up to 
85 years), sex, prior CVD, diabetes, or AF.116,131,443–445 With this strong 
evidence for the ‘the lower the better, but within reason’ paradigm, deci­
sion rules are required for selecting patients most likely to benefit from 
treatment.172 In this section, a summary of evidence for BP-lowering 
drug treatment is provided, followed by strategies for their use for pre­
venting CVD.
8.3.2. Drug classes with evidence on clinical outcomes 
in the target population
The major drug classes with robust evidence for BP-mediated reduction 
in CVD events are ACE inhibitors, ARBs, dihydropyridine CCBs, diuretics 
(thiazides and thiazide-like diuretics such as hydrochlorothiazide, 
chlorthalidone, and indapamide), and beta-blockers (see Supplementary 
data online, Tables S7 and S8).122,446,447 The first four are recommended 
as first-line options for starting hypertension treatment in the general 
population. Beta-blockers can be added preferentially in circumstances 
such as in the presence of angina or heart failure, after myocardial infarc­
tion, or for controlling heart rate, where they are the cornerstone of ther­
apy.122,448,449 In such settings, second-generation (cardioselective) and, 
specifically, third-generation (vasodilating) beta-blockers are preferred.450
However, beta-blockers are less effective than ACE inhibitors, ARBs, 
CCBs, or diuretics at preventing stroke, and have a higher discontinuation 
rate due to side effects.451,452 Beta-blockers and diuretics, especially when 
combined, are associated with an increased risk of new-onset diabetes in 
predisposed patients.453,454 The effect of RAS blockers and CCBs on pre­
venting progression of HMOD also appears to be superior to beta- 
blockers.455–458 Beta-blockers should also be avoided in patients with iso­
lated systolic hypertension or more generally with arterial stiffness, as they 
increase stroke volume (given the lower heart rate).218
When therapy and adherence with the above-mentioned drug classes 
is optimized but insufficient to reach BP goals, other drug classes can be 
used for treating hypertension. Of these, spironolactone, an MRA, ap­
pears to be the most effective at further lowering BP in resistant hyper­
tension; however, more evidence of CVD risk-lowering effects with 
MRAs among all hypertensive populations, especially those without re­
sistant hypertension, is needed.459 Specifically, while use of MRAs in pa­
tients with heart failure has provided clinical evidence on the 
effectiveness of MRAs for preventing CVD events, dedicated outcome 
trials in patients with primary hypertension without heart failure are lack­
ing. Because the present guidelines require trial evidence for CVD out­
come benefit for a BP-lowering drug or procedure to achieve a Class I 
recommendation, and given no outcome trials of MRAs have been con­
ducted in general samples of patients with primary hypertension, we have 
given MRAs a Class IIa recommendation (see below). We acknowledge 
that spironolactone was provided a Class I recommendation in the 2018 
ESC/ESH Guidelines on the management of arterial hypertension. 
However, to be consistent with our requirement for trial evidence for 
CVD outcomes benefit in patients with hypertension, the task force 
agreed to provide a Class IIa recommendation for spironolactone in 
these 2024 Guidelines. Importantly, it was also agreed that a Class IIa rec­
ommendation (i.e. should be considered) is an endorsement of MRAs for 
Recommendation Table 15 — Recommendations for 
non-pharmacological treatment of blood pressure and 
cardiovascular risk reduction (see Evidence Tables 22–26)
Recommendations
Classa
Levelb
Restriction of sodium to approximately 2 g per day is 
recommended where possible in all adults with 
elevated BP and hypertension [this is equivalent to 
about 5 g of salt (sodium chloride) per day or about a 
teaspoon or less].353,354
I
A
Moderate intensity aerobic exercise of ≥150 min/ 
week (≥30 min, 5–7 days/week) or alternatively 
75 min of vigorous intensity aerobic exercise per 
week over 3 days are recommended and should be 
complemented with low- or moderate-intensity 
dynamic or isometric resistance training (2–3 times/ 
week) to reduce BP and CVD risk. 1,381,390–393
I
A
It is recommended to aim for a stable and healthy 
BMI (e.g. 20–25 kg/m2) and waist circumference 
values (e.g. <94 cm in men and <80 cm in women) to 
reduce BP and CVD risk.399–401
I
A
Adopting a healthy and balanced diet, such as the 
Mediterranean or DASH diets, is recommended to 
help reduce BP and CVD risk.412,438,439
I
A
Men and women are recommended to drink less 
alcohol than the upper limit, which is about 
100 g/week of pure alcohol. How this translates into 
number of drinks depends on portion size (the 
standards of which differ per country), but most 
drinks contain 8–14 g of alcohol per drink. Preferably, 
it is recommended to avoid alcohol to achieve the 
best health outcomes.170,419,440,441
I
B
It is recommended to restrict free sugar 
consumption, in particular sugar-sweetened 
beverages, to a maximum of 10% of energy intake. It 
is also recommended to discourage consumption of 
sugar-sweetened beverages, such as soft drinks and 
fruit juices, starting at a young age.425–427
I
B
It is recommended to stop tobacco smoking, initiate 
supportive care and refer to smoking cessation 
programmes, as tobacco use strongly and 
independently causes CVD, CVD events, and 
all-cause mortality.428,429,431,437
I
A
In patients with hypertension without moderate to 
advanced CKD and with high daily sodium intake, an 
increase of potassium intake by 0.5–1.0 g/day—for 
example through sodium substitution with potassium- 
enriched salt (comprising 75% sodium chloride and 
25% potassium chloride) or through diets rich in fruits 
and vegetables—should be considered.348,368,373,374,442
IIa
A
In patients with CKD or taking potassium-sparing 
medication, such as some diuretics, ACE inhibitors, 
ARBs, or spironolactone, monitoring serum levels of 
potassium should be considered if dietary potassium 
is being increased.
IIa
C
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass 
index; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; 
DASH, Dietary Approaches to Stop Hypertension. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

treating resistant hypertension but one that acknowledges some uncer­
tainty of outcomes benefit. Future outcome trials of MRAs, perhaps in­
cluding finerenone,460–462 are encouraged in patients with hypertension.
Clinical outcome evidence from trials for other BP-lowering drug 
classes, such as alpha-blockers, hydralazine, minoxidil, other potassium- 
sparing diuretics, and centrally acting agents, is less compelling and caution 
regarding adverse effects is warranted. However, they may be a final add­
ition if all other therapeutic efforts are insufficient to decrease BP. Of note, 
in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack (ALLHAT) trial, the alpha-blocker arm was stopped early due to 
futility of benefit for the CVD outcome.463
8.3.3. New therapies with blood pressure-lowering 
properties that await supportive evidence from 
cardiovascular outcomes trials prior to guideline 
endorsement and routine use in hypertension
A few other drug classes with indication in heart failure have emerged 
that also have BP-lowering properties. For example, the angiotensin 
receptor–neprilysin inhibitor (ARNi) sacubitril/valsartan, which was ini­
tially developed for hypertension,464 reduces CVD mortality and 
morbidity in patients with heart failure, an effect that may have been 
mediated, in part, by superior BP lowering compared with enalapril 
alone.465,466 In a post hoc subgroup analysis, sacubitril/valsartan lowered 
BP in adults with both heart failure with preserved ejection fraction 
(HFpEF) and resistant hypertension.467 In the context of research stud­
ies, sacubitril/valsartan has been used in higher doses (200 mg or 
400 mg once daily) for treating hypertension.464,466,468,469
SGLT2 inhibitors have shown favourable effects on CVD events and 
renal haemodynamics in patients with and without type 2 diabetes, and 
in heart failure trials.470 In these trials, SGLT2 inhibitors did lower BP, 
though only modestly.471 Small trials among adults with hypertension 
have confirmed the potential for BP lowering with this drug class.472,473
Other new drugs with preliminary data include GLP-1 agonists and 
the new non-steroidal MRAs, e.g. finerenone, in managing hyperten­
sion.415,460,461 In addition, novel aldosterone synthase inhibitors (bax­
drostat and lorundrostat) have significantly lowered BP in patients 
with uncontrolled hypertension in phase 2 trials.474,475
The dual endothelin-A and -B receptor antagonist aprocitentan also 
reduced office and 24 h BP compared with placebo at 4 weeks in pa­
tients with resistant hypertension in a phase 3 trial.476 Zilebesiran, an 
investigational RNA interference agent administered subcutaneously, 
inhibits hepatic angiotensinogen synthesis and a single dose reduced 
24 h BP over approximately 6 months.477
8.3.4. Drug combinations and up-titrating strategies
To treat hypertension, many patients will require more than one 
BP-lowering medication. Combining drugs from different drug classes 
can have additive or synergistic effects and lead to greater BP reduction 
than increasing the dose of one drug.478–483 The superior BP-lowering 
efficacy of combination therapy is mediated, at least in part, by the po­
tential of combination therapy to target multiple pathophysiological 
pathways contributing to perturbed BP in each patient.484 A further 
benefit of combination therapy is the potential to use lower doses of 
each individual BP-lowering agent, which may reduce side effects and 
improve adherence and persistence,485 though the evidence for this hy­
pothesis has been questioned.486
Upfront low-dose combination therapy is therefore recommended 
in persons with hypertension, with the potential advantages of fewer 
side effects and swifter BP control being important for long-term ad­
herence.487–489 If combination BP-lowering therapy is pursued, single- 
pill combinations are preferred. For those with elevated BP who have 
an indication for BP-lowering treatment, monotherapy is recom­
mended in the first instance.
One caveat to combination therapy in hypertension is that patient-level 
response to individual BP-lowering drug classes can be heterogeneous (sug­
gesting some patients may benefit from more personalized treatment com­
pared with routine combinations).490 This is relevant also with respect to 
race/ethnicity (see Section 9). Another caveat is that the evidence for re­
duced CVD outcomes with BP-lowering drugs in combination therapy is 
based on observational studies.491–493 There are no outcomes data from 
prospective trials that prove superiority of upfront combination therapy (ei­
ther as single-pill combinations or as separate pills) over upfront monother­
apy in the isolated treatment of hypertension.486Therefore, we considered 
giving upfront combination therapy (either as separate pills or as single-pill 
combinations) a Class IIa recommendation in these guidelines. However, gi­
ven the totality of evidence for outcomes benefit in observational studies, 
randomized trial data for better BP control and adherence, and importantly, 
also given CVD outcomes benefit for polypills (a form of single-pill combin­
ation) in randomized trials,494–496we chose to provide a Class I recommen­
dation for upfront combination therapy in adults with confirmed 
hypertension, in agreement with 2018 ESC recommendations.
The major four drug classes (ACE inhibitors, ARBs, dihydropyridine 
CCBs, and thiazide or thiazide-like diuretics) are recommended as first- 
line BP-lowering medications, either alone or in combination.122,447,484,497
An exception is the combination of two RAS blockers, which is not re­
commended.498–500 For most hypertensive patients, a single-pill com­
bination, initially containing two of these major drug classes, and 
initially at low dose, is recommended.489,501,502 Doses of BP-lowering 
drugs are presented in the Supplementary data online, Tables S7 and S8.
When BP is still uncontrolled under maximally tolerated triple- 
combination (RAS blocker, CCB, and diuretic) therapy, and after adher­
ence is assessed, the patient should be considered resistant and 
referred to an expert centre for appropriate work-up (see Section 
7.5). At the same time, the addition of spironolactone should be consid­
ered.459 If spironolactone is not tolerated, eplerenone or other MRA, 
or beta-blockers (if not already indicated), should be considered. 
Eplerenone may need to be dosed higher (50–200 mg) for effective BP 
lowering. In a meta-analysis, eplerenone 25 mg did not lower BP.503 Due 
to the shorter time of action than spironolactone, eplerenone may need 
to be administered twice daily for treating hypertension. An alternative 
to MRA as fourth-line treatment for BP lowering is the use of beta-blockers 
for persons who do not already have a compelling indication. A vasodilating 
beta-blocker (e.g. labetalol, carvedilol, or nebivolol) is preferred when a 
beta-blocker is chosen.504 However, we note that the BP-lowering effects 
of beta-blockade appears to be less potent than spironolactone in the set­
ting of resistant hypertension.459
Only thereafter should hydralazine, other potassium-sparing diuretics 
(amiloride and triamterene), centrally acting BP-lowering medications, 
or alpha-blockers be considered. Given multiple side-effects, minoxidil 
should only be considered if all other pharmacological agents prove inef­
fective in resistant hypertension.505
As noted above, polypills combining fixed doses of BP-lowering 
treatment, lipid-lowering therapy and, if indicated, aspirin are effective 
in more general CVD prevention.496,506–509 However, the polypill is not 
available for routine clinical use in many European countries.
8.3.5. A practical algorithm for intensive, effective, 
and tolerable blood pressure lowering with drug 
therapy, including considerations around single-pill 
combinations
The aim of the algorithm in Figure 18 is to introduce a low-dose double- 
and then triple-combination strategy while monitoring tolerance 
ESC Guidelines                                                                                                                                                                                          3959


<!-- PAGE 49 -->

### Page 49

Low-dose double combinationa therapy
ACEi or ARBs / CCBs / Diuretics
(Class I)
BP controlled after 1–3 months
(assessment at 1 month preferred if possible)
Y
FU at least every year
Low-dose triple combination therapy 
ACEi or ARBs / CCBs / Diuretics
(Class I)
BP controlled after 1–3 months
(assessment at 1 month preferred if possible)
Y
FU at least every year
BP controlled after 1–3 months
(assessment at 1 month preferred if possible)
Y
FU at least every year
Refer to hypertension clinic
(Class IIa)
At any step:
add beta-blockers if compelling indications
(angina, post-myocardial infarction, systolic heart failure,
or heart rate control)
(Class I)
Maximally tolerated triple combination therapy 
ACEi or ARBs / CCBs / Diuretics
(Class I)
Test for adherence
(Class IIa)
Add spironolactone
(Class IIa)
Apparent resistant hypertension
N
N
N
 aInitial monotherapy preferred
Elevated BP category (120/70–139/89 mmHg)
Moderate-to-severe frailty
Symptomatic orthostatic hypotension
Age ≥85 years
See section on management of resistant hypertension for further steps as needed
Figure 18 Practical algorithm for pharmacological blood pressure lowering. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin recep­
tor blocker; BP, blood pressure; CCB, calcium channel blocker; FU, follow-up.


<!-- PAGE 50 -->

### Page 50

N
Patient centred care
Normal
Abnormal
≥10%
<5%
5% – <10%
Age <40 years, resistant hypertension,
suggestive signs and/or symptoms
Targeted secondary hypertension treatment
Screen for secondary hypertension
(Class I)
Calculate SCORE2/
SCORE2-OP
(Class I)
Assess risk modifiers
(Class IIa)
Consider risk tools
(Class IIb)
Age ≥85 years, moderate-to-severe frailty, 
symptomatic OH, short life expectancy
Established CVD, moderate-to-severe CKD,
hypertension-mediated organ damage, 
diabetes mellitusa, familial hypercholesterolaemia
Y
N
N
N
Y
Y
Y
Non-elevated BP
Office SBP <120 mmHg and
DBP <70 mmHg
Elevated BP
Office SBP 120–139 mmHg and/or DBP 70–89 mmHg
Hypertension
Office SBP ≥140 mmHg and/or
DBP ≥90 mmHg
ABPM / HBPM
preferred over office BP
Target SBP 120–129 mmHg
(Class I)
Target DBP 70–79 mmHg
(Class IIb)
Screen BP
opportunistically
Lifestyle measures
Drug treatment for confirmed
BP ≥130/80 mmHg
Monitor BP and medication toleranceb
Screening for hypertension
Opportunistic: every 3 years <40 years;
every year ≥40 years
HBPM/ABPM or repeated standardized office BP
Confirming hypertension
Lifestyle measures
Figure 19 Central Illustration. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; CKD, chronic kidney 
disease; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; OH, orthostatic hypotension; SBP, systolic blood pressure; SCORE2, 
Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. Summary algorithm for BP classification 
and management. See Section 5 for recommendations on out-of-office confirmation of the three BP categories. aAdults with type 2 diabetes mellitus 
only and younger than 60 years should be considered for SCORE2-Diabetes assessment. bThough scientific data demonstrate that, under research 
conditions, the optimal target BP is ≤120/70 mmHg, the target BP recommended by  these guidelines in routine practice is 120–129/70–79 mmHg. 
If achieving this target is not possible, or if treatment is not well tolerated, then BP should be treated to as low as reasonably achievable. For persons 
with elevated BP, treatment with lifestyle measures for 3 months is first recommended, prior to considering medications.  
ESC Guidelines                                                                                                                                                                                          3961


<!-- PAGE 51 -->

### Page 51

among patients with hypertension, and only afterwards to start up- 
titrating doses to maximum amounts.
Initiation with monotherapy, slower up-titration, and lower dosing 
should be considered in the setting of elevated BP and increased CVD 
risk, or in moderate-to-severe frailty, limited life expectancy, symptom­
atic orthostatic hypotension, or older people (aged ≥85 years). Ideally, 
BP should be treated to target within 3 months to retain the confidence 
of the patient, to ensure long-term adherence, and to reduce CVD risk.71
An overview of the recommended approach to BP management in all 
adult patients is provided in Figure 19 (Central Illustration). Also, of 
note, teleconsultation, multidisciplinary or nurse-led care, or patient 
self-monitoring can help with achieving BP control in certain healthcare 
systems.75,510,511
8.3.6. Timing of blood pressure-lowering drug 
treatment
Current evidence does not show benefit of diurnal timing of 
BP-lowering drug administration on major CVD outcomes.512 It is im­
portant that medication is taken at the most convenient time of day to 
improve adherence. Patients should also be encouraged to take medi­
cations at the same time each day and in a consistent setting, to help 
ensure adherence.246,513
8.4. Selecting patients for pharmacological 
blood pressure-lowering treatment
Commencement of BP-lowering treatment is often decided based on 
office BP measurements but, where possible, the present guidelines 
strongly recommend using out-of-office BP measurement for confirm­
ing elevated BP and hypertension (see Section 5). As detailed in Section 6, 
an office BP of <120/70 mmHg is categorized in these guidelines as 
non-elevated BP.
When a patient is diagnosed with confirmed hypertension (sustained 
BP ≥ 140/90 mmHg), starting BP-lowering treatment is recommended 
irrespective of CVD risk, which should consist of a simultaneous combin­
ation of lifestyle interventions and pharmacological therapy. Lifestyle in­
terventions are crucial as an initial treatment step, and must be strongly 
emphasized with the patient, but concurrent pharmacological therapy is 
recommended. This concurrent initiation of lifestyle and pharmacological 
therapy should not give patients the impression that lifestyle changes are 
of lesser importance, and the patient should be counselled that these life­
style changes may allow subsequent discontinuation or down-titration of 
medication, which can be used as motivation to persist with lifestyle 
changes. After treatment initiation, the patient should be seen frequently 
(e.g. every 1–3 months with a GP or specialist) until BP is controlled. BP 
should be controlled, preferably within 3 months (see also Section 6 and 
algorithm Figure 18). If lifestyle changes are effective in BP lowering, 
pharmacological treatments may subsequently be down-titrated or 
stopped as appropriate.
When office BP is 120–139/70–89 mmHg, the patient is considered 
as having elevated BP, and further CVD risk stratification is recom­
mended to guide therapy (Table 14). 
• In patients with elevated BP who are not at increased risk for CVD 
(10-year CVD risk <10%) and do not have other high-risk conditions 
or risk modifiers, BP-lowering lifestyle measures are recommended. 
Recommendation Table 16 — Recommendations for 
pharmacological 
treatment 
of 
hypertension 
(see 
Evidence Tables 27, 28, and 29)
Recommendations
Classa
Levelb
Among all BP-lowering drugs, ACE inhibitors, ARBs, 
dihydropyridine CCBs, and diuretics (thiazides and 
thiazide-like drugs such as chlorthalidone and 
indapamide) have demonstrated the most effective 
reduction of BP and CVD events, and are therefore 
recommended as first-line treatments to lower 
BP.122,446
I
A
It is recommended that beta-blockers are combined 
with any of the other major BP-lowering drug classes 
when there are other compelling indications for their 
use, e.g. angina, post-myocardial infarction, heart 
failure with reduced ejection fraction, or for heart 
rate control.122,448–450
I
A
It is recommended to take medications at the most 
convenient time of day for the patient to establish a 
habitual pattern of medication taking to improve 
adherence.246,513
I
B
Given trial evidence for more effective BP control vs. 
monotherapy, combination BP-lowering treatment is 
recommended for most patients with confirmed 
hypertension (BP ≥140/90 mmHg) as initial therapy. 
Preferred combinations are a RAS blocker (either an 
ACE inhibitor or an ARB) with a dihydropyridine 
CCB or diuretic. Exceptions to consider include 
patients aged ≥85 years, those with symptomatic 
orthostatic hypotension, moderate-to-severe frailty, 
or elevated BP (systolic BP 120–139 mmHg or 
diastolic BP 70–89 mmHg) with a concomitant 
indication for treatment.131,480,483,484,489
I
B
Continued
In patients receiving combination BP-lowering 
treatment, fixed-dose single-pill combination 
treatment is recommended.484,489,501,502,514
I
B
If BP is not controlled with a two-drug combination, 
increasing to a three-drug combination is 
recommended, usually a RAS blocker with a 
dihydropyridine CCB and a thiazide/thiazide-like 
diuretic, and preferably in a single-pill combination.489
I
B
If BP is not controlled with a three-drug combination, 
adding spironolactone should be considered.459
IIa
B
If BP is not controlled with a three-drug combination 
and in whom spironolactone is not effective or 
tolerated, treatment with eplerenone instead of 
spironolactone,503 or the addition of a beta-blocker if 
not already indicated459 and, next, a centrally acting 
BP-lowering medication,515 an alpha-blocker,515
hydralazine, or a potassium-sparing diuretic should 
be considered.516
IIa
B
Combining two RAS blockers (ACE inhibitor and an 
ARB) is not recommended.498–500,517
III
A
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood 
pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, renin– 
angiotensin system. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 52 -->

### Page 52

While there are not enough outcomes data for a drug recommenda­
tion in lower CVD risk adults with elevated BP, there is some evi­
dence to suggest that relative treatment effects of BP lowering are 
similar across a wide range of predicted risk categories, including 
among those with a <10% risk.518 Therefore, while we do not pro­
vide a formal recommendation for this, if initial lifestyle measures are 
not successful after 6–12 months, drug treatment might be discussed 
on an individual basis among lower CVD-risk adults when BP is be­
tween 130/80 and <140/90 mmHg.518
• In patients with elevated BP (office BP of 120–139/70–89 mmHg) 
who are at sufficiently high risk for CVD (e.g. 10-year CVD risk 
≥ 10%) or in the presence of high-risk conditions or borderline 
10-year CVD risk (5% - <10%) combined with risk modifiers or 
abnormal risk tool tests, BP-lowering lifestyle measures should be 
initiated for 3 months. Following this, pharmacological therapy is re­
commended for persons with confirmed BP of ≥130/80 mmHg, 
when these lifestyle changes have not worked or are not being imple­
mented (Section 8.2) Prompt addition of pharmacological therapy, if 
needed by 3 months, should be emphasized, to avoid therapeutic 
inertia.519 For those with BP of 120–129/70–79 mmHg, ongoing 
and intensified lifestyle intervention is preferred.
The above recommendations apply to all individuals with elevated BP, 
irrespective of age. However, recognizing the lack of conclusive evi­
dence and added risk of side effects among certain subgroups, the 
task force also recommends that, among patients with elevated BP, 
BP-lowering treatment should always be started based on individual 
clinical judgment and shared decision-making.
In addition, consideration of BP-lowering drug treatment should be 
deferred until BP is >140/90 mmHg in the following settings: pre- 
treatment symptomatic orthostatic hypotension, age ≥85 years, clinic­
ally significant moderate-to-severe frailty, and/or limited predicted life­
span (<3 years) due to high competing risk (including eGFR < 30 mL/ 
min/1.73 m2). Patients with elevated BP in these settings are less likely 
to obtain sufficient net benefit from BP-lowering drug therapy or to tol­
erate intensive drug therapy. Section 9 contains more information on 
the treatment of specific subgroups, including older and frail adults.
Table 14 Initiation of blood pressure-lowering treatment based on confirmed blood pressure category and cardiovas­
cular disease risk
Blood 
pressure 
(mmHg)
Non-elevated BP 
(<120/70)
Elevated BP (120/70 to 139/89)
Hypertension (≥140/90)
Risk
(a)
All adults with SBP 120– 
129 mmHg
(b)
SBP 130–139 AND 10-year 
estimated CVD risk <10% 
AND no high-risk 
conditions or risk modifiers 
or abnormal risk tool tests
(a)
SBP 130–139 AND high-risk conditions 
(e.g. established CVD, diabetes mellitus, 
CKD, FH or HMOD)
(b)
SBP 130–139 AND 10-year estimated 
CVD risk ≥10%
(c)
SBP 130–139 AND 10-year estimated 
CVD risk 5% - <10% AND risk 
modifiers or abnormal risk tool tests
Assumed all at sufficiently high risk to 
benefit from pharmacological 
treatment
Treatment
Lifestyle measures for 
prevention 
Screen BP and CVD risk 
opportunistically
Lifestyle measures for treatment 
Monitor BP and CVD risk yearly
Lifestyle measures and pharmacological 
treatment (after 3-month delay). 
Monitor BP yearly once treatment control is 
established
Lifestyle measures and 
pharmacological treatment 
(immediate) 
Monitor BP yearly once treatment 
control is established
Target (mmHg)
Maintain BP <120/70
Aim BP 120–129/70–79 mmHga
© ESC 2024
BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ 
damage; SBP, systolic blood pressure. 
aCaution in adults with orthostatic hypotension, moderate-to-severe frailty, limited life expectancy, and older patients (aged ≥85 years).
Recommendation Table 17 — Recommendations for 
initiating blood pressure-lowering treatment (see 
Evidence Tables 30–32)
Recommendations
Classa
Levelb
In adults with elevated BP and low/medium CVD 
risk (<10% over 10 years), BP lowering with 
lifestyle measures is recommended and can reduce 
the risk of CVD.119,120,348,408,411,520,521
I
B
In adults with elevated BP and sufficiently high CVD 
riskc, after 3 months of lifestyle intervention, BP 
lowering with pharmacological treatment is 
recommended for those with confirmed BP ≥130/ 
80 mmHg to reduce CVD risk.116,522
I
A
It is recommended that in hypertensive patients 
with confirmed BP ≥140/90 mmHg, irrespective of 
CVD risk, lifestyle measures and pharmacological 
BP-lowering treatment are initiated promptly to 
reduce CVD risk.116,121,122
I
A
It is recommended to maintain BP-lowering drug 
treatment lifelong, even beyond the age of 85 years, 
if well tolerated.523–525
I
A
Because the benefit in reducing CVD outcomes is 
uncertain in these settings, and noting that close 
monitoring of treatment tolerance is advised, 
BP-lowering treatment should only be considered 
from ≥140/90 mmHg among persons meeting the 
following criteria: pre-treatment symptomatic 
orthostatic hypotension, age ≥85 years, clinically 
significant moderate-to-severe frailty, and/or 
limited predicted lifespan (<3 years).131,524,526,527
IIa
B
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence. 
c10-year estimated CVD risk of ≥10%; or 10-year estimated CVD risk of 5% - ≤10% plus risk 
modifiers or abnormal risk tool tests; or high-risk conditions (e.g. established CVD, diabetes, 
moderate or severe CKD, familial hypercholesterolaemia, or hypertension-mediated organ damage).
ESC Guidelines                                                                                                                                                                                          3963


<!-- PAGE 53 -->

### Page 53

8.5. Intensity of blood pressure-lowering 
therapy and ideal treatment targets
8.5.1. Expected degree of blood pressure reduction 
with approved drugs
The magnitude of BP reduction achieved with the main classes of 
BP-lowering medications (ACE inhibitors, ARBs, dihydropyridine CCBs, 
diuretics, and beta-blockers) as monotherapy is similar overall.528,529 BP 
reduction with standard doses of any of these five classes can be expected 
to be approximately 9/5 mmHg with office BP and 5/3 mmHg with 
ABPM.478 These BP-lowering effects may attenuate over time.530
Combination therapy (e.g. with three drugs at half standard dose) over 
the short term can lower office BP by up to 20/11 mmHg.478,531 The rea­
son why beta-blockers are not considered first-line BP-lowering medica­
tions (outside of compelling indications) is not because of inferior 
BP-lowering properties (particularly for vasodilating beta-blockers),532
but because of inferior efficacy in reducing CVD events (particularly 
stroke) among patients with hypertension, and tolerance issues.533–536
The BP-lowering effect of each BP medication class generally increases 
with the dose administered, though this relationship is not linear.537
Effects of each medication can also vary at the individual level, sometimes 
requiring personalization by matching the patient with the best medica­
tion for them.490 The magnitude of BP reduction for any BP-lowering 
medication may increase as a function of the pre-treatment BP, which 
is also known as Wilders principle.538,539
The BP-lowering effect of pharmacological therapy is typically evi­
dent after 1–2 weeks of treatment,540 but the maximum effect might 
take longer to manifest. Therefore, the advised follow-up after 1–3  
months (1 month preferred with a GP or specialist) allows for assess­
ment of tolerance/safety, but also allows enough time to gauge the 
full BP-lowering effect of each drug titration (see Section 8.3.4).
8.5.2. The ideal target of blood pressure-lowering 
treatment
As discussed in Section 6, optimal control of BP translates into CVD 
risk reduction, thereby reducing morbidity and mortality in the 
population.116,478,541
BP threshold is defined as the BP at which BP-lowering treatment is 
initiated, while BP target is the BP goal with treatment.
The BP threshold to initiate BP-lowering therapy is not necessarily the 
same as the recommended BP target once therapy is commenced (in 
other words, treatment threshold and treatment target may not be the 
same for a given patient). Specifically, for hypertensive patients in whom 
BP-lowering treatment is recommended above a baseline BP of ≥140/ 
90 mmHg, the recommended target of BP-lowering therapy is 120–129/ 
70–79 mmHg, provided treatment is well tolerated (see Supplementary 
data online). Persons with elevated BP who receive treatment are also re­
commended to achieve a target of 120–129/70–79 mmHg.
Therefore, the treatment target in the 2024 Guidelines is always 
120–129/70–79 mmHg (but only if treatment is tolerated and with cer­
tain exceptions where more lenient targets are advised). In contrast, the 
treatment threshold may differ based on CVD risk, specifically in the ele­
vated BP category. For example, in addition to hypertensive adults with 
BP ≥140/90 mmHg, there are individuals with an office systolic BP of 
130–139 mmHg and/or diastolic BP of 80–89 mmHg who have suffi­
ciently high CVD risk to recommend BP-lowering drug treatment.
The BP target range of 120–129/70–79 mmHg recommended 
in these guidelines reflects the most current evidence from contempor­
aneous RCTs135,136,146,542–545 and from meta-analyses of RCTs.131 Of 
note, this treatment target reduces CVD events in older adults136,523
with evidence for efficacy of more intensive BP-lowering treatment 
targets established up to age 85 years.131 Furthermore, research 
data indicate that, to optimally reduce CVD risk, achieving an on- 
treatment BP of 120/70 mmHg is the best point on the BP target range 
provided in our guideline recommendations (Figure 20). However, while 
we strongly considered recommending a treatment target of exactly 
120/70 mmHg with out-of-office BP confirmation, we instead chose a 
target range of 120–129/70–79 mmHg (preferably with out-of-office 
BP confirmation but also allowing for office BP) for the following rea­
sons: providing flexibility to patients and clinicians; feedback from exter­
nal peer review; feedback from patients that lifestyle is preferred to 
medication unless BP is in the hypertensive range; the knowledge that 
contemporary treat-to-target intensive BP trials included only persons 
with baseline systolic BP of ≥130 mmHg; and a recognition that the 
BP values recorded under research conditions using systematic ap­
proaches to measurement (while strongly recommended by these 
guidelines) are not always the same as BP values recorded under rou­
tine clinical care, which can be 5–10 mmHg higher.65,66
In addition, the trial data confirming efficacy for our recommended 
treatment target of 120–129/70–79 mmHg do not necessarily apply 
to moderately-to-severely frail adults who were generally excluded 
from trials. Furthermore, the data supporting this BP target among 
adults aged >85 years are inconclusive.131 Frailty can occur at different 
ages and is, together with tolerability of BP-lowering treatment, an im­
portant characteristic when considering the BP target for a given pa­
tient. Accordingly, personalized BP-lowering treatment should be 
instituted in people aged ≥85 years and/or those with significant frailty. 
Recommended indicators of frailty in guiding BP-lowering treatment 
are given in Section 9.
Several important nuances are highlighted and warrant consideration 
prior to implementing the new BP target of 120–129/70–79 mmHg 
among patients receiving BP-lowering therapy: 
• Evidence for a systolic BP-lowering treatment target of 120–129 mmHg 
is strong (Class I, level of evidence A).
• Evidence for a specific diastolic BP-lowering treatment target 
is less strong in those who are treated to a systolic target of 
120–129 mmHg. While most adults treated to a systolic BP target 
of 120–129 mmHg will also achieve a diastolic BP of 70–79 mmHg, 
not all will.543,546 Furthermore, adults who achieve systolic BP con­
trol are generally at low relative risk for CVD, even when diastolic 
BP is 70–90 mmHg.547,548 Nonetheless, due in part to the known 
higher risk of isolated diastolic hypertension among younger 
adults,549 the task force agreed that it is reasonable to target an 
on-treatment diastolic BP of 70–79 mmHg among patients with 
diastolic BP of ≥80 mmHg who are already at the systolic BP tar­
get of 120–129 mmHg (Class IIb, level of evidence C).
• The task force acknowledges the 2021 ESC Guidelines on cardio­
vascular disease prevention in clinical practice,170 which take a step­
wise approach to their recommendations for BP-lowering treatment. 
The 2021 Guidelines recommended an on-treatment systolic BP tar­
get of 130–139 mmHg as the first step and then—based on patient 
preferences, risk, and frailty—to aim for a target on-treatment 
systolic BP of <130 mmHg as the second step. While we recognize 
the potential value of this two-step approach, which many clinicians 
may choose to follow, the current guidelines emphasize one on- 
treatment BP target (120–129/70–79 mmHg, provided treatment is 
tolerated). This one-step approach is based on the evidence, and mo­
tivated to discourage therapeutic inertia around BP lowering. As an 
illustrative example of the latter concern for therapeutic inertia, an


<!-- PAGE 54 -->

### Page 54

on-treatment systolic BP of 135 mmHg (office) may be considered 
reasonable when reviewing the 2021 ESC Guidelines on cardiovascu­
lar disease prevention in clinical practice but, we hope, will not be 
considered reasonable to those who follow the updated 2024 ESC 
Guidelines presented here. Specifically, it is well established that an 
on-treatment systolic BP of 135 mmHg is not optimal relative to 
more intensive control.116,131,135,136,445,542,543,545
• We acknowledge that the results from RCTs cannot always be extra­
polated to routine clinical care. In addition, we recognize the increased 
risk of side effects among patients receiving more intensive BP-lowering 
treatments, compared with traditional BP targets.545,550Accordingly, an 
important caveat to our treatment target of 120–129/70–79 mmHg is 
the recommendation to pursue this target only when treatment is well 
tolerated. In cases where BP-lowering treatment is not well tolerated 
and a target of 120–129/70–79 mmHg is not possible, it is recom­
mended to follow the ‘as low as reasonably achievable’ (ALARA) prin­
ciple, by targeting treatment to a BP that is as low as reasonably 
achievable.
• In addition to adults with significant frailty and/or who are ≥85  
years of age, the evidence for a BP-lowering treatment target of 
120–129/70–79 mmHg may also not generalize to patients with: 
(i) pre-treatment symptomatic orthostatic hypotension, (ii) limited 
predicted lifespan (e.g. <3 years),527 and/or (iii) high levels of 
competing risk for non-CVD death including CKD with eGFR 
< 30 mL/min/1.73 m2) (see Section 9).
Finally, as outlined in Section 5, these guidelines endorse a ‘trust but 
verify’ approach to office BP measurements, and, where possible, con­
firming BP with accurate out-of-office BP measurements (ABPM, 
HBPM) is recommended prior to starting treatment, to monitor the 
treatment effect of BP-lowering medication.
8.5.3. Personalizing treatment strategies
Though promising, there is little to no evidence to date from 
CVD outcome trials to use novel biomarkers for individualizing 
BP-lowering treatment.551,552 Nonetheless, different patient groups 
SBP 120 mmHg 
is the optimal point in this range if tolerated
SBP target range
120–129 mmHg 
(Class I)
Target SBP as low as reasonably achievable
(preferably <140)
if 120–129 mmHg target not tolerated or in these settings: 
Pre-treatment symptomatic orthostatic hypotension and/or age ≥85 years  
(Class IIa)
Clinically significant moderate-to-severe frailty at any age 
and/or limited predicted lifespan
(<3 years)
(Class IIb)
Exclude hypertensive emergency
Assess for symptoms or signs of hypotension
Non-elevated SBP
(<120 mmHg)
Elevated SBP
(120–139 mmHg)
20
40
60
80
120 130 140
160
180
200
220
240
100
110
260
280
mmHg
Systolic hypertension
(≥140 mmHg)
Figure 20 Systolic blood pressure categories and treatment target range. BP, blood pressure; SBP, systolic blood pressure.  
ESC Guidelines                                                                                                                                                                                          3965


<!-- PAGE 55 -->

### Page 55

can be identified, and medication initiation can be tailored to pre- 
existing conditions, such as diabetes mellitus, CKD, AF, post- 
myocardial infarction, heart failure, metabolic syndrome, and pro­
teinuria/albuminuria (Section 9). History of previous side effects 
and possible and compelling indications also need to be considered 
when selecting treatment (see Supplementary data online, Tables S9 
and S10). Cardioselective beta-blockers may be used in low dose in 
chronic asthma,553,554 in line with their use in patients with heart 
failure with chronic asthma.
For considerations of BP-lowering treatment among specific pa­
tient populations of interest, including different racial/ethnic popula­
tions, see Section 9.
8.5.4. Duration and monitoring of drug therapy
BP-lowering treatment is usually chronic, often lifelong. This raises 
the question of long-term efficiency, long-term side effects, adher­
ence, and persistence with therapy. While BP-lowering therapies 
typically provide an overall durable effect, some attenuation of 
effect may be seen over time.66,530 First-line BP-lowering medica­
tion classes appear to be safe for long-term use.555–557 Once BP is 
controlled, at least a yearly follow-up is advised. Because of the 
known temporal variability in BP558,559 and medication efficacy in 
the long term,530 medication changes may be necessary over 
time (see Supplementary data online).
8.6. Device-based blood pressure lowering
Several device-based therapies designed to lower BP have been inves­
tigated.560,561 To date, the best evidence exists for catheter-based renal 
denervation.
8.6.1. Catheter-based renal denervation
Sympathetic nervous system overactivity contributes to the develop­
ment and progression of hypertension.562 Renal denervation aims to 
interrupt afferent and efferent sympathetic nerves in the adventitia 
and perivascular tissue of the renal arteries.563 The 2018 ESC/ESH 
Guidelines on the management of arterial hypertension did not recom­
mend the use of device-based therapies for routine treatment of hyper­
tension, unless in the context of clinical studies and RCTs.1 This was 
based on negative data using first-generation radiofrequency catheters 
(see Supplementary data online).
More recent data from sham-controlled trials investigating second- 
generation radiofrequency and ultrasound catheters demonstrated a 
BP-lowering efficacy in a broad range of patients, with and without con­
comitant BP-lowering medications, including those with resistant 
hypertension.564–568 Long-term, non-randomized, follow-up data 
from the Global Symplicity Registry,569 Symplicity HTN-3 trial,570
Spyral HTN-ON MED pilot trial,571 and A Study of the Recor 
Medical Paradise System in Clinical Hypertension (RADIANCE-HTN) 
SOLO trial572 indicate a sustained BP-lowering effect for up to 3 years. 
A single-centre open-label study suggested sustained BP reductions up 
to 10 years.573 These data also highlight a potentially important advan­
tage of renal denervation, namely that the BP-lowering effect of this 
intervention might be ‘always on’, making this approach attractive for 
patients with suboptimal medication adherence.254 Some patients 
may prefer a one-off procedure rather than taking daily medications 
chronically and may request renal denervation.
Of significance, there are no reported procedure-related serious 
safety signals in the first- and second-generation trials beyond the usual 
risk of femoral arterial access procedures (noting that most trials to 
date were not powered for safety outcomes and that the task force 
could find no published meta-analysis data on exact rates of major 
bleeding and major femoral artery vascular access complications after 
renal denervation procedures). However, the rate of major bleeding 
Recommendation Table 18 — Recommendations for 
blood pressure targets with treatment (see Evidence 
Table 34)
Recommendations
Classa
Levelb
To reduce CVD risk, it is recommended that treated 
systolic BP values in most adults be targeted to 120– 
129 mmHg, provided the treatment is well 
tolerated.22,122,131,523,541
I
A
In cases where BP-lowering treatment is poorly 
tolerated and achieving a systolic of 120–129 mmHg 
is not possible, it is recommended to target a systolic 
BP level that is ‘as low as reasonably achievable’ 
(ALARA principle).22,122,131,523,541
I
A
Because the CVD benefit of an on-treatment systolic 
BP target of 120–129 mmHg may not generalize to 
the following specific settings, personalized and more 
lenient BP targets (e.g. <140 mmHg) should be 
considered among patients meeting the following 
criteria: pre-treatment symptomatic orthostatic 
hypotension, and/or age ≥85 years.131
IIa
C
Because the CVD benefit of an on-treatment systolic 
BP target of 120–129 mmHg may not generalize to 
the following specific settings, personalized and more 
lenient BP targets (e.g. <140/90 mmHg) may be 
considered among patients meeting the following 
criteria: clinically significant moderate-to-severe 
frailty at any age, and/or limited predicted lifespan 
(<3 years).
IIb
C
In cases where on-treatment systolic BP is at or below 
target (120–129 mmHg) but diastolic BP is not at 
target (≥80 mmHg), intensifying BP-lowering 
treatment to achieve an on-treatment diastolic BP of 
70–79 mmHg may be considered to reduce CVD risk.
IIb
C
© ESC 2024
ALARA, as low as reasonably achievable; BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 19 — Recommendations for 
follow-up in patients with treated hypertension (see 
Evidence Table 33)
Recommendation
Classa
Levelb
Once BP is controlled and stable under BP-lowering 
therapy, at least a yearly follow-up for BP and other 
CVD risk factors should be considered.
IIa
C
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 56 -->

### Page 56

and major femoral artery vascular access complications for coronary 
angiography using a femoral approach is typically reported as 
1%–4%574,575 but has been reported as 5%–10% in some studies.575
Trials investigating radial access for renal denervation are currently on­
going (ClinicalTrials.gov identifier: NCT05234788). After renal denerv­
ation, there is a 0.25%–0.5% rate of renal artery stenosis/dissection 
requiring stenting.576 Long-term follow-up data up to 3 years have 
not suggested worsening of renal function beyond the expected rates 
in patients with hypertension with mildly-to-moderately reduced renal 
function.569,577 Of note, sham-controlled trials to date excluded pa­
tients with severely reduced kidney function at baseline.564,566–568
Despite the clear promise of renal denervation in reducing BP, there 
are some concerns that warrant consideration, as we indicate in the re­
commendations. First, the effect of current renal denervation catheter 
technologies on BP lowering is relatively modest for an invasive proced­
ure (meta-analyses report placebo-corrected systolic BP lowering 
of approximately 6 mmHg on office BP assessment and 4 mmHg on 
24 h ABPM).578 As such, the average BP-lowering effect of renal de­
nervation appears no more than for one standard BP-lowering medica­
tion. Accordingly, many adults undergoing renal denervation will likely 
require ongoing, post-procedural, BP-lowering drugs.
Second, the cost-effectiveness of renal denervation has not been fully 
established. Since effects of current renal denervation technologies are 
similar to that of one standard BP-lowering medication, most of which 
are generic, it is difficult to see a scenario where renal denervation 
could be proven cost-effective for most patients. An exception might 
be patients who are at very high risk of CVD events and who have un­
controlled BP due to resistant hypertension (with or without 
non-adherence).579,580
Third, there are no adequately powered outcomes trials demon­
strating that renal denervation reduces CVD events and is safe in the 
long term. While observational reports have suggested associations be­
tween renal denervation and reduced risk for CVD events,581,582 these 
observational data have major inferential limitations including a signifi­
cant potential for confounding. While BP lowering is typically a good 
surrogate for CVD benefit, there is no guarantee that this is true 
with renal denervation and, furthermore, off-target effects independent 
of BP could influence CVD and other adverse-event rates after the pro­
cedure. Because of the lack of outcomes trials, renal denervation can­
not reach the Class I indication threshold set by this task force. 
Arguments that outcomes trials will not be funded are insufficient to 
influence guideline recommendations. However, it is hoped that the 
position of these guidelines will motivate industry to sponsor the neces­
sary renal denervation outcomes trials.
Fourth, related to the lack of outcomes data, the potentially ‘always 
on’ effect of renal denervation could backfire if late complications 
emerge. Medications causing complications or side effects can simply 
be stopped and replaced with alternative medications when such pro­
blems emerge; this is not true with renal denervation.
Fifth, the impact of scaling up renal denervation on usual cardiac de­
partment catheterization laboratory workflows is of some concern. 
Specifically, it is important that renal denervation procedures do not 
delay timely access to other elective procedures with proven efficacy 
in reducing CVD outcomes.583
Sixth, there is still no direct evidence to gauge whether renal denerv­
ation procedures are successful and that the kidneys are denervated 
and do not reinnervate over time.584 Relatedly, the concept of respon­
ders and non-responders to renal denervation (and the hypothesis that 
predictors of response might be found to help identify patients most 
suitable for the procedure) is questioned. Medical interventions, 
including drugs, are naturally subject to inter-individual variability in re­
sponse.567 Additionally, there are few examples in medicine of consist­
ent and clinically useful predictors of treatment response for medical 
conditions that have complex genetic and environmental underpinnings 
(i.e. conditions like hypertension).
A multidisciplinary hypertension team, including experts in hyperten­
sion and percutaneous cardiovascular interventions, is recommended to 
evaluate the indication and to perform the procedure.585 Based on the 
available evidence, renal denervation may be considered for patients 
who have uncontrolled, true resistant hypertension with a three-drug 
combination and who express a preference to undergo renal denerv­
ation.566,568,585 This recommendation is informed, in part, by the higher 
risk of CVD events in this subgroup, which represents a major unmet 
clinical need and which also means that cost-effectiveness considerations 
are likely to be optimal in this setting. In patients who are non-adherent 
or intolerant to multiple BP-lowering medications, particularly first-line 
agents, and who have high predicted CVD risk and a BP that is not at tar­
get, renal denervation may, for the same reasons, be considered if the pa­
tients express a preference to undergo renal denervation after a tailored 
shared decision-making process. The shared decision-making process re­
quires that the patients are fully informed about the benefits, limitations, 
and risks associated with renal denervation.
Recommendation Table 20 — Recommendations for 
device-based treatment of hypertension (see Evidence 
Table 35)
Recommendations
Classa
Levelb
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation 
may be considered for resistant hypertension 
patients who have BP that is uncontrolled despite a 
three BP-lowering drug combination (including a 
thiazide or thiazide-like diuretic), and who express a 
preference to undergo renal denervation after a 
shared risk-benefit discussion and multidisciplinary 
assessment.564,566–568,586–590
IIb
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation 
may be considered for patients with both increased 
CVD risk and uncontrolled hypertension on fewer 
than three drugs, if they express a preference to 
undergo renal denervation after a shared risk-benefit 
discussion and multidisciplinary assessment.564,566– 
568,586–590
IIb
A
Due to a lack of adequately powered outcomes trials 
demonstrating its safety and CVD benefits, renal 
denervation is not recommended as a first-line 
BP-lowering intervention for hypertension.
III
C
Renal denervation is not recommended for treating 
hypertension in patients with moderate-to-severely 
impaired renal function (eGFR <40 mL/min/1.73 m2) 
or secondary causes of hypertension, until further 
evidence becomes available.
III
C
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration 
rate. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3967


<!-- PAGE 57 -->

### Page 57

8.6.2. Other devices
Most device-based therapies investigated for BP-lowering therapy in 
hypertension have been aimed at modulating the autonomic nervous 
system activity (baroreflex activation therapy, endovascular barore­
flex amplification therapy, and carotid body ablation).560 Cardiac 
neuromodulation therapy aims to lower left ventricular preload by 
variably altering the atrioventricular interval using a dual-chamber, 
rate-responsive, implantable pulse generator in patients indicated 
for implantation or replacement of a dual-chamber pacemaker.591,592
Some, though not all, of these devices have shown promising results in 
non-randomized, single-arm studies. A sham-controlled trial investi­
gating central iliac arteriovenous stent anastomosis was terminated 
early after longer-term follow-up data indicated an increase in heart 
failure in the stent group.561 Therefore, the use of these device-based 
therapies is not recommended for routinely treating hypertension un­
til further evidence regarding their safety and efficacy becomes avail­
able (see Supplementary data online).
8.7. Unintended and potentially harmful 
consequences of blood pressure lowering 
and implications for treatment targets
8.7.1. Adverse effects of blood pressure-lowering 
medications
8.7.1.1. Symptomatic adverse effects
BP-lowering medications have multiple side effects, which may be more 
common in females.536,593,594 Although generally well tolerated, common 
side effects include headaches, cough, dizziness or light-headedness, diar­
rhoea or constipation, fatigue, ankle swelling, and erectile problems, de­
pending on the drug class (see Supplementary data online, 
Table S9).536,550,593–597
In randomized trials of adults aged >60 years, the overall rate of 
symptomatic BP-lowering drug withdrawal was higher than the rate 
of placebo withdrawal (approximately 15% vs. 5%).593 A systematic re­
view, which included 280 638 participants in 58 RCTs, reported no evi­
dence for an increased relative risk of falls in those taking BP-lowering 
drugs.550 There was, however, an increased relative risk of mild hyper­
kalaemia, acute kidney injury, hypotension, and syncope. Furthermore, 
very frail adults were excluded from BP-lowering trials, which is rele­
vant because such patients are more prone to adverse effects and poly­
pharmacy (see Supplementary data online).596
8.7.1.2. Renal effects
A systematic review reported an increased risk of acute kidney injury and 
hyperkalaemia associated with BP-lowering treatment.550 Analyses 
of outcomes by specific drug class showed that drugs affecting the 
RAAS were more likely to be associated with acute kidney injury 
and hyperkalaemia.550
Patients with significant CKD tend to be excluded from 
RCTs.137,545,598 It is important to remember these exclusion criteria, 
and that patients with CKD are more likely to suffer from resistant 
hypertension, when extrapolating the results of more intensive BP low­
ering to patients with moderate-to-severe CKD (see Section 9).599
8.7.1.3. Erectile dysfunction
Older classes of BP-lowering drugs (including diuretics, beta-blockers, 
and centrally acting medications) are associated with erectile 
dysfunction.600 However, newer classes have neutral effects.601
Angiotensin receptor antagonists may have beneficial effect on erectile 
function.602
8.7.2. Pill burden and non-adherence
More intensive treatment of elevated BP and hypertension may be as­
sociated with an increased risk of polypharmacy and pill burden, which 
are themselves associated with non-adherence.603,604 Single-pill, fixed- 
dose drug combinations can help to reduce pill burden and are recom­
mended to improve adherence (refer to Section 8.3.4).
Increased intensity of BP lowering (while ultimately cost reducing in 
terms of CVD reduction)605 can also result in higher upfront direct and 
indirect healthcare costs, with more people requiring medication and 
higher demand for technology-based adherence strategies, which can 
be challenging to implement, especially in resource-poor settings.604
8.7.3. Potentially harmful consequences of blood 
pressure lowering for frail older people
Unintended consequences of BP lowering (hypotension, syncope, falls) can 
be hazardous for frail older people in particular.606 Retrospective studies 
have shown that adults aged >75 years from the general population, 
who would have met the criteria for inclusion in the Systolic Blood 
Pressure Intervention Trial (SPRINT), had a rate of injurious falls and syn­
cope that was nearly five times that of the standard care group in the trial. 
This suggests that healthy participant bias may have contributed to the 
findings of SPRINT and other similar BP-lowering trials, and that the results 
may not fully generalize to older adults in more routine clinical care.607
Patients’ functional ability should be considered in addition to age to 
help negate any unintended consequences of BP lowering in a frailer co­
hort. Despite their chronological age, older patients with hypertension 
who are fit and can independently carry out activities of daily living will 
benefit from guideline-directed treatment similar to younger cohorts.131
However, tailoring treatment targets and treatment plans for frail older 
patients is necessary to avoid unintended consequences. This should in­
clude assessing frailty, including cognitive status, risk of falls, propensity 
for symptomatic orthostatic hypotension, polypharmacy, and other co­
morbid conditions.608,609 Of note, and as detailed in Section 9, some 
data indicate a benefit of more intensive BP-lowering on cognitive func­
tion.523,610,611 For those with loss of function but preserved activities of 
daily living, a more detailed geriatric assessment is required to explore 
the risks and benefits of treatment, as well as considerations for tailoring 
therapeutic strategies where appropriate. For patients who are both func­
tionally impaired and unable to carry out activities of daily living, the thera­
peutic goals of hypertension treatment should be personalized, and 
medications discontinued where appropriate (see Section 9.3).596
8.7.4. Clinical inertia in blood pressure lowering
The fear of serious adverse events with BP-lowering medications is of­
ten cited as a reason for clinical inertia, although the evidence to date 
from meta-analyses of RCTs suggests these side-effect concerns may 
be exaggerated.550,612 However, RCTs often select populations with 
less frailty and multimorbidity who are more likely to tolerate treat­
ment.613 Consequently, fewer adverse effects might be reported 
than would be expected in the general population. It remains up to in­
dividual clinicians to initiate shared decision-making with each patient, 
especially patients in vulnerable groups and those who have experi­
enced previous adverse events, weighing up potential benefits against 
risks of treatment.614,615


<!-- PAGE 58 -->

### Page 58

### 9 Managing specific patient groups

or circumstances
9.1. Young adulthood (18–40 years)
9.1.1. Definition and epidemiology
In the present guidelines ‘young adulthood’ is defined as age 18–40 years. 
The prevalence of hypertension in young adults is increasing in men and 
women.616–618 Unhealthy lifestyle, gender, obesity, and socio-economic 
factors contribute.617,619–621 Hypertension-attributable CVD burden in 
young adults, evaluated as mortality or years of living with disability, 
has increased in the last decades, especially in low- and middle-income 
countries and in men.622 Hypertension awareness, treatment, and con­
trol in young adults is lower than in other age categories, a result driven 
by worse control in young men.623
Systolic and diastolic hypertension and isolated diastolic hyperten­
sion are associated with increased CVD risk in the young (see 
Supplementary data online).624 Isolated systolic hypertension in the 
young is discussed in Section 9.4.
9.1.2. Secondary hypertension in young adulthood
Secondary hypertension is more frequent in younger than in later- 
onset hypertension, with a prevalence of 15%–30% in hypertensive 
young adults reported from some referral centres.625,626 Major causes 
of secondary hypertension include drug-induced hypertension (e.g. 
oestrogen-progesterone oral contraceptives; cold medication) and pri­
mary aldosteronism. The use of recreational drugs/substances, as well 
as supplements and energy drinks should be investigated (see Section 7).
Combined oestrogen-progesterone contraceptives are among the most 
common causes of drug-induced hypertension in young women,627,628 and 
should not be used in hypertensive women unless there is no other method 
available or acceptable to the patient.629Conversely, progestin-only contra­
ceptives are generally considered safe in women with hyperten­
sion.89,630,631 Fibromuscular dysplasia should be considered as a cause of 
secondary hypertension in young women,626,632 whereas primary aldoster­
onism, the most common form of secondary hypertension, is equally com­
mon in different age classes.316 Screening for secondary hypertension is 
thus recommended in young adults with hypertension. However, in obese 
young adults, primary hypertension is more common, though OSAS should 
also be considered in this instance.633
9.1.3. Measurement and management of blood 
pressure in young adults
Out-of-office BP measurement is recommended in young adults for 
confirming diagnosis, since the white-coat phenomenon occurs in the 
young.634 Because of the lower absolute CVD risk in this age category 
compared with older adults, hard-endpoint randomized trials of BP 
lowering in young adults have not been performed. However, since 
relative risk reduction by BP-lowering treatment is homogeneous in 
any age group, including those <55 years old,131 young adults with suit­
able indications are also expected to benefit from BP-lowering therapy. 
The hypertension management algorithm based on CVD risk proposed 
in Section 6 is not fully applicable in young adults, since SCORE2 has not 
been validated for individuals <40 years old. Even risk stratification 
based on lifetime risk assessment does not apply to very young adults 
(e.g. 20–30 years of age).128 In the absence of established CVD, diabetes 
mellitus, familial hypercholesterolaemia, and moderate or severe CKD 
a BP-lowering treatment initiation threshold of office 140/90 mmHg is 
appropriate in most young adults. However, HMOD assessment may 
be considered in patients aged <40 years to stratify individuals with ele­
vated BP into a higher risk category. For example, arterial stiffness bet­
ter reclassifies CVD risk in individuals aged <50 years than in older 
individuals.28,215 Echocardiographic left ventricular mass also maintains 
its added reclassification and discrimination on top of risk scores in 
young adults (see Section 6 for discussion of risk modifiers).289
Irrespective of cardiovascular risk, all young adults with elevated BP 
are recommended to follow lifestyle guidance for BP lowering. A dis­
cussion about family planning should be taken with young women of 
childbearing potential at each visit.635,636
Adherence to treatment is low in young adults, <50% in some stud­
ies.251 Therefore, communicating the importance of adherence, educa­
tion, and follow-up clinics is important. (see Sections 7 and 11).
9.2. Pregnancy
9.2.1. Definition and epidemiology
Hypertension in pregnancy is typically defined as systolic BP of 
≥140 mmHg and/or diastolic BP of ≥90 mmHg, measured using repeated 
BP readings in the office or hospital on two separate occasions or 
≥15 min apart in severe hypertension (≥160/110 mmHg).1,637,638
Hypertension in pregnancy is the second leading cause of maternal 
death after maternal peri-partum haemorrhage.639 Approximately 
7% of pregnancies are complicated by hypertension, of which 3% 
are due to pre-eclampsia and around 1% are chronic or pre-existing 
hypertension.640 Women with a history of hypertensive disorders 
during pregnancy are at increased risk of subsequent hypertension 
and CVD.640–642
9.2.2. Classifying hypertension in pregnancy
Hypertension in pregnancy includes:
• Chronic hypertension: precedes pregnancy, develops before 20  
weeks of gestation, persists for >6 weeks post-partum, and may be 
associated with proteinuria.
• Gestational hypertension: develops after 20 weeks of gestation 
and usually resolves within 6 weeks post-partum.
Recommendation Table 21 — Recommendations for 
managing hypertension in young adults (see Evidence 
Tables 36 and 37)
Recommendations
Classa
Levelb
Comprehensive screening for the main causes of 
secondary hypertension is recommended in adults 
diagnosed with hypertension before the age of 40 
years, except for obese young adults where it is 
recommended to start with an obstructive sleep 
apnoea evaluation.316,626
I
B
Since SCORE2 has not been validated for individuals 
<40 years, screening for HMOD may be considered in 
such young individuals with elevated BP without other 
increased CVD risk conditions to identify additional 
individuals for possible medical treatment.28,215
IIb
B
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease; HMOD, hypertension-mediated organ 
damage; SCORE2, Systematic COronary Risk Evaluation 2. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3969


<!-- PAGE 59 -->

### Page 59

• Antenatally unclassifiable hypertension: BP is first recorded 
after 20 weeks of gestation, and hypertension is diagnosed but it is 
unclear if chronic or not; reassessment is necessary 6 weeks 
post-partum.
• Pre-eclampsia: gestational hypertension accompanied by new- 
onset: (i) proteinuria (>0.3 g/day or ≥30 mg/mmol ACR), (ii) other 
maternal organ dysfunction, including acute kidney injury (serum cre­
atinine ≥ 1 mg/dL), liver dysfunction (elevated transaminases > 40  
UI/L with or without right upper quadrant or epigastric abdominal 
pain), neurological complications (convulsions, altered mental status, 
blindness, stroke, severe headaches, and persistent visual scotomata), 
or haematological complications (platelet count < 150 000/µL, disse­
minated intravascular coagulation, haemolysis), or (iii) uteroplacental 
dysfunction (such as foetal growth restriction, abnormal umbilical ar­
tery Doppler waveform analysis, or stillbirth).643 The only cure for 
pre-eclampsia is delivery, which is recommended at 37 weeks’ gesta­
tion, or earlier in high-risk cases. Of note, proteinuria is not manda­
tory for diagnosing pre-eclampsia but is present in about 70% of 
cases.644 Also, as proteinuria may be a late manifestation of 
pre-eclampsia, it should be suspected when de novo hypertension is 
accompanied by headache, visual disturbances, abdominal pain, or 
abnormal laboratory tests, specifically low platelets and/or abnormal 
liver function.
Other potential causes for high BP, including pain and anxiety, must be 
excluded when treating hypertension during pregnancy.
9.2.3. Measuring blood pressure in pregnancy
See Section 5.5.1 for information on BP measurement approaches in 
pregnancy.645 It is important to restate here that oscillometric devices 
tend to under-estimate the true BP and are unreliable in severe pre- 
eclampsia; only a few have been validated in pregnancy. Importantly, 
only the relatively few devices validated for measuring BP in pregnancy 
and pre-eclampsia should be used (https://stridebp.org).
9.2.4. Investigating hypertension in pregnancy
Basic laboratory investigations include urinalysis, blood count, haemato­
crit, liver enzymes, serum creatinine, and serum uric acid. Serum uric 
acid is increased in pre-eclampsia and identifies women at increased 
risk of adverse maternal and foetal outcomes in hypertensive 
pregnancies.646
All pregnant women should be assessed for proteinuria in early preg­
nancy (e.g. 11–14 weeks’ gestation).647 A dipstick test of ≥1+ should 
prompt further investigations, including ACR, which can be quickly de­
termined in a single spot-urine sample.648 An ACR of <30 mg/mmol 
(<0.3 mg/mg) can rule out proteinuria.649 Higher values should prompt 
24 h urine collection.
In one study, 10% of pregnant women with chronic hypertension had 
secondary hypertension (estimated to affect 0.24% of all pregnan­
cies).650 Secondary hypertension during pregnancy is associated with 
an increased risk of adverse outcomes.650 The most common cause 
of secondary hypertension during pregnancy is CKD. The onset of 
hypertension during the first trimester, at the peak of human chorionic 
gonadotropin (HCG) secretion, should prompt consideration of pri­
mary aldosteronism.651 Phaeochromocytoma in pregnant women is 
rare (0.002% of all pregnancies) but highly morbid.652,653
9.2.5. Preventing hypertension and pre-eclampsia
Low-to-moderate-intensity exercise, especially if supervised and in­
itiated during the first trimester of pregnancy, decreases the incidence 
of developing gestational hypertension.654 As such, after consultation 
with their obstetrician, all pregnant women should participate in phys­
ical activity, unless contraindicated.655 Factors indicating risk of pre- 
eclampsia are discussed in the Supplementary data online.
Women at high or moderate risk of pre-eclampsia should be advised 
to take 100–150 mg of aspirin daily at bedtime from gestational weeks 
12–36.647,656,657
Oral calcium supplementation of 0.5–2 g daily is recommended for 
preventing pre-eclampsia in women with low dietary intake of calcium 
(<600 mg daily).658,659
9.2.6. Treatment initiation and blood pressure 
targets
Acute management of BP in pre-eclampsia and eclampsia is detailed in 
Section 10.4.
Meta-analyses have found no evidence for an increased risk for deli­
vering small-for-gestational-age babies in pregnant women with mild 
hypertension receiving BP-lowering medications.660 Despite a historical 
paucity of trial data, previous European guidelines1,89 recommended 
initiating BP-lowering drug treatment (i) in all women with persistently 
elevated office BP of ≥150/90 mmHg, and (ii) in women with gestation­
al hypertension (with or without proteinuria), pre-existing hyperten­
sion with superimposed gestational hypertension, or hypertension 
with subclinical HMOD, when office BP is >140/90 mmHg.
In the CHAP trial, treating pregnant women with chronic hyperten­
sion and BP of ≥140/90 mmHg reduced the occurrence of pre- 
eclampsia with severe features, and reduced medically indicated 
pre-term birth <35 weeks, compared with only treating severe hyper­
tension (BP ≥ 160/105 mmHg).88 Tight BP control (target diastolic 
BP < 85 mmHg) compared with less-tight BP control (target diastolic 
BP < 100 mmHg) reduces the incidence of subsequent severe maternal 
hypertension (BP ≥ 160/110 mmHg), but not foetal or other maternal 
outcomes in women with mild hypertension at baseline (diastolic BP of 
85–105 mmHg).661
Treatment with BP-lowering drugs in all pregnant women with con­
firmed BP of ≥140/90 mmHg is recommended to reduce the progres­
sion to severe hypertension and the related risks for adverse pregnancy 
outcomes.660,661 In women with pre-existing and gestational hyperten­
sion with and without pre-eclampsia, we recommend lowering BP be­
low 140 mmHg for systolic and to 80–90 mmHg for diastolic BP.661
Evidence to support a BP target as low as 120–129/70–79 mmHg is 
lacking in pregnancy, though such evidence exists for non-pregnant pa­
tients receiving BP-lowering medication.
9.2.7. Managing mild hypertension in pregnancy 
(office blood pressure 140–159/90–109 mmHg)
RAS inhibitors are not recommended in pregnancy due to adverse foe­
tal and neonatal outcomes. The BP-lowering drugs of choice are: beta- 
blockers (most data are available for labetalol, a non-selective beta- 
blocker that also acts as an alpha-blocker in higher doses; metoprolol 
and bisoprolol are also considered safe), dihydropyridine CCBs (most 
data are available for nifedipine, which is generally considered first 
choice, also felodipine, nitrendipine, amlodipine, and isradipine can be 
used), and methyldopa.662,663 A meta-analysis suggests that beta- 
blockers and CCBs are more effective than methyldopa in preventing 
severe hypertension.660 Of note, however, atenolol should be avoided, 
as it is associated with foetal growth restriction.664,665 Methyldopa has 
been associated with an increased risk of post-partum depression and 
caution is therefore advised both intra-partum and post-partum.637


<!-- PAGE 60 -->

### Page 60

Hydralazine can be particularly effective for severe hypertension in 
pregnancy and can be administered intravenously in hypertensive ad­
missions (Section 10).666–668 While thiazide diuretics in pregnancy 
have limited safety data and should be used with caution, other diuretics 
such as furosemide are not contraindicated and may be necessary in 
some situations (see Supplementary data online).669
9.2.8. Managing severe hypertension in pregnancy 
(>160/110 mmHg)
Acute onset of severe hypertension persisting for more than 15 min is 
considered a hypertensive emergency in pregnancy and is covered in 
Section 10.4.2.
9.2.9. Managing blood pressure post-partum
For women with hypertension during pregnancy, BP should be mea­
sured within 6 h of delivery and, if possible, daily for at least a week after 
discharge from the hospital.637 Post-partum hypertension is common 
in the first week and associated with prolonged hospitalization.670
Women with hypertension in pregnancy are at increased risk of 
chronic hypertension,671 CKD,672 and CVD.177,223,640 The relative 
risk of chronic hypertension is highest in the first 6 months following 
delivery, motivating regular screening in these women.673 Women 
with gestational hypertension, especially those with pre-eclampsia, 
have higher risk of masked hypertension.674 BP measurements, ideally 
including out-of-office measurements, urine analyses, and CVD risk as­
sessment, should at least be performed 6–12 weeks, 6 months, and 
12 months post-partum and, after that, annually. Recent data indicate 
the potential utility of self-monitoring of BP during the busy early post- 
partum period.675
All BP-lowering drugs are excreted into breast milk.637 Except for 
propranolol, atenolol, acebutolol, and nifedipine, most drugs are ex­
creted in very low concentrations in breast milk (see Supplementary 
data online, Table S11).637
9.2.10. Risk of recurrence of hypertensive disorders 
in a subsequent pregnancy
About 20%–30% of women with hypertensive disorders in a previous 
pregnancy will experience recurrence in a subsequent pregnancy.676,677
The earlier the onset of hypertension in the first pregnancy, the higher 
the risk of recurrence in a subsequent pregnancy.677
Further details on managing hypertension and other cardiovascular 
disorders in pregnancy are available elsewhere.89,637
9.3. Very old age (≥85 years), frailty, 
multimorbidity, and polypharmacy
9.3.1. Definition of frailty
The most common definition of frailty is an age-associated, biological 
syndrome characterized by decreased biological reserves, due to dysre­
gulation of several physiological systems.682 This puts an individual at 
risk when facing physiological stressors, and is associated with poor 
outcomes, such as disability, hospitalization, and death.683 The esti­
mated prevalence of frailty in people aged >65 years is 7%–16% and 
is greater in women than in men.684,685 Although the main determinant 
of frailty is age, chronological age must be differentiated from biological 
age.686 An older patient can be fit and robust while a multimorbid 
young patient can be frail. Using multiple drugs may have more unpre­
dictable effects on BP in older patients, because of increased competi­
tion for underlying mechanisms responsible for their degradation and 
elimination, and because the ability of the baro-687 and chemo-reflex688
systems in maintaining a steady treated BP level can decline with ageing.
With respect to BP, two issues compound interpretation of the 
frailty literature. First, frailty on its own is a strong predictor of mortality 
and cardiovascular complications689 and is accompanied by a decrease 
in systolic BP.690 This raises the issue of the so-called BP J-curve (see 
Section 9.8) and reverse causality, with frailty rather than excessive 
BP lowering being the root cause of adverse health outcomes. Only 
properly randomized and controlled clinical trials can differentiate be­
tween the effects of frailty vs. overly intensive BP-lowering treatment, 
but unfortunately, few BP-lowering trials have included a substantial 
proportion of frail patients. Second, there is no consensus on how to 
grade frailty in day-to-day clinical practice.606 Complex frailty scales ex­
ist for application in research,523,691 but unless they are electronically 
generated,692 they are typically not practical in routine clinical care. 
Nonetheless, the clinical frailty scale (Figure 21) is intuitive and easy 
to administer and has been validated against 5-year risk of death.596,693
Recommendation Table 22 — Recommendations for 
managing hypertension in pregnancy (see Evidence 
Tables 38–40)
Recommendations
Classa
Levelb
In women with gestational hypertension, starting 
drug treatment is recommended for those with 
confirmed office systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg.661
I
B
In pregnant women with chronic hypertension, 
starting drug treatment is recommended for those 
with confirmed office systolic BP ≥140 mmHg or 
diastolic BP ≥90 mmHg.88,660,661,678
I
B
Continued
In women with chronic and gestational hypertension, 
it is recommended to lower BP below 140/90 mmHg 
but not below 80 mmHg for diastolic BP.
I
C
Dihydropyridine CCBs (preferably extended-release 
nifedipine), labetalol, and methyldopa are 
recommended first-line BP-lowering medications for 
treating hypertension in pregnancy.
I
C
In consultation with an obstetrician, low- to 
moderate-intensity exercise is recommended in all 
pregnant women without contraindications to 
reduce the risk of gestational hypertension and 
pre-eclampsia.654,655
I
B
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg 
in pregnancy can indicate an emergency, and 
immediate hospitalization should be considered.
IIa
C
HBPM and ABPM should be considered to exclude 
white-coat and masked hypertension, which are 
more common in pregnancy.679
IIa
C
RAS blockers are not recommended during 
pregnancy.680,681
III
B
© ESC 2024
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CCB, calcium channel 
blocker; HBPM, home blood pressure monitoring; RAS, renin–angiotensin system. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3971


<!-- PAGE 61 -->

### Page 61

9.3.2. Randomized controlled trials of blood pressure 
lowering in frail older patients
Few adults aged ≥85 years have been included in trials.131 In addition, 
generalizing data from RCTs to very frail patients may not be pos­
sible.692,694–697 However, the currently available evidence from RCTs 
has not demonstrated weakening of the benefits of BP-lowering treat­
ment (i.e. no effect modification) among frailer patients enrolled in 
these trials, although these participants likely had no more than mild 
frailty (see Supplementary data online).523,694,698
In the absence of robust randomized evidence, several observational 
studies have suggested that lowering BP might not be warranted or 
even be harmful in patients with significant frailty or multimorbidity, 
particularly when BP is not very high. For instance, a systematic review 
and meta-analysis of non-randomized studies that investigated 
associations between BP and risk of mortality in older patients found 
evidence for interaction by frailty status, suggesting that lowering BP 
might be harmful in this patient group.699 However, as noted above 
and in Section 9.8, these observational J-curve findings are unreliable 
when guiding clinical care, as unidentified biases potentially confound 
the results. For instance, in addition to reverse causality, stiffness of 
the large arteries is associated with both low diastolic BP and increased 
mortality.697 In addition, absolute CVD risk increases with age, indicat­
ing that fewer older than younger patients with hypertension may need 
to be treated to prevent one adverse health outcome.700
Therefore, 
given 
the 
totality 
of 
evidence 
from 
clinical 
trials,523,694,701,702 very old and frail patients with hypertension should 
not be denied the potential benefits of BP-lowering treatment down to 
a target of 120–129/70–79 mmHg. However, personalized decisionVery fit
1
People who are robust, 
active, energetic and 
motivated. These people 
commonly exercise regularly. They are among 
the fittest for their age.
Follow BP-lowering 
treatment guidelines as per 
younger cohorts, ensuring 
treatment is tolerated
Evidence for benefit in CV 
event reduction not as 
strong for people with 
moderate-to-severe frailty 
with functional impairment 
(poorly represented in 
clinical trials)
Evidence for benefits in 
reducing CVD events with 
more intensive treatment of 
BP
Exercise caution and clinical 
judgement in beginning and 
intensifying BP-lowering 
treatment, employing a 
shared decision-making 
approach
Low-dose combination 
therapy to achieve
BP control is reasonable
Single drug therapy may be reasonable in this cohort 
when initiating or maintaining 
BP-lowering treatment
ABPM if possible and 
regular review important, 
particularly if change in 
frailty
Monitor for symptomatic 
OH, asymptomatic OH 
with falls, poor treatment 
tolerance, or medication 
side effects. Use clinical 
judgement and APBM/HBPM to guide deprescribing 
or medication adjustment 
where appropriate
Well
2
People who have no active 
disease symptoms but are 
less fit than category I. 
Often, they exercise or are 
very active occasionally, e.g, 
seasonally.
Managing well
3
People whose medical 
problems are well 
controlled, but are not 
regularly active beyond 
routine walking.
Vulnerable
4
While not dependent on 
others for daily help, often 
symptoms limit activities. A 
common complaint is 
being "slowed up", and/or 
being tired during the day.
Mildly frail
5
These people often have more 
evident slowing, and need help 
in high order IADLs (finances, 
transportation, heavy 
housework, medications). 
Typically, mild frailty progressively impairs shopping and 
walking outside alone, meal 
preparation and housework.
Moderately frail
6
People need help with all outside activities and with 
keeping house. Inside, they 
often have problems with 
stairs and need help with 
bathing and might need 
minimal assistance cueing 
(prompting), standing by 
with dressing.
Severely frail
7
Completely dependent for 
personal care, from 
whatever cause (physical 
or cognitive). Even so, they 
seem stable and not at high risk of dying (within 
~6 months).
Very severely frail
8
Completely dependent,
approaching the end of life. 
Typically, they could not recover even from a 
minor illness.
Terminally ill
9
Approaching the end of 
life. This category applies 
to people with a life 
expectancy <6 months, 
who are not otherwise 
evidently frail.
Clinical Frailty
Scale 1–5
Clinical Frailty
Scale 6–9
Figure 21 Frailty assessment in the management of blood pressure. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CV, cardio­
vascular; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; IADLs, independent activities of daily living; OH, orthostatic hypoten­
sion. Adapted from Rockwood et al.693


<!-- PAGE 62 -->

### Page 62

making should be a priority in the very old and frail. Together with man­
agement of BP, a major consideration should also be whether reversible 
causes of frailty can be addressed,609 e.g. by treating underlying co­
morbidities or undergoing supervised muscle-strengthening physiother­
apy or supervised exercise and co-ordination and balance training.703
9.3.3. Starting blood pressure-lowering treatment in 
very old or frail patients
All patients must be fully informed about the benefits and risks of start­
ing BP-lowering treatment, so that their preference is considered. 
Among 34 hypertension guidelines, 18 recommended 150 mmHg as 
the systolic goal in frailer and/or older patients, but four endorsed sys­
tolic targets <130 mmHg or <120 mmHg.704 Treatment can be started 
with a long-acting dihydropyridine calcium channel antagonist.596,705
To achieve BP control, an ACE inhibitor, or if contraindicated, an 
ARB, can also be used. Thereafter, low-dose thiazides or thiazide-like 
diuretics are preferred unless there is a specific contraindication, such 
as gout, orthostatic hypotension, or disturbed micturition (including 
micturition syncope).596,705 Beta-blockers are less desirable as they 
reduce heart rate, cause fatigue, and increase the systolic pulse wave 
amplitude, which is insufficiently buffered in stiff central elastic arteries. 
Vasodilating beta-blockers and direct vasodilators (e.g. hydralazine and 
minoxidil) are associated with increased risk of orthostasis. Though 
data are conflicting,706 alpha-blockers are also considered less desirable 
as they appear to be associated with an increased risk of orthostasis and 
falls in very old patients (aged ≥85 years).707,708 Alpha-1 blockers, such 
as doxazosin, prazosin, terazosin (also used to treat prostate symp­
toms), are particularly prone to causing orthostasis.98 Once the appro­
priate combination is found, a combination tablet with variable 
composition of two agents may optimize adherence. Starting with com­
bination therapy is not advised in most very old and/or frail patients, un­
less BP is very high.
9.3.4. Maintaining blood pressure lowering in very old 
or frail patients
If very old and frail patients tolerate BP-lowering treatment well, there 
is no automatic need to deprescribe or discontinue treatment; how­
ever, this should be kept under review. In the case of progressive frailty, 
systolic BP tends to drop,709 such that deprescription of a BP-lowering 
drug might become necessary. To identify candidate drugs for depre­
scribing, a patient’s current medications should be reviewed to identify 
BP-lowering drugs that may have become contraindicated due to con­
comitant prescriptions or newly developed comorbidities.705 To help 
guide deprescription of BP-lowering agents, ABPM can be used to de­
tect orthostatic hypotension or a highly variable BP not buffered by 
autonomic nervous reflexes.687,688
9.4. Isolated systolic and diastolic 
hypertension
9.4.1. Definition of isolated systolic hypertension
Isolated systolic hypertension is typically defined as systolic BP of 
≥140 mmHg with a diastolic BP of <90 mmHg. While isolated systolic 
hypertension is uncommon in younger patients,713 it is the most common 
type of hypertension in older patients; >80% of untreated patients with 
hypertension aged >60 years have isolated systolic hypertension.714
9.4.2. Isolated systolic hypertension, risk factors, and 
ageing
Systolic BP increases with age in men and women until the eighth dec­
ade of life, while diastolic BP gradually increases up until the fifth or sixth 
decade of life, after which it either plateaus or decreases. As a result, the 
pulse pressure (the difference between the systolic and diastolic BP) 
gradually widens from middle age.34 These BP changes are related to 
increased aortic stiffening with age.715,716
Since most older patients with hypertension have isolated systolic 
hypertension, and since with advancing age, risk of CVD events is driven 
by systolic rather than diastolic BP,717 management of isolated systolic 
hypertension in older adults is broadly in line with that of combined 
systolic-diastolic hypertension seen in younger adults.718 Early isolated 
Recommendation Table 23 — Recommendations for 
managing hypertension in patients who are very old or 
frail (see Evidence Table 41)
Recommendations
Classa
Levelb
It is recommended that treatment of elevated BP and 
hypertension among older patients aged <85 years 
who are not moderately to severely frail follows the 
same guidelines as for younger people, provided 
BP-lowering treatment is well tolerated.131,523,524
I
A
Continued
It is recommended to maintain BP-lowering drug 
treatment lifelong, even beyond the age of 85 years, if 
well tolerated.523–525
I
A
Because the benefit in reducing CVD outcomes is 
uncertain in these settings, and noting that close 
monitoring of treatment tolerance is advised, 
BP-lowering treatment should only be considered 
from ≥140/90 mmHg among persons meeting the 
following criteria: pre-treatment symptomatic 
orthostatic hypotension, age ≥85 years, clinically 
significant moderate-to-severe frailty, and/or limited 
predicted lifespan (<3 years).131,524,526,527
IIa
B
As the safety and efficacy of BP treatment is less 
certain in individuals with moderate or severe frailty, 
clinicians should consider screening older adults for 
frailty using validated clinical tests; frail patients’ 
health priorities and a shared-decision approach 
should be considered when deciding on BP 
treatments and targets.523,524,613,710
IIa
C
When initiating BP-lowering treatment for patients 
aged ≥85 years, and/or with moderate-to-severe 
frailty (at any age), long-acting dihydropyridine CCBs 
or RAS inhibitors should be considered, followed if 
necessary by low-dose diuretic if tolerated, but 
preferably not a beta-blocker (unless compelling 
indications exist) or an alpha-blocker.711
IIa
B
If BP drops with progressing frailty, deprescription of 
BP-lowering medications (and other drugs that can 
reduce BP, such as sedatives and prostate-specific 
alpha-blockers) may be considered.712
IIb
C
© ESC 2024
BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, 
renin–angiotensin system. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3973


<!-- PAGE 63 -->

### Page 63

systolic hypertension studies used systolic BP treatment targets of 160 or 
150 mmHg.718 However, results from the SPRINT and the Strategy of 
Blood Pressure Intervention in Elderly Hypertensive Patients (STEP) trials 
(mean BP at study entry of 140/78 mmHg and 146/82 mmHg, respective­
ly, indicating that many of the patients had isolated systolic hypertension) 
confirm that lower systolic BP targets are effective in reducing CVD 
events 
in 
patients 
with 
isolated 
systolic 
hypertension 
(see 
Supplementary data online).135,136
Since relative risk reduction by BP-lowering treatment is homoge­
neous in any age group, whereas absolute risk reduction is larger 
with advancing age,131 therapeutic inertia in older patients with isolated 
systolic hypertension should be avoided (see Section 9.3). As noted earl­
ier, beta-blockers should be avoided in patients with isolated systolic 
hypertension or more generally with arterial stiffness, as they increase 
stroke volume (given the lower heart rate).218
9.4.3. Isolated systolic hypertension in young adults
In young adults (<40 years old), the presence of isolated systolic hyper­
tension poses different pathophysiological and clinical considerations. In 
young patients with isolated systolic hypertension, arterial stiffness713
and relative risk of CVD events624 appear to be similar to those without 
isolated systolic hypertension and lower than young adults with com­
bined systolic-diastolic hypertension and isolated diastolic hypertension. 
Indeed, younger patients with isolated systolic hypertension appear to 
comprise a heterogeneous group.719 For these reasons, it might be rea­
sonable to assess central BP and arterial stiffness in these individuals, as 
recommended by other scientific societies.720,721 Out-of-office BP meas­
urement is recommended to exclude white-coat hypertension, which is 
often associated with isolated systolic hypertension in the young.634
9.4.4. Isolated diastolic hypertension
Isolated diastolic hypertension is defined as a systolic BP of <140 mmHg 
with a diastolic BP of ≥90 mmHg. The isolated diastolic hypertension 
phenotype is more commonly seen in younger adults and, particularly, 
younger adults with obesity or other metabolic derangements.722,723 In 
older adults with this phenotype, consideration should be given to 
whether the diastolic BP was accurately measured.724
Patients with isolated diastolic hypertension appear to have a slightly 
increased relative risk for CVD of 5%–30%.548,723,725 However, be­
cause patients with isolated diastolic hypertension are younger, they 
tend to have few events, and very large samples are required to 
show this association. Furthermore, because the absolute risk for 
CVD among these individuals is low (typically <10% over 10 years), it 
is less clear if isolated diastolic hypertension should prompt initiation 
of BP-lowering medication, particularly among persons in whom base­
line systolic BP is already at the target of 120–129 mmHg.723
Irrespective, patients with isolated diastolic hypertension should be fol­
lowed up, as they are at increased risk for systolic hypertension.723
Finally, it is also worth noting that when a patient achieves a target 
systolic BP of 120–129 mmHg with BP-lowering treatment, there is lit­
tle to no high-quality trial evidence that further intensifying BP-lowering 
medication to achieve both systolic BP of <120 mmHg and also diastol­
ic BP of <70 mmHg improves CVD prognosis.547,723
9.5. Orthostatic hypotension with supine 
hypertension
Patients with orthostatic hypotension need not be hypotensive and in­
deed, many have supine elevated BP or supine hypertension. 
Furthermore, many patients with orthostatic hypotension are asymp­
tomatic. Orthostatic hypotension is present in around 10% of all adults 
with hypertension and is defined as a drop in BP of ≥20/10 mmHg after 
rising from either a sitting or lying position to a standing position (see 
Section 5.5.3).97,99 Assessment for orthostatic hypotension should be 
timed to occur at 1 and/or 3 min after standing. Because seated to 
standing assessment can lead to under-detection of orthostatic hypo­
tension, it is preferable, where possible, to test for orthostatic hypoten­
sion using a supine (lying) to standing assessment (see Section 5).56,98,726
Assessing for orthostatic hypotension is important in managing adults 
with elevated BP or hypertension for several reasons. First, findings of trials 
linking more intensive BP control to improved outcomes may not gener­
alize to patients with orthostatic hypotension, particularly when it is severe 
in magnitude (standing systolic BP < 110 mmHg97) and/or symptomatic. 
Second, orthostatic hypotension may be associated with symptoms that 
may limit the patient’s tolerability of more intensive BP-lowering 
approaches. Third, orthostatic hypotension may be associated with an in­
creased risk of adverse effects commonly co-attributed to pharmacological 
BP lowering (such as hospitalizations for hypotension).727 Fourth, ortho­
static hypotension is associated with increased risk for CVD.728
However, the frequency of orthostatic hypotension is not increased 
in the more intensive BP-lowering arms of randomized trials compared 
with the less intensive BP-lowering arms.726,727,729,730 As such, and in 
contrast to common belief, it does not appear that more intensive 
treatment of BP (which almost always requires more BP-lowering 
medication) worsens orthostatic hypotension. In contrast, there is 
some evidence that more intensive treatment of hypertension may ac­
tually reduce the risk of orthostatic hypotension.730,731
The aetiology of orthostatic hypotension may be considered as 
neurogenic or non-neurogenic, with the latter being far more com­
mon.99 Patients with orthostatic hypotension may have underlying neu­
rodegenerative diseases, diabetes, B12 deficiency,732 renal failure, 
dehydration, prolonged recumbency, deconditioning, and triggering 
medications (like alpha-blockers, beta-blockers, diuretics, nitrates, anti­
depressants, and antipsychotics). Of note, ACE inhibitors, ARBs, and 
dihydropyridine CCBs are examples of BP-lowering medications that 
appear to have less impact on orthostatic hypotension, and their ad­
verse impact, if any, on orthostatic hypotension typically occurs in 
the first 2 weeks or so after starting or intensifying treatment.733
Managing patients with supine hypertension and orthostatic hypoten­
sion is a common clinical conundrum. More detailed reviews on this topic 
are available elsewhere.98,99 The approach to managing orthostatic hypo­
tension should be non-pharmacological at first. Patients with orthostatic 
hypotension should be asked to change position slowly, maintain ad­
equate hydration, and avoid alcohol and large meals. Compression stock­
ings, crossing legs while standing, and abdominal binders may also help and 
should be trialled.734,735 Abdominal heating pads and a head-up bed pos­
ition can reduce supine (typically nocturnal) hypertension, which may re­
duce nocturnal diuresis and daytime orthostatic hypotension.736
The treatment of orthostatic hypotension among those with supine 
hypertension is not to automatically down-titrate BP-lowering medica­
tions. Rather, reversible causes should be sought and treated (including 
discontinuation of offending medications), and patients requiring 
BP-lowering medication should be switched to BP-lowering medications 
that are less likely to cause orthostatic hypotension. When symptoms are 
disabling and the above interventions do not help, particularly in neuro­
genic orthostatic hypotension, the best evidence exists for midodrine 
to reverse orthostatic hypotension, and this may be given in conjunction 
with ongoing BP-lowering medications when supine hypertension ex­
ists.99 An alternative option to midodrine is droxidopa, though this is 
less readily available. Specialist referral is prudent when persons with su­
pine hypertension are prescribed these orthostatic hypotension treat­
ments, as these agents can increase supine BP more than standing BP.


<!-- PAGE 64 -->

### Page 64

9.6. Diabetes
9.6.1. Diabetes and elevated blood pressure/ 
hypertension
Patients with diabetes (both type 1 and type 2) often have elevated BP 
or hypertension, and are about twice as likely to suffer a major CVD 
event over the medium to long term compared with those without dia­
betes.737 Diabetes is also a major cause of microvascular events, such as 
retinopathy and nephropathy.738,739 Although the risk of CVD in pa­
tients with diabetes varies by screening and diagnostic methods,740,741
as well as with the presence of other CVD risk factors,740,742 on aver­
age, patients with diabetes are at ≥10% 10-year risk for CVD. 
However, formal risk estimation with the use of SCORE2-Diabetes 
among type 2 diabetes mellitus patients should be considered if they 
are aged <60 years (see Section 6).164,739
9.6.2. J-shaped curve of blood pressure and risk of 
cardiovascular disease in patients with diabetes
Evidence on the BP threshold and target for treatment in patients with 
diabetes has been subject to debate. Reports of a J-shaped association 
between BP and risk of CVD in diabetes,743 and the lack of a clear bene­
fit of treatment on cardiac outcomes at lower BP in some 
meta-analyses,744–746 has led to some cautious recommendations for 
intensive treatment in this patient population.
An individual patient data meta-analysis by the Blood Pressure 
Lowering Treatment Trialists’ Collaboration tested treatment effects 
in 103 325 patients with diabetes and provided evidence against 
effect modification by categories of baseline BP down to a systolic BP 
of 120 mmHg.445 BP reduction in patients with diabetes is expected 
to reduce the risk of diabetes-associated complications including retin­
opathy, vasculopathy, and nephropathy (albuminuria and end-stage re­
nal disease), which adds weight to the importance of reducing BP in 
these patients (see Supplementary data online).745–747 This task force 
also considered the fact that a proportion of patients with diabetes 
have orthostatic hypotension due to diabetic neuropathy,748 which 
might affect the tolerability of BP lowering.
9.6.3. Managing blood pressure in diabetes
We recommend that all patients with diabetes are offered pharmaco­
logical BP-lowering treatment with a BP target of 120–129/70–79 mmHg, 
if feasible and tolerated.136,146,445,747,749–752 The task force further sees no 
strong evidence for a differential BP treatment targets in patients with dia­
betes and those without.136,146,445,746,747 While the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial reported a null primary 
endpoint for more intensive BP targets in diabetes, stroke was marginally re­
duced.137Furthermore, extended follow-up of ACCORD,750as well as ana­
lyses of intensive BP reduction in those randomized to the standard 
glycaemic arm,749 provide evidence suggesting benefit consistent with the 
SPRINT, STEP, and Effects of intensive Systolic blood Pressure lowering 
treatment in reducing RIsk of vascular evenTs (ESPRIT) trials.136,146,545
Overall, all major BP-lowering medication classes are effective in preventing 
CVD in people with or without diabetes. Of note, however, albuminuria is 
more common in diabetes and, for this reason, ACE inhibitors and ARBs 
have potential advantages that may warrant consideration for BP-lowering 
in patients with diabetes (see Supplementary data online, Table S10).753
Evidence for modifying BP-lowering treatment in patients with 
pre-diabetes is somewhat limited. Furthermore, the relative effect of BP 
lowering is relatively consistent across different categories of BMI as a 
measure of obesity.754,755 It is also noteworthy that elevated BP itself 
may increase the risk of diabetes,755 emphasizing the potential role of BP 
lowering in preventing diabetes in addition to preventing CVD. Among 
the major classes of BP-lowering drugs, ACE inhibitors and ARBs are effect­
ive in preventing new-onset diabetes and can be considered in patients at 
risk of diabetes and who are indicated for BP-lowering therapy.164,755
9.7. Chronic kidney disease
9.7.1. Relationship between hypertension and chronic 
kidney disease
Approximately 850 million people worldwide have CKD, with >80% of 
them hypertensive, and the prevalence is expected to rise to 1.56 billion 
Recommendation Table 24 — Recommendations for 
managing hypertension in patients with orthostatic 
hypotension
Recommendation
Classa
Levelb
Before starting or intensifying BP-lowering 
medication, it is recommended to test for orthostatic 
hypotension, by first having the patient sit or lie for 5  
min and then measuring BP 1 and/or 3 min after 
standing.97,99
I
B
It is recommended to pursue non-pharmacological 
approaches as the first-line treatment of orthostatic 
hypotension among persons with supine 
hypertension. For such patients, it is also 
recommended to switch BP-lowering medications 
that worsen orthostatic hypotension to an 
alternative BP-lowering therapy and not to simply 
de-intensify therapy.726,727,729,730
I
A
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 25 — Recommendations for 
managing hypertension in patients with diabetes
Recommendations
Classa
Levelb
In most adults with elevated BP and diabetes, after a 
maximum of 3 months of lifestyle intervention, BP 
lowering with pharmacological treatment is 
recommended for those with confirmed office BP 
≥130/80 mmHg to reduce CVD risk.445,749
I
A
BP-lowering drug treatment is recommended for 
people with pre-diabetes or obesity when confirmed 
office BP is ≥140/90 mmHg or when office BP is 
130–139/80–89 mmHg and the patient is at 
predicted 10-year risk of CVD ≥10% or with 
high-risk conditions, despite a maximum of 3 months 
of lifestyle therapy.445
I
A
In persons with diabetes who are receiving 
BP-lowering drugs, it is recommended to target 
systolic BP to 120–129 mmHg, if 
tolerated.136,146,445,747,749–752
I
A
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3975


<!-- PAGE 65 -->

### Page 65

by 2025.756–759 The pathogeneses of hypertension and CKD are closely 
entwined.760 Resistant hypertension, masked hypertension, HMOD, 
and higher night-time BP are common in patients with CKD.761 CVD 
is one of the largest contributors to mortality in patients with CKD, 
with hypertension being a major risk factor.760,762
For the purposes of these guidelines, adults with moderate-to-severe 
CKD and elevated BP are at sufficiently high risk to be considered for 
BP-lowering drug therapy as outlined in Section 8 and the Central 
Illustration (Figure 19). We use Kidney Disease: Improving Global 
Outcomes (KDIGO) categories to define CKD-based risk, and our def­
inition of moderate-to-severe CKD comprises persons with an eGFR of 
<60 mL/min/1.73 m2 and/or albuminuria of ≥30 mg/g (≥3 mg/mmol).19
For persons with mild CKD and elevated BP, a CVD risk assessment 
should be conducted before deciding on BP-lowering treatment.
9.7.2. Blood pressure lowering in chronic kidney 
disease
BP lowering in patients with CKD is associated with beneficial effect on 
CVD events and mortality.275,763–766 BP lowering reduces progression 
of CKD and the incidence of end-stage renal disease, but this tends to 
be only in those with significant proteinuria at baseline.766,767
9.7.3. Managing blood pressure in chronic kidney 
disease
Patients with CKD should receive lifestyle advice, especially regarding 
reducing sodium intake. Dietary potassium supplementation recom­
mendations are provided in Section 8, with caution required among per­
sons with moderate-to-severe CKD. While exercise appears to have 
little effect on improving BP in patients with CKD768 or patients on dia­
lysis,769 those with CKD on ACE inhibitor monotherapy have protec­
tion against adverse kidney outcomes, CVD events, cardiovascular 
death, and all-cause death.770,771 Both ACE inhibitors and ARBs reduce 
the risk of CVD events and kidney failure compared with placebo; how­
ever, ACE inhibitors appear to do so with higher probability than 
ARBs.772,773 Patients with CKD usually require combination therapy, 
and this should be initiated as a combination of a RAS inhibitor and a 
CCB or diuretic. In patients with eGFR < 30 mL/min/1.73 m2, an ad­
equately up-titrated loop diuretic is necessary to define resistant hyper­
tension. Chlorthalidone, typically added to a loop diuretic, also effectively 
lowers BP and reduces microalbuminuria in patients with resistant hyper­
tension with stage 4 CKD (eGFR of 15–30 mL/min/1.73 m2).774 The 
combination of an ACE inhibitor and an ARB is not recommended in 
CKD or any other BP-treatment scenario.
9.7.4. Blood pressure targets in chronic kidney 
disease
Evidence regarding BP targets in patients with CKD is complex and con­
troversial. The 2021 KDIGO Guideline suggested that adults with ele­
vated BP and CKD be treated to a target systolic BP of <120 mmHg, 
when tolerated, using standardized office BP measurement (Class of 
Recommendation IIb).19 This suggestion was based, in part, on the 
SPRINT trial.545 It should be noted that patients with 24 h urine protein 
excretion ≥ 1 g/day or eGFR < 20 mL/min/1.73 m2 were excluded 
from SPRINT. In patients with CKD, after a median follow-up of 3.3  
years, the hazard ratio for the primary composite cardiovascular out­
come was 0.81 (95% CI 0.63–1.05) and for all-cause death it was 
0.72 (95% CI 0.53–0.99). Although intensive BP lowering in SPRINT re­
sulted in greater early decline in eGFR, there was no evidence that this 
reduction in eGFR attenuated the beneficial effects of the SPRINT 
intervention on CVD events or death.775
Several systematic reviews have examined the benefit of intensive BP 
control in patients with CKD (see Supplementary data online). Some 
have shown no benefit of intensive BP control on renal out­
comes,764,767 while others showed lower mortality in intensively trea­
ted vs. non-intensively treated patients.275 Highlighting the beneficial 
effects of SGLT2 inhibitors in persons with CKD776,777 and finerenone 
in persons with CKD and diabetes460–462,778 is relevant, though these 
drugs are not currently marketed for BP-lowering effects alone.
9.8. Cardiac disease
9.8.1. Blood pressure thresholds and targets in 
patients with cardiac disease
Recommended BP thresholds for initiating BP-lowering therapy and re­
commended BP targets in patients receiving therapy are provided in 
Sections 6 and 8. All patients with a history of CVD (including coronary 
artery disease) are at increased risk of recurrent CVD. As such, these 
patients are recommended to be treated with BP-lowering therapy 
for confirmed baseline BP of ≥130/80 mmHg and the recommended 
treatment target BP of 120–129/70–79 mmHg, provided treatment is 
tolerated (see Sections 6 and 8). As stated in Section 8, it should be re­
membered that a systolic BP of 120 mmHg (especially by out-of-office 
assessment) is likely the optimal point in the target range recommended 
in these guidelines. In addition to considering patients with known CVD 
at sufficiently high risk for more intensive BP treatment targets, the 
Recommendation Table 26 — Recommendations for 
managing hypertension in patients with chronic kidney 
disease
Recommendations
Classa
Levelb
In patients with diabetic or non-diabetic 
moderate-to-severe CKD and confirmed BP ≥130/ 
80 mmHg, lifestyle optimization and BP-lowering 
medication are recommended to reduce CVD risk, 
provided such treatment is well tolerated.275,766
I
A
In adults with moderate-to-severe CKD who are 
receiving BP-lowering drugs and who have eGFR 
>30 mL/min/1.73 m2, it is recommended to target 
systolic BP to 120–129 mmHg, if tolerated. 
Individualized BP targets are recommended for those 
with lower eGFR or renal transplantation.274,779
I
A
In hypertensive patients with CKD and eGFR >20  
mL/min/1.73 m2, SGLT2 inhibitors are 
recommended to improve outcomes in the context 
of their modest BP-lowering properties.776,777
I
A
ACE inhibitors or ARBs are more effective at 
reducing albuminuria than other BP-lowering agents 
and should be considered as part of the treatment 
strategy for patients with hypertension and 
microalbuminuria or proteinuria.780–782
IIa
B
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood 
pressure; CKD, chronic kidney disease, eGFR, estimated glomerular filtration rate; 
SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 66 -->

### Page 66

task force considers patients with both severe valvular heart disease 
and symptomatic heart failure to also be at sufficiently high risk. We 
also note that, whether used for angina control or BP control, a beta- 
blocker should not be combined with a non-dihydropyridine CCB.
9.8.2. Coronary artery disease with particular 
reference to the blood pressure J-curve
Important considerations in patients with coronary artery disease are: 
(i) the BP J-curve (an observation suggesting that over-intensive BP low­
ering may increase CVD risk in some patients), and (ii) compelling indi­
cations for specific classes of BP-lowering medications.
The J-curve phenomenon describes increased risk for CVD observed 
among patients with the lowest and highest BP in the dataset, with the 
best CVD outcome rates typically observed among those with BP in the 
normal range (e.g. systolic BP of 100–120 mmHg and diastolic BP of 
60–80 mmHg). For this reason, the J-curve is sometimes also called 
the U-curve, with both terms typically used interchangeably.697,783,784
However, observational data do not consistently demonstrate a BP 
J-curve with CVD risk.697 It is more commonly observed among pa­
tients with established clinical CVD, such as those with coronary artery 
disease, or in secondary prevention cohorts.785,786 Furthermore, the 
J-curve is more commonly observed when analysing diastolic BP values 
vs. systolic BP values, though it has been described for both.114,697 This 
stronger relationship with diastolic BP has informed the hypothesis that 
the J-curve may be caused by reduced perfusion of major organs at low 
BP, which is particularly operative for diastolic BP in the coronary vas­
culature when considering ischaemic heart disease events (since coron­
ary blood flow is largely confined to diastole).786,787
If excessive lowering of BP causes CVD events, this needs to be 
addressed in treatment recommendations provided by BP manage­
ment guidelines. The 2018 ESC/ESH Guidelines on the management 
of arterial hypertension introduced, for the first time, lower bounds 
of BP-lowering treatment targets, implying that treatment be 
de-intensified for patients with on-treatment BP below these bounds 
(i.e. <120 mmHg systolic or <70 mmHg diastolic).1 The 2023 ESH docu­
ment also makes this argument.788
However, since 2018, compelling evidence has demonstrated that 
the BP J-curve evident in observational datasets is highly unlikely to re­
flect a causal process and can instead be attributed to residual con­
founding and/or reverse causation.33,114,115,546,697,789–793
Accordingly, while low BP can indicate a high-risk state, particularly 
among older adults and those with comorbidities, there is no evidence 
that this is a causal phenomenon. Indeed, if there is another indication 
for BP-lowering therapy (e.g. in a patient with wide pulse pressure and a 
baseline systolic BP of >140 mmHg but diastolic BP of <60 mmHg), the 
evidence suggests that such therapy should be provided if tolerated to 
reduce CVD risk.
There is a limit to how low BP can be treated without potentially tip­
ping the scales in favour of CVD harm vs. CVD benefit. However, it is 
not clear what that limit is and how much it differs based on comorbid­
ities. Currently, the data do not suggest that risk for CVD can be caus­
ally increased by treating any patient to the recommended intensive 
BP target outlined in these guidelines of as low as 120/70 mmHg. 
We also do not recommend stopping or de-intensifying BP-lowering 
medication among asymptomatic patients with on-treatment BP of 
<120/70 mmHg. It should be recognized, though, that there are no ro­
bust data demonstrating that an on-treatment systolic BP of <90 mmHg 
or an on-treatment diastolic BP of <50 mmHg is safe from a CVD 
perspective and there is clear potential for harm. Furthermore, it 
must be emphasized that the above discussion of the BP J-curve relates 
solely to CVD risk and does not consider the known non-CVD side ef­
fects of BP-lowering drugs, like, e.g. orthostatic hypotension, syncope, 
and renal injury. We do know that patients treated to a more intensive 
BP target of 120/70 mmHg are at increased risk for these side effects,550
which is why these guidelines stress that this more intensive target 
should only be pursued among those in whom treatment is being toler­
ated (Section 8).
The second consideration in managing BP in patients with coronary 
artery disease is the recommended use of BP-lowering medications 
with compelling indications based on outcomes trials that demon­
strated CVD outcomes benefits in the setting of coronary artery dis­
ease. These recommendations are provided in the recommendation 
table below.
9.8.3. Valvular heart disease
Most patients with both severe heart valve disease and heart failure, de­
fined by the 2021 ESC/European Association for Cardio-Thoracic 
Surgery (EACTS) Guidelines for the management of valvular heart dis­
ease,794 can be considered at increased risk of CVD. Accordingly, it is 
recommended they are treated with BP-lowering therapy for con­
firmed baseline BP of >130/80 mmHg, and their recommended target 
of treatment is BP of 120–129/70–79 mmHg, provided treatment is tol­
erated. Persons with mild-to-moderate heart valve disease should have 
a CVD risk assessment prior to deciding their BP-lowering treatment 
threshold and target.
Vasodilating ARBs/ACE inhibitors are preferable over vasodilating di­
hydropyridine CCBs because of the link between valvular heart disease 
and subsequent heart failure and given the stronger efficacy evidence 
for ARBs/ACE inhibitors in the setting of heart failure once mani­
fested.795 In aortic valve stenosis, concomitant hypertension influences 
both the aortic root, the aortic valve, and the left ventricular structure 
and function.796 In this subgroup, treatment preferably with ARBs/ACE 
inhibitors should be considered. A beta-blocker may be added if BP re­
mains >140/90 mmHg.796,797
9.8.4. Heart failure
Patients with symptomatic heart failure are at increased risk of CVD. 
Therefore, it is recommended that these patients are treated with 
BP-lowering therapy for confirmed baseline BP of >130/80 mmHg and 
their recommended treatment target is BP of 120–129/70–79 mmHg, 
provided treatment is tolerated and with out-of-office confirm­
ation of on-treatment BP. Of note, many patients with systolic 
heart failure on maximal heart failure therapies have BP of 
<120/70 mmHg, and we do not recommend de-intensifying such 
treatment unless indicated by symptomatic side effects. Besides 
referencing the new evidence for ARNi and SGLT2 inhibitor ther­
apies,795 our 2024 recommendations for heart failure are largely 
unchanged from the 2018 ESC/ESH Guidelines on the management 
of arterial hypertension. Non-dihydropyridine CCBs should not be 
used in heart failure. Frailty and hypotension risk should be as­
sessed in older heart failure patients being considered for ARNi 
and SGLT2 inhibitor therapies, and older patients should be closely 
followed to ensure they are tolerating such treatments. For more 
information on the management of heart failure, we direct readers 
to the latest ESC Guidelines for the diagnosis and treatment of 
acute and chronic heart failure.798
ESC Guidelines                                                                                                                                                                                          3977


<!-- PAGE 67 -->

### Page 67

9.8.5. Heart rhythm disease (including AF)
Not all patients with heart rhythm disease, including those with AF, 
are at increased risk for CVD and, as such, the management of BP 
among patients with heart rhythm disease should be the same as for 
the general adult population.443 However, there is a close relationship 
between increased BP and AF risk, hence, ensuring good BP control is 
important.801,802 Management of heart rhythm disorders should follow 
recommendations in guidelines specific to these conditions.803
9.9. Chronic cerebrovascular disease  
and/or cognitive impairment
9.9.1. Role of hypertension in chronic cerebrovascular 
disease
Hypertension is a risk factor for chronic cerebrovascular disease 
through its direct effects on brain structure and microvasculature. 
This manifests as transient ischaemic attack (TIA) and stroke in 
the acute setting, but chronic hypertension can lead to covert stroke 
and white-matter ischaemic change over time, resulting in cognitive 
decline and progressive vascular dementia.804–808 Hypertension is 
also associated with increased risk of Alzheimer’s disease,809 and 
is a risk factor for developing AF, heart failure, and CKD, all of which 
are associated with increased risk of developing cognitive impair­
ment and dementia.810–813 For the purposes of these guidelines, 
adults with a history of stroke or TIA and elevated BP are consid­
ered at sufficiently high risk to be considered for BP-lowering 
drug therapy as outlined in Section 8 and the Central Illustration 
(Figure 19).
9.9.2. Treatment in patients with history of prior 
stroke or transient ischaemic attack
In patients with a prior history of TIA and ischaemic stroke, 
BP-lowering treatment reduces the risk of any recurrent stroke by 
20%.814–817 The aetiology of stroke can affect the degree of risk reduc­
tion with pharmacological treatment, with greater reductions observed 
for intracerebral haemorrhage and lacunar ischaemic stroke syn­
dromes.818–820
Most prior guidelines recommend an intensive BP target in patients 
with a prior history of stroke, typically using combination treatment 
(ACE inhibitor/ARB plus either a calcium channel antagonist or a thia­
zide/thiazide-like diuretic), with therapy commencing immediately after 
TIA and within a few days of ischaemic stroke (see Supplementary data 
online and see Section 10.3 for acute BP management during hospital­
ization for stroke).814,815,821–824
Regimens containing an ACE inhibitor and thiazide/thiazide-like diur­
etic may be superior to beta-blockers in terms of stroke risk reduc­
tion.825,826 Regarding intensive BP control after stroke, typically 
targeting a systolic BP of <130 mmHg, individual trials were somewhat 
inconclusive, but a meta-analysis showed a reduced risk of recurrent 
stroke of 22% in the intensive treatment group randomized to a target 
systolic BP as low as 120 mmHg.543,824,827,828 Caveats to this recom­
mendation would be for frail patients, who have a much higher rate 
of stroke and recurrent stroke than the general population, and who 
are more sensitive to adverse effects of BP-lowering agents (see 
Section 9.3).596,606,607,829
9.9.3. Treatment in patients with chronic 
cerebrovascular disease and cognitive impairment
Treatment of hypertension represents a key mechanism for reducing 
the global burden of dementia at the population level.830
Epidemiological studies have reported associations between mid-life 
hypertension and development of cognitive decline in later life, with, 
e.g. mid-life hypertension increasing relative risk of lifetime dementia 
by 20%–54%.831–837 In one observational meta-analysis, an increased 
risk for dementia emerged with systolic BP of >130 mmHg.831
Evidence for lowering BP to reduce the risk of dementia is limited 
due to heterogeneity in populations studied, cognitive testing methods 
used, and the varied use of dementia or cognitive impairment or both as 
a primary outcome.838,839 Findings from individual studies have mixed 
results (see Supplementary data online).264,839–843 Studies on effects 
of BP-lowering treatment on white-matter intensities concluded that 
patients in the intensive-control arm had less white-matter intensity ac­
cumulation than in the standard-treatment arm.841,844 Studies in which 
people with stroke and TIA were included reported a reduced risk of 
dementia and cognitive decline for the active-treatment group, but a 
mixed signal for dementia alone.841,845 However, individual studies 
Recommendation Table 27 — Recommendations for 
managing hypertension in patients with cardiac disease
Recommendations
Classa
Levelb
In patients with a history of myocardial infarction 
who require BP-lowering treatment, beta-blockers 
and RAS blockers are recommended as part of that 
treatment.538
I
A
In patients with symptomatic angina who require 
BP-lowering treatment, beta-blockers and/or CCBs 
are recommended as part of that treatment.538
I
A
In patients with symptomatic HFrEF/HFmrEF, the 
following treatments with BP-lowering effects are 
recommended to improve outcomes: ACE inhibitors 
(or ARBs if ACE inhibitors are not tolerated) or 
ARNi, beta-blockers, MRAs, and SGLT2 
inhibitors.795
I
A
In hypertensive patients with symptomatic HFpEF, 
SGLT2 inhibitors are recommended to improve 
outcomes in addition to their modest BP-lowering 
properties.795
I
A
In patients with a history of aortic valve stenosis and/ 
or regurgitation who require BP-lowering treatment, 
RAS blockers should be considered as part of that 
treatment.794,796
IIa
C
In patients with a history of moderate-to-severe 
mitral valve regurgitation who require BP-lowering 
treatment, RAS blockers should be considered as 
part of that treatment.794
IIa
C
In patients with symptomatic HFpEF who have BP 
above target, ARBs and/or MRAs may be considered 
to reduce heart failure hospitalizations and reduce 
BP.795,799,800
IIb
B
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNi, 
angiotensin receptor–neprilysin inhibitor; BP, blood pressure; CCB, calcium channel 
blocker; HFpEF, heart failure with preserved ejection fraction; HF(m)rEF, heart failure 
with (mildly) reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; 
RAS, renin–angiotensin system; SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 68 -->

### Page 68

may have been under-powered and more recent meta-analyses do 
convincingly support efficacy in reducing dementia with BP-lowering 
treatment.610,611 Indeed, these meta-analyses reported a reduced 
risk of incident dementia or cognitive impairment with BP lowering 
of 7%–13%.610,611 While one trial suggested superiority of long-acting 
CCBs,264 it is unclear if any first-line BP-lowering agent is preferable for 
preventing dementia and cognitive impairment.846,847
The role of competing risk mechanisms including orthostatic hypo­
tension848 and BP variability849 may be important factors in treatment 
decisions for people with frailty, multimorbidity, and/or chronic cere­
brovascular disease.
9.10. Aortopathy
9.10.1. Coarctation of the aorta
Aortic coarctation is associated with CVD in the long term, even follow­
ing early surgical or percutaneous treatment. The most common com­
plications are associated with hypertension, which is common in aortic 
coarctation. When aortic coarctation is not treated, patients often de­
velop severe hypertension and HMOD (especially LVH and left ventricu­
lar dysfunction, aortopathy, and cerebrovascular complications).850–852
No formal RCTs to define optimal medical treatment of hypertension 
in aortic coarctation have been conducted, therefore, patients not suit­
able for, or having undergone, intervention should be treated for hyper­
tension following the core algorithm for the general population.
9.10.2. Bicuspid aortic valve-related aortopathy
Bicuspid aortic valve is the most common congenital heart disease and is 
sometimes associated with aortopathy or aortic coarctation. Bicuspid aor­
tic valve disease is associated with an increased risk of valve malfunction 
and adverse aortic events.853,854 This risk is exacerbated by hypertension.
Beyond aortic dilation and aneurysm formation, bicuspid aortic valve 
disease is also a risk factor for aortic dissection and rupture.855 Blood 
pressure should be carefully monitored and controlled.856
9.10.3. Preventing aortic dilation and dissection in 
high-risk patients
A modest dilatation of the ascending aorta or aortic root is often asso­
ciated with chronic hypertension and HMOD. An additional cause of 
aortopathy (bicuspid valve, coarctation, Marfan or other syndromes) 
should be considered in more severe cases.857 Patients with aortic dila­
tation should have their BP optimally controlled following the core al­
gorithm for the general hypertension population.
In patients with Marfan syndrome, prophylactic use of ARBs, ACE inhi­
bitors, or beta-blockers may reduce complications or progression of aortic 
dilation.857–860 More information is available in the 2024 ESC Guidelines 
for the management of peripheral arterial and aortic diseases.861
9.11. Different ethnic groups
Influx and settlement of migrant populations in Europe have contribu­
ted to regional population growth and changes in its composition.862
Ethnic minority populations are disproportionally affected by hyperten­
sion and hypertension-mediated complications, compared with histor­
ically native Europeans, with data suggesting migrant women are 
particularly vulnerable.536,863 In particular, hypertension is more preva­
lent in those of African descent.863,864 The predominant group of 
European black ethnicity originates from sub-Saharan Africa,863 but 
specific studies on the management and control of hypertension in 
this population are lacking, and data are often extrapolated from studies 
in the African American population.864 This assumption requires cau­
tion, as differences likely exist between these populations in terms of 
CVD risk, economic, and sociological status,865,866 as well as responses 
to BP-lowering drugs.867
Black patients have a greater prevalence of low-renin, salt-sensitive 
hypertension and may be more predisposed to HMOD than white pa­
tients, possibly in part due to increased vascular stiffness.864,868,869 Salt 
restriction, thiazide or thiazide-like diuretics, and CCBs appear particu­
larly useful in black patients with hypertension, whereas RAS blocker 
monotherapy may be less effective.870–873 If combination therapy is 
needed, in a recent RCT conducted in sub-Saharan African countries, 
amlodipine plus either hydrochlorothiazide or perindopril proved to 
be equally effective and superior, respectively, to hydrochlorothiazide 
plus perindopril.874 When RAS blockers are used in combination ther­
apy, ARBs may be preferable to ACE inhibitors, as angioedema appears 
more common with ACE inhibitors in black patients.
Despite some recent progress,875 data on hypertension epidemi­
ology and management in European immigrant patients are still 
lacking.863,875–877
9.12. Nocturnal hypertension
9.12.1. Definition
Nocturnal hypertension is defined as night-time BP of >120 mmHg systol­
ic and/or >70 mmHg diastolic by 24 h ABPM. Nocturnal hypertension can 
occur as day–night sustained hypertension or isolated nocturnal hyperten­
sion (daytime BP < 135/85 mmHg on 24 h ABPM). Physiologically, BP is 
Recommendation Table 28 — Recommendations for 
managing hypertension in patients with chronic cere­
brovascular disease and cognitive impairment
Recommendations
Classa
Levelb
It is recommended that the BP-lowering drug 
treatment strategy for preventing recurrent stroke 
should comprise a RAS blocker plus a CCB or a 
thiazide-like diuretic.820,823,825,826
I
A
In patients with confirmed BP ≥130/80 mmHg with a 
history of TIA or stroke a systolic BP target of 120– 
129 mmHg is recommended to reduce CVD 
outcomes, provided treatment is tolerated.824,827,828
I
A
© ESC 2024
BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, 
renin–angiotensin system; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 29 — Recommendations for 
managing hypertension in different ethnic groups
Recommendation
Classa
Levelb
In black patients from Sub-Saharan Africa who 
require BP-lowering treatment, combination therapy 
including a CCB combined with either a thiazide 
diuretic or a RAS blocker should be considered.874
IIa
B
© ESC 2024
BP, blood pressure; CCB, calcium channel blocker; RAS, renin–angiotensin system. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3979


<!-- PAGE 69 -->

### Page 69

expected to decrease during sleep by 10%–20% relative to daytime BP.878
Night-time dipping patterns are classified into four groups:879,880
• Inverse dipping (riser): nocturnal increase in BP (night-to-day ra­
tio of >1.0).
• Non-dipper: reduced night-time BP dip of <10% (or night-to-day 
ratio of >0.9 and ≤1.0).
• Normal dipping: fall in night-time BP of >10% and <20% (or 
night-to-day ratio of 0.8 to 0.9).
• Extreme dipping: marked fall in night-time BP of >20% (or 
night-to-day ratio of <0.8).
Patients with nocturnal hypertension may be dippers or non-dippers. 
Of note, the long-term reproducibility of dipping patterns appears to 
be low.881,882
9.12.2. Epidemiology
Nocturnal hypertension has been observed in up to half of patients with 
hypertension,883–886 and is associated with increased HMOD,883 im­
paired renal function, and diabetes mellitus.887 Nocturnal hypertension 
appears to be more prevalent in black888–890 and Asian891,892 popula­
tions. Masked uncontrolled hypertension, which occurs in 30% of 
patients treated for hypertension, is more often due to poorly con­
trolled nocturnal BP than daytime BP on ABPM.893
Environmental factors, including sleep duration and higher humid­
ity,894 nocturia,895 OSAS,896 obesity, high salt intake in salt-sensitive pa­
tients,897 orthostatic hypotension, autonomic dysfunction, CKD,898–900
diabetic neuropathy/diabetes,901 and old age62 are associated with non- 
dipping. Moreover, nocturnal hypertension and absent night-time dip­
ping pattern are more common in secondary hypertension.902,903
9.12.3. Night-time blood pressure as a cardiovascular 
disease risk factor
Nocturnal hypertension is a risk factor for adverse CVD events,904
cerebrovascular disease, including stroke,905 and cardiovascular mor­
tality.891,906,907 Night-time BP may provide more prognostic infor­
mation than daytime BP, perhaps as it is less dependent on physical 
activities. Non-dipping908–910 and reverse dipping (nocturnal rise in 
BP) may also be associated with increased CVD risk.62,910–913 A noc­
turnal rise in BP is associated with an increased risk of dementia and 
Alzheimer’s disease in older men.914 There is also some evidence that 
extreme dipping, particularly in untreated patients, is associated with 
an increased risk for CVD events.35,886
9.12.4. Treatment of nocturnal hypertension
There is no reliable evidence that BP-lowering medication should be 
routinely dosed at bedtime. The diurnal timing of drug administration 
is discussed in Section 8.3.4. In patients with secondary hypertension, 
the underlying cause (OSAS, primary aldosteronism) should be treated 
as discussed in Section 9.14.
9.13. Resistant hypertension
9.13.1. Definition of resistant hypertension
Resistant hypertension is defined as BP remaining above goal despite 
three or more BP-lowering drugs of different classes at maximally tol­
erated doses, of which one is a diuretic (Table 11).915 Resistant hyper­
tension should be managed at specialized centres with the expertise 
and resources to exclude pseudo-resistant hypertension (adherence 
testing) and causes of secondary hypertension.916
9.13.2. Non-pharmacological interventions
The Treating Resistant Hypertension Using Lifestyle Modification to 
Promote Health (TRIUMPH) trial demonstrated significant clinic and 
ambulatory BP reductions in patients with resistant hypertension par­
ticipating in a 4-month lifestyle intervention comprising diet and exercise 
interventions delivered within a cardiac rehabilitation programme.917
9.13.3. Pharmacological interventions
BP-lowering treatment of resistant hypertension with single-pill combi­
nations is recommended to reduce the pill burden, thereby increasing 
drug adherence and persistence.492
As resistant hypertension often, and especially in CKD,918 represents a 
state of salt retention and volume expansion secondary to relative aldos­
terone excess,516,919,920 BP control may be improved by switching hydro­
chlorothiazide 
to 
long-acting 
thiazide-like 
diuretics, 
such 
as 
chlorthalidone.921,922 However, a recent trial of chlorthalidone vs. 
hydrochlorothiazide—which probably included a sizeable proportion of 
adults with resistant hypertension—did not demonstrate any difference 
in systolic BP or CVD outcomes between the two medications. In the sub­
group of patients with prior CVD, there was a strong trend of benefit with 
chlorthalidone on CVD outcomes.447 Of note, the risk of hypokalaemia 
was higher in the chlorthalidone group than in the hydrochlorothiazide 
group.447 In patients with eGFR < 30 mL/min/1.73 m2, an adequately up- 
titrated loop diuretic is necessary to define resistant hypertension.
Most patients with resistant hypertension require the addition of 
non-first-line BP-lowering drugs (Figure 22). Of these, low-dose spir­
onolactone (25–50 mg daily) should be considered first.459,515,923–925
In patients with resistant hypertension and type 2 diabetes, spironolac­
tone (25–50 mg daily) reduced BP and albuminuria.926 The use of spirono­
lactone can be precluded by limited tolerability due to anti-androgenic side 
effects resulting in breast tenderness or gynaecomastia (in about 6%), im­
potence in men, and menstrual irregularities in women.927 The efficacy and 
safety of spironolactone for treating resistant hypertension have not yet 
been established in patients with significant renal impairment. Moreover, 
spironolactone, especially in addition to RAS inhibitors, increases the risk 
of hyperkalaemia.927,928 Therefore, spironolactone should be restricted 
to patients with an eGFR of ≥30 mL/min/1.73 m2 and a plasma potassium 
concentration of ≤4.5 mmol/L.459 Steroidal MRAs are contraindicated in 
patients with an eGFR of <30 mL/min/1.73 m2. Serum electrolytes and kid­
ney function should be monitored soon after initiation and frequently 
thereafter. In patients with resistant hypertension and CKD (eGFR of 
25–45 mL/min/1.73 m2), the oral potassium binder patiromer enabled 
more patients to continue treatment with spironolactone.929
If spironolactone is not tolerated due to anti-androgen side ef­
fects, eplerenone may be used. If eplerenone is used, higher doses 
(i.e. 50–200 mg daily) and twice-daily dosing may be necessary to 
achieve a BP-lowering effect.503 Of note, eplerenone is not licensed 
for hypertension treatment in many countries.
When not already prescribed for a compelling indication, beta- 
blockers should be considered in the treatment of resistant hyperten­
sion, though their BP-lowering effects appear to be less potent than 
spironolactone in the setting of resistant hypertension.459
Amiloride and clonidine have data suggesting they are as effective as 
spironolactone for BP lowering, though they lack outcomes data. 
A non-exhaustive list of additional medications sometimes used for 
BP-lowering purposes includes other centrally acting BP-lowering med­
ications (e.g. methyldopa), hydralazine, aliskiren, minoxidil, triamterene, 
and loop diuretics (Figure 22).515,516 As noted earlier, minoxidil use is 
often limited by side effects.


<!-- PAGE 70 -->

### Page 70

9.13.4. Devices for blood pressure lowering
Several devices have been investigated for treating resistant hyper­
tension. Of these, the most evidence is available for catheter-based 
renal denervation. As discussed in Section 8.6.1, several randomized, 
sham-controlled trials have been published, demonstrating a 
BP-lowering efficacy over 24 h for radiofrequency and ultrasound 
renal denervation in a broad spectrum of hypertension, including re­
sistant hypertension.568,585 Other devices are still under investiga­
tion and are not recommended for routine use in clinical practice 
(Section 8.6.2).
Intensification of pharmacotherapy
If BP remains uncontrolled
Renal denervation
Interventional therapy
Shared risk-benefit discussion and multidisciplinary assessment
Beta-blocker (if not already recommended for a compelling indication)
Spironolactone
If spironolactone is not tolerated: eplerenone
True treatment-resistant hypertension
Office BP 140/90 mmHg despite 3 or more BP-lowering medications at maximally tolerated doses, including a diuretic
Referral to hypertension centre should be considered
Treatment optimization of BP-lowering medications (ideally three-drug SPC)
Exclusion of secondary and pseudo-resistant hypertension
Alpha blockers
Centrally acting
BP-lowering drugs
K+ sparing diuretics
Others
 (Class IIa)
 (Class IIa)
 (Class IIb)
 (Class IIa)
 (Class IIa)
Figure 22 Management of resistant hypertension. BP, blood pressure; K+, potassium; SPC, single-pill combination.  
Recommendation Table 30 — Recommendations for 
treating resistant hypertension (see Evidence Tables 42 
and 43)
Recommendations
Classa
Levelb
In patients with resistant hypertension and 
uncontrolled BP despite use of first-line BP lowering 
therapies, the addition of spironolactone to existing 
treatment should be considered.459,515
IIa
B
Continued
ESC Guidelines                                                                                                                                                                                          3981


<!-- PAGE 71 -->

### Page 71

9.14. Management of specific causes 
of secondary hypertension
9.14.1. General considerations
These guidelines will describe only the general principles of managing 
the most common forms of secondary hypertension. For the rarer 
forms of secondary hypertension, patients should be referred to specia­
lized hypertension centres.
By definition, secondary hypertension should be, for the most part, 
cured when the underlying cause has been unambiguously identified 
and removed. However, in clinical practice, this is not always the case. 
Vascular remodelling, a common feature of a delayed diagnosis of sec­
ondary hypertension, affects renal function and can account for residual 
high BP in some patients with secondary hypertension. The rate of cure is 
higher when the diagnosis is made early in the course of the disease. Most 
common forms of secondary hypertension are listed in Table 13.
9.14.2. Primary aldosteronism
Primary aldosteronism (Conn syndrome) is the most common form of 
secondary hypertension. The management of primary aldosteronism 
depends on its subtype, particularly on adrenal lesions being unilateral 
or bilateral, because the unilateral forms are amenable to surgical treat­
ment while the latter require lifelong medical treatment. In sporadic 
forms, unilateral primary aldosteronism is distinguished from bilateral 
primary aldosteronism by adrenal vein sampling or functional imaging 
with radiolabelled tracers.930–932 In the much less common familial 
forms (necessitating a family history be taken), genetic testing for germ­
line mutations is necessary.933
For unilateral primary aldosteronism, surgical removal of the offending 
adrenal gland is typically considered, unless the patient is older or has co­
morbidities of concern. Surgery is not an option for bilateral primary 
aldosteronism. Medical treatment is currently based on MRAs. Among 
MRAs, spironolactone is the most widely available. The effective dose, 
usually 50–100 mg once daily, can be titrated up to 300–400 mg once 
daily, if necessary. Eplerenone is also used and, despite being less potent 
than spironolactone and requiring twice-daily administration, it has the ad­
vantage of causing less gynaecomastia and erectile dysfunction in men.934
Newer agents, such as the non-steroidal MRAs finerenone and 
exarenone, and the aldosterone synthase inhibitor baxdrostat, which low­
er BP in resistant hypertension,326,474 are also being tested for treating pri­
mary aldosteronism. Of the familial forms, only glucocorticoid-remediable 
primary aldosteronism, now reclassified as familial hyperaldosteronism 
type 1, can be corrected with dexamethasone,935 usually with low doses 
that are free of glucocorticoid effects and can be safely used during preg­
nancy.936 For detailed information, readers are referred to the latest pri­
mary aldosteronism guidelines.328,329
9.14.3. Renovascular hypertension
Patients with RVH should receive medical therapy to reduce BP in the 
first instance. Percutaneous transluminal renal angioplasty (PTRA) 
without stenting is the treatment of choice for fibromuscular dysplasia, 
and can restore renal perfusion pressure and lower BP.937 When this is 
not feasible, RAS blockers are the drugs of choice for treatment, but 
they require careful monitoring of renal function over time, as they 
can cause acute renal failure in those with tight bilateral stenoses or a 
stenosed solitary functioning kidney. Possible involvement of the ca­
rotid, coronary, and other major arteries, possibly leading to dissection 
if BP is not controlled, should also be considered, as fibromuscular dys­
plasia is now recognized as a systemic disease affecting multiple vascular 
beds.
Patients with significant atherosclerotic renal artery stenosis are at 
very high risk of CVD and renal events. It is recommended that 
PTRA and stenting are performed in experienced centres due to the 
high risk of restenosis. Unfortunately, though these studies did not sole­
ly recruit patients with true significant atherosclerotic RVH, publication 
of some null trials938,939 have decreased the enthusiasm for investigat­
ing atherosclerotic renal artery stenosis. This could result in more un­
controlled hypertension, recurrent flash pulmonary oedema (Pickering 
syndrome), and worsening renal function ultimately leading to end- 
stage renal disease.940
In patients with resistant hypertension in whom 
spironolactone is not effective or tolerated, 
treatment with eplerenone instead of 
spironolactone,503 or the addition of a beta-blocker if 
not already indicated459 and, next, a centrally acting 
BP-lowering medication,515 an alpha-blocker,515
hydralazine, or a potassium-sparing diuretic516
should be considered.
IIa
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation 
may be considered for resistant hypertension 
patients who have BP that is uncontrolled despite a 
three BP-lowering drug combination, and who 
express a preference to undergo renal denervation 
after a shared risk-benefit discussion and 
multidisciplinary assessment.564,566–568,586–590
IIb
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 31 — Recommendations for 
managing hypertension in patients with renovascular 
hypertension (see Evidence Tables 44 and 45)
Recommendations
Classa
Levelb
Renal artery angioplasty without stenting should be 
considered for patients with hypertension and 
haemodynamically significant renal artery stenosis 
due to fibromuscular dysplasia.941
IIa
C
Renal artery angioplasty and stenting may be 
considered in patients with haemodynamically 
significant, atherosclerotic, renal artery stenosis 
(stenosis of 70%–99%, or 50%–69% with 
post-stenotic dilatation and/or significant 
trans-stenotic pressure gradient) with: 
• Recurrent heart failure, unstable angina, or sudden 
onset flash pulmonary oedema despite maximally 
tolerated medical therapy;
• Resistant hypertension;
• Hypertension with unexplained unilaterally small 
kidney or CKD;
• Bilateral renal artery stenosis or unilateral renal 
artery stenosis in a solitary viable kidney.942,943
IIb
C
Continued


<!-- PAGE 72 -->

### Page 72

9.14.4. Phaeochromocytoma/paraganglioma
Phaeochromocytomas are rare adrenal tumours that secrete catecho­
lamines and are present in <0.2% of patients with hypertension. A small 
percentage (<10%) of catecholamine-producing tumours are extra- 
adrenal and are derived from sympathetic and non-sympathetic nerves. 
More than 35% of the non-syndromic PPGLs are due to germline mu­
tations.338 These mutations should be screened for because, when 
found, they can drive management of the proband and the family and 
also inform the choice of functional imaging. Moreover, some germline 
mutations, such as those involving succinate dehydrogenase B, carry a 
risk of malignant adrenal tumours.301,336
Sympathetic PPGLs are usually secreting and present with chron­
ic, episodic, or labile hypertension. Adrenergic crises cause hyper­
tensive emergencies and should be treated with an intravenous 
(i.v.) alpha-1-blocker, such as phentolamine, doxazosin or terazosin, 
or labetalol. When given i.v. (1–2 mg/kg) twice weekly as a bolus over 
1 min followed by a continuous infusion, labetalol also has alpha- 
blocker properties and has the advantage of allowing titration of 
the infusion based on the BP response, and avoids tachycardia via 
beta-blockade.
Identifying a single tumour mandates surgical excision after ad­
equate pharmacological preparation, because secreting PPGLs can 
cause fatal events with no warning. Administering doxazosin or ter­
azosin, followed by a beta-blocker, usually controls BP and adrener­
gic crises. As PPGLs are associated with a redistribution of volume 
from the periphery to the cardiopulmonary system,944 patients 
with PPGLs have peripheral hypovolaemia that exposes them to 
the risk of profound hypotension, particularly right after tumour ex­
cision. Therefore, adequate fluid administration should be carefully 
managed.
9.14.5. Obstructive sleep apnoea syndrome
The management of this prevalent condition should be driven by the 
result of a polysomnography study, which should provide the value 
of the AHI (the average number of episodes per hour) and the sleep 
position in which apnoeic–hypopnoeic episodes occur. For mild 
OSAS (AHI < 15), weight loss and advice on sleep hygiene are usu­
ally sufficient. For moderate (AHI of 15–30) and severe (AHI > 30) 
OSAS, continuous positive airway pressure (CPAP) is indicated 
and usually improves BP control and helps to resolve resistant 
hypertension. If CPAP is not tolerated, the site of upper airway ob­
struction should be determined by an Ear, Nose, and Throat evalu­
ation with drug-induced sleep endoscopy as a potential step to 
corrective surgery.
9.14.6. Drug-induced hypertension
Over-the-counter medications, prescribed drugs, and drug abuse (rec­
reational substances and misuse of drugs) can cause hypertension 
(Supplementary data online, Table S4).
9.14.6.1. Anticancer drug-induced hypertension
Growing evidence indicates that, while contemporary anticancer and 
anti-angiogenic drugs improve cancer survival, they can also cause hyper­
tension (Supplementary data online, Table S4). This is especially evident 
in patients treated with vascular endothelial growth factor inhibitors, in 
whom BP increases in 80%–90%.945 Tyrosine kinase inhibitors and pro­
teasome inhibitors also increase BP, as do adjuvant therapies (corticos­
teroids, calcineurin inhibitors, non-steroidal anti-inflammatory drugs, and 
anti-androgen hormone therapy). Hypertension caused by anticancer 
drugs is often dose limiting and may be reversible after therapy interrup­
tion or discontinuation. Evidence-based clinical trials specifically addres­
sing patients who develop hypertension due to cancer therapy are 
lacking. It is recommended that management of hypertension in these pa­
tients follows that for the general population.945,946 Managing these com­
plex patients requires multidisciplinary healthcare involving oncologists, 
hypertension specialists, cardiologists, and nephrologists,945,946 as high­
lighted in the 2022 ESC Guidelines on cardio-oncology.946
9.14.7. Other forms of secondary hypertension
Other forms of secondary hypertension, such as genetic causes of 
hypertension (Liddle’s syndrome, glucocorticoid-remediable aldoster­
onism), excess liquorice, Cushing’s syndrome, thyroid disease, hyper­
parathyroidism, aortic coarctation, and acromegaly are rare. Affected 
patients should be referred to specialized centres for treatment.
10. Acute and short-term lowering 
of blood pressure
10.1. Acute blood pressure management in 
hypertensive emergencies
10.1.1. Definition and characteristics of hypertensive 
emergencies
Hypertensive emergency is defined as BP of ≥180/110 mmHg (see 
Figure 10) associated with acute HMOD, often in the presence of 
symptoms. Hypertensive emergencies are potentially life-threatening 
and require immediate and careful intervention to reduce BP, often 
with i.v. therapy.
Symptoms of hypertensive emergency depend on the organs affected 
but may include headache, visual disturbances, chest pain, shortness of 
breath, dizziness, and other neurological deficits. In patients with hyper­
tensive encephalopathy, somnolence, lethargy, tonic–clonic seizures, and 
cortical blindness may precede a loss of consciousness; however, focal 
neurological lesions are rare and should raise the suspicion of stroke.
As outlined in Section 7, we define HMOD among patients with 
chronically elevated BP or hypertension as the presence of specific car­
diac, vascular, and renal alterations.31,159 However, in the setting of 
hypertensive emergency, more acute manifestations of organ damage 
are relevant for management.
Acute manifestations of organ damage include:
• Patients with severe acute hypertension associated with other clinical 
conditions likely to require urgent reduction in BP, e.g. acute onset of 
aortic dissection, myocardial ischaemia, eclampsia, or heart failure.
In patients with an indication to renal artery 
revascularization and technically unfeasible, or failed, 
renal artery angioplasty and stenting, open surgical 
revascularization may be considered.
IIb
C
Renal artery angioplasty is not recommended in 
patients without confirmed haemodynamically 
significant renal artery stenosis.c 938,939
III
A
© ESC 2024
CKD, chronic kidney disease. 
aClass of recommendation. 
bLevel of evidence. 
cA haemodynamically relevant stenosis is usually defined by a luminal narrowing of >70% or 
50%–70% with post-stenotic dilatation.
ESC Guidelines                                                                                                                                                                                          3983


<!-- PAGE 73 -->

### Page 73

• Malignant hypertension, defined as extreme BP elevations and acute 
microvascular damage (microangiopathy) affecting various organs.947
The hallmark of this condition is small-artery fibrinoid necrosis in the kid­
neys, retina, and brain. The acute microangiopathy is typically character­
ized clinically by retinopathy (flame haemorrhages, cotton wool spots, 
and/or papilloedema). Other manifestations of microangiopathy include 
disseminated intravascular coagulation, encephalopathy (in about 15% of 
cases), acute heart failure, and acute deterioration in renal function.
• Patients with sudden severe hypertension due to phaeochromocyto­
ma, which can result in severe acute organ damage.
The term ‘hypertension urgency’ describes severe hypertension in pa­
tients without clinical evidence of acute organ damage. While these pa­
tients require BP reduction, they do not usually require admission to 
hospital, and BP reduction is best achieved with oral medication accord­
ing to the drug treatment algorithm presented in Section 8. However, 
these patients may require more urgent outpatient review to ensure 
that their BP is controlled.
Acute and severe increases in BP can sometimes be precipitated by 
sympathomimetics such as methamphetamine or cocaine, when cau­
tion around beta-blocker use is also needed. Many patients in an emer­
gency department with acute pain or distress may have acutely elevated 
BP that will normalize when the pain and distress are relieved, rather 
than requiring any specific intervention to lower BP.
A diagnostic work-up is necessary for patients with a suspected 
hypertensive emergency (see Supplementary data online, Table S12).
10.1.2. Acute management of hypertensive 
emergencies
Key considerations in defining treatment are: 
(1) Establishing the affected target organ(s) and whether they require 
any specific interventions other than BP lowering.
(2) Determining whether there is a precipitating cause for the acute 
rise in BP and/or another concomitant health condition present 
that might affect the treatment plan (e.g. pregnancy).
(3) The recommended timing and magnitude of BP lowering required 
for safe BP reduction.
These considerations will inform the type of BP-lowering treatment re­
quired. Regarding BP-lowering drugs, i.v. treatment using a short half- 
life drug is typically ideal to allow careful titration of the BP response 
to treatment. This requires a higher dependency clinical area with facil­
ities for continuous or near-continuous haemodynamic monitoring. 
Recommended drug treatments for specific hypertensive emergencies 
are provided in the Supplementary data online, Table S13.
Rapid and uncontrolled or excessive BP lowering is not recommended 
in hypertensive emergency as this can lead to further complications. 
Although i.v. drug administration is recommended for most hypertensive 
emergencies, oral therapy with ACE inhibitors, ARBs, or beta-blockers 
(shorter-acting formulations like captopril or metoprolol) can also be ef­
fective. However, low initial doses should be used because these patients 
can be very sensitive to these agents, and treatment should take place in 
hospital. Further comprehensive details on the clinical management of 
hypertensive emergencies are available elsewhere.242
10.1.3. Prognosis and follow-up
The survival of patients with hypertensive emergencies has improved 
over the past few decades, but these patients remain at high risk and 
should be screened for secondary hypertension.
10.2. Acute blood pressure management in 
acute intracerebral haemorrhage
In acute intracerebral haemorrhage, an increased BP is common and is 
associated with a greater risk of haematoma expansion and death, and a 
worse prognosis for neurological recovery. In trials testing immediate 
BP lowering (within <6 h) to a systolic target of <140 mmHg, the 
achieved systolic BP in the intervention group was typically 140–160  
mmHg and was reported to reduce the risk of haematoma expan­
sion.948,949 Excessive acute drops in systolic BP (>70 mmHg) may be 
associated with acute renal injury and early neurological deterioration 
and should be avoided.950,951
10.3. Acute blood pressure management in 
acute ischaemic stroke
The beneficial effects of BP reduction in acute ischaemic stroke remain un­
clear. In patients not receiving i.v. thrombolysis or mechanical thrombec­
tomy, there is no evidence for actively lowering BP unless it is extremely 
high (e.g. >220/120 mmHg). If BP is extremely high, an initial moderate 
relative reduction of 10%–15% over a period of hours may be consid­
ered.952 The reason for a more conservative approach to acute BP man­
agement is that cerebral autoregulation may be impaired in acute stroke, 
and maintaining cerebral perfusion relies on systemic BP.
In contrast, patients who are treated with i.v. thrombolysis or mechan­
ical thrombectomy (or both) should have more proactive management of 
severe hypertension, because they have an increased risk of reperfusion 
injury and intracranial haemorrhage. In patients undergoing treatment 
with i.v. thrombolysis, BP should be lowered to <185/110 mmHg prior 
to thrombolysis and then maintained at <180/105 mmHg over the 
following 24 h.953 In patients undergoing treatment with mechanical 
thrombectomy (with or without i.v. thrombolysis) there is limited 
evidence from clinical trials, but BP should also be lowered to 
<180/105 mmHg prior to thrombectomy and maintained over the 
next 24 h.953,954 Therefore, patients with acute ischaemic stroke and a 
BP of <180/105 mmHg in the first 72 h after stroke do not seem to bene­
fit from the introduction or reintroduction of BP-lowering medication.955
For stable patients who remain hypertensive (≥140/90 mmHg) ≥3 days 
after an acute ischaemic stroke, initiation or reintroduction of 
BP-lowering medication is recommended.
Recommendation Table 32 — Recommendations for 
acutely managing blood pressure in patients with intra­
cerebral haemorrhage or acute ischaemic stroke
Recommendations
Classa
Levelb
For patients with ischaemic stroke or TIA and an 
indication for BP lowering, it is recommended that 
BP-lowering therapy be commenced before hospital 
discharge.819,820,823
I
B
In patients with acute ischaemic stroke, early BP lowering with BP-lowering 
therapy should be considered in the first 24 h in the following settings:
• In patients who are eligible for re-perfusion 
therapy with intravenous thrombolysis or 
mechanical thrombectomy, BP should be carefully 
lowered and maintained at <180/105 mmHg for at 
least the first 24 h after treatment.956–960
IIa
B
Continued


<!-- PAGE 74 -->

### Page 74

10.4. Acute blood pressure management in 
pre-eclampsia and severe hypertension in 
pregnancy
10.4.1. Pre-eclampsia
Pre-eclampsia is discussed in Section 9. Here we focus on its management 
in the acute setting. Pre-eclampsia is cured by delivery. Most international 
societies, including the ESC, recommend an intensive approach to BP 
lowering in pre-eclampsia.89,964,965 In women with pre-eclampsia and se­
vere hypertension, immediately reducing systolic BP to <160 mmHg and 
diastolic BP to <105 mmHg using i.v. labetalol or nicardipine (with admin­
istration of magnesium sulfate if appropriate and consideration of deliv­
ery if appropriate) was recommended in the 2018 ESC/ESH Guidelines 
on the management of arterial hypertension and the 2022 ESC 
Guidelines for management of cardiovascular disease in pregnancy.1,89
The objective of treatment is to lower BP within 150–180 min.
Magnesium sulfate [4 g i.v. over 5 min, then 1 g/h i.v.; or 5 g intramus­
cularly (i.m.) into each buttock, then 5 g i.m. every 4 h] is recommended 
for eclampsia treatment but also for women with pre-eclampsia who 
have severe hypertension and proteinuria or hypertension and neuro­
logical symptoms or signs.966 There is a risk of hypotension when mag­
nesium is given concomitantly with nifedipine.967 If BP control is not 
achieved by 360 min despite two medications, consulting critical care 
is recommended for intensive care unit admission, stabilization, and de­
livery (if appropriate).966 Since plasma volume is reduced in pre- 
eclampsia, diuretic therapy should be avoided.
10.4.2. Severe acute hypertension in pregnancy
Severe hypertension in pregnancy (without pre-eclampsia) may neces­
sitate acute BP-lowering therapies. Severe hypertension in pregnancy is 
defined in general as systolic BP of >160 mmHg and diastolic BP of 
>110 mmHg and is associated with adverse maternal and peri-natal 
outcomes independent of pre-eclampsia and potentially of the same 
magnitude as eclampsia itself.89,968
There are differences in rate of BP control between i.v. labetalol and 
i.v. hydralazine in severe hypertension in pregnancy.969 While evidence 
is conflicting,667,668 hydralazine may be associated with more peri-natal 
adverse events than other drugs.970 Nifedipine seems to provide lower 
BP with lower rates of neonatal complications than labetalol.971
10.5. Peri-operative acute management of 
elevated blood pressure
Details are provided in the ESC Guidelines on cardiovascular assessment 
and management of patients undergoing non-cardiac surgery.972
Peri-operative hypertension, hypotension, and BP variability are associated 
with haemodynamic instability and poor clinical outcomes for patients 
undergoing surgery.973 Pre-operative risk assessment for BP management, 
therefore, should involve assessing for underlying end-organ damage and 
comorbidities.974 Postponing necessary non-cardiac surgery is not usually 
warranted for patients with minor or moderate elevations in BP, as they 
are not at higher CVD risk.130,975
Avoiding large fluctuations in BP in the peri-operative course is im­
portant, and planning a strategy for a patient should account for the 
baseline office BP.974–977
There is insufficient evidence for reduced or increased peri- 
operative BP targets compared to usual care BP targets to lower 
peri-operative events.978 No specific measure of BP appears better 
than any other for predicting risk of peri-operative events.975
10.5.1. Blood pressure-lowering drugs in the 
peri-operative phase
Routine initiation of a beta-blocker peri-operatively is not necessary.979
Pre-operative initiation of beta-blockers in advance of high-risk, 
non-cardiac surgery may be considered in patients who have 
known coronary artery disease or myocardial ischaemia980 or 
two or more significantly elevated clinical risk factors in order to 
reduce the incidence of peri-operative myocardial infarction.979
Peri-operative continuation of beta-blockers is recommended for 
patients currently taking beta-blockers.981
Some studies suggest that continued use of ACE inhibitors is asso­
ciated with a higher risk of peri-operative hypotension and subsequent 
end-organ damage including kidney injury, myocardial infarction, and 
stroke.982 In the Prospective Randomized Evaluation of Preoperative 
Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI) trial, transient 
pre-operative interruption of ACE inhibitor therapy was associated with 
a decreased risk of intra-operative hypotension.983 A subsequent system­
atic review also showed a decreased risk of intra-operative hypotension 
with withholding ACE inhibitors/ARBs before surgery, but no association 
• In patients with ischaemic stroke not receiving 
re-perfusion treatment and BP of ≥220/110  
mmHg, BP should be carefully lowered by 
approximately 15% during the first 24 h after 
stroke onset.956–960
IIa
C
In patients with intracerebral haemorrhage, 
immediate BP lowering (within 6 h of symptom 
onset) should be considered to a systolic target 140– 
160 mmHg to prevent haematoma expansion and 
improve functional outcome.948,949
IIa
A
In patients with intracerebral haemorrhage 
presenting with systolic BP ≥220 mmHg, acute 
reduction in systolic BP >70 mmHg from initial levels 
within 1 h of commencing treatment is not 
recommended.950,951,960–963
III
B
© ESC 2024
BP, blood pressure; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 33 — Recommendations for 
acutely managing blood pressure in patients with severe 
hypertension in pregnancy and pre-eclampsia (see 
Evidence Table 46)
Recommendation
Classa
Levelb
In pre-eclampsia or eclampsia with hypertensive 
crisis, drug treatment with i.v. labetalol or nicardipine 
and magnesium is recommended.971
I
C
In pre-eclampsia or eclampsia associated with 
pulmonary oedema, nitroglycerin given as an i.v. 
infusion is recommended.242
I
C
In severe hypertension in pregnancy: 
• drug treatment with i.v. labetalol, oral methyldopa, 
or oral nifedipine is recommended. Intravenous 
hydralazine is a second-line option.666–668,969,971
I
C
© ESC 2024
i.v., intravenous. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3985


<!-- PAGE 75 -->

### Page 75

with decreased mortality or CVD outcomes.984 On the other hand, vigi­
lance is needed because withholding ACE inhibitors has also been shown 
to increase post-operative hypertension.985 In patients with heart failure, 
loop diuretics can be continued in patients prone to volume overload.986
CCBs are generally considered safe pre-operatively.
11. Patient-centred care 
in hypertension
11.1. Definition
Patient-centred care is defined as an attitude of the healthcare profes­
sional that closely aligns with the patient’s preferences and needs.987
In the patient-centred approach (Figure 23), patients are viewed as ac­
tive participants in health services, who work as partners alongside 
healthcare professionals. A patient-centred approach is associated 
with higher satisfaction rates, better adherence to recommendations 
and prescriptions, and better treatment, particularly in the manage­
ment of chronic illness, such as hypertension.988 While there is limited 
evidence for the efficacy and effectiveness of specific shared decision- 
making intervention strategies in hypertension care,989 it is viewed as 
an ethical imperative in healthcare practice and health policy, and in 
clinical guidelines.130
11.2. Communicating consequences of 
treatment
In line with patient-centred care, it is important to assess whether patients 
understand their hypertension-related risk, the rationale for any hyperten­
sion treatment, the benefits and harms of hypertension treatment, and 
that the treatment plan is also centrally guided by what matters most to 
the patient. Risk communication is challenging, and providers need to be 
led by the individual’s preferences when presenting more detailed numeric 
and visual representations of risk and the likely benefits and harms of 
hypertension treatment. Socio-demographic differences in healthcare 
need to be considered in patient–provider communication.990,991
Standard approaches to communicate consequences of treatment 
can involve 10-year risk of a CVD event with SCORE2 or 
SCORE2-OP. Alternatively, individual risk and risk reduction can be 
communicated in terms of ‘risk age’ or ‘heart age’ (Section 7.3).
P
a t
i e
n t
Lifestyle
(inclusive of health behaviour and social context)
Medications
Multidisciplinary medical team
Self-care
Family
Figure 23 Patient-centred care.


<!-- PAGE 76 -->

### Page 76

11.3. Self-measuring and monitoring
Self-care refers to individual responsibility for healthy lifestyle beha­
viours, as well as the actions required to cope with health condi­
tions.996,997
In the context of hypertension, it also includes 
self-management and self-measurement of BP.
Self-management includes lifestyle behaviour (diet, exercise, smoking, 
alcohol), co-management of medical treatments, and support for adher­
ing to prescribed medication.998 Self-monitoring allows high BP to be de­
tected early,999 and enables patients to co-manage medications with 
their healthcare provider.1000,1001 Suitably validated and correctly used 
digital devices have the potential to support co-management,1002,1003
and facilitate remote monitoring of BP.76,81,1004
11.4. Facilitating medication adherence 
and persistence
Adherence (Figure 24) to BP-lowering drug regimens in clinical practice 
is almost always lower than seen in clinical trials.1007 Most apparent 
treatment-resistant hypertension is accounted for by non- 
adherence.1008 Adherence should always be assessed with a no-blame 
approach. Various methods are available to assess adherence and, along 
with details on barriers to adherence, are described in the 
Supplementary data online and Table S14.1009
Adherence may also be facilitated by an optimal therapeutic regi­
men, which can be achieved by medication reviews carried out at 
appropriate intervals. Several factors should be considered: (i) identify­
ing drug-related adverse events and appropriate dosing levels, (ii) using 
long-acting drugs that require once-daily dosing (preferably drugs that 
are long-acting due to pharmacokinetic properties rather than galenic 
formulation), (iii) avoiding complex dosing schedules, (iv) using single- 
pill combinations whenever feasible, (v) taking into account the financial 
capacity of the patient to pay for a given regimen in the longer term, if 
relevant, or other pertinent aspects of the local or national healthcare 
systems, and (vi) enlisting support of a family member or other social 
support to facilitate medication adherence and persistence (see 
Supplementary data online, Table S15).1010
While there have been advancements in digital tools to support self- 
management of chronic illness including hypertension, there is little 
efficacy evidence evaluating these interventions. Therefore, it is prema­
ture to make recommendations about specific digital tools.
11.5. Multidisciplinary management
A collaborative approach to managing hypertension, using team-based 
care among physicians, nurses, pharmacists, dietitians, and physiothera­
pists, 
offers 
significant 
benefits 
over 
physician-only 
care. 
Multidisciplinary care is intended to be collaborative and complemen­
tary to regular medical care1011 and is associated with lower systolic 
and diastolic BP227,229,1012,1013
and improved outcomes.230,1014
Task-shifting away from physicians is necessary to meet the huge 
need for the management of elevated BP and hypertension in the popu­
lation.1015 Prescribing remains a physician duty, but prescribing can be 
conducted under collaborative practice agreements with the multidis­
ciplinary team in many countries.
Further details on patient-centred care in hypertension is provided in 
the Supplementary data online.
Recommendation Table 34 — Recommendations for 
communicating 
consequences 
of 
treatment 
(see 
Evidence Table 47)
Recommendation
Classa
Levelb
An informed discussion about CVD risk and 
treatment benefits tailored to the needs of a patient 
is recommended as part of hypertension 
management.992
I
C
Motivational interviewing should be considered for 
patients with hypertension at hospitals and 
community health centres to assist patients in 
controlling their BP and to enhance treatment 
adherence.993,994
IIa
B
Physician–patient web communications are an 
effective tool that should be considered in primary 
care, including reporting on home BP readings.995
IIa
C
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 35 — Recommendations for 
self-measuring and monitoring blood pressure (see 
Evidence Table 48)
Recommendations
Classa
Levelb
Home BP measurement for managing hypertension 
by using self-monitored BP is recommended to 
achieve better BP control.
I
B
Self-measurement, when properly performed, is 
recommended due to positive effects on the 
acceptance of a diagnosis of hypertension, patient 
empowerment, and adherence to treatment.1001
I
C
Enhanced self-monitoring of BP using a device paired 
with a connected smartphone application may be 
considered, though evidence to date suggests that 
this may be no more effective than standard 
self-monitoring.1005,1006
IIb
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 36 — Recommendations for 
multi/interdisciplinary blood pressure management 
(see Evidence Table 49)
Recommendation
Classa
Levelb
Multidisciplinary approaches in the management of 
patients with elevated BP and hypertension, including 
appropriate and safe task-shifting away from 
physicians, are recommended to improve BP 
control.227,229,230,1012–1014,1016
I
A
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3987


<!-- PAGE 77 -->

### Page 77

### 12 Key messages

(1) Given the demographic transition and the worldwide ageing of 
populations, the number of individuals with elevated BP or hyper­
tension is increasing worldwide.
(2) The trajectory of BP control appears to be worsening in North 
America, in some (but not all) European countries, and elsewhere 
around the world.
(3) The risk for CVD attributable to BP is on a continuous log-linear 
exposure variable scale, not a binary scale of normotension vs. 
hypertension.
(4) BP-lowering drugs can reduce CVD risk even among individuals 
not traditionally classified as hypertensive. Accordingly, a new 
BP category called ‘elevated BP’ is introduced. Elevated BP is de­
fined as an office systolic BP of 120–139 mmHg or diastolic BP of 
70–89 mmHg. Hypertension remains defined as office BP of 
≥140/90 mmHg.
(5) Hypertension in women is under-studied in basic, clinical, and popu­
lation research.
(6) HMOD suggests long-standing or severe hypertension and is 
associated with increased CVD risk.
(7) Absolute CVD risk must be considered when assessing and man­
aging elevated BP.
(8) Despite the growing number of hypertension guidelines, the rates 
of diagnosis, treatment, and control of hypertension (and elevated 
BP) remain suboptimal. A major factor underlying this is poor 
e.g. affordability of medications and lack of social support to manage medications
Socio-economic factors e.g. experience of side-effects and challenges of polypharmacy
(treatment burden)
Therapy-related factors e.g. beliefs about hypertension and related medications, persistence of medication taking habits and emotional distress
Patient-related factors e.g. hypertension is a disease without an illness (asymptomatic)
and often one among many morbidities
Condition-related factors e.g. clarity and consistency of communication with patient,
quality of ongoing relationship with healthcare providers
Health system/healthcare team factors
Figure 24 The five dimensions of adherence (WHO, 2003) applied to hypertension.


<!-- PAGE 78 -->

### Page 78

implementation of evidence-based guidelines in real-world clinical 
practice.
(9) One of the most important changes in the 2024 Guidelines is the 
focus on evidence related to CVD outcomes of BP-lowering in­
terventions rather than BP lowering alone.
(10) Irrespective of the threshold BP above which BP-lowering treat­
ment (lifestyle or pharmacological or other treatment) is re­
commended, the on-treatment BP target is 120–129/70–79  
mmHg for all adults, provided this treatment is well tolerated. 
There are several important exceptions to these targets and in­
dividualized decision-making is always the most important 
priority.
13. Gaps in the evidence
(1) Drivers of worsening trajectories of BP control in women and 
men.
(2) Need for sex-specific data on epidemiology, risk factors, and 
pathophysiology of hypertension. Need for more prospective 
studies to assess women’s and men’s specific CVD risk factors 
pertinent to adults with elevated BP and hypertension, due to bio­
logical and socio-cultural conditions. This includes sex-specific 
weighting of traditional risk factors, as well as inclusion of sex- 
dependent, non-traditional, vascular risk factors such as stress, 
socio-economic conditions, and others.1017,1018 We are also lack­
ing data on sex-specific hormonal and genetic mechanisms and 
pathophysiology in the human.1019 Another important area in 
need of investigation is a better understanding of the role of gen­
der in the management of elevated BP and hypertension (including 
gender-driven barriers in accessing medical care and adherence).
(3) More widespread validation of home BP measuring devices. 
Validation protocols for cuffless BP measurement devices have 
just recently been proposed and need to be tested.
(4) Clinical effectiveness of HMOD in directing intensity of care and 
personalized approaches in managing elevated BP and hypertension.
(5) Best practice to screen and manage primary aldosteronism.
(6) Clinical benefits of treating low CVD-risk individuals with elevated 
BP and further data strengthening the use of BP-lowering 
medication among high-risk persons with baseline systolic BP 
of 120–129 mmHg.
(7) Need for more data on the sex-specific optimal dosing, effects, 
and adverse effects of BP-lowering drugs,1020 in particular from 
specifically planned prospective randomized trials.
(8) More consideration for overall CVD outcomes of BP-lowering 
interventions.
(9) More European data (RCTs, real life) about the beneficial effect of 
treating patients with elevated BP and hypertension with polypills 
(inclusive of non-BP lowering medications).
(10) CVD outcomes-based data on MRAs as add-on therapy solely for 
resistant hypertension.
(11) Trials on the BP-lowering effects of newer antidiabetic drugs 
(such as SGLT2 inhibitors and GLP-1 receptor agonists) or drugs 
that now have indications for other conditions, such as finerenone 
or sacubitril-valsartan.
(12) Beneficial BP and CVD effects of increasing dietary potassium in­
take and other lifestyle interventions. Studies to disentangle the 
effect of sodium reduction vs. the effect of potassium supplemen­
tation on BP control and CVD outcomes.
(13) RCTs comparing single-pill combination therapy with fixed doses 
vs. multiple monotherapies and their effects on CVD outcomes.
(14) Cardiovascular outcomes trials of renal denervation.
(15) BP-lowering treatment RCTs on different ethnic and migrant 
groups established in Europe.
(16) Pharmacological BP management in young adults (aged <40 years) 
and better data on the efficacy of a life-course approach for the 
drug management of BP.1021
(17) CVD outcomes in moderately to severely frail and/or very elderly 
persons where BP medications have been deprescribed, and the 
impact of competing risks.
(18) Management of renal artery disease with haemodynamically stable 
but severe stenosis (i.e. without high-risk features).
(19) Need for clinical trials on managing hypertension in patients trea­
ted with anticancer drugs or anti-rejection drugs in recipients of 
an allograft transplant.
(20) Hypertension management in the setting of climate changes, glo­
bal warming, air and other forms of pollution, pandemics, war 
zones, and in the context of drug restrictions experienced in 
some low-to-middle-income countries.
(21) Need to improve implementation of guidelines by healthcare 
providers.
(22) How to develop sustainable hypertension care at the intersection 
of growing numbers of patients and limited resources.
(23) Treat-to-target trials specifically testing BP-lowering drugs among 
drug-naïve persons with baseline BP of 120–129 mmHg and in­
creased CVD risk.
14. ‘What to do’ and ‘what not to 
do’ messages from the guidelines
A selected sample of the main messages from these guidelines are pro­
vided in Table 15.
Table 15 What to do and what not to do
Recommendations
Class
Level
5. Measuring blood pressure
It is recommended to measure BP using a validated and calibrated device, to enforce the correct measurement technique, and to apply a 
consistent approach to BP measurement for each patient.
I
B
All adult patients (≥18 years or older) are recommended to have their office and/or out-of-office BP measured on an opportunistic basis and 
recorded in their medical file, and be told what their current BP is.
I
C
Continued
ESC Guidelines                                                                                                                                                                                          3989


<!-- PAGE 79 -->

### Page 79

Out-of-office BP measurement is recommended for diagnostic purposes, particularly because it can detect both white-coat hypertension and 
masked hypertension. Where out-of-office measurements are not logistically and/or economically feasible, then it is recommended that the 
diagnosis be confirmed with a repeat office BP measurement using the correct standardized measurement technique.
I
B
It is recommended that office BP should be measured in both arms at least at the first visit, because a between-arm systolic BP difference of 
>10 mmHg is associated with an increased CVD risk and may indicate arterial stenosis.
I
B
If a between-arm difference of >10 mmHg in systolic BP is recorded, then it is recommended that all subsequent BP readings use the arm with 
the higher BP reading.
I
B
Out-of-office BP measurement is recommended for ongoing management to quantify the effects of treatment and guide BP-lowering 
medication titration, and/or identify possible causes of side effects (e.g. symptomatic hypotension). Where out-of-office measurements are 
not logistically and/or economically feasible then ongoing management is recommended to be based on repeated office BP measurements 
using the correct standardized measurement technique.
I
B
It is recommended that all patients undergoing BP measurement also undergo pulse palpation at rest to determine heart rate and arrhythmias 
such as AF.
I
C
6. Definition and classification of elevated blood pressure and hypertension
It is recommended that BP be categorized as non-elevated BP, elevated BP, and hypertension to aid treatment decisions.
I
B
It is recommended to use a risk-based approach in the treatment of elevated BP, and individuals with moderate or severe CKD, established 
CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia are considered at increased risk for CVD events.
I
B
SCORE2 is recommended for assessing 10-year risk of fatal and non-fatal CVD among individuals aged 40–69 years with elevated BP who are 
not already considered at increased risk due to moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial 
hypercholesterolaemia.
I
B
SCORE2-OP is recommended for assessing the 10-year risk of fatal and non-fatal CVD among individuals aged ≥70 years with elevated BP 
who are not already considered at increased risk due to moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial 
hypercholesterolaemia.
I
B
It is recommended that, irrespective of age, individuals with elevated BP and a SCORE2 or SCORE2-OP CVD risk of ≥10% be considered at 
increased risk for CVD for the purposes of risk-based management of their elevated BP.
I
B
7. Diagnosing hypertension and investigating underlying causes
In individuals with increased CVD risk where their screening office BP is 120–139/70–89 mmHg, it is recommended to measure BP 
out-of-office, using ABPM and/or HBPM or, if not logistically feasible, make repeated office BP measurements on more than one visit.
I
B
Where screening office BP is 140–159/90–99 mmHg, it is recommended that the diagnosis of hypertension should be based on out-of-office 
BP measurement with ABPM and/or HBPM. If these measurements are not logistically or economically feasible, then diagnosis can be made on 
repeated office BP measurements on more than one visit.
I
B
Where screening BP is ≥160/100 mmHg: 
• It is recommended that BP 160–179/100–109 mmHg is confirmed as soon as possible (e.g. within 1 month) preferably by either home or 
ambulatory BP measurements.
• It is recommended when BP is ≥180/110 mmHg that hypertensive emergency be excluded.
I
C
It is recommended to measure serum creatinine, eGFR, and urine ACR in all patients with hypertension.
I
A
If moderate-to-severe CKD is diagnosed, it is recommended to repeat measurements of serum creatinine, eGFR, and urine ACR at least 
annually.
I
C
A 12-lead ECG is recommended for all patients with hypertension.
I
B
Echocardiography is recommended in patients with hypertension and ECG abnormalities, or signs or symptoms of cardiac disease.
I
B
Fundoscopy is recommended if BP >180/110 mmHg in the work-up of hypertensive emergency and malignant hypertension, as well as in 
hypertensive patients with diabetes.
I
C
Routine genetic testing for patients with hypertension is not recommended.
III
C
It is recommended that patients with hypertension presenting with suggestive signs, symptoms, or medical history of secondary hypertension 
are appropriately screened for secondary hypertension.
I
B
8. Preventing and treating elevated blood pressure
Restriction of sodium to approximately 2 g per day is recommended where possible in all adults with elevated BP and hypertension [this is 
equivalent to about 5 g of salt (sodium chloride) per day or about a teaspoon or less].
I
A
Moderate-intensity aerobic exercise of ≥150 min/week [moderate aerobic exercise (≥30 min, 5–7 days/week) or alternatively 75 min of 
vigorous exercise per week over 3 days] is recommended and should be complemented with low- or moderate-intensity dynamic or 
isometric resistance training (2–3 times/week) to reduce BP and CVD risk.
I
A
It is recommended to aim for a stable and healthy BMI (20–25 kg/m2) and waist circumference values (<94 cm in men and <80 cm in women) 
to reduce BP and CVD risk.
I
A
Continued


<!-- PAGE 80 -->

### Page 80

Adopting a healthy and balanced diet such as the Mediterranean or DASH diets is recommended to help reduce BP and CVD risk.
I
A
Men and women are recommended to drink less alcohol than the upper limit, which is about 100 g/week of pure alcohol. How this translates 
into number of drinks depends on portion size (the standards of which differ per country), but most drinks contain 8–14 g of alcohol per drink. 
Preferably, it is recommended to avoid alcohol consumption to achieve best health outcomes.
I
B
It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake. It is 
also recommended to discourage consumption of sugar-sweetened beverages, such as soft drinks and fruit juices, starting at young age.
I
B
It is recommended to stop tobacco smoking, initiate supportive care, and refer to smoking cessation programmes, as tobacco use strongly and 
independently causes CVD, CVD events, and all-cause mortality.
I
A
Among all BP-lowering drugs, ACE inhibitors, ARBs, dihydropyridine CCBs, and diuretics (thiazides and thiazide-like drugs such as 
chlorthalidone and indapamide) have demonstrated the most effective reduction of BP and CVD events, and are therefore recommended as 
first-line treatments to lower BP.
I
A
It is recommended that beta-blockers are combined with any of the other major BP-lowering drug classes when there are other compelling 
indications for their use, e.g. angina, post-myocardial infarction, HFrEF, or for heart rate control.
I
A
It is recommended to take medications at the most convenient time of day for the patient to establish a habitual pattern of medication taking 
to improve adherence.
I
B
Given trial evidence for more effective BP control vs. monotherapy, combination BP-lowering treatment is recommended for most patients 
with confirmed hypertension (BP ≥140/90 mmHg) as initial therapy. Preferred combinations are a RAS blocker (either an ACE inhibitor or an 
ARB) with a dihydropyridine CCB or diuretic. Exceptions to consider include patients aged ≥85 years, symptomatic orthostatic hypotension, 
moderate-to-severe frailty, and those with elevated BP (systolic BP 120–139 mmHg or diastolic BP 70–89 mmHg) with a concomitant 
indication for treatment.
I
B
In patients receiving combination BP-lowering treatment, fixed-dose single-pill combination treatment is recommended.
I
B
If BP is not controlled with a two-drug combination, increasing to a three-drug combination is recommended, usually a RAS blocker with a 
dihydropyridine CCB and a thiazide/thiazide-like diuretic, and preferably in a single-pill combination.
I
B
Combining two RAS blockers (ACE inhibitor and an ARB) is not recommended.
III
A
In adults with elevated BP and low/medium CVD risk (<10% over 10 years), BP lowering with lifestyle measures is recommended and can 
reduce the risk of CVD.
I
B
In adults with elevated BP and sufficiently high CVD risk, after 3 months of lifestyle intervention, BP lowering with pharmacological treatment 
is recommended for those with confirmed BP ≥130/80 mmHg to reduce CVD risk.
I
A
It is recommended that in hypertensive patients with confirmed BP ≥140/90 mmHg, irrespective of CVD risk, lifestyle measures and 
pharmacological BP-lowering treatment is initiated promptly to reduce CVD risk.
I
A
It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.
I
A
8. Preventing and treating elevated blood pressure (blood pressure targets)
To reduce CVD risk, it is recommended that treated systolic BP values in most adults be targeted to 120–129 mmHg, provided the treatment 
is well tolerated.
I
A
In cases where BP-lowering treatment is poorly tolerated and achieving a target systolic of 120–129 mmHg is not possible, it is recommended 
to target a systolic BP level that is ‘as low as reasonably achievable’ (ALARA principle).
I
A
8. Preventing and treating elevated blood pressure (renal denervation)
Due to a lack of adequately powered outcomes trials demonstrating its safety and CVD benefits, renal denervation is not recommended as a 
first-line BP-lowering intervention for hypertension.
III
C
Renal denervation is not recommended for treating hypertension in patients with moderate-to-severely impaired renal function (eGFR <40  
mL/min/1.73 m2) or secondary causes of hypertension, until further evidence becomes available.
III
C
9. Managing specific patient groups or circumstances
Young adults
Comprehensive screening for the main causes of secondary hypertension is recommended in adults diagnosed with hypertension before the 
age of 40 years, except for obese young adults where it is recommended to start with an obstructive sleep apnoea evaluation.
I
B
Hypertension in pregnancy
In women with gestational hypertension, starting drug treatment is recommended for those with confirmed office systolic BP ≥140 mmHg or 
diastolic BP ≥90 mmHg.
I
B
In pregnant women with chronic hypertension, starting drug treatment is recommended for those with confirmed office systolic BP ≥140  
mmHg or diastolic BP ≥90 mmHg.
I
B
In women with chronic and gestational hypertension, it is recommended to lower BP below 140/90 mmHg but not below 80 mmHg for 
diastolic BP.
I
C
Continued
ESC Guidelines                                                                                                                                                                                          3991


<!-- PAGE 81 -->

### Page 81

Dihydropyridine CCBs (preferably extended-release nifedipine), labetalol, and methyldopa are recommended first-line BP-lowering 
medications for treating hypertension in pregnancy.
I
C
In consultation with an obstetrician, low- to moderate-intensity exercise is recommended in all pregnant women without contraindications to 
reduce the risk of gestational hypertension and pre-eclampsia.
I
B
RAS blockers are not recommended during pregnancy.
III
B
Very old and frail patients; orthostatic hypotension
It is recommended that treatment of elevated BP and hypertension among older patients aged <85 years who are not moderately to severely 
frail follows the same guidelines as for younger people, provided BP-lowering treatment is well tolerated.
I
A
It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.
I
A
Before starting or intensifying BP-lowering medication, it is recommended to test for orthostatic hypotension, by first having the patient sit or 
lie for 5 min and then measuring BP 1 and/or 3 min after standing.
I
B
It is recommended to pursue non-pharmacological approaches as the first-line treatment of orthostatic hypotension among persons with 
supine hypertension. For such patients, it is also recommended to switch BP-lowering medications that worsen orthostatic hypotension to an 
alternative BP-lowering therapy and not to simply de-intensify therapy.
I
A
Diabetes
In most adults with elevated BP and diabetes, after a maximum of 3 months of lifestyle intervention, BP lowering with pharmacological 
treatment is recommended for those with confirmed BP ≥130/80 mmHg to reduce CVD risk.
I
A
BP-lowering drug treatment is recommended for people with pre-diabetes or obesity when confirmed office BP is ≥140/90 mmHg or when 
office BP is 130–139/80–89 mmHg and the patient is at predicted 10-year risk of CVD ≥10% or with high-risk conditions, despite a maximum 
of 3 months of lifestyle therapy.
I
A
In persons with diabetes who are receiving BP-lowering drugs, it is recommended to target systolic BP to 120–129 mmHg, if tolerated.
I
A
Chronic kidney disease
In patients with diabetic or non-diabetic moderate-to-severe CKD and confirmed BP ≥130/80 mmHg, lifestyle optimization and BP-lowering 
medication are recommended to reduce CVD risk, provided such treatment is well tolerated.
I
A
In adults with moderate-to-severe CKD who are receiving BP-lowering drugs and who have eGFR >30 mL/min/1.73 m2, it is recommended to 
target systolic BP to 120–129 mmHg, if tolerated. Individualized BP targets are recommended for those with lower eGFR or renal 
transplantation.
I
A
In hypertensive patients with CKD and eGFR >20 mL/min/1.73 m2, SGLT2 inhibitors are recommended to improve outcomes in the context 
of their modest BP-lowering properties.
I
A
Cardiac disease
In patients with a history of myocardial infarction who require BP-lowering treatment, beta-blockers and RAS blockers are recommended as 
part of that treatment.
I
A
In patients with symptomatic angina who require BP-lowering treatment, beta-blockers and/or CCBs are recommended as part of that 
treatment.
I
A
In patients with symptomatic HFrEF/HFmrEF, the following treatments with BP-lowering effects are recommended to improve outcomes: 
ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) or ARNi, beta-blockers, MRAs, and SGLT2 inhibitors.
I
A
In hypertensive patients with symptomatic HFpEF, SGLT2 inhibitors are recommended to improve outcomes in the context of their modest 
BP-lowering properties.
I
A
Other conditions
It is recommended that the BP-lowering drug treatment strategy for preventing stroke should comprise a RAS blocker plus a CCB or a 
thiazide-like diuretic.
I
A
In patients with confirmed BP ≥130/80 mmHg with a history of TIA or stroke a systolic BP target 120–129 mmHg is recommended to reduce 
CVD outcomes, provided treatment is tolerated.
I
A
Renal artery angioplasty is not recommended in patients without confirmed haemodynamically significant renal artery stenosis.
III
A
10. Acute and short-term lowering of blood pressure
Intracerebral haemorrhage or acute ischaemic stroke
For patients with ischaemic stroke or TIA and an indication for BP lowering, it is recommended that BP lowering therapy should be 
commenced before hospital discharge.
I
B
In patients with intracerebral haemorrhage presenting with systolic BP ≥220 mmHg, acute reduction in systolic BP >70 mmHg from initial 
levels within 1 h of commencing treatment is not recommended.
III
B
Continued


<!-- PAGE 82 -->

### Page 82

### 15 Evidence tables

Evidence tables are available at European Heart Journal online.
16. Data availability statement
No new data were generated or analysed in support of this research.
17. Author information
Author/task force Member Affiliations: Cian P. McCarthy, 
Cardiovascular Division Massachusetts General Hospital and Harvard 
Medical School Boston, MA, United States of America; Rosa Maria 
Bruno, PARCC, Université Paris Cité, Inserm, Paris, France, and 
Pharmacology & Hypertension, AP-HP, Hôpital Européen Georges 
Pompidou, Paris, France; Sofie Brouwers, Cardiovascular Center 
Aalst, Department of Cardiology, OLV Clinic Aalst, Aalst, Belgium, 
and Department of Experimental Pharmacology, Faculty of Medicine 
and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; Michelle 
D. Canavan, School of Medicine, College of Medicine, Nursing and 
Health Sciences, University of Galway, Galway, Ireland, and 
Department of Geriatric Medicine, University Hospital Galway, Saolta 
Hospitals Group, Galway, Ireland; Claudio Ceconi, Motusmed 
Clinic, 
Brescia, 
Italy; 
Ruxandra 
Maria 
Christodorescu, 
Department V Internal Medicine, University of Medicine and 
Pharmacy V Babes, Timisoara, Romania, and Research Center, 
Institute of Cardiovascular Diseases, Timisoara, Romania; Stella 
S. Daskalopoulou, Medicine Research Institute of the McGill 
University Health Centre, McGill University, Montreal, Canada; 
Charles J. Ferro, Department of Renal Medicine, University 
Hospitals Birmingham, Birmingham, United Kingdom, and Institute of 
Cardiovascular Sciences University of Birmingham, Birmingham, 
United Kingdom; Eva Gerdts, Department of Clinical Science, 
University of Bergen, Bergen, Norway, and Department of Heart 
Disease, Haukeland University Hospital, Bergen, Norway; Henner 
Hanssen, Department Sport, Exercise and Health, Medical Faculty, 
University of Basel, Basel, Switzerland; Julie Harris (United 
Kingdom), ESC Patient Forum, Sophia Antipolis, France; Lucas 
Lauder, Department of cardiology, University hospital Basel, Basel, 
Switzerland, and Department of internal medicine III, Cardiology, 
Angiology, and Intensive Care Medicine, Saarland university medical 
center, Homburg, Germany; Richard J. McManus, Nuffield 
Department of Primary Care Health Sciences, University of Oxford, 
Oxford, United Kingdom; Gerard J. Molloy, School of Psychology, 
University of Galway, Galway, Ireland; Kazem Rahimi, Deep 
Medicine, Nuffield Department of Women’s and Reproductive 
Health, University of Oxford, Oxford, United Kingdom; Vera 
Regitz-Zagrosek, Charite, University Medicine Berlin, Gender in 
Medicine, Berlin, Germany; Gian Paolo Rossi, Department of 
Medicine, DIMED, University of Padua, Padua, Italy; Else Charlotte 
Sandset, Department of Neurology, Oslo University Hospital, Oslo, 
Norway, The Norwegian Air Ambulance Foundation, Oslo, Norway, 
and Institute of Clinical Medicine University of Oslo, Oslo, Norway; 
Bart Scheenaerts (Belgium), ESC Patient Forum, Sophia Antipolis, 
France; Jan A. Staessen, Non-Profit Research Association Alliance 
for the Promotion of Preventive Medicine, Mechelen, Belgium, and 
Biomedical Research Group, Faculty of Medicine, University of 
Leuven, Leuven, Belgium; Izabella Uchmanowicz, Department of 
Nursing and Obstetrics, Faculty of Health Sciences, Wroclaw Medical 
University, Wroclaw, Poland; and Maurizio Volterrani, Exercise 
Science and Medicine San Raffaele Open University, Rome, Italy, and 
Cardiopulmonary Department, IRCCS San Raffaele, Rome, Italy.
18. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Ana Abreu (CPG Review Co-ordinator) 
(Portugal), Michael Hecht Olsen (CPG Review Co-ordinator) 
(Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United 
Kingdom), Lia Evi Bang (Denmark), Jesper Nørgaard Bech (Denmark), 
Michael A. Borger (Germany), Pierre Boutouyrie (France), Luís 
Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), 
Maria Carmen De Pablo Zarzosa (Spain), Christian Delles (United 
Severe hypertension in pregnancy and pre-eclampsia
In pre-eclampsia or eclampsia with hypertensive crisis, drug treatment with i.v. labetalol or nicardipine and magnesium is recommended.
I
C
In pre-eclampsia or eclampsia associated with pulmonary oedema, nitroglycerin given as an i.v. infusion is recommended.
I
C
In severe hypertension in pregnancy: 
• drug treatment with i.v. labetalol, oral methyldopa, or oral nifedipine is recommended. Intravenous hydralazine is a second-line option.
I
C
11. Patient-centred care in hypertension
An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended as part of hypertension 
management.
I
C
Home BP measurement for managing hypertension by using self-monitored BP is recommended to achieve better BP control.
I
B
Self-measurement, when properly performed, is recommended due to positive effects on the acceptance of a diagnosis of hypertension, 
patient empowerment, and adherence to treatment.
I
C
Multidisciplinary approaches in the management of patients with elevated BP and hypertension, including appropriate and safe task-shifting 
away from physicians are recommended to improve BP control.
I
A
© ESC 2024
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin:creatinine ratio; AF, atrial fibrillation; ALARA, as low as reasonably achievable; ARB, 
angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; 
CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ESC, European Society of 
Cardiology; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection fraction; HF(m)rEF, heart failure with (mildly) reduced ejection fraction; HMOD, 
hypertension-mediated organ damage; i.v., intravenous; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; SCORE2, Systematic COronary Risk Evaluation 2; 
SCORE2-OP, Systematic COronary Risk Evaluation 2-Older Persons; SGLT2, sodium–glucose co-transporter 2; TIA, transient ischaemic attack.
ESC Guidelines                                                                                                                                                                                          3993


<!-- PAGE 83 -->

### Page 83

Kingdom), Maria Manuela Fiuza (Portugal), Rahima Gabulova 
(Azerbaijan), Bjørn Olav Haugen (Norway), Christian Heiss (United 
Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), Vikas Kapil 
(United Kingdom), Meral Kayikçioglu (Turkey), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Emanuela Teresa 
Locati (Italy), Sharon MacDonald (United Kingdom), Anastasia 
S. Mihailidou (Australia), Borislava Mihaylova (United Kingdom), 
Richard Mindham (United Kingdom) Martin Bodtker Mortensen 
(Denmark), Sandor Nardai (Hungary), Lis Neubeck (United 
Kingdom), Jens Cosedis Nielsen (Denmark), Peter M. Nilsson 
(Sweden), Agnes A. Pasquet (Belgium), Mónica Mendes Pedro 
(Portugal), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Ernst Rietzschel (Belgium), Bianca Rocca (Italy), Xavier Rossello 
(Spain), Jean-Paul Schmid (Switzerland), Eduard Shantsila (United 
Kingdom), Isabella Sudano (Switzerland), Ana Teresa Timóteo 
(Portugal), Georgios Tsivgoulis (Greece), Andrea Ungar (Italy), Ilonca 
Vaartjes (Netherlands), Frank Visseren (Netherlands), Heinz Voeller 
(Germany), Christiaan Vrints (Belgium), Adam Witkowski (Poland), 
Maria-Christina Zennaro (France), and Katja Zeppenfeld (Netherlands).
ESC National Cardiac Societies actively involved in the 
review process of the 2024 ESC Guidelines for the manage­
ment of elevated blood pressure and hypertension:
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: 
Algerian Society of Cardiology, Nadia Laredj; Austria: Austrian 
Society of Cardiology, Noemi Pavo; Azerbaijan: Azerbaijan Society 
of Cardiology, Ulvi Mirzoyev; Belgium: Belgian Society of 
Cardiology, Philippe van de Borne; Bosnia and Herzegovina: 
Association of Cardiologists of Bosnia and Herzegovina, Šekib 
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Arman 
Postadzhiyan; Croatia: Croatian Cardiac Society, Jure Samardzic; 
Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; 
Czechia: Czech Society of Cardiology, Jiri Widimsky; Denmark: 
Danish Society of Cardiology, Michael Hecht Olsen; Egypt: Egyptian 
Society of Cardiology, Wael M. El-Kilany; Estonia: Estonian Society 
of Cardiology, Priit Pauklin; Finland: Finnish Cardiac Society, Jari 
A. Laukkanen; France: French Society of Cardiology, Romain 
Boulestreau; Georgia: Georgian Society of Cardiology, Bezhan 
Tsinamdzgvrishvili; Germany: German Cardiac Society, Ulrich 
Kintscher; Greece: Hellenic Society of Cardiology, Maria Marketou; 
Hungary: Hungarian Society of Cardiology, Dénes Páll; Iceland: 
Icelandic Society of Cardiology, Þórdís Jóna Hrafnkelsdóttir; Ireland: 
Irish Cardiac Society, Eamon Dolan; Israel: Israel Heart Society, 
Talya Wolak; Italy: Italian Federation of Cardiology, Grzegorz Bilo; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Meiramgul 
Kapsimetovna Tundybayeva; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Erkin Mirrakhimov, Latvia: Latvian Society of 
Cardiology, Karlis Trusinskis; Lebanon: Lebanese Society of 
Cardiology, Ghassan Kiwan; Libya: Libyan Cardiac Society, Omar 
Msalem; Lithuania: Lithuanian Society of Cardiology, Jolita 
Badarienė; Luxembourg: Luxembourg Society of Cardiology, 
Cristiana-Astra Banu; Malta: Maltese Cardiac Society, Matthew 
Mercieca Balbi; Moldova (Republic of): Moldavian Society of 
Cardiology, Alexandru Caraus; Montenegro: Montenegro Society 
of Cardiology, Aneta Boskovic; Morocco: Moroccan Society of 
Cardiology, Najat Mouine; Netherlands: Netherlands Society of 
Cardiology, Tom Vromen; North Macedonia: National Society of 
Cardiology of North Macedonia, Marijan Bosevski; Norway: 
Norwegian Society of Cardiology, Helga B. Midtbø; Poland: Polish 
Cardiac Society, Adrian Doroszko; Portugal: Portuguese Society of 
Cardiology, Hélder Dores; Romania: Romanian Society of 
Cardiology, Elisabeta Badila; San Marino: San Marino Society of 
Cardiology, Roberto Bini; Serbia: Cardiology Society of Serbia, 
Dragan Vojislav Simić; Slovenia: Slovenian Society of Cardiology, 
Zlatko Fras; Spain: Spanish Society of Cardiology, Pilar Mazón; 
Sweden: Swedish Society of Cardiology, Jonas Spaak; Switzerland: 
Swiss Society of Cardiology, Thilo Burkard; Syrian Arab Republic: 
Syrian Cardiovascular Association, Elias Barakat; Tunisia: Tunisian 
Society of Cardiology and Cardiovascular Surgery, Salem Abdessalem; 
Türkiye: Turkish Society of Cardiology, Yilmaz Gunes; Ukraine: 
Ukrainian Association of Cardiology, Yurij M. Sirenko; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Adrian J. B. Brady; and Uzbekistan: Association 
of Cardiologists of Uzbekistan, Gulnoz Abdusattarovna Khamidullaeva.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
19. References
1. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension. Eur Heart J 2018;39: 
3021–104. https://doi.org/10.1093/eurheartj/ehy339
2. Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. 
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a system­
atic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1223–49. 
https://doi.org/10.1016/S0140-6736(20)30752-2
3. Mensah GA, Fuster V, Murray CJL, Roth GA, Mensah GA, Abate YH, et al. Global bur­
den of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol 2023;82: 
2350–473. https://doi.org/10.1016/j.jacc.2023.11.007
4. Johnson JL, Greaves L, Repta R. Better science with sex and gender: facilitating the use 
of a sex and gender-based analysis in health research. Int J Equity Health 2009;8:14. 
https://doi.org/10.1186/1475-9276-8-14
5. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero J-J, DeMeo DL, et al. 
Sex and gender: modifiers of health, disease, and medicine. Lancet 2020;396:565–82. 
https://doi.org/10.1016/s0140-6736(20)31561-0
6. Camm AJ, Lüscher TF, Maurer G, Serruys PW (eds). The ESC Textbook of Cardiovascular 
Medicine. Oxford University Press, 2018.
7. Mayfield SK, Foti K, Moran AE, Blakeman DE, Frieden TR. Hypertension call to action: 
will we respond to the call with action? Am J Hypertens 2022;35:214–6. https://doi.org/ 
10.1093/ajh/hpab191
8. Muntner P. The continuing challenge of low rates of blood pressure control among US 
adults. Am J Hypertens 2022;35:839–41. https://doi.org/10.1093/ajh/hpac075
9. Reuter H, Jordan J. Status of hypertension in Europe. Curr Opin Cardiol 2019;34:342–9. 
https://doi.org/10.1097/hco.0000000000000642
10. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The 
unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern 
Med 2020;173:10–20. https://doi.org/10.7326/m20-0065
11. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. 
Hypertension. Nat Rev Dis Primers 2018;4:18014. https://doi.org/10.1038/nrdp. 
2018.14
12. Navaneethabalakrishnan S, Smith HL, Arenaz CM, Goodlett BL, McDermott JG, 
Mitchell BM. Update on immune mechanisms in hypertension. Am J Hypertens 2022; 
35:842–51. https://doi.org/10.1093/ajh/hpac077
13. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of 
echocardiographically determined left ventricular mass in the Framingham heart study. 
N Engl J Med 1990;322:1561–6. https://doi.org/10.1056/nejm199005313222203
14. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. 
Prognostic significance of left ventricular mass change during treatment of hyperten­
sion. JAMA 2004;292:2350–6. https://doi.org/10.1001/jama.292.19.2350


<!-- PAGE 84 -->

### Page 84

15. de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart 
failure not related to previous myocardial infarction: the cardiovascular health study. 
Eur Heart J 2008;29:741–7. https://doi.org/10.1093/eurheartj/ehm605
16. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. 
Left ventricular hypertrophy as an independent predictor of acute cerebrovascular 
events in essential hypertension. Circulation 2001;104:2039–44. https://doi.org/10. 
1161/hc4201.097944
17. Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, et al. Cardiac 
biomarkers and left ventricular hypertrophy in relation to outcomes in patients with 
atrial fibrillation: experiences from the RE-LY trial. J Am Heart Assoc 2019;8: 
e010107. https://doi.org/10.1161/jaha.118.010107
18. Siedlinski M, Carnevale L, Xu X, Carnevale D, Evangelou E, Caulfield MJ, et al. 
Genetic analyses identify brain structures related to cognitive impairment asso­
ciated with elevated blood pressure. Eur Heart J 2023;44:2114–25. https://doi.org/ 
10.1093/eurheartj/ehad101
19. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clin­
ical practice guideline for the management of blood pressure in chronic kidney disease. 
Kidney International 2021;99:S1–87. https://doi.org/10.1016/j.kint.2020.11.003
20. Subbiah A, Bhowmik D. KDIGO recommendations on blood pressure management 
in chronic kidney disease. Kidney Int 2022;101:1299. https://doi.org/10.1016/j.kint. 
2022.02.036
21. Cheung CY, Biousse V, Keane PA, Schiffrin EL, Wong TY. Hypertensive eye disease. 
Nat Rev Dis Primers 2022;8:14. https://doi.org/10.1038/s41572-022-00342-0
22. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual 
blood pressure to vascular mortality: a meta-analysis of individual data for one million 
adults in 61 prospective studies. Lancet 2002;360:1903–13. https://doi.org/10.1016/ 
s0140-6736(02)11911-8
23. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular dis­
ease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200–4. 
https://doi.org/10.1161/01.Hyp.0000168052.00426.65
24. Gerdts E, Izzo R, Mancusi C, Losi MA, Manzi MV, Canciello G, et al. Left ventricular 
hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute 
Network). Int J Cardiol 2018;258:257–61. https://doi.org/10.1016/j.ijcard.2017.12.086
25. Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, et al. Gender 
differences in left ventricular structure and function during antihypertensive treat­
ment: the Losartan intervention for endpoint reduction in hypertension study. 
Hypertension 2008;51:1109–14. https://doi.org/10.1161/hypertensionaha.107.107474
26. Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, et al. Left atrial 
size and risk of major cardiovascular events during antihypertensive treatment: 
Losartan Intervention for Endpoint Reduction in Hypertension Trial. Hypertension 
2007;49:311–6. https://doi.org/10.1161/01.Hyp.0000254322.96189.85
27. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of 
target organ damage in mild essential hypertension. J Hypertens 2001;19:921–30. 
https://doi.org/10.1097/00004872-200105000-00013
28. Vasan RS, Pan S, Xanthakis V, Beiser A, Larson MG, Seshadri S, et al. Arterial stiffness 
and long-term risk of health outcomes: the Framingham heart study. Hypertension 
2022;79:1045–56. https://doi.org/10.1161/hypertensionaha.121.18776
29. Piskorz D. Hypertensive mediated organ damage and hypertension management. How 
to assess beneficial effects of antihypertensive treatments? High Blood Press Cardiovasc 
Prev 2020;27:9–17. https://doi.org/10.1007/s40292-020-00361-6
30. Vallelonga F, Cesareo M, Menon L, Airale L, Leone D, Astarita A, et al. Cardiovascular 
hypertension-mediated organ damage in hypertensive urgencies and hypertensive 
outpatients. Front Cardiovasc Med 2022;9:889554. https://doi.org/10.3389/fcvm. 
2022.889554
31. Vasan RS, Song RJ, Xanthakis V, Beiser A, DeCarli C, Mitchell GF, et al. 
Hypertension-mediated organ damage: prevalence, correlates, and prognosis in 
the community. Hypertension 2022;79:505–15. https://doi.org/10.1161/hypertensionaha. 
121.18502
32. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. 
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy 
life-years lost, and age-specific associations in 1·25 million people. Lancet 2014;383: 
1899–911. https://doi.org/10.1016/s0140-6736(14)60685-1
33. Malik R, Georgakis MK, Vujkovic M, Damrauer SM, Elliott P, Karhunen V, et al. 
Relationship between blood pressure and incident cardiovascular disease: linear and 
nonlinear Mendelian randomization analyses. Hypertension 2021;77:2004–13. https:// 
doi.org/10.1161/hypertensionaha.120.16534
34. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, et al. Sex differences 
in blood pressure trajectories over the life course. JAMA Cardiol 2020;5:19–26. https:// 
doi.org/10.1001/jamacardio.2019.5306
35. Salles GF, Reboldi G, Fagard RH, Cardoso CRL, Pierdomenico SD, Verdecchia P, et al. 
Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambu­
latory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. 
Hypertension 2016;67:693–700. https://doi.org/10.1161/hypertensionaha.115.06981
36. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and 
clinical implications. Hypertension 2000;35:844–51. https://doi.org/10.1161/01.hyp. 
35.3.844
37. Mauck GW, Smith CR, Geddes LA, Bourland JD. The meaning of the point of max­
imum oscillations in cuff pressure in the indirect measurement of blood pressure— 
part ii. J Biomech Eng 1980;102:28–33. https://doi.org/10.1115/1.3138195
38. Clark CE, Warren FC, Boddy K, McDonagh STJ, Moore SF, Goddard J, et al. 
Associations between systolic interarm differences in blood pressure and cardiovascu­
lar disease outcomes and mortality: individual participant data meta-analysis, develop­
ment and validation of a prognostic algorithm: the INTERPRESS-IPD collaboration. 
Hypertension 2021;77:650–61. https://doi.org/10.1161/hypertensionaha.120.15997
39. Picone DS, Deshpande RA, Schultz MG, Fonseca R, Campbell NRC, Delles C, et al. 
Nonvalidated home blood pressure devices dominate the online marketplace in 
Australia: major implications for cardiovascular risk management. Hypertension 2020; 
75:1593–9. https://doi.org/10.1161/hypertensionaha.120.14719
40. Picone DS, Campbell NRC, Schutte AE, Olsen MH, Ordunez P, Whelton PK, et al. 
Validation status of blood pressure measuring devices sold globally. JAMA 2022;327: 
680–1. https://doi.org/10.1001/jama.2021.24464
41. Stergiou GS, O’Brien E, Myers M, Palatini P, Parati G, Kollias A, et al. STRIDE BP inter­
national initiative for accurate blood pressure measurement: systematic review of pub­
lished validation studies of blood pressure measuring devices. J Clin Hypertens 
(Greenwich) 2019;21:1616–22. https://doi.org/10.1111/jch.13710
42. Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, et al. A universal stand­
ard for the validation of blood pressure measuring devices: Association for the 
Advancement of Medical Instrumentation/European Society of Hypertension/ 
International Organization for Standardization (AAMI/ESH/ISO) collaboration 
statement. Hypertension 2018;71:368–74. https://doi.org/10.1161/hypertensionaha. 
117.10237
43. Stergiou GS, Mukkamala R, Avolio A, Kyriakoulis KG, Mieke S, Murray A, et al. Cuffless 
blood pressure measuring devices: review and statement by the European Society of 
Hypertension working group on blood pressure monitoring and cardiovascular vari­
ability. J Hypertens 2022;40:1449–60. https://doi.org/10.1097/hjh.0000000000003224
44. Stergiou GS, Avolio AP, Palatini P, Kyriakoulis KG, Schutte AE, Mieke S, et al. European 
Society of Hypertension recommendations for the validation of cuffless blood pres­
sure measuring devices: European Society of Hypertension Working Group on 
Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens 2023;41: 
2074–87. https://doi.org/10.1097/hjh.0000000000003483
45. McAlister FA, Straus SE. Evidence based treatment of hypertension. Measurement of 
blood pressure: an evidence based review. BMJ 2001;322:908–11. https://doi.org/10. 
1136/bmj.322.7291.908
46. Fagius J, Karhuvaara S. Sympathetic activity and blood pressure increases with blad­
der distension in humans. Hypertension 1989;14:511–7. https://doi.org/10.1161/01. 
hyp.14.5.511
47. Stergiou GS, Kyriakoulis KG, Stambolliu E, Destounis A, Karpettas N, Kalogeropoulos 
P, et al. Blood pressure measurement in atrial fibrillation: review and meta-analysis of 
evidence on accuracy and clinical relevance. J Hypertens 2019;37:2430–41. https://doi. 
org/10.1097/hjh.0000000000002201
48. Clark CE, McDonagh STJ, McManus RJ. Accuracy of automated blood pressure mea­
surements in the presence of atrial fibrillation: systematic review and meta-analysis. 
J Hum Hypertens 2019;33:352–64. https://doi.org/10.1038/s41371-018-0153-z
49. Verberk WJ, Omboni S, Kollias A, Stergiou GS. Screening for atrial fibrillation with 
automated blood pressure measurement: research evidence and practice recom­
mendations. Int J Cardiol 2016;203:465–73. https://doi.org/10.1016/j.ijcard.2015. 
10.182
50. Manning DM, Kuchirka C, Kaminski J. Miscuffing: inappropriate blood pressure cuff ap­
plication. Circulation 1983;68:763–6. https://doi.org/10.1161/01.cir.68.4.763
51. Irving G, Holden J, Stevens R, McManus RJ. Which cuff should I use? Indirect blood 
pressure measurement for the diagnosis of hypertension in patients with obesity: a 
diagnostic accuracy review. BMJ Open 2016;6:e012429. https://doi.org/10.1136/ 
bmjopen-2016-012429
52. Keeley EC, Villanueva M, Chen YE, Gong Y, Handberg EM, Smith SM, et al. Attended vs 
unattended systolic blood pressure measurement: a randomized comparison in pa­
tients with cardiovascular disease. J Clin Hypertens (Greenwich) 2020;22:1987–92. 
https://doi.org/10.1111/jch.14037
53. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, et al. Conventional ver­
sus automated measurement of blood pressure in primary care patients with systolic 
hypertension: randomised parallel design controlled trial. BMJ 2011;342:d286. https:// 
doi.org/10.1136/bmj.d286
54. Clark CE. Inter-arm blood pressure difference, when is it a useful risk marker for car­
diovascular events? J Hum Hypertens 2022;36:117–9. https://doi.org/10.1038/s41371- 
021-00629-x
55. Clark CE, Steele AM, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Interarm 
blood pressure difference in people with diabetes: measurement and vascular and 
mortality implications: a cohort study. Diabetes Care 2014;37:1613–20. https://doi. 
org/10.2337/dc13-1576
56. Juraschek SP, Appel LJ, Mitchell CM, Mukamal KJ, Lipsitz LA, Blackford AL, et al. 
Comparison of supine and seated orthostatic hypotension assessments and their as­
sociation with falls and orthostatic symptoms. J Am Geriatr Soc 2022;70:2310–9. 
https://doi.org/10.1111/jgs.17804
ESC Guidelines                                                                                                                                                                                          3995


<!-- PAGE 85 -->

### Page 85

57. Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, et al. European 
Society of Hypertension practice guidelines for office and out-of-office blood pres­
sure measurement. J Hypertens 2021;39:1293–302. https://doi.org/10.1097/hjh. 
0000000000002843
58. Parati G, Stergiou GS, Bilo G, Kollias A, Pengo M, Ochoa J, et al. Home blood pressure 
monitoring: methodology, clinical relevance and practical application: a 2021 position 
paper by the working group on blood pressure monitoring and cardiovascular variabil­
ity of the European Society of Hypertension. J Hypertens 2021;39:1742–67. https://doi. 
org/10.1097/hjh.0000000000002922
59. Bradley CK, Choi E, Abdalla M, Mizuno H, Lam M, Cepeda M, et al. Use of different 
blood pressure thresholds to reduce the number of home blood pressure monitoring 
days needed for detecting hypertension. Hypertension 2023;80:2169–77. https://doi. 
org/10.1161/hypertensionaha.123.21118
60. Hodgkinson JA, Lee MM, Milner S, Bradburn P, Stevens R, Hobbs FDR, et al. Accuracy 
of blood-pressure monitors owned by patients with hypertension (ACCU-RATE 
study): a cross-sectional, observational study in central England. Br J Gen Pract 2020; 
70:e548–54. https://doi.org/10.3399/bjgp20X710381
61. Niiranen TJ, Asayama K, Thijs L, Johansson JK, Ohkubo T, Kikuya M, et al. 
Outcome-driven thresholds for home blood pressure measurement: international 
database of home blood pressure in relation to cardiovascular outcome. 
Hypertension 2013;61:27–34. https://doi.org/10.1161/hypertensionaha.111.00100
62. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of 
Hypertension practice guidelines for ambulatory blood pressure monitoring. 
J Hypertens 2014;32:1359–66. https://doi.org/10.1097/hjh.0000000000000221
63. Yang WY, Thijs L, Zhang ZY, Asayama K, Boggia J, Hansen TW, et al. Evidence-based 
proposal for the number of ambulatory readings required for assessing blood pressure 
level in research settings: an analysis of the IDACO database. Blood Press 2018;27: 
341–50. https://doi.org/10.1080/08037051.2018.1476057
64. Asayama K, Stolarz-Skrzypek K, Yang WY, Hansen TW, Brguljan-Hitij J, Odili AN, et al. 
What did we learn from the international databases on ambulatory and home blood 
pressure in relation to cardiovascular outcome? Hypertens Res 2023;46:934–49. 
https://doi.org/10.1038/s41440-023-01191-4
65. Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, et al. Concordance be­
tween blood pressure in the systolic blood pressure intervention trial and in routine 
clinical practice. JAMA Intern Med 2020;180:1655–63. https://doi.org/10.1001/ 
jamainternmed.2020.5028
66. Jaeger BC, Bress AP, Bundy JD, Cheung AK, Cushman WC, Drawz PE, et al. 
Longer-term all-cause and cardiovascular mortality with intensive blood pressure con­
trol: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2022;7:1138–46. 
https://doi.org/10.1001/jamacardio.2022.3345
67. Ntineri A, Niiranen TJ, McManus RJ, Lindroos A, Jula A, Schwartz C, et al. Ambulatory 
versus home blood pressure monitoring: frequency and determinants of blood pres­
sure difference and diagnostic disagreement. J Hypertens 2019;37:1974–81. https://doi. 
org/10.1097/hjh.0000000000002148
68. Sheppard JP, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. Predictors of the 
home-clinic blood pressure difference: a systematic review and meta-analysis. Am J 
Hypertens 2016;29:614–25. https://doi.org/10.1093/ajh/hpv157
69. Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in dia­
betes mellitus: treatment implications for clinical practice. Hypertension 2013;61: 
964–71. https://doi.org/10.1161/hypertensionaha.111.00289
70. Guirguis-Blake JM, Evans CV, Webber EM, Coppola EL, Perdue LA, Weyrich MS. 
Screening for hypertension in adults: updated evidence report and systematic review 
for the US preventive services task force. JAMA 2021;325:1657–69. https://doi.org/10. 
1001/jama.2020.21669
71. Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time 
to intensification, and time to follow-up in treatment of hypertension: population based 
retrospective cohort study. BMJ 2015;350:h158. https://doi.org/10.1136/bmj.h158
72. Antza C, Farmakis I, Doundoulakis I, Akrivos E, Stalikas N, Zafeiropoulos S, et al. 
Reproducibility of masked hypertension and office-based hypertension: a systematic 
review and meta-analysis. J Hypertens 2022;40:1053–9. https://doi.org/10.1097/hjh. 
0000000000003111
73. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in 
the management of hypertension: a systematic review and meta-analysis. Ann Intern 
Med 2013;159:185–94. https://doi.org/10.7326/0003-4819-159-3-201308060-00008
74. Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, et al. 
Self-monitoring of blood pressure in hypertension: a systematic review and individual 
patient data meta-analysis. PLoS Med 2017;14:e1002389. https://doi.org/10.1371/ 
journal.pmed.1002389
75. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of 
self-monitored blood pressure, with or without telemonitoring, for titration of antihy­
pertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet 
2018;391:949–59. https://doi.org/10.1016/s0140-6736(18)30309-x
76. McManus RJ, Little P, Stuart B, Morton K, Raftery J, Kelly J, et al. Home and Online 
Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention 
in poorly controlled hypertension: randomised controlled trial. BMJ 2021;372:m4858. 
https://doi.org/10.1136/bmj.m4858
77. Li R, Liang N, Bu F, Hesketh T. The effectiveness of self-management of hypertension in 
adults using mobile health: systematic review and meta-analysis. JMIR Mhealth Uhealth 
2020;8:e17776. https://doi.org/10.2196/17776
78. Acharya S, Neupane G, Seals A, Madhav KC, Giustini D, Sharma S, et al. Self-measured 
blood pressure-guided pharmacotherapy: a systematic review and meta-analysis of 
US-based telemedicine trials. Hypertension 2024;81:648–57. https://doi.org/10.1161/ 
hypertensionaha.123.22109
79. Monahan M, Jowett S, Nickless A, Franssen M, Grant S, Greenfield S, et al. 
Cost-effectiveness of telemonitoring and self-monitoring of blood pressure for antihy­
pertensive titration in primary care (TASMINH4). Hypertension 2019;73:1231–9. 
https://doi.org/10.1161/hypertensionaha.118.12415
80. Wood S, Greenfield SM, Sayeed Haque M, Martin U, Gill PS, Mant J, et al. Influence of eth­
nicity on acceptability of method of blood pressure monitoring: a cross-sectional study in 
primary care. Br J Gen Pract 2016;66:e577–586. https://doi.org/10.3399/bjgp16X685717
81. Stergiou GS, Karpettas N, Destounis A, Tzamouranis D, Nasothimiou E, Kollias A, et al. 
Home blood pressure monitoring alone vs. combined clinic and ambulatory measure­
ments in following treatment-induced changes in blood pressure and organ damage. 
Am J Hypertens 2014;27:184–92. https://doi.org/10.1093/ajh/hpt206
82. Staessen JA, Byttebier G, Buntinx F, Celis H, O’Brien ET, Fagard R. Antihypertensive 
treatment based on conventional or ambulatory blood pressure measurement. A ran­
domized controlled trial. Ambulatory blood pressure monitoring and treatment of 
hypertension investigators. JAMA 1997;278:1065–72. https://doi.org/10.1001/jama. 
1997.03550130039034
83. McEvoy JW, Leahy N, Parati G. The apples and oranges of blood pressure variability. 
Hypertension 2023;80:2556–8. https://doi.org/10.1161/hypertensionaha.123.21927
84. Ishikuro M, Obara T, Metoki H, Ohkubo T, Yamamoto M, Akutsu K, et al. Blood pres­
sure measured in the clinic and at home during pregnancy among nulliparous and mul­
tiparous women: the BOSHI study. Am J Hypertens 2013;26:141–8. https://doi.org/10. 
1093/ajh/hps002
85. Bello NA, Woolley JJ, Cleary KL, Falzon L, Alpert BS, Oparil S, et al. Accuracy of blood 
pressure measurement devices in pregnancy: a systematic review of validation studies. 
Hypertension 2018;71:326–35. https://doi.org/10.1161/hypertensionaha.117.10295
86. Tucker KL, Mort S, Yu LM, Campbell H, Rivero-Arias O, Wilson HM, et al. Effect of 
self-monitoring of blood pressure on diagnosis of hypertension during higher-risk 
pregnancy: the BUMP 1 randomized clinical trial. JAMA 2022;327:1656–65. https:// 
doi.org/10.1001/jama.2022.4712
87. Chappell LC, Tucker KL, Galal U, Yu L-M, Campbell H, Rivero-Arias O, et al. Effect of 
self-monitoring of blood pressure on blood pressure control in pregnant individuals 
with chronic or gestational hypertension: the BUMP 2 randomized clinical trial. 
JAMA 2022;327:1666–78. https://doi.org/10.1001/jama.2022.4726
88. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for 
mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–92. https:// 
doi.org/10.1056/NEJMoa2201295
89. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, 
De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases dur­
ing pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/eurheartj/ehy340
90. Tikhonoff V, Kuznetsova T, Thijs L, Cauwenberghs N, Stolarz-Skrzypek K, Seidlerová J, 
et al. Ambulatory blood pressure and long-term risk for atrial fibrillation. Heart 2018; 
104:1263–70. https://doi.org/10.1136/heartjnl-2017-312488
91. Lip GYH, Coca A, Kahan T, Boriani G, Manolis AS, Olsen MH, et al. Hypertension and 
cardiac arrhythmias: a consensus document from the European Heart Rhythm 
Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart 
Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad 
Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 
2017;19:891–911. https://doi.org/10.1093/europace/eux091
92. Šelmytė-Besusparė A, Barysienė J, Petrikonytė D, Aidietis A, Marinskis G, Laucevičius 
A. Auscultatory versus oscillometric blood pressure measurement in patients with at­
rial fibrillation and arterial hypertension. BMC Cardiovasc Disord 2017;17:87. https://doi. 
org/10.1186/s12872-017-0521-6
93. Omboni S, Ballatore T, Rizzi F, Tomassini F, Campolo L, Panzeri E, et al. 24-Hour am­
bulatory blood pressure telemonitoring in patients at risk of atrial fibrillation: results 
from the TEMPLAR project. Hypertens Res 2022;45:1486–95. https://doi.org/10. 
1038/s41440-022-00932-1
94. Seccia TM, Letizia C, Muiesan ML, Lerco S, Cesari M, Bisogni V, et al. Atrial fibrillation as 
presenting sign of primary aldosteronism: results of the prospective appraisal on the 
prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J Hypertens 
2020;38:332–9. https://doi.org/10.1097/hjh.0000000000002250
95. McDonagh STJ, Mejzner N, Clark CE. Prevalence of postural hypotension in primary, 
community and institutional care: a systematic review and meta-analysis. BMC Fam 
Pract 2021;22:1. https://doi.org/10.1186/s12875-020-01313-8
96. Tran J, Hillebrand SL, Meskers CGM, Iseli RK, Maier AB. Prevalence of initial orthostatic 
hypotension in older adults: a systematic review and meta-analysis. Age Ageing 2021; 
50:1520–8. https://doi.org/10.1093/ageing/afab090
97. Juraschek SP, Hu JR, Cluett JL, Ishak AM, Mita C, Lipsitz LA, et al. Orthostatic hypoten­
sion, hypertension treatment, and cardiovascular disease: an individual participant 
meta-analysis. JAMA 2023;330:1459–71. https://doi.org/10.1001/jama.2023.18497


<!-- PAGE 86 -->

### Page 86

98. Juraschek SP, Cortez MM, Flack JM, Ghazi L, Kenny RA, Rahman M, et al. Orthostatic 
hypotension in adults with hypertension: a scientific statement from the American 
Heart Association. Hypertension 2024;81:e16–30. https://doi.org/10.1161/hyp. 
0000000000000236
99. Raber I, Belanger MJ, Farahmand R, Aggarwal R, Chiu N, Al Rifai M, et al. Orthostatic 
hypotension in hypertensive adults: Harry Goldblatt award for early career investiga­
tors 2021. Hypertension 2022;79:2388–96. https://doi.org/10.1161/hypertensionaha. 
122.18557
100. Wieling W, Kaufmann H, Claydon VE, van Wijnen VK, Harms MPM, Juraschek SP, et al. 
Diagnosis and treatment of orthostatic hypotension. Lancet Neurol 2022;21:735–46. 
https://doi.org/10.1016/s1474-4422(22)00169-7
101. Juraschek SP, Daya N, Rawlings AM, Appel LJ, Miller ER, Windham BG, et al. 
Association of history of dizziness and long-term adverse outcomes with early vs later 
orthostatic hypotension assessment times in middle-aged adults. JAMA Intern Med 
2017;177:1316–23. https://doi.org/10.1001/jamainternmed.2017.2937
102. Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. Practical in­
structions for the 2018 ESC Guidelines for the diagnosis and management of syncope. 
Eur Heart J 2018;39:e43–80. https://doi.org/10.1093/eurheartj/ehy071
103. Rivasi G, Groppelli A, Brignole M, Soranna D, Zambon A, Bilo G, et al. Association be­
tween hypotension during 24 h ambulatory blood pressure monitoring and reflex syn­
cope: the SynABPM 1 study. Eur Heart J 2022;43:3765–76. https://doi.org/10.1093/ 
eurheartj/ehac347
104. Smith TO, Sillito JA, Goh CH, Abdel-Fattah A-R, Einarsson A, Soiza RL, et al. 
Association between different methods of assessing blood pressure variability 
and incident cardiovascular disease, cardiovascular mortality and all-cause mortal­
ity: a systematic review. Age Ageing 2020;49:184–92. https://doi.org/10.1093/ 
ageing/afz178
105. Kim S, Xiao X, Chen J. Advances in photoplethysmography for personalized cardiovas­
cular monitoring. Biosensors (Basel) 2022;12:863. https://doi.org/10.3390/bios12100863
106. Dagamseh A, Qananwah Q, Al Quran H, Shaker Ibrahim K. Towards a 
portable-noninvasive blood pressure monitoring system utilizing the photoplethysmo­
gram signal. Biomed Opt Express 2021;12:7732–51. https://doi.org/10.1364/boe.444535
107. Sharman JE, Avolio AP, Baulmann J, Benetos A, Blacher J, Blizzard CL, et al. Validation of 
non-invasive central blood pressure devices: ARTERY Society task force consensus 
statement on protocol standardization. Eur Heart J 2017;38:2805–12. https://doi. 
org/10.1093/eurheartj/ehw632
108. Sharman JE, O’Brien E, Alpert B, Schutte AE, Delles C, Hecht Olsen M, et al. Lancet 
Commission on Hypertension group position statement on the global improvement 
of accuracy standards for devices that measure blood pressure. J Hypertens 2020; 
38:21–9. https://doi.org/10.1097/hjh.0000000000002246
109. Lunardi M, Muhammad F, Shahzad A, Nadeem A, Combe L, Simpkin AJ, et al. 
Performance of wearable watch-type home blood pressure measurement devices in 
a real-world clinical sample. Clin Res Cardiol. 2023. https://doi.org/10.1007/s00392- 
023-02353-7
110. Clark CE, Warren FC, Boddy K, McDonagh STJ, Moore SF, Teresa Alzamora M, et al. 
Higher arm versus lower arm systolic blood pressure and cardiovascular outcomes: a 
meta-analysis of individual participant data from the INTERPRESS-IPD collaboration. 
Hypertension 2022;79:2328–35. https://doi.org/10.1161/hypertensionaha.121.18921
111. Margolis KL, Dehmer SP, Sperl-Hillen J, O’Connor PJ, Asche SE, Bergdall AR, et al. 
Cardiovascular events and costs with home blood pressure telemonitoring and 
pharmacist management for uncontrolled hypertension. Hypertension 2020;76: 
1097–103. https://doi.org/10.1161/hypertensionaha.120.15492
112. Sheppard JP, Tucker KL, Davison WJ, Stevens R, Aekplakorn W, Bosworth H B, et al. 
Self-monitoring of blood pressure in patients with hypertension-related multi- 
morbidity: systematic review and individual patient data meta-analysis. Am J 
Hypertens 2020;33:243–51. https://doi.org/10.1093/ajh/hpz182
113. Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation? A 
systematic review. J Fam Pract 2006;55:130–4.
114. Arvanitis M, Qi G, Bhatt DL, Post WS, Chatterjee N, Battle A, et al. Linear and non­
linear Mendelian randomization analyses of the association between diastolic blood 
pressure and cardiovascular events: the J-curve revisited. Circulation 2021;143: 
895–906. https://doi.org/10.1161/circulationaha.120.049819
115. Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima JAC, Budoff M, et al. Association of 
normal systolic blood pressure level with cardiovascular disease in the absence of risk 
factors. JAMA Cardiol 2020;5:1011–8. https://doi.org/10.1001/jamacardio.2020.1731
116. Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. 
Pharmacological blood pressure lowering for primary and secondary prevention of 
cardiovascular disease across different levels of blood pressure: an individual 
participant-level data meta-analysis. Lancet 2021;397:1625–36. https://doi.org/10. 
1016/S0140-6736(21)00590-0
117. Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, et al. Sex differences in blood 
pressure associations with cardiovascular outcomes. Circulation 2021;143:761–3. 
https://doi.org/10.1161/circulationaha.120.049360
118. Kringeland E, Tell GS, Midtbø H, Igland J, Haugsgjerd TR, Gerdts E. Stage 1 hyperten­
sion, sex, and acute coronary syndromes during midlife: the Hordaland health study. 
Eur J Prev Cardiol 2022;29:147–54. https://doi.org/10.1093/eurjpc/zwab068
119. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial 
of the effects of dietary patterns on blood pressure. DASH collaborative research group. 
N Engl J Med 1997;336:1117–24. https://doi.org/10.1056/nejm199704173361601
120. Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of 
the Mediterranean diet on blood pressure in the PREDIMED trial: results from a ran­
domized controlled trial. BMC Med 2013;11:207. https://doi.org/10.1186/1741-7015- 
11-207
121. Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Effects of 
blood pressure reduction in mild hypertension: a systematic review and meta-analysis. 
Ann Intern Med 2015;162:184–91. https://doi.org/10.7326/m14-0773
122. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood 
pressure lowering for prevention of cardiovascular disease and death: a systematic re­
view and meta-analysis. Lancet 2016;387:957–67. https://doi.org/10.1016/s0140- 
6736(15)01225-8
123. Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction 
with blood pressure to guide antihypertensive medication treatment. J Am Coll 
Cardiol 2017;69:2446–56. https://doi.org/10.1016/j.jacc.2017.02.066
124. Herrett E, Strongman H, Gadd S, Tomlinson L, Nitsch D, Bhaskaran K, et al. The im­
portance of blood pressure thresholds versus predicted cardiovascular risk on subse­
quent rates of cardiovascular disease: a cohort study in English primary care. Lancet 
Healthy Longev 2022;3:e22–30. https://doi.org/10.1016/s2666-7568(21)00281-6
125. Navar AM, Pencina MJ, Peterson ED. Assessing cardiovascular risk to guide hyperten­
sion diagnosis and treatment. JAMA Cardiol 2016;1:864–71. https://doi.org/10.1001/ 
jamacardio.2016.2861
126. Kovell LC, Ahmed HM, Misra S, Whelton SP, Prokopowicz GP, Blumenthal RS, et al. 
US hypertension management guidelines: a review of the recent past and recommen­
dations for the future. J Am Heart Assoc 2015;4:e002315. https://doi.org/10.1161/jaha. 
115.002315
127. McEvoy JW, Martin SS, Dardari ZA, Miedema MD, Sandfort V, Yeboah J, et al. 
Coronary artery calcium to guide a personalized risk-based approach to initiation 
and intensification of antihypertensive therapy. Circulation 2017;135:153–65. https:// 
doi.org/10.1161/circulationaha.116.025471
128. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, 
Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention: 
a report from the ESC Prevention of CVD Programme led by the European 
Association of Preventive Cardiology (EAPC) in collaboration with the Acute 
Cardiovascular Care Association (ACCA) and the Association of Cardiovascular 
Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol 2019;26:1534–44. 
https://doi.org/10.1177/2047487319846715
129. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA 
guidelines and in the real world. JAMA 2018;319:115–6. https://doi.org/10.1001/ 
jama.2017.19672
130. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, 
et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guide­
line for the prevention, detection, evaluation, and management of high blood pressure 
in adults: a report of the American College of Cardiology/American Heart Association 
task force on clinical practice guidelines. Circulation 2018;138:e484–594. https://doi.org/ 
10.1161/cir.0000000000000596
131. Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Wamil M, et al. 
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering 
pharmacotherapy for the prevention of cardiovascular disease and death: an individ­
ual participant-level data meta-analysis. Lancet 2021;398:1053–64. https://doi.org/ 
10.1016/S0140-6736(21)01921-8
132. Brunström M, Carlberg B. Association of blood pressure lowering with mortality 
and cardiovascular disease across blood pressure levels: a systematic review and 
meta-analysis. JAMA Intern Med 2018;178:28–36. https://doi.org/10.1001/ 
jamainternmed.2017.6015
133. Arguedas JA, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. 
Cochrane Database Syst Rev 2020;12:CD004349. https://doi.org/10.1002/14651858. 
CD004349.pub3
134. Saiz LC, Gorricho J, Garjón J, Celaya MC, Erviti J, Leache L. Blood pressure targets 
for the treatment of people with hypertension and cardiovascular disease. Cochrane 
Database Syst Rev 2022;11:CD010315. https://doi.org/10.1002/14651858.CD010315. 
pub5
135. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A ran­
domized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 
373:2103–16. https://doi.org/10.1056/NEJMoa1511939
136. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure 
control in older patients with hypertension. N Engl J Med 2021;385:1268–79. https:// 
doi.org/10.1056/NEJMoa2111437
137. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. 
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 
2010;362:1575–85. https://doi.org/10.1056/NEJMoa1001286
138. Ferrucci L, Furberg CD, Penninx BW, DiBari M, Williamson JD, Guralnik JM, et al. 
Treatment of isolated systolic hypertension is most effective in older patients with 
high-risk profile. Circulation 2001;104:1923–6. https://doi.org/10.1161/hc4101.097520
ESC Guidelines                                                                                                                                                                                          3997


<!-- PAGE 87 -->

### Page 87

139. Leening MJ, Ferket BS, Steyerberg EW, Kavousi M, Deckers JW, Nieboer D, et al. Sex dif­
ferences in lifetime risk and first manifestation of cardiovascular disease: prospective 
population based cohort study. BMJ 2014;349:g5992. https://doi.org/10.1136/bmj.g5992
140. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. 
Association of genetic variants related to combined exposure to lower low-density li­
poproteins and lower systolic blood pressure with lifetime risk of cardiovascular dis­
ease. JAMA 2019;322:1381–91. https://doi.org/10.1001/jama.2019.14120
141. Kannel WB. Risk stratification in hypertension: new insights from the Framingham 
study. Am J Hypertens 2000;13:S3–10. https://doi.org/10.1016/s0895-7061(99)00252-6
142. Weycker D, Nichols GA, O’Keeffe-Rosetti M, Edelsberg J, Khan Z, Kaura S, et al. 
Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J 
Hypertens 2007;20:599–607. https://doi.org/10.1016/j.amjhyper.2006.10.013
143. Constanti M, Floyd CN, Glover M, Boffa R, Wierzbicki AS, McManus RJ. 
Cost-effectiveness of initiating pharmacological treatment in stage one hypertension 
based on 10-year cardiovascular disease risk: a Markov modeling study. Hypertension 
2021;77:682–91. https://doi.org/10.1161/hypertensionaha.120.14913
144. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of 
hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. 
JAMA 2017;317:165–82. https://doi.org/10.1001/jama.2016.19043
145. Karmali KN, Ning H, Goff DC, Lloyd-Jones DM. Identifying individuals at risk for car­
diovascular events across the spectrum of blood pressure levels. J Am Heart Assoc 
2015;4:e002126. https://doi.org/10.1161/jaha.115.002126
146. Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to 
less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular 
risk with and without diabetes or previous stroke: an open-label, blinded-outcome, 
randomised trial. Lancet 2024;404:245–55. https://doi.org/10.1016/S0140-6736(24) 
01028-6
147. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. 
Prediction of coronary heart disease using risk factor categories. Circulation 1998; 
97:1837–47. https://doi.org/10.1161/01.cir.97.18.1837
148. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the 
use of antihypertensive medications. Circulation 2013;128:2309–17. https://doi.org/10. 
1161/circulationaha.113.002290
149. Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC, Yusuf S, Zanchetti A, et al. 
Blood pressure-lowering treatment strategies based on cardiovascular risk versus 
blood pressure: a meta-analysis of individual participant data. PLoS Med 2018;15: 
e1002538. https://doi.org/10.1371/journal.pmed.1002538
150. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis 
of hypertension guidelines in South Africa: absolute risk versus blood pressure level. 
Circulation 2005;112:3569–76. https://doi.org/10.1161/circulationaha.105.535922
151. Basu S, Sussman JB, Hayward RA. Black-white cardiovascular disease disparities 
after target-based versus personalized benefit-based lipid and blood pressure 
treatment. MDM Policy Pract 2017;2:2381468317725741. https://doi.org/10. 
1177/2381468317725741
152. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 
1296–305. https://doi.org/10.1056/NEJMoa041031
153. Klooster CCV, Bhatt DL, Steg PG, Massaro JM, Dorresteijn JAN, Westerink J, et al. 
Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interven­
tions in patients with established cardiovascular disease: results from UCC-SMART 
and REACH. Int J Cardiol 2021;325:140–8. https://doi.org/10.1016/j.ijcard.2020.09.053
154. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al. 
Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a 
secondary prevention population. Circulation 2016;134:1419–29. https://doi.org/10. 
1161/circulationaha.116.021314
155. Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, et al. Angina and future cardio­
vascular events in stable patients with coronary artery disease: insights from the 
Reduction of Atherothrombosis for Continued Health (REACH) registry. J Am 
Heart Assoc 2016;5:e004080. https://doi.org/10.1161/jaha.116.004080
156. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. Ten-year prognosis of heart failure in the com­
munity: follow-up data from the Echocardiographic Heart of England Screening 
(ECHOES) study. Eur J Heart Fail 2012;14:176–84. https://doi.org/10.1093/eurjhf/hfr170
157. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart 
failure with preserved, borderline, and reduced ejection fraction: 5–year outcomes. 
J Am Coll Cardiol 2017;70:2476–86. https://doi.org/10.1016/j.jacc.2017.08.074
158. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of 
atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998; 
98:946–52. https://doi.org/10.1161/01.cir.98.10.946
159. Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, et al. Incorporation 
of biomarkers into risk assessment for allocation of antihypertensive medication ac­
cording to the 2017 ACC/AHA high blood pressure guideline: a pooled cohort analysis. 
Circulation 2019;140:2076–88. https://doi.org/10.1161/circulationaha.119.043337
160. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson 
RA, et al. Risk of myocardial infarction in men and women with type 2 diabetes in 
the UK: a cohort study using the general practice research database. Diabetologia 
2008;51:1639–45. https://doi.org/10.1007/s00125-008-1076-y
161. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. 
High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort 
study using the general practice research database. Diabetes Care 2006;29:798–804. 
https://doi.org/10.2337/diacare.29.04.06.dc05-1433
162. Wong ND, Glovaci D, Wong K, Malik S, Franklin SS, Wygant G, et al. Global cardio­
vascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis 
Res 2012;9:146–52. https://doi.org/10.1177/1479164112436403
163. Paquette M, Bernard S, Cariou B, Hegele RA, Genest J, Trinder M, et al. Familial 
hypercholesterolemia-risk-score: a new score predicting cardiovascular events and 
cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc 
Biol 2021;41:2632–40. https://doi.org/10.1161/atvbaha.121.316106
164. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. 
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes 
in Europe. Eur Heart J 2023;44:2544–56. https://doi.org/10.1093/eurheartj/ 
ehad260
165. SCORE Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2 risk 
prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in 
Europe. Eur Heart J 2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309
166. SCORE OP working group and ESC Cardiovascular Risk Collaboration. SCORE2-OP 
risk prediction algorithms: estimating incident cardiovascular event risk in older per­
sons in four geographical risk regions. Eur Heart J 2021;42:2455–67. https://doi.org/ 
10.1093/eurheartj/ehab312
167. Pignone M, Phillips CJ, Elasy TA, Fernandez A. Physicians’ ability to predict the risk of 
coronary heart disease. BMC Health Serv Res 2003;3:13. https://doi.org/10.1186/1472- 
6963-3-13
168. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doc­
tors accurately assess coronary risk in their patients? Preliminary results of the coron­
ary health assessment study. BMJ 1995;310:975–8. https://doi.org/10.1136/bmj.310. 
6985.975
169. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists’ and cardiologists’ 
perceptions of cardiovascular risk and the outcomes of preventive therapy in cardio­
vascular disease. Ann Intern Med 1996;124:414–21. https://doi.org/10.7326/0003- 
4819-124-4-199602150-00005
170. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC guide­
lines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42: 
3227–337. https://doi.org/10.1093/eurheartj/ehab484
171. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood 
pressure lowering on cardiovascular and renal outcomes: updated systematic review 
and meta-analysis. Lancet 2016;387:435–43. https://doi.org/10.1016/s0140-6736(15) 
00805-3
172. Herrett E, Gadd S, Jackson R, Bhaskaran K, Williamson E, van Staa T, et al. Eligibility and 
subsequent burden of cardiovascular disease of four strategies for blood pressure- 
lowering treatment: a retrospective cohort study. Lancet 2019;394:663–71. https:// 
doi.org/10.1016/s0140-6736(19)31359-5
173. Matsushita K, Kaptoge S, Hageman SHJ, Sang Y, Ballew SH, Grams ME, et al. Including 
measures of chronic kidney disease to improve cardiovascular risk prediction by 
SCORE2 and SCORE2-OP. Eur J Prev Cardiol 2023;30:8–16. https://doi.org/10.1093/ 
eurjpc/zwac176
174. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in 
arterial hypertension. Eur Heart J 2022;43:4777–88. https://doi.org/10.1093/eurheartj/ 
ehac470
175. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease 
risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 
2013;28:1–19. https://doi.org/10.1007/s10654-013-9762-6
176. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, et al. Long-term 
cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol 
2019;74:2743–54. https://doi.org/10.1016/j.jacc.2019.09.052
177. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, et al. 
Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked elec­
tronic health records: a CALIBER study. Circulation 2019;140:1050–60. https://doi.org/ 
10.1161/circulationaha.118.038080
178. Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, et al. Association of con­
ventional cardiovascular risk factors with cardiovascular disease after hypertensive dis­
orders of pregnancy: analysis of the Nord-Trøndelag health study. JAMA Cardiol 2019; 
4:628–35. https://doi.org/10.1001/jamacardio.2019.1746
179. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. 
Preeclampsia and future cardiovascular health: a systematic review and 
meta-analysis. Circ Cardiovasc Qual Outcomes 2017;10:e003497. https://doi.org/10. 
1161/circoutcomes.116.003497
180. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovas­
cular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62: 
905–14. https://doi.org/10.1007/s00125-019-4840-2
181. Kyriacou H, Al-Mohammad A, Muehlschlegel C, Foster-Davies L, Bruco MEF, Legard 
C, et al. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced 
abortion: a systematic review and meta-analysis. Eur Heart J Open 2022;2:oeac065. 
https://doi.org/10.1093/ehjopen/oeac065


<!-- PAGE 88 -->

### Page 88

182. Kessous R, Shoham-Vardi I, Pariente G, Holcberg G, Sheiner E. An association be­
tween preterm delivery and long-term maternal cardiovascular morbidity. Am J 
Obstet Gynecol 2013;209:368.e1–8. https://doi.org/10.1016/j.ajog.2013.05.041
183. Markovitz AR, Stuart JJ, Horn J, Williams PL, Rimm EB, Missmer SA, et al. Does preg­
nancy complication history improve cardiovascular disease risk prediction? Findings 
from the HUNT study in Norway. Eur Heart J 2019;40:1113–20. https://doi.org/10. 
1093/eurheartj/ehy863
184. Saei Ghare Naz M, Sheidaei A, Aflatounian A, Azizi F, Ramezani Tehrani F. Does adding 
adverse pregnancy outcomes improve the Framingham cardiovascular risk score in 
women? Data from the Tehran Lipid and Glucose Study. J Am Heart Assoc 2022;11: 
e022349. https://doi.org/10.1161/jaha.121.022349
185. Gladstone RA, Pudwell J, Nerenberg KA, Grover SA, Smith GN. Cardiovascular risk 
assessment and follow-up of women after hypertensive disorders of pregnancy: a pro­
spective cohort study. J Obstet Gynaecol Can 2019;41:1157–67.e1. https://doi.org/10. 
1016/j.jogc.2018.10.024
186. Patel AP, Wang M, Kartoun U, Ng K, Khera AV. Quantifying and understanding the 
higher risk of atherosclerotic cardiovascular disease among South Asian individuals: re­
sults from the UK Biobank prospective cohort study. Circulation 2021;144:410–22. 
https://doi.org/10.1161/circulationaha.120.052430
187. Tillin T, Hughes AD, Whincup P, Mayet J, Sattar N, McKeigue PM, et al. Ethnicity and 
prediction of cardiovascular disease: performance of QRISK2 and Framingham scores 
in a U.K. tri-ethnic prospective cohort study (SABRE—Southall And Brent REvisited). 
Heart 2014;100:60–7. https://doi.org/10.1136/heartjnl-2013-304474
188. Rabanal KS, Igland J, Tell GS, Jenum AK, Klemsdal TO, Ariansen I, et al. Validation of the 
cardiovascular risk model NORRISK 2 in South Asians and people with diabetes. Scand 
Cardiovasc J 2021;55:56–62. https://doi.org/10.1080/14017431.2020.1821909
189. Veronesi G, Gianfagna F, Giampaoli S, Chambless LE, Mancia G, Cesana G, et al. 
Improving long-term prediction of first cardiovascular event: the contribution of family 
history of coronary heart disease and social status. Prev Med 2014;64:75–80. https:// 
doi.org/10.1016/j.ypmed.2014.04.007
190. Sivapalaratnam S, Boekholdt SM, Trip MD, Sandhu MS, Luben R, Kastelein JJP, et al. 
Family history of premature coronary heart disease and risk prediction in the 
EPIC-Norfolk prospective population study. Heart 2010;96:1985–9. https://doi.org/ 
10.1136/hrt.2010.210740
191. Kimenai DM, Pirondini L, Gregson J, Prieto D, Pocock SJ, Perel P, et al. Socioeconomic 
deprivation: an important, largely unrecognized risk factor in primary prevention of 
cardiovascular 
disease. 
Circulation 
2022;146:240–8. 
https://doi.org/10.1161/ 
circulationaha.122.060042
192. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident car­
diovascular events in patients with rheumatoid arthritis: a meta-analysis of observa­
tional studies. Ann Rheum Dis 2012;71:1524–9. https://doi.org/10.1136/annrheumdis- 
2011-200726
193. Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk 
scores to estimate the risk of cardiovascular disease in patients with rheumatoid arth­
ritis. Am J Cardiol 2012;110:420–4. https://doi.org/10.1016/j.amjcard.2012.03.044
194. Arts EE, Popa C, Den Broeder AA, Semb A G, Toms T, Kitas G D, et al. Performance of 
four current risk algorithms in predicting cardiovascular events in patients with early 
rheumatoid arthritis. Ann Rheum Dis 2015;74:668–74. https://doi.org/10.1136/ 
annrheumdis-2013-204024
195. Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, et al. Prediction 
of cardiovascular risk in rheumatoid arthritis: performance of original and adapted 
SCORE algorithms. Ann Rheum Dis 2016;75:674–80. https://doi.org/10.1136/ 
annrheumdis-2014-206879
196. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial 
infarction in patients with psoriasis. JAMA 2006;296:1735–41. https://doi.org/10.1001/ 
jama.296.14.1735
197. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular 
disease, and associated risk factors. J Am Acad Dermatol 2013;69:1014–24. https://doi. 
org/10.1016/j.jaad.2013.06.053
198. Eder L, Chandran V, Gladman DD. The Framingham risk score underestimates the ex­
tent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 
2014;73:1990–6. https://doi.org/10.1136/annrheumdis-2013-203433
199. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovas­
cular events: a systematic review and meta-analysis of observational studies. J Am Heart 
Assoc 2013;2:e000062. https://doi.org/10.1161/jaha.113.000062
200. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint 
AAD-NPF guidelines of care for the management and treatment of psoriasis with 
awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073–113. 
https://doi.org/10.1016/j.jaad.2018.11.058
201. Lu X, Wang Y, Zhang J, Pu D, Hu N, Luo J, et al. Patients with systemic lupus erythema­
tosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int 
Immunopharmacol 2021;94:107466. https://doi.org/10.1016/j.intimp.2021.107466
202. Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Underperformance 
of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk 
in systemic lupus erythematosus. Eur J Prev Cardiol. 2020. https://doi.org/10.1177/ 
2047487320906650
203. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atheroscler­
otic cardiovascular disease in people living with HIV: systematic review and meta-analysis. 
Circulation 2018;138:1100–12. https://doi.org/10.1161/circulationaha.117.033369
204. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular 
risk prediction functions underestimate risk in HIV infection. Circulation 2018;137: 
2203–14. https://doi.org/10.1161/circulationaha.117.028975
205. Triant VA, Lyass A, Hurley LB, Borowsky LH, Ehrbar RQ, H W, et al. Cardiovascular 
Risk Estimation Is Suboptimal in People With HIV. J Am Heart Assoc. 2024;13:e029228. 
https://doi.org/10.1161/JAHA.123.029228
206. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, 
incidence and mortality from cardiovascular disease in patients with pooled and specific 
severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 
controls. World Psychiatry 2017;16:163–80. https://doi.org/10.1002/wps.20420
207. Lambert AM, Parretti HM, Pearce E, Price MJ, Riley M, Ryan R, et al. Temporal trends in 
associations between severe mental illness and risk of cardiovascular disease: a system­
atic review and meta-analysis. PLoS Med 2022;19:e1003960. https://doi.org/10.1371/ 
journal.pmed.1003960
208. Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction 
of cardiovascular disease risk among people with severe mental illness: a cohort study. 
PLoS One 2019;14:e0221521. https://doi.org/10.1371/journal.pone.0221521
209. Yeboah J, Young R, McClelland RL, Delaney JC, Polonsky TS, Dawood FZ, et al. Utility 
of nontraditional risk markers in atherosclerotic cardiovascular disease risk assess­
ment. J Am Coll Cardiol 2016;67:139–47. https://doi.org/10.1016/j.jacc.2015.10.058
210. Akintoye E, Afonso L, Bengaluru Jayanna M, Bao W, Briasoulis A, Robinson J, et al. 
Prognostic utility of risk enhancers and coronary artery calcium score recommended 
in the 2018 ACC/AHA multisociety cholesterol treatment guidelines over the pooled 
cohort equation: insights from 3 large prospective cohorts. J Am Heart Assoc 2021;10: 
e019589. https://doi.org/10.1161/jaha.120.019589
211. Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for 
the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a sys­
tematic review. Heart 2012;98:177–84. https://doi.org/10.1136/heartjnl-2011-300747
212. Nicolaides AN, Panayiotou AG, Griffin M, Tyllis T, Bond D, Georgiou N, et al. Arterial 
ultrasound testing to predict atherosclerotic cardiovascular events. J Am Coll Cardiol 
2022;79:1969–82. https://doi.org/10.1016/j.jacc.2022.03.352
213. Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, 
Jiménez-Borreguero LJ, et al. Femoral and carotid subclinical atherosclerosis associ­
ation with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol 
2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056
214. López-Melgar B, Fernández-Friera L, Oliva B, García-Ruiz JM, Peñalvo JL, 
Gómez-Talavera S, et al. Subclinical atherosclerosis burden by 3D ultrasound in mid- 
life: the PESA study. J Am Coll Cardiol 2017;70:301–13. https://doi.org/10.1016/j.jacc. 
2017.05.033
215. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic 
pulse wave velocity improves cardiovascular event prediction: an individual participant 
meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 
2014;63:636–46. https://doi.org/10.1016/j.jacc.2013.09.063
216. Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, et al. Brachial-Ankle 
pulse wave velocity and the risk prediction of cardiovascular disease: an individual par­
ticipant data meta-analysis. Hypertension 2017;69:1045–52. https://doi.org/10.1161/ 
hypertensionaha.117.09097
217. Stone K, Veerasingam D, Meyer ML, Heffernan KS, Higgins S, Maria Bruno R, et al. 
Reimagining the value of brachial-ankle pulse wave velocity as a biomarker of cardio­
vascular disease risk-a call to action on behalf of VascAgeNet. Hypertension 2023;80: 
1980–92. https://doi.org/10.1161/hypertensionaha.123.21314
218. An DW, Hansen TW, Aparicio LS, Chori B, Huang Q-F, Wei F-F, et al. Derivation of an 
outcome-driven threshold for aortic pulse wave velocity: an individual-participant 
meta-analysis. Hypertension 2023;80:1949–59. https://doi.org/10.1161/hypertensionaha. 
123.21318
219. de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley W, et al. 
Multimodality strategy for cardiovascular risk assessment: performance in 2 
population-based cohorts. Circulation 2017;135:2119–32. https://doi.org/10.1161/ 
circulationaha.117.027272
220. Hageman SHJ, Petitjean C, Pennells L, Kaptoge S, Pajouheshnia R, Tillmann T, et al. 
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible 
addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol 2023;30:1705–14. 
https://doi.org/10.1093/eurjpc/zwad187
221. McEvoy JW, Chen Y, Nambi V, Ballantyne CM, Sharrett AR, Appel LJ, et al. 
High-sensitivity cardiac troponin T and risk of hypertension. Circulation 2015;132: 
825–33. https://doi.org/10.1161/circulationaha.114.014364
222. Hussain A, Sun W, Deswal A, de Lemos JA, McEvoy JW, Hoogeveen RC, et al. 
Association of NT-ProBNP, blood pressure, and cardiovascular events: the ARIC 
study. J Am Coll Cardiol 2021;77:559–71. https://doi.org/10.1016/j.jacc.2020.11.063
223. Stuart JJ, Tanz LJ, Cook NR, Spiegelman D, Missmer SA, Rimm EB, et al. Hypertensive 
disorders of pregnancy and 10-year cardiovascular risk prediction. J Am Coll Cardiol 
2018;72:1252–63. https://doi.org/10.1016/j.jacc.2018.05.077
ESC Guidelines                                                                                                                                                                                          3999


<!-- PAGE 89 -->

### Page 89

224. Timpka S, Fraser A, Schyman T, Stuart JJ, Åsvold BO, Mogren I, et al. The value of preg­
nancy complication history for 10-year cardiovascular disease risk prediction in 
middle-aged women. Eur J Epidemiol 2018;33:1003–10. https://doi.org/10.1007/ 
s10654-018-0429-1
225. Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ, et al. Troponin I 
and cardiovascular risk prediction in the general population: the BiomarCaRE consor­
tium. Eur Heart J 2016;37:2428–37. https://doi.org/10.1093/eurheartj/ehw172
226. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, et al. High 
population prevalence of cardiac troponin I measured by a high-sensitivity assay and 
cardiovascular risk estimation: the MORGAM biomarker project Scottish cohort. 
Eur Heart J 2014;35:271–81. https://doi.org/10.1093/eurheartj/eht406
227. Schoenthaler AM, Lancaster KJ, Chaplin W, Butler M, Forsyth J, Ogedegbe G, et al. 
Cluster randomized clinical trial of FAITH (faith-based approaches in the treatment 
of hypertension) in blacks. Circ Cardiovasc Qual Outcomes 2018;11:e004691. https:// 
doi.org/10.1161/circoutcomes.118.004691
228. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al. May 
Measurement Month 2019: the global blood pressure screening campaign of the inter­
national society of Hypertension. Hypertension 2020;76:333–41. https://doi.org/10. 
1161/hypertensionaha.120.14874
229. Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, et al. A cluster-randomized 
trial of blood-pressure reduction in black barbershops. N Engl J Med 2018;378: 
1291–301. https://doi.org/10.1056/NEJMoa1717250
230. Sun Y, Mu J, Wang DW, Ouyang N, Xing L, Guo X, et al. A village doctor-led multifa­
ceted intervention for blood pressure control in rural China: an open, cluster rando­
mised trial. Lancet 2022;399:1964–75. https://doi.org/10.1016/s0140-6736(22)00325-7
231. Schmidt BM, Durao S, Toews I, Bavuma CM, Hohlfeld A, Nury E, et al. Screening strat­
egies for hypertension. Cochrane Database Syst Rev 2020;5:CD013212. https://doi.org/ 
10.1002/14651858.CD013212.pub2
232. Kaczorowski J, Chambers LW, Dolovich L, Paterson JM, Karwalajtys T, Gierman T, 
et al. Improving cardiovascular health at population level: 39 community cluster rando­
mised trial of Cardiovascular Health Awareness Program (CHAP). BMJ 2011;342: 
d442. https://doi.org/10.1136/bmj.d442
233. Lindholt JS, Søgaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. 
Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl 
J Med 2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681
234. Sheppard JP, Schwartz CL, Tucker KL, McManus RJ. Modern management and diagno­
sis of hypertension in the United Kingdom: home care and self-care. Ann Glob Health 
2016;82:274–87. https://doi.org/10.1016/j.aogh.2016.02.005
235. Andersson H, Hedström L, Bergman S, Bergh H. The outcome of two-step blood pres­
sure screening in dental healthcare. Scand J Public Health 2018;46:623–9. https://doi. 
org/10.1177/1403494818759840
236. Zhang H, Thijs L, Kuznetsova T, Fagard RH, Li X, Staessen JA. Progression to hyper­
tension in the non-hypertensive participants in the Flemish study on environment, 
genes and health outcomes. J Hypertens 2006;24:1719–27. https://doi.org/10.1097/ 
01.hjh.0000242395.07473.92
237. Conen D, Aeschbacher S, Thijs L, Li Y, Boggia J, Asayama K, et al. Age-specific differ­
ences between conventional and ambulatory daytime blood pressure values. 
Hypertension 2014;64:1073–9. https://doi.org/10.1161/hypertensionaha.114.03957
238. Karnjanapiboonwong A, Anothaisintawee T, Chaikledkaew U, Dejthevaporn C, Attia J, 
Thakkinstian A. Diagnostic performance of clinic and home blood pressure measure­
ments compared with ambulatory blood pressure: a systematic review and 
meta-analysis. BMC Cardiovasc Disord 2020;20:491. https://doi.org/10.1186/s12872- 
020-01736-2
239. Viera AJ, Yano Y, Lin FC, Simel DL, Yun J, Dave G, et al. Does this adult patient have 
hypertension?: The rational clinical examination systematic review. JAMA 2021;326: 
339–47. https://doi.org/10.1001/jama.2021.4533
240. Green BB, Anderson ML, Cook AJ, Ehrlich K, Hall YN, Hsu C, et al. Clinic, home, and 
kiosk blood pressure measurements for diagnosing hypertension: a randomized diag­
nostic study. J Gen Intern Med 2022;37:2948–56. https://doi.org/10.1007/s11606-022- 
07400-z
241. Kim JS, Rhee MY, Kim CH, Kim YR, Do U, Kim J-H, et al. Algorithm for diagnosing 
hypertension using out-of-office blood pressure measurements. J Clin Hypertens 
(Greenwich) 2021;23:1965–74. https://doi.org/10.1111/jch.14382
242. van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC 
Council on Hypertension position document on the management of hypertensive 
emergencies. Eur Heart J Cardiovasc Pharmacother 2019;5:37–46. https://doi.org/10. 
1093/ehjcvp/pvy032
243. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness per­
ceptions and treatment beliefs. J Hum Hypertens 2004;18:607–13. https://doi.org/10. 
1038/sj.jhh.1001721
244. Hagger MS, Koch S, Chatzisarantis NLD, Orbell S. The common sense model of self- 
regulation: meta-analysis and test of a process model. Psychol Bull 2017;143:1117–54. 
https://doi.org/10.1037/bul0000118
245. Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: the ex­
ample of hypertension. Health Psychol 1985;4:115–35. https://doi.org/10.1037// 
0278-6133.4.2.115
246. O’Carroll RE, Chambers JA, Dennis M, Sudlow C, Johnston M. Improving adherence to 
medication in stroke survivors: a pilot randomised controlled trial. Ann Behav Med 
2013;46:358–68. https://doi.org/10.1007/s12160-013-9515-5
247. Hollands GJ, Usher-Smith JA, Hasan R, Alexander F, Clarke N, Griffin SJ. Visualising 
health risks with medical imaging for changing recipients’ health behaviours and risk 
factors: systematic review with meta-analysis. PLoS Med 2022;19:e1003920. https:// 
doi.org/10.1371/journal.pmed.1003920
248. Burnier M. Medication adherence and persistence as the cornerstone of effective anti­
hypertensive therapy. Am J Hypertens 2006;19:1190–6. https://doi.org/10.1016/j. 
amjhyper.2006.04.006
249. Parati G, Goncalves A, Soergel D, Bruno RM, Caiani EG, Gerdts E. New perspectives 
for hypertension management: progress in methodological and technological develop­
ments. Eur J Prev Cardiol 2023;30:48–60. https://doi.org/10.1093/eurjpc/zwac203
250. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular dis­
ease: meta-analysis on 376,162 patients. Am J Med 2012;125:882–7.e1. https://doi.org/ 
10.1016/j.amjmed.2011.12.013
251. Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National rates of 
nonadherence to antihypertensive medications among insured adults with hyperten­
sion, 2015. Hypertension 2019;74:1324–32. https://doi.org/10.1161/hypertensionaha. 
119.13616
252. Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström K, et al. 
Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J 
Clin Pharmacol 2013;69:1955–64. https://doi.org/10.1007/s00228-013-1555-z
253. Burnier M, Egan BM. Adherence in hypertension. Circ Res 2019;124:1124–40. https:// 
doi.org/10.1161/circresaha.118.313220
254. Curneen JMG, Rabbitt L, Browne D, O’Donoghue DF, Alansari Y, Harhen B, et al. 
Major disparities in patient-reported adherence compared to objective assessment 
of adherence using mass spectrometry: a prospective study in a tertiary-referral hyper­
tension clinic. Br J Clin Pharmacol 2022;89:1948–55. https://doi.org/10.1111/bcp.15292
255. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compli­
ance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29: 
610–8. https://doi.org/10.1097/HJH.0b013e328342ca97
256. Kim S, Shin DW, Yun JM, Hwang Y, Park SK, Ko Y-J, et al. Medication adherence and 
the risk of cardiovascular mortality and hospitalization among patients with newly pre­
scribed antihypertensive medications. Hypertension 2016;67:506–12. https://doi.org/ 
10.1161/hypertensionaha.115.06731
257. Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, et al. Nonadherence in 
hypertension: how to develop and implement chemical adherence testing. 
Hypertension 2022;79:12–23. https://doi.org/10.1161/hypertensionaha.121.17596
258. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adher­
ence: systematic review of qualitative research. BMJ 2012;345:e3953. https://doi.org/ 
10.1136/bmj.e3953
259. Schoenthaler A, Knafl GJ, Fiscella K, Ogedegbe G. Addressing the social needs of 
hypertensive patients: the role of patient–provider communication as a predictor of 
medication adherence. Circ Cardiovasc Qual Outcomes 2017;10:e003659. https://doi. 
org/10.1161/circoutcomes.117.003659
260. Schmieder RE, Wassmann S, Predel HG, Weisser B, Blettenberg J, Gillessen A, et al. 
Improved persistence to medication, decreased cardiovascular events and reduced all- 
cause mortality in hypertensive patients with use of single-pill combinations: results 
from the START-study. Hypertension 2023;80:1127–35. https://doi.org/10.1161/ 
hypertensionaha.122.20810
261. Ruzicka M, Leenen FHH, Ramsay T, Bugeja A, Edwards C, McCormick B, et al. Use of 
directly observed therapy to assess treatment adherence in patients with apparent 
treatment-resistant hypertension. JAMA Intern Med 2019;179:1433–4. https://doi. 
org/10.1001/jamainternmed.2019.1455
262. Pio-Abreu A, Trani-Ferreira F, Silva GV, Bortolotto LA, Drager LF. Directly observed 
therapy for resistant/refractory hypertension diagnosis and blood pressure control. 
Heart 2022;108:1952–6. https://doi.org/10.1136/heartjnl-2022-320802
263. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of 
non-adherence to antihypertensive treatment revealed by high-performance liquid 
chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 
2014;100:855–61. https://doi.org/10.1136/heartjnl-2013-305063
264. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihyperten­
sive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. 
Arch Intern Med 2002;162:2046–52. https://doi.org/10.1001/archinte.162.18.2046
265. Näslund U, Ng N, Lundgren A, Fhärm E, Grönlund C, Johansson H, et al. Visualization 
of asymptomatic atherosclerotic disease for optimum cardiovascular prevention 
(VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet 2019;393: 
133–42. https://doi.org/10.1016/s0140-6736(18)32818-6
266. Bengtsson A, Norberg M, Ng N, Carlberg B, Grönlund C, Hultdin J, et al. The bene­
ficial effect over 3 years by pictorial information to patients and their physician 
about subclinical atherosclerosis and cardiovascular risk: results from the 
VIPVIZA randomized clinical trial. Am J Prev Cardiol 2021;7:100199. https://doi. 
org/10.1016/j.ajpc.2021.100199
267. Sjölander M, Carlberg B, Norberg M, Näslund U, Ng N. Prescription of lipid-lowering 
and antihypertensive drugs following pictorial information about subclinical


<!-- PAGE 90 -->

### Page 90

atherosclerosis: a secondary outcome of a randomized clinical trial. JAMA Netw Open 
2021;4:e2121683. https://doi.org/10.1001/jamanetworkopen.2021.21683
268. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular 
concentric geometry during treatment adversely affects cardiovascular prognosis in 
hypertensive patients. Hypertension 2004;43:731–8. https://doi.org/10.1161/01.HYP. 
0000121223.44837.de
269. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM, et al. Impact of 
aortic stiffness attenuation on survival of patients in end-stage renal failure. 
Circulation 2001;103:987–92. https://doi.org/10.1161/01.cir.103.7.987
270. Cardoso CRL, Salles GF. Prognostic value of changes in aortic stiffness for cardiovas­
cular outcomes and mortality in resistant hypertension: a cohort study. Hypertension 
2022;79:447–56. https://doi.org/10.1161/hypertensionaha.121.18498
271. Laurent S, Chatellier G, Azizi M, Calvet D, Choukroun G, Danchin N, et al. SPARTE 
study: normalization of arterial stiffness and cardiovascular events in patients with 
hypertension at medium to very high risk. Hypertension 2021;78:983–95. https://doi. 
org/10.1161/hypertensionaha.121.17579
272. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. 
Summary of recommendation statements. Kidney Int Suppl (2011) 2013;3:5–14. 
https://doi.org/10.1038/kisup.2012.77
273. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular 
filtration rate and albuminuria for prediction of cardiovascular outcomes: a collabora­
tive meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3: 
514–25. https://doi.org/10.1016/s2213-8587(15)00040-6
274. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects 
of intensive BP control in CKD. J Am Soc Nephrol 2017;28:2812–23. https://doi.org/10. 
1681/asn.2017020148
275. Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association 
between more intensive vs less intensive blood pressure lowering and risk of mortality 
in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA 
Intern Med 2017;177:1498–505. https://doi.org/10.1001/jamainternmed.2017.4377
276. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synop­
sis of the kidney disease: improving global outcomes 2012 clinical practice guide­
line. Ann Intern Med 2013;158:825–30. https://doi.org/10.7326/0003-4819-158- 
11-201306040-00007
277. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 
ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in col­
laboration with the European Society for Vascular Surgery (ESVS): document cov­
ering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, 
renal, upper and lower extremity arteriesEndorsed by: the European Stroke 
Organization (ESO) The Task Force for the Diagnosis and Treatment of 
Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of 
the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. 
https://doi.org/10.1093/eurheartj/ehx095
278. Iribarren C, Round AD, Lu M, Okin PM, McNulty EJ. Cohort study of ECG left ven­
tricular hypertrophy trajectories: ethnic disparities, associations with cardiovascular 
outcomes, and clinical utility. J Am Heart Assoc 2017;6:e004954. https://doi.org/10. 
1161/jaha.116.004954
279. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlö f B. Baseline characteristics in 
relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: 
the Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. 
Hypertension 2000;36:766–73. https://doi.org/10.1161/01.hyp.36.5.766
280. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, et al. 
Prognostic value of changes in the electrocardiographic strain pattern during anti­
hypertensive treatment: the Losartan Intervention for End-point reduction in 
hypertension study (LIFE). Circulation 2009;119:1883–91. https://doi.org/10.1161/ 
circulationaha.108.812313
281. Lehtonen AO, Puukka P, Varis J, Porthan K, Tikkanen JT, Nieminen MS, et al. Prevalence 
and prognosis of ECG abnormalities in normotensive and hypertensive individuals. 
J Hypertens 2016;34:959–66. https://doi.org/10.1097/hjh.0000000000000882
282. Pewsner D, Jüni P, Egger M, Battaglia M, Sundström J, Bachmann LM. Accuracy of elec­
trocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: 
systematic review. BMJ 2007;335:711. https://doi.org/10.1136/bmj.39276.636354.AE
283. Kuznetsova T, Thijs L, Knez J, Cauwenberghs N, Petit T, Gu Y-M. Longitudinal changes 
in left ventricular diastolic function in a general population. Circ Cardiovasc Imaging 
2015;8:e002882. https://doi.org/10.1161/circimaging.114.002882
284. Zhao L, Zierath R, Claggett B, Dorbala P, Matsushita K, Kitzman D. Longitudinal 
changes in left ventricular diastolic function in late life: the ARIC study. JACC 
Cardiovasc Imaging 2023;16:1133–45. https://doi.org/10.1016/j.jcmg.2023.02.022
285. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. 
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating 
the scope of the heart failure epidemic. JAMA 2003;289:194–202. https://doi.org/10. 
1001/jama.289.2.194
286. Sundström J, Lind L, Arnlöv J, Zethelius B, André n B, Lithell HO. Echocardiographic and 
electrocardiographic diagnoses of left ventricular hypertrophy predict mortality inde­
pendently of each other in a population of elderly men. Circulation 2001;103:2346–51. 
https://doi.org/10.1161/01.cir.103.19.2346
287. Seko Y, Kato T, Yamaji Y, Haruna Y, Nakane E, Haruna T, et al. Discrepancy between 
left ventricular hypertrophy by echocardiography and electrocardiographic hyper­
trophy: clinical characteristics and outcomes. Open Heart 2021;8:e001765. https:// 
doi.org/10.1136/openhrt-2021-001765
288. Modin D, Biering-Sørensen SR, Mogelvang R, Landler N, Jensen JS, Biering-Sørensen T. 
Prognostic value of echocardiography in hypertensive versus nonhypertensive partici­
pants from the general population. Hypertension 2018;71:742–51. https://doi.org/10. 
1161/hypertensionaha.117.10674
289. Armstrong AC, Jacobs DR Jr, Gidding SS, Colangelo LA, Gjesdal O, Lewis CE, et al. 
Framingham score and LV mass predict events in young adults: CARDIA study. Int J 
Cardiol 2014;172:350–5. https://doi.org/10.1016/j.ijcard.2014.01.003
290. Kuznetsova T, Thijs L, Knez J, Herbots L, Zhang Z, Staessen JA. Prognostic value of left 
ventricular diastolic dysfunction in a general population. J Am Heart Assoc 2014;3: 
e000789. https://doi.org/10.1161/jaha.114.000789
291. Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echo­
cardiography in adult hypertension: a report from the European Association of 
Cardiovascular Imaging (EACVI) and the American Society of Echocardiography 
(ASE). Eur Heart J Cardiovasc Imaging 2015;16:577–605. https://doi.org/10.1093/ehjci/ 
jev076
292. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/ASE/ 
AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for 
echocardiography. A report of the American College of Cardiology Foundation appro­
priate use criteria task force, American Society of Echocardiography, American Heart 
Association, American Society of Nuclear Cardiology, Heart Failure Society of 
America, Heart Rhythm Society, Society for Cardiovascular Angiography and 
Interventions, Society of Critical Care Medicine, Society of Cardiovascular 
Computed Tomography, Society for Cardiovascular Magnetic Resonance American 
College of Chest Physicians. J Am Soc Echocardiogr 2011;24:229–67. https://doi.org/ 
10.1016/j.echo.2010.12.008
293. van Rosendael AR, Bax AM, Smit JM, van den Hoogen IJ, Ma X, Al’Aref S, et al. Clinical 
risk factors and atherosclerotic plaque extent to define risk for major events in pa­
tients without obstructive coronary artery disease: the long-term coronary computed 
tomography angiography CONFIRM registry. Eur Heart J Cardiovasc Imaging 2020;21: 
479–88. https://doi.org/10.1093/ehjci/jez322
294. Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS, Szklo M, et al. Predictive value of 
coronary artery calcium score categories for coronary events versus strokes: impact of 
sex and race: MESA and DHS. Circ Cardiovasc Imaging 2020;13:e010153. https://doi. 
org/10.1161/circimaging.119.010153
295. Bengtsson A, Lindvall K, Norberg M, Fhärm E. Increased knowledge makes a difference! 
—general practitioners’ experiences of pictorial information about subclinical athero­
sclerosis for primary prevention: an interview study from the VIPVIZA trial. Scand J 
Prim Health Care 2021;39:77–84. https://doi.org/10.1080/02813432.2021.1882083
296. Ibanez B, Fernández-Ortiz A, Fernández-Friera L, García-Lunar I, Andrés V, Fuster V. 
Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8. 
J Am Coll Cardiol 2021;78:156–79. https://doi.org/10.1016/j.jacc.2021.05.011
297. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ. 
Common carotid intima-media thickness measurements in cardiovascular risk 
prediction: a meta-analysis. JAMA 2012;308:796–803. https://doi.org/10.1001/ 
jama.2012.9630
298. Downie LE, Hodgson LA, DSylva C, McIntosh RL, Rogers SL, Connell P, et al. 
Hypertensive retinopathy: comparing the Keith-Wagener-Barker to a simplified clas­
sification. J Hypertens 2013;31:960–5. https://doi.org/10.1097/HJH.0b013e32835efea3
299. Liew G, Xie J, Nguyen H, Keay L, Kamran Ikram M, McGeechan K, et al. Hypertensive 
retinopathy and cardiovascular disease risk: 6 population-based cohorts meta-analysis. 
Int J Cardiol Cardiovasc Risk Prev 2023;17:200180. https://doi.org/10.1016/j.ijcrp. 
2023.200180
300. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hyper­
tension. Circ Res 2015;116:937–59. https://doi.org/10.1161/circresaha.116.303647
301. Casey R, Neumann HPH, Maher ER. Genetic stratification of inherited and sporadic 
phaeochromocytoma and paraganglioma: implications for precision medicine. Hum 
Mol Genet 2020;29:R128–137. https://doi.org/10.1093/hmg/ddaa201
302. Rossi GP, Ceolotto G, Caroccia B, Lenzini L. Genetic screening in arterial hyperten­
sion. Nat Rev Endocrinol 2017;13:289–98. https://doi.org/10.1038/nrendo.2016.196
303. Cascón A, Calsina B, Monteagudo M, Mellid S, Díaz-Talavera A, Currás-Freixes M, et al. 
Genetic bases of pheochromocytoma and paraganglioma. J Mol Endocrinol 2023;70: 
e220167. https://doi.org/10.1530/jme-22-0167
304. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. Lancet 2003; 
361:1629–41. https://doi.org/10.1016/s0140-6736(03)13302-8
305. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad 
MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical 
practice guideline. J Clin Endocrinol Metab 2014;99:1915–42. https://doi.org/10. 
1210/jc.2014-1498
306. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015;386:801–12. 
https://doi.org/10.1016/s0140-6736(14)61468-9
307. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities 
of hypertension prevalence and control: a systematic analysis of population-based 
ESC Guidelines                                                                                                                                                                                          4001


<!-- PAGE 91 -->

### Page 91

studies from 90 countries. Circulation 2016;134:441–50. https://doi.org/10.1161/ 
circulationaha.115.018912
308. Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant 
hypertension: state of the art. Nat Rev Nephrol 2018;14:428–41. https://doi.org/10. 
1038/s41581-018-0006-6
309. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb 
Cheryl R, et al. Resistant hypertension: detection, evaluation, and management: a sci­
entific statement from the American Heart Association. Hypertension 2018;72: 
e53–90. https://doi.org/10.1161/hyp.0000000000000084
310. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent 
treatment-resistant hypertension in the United States. Hypertension 2019;73: 
424–31. https://doi.org/10.1161/hypertensionaha.118.12191
311. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. 
JAMA 2014;311:2216–24. https://doi.org/10.1001/jama.2014.5180
312. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and 
stepped care standardised antihypertensive treatment with or without renal denerv­
ation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised 
controlled trial. Lancet 2015;385:1957–65. https://doi.org/10.1016/s0140-6736(14) 
61942-5
313. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study 
of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll 
Cardiol 2006;48:2293–300. https://doi.org/10.1016/j.jacc.2006.07.059
314. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LKG, Amaro ACS, et al. 
Obstructive sleep apnea: the most common secondary cause of hypertension asso­
ciated with resistant hypertension. Hypertension 2011;58:811–7. https://doi.org/10. 
1161/hypertensionaha.111.179788
315. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. 
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective 
observational study. Lancet 2008;371:1921–6. https://doi.org/10.1016/s0140- 
6736(08)60834-x
316. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and 
clinical manifestations of primary aldosteronism encountered in primary care practice. 
J Am Coll Cardiol 2017;69:1811–20. https://doi.org/10.1016/j.jacc.2017.01.052
317. Käyser SC, Deinum J, de Grauw WJ, Schalk BWM, Bor HJHJ, Lenders JWM, et al. 
Prevalence of primary aldosteronism in primary care: a cross-sectional study. Br J 
Gen Pract 2018;68:e114–22. https://doi.org/10.3399/bjgp18X694589
318. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, 
and how to screen? Eur Heart J 2014;35:1245–54. https://doi.org/10.1093/ 
eurheartj/eht534
319. Rossi GP, Bisogni V, Rossitto G, Maiolino G, Cesari M, Zhu R, et al. Practice recom­
mendations for diagnosis and treatment of the most common forms of secondary 
hypertension. High Blood Press Cardiovasc Prev 2020;27:547–60. https://doi.org/10. 
1007/s40292-020-00415-9
320. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. 
Hyperaldosteronism among black and white subjects with resistant hypertension. 
Hypertension 2002;40:892–6. https://doi.org/10.1161/01.hyp.0000040261.30455.b6
321. Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, et al. Screening rates for pri­
mary aldosteronism in resistant hypertension: a cohort study. Hypertension 2020;75: 
650–9. https://doi.org/10.1161/hypertensionaha.119.14359
322. Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, et al. Screening 
rates for primary aldosteronism among individuals with hypertension plus hypokal­
emia: a population-based retrospective cohort study. Hypertension 2022;79:178–86. 
https://doi.org/10.1161/hypertensionaha.121.18118
323. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. 
Cardiovascular events and target organ damage in primary aldosteronism compared 
with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes 
Endocrinol 2018;6:41–50. https://doi.org/10.1016/s2213-8587(17)30319-4
324. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with 
primary aldosteronism: a controlled cross-sectional study. Hypertension 2013;62: 
331–6. https://doi.org/10.1161/hypertensionaha.113.01060
325. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screen­
ing test to identify aldosterone-producing adenoma by measuring plasma renin activity. 
Results in hypertensive patients. Arch Intern Med 1981;141:1589–93. https://doi.org/ 
10.1001/archinte.1981.00340130033011
326. Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol 2019; 
74:2799–811. https://doi.org/10.1016/j.jacc.2019.09.057
327. Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM. Effects of min­
eralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in pri­
mary aldosteronism—the EMIRA study. J Clin Endocrinol Metab 2020;105:2060–7. 
https://doi.org/10.1210/clinem/dgaa080
328. Rossi GP, Bisogni V, Bacca AV, Bacca AV, Belfiore A, Cesari M, et al. The 2020 Italian 
Society of Arterial Hypertension (SIIA) practical guidelines for the management of pri­
mary aldosteronism. Int J Cardiol Hypertens 2020;5:100029. https://doi.org/10.1016/j. 
ijchy.2020.100029
329. Faconti L, Kulkarni S, Delles C, Kapil V, Lewis P, Glover M, et al. Diagnosis and man­
agement of primary hyperaldosteronism in patients with hypertension: a practical 
approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens 
2024;38:8–18. https://doi.org/10.1038/s41371-023-00875-1
330. Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, et al. Fibromuscular dys­
plasia: state of the science and critical unanswered questions: a scientific statement 
from the American Heart Association. Circulation 2014;129:1048–78. https://doi. 
org/10.1161/01.cir.0000442577.96802.8c
331. Faconti L, Morselli F, Sinha M, Chrysochou C, Chowienczyk PJ. Fibromuscular dysplasia 
and hypertension—a statement on behalf of the British and Irish Hypertension Society. 
J Hum Hypertens 2021;35:1051–3. https://doi.org/10.1038/s41371-020-00456-6
332. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, et al. First inter­
national consensus on the diagnosis and management of fibromuscular dysplasia. 
J Hypertens 2019;37:229–52. https://doi.org/10.1097/hjh.0000000000002019
333. Abrishami A, Khajehdehi A, Chung F. A systematic review of screening questionnaires 
for obstructive sleep apnea. Can J Anaesth 2010;57:423–38. https://doi.org/10.1007/ 
s12630-010-9280-x
334. Chai-Coetzer CL, Antic NA, Hamilton GS, McArdle N, Wong K, Yee BJ, et al. Physician 
decision making and clinical outcomes with laboratory polysomnography or limited- 
channel sleep studies for obstructive sleep apnea: a randomized trial. Ann Intern Med 
2017;166:332–40. https://doi.org/10.7326/m16-1301
335. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 
366:665–75. https://doi.org/10.1016/s0140-6736(05)67139-5
336. Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, 
diagnosis, management and future directions of research of phaeochromocytoma and 
paraganglioma: a position statement and consensus of the Working Group on 
Endocrine Hypertension of the European Society of Hypertension. J Hypertens 
2020;38:1443–56. https://doi.org/10.1097/hjh.0000000000002438
337. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric 
retrospective study. Eur J Endocrinol 1999;141:619–24. https://doi.org/10.1530/eje.0. 
1410619
338. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J 
Med 2019;381:552–65. https://doi.org/10.1056/NEJMra1806651
339. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic out­
comes and mortality in medically treated primary aldosteronism: a retrospective co­
hort study. Lancet Diabetes Endocrinol 2018;6:51–9. https://doi.org/10.1016/s2213- 
8587(17)30367-4
340. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to low­
er blood pressure and blood cholesterol based on an individual’s absolute cardiovas­
cular risk. Lancet 2005;365:434–41.
341. Yang L, Sun J, Zhao M, Liang Y, Bovet P, Xi B. Elevated blood pressure in childhood and 
hypertension risk in adulthood: a systematic review and meta-analysis. J Hypertens 
2020;38:2346–55. https://doi.org/10.1097/hjh.0000000000002550
342. Allen NB, Krefman AE, Labarthe D, Greenland P, Juonala M, Kähönen M, et al. 
Cardiovascular health trajectories from childhood through middle age and their asso­
ciation with subclinical atherosclerosis. JAMA Cardiol 2020;5:557–66. https://doi.org/10. 
1001/jamacardio.2020.0140
343. de Simone G, Mancusi C, Hanssen H, Genovesi S, Lurbe E, Parati G, et al. Hypertension 
in children and adolescents. Eur Heart J 2022;43:3290–301. https://doi.org/10.1093/ 
eurheartj/ehac328
344. Falkstedt D, Koupil I, Hemmingsson T. Blood pressure in late adolescence and early 
incidence of coronary heart disease and stroke in the Swedish 1969 conscription co­
hort. J Hypertens 2008;26:1313–20. https://doi.org/10.1097/HJH.0b013e3282ffb17e
345. Jacobs DR Jr, Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, et al. Childhood 
cardiovascular risk factors and adult cardiovascular events. N Engl J Med 2022;386: 
1877–88. https://doi.org/10.1056/NEJMoa2109191
346. Oikonen M, Nuotio J, Magnussen CG, Viikari JSA, Taittonen L, Laitinen T, et al. 
Repeated blood pressure measurements in childhood in prediction of hypertension 
in adulthood. Hypertension 2016;67:41–7. https://doi.org/10.1161/hypertensionaha. 
115.06395
347. Garcia-Lunar I, van der Ploeg HP, Fernández Alvira JM, van Nassau F, Castellano 
Vázquez JM, van der Beek AJ, et al. Effects of a comprehensive lifestyle intervention 
on cardiovascular health: the TANSNIP-PESA trial. Eur Heart J 2022;43:3732–45. 
https://doi.org/10.1093/eurheartj/ehac378
348. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on car­
diovascular events and death. N Engl J Med 2021;385:1067–77. https://doi.org/10. 
1056/NEJMoa2105675
349. He FJ, Tan M, Ma Y, MacGregor GA. Salt reduction to prevent hypertension and car­
diovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:632–47. 
https://doi.org/10.1016/j.jacc.2019.11.055
350. Ma Y, He FJ, Sun Q, Yuan C, Kieneker LM, Curhan GC, et al. 24-Hour urinary sodium 
and potassium excretion and cardiovascular risk. N Engl J Med 2022;386:252–63. 
https://doi.org/10.1056/NEJMoa2109794
351. Ma H, Xue Q, Wang X, Li X, Franco OH, Li Y, et al. Adding salt to foods and hazard 
of premature mortality. Eur Heart J 2022;43:2878–88. https://doi.org/10.1093/ 
eurheartj/ehac208
352. Huang L, Trieu K, Yoshimura S, M Woodward, N Campbell, D Lackland, et al. Effect of 
dose and duration of reduction in dietary sodium on blood pressure levels: systematic


<!-- PAGE 92 -->

### Page 92

review and meta-analysis of randomised trials. BMJ 2020;368:m315. https://doi.org/10. 
1136/bmj.m315
353. Graudal N, Hubeck-Graudal T, Jürgens G, Taylor RS. Dose-response relation between 
dietary sodium and blood pressure: a meta-regression analysis of 133 randomized con­
trolled trials. Am J Clin Nutr 2019;109:1273–8. https://doi.org/10.1093/ajcn/nqy384
354. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high so­
dium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and tri­
glyceride. Cochrane Database Syst Rev 2020;12:CD004022. https://doi.org/10.1002/ 
14651858.CD004022.pub5
355. Filippini T, Malavolti M, Whelton PK, Naska A, Orsini N, Vinceti M. Blood pressure ef­
fects of sodium reduction: dose–response meta-analysis of experimental studies. 
Circulation 2021;143:1542–67. https://doi.org/10.1161/circulationaha.120.050371
356. Gupta DK, Lewis CE, Varady KA, Su YR, Madhur MS, Lackland DT, et al. Effect of diet­
ary sodium on blood pressure: a crossover trial. JAMA 2023;330:2258 . https://doi.org/ 
10.1001/jama.2023.23651
357. He J, Gu D, Chen J, Jaquish CE, Rao DC, Hixson JE, et al. Gender difference in blood 
pressure responses to dietary sodium intervention in the GenSalt study. J Hypertens 
2009;27:48–54. https://doi.org/10.1097/hjh.0b013e328316bb87
358. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood 
pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension 
(DASH) diet. N Engl J Med 2001;344:3–10. https://doi.org/10.1056/nejm200101043440101
359. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind 
study of three sodium intakes and long-term effects of sodium restriction in essential 
hypertension. Lancet 1989;2:1244–7. https://doi.org/10.1016/s0140-6736(89)91852-7
360. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. 
Sodium reduction and weight loss in the treatment of hypertension in older persons: a 
randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). 
JAMA 1998;279:839–46. https://doi.org/10.1001/jama.279.11.839
361. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pres­
sure: Cochrane systematic review and meta-analysis of randomised trials. BMJ 2013; 
346:f1325. https://doi.org/10.1136/bmj.f1325
362. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerová J, Richart T, et al. 
Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes 
in relation to urinary sodium excretion. JAMA 2011;305:1777–85. https://doi.org/10. 
1001/jama.2011.574
363. Messerli FH, Hofstetter L, Syrogiannouli L, Rexhaj E, Siontis GCM, Seiler C, et al. 
Sodium intake, life expectancy, and all-cause mortality. Eur Heart J 2021;42: 
2103–12. https://doi.org/10.1093/eurheartj/ehaa947
364. Mente A, O’Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, et al. 
Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a 
community-level prospective epidemiological cohort study. Lancet 2018;392: 
496–506. https://doi.org/10.1016/s0140-6736(18)31376-x
365. Au Yeung SL, Schooling CM. Impact of urinary sodium on cardiovascular disease and 
risk factors: a 2 sample Mendelian randomization study. Clin Nutr 2021;40:1990–6. 
https://doi.org/10.1016/j.clnu.2020.09.018
366. Zanetti D, Bergman H, Burgess S, Assimes TL, Bhalla V, Ingelsson E. Urinary albumin, 
sodium, and potassium and cardiovascular outcomes in the UK Biobank: observational 
and Mendelian randomization analyses. Hypertension 2020;75:714–22. https://doi.org/ 
10.1161/hypertensionaha.119.14028
367. Nolan P, McEvoy JW. Salt restriction for treatment of hypertension—current state 
and future directions. Curr Opin Cardiol 2024;39:61–7. https://doi.org/10.1097/hco. 
0000000000001098
368. Yuan Y, Jin A, Neal B, Feng X, Qiao Q, Wang H, et al. Salt substitution and salt-supply 
restriction for lowering blood pressure in elderly care facilities: a cluster-randomized 
trial. Nat Med 2023;29:973–81. https://doi.org/10.1038/s41591-023-02286-8
369. Lechner K, Schunkert H. Recommendations on sodium intake for cardiovascular 
health: conviction or evidence? Eur Heart J 2020;41:3374–5. https://doi.org/10.1093/ 
eurheartj/ehaa545
370. O’Donnell M, Mente A, Alderman MH, Brady AJB, Diaz R, Gupta R, et al. Salt and car­
diovascular disease: insufficient evidence to recommend low sodium intake. Eur Heart J 
2020;41:3363–73. https://doi.org/10.1093/eurheartj/ehaa586
371. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of in­
creased potassium intake on cardiovascular risk factors and disease: systematic review 
and meta-analyses. BMJ 2013;346:f1378. https://doi.org/10.1136/bmj.f1378
372. O’Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, et al. Urinary so­
dium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014; 
371:612–23. https://doi.org/10.1056/NEJMoa1311889
373. Wouda RD, Boekholdt SM, Khaw KT, Wareham NJ, de Borst MH, Hoorn EJ, et al. 
Sex-specific associations between potassium intake, blood pressure, and cardiovascu­
lar outcomes: the EPIC-Norfolk study. Eur Heart J 2022;43:2867–75. https://doi.org/ 
10.1093/eurheartj/ehac313
374. Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, et al. Potassium intake 
and blood pressure: a dose-response meta-analysis of randomized controlled trials. 
J Am Heart Assoc 2020;9:e015719. https://doi.org/10.1161/jaha.119.015719
375. O’Donnell M, Yusuf S, Vogt L, Mente A, Messerli FH. Potassium intake: the Cinderella 
electrolyte. Eur Heart J 2023;44:4925–34. https://doi.org/10.1093/eurheartj/ehad628
376. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice 
guidelines on hypertension and antihypertensive agents in chronic kidney disease. 
Am J Kidney Dis 2004;43:S1–290. https://doi.org/10.1053/j.ajkd.2004.03.006
377. Ndanuko RN, Ibrahim R, Hapsari RA, Neale EP, Raubenheimer D, Charlton KE. 
Association between the urinary sodium to potassium ratio and blood pressure in 
adults: a systematic review and meta-analysis. Adv Nutr 2021;12:1751–67. https://doi. 
org/10.1093/advances/nmab036
378. Messerli FH, O’Donnell M, Mente A, Yusuf S. Settling the controversy of salt substi­
tutes and stroke: sodium reduction or potassium increase? Eur Heart J 2022;43: 
3365–7. https://doi.org/10.1093/eurheartj/ehac160
379. Yin X, Paige E, Tian M, Li Q, Huang L, Yu J, et al. The proportion of dietary salt replaced 
with potassium-enriched salt in the SSaSS: implications for scale-up. Hypertension 2023; 
80:956–65. https://doi.org/10.1161/hypertensionaha.122.20115
380. Xu X, Zeng L, Jha V, Cobb LK, Shibuya K, Appel LJ, et al. Potassium-enriched salt sub­
stitutes: a review of recommendations in clinical management guidelines. Hypertension 
2024;81:400–14. https://doi.org/10.1161/hypertensionaha.123.21343
381. Hanssen H, Boardman H, Deiseroth A, Moholdt T, Simonenko M, Kränkel N, et al. 
Personalized exercise prescription in the prevention and treatment of arterial hyper­
tension: a consensus document from the European Association of Preventive 
Cardiology (EAPC) and the ESC Council on Hypertension. Eur J Prev Cardiol 2022; 
29:205–15. https://doi.org/10.1093/eurjpc/zwaa141
382. Van Hoof R, Hespel P, Fagard R, Lijnen P, Staessen J, Amery A. Effect of endurance 
training on blood pressure at rest, during exercise and during 24 hours in sedentary 
men. Am J Cardiol 1989;63:945–9. https://doi.org/10.1016/0002-9149(89)90145-8
383. MacDonald HV, Johnson BT, Huedo-Medina TB, Livingston J, Forsyth KC, Kraemer 
WJ, et al. Dynamic resistance training as stand-alone antihypertensive lifestyle ther­
apy: a meta-analysis. J Am Heart Assoc 2016;5:e003231. https://doi.org/10.1161/jaha. 
116.003231
384. Hansford HJ, Parmenter BJ, McLeod KA, Wewege MA, Smart NA, Schutte AE, et al. 
The effectiveness and safety of isometric resistance training for adults with high blood 
pressure: a systematic review and meta-analysis. Hypertens Res 2021;44:1373–84. 
https://doi.org/10.1038/s41440-021-00720-3
385. Van Hoof R, Macor F, Lijnen P, Staessen J, Thijs L, Vanhees L, et al. Effect of strength 
training on blood pressure measured in various conditions in sedentary men. Int J 
Sports Med 1996;17:415–22. https://doi.org/10.1055/s-2007-972871
386. Leal JM, Galliano LM, Del Vecchio FB. Effectiveness of high-intensity interval training 
versus moderate-intensity continuous training in hypertensive patients: a systematic 
review and meta-analysis. Curr Hypertens Rep 2020;22:26. https://doi.org/10.1007/ 
s11906-020-1030-z
387. Rossi A, Dikareva A, Bacon SL, Daskalopoulou SS. The impact of physical activity on 
mortality in patients with high blood pressure: a systematic review. J Hypertens 
2012;30:1277–88. https://doi.org/10.1097/HJH.0b013e3283544669
388. Cuspidi C, Gherbesi E, Faggiano A, Sala C, Carugo S, Grassi G, et al. Masked hyperten­
sion and exaggerated blood pressure response to exercise: a review and meta-analysis. 
Diagnostics (Basel) 2023;13:1005. https://doi.org/10.3390/diagnostics13061005
389. Mariampillai JE, Liestøl K, Kjeldsen SE, Prestgaard EE, Engeseth K, Bodegard J, et al. 
Exercise systolic blood pressure at moderate workload is linearly associated with cor­
onary disease risk in healthy men. Hypertension 2020;75:44–50. https://doi.org/10. 
1161/hypertensionaha.119.13528
390. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S. 2020 ESC Guidelines on 
sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 
42:17–96. https://doi.org/10.1093/eurheartj/ehaa605
391. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health 
Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports 
Med 2020;54:1451–62. https://doi.org/10.1136/bjsports-2020-102955
392. Saco-Ledo G, Valenzuela PL, Ramírez-Jiménez M, Morales JS, Castillo-García A, 
Blumenthal JA, et al. Acute aerobic exercise induces short-term reductions in am­
bulatory blood pressure in patients with hypertension: a systematic review and 
meta-analysis. Hypertension 2021;78:1844–58. https://doi.org/10.1161/hypertensionaha. 
121.18099
393. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. 
American College of Sports Medicine position stand. Quantity and quality of exercise 
for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor 
fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports 
Exerc 2011;43:1334–59. https://doi.org/10.1249/MSS.0b013e318213fefb
394. Edwards JJ, Deenmamode AHP, Griffiths M, Arnold O, Cooper NJ, Wiles JD, et al. 
Exercise training and resting blood pressure: a large-scale pairwise and network 
meta-analysis of randomised controlled trials. Br J Sports Med 2023;57:1317–26. 
https://doi.org/10.1136/bjsports-2022-106503
395. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise 
standards for testing and training: a scientific statement from the American 
Heart Association. Circulation 2013;128:873–934. https://doi.org/10.1161/CIR. 
0b013e31829b5b44
396. Craft BB, Carroll HA, Lustyk MK. Gender differences in exercise habits and quality of 
life reports: assessing the moderating effects of reasons for exercise. Int J Lib Arts Soc Sci 
2014;2:65–76.
ESC Guidelines                                                                                                                                                                                          4003


<!-- PAGE 93 -->

### Page 93

397. Mathieu P, Poirier P, Pibarot P, Lemieux I, Després JP. Visceral obesity: the link among 
inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577–84. 
https://doi.org/10.1161/hypertensionaha.108.110320
398. Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, et al. The relationship of 
body mass and fat distribution with incident hypertension: observations from the 
Dallas heart study. J Am Coll Cardiol 2014;64:997–1002. https://doi.org/10.1016/j.jacc. 
2014.05.057
399. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on 
blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42: 
878–84. https://doi.org/10.1161/01.Hyp.0000094221.86888.Ae
400. Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and 
risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK 
primary care database. Int J Obes (Lond) 2021;45:1249–58. https://doi.org/10.1038/ 
s41366-021-00788-4
401. Moore LL, Visioni AJ, Qureshi MM, Bradlee ML, Ellison RC, D’Agostino R. Weight loss 
in overweight adults and the long-term risk of hypertension: the Framingham study. 
Arch Intern Med 2005;165:1298–303. https://doi.org/10.1001/archinte.165.11.1298
402. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, et al. Interventions 
that cause weight loss and the impact on cardiovascular risk factors: a systematic re­
view and meta-analysis. Obes Rev 2016;17:1001–11. https://doi.org/10.1111/obr.12433
403. Wing RR, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, et al. 
Association of weight loss maintenance and weight regain on 4-year changes in 
CVD risk factors: the action for health in diabetes (Look AHEAD) clinical trial. 
Diabetes Care 2016;39:1345–55. https://doi.org/10.2337/dc16-0509
404. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al. Effects of weight 
loss interventions for adults who are obese on mortality, cardiovascular disease, and 
cancer: systematic review and meta-analysis. BMJ 2017;359:j4849. https://doi.org/10. 
1136/bmj.j4849
405. Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A. Long-term ef­
fects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 
2021;2:CD008274. https://doi.org/10.1002/14651858.CD008274.pub4
406. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular ef­
fects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369: 
145–54. https://doi.org/10.1056/NEJMoa1212914
407. Pagidipati NJ, Phelan M, Page C, Clowse M, Henao R, Peterson ED, et al. The import­
ance of weight stabilization amongst those with overweight or obesity: results from a 
large health care system. Prev Med Rep 2021;24:101615. https://doi.org/10.1016/j. 
pmedr.2021.101615
408. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary prevention 
of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin ol­
ive oil or nuts. N Engl J Med 2018;378:e34. https://doi.org/10.1056/NEJMoa1800389
409. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, 
Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with 
a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled 
trial. Lancet 2022;399:1876–85. https://doi.org/10.1016/s0140-6736(22)00122-2
410. Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin P-H, et al. 
Effects of the DASH diet alone and in combination with exercise and weight loss on 
blood pressure and cardiovascular biomarkers in men and women with high blood 
pressure: the ENCORE study. Arch Intern Med 2010;170:126–35. https://doi.org/10. 
1001/archinternmed.2009.470
411. Juraschek SP, Miller ER III, Weaver CM, Appel LJ. Effects of sodium reduction and the 
DASH diet in relation to baseline blood pressure. J Am Coll Cardiol 2017;70:2841–8. 
https://doi.org/10.1016/j.jacc.2017.10.011
412. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of different dietary interventions on 
blood pressure: systematic review and meta-analysis of randomized controlled trials. 
Hypertension 2016;67:733–9. https://doi.org/10.1161/hypertensionaha.115.06853
413. Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, et al. 
Long-term effects of weight-reducing drugs in people with hypertension. 
Cochrane Database Syst Rev 2021;1:CD007654. https://doi.org/10.1002/14651858. 
CD007654.pub5
414. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances 
and challenges. Nat Rev Drug Discov 2022;21:201–23. https://doi.org/10.1038/s41573- 
021-00337-8
415. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. 
Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 
384:989–1002. https://doi.org/10.1056/NEJMoa2032183
416. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. 
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 
2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo- 
controlled, phase 3 trial. Lancet 2021;397:971–84. https://doi.org/10.1016/ 
s0140-6736(21)00213-0
417. Tasnim S, Tang C, Musini VM, Wright JM. Effect of alcohol on blood pressure. 
Cochrane Database Syst Rev 2020;7:CD012787. https://doi.org/10.1002/14651858. 
CD012787.pub2
418. Liu F, Liu Y, Sun X, Yin Z, Li H, Deng K, et al. Race- and sex-specific association be­
tween alcohol consumption and hypertension in 22 cohort studies: a systematic 
review and meta-analysis. Nutr Metab Cardiovasc Dis 2020;30:1249–59. https://doi. 
org/10.1016/j.numecd.2020.03.018
419. Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. 
Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic 
analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:1015–35. 
https://doi.org/10.1016/s0140-6736(18)31310-2
420. D’Elia L, La Fata E, Galletti F, Scalfi L, Strazzullo P. Coffee consumption and risk of 
hypertension: a dose–response meta-analysis of prospective studies. Eur J Nutr 
2019;58:271–80. https://doi.org/10.1007/s00394-017-1591-z
421. Hodgson JM, Puddey IB, Woodman RJ, Mulder TPJ, Fuchs D, Scott K, et al. Effects of 
black tea on blood pressure: a randomized controlled trial. Arch Intern Med 2012;172: 
186–8. https://doi.org/10.1001/archinte.172.2.186
422. Shah SA, Chu BW, Lacey CS, Riddock IC, Lee M, Dargush AE. Impact of acute energy 
drink consumption on blood pressure parameters: a meta-analysis. Ann Pharmacother 
2016;50:808–15. https://doi.org/10.1177/1060028016656433
423. Shah SA, Szeto AH, Farewell R, Shek A, Fan D, Quach KN, et al. Impact of high vol­
ume energy drink consumption on electrocardiographic and blood pressure para­
meters: a randomized trial. J Am Heart Assoc 2019;8:e011318. https://doi.org/10. 
1161/jaha.118.011318
424. Basrai M, Schweinlin A, Menzel J, Mielke H, Weikert C, Dusemund B, et al. Energy 
drinks induce acute cardiovascular and metabolic changes pointing to potential risks 
for young adults: a randomized controlled trial. J Nutr 2019;149:441–50. https://doi. 
org/10.1093/jn/nxy303
425. Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage 
consumption and risk of coronary heart disease in women. Am J Clin Nutr 2009;89: 
1037–42. https://doi.org/10.3945/ajcn.2008.27140
426. Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, et al. 
Association between soft drink consumption and mortality in 10 European coun­
tries. JAMA Intern Med 2019;179:1479–90. https://doi.org/10.1001/jamainternmed. 
2019.2478
427. Farhangi MA, Nikniaz L, Khodarahmi M. Sugar-sweetened beverages increases the risk 
of hypertension among children and adolescence: a systematic review and dose–re­
sponse meta-analysis. J Transl Med 2020;18:344. https://doi.org/10.1186/s12967-020- 
02511-9
428. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in 
patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. 
https://doi.org/10.1001/jama.290.1.86
429. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The ef­
fects of a smoking cessation intervention on 14.5-year mortality: a randomized clin­
ical trial. Ann Intern Med 2005;142:233–9. https://doi.org/10.7326/0003-4819-142- 
4-200502150-00005
430. Thomson B, Emberson J, Lacey B, Lewington S, Peto R, Jemal A. Association be­
tween smoking, smoking cessation, and mortality by race, ethnicity, and sex among 
US adults. JAMA Netw Open 2022;5:e2231480. https://doi.org/10.1001/jamanetworkopen. 
2022.31480
431. Yang JJ, Yu D, Shu XO, Wen W, Rahman S, Abe S. Reduction in total and major cause- 
specific mortality from tobacco smoking cessation: a pooled analysis of 16 population- 
based cohort studies in Asia. Int J Epidemiol 2022;50:2070–81. https://doi.org/10.1093/ 
ije/dyab087
432. Martinez-Morata I, Sanchez TR, Shimbo D, Navas-Acien A. Electronic cigarette use and 
blood pressure endpoints: a systematic review. Curr Hypertens Rep 2020;23:2. https:// 
doi.org/10.1007/s11906-020-01119-0
433. Kim SY, Jeong SH, Joo HJ, Park M, Park E-C, Kim JH, et al. High prevalence of hyper­
tension among smokers of conventional and e-cigarette: using the nationally represen­
tative community dwelling survey. Front Public Health 2022;10:919585. https://doi.org/ 
10.3389/fpubh.2022.919585
434. Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure in­
crease induced by heavy smoking. J Hypertens 1992;10:495–9. https://doi.org/10.1097/ 
00004872-199205000-00014
435. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between 
smoking and blood pressure: evidence from the health survey for England. 
Hypertension 2001;37:187–93. https://doi.org/10.1161/01.hyp.37.2.187
436. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. 
Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;2013: 
CD000165. https://doi.org/10.1002/14651858.CD000165.pub4
437. Rasmussen M, Lauridsen SV, Pedersen B, Backer V, Tønnesen H. Intensive versus short 
face-to-face smoking cessation interventions: a meta-analysis. Eur Respir Rev 2022;31: 
220063. https://doi.org/10.1183/16000617.0063-2022
438. Filippou CD, Thomopoulos CG, Kouremeti MM, Sotiropoulou LI, Nihoyannopoulos PI, 
Tousoulis DM, et al. Mediterranean diet and blood pressure reduction in adults with 
and without hypertension: a systematic review and meta-analysis of randomized con­
trolled trials. Clin Nutr 2021;40:3191–200. https://doi.org/10.1016/j.clnu.2021.01.030
439. Cowell OR, Mistry N, Deighton K, Matu J, Griffiths A, Minihane AM, et al. Effects of a 
Mediterranean diet on blood pressure: a systematic review and meta-analysis of ran­
domized controlled trials and observational studies. J Hypertens 2021;39:729–39. 
https://doi.org/10.1097/hjh.0000000000002667


<!-- PAGE 94 -->

### Page 94

440. Roerecke M, Tobe SW, Kaczorowski J, Bacon SL, Vafaei A, Hasan OSM, et al. 
Sex-specific associations between alcohol consumption and incidence of hypertension: 
a systematic review and meta-analysis of cohort studies. J Am Heart Assoc 2018;7: 
e008202. https://doi.org/10.1161/jaha.117.008202
441. Ding C, O’Neill D, Bell S, Stamatakis E, Britton A. Association of alcohol consumption 
with morbidity and mortality in patients with cardiovascular disease: original data and 
meta-analysis of 48,423 men and women. BMC Med 2021;19:167. https://doi.org/10. 
1186/s12916-021-02040-2
442. Marklund M, Singh G, Greer R, Cudhea F, Matsushita K, Micha R, et al. Estimated popu­
lation wide benefits and risks in China of lowering sodium through potassium enriched 
salt substitution: modelling study. BMJ 2020;369:m824. https://doi.org/10.1136/bmj.m824
443. Pinho-Gomes AC, Azevedo L, Copland E, Canoy D, Nazarzadeh M, Ramakrishnan R, 
et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in 
patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med 
2021;18:e1003599. https://doi.org/10.1371/journal.pmed.1003599
444. Bidel Z, Nazarzadeh M, Canoy D, Copland E, Gerdts E, Woodward M, et al. 
Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention 
of cardiovascular disease: an individual participant-level data meta-analysis. 
Hypertension 2023;80:2293–302. https://doi.org/10.1161/hypertensionaha.123.21496
445. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood 
pressure-lowering treatment for prevention of major cardiovascular diseases in peo­
ple with and without type 2 diabetes: an individual participant-level data meta-analysis. 
Lancet Diabetes Endocrinol 2022;10:645–54. https://doi.org/10.1016/s2213-8587(22) 
00172-3
446. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out­
come incidence in hypertension: 4. Effects of various classes of antihypertensive 
drugs—overview and meta-analyses. J Hypertens 2015;33:195–211. https://doi.org/ 
10.1097/hjh.0000000000000447
447. Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, et al. 
Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N 
Engl J Med 2022;387:2401–10. https://doi.org/10.1056/NEJMoa2212270
448. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, et al. Beta-blocker 
efficacy across different cardiovascular indications: an umbrella review and 
meta-analytic assessment. BMC Med 2020;18:103. https://doi.org/10.1186/s12916- 
020-01564-3
449. Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: 
overview and meta-analysis of randomized outcome trials. J Hypertens 2020;38: 
1669–81. https://doi.org/10.1097/hjh.0000000000002523
450. Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized beta- 
blocker treatment for high blood pressure dictated by medical comorbidities: indica­
tions beyond the 2018 European Society of Cardiology/European Society of 
Hypertension Guidelines. Hypertension 2022;79:1153–66. https://doi.org/10.1161/ 
hypertensionaha.122.19020
451. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evi­
dence for use of beta-blockers as first-line therapy for hypertension? Systematic re­
view and meta-analysis. J Hypertens 2006;24:2131–41. https://doi.org/10.1097/01.hjh. 
0000249685.58370.28
452. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hyper­
tension. Cochrane Database Syst Rev 2017;1:CD002003. https://doi.org/10.1002/ 
14651858.CD002003.pub5
453. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a net­
work meta-analysis. Lancet 2007;369:201–7. https://doi.org/10.1016/s0140-6736(07) 
60108-1
454. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients 
with hypertension treated with beta blockers to determine the risk of new-onset dia­
betes mellitus. Am J Cardiol 2007;100:1254–62. https://doi.org/10.1016/j.amjcard.2007. 
05.057
455. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent 
morbidity-mortality trials in hypertension. Hypertension 2009;54:388–92. https://doi. 
org/10.1161/hypertensionaha.109.133116
456. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of 
the effects of treatment on left ventricular mass in essential hypertension. Am J Med 
2003;115:41–6. https://doi.org/10.1016/s0002-9343(03)00158-x
457. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al. Calcium antag­
onist lacidipine slows down progression of asymptomatic carotid atherosclerosis: prin­
cipal results of the European Lacidipine Study on Atherosclerosis (ELSA), a 
randomized, double-blind, long-term trial. Circulation 2002;106:2422–7. https://doi. 
org/10.1161/01.cir.0000039288.86470.dd
458. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhib­
ition and beta-blockade for 2 years on function of small arteries from hypertensive pa­
tients. Hypertension 1995;25:699–703. https://doi.org/10.1161/01.hyp.25.4.699
459. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. 
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal 
treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double- 
blind, crossover trial. Lancet 2015;386:2059–68. https://doi.org/10.1016/s0140- 
6736(15)00257-3
460. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and 
kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney 
disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–84. https://doi.org/10. 
1093/eurheartj/ehab777
461. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, et al. Effect 
of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 dia­
betes. J Hypertens 2023;41:295–302. https://doi.org/10.1097/hjh.0000000000003330
462. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finere­
none on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383: 
2219–29. https://doi.org/10.1056/NEJMoa2025845
463. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research 
Group. Major cardiovascular events in hypertensive patients randomized to doxa­
zosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to pre­
vent heart attack trial (ALLHAT). JAMA 2000;283:1967–75. https://doi.org/10. 
1001/jama.283.15.1967
464. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure 
reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and 
neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. 
Lancet 2010;375:1255–66. https://doi.org/10.1016/s0140-6736(09)61966-8
465. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin– 
neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. 
https://doi.org/10.1056/NEJMoa1409077
466. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/ 
valsartan versus olmesartan in Japanese patients with essential hypertension: a rando­
mized, double-blind, multicenter study. Hypertens Res 2022;45:824–33. https://doi.org/ 
10.1038/s41440-021-00819-7
467. Jackson AM, Jhund PS, Anand IS, Düngen H-D, Lam CSP, Lefkowitz MP, et al. 
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients 
with heart failure and preserved ejection fraction. Eur Heart J 2021;42:3741–52. 
https://doi.org/10.1093/eurheartj/ehab499
468. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy 
and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian 
patients with hypertension: a randomized, double-blind, placebo-controlled study. 
Hypertension 2014;63:698–705. https://doi.org/10.1161/hypertensionaha.113.02002
469. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sa­
cubitril/valsartan versus olmesartan on central hemodynamics in the elderly with sys­
tolic hypertension: the PARAMETER study. Hypertension 2017;69:411–20. https://doi. 
org/10.1161/hypertensionaha.116.08556
470. Herrington WG, Savarese G, Haynes R, Marx N, Mellbin L, Lund LH, et al. Cardiac, 
renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a pos­
ition paper from the European Society of Cardiology ad-hoc task force on sodium- 
glucose co-transporter 2 inhibitors. Eur J Heart Fail 2021;23:1260–75. https://doi. 
org/10.1002/ejhf.2286
471. Gupta R, Maitz T, Egeler D, Mehta A, Nyaeme M, Hajra A, et al. SGLT2 inhibitors in 
hypertension: role beyond diabetes and heart failure. Trends Cardiovasc Med 2022; 
33:479–86. https://doi.org/10.1016/j.tcm.2022.05.005
472. Kario K, Ferdinand KC, Vongpatanasin W. Are SGLT2 inhibitors new hyperten­
sion drugs? Circulation 2021;143:1750–3. https://doi.org/10.1161/circulationaha. 
121.053709
473. Yan C, Thijs L, Cao Y, Trenson S, Zhang Z-Y, Janssens S, et al. Opportunities of anti­
diabetic drugs in cardiovascular medicine: a meta-analysis and perspectives for trial 
design. Hypertension 2020;76:420–31. https://doi.org/10.1161/hypertensionaha. 
120.14791
474. Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 
trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 2023;388: 
395–405. https://doi.org/10.1056/NEJMoa2213169
475. Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Aldosterone syn­
thase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN ran­
domized clinical trial. JAMA 2023;330:1140–50. https://doi.org/10.1001/jama.2023. 
16029
476. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. Dual en­
dothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicen­
tre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022;400:1927–37. 
https://doi.org/10.1016/s0140-6736(22)02034-7
477. Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA 
interference therapeutic agent for hypertension. N Engl J Med 2023;389:228–38. 
https://doi.org/10.1056/NEJMoa2208391
478. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment 
with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 
326:1427. https://doi.org/10.1136/bmj.326.7404.1427
479. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more effica­
cious than individual agents—a preliminary report. Hypertension 2007;49:272–5. 
https://doi.org/10.1161/01.HYP.0000254479.66645.a3
480. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus mono­
therapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 
trials. Am J Med 2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038
ESC Guidelines                                                                                                                                                                                          4005


<!-- PAGE 95 -->

### Page 95

481. Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose 
quadruple combination therapy for initial treatment of hypertension: placebo- 
controlled, crossover, randomised trial and systematic review. Lancet 2017;389: 
1035–42. https://doi.org/10.1016/s0140-6736(17)30260-x
482. Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treat­
ment with a single pill containing quadruple combination of quarter doses of blood 
pressure medicines versus standard dose monotherapy in patients with hypertension 
(QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 2021; 
398:1043–52. https://doi.org/10.1016/s0140-6736(21)01922-x
483. Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose 
triple combination antihypertensive medication vs usual care for blood pressure con­
trol in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical 
trial. JAMA 2018;320:566–79. https://doi.org/10.1001/jama.2018.10359
484. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, et al. 
Combination therapy is superior to sequential monotherapy for the initial treatment 
of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6: 
e006986. https://doi.org/10.1161/jaha.117.006986
485. Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of 
dual combination therapy of blood pressure-lowering drugs as initial treatment for 
hypertension: a systematic review and meta-analysis of randomized controlled trials. 
J Hypertens 2019;37:1768–74. https://doi.org/10.1097/hjh.0000000000002096
486. Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting antihy­
pertensive drug treatment with combination therapy: controversies in hypertension— 
con side of the argument. Hypertension 2021;77:788–98. https://doi.org/10.1161/ 
hypertensionaha.120.12858
487. Kahan T. Low-dose combination of blood pressure-lowering medicines. Lancet 2021; 
398:1022–3. https://doi.org/10.1016/s0140-6736(21)01964-4
488. Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and 
therapeutic 
inertia. 
Hypertension 
2018;72:846–53. 
https://doi.org/10.1161/ 
hypertensionaha.118.11308
489. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial 
monotherapy and combination therapy and hypertension control the first year. 
Hypertension 2012;59:1124–31. https://doi.org/10.1161/hypertensionaha.112.194167
490. Sundström J, Lind L, Nowrouzi S, Hagström E, Held C, Lytsy P, et al. Heterogeneity in 
blood pressure response to 4 antihypertensive drugs: a randomized clinical trial. JAMA 
2023;329:1160–9. https://doi.org/10.1001/jama.2023.3322
491. Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination 
therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence 
assessment of recent literature. J Hypertens 2020;38:1016–28. https://doi.org/10.1097/ 
hjh.0000000000002381
492. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free- 
equivalent combination therapy in hypertension: a systematic review and meta-analysis. 
Hypertension 2021;77:692–705. https://doi.org/10.1161/hypertensionaha.120.15781
493. Egan BM, Kjeldsen SE, Narkiewicz K, Kreutz R, Burnier M. Single-pill combinations, 
hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood 
Press 2022;31:164–8. https://doi.org/10.1080/08037051.2022.2095254
494. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without aspirin 
in persons without cardiovascular disease. N Engl J Med 2021;384:216–28. https://doi. 
org/10.1056/NEJMoa2028220
495. Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. 
Effectiveness of polypill for primary and secondary prevention of cardiovascular dis­
eases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:672–83. 
https://doi.org/10.1016/s0140-6736(19)31791-x
496. Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination 
therapies with and without aspirin for primary prevention of cardiovascular disease: an 
individual participant data meta-analysis. Lancet 2021;398:1133–46. https://doi.org/10. 
1016/s0140-6736(21)01827-4
497. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad J-J, et al. 
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a 
meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system in­
hibitors involving 158 998 patients. Eur Heart J 2012;33:2088–97. https://doi.org/10. 
1093/eurheartj/ehs075
498. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367: 
2204–13. https://doi.org/10.1056/NEJMoa1208799
499. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. 
Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J 
Med 2013;369:1892–903. https://doi.org/10.1056/NEJMoa1303154
500. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, 
or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. 
https://doi.org/10.1056/NEJMoa0801317
501. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose 
combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55: 
399–407. https://doi.org/10.1161/hypertensionaha.109.139816
502. Gnanenthiran SR, Wang N, Di Tanna GL, Salam A, Webster R, de Silva HA, et al. 
Association of low-dose triple combination therapy vs usual care with time at target 
blood pressure: a secondary analysis of the TRIUMPH randomized clinical trial. 
JAMA Cardiol 2022;7:645–50. https://doi.org/10.1001/jamacardio.2022.0471
503. Tam TS, Wu MH, Masson SC, Tsang MP, Stabler SN, Kinkade A, et al. Eplerenone for 
hypertension. Cochrane Database Syst Rev 2017;2:CD008996. https://doi.org/10.1002/ 
14651858.CD008996.pub2
504. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007; 
9:269–77. https://doi.org/10.1007/s11906-007-0050-2
505. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin 
Hypertens (Greenwich) 2004;6:283–7. https://doi.org/10.1111/j.1524-6175.2004.03585.x
506. Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for 
cardiovascular disease prevention in an underserved population. N Engl J Med 2019; 
381:1114–23. https://doi.org/10.1056/NEJMoa1815359
507. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. 
Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 
967–77. https://doi.org/10.1056/NEJMoa2208275
508. González-Juanatey JR, Cordero A, Castellano JM, Masana L, Dalmau R, Ruiz E, et al. The 
CNIC-polypill reduces recurrent major cardiovascular events in real-life secondary 
prevention patients in Spain: the NEPTUNO study. Int J Cardiol 2022;361:116–23. 
https://doi.org/10.1016/j.ijcard.2022.05.015
509. Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. 
Cost-effectiveness analysis of use of a polypill versus usual care or best practice for 
primary prevention in people at high risk of cardiovascular disease. PLoS One 2017; 
12:e0182625. https://doi.org/10.1371/journal.pone.0182625
510. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and 
self-management in the control of hypertension (TASMINH2): a randomised controlled 
trial. Lancet 2010;376:163–72. https://doi.org/10.1016/s0140-6736(10)60964-6
511. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve con­
trol of blood pressure in people with hypertension: systematic review and 
meta-analysis. BMJ 2010;341:c3995. https://doi.org/10.1136/bmj.c3995
512. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. 
Cardiovascular outcomes in adults with hypertension with evening versus morning 
dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, 
open-label, blinded-endpoint clinical trial. Lancet 2022;400:1417–25. https://doi.org/ 
10.1016/s0140-6736(22)01786-x
513. Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to improve 
medication adherence in hypertensive patients: systematic review and meta-analysis. 
Curr Hypertens Rep 2015;17:94. https://doi.org/10.1007/s11906-015-0606-5
514. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discon­
tinuation of antihypertensive treatment by two-drug combination as first step. 
Evidence from daily life practice. J Hypertens 2010;28:1584–90. https://doi.org/10. 
1097/HJH.0b013e328339f9fa
515. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. 
Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: 
the ReHOT randomized study (resistant hypertension optimal treatment). 
Hypertension 2018;71:681–90. https://doi.org/10.1161/hypertensionaha.117.10662
516. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. 
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure 
responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. 
Lancet Diabetes Endocrinol 2018;6:464–75. https://doi.org/10.1016/s2213-8587(18) 
30071-8
517. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal out­
comes with telmisartan, ramipril, or both, in people at high vascular risk (the 
ONTARGET study): a multicentre, randomised, double-blind, controlled trial. 
Lancet 2008;372:547–53. https://doi.org/10.1016/s0140-6736(08)61236-2
518. Jones DW, Whelton PK, Allen N, Clark D III, Gidding SS, Muntner P, et al. Management 
of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: fill­
ing a guidance gap: a scientific statement from the American Heart Association. 
Hypertension 2021;77:e58–67. https://doi.org/10.1161/hyp.0000000000000195
519. Ali DH, Kiliç B, Hart HE, Bots ML, Biermans MCJ, Spiering W, et al. Therapeutic inertia 
in the management of hypertension in primary care. J Hypertens 2021;39:1238–45. 
https://doi.org/10.1097/hjh.0000000000002783
520. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. 
Effects of comprehensive lifestyle modification on blood pressure control: main results 
of the PREMIER clinical trial. JAMA 2003;289:2083–93. https://doi.org/10.1001/jama. 
289.16.2083
521. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, et al. Effects of protein, 
monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: re­
sults of the OmniHeart randomized trial. JAMA 2005;294:2455–64. https://doi.org/10. 
1001/jama.294.19.2455
522. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment 
on outcome incidence. 12. Effects in individuals with high-normal and normal blood 
pressure: overview and meta-analyses of randomized trials. J Hypertens 2017;35: 
2150–60. https://doi.org/10.1097/hjh.0000000000001547
523. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow 
GM, et al. Intensive vs standard blood pressure control and cardiovascular disease


<!-- PAGE 96 -->

### Page 96

outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315: 
2673–82. https://doi.org/10.1001/jama.2016.7050
524. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, et al. Subgroup and per- 
protocol analyses from the hypertension in the very elderly trial. J Hypertens 2014;32: 
1478–87; discussion 1487. https://doi.org/10.1097/hjh.0000000000000195
525. Jowett S, Kodabuckus S, Ford GA, Hobbs FDR, Lown M, Mant J, et al. 
Cost-effectiveness of antihypertensive deprescribing in primary care: a Markov mod­
elling study using data from the OPTiMISE trial. Hypertension 2022;79:1122–31. https:// 
doi.org/10.1161/hypertensionaha.121.18726
526. Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, et al. Achieved 
blood pressure and outcomes in the secondary prevention of small subcortical 
strokes trial. Hypertension 2016;67:63–9. https://doi.org/10.1161/hypertensionaha. 
115.06480
527. Chen T, Shao F, Chen K, Wang Y, Wu Z, Wang Y, et al. Time to clinical benefit of in­
tensive blood pressure lowering in patients 60 years and older with hypertension: a 
secondary analysis of randomized clinical trials. JAMA Intern Med 2022;182:660–7. 
https://doi.org/10.1001/jamainternmed.2022.1657
528. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. 
Treatment of mild hypertension study. Final results. Treatment of mild hyperten­
sion study research group. JAMA 1993;270:713–24. https://doi.org/10.1001/jama. 
1993.03510060059034
529. Wu J, Kraja AT, Oberman A, Lewis C, Ellison R, Arnett D, et al. A summary of the ef­
fects of antihypertensive medications on measured blood pressure. Am J Hypertens 
2005;18:935–42. https://doi.org/10.1016/j.amjhyper.2005.01.011
530. Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes A-C, Salam A, 
et al. Antihypertensive drug effects on long-term blood pressure: an individual-level 
data meta-analysis of randomised clinical trials. Heart 2022;108:1281–9. https://doi. 
org/10.1136/heartjnl-2021-320171
531. Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S, et al. Treatment 
efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic 
review and meta-analysis of randomized clinical trials according to PRISMA statement. 
Medicine (Baltimore) 2016;95:e4071. https://doi.org/10.1097/md.0000000000004071
532. Morales-Salinas A, Kones R. Concerning the degradation of β-blocker use in the 2018 
ESC/ESH hypertension guidelines. Eur Heart J 2019;40:2091. https://doi.org/10.1093/ 
eurheartj/ehz125
533. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in 
the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545–53. 
https://doi.org/10.1016/s0140-6736(05)67573-3
534. Larochelle P, Tobe SW, Lacourcière Y. β-Blockers in hypertension: studies and 
meta-analyses over the years. Can J Cardiol 2014;30:S16–22. https://doi.org/10.1016/ 
j.cjca.2014.02.012
535. Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, et al. 
Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ 
ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and manage­
ment of high blood pressure in adults: a report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
Hypertension 2018;71:e116–35. https://doi.org/10.1161/hyp.0000000000000067
536. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst 
Rev 2018;4:CD001841. https://doi.org/10.1002/14651858.CD001841.pub3
537. Johnston GD. Dose-response relationships with antihypertensive drugs. Pharmacol 
Ther 1992;55:53–93. https://doi.org/10.1016/0163-7258(92)90029-y
538. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention 
of cardiovascular disease: meta-analysis of 147 randomised trials in the context of ex­
pectations from prospective epidemiological studies. BMJ 2009;338:b1665. https://doi. 
org/10.1136/bmj.b1665
539. Messerli FH, Bangalore S, Schmieder RE. Wilder’s principle: pre-treatment value deter­
mines post-treatment response. Eur Heart J 2015;36:576–9. https://doi.org/10.1093/ 
eurheartj/ehu467
540. Lasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive 
medication? Systematic review modelling blood pressure response from trial data. 
Heart 2011;97:1771–5. https://doi.org/10.1136/hrt.2010.221473
541. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out­
come incidence in hypertension. 1. Overview, meta-analyses, and meta-regression 
analyses of randomized trials. J Hypertens 2014;32:2285–95. https://doi.org/10.1097/ 
hjh.0000000000000378
542. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus 
tight control of systolic blood pressure in non-diabetic patients with hypertension 
(Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525–33. https://doi. 
org/10.1016/s0140-6736(09)61340-4
543. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. 
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised 
trial. Lancet 2013;382:507–15. https://doi.org/10.1016/s0140-6736(13)60852-1
544. Vaduganathan M, Claggett BL, Juraschek SP, Solomon SD. Assessment of long-term 
benefit of intensive blood pressure control on residual life span: secondary analysis 
of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol 2020;5: 
576–81. https://doi.org/10.1001/jamacardio.2019.6192
545. Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, et al. Final report of 
a trial of intensive versus standard blood-pressure control. N Engl J Med 2021;384: 
1921–30. https://doi.org/10.1056/NEJMoa1901281
546. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, et al. 
Influence of baseline diastolic blood pressure on effects of intensive compared with 
standard blood pressure control. Circulation 2018;137:134–43. https://doi.org/10. 
1161/circulationaha.117.030848
547. McEvoy JW, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, et al. 
Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood 
pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:329–38. 
https://doi.org/10.1001/jama.2019.21402
548. Jacobsen AP, Al Rifai M, Arps K, Whelton SP, Budoff MJ, Nasir K, et al. A cohort study 
and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide 
treatment. Eur Heart J 2021;42:2119–29. https://doi.org/10.1093/eurheartj/ehab111
549. McEvoy JW, Yang WY, Thijs L, Zhang Z-Y, Melgarejo JD, Boggia J, et al. Isolated diastol­
ic hypertension in the IDACO study: an age-stratified analysis using 24-hour ambula­
tory blood pressure measurements. Hypertension 2021;78:1222–31. https://doi.org/ 
10.1161/hypertensionaha.121.17766
550. Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association be­
tween antihypertensive treatment and adverse events: systematic review and 
meta-analysis. BMJ 2021;372:n189. https://doi.org/10.1136/bmj.n189
551. Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM, et al. Personalized 
medicine-a modern approach for the diagnosis and management of hypertension. Clin 
Sci (Lond) 2017;131:2671–85. https://doi.org/10.1042/cs20160407
552. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, et al. Plasma renin 
test–guided drug treatment algorithm for correcting patients with treated but uncon­
trolled hypertension: a randomized controlled trial. Am J Hypertens 2009;22:792–801. 
https://doi.org/10.1038/ajh.2009.63
553. Huang KY, Tseng PT, Wu YC, Tu Y-K, Stubbs B, Su K-P, et al. Do beta-adrenergic block­
ing agents increase asthma exacerbation? A network meta-analysis of randomized con­
trolled trials. Sci Rep 2021;11:452. https://doi.org/10.1038/s41598-020-79837-3
554. Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective 
β1-blockers in asthma: literature review and search of global pharmacovigilance safety re­
ports. ERJ Open Res 2021;7:00801-2020. https://doi.org/10.1183/23120541.00801-2020
555. Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs 
and risk of cancer. Pharmacoepidemiol Drug Saf 2008;17:1039–49. https://doi.org/10. 
1002/pds.1656
556. Zhang Y, Song M, Chan AT, Meyerhardt JA, Willett WC, Giovannucci EL. Long-term 
use of antihypertensive medications, hypertension and colorectal cancer risk and mor­
tality: a prospective cohort study. Br J Cancer 2022;127:1974–82. https://doi.org/10. 
1038/s41416-022-01975-4
557. Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog 
Cardiovasc Dis 2006;49:16–25. https://doi.org/10.1016/j.pcad.2006.06.002
558. Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability: clinical relevance 
and application. J Clin Hypertens (Greenwich) 2018;20:1133–7. https://doi.org/10. 
1111/jch.13304
559. Schutte AE, Kollias A, Stergiou GS. Blood pressure and its variability: classic and novel 
measurement techniques. Nat Rev Cardiol 2022;19:643–54. https://doi.org/10.1038/ 
s41569-022-00690-0
560. Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for ar­
terial hypertension. Nat Rev Cardiol 2020;17:614–28. https://doi.org/10.1038/ 
s41569-020-0364-1
561. Mahfoud F, Schlaich MP, Lobo MD. Device therapy of hypertension. Circ Res 2021;128: 
1080–99. https://doi.org/10.1161/circresaha.121.318091
562. DiBona GF. Sympathetic nervous system and hypertension. Hypertension 2013;61: 
556–60. https://doi.org/10.1161/hypertensionaha.111.00633
563. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal de­
nervation. Am J Physiol Regul Integr Comp Physiol 2010;298:R245–253. https://doi.org/ 
10.1152/ajpregu.00647.2009
564. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of 
catheter-based renal denervation in the absence of antihypertensive medications 
(SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. 
Lancet 2020;395:1444–51. https://doi.org/10.1016/s0140-6736(20)30554-7
565. Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, et al. The REDUCE 
HTN: REINFORCE: randomized, sham-controlled trial of bipolar radiofrequency renal 
denervation for the treatment of hypertension. JACC Cardiovasc Interv 2020;13: 
461–70. https://doi.org/10.1016/j.jcin.2019.10.061
566. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of 
renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month 
efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept ran­
domised trial. Lancet 2018;391:2346–55. https://doi.org/10.1016/s0140-6736(18) 
30951-6
567. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular 
ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a mul­
ticentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 
391:2335–45. https://doi.org/10.1016/s0140-6736(18)31082-1
ESC Guidelines                                                                                                                                                                                          4007


<!-- PAGE 97 -->

### Page 97

568. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denerv­
ation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a 
randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021;397: 
2476–86. https://doi.org/10.1016/s0140-6736(21)00788-1
569. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of 
renal denervation on kidney function and long-term outcomes: 3-year follow-up 
from the global SYMPLICITY registry. Eur Heart J 2019;40:3474–82. https://doi.org/ 
10.1093/eurheartj/ehz118
570. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, 
et al. Long-term outcomes after catheter-based renal artery denervation for resistant 
hypertension: final follow-up of the randomised SYMPLICITY HTN-3 trial. Lancet 
2022;400:1405–16. https://doi.org/10.1016/s0140-6736(22)01787-1
571. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. 
Long-term efficacy and safety of renal denervation in the presence of antihypertensive 
drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 
399:1401–10. https://doi.org/10.1016/s0140-6736(22)00455-x
572. Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, et al. Durability of blood pres­
sure reduction after ultrasound renal denervation: three-year follow-up of the treat­
ment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention 2022;18: 
e677–85. https://doi.org/10.4244/eij-d-22-00305
573. Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Götzinger F, et al. 
10-year outcomes of catheter-based renal denervation in patients with resistant hyper­
tension. J Am Coll Cardiol 2023;81:517–9. https://doi.org/10.1016/j.jacc.2022.11.038
574. Stone P, Campbell J, Thompson S, Walker J. A prospective, randomized study compar­
ing ultrasound versus fluoroscopic guided femoral arterial access in noncardiac vascu­
lar patients. J Vasc Surg 2020;72:259–67. https://doi.org/10.1016/j.jvs.2019.09.051
575. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al. Radial versus femoral 
access for coronary angiography and intervention in patients with acute coronary syn­
dromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377: 
1409–20. https://doi.org/10.1016/s0140-6736(11)60404-2
576. Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, et al. Review and 
meta-analysis of renal artery damage following percutaneous renal denervation with 
radiofrequency renal artery ablation. EuroIntervention 2020;16:89–96. https://doi.org/ 
10.4244/eij-d-19-00902
577. Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, et al. Renal safety 
of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial 
Transplant 2017;32:1440–7. https://doi.org/10.1093/ndt/gfx088
578. Ahmad Y, Francis DP, Bhatt DL, Howard JP. Renal denervation for hypertension: a sys­
tematic review and meta-analysis of randomized, blinded, placebo-controlled trials. 
JACC Cardiovasc Interv 2021;14:2614–24. https://doi.org/10.1016/j.jcin.2021.09.020
579. Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Cost-effectiveness of renal de­
nervation therapy for treatment-resistant hypertension: a best case scenario. Am J 
Hypertens 2018;31:1156–63. https://doi.org/10.1093/ajh/hpy108
580. Sharp ASP, Cao KN, Esler MD, Kandzari DE, Lobo MD, Schmieder RE, et al. 
Cost-effectiveness of catheter-based radiofrequency renal denervation for the treat­
ment of uncontrolled hypertension: an analysis for the UK based on recent clinical evi­
dence. Eur Heart J Qual Care Clin Outcomes 2024:qcae001. https://doi.org/10.1093/ 
ehjqcco/qcae001
581. Fengler K, Reimann P, Rommel KP, Kresoja K-P, Blazek S, Unterhuber M, et al. 
Comparison of long-term outcomes for responders versus non-responders following 
renal denervation in resistant hypertension. J Am Heart Assoc 2021;10:e022429. https:// 
doi.org/10.1161/jaha.121.022429
582. Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. 
Cardiovascular risk reduction after renal denervation according to time in therapeutic 
systolic blood pressure range. J Am Coll Cardiol 2022;80:1871–80. https://doi.org/10. 
1016/j.jacc.2022.08.802
583. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. ESC guidelines 
for the management of acute coronary syndromes. Eur Heart J 2023;44:3720–826. 
https://doi.org/10.1093/eurheartj/ehad191
584. Singh RR, Denton KM. Renal denervation. Hypertension 2018;72:528–36. https://doi. 
org/10.1161/hypertensionaha.118.10265
585. Barbato E, Azizi M, Schmieder RE, Lauder L, Böhm M, Brouwers S, et al. Renal denerv­
ation in the management of hypertension in adults. A clinical consensus statement of 
the ESC Council on Hypertension and the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI). Eur Heart J 2023;44:1313–30. https://doi.org/ 
10.1093/eurheartj/ehad054
586. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A con­
trolled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370: 
1393–401. https://doi.org/10.1056/NEJMoa1402670
587. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, et al. Randomized 
sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. 
Hypertension 2015;65:1202–8. https://doi.org/10.1161/hypertensionaha.115.05283
588. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, et al. Renal 
denervation in treatment-resistant essential hypertension. A randomized, 
SHAM-controlled, double-blinded 24–h blood pressure-based trial. J Hypertens 
2016;34:1639–47. https://doi.org/10.1097/hjh.0000000000000977
589. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. 
Catheter-based renal denervation in patients with uncontrolled hypertension in the 
absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, 
sham-controlled, proof-of-concept trial. Lancet 2017;390:2160–70. https://doi.org/ 
10.1016/s0140-6736(17)32281-x
590. Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. 
Catheter-based ultrasound renal denervation in patients with resistant hypertension: 
the randomized, controlled REQUIRE trial. Hypertens Res 2022;45:221–31. https://doi. 
org/10.1038/s41440-021-00754-7
591. Neuzil P, Merkely B, Erglis A, Marinskis G, de Groot JR, Schmidinger H, et al. 
Pacemaker-mediated programmable hypertension control therapy. J Am Heart Assoc 
2017;6:e006974. https://doi.org/10.1161/jaha.117.006974
592. Kalarus Z, Merkely B, Neužil P, Grabowski M, Mitkowski P, Marinskis G, et al. 
Pacemaker-based cardiac neuromodulation therapy in patients with hypertension: 
a pilot study. J Am Heart Assoc 2021;10:e020492. https://doi.org/10.1161/jaha.120. 
020492
593. Musini VM, Tejani AM, Bassett K, Puil L, Wright JM. Pharmacotherapy for hypertension 
in adults 60 years or older. Cochrane Database Syst Rev 2019;6:CD000028. https://doi. 
org/10.1002/14651858.CD000028.pub3
594. Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hyper­
tension in adults aged 18 to 59 years. Cochrane Database Syst Rev 2017;8:CD008276. 
https://doi.org/10.1002/14651858.CD008276.pub2
595. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment 
in hypertension: 9. Discontinuations for adverse events attributed to different classes 
of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016;34: 
1921–32. https://doi.org/10.1097/hjh.0000000000001052
596. Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older 
patients. Circ Res 2019;124:1045–60. https://doi.org/10.1161/circresaha.118.313236
597. Frey L, Gravestock I, Pichierri G, Steurer J, Burgstaller JM. Serious adverse events in 
patients with target-oriented blood pressure management: a systematic review. 
J Hypertens 2019;37:2135–44. https://doi.org/10.1097/hjh.0000000000002176
598. Palmer SC, Sciancalepore M, Strippoli GF. Trial quality in nephrology: how are we 
measuring up? Am J Kidney Dis 2011;58:335–7. https://doi.org/10.1053/j.ajkd.2011. 
06.006
599. Carriazo S, Sarafidis P, Ferro CJ, Ortiz A. Blood pressure targets in CKD 2021: the 
never-ending guidelines debacle. Clin Kidney J 2022;15:845–51. https://doi.org/10. 
1093/ckj/sfac014
600. Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global preva­
lence of erectile dysfunction: a review. BJU Int 2019;124:587–99. https://doi.org/10. 
1111/bju.14813
601. Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a pro­
posed management algorithm. J Clin Hypertens (Greenwich) 2006;8:359–64. https://doi. 
org/10.1111/j.1524-6175.2005.05285.x
602. Ismail SB, Noor NM, Hussain NHN, Sulaiman Z, Shamsudin MA, Irfan M. Angiotensin 
receptor blockers for erectile dysfunction in hypertensive men: a brief meta-analysis of 
randomized control trials. Am J Mens Health 2019;13:1557988319892735. https://doi. 
org/10.1177/1557988319892735
603. Lawson AJ, Hameed MA, Brown R, Cappuccio FP, George S, Hinton T, et al. 
Nonadherence to antihypertensive medications is related to pill burden in apparent 
treatment-resistant hypertensive individuals. J Hypertens 2020;38:1165–73. https:// 
doi.org/10.1097/hjh.0000000000002398
604. Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, et al. 
Medication adherence and blood pressure control: a scientific statement from the 
American heart association. Hypertension 2022;79:e1–14. https://doi.org/10.1161/ 
hyp.0000000000000203
605. Liao CT, Toh HS, Sun L, Yang C-T, Hu A, Wei D, et al. Cost-effectiveness of intensive 
vs standard blood pressure control among older patients with hypertension. JAMA 
Netw Open 2023;6:e230708. https://doi.org/10.1001/jamanetworkopen.2023.0708
606. O’Donoghue P, O’Halloran AM, Kenny RA, Romero-Ortuno R. Do the frail experi­
ence more adverse events from intensive blood pressure control? A 2-year prospect­
ive study in the Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine 2022;45: 
101304. https://doi.org/10.1016/j.eclinm.2022.101304
607. Sexton DJ, Canney M, O’Connell MDL, Moore P, Little MA, O’Seaghdha CM, et al. 
Injurious falls and syncope in older community-dwelling adults meeting inclusion cri­
teria for SPRINT. JAMA Intern Med 2017;177:1385–7. https://doi.org/10.1001/ 
jamainternmed.2017.2924
608. Masoli JAH, Sheppard JP, Rajkumar C. Hypertension management in older patients-are 
the guideline blood pressure targets appropriate? Age Ageing 2022;51:afab226. https:// 
doi.org/10.1093/ageing/afab226
609. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi­
ology: definition, assessment and clinical implications for general cardiology. A consen­
sus document of the Council for Cardiology Practice (CCP), Association for Acute 
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied 
Professions (ACNAP), European Association of Preventive Cardiology (EAPC), 
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases 
(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO),


<!-- PAGE 98 -->

### Page 98

Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, 
WG Thrombosis, of the European Society of Cardiology, European Primary Care 
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10. 
1093/eurjpc/zwaa167
610. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association 
of blood pressure lowering with incident dementia or cognitive impairment: a system­
atic review and meta-analysis. JAMA 2020;323:1934–44. https://doi.org/10.1001/jama. 
2020.4249
611. Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C, et al. Blood pressure low­
ering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J 
2022;43:4980–90. https://doi.org/10.1093/eurheartj/ehac584
612. Pathak A, Poulter NR, Kavanagh M, Kreutz R, Burnier M. Improving the management of 
hypertension by tackling awareness, adherence, and clinical inertia: a symposium re­
port. Am J Cardiovasc Drugs 2022;22:251–61. https://doi.org/10.1007/s40256-021- 
00505-6
613. Sheppard JP, Lown M, Burt J, Temple E, Lowe R, Ashby H, et al. Generalizability of 
blood pressure lowering trials to older patients: cross-sectional analysis. J Am Geriatr 
Soc 2020;68:2508–15. https://doi.org/10.1111/jgs.16749
614. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment 
in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug 
events—meta-analyses of randomized trials. J Hypertens 2016;34:1451–63. https://doi. 
org/10.1097/hjh.0000000000000972
615. Jordan J, Tank J, Reuter H. Risk-benefit assessment of intense blood pressure lowering. 
Hypertension 2019;74:1302–4. https://doi.org/10.1161/hypertensionaha.119.13835
616. Rietz H, Pennlert J, Nordström P, Brunström M. Prevalence, time-trends and clinical 
characteristics of hypertension in young adults: nationwide cross-sectional study of 
1.7 million Swedish 18-year-olds, 1969–2010. J Hypertens 2022;40:1231–8. https:// 
doi.org/10.1097/hjh.0000000000003141
617. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among 
adults aged 18 and over: United States, 2017–2018. NCHS Data Brief 2020;364:1–8.
618. O’Neil A, Scovelle AJ, Milner AJ, Kavanagh A. Gender/sex as a social determinant of 
cardiovascular 
risk. 
Circulation 
2018;137:854–64. 
https://doi.org/10.1161/ 
circulationaha.117.028595
619. Bruno RM, Pucci G, Rosticci M, Guarino L, Guglielmo C, Agabiti Rosei C, et al. 
Association between lifestyle and systemic arterial hypertension in young adults: a na­
tional, survey-based, cross-sectional study. High Blood Press Cardiovasc Prev 2016;23: 
31–40. https://doi.org/10.1007/s40292-016-0135-6
620. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, et al. Association of car­
diovascular health metrics with risk of transition to hypertension in non-hypertensive 
young adults. Am J Hypertens 2022;35:858–66. https://doi.org/10.1093/ajh/hpac057
621. Haggart RC, Bartels CM, Smith MA, Johnson HM. Sociodemographics and hyperten­
sion control among young adults with incident hypertension: a multidisciplinary group 
practice observational study. J Hypertens 2018;36:2425–33. https://doi.org/10.1097/ 
hjh.0000000000001872
622. Liu J, Bu X, Wei L, Wang X, Lai L, Dong C, et al. Global burden of cardiovascular dis­
eases attributable to hypertension in young adults from 1990 to 2019. J Hypertens 
2021;39:2488–96. https://doi.org/10.1097/hjh.0000000000002958
623. Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of 
hypertension among young adults in the United States, 1999 to 2014. Hypertension 
2017;70:736–42. https://doi.org/10.1161/hypertensionaha.117.09801
624. Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, et al. Isolated 
systolic hypertension in young and middle-aged adults and 31-year risk for cardiovas­
cular mortality: the Chicago Heart Association Detection Project in Industry study. 
J Am Coll Cardiol 2015;65:327–35. https://doi.org/10.1016/j.jacc.2014.10.060
625. Noilhan C, Barigou M, Bieler L, Amar J, Chamontin B, Bouhanick B, et al. Causes of sec­
ondary hypertension in the young population: a monocentric study. Ann Cardiol Angeiol 
(Paris) 2016;65:159–64. https://doi.org/10.1016/j.ancard.2016.04.016
626. Jones ESW, Esack I, Mangena P, Rayner BL. Hypertension in adolescents and young 
adults referred to a tertiary hypertension clinic in Cape Town, South Africa. 
Medicine (Baltimore) 2020;99:e23137. https://doi.org/10.1097/md.0000000000023137
627. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, et al. 
Prospective study of oral contraceptives and hypertension among women in the 
United States. Circulation 1996;94:483–9. https://doi.org/10.1161/01.cir.94.3.483
628. Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled 
blood pressure among hypertensive women. Contraception 2003;67:19–24. https://doi. 
org/10.1016/s0010-7824(02)00429-8
629. The American College of Obstetricians and Gynecologists. ACOG practice bulletin 
No. 206: use of hormonal contraception in women with coexisting medical conditions. 
Obstet Gynecol 2019;133:e128–50. https://doi.org/10.1097/aog.0000000000003072
630. Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between 
progestin-only contraceptive use and cardiometabolic outcomes: a systematic review 
and meta-analysis. Eur J Prev Cardiol 2018;25:1042–52. https://doi.org/10.1177/ 
2047487318774847
631. Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from 
a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception 
2015;92:439–44. https://doi.org/10.1016/j.contraception.2015.07.014
632. Pappaccogli M, Di Monaco S, Warchoł-Celińska E, Lorthioir A, Amar L, Aparicio LS, 
et al. The European/International Fibromuscular Dysplasia Registry and Initiative 
(FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients. 
Cardiovasc Res 2021;117:950–9. https://doi.org/10.1093/cvr/cvaa102
633. Thompson P, Logan I, Tomson C, Sheerin N, Ellam T. Obesity, sex, race, and early on­
set hypertension: implications for a refined investigation strategy. Hypertension 2020; 
76:859–65. https://doi.org/10.1161/hypertensionaha.120.15557
634. Saladini F, Fania C, Mos L, Mazzer A, Casiglia E, Palatini P. Office pulse pressure is a 
predictor of favorable outcome in young- to middle-aged subjects with stage 1 hyper­
tension. Hypertension 2017;70:537–42. https://doi.org/10.1161/hypertensionaha.117. 
09516
635. Hoeltzenbein M, Tissen-Diabaté T, Fietz AK, Zinke S, Kayser A, Meister R, et al. 
Increased rate of birth defects after first trimester use of angiotensin converting en­
zyme inhibitors—treatment or hypertension related? An observational cohort study. 
Pregnancy Hypertens 2018;13:65–71. https://doi.org/10.1016/j.preghy.2018.04.022
636. Ahmed B, Tran DT, Zoega H, Kennedy SE, Jorm LR, Havard A. Maternal and perinatal 
outcomes associated with the use of renin-angiotensin system (RAS) blockers for 
chronic hypertension in early pregnancy. Pregnancy Hypertens 2018;14:156–61. 
https://doi.org/10.1016/j.preghy.2018.09.010
637. Cífková R, Johnson MR, Kahan T, Brguljan J, Williams B, Coca A, et al. Peripartum man­
agement of hypertension: a position paper of the ESC Council on Hypertension and 
the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother 2020;6: 
384–93. https://doi.org/10.1093/ehjcvp/pvz082
638. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 
International Society for the Study of Hypertension in Pregnancy classification, diagno­
sis & management recommendations for international practice. Pregnancy Hypertens 
2022;27:148–69. https://doi.org/10.1016/j.preghy.2021.09.008
639. Kassebaum NJ, Barber RM, Bhutta ZA, Dandona L, Gething PW, Hay SI, et al. Global, 
regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for 
the Global Burden of Disease Study 2015. The Lancet 2016;388:1775–812. https://doi. 
org/10.1016/S0140-6736(16)31470-2
640. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, et al. 
Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll 
Cardiol 2020;75:2323–34. https://doi.org/10.1016/j.jacc.2020.03.028
641. Heida KY, Franx A, van Rijn BB, Eijkemans MJC, Boer JMA, Verschuren MWM, et al. 
Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hyper­
tensive disorder of pregnancy or gestational diabetes mellitus. Hypertension 2015;66: 
1116–22. https://doi.org/10.1161/hypertensionaha.115.06005
642. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, et al. 
Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. 
J Hypertens 2010;28:826–33. https://doi.org/10.1097/HJH.0b013e328335c29a
643. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. 
Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management 
recommendations for international practice. Hypertension 2018;72:24–43. https://doi. 
org/10.1161/hypertensionaha.117.10803
644. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel 
risk indicator in women with gestational hypertension. J Hypertens 2008;26:295–302. 
https://doi.org/10.1097/HJH.0b013e3282f1a953
645. Davis GK, Roberts LM, Mangos GJ, Brown MA. Comparisons of auscultatory hybrid 
and automated sphygmomanometers with mercury sphygmomanometry in hyperten­
sive and normotensive pregnant women: parallel validation studies. J Hypertens 2015; 
33:499–505; discussion 505–496. https://doi.org/10.1097/hjh.0000000000000420
646. Schmella MJ, Clifton RG, Althouse AD, Roberts JM. Uric acid determination in gesta­
tional hypertension: is it as effective a delineator of risk as proteinuria in high-risk wo­
men? Reprod Sci 2015;22:1212–9. https://doi.org/10.1177/1933719115572477
647. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. 
Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J 
Med 2017;377:613–22. https://doi.org/10.1056/NEJMoa1704559
648. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. BMJ 2008;336: 
968–9. https://doi.org/10.1136/bmj.39540.657928.BE
649. Jeon HR, Jeong DH, Lee JY, Woo EY, Shin GT, Kim S-Y. sFlt-1/PlGF ratio as a predictive 
and prognostic marker for preeclampsia. J Obstet Gynaecol Res 2021;47:2318–23. 
https://doi.org/10.1111/jog.14815
650. Bateman BT, Bansil P, Hernandez-Diaz S, Mhyre JM, Callaghan WM, Kuklina EV. 
Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of de­
livery admissions. Am J Obstet Gynecol 2012;206:134.e1–8. https://doi.org/10.1016/j. 
ajog.2011.10.878
651. Zhou J, Azizan EAB, Cabrera CP, Fernandes-Rosa FL, Boulkroun S, Argentesi G, et al. 
Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone- 
producing adenomas presenting in puberty, pregnancy or menopause. Nat Genet 
2021;53:1360–72. https://doi.org/10.1038/s41588-021-00906-y
652. Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G. Pheochromocytoma and 
pregnancy. Endocrinol Metab Clin North Am 2019;48:605–17. https://doi.org/10.1016/ 
j.ecl.2019.05.006
653. Bancos I, Atkinson E, Eng C, Young WF Jr, Neumann HPH, Yukina M, et al. Maternal and 
fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective 
ESC Guidelines                                                                                                                                                                                          4009


<!-- PAGE 99 -->

### Page 99

cohort study and systematic review of literature. Lancet Diabetes Endocrinol 2021;9: 
13–21. https://doi.org/10.1016/s2213-8587(20)30363-6
654. Martínez-Vizcaíno V, Sanabria-Martínez G, Fernández-Rodríguez R, Cavero-Redondo 
I, Pascual-Morena C, Álvarez-Bueno C, et al. Exercise during pregnancy for preventing 
gestational diabetes mellitus and hypertensive disorders: an umbrella review of rando­
mised controlled trials and an updated meta-analysis. Bjog 2023;130:264–75. https:// 
doi.org/10.1111/1471-0528.17304
655. Mottola MF, Davenport MH, Ruchat SM, Davies GA, Poitras VJ, Gray CE, et al. 2019 
Canadian guideline for physical activity throughout pregnancy. Br J Sports Med 2018;52: 
1339–46. https://doi.org/10.1136/bjsports-2018-100056
656. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for preven­
tion of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369: 
1791–8. https://doi.org/10.1016/s0140-6736(07)60712-0
657. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing 
pre-eclampsia and its complications. Cochrane Database Syst Rev 2019;2019: 
CD004659. https://doi.org/10.1002/14651858.CD004659.pub3
658. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR. Calcium supplementation during preg­
nancy for preventing hypertensive disorders and related problems. Cochrane Database 
Syst Rev 2018;10:CD001059. https://doi.org/10.1002/14651858.CD001059.pub5
659. Dwarkanath P, Muhihi A, Sudfeld CR, Wylie BJ, Wang M, Perumal N, et al. Two ran­
domized trials of low-dose calcium supplementation in pregnancy. N Engl J Med 2024; 
390:143–53. https://doi.org/10.1056/NEJMoa2307212
660. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to 
moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10: 
CD002252. https://doi.org/10.1002/14651858.CD002252.pub4
661. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight ver­
sus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407–17. https:// 
doi.org/10.1056/NEJMoa1404595
662. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 
1976;2:753–6. https://doi.org/10.1016/s0140-6736(76)90597-3
663. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension 
during pregnancy: the effects of specific treatment on the growth and development of 
the children. Lancet 1982;1:647–9. https://doi.org/10.1016/s0140-6736(82)92202-4
664. Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative ef­
ficacy and safety of oral antihypertensive agents in pregnant women with chronic 
hypertension: a network metaanalysis. Am J Obstet Gynecol 2020;223:525–37. 
https://doi.org/10.1016/j.ajog.2020.03.016
665. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies 
complicated by hypertension. Am J Hypertens 1999;12:541–7. https://doi.org/10.1016/ 
s0895-7061(99)00031-x
666. Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a net­
work meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin 
Pharmacol 2018;84:1906–16. https://doi.org/10.1111/bcp.13649
667. Bhat AD, Keasler PM, Kolluru L, Dombrowski MM, Palanisamy A, Singh PM, et al. 
Treatment of acute-onset hypertension in pregnancy: a network meta-analysis of ran­
domized controlled trials comparing anti-hypertensives and route of administration. 
Pregnancy Hypertens 2023;34:74–82. https://doi.org/10.1016/j.preghy.2023.10.005
668. Ehikioya E, Okobi OE, Beeko MAE, Abanga R, Abah NNI, Briggs L, et al. Comparing 
intravenous labetalol and intravenous hydralazine for managing severe gestational 
hypertension. Cureus 2023;15:e42332. https://doi.org/10.7759/cureus.42332
669. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM, et al. 
Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art 
review. J Am Coll Cardiol 2019;73:457–76. https://doi.org/10.1016/j.jacc.2018.10.075
670. Goel A, Maski MR, Bajracharya S, Wenger JB, Zhang D, Salahuddin S, et al. 
Epidemiology and mechanisms of de novo and persistent hypertension in the post­
partum period. Circulation 2015;132:1726–33. https://doi.org/10.1161/circulationaha. 
115.015721
671. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of post- 
pregnancy hypertension in women with a history of hypertensive disorders of 
pregnancy: nationwide cohort study. BMJ 2017;358:j3078. https://doi.org/10. 
1136/bmj.j3078
672. Barrett PM, McCarthy FP, Evans M, Kublickas M, Perry IJ, Stenvinkel P, et al. 
Hypertensive disorders of pregnancy and the risk of chronic kidney disease: a 
Swedish registry-based cohort study. PLoS Med 2020;17:e1003255. https://doi.org/ 
10.1371/journal.pmed.1003255
673. Giorgione V, Ridder A, Kalafat E, Khalil A, Thilaganathan B. Incidence of postpartum 
hypertension within 2 years of a pregnancy complicated by pre-eclampsia: a systematic 
review and meta-analysis. BJOG 2021;128:495–503. https://doi.org/10.1111/1471- 
0528.16545
674. Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers EAP, Roeters van 
Lennep JE, et al. Blood pressure profile 1 year after severe preeclampsia. Hypertension 
2018;71:491–8. https://doi.org/10.1161/hypertensionaha.117.10338
675. Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, et al. Long-term blood pres­
sure control after hypertensive pregnancy following physician-optimized self- 
management: the POP-HT randomized clinical trial. JAMA 2023;330:1991–9. https:// 
doi.org/10.1001/jama.2023.21523
676. van Oostwaard MF, Langenveld J, Schuit E, Papatsonis DNM, Brown MA, Byaruhanga 
RN, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data 
metaanalysis. Am J Obstet Gynecol 2015;212:624.e1–17. https://doi.org/10.1016/j.ajog. 
2015.01.009
677. Brown MA, Mackenzie C, Dunsmuir W, Roberts L, Ikin K, Matthews J, et al. Can we 
predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007;114: 
984–93. https://doi.org/10.1111/j.1471-0528.2007.01376.x
678. Heimberger S, Perdigao JL, Mueller A, Shahul S, Naseem H, Minhas R, et al. Effect of 
blood pressure control in early pregnancy and clinical outcomes in African 
American women with chronic hypertension. Pregnancy Hypertens 2020;20:102–7. 
https://doi.org/10.1016/j.preghy.2020.03.008
679. Salazar MR, Espeche WG, Balbín E, Leiva Sisnieguez CE, Leiva Sisnieguez BC, Stavile 
RN, et al. Office blood pressure values and the necessity of out-of-office measure­
ments in high-risk pregnancies. J Hypertens 2019;37:1838–44. https://doi.org/10. 
1097/hjh.0000000000002140
680. Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy 
outcomes associated with first-trimester exposure to angiotensin-converting enzyme 
inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis. 
Pharmacol Res Perspect 2020;8:e00644. https://doi.org/10.1002/prp2.644
681. Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te 
Winkel B, et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting 
enzyme inhibitors: an observational study. J Hypertens 2020;38:133–41. https://doi.org/ 
10.1097/hjh.0000000000002233
682. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging 2014;9: 
433–41. https://doi.org/10.2147/cia.S45300
683. Rodriguez-Mañas L, Fried LP. Frailty in the clinical scenario. Lancet 2015;385:e7–9. 
https://doi.org/10.1016/s0140-6736(14)61595-6
684. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in 
older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–156. 
https://doi.org/10.1093/gerona/56.3.m146
685. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors 
for 5-year mortality in older adults: the cardiovascular health study. JAMA 1998;279: 
585–92. https://doi.org/10.1001/jama.279.8.585
686. Martens DS, Thijs L, Latosinska A, Trenson S, Siwy J, Zhang Z-Y, et al. Urinary pep­
tidomic profiles to address age-related disabilities: a prospective population study. 
Lancet Healthy Longev 2021;2:e690–703. https://doi.org/10.1016/s2666-7568(21) 
00226-9
687. Monahan KD. Effect of aging on baroreflex function in humans. Am J Physiol Regul Integr 
Comp Physiol 2007;293:R3–r12. https://doi.org/10.1152/ajpregu.00031.2007
688. Paleczny B, Niewiński P, Rydlewska A, Piepoli MF, Borodulin-Nadzieja L, Jankowska 
EA, et al. Age-related reflex responses from peripheral and central chemoreceptors 
in healthy men. Clin Auton Res 2014;24:285–96. https://doi.org/10.1007/s10286- 
014-0263-9
689. Anker D, Santos-Eggimann B, Zwahlen M, Santschi V, Rodondi N, Wolfson C, et al. 
Blood pressure in relation to frailty in older adults: a population-based study. J Clin 
Hypertens (Greenwich) 2019;21:1895–904. https://doi.org/10.1111/jch.13722
690. Ravindrarajah R, Hazra NC, Hamada S, Charlton J, Jackson SHD, Dregan A, et al. 
Systolic blood pressure trajectory, frailty, and all-cause mortality >80 years of age: co­
hort study using electronic health records. Circulation 2017;135:2357–68. https://doi. 
org/10.1161/circulationaha.116.026687
691. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure 
for creating a frailty index. BMC Geriatr 2008;8:24. https://doi.org/10.1186/1471- 
2318-8-24
692. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and val­
idation of an electronic frailty index using routine primary care electronic health re­
cord data. Age Ageing 2016;45:353–60. https://doi.org/10.1093/ageing/afw039
693. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global 
clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489–95. https:// 
doi.org/10.1503/cmaj.050051
694. Nguyen TN, Harris K, Woodward M, Chalmers J, Cooper M, Hamet P, et al. The im­
pact of frailty on the effectiveness and safety of intensive glucose control and blood 
pressure-lowering therapy for people with type 2 diabetes: results from the 
ADVANCE trial. Diabetes Care 2021;44:1622–9. https://doi.org/10.2337/dc20-2664
695. Masoli JAH, Delgado J, Pilling L, Strain D, Melzer D. Blood pressure in frail older adults: 
associations with cardiovascular outcomes and all-cause mortality. Age Ageing 2020;49: 
807–13. https://doi.org/10.1093/ageing/afaa028
696. Aparicio LS, Thijs L, Boggia J, Jacobs L, Barochiner J, Odili AN, et al. Defining thresholds 
for home blood pressure monitoring in octogenarians. Hypertension 2015;66:865–73. 
https://doi.org/10.1161/hypertensionaha.115.05800
697. Gaffney B, Jacobsen AP, Pallippattu AW, Leahy N, McEvoy JW. The diastolic blood 
pressure J-curve in hypertension management: links and risk for cardiovascular disease. 
Integr Blood Press Control 2021;14:179–87. https://doi.org/10.2147/ibpc.S286957
698. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evi­
dence that frailty modifies the positive impact of antihypertensive treatment in 
very elderly people: an investigation of the impact of frailty upon treatment effect 
in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind,


<!-- PAGE 100 -->

### Page 100

placebo-controlled study of antihypertensives in people with hypertension aged 80 
and over. BMC Med 2015;13:78. https://doi.org/10.1186/s12916-015-0328-1
699. Todd OM, Wilkinson C, Hale M, Wong NL, Hall M, Sheppard JP, et al. Is the association 
between blood pressure and mortality in older adults different with frailty? A system­
atic review and meta-analysis. Age Ageing 2019;48:627–35. https://doi.org/10.1093/ 
ageing/afz072
700. Li Y, Thijs L, Zhang ZY, Asayama K, Hansen TW, Boggia J, et al. Opposing age-related 
trends in absolute and relative risk of adverse health outcomes associated with 
out-of-office blood pressure. Hypertension 2019;74:1333–42. https://doi.org/10. 
1161/hypertensionaha.119.12958
701. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of 
hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887–98. 
https://doi.org/10.1056/NEJMoa0801369
702. Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C. Treating hypertension 
in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the 
very elderly trial. Eur Heart J 2014;35:1712–8. https://doi.org/10.1093/eurheartj/eht464
703. Travers J, Romero-Ortuno R, Bailey J, Cooney MT. Delaying and reversing frailty: a sys­
tematic review of primary care interventions. Br J Gen Pract 2019;69:e61–9. https://doi. 
org/10.3399/bjgp18X700241
704. Bogaerts JMK, von Ballmoos LM, Achterberg WP, Gussekloo J, Streit S, van der Ploeg 
MA, et al. Do we AGREE on the targets of antihypertensive drug treatment in older 
adults: a systematic review of guidelines on primary prevention of cardiovascular dis­
eases. Age Ageing 2022;51:afab192. https://doi.org/10.1093/ageing/afab192
705. Sheppard JP, Benetos A, McManus RJ. Antihypertensive deprescribing in older adults: a 
practical guide. Curr Hypertens Rep 2022;24:571–80. https://doi.org/10.1007/s11906- 
022-01215-3
706. McDonnell CC, Rogers KC, Regen SM, Finks SW. The Fall Risk with Alpha blockers 
Given InitiaL dose or Elderly status (FRAGILE) study. Ann Pharmacother 2020;54: 
226–31. https://doi.org/10.1177/1060028019880305
707. Hiremath S, Ruzicka M, Petrcich W, McCallum MK, Hundemer GL, Tanuseputro P, 
et al. Alpha-blocker use and the risk of hypotension and hypotension-related clinical 
events in women of advanced age. Hypertension 2019;74:645–51. https://doi.org/10. 
1161/hypertensionaha.119.13289
708. Li H, Xu TY, Li Y, Chia Y-C, Buranakitjaroen P, Cheng H-M, et al. Role of α1-blockers in 
the current management of hypertension. J Clin Hypertens (Greenwich) 2022;24: 
1180–6. https://doi.org/10.1111/jch.14556
709. Ravindrarajah R, Dregan A, Hazra NC, Hamada S, Jackson SHD, Gulliford MC, et al. 
Declining blood pressure and intensification of blood pressure management among 
people over 80 years: cohort study using electronic health records. J Hypertens 
2017;35:1276–82. https://doi.org/10.1097/hjh.0000000000001291
710. Chun S, Han K, Lee S, Cho M-H, Jeong S-M, Jung H-W, et al. Impact of frailty on the 
relationship between blood pressure and cardiovascular diseases and mortality in 
young-old adults. J Pers Med 2022;12:418. https://doi.org/10.3390/jpm12030418
711. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of 
hypertension: a meta-analysis. CMAJ 2006;174:1737–42. https://doi.org/10.1503/cmaj. 
060110
712. Lavan AH, Gallagher P, Parsons C, O’Mahony D. STOPPFrail (Screening Tool of Older 
Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. 
Age Ageing 2017;46:600–7. https://doi.org/10.1093/ageing/afx005
713. Eeftinck Schattenkerk DW, van Gorp J, Vogt L, Peters RJ, van den Born BH. Isolated 
systolic hypertension of the young and its association with central blood pressure in 
a large multi-ethnic population. The HELIUS study. Eur J Prev Cardiol 2018;25: 
1351–9. https://doi.org/10.1177/2047487318777430
714. Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated 
systolic hypertension among middle-aged and elderly US hypertensives: analysis based 
on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 
2001;37:869–74. https://doi.org/10.1161/01.hyp.37.3.869
715. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, 
et al. Expert consensus document on the measurement of aortic stiffness in daily prac­
tice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445–8. https://doi. 
org/10.1097/HJH.0b013e32834fa8b0
716. The Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave 
velocity in healthy people and in the presence of cardiovascular risk factors: ‘establish­
ing normal and reference values’. Eur Heart J 2010;31:2338–50. https://doi.org/10. 
1093/eurheartj/ehq165
717. Li Y, Wei FF, Thijs L, Boggia J, Asayama K, Hansen TW, et al. Ambulatory hypertension 
subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predic­
tors in 8341 untreated people recruited from 12 populations. Circulation 2014;130: 
466–74. https://doi.org/10.1161/circulationaha.113.004876
718. Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel J-P, et al. Risks of untreat­
ed and treated isolated systolic hypertension in the elderly: meta-analysis of outcome 
trials. Lancet 2000;355:865–72. https://doi.org/10.1016/s0140-6736(99)07330-4
719. McEniery CM, Yasmin, Wallace S, Maki-Petaja K, McDonnell B, Sharman JE, et al. 
Increased stroke volume and aortic stiffness contribute to isolated systolic hyperten­
sion in young adults. Hypertension 2005;46:221–6. https://doi.org/10.1161/01.HYP. 
0000165310.84801.e0
720. Palatini P, Rosei EA, Avolio A, Bilo G, Casiglia E, Ghiadoni L, et al. Isolated systolic 
hypertension in the young: a position paper endorsed by the European Society of 
Hypertension. 
J 
Hypertens 
2018;36:1222–36. 
https://doi.org/10.1097/hjh. 
0000000000001726
721. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 
International Society of Hypertension global hypertension practice guidelines. 
Hypertension 2020;75:1334–57. https://doi.org/10.1161/hypertensionaha.120.15026
722. Yano Y, Chang Kim H, Lee H, Azahar N, Ahmed S, Kitaoka K, et al. Response to iso­
lated diastolic hypertension and risk of cardiovascular disease: controversies in hyper­
tension—con side of the argument. Hypertension 2022;79:1579. https://doi.org/10. 
1161/hypertensionaha.122.19493
723. Jacobsen AP, McKittrick M, Daya N, Al Rifai M, McEvoy JW. Isolated diastolic 
hypertension and risk of cardiovascular disease: controversies in hypertension— 
con side of the argument. Hypertension 2022;79:1571–8. https://doi.org/10.1161/ 
hypertensionaha.122.18458
724. Blank SG, Mann SJ, James GD, West JE, Pickering TG. Isolated elevation of diastolic 
blood pressure. Real or artifactual? Hypertension 1995;26:383–9. https://doi.org/10. 
1161/01.hyp.26.3.383
725. Cho SMJ, Lee H, Koyama S, Zou RS, Schuermans A, Ganesh S, et al. Cumulative dia­
stolic blood pressure burden in normal systolic blood pressure and cardiovascular 
disease. Hypertension 2024;81:273–81. https://doi.org/10.1161/hypertensionaha. 
123.22160
726. Grobman B, Turkson-Ocran RN, Staessen JA, Yu Y-L, Lipsitz LA, Mukamal KJ, et al. 
Body position and orthostatic hypotension in hypertensive adults: results from the 
Syst-Eur trial. Hypertension 2023;80:820–7. https://doi.org/10.1161/hypertensionaha. 
122.20602
727. Juraschek SP, Taylor AA, Wright JT Jr, Evans GW, Miller ER, Plante TB, et al. 
Orthostatic hypotension, cardiovascular outcomes, and adverse events: results 
from SPRINT. Hypertension 2020;75:660–7. https://doi.org/10.1161/hypertensionaha. 
119.14309
728. Juraschek SP, Daya N, Appel LJ, Miller ER, McEvoy JW, Matsushita K, et al. Orthostatic 
hypotension and risk of clinical and subclinical cardiovascular disease in middle-aged 
adults. J Am Heart Assoc 2018;7:e008884. https://doi.org/10.1161/jaha.118.008884
729. Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, et al. Orthostatic hypo­
tension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood 
pressure trial: prevalence, incidence, and prognostic significance. Hypertension 2016; 
68:888–95. https://doi.org/10.1161/hypertensionaha.116.07474
730. Juraschek SP, Hu JR, Cluett JL, Ishak A, Mita C, Lipsitz LA, et al. Effects of intensive 
blood pressure treatment on orthostatic hypotension : a systematic review and indi­
vidual participant-based meta-analysis. Ann Intern Med 2021;174:58–68. https://doi. 
org/10.7326/m20-4298
731. Ylitalo A, Airaksinen KE, Sellin L, Huikuri HV. Effects of combination antihypertensive 
therapy on baroreflex sensitivity and heart rate variability in systemic hypertension. Am 
J Cardiol 1999;83:885–9. https://doi.org/10.1016/s0002-9149(98)01067-4
732. Ganjehei L, Massumi A, Razavi M, Wilson JM. Orthostatic hypotension as a manifest­
ation of vitamin B12 deficiency. Tex Heart Inst J 2012;39:722–3.
733. Shimbo D, Barrett Bowling C, Levitan EB, Deng L, Sim JJ, Huang L, et al. Short-term risk 
of serious fall injuries in older adults initiating and intensifying treatment with antihy­
pertensive medication. Circ Cardiovasc Qual Outcomes 2016;9:222–9. https://doi.org/ 
10.1161/circoutcomes.115.002524
734. Krediet CT, van Lieshout JJ, Bogert LW, Immink RV, Kim Y-S, Wieling W, et al. Leg 
crossing improves orthostatic tolerance in healthy subjects: a placebo-controlled 
crossover study. Am J Physiol Heart Circ Physiol 2006;291:H1768–72. https://doi.org/ 
10.1152/ajpheart.00287.2006
735. Okamoto LE, Diedrich A, Baudenbacher FJ, Harder R, Whitfield JS, Iqbal F, et al. 
Efficacy of servo-controlled splanchnic venous compression in the treatment of ortho­
static hypotension: a randomized comparison with midodrine. Hypertension 2016;68: 
418–26. https://doi.org/10.1161/hypertensionaha.116.07199
736. Okamoto LE, Celedonio JE, Smith EC, Gamboa A, Shibao CA, Diedrich A, et al. Local 
passive heat for the treatment of hypertension in autonomic failure. J Am Heart Assoc 
2021;10:e018979. https://doi.org/10.1161/jaha.120.018979
737. Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G. Type 2 diabetes mel­
litus and risk of coronary heart disease: results of the 10-year follow-up of the 
PROCAM study. Eur J Cardiovasc Prev Rehabil 2007;14:230–6. https://doi.org/10. 
1097/HJR.0b013e3280142037
738. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328: 
1676–85. https://doi.org/10.1056/nejm199306103282306
739. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
740. Pylypchuk R, Wells S, Kerr A, Poppe K, Harwood M, Mehta S, et al. Cardiovascular risk 
prediction in type 2 diabetes before and after widespread screening: a derivation and 
validation study. Lancet 2021;397:2264–74. https://doi.org/10.1016/s0140-6736(21) 
00572-9
741. Danaei G, Fahimi S, Lu Y, Zhou B, Hajifathalian K, Di Cesare M, et al. Effects of diabetes 
definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis 
ESC Guidelines                                                                                                                                                                                          4011


<!-- PAGE 101 -->

### Page 101

of 96 population-based studies with 331288 participants. Lancet Diabetes Endocrinol 
2015;3:624–37. https://doi.org/10.1016/S2213-8587(15)00129-1
742. Wright AK, Suarez-Ortegon MF, Read SH, Kontopantelis E, Buchan I, Emsley R, et al. 
Risk factor control and cardiovascular event risk in people with type 2 diabetes in pri­
mary and secondary prevention settings. Circulation 2020;142:1925–36. https://doi. 
org/10.1161/circulationaha.120.046783
743. Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, Rosengren A, Svensson A-M, 
Miftaraj M, et al. Blood pressure and complications in individuals with type 2 diabetes 
and no previous cardiovascular disease: national population based cohort study. BMJ 
2016;354:i4070. https://doi.org/10.1136/bmj.i4070
744. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pres­
sure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 
2016;352:i717. https://doi.org/10.1136/bmj.i717
745. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering 
in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603–15. 
https://doi.org/10.1001/jama.2014.18574
746. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment 
on outcome incidence in hypertension: 10 – Should blood pressure management differ 
in hypertensive patients with and without diabetes mellitus? Overview and 
meta-analyses of randomized trials. J Hypertens 2017;35:922–44. https://doi.org/10. 
1097/hjh.0000000000001276
747. Rahman F, McEvoy JW, Ohkuma T, Marre M, Hamet P, Harrap S, et al. Effects of blood 
pressure lowering on clinical outcomes according to baseline blood pressure and car­
diovascular risk in patients with type 2 diabetes mellitus. Hypertension 2019;73:1291–9. 
https://doi.org/10.1161/hypertensionaha.118.12414
748. Agashe S, Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist 
Debakey Cardiovasc J 2018;14:251–6. https://doi.org/10.14797/mdcj-14-4-251
749. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, et al. 
Effects of intensive systolic blood pressure lowering on cardiovascular events and mor­
tality in patients with type 2 diabetes mellitus on standard glycemic control and in 
those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. 
J Am Heart Assoc 2018;7:e009326. https://doi.org/10.1161/jaha.118.009326
750. Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW. 
Intensive versus standard blood pressure control in SPRINT-eligible participants of 
ACCORD-BP. Diabetes Care 2017;40:1733–8. https://doi.org/10.2337/dc17-1366
751. Brouwer TF, Vehmeijer JT, Kalkman DN, Berger WR, van den Born B-JH, Peters RJ, 
et al. Intensive blood pressure lowering in patients with and patients without type 2 
diabetes: a pooled analysis from two randomized trials. Diabetes Care 2018;41: 
1142–8. https://doi.org/10.2337/dc17-1722
752. Shi S, Gouskova N, Najafzadeh M, Wei LJ, Kim DH. Intensive versus standard blood 
pressure control in type 2 diabetes: a restricted mean survival time analysis of a ran­
domised controlled trial. BMJ Open 2021;11:e050335. https://doi.org/10.1136/ 
bmjopen-2021-050335
753. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative 
efficacy and safety of blood pressure-lowering agents in adults with diabetes and kid­
ney disease: a network meta-analysis. Lancet 2015;385:2047–56. https://doi.org/10. 
1016/s0140-6736(14)62459-4
754. Ying A, Arima H, Czernichow S, Woodward M, Huxley R, Turnbull F, et al. Effects of 
blood pressure lowering on cardiovascular risk according to baseline body-mass index: 
a meta-analysis of randomised trials. Lancet 2015;385:867–74. https://doi.org/10.1016/ 
s0140-6736(14)61171-5
755. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pres­
sure lowering and risk of new-onset type 2 diabetes: an individual participant data 
meta-analysis. Lancet 2021;398:1803–10. https://doi.org/10.1016/s0140-6736(21) 
01920-6
756. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J, et al. Global bur­
den of hypertension: analysis of worldwide data. Lancet 2005;365:217–23. https://doi. 
org/10.1016/s0140-6736(05)17741-1
757. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C, et al. A single num­
ber for advocacy and communication—worldwide more than 850 million indivi­
duals have kidney diseases. Kidney Int 2019;96:1048–50. https://doi.org/10.1016/j. 
kint.2019.07.012
758. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. 
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality 
for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 coun­
tries and territories. Lancet 2018;392:2052–90. https://doi.org/10.1016/s0140- 
6736(18)31694-5
759. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, De-Sequera-Ortiz P, Fernández-Giráldez 
E, García-Maset R, et al. The Spanish Society of Nephrology (SENEFRO) commentary to 
the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health author­
ities will only magnify the problem. Nefrologia (Engl Ed) 2019;39:29–34. https://doi.org/ 
10.1016/j.nefro.2018.09.002
760. Law JP, Pickup L, Pavlovic D, Townend JN, Ferro CJ. Hypertension and cardiomy­
opathy associated with chronic kidney disease: epidemiology, pathogenesis and 
treatment considerations. J Hum Hypertens 2023;37:1–19. https://doi.org/10. 
1038/s41371-022-00751-4
761. Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney 
Dis 2021;77:110–21. https://doi.org/10.1053/j.ajkd.2020.04.017
762. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 2017; 
389:1238–52. https://doi.org/10.1016/s0140-6736(16)32064-5
763. Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, et al. Blood pressure low­
ering and major cardiovascular events in people with and without chronic kidney dis­
ease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680. https://doi. 
org/10.1136/bmj.f5680
764. Aggarwal R, Petrie B, Bala W, Chiu N. Mortality outcomes with intensive blood pres­
sure targets in chronic kidney disease patients. Hypertension 2019;73:1275–82. https:// 
doi.org/10.1161/hypertensionaha.119.12697
765. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. 
Optimal systolic blood pressure target after SPRINT: insights from a network 
meta-analysis of randomized trials. Am J Med 2017;130:707–19.e8. https://doi.org/ 
10.1016/j.amjmed.2017.01.004
766. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, et al. Effects of intensive 
blood pressure lowering on the progression of chronic kidney disease: a systematic 
review and meta-analysis. CMAJ 2013;185:949–57. https://doi.org/10.1503/cmaj. 
121468
767. Tsai WC, Wu HY, Peng YS, Yang J-Y, Chen H-Y, Chiu Y-L, et al. Association of inten­
sive blood pressure control and kidney disease progression in nondiabetic patients 
with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 
2017;177:792–9. https://doi.org/10.1001/jamainternmed.2017.0197
768. Thompson S, Wiebe N, Padwal RS, Gyenes G, Headley SAE, Radhakrishnan J, et al. The 
effect of exercise on blood pressure in chronic kidney disease: a systematic review and 
meta-analysis of randomized controlled trials. PLoS One 2019;14:e0211032. https://doi. 
org/10.1371/journal.pone.0211032
769. Huang M, Lv A, Wang J, Xu N, Ma G, Zhai Z, et al. Exercise training and outcomes in 
hemodialysis patients: systematic review and meta-analysis. Am J Nephrol 2019;50: 
240–54. https://doi.org/10.1159/000502447
770. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE inhibitor benefit to kidney 
and cardiovascular outcomes for patients with non-dialysis chronic kidney disease 
stages 3–5: a network meta-analysis of randomised clinical trials. Drugs 2020;80: 
797–811. https://doi.org/10.1007/s40265-020-01290-3
771. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of 
chronic kidney disease: the role of blood pressure control, proteinuria, and 
angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern 
Med 2003;139:244–52. https://doi.org/10.7326/0003-4819-139-4-200308190-00006
772. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system 
inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian 
network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016;67:728–41. 
https://doi.org/10.1053/j.ajkd.2015.10.011
773. Wu HY, Huang JW, Lin HJ, Liao W-C, Peng Y-S, Hung K-Y, et al. Comparative effect­
iveness of renin-angiotensin system blockers and other antihypertensive drugs in pa­
tients with diabetes: systematic review and Bayesian network meta-analysis. BMJ 
2013;347:f6008. https://doi.org/10.1136/bmj.f6008
774. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. 
Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 
2021;385:2507–19. https://doi.org/10.1056/NEJMoa2110730
775. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, et al. Implications of 
early decline in eGFR due to intensive BP control for cardiovascular outcomes in 
SPRINT. J Am Soc Nephrol 2019;30:1523–33. https://doi.org/10.1681/asn.2018121261
776. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. 
Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388: 
117–27. https://doi.org/10.1056/NEJMoa2204233
777. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, 
et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 
1436–46. https://doi.org/10.1056/NEJMoa2024816
778. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular 
events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 
385:2252–63. https://doi.org/10.1056/NEJMoa2110956
779. Ku E, McCulloch CE, Inker LA, Tighiouart H, Schaefer F, Wühl E, et al. Intensive BP 
control in patients with CKD and risk for adverse outcomes. J Am Soc Nephrol 
2023;34:385–93. https://doi.org/10.1681/asn.0000000000000072
780. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective 
effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy 
due to type 2 diabetes. N Engl J Med 2001;345:851–60. https://doi.org/10.1056/ 
NEJMoa011303
781. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. 
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 dia­
betes and nephropathy. N Engl J Med 2001;345:861–9. https://doi.org/10.1056/ 
NEJMoa011161
782. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). 
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular fil­
tration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. 
Lancet 1997;349:1857–63. https://doi.org/10.1016/S0140-6736(96)11445-8


<!-- PAGE 102 -->

### Page 102

783. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering 
high blood pressure. Lancet 1987;1:581–4. https://doi.org/10.1016/s0140-6736(87) 
90231-5
784. Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, et al. Relation be­
tween mortality and treated blood pressure in elderly patients with hypertension: re­
port of the European working party on high blood pressure in the elderly. BMJ 1989; 
298:1552–6. https://doi.org/10.1136/bmj.298.6687.1552
785. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved 
blood pressure and cardiovascular outcomes in high-risk patients: results from 
ONTARGET and TRANSCEND trials. Lancet 2017;389:2226–37. https://doi.org/10. 
1016/s0140-6736(17)30754-7
786. Böhm M, Ferreira JP, Mahfoud F, Duarte K, Pitt B, Zannad F, et al. Myocardial reperfu­
sion reverses the J-curve association of cardiovascular risk and diastolic blood pressure 
in patients with left ventricular dysfunction and heart failure after myocardial infarc­
tion: insights from the EPHESUS trial. Eur Heart J 2020;41:1673–83. https://doi.org/ 
10.1093/eurheartj/ehaa132
787. McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. 
Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implica­
tions for blood pressure control. J Am Coll Cardiol 2016;68:1713–22. https://doi.org/ 
10.1016/j.jacc.2016.07.754
788. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 
ESH Guidelines for the management of arterial hypertension The Task Force for the 
management of arterial hypertension of the European Society of Hypertension: 
Endorsed by the International Society of Hypertension (ISH) and the European 
Renal Association (ERA). J Hypertens 2023;41:1874–2071. https://doi.org/10.1097/hjh. 
0000000000003480
789. Carvalho JJ, Baruzzi RG, Howard PF, Poulter N, Alpers M P, Franco L J, et al. Blood 
pressure in four remote populations in the INTERSALT study. Hypertension 1989; 
14:238–46. https://doi.org/10.1161/01.hyp.14.3.238
790. Birrane JP, Foschi M, Sacco S, McEvoy JW. Another nail in the coffin of causality for the 
diastolic blood pressure J curve. Hypertension 2022;79:794–7. https://doi.org/10.1161/ 
hypertensionaha.122.18997
791. Mueller NT, Noya-Alarcon O, Contreras M, Appel LJ, Dominguez-Bello MG. 
Association of age with blood pressure across the lifespan in isolated Yanomami and 
Yekwana villages. JAMA Cardiol 2018;3:1247–9. https://doi.org/10.1001/jamacardio. 
2018.3676
792. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, et al. The influence 
of baseline diastolic blood pressure on the effects of intensive blood pressure lowering 
on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care 
2020;43:1878–84. https://doi.org/10.2337/dc19-2047
793. Shihab S, Boucher RE, Abraham N, Wei G, Beddhu S. Influence of baseline diastolic 
blood pressure on the effects of intensive systolic blood pressure lowering on the 
risk of stroke. Hypertension 2022;79:785–93. https://doi.org/10.1161/hypertensionaha. 
121.18172
794. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ 
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 
561–632. https://doi.org/10.1093/eurheartj/ehab395
795. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368
796. Mancusi C, de Simone G, Brguljan Hitij J, Sudano I, Mahfoud F, Parati G, et al. 
Management of patients with combined arterial hypertension and aortic valve stenosis: 
a consensus document from the Council on Hypertension and Council on Valvular 
Heart Disease of the European Society of Cardiology, the European Association of 
Cardiovascular Imaging (EACVI), and the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother 2021;7: 
242–50. https://doi.org/10.1093/ehjcvp/pvaa040
797. Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, et al. Assessing 
optimal blood pressure in patients with asymptomatic aortic valve stenosis: the simvas­
tatin ezetimibe in aortic stenosis study (SEAS). Circulation 2016;134:455–68. https:// 
doi.org/10.1161/circulationaha.115.021213
798. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 
focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure. Eur Heart J 2023;44:3627–39. https://doi.org/10.1093/ 
eurheartj/ehad195
799. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of 
candesartan in patients with chronic heart failure and preserved left-ventricular ejec­
tion fraction: the CHARM-preserved trial. Lancet 2003;362:777–81. https://doi.org/10. 
1016/s0140-6736(03)14285-7
800. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone 
for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92. 
https://doi.org/10.1056/NEJMoa1313731
801. Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Canoy D, Dehghan A, Byrne KS, et al. 
Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a 
Mendelian randomization study. Genome Med 2021;13:38. https://doi.org/10.1186/ 
s13073-021-00849-3
802. Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, 
et al. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million 
adults. Int J Epidemiol 2017;46:162–72. https://doi.org/10.1093/ije/dyw053
803. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col­
laboration with the European Association for Cardio-Thoracic Surgery (EACTS): The 
Task Force for the diagnosis and management of atrial fibrillation of the European 
Society of Cardiology (ESC) Developed with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 
373–498. https://doi.org/10.1093/eurheartj/ehaa612
804. Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, et al. White matter hyperin­
tensities in vascular contributions to cognitive impairment and dementia (VCID): 
knowledge gaps and opportunities. Alzheimers Dement (N Y) 2019;5:107–17. https:// 
doi.org/10.1016/j.trci.2019.02.001
805. Georgakis MK, Duering M, Wardlaw JM, Dichgans M. WMH and long-term outcomes 
in ischemic stroke: a systematic review and meta-analysis. Neurology 2019;92: 
e1298–308. https://doi.org/10.1212/wnl.0000000000007142
806. Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, et al. Global 
burden of small vessel disease-related brain changes on MRI predicts cognitive and func­
tional decline. Stroke 2020;51:170–8. https://doi.org/10.1161/strokeaha.119.026170
807. Potter T, Lioutas VA, Tano M, Pan A, Meeks J, Woo D, et al. Cognitive impairment 
after intracerebral hemorrhage: a systematic review of current evidence and knowl­
edge gaps. Front Neurol 2021;12:716632. https://doi.org/10.3389/fneur.2021.716632
808. Wang F, Hua S, Zhang Y, Zhu J, Liu R, Jiang Z. Association between small vessel disease 
markers, medial temporal lobe atrophy and cognitive impairment after stroke: a sys­
tematic review and meta-analysis. J Stroke Cerebrovasc Dis 2021;30:105460. https:// 
doi.org/10.1016/j.jstrokecerebrovasdis.2020.105460
809. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, et al. 
Hypertension-induced cognitive impairment: from pathophysiology to public health. 
Nat Rev Nephrol 2021;17:639–54. https://doi.org/10.1038/s41581-021-00430-6
810. Kelly D, Rothwell PM. Disentangling the multiple links between renal dysfunction and 
cerebrovascular disease. J Neurol Neurosurg Psychiatry 2020;91:88–97. https://doi.org/ 
10.1136/jnnp-2019-320526
811. Papanastasiou CA, Theochari CA, Zareifopoulos N, Arfaras-Melainis A, Giannakoulas 
G, Karamitsos TD, et al. Atrial fibrillation is associated with cognitive impairment, all- 
cause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and 
meta-analysis. J Gen Intern Med 2021;36:3122–35. https://doi.org/10.1007/s11606- 
021-06954-8
812. Li J, Wu Y, Zhang D, Nie J. Associations between heart failure and risk of dementia: a 
PRISMA-compliant meta-analysis. Medicine (Baltimore) 2020;99:e18492. https://doi. 
org/10.1097/md.0000000000018492
813. Canavan M, O’Donnell MJ. Hypertension and cognitive impairment: a review of me­
chanisms and key concepts. Front Neurol 2022;13:821135. https://doi.org/10.3389/ 
fneur.2022.821135
814. Dawson J, Béjot Y, Christensen LM, De Marchis GM, Dichgans M, Hagberg G, et al. 
European Stroke Organisation (ESO) guideline on pharmacological interventions for 
long-term secondary prevention after ischaemic stroke or transient ischaemic attack. 
Eur Stroke J 2022;7:I–XLI. https://doi.org/10.1177/23969873221100032
815. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, 
et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient 
ischemic attack: a guideline from the American Heart Association/American Stroke 
Association. Stroke 2021;52:e364–467. https://doi.org/10.1161/str.0000000000000375
816. Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan RJ, Roos YB, et al. 
Blood pressure-lowering treatment for preventing recurrent stroke, major vascular 
events, and dementia in patients with a history of stroke or transient ischaemic attack. 
Cochrane Database Syst Rev 2018;7:CD007858. https://doi.org/10.1002/14651858. 
CD007858.pub2
817. Boncoraglio GB, Del Giovane C, Tramacere I. Antihypertensive drugs for secondary pre­
vention after ischemic stroke or transient ischemic attack: a systematic review and 
meta-analysis. Stroke 2021;52:1974–82. https://doi.org/10.1161/strokeaha.120.031945
818. Fischer U, Cooney MT, Bull LM, Silver LE, Chalmers J, Anderson CS, et al. Acute post- 
stroke blood pressure relative to premorbid levels in intracerebral haemorrhage ver­
sus major ischaemic stroke: a population-based study. Lancet Neurol 2014;13:374–84. 
https://doi.org/10.1016/s1474-4422(14)70031-6
819. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, et al. Telmisartan to 
prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225–37. 
https://doi.org/10.1056/NEJMoa0804593
820. PROGRESS Collaborative Group. Randomised trial of a perindopril-based 
blood-pressure-lowering regimen among 6,105 individuals with previous stroke or 
transient ischaemic attack. Lancet 2001;358:1033–41. https://doi.org/10.1016/s0140- 
6736(01)06178-5
821. McGurgan IJ, Kelly PJ, Turan TN, Rothwell PM. Long-term secondary prevention: man­
agement of blood pressure after a transient ischemic attack or stroke. Stroke 2022;53: 
1085–103. https://doi.org/10.1161/strokeaha.121.035851
822. Rudd AG, Bowen A, Young GR, James MA. The latest national clinical guideline for 
stroke. Clin Med (Lond) 2017;17:154–5. https://doi.org/10.7861/clinmedicine.17-2-154
ESC Guidelines                                                                                                                                                                                          4013


<!-- PAGE 103 -->

### Page 103

823. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. Lower tar­
get blood pressures are safe and effective for the prevention of recurrent stroke: the 
PROGRESS trial. J Hypertens 2006;24:1201–8. https://doi.org/10.1097/01.hjh. 
0000226212.34055.86
824. Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of 
standard vs intensive blood pressure control on the risk of recurrent stroke: a rando­
mized clinical trial and meta-analysis. JAMA Neurol 2019;76:1309–18. https://doi.org/10. 
1001/jamaneurol.2019.2167
825. Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. 
Comprehensive comparative effectiveness and safety of first-line antihypertensive 
drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394: 
1816–26. https://doi.org/10.1016/s0140-6736(19)32317-7
826. Wang WT, You LK, Chiang CE, Sung S-H, Chuang S-Y, Cheng H-M, et al. Comparative 
effectiveness of blood pressure-lowering drugs in patients who have already suffered 
from stroke: traditional and Bayesian network meta-analysis of randomized trials. 
Medicine (Baltimore) 2016;95:e3302. https://doi.org/10.1097/md.0000000000003302
827. Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, et al. Intensive ver­
sus guideline blood pressure and lipid lowering in patients with previous stroke: main 
results from the pilot ‘Prevention of Decline in Cognition after Stroke Trial’ 
(PODCAST) randomised controlled trial. PLoS One 2017;12:e0164608. https://doi. 
org/10.1371/journal.pone.0164608
828. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic 
blood pressure targets for people with history of stroke or transient ischaemic attack: 
PAST-BP (Prevention After Stroke—Blood Pressure) randomised controlled trial. BMJ 
2016;352:i708. https://doi.org/10.1136/bmj.i708
829. Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke—a systematic re­
view and meta-analysis. J Stroke Cerebrovasc Dis 2021;30:105935. https://doi.org/10. 
1016/j.jstrokecerebrovasdis.2021.105935
830. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia 
prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 
2020;396:413–46. https://doi.org/10.1016/s0140-6736(20)30367-6
831. Ou YN, Tan CC, Shen XN, Xu W, Hou X-H, Dong Q, et al. Blood pressure and 
risks of cognitive impairment and dementia: a systematic review and meta-analysis 
of 209 prospective studies. Hypertension 2020;76:217–25. https://doi.org/10.1161/ 
hypertensionaha.120.14993
832. Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M, et al. Association 
between systolic blood pressure and dementia in the Whitehall II cohort study: role of 
age, duration, and threshold used to define hypertension. Eur Heart J 2018;39: 
3119–25. https://doi.org/10.1093/eurheartj/ehy288
833. Alpérovitch A, Blachier M, Soumaré A, Ritchie K, Dartigues J-F, Richard-Harston S, 
et al. Blood pressure variability and risk of dementia in an elderly cohort, the 
Three-City study. Alzheimers Dement 2014;10:S330–337. https://doi.org/10.1016/j. 
jalz.2013.05.1777
834. McGrath ER, Beiser AS, DeCarli C, Plourde KL, Vasan RS, Greenberg S, et al. Blood 
pressure from mid- to late life and risk of incident dementia. Neurology 2017;89: 
2447–54. https://doi.org/10.1212/wnl.0000000000004741
835. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, et al. 15-year longitu­
dinal study of blood pressure and dementia. Lancet 1996;347:1141–5. https://doi.org/ 
10.1016/s0140-6736(96)90608-x
836. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife 
blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. 
JAMA 1995;274:1846–51. https://doi.org/10.1001/jama.1995.03530230032026
837. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM, et al. Associations 
between midlife vascular risk factors and 25-year incident dementia in the atheroscler­
osis risk in Communities (ARIC) cohort. JAMA Neurol 2017;74:1246–54. https://doi. 
org/10.1001/jamaneurol.2017.1658
838. Levine DA, Springer MV, Brodtmann A. Blood pressure and vascular cognitive impair­
ment. Stroke 2022;53:1104–13. https://doi.org/10.1161/strokeaha.121.036140
839. Bosch J, O’Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, et al. Effects of 
blood pressure and lipid lowering on cognition: results from the HOPE-3 study. 
Neurology 2019;92:e1435–46. https://doi.org/10.1212/wnl.0000000000007174
840. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the 
treatment of isolated systolic hypertension on behavioral variables. Results from the 
systolic hypertension in the elderly program. Arch Intern Med 1994;154:2154–60. 
https://doi.org/10.1001/archinte.1994.00420190047006
841. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. 
Effect of intensive vs standard blood pressure control on probable dementia: a rando­
mized clinical trial. JAMA 2019;321:553–61. https://doi.org/10.1001/jama.2018.21442
842. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident demen­
tia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive 
function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 
Neurol 2008;7:683–9. https://doi.org/10.1016/s1474-4422(08)70143-1
843. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on 
Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized 
double-blind intervention trial. J Hypertens 2003;21:875–86. https://doi.org/10.1097/ 
00004872-200305000-00011
844. White WB, Wakefield DB, Moscufo N, Guttmann CRG, Kaplan RF, Bohannon RW, 
et al. Effects of intensive versus standard ambulatory blood pressure control on cere­
brovascular outcomes in older people (INFINITY). Circulation 2019;140:1626–35. 
https://doi.org/10.1161/circulationaha.119.041603
845. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. 
Effects of blood pressure lowering with perindopril and indapamide therapy on de­
mentia and cognitive decline in patients with cerebrovascular disease. Arch Intern 
Med 2003;163:1069–75. https://doi.org/10.1001/archinte.163.9.1069
846. Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. Investigation 
of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology 
2020;94:e267–81. https://doi.org/10.1212/wnl.0000000000008732
847. Yang W, Luo H, Ma Y, Si S, Zhao H. Effects of antihypertensive drugs on cognitive func­
tion in elderly patients with hypertension: a review. Aging Dis 2021;12:841–51. https:// 
doi.org/10.14336/ad.2020.1111
848. Iseli R, Nguyen VTV, Sharmin S, Reijnierse EM, Lim WK, Maier AB, et al. Orthostatic 
hypotension and cognition in older adults: a systematic review and meta-analysis. Exp 
Gerontol 2019;120:40–9. https://doi.org/10.1016/j.exger.2019.02.017
849. Ernst ME, Ryan J, Chowdhury EK, Margolis KL, Beilin LJ, Reid CM, et al. Long-term 
blood pressure variability and risk of cognitive decline and dementia among older 
adults. J Am Heart Assoc 2021;10:e019613. https://doi.org/10.1161/jaha.120.019613
850. Nakamura K, Stefanescu Schmidt A. Treatment of hypertension in coarctation of the 
aorta. Curr Treat Options Cardiovasc Med 2016;18:40. https://doi.org/10.1007/s11936- 
016-0462-x
851. Dijkema EJ, Leiner T, Grotenhuis HB. Diagnosis, imaging and clinical management of 
aortic coarctation. Heart 2017;103:1148–55. https://doi.org/10.1136/heartjnl-2017- 
311173
852. Panzer J, Bové T, Vandekerckhove K, De Wolf D. Hypertension after coarctation 
repair-a systematic review. Transl Pediatr 2022;11:270–9. https://doi.org/10.21037/ 
tp-21-418
853. Schaefer BM, Lewin MB, Stout KK, Gill E, Prueitt A, Byers P H, et al. The bicuspid aortic 
valve: an integrated phenotypic classification of leaflet morphology and aortic root 
shape. Heart 2008;94:1634–8. https://doi.org/10.1136/hrt.2007.132092
854. Wang J, Deng W, Lv Q, Li Y, Liu T, Xie M, et al. Aortic dilatation in patients with bi­
cuspid aortic valve. Front Physiol 2021;12:615175. https://doi.org/10.3389/fphys.2021. 
615175
855. Davies RR, Kaple RK, Mandapati D, Gallo A, Botta DM, Elefteriades JA, et al. Natural 
history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic 
valve. Ann Thorac Surg 2007;83:1338–44. https://doi.org/10.1016/j.athoracsur.2006. 
10.074
856. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. 
Circulation 2013;128:1281–3. https://doi.org/10.1161/circulationaha.113.005275
857. Erbel R, Aboyans V, Boileau C, Bossone E, Di Bartolomeo R, Eggebrecht H, et al. 2014 
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering 
acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The 
Task Force for the Diagnosis and Treatment of Aortic Diseases of the European 
Society of Cardiology (ESC). Eur Heart J 2014;35:2873–926. https://doi.org/10.1093/ 
eurheartj/ehu281
858. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the 
benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med 
1994;330:1335–41. https://doi.org/10.1056/nejm199405123301902
859. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, 
et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a ran­
domized controlled trial. Eur Heart J 2013;34:3491–500. https://doi.org/10.1093/ 
eurheartj/eht334
860. Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al. Angiotensin receptor 
blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of ran­
domised trials. Lancet 2022;400:822–31. https://doi.org/10.1016/s0140-6736(22)01534-3
861. Mazzolai L, Rodriguez-Palomares JF, Teixido-Tura G, Lanzi S, Boc V, Bossone E, et al. 
Heart J 2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179
862. Rechel B, Mladovsky P, Ingleby D, Mackenbach JP, McKee M. Migration and health in an 
increasingly diverse Europe. Lancet 2013;381:1235–45. https://doi.org/10.1016/s0140- 
6736(12)62086-8
863. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic 
differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS 
One 2016;11:e0147601. https://doi.org/10.1371/journal.pone.0147601
864. Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, et al. 
Research needs to improve hypertension treatment and control in African Americans. 
Hypertension 2016;68:1066–72. https://doi.org/10.1161/hypertensionaha.116.07905
865. Kaufman JS, Cooper RS, McGee DL. Socioeconomic status and health in blacks and 
whites: the problem of residual confounding and the resiliency of race. Epidemiology 
1997;8:621–8.
866. Agyemang C, van Oeffelen AA, Norredam M, Kappelle LJ, Klijn CJM, Bots ML, et al. 
Socioeconomic inequalities in stroke incidence among migrant groups: analysis of 
nationwide data. Stroke 2014;45:2397–403. https://doi.org/10.1161/strokeaha. 
114.005505


<!-- PAGE 104 -->

### Page 104

867. Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, et al. 
Blood pressure response to metoprolol and chlorthalidone in European and African 
Americans with hypertension. J Clin Hypertens (Greenwich) 2017;19:1301–8. https:// 
doi.org/10.1111/jch.13094
868. Faconti L, McNally RJ, Farukh B, Adeyemi O, Cruickshank JK, Wilkinson IB, et al. 
Differences in hypertension phenotypes between Africans and Europeans: role of envir­
onment. J Hypertens 2020;38:1278–85. https://doi.org/10.1097/hjh.0000000000002403
869. Schutte AE, Kruger R, Gafane-Matemane LF, Breet Y, Strauss-Kruger M, Cruickshank 
JK, et al. Ethnicity and arterial stiffness. Arterioscler Thromb Vasc Biol 2020;40:1044–54. 
https://doi.org/10.1161/atvbaha.120.313133
870. Erlinger TP, Vollmer WM, Svetkey LP, Appel LJ. The potential impact of nonpharma­
cologic population-wide blood pressure reduction on coronary heart disease events: 
pronounced benefits in African-Americans and hypertensives. Prev Med 2003;37: 
327–33. https://doi.org/10.1016/s0091-7435(03)00140-3
871. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. 
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting 
enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 
2981–97. https://doi.org/10.1001/jama.288.23.2981
872. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in 
hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and 
lisinopril. JAMA 2005;293:1595–608. https://doi.org/10.1001/jama.293.13.1595
873. Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. 
Clinical outcomes by race in hypertensive patients with and without the metabolic syn­
drome: antihypertensive and lipid-lowering treatment to prevent heart attack trial 
(ALLHAT). Arch Intern Med 2008;168:207–17. https://doi.org/10.1001/archinternmed. 
2007.66
874. Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of 
dual therapies for lowering blood pressure in Black Africans. N Engl J Med 2019; 
380:2429–39. https://doi.org/10.1056/NEJMoa1901113
875. van der Linden EL, Couwenhoven BN, Beune E, Daams JG, van den Born B-JH, 
Agyemang C. Hypertension awareness, treatment and control among ethnic minority 
populations in Europe: a systematic review and meta-analysis. J Hypertens 2021;39: 
202–13. https://doi.org/10.1097/hjh.0000000000002651
876. Agyemang C, Nyaaba G, Beune E, Meeks K, Owusu-Dabo E, Addo J, et al. Variations in 
hypertension awareness, treatment, and control among Ghanaian migrants living in 
Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban 
Ghana—the RODAM study. J Hypertens 2018;36:169–77. https://doi.org/10.1097/ 
hjh.0000000000001520
877. van Laer SD, Snijder MB, Agyemang C, Peters RJ, van den Born BH. Ethnic differences 
in hypertension prevalence and contributing determinants – the HELIUS study. Eur J 
Prev Cardiol 2018;25:1914–22. https://doi.org/10.1177/2047487318803241
878. Costello HM, Gumz ML. Circadian rhythm, clock genes, and hypertension: recent ad­
vances in hypertension. Hypertension 2021;78:1185–96. https://doi.org/10.1161/ 
hypertensionaha.121.14519
879. O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet 1988;2:397. https:// 
doi.org/10.1016/s0140-6736(88)92867-x
880. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J 
Med 2006;354:2368–74. https://doi.org/10.1056/NEJMra060433
881. Abdalla M, Goldsmith J, Muntner P, Diaz KM, Reynolds K, Schwartz JE, et al. Is isolated 
nocturnal hypertension a reproducible phenotype? Am J Hypertens 2016;29:33–8. 
https://doi.org/10.1093/ajh/hpv058
882. Mancia G, Facchetti R, Bombelli M, Quarti-Trevano F, Cuspidi C, Grassi G. Short- and 
long-term reproducibility of nighttime blood pressure phenotypes and nocturnal 
blood pressure reduction. Hypertension 2021;77:1745–55. https://doi.org/10.1161/ 
hypertensionaha.120.16827
883. Nolde JM, Kiuchi MG, Lugo-Gavidia LM, Ho JK, Chan J, Matthews VB, et al. Nocturnal 
hypertension: a common phenotype in a tertiary clinical setting associated with in­
creased arterial stiffness and central blood pressure. J Hypertens 2021;39:250–8. 
https://doi.org/10.1097/hjh.0000000000002620
884. Thomas SJ, Booth JN III, Jaeger BC, Hubbard D, Sakhuja S, Abdalla M, et al. Association 
of sleep characteristics with nocturnal hypertension and nondipping blood pressure in 
the CARDIA study. J Am Heart Assoc 2020;9:e015062. https://doi.org/10.1161/jaha. 
119.015062
885. Kario K, Hoshide S, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Sleep blood 
pressure self-measured at home as a novel determinant of organ damage: Japan morn­
ing surge home blood pressure (J-HOP) study. J Clin Hypertens (Greenwich) 2015;17: 
340–8. https://doi.org/10.1111/jch.12500
886. de la Sierra A, Gorostidi M, Banegas JR, Segura J, de la Cruz JJ, Ruilope LM, et al. 
Nocturnal hypertension or nondipping: which is better associated with the cardiovas­
cular risk profile? Am J Hypertens 2014;27:680–7. https://doi.org/10.1093/ajh/hpt175
887. Wijkman M, Länne T, Engvall J, Lindström T, Östgren CJ, Nystrom FH, et al. Masked 
nocturnal hypertension—a novel marker of risk in type 2 diabetes. Diabetologia 
2009;52:1258–64. https://doi.org/10.1007/s00125-009-1369-9
888. Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, et al. Racial differences 
in abnormal ambulatory blood pressure monitoring measures: results from the 
coronary artery risk development in young adults (CARDIA) study. Am J Hypertens 
2015;28:640–8. https://doi.org/10.1093/ajh/hpu193
889. Thomas SJ, Booth JN III, Bromfield SG, Seals SR, Spruill TM, Ogedegbe G, et al. Clinic 
and ambulatory blood pressure in a population-based sample of African Americans: 
the Jackson heart study. J Am Soc Hypertens 2017;11:204–212.e205. https://doi.org/ 
10.1016/j.jash.2017.02.001
890. Husain A, Lin FC, Tuttle LA, Olsson E, Viera AJ. The reproducibility of racial differences 
in ambulatory blood pressure phenotypes and measurements. Am J Hypertens 2017; 
30:961–7. https://doi.org/10.1093/ajh/hpx079
891. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. 
Hypertension 2013;61:278–83. https://doi.org/10.1161/hypertensionaha.111.00217
892. Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas JR, et al. Ethnic differ­
ences in the degree of morning blood pressure surge and in its determinants between 
Japanese and European hypertensive subjects: data from the ARTEMIS study. 
Hypertension 2015;66:750–6. https://doi.org/10.1161/hypertensionaha.115.05958
893. Banegas JR, Ruilope LM, de la Sierra A, Gorostidi M, Segura J, Martell N, et al. High 
prevalence of masked uncontrolled hypertension in people with treated hypertension. 
Eur Heart J 2014;35:3304–12. https://doi.org/10.1093/eurheartj/ehu016
894. Huang JF, Zhang DY, Sheng CS, An D-W, Li M, Cheng Y-B, et al. Isolated nocturnal 
hypertension in relation to host and environmental factors and clock genes. J Clin 
Hypertens (Greenwich) 2022;24:1255–62. https://doi.org/10.1111/jch.14532
895. Matsumoto T, Tabara Y, Murase K, Setoh K, Kawaguchi T, Nagashima S, et al. Nocturia 
and increase in nocturnal blood pressure: the Nagahama study. J Hypertens 2018;36: 
2185–92. https://doi.org/10.1097/hjh.0000000000001802
896. Seif F, Patel SR, Walia HK, Rueschman M, Bhatt DL, Blumenthal RS, et al. 
Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients 
at increased cardiovascular risk. J Hypertens 2014;32:267–75. https://doi.org/10. 
1097/hjh.0000000000000011
897. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: 
the keys to connect CKD with cardiovascular events. Hypertens Res 2010;33:515–20. 
https://doi.org/10.1038/hr.2010.47
898. Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, et al. Masked 
hypertension and elevated nighttime blood pressure in CKD: prevalence and associ­
ation with target organ damage. Clin J Am Soc Nephrol 2016;11:642–52. https://doi. 
org/10.2215/cjn.08530815
899. Kanno A, Metoki H, Kikuya M, Terawaki H, Hara A, Hashimoto T, et al. Usefulness of 
assessing masked and white-coat hypertension by ambulatory blood pressure moni­
toring for determining prevalent risk of chronic kidney disease: the Ohasama study. 
Hypertens Res 2010;33:1192–8. https://doi.org/10.1038/hr.2010.139
900. Kushiro T, Kario K, Saito I, Teramukai S, Sato Y, Okuda Y, et al. Increased cardiovas­
cular risk of treated white coat and masked hypertension in patients with diabetes and 
chronic kidney disease: the HONEST study. Hypertens Res 2017;40:87–95. https://doi. 
org/10.1038/hr.2016.87
901. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, et al. Increase in nocturnal 
blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 
2002;347:797–805. https://doi.org/10.1056/NEJMoa013410
902. Cuspidi C, Sala C, Tadic M, Gherbesi E, De Giorgi A, Grassi G, et al. Clinical and 
prognostic significance of a reverse dipping pattern on ambulatory monitoring: an 
updated review. J Clin Hypertens (Greenwich) 2017;19:713–21. https://doi.org/10. 
1111/jch.13023
903. Wu Q, Hong M, Xu J, Tang X, Zhu L, Gao P, et al. Diurnal blood pressure pattern and 
cardiac damage in hypertensive patients with primary aldosteronism. Endocrine 2021; 
72:835–43. https://doi.org/10.1007/s12020-021-02606-3
904. Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime 
blood pressure phenotype and cardiovascular prognosis: practitioner-based nation­
wide 
JAMP 
study. 
Circulation 
2020;142:1810–20. 
https://doi.org/10.1161/ 
circulationaha.120.049730
905. Kario K, Hoshide S, Nagai M, Okawara Y, Kanegae H. Sleep and cardiovascular out­
comes in relation to nocturnal hypertension: the J-HOP nocturnal blood pressure 
study. Hypertens Res 2021;44:1589–96. https://doi.org/10.1038/s41440-021-00709-y
906. Wang Q, Wang Y, Wang J, Zhang L, Zhao MH. Nocturnal systolic hypertension and 
adverse prognosis in patients with CKD. Clin J Am Soc Nephrol 2021;16:356–64. 
https://doi.org/10.2215/cjn.14420920
907. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime 
blood pressure. Hypertension 2011;57:3–10. https://doi.org/10.1161/hypertensionaha. 
109.133900
908. Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW, et al. Predicting car­
diovascular risk using conventional vs ambulatory blood pressure in older patients with sys­
tolic hypertension. JAMA 1999;282:539–46. https://doi.org/10.1001/jama.282.6.539
909. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. 
Ambulatory blood pressure. An independent predictor of prognosis in essential hyper­
tension. Hypertension 1994;24:793–801. https://doi.org/10.1161/01.hyp.24.6.793
910. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. 
Prognostic significance of the nocturnal decline in blood pressure in individuals with 
and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002;20: 
2183–9. https://doi.org/10.1097/00004872-200211000-00017
ESC Guidelines                                                                                                                                                                                          4015


<!-- PAGE 105 -->

### Page 105

911. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an 
independent determinant of brain atrophy and cognitive function in elderly hyperten­
sion. J Hypertens 2008;26:1636–41. https://doi.org/10.1097/HJH.0b013e3283018333
912. Staessen JA, Thijs L, Ohkubo T, Kikuya M, Richart T, Boggia J, et al. Thirty years of 
research on diagnostic and therapeutic thresholds for the self-measured blood 
pressure at home. Blood Press Monit 2008;13:352–65. https://doi.org/10.1097/ 
MBP.0b013e3283108f93
913. Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hyper­
tension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 
2004;26:177–89. https://doi.org/10.1081/ceh-120028556
914. Tan X, Sundström J, Lind L, Franzon K, Kilander L, Benedict C, et al. Reverse dipping of 
systolic blood pressure is associated with increased dementia risk in older men: a lon­
gitudinal study over 24 years. Hypertension 2021;77:1383–90. https://doi.org/10.1161/ 
hypertensionaha.120.16711
915. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence 
and outcomes. J Hum Hypertens 2014;28:463–8. https://doi.org/10.1038/jhh.2013.140
916. Denker MG, Haddad DB, Townsend RR, Cohen DL. Blood pressure control 1 year 
after referral to a hypertension specialist. J Clin Hypertens (Greenwich) 2013;15: 
624–9. https://doi.org/10.1111/jch.12146
917. Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects 
of lifestyle modification on patients with resistant hypertension: results of the 
TRIUMPH randomized clinical trial. Circulation 2021;144:1212–26. https://doi.org/10. 
1161/circulationaha.121.055329
918. Hung SC, Kuo KL, Peng CH, Wu C-H, Lien Y-C, Wang Y-C, et al. Volume overload 
correlates with cardiovascular risk factors in patients with chronic kidney disease. 
Kidney Int 2014;85:703–9. https://doi.org/10.1038/ki.2013.336
919. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic 
management to specialist care. Hypertension 2002;39:982–8. https://doi.org/10.1161/ 
01.hyp.0000016176.16042.2f
920. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. 
Characterization of resistant hypertension: association between resistant hyperten­
sion, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 
2008;168:1159–64. https://doi.org/10.1001/archinte.168.11.1159
921. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of 
hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and meta­
bolic effects. Hypertension 2015;65:1041–6. https://doi.org/10.1161/hypertensionaha. 
114.05021
922. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response re­
lationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood 
pressure, serum potassium, and urate. Hypertension 2012;59:1104–9. https://doi.org/ 
10.1161/hypertensionaha.111.190637
923. Chen C, Zhu XY, Li D, Lin Q, Zhou K. Clinical efficacy and safety of spironolactone in 
patients with resistant hypertension: a systematic review and meta-analysis. Medicine 
(Baltimore) 2020;99:e21694. https://doi.org/10.1097/md.0000000000021694
924. Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in 
patients with resistant hypertension. Int J Cardiol 2017;233:113–7. https://doi.org/10. 
1016/j.ijcard.2016.12.158
925. Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on 
blood pressure lowering: overview and meta-analysis of randomized controlled 
trials in hypertension. J Hypertens 2018;36:987–94. https://doi.org/10.1097/hjh. 
0000000000001671
926. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spir­
onolactone reduces blood pressure in patients with resistant hypertension and type 2 
diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013;31: 
2094–102. https://doi.org/10.1097/HJH.0b013e3283638b1a
927. Desai R, Park H, Brown JD, Mohandas R, Pepine CJ, Smith SM. Comparative safety and 
effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in pa­
tients with apparent resistant hypertension. Hypertension 2022;79:2305–15. https:// 
doi.org/10.1161/hypertensionaha.122.19280
928. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hy­
perkalemia after publication of the randomized aldactone evaluation study. N Engl J 
Med 2004;351:543–51. https://doi.org/10.1056/NEJMoa040135
929. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer 
versus placebo to enable spironolactone use in patients with resistant hypertension 
and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo- 
controlled trial. Lancet 2019;394:1540–50. https://doi.org/10.1016/s0140-6736(19) 
32135-x
930. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the 
sensitivity and specificity of (11)C-metomidate positron emission tomography 
(PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol 
Metab 2012;97:100–9. https://doi.org/10.1210/jc.2011-1537
931. Rossi GP, Maiolino G, Seccia TM. Adrenal venous sampling: where do we stand? 
Endocrinol Metab Clin North Am 2019;48:843–58. https://doi.org/10.1016/j.ecl. 
2019.08.012
932. Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, et al. [(11)C] 
metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable 
primary aldosteronism: a prospective, within-patient trial. Nat Med 2023;29: 
190–202. https://doi.org/10.1038/s41591-022-02114-5
933. Lenzini L, Prisco S, Caroccia B, Rossi GP. Saga of familial hyperaldosteronism: yet a 
new channel. Hypertension 2018;71:1010–4. https://doi.org/10.1161/hypertensionaha. 
118.11150
934. Parthasarathy HK, Ménard J, White WB, Young WF, Williams GH, Williams B, et al. A 
double-blind, randomized study comparing the antihypertensive effect of eplerenone 
and spironolactone in patients with hypertension and evidence of primary aldosteron­
ism. J Hypertens 2011;29:980–90. https://doi.org/10.1097/HJH.0b013e3283455ca5
935. Shagjaa T, Sanga V, Rossi GP. Skin hyperpigmentation due to post-surgical adrenal in­
sufficiency regressed with the dexamethasone treatment. J Clin Med 2022;11:5379. 
https://doi.org/10.3390/jcm11185379
936. Sanga V, Lenzini L, Seccia TM, Rossi GP. Familial hyperaldosteronism type 1 and preg­
nancy: successful treatment with low dose dexamethasone. Blood Press 2021;30: 
133–7. https://doi.org/10.1080/08037051.2020.1863771
937. Persu A, Touzé E, Mousseaux E, Barral X, Joffre F, Plouin P-F. Diagnosis and manage­
ment of fibromuscular dysplasia: an expert consensus. Eur J Clin Invest 2012;42:338–47. 
https://doi.org/10.1111/j.1365-2362.2011.02577.x
938. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization ver­
sus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953–62. https:// 
doi.org/10.1056/NEJMoa0905368
939. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting 
and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370: 
13–22. https://doi.org/10.1056/NEJMoa1310753
940. Bailey SR, Beckman JA, Dao TD, Misra S, Sobieszczyk PS, White CJ, et al. ACC/AHA/ 
SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a re­
port of the American College of Cardiology Appropriate Use Criteria Task Force, 
American Heart Association, Society for Cardiovascular Angiography and 
Interventions, Society of Interventional Radiology, and Society for Vascular 
Medicine. J Am Coll Cardiol 2019;73:214–37. https://doi.org/10.1016/j.jacc.2018.10.002
941. Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascu­
larization for renal artery stenosis caused by fibromuscular dysplasia: a systematic re­
view and meta-analysis. Hypertension 2010;56:525–32. https://doi.org/10.1161/ 
hypertensionaha.110.152918
942. Sanga V, Bertoli E, Crimì F, Barbiero G, Battistel M, Teresa Seccia M, et al. Pickering 
syndrome: an overlooked renovascular cause of recurrent heart failure. J Am Heart 
Assoc 2023;12:e030474. https://doi.org/10.1161/jaha.123.030474
943. Bhalla V, Textor SC, Beckman JA, Casanegra AI, Cooper CJ, Kim ESH, et al. 
Revascularization for renovascular disease: a scientific statement from the 
American Heart Association. Hypertension 2022;79:e128–43. https://doi.org/10. 
1161/hyp.0000000000000217
944. Bravo E, Fouad-Tarazi F, Rossi G, Imamura M, Lin WW, Madkour MA, et al. A re­
evaluation of the hemodynamics of pheochromocytoma. Hypertension 1990;15: 
I128–131. https://doi.org/10.1161/01.hyp.15.2_suppl.i128
945. Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. 
Cancer therapy-related hypertension: a scientific statement from the American 
Heart Association. Hypertension 2023;80:e46–57. https://doi.org/10.1161/hyp. 
0000000000000224
946. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
ESC guidelines on cardio-oncology developed in collaboration with the European 
Hematology Association (EHA), the European Society for Therapeutic Radiology 
and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur 
Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
947. Boulestreau R, van den Born BH, Lip GYH, Gupta A. Malignant hypertension: current 
perspectives and challenges. J Am Heart Assoc 2022;11:e023397. https://doi.org/10. 
1161/jaha.121.023397
948. Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, et al. The third intensive care bundle 
with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an 
international, stepped wedge cluster randomised controlled trial. Lancet 2023;402: 
27–40. https://doi.org/10.1016/s0140-6736(23)00806-1
949. Moullaali TJ, Wang X, Sandset EC, Woodhouse LJ, Law ZK, Arima H, et al. Early low­
ering of blood pressure after acute intracerebral haemorrhage: a systematic review 
and meta-analysis of individual patient data. J Neurol Neurosurg Psychiatry 2022;93: 
6–13. https://doi.org/10.1136/jnnp-2021-327195
950. Wang X, Di Tanna GL, Moullaali TJ, Martin R’ H, Shipes VB, Robinson TG, et al. J-shape 
relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: 
a pooled analysis of INTERACT2 and ATACH-II individual participant data. Int J Stroke 
2022;17:1129–36. https://doi.org/10.1177/17474930211064076
951. Qureshi AI, Huang W, Lobanova I, Barsan WG, Hanley DF, Hsu CY, et al. Outcomes 
of intensive systolic blood pressure reduction in patients with intracerebral hemor­
rhage and excessively high initial systolic blood pressure: post hoc analysis of a ran­
domized clinical trial. JAMA Neurol 2020;77:1355–65. https://doi.org/10.1001/ 
jamaneurol.2020.3075
952. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute 
stroke. Cochrane Database Syst Rev 2014;2014:CD000039. https://doi.org/10.1002/ 
14651858.CD000039.pub3


<!-- PAGE 106 -->

### Page 106

953. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. 
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute 
ischaemic stroke. Eur Stroke J 2021;6:I–LXII. https://doi.org/10.1177/2396987321989865
954. LeCouffe NE, Kappelhof M, Treurniet KM, Lingsma HF, Zhang G, van den Wijngaard 
IR, et al. 2B, 2C, or 3: what should be the angiographic target for endovascular treat­
ment in ischemic stroke? Stroke 2020;51:1790–6. https://doi.org/10.1161/strokeaha. 
119.028891
955. Mistry EA, Hart KW, Davis LT, Gao Y, Prestigiacomo CJ, Mittal S, et al. Blood pressure 
management after endovascular therapy for acute ischemic stroke: the BEST-II rando­
mized clinical trial. JAMA 2023;330:821–31. https://doi.org/10.1001/jama.2023.14330
956. Lee M, Ovbiagele B, Hong KS, Wu Y-L, Lee J-E, Rao NM, et al. Effect of blood pressure 
lowering in early ischemic stroke: meta-analysis. Stroke 2015;46:1883–9. https://doi. 
org/10.1161/strokeaha.115.009552
957. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, et al. Intensive blood 
pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke 
(ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 
trial. Lancet 2019;393:877–88. https://doi.org/10.1016/s0140-6736(19)30038-8
958. Mazighi M, Richard S, Lapergue B, Sibon I, Gory B, Berge J, et al. Safety and efficacy of 
intensive blood pressure lowering after successful endovascular therapy in acute is­
chaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. 
Lancet Neurol 2021;20:265–74. https://doi.org/10.1016/s1474-4422(20)30483-x
959. Yang P, Song L, Zhang Y, Zhang X, Chen X, Li Y, et al. Intensive blood pressure control 
after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a 
multicentre, open-label, blinded-endpoint, randomised controlled trial. Lancet 2022; 
400:1585–96. https://doi.org/10.1016/s0140-6736(22)01882-7
960. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gąsecki D, et al. 
European Stroke Organisation (ESO) guidelines on blood pressure management in 
acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J 2021;6: 
Xlviii–lxxxix. https://doi.org/10.1177/23969873211012133
961. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood- 
pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 
2013;368:2355–65. https://doi.org/10.1056/NEJMoa1214609
962. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive 
blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 
2016;375:1033–43. https://doi.org/10.1056/NEJMoa1603460
963. Moullaali TJ, Wang X, Woodhouse LJ, Law ZK, Delcourt C, Sprigg N, et al. Lowering 
blood pressure after acute intracerebral haemorrhage: protocol for a systematic re­
view and meta-analysis using individual patient data from randomised controlled trials 
participating in the blood pressure in acute stroke collaboration (BASC). BMJ Open 
2019;9:e030121. https://doi.org/10.1136/bmjopen-2019-030121
964. American College of Obstetricians and Gynecologists. Gestational hypertension and 
preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol 2020;135: 
e237–60. https://doi.org/10.1097/aog.0000000000003891
965. Garovic VD, Dechend R, Easterling T, Karumanchi SA, Baird SM, Magee LA, et al. 
Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a 
scientific statement from the American Heart Association. Hypertension 2022;79: 
e21–41. https://doi.org/10.1161/hyp.0000000000000208
966. Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med 2022;386: 
1817–32. https://doi.org/10.1056/NEJMra2109523
967. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with 
pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: 
a randomised placebo-controlled trial. Lancet 2002;359:1877–90. https://doi.org/10. 
1016/s0140-6736(02)08778-0
968. Poon LC, Magee LA, Verlohren S, Shennan A, von Dadelszen P, Sheiner E, et al. A lit­
erature review and best practice advice for second and third trimester risk stratifica­
tion, monitoring, and management of pre-eclampsia: compiled by the pregnancy and 
non-communicable diseases committee of FIGO (the International Federation of 
Gynecology and Obstetrics). Int J Gynaecol Obstet 2021;154 Suppl 1:3–31. https:// 
doi.org/10.1002/ijgo.13763
969. Muhammad S, Usman H, Dawha YM, Yahya A, Yekeen A, Bako B. Comparison of intra­
venous labetalol and hydralazine for severe hypertension in pregnancy in 
Northeastern Nigeria: a randomized controlled trial. Pregnancy Hypertens 2022;29: 
1–6. https://doi.org/10.1016/j.preghy.2022.05.001
970. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treat­
ment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955–60. 
https://doi.org/10.1136/bmj.327.7421.955
971. Wu HZ, Cheng Y, Yu D, Li J-B, Jiang Y-F, Zhu Z-N. Different dosage regimens of ni­
fedipine, labetalol, and hydralazine for the treatment of severe hypertension during 
pregnancy: a network meta-analysis of randomized controlled trials. Hypertens 
Pregnancy 2022;41:126–38. https://doi.org/10.1080/10641955.2022.2056196
972. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC 
Guidelines on cardiovascular assessment and management of patients undergoing non- 
cardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/eurheartj/ehac270
973. Lizano-Díez I, Poteet S, Burniol-Garcia A, Cerezales M. The burden of perioperative 
hypertension/hypotension: a systematic review. PLoS One 2022;17:e0263737. 
https://doi.org/10.1371/journal.pone.0263737
974. Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, et al. Effect of individua­
lized vs standard blood pressure management strategies on postoperative organ dys­
function among high-risk patients undergoing major surgery: a randomized clinical trial. 
JAMA 2017;318:1346–57. https://doi.org/10.1001/jama.2017.14172
975. Sanders RD, Hughes F, Shaw A, Thompson A, Bader A, Hoeft A, et al. Perioperative 
quality initiative consensus statement on preoperative blood pressure, risk and out­
comes for elective surgery. Br J Anaesth 2019;122:552–62. https://doi.org/10.1016/j. 
bja.2019.01.018
976. Messina A, Robba C, Calabrò L, Zambelli D, Iannuzzi F, Molinari E, et al. Association 
between perioperative fluid administration and postoperative outcomes: a 20-year 
systematic review and a meta-analysis of randomized goal-directed trials in major vis­
ceral/noncardiac surgery. Crit Care 2021;25:43. https://doi.org/10.1186/s13054-021- 
03464-1
977. Meng L, Yu W, Wang T, Zhang L, Heerdt PM, Gelb AW. Blood pressure targets in peri­
operative care. Hypertension 2018;72:806–17. https://doi.org/10.1161/hypertensionaha. 
118.11688
978. Wanner PM, Wulff DU, Djurdjevic M, Korte W, Schnider TW, Filipovic M. Targeting 
higher intraoperative blood pressures does not reduce adverse cardiovascular events 
following noncardiac surgery. J Am Coll Cardiol 2021;78:1753–64. https://doi.org/10. 
1016/j.jacc.2021.08.048
979. Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager O, et al. 
Perioperative beta-blockers for preventing surgery-related mortality and morbidity in 
adults undergoing non-cardiac surgery. Cochrane Database Syst Rev 2019;9:CD013438. 
https://doi.org/10.1002/14651858.CD013438
980. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative beta blockade: 
what is the actual risk reduction? Surgery 2005;138:171–9. https://doi.org/10.1016/j. 
surg.2005.03.022
981. Kertai MD, Cooter M, Pollard RJ, Buhrman W, Aronson S, Mathew JP, et al. Is compli­
ance with surgical care improvement project cardiac (SCIP-Card-2) measures for peri­
operative β-blockers associated with reduced incidence of mortality and 
cardiovascular-related critical quality indicators after noncardiac surgery? Anesth 
Analg 2018;126:1829–38. https://doi.org/10.1213/ane.0000000000002577
982. Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Côté EP, et al. 
Withholding versus continuing angiotensin-converting enzyme inhibitors or angioten­
sin II receptor blockers before noncardiac surgery: an analysis of the vascular events in 
noncardiac surgery patIents cOhort evaluatioN prospective cohort. Anesthesiology 
2017;126:16–27. https://doi.org/10.1097/aln.0000000000001404
983. Shiffermiller JF, Monson BJ, Vokoun CW, Beachy MW, Smith MP, Sullivan JN, et al. 
Prospective randomized evaluation of preoperative angiotensin-converting en­
zyme inhibition (PREOP-ACEI). J Hosp Med 2018;13:661–7. https://doi.org/10. 
12788/jhm.3036
984. Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated 
with withholding or continuing angiotensin-converting enzyme inhibitors and angio­
tensin receptor blockers before noncardiac surgery. Anesth Analg 2018;127:678–87. 
https://doi.org/10.1213/ane.0000000000002837
985. Ackland GL, Patel A, Abbott TEF, Begum S, Dias P, Crane DR, et al. Discontinuation vs. 
continuation of renin–angiotensin system inhibition before non-cardiac surgery: the 
SPACE trial. Eur Heart J 2024;45:1146–55. https://doi.org/10.1093/eurheartj/ehad716
986. McEvoy MD, Gupta R, Koepke EJ, Feldheiser A, Michard F, Levett D, et al. 
Perioperative quality initiative consensus statement on postoperative blood pressure, 
risk and outcomes for elective surgery. Br J Anaesth 2019;122:575–86. https://doi.org/ 
10.1016/j.bja.2019.01.019
987. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered 
care—ready for prime time. Eur J Cardiovasc Nurs 2011;10:248–51. https://doi.org/10. 
1016/j.ejcnurse.2011.06.008
988. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging patients in decision-making 
and behavior change to promote prevention. Stud Health Technol Inform 2017; 
240:284–302. https://doi.org/10.3233/ISU-170826
989. Johnson RA, Huntley A, Hughes RA, Hughes RA, Cramer H, Turner KM, et al. 
Interventions to support shared decision making for hypertension: a systematic re­
view of controlled studies. Health Expect 2018;21:1191–207. https://doi.org/10. 
1111/hex.12826
990. Johnson RL, Roter D, Powe NR, Cooper LA. Patient race/ethnicity and quality of pa­
tient–physician communication during medical visits. Am J Public Health 2004;94: 
2084–90. https://doi.org/10.2105/ajph.94.12.2084
991. Williams MV, Davis T, Parker RM, Weiss BD. The role of health literacy in patient- 
physician communication. Fam Med 2002;34:383–9.
992. Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk 
scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst 
Rev 2017;3:CD006887. https://doi.org/10.1002/14651858.CD006887.pub4
993. Ma C, Zhou Y, Zhou W, Huang C. Evaluation of the effect of motivational interviewing 
counselling on hypertension care. Patient Educ Couns 2014;95:231–7. https://doi.org/ 
10.1016/j.pec.2014.01.011
994. Huang X, Xu N, Wang Y, Sun Y, Guo A. The effects of motivational interviewing on 
hypertension management: a systematic review and meta-analysis. Patient Educ 
Couns 2023;112:107760. https://doi.org/10.1016/j.pec.2023.107760
ESC Guidelines                                                                                                                                                                                          4017


<!-- PAGE 107 -->

### Page 107

995. Glaser E, Richard C, Lussier MT. The impact of a patient web communication interven­
tion on reaching treatment suggested guidelines for chronic diseases: a randomized 
controlled trial. Patient Educ Couns 2017;100:2062–70. https://doi.org/10.1016/j.pec. 
2017.05.022
996. Richard AA, Shea K. Delineation of self-care and associated concepts. J Nurs Scholarsh 
2011;43:255–64. https://doi.org/10.1111/j.1547-5069.2011.01404.x
997. Wilkinson A, Whitehead L. Evolution of the concept of self-care and implications for 
nurses: a literature review. Int J Nurs Stud 2009;46:1143–7. https://doi.org/10.1016/j. 
ijnurstu.2008.12.011
998. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of 
chronic disease in primary care. JAMA 2002;288:2469–75. https://doi.org/10.1001/ 
jama.288.19.2469
999. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches 
for people with chronic conditions: a review. Patient Educ Couns 2002;48:177–87. 
https://doi.org/10.1016/s0738-3991(02)00032-0
1000. Hallberg I, Ranerup A, Kjellgren K. Supporting the self-management of hypertension: 
patients’ experiences of using a mobile phone-based system. J Hum Hypertens 2016; 
30:141–6. https://doi.org/10.1038/jhh.2015.37
1001. Almeida GO, Aidar FJ, Matos DG, Almeida-Neto PF, Melo EV, Barreto Filho JAS, et al. 
Non-targeted self-measurement of blood pressure: association with self-medication, 
unscheduled emergency visits and anxiety. Medicina (Kaunas) 2021;57:75. https://doi. 
org/10.3390/medicina57010075
1002. Greaves F, Joshi I, Campbell M, Roberts S, Patel N, Powell J, et al. What is an appro­
priate level of evidence for a digital health intervention? Lancet 2019;392:2665–7. 
https://doi.org/10.1016/s0140-6736(18)33129-5
1003. Morton K, Dennison L, May C, Murray E, Little P, McManus RJ, et al. Using digital in­
terventions for self-management of chronic physical health conditions: a 
meta-ethnography review of published studies. Patient Educ Couns 2017;100: 
616–35. https://doi.org/10.1016/j.pec.2016.10.019
1004. McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S, et al. Telemonitoring 
based service redesign for the management of uncontrolled hypertension: multicentre 
randomised controlled trial. BMJ 2013;346:f3030. https://doi.org/10.1136/bmj.f3030
1005. Persell SD, Peprah YA, Lipiszko D, Lee JY, Li JJ, Ciolino JD, et al. Effect of home 
blood pressure monitoring via a smartphone hypertension coaching application 
or tracking application on adults with uncontrolled hypertension: a randomized 
clinical trial. JAMA Netw Open 2020;3:e200255. https://doi.org/10.1001/ 
jamanetworkopen.2020.0255
1006. Andersson U, Nilsson PM, Kjellgren K, Hoffmann M, Wennersten A, Midlöv P, et al. 
PERson-centredness in Hypertension management using Information Technology: a 
randomized controlled trial in primary care. J Hypertens 2023;41:246–53. https://doi. 
org/10.1097/hjh.0000000000003322
1007. Bergland OU, Halvorsen LV, Søraas CL, Hjørnholm U, Kjær VN, Rognstad S, et al. 
Detection of nonadherence to antihypertensive treatment by measurements of ser­
um drug concentrations. Hypertension 2021;78:617–28. https://doi.org/10.1161/ 
hypertensionaha.121.17514
1008. Durand H, Hayes P, Morrissey EC, Newell J, Casey M, Murphy AW, et al. Medication 
adherence among patients with apparent treatment-resistant hypertension: 
systematic review and meta-analysis. J Hypertens 2017;35:2346–57. https://doi.org/ 
10.1097/hjh.0000000000001502
1009. Kronish IM, Thorpe CT, Voils CI. Measuring the multiple domains of medication non­
adherence: findings from a Delphi survey of adherence experts. Transl Behav Med 
2021;11:104–13. https://doi.org/10.1093/tbm/ibz133
1010. DiMatteo MR. Social support and patient adherence to medical treatment: a 
meta-analysis. Health Psychol 2004;23:207–18. https://doi.org/10.1037/0278- 
6133.23.2.207
1011. Houle SK, Chatterley T, Tsuyuki RT. Multidisciplinary approaches to the management 
of high blood pressure. Curr Opin Cardiol 2014;29:344–53. https://doi.org/10.1097/ 
hco.0000000000000071
1012. Woodham NS, Taneepanichskul S, Somrongthong R, Kitsanapun A, Sompakdee B. 
Effectiveness of a multidisciplinary approach intervention to improve blood pressure 
control among elderly hypertensive patients in rural Thailand: a quasi-experimental 
study. J Multidiscip Healthc 2020;13:571–80. https://doi.org/10.2147/jmdh.S254286
1013. Mattei da Silva ÂT, de Fátima Mantovani M, Castanho Moreira R, Perez Arthur J, 
Molina de Souza R. Nursing case management for people with hypertension in pri­
mary health care: a randomized controlled trial. Res Nurs Health 2020;43:68–78. 
https://doi.org/10.1002/nur.21994
1014. He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, et al. Effectiveness of a non-physician 
community health-care provider-led intensive blood pressure intervention versus 
usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, 
cluster-randomised trial. Lancet 2023;401:928–38. https://doi.org/10.1016/ 
s0140-6736(22)02603-4
1015. Creegan D, McEvoy JW. Selected highlights in the updated treatment of hyperten­
sion. Trends Cardiovasc Med https://doi.org/10.1016/j.tcm.2023.11.001
1016. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control as­
sociated with a large-scale hypertension program. JAMA 2013;310:699–705. https:// 
doi.org/10.1001/jama.2013.108769
1017. Hänsel M, Steigmiller K, Luft AR, Gebhard C, Held U, Wegener S, et al. Neurovascular 
disease in Switzerland: 10-year trends show non-traditional risk factors on the rise 
and higher exposure in women. Eur J Neurol 2022;29:2851–60. https://doi.org/10. 
1111/ene.15434
1018. de Ruiter SC, Schmidt AF, Grobbee DE, den Ruijter HM, Peters SAE. Sex-specific 
Mendelian randomisation to assess the causality of sex differences in the effects of 
risk factors and treatment: spotlight on hypertension. J Hum Hypertens 2023;37: 
602–8. https://doi.org/10.1038/s41371-023-00821-1
1019. Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi-Ankrah B, et al. 
Arterial hypertension in women: state of the art and knowledge gaps. Hypertension 
2023;80:1140–9. https://doi.org/10.1161/hypertensionaha.122.20448
1020. Tamargo J, Caballero R, Mosquera ED. Sex and gender differences in the treatment of 
arterial hypertension. Expert Rev Clin Pharmacol 2023;16:329–47. https://doi.org/10. 
1080/17512433.2023.2189585
1021. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to 
action and a lifecourse strategy to address the global burden of raised blood pressure 
on current and future generations: the Lancet Commission on hypertension. Lancet 
2016;388:2665–712. https://doi.org/10.1016/s0140-6736(16)31134-5

<!-- 2024_Peripheral_Arterial_Aortic.md -->

# ESC Guidelines: Peripheral Arterial Aortic (2024)

**Source**: `2024_Peripheral_Arterial_Aortic.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 163

---

## Table of Contents

- [2024 ESC Guidelines for the management of peripheral arterial and aortic diseases](#2024-esc-guidelines-for-the-management-of-peripher) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 10)*
  - [2. Introduction](#2-introduction) *(p. 11)*
  - [3. What is new](#3-what-is-new) *(p. 13)*
  - [4. Epidemiology and risk factors](#4-epidemiology-and-risk-factors) *(p. 21)*
    - [4.1. Epidemiology](#41-epidemiology) *(p. 21)*
    - [4.2. Risk factors](#42-risk-factors) *(p. 22)*
  - [5. Evaluation of peripheral arteries and aorta](#5-evaluation-of-peripheral-arteries-and-aorta) *(p. 23)*
    - [5.1. Clinical history and examination, and laboratory assessment, in patients with peripheral arterial and aortic diseases](#51-clinical-history-and-examination,-and-laborator) *(p. 23)*
    - [5.2. Functional and quality of life assessment in patients with peripheral arterial and aortic diseases](#52-functional-and-quality-of-life-assessment-in-pa) *(p. 23)*
    - [5.3. Vascular examination of peripheral arteries](#53-vascular-examination-of-peripheral-arteries) *(p. 24)*
      - [5.3.1. Duplex ultrasound](#531-duplex-ultrasound) *(p. 25)*
      - [5.3.2. Digital subtraction angiography, computed tomography angiography, and magnetic resonance angiography](#532-digital-subtraction-angiography,-computed-tomo) *(p. 25)*
    - [5.4. Evaluation of the aorta](#54-evaluation-of-the-aorta) *(p. 25)*
      - [5.4.1. Aortic measurements](#541-aortic-measurements) *(p. 25)*
      - [5.4.2. Normal aortic values](#542-normal-aortic-values) *(p. 28)*
      - [5.4.3. Chest X-ray and electrocardiogram](#543-chest-x-ray-and-electrocardiogram) *(p. 28)*
      - [5.4.4. Echocardiography](#544-echocardiography) *(p. 28)*
      - [5.4.5. Duplex ultrasound imaging of the abdominal aorta](#545-duplex-ultrasound-imaging-of-the-abdominal-aor) *(p. 29)*
      - [5.4.6. Cardiovascular computed tomography](#546-cardiovascular-computed-tomography) *(p. 29)*
      - [5.4.7. Cardiovascular magnetic resonance](#547-cardiovascular-magnetic-resonance) *(p. 29)*
      - [5.4.8. Positron emission tomography](#548-positron-emission-tomography) *(p. 29)*
      - [5.4.9. Intravascular ultrasound](#549-intravascular-ultrasound) *(p. 30)*
      - [5.4.10. Digital subtraction aortography](#5410-digital-subtraction-aortography) *(p. 30)*
  - [6. Screening for carotid, peripheral arterial, and aortic diseases](#6-screening-for-carotid,-peripheral-arterial,-and-) *(p. 30)*
    - [6.1. Screening for carotid and peripheral arterial diseases](#61-screening-for-carotid-and-peripheral-arterial-d) *(p. 30)*
      - [6.1.1. Lower-extremity peripheral arterial disease](#611-lower-extremity-peripheral-arterial-disease) *(p. 30)*
      - [6.1.2. Carotid artery stenosis](#612-carotid-artery-stenosis) *(p. 30)*
      - [6.1.3. Multisite artery disease](#613-multisite-artery-disease) *(p. 30)*
    - [6.2. Screening for aortic diseases](#62-screening-for-aortic-diseases) *(p. 31)*
      - [6.2.1. Screening for abdominal aortic aneurysm](#621-screening-for-abdominal-aortic-aneurysm) *(p. 31)*
      - [6.2.2. Screening for thoracic aortic aneurysm](#622-screening-for-thoracic-aortic-aneurysm) *(p. 31)*
  - [7. Optimal medical treatment](#7-optimal-medical-treatment) *(p. 31)*
    - [7.1. Lifestyle, exercise, patient education](#71-lifestyle,-exercise,-patient-education) *(p. 31)*
      - [7.1.1. Diet](#711-diet) *(p. 31)*
      - [7.1.2. Physical activity](#712-physical-activity) *(p. 32)*
      - [7.1.3. Smoking](#713-smoking) *(p. 33)*
      - [7.1.4. Patient education](#714-patient-education) *(p. 33)*
      - [7.1.5. Risk scoring models in secondary prevention](#715-risk-scoring-models-in-secondary-prevention) *(p. 33)*
    - [7.2. Principles of pharmacological medical therapy](#72-principles-of-pharmacological-medical-therapy) *(p. 34)*
      - [7.2.1. Antithrombotic therapy](#721-antithrombotic-therapy) *(p. 34)*
      - [7.2.2. Antihypertensive therapy](#722-antihypertensive-therapy) *(p. 34)*
        - [7.2.2.1. Renovascular hypertension](#7221-renovascular-hypertension) *(p. 34)*
      - [7.2.3. Lipid-lowering therapy](#723-lipid-lowering-therapy) *(p. 35)*
        - [7.2.3.1. Statins](#7231-statins) *(p. 35)*
        - [7.2.3.2. Ezetimibe](#7232-ezetimibe) *(p. 35)*
        - [7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors](#7233-proprotein-convertase-subtilisin/kexin-type-9) *(p. 35)*
        - [7.2.3.4. Bempedoic acid](#7234-bempedoic-acid) *(p. 35)*
        - [7.2.3.5. Hypertriglyceridaemia](#7235-hypertriglyceridaemia) *(p. 35)*
      - [7.2.4. Diabetes and pre-diabetes conditions](#724-diabetes-and-pre-diabetes-conditions) *(p. 36)*
      - [7.2.5. Other pharmacological therapy](#725-other-pharmacological-therapy) *(p. 37)*
  - [8. Peripheral arterial disease](#8-peripheral-arterial-disease) *(p. 37)*
    - [8.1. Lower-extremity peripheral arterial disease](#81-lower-extremity-peripheral-arterial-disease) *(p. 37)*
      - [8.1.1. Peripheral arterial disease syndromes](#811-peripheral-arterial-disease-syndromes) *(p. 37)*
        - [8.1.1.1. Clinical presentation and diagnosis](#8111-clinical-presentation-and-diagnosis) *(p. 37)*
          - [8.1.1.1.1. Diagnostic tests](#81111-diagnostic-tests) *(p. 38)*
          - [8.1.1.1.2. Imaging methods](#81112-imaging-methods) *(p. 39)*
        - [8.1.1.2. Medical treatment](#8112-medical-treatment) *(p. 41)*
          - [8.1.1.2.1. Exercise therapy](#81121-exercise-therapy) *(p. 41)*
          - [8.1.1.2.2. Pharmacological treatment](#81122-pharmacological-treatment) *(p. 45)*
          - [8.1.1.2.3. Aorto-iliac lesion revascularization](#81123-aorto-iliac-lesion-revascularization) *(p. 46)*
          - [8.1.1.2.4. Femoro-popliteal lesion revascularization](#81124-femoro-popliteal-lesion-revascularization) *(p. 47)*
          - [8.1.1.2.5. Below-the-knee artery revascularization](#81125-below-the-knee-artery-revascularization) *(p. 47)*
        - [8.1.1.3. Follow-up](#8113-follow-up) *(p. 48)*
      - [8.1.2. Chronic limb-threatening ischaemia](#812-chronic-limb-threatening-ischaemia) *(p. 48)*
        - [8.1.2.1. Clinical presentation and diagnosis](#8121-clinical-presentation-and-diagnosis) *(p. 48)*
          - [8.1.2.1.1. Definition](#81211-definition) *(p. 48)*
          - [8.1.2.1.2. Initial assessment and risk of amputation](#81212-initial-assessment-and-risk-of-amputation) *(p. 48)*
          - [8.1.2.1.3. Imaging](#81213-imaging) *(p. 48)*
          - [8.1.2.1.4. Mortality risk assessment](#81214-mortality-risk-assessment) *(p. 48)*
        - [8.1.2.2. Medical treatment](#8122-medical-treatment) *(p. 49)*
        - [8.1.2.3. Interventional treatment](#8123-interventional-treatment) *(p. 49)*
          - [8.1.2.3.1. Revascularization](#81231-revascularization) *(p. 49)*
          - [8.1.2.3.2. Spinal cord stimulation](#81232-spinal-cord-stimulation) *(p. 50)*
          - [8.1.2.3.3. Amputation](#81233-amputation) *(p. 50)*
        - [8.1.2.4. Follow-up](#8124-follow-up) *(p. 50)*
      - [8.1.3. Acute limb ischaemia](#813-acute-limb-ischaemia) *(p. 50)*
        - [8.1.3.1. Clinical presentation and diagnosis](#8131-clinical-presentation-and-diagnosis) *(p. 50)*
          - [8.1.3.1.1. Clinical examination](#81311-clinical-examination) *(p. 51)*
          - [8.1.3.1.2. Imaging and functional tests](#81312-imaging-and-functional-tests) *(p. 51)*
        - [8.1.3.2. Medical treatment](#8132-medical-treatment) *(p. 51)*
        - [8.1.3.3. Surgical and interventional treatment](#8133-surgical-and-interventional-treatment) *(p. 51)*
        - [8.1.3.4. Follow-up](#8134-follow-up) *(p. 53)*
    - [8.2. Extracranial carotid and vertebral artery disease](#82-extracranial-carotid-and-vertebral-artery-disea) *(p. 53)*
      - [8.2.1. Clinical presentation and diagnosis](#821-clinical-presentation-and-diagnosis) *(p. 53)*
        - [8.2.1.1. Clinical presentation](#8211-clinical-presentation) *(p. 53)*
        - [8.2.1.2. Diagnosis](#8212-diagnosis) *(p. 53)*
      - [8.2.2. Asymptomatic carotid artery stenosis](#822-asymptomatic-carotid-artery-stenosis) *(p. 54)*
        - [8.2.2.1. Medical treatment](#8221-medical-treatment) *(p. 54)*
          - [8.2.2.1.1. Lipid-lowering therapy](#82211-lipid-lowering-therapy) *(p. 54)*
          - [8.2.2.1.2. Antihypertensive therapy](#82212-antihypertensive-therapy) *(p. 54)*
          - [8.2.2.1.3. Glucose-lowering therapy](#82213-glucose-lowering-therapy) *(p. 54)*
          - [8.2.2.1.4. Antithrombotic therapy](#82214-antithrombotic-therapy) *(p. 54)*
        - [8.2.2.2. Interventional treatment](#8222-interventional-treatment) *(p. 55)*
          - [8.2.2.2.1. Open surgery vs. medical therapy](#82221-open-surgery-vs-medical-therapy) *(p. 55)*
          - [8.2.2.2.2. Carotid revascularization: surgery vs. stenting](#82222-carotid-revascularization:-surgery-vs-stenti) *(p. 55)*
      - [8.2.3. Symptomatic carotid artery stenosis](#823-symptomatic-carotid-artery-stenosis) *(p. 57)*
        - [8.2.3.1. Medical treatment](#8231-medical-treatment) *(p. 57)*
          - [8.2.3.1.1. Lipid-lowering therapy](#82311-lipid-lowering-therapy) *(p. 57)*
          - [8.2.3.1.2. Antihypertensive therapy](#82312-antihypertensive-therapy) *(p. 57)*
          - [8.2.3.1.3. Glucose-lowering therapy](#82313-glucose-lowering-therapy) *(p. 57)*
          - [8.2.3.1.4. Antithrombotic therapy](#82314-antithrombotic-therapy) *(p. 57)*
        - [8.2.3.2. Interventional treatment](#8232-interventional-treatment) *(p. 58)*
          - [8.2.3.2.1. Open surgery](#82321-open-surgery) *(p. 58)*
          - [8.2.3.2.2. Endovascular therapy vs. open surgery](#82322-endovascular-therapy-vs-open-surgery) *(p. 58)*
          - [8.2.3.2.3. Vertebral arteries](#82323-vertebral-arteries) *(p. 58)*
        - [8.2.3.3. Follow-up](#8233-follow-up) *(p. 59)*
    - [8.3. Other arterial locations](#83-other-arterial-locations) *(p. 59)*
      - [8.3.1. Subclavian artery disease](#831-subclavian-artery-disease) *(p. 59)*
        - [8.3.1.1. Clinical presentation and diagnosis](#8311-clinical-presentation-and-diagnosis) *(p. 59)*
        - [8.3.1.2. Treatment strategy (medical and interventional)](#8312-treatment-strategy-(medical-and-interventiona) *(p. 60)*
        - [8.3.1.3. Follow-up](#8313-follow-up) *(p. 60)*
      - [8.3.2. Renal artery disease](#832-renal-artery-disease) *(p. 61)*
        - [8.3.2.1. Clinical presentation and diagnosis](#8321-clinical-presentation-and-diagnosis) *(p. 61)*
          - [8.3.2.1.1. Epidemiology](#83211-epidemiology) *(p. 61)*
          - [8.3.2.1.2. Clinical presentation](#83212-clinical-presentation) *(p. 61)*
          - [8.3.2.1.3. Diagnosis of renal artery disease](#83213-diagnosis-of-renal-artery-disease) *(p. 61)*
          - [8.3.2.1.4. Prognosis](#83214-prognosis) *(p. 61)*
        - [8.3.2.2. Treatment strategy (medical and interventional)](#8322-treatment-strategy-(medical-and-interventiona) *(p. 61)*
          - [8.3.2.2.1. Medical therapy](#83221-medical-therapy) *(p. 61)*
          - [8.3.2.2.2. Revascularization](#83222-revascularization) *(p. 61)*
        - [8.3.2.3. Follow-up](#8323-follow-up) *(p. 63)*
      - [8.3.3. Visceral artery disease](#833-visceral-artery-disease) *(p. 63)*
        - [8.3.3.1. Acute mesenteric ischaemia](#8331-acute-mesenteric-ischaemia) *(p. 63)*
          - [8.3.3.1.1. Clinical presentation and diagnosis](#83311-clinical-presentation-and-diagnosis) *(p. 63)*
          - [8.3.3.1.2. Treatment strategy](#83312-treatment-strategy) *(p. 63)*
          - [8.3.3.1.3. Follow-up](#83313-follow-up) *(p. 64)*
        - [8.3.3.2. Chronic mesenteric artery disease](#8332-chronic-mesenteric-artery-disease) *(p. 64)*
          - [8.3.3.2.1. Clinical presentation and diagnosis](#83321-clinical-presentation-and-diagnosis) *(p. 64)*
          - [8.3.3.2.2. Treatment strategy](#83322-treatment-strategy) *(p. 65)*
          - [8.3.3.2.3. Follow-up](#83323-follow-up) *(p. 65)*
  - [9. Aorta](#9-aorta) *(p. 65)*
    - [9.1. Atheromatous disease of the aorta](#91-atheromatous-disease-of-the-aorta) *(p. 65)*
      - [9.1.1. General concepts](#911-general-concepts) *(p. 65)*
      - [9.1.2. Treatment](#912-treatment) *(p. 65)*
        - [9.1.2.1. Primary prevention](#9121-primary-prevention) *(p. 65)*
        - [9.1.2.2. Secondary prevention](#9122-secondary-prevention) *(p. 65)*
    - [9.2. Aortic aneurysms](#92-aortic-aneurysms) *(p. 66)*
      - [9.2.1. General concepts](#921-general-concepts) *(p. 66)*
        - [9.2.1.1. Definitions](#9211-definitions) *(p. 66)*
      - [9.2.2. Thoracic aortic aneurysms](#922-thoracic-aortic-aneurysms) *(p. 66)*
        - [9.2.2.1. Aetiology, risk factors, and natural history](#9221-aetiology,-risk-factors,-and-natural-history) *(p. 66)*
        - [9.2.2.2. Ascending thoracic aorta and arch aneurysms](#9222-ascending-thoracic-aorta-and-arch-aneurysms) *(p. 66)*
        - [9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta aneurysms](#9223-descending-thoracic-aorta-and-thoracoabdomina) *(p. 67)*
        - [9.2.2.4. Surveillance](#9224-surveillance) *(p. 70)*
      - [9.2.3. Abdominal aortic aneurysms](#923-abdominal-aortic-aneurysms) *(p. 70)*
        - [9.2.3.1. General concepts](#9231-general-concepts) *(p. 70)*
        - [9.2.3.2. Aetiology, risk factors, and natural history](#9232-aetiology,-risk-factors,-and-natural-history) *(p. 70)*
        - [9.2.3.3. Surveillance](#9233-surveillance) *(p. 70)*
      - [9.2.4. Optimal medical treatment of aortic aneurysms](#924-optimal-medical-treatment-of-aortic-aneurysms) *(p. 72)*
      - [9.2.5. Surgical management of aortic aneurysms](#925-surgical-management-of-aortic-aneurysms) *(p. 72)*
        - [9.2.5.1. Surgical treatment of aortic root and ascending aorta](#9251-surgical-treatment-of-aortic-root-and-ascendi) *(p. 72)*
        - [9.2.5.2. Surgical treatment of aortic arch aneurysms](#9252-surgical-treatment-of-aortic-arch-aneurysms) *(p. 74)*
        - [9.2.5.3. Surgical treatment of the thoracic descending aorta](#9253-surgical-treatment-of-the-thoracic-descending) *(p. 75)*
          - [9.2.5.3.1. General considerations](#92531-general-considerations) *(p. 75)*
          - [9.2.5.3.2. Open repair](#92532-open-repair) *(p. 75)*
          - [9.2.5.3.3. Endovascular repair](#92533-endovascular-repair) *(p. 75)*
        - [9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms](#9254-surgical-treatment-of-thoracoabdominal-aorta-) *(p. 75)*
          - [9.2.5.4.1. General considerations](#92541-general-considerations) *(p. 75)*
          - [9.2.5.4.2. Open repair](#92542-open-repair) *(p. 75)*
          - [9.2.5.4.3. Endovascular repair](#92543-endovascular-repair) *(p. 75)*
        - [9.2.5.5. Surgical treatment of abdominal aorta aneurysms](#9255-surgical-treatment-of-abdominal-aorta-aneurys) *(p. 76)*
          - [9.2.5.5.1. General considerations](#92551-general-considerations) *(p. 76)*
          - [9.2.5.5.2. Pre-operative cardiovascular evaluation and choice of treatment](#92552-pre-operative-cardiovascular-evaluation-and-) *(p. 76)*
          - [9.2.5.5.3. Open abdominal aorta aneurysm repair](#92553-open-abdominal-aorta-aneurysm-repair) *(p. 78)*
          - [9.2.5.5.4. Endovascular abdominal aorta aneurysm repair](#92554-endovascular-abdominal-aorta-aneurysm-repair) *(p. 78)*
      - [9.2.6. Endoleaks](#926-endoleaks) *(p. 78)*
      - [9.2.7. Long-term follow-up after aortic repair](#927-long-term-follow-up-after-aortic-repair) *(p. 80)*
        - [9.2.7.1. Follow-up after thoracic aortic aneurysm treatment](#9271-follow-up-after-thoracic-aortic-aneurysm-trea) *(p. 80)*
        - [9.2.7.2. Follow-up after abdominal aortic aneurysm treatment](#9272-follow-up-after-abdominal-aortic-aneurysm-tre) *(p. 80)*
    - [9.3. Acute thoracic aortic syndromes](#93-acute-thoracic-aortic-syndromes) *(p. 81)*
      - [9.3.1. General concepts](#931-general-concepts) *(p. 81)*
        - [9.3.1.1. Epidemiology and risk factors](#9311-epidemiology-and-risk-factors) *(p. 81)*
          - [9.3.1.1.1. Sex differences](#93111-sex-differences) *(p. 83)*
          - [9.3.1.1.2. Chronobiology](#93112-chronobiology) *(p. 84)*
          - [9.3.1.1.3. Outcomes](#93113-outcomes) *(p. 84)*
        - [9.3.1.2. Clinical presentation](#9312-clinical-presentation) *(p. 85)*
        - [9.3.1.3. Diagnostic work-up](#9313-diagnostic-work-up) *(p. 85)*
        - [9.3.1.4. Therapeutic intervention in acute aortic dissection](#9314-therapeutic-intervention-in-acute-aortic-diss) *(p. 85)*
          - [9.3.1.4.1. Initial treatment](#93141-initial-treatment) *(p. 85)*
          - [9.3.1.4.2. Type A aortic dissection interventional treatment](#93142-type-a-aortic-dissection-interventional-trea) *(p. 86)*
          - [9.3.1.4.3. Acute type B aortic dissection interventional treatment](#93143-acute-type-b-aortic-dissection-interventiona) *(p. 91)*
          - [9.3.1.4.4. Chronic type B aortic dissection interventional treatment](#93144-chronic-type-b-aortic-dissection-interventio) *(p. 92)*
          - [9.3.1.4.5. Management during pregnancy](#93145-management-during-pregnancy) *(p. 92)*
      - [9.3.2. Intramural haematoma](#932-intramural-haematoma) *(p. 93)*
        - [9.3.2.1. Diagnostic work-up](#9321-diagnostic-work-up) *(p. 93)*
        - [9.3.2.2. Clinical outcomes](#9322-clinical-outcomes) *(p. 93)*
        - [9.3.2.3. Geographical variations](#9323-geographical-variations) *(p. 93)*
        - [9.3.2.4. Management](#9324-management) *(p. 93)*
          - [9.3.2.4.1. Type A intramural haematoma](#93241-type-a-intramural-haematoma) *(p. 93)*
          - [9.3.2.4.2. Type B intramural haematoma](#93242-type-b-intramural-haematoma) *(p. 93)*
      - [9.3.3. Penetrating atherosclerotic ulcer](#933-penetrating-atherosclerotic-ulcer) *(p. 94)*
        - [9.3.3.1. Diagnosis](#9331-diagnosis) *(p. 94)*
        - [9.3.3.2. Treatment](#9332-treatment) *(p. 94)*
      - [9.3.4. Aortic pseudo-aneurysm](#934-aortic-pseudo-aneurysm) *(p. 95)*
      - [9.3.5. Traumatic aortic injury](#935-traumatic-aortic-injury) *(p. 96)*
        - [9.3.5.1. Diagnosis and therapeutic interventions](#9351-diagnosis-and-therapeutic-interventions) *(p. 96)*
        - [9.3.5.2. Long-term surveillance in traumatic aortic injury](#9352-long-term-surveillance-in-traumatic-aortic-in) *(p. 96)*
      - [9.3.6. Iatrogenic aortic injuries](#936-iatrogenic-aortic-injuries) *(p. 96)*
      - [9.3.7. Long-term follow-up of acute aortic syndrome](#937-long-term-follow-up-of-acute-aortic-syndrome) *(p. 96)*
        - [9.3.7.1. Follow-up after invasive treatment](#9371-follow-up-after-invasive-treatment) *(p. 97)*
        - [9.3.7.2. Follow-up under medical treatment (chronic type B aortic dissection, intramural haematoma, penetrating atherosclerotic ulcer)](#9372-follow-up-under-medical-treatment-(chronic-ty) *(p. 99)*
  - [10. Genetic and congenital diseases of the aorta](#10-genetic-and-congenital-diseases-of-the-aorta) *(p. 100)*
    - [10.1. Genetic and chromosomal diseases](#101-genetic-and-chromosomal-diseases) *(p. 100)*
      - [10.1.1. Turner syndrome](#1011-turner-syndrome) *(p. 101)*
        - [10.1.1.1. Diagnosis, clinical presentation, and natural history](#10111-diagnosis,-clinical-presentation,-and-natura) *(p. 101)*
        - [10.1.1.2. Medical treatment](#10112-medical-treatment) *(p. 103)*
        - [10.1.1.3. Surgery of aortic aneurysms](#10113-surgery-of-aortic-aneurysms) *(p. 103)*
        - [10.1.1.4. Pregnancy and physical exercise](#10114-pregnancy-and-physical-exercise) *(p. 103)*
      - [10.1.2. Vascular Ehlers–Danlos syndrome](#1012-vascular-ehlers–danlos-syndrome) *(p. 104)*
        - [10.1.2.1. Diagnosis, clinical presentation, and natural history](#10121-diagnosis,-clinical-presentation,-and-natura) *(p. 104)*
        - [10.1.2.2. Surveillance and imaging](#10122-surveillance-and-imaging) *(p. 104)*
        - [10.1.2.3. Medical treatment](#10123-medical-treatment) *(p. 104)*
        - [10.1.2.4. Surgical treatment](#10124-surgical-treatment) *(p. 104)*
        - [10.1.2.5. Pregnancy](#10125-pregnancy) *(p. 104)*
      - [10.1.3. Marfan syndrome](#1013-marfan-syndrome) *(p. 104)*
        - [10.1.3.1. Diagnosis, clinical presentation, and natural history](#10131-diagnosis,-clinical-presentation,-and-natura) *(p. 104)*
        - [10.1.3.2. Imaging surveillance](#10132-imaging-surveillance) *(p. 104)*
        - [10.1.3.3. Medical treatment](#10133-medical-treatment) *(p. 105)*
        - [10.1.3.4. Aortic surgery](#10134-aortic-surgery) *(p. 105)*
        - [10.1.3.5. Pregnancy and physical exercise](#10135-pregnancy-and-physical-exercise) *(p. 106)*
      - [10.1.4. Other syndromic and non-syndromic heritable thoracic aortic diseases and/or arterial disorders](#1014-other-syndromic-and-non-syndromic-heritable-t) *(p. 106)*
        - [10.1.4.1. Loeys–Dietz syndrome](#10141-loeys–dietz-syndrome) *(p. 106)*
          - [10.1.4.1.1. Diagnosis, clinical presentation, and natural evolution](#101411-diagnosis,-clinical-presentation,-and-natur) *(p. 106)*
        - [10.1.4.2. ACTA2-related heritable thoracic aortic disease](#10142-acta2-related-heritable-thoracic-aortic-dise) *(p. 108)*
    - [10.2. Aortic disease associated with bicuspid aortic valves](#102-aortic-disease-associated-with-bicuspid-aortic) *(p. 109)*
    - [10.3. Coarctation of the aorta and aortic arch variants](#103-coarctation-of-the-aorta-and-aortic-arch-varia) *(p. 111)*
      - [10.3.1. Coarctation of the aorta](#1031-coarctation-of-the-aorta) *(p. 111)*
        - [10.3.1.1. Diagnostic work-up](#10311-diagnostic-work-up) *(p. 111)*
        - [10.3.1.2. Treatment and follow-up](#10312-treatment-and-follow-up) *(p. 111)*
      - [10.3.2. Aortic arch anatomic variants](#1032-aortic-arch-anatomic-variants) *(p. 113)*
      - [10.3.3. Aberrant subclavian artery and Kommerell’s diverticulum](#1033-aberrant-subclavian-artery-and-kommerell’s-di) *(p. 113)*
  - [11. Polyvascular peripheral arterial disease and peripheral arterial disease in patients with cardiac diseases](#11-polyvascular-peripheral-arterial-disease-and-pe) *(p. 113)*
    - [11.1. Polyvascular disease](#111-polyvascular-disease) *(p. 113)*
      - [11.1.1. Epidemiology and prognosis](#1111-epidemiology-and-prognosis) *(p. 113)*
      - [11.1.2. Screening for atherosclerosis in other arterial territories](#1112-screening-for-atherosclerosis-in-other-arteri) *(p. 113)*
        - [11.1.2.1. Screening for coronary artery disease in patients with symptomatic peripheral arterial disease](#11121-screening-for-coronary-artery-disease-in-pat) *(p. 114)*
        - [11.1.2.2. Screening for peripheral arterial disease in patients with coronary artery disease](#11122-screening-for-peripheral-arterial-disease-in) *(p. 114)*
        - [11.1.2.3. Screening for coronary artery disease in patients with carotid stenosis](#11123-screening-for-coronary-artery-disease-in-pat) *(p. 114)*
        - [11.1.2.4. Screening for carotid stenosis in patients with coronary artery disease](#11124-screening-for-carotid-stenosis-in-patients-w) *(p. 114)*
      - [11.1.3. Management of patients with polyvascular disease](#1113-management-of-patients-with-polyvascular-dise) *(p. 114)*
    - [11.2. Peripheral arterial disease and heart failure](#112-peripheral-arterial-disease-and-heart-failure) *(p. 114)*
    - [11.3. Peripheral arterial disease and AF](#113-peripheral-arterial-disease-and-af) *(p. 115)*
    - [11.4. Peripheral arterial disease and aortic stenosis](#114-peripheral-arterial-disease-and-aortic-stenosi) *(p. 115)*
  - [12. Key messages](#12-key-messages) *(p. 115)*
  - [13. Gaps in evidence](#13-gaps-in-evidence) *(p. 116)*
  - [14. Sex differences](#14-sex-differences) *(p. 116)*
  - [15. ‘What to do’ and ‘What not to do’ messages from the guidelines](#15-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 116)*
  - [16. Evidence tables](#16-evidence-tables) *(p. 124)*
  - [17. Data availability statement](#17-data-availability-statement) *(p. 124)*
  - [18. Author information](#18-author-information) *(p. 124)*
  - [Appendix](#appendix) *(p. 125)*
  - [References](#references) *(p. 126)*
  - [References](#references) *(p. 126)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management 
of peripheral arterial and aortic diseases
Developed by the task force on the management of peripheral arterial 
and aortic diseases of the European Society of Cardiology (ESC)  
Endorsed by the European Association for Cardio-Thoracic Surgery 
(EACTS), the European Reference Network on Rare Multisystemic 
Vascular Diseases (VASCERN), and the European Society of Vascular 
Medicine (ESVM)  
Authors/Task Force Members: Lucia Mazzolai  *†, (Chairperson) (Switzerland), 
Gisela Teixido-Tura  
‡, (Task Force Co-ordinator) (Spain), Stefano Lanzi  
‡, 
(Task Force Co-ordinator) (Switzerland), Vinko Boc  
(Slovenia), 
Eduardo Bossone  
(Italy), Marianne Brodmann  
1 (Austria), 
Alessandra Bura-Rivière  
(France), Julie De Backer  
2 (Belgium), 
Sebastien Deglise  
(Switzerland), Alessandro Della Corte  
(Italy), 
Christian Heiss  
(United Kingdom), Marta Kałużna-Oleksy  
(Poland), 
Donata Kurpas  
(Poland), Carmel M. McEniery  
(United Kingdom), 
Tristan Mirault  
(France), Agnes A. Pasquet  
(Belgium), Alex Pitcher  
(United Kingdom), Hannah A.I. Schaubroeck  
(Belgium), Oliver Schlager  
(Austria), Per Anton Sirnes  
(Norway), Muriel G. Sprynger  
(Belgium), 
Eugenio Stabile  
(Italy), Françoise Steinbach (France), Matthias Thielmann  
(Germany), Roland R.J. van Kimmenade  
(Netherlands), Maarit Venermo  
(Finland), Jose F. Rodriguez-Palomares  *†, (Chairperson) (Spain), 
and ESC Scientific Document Group
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
*  Corresponding authors: Lucia Mazzolai, Department of Angiology, Lausanne University Hospital (CHUV), and Medical School, Lausanne University (UNIL) Lausanne, Switzerland. Tel: +41 
(0)21 314 0750. Email: Lucia.Mazzolai@chuv.ch; and Jose F. Rodriguez-Palomares, Cardiovascular Imaging Section and Aortic Diseases Unit (VASCERN), Department of Cardiology, Vall 
d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Centro de Investigación Biomédica en Red de 
Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain, and Department of Medicine, Universitat Autònoma de Barcelona, Spain. Tel: +34 93 882 3881. Email: 
josefernando.rodriguez@vallhebron.cat
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Society of Vascular Medicine (ESVM)
2 Representing the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Surgery, Thrombosis.
Patient Forum
https://doi.org/10.1093/eurheartj/ehae179
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Alessia Gimelli, (CPG Review Co-ordinator) (Italy), Jean-Baptiste Ricco, (CPG Review 
Co-ordinator) (France), Elena Arbelo (Spain), Christian-Alexander Behrendt (Germany), Michael Böhm 
(Germany), Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio Buccheri (Sweden), 
Gill Louise Buchanan (United Kingdom), Christina Christersson (Sweden), Gert J. de Borst (Netherlands), 
Marco De Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United Kingdom), Lynne Hinterbuchner (Austria), 
Borja Ibanez (Spain), Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan (Sweden), 
Klaus Kallenbach2 (Luxemburg), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Juraj Madaric1 
(Slovakia), Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer (Israel), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen (Denmark), 
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Barbara Rantner (Germany), Bianca Rocca (Italy), 
Xavier Rossello (Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland), Sabine Steiner (Germany), 
Isabella Sudano (Switzerland), Martin Teraa (Netherlands), Ilonca Vaartjes (Netherlands), Rafael Vidal-Perez (Spain), 
Christiaan Vrints (Belgium), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest which 
are reported in a supplementary document to the guidelines. See the European Heart Journal online or  
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and 
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, 
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant 
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged 
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do 
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated 
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s 
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC 
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational 
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written 
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of 
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Acute aortic syndrome • Aortic aneurysm • Aortic atherosclerosis • Aortic dissection • Aortic surgery 
• Carotid artery disease • Chronic limb-threatening ischaemia • Endovascular repair • Exercise • Genetic aortic 
diseases • Intramural haematoma • Lower extremity artery disease • Penetrating atherosclerotic ulcer • Peripheral 
arterial disease • Polyvascular disease • Renal artery disease
ESC Guidelines                                                                                                                                                                                          3539


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble .............................................................................................................. 3547
2. Introduction ....................................................................................................... 3548
3. What is new ....................................................................................................... 3550
4. Epidemiology and risk factors ..................................................................... 3558
4.1. Epidemiology ............................................................................................
3558
4.2. Risk factors ................................................................................................
3559
5. Evaluation of peripheral arteries and aorta .......................................... 3560
5.1. Clinical history and examination, and laboratory assessment, 
in patients with peripheral arterial and aortic diseases ..................
3560
5.2. Functional and quality of life assessment in patients with 
peripheral arterial and aortic diseases ...................................................
3560
5.3. Vascular examination of peripheral arteries ...............................
3561
5.3.1. Duplex ultrasound ......................................................................... 3562
5.3.2. Digital subtraction angiography, computed tomography 
angiography, and magnetic resonance angiography ..................... 3562
5.4. Evaluation of the aorta .........................................................................
3562
5.4.1. Aortic measurements ................................................................... 3562
5.4.2. Normal aortic values ..................................................................... 3565
5.4.3. Chest X-ray and electrocardiogram ....................................... 3565
5.4.4. Echocardiography ........................................................................... 3565
5.4.5. Duplex ultrasound imaging of the abdominal aorta ........ 3566
5.4.6. Cardiovascular computed tomography ................................ 3566
5.4.7. Cardiovascular magnetic resonance ....................................... 3566
5.4.8. Positron emission tomography ................................................. 3566
5.4.9. Intravascular ultrasound ............................................................... 3567
5.4.10. Digital subtraction aortography ............................................. 3567
6. Screening for carotid, peripheral arterial, and aortic diseases ..... 3567
6.1. Screening for carotid and peripheral arterial diseases ...........
3567
6.1.1. Lower-extremity peripheral arterial disease ....................... 3567
6.1.2. Carotid artery stenosis ................................................................ 3567
6.1.3. Multisite artery disease ................................................................. 3567
6.2. Screening for aortic diseases .............................................................
3568
6.2.1. Screening for abdominal aortic aneurysm ........................... 3568
6.2.2. Screening for thoracic aortic aneurysm ................................ 3568
7. Optimal medical treatment ......................................................................... 3568
7.1. Lifestyle, exercise, patient education .............................................
3568
7.1.1. Diet ....................................................................................................... 3568
7.1.2. Physical activity ................................................................................ 3569
7.1.3. Smoking ............................................................................................... 3570
7.1.4. Patient education ............................................................................ 3570
7.1.5. Risk scoring models in secondary prevention .................... 3570
7.2. Principles of pharmacological medical therapy ..........................
3571
7.2.1. Antithrombotic therapy ............................................................... 3571
7.2.2. Antihypertensive therapy ............................................................ 3571
7.2.2.1. Renovascular hypertension ................................................
3571
7.2.3. Lipid-lowering therapy ................................................................. 3572
7.2.3.1. Statins ..........................................................................................
3572
7.2.3.2. Ezetimibe ...................................................................................
3572
7.2.3.3. Proprotein convertase subtilisin/kexin type 9 
inhibitors ....................................................................................................
3572
7.2.3.4. Bempedoic acid .......................................................................
3572
7.2.3.5. Hypertriglyceridaemia ..........................................................
3572
7.2.4. Diabetes and pre-diabetes conditions ................................... 3573
7.2.5. Other pharmacological therapy ............................................... 3574
8. Peripheral arterial disease ............................................................................ 3574
8.1. Lower-extremity peripheral arterial disease ..............................
3574
8.1.1. Peripheral arterial disease syndromes ................................... 3574
8.1.1.1. Clinical presentation and diagnosis .................................
3574
8.1.1.1.1. Diagnostic tests ..............................................................
3575
8.1.1.1.2. Imaging methods ............................................................
3576
8.1.1.2. Medical treatment ..................................................................
3578
8.1.1.2.1. Exercise therapy ............................................................
3578
8.1.1.2.2. Pharmacological treatment .......................................
3582
8.1.1.2.3. Aorto-iliac lesion revascularization ........................
3583
8.1.1.2.4. Femoro-popliteal lesion revascularization ..........
3584
8.1.1.2.5. Below-the-knee artery revascularization ...........
3584
8.1.1.3. Follow-up ...................................................................................
3585
8.1.2. Chronic limb-threatening ischaemia ....................................... 3585
8.1.2.1. Clinical presentation and diagnosis .................................
3585
8.1.2.1.1. Definition ..........................................................................
3585
8.1.2.1.2. Initial assessment and risk of amputation ...........
3585
8.1.2.1.3. Imaging ...............................................................................
3585
8.1.2.1.4. Mortality risk assessment ...........................................
3585
8.1.2.2. Medical treatment ..................................................................
3586
8.1.2.3. Interventional treatment .....................................................
3586
8.1.2.3.1. Revascularization ............................................................
3586
8.1.2.3.2. Spinal cord stimulation ................................................
3587
8.1.2.3.3. Amputation ......................................................................
3587
8.1.2.4. Follow-up ...................................................................................
3587
8.1.3. Acute limb ischaemia .................................................................... 3587
8.1.3.1. Clinical presentation and diagnosis .................................
3587
8.1.3.1.1. Clinical examination .....................................................
3588
8.1.3.1.2. Imaging and functional tests ......................................
3588
8.1.3.2. Medical treatment ..................................................................
3588
8.1.3.3. Surgical and interventional treatment ...........................
3588
8.1.3.4. Follow-up ...................................................................................
3590
8.2. Extracranial carotid and vertebral artery disease .....................
3590
8.2.1. Clinical presentation and diagnosis ......................................... 3590
8.2.1.1. Clinical presentation .............................................................
3590
8.2.1.2. Diagnosis ....................................................................................
3590
8.2.2. Asymptomatic carotid artery stenosis .................................. 3591
8.2.2.1. Medical treatment ..................................................................
3591
8.2.2.1.1. Lipid-lowering therapy ................................................
3591
8.2.2.1.2. Antihypertensive therapy ...........................................
3591
8.2.2.1.3. Glucose-lowering therapy .........................................
3591
8.2.2.1.4. Antithrombotic therapy .............................................
3591
8.2.2.2. Interventional treatment .....................................................
3592
8.2.2.2.1. Open surgery vs. medical therapy .........................
3592
8.2.2.2.2. Carotid revascularization: surgery vs. stenting .
3592
8.2.3. Symptomatic carotid artery stenosis ..................................... 3594
8.2.3.1. Medical treatment ..................................................................
3594
8.2.3.1.1. Lipid-lowering therapy ................................................
3594
8.2.3.1.2. Antihypertensive therapy ...........................................
3594
8.2.3.1.3. Glucose-lowering therapy .........................................
3594
8.2.3.1.4. Antithrombotic therapy .............................................
3594
8.2.3.2. Interventional treatment .....................................................
3595
8.2.3.2.1. Open surgery ..................................................................
3595
8.2.3.2.2. Endovascular therapy vs. open surgery ................
3595
8.2.3.2.3. Vertebral arteries ..........................................................
3595
8.2.3.3. Follow-up ...................................................................................
3596
8.3. Other arterial locations .......................................................................
3596
8.3.1. Subclavian artery disease ............................................................. 3596
8.3.1.1. Clinical presentation and diagnosis .................................
3596
8.3.1.2. Treatment strategy (medical and interventional) .....
3597
8.3.1.3. Follow-up ...................................................................................
3597
8.3.2. Renal artery disease ....................................................................... 3598


<!-- PAGE 4 -->

### Page 4

8.3.2.1. Clinical presentation and diagnosis .................................
3598
8.3.2.1.1. Epidemiology ...................................................................
3598
8.3.2.1.2. Clinical presentation .....................................................
3598
8.3.2.1.3. Diagnosis of renal artery disease ............................
3598
8.3.2.1.4. Prognosis ...........................................................................
3598
8.3.2.2. Treatment strategy (medical and interventional) .....
3598
8.3.2.2.1. Medical therapy ..............................................................
3598
8.3.2.2.2. Revascularization ............................................................
3598
8.3.2.3. Follow-up ...................................................................................
3600
8.3.3. Visceral artery disease .................................................................. 3600
8.3.3.1. Acute mesenteric ischaemia ..............................................
3600
8.3.3.1.1. Clinical presentation and diagnosis ........................
3600
8.3.3.1.2. Treatment strategy .......................................................
3600
8.3.3.1.3. Follow-up ..........................................................................
3601
8.3.3.2. Chronic mesenteric artery disease .................................
3601
8.3.3.2.1. Clinical presentation and diagnosis ........................
3601
8.3.3.2.2. Treatment strategy .......................................................
3602
8.3.3.2.3. Follow-up ..........................................................................
3602
9. Aorta ..................................................................................................................... 3602
9.1. Atheromatous disease of the aorta ...............................................
3602
9.1.1. General concepts ............................................................................ 3602
9.1.2. Treatment .......................................................................................... 3602
9.1.2.1. Primary prevention ................................................................
3602
9.1.2.2. Secondary prevention ..........................................................
3602
9.2. Aortic aneurysms ...................................................................................
3603
9.2.1. General concepts ............................................................................ 3603
9.2.1.1. Definitions .................................................................................
3603
9.2.2. Thoracic aortic aneurysms ......................................................... 3603
9.2.2.1. Aetiology, risk factors, and natural history .................
3603
9.2.2.2. Ascending thoracic aorta and arch aneurysms .........
3603
9.2.2.3. Descending thoracic aorta and thoracoabdominal 
aorta aneurysms .....................................................................................
3604
9.2.2.4. Surveillance ...............................................................................
3607
9.2.3. Abdominal aortic aneurysms ..................................................... 3607
9.2.3.1. General concepts ...................................................................
3607
9.2.3.2. Aetiology, risk factors, and natural history .................
3607
9.2.3.3. Surveillance ...............................................................................
3607
9.2.4. Optimal medical treatment of aortic aneurysms .............. 3609
9.2.5. Surgical management of aortic aneurysms .......................... 3609
9.2.5.1. Surgical treatment of aortic root and ascending 
aorta ............................................................................................................
3609
9.2.5.2. Surgical treatment of aortic arch aneurysms .............
3611
9.2.5.3. Surgical treatment of the thoracic descending aorta
3612
9.2.5.3.1. General considerations ...............................................
3612
9.2.5.3.2. Open repair .....................................................................
3612
9.2.5.3.3. Endovascular repair ......................................................
3612
9.2.5.4. Surgical treatment of thoracoabdominal aorta 
aneurysms .................................................................................................
3612
9.2.5.4.1. General considerations ...............................................
3612
9.2.5.4.2. Open repair .....................................................................
3612
9.2.5.4.3. Endovascular repair ......................................................
3612
9.2.5.5. Surgical treatment of abdominal aorta aneurysms ..
3613
9.2.5.5.1. General considerations ...............................................
3613
9.2.5.5.2. Pre-operative cardiovascular evaluation and 
choice of treatment .........................................................................
3613
9.2.5.5.3. Open abdominal aorta aneurysm repair .............
3615
9.2.5.5.4. Endovascular abdominal aorta aneurysm repair
3615
9.2.6. Endoleaks ........................................................................................... 3615
9.2.7. Long-term follow-up after aortic repair ............................... 3617
9.2.7.1. Follow-up after thoracic aortic aneurysm treatment
3617
9.2.7.2. Follow-up after abdominal aortic aneurysm 
treatment ...................................................................................................
3617
9.3. Acute thoracic aortic syndromes ....................................................
3618
9.3.1. General concepts ............................................................................ 3618
9.3.1.1. Epidemiology and risk factors ...........................................
3618
9.3.1.1.1. Sex differences ................................................................
3620
9.3.1.1.2. Chronobiology ................................................................
3621
9.3.1.1.3. Outcomes .........................................................................
3621
9.3.1.2. Clinical presentation .............................................................
3622
9.3.1.3. Diagnostic work-up ...............................................................
3622
9.3.1.4. Therapeutic intervention in acute aortic dissection
3622
9.3.1.4.1. Initial treatment ..............................................................
3622
9.3.1.4.2. Type A aortic dissection interventional 
treatment ..............................................................................................
3623
9.3.1.4.3. Acute type B aortic dissection interventional 
treatment ..............................................................................................
3628
9.3.1.4.4. Chronic type B aortic dissection interventional 
treatment ..............................................................................................
3629
9.3.1.4.5. Management during pregnancy ................................
3629
9.3.2. Intramural haematoma ................................................................. 3630
9.3.2.1. Diagnostic work-up ...............................................................
3630
9.3.2.2. Clinical outcomes ...................................................................
3630
9.3.2.3. Geographical variations .......................................................
3630
9.3.2.4. Management .............................................................................
3630
9.3.2.4.1. Type A intramural haematoma ...............................
3630
9.3.2.4.2. Type B intramural haematoma ................................
3630
9.3.3. Penetrating atherosclerotic ulcer ............................................ 3631
9.3.3.1. Diagnosis ....................................................................................
3631
9.3.3.2. Treatment .................................................................................
3631
9.3.4. Aortic pseudo-aneurysm ............................................................. 3632
9.3.5. Traumatic aortic injury ................................................................. 3633
9.3.5.1. Diagnosis and therapeutic interventions ......................
3633
9.3.5.2. Long-term surveillance in traumatic aortic injury ....
3633
9.3.6. Iatrogenic aortic injuries .............................................................. 3633
9.3.7. Long-term follow-up of acute aortic syndrome ............... 3633
9.3.7.1. Follow-up after invasive treatment ................................
3634
9.3.7.2. Follow-up under medical treatment (chronic type B 
aortic dissection, intramural haematoma, penetrating 
atherosclerotic ulcer) ...........................................................................
3636
10. Genetic and congenital diseases of the aorta ................................... 3637
10.1. Genetic and chromosomal diseases ............................................
3637
10.1.1. Turner syndrome ......................................................................... 3638
10.1.1.1. Diagnosis, clinical presentation, and natural history
3638
10.1.1.2. Medical treatment ...............................................................
3640
10.1.1.3. Surgery of aortic aneurysms ...........................................
3640
10.1.1.4. Pregnancy and physical exercise ...................................
3640
10.1.2. Vascular Ehlers–Danlos syndrome ....................................... 3641
10.1.2.1. Diagnosis, clinical presentation, and natural history
3641
10.1.2.2. Surveillance and imaging ...................................................
3641
10.1.2.3. Medical treatment ...............................................................
3641
10.1.2.4. Surgical treatment ...............................................................
3641
10.1.2.5. Pregnancy ................................................................................
3641
10.1.3. Marfan syndrome ......................................................................... 3641
10.1.3.1. Diagnosis, clinical presentation, and natural history
3641
10.1.3.2. Imaging surveillance ............................................................
3641
10.1.3.3. Medical treatment ...............................................................
3642
10.1.3.4. Aortic surgery .......................................................................
3642
10.1.3.5. Pregnancy and physical exercise ...................................


<!-- PAGE 5 -->

### Page 5

10.1.4. Other syndromic and non-syndromic heritable thoracic 
aortic diseases and/or arterial disorders ........................................... 3643
10.1.4.1. Loeys–Dietz syndrome .....................................................
3643
10.1.4.1.1. Diagnosis, clinical presentation, and natural 
evolution ...............................................................................................
3643
10.1.4.2. ACTA2-related heritable thoracic aortic disease ....
3645
10.2. Aortic disease associated with bicuspid aortic valves ..........
3646
10.3. Coarctation of the aorta and aortic arch variants ................
3648
10.3.1. Coarctation of the aorta ........................................................... 3648
10.3.1.1. Diagnostic work-up ............................................................
3648
10.3.1.2. Treatment and follow-up .................................................
3648
10.3.2. Aortic arch anatomic variants ................................................ 3650
10.3.3. Aberrant subclavian artery and Kommerell’s 
diverticulum ................................................................................................... 3650
11. Polyvascular peripheral arterial disease and peripheral arterial 
disease in patients with cardiac diseases ..................................................... 3650
11.1. Polyvascular disease ............................................................................
3650
11.1.1. Epidemiology and prognosis .................................................... 3650
11.1.2. Screening for atherosclerosis in other arterial 
territories ....................................................................................................... 3650
11.1.2.1. Screening for coronary artery disease in patients 
with symptomatic peripheral arterial disease ............................
3651
11.1.2.2. Screening for peripheral arterial disease in patients 
with coronary artery disease ............................................................
3651
11.1.2.3. Screening for coronary artery disease in patients 
with carotid stenosis ............................................................................
3651
11.1.2.4. Screening for carotid stenosis in patients with 
coronary artery disease .......................................................................
3651
11.1.3. Management of patients with polyvascular disease ....... 3651
11.2. Peripheral arterial disease and heart failure .............................
3651
11.3. Peripheral arterial disease and AF ................................................
3652
11.4. Peripheral arterial disease and aortic stenosis ........................
3652
12. Key messages .................................................................................................. 3652
13. Gaps in evidence ............................................................................................ 3653
14. Sex differences ............................................................................................... 3653
15. ‘What to do’ and ‘What not to do’ messages from the 
guidelines .................................................................................................................. 3653
16. Evidence tables ............................................................................................... 3661
17. Data availability statement ......................................................................... 3661
18. Author information ...................................................................................... 3661
19. Appendix ........................................................................................................... 3662
20. References ........................................................................................................ 3663
Tables of Recommendations
Recommendation Table 1 — Recommendations for clinical and 
laboratory, and for functional and quality of life, assessment in patients 
with peripheral arterial and aortic disease (see also Evidence Table 1)
3560
Recommendation Table 2 — Recommendations for diagnostic tests 
in patients with peripheral arterial disease ................................................ 3562
Recommendation Table 3 — Recommendations for imaging of the 
aorta (see also Evidence Table 2) .................................................................. 3565
Recommendation Table 4 — Recommendations for thoracic aortic 
measurements ........................................................................................................ 3566
Recommendation Table 5 — Recommendations for peripheral 
arterial disease screening (see also Evidence Table 3) .......................... 3568
Recommendation Table 6 — Recommendations for abdominal 
aortic aneurysm screening ................................................................................ 3568
Recommendation Table 7 — Recommendations for lifestyle, 
physical activity, and patient education (see also Evidence Table 4)
3570
Recommendation Table 8 — Recommendations for 
antihypertensive therapy in patients with peripheral and aortic 
disease ........................................................................................................................ 3571
Recommendation Table 9 — Recommendations for lipid-lowering 
therapy in patients with peripheral arterial and aortic diseases ....... 3572
Recommendation Table 10 — Recommendations for the medical 
management of patients with peripheral arterial and aortic diseases 
and diabetes ............................................................................................................ 3573
Recommendation Table 11 — Recommendations for diagnostic 
tests in patients with peripheral arterial disease and diabetes, renal 
failure, and wounds .............................................................................................. 3577
Recommendation Table 12 — Recommendations for imaging in 
patients with peripheral arterial disease ..................................................... 3577
Recommendation Table 13 — Recommendations for exercise 
therapy in patients with peripheral arterial disease (see also Evidence 
Table 5) ..................................................................................................................... 3582
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with peripheral arterial disease 
(see also Evidence Table 6) .............................................................................. 3582
Recommendation Table 15 — Recommendations for interventional 
treatment of asymptomatic and symptomatic peripheral arterial 
disease (general) .................................................................................................... 3584
Recommendation Table 16 — Recommendations for interventional 
treatment of patients with symptomatic peripheral arterial disease 
(per arterial bed) ................................................................................................... 3585
Recommendation Table 17 — Recommendations in patients with 
peripheral arterial disease: follow-up of patients with peripheral 
arterial disease ........................................................................................................ 3585
Recommendation Table 18 — Recommendations for the 
management of chronic limb-threatening ischaemia ............................. 3586
Recommendation Table 19 — Recommendations for medical 
treatment in patients with chronic limb-threatening ischaemia (see 
also Evidence Table 7) ........................................................................................ 3586
Recommendation Table 20 — Recommendations for interventional 
treatment of chronic limb-threatening ischaemia ................................... 3587
Recommendation Table 21 — Recommendations for follow-up in 
patients with chronic limb-threatening ischaemia .................................. 3587
Recommendation Table 22 — Recommendations for the 
management of patients presenting with acute limb ischaemia (see 
also Evidence Table 8) ........................................................................................ 3590
Recommendation Table 23 — Recommendations for carotid artery 
stenosis assessment ............................................................................................. 3590
Recommendation Table 24 — Recommendations for 
antithrombotic treatment in patients with carotid stenosis .............. 3592
Recommendation Table 25 — Recommendations for interventional 
treatment in patients with asymptomatic carotid artery stenosis ... 3594
Recommendation Table 26 — Recommendations for evaluation and 
medical treatment in patients with symptomatic carotid artery 
stenosis ...................................................................................................................... 3594
Recommendation Table 27 — Recommendations for interventions 
in patients with symptomatic carotid artery stenosis ........................... 3596
Recommendation Table 28 — Recommendations for follow-up in 
patients with carotid artery stenosis ............................................................ 3596
Recommendation Table 29 — Recommendations for the 
management of subclavian artery stenosis (see also Evidence 
Table 9) ..................................................................................................................... 3597
Recommendation Table 30 — Recommendations for diagnostic 
strategies for renal artery disease .................................................................. 3600


<!-- PAGE 6 -->

### Page 6

Recommendation Table 31 — Recommendations for treatment 
strategies for renal artery disease (see also Evidence Table 10) ...... 3600
Recommendation Table 32 — Recommendations in patients with 
visceral artery stenosis ........................................................................................ 3602
Recommendation Table 33 — Recommendations for primary and 
secondary prevention in aortic atheromatous plaques ........................ 3602
Recommendation Table 34 — Recommendations for initial 
evaluation of thoracic aortic aneurysm and abdominal aortic 
aneurysm .................................................................................................................. 3603
Recommendation Table 35 — Recommendation for the surveillance 
of patients with thoracic aortic aneurysms (non-heritable thoracic 
aortic disease) ......................................................................................................... 3607
Recommendation Table 36 — Recommendations for surveillance of 
patients with abdominal aortic aneurysm .................................................. 3609
Recommendation Table 37 — Recommendations for medical 
treatment in patients with thoracic aorta or abdominal aortic 
aneurysms ................................................................................................................ 3609
Recommendation Table 38 — Recommendations for surgery in 
aortic root and ascending aorta dilatation associated with tricuspid 
aortic valve (see also Evidence Table 11) ................................................... 3611
Recommendation Table 39 — Recommendations for surgery in 
aortic arch aneurysms ......................................................................................... 3611
Recommendation Table 40 — Recommendations for the 
management of patients presenting with descending thoracic aortic 
and thoracoabdominal aortic aneurysms ................................................... 3613
Recommendation Table 41 — Recommendations for the 
management of patients presenting with abdominal aortic 
aneurysm .................................................................................................................. 3615
Recommendation Table 42 — Recommendations for the 
management of patients presenting with endoleaks ............................. 3617
Recommendation Table 43 — Recommendations for follow-up 
after treatment of aortic aneurysms (see also Evidence Table 12)
3618
Recommendation Table 44 — Recommendations for diagnostic 
work-up of acute aortic syndromes ............................................................. 3622
Recommendation Table 45 — Recommendation for medical 
treatment in acute aortic syndromes ........................................................... 3623
Recommendation Table 46 — Recommendations for intervention 
in type A acute aortic dissection .................................................................... 3624
Recommendation Table 47 — Recommendations for aortic repair 
strategies in type A acute aortic dissection ............................................... 3624
Recommendation Table 48 — Recommendations for the 
management of malperfusion in the setting of acute aortic 
dissection .................................................................................................................. 3628
Recommendation Table 49 — Recommendations for the 
management of patients presenting with acute type B aortic 
dissection .................................................................................................................. 3629
Recommendation Table 50 — Recommendations for the 
management of patients presenting with chronic type B aortic 
dissection .................................................................................................................. 3629
Recommendation Table 51 — Recommendations for the 
management of intramural haematoma ...................................................... 3631
Recommendation Table 52 — Recommendations for the 
management of penetrating atherosclerotic ulcer ................................. 3631
Recommendation Table 53 — Recommendations for traumatic 
aortic injury .............................................................................................................. 3633
Recommendation Table 54 — Recommendations for follow-up 
after treatment of acute aortic syndrome ................................................. 3637
Recommendation Table 55 — Recommendations for the 
management of patients with heritable thoracic aortic disease ....... 3637
Recommendation Table 56 — Recommendations for genetic testing 
and aortic screening in aortic disease .......................................................... 3638
Recommendation Table 57 — Recommendations for imaging in 
women with Turner syndrome ...................................................................... 3638
Recommendation Table 58 — Recommendations for aortic surgery 
in women with Turner syndrome ................................................................. 3640
Recommendation Table 59 — Recommendations for medical 
treatment in patients with vascular Ehlers–Danlos syndrome (see 
also Evidence Table 13) ...................................................................................... 3641
Recommendation Table 60 — Recommendations for vascular 
imaging in Marfan syndrome ............................................................................ 3642
Recommendation Table 61 — Recommendations for medical 
treatment in Marfan syndrome (see also Evidence Table 14) ........... 3642
Recommendation Table 62 — Recommendations for aortic surgery 
in Marfan syndrome ............................................................................................. 3642
Recommendation Table 63 — Recommendations for pregnancy in 
women with Marfan syndrome ...................................................................... 3643
Recommendation Table 64 — Recommendations for physical 
exercise in patients with Marfan syndrome .............................................. 3643
Recommendation Table 65 — Recommendations for imaging 
follow-up in Loeys–Dietz syndrome ............................................................ 3644
Recommendation Table 66 — Recommendations for aortic root 
surgery in Loeys–Dietz syndrome ................................................................. 3644
Recommendation Table 67 — Recommendations for imaging and 
surgery in ACTA2-related heritable thoracic aortic disease (see also 
Evidence Table 11) ............................................................................................... 3645
Recommendation Table 68 — Recommendations for bicuspid aortic 
valve-associated aortopathy management ........................................................
3647
Recommendation Table 69 — Recommendations for evaluation and 
medical treatment of patients with coarctation of the aorta ............ 3648
Recommendation Table 70 — Recommendations for screening and 
management of polyvascular disease and peripheral arterial disease 
with cardiac diseases (see also Evidence Table 15) ............................... 3652
List of tables
Table 1 Classes of recommendations .......................................................... 3547
Table 2 Levels of evidence ................................................................................ 3548
Table 3 New recommendations .................................................................... 3550
Table 4 Revised recommendations ............................................................... 3555
Table 5 Main aortic imaging techniques ...................................................... 3564
Table 6 High-risk populations for carotid artery stenosis .................. 3567
Table 7 Peripheral arterial disease categorized according to clinical 
presentation ............................................................................................................ 3574
Table 8 Assessment of the risk of amputation: the Wound, 
Ischaemia, and foot Infection classification ................................................ 3577
Table 9 Clinical categories of acute limb ischaemia ............................... 3588
Table 10 Peak systolic velocity criteria for grading internal carotid 
artery stenosis ........................................................................................................ 3591
Table 11 High-risk features associated with increased risk of stroke 
in patients with asymptomatic internal carotid artery stenosis on 
optimal medical treatment ................................................................................ 3592
Table 12 High-risk peri-operative features for carotid 
endarterectomy ..................................................................................................... 3595
Table 13 Clinical signs suggestive of renal artery disease .................... 3598
Table 14 Grading of atherosclerotic aortic plaques .............................. 3603
Table 15 Overview of factors favouring open vs. endovascular repair 
in thoracoabdominal aortic aneurysm ......................................................... 3613
Table 16 High-risk features of intramural haematoma type A and B
3630
Table 17 Need for assessment of associated atherosclerotic disease in 
additional vascular territories in symptomatic patients with coronary 
artery disease, peripheral arterial disease, or carotid stenosis ...............
3651
Table 18 ‘What to do’ and ‘What not to do’ .......................................... 3654
ESC Guidelines                                                                                                                                                                                          3543


<!-- PAGE 7 -->

### Page 7

List of figures
Figure 1 Central illustration: from diagnosis to treatment, a holistic 
multidisciplinary peripheral arterial and aortic diseases approach .. 3549
Figure 2 Estimated specific prevalence of peripheral arterial disease, 
by sex, in people aged 40 years and older ................................................. 3558
Figure 3 Main risk factors associated with atherosclerosis in 
peripheral arterial and aortic diseases ......................................................... 3559
Figure 4 Haemodynamic assessment of peripheral arterial disease
3561
Figure 5 Anatomy and aortic segments and upper normal values for 
aortic dimensions .................................................................................................. 3563
Figure 6 Conventional measurements of the aorta at different 
levels by echocardiography or duplex ultrasound (A, B, C), 
cardiovascular computed tomography or cardiovascular magnetic 
resonance (D, E, F) ......................................................................................... 3564
Figure 7 Cardiovascular risk modification and healthy lifestyle 
interventions and targets in patients with peripheral arterial and 
aortic diseases ........................................................................................................ 3569
Figure 8 Cardiovascular risk in patients with peripheral arterial disease
3575
Figure 9 Diagnostic algorithm for peripheral arterial disease ............ 3576
Figure 10 Optimal medical treatment in patients with peripheral 
arterial disease ........................................................................................................ 3578
Figure 11 Treatment algorithm in peripheral arterial disease without 
wounds ................................................................................................................................
3579
Figure 12 Treatment algorithm in peripheral arterial disease with 
wounds ...................................................................................................................... 3580
Figure 13 Exercise training characteristics and benefits in patients 
with peripheral arterial disease ....................................................................... 3581
Figure 14 Long-term antithrombotic therapy in patients with 
symptomatic peripheral arterial disease ..........................................................
3583
Figure 15 Patients with chronic symptomatic PAD after 
endovascular revascularization ........................................................................ 3584
Figure 16 Management of acute limb ischaemia ...................................... 3589
Figure 17 North American Symptomatic Carotid Endarterectomy 
Trial/European Carotid Surgery Trial methods ....................................... 3591
Figure 18 Algorithm of carotid artery stenosis management ............ 3593
Figure 19 Diagnostic and treatment algorithm for renal artery 
stenosis ...................................................................................................................... 3599
Figure 20 Algorithm of chronic mesenteric ischaemia management
3601
Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, 
screening and diagnostic methods ................................................................. 3604
Figure 22 Classification of thoracoabdominal and abdominal aortic 
aneurysms ................................................................................................................ 3605
Figure 23 Risk factors for thoracic and abdominal aneurysm rupture
3606
Figure 24 Surveillance of patients with non-heritable thoracic 
aortic disease and abdominal aortic aneurysms ...................................... 3608
Figure 25 Peri-operative algorithm for the management of patients 
with surgically treated aortic root and ascending aortic aneurysm
3610
Figure 26 Algorithm for individual decision-making process in the 
treatment of patients with abdominal aortic aneurysm ...................... 3614
Figure 27 Algorithm for follow-up after thoracic endovascular aortic 
aneurysm repair, and management of endoleaks and their classification
3616
Figure 28 Anatomical and temporal classification of acute aortic 
syndrome .................................................................................................................. 3619
Figure 29 Aortic dissection classification system based on the 2020 
Society for Vascular Surgery/Society of Thoracic Surgeons 
Reporting Standards and the European update of the Stanford 
classification—Type Entry Malperfusion classification .......................... 3620
Figure 30 Multiparametric diagnostic work-up of acute aortic 
syndrome .................................................................................................................. 3621
Figure 31 Medical management of acute aortic syndrome ................. 3623
Figure 32 Complications in acute aortic syndromes, clinical evidence 
associated with malperfusion syndrome, and in-hospital mortality 
associated with these complications ............................................................ 3625
Figure 33 Interventional treatment algorithm in acute aortic 
dissection .................................................................................................................. 3626
Figure 34 Mechanisms and clinical management of aortic branch 
obstruction in acute aortic dissection .......................................................... 3627
Figure 35 High-risk features in penetrating atherosclerotic ulcer and 
management of patients with type B penetrating atherosclerotic 
ulcer ............................................................................................................................ 3632
Figure 36 Classification and treatment of traumatic aortic injuries
3634
Figure 37 Aetiology, risk factors, and classification of iatrogenic 
aortic injuries .......................................................................................................... 3635
Figure 38 Algorithm for follow-up after acute aortic syndrome ..... 3636
Figure 39 Algorithm for genetic and imaging screening in patients 
with thoracic aortic disease .............................................................................. 3639
Figure 40 Algorithm for surveillance in women (≥15 years) with 
Turner syndrome .................................................................................................. 3640
Figure 41 Algorithm for imaging surveillance in patients with 
syndromic and non-syndromic heritable thoracic aortic disease ..... 3644
Figure 42 Suggested thresholds for prophylactic aortic root/ 
ascending replacement in Loeys–Dietz syndrome ................................. 3645
Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature . 3646
Figure 44 Criteria for significant coarctation/re-coarctation of the 
aorta and management algorithm .................................................................. 3649
Figure 45 Reported rate ranges of other localizations of 
atherosclerosis in patients with a specific arterial disease .................. 3650
Abbreviations and acronyms
18F–NaF
Fluorine-18–sodium fluoride
6MWD
Six-minute walking distance
6MWT
Six-minute walk test
AA
Abdominal aorta
AAA
Abdominal aortic aneurysm
AAD
Acute aortic dissection
AAE
Aortic adverse events
AAL
Ascending aortic length
AAS
Acute aortic syndrome
ABI
Ankle–brachial index
ACAS
Asymptomatic Carotid Atherosclerosis Study
ACB
Asymptomatic Cervical Bruit Study
ACC/AHA
American College of Cardiology and American 
Heart Association
ACEI
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
ACST
Asymptomatic Carotid Surgery Trial
ACTA2
Alpha-actin gene
AD
Aortic dissection
ADAM
American Aneurysm Detection and Management
ADD-RS
Aortic dissection detection-risk score
AF
Atrial fibrillation
AHI
Aortic height index
ALI
Acute limb ischaemia
AMI
Acute mesenteric ischaemia
AP
Antero-posterior
ARB
Angiotensin receptor blocker
ARR
Absolute risk reduction
ASCVD
Atherosclerotic cardiovascular disease
ASE
American Society of Echocardiography


<!-- PAGE 8 -->

### Page 8

ASI
Aortic size index
BASIL
Bypass versus Angioplasty in Severe Ischaemia of 
the Leg trial
BAV
Bicuspid aortic valve
BB
Beta-blocker
BEST-CLI
Best Endovascular versus Best Surgical Therapy for 
Patients with Critical Limb Ischemia trial b.i.d.
Bis in die (twice daily)
BMI
Body mass index
BP
Blood pressure b.p.m.
Beats per minute
BSA
Body surface area
BTK
Below-the-knee
CABG
Coronary artery bypass grafting
CAD
Coronary artery disease
CANTOS
Canakinumab Anti-Inflammatory Thrombosis 
Outcomes Study
CANVAS
Canagliflozin Cardiovascular Assessment Study
CAS
Carotid artery stenting
CCA
Common carotid artery
CCB
Calcium channel blocker
CCT
Cardiovascular computed tomography
CDT
Catheter-based thrombectomy cdTLR
Clinically driven target lesion revascularization
CEA
Carotid endarterectomy
CEUS
Contrast-enhanced ultrasound
CHA2DS2-VASc
Congestive heart failure, hypertension, age ≥75 
(doubled), diabetes, stroke (doubled), vascular 
disease, age 65 to 74 and sex category (female)
CI
Confidence interval cIMT
Carotid intima media thickness
CK
Creatinine kinase
CKD
Chronic kidney disease
CLTI
Chronic limb-threatening ischaemia
CMI
Chronic mesenteric ischaemia
CMR
Cardiovascular magnetic resonance
CoA
Coarctation of the aorta
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COPD
Chronic obstructive pulmonary disease
CP
Carotid plaque
CREDENCE
Canagliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evaluation
CREST-2
Carotid Revascularization Endartectomy vs. 
Stenting Trial 2
CRP
C-reactive protein
CS
Carotid artery stenosis
CSA/h
Cross-sectional area-to-height ratio
CT
Computed tomography
CTA
Computed tomography angiography
CV
Cardiovascular
CVD
Cardiovascular disease
CVRF
Cardiovascular risk factor
DAPT
Dual antiplatelet therapy
DBP
Diastolic blood pressure
DD
D-dimer
DISSECT
Duration, Intimal tear, Size, Segmental Extent, 
Clinical complications, Thrombosis
DPI
Dual pathway inhibition
DSA
Digital subtraction angiography
DTA
Descending thoracic aorta
DUS
Duplex ultrasound
DWI
Diffusion-weighted imaging
ECG
Electrocardiogram
ECST
European Carotid Surgery Trial eGFR
Estimated glomerular filtration rate
EMPA-REG 
OUTCOME
(Empagliflozin) Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients
ESC
European Society of Cardiology
ESH
European Society of Hypertension
ESRD
End-stage renal disease
EUCLID
Examining Use of tiCagreLor In peripheral artery 
Disease
FDA
(United States) Food and Drug Administration
FDG
Fluorodeoxyglucose
FDR
First-degree relative
FET
Frozen elephant trunk
FID
Focal intimal disruption
FL
False lumen
GERAADA
German Registry of Acute Aortic Dissection Type 
A
GFR
Glomerular filtration rate
GLP-1RA
Glucagon-like peptide-1 receptor agonist
GSV
Great saphenous vein
HADS
Hospital anxiety and depression score
HbA1c
Glycated haemoglobin
HBET
Home-based exercise training
HF
Heart failure
HITS
High-intensity transient signal
HOME
Hyperinsulinaemia: the Outcomes of its Metabolic 
Effects
HR
Hazard ratio
HRQoL
Health-related quality of life hs-CRP
High-sensitivity C-reactive protein
HSR
High surgical risk
HTAD
Heritable thoracic aortic disease
IC
Intermittent claudication
ICA
Internal carotid artery
ID
Intimal disruption
IL
Interleukin
ILT
Intensive lipid-lowering therapy
IMA
Inferior mesenteric artery
IMH
Intramural haematoma
IMPROVE-AD
The Improving outcomes in vascular disease— 
aortic dissection trial
IMPROVE-IT
IMProved Reduction of Outcomes: Vytorin 
Efficacy International Trial
IPE
Icosapent ethyl
IRAD
International Registry of Acute Aortic Dissection
ISTH
International Society on Thrombosis and 
Haemostasis i.v.
Intravenous
IVUS
Intravascular ultrasound
LDL-C
Low-density lipoprotein cholesterol
LEADER
Liraglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome Results 
trial
LSA
Left subclavian artery
LV
Left ventricular
MACE
Major adverse cardiac event
ESC Guidelines                                                                                                                                                                                          3545


<!-- PAGE 9 -->

### Page 9

MAD
Multisite artery disease
MALE
Major adverse limb event
MAP
Mean arterial pressure
MESA
Multi-Ethnic Study of Atherosclerosis
MFS
Marfan syndrome
MHV
Mechanical heart valve
MI
Myocardial infarction
MRA
Magnetic resonance angiography
MRI
Magnetic resonance imaging
MWD
Maximal walking distance
NASCET
North American Symptomatic Carotid 
Endarterectomy Trial
OAC
Oral anticoagulation o.d.
Once daily
OMT
Optimal medical treatment
OR
Odds ratio
PAAD
Peripheral arterial and aortic diseases
PA
Popliteal aneurysm
PAD
Peripheral arterial disease
PAU
Penetrating atherosclerotic ulcer
PC-AKI
Post-contrast acute kidney injury
PCSK9
Proprotein convertase subtilisin/kexin type 9
PET
Positron emission tomography
PET-CT
PET-computed tomography
PFWD
Pain-free walking distance
PROM
Patient-reported outcome measure
PSV
Peak systolic velocity
PSVr
Peak systolic velocity ratio
PVD
Polyvascular disease
QoL
Quality of life
RAR
Renal-aortic peak flow velocity ratio
RAS
Renal artery stenosis
RCT
Randomized controlled trial
REACH
The REduction of Atherothrombosis for 
Continued Health
REDUCE-IT
Reduction of Cardiovascular Events With 
Icosapent Ethyl–Intervention Trial
ROMS
Retrograde open mesenteric stenting
ROPAC
Registry Of Pregnancy And Cardiac disease
RPE
Rate of perceived exertion
RR
Relative risk
SAMMPRIS
Stenting and Aggressive Medical Management for 
Preventing Recurrent Stroke in Intracranial 
Stenosis trial
SAPPHIRE
Stenting and Angioplasty with Protection in 
Patients at High Risk for Endarterectomy trial
SAPT
Single antiplatelet therapy
SBP
Systolic blood pressure
SCI
Spinal cord ischaemia
SCS
Spinal cord stimulation
SET
Supervised exercise training
SF-36
Short-form 36-item health questionnaire
SGLT2i
Sodium-glucose co-transporter-2 inhibitor
SMA
Superior mesenteric artery
SMART
Secondary Manifestation of ARTerial disease
SOCRATES
Acute Stroke or Transient Ischaemic Attack 
Treated with Aspirin or Ticagrelor and Patient 
Outcomes trial
SCORE2
Systematic Coronary Risk Evaluation 2
SCORE2-Diabetes
Systematic Coronary Risk Evaluation 2 - diabetes
SCORE2-OP
Systematic Coronary Risk Evaluation 2–Older 
Persons
SPACE-2
Stent Protected Angioplasty versus Carotid 
Endarterectomy study
SPPB
Short physical performance battery
SRUCC
Society of Radiologists in Ultrasound
SS
Subclavian stenosis
SSFP
Steady-state free precession
STJ
Sinotubular junction
STS/AATS
Society of Thoracic Surgeons/American 
Association for Thoracic Surgery
SUSTAIN-6
Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes with Semaglutide in 
Subjects with Type 2 Diabetes
SVS
Society for Vascular Surgery
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TAA
Thoracic aortic aneurysm
TAAA
Thoracoabdominal aortic aneurysm
TAAD
Type A aortic dissection
TAD
Thoracic aortic disease
TAI
Traumatic aortic injury
TAV
Tricuspid aortic valve
TAVI
Transcatheter aortic valve implantation
TBAD
Type B aortic dissection
TBI
Toe–brachial index
TCAR
Transcarotid artery revascularization
TcPO2
Transcutaneous oxygen pressure
TOE
Transoesophageal echocardiography
TEM
Type entry malperfusion classification
TEVAR/EVAR
Thoracic endovascular aortic aneurysm  
repair
TFCAS
Transfemoral carotid artery stenting
THALES
Acute Stroke or Transient Ischaemic Attack 
Treated with Ticagrelor and acetylsalicylic acid for 
Prevention of Stroke and Death trial
TIA
Transient ischaemic attack
TIMI
Thrombolysis in myocardial infarction
TP
Toe pressure
TS
Turner syndrome
TTE
Transthoracic echocardiography
UEAD
Upper-limb artery disease
UKPDS
United Kingdom Prospective Diabetes Study: 
clinical and therapeutic implications for type 2 
diabetes uTBAD
Uncomplicated type B aortic dissection
VascuQoL
Vascular quality of life questionnaire
VAST
Vertebral Artery Stenting Trial vEDS
Vascular Ehlers–Danlos syndrome
VIST
Vertebral Artery Ischaemia Stenting Trial
VKA
Vitamin K antagonist
WELCH
Walking Estimated Limitation Calculated by 
History
WIfI
Wound, Ischaemia, foot Infection classification
WIQ
Walking Impairment Questionnaire


<!-- PAGE 10 -->

### Page 10

### 1 Preamble

Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription and to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated when warranted by new evidence. ESC 
Policies and Procedures for formulating and issuing ESC Guidelines can 
be found on the ESC website (https://www.escardio.org/Guidelines/ 
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- 
Guidelines). This guideline updates and replaces the previous periph­
eral arterial disease and aortic disease guidelines from 2017 and 
2014, respectively.
The Members of this task force were selected by the ESC to include 
professionals involved with the medical care of patients with this path­
ology as well as patient representatives and methodologists. The selec­
tion procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
and inclusion, notably with respect to gender and country of origin. 
The task force performed a critical review and evaluation of the pub­
lished literature on diagnostic and therapeutic approaches including as­
sessment of the risk–benefit ratio. The strength of every 
recommendation and the level of evidence supporting them were 
weighed and scored according to pre-defined scales as outlined in 
Tables 1 and 2 below. Patient-reported outcome measures (PROMs) 
and patient-reported experience measures (PREMs) were also evalu­
ated as the basis for recommendations and/or discussion in these 
guidelines. The task force followed ESC voting procedures and all ap­
proved recommendations were subject to a vote and achieved at least 
75% agreement among voting members. Members of the task force 
with declared interests on specific topics were asked to abstain from 
voting on related recommendations.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules which 
can be found on the ESC website (http://www.escardio.org/guidelines) 
and have been compiled in a report published in a supplementary docu­
ment with the guidelines. Funding for the development of ESC 
Guidelines is derived entirely from the ESC with no involvement of 
the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. In addition to review by the CPG 
Committee, ESC Guidelines undergo multiple rounds of double-blind 
peer review by external experts, including members from across the 
whole of the ESC region, all National Cardiac Societies of the ESC 
and from relevant ESC Subspecialty Communities. After appropriate 
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
ESC Guidelines                                                                                                                                                                                          3547


<!-- PAGE 11 -->

### Page 11

revisions, the guidelines are signed off by all the experts in the task 
force. The finalized document is signed off by the CPG Committee 
for publication in the European Heart Journal.
ESC Guidelines are based on analyses of published evidence, chiefly 
on clinical trials and meta-analyses of trials, but potentially including 
other types of studies. Evidence tables summarizing key information 
from relevant studies are generated early in the guideline development 
process to facilitate the formulation of recommendations, to enhance 
comprehension of recommendations after publication, and reinforce 
transparency in the guidelines development process. The tables are 
published in their own section of ESC Guidelines and reference specific 
recommendation tables.
Off-label use of medication may be presented in this guideline if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Peripheral arterial and aortic diseases (PAAD) are highly prevalent 
and significantly increase cardiovascular (CV) mortality and 
morbidity in the general population,1,2 consequently, intensive pre­
ventive strategies are needed. However, patients with PAAD are 
generally underdiagnosed and undertreated3,4 compared with pa­
tients with coronary artery disease (CAD).5 Common risk factors 
in PAAD often coexist, requiring a multidisciplinary approach for ef­
fective management.5 Early diagnosis is crucial for better outcomes. 
These guidelines address PAAD, updating and merging the 2017 
peripheral arterial diseases and 2014 aortic diseases guidelines. 
The focus is primarily on atherosclerotic arterial diseases, but 
they also address some non-atherosclerotic genetic conditions. 
While not exhaustive, these 2024 guidelines offer guidance on 
diagnosis, surveillance, and treatment. A number of new and revised 
recommendations are summarized in Tables 3 and 4, respectively. 
Readers should consider non-atherosclerotic conditions and refer 
to specific documents.6–9
A general approach to PAAD is provided in the central illustration 
(Figure 1).
In the management of PAAD, the following aspects must be 
highlighted: 
• Shared 
decision-making 
to 
involve 
patients, 
explore 
treatment options, assess patient values, and reach decisions 
collaboratively.
• Multidisciplinary approach (Figure 1) in expert and high-volume 
PAAD centres for complex patients or procedures. These centres 
provide diverse services, including diagnosis, treatment planning, 
minimally invasive procedures, open surgery, post-operative and out­
patient care, and ideally, research and innovation. They should provide 
continuous clinical service (24/7) and have access to digital imaging. 
These guidelines recognize variations in healthcare systems, population 
sizes, and needs, impacting the definition of ‘high volume’ in PAAD care 
across countries.
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024


<!-- PAGE 12 -->

### Page 12

Diagnosis
Cardiologist
Angiologist
Vascular surgeon
Geneticist
Cardiac surgeon
CV radiologist
CV intensive care specialist
Neurologist
Anaesthetist
Nurse
Nephrologist
Exercise therapist
Follow-up
Treatment
Prevention
Goals
Initial steps
Clinical assessment
Functional assessment
QoL assessment
Use of non-invasive tools
Imaging, if appropriate
Optimal medical treatment
Patient education
CVRFs control
Exercise/rehabilitation programmes
Need for intervention/
surgery?
Regular follow-up
Optimal medical treatment
CVRFs management
Patient education
Patient’s tailored targets and goals
Family screening, if appropriate
Increase awareness
CVRFs management
Screening
Genetic counselling
Prevent development of peripheral and aortic atherosclerosis
Prevent aortic dilation or lesions
Improve patients’ QoL and functioning
Reduce risk of MACE and MALE
Improve survival
Reduce the risk of hospitalization
Reduce the need for intervention/surgery
Screen patients at risk of PAAD
Enable early access to treatment
Ensure optimal medical treatment
Figure 1 Central illustration: from diagnosis to treatment, a holistic multidisciplinary peripheral arterial and aortic diseases approach. CV, cardiovas­
cular; CVRFs, cardiovascular risk factors; MACE, major adverse cardiac event; MALE, major adverse limb event; PAAD, peripheral arterial and aortic 
diseases; QoL, quality of life.
ESC Guidelines                                                                                                                                                                                          3549


<!-- PAGE 13 -->

### Page 13

### 3 What is new

Table 3 New recommendations
Recommendations
Class
Level
Recommendations for clinical and laboratory, and for functional quality of life, assessment in patients with peripheral arterial and aortic 
disease
When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of arterial circulation.
I
B
Recommendations for peripheral arterial disease screening
In patients with AAA, femoro-popliteal aneurysm screening with DUS should be considered.
IIa
C
In patients needing intervention with transfemoral access, screening for iliofemoral artery disease may be considered.
IIb
C
In patients with two or more CVRFs, screening for asymptomatic CS may be considered.
IIb
C
Recommendations for abdominal aortic aneurysm screening
Opportunistic AAA screening with DUS should be considered in symptomatic/asymptomatic PAD patients.
IIa
B
Recommendations for lifestyle, physical activity, and patient education
Use of web- or app-based secondary prevention risk calculators should be considered in the shared decision-making to improve patient 
adherence to treatment and lifestyle changes.
IIa
C
E-cigarettes may be considered as an aid to quitting tobacco smoking, but it is advisable to limit their use and avoid simultaneous use with 
conventional cigarettes due to unknown long-term effects.
IIb
C
Recommendations for lipid-lowering therapy in patients with peripheral arterial and aortic diseases
In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended.
I
A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with 
atherosclerotic PAAD.
I
A
If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in 
patients with atherosclerotic PAAD, to achieve target values.
I
A
If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to achieve 
the given target values.
I
B
For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is 
recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.
I
B
Statins for the reduction of growth and rupture of AAA should be considered.
IIa
B
Statins for the reduction of growth and rupture of TAA may be considered.
IIb
B
In high-risk patients with PAAD and triglycerides >1.5 mmol/L despite lifestyle measures and statin therapy, icosapent ethyl 2 g b.i.d. may be 
considered in addition to a statin.
IIb
B
Fibrates are not recommended for cholesterol lowering.
III
B
Recommendations for exercise therapy in patients with peripheral arterial disease
In patients with symptomatic PAD, SET is recommended.
I
A
In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy.
I
A
When SET is not available or feasible, a structured and monitored (calls, logbooks, connected devices) HBET programme should be 
considered.
IIa
A
Walking should be considered as the first-line training modality. When walking exercise is not an option, alternative exercise modes (strength 
training, arm cranking, cycling, and combinations of different training modes) should also be considered.
IIa
A
Walking training performed at high intensity (77%–95% of maximal heart rate or 14–17 self-perceived exertion on Borg’s scale) should be 
considered to improve walking performance, and high-intensity exercise training (various aerobic training modes) should be considered to 
improve cardiorespiratory fitness.
IIa
A
Training frequency of at least three times per week, training session duration of at least 30 min, and training programme duration of at least 12 
weeks should be considered.
IIa
B
In patients with PAD, exercise training to moderate-severe claudication pain may be considered to improve walking performance. However, 
improvements are also achievable with lesser claudication pain severities (low-mild pain or pain-free).
IIb
B
Based on patient’s tolerance, a progressive increase (every 1–2 weeks) in exercise training load may be considered.
IIb
C
Continued


<!-- PAGE 14 -->

### Page 14

Recommendations for antithrombotic therapy in patients with peripheral arterial disease
Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD and high 
ischaemic risk, and non-high bleeding risk.
IIa
A
Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD and non-high 
bleeding risk following lower-limb revascularization.
IIa
B
Aspirin (75–100 mg) for primary prevention may be considered in patients with asymptomatic PAD and DM, in the absence of 
contraindications.
IIb
A
Recommendations for interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)
In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended.
I
B
It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general 
patient condition.
I
C
In patients with symptomatic PAD and impaired PAD-related QoL after a 3 month period of OMT and exercise therapy, revascularization 
may be considered.
IIb
B
In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI.
III
B
In patients with asymptomatic PAD, revascularization is not recommended.
III
C
Recommendations for interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed)
In femoro-popliteal lesions, drug-eluting treatment should be considered as the first-choice strategy.
IIa
A
In femoro-popliteal lesions, if revascularization is indicated, an open surgical approach should be considered when an autologous vein (e.g. 
GSV) is available in patients with low surgical risk.
IIa
C
In patients with severe IC undergoing endovascular femoro-popliteal revascularization, treatment of BTK arteries may be considered in the 
same intervention.
IIb
C
Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease
It is recommended to regularly, at least once a year, follow-up patients with PAD, assessing clinical and functional status, medication 
adherence, limb symptoms, and CVRFs, with DUS assessment as needed.
I
C
Recommendations for the management of chronic limb-threatening ischaemia
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage.
I
C
Recommendations for medical treatment in patients with chronic limb-threatening ischaemia
It is recommended that patients with CLTI are managed by a vascular team.
I
C
In patients with CLTI and ulcers, offloading mechanical tissue stress is indicated to allow wound healing.
I
C
Lower-limb exercise training is not recommended in patients with CLTI and wounds.
III
C
Recommendations for interventional treatment of chronic limb-threatening ischaemia
In CLTI patients, it is recommended to perform revascularization as soon as possible.
I
B
In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery.
I
B
In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions.
I
C
In CLTI patients with good autologous veins and low surgical risk (<5% peri-operative mortality, >50% 2 year survival), infra-inguinal bypass 
may be considered.
IIb
B
In CLTI patients, endovascular treatment may be considered as first-line therapy, especially in patients with increased surgical risk or 
inadequate autologous veins.
IIb
B
Recommendations for follow-up in patients with chronic limb-threatening ischaemia
In patients with CLTI, following revascularization it is recommended to follow-up patients on a regular basis.
I
C
At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs.
I
C
Recommendations for carotid artery stenosis assessment
It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis.
I
B
It is not recommended to use the ECST method for ICA stenosis assessment.
III
C
Recommendations for the management of subclavian artery stenosis
Bilateral arm BP measurement is recommended for all patients with PAAD.
I
B
Endovascular revascularization may be considered over surgery, despite similar long-term outcomes, due to lower complication rates.
IIb
B
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended.
III
C
Recommendations for diagnostic strategies for renal artery disease
DUS is recommended as the first-line imaging modality in patients with suspicion of RAS.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3551


<!-- PAGE 15 -->

### Page 15

Recommendations for treatment strategies for renal artery disease
Revascularization
In patients with atherosclerotic unilateral >70% RAS, concomitant high-risk features, and signs of kidney viability, renal artery revascularization 
should be considered after OMT has been established.
IIa
B
In patients with atherosclerotic bilateral (>70%) RAS or RAS in a solitary kidney, concomitant high risk features, and signs of kidney viability, 
renal artery revascularization should be considered.
IIa
B
In patients with hypertension and/or signs of renal dysfunction due to RAS caused by fibromuscular dysplasia, concomitant high-risk features, 
and signs of kidney viability, revascularization with primary balloon angioplasty and bailout stenting should be considered.
IIa
B
In patients with an indication for renal artery revascularization and complex anatomy, or after failed endovascular revascularization, open 
surgical revascularization should be considered.
IIa
B
In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended.
III
A
Recommendations in patients with visceral artery stenosis
In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended.
I
C
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended.
III
C
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
In patients with dilatation of the tubular ascending aorta who can be offered surgery with low predicted risk, ascending aortic replacement 
should be considered at a maximum diameter >52 mm.
IIa
B
In patients undergoing surgery for tricuspid aortic valve disease who have concomitant dilatation of the aortic root or ascending tubular aorta, 
and low predicted surgical risk, ascending aorta or root replacement should be considered at a maximum diameter ≥45 mm, otherwise 
≥50 mm.
IIa
B
SAPT with low-dose aspirin (75–100 mg/day) should be considered for the first 3 months after valve-sparing aortic surgery when there are no 
other baseline indications for OAC.
IIa
C
In patients undergoing non-aortic-valve cardiac surgery who have concomitant dilatation of the ascending aorta or aortic root with a 
maximum diameter ≥50 mm, concomitant aortic surgery should be considered.
IIa
C
Recommendations for surgery in aortic arch aneurysms
In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to 
non-aortic causes, open surgical replacement of the arch is recommended.
I
C
In patients undergoing open surgical repair of an aortic arch aneurysm, an elephant trunk or frozen elephant trunk procedure should be 
considered if the aneurysmal disease extends into the proximal descending thoracic aorta.
IIa
C
Recommendations for follow-up after treatment of aortic aneurysms
After open repair of TAA, an early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years 
and every 5 years thereafter is recommended if findings are stable.
I
B
After 5 post-operative years without complications, continuing long-term follow-up of TEVAR by CCT every 5 years should be considered.
IIa
B
If growth of the excluded aneurysm is observed, without evidence of type I or III endoleak, repeating CCT every 6–12 months, depending on 
the growth rate observed, should be considered.
IIa
C
In low-risk patients, from 1 year post-operatively after EVAR, repeating DUS/CEUS every 2 years should be considered.
IIa
B
If any abnormality during DUS/CEUS is found, confirmation should be considered using additional CCT or CMR (based on potential artefacts).
IIa
B
Recommendations for diagnostic work-up of acute aortic syndrome
CCT from neck to pelvis is recommended as the first-line imaging technique in patients with suspected AAS since it is widely available, 
accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).
I
C
In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications.
I
C
Recommendations for medical treatment in acute aortic syndromes
In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching to 
oral BBs and, if necessary, up-titration of other BP-lowering agents is recommended after 24 h if gastrointestinal transit is preserved.
I
B
If the patient has a contraindication for BBs, a non-dihydropyridine calcium blocker should be considered.
IIa
B
Recommendations for intervention in type A acute aortic dissection
In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic 
root replacement is recommended with a mechanical or biological valved conduit.
I
B
In patients presenting with acute TAAD, transfer from a low- to a high-volume aortic centre with the presence of a multidisciplinary team 
should be considered to improve survival if transfer can be accomplished without significant delay in surgery.
IIa
B
In selected patients, a valve-sparing root repair may be considered, when performed by experienced surgeons.
IIb
B
Continued


<!-- PAGE 16 -->

### Page 16

Recommendations for aortic repair strategies in type A acute aortic dissection
In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is 
recommended over valve replacement.
I
B
In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL 
thrombosis rates.
I
B
In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more 
extensive arch replacement.
I
B
In patients with acute TAAD and a secondary intimal tear in the arch or proximal DTA, extended aortic repair with stenting of the proximal 
DTA (e.g. by the frozen elephant technique) may be considered to reduce late distal aortic complications (e.g. aneurysm evolution of the 
remaining dissected descending aorta).
IIb
C
Recommendations for the management of malperfusion in the setting of acute aortic dissection
In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is 
recommended.
I
B
In patients with acute TAAD presenting with cerebral malperfusion or non-haemorrhagic stroke, immediate aortic surgery should be 
considered to improve neurological outcome and reduce mortality.
IIa
B
In patients with acute TAAD presenting with clinically significant mesenteric malperfusion syndrome, immediate invasive angiographic 
diagnostics to evaluate percutaneous malperfusion repair before or directly after aortic surgery, in aortic centres with expertise, should be 
considered.
IIa
C
Recommendations for the management of patients presenting with acute type B aortic dissection
In patients with uncomplicated acute TBAD, TEVAR in the subacute phase (between 14 and 90 days) should be considered in selected 
patients with high-risk features to prevent aortic complications.
IIa
B
Recommendations for the management of patients presenting with chronic type B aortic dissection
In chronic TBAD and with a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable surgical risk.
I
B
In patients with chronic TBAD and a descending thoracic aortic diameter ≥55 mm, an indication for intervention should be considered in 
patients with low procedural risk.
IIa
C
In patients with chronic post-dissection thoracoabdominal aortic aneurysms, the use of fenestrated/branched stent grafts may be considered, 
when treatment is indicated.
IIb
C
Recommendations for the management of penetrating atherosclerotic ulcer
In uncomplicated type B PAU with high-risk imaging features, endovascular treatment should be considered.
IIa
C
Recommendations for traumatic aortic injury
In cases of severe aortic injury (grade 4), immediate repair is recommended.
I
A
In minimal aortic injury (grades 1 or 2), initial medical therapy under careful clinical and imaging surveillance should be considered.
IIa
C
In cases of progression of the IMH (grade 2), semi-elective repair (within 24–72 h) should be considered.
IIa
C
Recommendations for follow-up after treatment of acute aortic syndrome
In medically treated type B AAS or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging findings 
are stable.
I
C
In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable.
I
C
After open surgery for AAS, follow-up imaging by CCT and TTE within 6 months, then CCT at 12 months and then yearly if findings are stable, 
should be considered.
IIa
B
If no complications occur within the first 5 years, CCT every 2 years thereafter should be considered.
IIa
B
If no residual patent FL is documented for 3 post-operative years, subsequent surveillance by CCT every 2–3 years should be considered.
IIa
C
In the follow-up of medically treated PAU, after 2 years of imaging stability, larger intervals should be considered in low-risk patients.
IIa
C
Recommendations for the management of patients with heritable thoracic aortic disease
It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making.
I
C
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in 
the care of this patient group.
I
C
Recommendations for genetic testing and aortic screening in aortic disease
In patients with HTAD, guidance of clinical management by the underlying gene/variant, when known, should be considered.
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3553


<!-- PAGE 17 -->

### Page 17

Recommendations for imaging in women with Turner syndrome
To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to BSA 
[m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and assess 
the risk of aortic dissection.
I
C
It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending 
ASI and concomitant lesions.
I
C
Recommendations for aortic surgery in women with Turner syndrome
Elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered in women with TS who are ≥15 years of age, 
have an ascending ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, and have associated risk factors for aortic dissection or are planning 
pregnancy.
IIa
C
Elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women with TS who are ≥15 years of age, 
have an ascending ASI >25 mm/m2, an AHI >25 mm/m, a z-score >4, and who do not have associated risk factors for aortic dissection.
IIb
C
Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome
In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended.
I
C
Treatment with celiprolol should be considered in patients with vEDS.
IIa
B
Recommendations for vascular imaging in Marfan syndrome
In patients with MFS, TTE is recommended: 
• At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factors
• At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factors
• At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factors
I
C
In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aortic imaging by CMR or CCT and DUS is 
recommended at the first evaluation, and subsequently every 3–5 years if stable.
I
C
Recommendations for medical treatment in Marfan syndrome
In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to reduce 
the rate of aortic dilatation.
I
A
In patients with MFS, the use of both a BB and an ARB, in maximally tolerated doses (unless contraindicated), should be considered to reduce 
the rate of aortic dilatation.
IIa
A
Recommendations for pregnancy in women with Marfan syndrome
It is recommended that all women with MFS: 
• Have a pre-conception evaluation to address the risks of maternal CV and other complications
• Have follow-up in a centre with access to a pregnancy heart and vessel team
I
C
It is recommended that couples in which a partner has or is at risk of HTAD be offered pre-conception genetic counselling.
I
C
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy.
I
C
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth.
I
C
Intake of BBs during pregnancy is recommended.
I
C
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm.
I
C
Prophylactic aortic root surgery may be considered in women desiring pregnancy with aortic diameters of 40–45 mm.
IIb
C
Recommendations for physical exercise in patients with Marfan syndrome
It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and 
pre-existing fitness.
I
C
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS.
I
C
For patients who present with aortic dissection and/or have undergone aortic surgery, post-operative cardiac rehabilitation aiming at 
improving both physical and mental health should be considered.
IIa
B
Recommendations for imaging follow-up in Loeys–Dietz syndrome
In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth, is 
recommended.
I
C
In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance 
with CMR or CCT or DUS every 1–3 years is recommended.
I
C
Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease
Annual monitoring of the aortic root/ascending aorta with TTE to evaluate for aortic root/ascending aorta enlargement is recommended.
I
C
Imaging of the aorta with CMR/CCT every 3–5 years is recommended.
I
C
Prophylactic aortic root surgery should be considered with a diameter ≥45 mm, or lower in cases with other risk factors.
IIa
C
Continued


<!-- PAGE 18 -->

### Page 18

Recommendations for bicuspid aortic valve-associated aortopathy management
Surgery for bicuspid aortopathy of the root phenotype is recommended when the maximum aortic diameter is ≥50 mm.
I
B
Screening by TTE in FDRs of BAV patients with root phenotype aortopathy and/or isolated aortic regurgitation is recommended.
I
C
In patients with low surgical risk, surgery for bicuspid aortopathy of ascending phenotype should be considered when the maximum aortic 
diameter is >52 mm.
IIa
B
Recommendations for evaluation and medical treatment of patients with coarctation of the aorta
In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR 
every 3–5 years (adapted to clinical status and previous imaging findings).
I
B
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.
I
A
In patients with stable PVD who are symptomatic in at least one territory and without high bleeding risk, treatment with a combination of 
rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered.
IIa
A
© ESC 2024
AAA, abdominal aortic aneurysm; AAD, acute aortic dissection; AAS, acute aortic syndrome; AHI, aortic height index; ARB, angiotensin receptor blocker; ASI, aortic size index; BAV, bicuspid 
aortic valve; BB, beta-blocker; b.i.d., twice daily; BP, blood pressure; BTK, below-the-knee; BSA, body surface area; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced 
ultrasound; CLTI, chronic limb-threatening ischaemia; CMR, cardiovascular magnetic resonance; CS, carotid artery stenosis; CV, cardiovascular; CVRFs, cardiovascular risk factors; DM, 
diabetes mellitus; DTA, descending thoracic aorta; DUS, duplex ultrasound; ECST, European Carotid Surgery Trial; FDR, first-degree relative; FL, false lumen; GSV, great saphenous vein; 
HBET, home-based exercise training; HTAD, heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; IC, intermittent claudication; i.v., intravenous; 
LDL-C, low-density lipoprotein cholesterol; MFS, Marfan syndrome; NASCET, North American Symptomatic Carotid Endarterectomy Trial; OAC, oral anticoagulation; o.d., once daily; 
OMT, optimal medical treatment; PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; PVD, polyvascular disease; 
QoL, quality of life; RAS, renal artery stenosis; SAPT, single antiplatelet therapy; SET, supervised exercise training; TAA, thoracic aortic aneurysm; TAAD, type A aortic dissection; 
TBAD, type B aortic dissection; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TS, Turner syndrome; TTE, transthoracic 
echocardiography; vEDS, vascular Ehlers–Danlos syndrome.
Table 4 Revised recommendations
Recommendations in 2017 (PAD) and 2014 
(Aortic)
Class
Level
Recommendations in 2024
Class
Level
Recommendations for abdominal aortic aneurysm screening
Screening for AAA with DUS
Is recommended in all men >65 years of age.
I
A
Is recommended in men aged ≥65 years with a history of 
smoking to reduce the risk of death from ruptured AAA.
I
A
(i) May be considered in women >65 years of age with 
history of current/past smoking.
IIb
C
May be considered in men aged ≥75 years (irrespective of 
smoking history) or in women aged ≥75 years who are 
current smokers, hypertensive, or both.
IIb
C
(ii) Is not recommended in female non-smokers without 
familial history.
III
C
Family AAA screening with DUS
Targeted screening for AAA with ultrasound should be 
considered in first-degree siblings of a patient with AAA.
IIa
B
Is recommended for FDRs of patients with AAA aged 
≥50, unless an acquired cause can be clearly identified.
I
C
Opportunistic AAA screening with DUS
Targeted screening for AAA with ultrasound should be 
considered in first-degree siblings of patients with AAA.
IIa
B
Should be considered in men ≥65 years and in women 
aged ≥75 years during TTE.
IIa
B
Recommendations for antihypertensive therapy in patients with peripheral and aortic disease
In patients with PAD and hypertension, it is recommended 
to control blood pressure at <140/90 mmHg
I
A
In patients with PAAD and hypertension an SBP target 
towards 120–129 mmHg, if tolerated, is recommended.
I
A
ACEIs or ARBs should be considered as first-line therapy 
in patients with PAD and hypertension.
IIa
B
ACEIs/ARBs may be considered in all patients with PAD, 
regardless of BP levels, in the absence of contraindications.
IIb
B
Recommendations for lipid-lowering therapy for patients with peripheral arterial and aortic diseases
In patients with PAD, it is recommended to reduce LDL-C 
to <1.8 mmol/L (70 mg/dL) or decrease it by >50% if 
baseline values are 1.8–3.5 mmol/L (70–135 mg/dL).
I
C
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a 
>50% reduction in LDL-C vs. baseline are recommended 
in patients with atherosclerotic PAAD.
I
A
Recommendations for carotid artery stenosis assessment
DUS (as first-line imaging), CTA, and/or MRA are 
recommended for evaluating the extent and severity of 
extracranial carotid stenosis.
I
B
It is recommended to use DUS as first-line imaging to 
diagnose ICA stenosis.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3555


<!-- PAGE 19 -->

### Page 19

Recommendations in patients with visceral artery stenosis
In patients with acute embolic occlusion of the SMA, both 
endovascular and open surgery therapy should be 
considered.
IIa
B
In patients with acute mesenteric ischaemia due to acute 
occlusion of the SMA, endovascular revascularization is 
recommended.
I
B
Recommendations for surveillance of patients with abdominal aorta aneurysm
In patients with small (30–55 mm) AAA, the following 
time interval should be considered: 
• Every 3 years for AAA of 30–39 mm diameter
• Every 2 years for AAA of 40–44 mm diameter
• Every year for AAA >45 mm diameter.
IIa
B
DUS surveillance should be considered annually in women 
with AAA of 40–45 mm and in men with AAA of 40– 
49 mm.
IIa
B
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
Surgery should be considered in patients who have 
isolated aortic arch aneurysm with a maximal diameter 
≥55 mm.
IIa
C
Surgery is recommended in patients with dilatation of the 
aortic root or ascending aorta with a tricuspid aortic valve 
and a maximum diameter of ≥55 mm.
I
B
Aortic valve repair using the reimplantation technique or 
remodelling with aortic annuloplasty is recommended in 
young patients with aortic root dilation and tricuspid 
aortic valves.
I
C
Valve-sparing aortic root replacement is recommended in 
patients with aortic root dilatation if performed in 
experienced centres and durable results are expected.
I
B
Lower thresholds for intervention may be considered 
according to BSA in patients with small stature or in the 
case of rapid progression, aortic valve regurgitation, 
planned pregnancy, and patient’s preference.
IIb
C
Ascending aortic or root replacement may be considered 
at a maximum diameter of ≥50 mm in patients with 
proximal aorta dilatation who can be offered surgery with 
low predicted risk and present with any of the following: 
• Growth of the aortic diameter ≥3 mm per year
• Resistant hypertension
• Short stature (<1.69 m)
• Root phenotype
• Aortic length >11 cm
• Age <50 years
• Desire for pregnancy
• Aortic coarctation.
IIb
B
Recommendations for surgery in aortic arch aneurysms
Aortic arch repair may be considered in patients with 
aortic arch aneurysm who already have an indication for 
surgery of an adjacent aneurysm located in the ascending 
or descending aorta.
IIb
C
In patients undergoing open surgical repair of an ascending 
aortic aneurysm, concomitant hemi-arch replacement 
should be considered if the dilatation extends into the 
proximal aortic arch (>50 mm).
IIa
C
Recommendations for follow-up after treatment of aortic aneurysms
After TEVAR or EVAR, surveillance is recommended after 
1, 6, and 12 months and then yearly. Shorter intervals can 
be proposed in the event of abnormal findings requiring 
closer surveillance.
I
C
After TEVAR, follow-up imaging is recommended at 1 and 
12 months post-operatively, then yearly until the fifth 
post-operative year if no abnormalities are documented.
I
B
Long-term surveillance of open abdominal aortic repair 
may be considered at loose (5 year) intervals using colour 
DUS or CCT imaging.
IIb
C
After open repair of AAA, first follow-up imaging is 
recommended within 1 post-operative year, and every 5 
years thereafter if findings are stable.
I
A
If neither endoleak nor AAA sac enlargement is 
documented during first year after EVAR, then colour 
DUS, with or without contrast agents, should be 
considered for annual post-operative surveillance, with 
non-contrast CT imaging every 5 years.
IIa
C
After EVAR, follow-up imaging is recommended with CCT 
(or CMR) and DUS/CEUS at 1 month and 12 months 
post-operatively, then, if no abnormalities are documented, 
DUS/CEUS is recommended every year, repeating CCT or 
CMR (based on potential artefacts) every 5 years.
I
A
Recommendations for diagnostic work-up of acute aortic syndrome
TTE is recommended as an initial imaging investigation. 
In stable patients with a suspicion of AAS, the following 
imaging modalities are recommended (or should be 
considered according to local availability and expertise):
I
C
In patients with suspected AAS, focused TTE (with use of 
contrast if feasible) is recommended during the initial 
evaluation.
I
C
MRI
I
C
In patients with suspected AAS, CMR should be 
considered as an alternative imaging technique if CCT is 
not available.
IIa
C
Continued


<!-- PAGE 20 -->

### Page 20

TOE
IIa
C
In patients with suspected AAS, TOE is recommended to 
guide peri-operative management and detect 
complications.
I
C
Recommendations for medical treatment in acute aortic syndromes
In all patients with AD, medical therapy, including pain 
relief and blood pressure control, is recommended.
I
C
Invasive monitoring with an arterial line and continuous 
three-lead ECG recording, as well as admission to an 
intensive care unit, is recommended.
I
B
Recommendations for the management of patients presenting with acute type B aortic dissection
In complicated TBAD, TEVAR is recommended.
I
C
In patients with complicated acute TBAD, emergency 
intervention is recommended.
I
B
In complicated TBAD, surgery may be considered.
IIb
C
In complicated TBAD, TEVAR may be recommended.
IIb
C
In patients with complicated acute TBAD, TEVAR is 
recommended as the first-line therapy.
I
B
In complicated TBAD, surgery may be considered.
IIb
C
Recommendations for the management of intramural haematoma
In complicated type B IMH, TEVAR should be considered.
IIa
C
In complicated type B IMH, TEVAR is recommended.
I
C
Recommendations for the management of penetrating atherosclerotic ulcer
In the case of type A PAU, surgery should be considered.
IIa
C
In the case of type A PAU, surgery is recommended.
I
C
In complicated type B PAU, TEVAR should be considered.
IIa
C
In complicated type B PAU, endovascular treatment is 
recommended.
I
C
Recommendations for traumatic aortic injury
In cases of TAI with suitable anatomy requiring 
intervention, TEVAR should be preferred to surgery.
IIa
C
In cases of TAI with suitable anatomy requiring 
intervention, TEVAR is recommended over open surgery.
I
A
Recommendations for genetic testing and aortic screening in aortic disease
It is recommended to investigate FDRs (siblings and 
parents) of a subject with TAAD to identify a familial form 
in which relatives all have a 50% chance of carrying the 
family mutation/disease.
I
C
Imaging screening of family members of patients with 
TAD with risk factors for HTAD in whom no (likely) 
pathogenic variant is identified should be considered 
starting at age 25, or 10 years below the youngest case, 
whichever is younger. If the initial screening is normal, 
continued screening every 5 years until the age of 60 
should be considered.
IIa
C
Recommendations for bicuspid aortic valve-associated aortopathy management
Cardiac MRI or CT is indicated in patients with BAV when 
the morphology of the aortic root and the ascending aorta 
cannot be accurately assessed by TTE.
I
C
CCT or CMR of the entire thoracic aorta is 
recommended at first diagnosis and when important 
discrepancies in measurements are found between 
subsequent TTE controls during surveillance, or when the 
diameter of the aorta exceeds 45 mm.
I
C
In the case of aortic diameter >50 mm or an increase of 
>3 mm per year measured by echocardiography, 
confirmation of the measurement is indicated, using 
another imaging modality (CT or MRI).
I
C
In the case of a diameter of the aortic root or the 
ascending aorta >45 mm or an increase of >3 mm per 
year measured by echocardiography, annual 
measurement of aortic diameter is indicated.
I
C
Surveillance serial imaging by TTE is recommended in BAV 
patients with a maximum aortic diameter >40 mm, either 
with no indication for surgery or after isolated aortic valve 
surgery, after 1 year, then if stability is observed, every 2–3 
years.
I
C
In cases of BAV, surgery of the ascending aorta is indicated 
in the case of: 
• Aortic root or ascending aortic diameter >50 mm in the 
presence of other risk factors (coarctation of the aorta, 
systemic hypertension, family history of dissection, or 
increase in aortic diameter of >3 mm per year).
I
C
In patients with low surgical risk and ascending phenotype 
bicuspid aortopathy, surgery should be considered at a 
maximum diameter ≥50 mm if any of the following is the 
case: 
• Age <50 years
• Short stature
• Ascending aortic length ≥11 cm
• Aortic diameter growth rate >3 mm per year
• Family history of acute aortic syndrome
• Aortic coarctation
• Resistant hypertension
• Concomitant non-aortic-valve cardiac surgery
• Desire for pregnancy
IIa
C
Continued 
ESC Guidelines                                                                                                                                                                                          3557


<!-- PAGE 21 -->

### Page 21

### 4 Epidemiology and risk factors

4.1. Epidemiology
Peripheral arterial disease (PAD) is prevalent worldwide and affects 113 
million people aged 40 and older, of which 42.6% are in countries with a 
low-to-middle sociodemographic index. Global prevalence is 1.52%, in­
creases with age (14.91% in those aged 80–84 years), and is higher in 
females than in males (18.03% vs. 10.56%, in the same age group).10–13
PAD prevalence rose by 72% from 1990 to 2019, considering a 
45% growth rate in the world population.10,11,14 The overall global 
age-standardized prevalence is about 1470 per 100 000 persons (Figure 2).14
Ischaemic cerebral disease, mainly linked to carotid stenosis (65% of 
cases), has a prevalence of 77.19 million, marking a 95% increase from 
1990 to 2019.15
The overall prevalence of aortic disease including aneurysm and 
dissections is estimated at around 1% to 3% in the general population, 
with up to 10% prevalence in older age groups. European studies show 
a decrease in abdominal aortic aneurysm (AAA) prevalence in screened 
men >65 years of age, at 1.3%–3.3%,16,17 contrasting with the United 
States of America’s 5% found in screened male smokers.16,17
Globally, in 2019, there were 172 000 aortic aneurysm-related deaths 
(82.1% increase from 1990).10
In cases of BAV, surgery of the ascending aorta is indicated 
in the case of: 
• Aortic root or ascending aortic diameter >45 mm 
when surgical aortic valve replacement is scheduled.
I
C
Surgery for bicuspid aortopathy in patients undergoing 
aortic valve surgery should be considered at a root or 
ascending diameter ≥45 mm.
IIa
C
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients undergoing CABG, DUS is recommended in 
patients with a recent (<6 months) history of TIA/stroke.
I
B
Carotid DUS should be considered for stable patients 
scheduled for CABG with TIA/stroke within the past 6 
months without carotid revascularization.
IIa
B
© ESC 2024
AAA, abdominal aortic aneurysm; AAS, acute aortic syndrome; ACEI, angiotensin-converting enzyme inhibitor; AD, aortic dissection; ARB, angiotensin receptor blocker; BAV, bicuspid aortic 
valve; BP, blood pressure; BSA, body surface area; CABG, coronary artery bypass grafting; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced ultrasound; CMR, 
cardiovascular magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; DUS, duplex ultrasound; ECG, electrocardiogram; FDR, first-degree relative; 
HTAD, heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; LDL-C, low-density lipoprotein cholesterol; MRA, magnetic resonance angiography; 
MRI, magnetic resonance imaging; PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; SBP, systolic blood pressure; 
SMA, superior mesenteric artery; TAAD, type A aortic dissection; TAD, thoracic aortic disease; TAI, traumatic aortic injury; TBAD, type B aortic dissection; TOE, transoesophageal 
echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TIA, transient ischaemic attack; TTE, transthoracic echocardiography.
30 000
25 000
20 000
15 000
10 000
5000
0
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
Female
Male
Age (years)
Prevalence rate (per 100 000 population)
Figure 2 Estimated specific prevalence of peripheral arterial disease, by sex, in people aged 40 years and older. Adapted from12 under the terms of the 
Open access Creative Commons CC-BY license.


<!-- PAGE 22 -->

### Page 22

4.2. Risk factors
Main PAAD risk factors are summarized in Figure 3. Traditional risk factors 
in tools like Framingham, Reynolds, Atherosclerotic Cardiovascular Disease 
(ASCVD) risk estimator Plus (United States of America), SCORE2 
(Systematic Coronary Risk Evaluation 2, age 40–69 years), SCORE2- 
Diabetes (Systematic Coronary Risk Evaluation 2 - diabetes), and 
SCORE2-OP (Systematic Coronary Risk Evaluation 2–Older Persons) 
(Europe)18 also contribute to PAAD’s pathophysiology and development. 
More details are available in Supplementary data online, Section 1.1, and the 
Low-density lipoprotein cholesterol (LDL-C) is a pivotal factor in 
atherosclerosis,19 with diabetes and tobacco exposure significantly 
A
t h
e r
o s
c l
e r
o t
i c
 
P
A
A
D
Traditional risk factors
Non-traditional risk factors
Female-specific risk factors
Non-modifiable risk factors
Modifiable risk factors
Overweight
Sedentary lifestyle
Sleep disorders
Apolipoproteins
Environmental pollution
Socio-economic status
Menopause
Pregnancy-induced hypertension/
diabetes
Polygenic and family inheritance
Sex
Age
Tobacco
Diabetes
Lipids
Hypertension
Stressful lifestyle
Alcohol
Diet
Inﬂammation
Autoimmune disease
Figure 3 Main risk factors associated with atherosclerosis in peripheral arterial and aortic diseases. PAAD, peripheral arterial and aortic diseases.
ESC Guidelines                                                                                                                                                                                          3559


<!-- PAGE 23 -->

### Page 23

amplifying PAD risk by 2–4 times each.20 Both men and women face a 
similar risk of PAD, but women have distinct risk factors (Figure 3).21
Hypertension and male sex are major risk factors for AAA, whereas dia­
betes mellitus lowers its incidence by 25%.22–24 Thoracic aortic aneurysm 
(TAA) or dissection share atherosclerotic risk factors, yet monogenic or 
polygenic diseases like Marfan syndrome (MFS), more prevalent in young­
er individuals, also contribute.24,25 Inflammation as a risk factor can be ob­
served in PAAD26 and the potential for inflammation to be a modifiable 
risk factor is indicated by research related to colchicine and the effects 
demonstrated by canakinumab (a monoclonal antibody that reduces in­
flammation by inhibiting interleukin-1 beta).27,28
5. Evaluation of peripheral arteries 
and aorta
To be consistent with existing literature, the term PAD is used to refer 
to lower-extremity atherosclerotic arterial disease.
5.1. Clinical history and examination, and 
laboratory assessment, in patients with 
peripheral arterial and aortic diseases
Clinical evaluation encompassing history (including family history), 
review of symptoms, and physical examination are the first steps 
in diagnosing and assessing patients with PAAD. Pulse palpation, 
femoral, carotid, and abdominal bruit auscultation, heart ausculta­
tion, and observation of the legs and feet need to be part of the vas­
cular examination.
Clinical signs, beyond aiding diagnosis, offer prognostic insights. 
Carotid bruits double the risk of myocardial infarction (MI) and CV 
death,29,30 while a brachial systolic blood pressure (SBP) difference of 
more than 15 mmHg raises CV death risk by 50%.31 Hence, bilateral 
arm blood pressure (BP) measurement is recommended.32 Lab assess­
ments should include lipid profile (including lipoprotein[a] at least once 
in a lifetime),33 fasting glycaemia, glycated haemoglobin (HbA1c), renal 
function, blood count, coagulation studies, liver function, electrolytes, 
and inflammatory markers (C-reactive protein [CRP] and erythrocyte 
sedimentation rate). Additional evaluations, like thyroid function tests, 
are advised as needed.
5.2. Functional and quality of life 
assessment in patients with peripheral 
arterial and aortic diseases
Patients with PAD have decreased walking performance and self- 
reported physical and mental health-related quality of life 
(HRQoL).34–40 Muscle strength and balance are also impaired,41–45
leading to a faster decline in functional (physical functioning) perform­
ance in both symptomatic and asymptomatic patients.46,47 Depression 
is associated with greater impairment in functional performance.48,49
Impaired functional status is related to decreased self-reported 
HRQoL,50,51 and predicts further mobility loss and CV mortality.52,53
Very poor HRQoL has been found in patients with chronic limb- 
threatening ischaemia (CLTI).54
Different questionnaires are available assessing different facets (func­
tional, mental, and social status) of patient-reported outcome measures 
(PROMs).34–36,38 The Short-form 36-item health questionnaire (SF-36) 
(including physical- and mental health-related items) is the most used 
generic questionnaire in PAD.35,36,38 The Edinburgh Claudication 
Questionnaire is a modified version of the initially developed Rose ques­
tionnaire and has a sensitivity of 91% and a specificity of 99% in compari­
son with a physician-based diagnosis.55,56 The Walking Impairment 
Questionnaire (WIQ), the Walking Estimated Limitation Calculated by 
History (WELCH), and the Vascular quality of life (VascuQoL) question­
naire are the most used PAD-specific questionnaires.34–36,38
Treadmill testing, using standardized criteria, is the gold standard to as­
sess walking performance.37,57–62 Patients are asked to walk until max­
imal pain levels, defining the maximal walking distance (MWD). 
Patients are also asked to indicate the point at which pain begins, defining 
the pain-free walking distance (PFWD). Constant-load protocols have 
poorer reliability than graded protocols.60–64 Additionally, the six-minute 
walk test (6MWT) should be performed to assess functional walking per­
formance.62,65 For muscular lower-limb strength assessment,66 isokinetic 
dynamometry has good test–retest reliability.67 Alternatively, the Short 
physical performance battery (SPPB) test should be used.62,64,68,69 The 
SPPB has good test–retest reliability.64
Few data exist on HRQoL, functional assessment, and exercise cap­
acity in patients with aortic diseases.70,71 Those with acute aortic dis­
section (AAD), as well as patients who had aortic valve or thoracic 
aortic surgery, may present with depression and anxiety, leading to 
mental health issues72,73 that can also be assessed with the SF-36 ques­
tionnaire or the hospital anxiety and depression score (HADS).72
Patients with MFS have reduced HRQoL and a significant decline 
over time in physical HRQoL.74,75 Assessing HRQoL in aortic disease 
patients is crucial for understanding well-being, disease impact, and 
treatment effects. This involves PROMs, including surveys, symptom 
assessment, functional evaluation, psychological well-being (HADS), 
social and occupational function, and medication/treatment side effects. 
It also covers healthcare utilization and patient satisfaction, informing 
care and enhancing aortic disease management.
Recommendation Table 1 — Recommendations for clin­
ical and laboratory, and for functional and quality of life, as­
sessment in patients with peripheral arterial and aortic 
disease (see also Evidence Table 1)
Recommendations
Classa
Levelb
When managing PAAD, it is recommended to adopt 
a comprehensive approach that addresses the 
entirety of the arterial circulation.76
I
B
To assess PAAD, it is recommended to perform 
thorough clinical, vascular, and CVRFs laboratory 
evaluation.77
I
C
Overall evaluation of functional (physical functioning) 
performance with objective tests should be 
considered in patients with symptomatic and 
asymptomatic chronic PAD.57,61,63
IIa
B
Overall evaluation of self-reported (i.e. by 
questionnaire) physical and mental/social HRQoL 
should be considered in patients with  
PAAD.34–36,38,72
IIa
B
© ESC 2024
CVRFs, cardiovascular risk factors; HRQoL, health-related quality of life; PAAD, peripheral 
arterial and aortic diseases; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 24 -->

### Page 24

5.3. Vascular examination of peripheral 
arteries
The ankle-brachial index (ABI)78,79 is a low-cost, easy, and largely used 
tool, used both at rest or after exercise80–84 for PAD diagnosis and sur­
veillance (Figure 4). Both oscillometric and Doppler methods have 
shown good concordance.78
Resting ABI has a 68%–84% sensitivity and an 84%–99% specificity 
for PAD diagnosis (Figure 4).79 An ABI ≤0.90 confirms PAD 
diagnosis.79,85–87 For values >1.40, the term ‘non-compressible arteries’ 
should be used.
Ankle–brachial index >1.40, seen in arterial stiffness (diabetes, 
severe kidney failure, or advanced age), correlates with increased CV 
events and mortality risk.88,89 For ABI >1.40, assessing resting toe– 
brachial index (TBI) is recommended.79,90–95
Toe–brachial index addresses medium-calibre artery rigidity96 measur­
ing pressure on the hallux, second, or third toe using laser Doppler probe 
or plethysmography.97,98 Sensitivity and specificity for PAD diagnosis 
Ankle-brachial index (ABI)
Haemodynamic criteria for PAD
Haemodynamic criteria for CLTI
Higher systolic ankle pressure of target leg
(posterior tibial or dorsalis pedis artery)
Higher systolic brachial pressure, 
irrespective of target leg
Toe-brachial index (TBI)
Toe pressure of target leg
Higher systolic brachial pressure, 
irrespective of target leg
Borderline ABI
0.90
1.0
0.70
1.40
Abnormal low ABI
Abnormal low TBI
Abnormal high ABI
Normal
ABI
Normal
TBI
Ankle pressure <50 mmHg
How to measure
Transcutaneous oxygen partial pressure (TcPO2)
Toe pressure <30 mmHg
TcPO2 <30 mmHg
In supine position, 5–10 min resting, constant room temperature
ABI and ankle pressure: cuffs on upper arms and lower limbs (just above the ankle)
TBI and toe pressure: cuffs on upper arms and photoplethysmography probe on distal pulp of first or second toe
TcPO2: preferred position of measurement electrode at first intermetatarsal position
Figure 4 Haemodynamic assessment of peripheral arterial disease. ABI, ankle–brachial index; CLTI, chronic limb-threatening ischaemia; PAD, 
peripheral arterial disease; TBI, toe–brachial index; TcPO2, transcutaneous oxygen pressure.
ESC Guidelines                                                                                                                                                                                          3561


<!-- PAGE 25 -->

### Page 25

range from 45% to 100% and 17% to 100%, respectively.91 The usual 
pathological threshold for TBI is ≤0.70 (Figure 4).99
Used within the Framingham risk score, ABI enables the upgrading of 
risk estimation in ‘low-risk’ women and men,77,88 it allows CV risk as­
sessment in diverse ethnic groups independently of risk factors,77,89
and is inexpensive and minimally time-consuming.100 Trained physicians 
have better reproducibility than inexperienced ones.101,102
In patients with exertional limb pain relieved by rest and a resting 
ABI >0.90, exercise testing with post-exercise ABI measurements 
or exercise oximetry has been proposed to diagnose lower-limb ar­
terial stenoses.103–105
The post-exercise ABI is determined 1 min after the cessation of 
a standardized treadmill exercise.106 The physician measures bilat­
eral ankle BP, starting with the symptomatic leg, using the ankle ar­
tery used for the reference resting ABI measurement. Brachial SBP 
should simultaneously be measured to enable calculation of the 
post-exercise ABI.104
Discrepancies in PAD diagnosis exist between exercise criteria, such 
as a fall in absolute ankle BP >30 mmHg or a drop of >20% in the post- 
exercise ABI.104 Recent studies identified numerous false positives in a 
healthy population when using a post-exercise ABI drop of >20% as the 
diagnostic threshold, as commonly proposed.103
Measurement of transcutaneous oxygen pressure (TcPO2) is a 
means of evaluating tissue viability and is proposed as a diagnostic cri­
terion of CLTI (Figure 4).107 TcPO2 is affected by local and general fac­
tors such as skin thickness, probe temperature, inflammation, and 
oedema,108,109 resulting in misleading values.
Resting TcPO2 >30 mmHg is a favourable indicator of wound heal­
ing;110–112 however, resting TcPO2 <10 mmHg is associated with bad 
prognosis for wound healing and amputation in CLTI patients treated 
with bone marrow-derived stem cells.107 When performed at succes­
sive levels on an ischaemic limb, TcPO2 measurement may help to de­
termine amputation level.113–115
Exercise transcutaneous oximetry has also been proposed.116,117
This seems of interest to detect proximal (buttock) claudication105
or unsuspected exercise-induced hypoxaemia118 in patients with inter­
mittent claudication (IC).117
5.3.1. Duplex ultrasound
Duplex ultrasound (DUS) is a first step in the vascular work-up for PAD 
screening and diagnosis, allowing a dynamic, non-invasive, radiation- and 
contrast-free examination. It localizes vascular lesions and quantifies 
their extent and severity through velocity criteria.119–121 In combin­
ation with ABI or TBI, DUS permits determining the haemodynamic 
relevance of arterial lesions122,123 and estimation of ABI.124 DUS has 
a sensitivity of 88% and specificity of 95% for >50% stenosis detec­
tion.125 Post-exercise DUS can reveal borderline arterial lesions if initial 
findings are inconclusive.122,126,127
Duplex ultrasound distinguishes atherosclerotic (even subclinical dis­
ease) from non-atherosclerotic lesions, but its reliability relies on the 
sonographer’s expertise.122 Cross-sectional imaging is advisable for re­
vascularization planning. ABI and DUS are recommended for PAD pa­
tient follow-up post-revascularization.128
More recent techniques, such as flow imaging, 3D echography, ultra­
fast ultrasound, and shear wave elastography, as well as the use of 
contrast-enhanced ultrasound (CEUS), could further improve DUS 
performance.129
5.3.2. Digital subtraction angiography, computed 
tomography angiography, and magnetic resonance 
angiography
Detailed information about these techniques can be found in the 
Supplementary data online, Section 1.2 (Table S1). Digital subtraction 
angiography (DSA) remains mostly limited to revascularization proce­
dures. Computed tomography angiography (CTA) offers better spatial 
resolution than magnetic resonance angiography (MRA) and better cal­
cification visualization; however, it can also overestimate stenosis sever­
ity due to the blooming effect. MRA allows arterial wall and lumen 
assessment as well as tissue and organ perfusion distal to or surround­
ing the explored arterial territory.
5.4. Evaluation of the aorta
The aorta can be divided into different anatomical regions (from prox­
imal to distal) for reporting purposes. The main anatomical aortic re­
gions are the aortic root, ascending aorta, aortic arch, descending 
thoracic aorta (DTA), abdominal aorta (AA), infrarenal aorta, and the 
iliac arteries (Figure 5).134,135
5.4.1. Aortic measurements
The main imaging techniques used for aortic evaluation are illustrated in 
Table 5.
Evaluating aortic dilation and progression depends on standardized 
measurements. In echocardiography, aortic diameters should be mea­
sured using the leading-to-leading edge method during end-diastole 
(as systole sees about a 2 mm aortic expansion) in all segments 
(Figure 6).137,138
Most studies supporting prophylactic surgery have used this ap­
proach. Furthermore, better agreement exists between echo’s 
leading-to-leading edge and cardiovascular computed tomography 
(CCT)/cardiovascular magnetic resonance (CMR)’s inner-to-inner 
edge during end-diastole.137,139,140 However, when the aortic wall 
thickens (e.g. atheroma, thrombus, intramural haematoma [IMH], or 
aortitis) or in cases of aortic dissection (AD), also report the 
outer-to-outer diameter (Figure 6).
Recommendation Table 2 — Recommendations for 
diagnostic tests in patients with peripheral arterial 
disease
Recommendations
Classa
Levelb
Measurement of the ABI is recommended as the 
first-line non-invasive test for screening and diagnosis 
of PAD, using an ABI ≤0.90 as a diagnostic 
criterion.79,90,130,131
I
B
In the case of non-compressible ankle arteries or ABI 
>1.40, additional methods such as TP, TBI or 
Doppler waveform analysis are 
recommended.90,91,124,132,133
I
B
© ESC 2024
ABI, ankle–brachial index; PAD, peripheral arterial disease; TBI, toe–brachial index; TP, toe 
pressure. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 26 -->

### Page 26

Distal descending aorta
Aortic arch
Thoracic descending aorta
Mid aortic arch
Proximal aortic arch
Ascending aorta
37 mm
40 mm
34 mm
36 mm
Sinotubular junction
Sinus of Valsalva
(<22 mm/m2)
38 mm
40 mm
33 mm
34 mm
0
1 23
4
5
6
7
8
9
10
11
29 mm 26 mm
23 mm 20 mm
34 mm 31 mm
Abdominal aorta
23 mm 19 mm
Proximal descending aorta
Figure 5 Anatomy and aortic segments and upper normal values for aortic dimensions. Numbers represent the 11 aortic segments based on the 
Society for Vascular  Surgery/Society of Thoracic Surgeons (SVS/STS) classification for surgical and endovascular purposes.136 Z-scores can be calcu­
lated for aortic root and ascending aorta. Calculation of z-scores can be performed following these links: https://www.marfan.fr/accueil/z-score-calculus/
or https://marfan.org/dx/z-score-adults.
ESC Guidelines                                                                                                                                                                                          3563


<!-- PAGE 27 -->

### Page 27

Table 5 Main aortic imaging techniques
TTE/DUS
TOE
CCT
CMR
Availability
++++
+++
++
+
Cost
+
++
+++
++++
Time requirement
+
+++
+++
++++
Radiation
0
0
+++
0
Spatial resolution
1 mm
1 mm
0.6 mm
1–2 mm
Temporal resolution
20 msec
20 msec
80 msec
30 msec
Nephrotoxicity
0
0
+++
+
Accuracy
++
++++
++++
++++
Serial examination
++++
++
++
++++
Aortic wall visualization
++
+++
++++
++++
Aortic valve function
+++
++++
+
++++
RV/LV function
+++
+++
+++a
++++
Aortic root assessment
+++
+++
++++
++++
Aortic arch assessment
++
+++
++++
++++
Thoracic aorta assessment
+
++
++++
++++
Abdominal aorta assessment
+++
-
++++
++++
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; LV, left ventricle; RV right ventricle; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography. 
aCCT can be used to evaluate left and right ventricular function only if retrospective gating is used.
A
B
C
D
E
F
AoR ASC
Figure 6 Conventional measurements of the aorta at different levels by echocardiography or duplex ultrasound (A, B, C), cardiovascular computed 
tomography or cardiovascular magnetic resonance (D, E, F). (A) Echocardiographic measurements of the aortic root and ascending aorta using the 
leading-to-leading edge methodology. (B) The outer-to-outer convention in the abdominal aorta in cases with aortic wall disease in a longitudinal 
view. This method can be used in a non-circular section as an alternative. (C) The outer-to-outer antero-posterior diameter of the abdominal aorta 
in a cross-sectional view. Evaluation of the aortic root using the cusp-to-cusp diameter (D) and the cusp-to-commissure convention (E); (F) meas­
urement of the ascending aorta and the descending aorta with the double-oblique technique. AoR, aortic root; ASC, proximal ascending aorta.


<!-- PAGE 28 -->

### Page 28

Given the high incidence of atherosclerotic plaques/thrombi in the 
AA, the outer-to-outer convention should be preferred (also present­
ing the best agreement with CCT and CMR) (Figure 6).141,142
Regarding CCT and CMR, measurements must be performed using 
the inner-to-inner edge method (Figure 6) in end-diastole (fewer mo­
tion artefacts).137,143,144
The aortic root is measured in the parasternal long axis by transthor­
acic echocardiography (TTE),137,139,140,145 since the short axis underesti­
mates the diameter due to possible plane obliquity. By CMR or CCT, the 
cusp-to-cusp diameter best correlates with echocardiography (Figure 6). 
A diameter difference >5 mm (among root diameters within the same 
imaging modality) indicates root asymmetry, frequent in bicuspid aortic 
valve (BAV) or genetic aortopathies, which is important to be determined 
since it generates underestimations.146 While 3D echocardiography is a 
potential surveillance alternative in these cases (especially if CMR/CCT 
is limited for serial follow-up), validation studies are lacking.147
In end-diastole, measure the ascending aorta by moving the transducer 
1–2 intercostal spaces up in the parasternal long axis. Echocardiography 
provides information on aortic arch or DTA enlargement, but diagnostic 
certainty (precise measurement of the diameters) is lacking. CCT or 
CMR uses the double-oblique technique to measure aortic diameters, re­
porting antero-posterior and perpendicular dimensions for accurate as­
sessment.148 It is recommended to report aortic measurements by 
specific segments based on anatomical landmarks and to relate the largest 
diameter to a nearby anatomical structure for reference.
Changes in aortic diameter require a ≥3 mm increase in echocardi­
ography, which should be confirmed with CCT/CMR and compared 
with baseline measurements. For accurate assessment, stick to the 
same imaging technique, centre, methodology, and side-by-side 
comparisons.137,140
5.4.2. Normal aortic values
When evaluating aortic dimensions and clinical relevance, consider fac­
tors like aortic region, anthropometric measurements, patient history, 
and underlying medical conditions. Factors influencing aortic and per­
ipheral artery size in the normal population include age, sex, ethnicity, 
body surface area (BSA), and, particularly, height.149
Body surface area is the most used method to normalize aortic dimen­
sions based on an individual’s body size, thus an ascending thoracic aorta 
>22 mm/m2 or a DTA >16 mm/m2 is considered aortic dilatation.150–152
However, extremes of low or high body weight pose limitations. In such 
cases, surgical thresholds may involve indexing aortic diameter by height 
(an aorta height index >32.1 mm/m is associated with a 12% yearly risk 
of aortic adverse events [AAE]),153 aortic cross-sectional area to patient 
height (a ratio ≥10 cm2/m implies reduced long-term survival),154 or aor­
tic length (from the aortic annulus to the innominate artery, considering a 
length >11 cm a threshold for surgery).155
To correlate measured diameter with the expected one based on 
age, sex, and body surface, use nomograms or z-score calculation for­
mulas, especially in heritable thoracic aortic disease (HTAD). 
Supplementary data online, Figure S1 and Table S2, presents nomo­
grams developed for echocardiography, applicable also to CCT 
and CMR.156,157 Calculation of z-scores can be performed following 
these links: https://www.marfan.fr/accueil/z-score-calculus/ or https:// 
marfan.org/dx/z-score-adults/; reference values used for their esti­
mation may vary depending on age and other factors. However, 
z-scores are limited by the fact that not all ethnic groups are equally 
represented (mostly white) and over- or underweight can lead to an 
over- or underestimation.158
Moreover, with ageing and loss of elastic properties, the aorta tends 
to enlarge. Aortic growth in adults is about 0.9 mm per 10 years in 
males and 0.7 mm per 10 years in females, which may be influenced 
by BP, physical activity, and genetic factors.
5.4.3. Chest X-ray and electrocardiogram
Chest X-ray obtained for other indications in asymptomatic patients or 
in cases of acute aortic syndrome (AAS) suspicion may detect abnor­
malities of aortic size/contour that need to be confirmed by another im­
aging technique. It presents limited sensitivity (64%) and specificity 
(86%) in the diagnosis of aortic diseases;162 thus, a normal chest 
X-ray may not rule out the diagnosis of AAS.162–164 On the contrary, 
chest X-ray may identify other causes of chest pain (e.g. pleural effusion 
or pneumothorax).
Electrocardiogram (ECG) might be useful to rule out other causes of 
chest pain (e.g. MI) or AAS complications (coronary occlusion/dissec­
tion) but it is not useful for AAS diagnosis.
5.4.4. Echocardiography
It is considered the first-line imaging technique in the evaluation of aor­
tic disease, assessing all echocardiographic windows and the aortic 
valve. It provides key anatomic information (i.e. dilatation, atheroscler­
otic lesions, or dissection) for the ascending aorta, arch, and AA; how­
ever, it is not useful to assess the exact diameters of the aortic arch and 
DTA (requiring confirmation with CCT/CMR). Also, the distal ascend­
ing aorta and proximal arch (blind spot) are inadequately visualized due 
to left mainstem bronchus interposition.
Transthoracic echocardiography can identify AAS complications (e.g. 
aortic regurgitation, tamponade, or wall motion abnormalities), but its 
diagnostic accuracy for AAS is limited (sensitivity: 78%–100% for type 
A, 31%–55% for type B). Contrast enhancement improves diagnosis.165
Recommendation Table 3 — Recommendations for 
imaging of the aorta (see also Evidence Table 2)
Recommendations
Classa
Levelb
It is recommended that aortic diameters are 
measured at pre-specified anatomical landmarks, and 
the largest diameter of the section be perpendicular 
to the longitudinal axis.134,135
I
C
It is recommended in cases of serial imaging of the 
aorta over time to use the same imaging modality 
with the same measurement method.159
I
C
It is recommended to consider renal function, 
pregnancy, age, and history of allergy to contrast 
media to select the optimal imaging modality with 
minimal radiation exposure and lowest iatrogenic 
risk, except for emergency cases.159–161
I
C
Indexing aortic diameters to BSA, along with the use 
of nomograms, z-scores, or other indexing methods, 
should be considered for more accurate assessment 
of aortic size, especially for body sizes at the lower 
end of the normal distribution.156–158
IIa
B
© ESC 2024
BSA, body surface area. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3565


<!-- PAGE 29 -->

### Page 29

Transoesophageal echocardiography (TOE) is highly accurate (sensitiv­
ity: up to 99%, specificity: 89% for AAS), except with absolute contra­
indications like oesophageal issues, bleeding, recent gastro-oesophageal 
surgery, or respiratory distress. TOE is convenient for bedside and in­
traoperative use but less suitable for long-term surveillance, which re­
quires evaluation with CCT/CMR.
5.4.5. Duplex ultrasound imaging of the abdominal 
aorta
After scanning both transversally and longitudinally, the antero- 
posterior (AP) diameter in a cross-sectional view of the AA should 
be measured. Ensure the DUS beam is perpendicular to the AA axis, 
forming a circular vessel section. If the AA is sinuous or dilated, achiev­
ing equal AP and transverse diameters may be challenging. In such in­
stances, calculate the mean ellipse diameter or measure the AA 
diameter in a clear longitudinal view with a perpendicular diameter 
(Figure 6).122 The outer-to-outer (Figure 6) method is the one 
recommended by the American Institute of Ultrasound in Medicine, 
the American College of Cardiology/American Heart Association 
(ACC/AHA), and the European Society of Cardiology (ESC), since it 
is more reliable in cases of atherosclerotic plaque or intravascular 
thrombus and best correlates with CCT and CMR. However, the 
most effective methodology is under debate and further studies are 
needed to determine the best convention.169
Normal diameters of the AA are reported in Figure 5 and 
Supplementary data online, Section 1.3.
5.4.6. Cardiovascular computed tomography
Cardiovascular computed tomography, due to its quick acquisition, 
wide availability, high reproducibility, and suitability for emergency de­
partments, is the primary imaging method for aortic disease diagnosis, 
prognosis, and therapy planning (sensitivity 100%, specificity 98% for 
AAS).170–172 ‘Double or triple rule-out’ protocols concurrently assess 
the aorta, pulmonary, and coronary arteries.173,174
Electrocardiogram triggering is crucial to prevent motion artefacts 
(especially in the aortic root and ascending aorta), which can distort 
measurements or resemble dissection flaps, facilitating coronary artery 
assessment. The standard protocol comprises non-enhanced scans (for 
calcification, IMH, or surgical material), contrast-enhanced CCT angiog­
raphy, and a late scan (to visualize contrast leakage or aortic wall late 
enhancement suggestive of inflammation or infection).175
Iodinated contrast agents carry potential allergic reactions and post- 
contrast acute kidney injury (PC-AKI) risks.176 In these cases, opt for 
contrast-free CCT for accurate aortic diameter measurement (also 
for CMR-intolerant patients). Moreover, excessive radiation caution 
is crucial, particularly in young females, when performing CCT for mon­
itoring chronic aortic diseases.177
5.4.7. Cardiovascular magnetic resonance
Cardiovascular magnetic resonance comprehensively evaluates the 
aorta, including shape, diameter, tissue characteristics (inflammation, in­
fection, atheroma, bleeding),178 lesion extent, side branches, adjacent 
structures, and mural thrombus. It assesses ventricular and valve func­
tion, quantifies flow, and employs cine steady-state free precession 
(SSFP) or ECG-gated angio-CMR for the aortic root, while non-gated 
sequences suffice for the rest. Recently, 4D flow sequences179 have 
been developed to evaluate complex intravascular flows,180,181 com­
plex flow parameters (wall shear stress, pulse wave velocity, or kinetic 
energy), or flow quantification at different levels in one unique acquisi­
tion (useful in AD or congenital diseases).182,183
Cardiovascular magnetic resonance obviates ionizing radiation and 
iodinated contrast (3D contrast CMR), making it ideal for young pa­
tients, women, and pregnancy. Caution is warranted, especially with 
non-macrocyclic gadolinium, for estimated glomerular filtration 
rate (eGFR) <30 mL/min/1.73 m² (Supplementary data online, 
Section 1.2). CMR is increasingly used in patients with intracardiac de­
vices (pacemakers/implantable cardioverter defibrillators, CMR- and 
non-CMR-compatible devices) with proper monitoring, but not for 
those with cochlear implants or intracranial clips.184,185
In the acute setting, CMR use is limited because of low availability, dif­
ficulties in monitoring unstable patients, and longer acquisition 
times.166,186
5.4.8. Positron emission tomography
Positron emission tomography (PET) usually uses 18F-fluorodeoxyglucose 
(FDG), allowing non-invasive assessments of metabolic activity 
Recommendation Table 4 — Recommendations for 
thoracic aortic measurements
Recommendations
Classa
Levelb
TTE is recommended as the first-line imaging 
technique in evaluating thoracic aortic diseases.159,165
I
B
It is recommended to report aortic diameters using 
the leading-to-leading edge convention in 
end-diastole by echocardiography.137,139,140,159
I
C
It is recommended to report aortic diameters using 
the inner-to-inner edge convention in end-diastole 
by CCT or CMR.137,143,144,159
I
C
It is recommended to report aortic diameters from 
images obtained with the double-oblique technique 
(not axial images) by CCT or CMR.148
I
C
ECG-triggered CCT is recommended for 
comprehensive diagnosis, follow-up, and pre-invasive 
treatment assessment of the entire aorta, particularly 
the root and ascending aorta.159
I
C
CMR is recommended for diagnosis and follow-up of 
thoracic aortic diseases, especially when chronic 
follow-up is required.166–168
I
C
The aortic root should be measured using the 
cusp-to-cusp distance. Also, the presence of 
asymmetry (>5 mm) among distances should be 
reported.137,146
IIa
C
If an increase of ≥3 mm per year in aortic diameters 
by TTE is observed, confirmation by CCT/CMR 
should be considered.137,159
IIa
C
Chest X-ray may be considered in cases of low 
clinical probability of AAS; however, a negative 
exploration should not delay dedicated aortic 
imaging in high-risk patients.162–164
IIb
C
© ESC 2024
AAS, acute aortic syndrome; CCT, cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; ECG, electrocardiogram; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 30 -->

### Page 30

(inflammation/infection) and treatment response.187,188 Although differ­
ent tracers have been tested to identify calcification, fibrosis and/or 
thrombus formation, most PET studies have focused on vasculitis.
The relationship between FDG-PET images and AAA progression is 
controversial. However, fluorine-18–sodium fluoride (18F–NaF) 
PET-computed tomography (PET-CT), a marker of active vascular cal­
cification and high-risk plaques, has shown a correlation between in­
creased tracer uptake, AAA growth, and CV events.189
PET-CT has shown better diagnostic accuracy in identifying lesions 
and detecting graft infection or infectious aortic diseases.190–193 High 
radiation exposure, high costs, and limited availability are the main lim­
itations of PET.
5.4.9. Intravascular ultrasound
Intravascular ultrasound (IVUS) provides high-resolution imaging for ar­
tery and vein diseases, aiding complex aortic disease management by 
distinguishing true and false lumens and guiding stent placement. It is 
operator-dependent, costly, and less accessible, but seems to provide 
better measurements for acute aortic syndromes.194
5.4.10. Digital subtraction aortography
Non-invasive imaging modalities have replaced DSA in first-line 
diagnostic testing, both in suspected AAS or known chronic AD; 
however, DSA might be useful if findings in non-invasive techniques 
are ambiguous or incomplete. It is primarily used for the percutan­
eous treatment of CAD, aortic visceral branches, or for monitoring 
thoracic endovascular aortic aneurysm repair (TEVAR/EVAR) 
implantation.
6. Screening for carotid, 
peripheral arterial, and aortic 
diseases
6.1. Screening for carotid and peripheral 
arterial diseases
6.1.1. Lower-extremity peripheral arterial disease
Due to elevated CV risk in chronic PAD, early diagnosis, preven­
tion, and robust cardiovascular risk factor (CVRF) control are es­
sential, even in asymptomatic cases. ‘Intermediary CV risk’ 
individuals may be reclassified as ‘high or very high risk’, prompting 
adapted prevention. ABI is the preferred first-line test for asymp­
tomatic individuals aged ≥65 years,14,195 especially women.196
Screening might also be beneficial at a younger age in case of 
CVRFs, but data are still lacking. Clinical examination, functional 
status, and walking capacity assessment are recommended to de­
tect ‘masked PAD’.77
In diabetes, early PAD (and foot neuropathy) diagnosis is crucial. 
Effective CVRF management and treatment can prevent CV disease, 
foot wounds, and amputation.197 In patients with diabetes and normal 
resting ABI, TBI measurement should be considered.
The prevalence of popliteal aneurysms (PAs) is high in patients with 
AAA and subaneurysmal aortic dilatation, warranting screening. PAs 
are correlated with iliac and femoral artery diameters.76 In patients 
needing transfemoral access, screening for iliofemoral artery disease 
may be considered.198
6.1.2. Carotid artery stenosis
Due to the low prevalence of ≥70% asymptomatic carotid artery 
stenosis (CS) in the general population (0%–3.1%), widespread 
screening is not recommended since it does not reduce stroke 
risk and might lead to inappropriate stress and invasive proce­
dures.199,200 Conversely, screening for significant CS in a highly se­
lected population might be cost-effective, especially if prevalence is 
≥20% (Table 6).201 When the degree of asymptomatic CS is ≥70%, 
the 5 year ipsilateral stroke risk is significantly increased (14.6%) and 
revascularization may be beneficial.202 Selective screening aims to 
prevent CV events, rather than identifying candidates for an 
intervention.203
6.1.3. Multisite artery disease
Multisite artery disease (MAD) is defined as the presence of athero­
sclerosis in two or more vascular beds.204 This is a common condition 
in patients with atherosclerotic diseases. Although associated with 
worse clinical outcomes, screening for asymptomatic disease in add­
itional vascular sites did not seem to improve outcomes.77 More re­
cently, screening for coronary calcifications (coronary artery calcium 
[CAC] score) and screening for carotid and femoral plaques have 
Table 6 High-risk populations for carotid artery 
stenosis
Population
Prevalence of carotid stenosis 
(%)
>60 years + CVRFs (hypertension, 
CAD, current smoking, 
first-degree family history of 
stroke)210
Two CVRFs: 14% 
Three CVRFs: 16% 
Four CVRFs: 67%
Hypertension + cardiac disease211
22%
HD212
• In HD patients, prevalence of 
carotid stenosis is high, and is 
associated with high 
peri-operative and long-term 
stroke or death rates
• Carotid stenosis is a predictor of 
death in patients with long-term 
dialysis and aged ≥70 years at time 
of surgery
• Lower risk if previous renal 
transplant.
PAD213
23.2%
Severe CAD (before CABG)
• Almost 20%214
• Carotid bruit and T2DM: 
increased predictive value215
• Carotid stenosis = risk factors for 
peri-operative stroke.215
Carotid bruit216
31%
Previous neck irradiation217
21.7% (70%–99% stenosis)
© ESC 2024
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVRFs, 
cardiovascular risk factors; HD, haemodialysis; PAD, peripheral arterial disease; T2DM, 
type 2 diabetes mellitus.
ESC Guidelines                                                                                                                                                                                          3567


<!-- PAGE 31 -->

### Page 31

been shown to be of potential assistance in CV risk reclassification of 
‘presumed moderate-risk patients’ into a higher-risk category, leading 
to more aggressive prevention strategies.205–209
6.2. Screening for aortic diseases
6.2.1. Screening for abdominal aortic aneurysm
Abdominal aortic aneurysm screening by DUS is effective in reducing 
rupture-related mortality in populations with high AAA prevalence (es­
pecially male smokers aged ≥65 years).221–224 However, no such effect 
has been found in a single large study in which AAA prevalence was low 
(current or former smoking women aged 65–74 years, or with a history 
of CAD).225
Screening for AAA by non-contrast computed tomography (CT) 
was not found to be effective over 5 years in males aged 65–74 years 
in a Danish trial.226 Longer-term follow-up is planned, and as the tech­
nique involves ionizing radiation, no recommendation is made in rela­
tion to CT at present.
Screening may be considered in populations at intermediate risk, 
such as men aged >75 years, or women aged >75 years who are hyper­
tensive, smokers, or both, since almost all women in a contemporary 
population-based study who had ruptured AAA and were aged 
>75 years were either smokers or hypertensive.227,228
Screening for AAA is recommended in first-degree relatives (FDRs) of 
patients with AAA (especially siblings), as they are at increased risk of 
AAA when >50 years of age.229 The risk associated with family history 
is uncertain, but a population-based study estimated a relative risk of 
around 2.230 Screening should be repeated periodically if initial assessment 
is reassuring and performed at a relatively young age.231
Opportunistic screening (during TTE) identified AAA in about 2% of 
subjects, thus it may be considered in high-prevalence populations 
(males ≥65 or women ≥75 years of age).232 Additionally, opportunistic 
screening detects AAA in patients with symptomatic/asymptomatic 
PAD (with a 12% cumulative incidence in symptomatic PAD), making 
it worthwhile in this population.233
6.2.2. Screening for thoracic aortic aneurysm
Screening for TAA is described in detail in Section 10.1 and Section 10.2.
7. Optimal medical treatment
Optimal medical treatment (OMT), including lifestyle measures and 
pharmacological treatment, is recommended for all patients with 
PAAD (Figure 7).
7.1. Lifestyle, exercise, patient education
Apart from genetic-related TAA, hypertension and ASCVD are the 
main causative factors for PAAD. As lifestyle factors are strongly re­
lated to ASCVD,11 patients with PAAD should strive to maintain a 
healthy lifestyle. The 2021 ESC Guidelines on cardiovascular prevention19
give comprehensive guidance on risk factors for ASCVD and their 
treatment.
7.1.1. Diet
A Mediterranean diet rich in legumes, dietary fibre, nuts, fruits, and 
vegetables proves crucial and efficacious for primary and CV pre­
vention in PAAD.238 It has demonstrated notable reductions in chol­
esterol and BP,239–247 and holds potential protective benefits against 
PAAD development.248,249 In a large cohort with 17.5 years of 
follow-up, adherence to a Mediterranean diet was associated with 
reduced AAA risk in current and ex-smokers.249,250 Malnutrition 
and metabolic disorders can complicate post-invasive procedure re­
covery and nutritional support may improve nutritional status and 
HRQoL.251
Recommendation Table 5 — Recommendations for 
peripheral arterial disease screening (see also Evidence 
Table 3)
Recommendations
Classa
Levelb
In patients with diabetes or chronic kidney disease, 
and normal resting ABI, TBI measurement should be 
considered.
IIa
B
In patients ≥65 years of age with CVRFs, screening 
for PAD by ABI or TBI should be considered.77,218,219
IIa
C
In patients with AAA, femoro-popliteal aneurysm 
screening with DUS should be considered.76
IIa
C
In patients ≥65 years without CVRFs, screening for 
PAD by ABI or TBI may be considered.220
IIb
C
In patients needing intervention with transfemoral 
access, screening for iliofemoral artery disease may 
be considered.198
IIb
C
In patients with two or more CVRFs, screening for 
CS may be considered.201,203,210
IIb
C
© ESC 2024
AAA, abdominal aortic aneurysm; ABI, ankle–brachial index; CS, carotid artery stenosis; 
CVRFs, cardiovascular risk factors; DUS, duplex ultrasound; PAD, peripheral arterial 
disease; TBI, toe–brachial index. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 6 — Recommendations for 
abdominal aortic aneurysm screening
Recommendations
Classa
Levelb
Screening for AAA with DUS:
Is recommended in men aged ≥65 years with a 
history of smoking to reduce the risk of death from 
ruptured AAA.221–224,234
I
A
May be considered in men aged ≥75 years 
(irrespective of smoking history) or in women aged 
≥75 years who are current smokers, hypertensive, 
or both.227,228,235–237
IIb
C
Family AAA screening with DUS:
Is recommended for FDRs of patients with AAA aged 
≥50, unless an acquired cause can be clearly 
identified.231
I
C
Opportunistic AAA screening with DUS:
Should be considered in symptomatic/asymptomatic 
PAD patients.233
IIa
B
Should be considered in men aged ≥65 years and in 
women aged ≥75 years during TTE.232
IIa
B
© ESC 2024
AAA, abdominal aortic aneurysm; FDR, first-degree relative; DUS, duplex ultrasound; PAD, 
peripheral arterial disease; TTE, transthoracic echocardiography. 
Smoking is defined as lifetime smoking of >100 cigarettes or equivalent. This threshold is 
used to distinguish between substantial exposure and occasional use. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 32 -->

### Page 32

7.1.2. Physical activity
Few patients with chronic symptomatic PAD meet the physical activity guide­
lines252 for reducing the risk of major adverse cardiac events (MACE).253,254
Better ambulation, HRQoL, and vascular outcomes have been observed in 
patients meeting the physical activity time-intensity guidelines.19,255 Regular 
physical activity is also relevant in patients with aortic diseases70,71,256–259
and lowers resting heart rate and BP, thus decreasing the risk of aortic com­
plications.256,259 Few data exist on the practice of exercise and sports in pa­
tients with aortic diseases.70,71,256–259 Recommendations should be 
individualized and based on risk stratification.71
Medications
Lifestyle
Targets
Targets
Systolic blood pressure
≤120–129 mmHg
Beta-blockers
ACEi or ARB
Calcium channel blockers
Antiplatelet therapy
Statins
Ezetimibe
PCSK9i
Bempedoic acid
Reducing risk of atherothrombosis
Optimal glucose control (HbA1c <7%)
Educational programmes
Psychological support
Genetic counselling
Supervised exercise training
LDL <55 mg/dL (<1.4 mmol/L)
Healthy diet
BMI 20–25 kg/m2
Waist: <94 cm men; <80 cm women
Low-to-moderate exercise training
Limit isometric exercise in aortic diseases
Avoid excessive alcohol intake
Avoid smoking/smoking cessation
Avoid cocaine and stimulating drugs
Glucose-lowering agents
Diastolic blood pressure 
≤70–79 mmHg
Anticoagulants
Figure 7 Cardiovascular risk modification and healthy lifestyle interventions and targets in patients with peripheral arterial and aortic diseases. ACEi, 
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; LDL, low-density lipoprotein; PCSK9i, proprotein 
convertase subtilisin/kexin type 9 inhibitor; HbA1c, glycated haemoglobin.
ESC Guidelines                                                                                                                                                                                          3569


<!-- PAGE 33 -->

### Page 33

7.1.3. Smoking
Patients with PAAD who smoke should strongly be advised to quit (see 
Supplementary data online, Section 1.1.5). Complete smoking cessation 
and avoiding second-hand smoke or environmental particle air pollu­
tion are crucial in patients with PAAD to reduce the risk of death, 
AD, acute mesenteric ischaemia (AMI), AAA, and PAD.119,260–267
Smokers should be offered structural follow-up support, including nico­
tine replacement therapy, varenicline, and bupropion, individually or in 
combination.19,268,269 Smoking avoidance also includes cannabis, asso­
ciated with premature ASCVD.266
Vaping and e-cigarette use has surged in the past decade, viewed by 
some as a healthier option than smoked tobacco, though long-term 
health effects remain unknown.270 E-cigarettes may be considered as 
an aid to quit tobacco smoking, as a recent Cochrane review found 
that they increase quit rates as compared with nicotine replacement 
therapy,271 but their use has been associated with adverse effects on 
CV, respiratory, immunological, and periodontal health compared with 
non-users, but with a milder impact than smoked cigarettes.272–274
However, their use should be brief and preferably not concurrent with 
traditional cigarettes.271,275
The main limitation of the evidence base remains imprecision due to 
the small number of randomized controlled trials (RCTs), often with 
low event rates and follow-up limited to 2 years.
7.1.4. Patient education
While detailed explanations of CVRFs might not always inspire lifestyle 
changes,276 providing plain language and visual aids is essential for pa­
tient understanding.277 Structured programmes, incorporating psycho­
logical and behavioural aspects, are pivotal in fostering desired 
changes.276 Engaging patients’ families, friends, and support networks 
significantly contributes to perpetuating these changes (particularly in 
self-care),276 and increases treatment compliance and self-efficacy, re­
ducing hospitalization risk and enriching patient HRQoL.278,279 When 
caregivers disconnect from healthcare professionals, they should be re­
cognised to receive better support systems.280,281 Psychosocial inter­
ventions are crucial to navigating complexities with resilience.282
Advocating active involvement, education, clear communication, and 
shared decision-making is key for achieving optimal patient out­
comes.276–283
7.1.5. Risk scoring models in secondary prevention
Recent ESC CV prevention guidelines discuss risk models for develop­
ing vascular disease in healthy individuals and ASCVD patients.19
Several registries enabling risk prediction in ASCVD have been 
developed: REACH (The REduction of Atherothrombosis for 
Continued Health)284 and SMART (Secondary Manifestation of 
ARTerial disease)285 which use clinical parameters such as medical his­
tory, SBP, and common biomarkers. Addition of carotid ultrasound 
did not improve the model.286 A new algorithm combining the 
SMART and REACH models287 enables calculation of lifetime risk 
and treatment effects. The SMART model has recently been updated 
and validated288,289 with the SMART-2 algorithm. These tools are avail­
able online as clinical risk calculators (see www.u-preveotnt.com) and 
smartphone apps on the ESC website (https://www.escardio.org/ 
Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/SMART- 
Risk-Score).
Recommendation Table 7 — Recommendations for 
lifestyle, physical activity, and patient education (see 
also Evidence Table 4)
Recommendations
Classa
Levelb
In patients with PAAD, cessation and abstinence from 
smoking of any kind is recommended to reduce the 
risk of AD, MI, death, and limb ischaemia.119,261–267
I
A
A healthy diet rich in legumes, dietary fibre, nuts, 
fruits, and vegetables, with a high flavonoid intake 
(Mediterranean diet), is recommended for CV 
disease prevention in patients with PAAD.239– 
241,249,290–293
I
A
Low- to moderate-intensity (or high if tolerated)c 
aerobic activities are recommended in patients with 
PAD to increase overall and pain-free walking 
distance.37,294
I
A
In patients with PAAD, behavioural counselling to 
promote healthy diet, smoking cessation, and 
physical activity is recommended to improve the CV 
risk profile.241,249,253,295
I
B
It is recommended to promote patient and 
caregivers’ education and empowerment through 
tailored guidance on lifestyle adjustments and the 
importance of regular physical activity.276,277,283
I
C
In patients with PAAD, avoidance of exposure to 
second-hand smoke and air pollution should be 
considered.261
IIa
C
Physical exercise and sports activities should be 
considered in patients with aortic diseases based on 
prior risk stratification (based on the extent of the 
aneurysm, risk of dissection, and BP control).71
IIa
C
Use of web- or app-based secondary prevention risk 
calculators should be considered in the shared 
decision-making to improve patient adherence to 
treatment and lifestyle changes.288,289
IIa
C
E-cigarettes may be considered as an aid to quit 
tobacco smoking, but it is advisable to limit their use 
and avoid simultaneous use with conventional 
cigarettes due to unknown long-term 
effects.119,271,296,297
IIb
C
© ESC 2024
AD, aortic dissection; BP, blood pressure; CV, cardiovascular; MI, myocardial infarction; 
PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence. 
cLow intensity refers to an exercising heart rate (HR) of 57%–63% HRmax or a rate of 
perceived exertion (RPE) on the Borg’s scale of 9–11. Moderate intensity refers to an 
exercising heart rate of 64%–76% HRmax or RPE of 12–13. Vigorous intensity refers to 
an exercising heart rate of 77%–95% HRmax or RPE of 14–17.298


<!-- PAGE 34 -->

### Page 34

7.2. Principles of pharmacological medical 
therapy
7.2.1. Antithrombotic therapy
Antithrombotic therapy is crucial for patients with symptomatic PAAD at 
high CV risk. While trials are fewer than in CAD, recent evidence should 
guide practice. In the absence of specific indications for chronic oral antic­
oagulation (OAC) in concomitant CV disease, a single antiplatelet agent is 
the primary long-term treatment for patients with symptomatic PAAD. 
Combining it with another antiplatelet agent or low-dose anticoagulants 
depends on the patient’s ischaemic and bleeding risk, as well as therapeutic 
paths (e.g. endovascular therapy). Recent guidelines299 propose a tool for 
bleeding risk assessment in PAD patients (OAC3 PAD score).
Antithrombotic strategy is detailed in Sections 8 and 9 for each arter­
ial territory.
7.2.2. Antihypertensive therapy
New 2024 ESC Guidelines on hypertension are currently published and 
should be reviewed for further details.300 Patients with hypertension 
and PAAD are considered to have target organ damage and are at 
high CV risk.300
Different meta-analyses showed that systolic BP treatments reduce 
CV risk in all ages up to 85 years down to a level of 120– 
129 mmHg.301,302 There is no need to increase the BP target in healthy 
patients up to the age of 85 years.303,304 To reduce cardiovascular disease 
(CVD) risk, it is recommended that treated SBP values in most adults be 
targeted to 120–129 mmHg, provided the treatment is well tolerated. 
However, in cases where BP-lowering treatment is poorly tolerated 
and achieving an SBP of 120–129 mmHg is not possible, it is recom­
mended to target an SBP level that is ‘as low as reasonably achievable’ 
(ALARA principle).301,302,305 To avoid overtreatment, out-of-office BP 
measurements may be helpful when pursuing this target.
If on-treatment SBP is on target, but diastolic blood pressure (DBP) 
is ≥80 mmHg, intensified treatment may be considered to further re­
duce the CV risk.306
Because the CVD benefit of an on-treatment BP target of 120– 
129 mmHg may not generalize to some groups, setting personalized 
and more lenient BP targets (e.g. <140/90 mmHg) has to be considered 
in patients with pre-treatment orthostatic hypotension, age ≥85 years, 
clinically significant frailty at any age, or a limited lifespan (<3 years).301
Patients with both PAAD and hypertension face a high or very high 
CV risk. Antihypertensive medications such as diuretics, beta-blockers 
(BBs), calcium channel blockers (CCBs), angiotensin-converting en­
zyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) 
are all appropriate options for managing hypertension in PAAD. 
These agents can be used as monotherapy or in various combinations 
(excluding ARBs+ACEIs), considering individual patients’ conditions. It 
is often necessary to implement combination therapy, preferably in 
the form of a single pill, to effectively achieve the recommended treat­
ment goals. However, ACEIs or ARBs should be considered as first-line 
antihypertensive therapy to reduce CV events.300,307–312
Regardless of BP levels and in the absence of contraindications, 
ACEIs/ARBs may be considered in all patients with PAD to reduce car­
diovascular events.312,313 A meta-analysis suggests that antihypertensive 
treatment may improve mean walking distance in patients with PAD.310
Beta-blockers can be prescribed, if necessary, to patients with inter­
mittent claudication, since they do not worsen walking capacity or limb 
events.314 There is some evidence suggesting a higher amputation 
rate315 or increased rate of re-intervention316 in patients with CLTI 
treated with ACEIs, although in one smaller study no effect on 
limb-related outcomes was observed.317 Thus, they remain a treatment 
option in hypertensive patients with PAD, especially in those with con­
comitant CAD.318 BBs were not associated with worsened clinical out­
comes in a retrospective study319 on CLTI patients, but it seems 
prudent to avoid excessively low heart rates in these patients.
7.2.2.1. Renovascular hypertension
Angiotensin-converting enzyme inhibitors and ARBs effectively manage 
unilateral renal artery stenosis (RAS) by blocking the renin–angiotensin 
system, potentially reducing renal capillary perfusion pressure.320–322
This transiently lowers glomerular filtration rate (GFR) and raises ser­
um creatinine. For bilateral RAS, regular follow-up assessments of renal 
function and kidney perfusion are advised.
Angiotensin-converting enzyme inhibitors and ARBs additionally 
(combined with hydrochlorothiazide and/or CCBs if needed) contrib­
ute to CV risk reduction in patients with atherosclerotic disease and re­
duced eGFR.307,323,324
Recommendation Table 8 — Recommendations for 
antihypertensive therapy in patients with peripheral 
and aortic disease
Recommendations
Classa
Levelb
In patients with PAAD and hypertension an SBP 
target towards 120–129 mmHg, if tolerated, is 
recommended.301–305,325
I
A
In unilateral RAS patients, it is recommended that 
antihypertensive medication include ACEIs/ 
ARBs.307,320–323
I
B
In patients with PAAD and hypertension, ACEIs or 
ARBs should be considered as first-line 
antihypertensive therapy.307,312
IIa
B
In RAS-related hypertension, the combination of 
ACEIs/ARBs with diuretics and/or calcium channel 
blockers should be considered.324
IIa
B
An individualized, more lenient BP goal (e.g. <140/ 
90 mmHg) should be considered in:301
• Age ≥85 years
• Residential care
• Symptomatic orthostatic hypotension
IIa
C
An individualized, more lenient BP goal (e.g. <140/ 
90 mmHg) may be considered in:301
• Clinically severe frailty at any age
• Limited life expectancy (<3 years)
IIb
C
In patients with bilateral RAS, antihypertensive 
medication including ACEIs/ARBs may be considered 
if close patient monitoring (renal function) is 
feasible.321
IIb
B
ACEIs/ARBs may be considered in all patients with 
PAD, regardless of BP levels, in the absence of 
contraindications.312,313
IIb
B
Continued 
ESC Guidelines                                                                                                                                                                                          3571


<!-- PAGE 35 -->

### Page 35

7.2.3. Lipid-lowering therapy
Patients with symptomatic PAAD are at very high CV risk but are usually 
inadequately managed compared with patients with CAD.5,247,326–332
Both LDL-C reduction by ≥50% from baseline and an LDL-C goal of 
<1.4 mmol/L (<55 mg/dL) are recommended to obtain a reduction in 
CV death, MI, and stroke, and to improve walking distance.242,333–336
7.2.3.1. Statins
Statins demonstrate mortality and CV event reduction in RCTs for 
PAD, CS, and severe aortic arch plaques.243–245 Even in advanced dis­
ease stages, they are linked to lower MACE and mortality.246
Statins significantly improve CV outcomes in patients with PAD, redu­
cing major adverse limb events (MALE).244,327–329,337,338 Meta-analyses 
show enhanced walking distances.244,338,339
For CS, statin pre-treatment lowers recurrent stroke risk post- 
transient ischaemic attack (TIA).19,340–343 While lacking RCTs in reno­
vascular or visceral artery disease, statins benefit cardiorenal events and 
post-RAS stenting prognosis.344–346
Mixed evidence suggests statins may mitigate AAA and TAA 
growth.347–352 However, since most patients with AAA or TAA pre­
sent with associated CVRFs, liberal use of lipid-lowering treatment19
should be considered, using an individualized approach with shared 
decision-making and considering residual CV risk.353 Pre-operative sta­
tin use links to increased 5 year survival after TEVAR.19
Statin use was associated with a mean AAA growth rate reduction 
and a lower rupture risk.347–349,352,354
Some evidence suggests that statins may reduce TAA growth rate 
and risk of rupture.350,351,355
No benefit on AAA or TAA growth rate was shown with fenofibrate 
therapy.356,357
7.2.3.2. Ezetimibe
Ezetimibe combined with statins benefits selected patients with 
PAAD, particularly when the target LDL-C level is not met.335 In 
an IMProved Reduction of Outcomes: Vytorin Efficacy International 
Trial (IMPROVE-IT) subanalysis, involving acute coronary syndrome 
(ACS) patients with PAD, ezetimibe consistently reduced CV risk, espe­
cially in high-risk subgroups.247,331
7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in addition 
to statins, reduce CV events in symptomatic atherosclerotic disease patients 
with LDL-C ≥1.8 mmol/L.336 Adding them to statins further reduces MACE 
and MALE risk in patients with PAD and improves walking distance;333 how­
ever, their potential in TAA/AAA is an emerging area of research.247
Inclisiran, administered semi-annually, has proved a notable 26% 
MACE risk reduction in a pooled phase III analysis,358 but its role in 
PAAD is not firmly established and ongoing RCTs including PAD parti­
cipants (e.g. ClinicalTrials.gov NCT05030428) aim to provide insights.
7.2.3.4. Bempedoic acid
Bempedoic acid, acting upstream of statins in cholesterol metabolism, 
has been shown to reduce cholesterol levels by 17%–28%359,360 and 
demonstrated a decrease in the incidence of MACE in statin-intolerant 
PAD patients.361 However, its impact on aortic diseases and AAA still 
requires further research.
7.2.3.5. Hypertriglyceridaemia
Beyond LDL-C, evidence shows insulin resistance, elevated triglycer­
ides, and remnant lipoproteins are associated with ASCVD, particularly 
in PAD.362–365 However, in a meta-analysis and an RCT, fibrates 
showed no benefit over placebo in reducing MACE in patients with 
PAD for a composite outcome of non-fatal stroke, non-fatal MI, and 
vascular death.366 Fibrates showed no benefit over placebo in reducing 
coronary and cerebrovascular events in patients with PAD in an 
RCT.367 While the relationship between triglycerides and aortic dis­
eases is complex and not fully understood, some evidence suggests 
that triglyceride levels may contribute to the development and progres­
sion of aortic diseases.
In contrast, icosapent ethyl (IPE) demonstrated a reduction 
in mortality and morbidity among individuals with hypertrigly­
ceridaemia in the Reduction of Cardiovascular Events With 
Icosapent Ethyl–Intervention Trial (REDUCE-IT).368 Its impact 
on patients with PAAD is unexplored,369 although a small pilot 
RCT suggested an improved ABI in hyperglycaemic haemodialysis 
patients.370
In cases where on-treatment SBP is at or below 
target (120–129 mmHg) but DBP is not at target 
(≥80 mmHg), intensifying BP-lowering treatment to 
achieve an on-treatment DBP of 70–79 mmHg may 
be considered to reduce CVD risk.306
IIb
C
© ESC 2024
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BP, 
blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; PAAD, 
peripheral arterial and aortic diseases; PAD, peripheral arterial disease; RAS, renal artery 
stenosis; SBP, systolic blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 9 — Recommendations for 
lipid-lowering therapy in patients with peripheral 
arterial and aortic diseases
Recommendations
Classa
Levelb
In patients with atherosclerotic PAAD, lipid-lowering 
therapy is recommended.242,334–336
I
A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) 
and a >50% reduction in LDL-C vs. baseline are 
recommended in patients with atherosclerotic 
PAAD.19,242,246,300,335
I
A
Statins are recommended in all patients with 
PAD.328,329,337,371
I
A
If the target LDL-C level is not achieved on maximally 
tolerated statins and ezetimibe, treatment with a 
PCSK9 inhibitor is recommended in patients with 
atherosclerotic PAAD, to achieve target 
values.372,373
I
A
If the target LDL-C level is not achieved, a 
combination of statins and ezetimibe is indicated in 
patients with atherosclerotic PAAD, to achieve the 
given target values.247
I
B
For statin-intolerant patients with atherosclerotic 
PAAD, at high CV risk, who do not achieve their 
LDL-C goal on ezetimibe, it is recommended to add 
bempedoic acid either alone or in combination with a 
PCSK9 inhibitor.361
I
B
Statins for the reduction of growth and rupture of 
AAA should be considered.347–349,352,354
IIa
B
Continued


<!-- PAGE 36 -->

### Page 36

7.2.4. Diabetes and pre-diabetes conditions
Screening for diabetes or pre-diabetes is recommended in PAAD. Recent 
ESC Guidelines on diabetes and CVD374 provide detailed diagnostic cri­
teria and underscore the importance of diagnosing diabetes in ASCVD pa­
tients and vice versa. Both Type 1 (T1DM) and Type 2 (T2DM) diabetes 
mellitus imply significantly increased risk of PAD, carotid stenosis, and 
polyvascular disease, depending on disease duration and the status 
of other CVRFs. Diabetes is present in 30% of patients with IC and 
50%–70% of those with CLTI.375,376 Although the prevalence of PAD 
in patients with diabetes is 20%–30%, only half of them are symptomatic 
because of peripheral neuropathy with decreased pain sensitivity.377 As 
already detailed in Section 4, diabetes implies reduced risk of TAA, 
AAA, or aortic dissection. However, patients with T2DM and PAAD 
are in the very high-risk group for stroke, MI, and CV death,374 and for 
T1DM, an online risk prediction tool has recently been developed.377–380
For non-pregnant PAAD patients, aiming for an HbA1c level of 
<53 mmol/mol (7%) to avoid significant hypoglycaemia is appropriate. 
Consider a higher threshold (<69 mmol/mol [8.5%]) for limited life ex­
pectancy or when treatment risks outweigh benefits.374
In PAAD, it is recommended to aim for tight glycaemic control, pref­
erably with agents with proven CV benefits such as sodium-glucose 
co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 re­
ceptor agonists (GLP-1RA), adding metformin and other glucose- 
lowering agents as necessary.374,381–384
The Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results (LEADER) trial and Trial to Evaluate 
Cardiovascular and Other Long-term Outcomes with Semaglutide 
in Subjects with Type 2 Diabetes (SUSTAIN-6) investigated subcutane­
ous GLP-1RAs liraglutide (≤1.8 mg/day) and semaglutide (0.5 or 
1.0 mg/week), respectively, vs. placebo in T2DM patients with high CV 
risk. Overall, 12.7% of patients in LEADER and 14.0% in SUSTAIN-6 pre­
sented with PAD at baseline. Although non-statistically significant due to 
a lack of power, the effects on MACE showed a consistently beneficial 
trend in PAD: liraglutide (hazard ratio (HR), 0.77; 95% confidence interval 
(CI), 0.58–1.01) and semaglutide (HR, 0.61; 95% CI, 0.33–1.13).381
The (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 
Diabetes Mellitus Patients (EMPA-REG OUTCOME) investigated the 
SGLT2i empagliflozin (10 mg or 25 mg per day) vs. placebo in patients 
with T2DM and high CV risk. Overall, 20.8% of patients presented 
with PAD at baseline. In these patients, empagliflozin reduced CV death 
(HR, 0.57; 95% CI, 0.37–0.88) and all-cause mortality (HR, 0.62; 95% CI, 
0.44–0.88), and there was a non-significant reduction in limb amputa­
tion: 5.5% with empagliflozin vs. 6.3% with placebo (HR, 0.84; 95% CI, 
0.54–1.32).382 In the Canagliflozin Cardiovascular Assessment Study 
(CANVAS)385 investigating canagliflozin, there was an increased risk of 
amputation, but this was not confirmed in the Canagliflozin and Renal 
Events in Diabetes with Established Nephropathy Clinical Evaluation 
(CREDENCE) trial investigating canagliflozin in patients with T2DM 
and chronic kidney disease (CKD).386 Still, the use of other SLGT2is 
seems reasonable in PAD patients.
Patients with carotid stenosis were included in trials testing GLP-1RA 
and SGLT2i, but no analysis on this subpopulation was performed. A 
meta-analysis of eight trials investigating GLP-1RAs vs. placebo in pa­
tients with T2DM reported a reduction in all strokes (HR, 0.84; 95% 
CI, 0.75–0.93).387 Among patients with T2DM and prior history of MI 
or non-fatal stroke, GLP-1RAs reduced the incidence of recurrent 
MACE (HR, 0.86; 95% CI, 0.8–0.92).388 SGLT2is do not appear to re­
duce stroke in patients with T2DM, but patients with a stroke history 
experienced similar cardiorenal benefits as the rest of the population.389
Before the era of GLP-1RAs and SGLT2is, different studies (United 
Kingdom 
Prospective 
Diabetes 
Study 
[UKPDS] 
34390
and 
Hyperinsulinaemia: the Outcomes of its Metabolic Effects [HOME] 
trials391) showed that metformin reduced the risk of MALE and 
MACE in patients with PAD.391,392 But a recent study with GLP-1RA 
dulaglutide found the same risk reduction in MACE between patients 
with and without baseline metformin, calling into question its add-on 
value.384,393 However, there are studies suggesting that metformin 
may reduce AAA growth (see Section 9.2.4).
Statins for the reduction of growth and rupture of 
TAA may be considered.350,351,355
IIb
B
In high-risk patients with PAAD and triglycerides 
>1.5 mmol/L despite lifestyle measures and statin 
therapy, icosapent ethyl 2 g b.i.d. may be considered 
in addition to a statin.368
IIb
B
Fibrates are not recommended for cholesterol 
lowering.367
III
B
© ESC 2024
AAA, abdominal aortic aneurysm; b.i.d., twice daily; CV, cardiovascular; LDL-C, low-density 
lipoprotein cholesterol; PAAD, peripheral arterial and aortic diseases; PAD, peripheral 
arterial disease; PCSK9, proprotein convertase subtilisin/kexin type 9; TAA, thoracic 
aortic aneurysm. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 10 — Recommendations for 
the medical management of patients with peripheral 
arterial and aortic diseases and diabetes
Recommendations
Classa
Levelb
It is recommended to apply tight glycaemic control 
(HbA1c <53 mmol/mol [7%]) to reduce microvascular 
complications in patients with PAAD.374,394–397
I
A
SGLT2i with proven CV benefit are recommended 
in patients with T2DM and PAAD to reduce CV 
events, independent of baseline or target HbA1c 
and concomitant glucose-lowering 
medication.382,386,398–402
I
A
GLP-1RAs with proven CV benefit are 
recommended in patients with T2DM and PAAD to 
reduce CV events, independent of baseline or target 
HbA1c and concomitant glucose-lowering 
medication.381,403–407
I
A
It is recommended to avoid hypoglycaemia in 
patients with PAAD.374,408–412
I
B
It is recommended to individualize HbA1c targets 
according to comorbidities, diabetes duration, and 
life expectancy.408,411
I
C
It is recommended to prioritize the use of 
glucose-lowering agents with proven CV benefits,c,d 
followed by agents with proven CV safety,e over 
agents without proven CV benefit or safety.374
I
C
If additional glucose control is needed, metformin 
should be considered in patients with T2DM and 
PAAD.374,384,393
IIa
B
© ESC 2024
CV, cardiovascular; GLP-1RAs, glucagon-like peptide-1 receptor agonists; HbA1c, glycated 
haemoglobin; PAAD, peripheral arterial and aortic diseases; SGLT2i, sodium-glucose 
co-transporter-2 inhibitors; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cEmpagliflozin, canagliflozin, dapagliflozin, sotagliflozin. 
dLiraglutide, semaglutide subcutaneous, dulaglutide, efpeglenatide. 
eMetformin, pioglitazone, dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, alogliptin, 
linagliptin), glimepiride, gliclazide, insulin glargine, insulin degludec, ertugliflozin, 
lixisenatide, exenatide (extended release), oral semaglutide.
ESC Guidelines                                                                                                                                                                                          3573


<!-- PAGE 37 -->

### Page 37

7.2.5. Other pharmacological therapy
Increased attention is focused on inflammation in ASCVD,413 sup­
ported by the Canakinumab Anti-Inflammatory Thrombosis 
Outcomes Study (CANTOS),414 which showed that canakinumab, 
a monoclonal antibody targeting interleukin (IL)-1β, reduced MACE 
in high-risk patients with previous MI and increased high-sensitivity 
(hs)-CRP. Data for patients with PAAD are not reported. 
Furthermore, low-dose colchicine (0.5 mg/day) has been shown to 
reduce MACE among those with stable atherosclerosis after recent 
MI.415 However, the effect of colchicine and other anti-inflammatory 
drugs in PAAD remains unproven.416
8. Peripheral arterial disease
8.1. Lower-extremity peripheral arterial 
disease
8.1.1. Peripheral arterial disease syndromes
8.1.1.1. Clinical presentation and diagnosis
Atheromatous lower-extremity PAD is a chronic disease with different 
clinical manifestations. PAD may be symptomatic or asymptomatic and 
may or may not be associated with limb wounds. Wound healing and 
amputation risk may be affected by the concomitant presence of 
PAD, diabetes, and/or infection;417 therefore, amputation risk assess­
ment should be systematically performed using the Wound, 
Ischaemia, and foot Infection (WIfI) classification.
PAD presents as: 
• Asymptomatic PAD: suspected by lower-limb pulse abolition or im­
aging studies performed for other purposes and detected by patho­
logical ABI or TBI.418,419 These patients do not present with IC or 
atypical effort-related symptoms. However, attention should be 
paid to those with wounds, with masked effort-related symptoms 
due to reduced walking capacity (for reasons other than PAD), or re­
duced pain sensitivity. ‘Masked PAD’ is defined as PAD without pro­
voked leg pain because of reduced walking capacity for other reasons 
or reduced pain sensitivity.420
• Symptomatic (effort-related) PAD: patients with pathological ABI or 
TBI, presenting with IC, atypical effort-related symptoms, or chronic 
lower-limb wounds (diabetic foot or non-healing ulceration/gangrene 
≥2 weeks) without critically reduced limb perfusion.417,421 In these 
patients, IC is characterized by exertional muscle pain and dysfunc­
tion in the supply area of the obstructed arterial segment, which is 
relieved at rest.422 Some patients may present with atypical 
symptoms or with ‘masked PAD’.420,423 In women, the prevalence 
of IC is lower than in men, while atypical symptoms are more 
common.424
• CLTI represents the more severe chronic PAD presentation and un­
derlies poor limb outcomes without intervention. In addition to com­
mon signs of chronic PAD, patients with CLTI present with a critical 
haemodynamic status (ankle pressure <50 mmHg, toe pressure [TP] 
<30 mmHg, or TcPO2 <30 mmHg) responsible for ischaemic rest 
pain, non-healing chronic (>2 weeks of duration) ulceration, or 
foot gangrene.425,426
PAD syndromes can be categorized according to their clinical presen­
tation (Table 7). 
The 5 year cumulative incidence of clinical deterioration from 
asymptomatic PAD to IC is 7%, and 21% from IC to CLTI.427 All pa­
tients with PAD are at high risk of MACE, cerebrovascular disease, 
and MALE (Figure 8).428–430 The 5 year cumulative incidence of CV 
mortality is 9% in asymptomatic PAD and 13% in symptomatic pa­
tients. In comparison with symptomatic PAD, CLTI further increases 
all-cause mortality risk (relative risk [RR] 2.26) and the risk of MACE 
(RR 1.73).431 Health insurance data reveal a major amputation rate of 
9% in patients with CLTI and 1% in patients with IC, while consider­
ably higher amputation rates were reported in trials and registries 
data focusing on patients with CLTI.432–435 Among patients with 
PAD, development of MALE is associated with poor prognosis, 
with a three-fold increase in death and a 200-fold increase in subse­
quent lower-extremity amputation.429
Prevention of MALE is crucial, and the risk of MACE/MALE increases 
with the increased number of arterial beds involved.
Table 7 Peripheral arterial disease categorized according to clinical presentation
Clinical characteristics of PAD
Rutherford classification
Fontaine classification
Category
Signs and symptoms
Stage
Signs and symptoms
Asymptomatic PAD
0
Asymptomatic
I
Asymptomatic
Symptomatic (effort-related) PAD
1
Mild claudication
IIa
Non-disabling intermittent claudication
2
Moderate claudication
IIb
Disabling intermittent claudication
3
Severe claudication
Chronic limb-threatening Ischaemia
4
Ischaemic rest pain
III
Ischaemic rest pain
5
Minor tissue loss
IV
Ischaemic ulceration or gangrene
6
Major tissue loss
© ESC 2024
PAD, peripheral arterial disease.


<!-- PAGE 38 -->

### Page 38

8.1.1.1.1. Diagnostic tests. Vascular assessment: ABI, TBI, TcPO2 
measurements (refer to Section 5.3)
Ankle–brachial index is the proposed initial non-invasive diagnostic 
test to confirm lower-limb decreased perfusion status90,436,437 and 
needs to be reported separately for each leg (see Recommendation 
Table 2). An ABI ≤0.90 confirms PAD diagnosis.90,436,437 In cases of 
an ABI >0.90 and clinical suspicion of PAD, post-exercise ABI measure­
ments should be considered, along with imaging studies (preferably by 
treadmill). A post-exercise ABI decrease of >20% may serve as a PAD 
diagnostic criterion.438,439
In cases of abnormally high ABI values (ABI >1.4; see 
Recommendation Table 2) and patients with CLTI and diabetes440
(see Recommendation Table 11), TP measurements, the calculation 
of TBI and TcPO2, as well as pulse volume recordings or analysis of dis­
tal arterial Doppler waveforms, should be considered,90,91,132,133,441
and ABI can be estimated from distal Doppler waveforms independent 
of diabetes and media sclerosis.124
Apart from the assessment of limb perfusion, ABI serves as a surro­
gate marker for CV and all-cause mortality.88,442,443 A diagnostic PAD 
algorithm is depicted in Figure 9.
4–5x increased risk of
CV events compared with patients without PAD
Cardiac disease (MACE):
Cerebrovascular disease
Lower limb disease (MALE):
CV mortality
Myocardial infarction
Coronary revascularization
Hospitalization for heart failure
Amputation
Chronic or acute lower limb ischaemia
Lower limb revascularization
Increased death and vascular amputation risk
Figure 8 Cardiovascular risk in patients with peripheral arterial disease. CV, cardiovascular; MACE, major adverse cardiac event; MALE, major adverse limb 
event; PAD, peripheral arterial disease.
ESC Guidelines                                                                                                                                                                                          3575


<!-- PAGE 39 -->

### Page 39

Walking impairment questionnaires, assessment of functional and 
walking capacity
Determining walking impairment, capacity, and functional status in all 
patients with PAD is mandatory (refer to Section 5.2).
Assessment of amputation risk
In patients with PAD and chronic lower-limb wounds (diabetic 
foot ulcer, non-healing lower-limb ulceration, or gangrene of ≥2 
weeks of duration), even without haemodynamic parameters of 
critical limb perfusion, the additional presence of comorbidities 
such as diabetes and/or wound infection may contribute to an 
increased risk of amputation. The WIfI classification system takes 
the patients’ limb perfusion, wound size, and the extent of foot 
infection into account to determine the amputation risk 
(Table 8).417,444–446
8.1.1.1.2. Imaging methods. Duplex ultrasound is recommended as 
the first-line imaging method for PAD screening and diagnosis. CTA 
and/or MRA are recommended as adjuvant imaging. For details refer 
to Supplementary data online, Section 1.4.
Suspicion of PAD
Clinical assessment (personal history, physical examination),
 walking impairment assessment (questionnaire, treadmill),
 and functional assessment (6MWT, SPPB)
Haemodynamic/vascular assessment
 (ABI, AP, TP, TcPO2, DUS), 
wound assessment (WIfl)
PAD
Y
Typical symptoms
Y
N
Ischaemic rest pain or gangrene
 or non-healing chronic wound and critical limb perfusion
 (AP <50 mmHg, TP <30 mmHg or TcPO2 <30 mmHg)
N
Masked PAD
N
Asymptomatic PAD
 with or without wound
N
Symptomatic PAD
 with or without wound
Y
Chronic limb-threatening ischaemia
Other diagnosis
Figure 9 Diagnostic algorithm for peripheral arterial disease. 6MWT, six-minute walk test; ABI, ankle–brachial index; AP, ankle pressure; DUS, duplex 
ultrasound; PAD, peripheral arterial disease; SPPB, short physical performance battery; TcPO2, transcutaneous oxygen pressure; TP, toe pressure; WIfI, 
Wound, Ischaemia, and foot Infection classification.


<!-- PAGE 40 -->

### Page 40

Table 8 Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification
Component
Score
Description
W (Wound)
0
No ulcer (ischaemic rest pain)
1
Small, shallow ulcer on distal leg or foot without gangrene
2
Deeper ulcer with exposed bone, joint or tendon ± gangrenous changes limited to toes
3
Extensive deep ulcer, full thickness heel ulcer ± calcaneal involvement ± extensive gangrene
I (Ischaemia)
ABI
Ankle pressure (mmHg)
Toe pressure or TcPO2
0
≥0.80
>100
≥60
1
0.60–0.79
70–100
40–59
2
0.40–0.59
50–70
30–39
3
<0.40
<50
<30
fl (foot infection)
0
No symptoms/signs of infection
1
Local infection involving only skin and subcutaneous tissue
2
Local infection involving deeper than skin/subcutaneous tissue
3
Systemic inflammatory response syndrome
Ischaemia – 0
Ischaemia – 1
Ischaemia – 2
Ischaemia – 3
W–0
VL
VL
VL
VL
VL
L
L
M
L
L
M
M
M
H
H
H
W–1
VL
VL
VL
VL
L
M
M
M
M
H
H
H
H
H
H
H
W–2
VL
VL
VL
VL
M
M
H
H
H
H
H
H
H
H
H
H
W–3
VL
VL
VL
VL
M
M
M
H
H
H
H
H
H
H
H
H
fl–0
fl–1
fl–2
fl–3
fl–0
fl–1
fl–2
fl–3
fl–0
fl–1
fl–2
fl–3
fl–0
fl–1
fl–2
fl–3
© ESC 2024
Very low (green) = VL = clinical stage 1; low (yellow) = L = clinical stage 2; moderate (orange) = M = clinical stage 3; high (red) = H = clinical stage 4. 
ABI, ankle–brachial index; TcPO2, transcutaneous oxygen pressure. 
The Wound, Ischaemia and foot Infection (WIfI) classification allows the assessment of the individual risk of amputation in PAD patients: it comprises scores for wound size (W), degree of 
ischaemia (I), as assessed by the ABI, ankle pressure, and toe pressure or TcPO2, and extent of foot infection (fI) as depicted in the respective table. The combination of all three components 
results in the amputation risk stratification (VL = very low, L = low, M = moderate, H = high). Table reproduced with permission from.417
Recommendation Table 11 — Recommendations for 
diagnostic tests in patients with peripheral arterial dis­
ease and diabetes, renal failure, and wounds
Recommendations
Classa
Levelb
Measuring TP or TBI is recommended in patients 
with diabetes or renal failure if resting ABI is 
normal.90,91,94,440
I
C
In patients with PAD and chronic wounds, the WIfI 
classification system should be considered to 
estimate individual risk of amputation.417,444–446
IIa
C
© ESC 2024
ABI, ankle–brachial index; PAD, peripheral arterial disease; TBI, toe–brachial index; TP, toe 
pressure; WIfI, Wound, Ischaemia, and foot Infection classification. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 12 — Recommendations for 
imaging in patients with peripheral arterial disease
Recommendations
Classa
Levelb
DUS is recommended as the first-line imaging 
method to confirm PAD lesions.122,123,447
I
C
In symptomatic patients with aorto-iliac or 
multisegmental/complex disease, CTA and/or MRA 
are recommended as adjuvant imaging techniques for 
preparation of revascularization procedures.448,449
I
C
Analysis of anatomical imaging tests in conjunction 
with symptoms and haemodynamic tests prior to an 
invasive procedure is recommended.426
I
C
© ESC 2024
CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic 
resonance angiography; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3577


<!-- PAGE 41 -->

### Page 41

8.1.1.2. Medical treatment
Patients with PAD should receive comprehensive OMT, including 
supervised exercise training and lifestyle modification (Figures 10–
12). A personalized programme of guidelines-guided pharmacother­
apy to reduce MACE and MALE should be prescribed and tightly 
followed.
Patients with PAD are less likely to receive OMT than patients with 
CAD.450–452 For general lifestyle and pharmacological therapy see 
Section 7.
8.1.1.2.1. Exercise therapy. A consensus document on exercise and 
PAD has been published recently.62 Symptomatic patients should be 
medically screened before any supervised exercise training (SET) pro­
gramme initiation.37,62 In patients with symptomatic PAD, SET is safe 
and improves treadmill PFWD, MWD, functional walking as measured 
by six-minute walking distance (6MWD), HRQoL, and cardiorespira­
tory fitness (Figure 13).294,453–463 Exercise has not been found to 
improve ABI.457,458 Ideally, SET should be co-ordinated by vascular 
physicians, and training sessions supervised by clinical exercise 
physiologists or physiotherapists.62
In Europe, SET is usually 
underused.464,465
When SET is not available, home-based exercise training (HBET) 
should be proposed (Figure 13), although it is inferior with regard to im­
proving walking performance.466–469 HBET is safe and its inferiority is 
reduced if monitoring is implemented.469,470 Compared with no exer­
cise, HBET improves walking performance.471 SET training frequency 
should be at least three times per week, for 30–60 min, and the pro­
gramme last for at least 12 weeks.37,58,59,454,472,473 Patients should ex­
ercise to moderate-severe claudication pain to improve walking 
performance.37,294,453,454,456–458,474 However, prescribing high-pain 
exercise may hinder programme uptake and adherence. Additionally, 
it has been reported that improvements in walking performance may 
be obtained with less severe claudication pain.455,460 Therefore, a 
flexible approach is recommended, considering the patient’s needs 
Optimal medical treatment
Address lower limbs-related symptoms
Improve quality of life
Address general CV risk prevention
Smoking cessation
Weight loss
Healthy diet
Supervised exercise training
Antihypertensive drugs
Optimal glucose control in diabetics
Cholesterol-lowering drugs
Antithrombotic drugs
+
Figure 10 Optimal medical treatment in patients with peripheral arterial disease. CV, cardiovascular.


<!-- PAGE 42 -->

### Page 42

and preferences.62 Alternative training modalities, such as strength 
training, arm cranking, cycling, and combinations of different modes, 
have proven effective in improving walking performance compared 
with traditional walking training, with limited evidence for HRQoL.475
However, this evidence is low due to small sample size and risk of 
bias.475 Vigorous intensity exercise training (77%–95% of maximal heart 
rate or 14–17 on the rate of perceived exertion on Borg’s scale) has 
been shown to induce the best walking and cardiorespiratory fitness 
improvements.294,457
Training 
programmes 
should 
begin 
at 
low-to-moderate intensity, gradually advancing to vigorous exercise if 
well tolerated.62 This approach assesses patient response and mini­
mizes complications.37,62
N
N
Chronic PAD syndromes (without wounds)
Vascular follow-up (clinical, physical, functional, vascular assessment)
Asymptomatic PAD
Symptomatic PAD
CLTI
Optimal medical treatment
Optimal medical treatment
Optimal medical treatment
Vascular team assessment
Revascularization feasible
Supervised or structured home-based exercise training
Vascular team assessment
Improved PAD-related symptoms
Revascularization indicated and reasonable
Revascularization indicated and reasonable
Revascularization and supervised or structured
 home-based exercise training
Supervised or structured
 home-based
 exercise training
Evaluate alternative
 treatment strategy
(pharmacological,
amputation)
Revascularization feasible
Revascularization
Y
Y
Y
N
N
Y
Y
N
Figure 11 Treatment algorithm in peripheral arterial disease without wounds. CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.
ESC Guidelines                                                                                                                                                                                          3579


<!-- PAGE 43 -->

### Page 43

N
N
N
N
N
N
N
Chronic PAD syndromes (with wounds)
Vascular follow-up (clinical, physical, functional, vascular assessment)
Asymptomatic PAD
Symptomatic PAD
CLTI
Optimal medical treatment
Optimal medical treatment
Optimal medical treatment
Wound care
Wound care
Wound care
Healing
Healing
Vascular team assessment
Revascularization feasible
Supervised or structured home-based exercise training
Vascular team assessment
Vascular team assessment
Improved PAD-related symptoms
Revascularization indicated and reasonable
Revascularization indicated and reasonable
Revascularization and
Wound care
Revascularization and
Wound care
Evaluate alternative
 treatment strategy
(pharmacological,
amputation)
Revascularization and supervised or structured home-based exercise training
Supervised or structured home-based exercise training
Revascularization feasible
Revascularization indicated and reasonable
Y
Revascularization feasible
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Figure 12 Treatment algorithm in peripheral arterial disease with wounds. CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.


<!-- PAGE 44 -->

### Page 44

Data on the efficacy of exercise therapy in women compared with 
men are scarce. Women may respond less well than men,476,477 al­
though discrepancies among studies exist.478–481
SET combined with endovascular revascularization significantly improves 
walking performance, HRQoL, and reduces future revascularization.482,483
An exercise therapy algorithm in PAD has been recently described.62
Supervised hospital-based exercise programmes
Supervised home-based exercise programmes
Training characteristics
Training benefits
Potential involved mechanisms
Mitochondrial content/function
Symptoms
Quality of life
Walking performance
Patient awareness
 CVR
Functional status
Arteriogenesis
 
Endothelial function
Myofibre size
Inflammation
Supervised group sessions
Different training modes
Remote monitoring,
logbook and connected devices
At least three times per week
Different levels of elicited pain
Low-to-moderate exercise intensity (or high if tolerated)
Session duration of at least
30 min. Programmes duration of at least 12 weeks.
Figure 13 Exercise training characteristics and benefits in patients with peripheral arterial disease. CVR, cardiovascular risk.
ESC Guidelines                                                                                                                                                                                          3581


<!-- PAGE 45 -->

### Page 45

8.1.1.2.2. Pharmacological treatment. Antithrombotic therapy
Asymptomatic PAD
Although patients with PAD are at very high CV risk,404,484 a trial 
evaluating the effect of antiplatelet agents in asymptomatic patients 
with an ABI ≤0.95 did not show an effect on MACE or revasculariza­
tion.485 Another trial on patients with an ABI ≤0.99 and diabetes also 
failed to show any difference in MACE or amputation.486 However, 
these data were not powered to analyse subgroups and do not rule 
out the possibility that aspirin could provide a benefit in subjects at in­
creased risk of CV events. In a randomized trial evaluating aspirin in the 
prevention of cancer and CVD in patients with diabetes without known 
arterial disease, MACE occurred in a significantly lower percentage of 
participants in the aspirin group than in the placebo group, with 
more major bleeding events in the aspirin group.487 The effect of antith­
rombotics in patients with higher-risk PAD (i.e. ABI <0.90 and other 
CV risk factors) has not been evaluated in randomized trials. 
Antithrombotic therapy should not be systematically administered in 
patients with asymptomatic PAD.
Symptomatic PAD
In patients with symptomatic PAD, antithrombotic therapy improves 
CV prognosis.488–492 Clopidogrel may have a modest advantage over 
aspirin (Figure 14).493,494 In the Examining Use of tiCagreLor In periph­
eral artery Disease (EUCLID) trial, single antiplatelet therapy (SAPT) 
with ticagrelor showed no superior benefit in the reduction of 
MACE or major bleeding compared with clopidogrel.495–497
Dual antithrombotic therapy with aspirin and vascular-dose rivarox­
aban (2.5 mg b.i.d.) in patients with PAD is more effective than aspirin 
alone, reducing MACE, MALE, and preventing acute limb ischaemia 
(ALI), but with increased major bleeding risk.429,430,498,499 Patients 
with high-risk limb presentation (CLTI, previous amputation, or revas­
cularization) or high-risk comorbidities (heart failure [HF], diabetes, or 
polyvascular disease [PVD]) benefit the most.498
After endovascular therapy, dual antiplatelet therapy (DAPT) for 1–3 
months is supported by rare randomized studies.500,501 DAPT is not asso­
ciated with reduced CV mortality or MACE,501 but seems to improve 
patency without increasing bleeding (Figure 15).502–504 The combination 
of aspirin 100 mg and vascular-dose rivaroxaban (2.5 mg b.i.d.), started 
post-revascularization, showed a moderate but significantly lower incidence 
of MALE and MACE compared with aspirin alone,490,505without an increase 
in thrombolysis in myocardial infarction (TIMI) major bleedings, but with an 
increase in International Society on Thrombosis and Haemostasis (ISTH) 
major bleedings, especially when clopidogrel was given for >1 month.506
Patients with CLTI are at high risk of MACE and MALE.429,431,507
Among CLTI patients, there is no robust evidence favouring a specific an­
tithrombotic strategy for vein graft maintenance. DAPT with clopidogrel 
and aspirin is not superior to aspirin alone in below-the-knee (BTK) by­
pass grafts.508–510 Vitamin K antagonists (VKAs) may be considered for 
high-risk conduits with low bleeding risk.509
Dual antiplatelet therapy could confer benefit for prosthetic conduit 
(occlusion, revascularization, amputation, or death), without increasing 
major bleeding.510 VKAs with an international normalized ratio (INR) of 
3–4.5 are slightly beneficial in venous conduits, but with a 1.9-fold and 
1.3-fold increase in major and fatal bleedings, respectively.509 A study 
suggested that VKAs could be associated with prolonged patency of 
at-risk prosthetic grafts due to poor run-off.511
In patients with another indication for OAC (such as atrial fibrillation 
[AF] or mechanic valve replacement) and PAD, anticoagulation is war­
ranted.512 Additional SAPT post-endovascular therapy should be brief.
Recommendation Table 13 — Recommendations for 
exercise therapy in patients with peripheral arterial 
disease (see also Evidence Table 5)
Recommendations
Classa
Levelb
In patients with symptomatic PAD, SET is 
recommended.294,453,456–458,462
I
A
In those patients undergoing endovascular 
revascularization, SET is recommended as an 
adjuvant therapy.482,483
I
A
When SET is not available or feasible, a structured 
and monitored (calls, logbooks, connected devices) 
HBET programme should be considered.468,469,471
IIa
A
Walking should be considered as a first-line training 
modality. When walking exercise is not an option, 
alternative exercise modes (strength training, arm 
cranking, cycling, and combinations of different 
training modes) should also be considered.475
IIa
A
Walking training performed at high intensity (77%– 
95% of maximal heart rate or 14–17 self-perceived 
exertion on Borg’s scale) should be considered to 
improve walking performance,294 and high-intensity 
exercise training (various aerobic training modes) 
should be considered to improve cardiorespiratory 
fitness.294,457
IIa
A
Training frequency of at least three times per week, 
training session duration of at least 30 min, and 
training programme duration of at least 12 weeks 
should be considered.472
IIa
B
In patients with PAD, exercise training to 
moderate-severe claudication pain may be 
considered to improve walking 
performance.37,454,456,458 However, improvements 
are also achievable with lesser claudication pain 
severities (low-mild pain or pain-free).455,460
IIb
B
Based on patient’s tolerance, a progressive increase 
(every 1–2 weeks) in exercise training load may be 
considered.37,62
IIb
C
© ESC 2024
HBET, home-based exercise training; PAD, peripheral arterial disease; SET, supervised 
exercise training. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with peripheral 
arterial disease (see also Evidence Table 6)
Recommendations
Classa
Levelb
Use of antiplatelet therapy with aspirin alone (range 
75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is 
recommended for the reduction of MACE in patients 
with symptomatic PAD.488–490
I
A
Treatment with combination rivaroxaban (2.5 mg 
b.i.d.) and aspirin (100 mg o.d.) should be considered 
for patients with PAD, high ischaemic risk,c and 
non-high bleeding risk.d,429,498,499
IIa
A
Continued


<!-- PAGE 46 -->

### Page 46

Pharmacotherapy to decrease walking impairment
Verapamil,516 statins,517,518 antiplatelet agents, and prostanoids 
(prostaglandins I2 and E1)519 can alleviate walking impairment in patients 
with symptomatic PAD. However, drugs like cilostazol, naftidrofuryl, 
pentoxifylline, buflomedil, carnitine, and propionyl-L-carnitine are sug­
gested to increase walking distance in patients with IC without impact­
ing CV health.339,520 Their objective benefit is generally limited, ranging 
from mild to moderate, with considerable variability.339 The additional 
benefit of these drugs alongside antithrombotics, antihypertensives, and 
statins remains unknown.
Cilostazol, a phosphodiesterase type III inhibitor, improved MWD 
compared with placebo and pentoxifylline.520–522 In a Cochrane analysis, 
100 mg twice daily increased MWD by 76%,521 while another review re­
ported a 25% average improvement.520 Cilostazol also has antiplatelet ef­
fects, requiring cautious combination with other anticoagulant and 
antiplatelet treatments.522 Notably, it increases bleeding complications.523
Naftidrofuryl oxalate, tested for IC,524 demonstrated a 74% average 
increase in MWD and improved HRQoL.524,525 In a systematic review, 
the average MWD improvement was 60% compared with placebo.520
However, inconsistent results for other medications, such as prosta­
noids, pentoxifylline, L-arginine, buflomedil, or Gingko biloba, preclude 
their recommendation for patients with IC.519,526,527
8.1.1.2.3. Aorto-iliac lesion revascularization. Aorto-iliac lesions can 
be treated by either an endovascular or a surgical approach according 
to the lesion morphology and patient risk. Long-term patency with a 
low risk of complications can be achieved by balloon angioplasty with 
or without stenting in external iliac arteries or primary stenting in com­
mon iliac arteries.528 A meta-analysis evaluated outcomes of open surgery 
vs. an endovascular approach in aorto-iliac lesions (TASC II C-D) and 
found that short-term morbidity and mortality favours the endovascular 
approach, but early and mid-term primary patency favours open surgery; 
however, secondary patency is comparable in all groups.
Treatment with combination rivaroxaban (2.5 mg 
b.i.d.) and aspirin (100 mg o.d.) should be considered 
for patients with PAD and non-high bleeding risk 
following lower-limb revascularization.490,505
IIa
B
Use of antiplatelet therapy with clopidogrel alone 
(75 mg o.d.) may be considered over aspirin to 
reduce MI, stroke, and vascular death.493,494
IIb
B
Aspirin (75–100 mg) for primary prevention may be 
considered in patients with asymptomatic PAD and 
DM, in the absence of contraindications.419,487
IIb
A
DAPT for at least 1 month after revascularization 
may be considered to reduce limb 
events.500,501,503,513,514
IIb
B
Long-term DAPT in patients with PAD is not 
recommended.489
III
A
Oral anticoagulant monotherapy for PAD (unless for 
another indication) is not recommended.515
III
A
The routine use of ticagrelor in patients with PAD is 
not recommended.495
III
A
It is not recommended to systematically treat 
patients with asymptomatic PAD without any sign of 
clinically relevant ASCVD with antiplatelet drugs.485
III
B
© ESC 2024
ASCVD, atherosclerotic cardiovascular disease; DAPT, dual antiplatelet therapy; DM, 
diabetes mellitus; MACE, major adverse cardiovascular events; MI, myocardial infarction; 
o.d., once daily; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence. 
cHigh ischaemic risk: previous amputation, critical limb threatening ischaemia, previous 
revascularization, high-risk comorbidities (heart failure, diabetes, vascular disease in two 
or more vascular beds), eGFR <60 mL/min/1.73 m2.498
dHigh bleeding risk: dialysis or renal impairment GFR <15 mL/min/1.73 m2, acute coronary 
syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically 
significant bleeding.
Patients with chronic symptomatic PAD
Assess risk level at every follow-up
High-risk limb presentation
 or high-risk comorbiditiesa without high bleeding risk
Non high-risk limb presentation
 or high-risk comorbiditiesa
Single antiplatelet therapy
 (ASA or clopidogrel)
(Class I)
ASA
 and 2.5 mg rivaroxaban b.i.d.
(Class IIa)
Single OAC
monotherapy
(Class IIb)
Patients requiring
 long-term anticoagulation
Figure 14 Long-term antithrombotic therapy in patients with symptomatic peripheral arterial disease. b.i.d., twice daily; OAC, oral anticoagulant; PAD, 
peripheral arterial disease; ASA, aspirin aHigh-risk limb presentation: previous amputation, chronic limb-threatening ischaemia, previous revascularization, 
high-risk comorbidities: heart failure, diabetes, vascular disease in two or more vascular beds, moderate kidney dysfunction; eGFR <60 mL/min/1.73 m2.
ESC Guidelines                                                                                                                                                                                          3583


<!-- PAGE 47 -->

### Page 47

8.1.1.2.4. Femoro-popliteal lesion revascularization. If revasculariza­
tion is indicated, endovascular therapy should be the first choice 
even for complex lesions, especially in surgical high-risk pa­
tients.119,529–531
Endovascular therapy faces the challenge of sustaining long-term 
patency and durability in the femoro-popliteal region, particularly 
post-stent placement in a highly mobile artery. Drug-eluting balloons 
have improved long-term patency in complex patient cohorts and le­
sions.532 With regard to paclitaxel-coated devices, a meta-analysis 
caused a decline in their usage, especially as the United States 
Food and Drug Administration (FDA) reacted and restricted their 
use.533 Consequently, data from large national databases were eval­
uated and the mortality signal could not be confirmed. The FDA re­
vised its position, and drug-eluting treatment is now deemed to be 
a safe and efficient treatment strategy for femoro-popliteal 
lesions.534–538
An open surgical approach in femoro-popliteal lesions should be 
considered when an autologous vein (e.g. great saphenous vein 
[GSV]) is available and the patient shows low surgical risk, and in com­
plex lesions after an interdisciplinary team discussion.
8.1.1.2.5. Below-the-knee artery revascularization. In patients with 
severe IC in whom endovascular femoro-popliteal treatment is per­
formed, BTK arteries can be treated in the same intervention if there 
is substantially impaired outflow.539
N
Y
Patients with chronic symptomatic PAD after endovascular revascularization
Long-term anticoagulation required
Bleeding risk
No high bleeding risk
High bleeding riska
No high bleeding risk
High bleeding riska
Bleeding risk
ASA and 2.5 mg rivaroxaban b.i.d. +/- clopidogrel for 1 month
(Class IIa)
ASA + 2.5 mg rivaroxaban b.i.d.
(Class IIa)
OAC
 monotherapy
(Class IIa)
OAC
 monotherapy
(Class IIa)
SAPT
(ASA or clopidogrel)
(Class I)
DAPT
1–3 months
(Class IIa)
SAPT 1–3 months
 and OAC
(Class IIa)
Figure 15 Patients with chronic symptomatic PAD after endovascular revascularization. b.i.d., twice daily; DAPT, dual antiplatelet therapy; OAC, oral 
anticoagulant; PAD, peripheral arterial disease; ASA, aspirin; SAPT, single antiplatelet therapy aHigh bleeding risk: dialysis or a renal impairment glom­
erular filtration rate <15 mL/min/1.73 m2, acute coronary syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically 
significant bleeding.
Recommendation Table 15 — Recommendations for 
interventional treatment of asymptomatic and symp­
tomatic peripheral arterial disease (general)
Recommendations
Classa
Levelb
In patients with symptomatic PAD, after a 3 month 
period of OMT and exercise therapy, PAD-related 
QoL assessment is recommended.119
I
B
It is recommended to adapt the mode and type of 
revascularization options to anatomical lesion location, 
lesion morphology, and general patient condition.119
I
C
In patients with symptomatic PAD and impaired 
PAD-related quality of life after a 3 month period of 
OMT and exercise therapy, revascularization may be 
considered.465,540
IIb
B
In patients with PAD, revascularization is not 
recommended if the reason is to solely prevent 
progression to CLTI.541–544
III
B
In patients with asymptomatic PAD, 
revascularization is not recommended.119,529
III
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia; OMT, optimal medical treatment; PAD, 
peripheral arterial disease; QoL, quality of life. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

8.1.1.3. Follow-up
Asymptomatic and symptomatic PAD are at increased risk of leg symp­
tom worsening427 and of CV mortality and morbidity.419,431,551
Follow-up post-revascularization is crucial to ensure perfusion improve­
ment, address CVRFs, optimize pharmacological treatment adherence, 
identify disease progression, and evaluate mental health and functional 
capacity. Experienced vascular care physicians should conduct follow-up, 
although specific protocols are currently undefined.128,552 Data on asymp­
tomatic PAD follow-up are limited.553 For symptomatic PAD or post- 
intervention, annual follow-up are advised, including ABI/TBI measure­
ment and DUS for new or worsening symptoms.
8.1.2. Chronic limb-threatening ischaemia
8.1.2.1. Clinical presentation and diagnosis
Chronic limb-thretening ischaemia describes chronic lower-limb hypo­
perfusion responsible for ischaemic rest pain, or non-healing ulceration 
or gangrene (typically in distal segments).555,556 Ischaemic rest pain pri­
marily affects the patient’s forefoot and aggravates in a supine position, 
while lowering of the affected leg eases ischaemic symptoms.
8.1.2.1.1. Definition. Chronic limb-thretening ischaemia should be 
considered in the presence of one of the following lower-limb clinical 
signs or symptoms: 
• Ischaemic rest pain
• Non-healing lower-limb wound of ≥2 weeks’ duration
• Lower-limb gangrene
The following haemodynamic criteria may be used to guide diagnosis 
in patients with suspicion of CLTI: 
• Ankle pressure <50 mmHg
• TP <30 mmHg
• TcPO2 <30 mmHg
8.1.2.1.2. Initial assessment and risk of amputation. For patients 
with CLTI, initial diagnostic steps involve clinical examination and limb 
perfusion 
assessment 
through 
haemodynamic 
measurements. 
Regarding haemodynamic assessment in CLTI, standard ABI may be 
normal or falsely elevated due to non-compressible arteries related 
to medial sclerosis (common in diabetes or CKD),557 which can be 
overcome by estimation of ABI based on Doppler waveforms.124
Therefore, standard ankle pressure alone may not be reliable in esti­
mating limb loss risk.441,558 In addition, a large proportion of patients 
with ulcers may have below-the-ankle lesions.440 In patients with 
CLTI, TP, TBI, or TcPO2 should additionally be obtained.90,441,559
Particularly in patients with CLTI, the WIfI classification system 
should be applied. In addition to patients’ limb perfusion, the WIfI clas­
sification considers the wound size and the extent of foot infection to 
determine the individual risk of amputation.417,444–446
8.1.2.1.3. Imaging. In all patients with CLTI, comprehensive vascular 
imaging is mandatory to evaluate revascularization options. CLTI com­
monly affects more than one arterial segment of the lower limbs, involving 
infra-popliteal arteries (BTK and below-the-ankle arteries) in most cases. 
While non-invasive imaging (DUS, CTA, MRA) provides reliable results 
for above-the-knee arteries, imaging of BTK arteries, especially below 
the ankle, may be hampered by severe calcification.448,560,561 Therefore, 
in CLTI additional DSA with dedicated views of the foot should be con­
sidered for the assessment of BTK arteries.560 Even in patients who are 
not candidates for revascularization, DSA should be obtained to prevent 
unnecessary amputation or to minimize amputation extent.560,562
8.1.2.1.4. Mortality risk assessment. All-cause mortality and event 
rates of MI are more than two-fold higher in CLTI patients than in un­
selected patients with an ABI ≤0.90.431
In CLTI patients undergoing revascularization, the post-revascularization 
period is particularly associated with an increased risk of MALE and 
MACE.563 The management of patients with CLTI should therefore in­
clude an individual peri-procedural risk assessment. Referring to the peri- 
procedural risk patients can be categorized as average procedural risk 
(peri-procedural mortality <5% and 2 year survival >50%) or high proced­
ural risk (peri-procedural mortality ≥5% and 2 year survival ≤50%).564,565
Besides revascularization, it also needs to be considered that lower- 
limb amputation is associated with 30 day mortality rates of up to 
22%.566
Recommendation Table 16 — Recommendations for 
interventional treatment of patients with symptomatic 
peripheral arterial disease (per arterial bed)
Recommendations
Classa
Levelb
In femoro-popliteal lesions, drug-eluting treatment 
should be considered as the first-choice strategy.534–537
IIa
A
In iliac lesions, balloon angioplasty with or without 
stenting in external iliac arteries, or primary stenting in 
common iliac arteries, should be considered.545–548
IIa
B
In femoro-popliteal lesions, if revascularization is 
indicated, endovascular therapy should be 
considered.119,529–531
IIa
B
In femoro-popliteal lesions, if revascularization is 
indicated, an open surgical approach should be 
considered when an autologous vein (e.g. GSV) is 
available in patients with low surgical risk.119,529
IIa
C
In patients with severe IC undergoing endovascular 
femoro-popliteal revascularization, treatment of 
BTK arteries may be considered in the same 
intervention.549,550
IIb
C
© ESC 2024
BTK, below-the-knee; GSV, great saphenous vein; IC, intermittent claudication. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 17 — Recommendations in 
patients with peripheral arterial disease: follow-up of 
patients with peripheral arterial disease
Recommendations
Classa
Levelb
It is recommended to regularly, at least once a year, 
follow up patients with PAD, assessing clinical and 
functional status, medication adherence, limb 
symptoms, and CVRFs, with DUS assessment as 
needed.553,554
I
C
© ESC 2024
CVRFs, cardiovascular risk factors; DUS, duplex ultrasound; PAD, peripheral arterial 
disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3585


<!-- PAGE 49 -->

### Page 49

8.1.2.2. Medical treatment
Chronic limb-thretening ischaemia is associated with a high risk of is­
chaemic events,429,431 thus management of patients with CLTI must in­
clude OMT.
In addition, rest pain, optimal wound care, and infection control should 
be managed. A vascular team, including at least a vascular physician, a vas­
cular surgeon, and a radiologist, should be involved to prevent amputa­
tion.568 Lower-limb exercise training is contraindicated until ulcers are 
healed and aggressive offloading should be ensured to allow healing. 
Depending on infection extent, oral antibiotics may suffice, however, if 
extensive with systemic signs of inflammation, admission for intravenous 
(i.v.) antibiotic administration may be required.569,570
Good-quality evidence on the advantages of one type of wound 
dressing over others is lacking, while in selected patients individualized 
treatments with antimicrobial dressing,571 silver dressing,572 collagen 
dressing,573 honey- or iodine-based dressings,574 platelet-rich plasma, 
or negative pressure therapy575,576 may accelerate wound healing, 
shorten hospital stay, and prevent amputations. If deep-seated infection 
is suspected, X-ray or MRA are required to diagnose osteomyelitis, in 
which case a longer course of antibiotics may be necessary.577
Antibiotics for osteomyelitis treatment may be empirical, however, 
they should be adapted according to (preferably tissue) cultures.578–581
Ulcers require assessment of venous aetiology and potential for en­
dovenous therapy, while mixed ulcers require compression therapy 
after revascularization.582
8.1.2.3. Interventional treatment
8.1.2.3.1. Revascularization. In CLTI, revascularization should be at­
tempted to rapidly restore an inline direct blood flow to the 
foot.585–588 Three RCTs compared endovascular therapy with open 
surgery in infra-inguinal arteries. In the Bypass versus Angioplasty in 
Severe Ischaemia of the Leg (BASIL) trial, no significant difference 
was found regarding mortality or amputation-free survival at 2 years.589
However, surgery was associated with a significantly reduced risk of 
amputation, death, or both after 2 years.564,589 In the Best 
Endovascular versus Best Surgical Therapy for Patients with Critical 
Limb Ischemia (BEST-CLI) trial (median follow-up of 2.7 years), the in­
cidence of MALE or death was lower in patients in which one segment 
of the GSV was available for surgical revascularization than in patients 
who underwent endovascular revascularization. In the same trial, out­
comes of patients for whom an alternative bypass conduit was needed 
for surgical revascularization were similar to those of patients who 
underwent endovascular revascularization.567
In the BASIL-2 trial, which included patients requiring infra-popliteal, 
with or without additional further proximal infra-inguinal, revasculariza­
tion procedures, endovascular revascularization was associated with 
better amputation-free survival than surgical revascularization, which 
was primarily due to fewer deaths in this group.590 It is important to 
consider591 both revascularization options individually in each patient, 
considering the complexity of the diseased anatomical region.
Multilevel disease
Patients with CLTI commonly present with multilevel disease.592
Especially for complex lesions, comprehensive patient assessment, in­
cluding the individual patient’s clinical presentation, the lesion morph­
ology, and the peri-procedural risk, needs to be undertaken by a 
multidisciplinary vascular team to weigh the risks against the benefits 
of the respective methods of revascularization (endovascular vs. surgi­
cal).590,593–596 A structured approach is essential to achieve rapid and 
durable restoration of an inline flow to the foot. When possible, the an­
giosome concept can be considered, targeting the most affected ischae­
mic area.597 When CLTI leaves no viable revascularization options, 
transcatheter arterialization of deep veins may be considered.598
Aorto-iliac disease
An endovascular approach is the first choice, commonly employing 
bare metal or covered stents.599–603 Surgery is reserved for extensive 
obstructions and lesions treated unsuccessfully with an endovascular 
procedure.604 Hybrid revascularization should be considered in occlu­
sion of the common femoral artery or profunda femoris artery requir­
ing endarterectomy, in addition to inflow and/or outflow disease 
amenable to endovascular therapy. Hybrid procedures should be en­
couraged in a one-step modality.605
Femoro-popliteal disease
Chronic limb-threatening ischaemia is unlikely to be related to iso­
lated superficial femoral artery lesions; femoro-popliteal involvement 
in combination with aorto-iliac or infra-popliteal disease is frequently 
found. In 40% of cases, inflow treatment of femoro-popliteal disease 
is necessary.606 The revascularization strategy should be selected ac­
cording to lesion complexity.422 If endovascular therapy is chosen, land­
ing zones for potential bypass grafts should be preserved. When bypass 
surgery is decided, the bypass should be as short as possible, using the 
saphenous veins.567
Infra-popliteal disease
Extended infra-popliteal disease is mainly seen in patients with dia­
betes607–610 and CKD,611,612 often being associated with superficial 
femoral artery lesions. In short infra-popliteal lesions, endovascular 
Recommendation Table 18 — Recommendations for 
the management of chronic limb-threatening ischaemia
Recommendations
Classa
Levelb
For limb salvage in patients with CLTI, 
revascularization is recommended.564,567
I
B
Early recognition of CLTI and referral to the vascular 
team are recommended for limb salvage.417,560
I
C
In patients with CLTI, imaging of the entire affected 
limb should be considered.560
IIa
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 19 — Recommendations for 
medical treatment in patients with chronic limb- 
threatening ischaemia (see also Evidence Table 7)
Recommendations
Classa
Levelb
It is recommended that patients with CLTI are 
managed by a vascular team.568
I
C
In patients with CLTI and ulcers, offloading 
mechanical tissue stress is recommended to allow 
wound healing.583,584
I
C
It is recommended to treat infection with 
antibiotics.569,570
I
C
Lower-limb exercise training is not recommended in 
patients with CLTI and wounds.584
III
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 50 -->

### Page 50

therapy is the first choice.593 Drug-eluting balloons607 and bare metal 
stent implantation613 have shown no superiority over plain balloon 
angioplasty, although drug-eluting stents may be used for relatively 
short proximal lesions.614–616
8.1.2.3.2. Spinal cord stimulation. Spinal cord stimulation (SCS) may 
be considered in treating patients with CLTI and no viable revascular­
ization options. SCS offers modest pain relief and an 11% reduction 
in amputation rate compared with conservative management at 1 
year. No effect was seen in ulcer healing and benefits should be weighed 
against the high cost and possible complications.617 Recent technologic­
al advances in neuromodulation may improve the treatment value of 
this modality.618
8.1.2.3.3. Amputation. Minor amputation, usually up to the forefoot, 
is often needed for necrotic tissue removal with minor impact on patient 
mobility. Pre-amputation revascularization enhances wound healing. In 
cases of extensive necrosis or infectious gangrene, primary major ampu­
tation without revascularization may be preferable to avoid complica­
tions. Secondary amputation is indicated when revascularization fails, 
re-intervention is not possible, or limb deterioration persists despite a 
patent graft and optimal management. BTK amputation allows better 
mobility with a prosthesis. For bedridden patients, above-the-knee am­
putation may be the preferred choice.
8.1.2.4. Follow-up
In patients with CLTI, the incidence of CV events is increased.619,620
Follow-up should focus on general clinical CV condition, prevention 
of revascularization failure, wound healing, and contralateral limb status. 
After revascularization, at least an annual appointment with a vascular 
physician expert in CLTI management is warranted. Due to the lack of 
evidence, recommendations are largely based on consensus and expert 
opinions.128
First-year incidence of vein graft stenosis is 20%;621 however, if un­
eventful for 12 months, late issues are scarce.622 Clinical examination, 
ABI (or TBI) measurement, and DUS should be performed within 4– 
6 weeks and thereafter at 3, 6, 12, and 24 months after bypass 
surgery.128
After endovascular treatment, restenosis and occlusion ranges from 
5% in the pelvic region to >50% in the infra-popliteal arteries.623,624
Unlike after surgery, no plateau phase is seen, and the failure rate is con­
stant for at least 5 years. Surveillance includes clinical assessment looking 
for recurrent symptoms or signs, ABI measurement, and DUS based on 
the first check-up: if normal, DUS is recommended if symptoms reappear; 
if abnormal, initial DUS, re-intervention, or closer DUS follow-up on a 
case-by-case basis are recommended.128 Post-procedural ankle duplex- 
based estimated ABI of <0.90 predicts suboptimal wound healing, clinic­
ally driven target lesion revascularization (cdTLR), and MALE.625
After revascularization, closer follow-up and wound care are recom­
mended until healing. Thereafter, annual appointments with vascular 
physicians with expertise in CLTI management should be scheduled 
to check for symptoms, foot condition, ABI, and CVRFs, including avail­
ability for TP and TcPO2 if needed. Recurrence of symptoms may also 
be due to the progression of atherosclerotic disease above or below 
the bypass or angioplasty site.427
8.1.3. Acute limb ischaemia
8.1.3.1. Clinical presentation and diagnosis
Acute limb ischaemia is caused by an abrupt decrease in arterial limb per­
fusion. Potential causes are PAD progression, cardiac/aortic embolization, 
AD, graft thrombosis, aneurysm thrombosis, popliteal artery entrapment 
syndrome, trauma, phlegmasia cerulea dolens, ergotism, hypercoagulable 
states, and iatrogenic complications related to vascular procedures. ALI is 
a medical emergency and timely recognition is crucial to successful treat­
ment.629–632 Patients should be rapidly evaluated by a vascular specialist633
or rapidly transferred to a facility with such resources.
The time constraint is due to the period that skeletal muscle and 
nerves will tolerate ischaemia—roughly 4–6 h.634 Lower-extremity 
symptoms can include both pain and loss of function. The longer and 
the stronger these symptoms are, the less likely the possibility of limb 
salvage.
Recommendation Table 20 — Recommendations for 
interventional treatment of chronic limb-threatening 
ischaemia
Recommendation
Classa
Levelb
In CLTI patients, it is recommended to perform 
revascularization as soon as possible.564
I
B
In CLTI, it is recommended to use autologous veins 
as the preferred conduit for infra-inguinal bypass 
surgery.567,593
I
B
In multilevel vascular disease, it is recommended to 
eliminate inflow obstructions when treating 
downstream lesions.
I
C
An individual risk assessment (weighing the patient’s 
individual procedural risk of endovascular vs. surgical 
revascularization) by a multidisciplinary vascular team 
is recommended.
I
C
In CLTI patients with good autologous veins and low 
surgical risk (<5% peri-operative mortality, >50% 2 
year survival), infra-inguinal bypass may be 
considered.564,567,590
IIb
B
In CLTI patients, endovascular treatment may be 
considered as first-line therapy, especially in patients 
with increased surgical risk or inadequate autologous 
veins.564,567,590
IIb
B
© ESC 2024
CLTI, chronic limb-threatening ischaemia. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 21 — Recommendations for 
follow-up in patients with chronic limb-threatening 
ischaemia
Recommendations
Classa
Levelb
In patients with CLTI, following revascularization it is 
recommended to follow up patients on a regular 
basis.552,626,627
I
C
At follow-up, it is recommended to assess clinical, 
haemodynamic and functional status, limb symptoms, 
treatment adherence, and CVRFs.552,625–628
I
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia; CVRFs, cardiovascular risk factors. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3587


<!-- PAGE 51 -->

### Page 51

8.1.3.1.1. Clinical examination. The emergency level and the choice 
of therapeutic strategy depend on the clinical presentation, mainly ac­
cording to neurological deficits. Clinical assessment must include symp­
tom duration as well as sensory and motor deficit severity to distinguish 
a threatened from a non-viable extremity. Neurological deficits (sen­
sory loss or especially motor deficit) are signs of limb threat and require 
emergency imaging and revascularization.635 Severe sensory deficit and 
paralysis suggest the limb may be unsalvageable. Clinical ALI categories 
are presented in Table 9.
8.1.3.1.2. Imaging and functional tests. The imaging method de­
pends on availability and aims to diagnose clot presence and assess 
haemodynamic severity. DSA, CTA, DUS, and contrast-enhanced 
(CE)-MRA are options based on local expertise, availability, and prefer­
ence.636 DUS helps determine treatment urgency when assessing 
neurological deficit is challenging. Loss of arterial signal suggests limb 
threat, while a present signal may indicate the limb is not immediately 
threatened, allowing for ABI measurement. The absence of both arter­
ial and venous Doppler signals, coupled with extensive motor deficit, 
suggests the limb may be irreversibly damaged (non-salvageable).637
In addition, biomarkers of muscle damage such as creatinine kinase 
(CK) or myoglobin may be useful as high levels indicate rhabdomyolysis, 
risk of amputation,638 kidney failure, and mortality.639 In limb ischaemia, 
CK and myoglobin elevations may be lower in chronic cases, possibly 
due to ischaemic pre-conditioning and collateral development.640
8.1.3.2. Medical treatment
Upon clinical diagnosis, initiate analgesia, anticoagulation, and i.v. fluids. 
Addressing acidosis and hyperkalaemia may be necessary. Administer 
i.v. unfractionated heparin (bolus 5000 IU or 70–100 IU per kg body 
weight, followed by continuous infusion with dose adjustment based 
on patient response, monitored by activated clotting time or activated 
partial thromboplastin time) or subcutaneous low molecular weight 
heparin (e.g. enoxaparin 1 mg per kg twice daily) to prevent further em­
bolization and thrombus propagation.
8.1.3.3. Surgical and interventional treatment
For a salvageable limb, urgent revascularization is essential. Diagnostic 
imaging, if it will not delay treatment, is recommended to guide therapy. 
If the limb is deemed unsalvageable, primary amputation or comfort 
care is indicated.
Different revascularization modalities can be applied, including per­
cutaneous catheter-directed thrombolytic therapy, percutaneous 
mechanical thrombus extraction or thrombo-aspiration (with or with­
out thrombolytic therapy), or surgical thrombectomy, bypass, and/or 
arterial repair.642 Moreover, these modalities can be combined, with 
the strategy determined by factors such as neurological deficit, ischae­
mia duration, localization, size, aetiology, comorbidities, type of conduit 
(artery or graft), and therapy-related risks and outcomes. Current en­
dovascular approaches to ALI boast high technical success rates.626 To 
reduce morbidity and mortality, an endovascular-first approach is often 
preferred, especially in patients with severe comorbidities. Thrombus 
extraction, thrombo-aspiration, and surgical thrombectomy are indi­
cated in cases of neurological deficit, while catheter-directed thrombo­
lytic therapy is more appropriate in less severe cases without 
neurological deficit. Modern catheter-based thrombectomy (CDT) is 
associated with 12-month amputation rates of <10% in Rutherford 
IIB.643 A meta-analysis showed that although CDT in the treatment 
of not immediately threatening ALI showed high angiographic success, 
the long-term outcomes were relatively poor, with low patency and a 
substantial risk of major amputation.644 Systemic thrombolysis has no 
role in the treatment of patients with ALI.
A meta-analysis showed that CDT and surgery have similar limb sal­
vage rates.645 Recent analyses indicate benefits of endovascular ap­
proaches in terms of mortality at similar amputation rates.646,647
A comparison of percutaneous thrombectomy vs. ultrasound- 
accelerated thrombolysis for the initial management of ALI showed 
no difference in terms of amputation, bleeding, clinical success, and ad­
verse events, with primary patency at 30 days of 82% and 71%, 
respectively.629,648,649
After thrombus removal, in cases of pre-existing arterial lesions, 
these should be treated by endovascular therapy or open surgery. If 
surgical treatment is required, it should be ideally performed in a hybrid 
room with capacity to allow sufficient completion angiographic imaging 
and initiation of local lysis if any remaining clot is visualized. 
Lower-extremity four-compartment fasciotomies should be per­
formed in patients with long-lasting ischaemia to prevent post- 
reperfusion compartment syndrome.637 The management of ALI is 
summarized in Figure 16.
Table 9 Clinical categories of acute limb ischaemia
Grade
Category
Sensory 
loss
Motor deficit
Arterial 
Doppler 
signal
Venous 
Doppler 
signal
Capillary 
refill
Biomarkers
Prognosis
I
Viable
None
None
Yes
Yes
Yes
Not elevated
No immediate 
threat
IIA
Marginally 
threatened
None or 
minimal 
(toes)
None
No
Yes
Salvageable if 
promptly treated
IIB
Immediately 
threatened
More than 
toes
Mild-moderate
No
Yes
Salvageable if 
promptly 
revascularized
III
Irreversible
Profound, 
anaesthetic
Profound 
paralysis (rigor)
No
No
No
Massively 
elevated
Major tissue loss, 
permanent nerve 
damage inevitable
© ESC 2024
Adapted with permission from.641


<!-- PAGE 52 -->

### Page 52

Neurological function
No sensory loss
Normal motor function
Sensory loss limited to toes
No muscle weakness
Sensory loss more than toes and rest pain
Mild-to-moderate muscle weakness
Complete sensory loss 
and loss of motor function
Capillary refill
Intact
Slow-intact
Slow-absent
Absent
Arterial Doppler
Audible
Inaudible
Venous Doppler
Audible
I: Viable
IIA: Marginally threatened
IIB: Immediately threatened
III: Irreversible
Inaudible
Muscle biomarkers
Elevated
Suspected ALI
Acutely cold and painful leg
Pain management
Medical management and follow-up
Imaging
(DUS, CTA, DSA, MRA)
Imaginga
(DUS, CTA, DSA, MRA)
Urgent revascularization
AND anticoagulation unless contraindicated
Emergency revascularization
AND anticoagulation unless contraindicated
Primary amputation or palliative care
Clinical evaluation by experienced clinician
Figure 16 Management of acute limb ischaemia. ALI, acute limb ischaemia; CTA, computed tomography angiography; DSA, digital subtraction angi­
ography; DUS, duplex ultrasound; MRA, magnetic resonance angiography. aShould not delay treatment.
ESC Guidelines                                                                                                                                                                                          3589


<!-- PAGE 53 -->

### Page 53

8.1.3.4. Follow-up
After revascularization or amputation, haemodynamic success should 
be established, aetiology of ALI investigated, and OMT ensured. 
Statins improve outcomes after revascularization.552,630 Since ALI is 
frequently caused by thrombo-embolism, Holter-ECG, echocardio­
gram, and aortic imaging are useful to allow initiation of appropriate 
therapy, in particular anticoagulation.650 Additionally, consider other 
prothrombotic syndromes, such as antiphospholipid syndromes and 
vasculitis, if clinically suspected. While there is only sparse evidence, 
the inclusion of PAD patients after revascularization into structured 
follow-up may improve their functional outcomes.627
8.2. Extracranial carotid and vertebral 
artery disease
8.2.1. Clinical presentation and diagnosis
8.2.1.1. Clinical presentation
Atherosclerotic CS represents one of the major causes of acute ischae­
mic stroke (20%).657
CS may be revealed by a cervical bruit, but also by a TIA or stroke.
8.2.1.2. Diagnosis
Atherosclerotic lesions are primarily located in specific arterial segments, 
including the carotid bifurcation, siphon, M1 segment of the middle cere­
bral artery, brachiocephalic trunk, subclavian artery, first and fourth seg­
ments of the vertebral artery, or first segment of the basilar artery. 
Carotid plaques (CP), originating in the intima, offer a better representa­
tion of the atherosclerotic process than carotid intima-media thickness 
(cIMT). CP may be diffuse or focal (protuberant). According to the 
Mannheim carotid plaque consensus, a CP is defined as a focal structure 
encroaching into the arterial lumen by ≥0.5 mm or ≥50% of the sur­
rounding vessel.658 The American Society of Echocardiography (ASE) re­
cently proposed a definition that includes any focal thickening considered 
atherosclerotic in origin and encroaching into the lumen of any carotid 
artery segment (protuberant-type plaque) or, in the case of diffuse vessel 
wall atherosclerosis, when cIMT measures ≥1.5 mm in any carotid artery 
segment.659 Plaques can progress to CS, defined as ≥50% narrowing of 
the extracranial internal carotid artery (ICA), with stenosis severity esti­
mated using the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) method or its non-invasive equivalent assessed by DUS 
(Figure 17).122,660 Other methods are described in the Supplementary 
data online, Section 1.5. The European Carotid Surgery Trial (ECST) 
and the area methods overestimate the severity of the CS and are not 
recommended.77
Carotid DUS is safe, accurate, and reliable if performed by a skilled vas­
cular specialist. It is the first-line imaging modality for screening, diagnosis, 
and surveillance of extracranial carotid arteries.77 The degree of stenosis 
is mostly based on Doppler analysis of blood flow in the common carotid 
artery (CCA), ICA, and external carotid artery (Table 10).661,662
Vertebral and subclavian arteries must also be checked. In some cases, 
indirect signs of severe stenosis have to be evaluated by transcranial 
and/or ophthalmic artery Doppler. Severe arterial calcification can de­
crease DUS accuracy.122
Recommendation Table 22 — Recommendations for 
the management of patients presenting with acute 
limb ischaemia (see also Evidence Table 8)
Recommendations
Classa
Levelb
In patients with ALI, it is recommended that an 
urgent evaluation is performed by a vascular clinician 
with sufficient experience to assess limb viability and 
implement appropriate therapy.635
I
C
In cases of neurological deficit, urgent 
revascularization is recommended; diagnostic 
imaging is recommended to guide treatment, 
provided it does not delay treatment, or if the need 
for primary amputation is obvious.422,635,651,652
I
C
In the absence of severe neurological deficit, 
revascularization is recommended within hours of 
initial imaging in a case-by-case decision.422,635,652
I
C
Treatment with analgesics is recommended as soon 
as possible for pain control.
I
C
It is recommended to monitor for compartment 
syndrome after revascularization and treat 
(fasciotomy).637,652
I
C
It is recommended to assess clinical and 
haemodynamic success following 
revascularization.627
I
C
In patients with ALI, it is recommended to obtain a 
comprehensive medical history and determine the 
cause of thrombosis and/or embolization.650
I
C
In patients with ALI, following revascularization if not 
on anticoagulation for other reasons, DAPT or 
rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) 
should be considered.514,653
IIa
C
Upon confirmation of ALI diagnosis, treatment with 
heparin may be considered.635,654–656
IIb
C
© ESC 2024
ALI, acute limb ischaemia; b.i.d., twice daily; DAPT, dual antiplatelet therapy; DPI, dual 
pathway inhibition; o.d., once daily. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 23 — Recommendations for 
carotid artery stenosis assessment
Recommendations
Classa
Levelb
It is recommended to use the NASCET method or its 
non-invasive equivalent to assess ICA 
stenosis.77,122,660
I
B
It is recommended to use DUS as first-line imaging to 
diagnose ICA stenosis.77,663
I
C
It is not recommended to use the ECST method for 
ICA stenosis assessment.77,122,660
III
C
© ESC 2024
DUS, duplex ultrasound; ECST, European Carotid Surgery Trial; ICA, internal carotid 
artery; NASCET, North American Symptomatic Carotid Endarterectomy Trial. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

8.2.2. Asymptomatic carotid artery stenosis
8.2.2.1. Medical treatment
Optimal medical treatment is based on CVRF correction through 
lifestyle intervention and pharmacological treatment, with the goal of 
reducing cerebrovascular and global CV events.19 Concerning hyper­
tension, similar target values as those presented in the general section 
are recommended for patients with asymptomatic CS.
8.2.2.1.1. Lipid-lowering therapy. See Section 7.
8.2.2.1.2. Antihypertensive therapy. See Section 7. 
8.2.2.1.3. Glucose-lowering therapy. See Section 7. 
8.2.2.1.4. Antithrombotic therapy. The clinical benefit of antithrom­
botic treatment in patients with asymptomatic CS remains 
unproven.664 The only RCT (the Asymptomatic Cervical Bruit 
Study [ACB]) addressing the issue enrolled only 188 patients per 
arm, and failed to show superiority of aspirin vs. placebo in reducing 
TIA, stroke, MI, or death.665 In observational studies, SAPT (mainly 
low-dose aspirin) was associated with reduced risk of MACE, 
although data were conflicting for moderate stenosis (i.e. 50%– 
75%);664 DAPT, combining aspirin and clopidogrel, has no benefit 
over SAPT.496,497
The Cardiovascular Outcomes for People Using Anticoagulation 
Strategies (COMPASS) trial reported a non-significant decrease in 
MACE in patients with either history of carotid revascularization or 
asymptomatic patients with >50% CS and CVRFs allocated to dual an­
tithrombotic therapy (aspirin 100 mg o.d. and rivaroxaban 2.5 mg b.i.d.) 
NASCET
(% stenosis)
ECST
(% stenosis)
50
75
60
80
70
85
80
91
90
97
A
C
B
Carotid artery stenosis equivalents between
NASCET and ECST criteria
ECST method
C
NASCET method x 100%
(C-A)
B
x 100%
(B-A)
Figure 17 North American Symptomatic Carotid Endarterectomy Trial/European Carotid Surgery Trial methods. ECST, European Carotid Surgery 
Trial; NASCET, North American Symptomatic Carotid Endarterectomy trial.
Table 10 Peak systolic velocity criteria for grading internal carotid artery stenosis
% stenosis
Reference
50%–69% (moderate stenosis)
≥70% (severe stenosis)
PSV threshold
SRUCC662
------------------------- 
Gornik et al.661
125–230 cm/s  
------------------------- 
≥180 cm/s 
or 
≥125 cm/s + PSV ICA/CCA ≥2
>230 cm/s  
------------------------- 
Overestimation with SRUCC criteria but no consensus
© ESC 2024
CCA, common carotid artery; ICA, internal carotid artery; PSV, peak systolic velocity; SRUCC, Society of Radiologists in Ultrasound.
ESC Guidelines                                                                                                                                                                                          3591


<!-- PAGE 55 -->

### Page 55

vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone. However, specific data 
on asymptomatic CS were not reported.
Since these patients present a two times higher risk of MI,30 lifelong 
low-dose aspirin should be considered in asymptomatic CS patients at 
increased risk for CV events (i.e. diabetic patients) and low bleeding 
risk497 to reduce stroke and CV risk.19,299,488,666
8.2.2.2. Interventional treatment
8.2.2.2.1. Open surgery vs. medical therapy. The rationale for carotid 
endarterectomy (CEA) in asymptomatic CS stems from two trials that 
were published some time ago. The Asymptomatic Carotid 
Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery 
Trial 1 (ACST-1) compared CEA with medical therapy in asymptomatic 
patients with 60%–99% CS.672–674 In ACAS, 5 year rates of ipsilateral 
stroke/death under CEA vs. medical therapy were 5.1% vs. 11.0%. 
ACST-1 reported 5 year rates of any stroke of 6.4% vs. 11.8%, respect­
ively. In a combined analysis of both trials, CEA conferred less benefit in 
women at 5 years.675 At 10 years, however, ACST-1674 reported that 
females benefit following CEA (absolute risk reduction [ARR] 5.8%) 
to the same extent as men (ARR 5.5%).
Medical treatment has advanced following the recruitment of patients 
in these trials.672–676 A 60%–70% decline in annual stroke rates was also 
observed in medically treated patients in both trials over 1995 to 2010.676
This reduction was attributed to better medical treatment and lower 
smoking incidence. The Stent Protected Angioplasty versus Carotid 
Endarterectomy study (SPACE-2) compared OMT alone against OMT 
plus CEA/carotid artery stenting (CAS) in asymptomatic patients with 
CS ≥70% according to ECST criteria. Due to slow recruitment, the study 
was underpowered. The 1 year rate of the major secondary endpoint was 
2.5% after CEA, 3.0% after CAS, and 0.9% after OMT.677 Incidence of any 
stroke or death from any cause within 30 days or any ipsilateral ischaemic 
stroke within 5 years (primary efficacy endpoint) was 2.5% with CEA plus 
OMT, 4.4% with CAS plus OMT, and 3.1% with OMT alone. Results from 
the Carotid Revascularization Endartectomy vs. Stenting Trial 2 
(CREST-2) are awaited to clarify whether intervention is beneficial in 
the treatment of asymptomatic CS compared with modern OMT.
The ARR in stroke favouring surgery over OMT was only 4.6% at 10 
years in ACST-1, indicating that 95% of asymptomatic patients ultim­
ately underwent unnecessary interventions.674,678
A recent meta-analysis confirmed the role of modern OMT in redu­
cing major stroke, combined stroke, and mortality in asymptomatic pa­
tients, suggesting that OMT has the potential to reduce the 
requirement for surgical intervention in patients with asymptomatic 
carotis stenosis.679
In conclusion, for invasive treatment of asymptomatic carotid sten­
osis, the overall risk reduction is low compared with OMT. Current 
data are not available to assess subgroups that may still benefit from 
intervention. However, there is a need to target revascularization in a 
subgroup of patients with clinical and/or imaging features that increase 
the risk for stroke on OMT (Table 11).678,680
Importantly, ACST-1 found no evidence that age >75 years at base­
line was associated with any ipsilateral stroke reduction at 5–10 
years.676–678,696 Neither the ACAS nor ACST-1 studies found any evi­
dence that stenosis severity or contralateral occlusion increased late 
stroke risk.672,674,697 In a recent meta-analysis, increasing stenosis was 
associated with late ipsilateral stroke only in the presence of concomi­
tant high-risk features.698 The general algorithm of CS management is 
presented in Figure 18.552
8.2.2.2.2. Carotid revascularization: surgery vs. stenting. In a recent 
meta-analysis update on RCTs in asymptomatic patients comparing 
CEA vs. CAS, including altogether 7092 patients, CAS was associated 
with significantly higher rates of 30 day ‘any’ stroke and 30 day death/ 
any stroke, while CEA was associated with significantly higher rates 
of 30 day MI. No significant differences were seen in 30 day death, 
30 day disabling stroke, 30 day death/disabling stroke, or 30 day 
death/any stroke/MI when CAS was compared with CEA.699 In the lar­
gest RCT, ACST-2, post-operative death and major stroke were similar 
(1.0%) between groups.700,701
No significant difference was found in the 5 and 10 year incidence of 
ipsilateral stroke and any stroke between CEA and CAS.696,702,703 The 
5 year non-procedural stroke rate in ACST-2 was 2.5% in each group 
for fatal/disabling stroke, and 5.3% with CAS vs. 4.5% with CEA for any 
stroke.700,701
Recommendation Table 24 — Recommendations for 
antithrombotic treatment in patients with carotid 
stenosis
Recommendations
Classa
Levelb
Carotid artery disease
In patients with symptomatic CS, not undergoing 
carotid endarterectomy or stenting, DAPT with 
low-dose aspirin and clopidogrel (75 mg) is 
recommended for the first 21 days or longer, 
followed by clopidogrel 75 mg or long-term aspirin 
to reduce the risk of stroke.667–669
I
A
In patients with asymptomatic >50% CS, long-term 
antiplatelet therapy (commonly low-dose aspirin) 
should be considered if bleeding risk is 
low.488,497,670,671
IIa
C
© ESC 2024
CS, carotid artery stenosis; DAPT, dual antiplatelet therapy. 
aClass of recommendation. 
bLevel of evidence.
Table 11 High-risk features associated with increased 
risk of stroke in patients with asymptomatic internal ca­
rotid artery stenosis on optimal medical treatment
Clinicala
Contralateral TIA/stroke681,682
Cerebral imaging
Ipsilateral silent infarction683–685
Ultrasound/CT 
imaging
Stenosis progression (>20%)340,684,685
Spontaneous embolization on transcranial Doppler 
(HITS)341,686
Impaired cerebral vascular reserve687,688
Large plaques689,690
Echolucent plaques136,691
Increased juxta-luminal black (hypoechogenic) 
area689,690
MRAb
Intraplaque haemorrhage692,693
Lipid-rich necrotic core694,695
© ESC 2024
CT, computed tomography; HITS, high-intensity transient signal; MRA, magnetic resonance 
angiography; TIA, transient ischaemic attack. 
aAge is not a predictor of poorer outcome. 
bMore than 40 mm2 on digital analysis.


<!-- PAGE 56 -->

### Page 56

Duplex ultrasound
Individual risk assessmenta
Average-to-high surgical risk
<60% carotid stenosis
60–99% carotid stenosis
100% carotid occlusion
Asymptomatic patient
OMT
(Class I)
Revascularization
 (Class III)
Revascularization
 (Class IIb)
CTA and/or MRA
 (incl. aortic arch)
CEA
or CAS/TCAR decision by vascular team based on an individual patient approach
Surgical/endovascular risk assessmenta
Routine revascularization
 (Class III)
OMT
(Class I)
Revascularization
 (Class III)
OMT
(Class I)
Vascular team 
and neurologist
N
Y
Duplex ultrasound
CTA and/or MRA
(incl. aortic arch)
<50% carotid stenosis
50–69% carotid stenosis
100% carotid occlusion
Symptomatic patient
OMT
(Class I)
Routine revascularization
 (Class III)
OMT
(Class I)
Revascularization
 (Class III)
OMT
(Class I)
Revascularization
 (Class IIa)
70–99% carotid stenosis
OMT
(Class I)
Revascularization
 (Class I)
CEA
or CAS/TCAR decision by vascular team based on an individual patient approach
Figure 18 Algorithm of carotid artery stenosis management. CAS, carotid artery stenting; CEA, carotid endarterectomy; CTA, computed tomog­
raphy angiography; MRA, magnetic resonance angiography; OMT, optimal medical treatment; TCAR, transcarotid artery revascularization; TIA, tran­
sient ischaemic attack. aAssess presence of high-risk features according to Table 11. If surgery/revascularization is considered, assess the overall risk 
related to surgery according to Table 12.
ESC Guidelines                                                                                                                                                                                          3593


<!-- PAGE 57 -->

### Page 57

The Stenting and Angioplasty with Protection in Patients at High Risk 
for Endarterectomy (SAPPHIRE) trial randomized symptomatic and 
asymptomatic patients deemed ‘high-risk for surgery’ to either CEA 
or CAS (using embolic protection devices).704 Overall, 71% of 
SAPPHIRE patients were asymptomatic, and in these patients the 30 
day rate of death/stroke after CAS was 5.8% vs. 6.1% after CEA704— 
both beyond the recommended 3%. If these procedural risk levels re­
flect contemporary practice, most ‘high-risk for surgery’ asymptomatic 
patients would be better treated medically.
A small sample size RCT has provided evidence that the use of a 
double-layer mesh stent can reduce the occurrence of peri-procedural 
diffusion-weighted imaging (DWI)-detected ischaemic lesion after ca­
rotid stents, when compared with conventional stents. At 1 year follow- 
up the use of a double-layer mesh stent was associated with a significant 
reduction in the composite endpoint of MACE and in-stent restenosis or 
occlusion. The clinical benefit of these findings has to be proven.705,706
Transcarotid artery revascularization (TCAR) has been introduced 
recently. Although no RCTs are available, large registry-based analyses 
report a 99.7% technical success rate and low 30 day complication rates 
(<3% in 30 day stroke/death and <1% MI).681
In a large-scale registry the 1 year rate of stroke or death was 6.4% 
for TCAR, 5.2% for CEA, and 9.7% for transfemoral carotid artery 
stenting (TFCAS).707
Properly conducted RCTs comparing TCAR with CEA in asymp­
tomatic patients are required to establish the true place of TCAR in ca­
rotid revascularization.708
8.2.3. Symptomatic carotid artery stenosis
8.2.3.1. Medical treatment
8.2.3.1.1. Lipid-lowering therapy. See Section 7.
8.2.3.1.2. Antihypertensive therapy. See Section 7.
8.2.3.1.3. Glucose-lowering therapy. See Section 7.
8.2.3.1.4. Antithrombotic therapy. Symptomatic CS is associated 
with a high risk of early recurrence of cerebrovascular ischaemic 
events.667–669,683 DAPT with low-dose aspirin and clopidogrel is re­
commended for all patients with symptomatic CS for at least 
3 months.669 Those undergoing surgical revascularization can stop clo­
pidogrel after surgery.711 Those undergoing endovascular revasculari­
zation should continue DAPT with clopidogrel and low-dose aspirin 
for 4 weeks after the procedure.488,666,711,712 In patients with stroke re­
lated to extracranial arterial disease, aspirin was more effective than 
VKAs in reducing recurrencies.687,713 Subgroup analysis from the 
Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or 
Ticagrelor and Patient Outcomes (SOCRATES) trial suggested a lower 
rate of MACE in patients receiving ticagrelor vs. aspirin;689 however, 
this analysis was underpowered to make any conclusions regarding 
the benefit of ticagrelor.
A combination of aspirin and clopidogrel in the early phase of symp­
tomatic carotid stenosis reduces asymptomatic cerebral embolization 
and stroke.692,694,714 It also reduces stroke recurrence after a minor 
stroke/TIA.667,668
Recently, the Acute Stroke or Transient Ischaemic Attack Treated 
with Ticagrelor and acetylsalicylic acid for Prevention of Stroke and 
Death (THALES) trial showed a 17% reduction in the risk of death 
or stroke when using ticagrelor and aspirin vs. aspirin alone in patients 
with minor stroke or high-risk TIA;715 however, bleeding events oc­
curred more frequently in the ticagrelor plus aspirin group.700,716 Of 
note, COMPASS data cannot be applied to symptomatic carotid sten­
osis since these patients were excluded because of intracranial bleeding 
risk.499
Recommendation Table 25 — Recommendations for 
interventional treatment in patients with asymptomatic 
carotid artery stenosis
Recommendations
Classa
Levelb
When ICA revascularization is considered, 
documented peri-operative stroke/death rates 
should be <3% and the patient’s life expectancy 
should be considered >5 years after careful 
consideration of the risks and benefits by a vascular 
team. 674,709
IIa
B
In ‘average surgical risk’ patients over 75 years of age 
with a CS of 60%–99%, in the presence of high-risk 
features, CEA, in addition to OMT, should be 
considered.674,709
IIa
B
In ‘high surgical risk’ patients with a CS of 60%–99%, 
in the presence of high-risk features, CAS, in addition 
to OMT, may be considered.699,701,704
IIb
B
In ‘average surgical risk’ patients with a CS of 60%– 
99%, in the presence of high-risk features, CAS, in 
addition to OMT, may be considered as an 
alternative to CEA.696,701,702,710
IIb
B
In asymptomatic patients with ICA stenosis, in the 
absence of high-risk features and with a life 
expectancy <5 years, routine revascularization is not 
recommended.674
III
A
© ESC 2024
CAS, carotid artery stenting; CEA, carotid endarterectomy; CS, carotid artery stenosis; 
ICA, internal carotid artery; OMT, optimal medical treatment. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 26 — Recommendations for 
evaluation and medical treatment in patients with 
symptomatic carotid artery stenosis
Recommendations
Classa
Levelb
DAPT is recommended in the early phase of minor 
strokes in patients with ICA stenosis, if not 
revascularized, for at least 21 days, considering the 
bleeding risk.667,668
I
A
It is recommended that symptomatic ICA stenosis 
patients are assessed by a vascular team including a 
neurologist.667,668
I
C
Long-term treatment with SAPT should be 
considered following ICA revascularization.667,668
IIa
C
DAPT may be considered in the early phase of minor 
stroke in patients with ICA stenosis for up to 90 days, 
considering the bleeding risk.667,668
IIb
B
© ESC 2024
DAPT, dual antiplatelet therapy (aspirin and clopidogrel); ICA, internal carotid artery; 
SAPT, single antiplatelet therapy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 58 -->

### Page 58

8.2.3.2. Interventional treatment
8.2.3.2.1. Open surgery. Optimal medical treatment is recommended 
for all symptomatic patients with CS. In recently symptomatic patients 
with <50% stenosis, CEA (plus OMT) did not prevent stroke. 
However, surgery reduced stroke risk in patients with moderate 
(50%–69%) and severe (70%–99%) stenosis. The benefit from surgery 
increased with increasing severity of stenosis, except for ‘near- 
occlusion’ lesions (95%–99% stenosis with distal ICA collapse or a nar­
row calibre lumen with ‘trickle flow’).660,717–720
Some features are associated with a higher increase of stroke in symp­
tomatic patients (50%–99% stenosis) medically treated: age (>75 years), 
symptoms within 14 days, male sex, hemispheric (vs. retinal) symptoms, 
cortical (vs. lacunar) stroke, increasing comorbidities, irregular stenosis, 
stenosis severity, contralateral occlusion, tandem intracranial stenosis, 
and failure to recruit intracranial collaterals.721
Large-scale registries suggest that CEA can be performed safely in 
the first 7 days after TIA/minor stroke.722–724 However, not all patients 
benefit from urgent revascularization, and controversy exists over the 
safety of performing CEA within the first 48 h after symptom onset due 
to an increased risk of haemorrhagic transformation. Higher-risk pa­
tients include those with acute carotid occlusion, a persisting major 
neurological deficit, an area of middle cerebral artery infarction exceed­
ing one-third, evidence of pre-existing parenchymal haemorrhage, and 
signs of impaired consciousness.724,725
The choice to perform carotid revascularization within 48 h from 
symptom onset is still debatable.726
8.2.3.2.2. Endovascular therapy vs. open surgery. Contemporary 
RCTs comparing CEA with CAS in symptomatic patients reported a 
significantly higher risk of 30 day ‘any stroke’ and ‘death/stroke’ follow­
ing CAS. This is mainly due to higher rates of minor stroke, which were 
non-disabling and resolved within 6 months.711,727
However, the occurrence of a peri-operative stroke is associated 
with three-fold poorer long-term survival,727 similar to a post- 
procedural MI (which was more frequent after CEA).728
In CAS patients, the risk increased in those aged >60 years, especially 
for those aged >80 years, who are four times more likely to experience 
a procedural stroke/death. When comparing CAS with CEA, the 
age-related effect became apparent in patients aged 60–65 years, and 
CEA is superior to CAS in patients aged >70 years.729,730
Elderly CAS patients may experience more peri-operative strokes, 
mainly minor ipsilateral strokes, possibly due to a higher burden of aor­
tic arch disease. In these cases, operator/institution experience may 
play a role in determining peri-procedural outcomes. CAS is associated 
with significantly lower risks for MI, transient cranial nerve injury, and 
haematoma.731,732
Beyond the 30 day peri-operative period, long-term data suggest that 
outcomes after CAS are similar to those with CEA.703,733 The pre­
dicted magnitude of 30 day risk (according to clinical/anatomical char­
acteristics and operator/centre experience) will thus largely 
determine whether CEA or CAS is preferable in individual patients.
Post-hoc trial analysis revealed enhanced benefits of CEA when per­
formed within 2 weeks of the ischaemic event,734 with reduced compli­
cations compared with CAS performed within 1 week of stroke/TIA. 
The Carotid Stenosis Trialists’ Collaboration found a higher stroke/ 
death rate (8.3% with CAS vs. 1.3% with CEA) for CAS in patients trea­
ted within 1 week of the last symptomatic event.735 These findings sup­
port a preference for early CEA in symptomatic patients. However, 
these trials, initiated over 30 years ago, lack evaluation of current 
OMT. Initially designed as an alternative for high surgical risk (HSR) pa­
tients,704,736 carotid stenting’s efficacy needs consideration in contem­
porary practice (Table 12).735
In conclusion, CEA is still the treatment choice for patients with 
symptomatic carotid stenosis. However, in patients eligible for ca­
rotid revascularization but deemed high surgical risk by a multidiscli­
plinary team, CAS may be preferred over CEA—the patient must be 
a suitable candidate for CAS, and the complication rate should not 
surpass 6%.
At present, TCAR results have been analysed in registries only. In 
these studies, in-hospital stroke/death has been significantly lower after 
TCAR compared with transfemoral CAS.707,737 Similar to the previous 
results established for CEA, symptomatic patients undergoing TCAR 
demonstrate similar outcomes if the procedure is performed >48 h 
after the neurological event.738 However, TCAR has not yet been eval­
uated in RCTs and has not been compared with CEA or OMT.
8.2.3.2.3. Vertebral arteries. The evidence on the use of lifestyle 
modifications and medical therapy in cases of symptomatic vertebral ar­
tery stenosis is lacking, but their use is reasonable given the overall CV 
risk in these patients.
Evidence on the use of preventive strategies and antithrombotic 
agents is lacking, but their use is reasonable in the presence of other 
CVRFs.
Surgery on extracranial vertebral stenosis (with transposition to CCA, 
trans-subclavian vertebral endarterectomy, distal venous bypass) can be 
performed with low stroke/death rates in experienced centres.739,740
However, with limited expertise in complex vertebral artery reconstruc­
tions, open surgery has been mostly replaced by endovascular interventions.
In a combined analysis of the the Vertebral Artery Ischaemia Stenting 
Trial (VIST), the Vertebral Artery Stenting Trial (VAST), and the 
Stenting and Aggressive Medical Management for Preventing 
Table 12 High-risk peri-operative features for carotid 
endarterectomy
Clinical
Congestive heart failure (NYHA functional class III/IV)
Unstable angina (CCS III/IV)
CAD with LM or >1 vessel with 70% stenosis
Recent MI (<30 days)
Planned open heart surgery (<30 days)
LVEF <30%
Severe pulmonary disease
Severe renal disease
Anatomical
Surgically inaccessible lesions 
• At or above C2
• Below the clavicle
Ipsilateral neck irradiation
Spinal immobility of the neck
Contralateral carotid artery occlusion (increases risk for stroke)
Contralateral laryngeal palsy
Tracheostomy
© ESC 2024
CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; LM, left main; LVEF, 
left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart 
Association.
ESC Guidelines                                                                                                                                                                                          3595


<!-- PAGE 59 -->

### Page 59

Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial,741 no clear 
benefit was shown for extracranial vertebral artery stenting.
Randomized controlled trials have not assessed surgical techniques 
like vertebral artery endarterectomy or transposition. While case ser­
ies exist, they often lack a control group following a consistent medical 
treatment protocol.742 As a result, the effectiveness of these proce­
dures remains uncertain.
8.2.3.3. Follow-up
Peri-operative and post-procedural medical management after carotid 
revascularization should include OMT. Post-operative hypertension is a 
risk factor for stroke and TIAs, wound bleeding, and intracranial haem­
orrhage.743 Therefore, proper pharmacological BP control is important 
in optimizing outcomes.744
Fluctuations of hypertension and hypotension are not uncommon 
and should be treated promptly.744,745
An intensive lipid-lowering therapy (ILT) aiming at >50% LDL-C re­
duction and LDL-C <1.4 mmol/L (55 mg/dL) is also recommended.19
Antiplatelet therapy should be tailored according to type of interven­
tion. In CEA, the reduction in peri-procedural and long-term ischaemic 
events under low-dose aspirin has been demonstrated.746,747 After ca­
rotid stenting, DAPT (aspirin and clopidogrel) is recommended, while 
optimal duration is debated.748 In the peri-operative period after 
CAS, DAPT should be prescribed and continued for at least 30 days 
post-procedure.77,749,750 Ticagrelor, when included in DAPT following 
CAS/TCAR, presents a drawback due to its elevated bleeding risk com­
pared with clopidogrel.751–753
Duplex ultrasound is the first-line technique to evaluate patients 
after CEA or CAS. CTA and MRA are alternative methods for deter­
mining restenosis.749,754
After CEA or CAS, DUS is recommended at baseline (<3 months) 
and annually thereafter until the patient is stable (i.e. until no restenosis 
is observed in two consecutive annual scans). Regular surveillance (e.g. 
every 2 years) can be performed based on the stenosis of the contra­
lateral ICA, risk profile, and patient’s life expectancy.749,754
For patients combining multiple CVRFs after the procedure, DUS 
may be beneficial every 6 months until a stable clinical pattern is estab­
lished, and annually thereafter.749,754
Early surveillance, especially within 1–3 months and particularly in 
cases where intraoperative completion imaging is absent (e.g. after 
CEA), aids in detecting technical errors and setting a baseline for future 
comparisons.
Follow-up enables the identification of ipsilateral carotid restenosis 
and contralateral disease progression, offering a chance for timely inter­
vention to minimize the risk of stroke. Nevertheless, this concept is fa­
cing growing challenges due to a reduced and selective role for 
intervention in asymptomatic patients. A surveillance protocol holds 
significance when anticipated outcomes are expected to cost- 
effectively influence a medical or interventional treatment plan.749,754
8.3. Other arterial locations
8.3.1. Subclavian artery disease
8.3.1.1. Clinical presentation and diagnosis
Atherosclerotic upper-limb artery disease (UEAD) is most frequently 
located in the subclavian artery.755,756 Digital ischaemia is most fre­
quently caused by non-atherosclerotic aetiologies, including thrombo- 
embolism, systemic sclerosis, idiopathic, thromboangiitis obliterans, 
iatrogenic, or cancer.757 Isolated subclavian stenosis (SS) is often 
asymptomatic and may be suspected because of an absolute inter-arm 
SBP difference >10–15 mmHg.758 In the Multi-Ethnic Study of 
Atherosclerosis (MESA), prevalence of asymptomatic SS was approxi­
mately 4.5% (male: 5.1%, female: 3.9%) in adults and more frequent in 
patients with PAD (11.4%).759 In patients attending CV clinics, a 
Recommendation Table 27 — Recommendations for 
interventions in patients with symptomatic carotid 
artery stenosis
Recommendations
Classa
Levelb
It is recommended to perform CEA of symptomatic 
70%–99% ICA stenosis provided a documented 30 
day risk of procedural death/stroke is <6%.660,719
I
A
If indicated, it is recommended to perform CEA 
within 14 days in symptomatic ICA stenosis 
patients.734
I
B
OMT is recommended for all symptomatic ICA 
stenosis patients.19
I
A
CEA of symptomatic 50%–69% ICA stenosis should 
be considered provided a documented 30 day risk of 
procedural death/stroke is <6%.660,719
IIa
A
For symptomatic patients at high risk for CEA with a 
70%–99% ICA stenosis, CAS should be considered 
provided a documented 30 day risk of procedural 
death/stroke is <6%.703
IIa
B
For symptomatic patients <70 years of age with a 
70%–99% ICA stenosis, CAS may be considered 
provided a documented 30 day risk of procedural 
death/stroke is <6%.703
IIb
A
Revascularization is not recommended in patients 
with ICA lesions <50%.660,719
III
A
© ESC 2024
CAS, carotid artery stenting; CEA, carotid endarterectomy; ICA, internal carotid artery; 
OMT, optimal medical treatment. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 28 — Recommendations for 
follow-up in patients with carotid artery stenosis
Recommendations
Classa
Levelb
Once-yearly follow-up is recommended to check for 
CVRFs and treatment compliance.754
I
A
After ICA stent implantation, DAPT with aspirin and 
clopidogrel is recommended for at least 1 
month.77,749,750
I
A
After ICA revascularization, long-term aspirin or 
clopidogrel is recommended.746,747
I
B
During follow-up, it is recommended to assess 
neurological symptoms, CVRFs, and treatment 
adherence at least yearly in patients with CS.754
I
C
After ICA revascularization, surveillance with DUS is 
recommended within the first month.749,754
I
C
© ESC 2024
CS, carotid artery stenosis; CVRFs, cardiovascular risk factors; DAPT, dual antiplatelet 
therapy; DUS, duplex ultrasound; ICA, internal carotid artery. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 60 -->

### Page 60

>25 mmHg SBP difference doubles prevalence and independently pre­
dicts mortality.32,758 As obstructive disease progresses, particularly af­
fecting vertebral vessels, the risk of ischaemia or steal symptoms 
significantly rises. Visual disturbances, syncope, ataxia, vertigo, dyspha­
sia, dysarthria, and facial sensory deficits during arm movements may 
indicate subclavian steal syndrome, correlating with inter-arm BP differ­
ence.760 Brachiocephalic occlusive disease can lead to stroke or TIA in 
carotid and vertebral territories, manifesting as exercise-induced fa­
tigue, pain, and arm claudication. Severe cases, especially with distal dis­
ease, may result in rest pain and digital ischaemia with necrosis.
Duplex ultrasound assessment of subclavian arteries enables the de­
tection of SS via intrastenotic high-velocity flows (50% stenosis: peak 
systolic velocity [PSV] ≥230 cm/s, PSV ratio [PSVr] ≥2.2; 70% stenosis 
PSV ≥340 cm/s and PSVr ≥3.0) or monophasic post-stenotic wave­
forms.761 The majority of patients (>90%) with at least 50% proximal 
SS have either intermittent or continuous flow reversal in the vertebral 
artery, though not all will be symptomatic.760,762 When subclavian steal 
syndrome is suspected, flow reversal should be assessed in the ipsilat­
eral extracranial vertebral artery by hyperaemia testing and if available 
transcranial Doppler.762 Severe stenosis or occlusion of the right bra­
chiocephalic trunk is associated with reduced flow velocities in the ip­
silateral subclavian artery and the CCA. Abnormal or doubtful DUS 
should lead to anatomic imaging (CTA/MRA).763 CTA is excellent for 
supra-aortic lesions and can provide extravascular information, espe­
cially when thoracic outlet syndrome is a differential diagnosis. MRA 
provides both functional and morphological information useful to dis­
tinguish antegrade from retrograde perfusion and to estimate stenosis 
severity.764 DSA is performed if endovascular therapy is indicated. PET 
is useful for the diagnosis of arteritis but not for assessment of athero­
sclerotic lesions in clinical practice.
8.3.1.2. Treatment strategy (medical and interventional)
Optimal medical treatment is recommended in all patients with symptom­
atic UEAD to reduce CV risk.32 Revascularization is indicated in symptom­
atic patients with TIA/stroke, coronary subclavian steal syndrome, 
ipsilateral haemodialysis access dysfunction, or impaired HRQoL. 
Revascularization should be considered in asymptomatic patients with 
planned coronary artery bypass grafting (CABG) using the internal mam­
mary artery and those with ipsilateral haemodialysis access, as well as 
asymptomatic patients with significant bilateral SS/occlusion for adequate 
BP surveillance. For revascularization, both endovascular and surgical pro­
cedures are available. There are no RCTs comparing endovascular vs. open 
repair but individual studies, including the Danish Vascular Registry, indicate 
similar long-term symptom resolution but higher general complication 
rates and hospital length of stay for open surgery.765 The risk of severe 
complications, including vertebrobasilar stroke, is low with both ap­
proaches. The post-procedural stroke rate is reported at 1.3% for endo­
vascular therapy765 and 0.9%–2.4% after open surgery.765–767
Percutaneous angioplasty for subclavian arterial stenosis is often used 
with stenting. There is no conclusive evidence to determine whether 
stenting is more effective than balloon angioplasty.768 Similar results 
were reported for endovascular therapy of the innominate artery.769
In heavily calcified ostial lesions, balloon-expandable stents give more ra­
dial force than nitinol stents. An endovascular approach is often the de­
fault strategy. However, in selected patients with low operative risk, 
with subclavian artery occlusion or after endovascular therapy failure, 
surgical subclavian–carotid transposition is safe with excellent long-term 
patency results (5 year patency 96%).766 Carotid–subclavian bypass sur­
gery with a prosthetic graft showed long-term benefit with low opera­
tive mortality and morbidity, especially in patients with extensive disease 
or re-occlusion after stenting (5 year patency 97%).770 Other options 
are extrathoracic extra-anatomic bypass procedures (axillo-axillary, ca­
rotid–axillary, or carotid–carotid bypass);771,772 however, axillo-axillary 
bypasses may occlude at 1 year in 14% of cases.773 The transthoracic ap­
proach is an option in patients with multivessel disease involving the aor­
tic arch and several supra-aortic vessels.767
While critical hand ischaemia owing to below-the-elbow atherosclerot­
ic occlusive disease is relatively uncommon, interventions are associated 
with a high rate of success, major amputations are rare, and many can 
be treated non-operatively.756 In appropriately selected patients, both en­
dovascular and open interventions have a high rate of success.755,756
In symptomatic patients with contraindications for endovascular ther­
apy or open surgery, prostanoid infusion or thoracic sympathectomy 
may be considered.774
8.3.1.3. Follow-up
Patients with UEAD should be followed up to ensure optimal CV 
prevention. Tighter follow-up is required in symptomatic patients to re- 
assess indication for revascularization as a large proportion of symptoms 
resolve spontaneously.775 After revascularization, patients should be fol­
lowed up to allow early detection and treatment of impending late proced­
ural failure.
Recommendation Table 29 — Recommendations for 
the management of subclavian artery stenosis (see also 
Evidence Table 9)
Recommendations
Classa
Levelb
Bilateral arm BP measurement is recommended for 
all patients with PAAD.32,758
I
B
In symptomatic patients with atherosclerotic 
subclavian artery disease (TIA/stroke, coronary 
subclavian steal syndrome, ipsilateral haemodialysis 
access dysfunction, severe ischaemia), both 
revascularization options (endovascular ± stenting 
or surgery) should be considered and discussed case 
by case by a vascular team.776
IIa
B
Endovascular revascularization may be considered 
over surgery, despite similar long-term outcomes, 
due to lower complication rates.765
IIb
B
In patients with atherosclerotic subclavian artery disease, 
revascularization:
Should be considered in cases of proximal stenosis in 
patients undergoing CABG using the ipsilateral 
internal mammary artery.777–781
IIa
C
Should be considered in cases of proximal stenosis in 
patients who already have the ipsilateral internal 
mammary artery grafted to coronary arteries with 
evidence of myocardial ischaemia.777,778,780
IIa
C
Should be considered in cases of ipsilateral 
haemodialysis arteriovenous access.778
IIa
C
Routine revascularization in patients with 
atherosclerotic subclavian artery disease is not 
recommended.776
III
C
© ESC 2024
BP, blood pressure; CABG, coronary artery bypass grafting; PAAD, peripheral arterial and 
aortic diseases; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3597


<!-- PAGE 61 -->

### Page 61

8.3.2. Renal artery disease
8.3.2.1. Clinical presentation and diagnosis
8.3.2.1.1. Epidemiology. In >90% of cases, RAS is caused by athero­
sclerosis and typically involves the ostial renal arterial segment 
(Table 13).782 Above 65 years of age, overall prevalence of ≥60% RAS 
is 6.8%, with a higher prevalence in men (9.1%) than in women 
(5.5%).783 In patients with PAD, RAS prevalence ranges between 7% 
and 42%, influenced by diagnostic criteria.784
8.3.2.1.2. Clinical presentation. Clinical presentation comprises reno­
vascular hypertension, renal function impairment and eventually, flash pul­
monary oedema (Table 13). RAS reduces the filtration capacity of the 
affected kidney, which activates the renin–angiotensin–aldosterone path­
way, potentially resulting in renovascular hypertension.782,785 In unilateral 
RAS, the functioning contralateral kidney may increase sodium excretion 
to prevent sodium retention and volume overload. In high-grade bilateral 
RAS or in unilateral RAS without a functioning second kidney, the risk of 
cardiorenal deterioration is higher than in unilateral disease.786
8.3.2.1.3. Diagnosis of renal artery disease. First diagnostic steps in­
clude laboratory tests to examine renal function, analysis of office and 
out-of-office BP recordings (ambulatory BP monitoring or home BP 
monitoring, as recommended by [upcoming] ESC/European Society 
of Hypertension [ESH] Guidelines for arterial hypertension), and non- 
invasive haemodynamic assessment of renal arteries by DUS.787
Renal artery PSV >200 cm/s measured by DUS allows the diagnosis of 
a >50% RAS (sensitivity 95%, specificity 90%).788 A renal-aortic peak flow 
velocity ratio (RAR = renal artery PSV/aortic PSV) >3.5 has 84%–91% 
sensitivity and 95%–97% specificity for the detection of ≥60% RAS.789
A side-to-side difference of the intrarenal resistance index ≥0.5 between 
both kidneys may serve as an additional haemodynamic criterion for 
haemodynamically relevant RAS.787,790 Other DUS criteria (acceleration 
time, acceleration index) have lower diagnostic accuracy.791
Sensitivity and specificity of contrast-enhanced MRA in the diagnosis 
of RAS is 88% and 100%, respectively;789 however, MRA overestimates 
the degree of RAS by 26%–32%.789 The advantages of MRA are the 
possibility of assessing renal parenchymal blood flow and freedom 
from radiation and iodinated contrast agents.
Spiral multidetector CTA allows renal artery diameter measure­
ments and provides information on vessel wall calcification and mural 
plaques. RAS diagnosis by CTA presents 64%–100% sensitivity and 
92%–98% specificity.789 CTA drawbacks include radiation exposure, 
the need for contrast media in patients with impaired renal function, 
and limited haemodynamic assessment of RAS.
Catheter angiography is the gold standard for diagnosing RAS, enab­
ling additional haemodynamic measures (Figure 19).792 Considering the 
potential risks of invasive procedures, DUS and other non-invasive mo­
dalities (CTA or MRA) should precede catheter angiography and inva­
sive haemodynamic measurements (Figure 19).
Renal scintigraphy, plasma renin measurements before and after 
ACEI provocation, and venous renin measurements are not considered 
for RAS evaluation.
8.3.2.1.4. Prognosis. Atherosclerotic RAS progresses with respect to 
the degree of stenosis, while total renal artery occlusions occur less 
frequently.793 The presence of significant RAS is a strong predictor for 
mortality794 and renovascular disease is an important risk factor for the 
development of end-stage renal disease (ESRD).795 The risk of RAS- 
related ESRD is higher in men than in women and increases with age.795
8.3.2.2. Treatment strategy (medical and interventional)
8.3.2.2.1. Medical therapy. Optimal medical treatment is recom­
mended in RAS patients.785 Data on antithrombotic therapy in patients 
with atherosclerotic RAS are scarce and retrospective.796 However, 
the use of an antiplatelet agent is reasonable in atherosclerotic RAS.
No prospective study has specifically examined antithrombotic ther­
apy post-RAS stenting, and information from existing RAS stenting 
trials is limited.797 Following the antithrombotic treatment approach 
in non-coronary arterial beds, it is suggested to use DAPT for at least 
1 month after RAS stent implantation.666
8.3.2.2.2. Revascularization. Revascularization in atherosclerotic RAS
Prospective RCTs comparing endovascular revascularization with 
OMT in atherosclerotic RAS favoured renal artery stenting over bal­
loon angioplasty.792
However, renal artery stenting showed no superiority over OMT in 
reducing BP, CV events, renal events, or mortality in unilateral athero­
sclerotic RAS.788,798,799 A trial suggested a potential benefit of renal ar­
tery angioplasty for BP in bilateral RAS, but subsequent RCTs did not 
confirm this.800–802 Data on the benefit of renal artery stenting in spar­
ing antihypertensive drugs are inconsistent.324,800,801,803,804
In specific circumstances or RAS aetiologies, revascularization should 
be considered (Figure 19). Open surgical renal artery revascularization 
appears comparable to endovascular treatment regarding BP and renal 
function.805,806 Thus, open surgery can be an alternative approach in 
cases with a revascularization indication and complex anatomy or failed 
endovascular repair.
Table 13 Clinical signs suggestive of renal artery 
disease
Hypertension onset before 30 years of age
Severe hypertension after the age of 55 years, when associated with CKD or 
heart failure
Hypertension and abdominal bruit
Rapid and persistent worsening of previously controlled hypertension
Resistant hypertension 
• Three antihypertensive drugs including a diuretic agent 
or
• ≥4 antihypertensive drugs 
and
• Other secondary form unlikely
Hypertensive crisis (i.e. acute renal failure, acute heart failure, hypertensive 
encephalopathy, or grade 3–4 retinopathy)
New azotaemia or worsening of renal function after treatment with RAAS 
blockers
Unexplained atrophic kidney or discrepancy in kidney size, or unexplained 
renal failure
Flash pulmonary oedema
© ESC 2024
CKD, chronic kidney disease; RAAS, renin–angiotensin–aldosterone system.


<!-- PAGE 62 -->

### Page 62

N
N
N
N
N
N
Patient with suspicion of RAS
Duplex ultrasound
Renal artery revascularization
(Class III)
Diagnostic
Kidney viablea
Catheter-based angiography
>70% RAS or haemodynamically relevant 50–70% RASc
Evaluation of high-risk
 features after confirmed OMTb
Presence of high-risk featuresb
Kidney viablea
Kidney viablea
No RAS
RAS exclusion
RAS exclusion
PSV ≥200 cm/s (>50% RAS), RAR >3.5 (≥60%)
 side-to-side difference of intrarenal resistance index ≥0.5
Morphologically significant RAS
Bilateral high-grade atherosclerotic
 RAS (>70%)
Non-atherosclerotic RAS and
 special populations
Unilateral atherosclerotic
 RAS (>70%)
Inconclusive DUS or 
suspicion of haemodynamically significant RAS
MRA/CTA
(Class I)
OMT
 (Class I)
OMT
 (Class I)
Renal artery revascularization
(Class III)
Renal artery revascularization
(Class IIa)
OMT
 (Class I)
Y
Y
Y
Y
Y
Y
Figure 19 Diagnostic and treatment algorithm for renal artery stenosis. CTA, computed tomography angiography; MRA, magnetic resonance angi­
ography; OMT, optimal medical treatment; Pd/Pa, distal coronary pressure to aortic pressure ratio; PSV, peak systolic velocity; RAR, renal-aortic peak 
flow velocity ratio; RAS, renal artery stenosis.  
asee table below   
aKidney viability in RAS
Signs of viability
Signs of non-viability
Renal size
>8 cm
<7 cm
Renal cortex
Distinct cortex (>0.5 cm)
Loss of corticomedullar differentiation
Proteinuria
Albumin-creatinine ratio <20 mg/mmol
Albumin-creatinine ratio >30 mg/mmol
Renal resistance index
<0.8
>0.8
© ESC 2024
bRapidly progressive, treatment-resistant arterial hypertension; rapidly declining renal function; flash pulmonary oedema; solitary kidney. 
cResting mean pressure gradient >10 mmHg; systolic hyperaemic pressure gradient >20 mmHg; renal PdPa ≤ 0.9 (or 0.8).
ESC Guidelines                                                                                                                                                                                          3599


<!-- PAGE 63 -->

### Page 63

8.3.2.3. Follow-up
Following the diagnosis of significant RAS and the implementation of 
OMT and/or renal artery revascularization, regular follow-up exams 
are crucial. Monitoring should encompass laboratory tests to assess re­
nal function, analysis of office and out-of-office BP recordings (ambula­
tory or home BP monitoring per upcoming ESC/ESH Guidelines for 
arterial hypertension), and renal artery DUS. DUS, comprising renal 
PSV, RAR, side-to-side difference of the resistance index, and kidney 
size, is the preferred imaging modality during follow-up.787
In conservatively managed RAS patients, follow-up assessment 
should re-evaluate potential indications for renal artery revasculariza­
tion (Figure 19).
After renal artery stenting, the initial follow-up is recommended at 1 
month and subsequently every 12 months or when new signs or symp­
toms arise.807 Re-intervention may be considered for in-stent resten­
osis ≥60% detected by DUS, recurrent signs and symptoms (diastolic 
BP >90 mmHg on >3 antihypertensive drugs, or a >20% increase in 
serum creatinine).787,808
8.3.3. Visceral artery disease
8.3.3.1. Acute mesenteric ischaemia
Acute mesenteric ischaemia can be caused by arterial embolism or 
thrombosis in situ, non-occlusive mesenteric ischaemia (usually due 
to superior mesenteric artery [SMA] vasoconstriction), and venous 
thrombosis. In recent decades, embolism decreased from 46% to 
35%, while arterial thrombosis increased from 20% to 35%.815–817
Acute thrombo-embolic occlusion most frequently affects the SMA. 
Due to extensive collaterals, it infrequently leads to intestinal infarction.
8.3.3.1.1. Clinical presentation and diagnosis. Clinical examination
Early diagnosis of AMI is based on high clinical suspicion. Embolic AMI 
typically manifests as sudden onset intense abdominal pain, accompan­
ied by minimal physical findings, bowel emptying (vomiting, diarrhoea), 
and a common embolic source (primarily AF).818–820 Emboli may also 
lodge in other locations, aiding diagnosis. Acute arterial thrombosis 
tends to occur in areas with pre-existing atherosclerotic disease, result­
ing in a less dramatic clinical presentation. Patients may have previous 
symptoms of chronic mesenteric ischaemia (CMI) or other atheroscler­
otic manifestations.821
Laboratory tests are unreliable for the diagnosis of AMI, although ele­
vated levels of l-lactate, leucocytosis, and D-dimer (DD) may exist.822–825
Imaging
Computed tomography angiography is the gold standard for diagno­
sis,826,827 allowing the detection of thrombi and/or emboli in the SMA 
trunk or its branches together with the recognition of intestinal ischae­
mic signs. A plain abdominal X-ray lacks specificity. A normal result does 
not rule out the diagnosis.828
8.3.3.1.2. Treatment strategy. Most patients require immediate re­
vascularization to survive. There are no RCTs comparing surgical vs. en­
dovascular intervention in AMI. Two meta-analyses found endovascular 
revascularization to be superior to surgical intervention in terms of in- 
hospital mortality and rates of bowel resection.829,830 An open surgical 
approach is most appropriate in centres where endovascular interven­
tions are less available and in patients with peritonitis.831 Retrograde 
open mesenteric stenting (ROMS) is an alternative that offers shorter 
operative time; the SMA is punctured in the open abdomen, followed 
by stenting.832
Recommendation Table 30 — Recommendations for 
diagnostic strategies for renal artery disease
Recommendations
Classa
Levelb
DUS is recommended as the first-line imaging 
modality in patients with suspicion of RAS.787,789–791
I
B
In cases of DUS-based suspicion of RAS or 
inconclusive DUS, MRA, or CTA are 
recommended.789,791
I
B
In patients with atherosclerotic RAS, it is 
recommended to assess clinical high-risk features and 
kidney viability when evaluating renal artery 
revascularization.809,810
I
B
© ESC 2024
CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic 
resonance angiography; RAS, renal artery stenosis. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 31 — Recommendations for 
treatment strategies for renal artery disease (see also 
Evidence Table 10)
Recommendations
Classa
Levelb
Medical therapy
In patients with atherosclerotic RAS the use of 
low-dose aspirin may be considered.811
IIb
C
Revascularization
In patients with atherosclerotic unilateral >70% RAS, 
concomitant high-risk features, and signs of kidney 
viability, renal artery revascularization should be 
considered after OMT has been 
established.798,809,810
IIa
B
In patients with atherosclerotic bilateral (>70%) RAS 
or RAS in a solitary kidney, concomitant high risk 
features, and signs of kidney viability, renal artery 
revascularization should be considered.800–802
IIa
B
Continued 
In patients with hypertension and/or signs of renal 
dysfunction due to RAS caused by fibromuscular 
dysplasia, concomitant high-risk features, and signs of 
kidney viability, revascularization with primary 
balloon angioplasty and bailout stenting should be 
considered.812,813
IIa
B
In patients with an indication for renal artery 
revascularization and complex anatomy, or after 
failed endovascular revascularization, open surgical 
revascularization should be considered.805,806
IIa
B
In patients with atherosclerotic unilateral RAS, 
routine revascularization is not 
recommended.324,800–804,814
III
A
© ESC 2024
RAS, renal artery stenosis. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 64 -->

### Page 64

8.3.3.1.3. Follow-up. Most patients treated for AMI require lifelong 
anticoagulant/antiplatelet therapy to prevent recurrence. Patients 
undergoing revascularization should have surveillance with CTA or 
DUS within 6 months,833 as recurrent AMI after mesenteric revascular­
ization accounts for 6%–8% of late deaths.834 Current Society for 
Vascular Surgery (SVS) Guidelines recommend DUS at 1, 6, and 12 
months after the intervention, and then annually thereafter.754
8.3.3.2. Chronic mesenteric artery disease
Occlusive CMI is mostly caused by atherosclerosis and more frequently 
affects females (65%–72%).835,836 Symptoms typically manifest when at 
least two mesenteric vessels are involved due to extensive collaterals. 
Prevalence of asymptomatic coeliac artery and/or SMA stenosis is 3% 
in patients under 65 years of age and 18% in those aged >65.837
However, inadequate anastomoses can result in symptomatic ischae­
mia even with a single-vessel atherosclerotic occlusion.838,839
8.3.3.2.1. Clinical presentation and diagnosis. Clinical examination
Like AMI, early diagnosis of CMI relies on clinical suspicion. Classic 
symptoms include post-prandial abdominal pain, weight loss, and 
gastrointestinal disturbances like diarrhoea or constipation. Patients 
may develop food aversion to avoid pain, but their appetite remains 
Patient with suspected CMI
Exclude other causes
Diagnosis
Functional test
Confirmed
Isolated CA or SMA stenosis
No stenosis
Chronic NOMI
MALS
Atherosclerosis
Multidisciplinary meeting for consensus treatment
Endovascular or 
surgical revascularization
Secondary prevention 
of atherosclerosis
Therapy of underlying condition
Multi-vessel stenosis
CTA
(Class I)
Figure 20 Algorithm of chronic mesenteric ischaemia management. CA, coeliac artery; CMI, chronic mesenteric ischaemia; CTA, computed tom­
ography angiography; MALS, median arcuate ligament syndrome; NOMI, non-occlusive mesenteric ischaemia; SMA, superior mesenteric artery.
ESC Guidelines                                                                                                                                                                                          3601


<!-- PAGE 65 -->

### Page 65

unaffected, distinguishing them from individuals with malignancies. An 
abdominal examination might reveal a bruit.
Lactate, lactate dehydrogenase, and/or leucocyte count are unhelpful 
in CMI diagnosis.840,841 Functional testing (tonometry, visible light spec­
troscopy) is applicable in patients with symptomatic mesenteric sten­
osis and single-vessel disease.842
Imaging
Duplex ultrasound is valuable due to its low costs, absence of the 
need for contrast agents, and no radiation. However, skilled investiga­
tors in specialized centres are required for the examination. Despite 
suggested diagnostic criteria, consensus is lacking.843,844 Anatomical 
mapping for treatment planning typically involves CTA or MRA, 
845,846 with DSA reserved only for therapeutic purposes (Figure 20).
8.3.3.2.2. Treatment strategy. Optimal medical treatment is the basis 
of CMI management. Prophylactic revascularization is not recom­
mended for asymptomatic CMI. In symptomatic cases, a meta-analysis 
favoured endovascular over open surgery due to fewer complications 
and a trend towards lower 30 day mortality.835 However, open surgery 
showed superior long-term results, with fewer symptom recurrences 
and higher 1 and 5 year primary patency rates in two additional 
meta-analyses.847,848 Despite the growing use of endovascular therapy, 
open surgery remains indicated after failed endovascular therapy with­
out the option for repeat intervention, and in cases with extensive oc­
clusions, calcifications, or technical challenges.
8.3.3.2.3. Follow-up. Following CMI revascularization, lifelong medical 
treatment, including lifestyle changes and OMT for atherosclerosis, is 
recommended. SVS guidelines propose mesenteric DUS surveillance 
for recurrent stenosis. A potential follow-up schedule involves controls 
within 1 month post-procedure, biannually for the first 2 years, and an­
nually thereafter.849
9. Aorta
9.1. Atheromatous disease of the aorta
9.1.1. General concepts
Atheromatous disease of the aorta has an estimated incidence of 
40%–51.3%, being complicated in 7.6% of cases.850–853 Earlier stages of ath­
erosclerosis, presenting as plaque inflammation, can be present in 48% of 
asymptomatic individuals.850 Atherosclerotic plaque classification is based 
on plaque thickness and the presence of ulceration or mobile components 
(Table 14).159,171,854 This classification is crucial because severe or complex 
atherosclerotic plaques in the aortic arch or ascending aorta are strongly 
linked to cerebrovascular events (odds ratio [OR] 4–9.1 for plaques 
≥4 mm).855–860 Additionally, the annual incidence of stroke recurrence re­
mains high (up to 16%) despite antiplatelet or anticoagulant therapy.855,861
9.1.2. Treatment
9.1.2.1. Primary prevention
Asymptomatic non-severe/non-complex aortic plaques (Table 14) should 
not mandate antiplatelet therapy. Nonetheless, in severe/complex plaques, 
statins should be indicated to decrease plaque progression or CV 
events,862 and SAPT with clopidogrel or low-dose aspirin should be con­
sidered after risk/benefit evaluation.493,666,861,863 However, in this scenario, 
anticoagulation861 or DAPT (low-dose aspirin and clopidogrel) are not in­
dicated.666,863 Floating aortic thrombi and complex mobile plaques are 
rare, with limited large-scale trials on their management. Guidance relies 
on case reports, observational studies, and expert opinions, yet there is evi­
dence favouring anticoagulation, particularly for symptomatic cases.864
9.1.2.2. Secondary prevention
Secondary prevention with antiplatelet therapy after an embolic event is 
recommended to prevent recurrences.666,865,866 While the value of 
DAPT vs. SAPT remains uncertain, recent studies indicate that prolonged 
DAPT raises bleeding risk without added antithrombotic bene­
fits.667,863,867 Treatment duration is unclear and must strike a balance be­
tween early benefit (notably within 7 days post-emboli) and steady 
bleeding risk. Statins (LDL target below 1.4 mmol/L [55 mg/dL]) prove ef­
fective in preventing strokes regardless of the aetiology.862,865,868
Additionally, a healthy lifestyle is crucial for improving CV health and redu­
cing complications.
Recommendation Table 32 — Recommendations in 
patients with visceral artery stenosis
Recommendations
Classa
Levelb
In patients with acute mesenteric ischaemia due to 
acute occlusion of the SMA, endovascular 
revascularization is recommended.829–831
I
B
In patients with suspected acute or chronic 
mesenteric ischaemia, CTA is 
recommended.826,827,845,846
I
C
In patients with acute or chronic mesenteric 
ischaemia, assessment by a vascular team is 
recommended.
I
C
Revascularization of asymptomatic atherosclerotic 
visceral artery stenosis is not recommended.
III
C
© ESC 2024
CTA, computed tomography angiography; SMA, superior mesenteric artery. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 33 — Recommendations for 
primary and secondary prevention in aortic atheroma­
tous plaques
Recommendations
Classa
Levelb
Primary prevention
In patients with severe/complex aortic atheromatous 
plaques, statins should be considered to decrease 
progression and risk of CV events.862
IIa
C
SAPT with clopidogrel or low-dose aspirin should be 
considered in severe/complex plaques.493,666,861,863
IIa
C
Anticoagulation861 or DAPT863 are not 
recommended in aortic plaques since they present 
no benefit and increase bleeding risk.666
III
C
Secondary prevention after an embolic event related to aortic 
atherosclerosis
In patients with an embolic event and evidence of an 
aortic arch atheroma, intensive lipid management to 
an LDL-C target <1.4 mmol/L (<55 mg/dL) is 
recommended to prevent recurrences.242,862,865,868
I
A
In patients with an embolic event and evidence of an 
aortic arch atheroma, SAPT is recommended to 
prevent recurrences.666,865,866
I
C
© ESC 2024
CV, cardiovascular; DAPT, dual antiplatelet therapy; LDL-C, low-density lipoprotein 
cholesterol; SAPT, single antiplatelet therapy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 66 -->

### Page 66

9.2. Aortic aneurysms
9.2.1. General concepts
9.2.1.1. Definitions
Aortic dilatation, the second most frequent aortic disease after athero­
sclerosis, is defined as an aortic diameter >2 standard deviations of 
the predicted mean diameter depending on age, sex, and body size 
(z-score >2). However, in clinical practice, aortic root dilatation 
can be suspected in male adults when aortic diameter is >40 mm and 
in females at >36 mm,138,149,869 or with an indexed diameter/BSA 
(aortic size index [ASI]) >22 mm/m2. In extreme BSA and age values, 
use of z-scores is recommended (see Section 5.4 for their calculation).
Arterial aneurysm is defined as a diameter >1.5 times (>50%) lar­
ger than the predicted one. This definition, as well as the use of 
z-scores, introduces the need for normal values and correction for 
age, sex, and body size. However, correcting for BSA can lead to 
underestimation in overweight patients,870 therefore a correction 
for height (aortic height index [AHI]) is becoming more popular.153
In terms of clinical risk, both ASI and AHI have been shown to improve 
risk stratification for AAE.153,871 Since in many cases of aortic dilata­
tion the surgical indication is established before achieving this aneur­
ysmal diameter, we strongly recommend the use of significant aortic 
dilation specifying the diameter or the indexed diameter value rather 
than the term ‘aneurysm’.
Thoracic aortic aneurysms (TAAs) are more prevalent in men than in 
women (ratio 4:1);872 however, the growth rate is greater in women 
(0.96 ± 1.00 mm per year) than in men (0.45 ± 0.58 mm per year), 
and thus the risk of AAE.873
Aneurysms can be fusiform or saccular based on morphology. 
Saccular aneurysms relate to infection, penetrating atherosclerotic 
ulcer (PAU), trauma, or inflammatory diseases, while fusiform aneur­
ysms connect with degenerative and connective tissue conditions. 
Although evidence about their natural course is limited, saccular aneur­
ysms are considered more malignant in terms of AAE. Based on loca­
tion, aortic aneurysms are classified into TAA and abdominal aortic 
aneurysm (AAA) (Figure 21). They differ in treating specialists, causes, 
age at onset, risk factors, and complications. However, this binary clas­
sification is artificial due to the prevalence of thoracoabdominal aortic 
aneurysms (TAAA) and tandem lesions (20%–30% of AAA patients 
also have TAA),874,875 emphasizing the importance of comprehensive 
aortic and vascular assessments at diagnosis. When detecting an aortic 
aneurysm at any site, it is advisable to conduct a thorough evaluation of 
the entire aorta initially and during subsequent follow-ups. Specifically, 
when diagnosing a TAA, it is crucial to assess the aortic valve, particu­
larly in cases of BAV. Data on peripheral aneurysms in TAA, particularly 
in femoro-popliteal segments, is less clear compared with AAA. 
However, cerebral aneurysms, notably prevalent in women and those 
with HTAD, warrant thorough screening, particularly in symptomatic 
cases.876–878
9.2.2. Thoracic aortic aneurysms
9.2.2.1. Aetiology, risk factors, and natural history
Thoracic aortic aneurysms occur in 5–10/100 000 person-years,884
with an approximate predominance of root and/or ascending aorta 
of ∼60%, arch of ∼10%, and descending aorta of ∼30%.885,886
Hypertension is the main risk factor (80%); however, genetics may be 
involved in 20% of cases.887 The decision to refer patients for genetic 
evaluation should consider age, family history, and presence of syn­
dromic features,25,888 as reported in more detail in Section 10.1.
9.2.2.2. Ascending thoracic aorta and arch aneurysms
(1) Aortic root aneurysms (including sinuses of Valsalva: annulo- 
aortic ectasia). They can be idiopathic, associated with HTAD (syn­
dromic/non-syndromic), or found in 20%–30% of BAV patients 
(see Section 10).879,880 Patients are usually younger (30–50 years 
of age), with aortic regurgitation, and with a 1:1 sex ratio.
(2) Supra-coronary aortic aneurysms (above sinuses of 
Valsalva). Caused by atherosclerosis in relation to hypertension af­
fecting older patients (59–69 years) and males (ratio 3:1),880 or re­
lated to medial degeneration (isolated or associated with aortic 
valve disease, including BAV) (see Section 10). Primary bacterial in­
fection or syphilis are uncommon. Arteritis is rare, but Takayasu’s 
and giant cell arteritis can lead to aneurysm formation.
(3) Aortic arch aneurysms. Often accompanying adjacent ascend­
ing or descending aorta aneurysms, aortic arch aneurysms present 
surgical challenges due to potential neurological and CV risks. They 
are typically linked to atherosclerosis, with cystic medial degener­
ation primarily affecting ascending aorta-related arch aneurysms. 
Deceleration injuries or coarctation may extend into the aortic 
arch.889
Recommendation Table 34 — Recommendations for 
initial evaluation of thoracic aortic aneurysm and 
abdominal aortic aneurysm
Recommendations
Classa
Levelb
When an aortic aneurysm is identified at any 
location, assessment of the entire aorta is 
recommended at baseline and during 
follow-up.874,875
I
C
When a TAA is identified, assessment of the aortic 
valve (especially for BAV) is recommended.879,880
I
C
When an AAA is identified, evaluation of the 
presence of aneurysm in the femoro-popliteal 
arterial segment should be considered.876–878,881
IIa
C
Patients with aortic aneurysm are at increased risk of 
CVD, thus general CV prevention should be 
considered.26,882,883
IIa
C
© ESC 2024
AAA, abdominal aortic aneurysm; BAV, bicuspid aortic valve; CV, cardiovascular; CVD, 
cardiovascular disease; TAA, thoracic aortic aneurysm. 
aClass of recommendation. 
bLevel of evidence.
Table 14 Grading of atherosclerotic aortic plaques
Grade
Severity (atheroma 
thickness)
Description
1
Normal
Intimal thickness <2 mm
2
Mild
Intimal thickening of 2 to <3 mm
3
Moderate
Atheroma ≥3 to <4 mm (no 
mobile/ulcerated components)
4
Severe
Atheroma ≥4 mm (no mobile/ 
ulcerated components)
5
Complex
Grade 2, 3, or 4 atheroma plus 
mobile/ulcerated components
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3603


<!-- PAGE 67 -->

### Page 67

Thoracic aortic aneurysm patients are usually asymptomatic, diagnosed 
incidentally during unrelated imaging or screenings. Symptoms such as 
chest pain, aortic regurgitation, and compression-related issues may oc­
cur.890 Patients with aortic root involvement (as seen in HTAD) are 
more prone to suffer from AAE.891,892
Thoracic aortic aneurysm growth rate is variable, associated with 
aetiology, location, and baseline aortic diameter.893–895 Degenerative 
TAAs grow faster in women than men and are associated with a three- 
fold higher risk of AAE.24,873,896 When the aorta reaches 57.5 mm in 
size, reported yearly rates of rupture, dissection, and death are 3.6%, 
3.7%, and 10.8%, respectively.897–899
9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta 
aneurysms
They can involve different parts of the DTA and may extend to the AA: 
TAAA. TAAAs are divided into five groups900 according to the modi­
fied TAAA classification scheme (Figure 22), which is crucial for risk stra­
tification. By classifying aneurysm extent, surgeons can anticipate 
procedure complexity, select suitable techniques, and reduce risks dur­
ing surgical planning.
Most DTA aneurysms and TAAA are degenerative with calcification, 
although other causes include trauma, infection, inflammation, or gen­
etic factors901,902 (Figure 21). Patients with HTAD rarely develop 
Media degeneration
Inflammation
Genetic disorders
Infection
Thoracic aortic aneurysm (TAA)
Aetiology
Screening 
Diagnostic
TTE
TTE or TOE plus CCT or CMR
Root and ascending aorta
Descending aorta
HTAD
BAV
Sporadic TAA
Atherosclerosis
Aortitis (infectious or not)
Trauma
Abdominal aortic aneurysm (AAA)
Aetiology
Screening 
Diagnostic
DUS
DUS or CEUS, CCT or CMR
Atherosclerosis
Coarctation
Atherosclerosis
Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, screening and diagnostic methods. AAA, abdominal aortic aneurysm; BAV, bicuspid 
aortic valve; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced Doppler ultrasound; CMR, cardiovascular magnetic resonance; 
DUS, Doppler ultrasound; HTAD, heritable thoracic aortic disease; TAA, thoracic aortic aneurysm; TOE, transoesophageal echocardiography; TTE, 
transthoracic echocardiography.


<!-- PAGE 68 -->

### Page 68

Suprarenal AAA
Pararenal AAA
Juxtarenal AAA
Infrarenal AAA
Type I
Type III
Type IV
Type V
Type II
SMA
IMA
Left renal artery
Coeliac trunk
Innominate artery
Left carotid artery
Left subclavian artery
Classification of thoracoabdominal aortic aneurysms
Classification of abdominal aortic aneurysms
Figure 22 Classification of thoracoabdominal900 and abdominal aortic aneurysms. AAA, abdominal aortic aneurysm; IMA, inferior mesenteric artery; 
SMA, superior mesenteric artery.
ESC Guidelines                                                                                                                                                                                          3605


<!-- PAGE 69 -->

### Page 69

thoracoabdominal aortic aneurysms without dissection. Mean age at 
diagnosis is 59–69, with a male predominance of 2–4:1. Aneurysm 
growth rate is 1.9–3.4 mm per year,902,903 but tends to increase notably 
with diameters over 50 mm or post-proximal aorta surgery in patients 
with MFS. In this population, debate continues as to whether this re­
flects a more vulnerable aorta associated to the genetic disease or 
haemodynamic changes post-surgery.
For untreated DTA aneurysm patients, 5 year survival is about 54%, 
with aortic rupture as the leading cause of death.904 Rupture risk factors 
include HTAD, a diameter over 50 mm, hypertension, smoking, chronic 
obstructive pulmonary disease (COPD), symptoms, chronic aortic dis­
section, and age. A significant rise in AAE risk occurs at a 60 mm diam­
eter. Although dissection can occur in smaller aortas, the individual risk 
is low.899 High-risk features for rupture are represented in Figure 23.
High-risk features for TAAA rupture beyond aortic diameter
Aortic root and ascending aorta
Thoracoabdominal aorta
Radiological signs of AAA rupture
Retroperitoneal haematoma
Contrast extravasation
High crescent sign
Paraortic fat stranding
Tangential calcification
Calcification discontinuity
Thrombus fissuration
Draped aorta sign
Relation with patient’s height
Upper normal limits of aortic diameter by age
Uncontrolled resistant hypertension
Saccular aneurysm associated to PAU
Uncontrolled resistant hypertension
COPD
Aortic length measurement
Yearly rate of diameter growth
Root vs 
ascending phenotype
Genetic predisposition
Aortic growth rate:
Ascending aorta and arch ≥ 3mm/year
DTAA ≥ 10mm/year (or ≥ 5mm/6 months) 
AAA ≥ 10mm/year (or ≥ 5mm/6 months)
Symptoms
Descending thoracic aorta
Figure 23 Risk factors for thoracic and abdominal aneurysm rupture. AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; 
DTAA, descending thoracic aorta aneurysm; PAU, penetrating atherosclerotic ulcer; TAAA, thoracoabdominal aortic aneurysm.905–908


<!-- PAGE 70 -->

### Page 70

9.2.2.4. Surveillance
Patients with TAA who do not meet surgical criteria require chronic 
follow-up that includes clinical evaluation and imaging techniques. 
The best imaging modality depends on aneurysm location: TTE, 
CCT, or CMR when affecting the aortic root and the ascending aorta; 
CMR and CCT when involving the distal ascending aorta, the aortic 
arch, or the DTA.159,171 Follow-up should be conducted with the 
same imaging technique and in the same centre.909 If a TAA is only 
moderate in size and remains relatively stable over time, CMR rather 
than CCT is reasonable to minimize radiation exposure.172,910
Follow-up for aortic aneurysms associated with HTAD is described 
in Section 10.1.3.2.
Figure 24 proposes a follow-up algorithm for patients with TAA. In 
cases of aortic root or proximal ascending aorta dilatation, after ini­
tial diagnosis by TTE the basal diameter and extension must be con­
firmed by CMR or CCT. If there is agreement between techniques, 
TTE can be used for follow-up; however, if there is a difference of 
≥3 mm, surveillance must be performed by CMR or CCT. After 
the initial diagnosis, imaging is required at 6–12 months, depending 
on aetiology and baseline diameter (Figure 24); see Sections 5.4.2
and 9.2.1 about indexed values of aortic dimensions, to ensure sta­
bility.159,911 Subsequently, imaging can be performed annually if there 
is no expansion/extension or customized according to the underlying 
condition. If the aorta shows rapid expansion (≥3 mm per year) or 
approaches the surgery/endovascular repair threshold, a closer evalu­
ation is recommended every 6 months. In contrast, stability in aortic 
diameters over years could lengthen these intervals (especially in 
non-genetic aneurysms and those <45 mm). In cases of dilatation 
of aortic arch or DTA, diameters obtained by TTE are deemed 
less precise and need confirmation by CMR or CCT. In those types 
of aneurysms, follow-up frequency will depend on the baseline diam­
eter and aetiology and will follow the same criteria established in the 
algorithm in Figure 24 for the 40–49 mm range. However, for the 
50–55 mm range, the aorta should be re-imaged every 6 months un­
til the threshold for intervention is reached (see Sections 9.2.5.3 and 
9.2.5.4).
9.2.3. Abdominal aortic aneurysms
9.2.3.1. General concepts
An AAA is defined as a focal dilation at least 1.5 times its normal diam­
eter, generally ≥30 mm. Most AAAs are fusiform, and many are lined 
with laminated thrombi.916 Their prevalence increases with age, with 
a 4:1 male/female ratio.872 They are commonly classified based on their 
relation to renal arteries (Figure 22) because of the complexity of sur­
gical treatment. AAA extends to the common iliac arteries in 25% of 
cases and in up to 20% of patients is associated with peripheral femoral 
and/or popliteal artery aneurysm.876–878
9.2.3.2. Aetiology, risk factors, and natural history
Smoking, age, male sex, and familial history of aneurysmal disease are ma­
jor risk factors,917–921 whereas diabetes is associated with a decreased 
risk922,923 and slower growth rate924 (Figure 21, see also Section 5). 
Other aetiologies include inflammation (5%–10% of all AAA),925 genetic 
disorders, and infection. The mean growth rate is around 3 mm per year 
(1–6 mm)906,926 and depends on sac diameter, presence of genetic disor­
ders, continuous smoking, metabolism (presence of inflammation), and 
aortic wall calcification.927–929 Risk of rupture rises exponentially de­
pending on diameter, being higher in women.930,931
AAAs are asymptomatic in two-thirds of cases and if they become 
symptomatic, rupture is the main manifestation. They often represent 
incidental imaging findings, as the sensitivity of clinical examination— 
especially palpation of an abdominal mass—is generally poor. 
Symptoms may include acute abdominal or back pain, and in some 
cases, hypovolaemic shock. However, contained rupture may present 
with atypical low flank or abdominal pain (see Figure 23 for high-risk fac­
tors and radiological signs or AAA rupture).932–935 Independently of 
risk of rupture, patients with AAA have impaired survival: the 5 year 
mortality rate is higher (×4 in women, ×2 in men) despite AAA repair, 
likely due to the presence of cardiovascular disease in other areas.936
9.2.3.3. Surveillance
Those with an aortic diameter <25 mm present low risk of developing 
large AAA in 10 years, whereas a diameter of 25–29 mm deserves re­
assessment after 4 years.937,938 DUS is the standard imaging technique 
for surveillance; however, CCT provides superior visualization of the 
AA and its branches, especially for pre-operative planning. CMR is rea­
sonable in selected patients (young and female) when a long follow-up is 
considered, to avoid radiation.
Recommendation Table 35 — Recommendation 
for the surveillance of patients with thoracic aortic an­
eurysms (non-heritable thoracic aortic disease)
Recommendations
Classa
Levelb
In thoracic aortic dilatation, TTE is recommended at 
diagnosis to assess aortic valve anatomy and function, 
aortic root, and ascending aorta diameters. 
Additionally, a global aortic evaluation using all 
echocardiographic views is recommended.159
I
C
CMR or CCT is recommended for surveillance of 
patients with aneurysm at the distal ascending aorta, 
aortic arch, DTA, or TAAA.70,159,172,912–915
I
C
In thoracic aortic dilatation, CCT or CMR is 
recommended to confirm TTE measurements, rule 
out aortic asymmetry, and determine baseline 
diameters for follow-up.137,143,144
I
C
Continued 
Follow-up imaging with TTE, CCT, or CMR (based 
on aneurysm location) should be considered annually 
if there is no expansion/extension or customized 
according to baseline aortic diameter and the 
underlying condition.70,159,172
IIa
C
TTE is not recommended for the surveillance of 
aneurysms in the distal ascending aorta, aortic arch, 
or DTA.159,171
III
C
© ESC 2024
CCT, Cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DTA, descending thoracic aorta; TAAA, thoracoabdominal aortic aneurysm; TTE, 
transthoracic echocardiography. 
See proposed algorithm in Figure 24. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3607


<!-- PAGE 71 -->

### Page 71

Surveillance of AAA
N
Y
Root or ascending dilatation with TAV or BAV (and normal valve function)
at first or susbsequent echocardiography
40–44 mmª
45–49 mm
50–52 mm
Ascending
Ascending
53–54 mm
≥55 mm
<3 mm/y
≥3 mm/y
<3 mm/y
≥3 mm/y
Surgery if low operative risk
(Class IIb)
Otherwise
Surgery if low operative risk
(Class IIa)
Otherwise
Confirm by
CCT or CMR
Confirm by
CCT or CMR
Baseline CCT/CMR
and reimage by
TTE in one year
Reimage by CCT/
CMR 6 months later to define projected growth rate
Reimage by TTE yearly
(or every 6 months if growth rate ≥3 mm/y)
Reimage by TTE
every
2 or 3 years
Reimage every 6 months
Confirm by
CCT or CMR
Confirm by
CCT or CMR
Aortic diameter
Phenotype
High-risk featuresb
Root
TAV
BAV
Growth rate
Growth rate
Phenotype
TAV/BAV
Every
4 years
Every
4 years
Consider follow-up
Follow-up
Every
3 years
Every
3 years
Every 12
months
Every 12 months
Every 6
months
Consider intervention
(Class I)
Every 6
months
Surgery
(Class I)
Surgery
(Class I)
AAA size 
(mm)
Women
Men
25
30
35
40
45
50
55
Consider intervention
(Class I)
Figure 24 Surveillance of patients with non-heritable thoracic aortic disease and abdominal aortic aneurysms. AAA, abdominal aortic aneurysm, 
BAV, bicuspid aortic valve; CCT, cardiovascular computed tomography; HTAD, heritable thoracic aortic disease; CMR, cardiovascular magnetic res­
onance; TAV, tricuspid aortic valve; TTE, transthoracic echocardiography. a36–44 mm in women. bFor TAV and BAV: age <50 years; height 
<1.69 m; ascending length >11 cm; uncontrolled hypertension; and, for BAV: coarctation; family history of acute aortic events.


<!-- PAGE 72 -->

### Page 72

A meta-analysis advises follow-up intervals for AAAs based on size: 3 
years for 30–39 mm, 1 year for 40–44 mm, and 6 months for 45– 
54 mm in men, with <1% rupture risk.938 Women have similar growth 
rates but a four-fold higher rupture risk.938 A proposed follow-up algo­
rithm is displayed in Figure 24. Consider shorter intervals for rapid 
growth (≥10 mm per year or ≥5 mm per 6 months), in which case re­
pair may be considered.
9.2.4. Optimal medical treatment of aortic aneurysms
In patients with aortic aneurysms, the role of antithrombotic therapy is 
uncertain. In complicated aortic atherosclerotic plaques, concomitant 
CAD is common (OR 2.99) and SAPT should be considered (see 
Section 9.1). In patients with AAA, results of observational studies 
are conflicting in relation to aneurysm growth. Low-dose aspirin is 
not associated with a higher risk of AAA rupture but could worsen 
prognosis in cases of rupture.944 In an RCT of patients with AAA 
(35–44 mm), ticagrelor did not reduce growth rate.945
Optimal medical treatment for aortic aneurysms aims to lower CV 
morbidity, slow growth rate, delay surgery, reduce peri-operative 
risk, and prevent AAE. Aneurysm patients face elevated CV risk due 
to common CVRFs, and the 10 year CV event mortality risk (heart at­
tacks or strokes) is 15 times higher than AAE risk, even after re­
pair.882,883 According to the SMART risk score algorithm, optimal 
implementation of risk management guidelines would reduce the 10 
year risk of MACE from 43% to 14% in patients with AAA.936 Thus, life­
style modification, exercise, smoking cessation, and treatment of risk 
factors are crucial (see Section 7).
Risk factors and possible drug treatment to reduce AAA growth and/ 
or the risk of rupture have been thoroughly discussed in a recent review 
paper.946 Their meta-analysis suggested a possible effect of ACEIs (but 
not ARBs) on the risk of rupture, whereas another meta-analysis947 did 
not indicate an effect of ACEIs on AAA growth. A reduction of AAA 
growth by statins is indicated in a recent meta-analysis.352
Furthermore, reduced AAA growth by the antidiabetic drug metformin 
has been suggested in several meta-analyses352,948,949 and there are sev­
eral ongoing RCTs to explore this. For BP, follow general hypertension 
guidelines. Aim for BP below 140/90 mmHg, with a target of 120/80 
mmHg, if tolerated.300,302,305 Data on the specific positive effects of 
beta-blockers and ARBs in TAA and AAA are limited (mostly derived 
from MFS populations). However, it is reasonable to use BBs and/or 
ARBs as first-line antihypertensive drugs in TAA and AAA.
Consider moderate/high-intensity statins in TAA patients but skip 
for those with low CV risk and non-atherosclerotic (HTAD). In 
AAA, consider statins to reduce aneurysm risks, including growth, rup­
ture, and peri-operative mortality.330,347,348 Low-dose aspirin is de­
bated but may be reasonable given elevated CV risk factors in TAA 
and AAA patients.666,950 Additionally, apply all CVD secondary preven­
tion measures to these patients (see Section 7).
Some evidence suggests that fluoroquinolones could be associated 
with an increased risk for aneurysm progression and dissection,951–956
but conflicting analyses do not support this association. The cautious 
use of fluoroquinolones should not be discouraged when there is a clin­
ical indication, even considering concerns regarding aortic aneurysm 
and dissection (AA/AD). Note that AA/AD risk (both thoracic and ab­
dominal) may increase due to infection itself, regardless of the antibiotic 
chosen. Infectious disease specialists discourage routine fluoroquino­
lone use as a first-line antibiotic if equally effective alternatives exist. 
Hence, do not withhold this therapy in aortic disease cases when clin­
ically necessary. All medical and lifestyle recommendations are summar­
ized in Figure 7.
9.2.5. Surgical management of aortic aneurysms
9.2.5.1. Surgical treatment of aortic root and ascending aorta
In isolated dilatation of the ascending tubular (supra-coronary) aorta, a 
supra-commissural tubular graft is inserted with the distal anastomosis 
just before the aortic arch. For aneurysms extending proximally below 
the sinotubular junction (STJ) with involvement of aortic sinuses, the 
surgical approach depends on the aortic annulus and valve condition. 
If the aortic valve cusps are pliable, experienced centres may recom­
mend aortic valve-sparing techniques,961–965 such as David’s procedure 
(reimplantation) or the Yacoub technique (remodelling).890,966–968
Recommendation Table 36 — Recommendations for 
surveillance of patients with abdominal aortic aneurysm
Recommendations
Classa
Levelb
DUS surveillance is recommended every 6 months in 
men with AAA of 50–55 mm and in women with 
AAA of 45–50 mm.938
I
B
CCT or CMR is recommended if DUS does not 
allow adequate measurement of AAA 
diameter.148,939–942
I
B
DUS is recommended for AAA surveillance.943
I
C
DUS surveillance every 3 years should be considered 
in patients with AAA of 30–<40 mm.938
IIa
B
DUS surveillance should be considered annually in 
women with AAA of 40–<45 mm and in men with 
AAA of 40–<50 mm.938
IIa
B
DUS surveillance should be considered every 4 years 
in patients with aortic diameter ≥25 mm and 
<30 mm and life expectancy >2 years.937,938
IIa
C
© ESC 2024
AAA, abdominal aortic aneurysm; CCT, Cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; DUS, duplex ultrasound. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 37 — Recommendations for 
medical treatment in patients with thoracic aorta or 
abdominal aortic aneurysms
Recommendations
Classa
Levelb
In patients with aortic aneurysm (TAA and/or AAA), 
optimal implementation of CV risk management and 
medical treatment (see detailed recommendations in 
dedicated Tables of Recommendationsc) are 
recommended to reduce MACE.936
I
C
Fluoroquinolones, while generally discouraged for 
patients with aortic aneurysms, may be considered if 
there is a compelling clinical indication and no other 
reasonable alternative.951–960
IIb
B
© ESC 2024
AAA, abdominal aortic aneurysm; CV, cardiovascular; MACE, major adverse cardiovascular 
events; TAA, thoracic aortic aneurysm. 
aClass of recommendation. 
bLevel of evidence. 
csee Tables of Recommendations 7 to 10.
ESC Guidelines                                                                                                                                                                                          3609


<!-- PAGE 73 -->

### Page 73

Otherwise, composite replacement of the aortic root and valve with 
the Bentall procedure is indicated.
Pre-operative evaluation890 and initial follow-up of patients is defined 
in Figure 25. Patients with a bioprosthetic valve should be monitored by 
TTE annually. However, in patients with mechanical prosthesis or na­
tive aortic valve, clinical evaluation and TTE should be performed as 
soon as possible if new heart symptoms develop.969 SAPT with low- 
dose aspirin (75–100 mg per day) should be considered for the first 
3 months after conservative aortic valve surgery if there are no indica­
tions for OAC. Lifelong OAC with a VKA is recommended for all pa­
tients with a Bentall mechanical prosthesis.970,971 However, in 
patients with no baseline indications for OAC, low-dose aspirin (75– 
100 mg/day) or OAC using a VKA should be considered for the first 
3 months after Bentall surgery with a bioprosthesis.972,973
TTE and TOE
Aortic valve assessment
CCT or CMR
Annulus/root/
ascending aorta assessment
Supracommisural tubular graft
Aortic valve sparing
Annuloplasty
Bentall procedure
Pre-surgery
STJ dilatation
(Ia)
STJ and aortic root dilatation (Ib)
Annulus dilatation
(Ic)
Aortic valve disease
TTE 
Immediate cardiac complications
(i.e. pericardial effusion...)
CCT or CMR
Rule out aortic complications
Before discharge
1 month
From
1 year
TTE 
Aortic valve function and gradients 
Aortic root and proximal ascending aorta assessment
TTE 
Aortic valve function and gradients 
Aortic root and proximal ascending aorta assessment
Mechanical prosthesis or native valve:
Bioprosthesis:
TTE/year
CCT or CMR
Evaluation of aortic disease progression and rule out complications
Aorta totally repaired:
Follow-up at 2 years and then every 5 years link with aneurysm 
follow-up algorithm
TTE based on gradients,
symptoms or residual AR
Aorta not fully repaired:
Figure 25 Peri-operative algorithm for the management of patients with surgically treated aortic root and ascending aortic aneurysm. AR, aortic 
regurgitation; CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; STJ, sinotubular junction; TOE, transoesophageal 
echocardiography; TTE, transthoracic echocardiography.


<!-- PAGE 74 -->

### Page 74

Although many risk factors associated with AAE have been described 
(such as elongation, angulation, and unfavourable biomechanics), aortic 
diameter is still the main determinant of aortic complications and 
death.974–976 AAE rates decreased with prophylactic aortic surgery 
over a decade,977 and additionally, surgical risk for ascending aortic/aor­
tic root surgery dropped significantly.978–980 Now, experienced cardiac 
surgery centres report <1% mortality with elective surgery.980,981
Most acute type A aortic dissections (acute TAAD) occur at diameters 
below 55 mm. However, the risk exceeds 1% between 50 and 54 mm,982
with a critical point at 52–53 mm.153,981,983 Pre-dissection aortic diam­
eter at the tubular level is 25%–30% smaller than post-dissection. 
Over 60% of non-MFS, non-BAV acute TAAD patients have a non- 
dilated ascending aorta before dissection.984,985 Additionally, the ‘root 
phenotype’ has been reported to be more malignant than those with as­
cending phenotype, with higher velocity of progression and AAE 
risk.154,891,892,986
Novel parameters, like ascending aortic length (AAL) and the 
ascending-arch angle, correlate with acute TAAD risk.155,976 AAL 
≥13 cm links to nearly five-fold higher yearly AAE rates compared 
with AAL <9 cm, with a threshold of >11 cm as a risk indicator.155
Indexing aortic diameters to anthropometric parameters has been sug­
gested and a proportional increase in the risk of AAE has been retro­
spectively demonstrated for increasing diameter indexed to BSA,904
diameter indexed to patient height,153 or cross-sectional area indexed 
to patient height.154 However, these diameter-based indexing methods 
share the same limitations in risk prediction as the absolute diameter in 
the general population,984,985 whereas they can be advantageous in pa­
tients with small body size.153,154 These additional risk factors (beyond 
the diameter) are summarized in Figure 23.
9.2.5.2. Surgical treatment of aortic arch aneurysms
Surgery for arch aneurysms is challenging, primarily due to risks like 
hypothermic circulatory arrest and the need for brain protection, re­
sulting in higher mortality and stroke rates. Isolated aortic arch surgery 
is appropriate for asymptomatic degenerative aortic arch aneurysms 
≥55 mm in diameter or symptoms or signs of local compression. 
Hemi-arch or total arch replacement are frequently required in patients 
who have an indication for surgery on an adjacent aneurysm of the as­
cending aorta. In specific cases, supra-aortic vessel transposition via off- 
pump debranching followed by TEVAR of the arch can be an alternative 
to traditional surgery, particularly when avoiding hypothermic circula­
tory arrest is a concern.992–996 When the disease involves the proximal 
descending aorta or future need for treatment of the descending aorta 
is anticipated, the frozen elephant trunk (FET) technique is a good op­
tion.997 Assessment of patency and morphology of the circle of Willis is 
recommended when treatment involves the aortic arch.998,999
Recommendation Table 38 — Recommendations for 
surgery in aortic root and ascending aorta dilatation 
associated with tricuspid aortic valve (see also 
Evidence Table 11)
Recommendations
Classa
Levelb
Surgery is recommended in patients with dilatation 
of the aortic root or ascending aorta with a tricuspid 
aortic valve and a maximum diameter of 
≥55 mm.172,894,899,904
I
B
Valve-sparing aortic root replacement is 
recommended in patients with aortic root dilatation 
if performed in experienced centres and durable 
results are expected.961–965
I
B
VKAs are recommended lifelong for all patients with 
a Bentall procedure with an MHV prosthesis.970,971
I
B
In patients with dilatation of the tubular ascending 
aorta who can be offered surgery with low predicted 
risk,c ascending aortic replacement should be 
considered at a maximum diameter 
>52 mm.153,981,983
IIa
B
In patients undergoing surgery for tricuspid aortic 
valve disease who have concomitant dilatation of the 
aortic root or ascending tubular aorta, and low 
predicted surgical risk, ascending aorta or root 
replacement should be considered at a maximum 
diameter ≥45 mm, otherwise ≥50 mm.70,987–989
IIa
B
Continued 
SAPT with low-dose aspirin (75–100 mg per day) 
should be considered for the first 3 months after 
valve-sparing aortic surgery when there are no other 
baseline indications for OAC.
IIa
C
In patients undergoing non-aortic-valve cardiac 
surgery who have concomitant dilatation of the 
ascending aorta or aortic root with a maximum 
diameter ≥50 mm, concomitant aortic surgery 
should be considered.70,990,991
IIa
C
Ascending aortic or root replacement may be 
considered at a maximum diameter of ≥50 mm in 
patients with proximal aorta dilatation who can be 
offered surgery with low predicted riskc and present 
with any of the following:153–155,891,892
• Growth of the aortic diameter ≥3 mm per year
• Resistant hypertensiond
• Short stature <1.69 m
• Root phenotype
• Aortic lengthe >11 cm
• Age <50 years
• Desire for pregnancy
• Aortic coarctation
IIb
B
© ESC 2024
MHV, mechanical heart valve; OAC, oral anticoagulation; SAPT, single antiplatelet therapy; 
VKA, vitamin K antagonist. 
For heritable thoracic aortic disease and bicuspid aortic valve-related thoracic aortic 
aneurysm refer to Section 10. 
aClass of recommendation. 
bLevel of evidence. 
cIndividual patient’s risk <3%. 
dHypertension that cannot be adequately controlled despite use of three or more agents 
recommended by a physician with expertise in the management of hypertension. 
eCurvilinear distance at aortic centreline between the ventriculo-aortic junction and the 
origin of the innominate artery.
Recommendation Table 39 — Recommendations for 
surgery in aortic arch aneurysms
Recommendations
Classa
Levelb
In patients with low or intermediate operative risk with 
an aortic arch aneurysm and recurrent episodes of 
chest pain not attributable to non-aortic causes, open 
surgical replacement of the arch is recommended.70,172
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3611


<!-- PAGE 75 -->

### Page 75

9.2.5.3. Surgical treatment of the thoracic descending aorta
9.2.5.3.1. General considerations. At 60 mm diameter, a DTA aneur­
ysm has a 10% annual rupture risk, justifying intervention at 
≥55 mm.902,1002 Intervention at a diameter <55 mm may not bring 
any further survival benefit except for women,904,1003 patients with 
connective tissue disorders,904 or rapid growth (≥10 mm per year or 
≥5 mm every 6 months),1004 (for high-risk factors see Figure 23). 
This threshold may be increased in high surgical risk patients.1005 It is 
advisable to centralize complex procedures in centres with expertise 
in aortic diseases and a multidisciplinary team for effective patient 
management.
9.2.5.3.2. Open repair. Thoracic endovascular aortic aneurysm 
repair is recommended as first-choice intervention for DTA aneur­
ysms,1006–1010 thus open repair is limited to patients with unsuitable 
anatomy for TEVAR1011 or connective tissue disorders.1012 The early 
mortality benefit of TEVAR seems to decrease after 1 year, and there­
after long-term survival (10 years) seems better with open repair.1013
Therefore, open repair is advisable for young, healthy patients with un­
suitable TEVAR anatomy and prolonged life expectancy, particularly 
when symptoms from aneurysm rupture or compression arise.
However, open repair involves significant post-operative risks, ne­
cessitating thorough pre-operative evaluations for cardiac, pulmonary, 
renal function, carotid, and peripheral arterial diseases. Risks include 
stroke, mesenteric and renal ischaemia due to clamping dur­
ation,1014,1015 and paraplegia tied to the extent of aneurysmal dis­
ease.1016,1017 Outside experienced centres, outcomes have shown 
minimal improvement in recent years, with mortality rates around 
10% and spinal cord ischaemia rates at 11%–15%.1016,1018
9.2.5.3.3. Endovascular repair. Comparative studies favour TEVAR 
over open repair, showing lower mortality (6%) and morbid­
ity.1006,1019,1020 However, TEVAR’s survival advantage is balanced by 
an increased risk of follow-up re-intervention. It reduces spinal cord in­
jury risk (3%).1021–1024 Left subclavian artery (LSA) coverage during 
TEVAR for proximal sealing is required in up to 50% of cases.1025
This is associated with an increased risk of cerebrovascular events, 
spinal cord ischaemia (SCI), and upper-limb ischaemia,1026,1027 justifying 
previous surgical or concomitant endovascular (with branched or fene­
strated grafts) revascularization of the LSA in an elective set­
ting.1026,1028,1029 In cases of inadequate distal zone sealing, safe 
coverage of the coeliac artery has been proposed when sufficient col­
lateral circulation exists,1030,1031 but results are controversial.1032
9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms
9.2.5.4.1. General considerations. Since AAEs increase when TAAA 
diameter exceeds 60 mm,902,1002,1033 and there are more technical sur­
gical challenges in TAAA repair (compared with DTA aneurysm or 
AAA), TAAA repair, in low-moderate surgical risk patients, is proposed 
if the aortic diameter is ≥60 mm. However, surgical repair should be 
considered at diameters ≥55 mm if patients present with high-risk fea­
tures (Figure 24) or are at very low risk and under the care of experi­
enced surgeons in a multidisciplinary aorta team.1004,1033,1034 HTAD, 
distal location, chronic dissection, and BAV903 are associated with rapid 
growth rate and will require closer follow-up.
9.2.5.4.2. Open repair. Open TAAA repair is a complex aortic pro­
cedure. Post-operative mortality risk increases with left ventricular 
(LV) dysfunction, renal insufficiency, and advanced age.1035–1037 Since 
organs and tissues distal to the aortic clamp will suffer from prolonged 
ischaemia, extracorporeal circulation is mandatory to reduce complica­
tions,1011,1038 especially SCI (2.5%–15%).1011,1039–1044 The mortality 
rate after open TAAA repair varies between 6% and 8% in high-volume 
centres1006,1011,1039 vs. 30% in less experienced centres,1045,1046 raising 
the recommendation to perform these complex procedures only in 
specialized institutions.
9.2.5.4.3. Endovascular repair. Endovascular repair is a promising al­
ternative for treating challenging aortic anatomy like juxta-renal AAA 
(Figure 22).1047,1048 The use of fenestrated and branched endografts 
has shown excellent results, allowing perfusion of visceral ves­
sels.1049–1053 While direct comparison studies with open TAAA repair 
are lacking,1054 the increasing adoption of endovascular procedures is 
notable, especially for high-risk patients, with low post-operative mor­
tality rates (<10%).1051,1052,1055–1058 A recent meta-analysis confirms 
these excellent outcomes, endorsing endovascular repair for 
TAAA.1059 The incidence of post-operative SCI (around 5%) is similar 
between endovascular and open repair.1052,1057,1060,1061 Thus, at 
mid-term follow-up, endovascular repair is durable with acceptable 
secondary re-intervention rates, which remain one of the major limita­
tions.1052,1057,1058,1060,1061 Factors favouring endovascular vs. open re­
pair in TAAA are presented in Table 15.
In patients with an isolated aortic arch aneurysm who 
are asymptomatic and have low operative risk, open 
surgical replacement should be considered at an arch 
diameter of ≥55 mm.70,172,899
IIa
B
In patients undergoing open surgical repair of an 
ascending aortic aneurysm, concomitant hemi-arch 
replacement should be considered if the dilatation 
extends into the proximal aortic arch 
(>50 mm).70,172,1000
IIa
C
In patients undergoing open surgical repair of an 
aortic arch aneurysm, an elephant trunk or frozen 
elephant trunk procedure should be considered if the 
aneurysmal disease extends into the proximal 
descending thoracic aorta.70,172,997,1001
IIa
C
In patients undergoing open surgical repair of an 
ascending aortic aneurysm, concomitant hemi-arch 
or arch replacement may be considered in 
experienced centres if the dilatation extends into the 
aortic arch (>45 mm).70,172,1001
IIb
C
In patients with an aortic arch aneurysm who meet 
criteria for intervention but have high surgical risk, a 
hybrid or endovascular approach may be 
considered.70,172
IIb
C
© ESC 2024
For heritable thoracic aortic disease refer to Section 10. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 76 -->

### Page 76

9.2.5.5. Surgical treatment of abdominal aorta aneurysms
9.2.5.5.1. General considerations. Rupture remains the most feared 
AAA complication, and is associated with the maximum diameter,1063
as well as other risk factors (Figure 23). Different studies1064–1071 (in­
cluding the United Kingdom Small Aneurysm Trial [UKSAT] and 
American Aneurysm Detection and Management [ADAM] trial) re­
ported no benefits from open or endovascular interventions (despite 
lower peri-operative complication rates) in asymptomatic AAA pa­
tients with a maximal diameter <55 mm in men and <50 mm in wo­
men. Evidence that women are more likely to rupture under 
surveillance and at a smaller aortic diameter justified a lower 
(50 mm) threshold. Another interesting method to quantify the risk 
of rupture based on body size, which seems a better predictor in wo­
men, has been proposed.1072 However, in the absence of recent stud­
ies, thresholds for intervention have not changed in recent years. 
Considering the complexity of patient management, it is advisable to 
centralize complex procedures in centres with a high level of expertise 
in aortic diseases and a multidisciplinary team.
9.2.5.5.2. Pre-operative cardiovascular evaluation and choice of 
treatment. Coronary artery disease is the leading cause of early mor­
tality after AAA repair,937,1073 and is associated with a 5%–10% rate of 
peri-operative CV complications such as death, MI, or stroke.1074,1075
Since endovascular repair is associated with lower mortality (<1%) 
and CV complications,1076–1079 the need for pre-operative cardiac 
Recommendation Table 40 — Recommendations for 
the management of patients presenting with descending 
thoracic aortic and thoracoabdominal aortic aneurysms
Recommendations
Classa
Levelb
In patients with unruptured DTA aneurysm (without 
HTAD), elective repair is recommended if diameter 
≥55 mm.902,1002
I
B
In patients without HTAD with unruptured DTA 
aneurysm, when elective repair is indicated and 
anatomy is suitable, TEVAR is recommended over 
open repair.1006,1019,1020
I
B
In patients with DTA aneurysm who undergo 
TEVAR with planned LSA coverage, it is 
recommended to revascularize the LSA before 
TEVAR to reduce the risk of SCI and 
stroke.1026,1028,1029
I
B
In patients with unruptured degenerative TAAA, 
elective repair is recommended when the diameter is 
≥60 mm.902,1002,1033
I
B
In patients without significant comorbidities and with 
unruptured DTA aneurysm, when elective repair is 
indicated and anatomy is unsuitable for TEVAR, open 
repair should be considered if life expectancy 
exceeds 2 years.1013
IIa
B
In TAAA, surgical repair should be considered at 
diameters ≥55 mm if patients present with high-risk 
features, are at very low risk, and are under the care 
of experienced surgeons in a multidisciplinary aorta 
team.1004,1033,1034
IIa
B
In patients with unruptured degenerative TAAA and 
suitable anatomy, when elective repair is indicated, 
endovascular repair using fenestrated and/or 
branched endografts should be considered in 
experienced centres.1051,1052,1055–1059
IIa
B
Continued 
In patients with unruptured DTA aneurysm (without 
HTAD) and high-risk features,c elective repair may 
be considered if the diameter is 
<55 mm.904,1003,1004,1033,1034
IIb
B
© ESC 2024
DTA, descending thoracic aorta; HTAD, heritable thoracic aortic disease; LSA, left 
subclavian artery; SCI, spinal cord ischaemia; TAAA, thoracoabdominal aortic aneurysm; 
TEVAR, thoracic endovascular aortic aneurysm repair. 
For heritable thoracic aortic disease refer to Section 10. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 23 for high-risk features.
Table 15 Overview of factors favouring open vs. endovascular repair in thoracoabdominal aortic aneurysm
Characteristic
Favours open repair
Favours endovascular repair
Biological age and life 
expectancy
• Younger age
• Considerable life expectancy with acceptable 
quality of life
• Older age
• Limited life expectancy
Anatomical considerations
• If aortic and branch anatomy preclude endovascular 
approach
• Poor vascular access
• Suitable proximal and distal landing zones
• Favourable visceral and renal configuration
• Vascular access obtainable
Pathological
• Chronic dissection
• Acute dissection
Background/causal factor
• Hereditary aortic disease
• Degenerative aortic disease
Cardiopulmonary condition
• Good cardiopulmonary reserve
• Poor cardiopulmonary reserve
Fitness
• No significant comorbidities
• Successful rehabilitation likely
• Severe organ impairment (renal, kidney, pulmonary)
• Obesity
• Limited mobility, unlikely to rehabilitate successfully
Urgency
• Elective repair
• Emergency repair without a viable endovascular 
solution
• Elective repair
• Emergency repair with time for custom-made graft or suitable for 
standard grafts
© ESC 2024
Adapted from Ouzounian et al. with permission.1062
ESC Guidelines                                                                                                                                                                                          3613


<!-- PAGE 77 -->

### Page 77

Patients with abdominal aortic aneurysm
Aortic aneurysm
Graft
Aortic aneurysm
Stent graft
Surveillance
(See aneurysm follow-up algorithm)
N
N
Low/medium
High
Prohibitive
Either of the following:
Life expectancy 2 years
Operative mortality risk
Elective repair
Anatomy appropriate for EVAR
Open repair
(Class I)
If suitable anatomy,
EVAR (Class IIa) 
Optimal medical treatment
Elective repair
(Class III)
EVAR
(Class IIa)
Fusiform AAA ≥55 mm (men), ≥50 mm (women)
Saccular aneurysm 45 mm
N
Y
Y
Y
A
B
Figure 26 Algorithm for individual decision-making process in the treatment of patients with abdominal aortic aneurysm. (A) Illustration of open 
repair (graft). (B) Illustration of endovascular treatment (EVAR). AAA, abdominal aortic aneurysm; EVAR, endovascular aortic aneurysm repair.


<!-- PAGE 78 -->

### Page 78

work-up will depend on procedure risk, symptoms, and patient-specific 
CVRFs (see Sections 4 and 12, and the 2022 ESC Guidelines on cardiovas­
cular assessment and management of patients undergoing non-cardiac sur­
gery).1080 Coronary revascularization before elective aortic surgery in 
patients with stable cardiac symptoms cannot be recommended, since 
there is evidence that this strategy does not improve outcomes or re­
duce the 30 day MI rate.1080,1081
A complete vascular evaluation (that includes not only the AA but 
also the entire aorta: ascending, arch, and descending aorta) is manda­
tory to determine the best strategy in AAA management, CCT being, 
by consensus, the optimal pre-operative imaging modality.1082,1083
When CCT is contraindicated, consider CMR, though calcification as­
sessment is challenging. Pre-operative planning should determine 
EVAR feasibility by sizing the aorto-iliac system, yet adherence to 
device-specific instructions remains uncertain.1084–1090 DUS assess­
ment of the femoro-popliteal segment is advocated since femoro- 
popliteal aneurysms are commonly associated with AAA.1091,1092
Additionally, the technique of choice should be discussed between 
the treating physician and the patient based on the patient’s life expect­
ancy and preferences, operator and hospital volumes, and surveillance 
compliance.910,1093–1097 Elective AAA repair is not recommended in 
frail patients or those with life expectancy <2 years.1098,1099 The indi­
vidual decision-making process in AAA patients is displayed in Figure 26.
Different studies have demonstrated a significant short-term survival 
benefit for EVAR, but with similar long-term outcomes compared with 
open repair (up to 15 years)1100–1103 also reported in females.1104
However, loss of early benefit is associated with an increased rate of 
late complications occurring after 8 years, especially late ruptures.1079
These trials used earlier-generation EVAR devices, so the durability 
of the latest-generation devices remains uncertain. Recent data, how­
ever, suggest a reduced risk of late complications and fewer re- 
interventions.1105–1108
9.2.5.5.3. Open abdominal aorta aneurysm repair. Open AAA re­
pair through mid-line laparotomy (with <30 min clamping time) 
with a Dacron graft has been the preferred choice for years, despite 
notable CV morbidity1078,1100,1109–1113 and a 2%–5% mortality 
rate.1110,1111,1113,1114 In ruptured AAA, open repair results are worse 
than those of elective surgery, with an unchanged complication rate 
of around 48%.1115 Thus, endovascular repair is recommended to re­
duce peri-operative morbidity and mortality.1116–1118
Open AAA repair raises incisional hernia risk, particularly in obese 
patients, suggesting prophylactic mesh use in high-risk cases.1119–1121
9.2.5.5.4. Endovascular abdominal aorta aneurysm repair.
Endovascular abdominal aorta aneurysm repair reduces peri-operative 
mortality to <1%, although it implies higher risk of re-intervention in 
the long term.1122–1124 Current devices offer features like active fix­
ation, repositioning ability, low-profile design, and polymer-filled rings 
for improved sealing.1106,1125–1128 New devices demonstrate similar 
long-term outcomes with reduced re-intervention risk,1090 expanding 
treatment possibilities to 60%–70% of infrarenal AAA cases.1129,1130
In cases of juxta- or para-renal AAA (Figure 22), both open and en­
dovascular treatment can be proposed in high-volume centres, with 
similar short- and long-term results. The choice between open surgical 
repair and endovascular repair depends on various factors, including the 
patient’s anatomy, overall health, and the extent of the aneurysm 
(see Table 15). In cases of complex endovascular treatment, a fene­
strated or branch stent endograft should be considered.1096,1131
A percutaneous femoral approach is suitable since it provides quick­
er access, reduced invasiveness, and allows local anaesthesia. Some evi­
dence supports the use of ultrasound-guided percutaneous access for 
EVAR due to a lower rate of access-related complications and a shorter 
operation time.1132–1135
As patients treated by EVAR are more prone to late complications 
(endoleaks, migration, or rupture) and re-interventions, lifelong surveil­
lance is currently mandatory.1096,1136–1140
9.2.6. Endoleaks
Endoleaks are defined as the persistence of blood flow outside the graft 
but inside the aneurysm sac, preventing complete thrombosis 
(Figure 27). They are the most common complication, with an incidence 
up to one-third of either early or late procedures (those appearing after 
1 year).1145 Chronic anticoagulation constitutes a risk factor for 
re-intervention, late conversion surgery, or mortality.1146 Endoleaks 
exposing the aneurysm sac to systemic pressure and expansion will 
require re-intervention to prevent rupture.
Five types of endoleaks have been described, as detailed in Figure 27. 
Type I and type III require correction with a new (endovascular) pro­
cedure. Type II is present in about 25% of patients but may seal 
Recommendation Table 41 — Recommendations for 
the management of patients presenting with abdominal 
aortic aneurysm
Recommendations
Classa
Levelb
Elective repair is recommended if AAA diameter is 
≥55 mm in men or ≥50 mm in women.1064–1067
I
A
In ruptured AAA with suitable anatomy, 
endovascular repair is recommended over open 
repair to reduce peri-operative morbidity and 
mortality.1116–1118
I
B
Prior to AAA repair, DUS assessment of the 
femoro-popliteal segment, to detect concomitant 
aneurysms, should be considered.1091,1092
IIa
B
In patients with AAA with suitable anatomy and 
reasonable life expectancy (>2 years), EVAR should 
be considered as the preferred therapy, based on 
shared decision-making.910,1096,1141–1143
IIa
B
In patients with unruptured AAA and aneurysm 
growth ≥5 mm in 6 months or ≥10 mm per year, 
repair may be considered.1064,1065
IIb
C
Elective repair for patients presenting with a saccular 
aneurysm ≥45 mm may be considered.1144
IIb
C
In patients with AAA and limited life expectancy 
(<2 years), elective AAA repair is not 
recommended.1098,1099
III
B
Prior to AAA repair, routine evaluation with 
coronary angiography and systematic 
revascularization in patients with chronic coronary 
syndromes is not recommended.1080,1081
III
C
© ESC 2024
AAA, abdominal aortic aneurysm; DUS, duplex ultrasound; EVAR, endovascular aortic 
aneurysm repair; TAA, thoracic aortic aneurysm. 
See also Figure 23. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3615


<!-- PAGE 79 -->

### Page 79

Y
N
Classification of endoleak types
Type Ia
Type Ib
Type II
Type III
Type IV
Type V
Surveillance after TEVAR/EVAR and management of endoleaks
CCT and DUS/CEUSa at 1 month and 1 year post-op
No new endoleak
Type I or type III endoleak
Consider re-intervention
(Class I)
Type II endoleak
Detected at
1 month post-op
CCT re-evaluation at 6–12 months
Annual surveillance with
CCT or DUS/CEUSa 
for the first 5 years
<10 mm or shrinking
Consider open surgery,
if growing aneurysm sac
CCT or DUS/CEUSa surveillance every 6 months for 24 months
New endoleak or growing aneurysm sac
CCT, or non-contrast CCT with
DUS/CEUS every 5 yearsa
Growing aneurysm sac
Consider embolization,
if feasible
(Class IIa)
CCT
Proceed to endoleak type
CCT or DUS/CEUSa surveillance at 6–12 months
New endoleak
≥10 mm
Y
N
Figure 27 Algorithm for follow-up after thoracic endovascular aortic aneurysm repair, and management of endoleaks and their classification. CEUS, 
contrast-enhanced ultrasound; CCT, cardiovascular computed tomography; DUS, duplex ultrasound; TEVAR, thoracic endovascular aortic aneurysm repair; 
EVAR: Endovascular aortic repair. aIn cases of TEVAR, CCT is the preferred imaging technique since DUS/CEUS does not permit the correct evaluation of the 
thoracic aorta. In cases of renal failure, non-contrast CCT is a good alternative to monitor aneurysm sac growing and is associated to DUS/CEUS for EVAR 
monitoring. Endoleaks are classified into five types: Type Ia, proximal attachment site endoleak; Type Ib, distal attachment site endoleak; Type II, backfilling of 
the aneurysm sac through branch vessels of the aorta; Type III, graft defect or component misalignment; Type IV, leakage through the graft wall attributable to 
endograft porosity; and Type V; caused by ‘endotension’, possibly resulting from aortic pressure transmitted through the graft/thrombus to the aneurysm sac. 
Adapted from Rokosh et al. with permission.1147


<!-- PAGE 80 -->

### Page 80

spontaneously in approximately 50% of cases. Risk factors for type II 
endoleaks include patent collaterals, presence of accessory arteries, 
and anticoagulation. In cases of significant sac expansion (≥10 mm), 
re-intervention should be considered, preferably by vessel or sac em­
bolization. Type IV, attributed to device porosity, is rare with modern 
devices and no intervention is needed. Type V induces sac expansion 
without any visible endoleak. Treatment may be considered for signifi­
cant sac growth (≥10 mm) and consists of stent graft relining or defini­
tive endograft explant and open surgical repair.
Cardiovascular computed tomography with(out) contrast, and DUS 
and/or CEUS, are the main imaging modalities for TEVAR/EVAR follow- 
up. Imaging within the first 30 days is recommended to assess treat­
ment success and/or complications. For TEVAR, contrast-enhanced 
CCT is the preferred imaging technique for follow-up and should be 
performed regularly (shorter or longer intervals are based on the ex­
pansion rate). In renally impaired patients, combined follow-up using 
DUS and non-contrast enhanced CCT is a suitable alternative (see 
follow-up algorithm, Figure 27). For EVAR, CCT and DUS/CEUS are re­
commended at 1 month following repair. Thereafter, surveillance 
should be based on the risk of late complications and includes DUS 
and/or CEUS (Figure 27).
9.2.7. Long-term follow-up after aortic repair
Long-term success in the management of aortic aneurysms depends 
also on strict post-treatment surveillance, for both secondary preven­
tion of the aortic disease and early identification of post-repair 
complications.
In endovascularly treated patients, surveillance aims to detect endo­
leaks, aneurysmal sac dilatation, and graft structural failure or migra­
tion.1150 Surgical treatments, while carrying higher operative risks, 
often yield more durable results with rarer late complications mostly 
related to laparotomy.1151
After intervention on the thoracic aorta, TTE, TOE, CCT, and CMR 
are used for follow-up, CCT being the most used and available method 
for both endovascular and surgical treatments.1150–1152 After interven­
tion on the AA, CCT, CMR, and DUS/CEUS are used. DUS/CEUS can 
detect the most common drawbacks of EVAR, except for graft struc­
tural issues. For chronic and periodic monitoring, the use of CMR, es­
pecially in young women, should be considered (to reduce radiation 
exposure). However, the choice between these modalities should con­
sider patient factors, potential artefacts, and local imaging expertise and 
availability. Both for the thoracic and abdominal aorta, due to the lack of 
studies systematically comparing different surveillance time intervals, 
recommendations are mostly based on consensus or evidence from 
single-centre observational studies.70,1153
9.2.7.1. Follow-up after thoracic aortic aneurysm treatment
Complications after ascending aorta graft replacement, though rare, 
include pseudo-aneurysms and graft infections. Pseudo-aneurysms, 
occurring in roughly 5% of cases, are most common within the first 2 
post-operative years, linked to aortic dissection surgery, HTAD, and 
synthetic glues.1154
CMR studies systematically following peri- 
anastomotic haematomas have reported higher rates (15%).1155
Graft infections can occur in 0.5%–6% of surgical patients with high 
morbidity and mortality rates, requiring rapid diagnosis. Treatment typ­
ically involves surgery and antibiotics, tailored to factors like overall 
health, infection severity, and underlying conditions.1156 Residual aortic 
disease progression depends on the underlying condition, such as 
HTAD, and requires individualized surveillance.
After TEVAR for DTA aneurysm, late complications are higher 
than with surgery (up to 38%), leading to re-operation in 24% of 
cases.1150 However, over 80% of TEVAR complications arise within 
the initial post-operative years.1157 Notably, FET results in fewer stent 
graft-related complications: 2% stent-induced intimal tear, 3% endo­
leak, and 7% need for additional TEVAR.1158
After surgical treatment of TAAs, the protocol is a first CCT scan at 
discharge or 1 month, then another in the first post-operative year (at 
6, 9, or 12 months), followed by a 2 year scan, and if no issues arise, 
scans every 5 years thereafter (Figure 25).1062,1159 Stricter lifelong sur­
veillance is recommended after TEVAR: after first imaging at 1 month, 
yearly controls are recommended for at least the first 5 post-operative 
years, then less frequently if no complications are detected (Figure 27).
Cardiovascular risk profile modification, cardiac rehabilitation, and 
lifestyle adjustments are an integral part of post-aneurysm repair 
follow-up (Figure 7).24
9.2.7.2. Follow-up after abdominal aortic aneurysm treatment
Evidence for follow-up after AAA is more robust than after TAA re­
pair.70,1096 Post-surgery, anastomotic or para-anastomotic complica­
tions are rare (2%–4%).1160
In contrast, EVAR has higher 
complication rates (16%–30%), necessitating lifelong surveil­
lance.1079,1150 EVAR’s survival advantage over surgery diminishes after 
8 years, with higher aneurysm-related mortality risk for EVAR.1079
However, most failures are detectable early, and complications seldom 
occur later in patients with normal early controls.1161,1162 CCT effect­
ively detects early EVAR abnormalities,1163 but DUS/CEUS surveillance 
proves accurate, reducing the need for radiation and nephrotoxic 
agents, and lowering costs (Figure 27).1164–1167
Interestingly, a meta-analysis found low compliance of patients to 
post-operative surveillance without differences in all-cause mortality, 
aneurysm-related mortality, and re-intervention between compliant 
and non-compliant patients.1168 Altogether, the above-mentioned evi­
dence supports stratified methods of surveillance,1096
with 
Recommendation Table 42 — Recommendations for 
the management of patients presenting with endoleaks
Recommendations
Classa
Levelb
It is recommended to perform 30 day imaging after 
TEVAR/EVAR, by CCT and DUS/CEUS, to assess the 
success of intervention.1096
I
B
It is recommended to re-intervene to achieve a seal 
in patients with type I endoleak after TEVAR/ 
EVAR.1137,1148
I
B
It is recommended to re-intervene, principally by 
endovascular means, to achieve a seal in patients with 
type III endoleak after TEVAR/EVAR.1139
I
B
Re-intervention, principally with an endovascular 
approach or embolization, should be considered in 
patients with type II or V endoleak and significant sac 
expansion ≥10 mm or significantly decreasing 
proximal or distal seal.1096,1149
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; CEUS, contrast-enhanced ultrasound; DUS, 
Duplex ultrasound; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3617


<!-- PAGE 81 -->

### Page 81

identification of high-risk situations (e.g. older patients, inadequate seal­
ing, type II endoleaks, no early post-procedural shrinkage of the aneur­
ysmal sac) for which more frequent evaluation should be 
planned.1161,1169,1170
Follow-up of OMT is highly important in AAA patients (Figure 7).24
Statin use after AAA repair (surgical or EVAR) is associated with de­
creased short- and long-term mortality.1171 In addition, surveillance 
for aneurysm development in other arterial locations is recommended.
9.3. Acute thoracic aortic syndromes
9.3.1. General concepts
Acute aortic syndromes are life-threatening emergencies, including classic 
AAD, IMH, PAU, aortic pseudo-aneurysm, and traumatic aortic injuries 
(TAI). They involve aortic wall damage and share a dynamic, overlapping 
pathophysiology, clinical presentation, and diagnostic and therapeutic ap­
proaches.24,172,174,910 AAS may also be iatrogenic following open or endo­
vascular/percutaneous procedures, or cardiac surgery.1172
To guide AAS management, several anatomical classifications have 
been developed, the Stanford and the DeBakey systems being the 
most widely used. The Stanford system classifies AAS according to 
whether the ascending aorta is involved (type A or DeBakey type I 
and type II) or not (type B or DeBakey type IIIa and type IIIb) regardless 
of the site of origin of the intimal tear.172,174,910,1173 This classification 
considers not only anatomical and treatment aspects, but also prognos­
tic implications, since patients with DeBakey type II AAS will probably 
be left without structural aortic wall lesions after surgery (Figure 28).
Furthermore, if time elapsed from symptom onset to diagnosis is con­
sidered, AAS can be divided into hyperacute (<24 h), acute (1–14 days), 
subacute (15–90 days), and chronic (>90 days) (Figure 28).1174–1176
A new classification considers the intimal tear’s entry site and dissec­
tion extension (Figure 29).136 Subscript P describes the proximal in­
volved aorta, and subscript D indicates the distal zone. This 
classification guides treatment decisions for sealing the entry tear. 
AADs limited to the aortic arch or originating as retrograde dissections 
from the descending aorta that extend into the arch and stop before 
the ascending aorta are termed as non-A non-B AD.1177–1179
Recently, a European update of the Stanford classification—Type 
Entry Malperfusion (TEM) classification—has been proposed.1180 This 
combines information about the type of dissection, its extent, and 
the presence of complications (malperfusion), thus providing greater 
prognostic insights (Figure 29). This classification is recommended by 
the European Association for Cardio-Thoracic Surgery. The TEM and 
other classifications are described in the Supplementary data online, 
Section 1.6.
9.3.1.1. Epidemiology and risk factors
Classic AAD (comprising 80%–90% of AAS; incidence of 2.6–3.5 cases 
per 100 000 person-years)24,1181 is characterized by the presence of an 
intimal flap separating the true from the false lumen (FL).24,172,910
Recommendation Table 43 — Recommendations for 
follow-up after treatment of aortic aneurysms (see 
also Evidence Table 12)
Recommendations
Classa
Levelb
Thoracic aortic aneurysm
After open repair of TAA, an early CCT is 
recommended within 1 month, and then yearly CCT 
follow-up for the first 2 post-operative years and 
every 5 years thereafter is recommended if findings 
are stable.c,70,1153,1159
I
B
After TEVAR, follow-up imaging is recommended at 
1 and 12 months post-operatively, then yearly until 
the fifth post-operative year if no abnormalitiesd are 
documented.70,1153,1158
I
B
After 5 post-operative years without complications, 
continuing long-term follow-up of TEVAR by CCT 
every 5 years should be considered.70,1153,1158
IIa
B
If growth of the excluded aneurysm is observed, 
without evidence of type I or III endoleak, repeating 
CCT every 6–12 months, depending on the growth 
rate observed, should be considered.1150
IIa
C
When frequent controls are required in TAA 
patients treated either by open or endovascular 
repair, CMR should be considered instead of CCT 
after the first year of follow-up. However, the choice 
between these imaging modalities should be based 
on individual patient factors, the potential for 
artefacts, and the local availability and expertise in 
specific imaging techniques.1155
IIa
C
Abdominal aortic aneurysm
After open repair of AAA, first follow-up imaging is 
recommended within 1 post-operative year, and 
every 5 years thereafter if findings are stable.1079,1096
I
A
After EVAR, follow-up imaging is recommended with 
CCT (or CMR) and DUS/CEUS at 1 month and 12 
months post-operatively, then, if no abnormalitiesd 
are documented, DUS/CEUS is recommended every 
year, repeating CCT or CMR (based on potential 
artefacts) every 5 years.70,1079,1100,1163–1165,1167
I
A
In higher-risk patients, i.e. with inadequate sealing or 
type II endoleak at first CCT control, more frequent 
DUS/CEUS imaging should be 
considered.e,1096,1161,1164,1165,1167
IIa
B
In low-riskf patients, from 1 year post-operatively 
after EVAR, repeating DUS/CEUS every 2 years 
should be considered.1096
IIa
B
Continued 
If any abnormality during DUS/CEUS is found, 
confirmation should be considered using additional 
CCT or CMR (based on potential artefacts).1163,1166
IIa
B
In post-treatment surveillance, administration of 
OMT (see 8.1.2.2 and 8.2.4) and assessment of 
aneurysm development/growth in other arterial 
segments should be considered.
IIa
C
© ESC 2024
AAA, abdominal aortic aneurysm; CCT, cardiovascular computed tomography; CEUS, 
contrast-enhanced ultrasound; CMR, cardiovascular magnetic resonance; DUS, Duplex 
ultrasound; EVAR, endovascular aortic repair; OMT, optimal medical treatment; TAA, 
thoracic aortic aneurysm; TEVAR, thoracic endovascular aortic repair. 
aClass of recommendation. 
bLevel of evidence. 
cBoth at the level of the treated segment and in the residual native aorta. 
dIncluding: endoleak (any type), enlargement of the excluded aneurysm, and stent graft 
migration/separation/fracture. 
ee.g. imaging every 6 months during the first year, thereafter every 2–3 years. 
fLow-risk: early sac shrinkage >10 mm, relatively younger age (<70 years), proximal and 
distal sealing >10 mm, no endoleak.


<!-- PAGE 82 -->

### Page 82

Acute aortic dissection occurs mostly in males (∼65%) and in the 
seventh decade of life (∼63 years).1175,1182 Multiple risk factors often 
coexist directly linked to factors like wall stress (with systemic hyper­
tension being the most common) and/or aortic media abnormalities, 
including syndromic and non-syndromic genetic diseases. HTAD, 
BAV, prior aortic surgery, and larger aortic dimensions are more fre­
quent among young patients (<40 years).24,1182,1183 Systemic hyperten­
sion and cocaine abuse are more common among African-American 
Classification of timing 
Frequency of acute aortic syndrome
Classification of acute aortic syndromes
DeBakey I 
Stanford A
Stanford B
DeBakey II 
DeBakey IIIa
DeBakey IIIb 
60%
10–15%
25–30%
Hyperacute
AAS
Time
Acute
AAS
Subacute
AAS
Chronic
AAS
AAS
onset
24 hours post-AAS
14 days post-AAS
90 days post-AAS
Figure 28 Anatomical and temporal classification of acute aortic syndrome. AAS, acute aortic syndrome.
ESC Guidelines                                                                                                                                                                                          3619


<!-- PAGE 83 -->

### Page 83

than among white patients.1184,1185 Of note, the incidence of iatrogenic 
AD during cardiac catheterization is very low (around 0.01%–0.02%) 
and during cardiac surgery is 0.06%–0.23%, with favourable in-hospital 
and long-term prognosis.1186,1187
9.3.1.1.1. Sex differences. A specific female sex phenotype appears to 
be evident in acute TAAD. At admission, acute TAAD female patients 
are usually older but have lower body mass index (BMI), BSA, and cre­
atinine plasma levels. They present less frequently with active smoking, 
Proximal extent
Distal extent
Type
AD
Entry tear:
Zone 0
0
1
2
3
4
5
6
7
8
9
10
11
12
0
1
2
3
4
5
6
7
8
9
10
11
12
BPD
Entry tear:
≥Zone 1
ID
Unidentified entry tear involving
Zone 0
Type
Entry
0
1
2
3
4
5
6
7
8
9
10
11
11
10
A
B
Non-A non-B
M0 - no malperfusion
M1 - coronary
M2 - supra-aortic
M3 - spinal, visceral, iliac
(-) no clinical symptoms
(+) clinical symptoms
E0
E1
E
E
E
E2
E3
E
E0
E3
E
E
E0
E3
E2
Malperfusion
T
E
M
TEM aortic dissection classification
Figure 29 Aortic dissection classification system based on the 2020 Society for Vascular Surgery/Society of Thoracic Surgeons Reporting Standards 
and the European update of the Stanford classification—Type Entry Malperfusion classification. A, type A aortic dissection; B, type B aortic dissection; 
non-A, non-B, aortic dissection limited to the aortic arch or retrograde dissection extending into the arch (but not in the ascending aorta). Upper panel: 
Classification of AAD considering the intimal tear’s entry site and dissection extension. Subscript P describes the proximal involved aorta, and subscript 
D indicates the distal zone. Lower panel: The TEM classification is the European update of the Stanford classification combining information about the 
Type of dissection (T), the Entry site (E), and the presence of Malperfusion (M). Also refer to Supplementary data online, Section 1.6. Society for Vascular 
Surgery/Society of Thoracic Surgeons (SVS/STS). Reproduced with permission from.136,1180


<!-- PAGE 84 -->

### Page 84

BAV, and previous cardiac surgery,1188 but diabetes mellitus is more 
common in women than in men. In-hospital surgical mortality does 
not differ between sexes, although 10 year survival appears to be higher 
in men. Among only medically treated acute TAAD patients, prohibitive 
high in-hospital mortality has been equally registered for both sexes 
(men 58.6% vs. women 53.8%).1188 However, further studies are 
needed to explore AAD sex differences to design appropriate diagnos­
tic and therapeutic interventions and preventive strategies.1189
Pregnancy increases the risk of AAS, more often in the last trimester 
(50%) or post-partum (33%).1190
9.3.1.1.2. Chronobiology. Acute aortic dissection presents chrono­
biological patterns, with a higher incidence in morning hours (peak be­
tween 8 am and 9 am) and winter (peak in January in the Northern 
Hemisphere).24,1175
9.3.1.1.3. Outcomes. For acute TAAD, in-hospital mortality has de­
creased from 31% to 22% due to better surgical outcomes; for acute 
type B aortic dissection (acute TBAD), in-hospital mortality has remained 
stable over the years (14%).1175,1182 Including deaths before admission, 30 
day mortality for AAD ranges from 23% to 55.8% in Western Europe.1181
D-dimer and chest X-Ray
D-dimer
Chest X-Ray
POCUS
High risk: ADD-RS ≥2
AAS confirmed
AAS excluded
+
+
+
–
Low risk: ADD-RS <2
Clinical suspicion of AAS: determine ADD-RSa
ECG: exclude STEMI (2023 ESC ACS Guidelines)
Chest X-Ray and laboratory test and POCUS (if available)
Consider alternative diagnosis
CCT neck-pelvis without delay and/or focused TTEa + ECG
CCT
Aortic dissection detection-risk score (ADD-RS)a
High-risk examination feature
High-risk pain feature
High-risk condition
If one present = 1 ADD-RS point
If present = 1 ADD-RS point
If one present = 1 ADD-RS point
Marfan syndrome
Family history of aortic disease
Known aortic valve disease
Recent aortic manipulation
Known aortic aneurysm
Haemodynamic instability
(hypotension/shock)
Perfusion deficit (pulse deficit,
differential systolic blood pressure)
Focal neurological deficit
New AR murmur
Chest, back, or abdominal pain described as abrupt onset,  severe intensity, or ripping/tearing
+
–
Figure 30 Multiparametric diagnostic work-up of acute aortic syndrome. AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk 
score; CCT, cardiovascular computed tomography; ECG, electrocardiogram; POCUS, point-of-care ultrasound; STEMI, ST elevation myocardial infarc­
tion; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; +, findings compatible with AAS. aIn haemodynamically unstable 
patients: consider TTE and/or TOE as first-line imaging technique depending on local expertise and availability.
ESC Guidelines                                                                                                                                                                                          3621


<!-- PAGE 85 -->

### Page 85

Non-A, non-B dissection patients tend to be younger (median age 59 
years) and have a lower mortality than acute TAAD patients.1180,1191
The 30 day mortality in patients medically treated is around 14%,1179
and 4.4% for those successfully treated surgically.1177
9.3.1.2. Clinical presentation
Acute TAAD typically presents with sudden, severe chest/back pain, 
often described as ‘sharp’, alongside a history of arterial hypertension. 
However, around 6.4% of patients do not experience pain.1182,1192,1193
Hypotension and shock are frequent. Unique clinical features specific to 
acute TAAD include pericardial effusion, aortic regurgitation, and cor­
onary artery involvement leading to ACS (particularly the right coron­
ary artery).1194 Stroke may occur when supra-aortic branches are 
involved. Additional complications encompass paraplegia (resulting 
from spinal ischaemia), acute kidney injury, intestinal ischaemia, or 
limb ischaemia. Isolated abdominal aortic dissection occurs in about 
1.3% of acute TBAD cases when the intimal flap originates below or 
at the renal arteries.1195
A complete clinical evaluation is mandatory, consisting of a central 
neurological evaluation, heart and lung auscultation (aortic diastolic 
murmur, pericardial rubbing, etc.), abdominal palpation (tenderness, 
etc.), and assessment of peripheral pulsations as well as mobility and 
sensibility in upper and lower limbs. SBP differences (pulse deficit) 
should be sought.
9.3.1.3. Diagnostic work-up
Early diagnosis is still a major pitfall in managing AAD patients, there­
fore, a diagnostic multiparametric algorithm is proposed (Figure 30). 
It combines the aortic dissection detection-risk score (ADD-RS) with 
D-dimer (DD) and has been validated with an excellent capacity to 
rule out AAS.1196–1200
In patients presenting with chest pain, a routine chest radiography 
and ECG are recommended to exclude other aetiologies; however, 
the absence of these findings should not delay further investigations.163
Laboratory tests should be obtained, but awaiting results should not 
delay imaging if there is a high probability of AAD. The most common 
finding is an increase in DD level, which is the case in several other con­
ditions such as pulmonary embolism or infections. When DD levels are 
below 500 ng/mL, AAD is unlikely.172,1201
A focused TTE at the emergency department, if available, is recom­
mended1202,1203 to assess pericardial effusion, wall motion abnormal­
ities, aortic regurgitation, and aortic diameters. Sometimes a 
dissection flap can be visualized, especially when using contrast.165
When AAD is suspected, ECG-gated CCT from neck to pelvis is the 
preferred imaging technique, with 100% sensitivity and 98% specificity, 
and should be performed as soon as possible to confirm diagnosis, lo­
calize entry tear, extension (type A vs. type B), and malperfu­
sion.170,172,1182,1204 When ACS or pulmonary embolism are still in 
the differential diagnosis, a triple rule-out ECG-gated CCT scan proto­
col can be performed be performed to avoid motion artefacts mimick­
ing acute TAAD.170,1205,1206 However, this strategy is associated with 
higher contrast and radiation doses, might be less accurate for AAS, 
and does not reduce the need for additional imaging tests.170,1207 If 
CCT is not available or in haemodynamically unstable patients, TOE 
can confirm diagnosis. TOE is especially useful pre-, intra, and post- 
operatively to monitor changes in the anatomical AAD configuration 
or surgical complications. CMR could be a valuable alternative for 
CCT, however, it is less available, requires a longer examination time, 
relies on patient collaboration, and consequently, is less frequently 
used in the acute setting. CCT, CMR, and TOE all provide good diagnos­
tic accuracy172,1204 (See Supplementary data online, Table S4).
9.3.1.4. Therapeutic intervention in acute aortic dissection
9.3.1.4.1. Initial treatment. Acute aortic syndrome care should be 
centralized in experienced centres and managed by aorta teams.1211
The cornerstone in AAS is initial reduction of the pulse pressure by low­
ering SBP below 120 mmHg and heart rhythm ≤60 beats per minute 
(b.p.m.). The aim is to decrease aortic wall stress to avoid further exten­
sion of dissection with possible rupture or malperfusion.174,1212–1216
Intravenous beta blockade (labetalol as a first choice due to its alpha- 
and beta-blocking properties) is generally accepted as the best option. 
Also, esmolol, an ultra-short-acting beta-blocker, can be titrated quickly 
and easily, making it particularly useful in the acute setting. If contraindi­
cated, i.v. non-dihydropyridine CCBs could be used for heart rate control. 
If the BP target is not reached after initiating beta-blockers, i.v. vasodilators 
such as nitrates or dihydropyridine CCBs (e.g. nicardipine) can be adminis­
tered concomitantly with rate-controlling agents first to avoid reflex 
tachycardia. In cases of malperfusion, higher BP could be tolerated to op­
timize perfusion to the threatened region. Early placement of an arterial 
line to monitor BP invasively is mandatory and admission to an intensive 
care unit is advisable (including ECG and urine output monitor­
ing).1205,1217,1218 Antihypertensive treatment can be gradually switched 
to oral therapy once BP and heart rate targets are reached and the patient 
has normal gastrointestinal transit. Adequate pain control is necessary to 
help reach these haemodynamic goals. Intravenous morphine can be cau­
tiously titrated to induce pain relief (Figure 31).
In-hospital mortality, reaching 60%, correlates with AAS type, loca­
tion, patient comorbidities, and treatment. Risk rises with complications 
like pericardial tamponade, coronary involvement, or malperfusion. 
Figure 32 describes the main signs and symptoms of complications and 
the mortality rate associated with them.1219–1223
Recommendation Table 44 — Recommendations for 
diagnostic work-up of acute aortic syndromes
Recommendations
Classa
Levelb
In unstable patients who cannot be transferred to CCT, 
TOE is recommended for diagnosis1204,1208,1209 and 
evaluation of the coeliac trunk and mesenteric artery.1210
I
B
In patients presenting with clinical features compatible 
with possible AAS, a multiparametric algorithm for 
ruling in or out AAS using the ADD-RS is 
recommended.1196–1200
I
B
ECG-gated CCT from neck to pelvis is recommended 
as the first-line imaging technique in patients with a 
suspected AAS since it is widely available, accurate, 
and provides information about the entry tear, 
extension, and possible complications (malperfusion, 
dilatation, or rupture).170
I
C
In patients with suspected AAS, focused TTE (with 
use of contrast if feasible) is recommended during the 
initial evaluation.170
I
C
In patients with suspected AAS, TOE is 
recommended to guide peri-operative management 
and detect complications.170
I
C
In patients with suspected AAS, CMR should be 
considered as an alternative imaging technique if CCT 
is not available.170
IIa
C
© ESC 2024
AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk score; CCT, 
cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; ECG, 
electrocardiogram; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography. 
See also Figure 30. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 86 -->

### Page 86

Interventional treatment in acute TAAD and acute TBAD is de­
scribed in the next sections and summarized in Figure 33.
9.3.1.4.2. Type A aortic dissection interventional treatment.
Immediate surgical repair is recommended for acute TAAD, however, 
a high mortality rate (∼50% and 1%–2% per hour) within the first 48 h 
is described if managed medically only.1232 Despite advances in surgi­
cal and anaesthetic techniques, there is still a high risk of peri- 
operative mortality (17%–25%) and neurological complications 
(18%).1233 In recent reports from the International Registry of 
Acute Aortic Dissection (IRAD), medically managed patients had a 
23.7% mortality rate (0.5% per hour) compared with 4.4% (0.09% 
per hour) for those undergoing surgery.1234 Analyses of pre- and 
post-July 2007 IRAD data showed no difference in 48 h mortality 
for medically treated patients, but surgical mortality decreased 
(from 5.5% to 3.9%).1234 As surgical techniques have improved, data 
have shown improved post-operative survival rates.1235 The use of 
the GERAADA (German Registry of Acute Aortic Dissection Type 
A) score1236 should be considered in patients undergoing surgery to 
determine 30 day mortality (https://www.dgthg.de/de/GERAADA_ 
Score).
Surgical intervention surpasses conservative therapy in long-term 
follow-up,1237 even for challenging cases. Thus, all acute TAAD pa­
tients should receive surgical treatment; however, cardiogenic shock 
secondary to pericardial tamponade, malperfusion of coronary arter­
ies, mesenteric circulation, lower extremities, kidneys, or brain, and/ 
or coma are major predictors for post-operative mortality 
(Figure 32).1234,1238 Among octogenarians, in-hospital mortality 
was lower after surgery than with conservative treatment 
(37.9% vs. 55.2%), but with a non-significant difference due to small 
sample size.1239 While some have reported excellent surgical and 
quality of life (QoL) outcomes in elderly patients,1239 others found 
(Class I)
(Class I)
(Class I)
+
1
2
3
Intravenous labetalol or esmolol
(if contraindication to beta-blockade,
substitute with diltiazem or verapamil)
Titrate to heart rate ≤60 b.p.m.
Intravenous opiates
Titrate to pain control
Intravenous vasodilator (nitroprusside or angiotensin-converting enzyme inhibitor)
(Goal is lowest possible BP that maintains adequate organ perfusion)
Continue to step 3
if systolic
BP ≥ 120mmHg
Titrate to BP <120 mmHg
Rate/pressure control
Pain control
Pressure control
Figure 31 Medical management of acute aortic syndrome. BP, blood pressure; b.p.m: beats per minute.
Recommendation Table 45 — Recommendation for 
medical treatment in acute aortic syndromes
Recommendations
Classa
Levelb
In patients with AAS, immediate anti-impulse 
treatment targeting SBP <120 mmHg and heart rate 
≤60 b.p.m. is recommended. In cases of spinal 
ischaemia or concomitant brain injury, maintaining 
higher MAP is recommended.1214–1216
I
B
Intravenous BBs (e.g. labetalol or esmolol) are 
recommended as first-line agents. If necessary, i.v. 
vasodilators (e.g. dihydropyridine calcium blockers or 
nitrates) could be added.174,1224
I
B
Invasive monitoring with an arterial line and continuous 
three-lead ECG recording, as well as admission to an 
intensive care unit, is recommended.1205,1217,1218,1225
I
B
In patients with AAS who can be managed 
conservatively and who achieved haemodynamic 
targets with i.v. anti-impulse therapy, switching to 
oral BBs and, if necessary, up-titration of other 
BP-lowering agents, is recommended after 24 h if 
gastrointestinal transit is preserved.174,1216
I
B
Adequate pain control to achieve haemodynamic 
targets is recommended.174
I
C
If the patient has a contraindication for BBs, a 
non-dihydropyridine calcium blocker should be 
considered.174,1224
IIa
B
© ESC 2024
AAS, acute aortic syndrome; BB, beta-blocker; BP, blood pressure; b.p.m., beats per minute; ECG, 
electrocardiogram; i.v., intravenous; MAP, mean arterial pressure; SBP, systolic blood 
pressure. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3623


<!-- PAGE 87 -->

### Page 87

a higher rate of post-operative neurological complications.1240 Based 
on the current evidence, age per se should not be considered an ex­
clusion criterion for surgery.
For optimal repair of acute TAAD regarding long-term outcomes, 
including risk of late death and late re-operation, the following points 
need to be addressed. First, in most cases of aortic regurgitation as­
sociated with acute TAAD, the aortic valve is essentially normal and 
can be preserved.1241–1243 Alternatively, valve replacement can be 
performed in cases of pre-existent structural valve disease. The de­
cision whether to replace the aortic root is based on the presence of 
tears in the sinuses, extensive dissection of sinuses/coronary ostia, 
or significant dilatation of the root. The risk of late dilatation of 
the aortic sinuses when spared should be considered.1242,1244
Additionally, the distal extent of aortic repair is a topic of debate. 
Ascending aortic replacement or hemi-arch replacement alone is technic­
ally easier and effectively closes the entry site but leaves a large part of the 
diseased aorta untreated. In acute TAAD with visceral or renal malperfu­
sion, the primary entry tear is often in the descending aorta. Consider ex­
tended therapies like FET repair for these patients, offering a complete 
repair with a low chance of late re-intervention despite increased tech­
nical complexity.1245–1247
For potential cardiac arrest from pericardial tamponade, consider an 
emergency pericardial puncture as a temporary life-saving measure be­
fore transferring to the operating room.1248,1249
The frozen elephant trunk technique
The FET technique addresses complex aortic and aortic arch 
issues in a single operation,1260–1263 creating a secure landing zone 
for future interventions. Recent advances involve ‘proximalization’— 
placing the FET in the aortic arch’s zone 0 or 1, treating proximal 
arch aortic issues, and enhancing the landing zone for downstream 
procedures—which surpasses the standard elephant trunk 
technique.1264,1265
Malperfusion in type A aortic dissection
In acute TAAD with malperfusion, operative mortality correlates 
with the number of affected organs. Around 30% of patients develop 
malperfusion syndrome due to elevated pressure in the FL caused by 
substantial proximal inflow and insufficient distal outflow, leading to 
visceral organ and limb ischaemia.1175 The intimal flap may extend 
into peripheral arteries, causing a static ‘stenosis-like’ blockage. 
Malperfusion typically combines dynamic and static obstructions, ne­
cessitating surgical and hybrid interventions for affected patients 
(Figure 34).
Mesenteric malperfusion, a life-threatening complication with a 
mortality rate of 65%–95%, leads to diverse treatment approaches. 
Some centres prefer early direct reperfusion before aortic surgery, 
Recommendation Table 46 — Recommendations for 
intervention in type A acute aortic dissection
Recommendations
Classa
Levelb
In patients with acute TAAD, emergency 
surgical consultation and evaluation 
and immediate surgical intervention 
is recommended.1182,1250
I
B
In patients with acute TAAD who have 
extensive destruction of the aortic root, a 
root aneurysm, or a known genetic aortic 
disorder, aortic root replacement is 
recommended with a mechanical or 
biological valved conduit.1251–1255
I
B
In patients presenting with acute TAAD, transfer 
from a low- to a high-volume aortic centre with the 
presence of a multidisciplinary team should be 
considered to improve survival if transfer can be 
accomplished without significant delay in 
surgery.1256,1257
IIa
B
In selected patients, a valve-sparing root repair may 
be considered, when performed by experienced 
surgeons.1251,1258,1259
IIb
B
© ESC 2024
TAAD, type A aortic dissection. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 47 — Recommendations for 
aortic repair strategies in type A acute aortic dissection
Recommendations
Classa
Levelb
In patients with acute TAAD and a partially dissected 
aortic root but no significant aortic valve leaflet 
pathology, aortic valve resuspension is 
recommended over valve replacement.1251–1255
I
B
In patients with acute TAAD undergoing aortic 
repair, an open distal anastomosis is recommended 
to improve survival and increase FL thrombosis rates. 
1266–1269
I
B
In patients with acute TAAD without an intimal tear 
in the arch or a significant arch aneurysm, hemi-arch 
repair is recommended over more extensive arch 
replacement.1270–1272
I
B
In patients with acute TAAD and a secondary intimal 
tear in the arch or proximal DTA, an extended aortic 
repair with stenting of the proximal DTA (e.g. by 
using the frozen elephant trunk technique) may be 
considered to reduce late distal aortic complications 
(e.g. aneurysm evolution of the remaining dissected 
descending aorta).1273,1274
IIb
C
© ESC 2024
DTA, descending thoracic aorta; FL, false lumen; TAAD, type A aortic dissection. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 88 -->

### Page 88

while others favour conventional central aortic repair.1275
The IRAD registry highlights the superiority of a surgical and hybrid 
approach over medical or endovascular therapy alone. Central aor­
tic repair effectively restores perfusion, showing promising results 
for renal malperfusion, extremity malperfusion, uncomplicated 
mesenteric malperfusion, or combinations.
Cerebral malperfusion, equally grave, triggers treatment debates ne­
cessitating a multidisciplinary strategy. Evidence supports surgical 
Hypotension/shock
Cardiogenic shock related to:
Tamponade (pulsus paradoxus)
Aortic regurgitation (diastolic murmur)
Major coronary occlusion by compression or dissection flap
Hypovolaemic shock (aortic rupture)
Branch vessel involvement
Bowel ischaemia
Lactic acidosis
Elevation liver function test
Hemiplegia, hemiparesis or paraplegia
Stroke, coma or altered mental status
Acute kidney injury or oliguria
Peri-aortic haematoma
Mortality
56%
28.6%
10.5%
4.4% 
N
N
N
Y
Y
Y
Figure 32 Complications in acute aortic syndromes, clinical evidence associated with malperfusion syndrome, and in-hospital mortality associated 
with these complications.
ESC Guidelines                                                                                                                                                                                          3625


<!-- PAGE 89 -->

### Page 89

Initial diagnosis based on CCT
Type A AAD
Type B AAD
Favourable TEVAR anatomyc
Favourable TEVAR anatomyc
 + life expectancy >5 years
OMT + surveillance
Complicated type B AAD
Uncomplicated type B AAD
Open cardiac surgery
(Class I)
Endovascular repair
(Class I)
Open surgical repair
(Class I)
Endovascular repair in the subacute phased
(Class IIa) 
OMT + more frequent surveillance
One of the following:
Contained or free aortic rupture
Organ malperfusion
Extension of the dissectionª
Progressive aortic enlargementª
One of the following:
High-risk features at CCT or CMR
Ao diameter >40 mm
FL diameter >20–22 mm
Entry tear >10 mm
Entry tear at lesser curvature
Haemorrhagic pleural effusion
Evidence of malperfusion
High-risk clinical features
Refractory hypertensionb
Refractory pain >12 h
Need for readmission
   Total Ao diameter >5 mmª
Y
N
Y
N
Y
N
Y
N
Reappearance of pain/symptoms
Figure 33 Interventional treatment algorithm in acute aortic dissection. AAD, acute aortic dissection; Ao, aorta; CCT, cardiovascular computed tom­
ography; OMT, optimal medical treatment; TEVAR, thoracic endovascular aortic repair. aOn serial imaging in the acute phase during the hospital stay. 
bOngoing hypertension despite more than three classes of antihypertensive drugs. cDefined as the presence of adequate proximal and distal landing 
zones for the prosthesis and adequate iliac/femoral vessels for vascular access. dBetween 14 and 90 days after dissection onset.172,1226–1231


<!-- PAGE 90 -->

### Page 90

(Class I)
(Class IIa)
(Class IIa)
(Class I)
Acute type A aortic dissection
Acute type B aortic dissection
Check for presence of acute type A aortic dissection complications
Aortic rupture or CPR
Tamponade
Consider pericardial drainage
Cerebral malperfusion or stroke
Mesenteric malperfusion
Lower extremity malperfusion
Invasive diagnostics  and/or percutaneous malperfusion repair or TEVAR/EVAR
If not performed before aortic surgery and malperfusion persists, optional angiographic control and/or percutaneous malperfusion repair/TEVAR/EVAR
Direct admission to hybrid-OR with onsite aortic team
Anaesthesiological monitoring and intraoperative TOE (if feasible) and preparation for surgery
Immediate aortic surgery (ascending and consider aortic arch or FET based on extension)
Angiographic control and/or percutaneous malperfusion repair or TEVAR or EVAR
Check for presence of acute type B aortic dissection complications
If malperfusion persists
Aortic rupture/
tamponadea
Cerebral 
malperfusion/strokea
Mesenteric malperfusion
Lower extremity malperfusion
TEVAR or EVAR and/or percutaneous malperfusion repair
Static thrombus thrombus
Dynamic
Static + dynamic
F
T
thrombus
Consider pericardial drainage
In case of retrograde aortic dissection, immediate aortic surgery (ascending aorta, aortic arch or
FET, based on extension)
Consider extra-anatomic bypass if lower extremity malperfusion persists
Figure 34 Mechanisms and clinical management of aortic branch obstruction in acute aortic dissection. CPR, cardiopulmonary resuscitation; F, false 
lumen; FET, frozen elephant trunk; OR, operating room; T, true lumen; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular 
aortic aneurysm repair. aDevelops only in retrograde type A dissection.
ESC Guidelines                                                                                                                                                                                          3627


<!-- PAGE 91 -->

### Page 91

intervention, reducing mortality rates to 25%–27%, compared with 
76% with medical management alone.1255,1276 Close monitoring and ra­
pid intervention are essential to achieve optimal outcomes and minim­
ize the risk of permanent neurological damage. A recommended 
algorithm for malperfusion management is displayed in Figure 34.
Endovascular treatment in type A aortic dissection
Endovascular therapy alone has been attempted in highly selected 
cases and the concept of a single endovascular valve-carrying conduit 
was suggested recently but has not yet been validated.1281,1282
Treatment in non-A non-B aortic dissection
Conservative management leads to high mortality (malperfusion, 
aortic rupture); thus, surgery or endovascular therapy is favoured 
within 14 days of symptom onset. For complicated non-A non-B 
aortic dissection with an arch tear, consider FET repair, though if 
feasible, stent-graft implantation for primary tear coverage is an 
alternative.1179,1283
9.3.1.4.3. Acute type B aortic dissection interventional treatment.
Acute TBAD presents without complications (uncomplicated) in 
around 50% of cases.1250 Complicated acute TBAD includes aortic rup­
ture, malperfusion-related issues, rapid aortic expansion, paraplegia/ 
paraparesis, aortic haematoma, refractory pain, and hypertension des­
pite optimal therapy, which associates with an approximately 50% mor­
tality risk with conservative treatment.1193,1250,1284,1285
Open surgery used to be the sole option for complicated acute 
TBAD but carried a mortality rate of 25%–50%. Consequently, 
medical management, now considered the standard for uncompli­
cated cases, significantly reduces mortality. Goals include lowering 
SBP and heart rate with BBs (see Section 9.3.1.4.1). However, adher­
ence is the main limitation of chronic medical treatment, with a rate 
below 50%.1286,1287 Compliance increases with previous aortic sur­
gery, severity of hypertension, and understanding of the disease pro­
cess. Thus, surveillance and disease awareness are imperative for 
these patients.
Endovascular therapy for complicated acute TBAD is now the first- 
line treatment, provided there is favourable anatomy, due to positive 
short- and long-term outcomes.1288–1294 Open surgery is reserved 
for unsuitable cases, and fenestration could be considered as an ultima 
ratio. In selected instances, correcting side branch compression before 
proximal sealing may be considered.136
In recent years, the ADSORB (Acute Dissection Stentgraft OR Best 
Medical Treatment) and INSTEAD-XL (Investigation of Stent Grafts in 
Aortic Dissection with extended length of follow-up) trials1219,1226,1295
have reported that early intervention for uncomplicated acute and sub­
acute TBAD is beneficial compared with medical management, and there 
is important debate on whether to treat patients with uncomplicated 
acute TBAD to improve their life expectancy.1296–1298 Intervention is con­
sidered early within 90 days after onset of symptoms and may be safer 
when performed in the subacute phase (>14 days after onset of symp­
toms), but data are scarce.1298–1300 The Society of Thoracic Surgeons/ 
American Association for Thoracic Surgery (STS/AATS) 2022 
guidelines1294 state that prophylactic TEVAR may be considered also in pa­
tients with suitable anatomy and high-risk features (Figure 33) to reduce 
late aortic-related adverse events. However, this matter is not entirely 
settled, and the Improving outcomes in vascular disease—aortic dissection 
(IMPROVE-AD trial) is currently underway. This trial aims to evaluate clin­
ical outcomes in patients with subacute (from 48 h to 6 weeks) uncompli­
cated type B aortic dissection (uTBAD), comparing upfront TEVAR plus 
medical therapy against medical therapy with surveillance for deterioration.
Aortic characteristics change over time, and endovascular treatment in 
the chronic phase offers limited potential for aortic remodelling. 
Identifying specific characteristics at the time of acute TBAD diagnosis 
that predict a complicated course has been attempted. Independent pre­
dictors of TBAD outcomes include a primary entry tear >10 mm located 
at the inner aortic curvature,1301 initial aortic diameter >40 mm,1301,1302
initial FL diameter >20 mm,1301 number/size of fenestrations between the 
true lumen and FL,1303 stent graft-induced new entry tear,1304,1305 and 
partial FL thrombosis.1306,1307 These parameters are summarized in a 
new system for the categorization of AD, DISSECT (Duration from onset 
of symptoms, Intimal tear location, Size of the aorta based on maximum 
trans-aortic diameter, Segmental Extent, Clinical complications related to 
the dissection, Thrombosis of the FL),1308 which serves as a guide to sup­
port a therapeutic decision (Figure 33).1308 A recent meta-analysis found 
TEVAR to be superior to best medical therapy in uncomplicated acute 
TBAD. Early outcomes were similar, but TEVAR was associated with few­
er long-term events and better aortic remodelling.1297,1298,1309 Thus, in 
stable TBAD with suitable anatomy and high-risk features, pre-emptive 
TEVAR to improve the late outcome should be considered.
Accurate endograft sizing is vital for TEVAR success, as errors may lead 
to complications. Disease-specific factors, such as acute thoracic aortic 
syndromes, pose challenges due to fluctuations in aorta diameter from 
haemorrhagic shock and resuscitation. Sizing decisions must account 
for these changes. Measuring the thoracic aorta based on admission 
CCT may be imprecise, even with proper centreline measurements. 
Real-time imaging, especially IVUS, enhances accuracy, particularly in 
hypovolaemic cases. However, further research is required to clarify 
the role of intraoperative imaging methods (e.g. IVUS, TOE, 3D CCT) 
in endograft sizing and long-term outcomes for optimal patient care.194
Recommendation Table 48 — Recommendations for 
the management of malperfusion in the setting of acute 
aortic dissection
Recommendations
Classa
Levelb
In patients with acute TAAD presenting with 
malperfusion (cerebral, mesenteric, lower limb, or 
renal), immediate aortic surgery is 
recommended.1275,1277
I
B
In patients with acute TAAD presenting with 
cerebral malperfusion or non-haemorrhagic stroke, 
immediate aortic surgery should be considered to 
improve neurological outcome and reduce 
mortality.1255,1276,1278
IIa
B
In patients with acute TAAD presenting with clinically 
significant mesenteric malperfusion syndrome, 
immediate invasive angiographic diagnostics to evaluate 
percutaneous malperfusion repair before or directly 
after aortic surgery, in aortic centres with expertise, 
should be considered.1278–1280
IIa
C
© ESC 2024
TAAD, type A aortic dissection. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 92 -->

### Page 92

9.3.1.4.4. Chronic type B aortic dissection interventional treatment.
Type B aortic dissection is considered as chronic 3 months after the onset 
of symptoms, but it also includes residual type B dissection after repair of 
TAAD. Aortic complications, especially aneurysmal degeneration, will oc­
cur in up to 50% of these patients.1302,1313 Therefore, in chronic TBAD, 
indications for treatment include the onset of new aortic symptoms such 
as rapid expansion, malperfusion, or rupture.1314 In asymptomatic pa­
tients, aneurysmal dilatation is the most important risk factor for rupture, 
reaching 20% when the diameter exceeds 55 mm.1302,1315 Risk of rupture 
increases with diameter; it has been reported a risk of 15.3% and 18.8% 
between 50–55 mm and 54–56 mm, respectively, thus suggesting 
50–55 mm as a threshold for elective surgery.1316 However, smaller 
diameters should be considered in patients with HTAD. According to sev­
eral studies, mortality in the chronic phase is high (40%–70%) and it is 
mainly related to patients’ comorbidities, such as heart disease and stroke.
Open repair
Despite the lack of data comparing open repair vs. TEVAR in chronic 
TBAD, open surgery remains the first-line treatment in low-risk pa­
tients or those with HTAD. The STS/AATS guidelines1294 state that 
open repair should be considered in chronic TBAD patients with indi­
cation for intervention, unless comorbidities are prohibitive or anatomy 
is not suitable for TEVAR. The surgical technique for chronic TBAD is 
like those for degenerative aneurysms, but repair is more complex due 
to the dissection flap.1317 Surgical mortality rates between 6% and 11% 
and SCI rates between 3% and 11% have been reported.1317–1321
Patients treated in low-volume centres present higher mortality rates 
(up to 20%), which reinforces the recommendation for centralization 
in experienced centres.
Endovascular repair
Thoracic endovascular aortic aneurysm repair (TEVAR) is the pre­
ferred treatment for eligible chronic TBAD patients, offering low early 
mortality (<5%), with stroke and SCI rates below 3%. It is also suitable 
for high-risk patients who are not candidates for open repair. The pri­
mary goal is to close the entry tear, induce FL thrombosis, and promote 
aortic remodelling to mitigate growth and rupture risk.1322,1323 A sys­
tematic review showed 90% immediate technical success and 86% 
complete FL thrombosis. However, FL thrombosis usually occurs 
above the coeliac trunk, necessitating lifelong distal FL surveillance.1324
Coverage of the LSA is often necessary and should be associated with 
revascularization. In a recent meta-analysis1325 comparing TEVAR to 
open repair in chronic TBAD, TEVAR showed lower early mortality, 
stroke rates, SCI, and respiratory complications but a higher re- 
intervention rate. Long-term survival rates were similar, but open re­
pair offered greater durability.1326
Adequate distal sealing poses a challenge due to the dissection extend­
ing to the iliac artery, with additional re-entries, allowing retrograde flow 
into the thoracic aneurysm. In chronic TBAD patients with AA enlarge­
ment, insufficient distal landing, or large re-entry tears, TEVAR alone is 
discouraged. Instead, a comprehensive repair involving the visceral aorta, 
infra-renal aorta, and iliac artery is needed. Recent studies have shown 
favourable results using custom or improvized fenestrated/branched en­
dografts with careful patient selection.1062,1327–1329 A multidisciplinary 
team-based approach in experienced centres is necessary for good 
outcomes.1330
9.3.1.4.5. Management during pregnancy. Management of AD dur­
ing pregnancy requires a multidisciplinary team and specialized centres. 
Initial care should consider general medical recommendations (as pre­
viously described), using drugs with the lowest teratogenic impact.
In cases of type A dissection, if the foetus is viable, caesarean delivery 
will be performed before aortic repair. If the foetus is not viable, surgery 
will be done with the foetus in place.1335,1336 In uncomplicated type B 
Recommendation Table 49 — Recommendations for 
the management of patients presenting with acute 
type B aortic dissection
Recommendations
Classa
Levelb
Medical therapy including pain relief and blood 
pressure control is recommended in all patients with 
acute TBAD.1215,1219,1310,1311
I
B
In patients with complicated acute TBAD, 
emergency intervention is 
recommended.1193,1250,1284,1285,1288,1289,1291–1293
I
B
In patients with complicated acute TBAD, TEVAR is 
recommended as the first-line therapy.c,910,1288–1293
I
B
In patients with acute TBAD, BBs should be 
considered as the first-line medical therapy.1216,1312
IIa
B
In patients with uncomplicated acute TBAD, TEVAR 
in the subacute phase (between 14 and 90 days) 
should be considered in selected patients with 
high-risk featuresd to prevent aortic 
complications.1219,1226,1295,1297,1298,1308,1309
IIa
B
© ESC 2024
BBs, beta-blockers; HTAD, heritable thoracic aortic disease; TBAD, type B aortic 
dissection; TEVAR, thoracic endovascular aortic repair. 
See also Figure 33. 
aClass of recommendation. 
bLevel of evidence. 
cExcept in patients with known or suspected HTAD. 
dFor high-risk features see Figure 33.
Recommendation Table 50 — Recommendations for 
the management of patients presenting with chronic 
type B aortic dissection
Recommendations
Classa
Levelb
Antihypertensive therapy is recommended in all 
patients with chronic TBAD.1331–1333
I
B
In chronic TBAD with acute symptoms of 
malperfusion, rupture, or progression of disease, 
emergency intervention is 
recommended.1302,1313,1314
I
C
In patients with chronic TBAD and a descending 
thoracic aortic diameter ≥60 mm, treatment is 
recommended in patients at reasonable surgical 
risk.1302,1315,1334
I
B
In patients with chronic TBAD and a descending 
thoracic aortic diameter ≥55 mm, an indication for 
intervention should be considered in patients with 
low procedural risk.1302,1316
IIa
C
In patients with chronic post-dissection 
thoracoabdominal aortic aneurysms, the use of 
fenestrated/branched stent grafts may be considered, 
when treatment is indicated.1062,1327–1329
IIb
C
© ESC 2024
TBAD, type B aortic dissection. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3629


<!-- PAGE 93 -->

### Page 93

dissections, strict control of the pregnant patient and foetus with con­
servative medical management is recommended.1224,1335 Although lim­
ited to selected cases, successful TEVAR has been described in 
complicated TBAD.1227 More information is detailed in the 2018 ESC 
Guidelines for the management of cardiovascular diseases during 
pregnancy.1337
9.3.2. Intramural haematoma
Intramural haematoma, constituting 5%–25% of AAS cases, involves 
vasa vasorum haemorrhage within the aortic media, with or without in­
timal disruption (ID).70,172,1338 Most cases (60%–70%) involve the DTA 
(ascending aorta ∼30%, aortic arch ∼10%).70,172,1192 Although it usually 
occurs at an older age than AAD, risk factors and symptoms are simi­
lar;70,172,1192,1338 however, aortic regurgitation, malperfusion syn­
drome, and pulse deficits are less frequent in type A IMH than in 
TAAD.70,172
9.3.2.1. Diagnostic work-up
Diagnostic IMH work-up should be similar to that proposed for AAS 
(Figure 30), but with different morphological features in the imaging 
techniques.
CCT and CMR (followed by TOE) are the leading techniques for 
diagnosis.70,159,171–173 Unenhanced followed by contrast-enhanced 
CCT represents the most used tool in the acute setting (hyperin­
tense signal of aortic wall before contrast administration).70,171,172
The IMH diagnostic hallmark consists of crescentic or circular aortic 
wall thickening in the absence of an intimal flap or aortic wall en­
hancement following contrast administration.70,171,172 CMR is an ex­
cellent imaging technique to detect small IMHs and for the 
differentiation of IMH (hyperenhanced images in T1-weighted 
images) from atherosclerotic thickening of the aorta, thrombus, or 
thrombosed dissection.172 TTE yields low sensitivity (<40% for 
IMH cut-off limit of 5 mm).171
9.3.2.2. Clinical outcomes
Intramural haematoma may evolve into AAD (12% of patients), saccu­
lar (8%) or fusiform aneurysm (22%), and/or ID (54%).1192,1339–1342
Partial or total regression is reported in 34% of patients.70,1192,1343
Outcomes are comparable to those in AAD. In-hospital mortality for 
type A IMH is 26.6% (surgical 24.1% and medical 40.0%). In this regard, 
higher mortality for IMH involving the aortic valvular complex has been 
observed.1175 In-hospital mortality for type B IMH is 4.4% but worsens 
once surgery is indicated (surgical 20.0% vs. medical 3.8%).1175,1344
9.3.2.3. Geographical variations
Reports from South Korea and Japan reveal notable disparities with 
Western nations in IMH incidence (28.9% vs. 5.7% of overall AAD as 
reported by IRAD), treatment strategies, and outcomes. In Eastern 
regions, the majority (80.8%) of type A IMH patients received med­
ical treatment, resulting in significantly improved clinical outcomes 
(in-hospital mortality 6.6% [5.9% for medical and 9.4% for surgi­
cal]).1345 These results may be partially explained by the detection 
of early-stage IMH (mild, uncomplicated cases) at primary cen­
tres.1345–1347
9.3.2.4. Management
Current IMH therapeutic interventions are similar to AAD, with the 
first step consisting mainly of pain and BP control regardless of the ana­
tomopathological features (Figure 31).
9.3.2.4.1. Type A intramural haematoma. As in AAD, type A IMH 
involves the ascending aorta. Surgery (emergency or urgent depend­
ing on clinical status) is recommended. In selected patients with in­
creased operative risk (i.e. multiple comorbidities) and uncomplicated 
type A IMH without high-risk imaging features (Table 16) a 
‘wait-and-see strategy’ in a reference/experienced centre may be 
reasonable.70,172,1348,1349
9.3.2.4.2. Type B intramural haematoma. In type B IMH, the disease 
is in the descending aorta, distal to the left subclavian artery. For un­
complicated type B IMH, initial management involves medical treat­
ment and thorough clinical and imaging monitoring.70,172
If 
uncomplicated type B IMH presents high-risk imaging characteristics 
(see Table 16), the multidisciplinary team should consider endovascu­
lar repair as an option. In contrast, complicated type B IMH warrants 
consideration of TEVAR.1350,1351 However, in unfavourable anat­
omy, open surgery remains an alternative.
ID has been described in 54% of type B IMH cases.1192,1339–1342
Approximately 28% of them are tiny intimal disruptions (≤3 mm) 
that are not related to AAEs. However, 14% of them evolve into focal 
intimal disruptions (FID) (>3 mm), with prognostic implications; thus, 
all patients with ID require close follow-up with imaging techniques. 
In the acute phase, FID has a poor prognosis owing to the high risk 
of aortic rupture and should be treated early and invasively, especially 
large FID (≥10 mm length and ≥5 mm depth).1342,1352 However, in 
the chronic phase, most FIDs evolve with slow aortic dilatation and 
without complications, and they can be managed with medical treat­
ment and close imaging surveillance.1352
Table 16 High-risk features of intramural haematoma 
type A and B
Ascending aorta involvement
Difficult BP control
Persistent/recurrent pain despite aggressive BP control
Maximum aortic diameter: 
• Type A: >45–50 mm
• Type B: >47–50 mm
Progression to aortic dissection
Focal intimal disruption with ulcer-like projection
Haematoma thickness >10 mm (type A) or >13 mm (type B)
Enlarging haematoma thickness
Enlarging aortic diameter
Pericardial effusion at admission (type A)
Recurrent pleural effusion
Detection of organ malperfusion
© ESC 2024
BP, blood pressure. 
Adapted with permission from.172


<!-- PAGE 94 -->

### Page 94

9.3.3. Penetrating atherosclerotic ulcer
Penetrating atherosclerotic ulcer (2%–7% of all AAS cases) is character­
ized by localized ulceration of an aortic atherosclerotic plaque penetrat­
ing through the internal elastic lamina into the media, frequently 
associated with IMH and diffuse atherosclerosis.70,172,174,910,1338,1343
Often, multiple PAUs are present, ranging from 5 to 25 mm in diam­
eter and 4 to 30 mm in depth.70,172,174,1338 They occur mostly in the 
middle and lower DTA, with the aortic arch and AA less involved. 
The ascending aorta is rarely affected,70,172,910,1192 but when this occurs, 
especially complicated with IMH, the risk of rupture is 33%–75% and 
progression to dissection is associated with a high mortality rate.
Most patients are older males, smokers, aged >65, with multiple co­
morbidities like systemic hypertension, CAD, COPD, renal insuffi­
ciency, and concurrent abdominal aneurysm.24,172,910,1357
Symptoms are like those in AAD and may manifest in older age after a 
long asymptomatic phase (often PAU is diagnosed as an incidental finding 
during an imaging examination).24,172,910,1357 It should be highlighted that 
symptom onset may indicate PAU expansion (tunica adventitia involve­
ment); thus, urgent imaging (CCT or CMR) and appropriate therapeutic 
intervention are needed to prevent aortic rupture.70,171,172,174
9.3.3.1. Diagnosis
Diagnostic work-up is described in Figure 30. CCT represents the tech­
nique of choice for diagnosis. TOE and CMR represent possible valid 
alternatives considering availability and local expertise.70,159,171–173 Of 
note, 18FDG-PET-CT is a promising technique since it can detect in­
creased glucose uptake in PAUs as a marker of increased metabolic 
activity and inflammation, which has been associated with major ad­
verse events.1358,1359 This information may be used to guide treatment 
decisions, such as the selection of patients who may benefit from endo­
vascular or surgical intervention.1360
9.3.3.2. Treatment
Medical treatment as described for AD is recommended (Figure 31). 
Management of incidental cases is not clearly defined.174 Small series 
suggest that isolated, asymptomatic, small PAUs may be safely managed 
conservatively with regular surveillance.1361,1362
Surgery is recommended in type A PAU with the option of a 
‘wait-and-see strategy’ in highly selected high-risk patients with no high- 
risk features (Figure 35). However, in uncomplicated type B PAU, med­
ical treatment along with careful clinical and imaging surveillance is re­
commended.174,1350 When intervention is needed, endovascular 
treatment (early and 3 year aortic mortality 7.2% and 10.4%, respect­
ively)1350 should be preferred to open surgery (early and 3 year aortic 
mortality of 15.9% and 25.0%, respectively).174,1350 In cases of uncom­
plicated PAU with high-risk imaging features1363–1365 (Figure 35), endo­
vascular treatment should also be considered. The natural history of 
PAU of the abdominal aorta (AA) with associated IMH is less known. 
In a review of PAU of the AA, endovascular stenting was the preferred 
treatment of choice (62%), followed by open surgical repair (35%) and 
conservative therapy (3%).1366
Recommendation Table 51 — Recommendations for 
the management of intramural haematoma
Recommendations
Classa
Levelb
In patients with IMH, medical therapy including pain 
relief and blood pressure control is 
recommended.24,172
I
C
In type A IMH, urgent surgery is 
recommended.172,1175,1192
I
C
In type B IMH, initial medical therapy under careful 
surveillance is recommended.1175,1192,1347,1350,1353
I
C
In uncomplicatedc type B IMH, repetitive imaging 
(CCT or CMR) is indicated.1175,1192,1347,1350,1353
I
C
In complicatedc type B IMH, TEVAR is 
recommended.1175,1192,1347,1350,1353
I
C
In uncomplicatedc type B IMH but with high-risk 
imaging featuresd, TEVAR should be 
considered.1347,1350
IIa
C
In complicatedc type B IMH, surgery may be 
considered in patients with anatomy unfavourable 
for TEVAR.1175,1192,1347,1350,1353
IIb
C
In selected patients with increased operative risk and 
uncomplicatedc type A IMH without high-risk 
imaging featuresd, a ‘wait and see’ strategy may be 
considered.1348,1354–1356
IIb
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
IMH, intramural haematoma; TEVAR, thoracic endovascular aortic repair. 
aClass of recommendation. 
bLevel of evidence. 
cUncomplicated/complicated IMH refers to the absence or presence of recurrent pain, 
expansion of the IMH, periaortic haematoma, and intimal disruption. 
dHigh-risk features of intramural hematoma type A and B are described in Table 16.
Recommendation Table 52 — Recommendations for 
the management of penetrating atherosclerotic ulcer
Recommendations
Classa
Levelb
In all patients with PAU, medical therapy including 
pain relief and blood pressure control is 
recommended.24,172
I
C
In cases of type A PAU, surgery is recommended.172
I
C
In cases of type B PAU, initial medical therapy under 
careful surveillance is recommended.1347,1350
I
C
In uncomplicated type B PAU, repetitive imaging 
(CMR, CCT, or TOE) is recommended.1347,1350
I
C
In complicated type B PAU, endovascular treatment 
(TEVAR) is recommended.1347,1350,1357
I
C
In uncomplicated type B PAU with high-risk imaging 
features,c endovascular treatment should be 
considered.1347,1350
IIa
C
In selected patients with increased operative risk and 
uncomplicated type A PAU without high-risk imaging 
features,c a ‘wait-and-see’ strategy may be 
considered.1367
IIb
C
In complicated type B PAU, surgery may be 
considered based on anatomy and medical 
comorbidities.1347,1350
IIb
C
In isolated, asymptomatic, small PAUs with no 
high-risk features,c conservative management with 
regular surveillance and medical treatment may be 
considered.24,1361
IIb
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
PAU, penetrating atherosclerotic ulcer; TOE, transoesophageal echocardiography; 
TEVAR, thoracic endovascular aortic repair. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 35 for high-risk imaging features of PAU.
ESC Guidelines                                                                                                                                                                                          3631


<!-- PAGE 95 -->

### Page 95

9.3.4. Aortic pseudo-aneurysm
Aortic pseudo-aneurysms, or false aneurysms, result from aortic wall disrup­
tion, typically caused by factors like trauma,1368 surgery, or infections. They 
are often symptomless, detected incidentally during post-aortic procedure 
imaging. Symptoms may include chest pain, compression, and if untreated, 
they can lead to fatal rupture or other severe complications.1369,1370
Type B PAU
Acute or symptomatic PAU
Chronic or asymptomatic PAU
Follow-up
Appearance of symptoms or signs of impending rupture
Endovascular treatment
(Class IIa)
Optimal medical treatment
(Class I)
Endovascular treatment
(Class I)
Haemodynamic instability
Rupture, contained rupture or signs of impending rupture
Refractory pain
Aortic diameter 55 mm (C)
Large pseudoaneurysm
Presence of IMH or high-risk imaging features (see box below)
High-risk imaging features of PAUs
Maximum PAU width (A) 13–20 mm
Maximum PAU depth (B) 10 mm
Significant growth of PAU width
(A) or depth (B) >5 mm/year
PAU associated with a saccular aneurysm
PAU with an increasing pleural effusion
Significant growth of PAU width
(A) or depth (B) >5 mm/yr 
Aortic diameter 55 mm (C)
High-risk imaging features 
(see box below)
N
Y
Y
Y
N
N
A
B
C
Presence of any of the following
Presence of any of the following
Figure 35 High-risk features in penetrating atherosclerotic ulcer and management of patients with type B penetrating atherosclerotic ulcer. IMH, 
intramural haematoma; PAU, penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair. (A) Maximum PAU width. (B) 
Maximum PAU depth; (C) Maximal aortic diameter at the site of the PAU.910


<!-- PAGE 96 -->

### Page 96

Pseudo-aneurysm repair seems always indicated regardless of size or 
position to prevent progression and rupture. Nevertheless, in some cir­
cumstances and under close follow-up, patients could be moni­
tored by CCT, CMR, or TOE and intervention could be 
postponed unless size expansion, symptoms, or compression of 
surrounding structures occur.1371 Pseudo-aneurysms could be 
treated by open surgery or endovascular treatment (occluders, 
stent grafts, or coils). There is no randomized study comparing 
open surgery vs. TEVAR; however, treatment of choice is com­
monly based on anatomical features, clinical presentation, and 
the patient’s comorbidities and decided by a multidisciplinary 
team in specialized centres.1045,1371
9.3.5. Traumatic aortic injury
Traumatic aortic injury (TAI), commonly from high-speed motor 
accidents or falls, involves partial or complete aorta transection. It 
results from rapid deceleration causing torsion and shearing forces, 
often affecting relatively immobile aorta segments like the aortic isth­
mus (90%), aortic root (5%), or diaphragmatic hiatus (5%).24,70,172
Traumatic aortic injury is classified based on the degree of lesion 
in the aortic wall (Figure 36): grade I (intimal tear), grade II (IMH), 
grade III (pseudo-aneurysm), and grade IV (aortic rupture). In the 
Crash Injury Study, 130/613 deaths (21%) were associated with TAI 
(mortality associated with aortic rupture 91%; at-scene survival 
9%).1372
9.3.5.1. Diagnosis and therapeutic interventions
Due to non-specific symptoms and signs (often obscured by con­
comitant multiple organ injury) a timely diagnosis relies on a high level 
of clinical suspicion.70,172 CCT (accuracy close to 100%) represents 
the technique of choice, acting as a ‘one-stop shop’ to rapidly assess 
the entire skeletal system and internal organs.70,171,172 TOE may be 
an alternative, although limited by availability, local expertise, and po­
tentially a patient’s multiple traumas.24,70,172 Therapeutic interven­
tions are dependent on the extent of aorta lesion and patient 
clinical status as assessed by a multidisciplinary team. Generally, ag­
gressive fluid administration should be avoided because it may ex­
acerbate bleeding, coagulopathy, and hypertension. To reduce risk 
of rupture, mean BP should not exceed 80 mmHg.172 Minimal aortic 
injury (grades 1 and 2) may be managed medically along with strict 
clinical and imaging surveillance; moderate aortic injury (grade 3) 
with semi-elective repair (within 24–72 h) to allow patient stabiliza­
tion (though in some patients urgent repair is needed);24,1373 and se­
vere aortic injury (grade 4) with immediate repair.1374 If there is 
progression of the IMH (grade 2), semi-elective repair (within 
24–72 h) may be considered. TEVAR is preferred (if feasible) to 
open surgery (in-hospital mortality 7.9% vs. 20% and 1 year mortality 
8.7% vs. 17%). In semi-elective repair, if the LSA needs to be covered, 
prior LSA revascularization before TEVAR is suggested to reduce the 
risk of paraplegia 172,1373,1374
9.3.5.2. Long-term surveillance in traumatic aortic injury
In addition to clinical assessment, CCT is the imaging choice for follow- 
up.70,171,172 Cumulative exposure to radiation and iodinated contrast 
medium remains the major limitation in young patients, especially in 
women. A combination of a chest X-ray and CMR (if no graft artefacts) 
would be a valid alternative.24,171,172
9.3.6. Iatrogenic aortic injuries
Iatrogenic aortic lesions are those associated with invasive procedures 
(cardiac surgery, most commonly dissection type A, or coronary angi­
ography, with a similar proportion of type A and B dissections) (see 
Section 9.3.2.1). Incidence is low and ADs are the most common lesions. 
Main risk factors are advanced age, presence of CVRFs, atherosclerosis, 
aortic aneurysms, or PAD (Figure 37). Patients with iatrogenic AAS are 
often painless with correspondingly less chest or back pain.1375
While historically associated with high mortality,1375 recent registries 
like the German GERAADA indicate a mortality rate similar to that for 
spontaneous dissections.1186
Clinical management is based on the underlying lesion (AAD, IMH) 
and location; however, conservative management has been described 
with good results in type A iatrogenic dissection if the coronary flow 
is preserved and the dissection is small.1376 Iatrogenic lesion classifica­
tion is depicted in Figure 37.1377 Although scarce, data support a conser­
vative approach based on evolution in type 1 and 2 lesions (Dunning 
classification), and surgery in type 3.1377 In cases of coronary involve­
ment, stent implantation sealing the flap may be proposed.1376,1377
9.3.7. Long-term follow-up of acute aortic syndrome
Imaging modalities and time intervals for surveillance vary according to le­
sion location (ascending/descending aorta), type of treatment (medical, en­
dovascular, surgical), and underlying disease (HTAD).70,1062,1153Compared 
with the chronic disease setting, follow-up of AAS patients is characterized 
by a higher risk of complications and need for re-operation.1378 Patients re­
ceiving TEVAR for AAS involving the descending aorta are more prone 
Recommendation Table 53 — Recommendations for 
traumatic aortic injury
Recommendations
Classa
Levelb
In cases of severe aortic injury (grade 4), immediate 
repair is recommended.24,1373,1374
I
A
In cases of TAI with suitable anatomy requiring 
intervention, TEVAR is recommended over open 
surgery.24,1373,1374
I
A
In all TAI patients, medical therapy including pain 
relief, and blood pressure and heart rate control, is 
recommended.24,172
I
C
In cases of TAI suspicion, CCT is 
recommended.159,172
I
C
In cases of moderate aortic injury (grade 3), repair is 
recommended.24,1373
I
C
If CCT is not available, TOE should be 
considered.159,172
IIa
C
In minimal aortic injury (grades 1 or 2), initial medical 
therapy under careful clinical and imaging surveillance 
should be considered.24,1374
IIa
C
In cases of progression of the IMH (grade 2), 
semi-elective repair (within 24–72 h) should be 
considered.24,1374
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; IMH, intramural haematoma; TAI, traumatic 
aortic injury; TOE, transoesophageal echocardiography; TEVAR, thoracic endovascular 
aortic repair. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3633


<!-- PAGE 97 -->

### Page 97

(27%–49%) to requiring a second intervention than patients undergoing 
surgical repair.1379,1380 However, need for re-intervention at follow-up 
(after initial treatment of AAD) seems to have a significant impact on sur­
vival for TAAD1381 but not for TBAD.1380
9.3.7.1. Follow-up after invasive treatment
Following surgery for AAS, imaging surveillance will focus on persist­
ence/obliteration of the FL, anastomotic dehiscence, progressive dilata­
tion of residual native aorta (with or without residual dissection), or 
graft infection. CCT is the most used modality, but in patients requiring 
frequent examinations CMR can be considered to reduce radiation.
Compared with outcomes of open surgery for aortic aneurysms, time 
to re-intervention in patients developing complications is significantly 
shorter,1159 also due to the faster average growth of the dissected aorta 
(about 1 mm per year).70 Considering the reported incidence rates 
(around 10%) of complications requiring re-operation, it is reasonable 
to follow patients every 6 months in the first year (including an 
early—within 1 month—echocardiography to follow native or pros­
thetic aortic valve function), then yearly up to the third post-operative 
GRADE
I
GRADE
II
GRADE
III
GRADE
IV
MedTX
(Class IIa)
Med
TX/TEVAR
(Class IIa)
TEVAR/OR
(Class I)
TEVAR/OR
(Emergent)
(Class I)
Intimal tear
Intramural haematoma
Pseudoaneurysm
Rupture
Figure 36 Classification and treatment of traumatic aortic injuries. Med, medical; OR, open surgery repair; TEVAR, thoracic endovascular aortic re­
pair; Tx, treatment.


<!-- PAGE 98 -->

### Page 98

Grade 1
Grade 2
Grade 3
Dunning classification
Older age
Cardiovascular risk factors
Atherosclerosis
Aortic aneurysm
PAD
Risk factors
Aortic canulation
Coronary angiography
4 cm
Aetiology
4 cm
4 cm
Figure 37 Aetiology, risk factors, and classification of iatrogenic aortic injuries. PAD, peripheral arterial disease. Dunning classification of iatrogenic 
aortic dissection:1377: type 1, dissection limited to the sinuses of Valsalva; type 2, dissection of the ascending aorta outside the sinuses but < 40 mm from 
the aortic annulus. type 3, dissection > 40 mm from the annulus.
ESC Guidelines                                                                                                                                                                                          3635


<!-- PAGE 99 -->

### Page 99

year and then every 2–3 years if there are no complications 
(Figure 38).1153,1159
TEVAR implies a higher risk for late re-interventions,1159,1378 and a 
sequence of imaging intervals at 1, 6, 12, 24, 36, 48, and 60 months is 
recommended if no abnormality is detected (shorter intervals should 
be considered in high-risk patients). Thereafter, controls can be per­
formed every 2–3 years. Compared with the time points after surgery, 
an adjunctive early control at 1 month is necessary to exclude asymp­
tomatic retrograde type A dissection induced by TEVAR (70% of cases 
occurring within 30 post-operative days).1382
Besides imaging surveillance, clinical follow-up is aimed at achieving 
strict BP control, limiting the burden of CVRFs, and providing patients 
with counselling for lifestyle modifications and prescriptions for sport 
activity.24 There is evidence that statin treatment may improve survival 
in AAS patients under medical treatment, whereas BBs may improve 
survival in surgically treated patients.1333
9.3.7.2. Follow-up under medical treatment (chronic type B aortic 
dissection, intramural haematoma, penetrating atherosclerotic ulcer)
Around 70% of TBAD patients survive the hyperacute phase. If there is 
no malperfusion, uncontrolled hypertension, or impending rupture, ini­
tiate anti-impulse therapy alongside surveillance.
Chronic aortic dilatation, reaching 55 mm, is the leading cause (about 
40%) of intervention, while acute complications necessitating immediate 
treatment are rare.1301,1383 Imaging controls should be performed at least 
at 1, 6, and 12 months after discharge and yearly thereafter; however, one 
additional earlier scan, e.g. within 3 months, may reveal important changes 
occurring in the subacute phase, when the dissected aorta remains suc­
cessfully amenable to early TEVAR.1383 During surveillance, late complica­
tions may be predicted by imaging features, including the number and 
location of the entry tear(s), and dimensions of the FL, total (true + false) 
lumen, or entry tear.1383 This might help in risk stratification to modulate 
the stringency of surveillance in the individual patient (Figure 33).1213
Concerning findings
Stable
1
6
months
3
1
year
2
years
3
years
4
years
5
years
6
years
Pre-discharge
(1 month)
Pre-discharge
Recommendation for CCT or CMR
From this point on, extend the time intervals for monitoring according to the clinical context
Residual false lumen
No false lumen
Stable
(AD or IMH)
PAU or concerning findings
Treated AAS
(open or endovascular repair)
Medically treated AAS
Figure 38 Algorithm for follow-up after acute aortic syndrome. AAS, acute aortic syndrome; AD, aortic dissection; CMR, cardiovascular magnetic 
resonance; CCT, cardiovascular computed tomography IMH, intramural haematoma; PAU, penetrating atherosclerotic ulcer.


<!-- PAGE 100 -->

### Page 100

Type B IMH and PAU are usually conservatively treated with antihyper­
tensive therapy and watchful monitoring. Most of the medically treated 
IMHs have a favourable course, whereas PAUs are less predictable in terms 
of risk of acute TBAD or rupture.1350 Therefore, for IMH the same surveil­
lance criteria as for medically treated uncomplicated TBAD can be em­
ployed; for PAU more frequent controls are advisable, i.e. one every 6 
months instead of every year. Selectively, in asymptomatic patients with 
2 year growth-rate stabilization and no high-risk features, intervals be­
tween controls can be longer (every 1–2 years) (Figures 35 and 38).70,1384
10. Genetic and congenital diseases 
of the aorta
10.1. Genetic and chromosomal diseases
This section discusses genetic and congenital aortic diseases. 
Aortic root and ascending aortic disease is commonly linked to 
congenital or hereditary factors, while descending aortic pro­
blems, especially in the AA, often result from atherosclerosis.1385
Unless noted otherwise, recommendations provided herein are 
intended for adults.
Genetic diseases affecting the thoracic aorta are grouped under 
the broader term of HTAD. HTAD comprises a clinically and genet­
ically heterogeneous group of disorders sharing the common de­
nominator of aneurysm or dissection of the thoracic aorta. 
Familial forms (thoracic aortic disease [TAD] affecting ≥2 individuals 
in one family) or confirmed genetic entities (familial or sporadic) as 
well as syndromes conferring a risk for TAD fall under the definition 
of HTAD.70 Due to the rarity of these conditions, robust evidence 
for many scenarios, such as intervention thresholds, surgical meth­
ods, open surgery vs. endovascular approaches, and pregnancy plan­
ning, is lacking. Thus, a multidisciplinary and individualized approach 
is advisable.70,1386,1387
Clinically, HTADs can manifest as either syndromic or non- 
syndromic entities. The genes identified to date may underly both 
entities and predominantly show autosomal dominant inheritance 
patterns. While TAD is the primary feature in HTAD, extra-aortic 
features (skeletal/ocular) may be key to diagnosing certain syndrom­
ic cases. In some cases, the presence of extra-aortic manifestations 
may aid in risk stratification and hence in defining optimal manage­
ment.1388–1390 The main clinical and genetic data on syndromic 
and non-syndromic HTADs are summarized in the Supplementary 
data online, Table S5.
Numerous underlying gene defects have been discovered in both 
syndromic and non-syndromic cases, leading to the constitution of 
three major molecular groups: genes encoding components of: (i) the 
extracellular matrix; (ii) the transforming growth factor-beta (TGF-ß) 
signalling pathway; and (iii) the smooth muscle cell contractile appar­
atus. Clinical and CV outcomes vary between these groups and will 
Recommendation Table 54 — Recommendations for 
follow-up after treatment of acute aortic syndrome
Recommendations
Classa
Levelb
After TEVAR for AAS, follow-up imaging is 
recommended at 1, 6, and 12 months 
post-operatively, then yearly until the fifth 
post-operative year if no abnormalitiesc are 
documented.1159,1378,1382
I
B
In medically treated type B AAS or IMH, follow-up 
imaging is recommended at 1, 3, 6, and 12 months 
after onset, then yearly if imaging findings are 
stable.1301,1383
I
C
In medically treated PAU, follow-up imaging is 
recommended at 1 month after diagnosis, then every 
6 months if imaging findings are stable.70,1350,1384
I
C
After open surgery for AAS, follow-up imaging by 
CCT and TTE within 6 months, then CCT at 12 
months and then yearly if findings are stable,d should 
be considered.1153,1159,1383
IIa
B
If no complicationsc occur within the first 5 years, 
CCT every 2 years thereafter should be 
considered.1159,1378
IIa
B
If no residual patent FL is documented for 3 
post-operative years, subsequent surveillance by 
CCT every 2–3 years should be 
considered.1153,1159,1383
IIa
C
If abnormalitiesc are documented at any time of 
follow-up after TEVAR for AAS, then CCT should be 
considered every 3–6 months.1159,1378,1382
IIa
C
When frequent controls are required in AAS 
patients treated either by open or endovascular 
repair, CMR should be considered instead of CCT 
after the first-year follow-up.70,1153
IIa
C
In the follow-up of medically treated PAU, after 2 
years of imaging stability, larger intervals should be 
considered in low-risk patientse.70,1350,1384
IIa
C
© ESC 2024
AAS, acute aortic syndrome; CCT, cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; FL, false lumen; IMH, intramural haematoma; PAU, 
penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair; TTE, 
transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cIncluding: pseudo-aneurysm, graft infection, endoleak (any type), enlargement of the 
excluded aneurysm, and stent graft migration/separation/fracture. 
dBoth in terms of extent of residual FL and of aortic diameters at any level. 
eLow-risk: based on width and depth of PAU (See Figure 35 for high-risk features).
Recommendation Table 55 — Recommendations for 
the management of patients with heritable thoracic aor­
tic disease
Recommendations
Classa
Levelb
It is recommended that medical management of 
patients with HTAD is individualized and based on 
shared decision-making.1386
I
C
It is recommended that patients with known or 
suspected syndromic or non-syndromic HTAD are 
evaluated in a centre with experience in the care of 
this patient group.888
I
C
© ESC 2024
HTAD, heritable thoracic aortic disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3637


<!-- PAGE 101 -->

### Page 101

help pave the way to precision medicine in HTAD.1391 Extensive clinical 
and imaging studies in HTAD revealed arterial vasculature involvement 
beyond the thoracic aorta. Patients may develop aneurysms and/or dis­
sections beyond the aorta in diseases such as MFS, Loeys–Dietz or vas­
cular Ehlers–Danlos syndrome (vEDS),1390,1392,1393 or can be prone to 
occlusive vascular disease in the setting of alpha-actin gene (ACTA2) var­
iants.1394 Large clinical variability is observed within families carrying an 
identical variant and instances of incomplete penetrance (a ‘skipped 
generation’) are observed. All HTAD entities display cystic medial de­
generation, hindering precise diagnosis using pathology.
Both genetic testing and imaging (mainly by TTE, but also consider 
CMR or CCT if the aortic root/ascending aorta are not properly visua­
lized) in patients and family members are important in the diagnosis of 
HTAD. In those patients in whom no genetic cause is identified, but in 
whom there is a high suspicion of an underlying genetic defect, genetic 
re-evaluation needs to be considered after 3–5 years. Genetic testing 
should always be accompanied with appropriate counselling. 
Furthermore, appropriate assessment of HRQoL and psychological 
support should be offered to patients and families.1395 Indications for 
genetic testing and aortic screening in HTAD are illustrated in the algo­
rithm in Figure 39.
Although isolated AAA is less frequently associated with a genetic ba­
sis, patients with high-risk features (syndromic features, early onset of 
disease, absence of CVRFs, and/or family history of TAD or AAA) 
should be evaluated in centres with experience in HTAD to evaluate 
the need for genetic testing and specific surveillance, including active 
clinical screening in family members.
10.1.1. Turner syndrome
10.1.1.1. Diagnosis, clinical presentation, and natural history
Turner syndrome (TS), resulting from partial or complete monosomy 
of the X-chromosome, affects 1 in 2500 live-born females.
About 50% of patients experience CV issues like ascending aortic dila­
tation, BAV, aortic coarctation, elongated aortic arch, and partial abnormal 
pulmonary venous return.1417–1419 All women present with generalized ar­
teriopathy and TS itself is an independent risk factor for thoracic aortic dila­
tation. AD risk (type A in 85% and type B in 15%) is elevated in this 
population,1420–1422 although recent studies indicate that this risk may 
be lower with proper treatment guidelines.1423–1426 Risk factors include 
aortic dilatation, BAV, coarctation, and arterial hypertension. Defining aor­
tic dilatation in TS requires adjustment for anthropometric parameters and 
aortic growth data for dissection risk estimation.1427 Z-scores used in the 
general population are equivalent to Turner-specific z-scores.1428
Imaging surveillance
In newly diagnosed TS, TTE and CMR are recommended at baseline for 
the evaluation of congenital heart defects and aortic anatomy/diameters. 
For women aged 15 years and older with TS, adjusting for their smaller 
body size is essential when assessing aortic dimensions. Utilize metrics 
like the ascending aortic size index (ASI), aortic height index (AHI), or aor­
tic z-scores to gauge aortic dilation and dissection risk. Further follow-up 
is dictated by baseline aortic diameters, age, and risk factors (Figure 40).
Recommendation Table 57 — Recommendations for 
imaging in women with Turner syndrome
Recommendations
Classa
Levelb
To take the smaller body size of women (≥15 years) 
with TS into account, the use of the ascending ASI 
(ratio of aortic diameter [mm] to BSA [m2]), AHI 
(ratio of aortic diameter [mm] to height [m]), or 
aortic z-score is recommended to define the degree 
of aortic dilatation and assess the risk of aortic 
dissection.153,1417,1421,1423,1428,1429
I
C
It is recommended to define imaging and clinical 
surveillance intervals according to the estimated risk 
for dissection, based on the ascending ASI and 
concomitant lesions.c,1420,1421
I
C
© ESC 2024
AHI, aortic height index; ASI, aortic size index; BSA, body surface area; TS, Turner 
syndrome. 
aClass of recommendation. 
bLevel of evidence. 
cConcomitant lesions: hypertension, aortic coarctation, bicuspid aortic valve (Figure 40).
Recommendation Table 56 — Recommendations for 
genetic testing and aortic screening in aortic disease
Recommendations
Classa
Levelb
Genetic testing
In patients with aortic root/ascending aneurysms or 
thoracic aortic dissection, gathering family history 
information for at least three generations about 
TAD, unexplained sudden deaths, and peripheral 
and intracranial aneurysms is 
recommended.880,1396–1402
I
B
In patients with aortic root/ascending aortic 
aneurysms or thoracic aortic dissection and risk 
factors for HTAD,c genetic counselling at an expert 
centre and subsequent testing, if indicated, is 
recommended.1399,1403–1408
I
B
In patients with HTAD who have a pathogenic/likely 
pathogenic variant, genetic testing of at-risk biological 
relatives (i.e. cascade testing) is recommended, 
irrespective of age.70,1407,1409
I
C
In patients with HTAD, guidance of clinical 
management by the underlying gene/variant, when 
known, should be considered.70,1391,1410–1416
IIa
B
Aortic imaging screening
In patients with TAD with risk factors for HTAD,c 
with a negative family history of TAD and in whom 
no (likely) pathogenic variant is identified, TTEd 
screening aortic imaging of FDRse is 
recommended.1396,1402
I
B
Continued 
Imaging screening of family members of patients with 
TAD with risk factors for HTADc in whom no (likely) 
pathogenic variant is identified should be considered 
starting at age 25, or 10 years below the youngest 
case, whichever is younger. If the initial screening is 
normal, continued screening every 5 years until the 
age of 60 should be considered.25
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
FDR, first-degree relative; HTAD, heritable thoracic aortic disease; TAD, thoracic aortic 
disease; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 39. 
dCMR/CCT may be indicated if the aortic root/ascending aorta cannot be visualized 
adequately. 
eParents, siblings, children.


<!-- PAGE 102 -->

### Page 102

≤ 60 years
HTN
HTN
Patient with TAD
Aortic dilatation
Aortic dissection
Aortic root/ascending
 z-score ≥3 or any additional risk feature
(see box below)
Aortic root/ascending z-score ≥3
 or aortic dissection
Genetic testing
(Class I)
Re-evaluate genetic testing
 in the proband (after 3–5 years)
Cascade screening
(Class I)
Gene-based management
(Class IIa)
Reimaging of FDRs (after 5 years)
(Class IIa)
Aortic imaginga screening of FDRs
(Class I)
No further
 investigation for HTAD
No further
 investigation for HTAD
Referral to a centre with
 experience in the care of this patient group
(Class I)
Any additional risk feature
(see box below)
Syndromic features of:
Y
N
Y
N
Y
N
Y
N
Y
N
Marfan syndrome
Loeys-Dietz syndrome
Vascular Ehlers-Danlos syndrome
Family history of (either one):
TAD
Peripheral/intracranial artery aneurysm
Unexplained Sudden death <60 years
Positive
Negative or VUS
Any additional risk feature 
Figure 39 Algorithm for genetic and imaging screening in patients with thoracic aortic disease. CCT, cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; FDR, first-degree relative; HTAD, heritable thoracic aortic disease; HTN, arterial hypertension; TAD, thoracic aor­
tic disease; TTE, transthoracic echocardiography; VUS, variant of uncertain significance. amainly by TTE, but also consider CMR or CCT if the aortic 
root/ascending aorta are not properly visualized.
ESC Guidelines                                                                                                                                                                                          3639


<!-- PAGE 103 -->

### Page 103

10.1.1.2. Medical treatment
In the absence of clinical trials, a pragmatic approach in a shared-decision 
model is adopted regarding TS medical treatment. Adoption of the 
strategy for inhibition of aortic growth with BBs and/or ARBs as in 
MFS may be considered. Hypertension should be treated according 
to general guidelines.300
Hormonal treatment with growth hormone (in childhood), sex (oestro­
gen and/or progesterone), and thyroid hormones needs to be discussed in a 
multidisciplinary team with the paediatrician and endocrinologist.1430–1434
10.1.1.3. Surgery of aortic aneurysms
Aortic aneurysm surgery in TS should be informed, individualized, and 
consider factors beyond aortic diameter (indexed). These include BAV, 
coarctation, uncontrolled hypertension (despite more than three 
classes of antihypertensive drugs), rapid aortic growth (≥3 mm per 
year) and planned pregnancy.
10.1.1.4. Pregnancy and physical exercise
Turner syndrome often involves fertility challenges, but assisted 
reproductive therapy has increased pregnancy rates. However, preg­
nancy in TS can elevate the risk of AD, particularly with additional 
risk factors (Figure 40). Recent studies suggest improved pregnancy out­
comes due to better guideline adherence.1435,1436 Prophylactic aortic 
root surgery in women with TS contemplating pregnancy is recom­
mended when the ASI reaches 25 mm/m2.1337 These decisions should 
be made by an expert team in a shared-decision process.
Physical exercise has a beneficial impact on CVD risk and HRQoL 
in TS.1437 Structural congenital heart defects and aortic diameters 
(ASI, AHI and z-score) (Figure 40) need to be considered in the recom­
mendations on the level of sports practice.1418
ASI
AHI
Z-score
Risk group
Low
Moderate
Moderate
Moderate
High
High
<20 mm/m2
≥20–<23 mm/m2
≥23–25 mm/m2
>25 mm/m2
>25 mm/m
>4
≥23–25 mm/m
≥20–<23 mm/m
<20 mm/m
3.5–4
23 mm/m2
>23 mm/m2
>23 mm/m
23 mm/m
-
-
>3.5
-
Every 5–10
years:
Cardiology evaluation and
TTEb
Every 3–5
years:
Cardiology evaluation and
TTEb
Every 2–3
years:
Cardiology evaluation and
TTEb
Every year:
Cardiology evaluation and
TTEb
Consider surgery
(Class IIb)
Consider surgery
(Class IIa)
None of CoA, BAV,  HTNa
CoA, BAV, HTNa or aortic growth ≥3 mm/year
Figure 40 Algorithm for surveillance in women (≥15 years) with Turner syndrome. AHI, aortic height index (ratio of aortic diameter [mm] to height 
[m]); ASI, aortic size index (ratio of aortic diameter [mm] to BSA [m2]); BAV, bicuspid aortic valve; BSA, body surface area; CCT, Cardiovascular 
Computed Tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; HTN, arterial hypertension; TTE, transthoracic 
echocardiography. aHTN: arterial hypertension, not under control despite more than three classes of antihypertensive drugs. bCMR (preferably) or 
CCT if inadequate visualization of the ascending aorta.
Recommendation Table 58 — Recommendations for 
aortic surgery in women with Turner syndrome
Recommendations
Classa
Levelb
Elective surgery for aneurysms of the aortic root and/ 
or ascending aorta should be considered in women 
with TS who are ≥15 years of age, have an ascending 
ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, 
and have associated risk factors for aortic dissectionc 
or are planning pregnancy.70,1417,1421
IIa
C
Continued 
Elective surgery for aneurysms of the aortic root and/ 
or ascending aorta may be considered for women 
with TS who are ≥15 years of age, have an ascending 
ASI >25 mm/m2, an AHI >25 mm/m, a z-score >4, 
and who do not have associated risk factors for 
aortic dissectionc.70,1417,1421
IIb
C
© ESC 2024
AHI, aortic height index (ratio of aortic diameter [mm] to height [m]); ASI, aortic size index 
(ratio of aortic diameter [mm] to BSA [m2]); TS, Turner syndrome. 
aClass of recommendation. 
bLevel of evidence. 
cBicuspid aortic valve, elongation of the transverse aorta, coarctation of the aorta, and/or 
uncontrolled hypertension (despite more than three classes of antihypertensive drugs). See 
Figure 40.


<!-- PAGE 104 -->

### Page 104

10.1.2. Vascular Ehlers–Danlos syndrome
10.1.2.1. Diagnosis, clinical presentation, and natural history
Vascular Ehlers–Danlos syndrome is a rare (prevalence of 1/50 000 to 
1/200 000) autosomal dominant disease caused by pathogenic variants 
in the COL3A1 gene, which encodes the pro-alpha1 chains of type III 
procollagen. The most common COL3A1 variants provoke a disruption 
in the assembly of type III collagen fibrils, causing an important loss of 
mechanical strength of arteries and other hollow organs, especially 
the bowel and uterus.1438 Identification of a causal COL3A1 variant is 
a requirement for the diagnosis of vEDS.1439
vEDS is the most severe form of Ehlers–Danlos syndrome because 
of its clinical life-threatening vascular complications, making early iden­
tification and a thorough family inquiry particularly crucial.
Clinical complications may start during adolescence and repeat at un­
predictable time intervals. The most common complications involve 
medium-sized arteries: dissections, aneurysms, arterial ruptures, and 
arteriovenous fistulas. AD (both type A and B) occurs in up to 10% 
of patients.1440
Prognosis depends on the type of COL3A1 variant, with null variants 
(no gene product or absence of function) showing a better out­
come.1441 The rate of recurrence of organic complications in patients 
with vEDS is 1.6 events per 5 year period. Life expectancy is reduced 
to an average of 51 years.1442
10.1.2.2. Surveillance and imaging
Management of vEDS is complex and requires a multidisciplinary ap­
proach. Recommendations include: lifestyle modification to minimize 
injury and risk of vessel/organ rupture, identification of a care team, in­
dividualized emergency care plans, maintaining BP in the normal range, 
aggressive hypertension treatment, and annual surveillance of the vas­
cular tree by DUS, CCT (low radiation alternatives), or CMR (if feas­
ible).1439 A recent survey among European expert centres indicated 
that arterial monitoring is standard clinical practice and that frequency 
of follow-up should be adapted individually.1443 The prognosis im­
proves when patients are properly managed.1441
10.1.2.3. Medical treatment
Medical management is based on optimal BP control. Celiprolol, a BB 
with vasodilatory properties, has been shown to reduce vascular mor­
bidity in two retrospective studies1441,1444 and one randomized, open- 
label trial.1445 There is no consensus about the age at which to start 
treatment, but starting after 10 years of age is considered reasonable 
by many experts.
10.1.2.4. Surgical treatment
Acute, unexplained pain requires urgent imaging to exclude arterial 
rupture. Acute arterial complications usually require hospitalization 
and a conservative approach in most cases. Interventional vascular or 
intestinal procedures are limited to vital risk. Procedures requiring or­
gan inflation should be avoided or performed with extreme caution. 
There are no clear recommendations regarding aortic/arterial dia­
meters at which to intervene in patients with vEDS. Thus, decisions 
need to be made on a case-by-case basis.
10.1.2.5. Pregnancy
Pregnancy in vEDS incurs a risk of (fatal) arterial and uterine complica­
tions. Pregnancy does not appear to affect overall mortality compared 
with nulliparous vEDS women.1446 However, patients need to be en­
gaged in a shared-decision process, informed by vascular status and 
underlying variant type.
10.1.3. Marfan syndrome
10.1.3.1. Diagnosis, clinical presentation, and natural history
Marfan syndrome, the most common syndromic HTAD condition 
(prevalence of 1/5000–1/10 000), arises from pathogenic fibrillin-1 
gene (FBN1) variants. Beyond the CV system, multiple organ systems 
are often affected, including the eyes and skeleton. Diagnosis relies 
on recognizing clinical features in line with the revised Ghent nosology, 
which includes genetic testing.1447
Aortic aneurysm and dissection involving the aortic root are a 
hallmark of the disease. Less commonly, the descending thoracic 
and abdominal aorta may be involved. With increasing survival 
and age in MFS, the prevalence of TBAD seems to be increasing, ex­
ceeding type A dissection rates in recent reports.1448,1449 TBAD 
will often occur at diameters below surgical thresholds. Previous 
aortic root replacement, mitral valve surgery, and a longer life 
span are associated with TBAD. Additional CV features include mi­
tral valve prolapse, extra-aortic arterial involvement, myocardial 
dysfunction, and arrhythmias.1393,1450–1452 Thanks to improved 
diagnosis in earlier stages, proper management including surveil­
lance, medical treatment, and timely prophylactic aortic surgery, 
life expectancy in MFS patients is now approaching that of the gen­
eral population.1416,1453
The major determinant of TAAD is the aortic root diameter, with 
increased risk of rupture when it exceeds 50 mm.1454 Other risk fac­
tors include family history of AAS at low diameter, aortic root growth 
rate (annualized growth rate ≥3 mm or more in adults), pregnancy, and 
hypertension (hypertension persisting notwithstanding three or more 
antihypertensive medications prescribed by a physician with experience 
in hypertension treatment). Increasing evidence for variant-based dif­
ferences in aortic risk is emerging and may be considered.1413,1416
10.1.3.2. Imaging surveillance
Transthoracic echocardiography is the appropriate imaging modality 
for initial evaluation and follow-up of the aortic root in most patients 
and allows evaluation of the distal segments of the aorta in many. 
Also, TTE is useful for assessing mitral and aortic valve regurgitation, mi­
tral valve prolapse with/out annular disjunction, and LV dysfunction. In 
some cases (especially when pectus abnormalities are present) TTE 
windows may be suboptimal, and CMR (preferably)/CCT may be pre­
ferred. Periodical evaluation of the global aorta and peripheral arteries 
with CMR/CCT and DUS (every 3–5 years based on the patient’s evo­
lution) is indicated since they also present a higher incidence of 
Recommendation Table 59 — Recommendations for 
medical treatment in patients with vascular Ehlers– 
Danlos syndrome (see also Evidence Table 13)
Recommendations
Classa
Levelb
In patients with vEDS, regular vascular surveillance of 
the aorta and peripheral arteries by DUS, CCT, or 
CMR is recommended.1439,1443
I
C
Treatment with celiprolol should be considered in 
patients with vEDS.1441,1444,1445
IIa
B
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DUS, duplex ultrasound; vEDS, vascular Ehlers–Danlos syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3641


<!-- PAGE 105 -->

### Page 105

peripheral aneurysms,1455 which are associated with more aggressive 
forms of the disease.1393 CMR is preferred over CCT to avoid radiation 
exposure; however, its use should be adapted to local availability/ex­
pertise. Additionally, CMR allows evaluation of biomechanical and 
haemodynamic parameters that can be useful in risk stratifica­
tion.181,1456,1457 Given its superior spatial resolution, CCT may be re­
commended for pre-operative planning and in cases of measurement 
inconsistency. Imaging of intracerebral vessels is indicated in cases of 
symptoms and/or clinical manifestations of aneurysms/rupture. 
Recommendations for imaging surveillance are illustrated in Figure 41
and should be adjusted to the individual patient, taking the history 
and presence of abnormalities during preceding studies into account.
10.1.3.3. Medical treatment
Medical treatment is described in Recommendation Table 61. Some 
caution may be warranted with the use of CCBs: these have shown an 
increased aortic risk in a mouse model and in retrospective case con­
trol studies,1460 and alternatives are preferred for hypertension 
treatment.
10.1.3.4. Aortic surgery
Open surgery is preferred over endovascular procedures in patients 
with MFS. Endovascular procedures may be considered in selected 
cases in emergency settings and/or in centres with a high level of ex­
pertise.1465 The thresholds for aortic root surgery need to take add­
itional risk factors, as well as the expertise of the team, into account.1466
Recommendation Table 60 — Recommendations for 
vascular imaging in Marfan syndrome
Recommendations
Classa
Levelb
In patients with MFS, TTE is 
recommended:70,171,1458,1459
• At least annually in patients with an aortic root 
diameter <45 mm in the absence of additional risk 
factorsc
• At least every 6 months in patients with an aortic 
root diameter <45 mm in the presence of 
additional risk factorsc
• At least every 6–12 months in patients with an 
aortic root diameter ≥45 mm in the absence of 
additional risk factorsc
I
C
In patients without previous aortic surgery, complete 
peripheral vascular and thoracoabdominal aorta 
imaging by CMR or CCT and DUS is recommended 
at the first evaluation, and subsequently every 3–5 
years if stable.70,1455,1459
I
C
In patients with MFS who have undergone aortic root 
replacement, surveillance imaging of the thoracic 
aorta by CMR (or CCT) is recommended at least 
every 3 years.70,1458
I
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DUS, duplex ultrasound; MFS, Marfan syndrome; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cRisk factors: aortic root diameter >40 to ≤45 mm and family history of aortic dissection at 
small aortic dimensions (i.e. <50 mm); resistant hypertension (hypertension persisting 
notwithstanding three or more antihypertensive medications prescribed by a physician 
with experience in hypertension treatment); and rapid growth of the aorta (annualized 
growth rate ≥3 mm or more in adults).
Recommendation Table 62 — Recommendations for 
aortic surgery in Marfan syndrome
Recommendations
Classa
Levelb
Surgery is indicated in patients with MFS who have 
aortic root disease with a maximal aortic sinus 
diameter ≥50 mm.70,172,1466–1468
I
B
Surgery to replace the aortic root and ascending 
aorta, using the valve-sparing surgery technique, is 
recommended in patients with MFS or related 
HTAD with aortic root dilatation when anatomical 
features of the valve allow its preservation and the 
surgeon has specific expertise.70,1466,1469
I
B
Surgery should be considered in patients with MFS 
who have an aortic root aneurysm with a maximal 
aortic sinus diameter ≥45 mm and additional risk 
factors.c,1467,1469
IIa
C
In patients with MFS and an aneurysm of the 
ascending aorta, aortic arch, descending thoracic 
aorta, or abdominal aorta of ≥50 mm, surgical 
replacement of the aneurysmal segment by a surgeon 
with specific expertise should be considered.1467,1469
IIa
C
© ESC 2024
HTAD, heritable thoracic aortic disease; MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence. 
cFamily history of aortic dissection at small aortic dimensions (i.e. <50 mm); resistant 
hypertension (hypertension persisting notwithstanding three or more antihypertensive 
medications prescribed by a physician with experience in hypertension treatment); and 
rapid growth of the aorta (annualized growth rate ≥3 mm or more in adults).
Recommendation Table 61 — Recommendations for 
medical treatment in Marfan syndrome (see also 
Evidence Table 14)
Recommendations
Classa
Levelb
In patients with MFS, treatment with either a BB or 
an ARB, in maximally tolerated doses (unless 
contraindicated), is recommended to reduce the rate 
of aortic dilatation.1461,1462
I
A
In patients with MFS, the use of both a BB and an 
ARB, in maximally tolerated doses (unless 
contraindicated), should be considered to reduce the 
rate of aortic dilatation.1463,1464
IIa
A
© ESC 2024
ARB, angiotensin receptor blocker; BB, beta-blocker; MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 106 -->

### Page 106

10.1.3.5. Pregnancy and physical exercise
In pregnant MFS women, the risk of AD increases up to eight times 
relative to the general population.1470 The risk for TAAD is deter­
mined by the aortic diameter, but type B dissections tend to occur 
even more commonly and may occur without prior dilata­
tion.1470,1471 Patients should be aware of the persisting risk of 
TBAD after aortic root replacement.1471 Women unaware of the 
diagnosis are at the highest risk of dissection.1470–1472
The Registry Of Pregnancy And Cardiac disease (ROPAC) indicates 
that women managed according to guidelines are at low risk of 
pregnancy-related complications and major effects of BBs on foetal 
growth were not shown, although this needs to be carefully 
monitored.70,1337,1435,1471,1472
Exercise is potentially associated with an increased risk of aortic dila­
tation and AAD. It is recommended to individualize physical activity in 
MFS based on aortic diameter, family history of dissection or sudden 
death, and pre-existing fitness status.71 Although competitive sports 
are contraindicated, moderate aerobic exercise is recommended 
with a level of intensity based on aortic diameters.71
Two studies1481,1482 showed that mild-moderate dynamic exercise 
improved aortic wall structure and function and reduced aortic growth 
rate in MFS mouse models. Recent data in MFS children and young adults 
indicate that adhering to daily physical exercise (10 000 steps a day) had 
a beneficial effect on aortic root growth.1483 Although a limited number 
of clinical studies have evaluated physical activity rehabilitation 
programmes, two studies1484,1485 evidenced that physical activity, up 
to a moderate specific intensity, may be recommended. Thus, although 
physical activity poses a dilemma, individualized adapted programmes 
are most likely successful in encouraging exercise in MFS.
10.1.4. Other syndromic and non-syndromic 
heritable thoracic aortic diseases and/or arterial 
disorders
Main clinical and genetic data of known syndromic and non-syndromic 
HTAD entities are summarized in the Supplementary data online, 
Table S5. The two most prevalent diseases for each entity include 
Loeys–Dietz syndrome and ACTA2-related HTAD, respectively. Given 
the rarity of these entities, specific recommendations regarding surveillance 
and treatment are lacking and largely adopted from the recommendations 
for MFS. Some disease-specific recommendations are mentioned below.
10.1.4.1. Loeys–Dietz syndrome
10.1.4.1.1. Diagnosis, clinical presentation, and natural evolution.
The spectrum of clinical presentations in Loeys–Dietz syndrome is very 
wide. Some patients fulfil criteria for MFS,1447 while some features such 
as bifid uvula and hypertelorism are very specific to the disease. Clinical 
manifestations are listed in the Supplementary data online, Table S5. 
There is a tendency for AD and rupture at lower vessel dimensions 
than is typically seen in other similar conditions.1390,1487 Pathogenic var­
iants in six genes (TGFBR1 and TGFBR2, TGFB2 and TGFB3, SMAD2 and 
SMAD3), all encoding components of the TGF-ß signalling pathway, cause 
Loeys–Dietz syndrome. Differences in clinical manifestations and aortic 
outcome according to the underlying gene and the extent of extra-aortic 
features have been reported and need to be considered in surveillance 
and defining thresholds for surgery.1388,1390,1391
Surveillance 
in 
Loeys–Dietz 
syndrome 
is 
described 
in 
Recommendation Table 65 and Figure 41. Although the indication for 
surgery must be considered according to the underlying genetic defect 
and the presence of risk factors (Recommendation Table 66 and 
Figure 42), a 45 mm aortic diameter threshold should be considered 
(≥40 mm in cases of associated high-risk features).
Recommendation Table 63 — Recommendations for 
pregnancy in women with Marfan syndrome
Recommendations
Classa
Levelb
It is recommended that all women with MFS: 
• Have a pre-conception evaluation to address the 
risks of maternal CV and other complications
• Have follow-up in a centre with access to a 
pregnancy heart and vessel team.1473
I
C
It is recommended that couples in which a partner 
has or is at risk for HTAD be offered pre-conception 
genetic counselling.
I
C
Imaging of the whole aorta (by CMR/CCT) is 
recommended prior to pregnancy.
I
C
Follow-up during pregnancy is recommended with a 
frequency determined by aortic diameter and 
growth.1337,1474,1475
I
C
Intake of BBs during pregnancy is recommended.1476
I
C
Prophylactic aortic root surgery is recommended in 
women desiring pregnancy with aortic diameters 
>45 mm.1435,1472
I
C
Prophylactic aortic root surgery may be considered 
in women desiring pregnancy with aortic diameters 
of 40–45 mm.1472,1475,1477
IIb
C
ARBs are not recommended during pregnancy.1478–1480
III
B
© ESC 2024
ARBs, angiotensin receptor blockers; BBs, beta-blockers; CCT, cardiovascular computed 
tomography; CMR, cardiovascular magnetic resonance; CV, cardiovascular; HTAD, 
heritable thoracic aortic disease; MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 64 — Recommendations for 
physical exercise in patients with Marfan syndrome
Recommendations
Classa
Levelb
It is recommended to individualize physical activity in 
patients with MFS based on aortic diameter, family 
history of aortic dissection, and pre-existing fitness.
I
C
Regular moderate aerobic exercise with a level of 
intensity informed by aortic diameter is 
recommended in most patients with MFS.
I
C
For patients who present with aortic dissection and/ 
or have undergone aortic surgery, post-operative 
cardiac rehabilitation aiming at improving both 
physical and mental health should be 
considered.73,1483,1484,1486
IIa
B
© ESC 2024
MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3643


<!-- PAGE 107 -->

### Page 107

CCTa
Surgery if risk factorsb
(Class IIa)
Aortic root/
ascending diameter (mm)
Marfan/FBN1
Loeys-Dietz/
TGF-ß genes
ACTA2/
SMC genes
TTE Follow-up
Every 6–12 months
Surgery
(Class I)
CMR/CCT head-to-pelvis every 1–3 years
Baseline CMR/CCT
Baseline CMR/CCT
Baseline CMR/CCT
TTE yearly
TTE yearly 
CMR/CCT every 3–5 years
CMR/CCT every 3–5 years
CCTa
CCTa
CCTa
35 mm
40 mm
42 mm
45 mm
50 mm
CCTa
Surgery if risk factorsb
(Class IIb)
Every 6–12 months
TTE yearly
Surgery
(Class IIa)
Surgery
(Class IIa)
Figure 41 Algorithm for imaging surveillance in patients with syndromic and non-syndromic heritable thoracic aortic disease. CCT, cardiovascular 
computed tomography; CMR, cardiovascular magnetic resonance; DUS, duplex ultrasound; HTAD, heritable thoracic aortic disease; SMC, smoth mus­
cle cell; TTE, transthoracic echocardiography. aPre-surgical CCT. bSee respective tables of recommendations for aortic surgery in Marfan (Table 62) and 
Loeys-Dietz syndrome (Table 66).
Recommendation Table 66 — Recommendations for 
aortic root surgery in Loeys–Dietz syndrome
Recommendations
Classa
Levelb
Aortic root replacement should be considered 
for patients with Loeys–Dietz syndrome if the 
aortic root diameter exceeds 
45 mm.1388,1390,1489–1492
IIa
C
It may be considered to adjust the threshold for 
surgery according to the underlying gene, taking 
associated risk featuresc into account.1391
IIb
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence. 
cHigh-risk features include certain specific pathogenic variants; women with TGFBR2 
variants and small body size; severe extra-aortic features; family history of aortic 
dissection (especially at young age or relatively small aortic diameter); and aortic growth 
rate ≥3 mm per year.
Recommendation Table 65 — Recommendations for 
imaging follow-up in Loeys–Dietz syndrome
Recommendations
Classa
Levelb
In patients with Loeys–Dietz syndrome, TTE at baseline 
and subsequently every 6–12 months, depending on 
aortic diameter and growth,c is recommended.70,1390,1488
I
C
In patients with Loeys–Dietz syndrome, a baseline 
arterial imaging study from head to pelvis with CMR or 
CCT and subsequent surveillance with CMR or CCT or 
DUS every 1–3 years is recommended.70,1488
I
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DUS, duplex ultrasound; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cMore frequent imaging if aortic root/ascending diameter >42 mm and aortic growth rate 
≥3 mm per year.


<!-- PAGE 108 -->

### Page 108

10.1.4.2. ACTA2-related heritable thoracic aortic disease
Pathogenic variants in the ACTA2 gene, encoding for smooth muscle- 
specific alpha-actin (a critical component of the vascular smooth 
muscle cell contractile apparatus), lead to aortic aneurysms and dis­
sections in non-syndromic patients.1496 Patients primarily present 
with type A or B aortic dissection, and with aneurysms that involve 
the root and/or ascending aorta. A subset of pathogenic variants pre­
disposes to occlusive vascular diseases.1497 Surveillance is summarized 
in Recommendation Table 67 and Figure 41. TAAD may occur at 
aortic diameters <45 mm, and consideration of surgery at diameters 
<45 mm should be informed by the presence of additional clinical and 
genetic risk factors.1410 Genetic and imaging cascade screening of 
first-degree family members is an essential element of care, as treat­
able disease may otherwise be missed in family members—with fatal 
consequences.
High risk features include:
Known high risk genetic variants (R528H/C in TGFBR2)
Women with TGFBR2 variants and small body size
Severe extra-aortic features
 Aortic root surgery if 
risk factors
(see box below)
 Aortic root surgery
Family history of aortic dissection (especially at young age or relatively small aortic diameter)
Aortic growth rate ≥3mm per year
TGFBR2a,b
35 mm
40 mm
45 mm
50 mm
55 mm
TGFBR1a
TGFBR2a
TGFBR1a
 Consider aortic root surgery
Consider aortic root surgery
SMAD3c,d
TGFB2e,f,g
TGFB3h,i
Figure 42 Suggested thresholds for prophylactic aortic root/ascending replacement in Loeys–Dietz syndrome. From a1388, b1391, c1492, d1491, e1490, 
f1489, g1493, h1494, i1495.
Recommendation Table 67 — Recommendations for 
imaging and surgery in ACTA2-related heritable thoracic 
aortic disease (see also Evidence Table 11)
Recommendations
Classa
Levelb
Annual monitoring of the aortic root/ascending aorta 
with TTE to evaluate aortic root/ascending aorta 
enlargement is recommended.1498
I
C
Imaging of the aorta with CMR/CCT every 3–5 years 
is recommended.1498
I
C
Prophylactic aortic root surgery should be 
considered with an aortic diameter ≥45 mm, or 
lower in cases with other risk factors.c,1499
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cRisk factors for aortic dissection: family history of dissection with no or minimal dilatation 
or young age; rapid growth ≥3 mm per year.
ESC Guidelines                                                                                                                                                                                          3645


<!-- PAGE 109 -->

### Page 109

10.2. Aortic disease associated with 
bicuspid aortic valves
Bicuspid aortic valves, the most common congenital heart defect 
(0.5%–2% of live births), besides being a risk factor for aortic valve dis­
ease, is associated with a peculiar form of aortopathy, characterized by 
morphological and clinical heterogeneity (bicuspid valvulo-aortopathy). 
Its inheritance is high, with autosomal dominant transmission of BAV in 
a minority of cases, but no single-gene model clearly explaining BAV 
inheritance.1500–1502 Several genes, generally implicated in embryogenesis 
and cell differentiation, have been associated with BAV/BAV-related aor­
topathy, but each of them explained <5% of cases.1503–1507 Therefore, 
1
2a
2b
Ascending phenotype
(70–75%)
Fused BAV (90–95% of BAV) 3 phenotypes
2-sinus BAV (5–7% of BAV) 2 phenotypes
Partial-fusion BAV - short fusion of 1 commisure
Right - left cusp fusion
(70–80%)
Right - non cusp fusion
(20–30%)
Left - non cusp fusion
(3–6%)
Root phenotype
(15–20%)
Extended phenotype
(5–10%)
BAV morphologies
Aortic phenotypes
L
A
A
P
P
L
Laterolateral
Anteroposterior
Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature. Modified from Michelena et al.1510 A, anterior; BAV, bicuspid aortic valve; L, lateral; 
P, posterior. Although preferential associations exist, each of the three valve types—‘fused BAV’, ‘2-sinus BAV’, and ‘partial-fusion BAV’—can be vari­
ably associated with dilatation predominantly located at the sinuses of Valsalva (‘root phenotype’, 15%–20%) or at the tubular (supra-coronary) tract 
(‘ascending phenotype’, 70%–75%). A minor proportion of patients present with equal dilatation of the sinusal and tubular segments or ascending dila­
tation extending into the proximal arch (‘extended phenotype’, 5%–10%).


<!-- PAGE 110 -->

### Page 110

genetic testing is not indicated for isolated BAV disease, but reserved 
for patients with syndromic features, family history of aortic disease, 
or aneurysms/dissections of medium-sized arteries other than the 
thoracic aorta, and may be considered in patients with the root 
phenotype.1389,1508,1509
We recommend adopting a new international consensus nomencla­
ture and classification, established by a panel of experts, to replace the 
previous various concurrent nomenclatures used1510 (Figure 43). 
Aneurysm prevalence reaches 40% in clinical series and 0.85 per 100 
patient-years in population studies. AAEs are rare, but 8- to 10-fold 
more frequent than in the general population.1001,1511 The longest 
available follow-up of BAV subjects was recently reported,1512 showing 
a total lifetime morbidity burden as high as 86%, a predominant part of 
which was driven by valve-related complications (aortic stenosis, endo­
carditis, HF).
When a BAV is first detected, a complete study of the thoracic aorta 
is necessary; vice versa, in every patient with ascending aortic dilatation, 
valve morphology should be ascertained.70,969 When TTE detects 
BAV-associated aortic dilatation, CCT or CMR is recommended to 
confirm measurements, exclude coarctation, and record baseline dia­
meters at different levels for subsequent periodic assessments.137,1001
Surveillance by TTE becomes necessary when the maximum diameter 
exceeds 40 mm. In mixed tricuspid aortic valve (TAV) and BAV series, 
AAEs occurred in 2/10 000 patient-years with a diameter >40 mm (vs. 
0.1–0.3/10 000 patient-years in the general population)894 (Figure 43). 
Considering average aortic diameter growth of 0.2–0.6 mm per 
year,893,1513 once fast progression is excluded, follow-up can be sched­
uled every 2–3 years (according to risk profile). In 5%–15% of cases, 
BAV patients have at least one FDR with either BAV or ascending aortic 
dilatation; root phenotype and aortic regurgitation in the proband pre­
dict ascending dilatation in FDRs.1514 FDR screening is considered cost- 
effective, but the age at which relatives should undergo TTE remains to 
be determined.1515,1516
A diameter exceeding 55 mm at any level mandates sur­
gery.70,969,1001 However, the historically known relation between diam­
eter and acute complications has been recently reappraised. Both in 
large mixed153 and purely BAV series,981 an ascending diameter of 
about 52 mm already marked an AAE risk increase from ∼1% to 
4%–5%. Additionally, early post-operative mortality for elective surgery 
of the proximal aorta ranges today between 0.25% and 2%.980,981
Therefore, aortic surgery in low surgical risk (<3%) patients with an as­
cending diameter >52 mm implies a lower risk than observed in the 
natural history of the disease. For aortic root dilatation in BAV patients, 
the ‘hinge point’ was at 50 mm;981 this phenotype is associated with fas­
ter growth rate,893 higher risk of events following isolated aortic valve 
replacement,1517 worse survival if not operated,1518 and higher risk of 
acute TAAD.976,1519
Surgery should be considered when the diameter is ≥50 mm in se­
lected ascending phenotype patients (Figures 23, 24 and 43).70,1001
Among those factors, family history of AAEs, poorly controlled hyper­
tension, aortic coarctation, and rapid (≥3 mm per year) diameter 
growth should be noted. Surgery at >50 mm may also be considered 
in a shared decision with the patient, taking lifestyle and psychological 
factors into consideration,70,1001 since 50 mm should correspond to 
an approximately 10-fold increase in the risk of AAEs.894 In a study 
of patients with aortic diameter ≥40 mm, those with diameters of 
50 mm faced a 1% risk of AAEs within 5 years, compared with 
0.1% for those with 40 mm diameters, explaining the 10-fold differ­
ence; however, this study did not exclusively involve BAV patients.894
Another recent study1520 specifically focused on BAV patients found 
a 0.4% incidence of AAEs per patient-year for diameters above 
50 mm, in contrast to the general BAV population’s 0.03% inci­
dence.1521 Previous guidelines also suggested aortic repair for a 
cross-sectional area-to-height ratio (CSA/h) >10 cm2/m;70 neverthe­
less, more recently, it has been suggested that the CSA/h threshold 
for the ascending tract in BAV should be 13 cm2/m.981 For the aver­
age height of male and female Europeans (1.8 m and 1.67 m, respect­
ively), a CSA/h of 10 cm2/m would correspond to a diameter of 
48 mm or 46 mm, respectively, whereas 13 cm2/m means 54 mm 
or 53 mm. It is reasonable to refer to the 13 cm2/m CSA/h cut-off 
for ascending aortic repair, especially in individuals ≤1.69 m in height 
(since 13 cm2/m corresponds to ≤52 mm diameter). Recently, be­
sides dilatation, aortic elongation is also considered a risk factor,974
and a curvilinear length >11.5 cm at the vessel’s centreline increases 
the yearly risk of AAEs.155 Age is another factor to consider: at 50 
years, a 40 mm ascending aorta corresponds to the upper normal 
limit for patients with large body size,149 and therefore the same 
diameter at a higher age could imply a lower risk of AAEs.
Recommendation Table 68 — Recommendations for 
bicuspid aortic valve-associated aortopathy management
Recommendations
Classa
Levelb
When a BAV is first diagnosed, initial TTE to assess 
diameters of the aorta at several levels is 
recommended.1001,1510,1522
I
B
Surgery for bicuspid aortopathy is recommended 
when the maximum aortic diameter is 
≥55 mm.70,172,899,969,1001
I
B
Surgery for bicuspid aortopathy of the root 
phenotypec is recommended when the maximum 
aortic diameter is ≥50 mm.70,893,981,986,1001,1519,1523
I
B
CCT or CMR of the entire thoracic aorta is 
recommended at first diagnosis and when important 
discrepancies in measurements are found between 
subsequent TTE controls during surveillance, or when 
the diameter of the aorta exceeds 45 mm.1001,1510
I
C
Screening by TTE in FDRs of BAV patients with root 
phenotypec aortopathy and/or isolated aortic 
regurgitation is recommended.1001,1510,1514
I
C
Surveillance serial imaging by TTE is recommended in 
BAV patients with a maximum aortic diameter 
>40 mm, either with no indication for surgery or 
after isolated aortic valve surgery, after 1 year, then if 
stability is observed, every 2–3 years.70,1001
I
C
Screening by TTE in FDRs of all BAV patients should 
be considered.70,1001,1500,1510,1515
IIa
B
In patients with low surgical risk, surgery for bicuspid 
aortopathy of ascending phenotyped should be 
considered when the maximum aortic diameter is 
>52 mm.153,172,981
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3647


<!-- PAGE 111 -->

### Page 111

10.3. Coarctation of the aorta and aortic 
arch variants
10.3.1. Coarctation of the aorta
This topic is extensively discussed in the ESC 2020 Guidelines for the man­
agement of adult congenital heart disease.1468 Coarctation of the aorta 
(CoA) manifests as a discrete stenosis or a hypoplastic segment typically 
located at the insertion of the ductus arteriosus. More distal locations 
are known as mid-aortic syndrome and require dedicated manage­
ment.1524 Associated lesions include BAV (up to 50%–85%), intracereb­
ral aneurysms (10%), and ascending aortic aneurysms.1525,1526 CoA may 
be associated with syndromes such as TS. Research indicates that up to 
12.6% of females diagnosed with CoA also have TS, and coarctation is 
observed in 7%–18% of patients with TS.1417,1468,1527
10.3.1.1. Diagnostic work-up
Mild cases of CoA may only become evident in adulthood. Symptoms 
reflect pre-stenotic hypertension (e.g. headache, nosebleeds) and post- 
stenotic hypoperfusion (e.g. abdominal angina and claudication). The 
natural course is largely driven by hypertension-related complications, in­
cluding HF, intracranial haemorrhage, premature coronary/cerebral artery 
disease, and aortic rupture/dissection.1528 Presently, there is no evidence 
supporting screening for intracerebral aneurysms in asymptomatic patients.
A systolic non-invasive gradient between upper and lower extremities, an 
abnormal ABI, or an invasive peak-to-peak gradient ≥20 mmHg indicates 
significant CoA. In the presence of collaterals or decreased LV function, gra­
dients or ABI may underestimate severity. A diastolic tail in the DTA or ab­
dominal diastolic antegrade flow by TTE is suggestive of significant 
narrowing. Criteria to consider significant CoA are listed in Figure 44. TTE 
is also useful to detect LV hypertrophy, which is a marker of disease. 
CMR and CCT are the preferred imaging techniques, depicting the narrow­
ing as well as the surrounding anatomy, necessary for interventional 
decision-making.
10.3.1.2. Treatment and follow-up
In native CoA and re-coarctation (Figure 44) covered stenting is the first- 
choice treatment. Interposition of a tube graft is the preferred surgical 
therapy if stenting is less suitable.1529 Hypertension remains an important 
complication, even after successful treatment, and is more common when 
the initial repair is performed in adulthood.1528 Right arm 24 h ambulatory 
BP measurement or exercise tests better detect hypertension.1530,1531
All CoA patients require lifelong follow-up.1532 Imaging of the aorta with 
CMR/CCT every 3–5 years, adjusted to previous imaging findings and type 
of intervention, is required to document post-repair or post-interventional 
complications (such as re-coarctation). Patch repairs are at particular risk 
of repair-site para-anastomotic aneurysms or pseudo-aneurysms, the lat­
ter possibly occurring following interposition grafts as well.1533
Recommendation Table 69 — Recommendations for 
evaluation and medical treatment of patients with 
coarctation of the aorta
Recommendations
Classa
Levelb
In patients with native or repaired coarctation, lifelong 
follow-up is recommended, including regular imaging 
of the aorta with CCT/CMR every 3–5 years (adapted 
to clinical status and previous imaging findings).1534,1535
I
B
Coarctation or re-coarctation repair (either surgical or 
endovascular) is indicated in patients with hypertension 
with an increased non-invasive gradient between the 
upper and lower limbs (decreased ABI) confirmed with 
invasive measurement (peak-to-peak >20 mmHg), with 
a preference for stenting when technically feasible.1536
I
C
In patients with coarctation, BP measurements at both 
arms and one lower extremity are recommended.
I
C
It is recommended to treat hypertension in patients 
with coarctation according to ESC hypertension 
guidelines.300
I
C
Endovascular treatment should be considered in 
patients with hypertension with >50% narrowing 
relative to the aortic diameter at the diaphragm, even 
if the invasive peak-to-peak gradient is <20 mmHg, 
when technically feasible.1537
IIa
C
Endovascular treatment should be considered in 
normotensive patients with an increased non-invasive 
gradient confirmed with invasive peak-to-peak gradient 
>20 mmHg, when technically feasible.1468
IIa
C
© ESC 2024
ABI, ankle–brachial index; BP, blood pressure; CCT, cardiovascular computed tomography; 
CMR, cardiovascular magnetic resonance; ESC, European Society of Cardiology. 
aClass of recommendation. 
bLevel of evidence.
In patients with low surgical risk and ascending 
phenotype bicuspid aortopathy, surgery should be 
considered at a maximum diameter ≥50 mm if any of 
the following is the case:70,153,155,981,1001
• Age <50 years
• Shorter staturee
• Ascending aortic length ≥11 cmf
• Aortic diameter growth rate ≥3 mm per yearg
• Family history of acute aortic syndrome
• Aortic coarctation
• Resistant hypertensionh
• Concomitant non-aortic-valve cardiac surgery
• Desire for pregnancy
IIa
C
Surgery for bicuspid aortopathy in patients 
undergoing aortic valve surgery should be considered 
at a root or ascending diameter ≥45 mm.70,172,969
IIa
C
© ESC 2024
BAV, bicuspid aortic valve; BP, blood pressure; CCT, cardiovascular computed tomography; 
CMR, cardiovascular magnetic resonance; CSA/h, cross-sectional area-to-height ratio; FDRs, 
first-degree relatives; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cRoot phenotype = aortic dilatation with sinus diameter > tubular diameter. 
dAscending phenotype = aortic dilatation with tubular diameter > sinus diameter. 
ePatient height between 1.50 and 1.69 m (yielding a CSA/h ratio >13 cm2/m). 
fCurvilinear distance at aortic centreline between the ventriculo-aortic junction and the origin 
of the innominate artery. 
gIn order to ascertain real rapid growth, side-by-side re-evaluation of images obtained with the 
same modality and technique should be performed. 
hHypertension persisting notwithstanding three or more antihypertensive medications 
prescribed by a physician with experience in hypertension treatment, including diuretics.


<!-- PAGE 112 -->

### Page 112

Y
N
≥20 mmHg
<20 mmHg
Perform catheterization
(Re)coarctation not likely
Surveillance: TTE every year and CMR or CCT 3–5 years
BP measurement and investigationa
Intervention
(Class IIa)
Intervention
(Class IIa)
Intervention
(Class I)
BP measurement and investigationa
≥50% narrowing on any imaging modality
HTN
HTN
N
Y
N
Y
N
Y
Suspicion of significant (re)coarctation: any of the following:
Non invasive (right arm-to-leg)
BP gradient >20 mmHg
>50% narrowing on any imaging modality
Abdominal antegrade diastolic flow on DUS
Diastolic run off in the descending thoracic aorta on DUS
Mean gradient >20 mmHg across the CoA region on DUS
Collateral flow >30%
on phase contrast CMR
A
A
B
B
C
C
E
E
D
D
F
F
D
>35 mmHg peak gradient
>20 mmHg mean gradient
Post CoAo
Pre CoAo mL/s
>30% increase
Figure 44 Criteria for significant coarctation/re-coarctation of the aorta and management algorithm. BP, blood pressure; CCT, cardiovascular com­
puted tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; DUS, duplex ultrasound; HTN, hypertension; TTE, trans­
thoracic echocardiography. aDiagnosis of hypertension may require confirmation with ambulatory BP measurement and should also be considered in 
cases of exercise-induced hypertension and/or left ventricular hypertrophy on TTE.
ESC Guidelines                                                                                                                                                                                          3649


<!-- PAGE 113 -->

### Page 113

10.3.2. Aortic arch anatomic variants
A type I arch, where the three great vessels directly arise from the aor­
ta, is the most common form, occurring in about 70% of the population. 
The type II (bovine) arch is the most frequent variant: type II-A (9% of 
the population) has the left common carotid artery arising from the in­
nominate artery, and type II-B (13% of the population) has both the in­
nominate and left common carotid arteries originating from a common 
point on the aortic arch.1538,1539 Limited data suggest that a bovine arch 
is associated with a higher risk of aortic dilation and aortic events/com­
plications.1540,1541 These variations are important to report as they can 
impact specific medical procedures and diagnostic interpretations.
10.3.3. Aberrant subclavian artery and Kommerell’s 
diverticulum
The most common variant is the aberrant right subclavian artery, where 
the right subclavian artery arises as the last branch of the aortic arch, 
usually after the left subclavian artery, and often passes behind the 
oesophagus through the mediastinum, potentially causing dysphagia 
lusoria, respiratory symptoms, or recurrent laryngeal nerve palsy. 
The less common variant, the aberrant left subclavian artery, is typically 
associated with congenital heart defects, such as a right aortic arch. 
However, in adulthood, both variations are often incidental findings.1542
Kommerell’s diverticulum is a remnant of the fourth dorsal aortic 
arch due to incomplete regression, found in 20%–60% of those with 
an aberrant subclavian artery.1543 Surgical intervention is advised for 
a diverticulum orifice >30 mm or combined diverticulum and adjacent 
descending aorta diameter >50 mm, or both.1544 Successful repair has 
been described using open, endovascular, or hybrid approaches de­
pending on anatomy, comorbidities, and expertise.1543
11. Polyvascular peripheral arterial 
disease and peripheral arterial 
disease in patients with 
cardiac diseases
11.1. Polyvascular disease
Polyvascular disease is defined as the simultaneous presence of clinically 
relevant obstructive atherosclerotic lesions in at least two major arter­
ial territories.
11.1.1. Epidemiology and prognosis
Approximately 1 in 4–6 patients with atherosclerosis have PVD 
(Figure 45).620,1545 According to the REACH registry, patients with 
PAD were most likely both to have PVD at baseline and to develop 
PVD over the observational period.1546,1547
PVD independently increases major CV event risk, roughly doubling 
it compared with single arterial bed symptoms.1547–1549 Event rates rise 
with the number of affected arterial beds.1546,1550
11.1.2. Screening for atherosclerosis in other arterial 
territories
Screening for PVD in atherosclerotic patients relies on medical 
history, clinical exam, and ABI measurement. If suspected, start with 
non-invasive DUS, followed by CTA/MRA if needed.1557 Assessing 
concurrent atherosclerosis in other vascular regions is detailed in 
Table 17.
CAD
Carotid stenosis >70%
PAD (ABI ≤0.90)
RAS >70%
9%
5%
16%
4%
61%
39%
22%
18%
7%
15%
25%
70%
60%
40%
20%
0%
19%
14%
23%
10%
CAD
Carotid stenosis >70%
PAD (ABI ≤0.90)
Figure 45 Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease. The graph reports the rates of 
concomitant arterial diseases in patients presenting an arterial disease in one territory (e.g. in patients with CAD, 5%–9% of cases have concomitant 
carotid stenosis >70%). Adapted from 2017 ESC Guidelines on PAD.77,493,784,1549,1551–1556 ABI, ankle–brachial index; CAD, coronary artery disease; 
PAD, peripheral arterial disease; RAS, renal artery stenosis.


<!-- PAGE 114 -->

### Page 114

11.1.2.1. Screening for coronary artery disease in patients with 
symptomatic peripheral arterial disease
The morbidity and mortality of patients with PAD is high due to CV 
complications. Given high CAD event rates in patients with PAD, 
CAD screening may be helpful to optimize medical treatment and is 
not intended to increase the rate of coronary interventions.431
Evaluation can be performed by stress testing or CCT; however, there 
is no evidence that systematic screening for CAD in stable PAD im­
proves outcomes. Coronary angiography is less suitable due to invasive­
ness. In patients requiring lower-limb revascularization, CAD 
management should be based on the 2022 ESC Guidelines on cardiovas­
cular assessment and management of patients undergoing non-cardiac 
surgery.1080
11.1.2.2. Screening for peripheral arterial disease in patients with 
coronary artery disease
In high-risk CAD patients with three-vessel disease or recent ACS, sys­
tematic screening for multisite atherosclerotic disease through ABI and 
DUS of carotids, lower-extremity, and renal arteries did not improve 
outcomes.1563 However, a subgroup analysis of the COMPASS trial 
suggests potential benefits when adding vascular-dose rivaroxaban to 
aspirin in stable patients with CAD and PAD, raising the question of 
whether identifying PAD in stable CAD patients could be advanta­
geous.429,1559 In patients undergoing CABG, the presence of concomi­
tant PAD is associated with a three-fold risk of subsequent CV events 
after CABG.1560,1561 The GSV should be spared whenever possible, 
since the success of peripheral arterial revascularization in complex le­
sions is strongly associated with the availability of sufficient autologous 
venous segments.567,1564
11.1.2.3. Screening for coronary artery disease in patients with 
carotid stenosis
Due to the high prevalence of CAD among patients scheduled for elect­
ive CEA,1565,1566 pre-operative CAD screening, including coronary 
angiography, may be considered in suspected patients.1558 CAD re­
quires prioritization of revascularization according to the patient’s clin­
ical status and the severity of carotid disease and CAD. Coronary 
revascularization should generally be performed first; the exception is 
recently symptomatic patients with unstable neurological symptoms 
in whom carotid revascularization should be prioritized.680
11.1.2.4. Screening for carotid stenosis in patients with coronary 
artery disease
Carotid artery stenosis screening may be useful in patients undergoing 
elective CABG. Ischaemic stroke after CABG is multifactorial,1567 but 
also depends on the degree of carotid disease.1556 Two studies suggest 
that limiting DUS to patients with at least one risk factor (age >65 
years, history of cerebrovascular disease, presence of a carotid bruit, 
multivessel CAD or PAD) identifies most patients with significant 
(≥70%) CS.1555,1562 Nevertheless, addition of CEA to CABG is unlikely 
to provide significant stroke reduction. In a study in patients with CAD 
with >80% CS undergoing staged or synchronous carotid procedures 
(two-thirds were neurologically asymptomatic and 73% had unilateral 
asymptomatic carotid stenosis), in-hospital stroke rates and 30 day 
mortality were similar in patients treated with CABG + CEA and in 
those treated with isolated CABG.1568 Another study suggests that se­
lective use of DUS should be considered before CABG in patients with 
a history of neurological events or PAD.1569
11.1.3. Management of patients with polyvascular 
disease
Polyvascular disease requires proactive management of all modifiable 
risk factors through lifestyle changes and drug therapy. Scientific evi­
dence suggests the benefit of intensified antithrombotic therapy, with 
no increase in risk of bleeding.1570 ILT offers comparable benefits for 
PVD patients and those with single arterial territory disease. 
However, the benefits of ILT in patients with PVD are not dependent 
on baseline LDL-C.1571
Revascularization should be reserved for symptomatic arterial terri­
tories, using the least invasive strategy in a multidisciplinary vascular 
team approach.
11.2. Peripheral arterial disease and heart 
failure
Left ventricular (LV) dysfunction is observed in 20%–30% of PAD pa­
tients,1572,1573 mostly associated with CAD.1574 High aortic stiffness 
Table 17 Need for assessment of associated atherosclerotic disease in additional vascular territories in symptomatic pa­
tients with coronary artery disease, peripheral arterial disease, or carotid stenosis
Leading disease
Assessment in 
other vascular 
territories
CAD
PAD
Carotid stenosis
CAD
May be helpful to optimize medical treatment431 and 
to be considered in patients scheduled for open 
vascular surgery with poor functional capacity or 
significant risk factors or symptoms. 1080
Consider in patients scheduled for 
carotid endarterectomy and 
suspected CAD.1558
PAD
Potential benefits in identifying 
high-risk patients and guiding 
treatment decisions.429,1559–1561
Carotid stenosis
Useful in patients undergoing elective 
CABG.1555,1562
© ESC 2024
CABG, coronary artery bypass grafting; CAD, coronary artery disease; PAD, peripheral arterial disease.
ESC Guidelines                                                                                                                                                                                          3651


<!-- PAGE 115 -->

### Page 115

can increase LV afterload and impair coronary blood flow, resulting in 
hypertension, LV hypertrophy, LV diastolic dysfunction, and 
HF.1575,1576 Skeletal muscle involvement and deconditioning due to 
PAD may aggravate HF severity.1577,1578
Peripheral arterial disease and HF are independently associated with 
poor outcomes and those with concomitant HF have a 30% higher risk 
of MACE and 40% higher risk of all-cause mortality.1574 Evaluation of 
LV function in patients with PAD may be useful for better CV risk strati­
fication and comprehensive management of their CV disease.1579 This is 
of particular importance when an intermediate- or high-risk vascular 
intervention is planned. Expectedly, the presence of PAD in patients 
with HF is also associated with poor outcomes.1580–1584 These patients 
represent a high-risk group in which intense risk-factor modification 
strategies and optimization of HF therapy are warranted.
11.3. Peripheral arterial disease and AF
The prevalence of AF among patients with PAD is around 12%.1585–1590
A meta-analysis revealed that in patients with AF and PAD, risk of all- 
cause mortality, CV mortality, and MACE is 40%, over 60%, and over 
70% higher, respectively compared with patients with AF without 
PAD.1591 PAD is included in the CHA2DS2-VASc (congestive heart fail­
ure, hypertension, age ≥75 [doubled], diabetes, stroke [doubled], vas­
cular disease, age 65 to 74 and sex category [female]) risk score, which 
underlies the prognostic importance of PAD in patients with AF.1592
11.4. Peripheral arterial disease and aortic 
stenosis
Peripheral arterial disease frequently accompanies symptomatic aortic 
stenosis, especially among patients not eligible for surgical aortic valve 
replacement (20%–30%).198,1593–1595 In these patients, pre-procedural 
CCT/CTA or CMR1596 of the aorta and major peripheral arteries is 
mandatory to evaluate the access site for transcatheter aortic valve im­
plantation (TAVI) and plan a closure strategy for the access site. 
Patients with PAD have increased risk of all-cause mortality and vascu­
lar complications after TAVI,198 thus, screening for PAD in these pa­
tients may be helpful.
12. Key messages
Peripheral arterial and aortic diseases are highly prevalent, often asymp­
tomatic, and linked to increased morbidity and mortality. Early diagnosis 
is crucial for better outcomes and management requires a multidiscip­
linary team. CVRF control is crucial to prevent progression and compli­
cations. Despite the benefit of medical therapy, lifestyle changes, 
healthy diet, abstinence from smoking, exercise/rehabilitation, and edu­
cation are essential for effective management. Patient empowerment is 
essential to improve adherence and close/regular monitoring is essen­
tial to improve prognosis. Use of web- or app-based calculators for es­
timation of CV risk in the secondary prevention of ASCVD may aid 
patient motivation for lifestyle changes and adherence to medication.
Peripheral arteries
Atherosclerotic lower-extremity PAD is a chronic disease needing 
lifelong follow-up.
Assessment of walking impairment, functional status, and amputation 
risk is crucial in PAD management.
Ankle–brachial index should be the initial diagnostic test for screen­
ing and diagnosing PAD, and serves as a surrogate marker for CV and 
all-cause mortality. DUS is the first-line imaging method to confirm 
PAD lesions.
Supervised exercise training or, if not available, HBET, improves 
walking and functional performances, and reduces CV risk. Exercise 
training remains underused and increased awareness is warranted.
In asymptomatic PAD patient revascularization is not recommended. 
In symptomatic PAD patient need for interventional treatment, follow­
ing a period of optimal medical treatment and exercise, should be dis­
cussed in a multidisciplinary setting.
Chronic limb-threatening ischaemia increases the risk of CV events, 
needs early diagnosis, rapid referral to a multidisciplinary vascular team, 
and revascularization for limb salvage.
Acute limb ischaemia warrants rapid clinical assessment by a vascular 
team and urgent revascularization.
Duplex ultrasound is the first-line diagnostic modality for carotid 
stenosis. Routine revascularization is not recommended if asymp­
tomatic. In symptomatic patients multidisciplinary assessment is 
recommended.
Recommendation Table 70 — Recommendations for 
screening and management of polyvascular disease and 
peripheral arterial disease with cardiac diseases (see 
also Evidence Table 15)
Recommendations
Classa
Levelb
In patients with PVD, an LDL-C reduction by ≥50% 
from baseline and an LDL-C goal of <1.4 mmol/L 
(<55 mg/dL) are recommended.242,1571
I
A
In patients with PAD and newly diagnosed AF with a 
CHA2DS2-VASc score ≥2, full oral anticoagulation is 
recommended.1597
I
C
Screening for ilio-femoral PAD is recommended in 
patients undergoing TAVI.198,1598
I
B
Carotid DUS should be considered for stable 
patients scheduled for CABG with TIA/stroke within 
the past 6 months without carotid 
revascularization.1556,1569
IIa
B
Continued 
In patients with stable PVD who are symptomatic in 
at least one territory and without high bleeding risk,c 
treatment with a combination of rivaroxaban (2.5 mg 
b.i.d.) and aspirin (100 mg o.d.) should be 
considered.429,1559
IIa
A
Carotid DUS may be considered for stable patients 
scheduled for CABG without TIA/stroke within the 
past 6 months.1555,1562
IIb
C
© ESC 2024
AF, atrial fibrillation; b.i.d., twice daily; CABG, coronary artery bypass grafting; 
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, 
stroke (doubled), vascular disease, age 65 to 74 and sex category (female); DUS, duplex 
ultrasound; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein 
cholesterol; o.d., once daily; PAD, peripheral arterial disease; PVD, polyvascular disease; 
TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence. 
cPrior history of intracerebral haemorrhage or ischaemic stroke, history of other 
intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible 
gastrointestinal blood loss, other gastrointestinal pathology associated with increased 
bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, 
or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.


<!-- PAGE 116 -->

### Page 116

Atherosclerotic UEAD is most frequently located in the subclavian 
artery and may be suspected because of an absolute inter-arm SBP dif­
ference >10–15 mmHg. DUS is first-line imaging and routine revascu­
larization is not recommended.
The key to early diagnosis of acute and chronic mesenteric ischae­
mia is a high level of clinical suspicion—laboratory tests are unreli­
able for the diagnosis. Acute SMA occlusion requires immediate 
revascularization.
Aorta
Aortic aneurysms are managed based on size, location, and growth 
rate. Small aneurysms are monitored regularly (Guidelines provide 
disease-specific follow-up algorithms), while larger ones may require 
surgical/endovascular repair to prevent rupture.
In aortic root aneurysms, aortic replacement may be considered at 
>52 mm in low-risk patients and at experienced centres.
Aortic diameter is the primary risk factor for aortic events. However, 
evidence supports diameter indexation (especially in extreme BSA po­
pulations) and the use of aortic length (>11 cm), the AHI (>32.1 mm/m), 
growth rate (≥3 mm per year for ascending aorta and arch or >5 mm 
per 6 months in the thoracoabdominall aorta), and age/sex for risk 
assessment.
Multidisciplinary collaboration, hybrid operating rooms, and ad­
vanced stent technology have increased the adoption of hybrid ap­
proaches and endovascular therapies for different thoracoabdominal 
aortic diseases.
Acute aortic syndrome management involves medical treatment in 
critical care units and selective surgical intervention based on location 
and complications. The main problem in these conditions continues 
to be a delay in diagnosing patients or transferring them to an aortic 
centre. Improved diagnostic algorithms and reduced surgical complica­
tions have lowered mortality rates. Surgical/endovascular treatment in 
the subacute phase is advised for high-risk patients with type B aortic 
syndrome.
Suspected genetic aortic conditions require evaluation at experi­
enced centres to assess both the patient and their FDRs for genetic 
studies. Genetic aortic conditions should be considered based on family 
history, syndromic features, age <60 years, and no CVRFs (Guidelines 
offer a screening algorithm for thoracic aorta disease). A comprehen­
sive evaluation of the entire aorta and other vascular territories is re­
commended in HTAD. Recent advances in genetics are enabling 
personalized and patient-centred assessment. This includes using differ­
ent aortic diameter thresholds to indicate surgery and implementing di­
verse surveillance algorithms.
13. Gaps in evidence
There are several areas where robust evidence is still lacking and which 
deserve to be addressed in future clinical research. 
(1) Epidemiology and risk factors in PAAD: 
(a) Improve PAAD risk definition.
(b) Provide contemporary data on PAAD prevalence in Europe.
(c) Inflammation biomarkers, metabolomics, and proteomics may 
have prognostic value in PAAD.
(2) Evaluation of peripheral arteries and aorta: 
(a) Follow-up algorithms can assist PAAD patient management 
but have limitations and evidence on cost-effectiveness is 
needed.
(b) The best methodology for aortic measurements remains to be 
elucidated.
(3) Screening for carotid, peripheral arterial, and aortic diseases: 
(a) Screening in specific populations: research is needed to under­
stand the nuances of screening in particular populations and 
whether modifications to current guidelines are necessary.
(b) Patient outcomes and benefits of screening: impact of screen­
ing on patient outcome should be assessed.
(4) OMT and PAAD: 
(a) Research needed on QoL and workability.
(b) Research needed for optimal preventive strategies.
(c) Exercise therapy and rehabilitation for PAAD should be more 
accessible and employed.
(d) Anti-inflammatory therapy should be investigated.
(e) Antithrombotic therapies in specific risk groups of PAAD and 
patients undergoing revascularization should be addressed.
(5) Aortic aneurysms: 
(a) Discovering novel individualized risk stratification parameters 
beyond well-established markers.
(b) Assessing the safety of fluoroquinolone use in patients with 
aortic aneurysm.
(6) Acute aortic syndromes: 
(a) Assess the management of pregnancy-related AAS.
(b) Identify diagnostic biomarkers other than D-dimer.
(c) Management in uncomplicated TBAD and IMH should be 
assessed.
(7) Genetic aortic diseases: 
(a) Need to refine risk estimation in AD, particularly in HTAD, es­
pecially the risk of type B aortic dissection.
(b) There is insufficient evidence to support the efficacy of any 
medication in reducing the risk of AD.
(8) Sex differences in PAAD: 
(a) Investigate sex and age differences.
(b) Assess the optimal parameter or indexed parameter to guide 
intervention decisions in women with aortic and PAD diseases.
14. Sex differences
Sex differences have been evaluated and discussed in the specific 
sections.
15. ‘What to do’ and ‘What not to 
do’ messages from the guidelines
Table 18 ‘What to do’ and ’What not to do’. ‘What to do and What not 
to do’ lists all Class I and Class III recommendations from the text.
ESC Guidelines                                                                                                                                                                                          3653


<!-- PAGE 117 -->

### Page 117

Table 18 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for clinical and laboratory, and for functional and quality of life, assessment in patients with peripheral arterial and 
aortic disease
When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of arterial circulation.
I
B
To assess PAAD, it is recommended to perform thorough clinical, vascular, and CVRF laboratory evaluation.
I
C
Recommendations for diagnostic tests in patients with peripheral arterial disease
Measurement of the ABI is recommended as the first-line non-invasive test for screening and diagnosis of PAD, using an ABI ≤0.90 as a 
diagnostic criterion.
I
B
In the case of non-compressible ankle arteries or ABI >1.40, additional methods such as TP, TBI or Doppler waveform analysis are 
recommended.
I
B
Recommendations for imaging of the aorta
It is recommended that aortic diameters are measured at prespecified anatomical landmarks, and the largest diameter of the section be 
perpendicular to the longitudinal axis.
I
C
It is recommended in cases of serial imaging of the aorta over time to use the same imaging modality with the same measurement method.
I
C
It is recommended to consider renal function, pregnancy, age, and history of allergy to contrast media to select the optimal imaging modality 
with minimal radiation exposure and lowest iatrogenic risk, except for emergency cases.
I
C
Recommendations for thoracic aortic measurements
TTE is recommended as the first-line imaging technique in evaluating thoracic aortic diseases.
I
B
It is recommended to report aortic diameters using the leading-to-leading edge convention in end-diastole by echocardiography.
I
C
It is recommended to report aortic diameters using the inner-to-inner edge convention in end-diastole by CCT or CMR.
I
C
It is recommended to report aortic diameters from images obtained with the double-oblique technique (not axial images) by CCT or CMR.
I
C
ECG-triggered CCT is recommended for comprehensive diagnosis, follow-up, and pre-invasive treatment assessment of the entire aorta, 
particularly the root and ascending aorta.
I
C
CMR is recommended for diagnosis and follow-up of thoracic aortic diseases, especially when chronic follow-up is required.
I
C
Recommendations for abdominal aortic aneurysm screening
Screening is recommended in men aged ≥65 years and with a history of smoking to reduce the risk of death from ruptured AAA.
I
A
Screening is recommended in FDRs of patients with AAA aged ≥50, unless an acquired cause can be clearly identified.
I
C
Recommendations for lifestyle, physical activity, and patient education
In patients with PAAD, cessation and abstinence from smoking of any kind is recommended to reduce the risk of AD, MI, death, and limb 
ischaemia.
I
A
A healthy diet rich in legumes, dietary fibre, nuts, fruits, and vegetables, with a high flavonoid intake (Mediterranean diet), is recommended 
for CV disease prevention in patients with PAAD.
I
A
Low- to moderate-intensity (or high if tolerated) aerobic activities are recommended in patients with PAD to increase overall and pain-free 
walking distance.
I
A
In patients with PAAD, behavioural counselling to promote healthy diet, smoking cessation, and physical activity is recommended to 
improve the CV risk profile.
I
B
It is recommended to promote patient and caregivers’ education and empowerment through tailored guidance on lifestyle adjustments and 
the importance of regular physical activity.
I
C
Recommendations for antihypertensive therapy in patients with peripheral and aortic disease
In patients with PAAD and hypertension an SBP target towards 120–129 mmHg, if tolerated, is recommended.
I
A
In unilateral RAS patients, it is recommended that antihypertensive medication include ACEIs/ARBs.
I
B
Recommendations for lipid-lowering therapy for patients with peripheral arterial and aortic diseases
In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended.
I
A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with 
atherosclerotic PAAD.
I
A
Statins are recommended in all patients with PAD.
I
A
If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to 
achieve the given target values.
I
B
Continued


<!-- PAGE 118 -->

### Page 118

If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in 
patients with atherosclerotic PAAD, to achieve target values.
I
A
For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is 
recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.
I
B
Fibrates are not recommended for cholesterol lowering.
III
B
Recommendations for the medical management of patients with peripheral arterial and aortic diseases and diabetes
It is recommended to apply tight glycaemic control (HbA1c <53 mmol/mol [7%]) to reduce microvascular complications in patients with 
PAAD.
I
A
SGLT2i with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or 
target HbA1c and concomitant glucose-lowering medication.
I
A
GLP-1RAs with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or 
target HbA1c and concomitant glucose-lowering medication.
I
A
It is recommended to avoid hypoglycaemia in patients with PAAD.
I
B
It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy.
I
C
It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits, followed by agents with proven CV safety, over 
agents without proven CV benefit or safety.
I
C
Recommendations for diagnostic tests in patients with peripheral arterial disease and diabetes, renal failure and wounds
Measuring TP or TBI is recommended in patients with diabetes or renal failure if resting ABI is normal.
I
C
Recommendations for imaging in patients with peripheral arterial disease
DUS is recommended as first-line imaging method to confirm PAD lesions.
I
C
In symptomatic patients with aorto-iliac or multisegmental/complex disease, CTA and/or MRA are recommended as adjuvant imaging 
techniques for preparation of revascularization procedures.
I
C
Analysis of anatomical imaging tests in conjunction with symptoms and haemodynamic tests prior to an invasive procedure is 
recommended.
I
C
Recommendations for exercise therapy in patients with peripheral arterial disease
In patients with symptomatic PAD, SET is recommended.
I
A
In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy.
I
A
Recommendations for antithrombotic therapy in patients with peripheral arterial disease
Use of antiplatelet therapy with aspirin alone (range 75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is recommended for the reduction of 
MACE in patients with symptomatic PAD.
I
A
Long-term DAPT in patients with PAD is not recommended.
III
A
Oral anticoagulant monotherapy for PAD (unless for another indication) is not recommended.
III
A
The routine use of ticagrelor in patients with PAD is not recommended.
III
A
It is not recommended to systematically treat patients with asymptomatic PAD without any sign of clinically relevant ASCVD with 
antiplatelet drugs.
III
B
Recommendations on interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)
In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended.
I
B
It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general 
patient condition.
I
C
In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI.
III
B
In patients with asymptomatic PAD, revascularization is not recommended.
III
C
Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease
It is recommended to regularly, at least once a year, follow-up patients with PAD, assessing clinical and functional status, medication 
adherence, limb symptoms, and CVRFs, with DUS assessment as needed.
I
C
Recommendations for the management of chronic limb-threatening ischaemia
For limb salvage in patients with CLTI, revascularization is recommended.
I
B
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage.
I
C
Recommendations for medical treatment in patients with chronic limb-threatening ischaemia
It is recommended that patients with CLTI are managed by a vascular team.
I
C
In patients with CLTI and ulcers, offloading mechanical tissue stress is recommended to allow wound healing.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3655


<!-- PAGE 119 -->

### Page 119

It is recommended to treat infection with antibiotics.
I
C
Lower-limb exercise training is not recommended in patients with CLTI and wounds.
III
C
Recommendations for interventional treatment of chronic limb-threatening ischaemia
In CLTI patients, it is recommended to perform revascularization as soon as possible.
I
B
In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery.
I
B
In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions.
I
C
An individual risk assessment (weighing the patient’s individual procedural risk of endovascular vs. surgical revascularization) by a 
multidisciplinary vascular team is recommended.
I
C
Recommendations for follow-up in patients with chronic limb-threatening ischaemia
In patients with CLTI, following revascularization it is recommended to follow-up patients on a regular basis.
I
C
At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs.
I
C
Recommendations for the management of patients presenting with acute limb ischaemia
In patients with ALI, it is recommended that an urgent evaluation is performed by a vascular clinician with sufficient experience to assess limb 
viability and implement appropriate therapy.
I
C
In cases of neurological deficit, urgent revascularization is recommended; diagnostic imaging is recommended to guide treatment, provided 
it does not delay treatment, or if the need for primary amputation is obvious.
I
C
In the absence of severe neurological deficit, revascularization is recommended within hours of initial imaging in a case-by-case decision.
I
C
Treatment with analgesics is recommended as soon as possible for pain control.
I
C
It is recommended to monitor for compartment syndrome after revascularization and treat (fasciotomy).
I
C
It is recommended to assess clinical and haemodynamic success following revascularization.
I
C
In patients with ALI, it is recommended to obtain a comprehensive medical history and determine the cause of thrombosis and/or 
embolization.
I
C
Recommendations for carotid artery stenosis assessment
It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis.
I
B
It is recommended to use DUS as first-line imaging to diagnose ICA stenosis.
I
C
It is not recommended to use the ECST method for ICA stenosis assessment.
III
C
Recommendations for antithrombotic treatment in patients with carotid stenosis
In patients with symptomatic CS, not undergoing carotid endarterectomy or stenting, DAPT with low-dose aspirin and clopidogrel (75 mg) 
is recommended for the first 21 days or longer, followed by clopidogrel 75 mg or long-term aspirin to reduce the risk of stroke.
I
A
Recommendations for interventional treatment in patients with asymptomatic carotid artery stenosis
In asymptomatic patients with ICA stenosis, in the absence of high-risk features and with a life expectancy <5 years, routine 
revascularization is not recommended.
III
A
Recommendations for evaluation and medical treatment in patients with symptomatic carotid artery stenosis
DAPT is recommended in the early phase of minor strokes in patients with ICA stenosis, if not revascularized, for at least 21 days, 
considering the bleeding risk.
I
A
It is recommended that symptomatic ICA stenosis patients are assessed by a vascular team including a neurologist.
I
C
Recommendations for interventions in patients with symptomatic carotid artery stenosis
It is recommended to perform CEA of symptomatic 70%–99% ICA stenosis provided a documented 30 day risk of procedural death/stroke 
is <6%.
I
A
If indicated, it is recommended to perform CEA within 14 days in symptomatic ICA stenosis patients.
I
B
OMT is recommended for all symptomatic ICA stenosis patients.
I
A
Revascularization is not recommended in patients with ICA lesions <50%.
III
A
Recommendations for follow-up in patients with carotid artery stenosis
Once-yearly follow-up is recommended to check for CVRFs and treatment compliance.
I
A
After ICA stent implantation, DAPT with aspirin and clopidogrel is recommended for at least 1 month.
I
A
After ICA revascularization, long-term aspirin or clopidogrel is recommended.
I
B
During follow-up, it is recommended to assess neurological symptoms, CVRFs, and treatment adherence at least yearly in patients with CS.
I
C
After ICA revascularization, surveillance with DUS is recommended within the first month.
I
C
Continued


<!-- PAGE 120 -->

### Page 120

Recommendations for the management of subclavian artery stenosis
Bilateral arm BP measurement is recommended for all patients with PAAD.
I
B
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended.
III
C
Recommendations for diagnostic strategies for renal artery disease
DUS is recommended as the first-line imaging modality in patients with suspicion of RAS.
I
B
In cases of DUS-based suspicion of RAS or in inconclusive DUS, MRA or CTA are recommended.
I
B
In patients with atherosclerotic RAS, it is recommended to assess clinical high-risk features and kidney viability when evaluating renal artery 
revascularization.
I
B
Recommendations for treatment strategies for renal artery disease
In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended.
III
A
Recommendations in patients with visceral artery stenosis
In patients with acute mesenteric ischaemia due to acute occlusion of the SMA, endovascular revascularization is recommended.
I
B
In patients with suspected acute or chronic mesenteric ischaemia, CTA is recommended.
I
C
In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended.
I
C
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended.
III
C
Recommendations for primary and secondary prevention in aortic atheromatous plaques
Anticoagulation or DAPT are not recommended in aortic plaques since they present no benefit and increase bleeding risk.
III
C
In patients with an embolic event and evidence of an aortic arch atheroma, intensive lipid management to an LDL-C target <1.4 mmol/L 
(<55 mg/dL) is recommended to prevent recurrences.
I
A
In patients with an embolic event and evidence of an aortic arch atheroma, SAPT is recommended to prevent recurrences.
I
C
Recommendations for initial evaluation of thoracic aorta aneurysm and abdominal aortic aneurysm
When an aortic aneurysm is identified at any location, assessment of the entire aorta is recommended at baseline and during follow-up.
I
C
When a TAA is identified, assessment of the aortic valve (especially for BAV) is recommended.
I
C
Recommendation for the surveillance of patients with thoracic aortic aneurysms (non-heritable thoracic aortic disease)
In thoracic aortic dilatation, TTE is recommended at diagnosis to assess aortic valve anatomy and function, aortic root, and ascending aorta 
diameters. Additionally, a global aortic evaluation using all echocardiographic views is recommended.
I
C
CMR or CCT is recommended for surveillance of patients with aneurysm at the distal ascending aorta, aortic arch, DTA, or TAAA.
I
C
In thoracic aortic dilatation, CCT or CMR is recommended to confirm TTE measurements, rule out aortic asymmetry, and determine 
baseline diameters for follow-up.
I
C
TTE is not recommended for the surveillance of aneurysms in the distal ascending aorta, aortic arch, or DTA.
III
C
Recommendations for surveillance of patients with abdominal aortic aneurysm
DUS surveillance is recommended every 6 months in men with AAA of 50–55 mm and in women with AAA of 45–50 mm.
I
B
DUS is recommended for AAA surveillance.
I
C
CCT or CMR is recommended if DUS does not allow adequate measurement of AAA diameter.
I
B
Recommendations for medical treatment in patients with thoracic aorta or abdominal aortic aneurysms
In patients with aortic aneurysm (TAA and/or AAA), optimal implementation of CV risk management and medical treatment (see detailed 
recommendations in dedicated Tables of Recommendations) are recommended to reduce MACE.
I
C
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
Surgery is recommended in patients with dilatation of the aortic root or ascending aorta with a tricuspid aortic valve and a maximum 
diameter of ≥55 mm.
I
B
Valve-sparing aortic root replacement is recommended in patients with aortic root dilatation if performed in experienced centres and 
durable results are expected.
I
B
VKAs are recommended lifelong for all patients with a Bentall procedure with an MHV prosthesis.
I
B
Recommendations for surgery in aortic arch aneurysms
In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to 
non-aortic causes, open surgical replacement of the arch is recommended.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3657


<!-- PAGE 121 -->

### Page 121

Recommendations for the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic  
aneurysms
In patients with unruptured DTA aneurysm (without HTAD), elective repair is recommended if diameter ≥55 mm.
I
B
In patients without HTAD with unruptured DTA aneurysm, when elective repair is indicated and anatomy is suitable, TEVAR is 
recommended over open repair.
I
B
In patients with DTA aneurysm who undergo TEVAR with planned LSA coverage, it is recommended to revascularize the LSA before 
TEVAR to reduce the risk of SCI and stroke.
I
B
In patients with unruptured degenerative TAAA, elective repair is recommended when the diameter is ≥60 mm.
I
B
Recommendations for the management of patients presenting with abdominal aortic aneurysm
Elective repair is recommended if AAA diameter is ≥55 mm in men or ≥50 mm in women.
I
A
In ruptured AAA with suitable anatomy, endovascular repair is recommended over open repair to reduce peri-operative morbidity and 
mortality.
I
B
In patients with AAA and limited life expectancy (<2 years), elective AAA repair is not recommended.
III
B
Prior to AAA repair, routine evaluation with coronary angiography and systematic revascularization in patients with chronic coronary 
syndromes is not recommended.
III
C
Recommendations for the management of patients presenting with endoleaks
It is recommended to perform 30 day imaging after TEVAR/EVAR, by CCT + DUS/CEUS, to assess the success of intervention.
I
B
It is recommended to re-intervene to achieve a seal in patients with type I endoleak after TEVAR/EVAR.
I
B
It is recommended to re-intervene, principally by endovascular means, to achieve a seal in patients with type III endoleak after TEVAR/EVAR.
I
B
Recommendations for follow-up after treatment of aortic aneurysms
After open repair of TAA, early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years 
and every 5 years thereafter is recommended if findings are stable.
I
B
After TEVAR, follow-up imaging is recommended at 1 and 12 months post-operatively, then yearly until the fifth post-operative year if no 
abnormalities are documented.
I
B
After open repair of AAA, first follow-up imaging is recommended within 1 post-operative year, and then every 5 years thereafter if findings 
are stable.
I
A
After EVAR, follow-up imaging is recommended with CCT (or CMR) and DUS/CEUS at 1 month and 12 months post-operatively, then, if 
no abnormalities are documented, DUS/CEUS is recommended every year, repeating CCT or CMR (based on potential artefacts) every 5 
years.
I
A
Recommendations for diagnostic work-up of acute aortic syndrome
In unstable patients who cannot be transferred to CCT, TOE is recommended for diagnosis and evaluation of the coeliac trunk and 
mesenteric artery.
I
B
In patients presenting with clinical features compatible with possible AAS, a multiparametric algorithm for ruling in or out AAS using the 
ADD-RS is recommended.
I
B
ECG-gated CCT from neck to pelvis is recommended as the first-line imaging technique in patients with a suspected AAS since it is widely 
available, accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).
I
C
In patients with suspected AAS, focused TTE (with use of contrast if feasible) is recommended during the initial evaluation.
I
C
In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications.
I
C
Recommendation for medical treatment in acute aortic syndromes
In patients with AAS, immediate anti-impulse treatment targeting SBP <120 mmHg and heart rate ≤60 b.p.m. is recommended. In cases of 
spinal ischaemia or concomitant brain injury, maintaining higher MAP is recommended.
I
B
Intravenous BBs (e.g. labetalol) are recommended as first-line agents. If necessary, i.v. vasodilators (e.g. dihydropyridine calcium blockers or 
nitrates) could be added.
I
B
Invasive monitoring with an arterial line and continuous three-lead ECG recording, as well as admission to an intensive care unit, is 
recommended.
I
B
In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching 
to oral BBs and, if necessary, up-titration of other BP-lowering agents, is recommended after 24 h if gastrointestinal transit is preserved.
I
B
Adequate pain control to achieve haemodynamic targets is recommended.
I
C
Continued


<!-- PAGE 122 -->

### Page 122

Recommendations for intervention in type A acute aortic dissection
In patients with acute TAAD, emergency surgical consultation and evaluation and immediate surgical intervention is recommended.
I
B
In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic 
root replacement is recommended with a mechanical or biological valved conduit.
I
B
Recommendations for aortic repair strategies in type A acute aortic dissection
In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is 
recommended over valve replacement.
I
B
In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL 
thrombosis rates.
I
B
In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more 
extensive arch replacement.
I
B
Recommendations for the management of malperfusion in the setting of acute aortic dissection
In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is 
recommended.
I
B
Recommendations for the management of patients presenting with acute type B aortic dissection
Medical therapy including pain relief and blood pressure control is recommended in all patients with acute TBAD.
I
B
In patients with complicated acute TBAD, emergency intervention is recommended.
I
B
In patients with complicated acute TBAD, TEVAR is recommended as the first-line therapy.
I
B
Recommendations for the management of patients presenting with chronic type B aortic dissection
Antihypertensive therapy is recommended in all patients with chronic TBAD.
I
B
In chronic TBAD with acute symptoms of malperfusion, rupture, or progression of disease, emergency intervention is recommended.
I
C
In patients with chronic TBAD and a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable 
surgical risk.
I
B
Recommendations for the management of intramural haematoma
In patients with IMH, medical therapy including pain relief and blood pressure control is recommended.
I
C
In type A IMH, urgent surgery is recommended.
I
C
In type B IMH, initial medical therapy under careful surveillance is recommended.
I
C
In uncomplicated type B IMH, repetitive imaging (CCT or CMR) is indicated.
I
C
In complicated type B IMH, TEVAR is recommended.
I
C
Recommendations for the management of penetrating atherosclerotic ulcer
In all patients with PAU, medical therapy including pain relief and blood pressure control is recommended.
I
C
In cases of type A PAU, surgery is recommended.
I
C
In cases of type B PAU, initial medical therapy under careful surveillance is recommended.
I
C
In uncomplicated type B PAU, repetitive imaging (CMR, CCT, or TOE) is recommended.
I
C
In complicated type B PAU, endovascular treatment (TEVAR) is recommended.
I
C
Recommendations for traumatic aortic injury
In cases of severe aortic injury (grade 4), immediate repair is recommended.
I
A
In cases of TAI with suitable anatomy requiring intervention, TEVAR is recommended over open surgery.
I
A
In all TAI patients, medical therapy including pain relief, and blood pressure and heart rate control, is recommended.
I
C
In cases of TAI suspicion, CCT is recommended.
I
C
In cases of moderate aortic injury (grade 3), repair is recommended.
I
C
Recommendations for follow-up after treatment of acute aortic syndrome
After TEVAR for AAS, follow-up imaging is recommended at 1, 6, and 12 months post-operatively, then yearly until the fifth post-operative 
year if no abnormalities are documented.
I
B
In medically treated type B AAD or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging 
findings are stable.
I
C
In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3659


<!-- PAGE 123 -->

### Page 123

Recommendations for the management of patients with heritable thoracic aortic disease
It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making.
I
C
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in 
the care of this patient group.
I
C
Recommendations for genetic testing and aortic screening in aortic disease
In patients with aortic root/ascending aneurysms or thoracic aortic dissection, gathering family history information for at least three 
generations about TAD, unexplained sudden deaths, and peripheral and intracranial aneurysms is recommended.
I
B
In patients with aortic root/ascending aortic aneurysms or thoracic aortic dissection and risk factors for HTAD, genetic counselling at an 
expert centre and subsequent testing, if indicated, is recommended.
I
B
In patients with HTAD who have a pathogenic/likely pathogenic variant, genetic testing of at-risk biological relatives (i.e. cascade testing) is 
recommended, irrespective of age.
I
C
In patients with TAD with risk factors for HTAD, with a negative family history of TAD and in whom no (likely) pathogenic variant is 
identified, TTE screening aortic imaging of FDRs is recommended.
I
B
Recommendations for imaging in women with Turner syndrome
To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to 
BSA [m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and 
assess the risk of aortic dissection.
I
C
It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending 
ASI and concomitant lesions.
I
C
Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome
In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended.
I
C
Recommendations for vascular imaging in Marfan syndrome
In patients with MFS, TTE is recommended: 
• At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factors
• At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factors
• At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factors
I
C
In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aorta imaging by CMR or CCT and DUS is 
recommended at the first evaluation, and subsequently every 3–5 years if stable.
I
C
In patients with MFS who have undergone aortic root replacement, surveillance imaging of the thoracic aorta by CMR (or CCT) is 
recommended at least every 3 years.
I
C
Recommendations for medical treatment in Marfan syndrome
In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to 
reduce the rate of aortic dilatation.
I
A
Recommendations for aortic surgery in Marfan syndrome
Surgery is indicated in patients with MFS who have aortic root disease with a maximal aortic sinus diameter ≥50 mm.
I
B
Surgery to replace the aortic root and ascending aorta, using the valve-sparing surgery technique, is recommended in patients with MFS or 
related HTAD with aortic root dilatation when anatomical features of the valve allow its preservation and the surgeon has specific expertise.
I
B
Recommendations for pregnancy in women with Marfan syndrome
It is recommended that all women with MFS: 
• Have a pre-conception evaluation to address the risks of maternal CV and other complications
• Have follow-up in a centre with access to a pregnancy heart and vessel team
I
C
It is recommended that couples in which a partner has or is at risk of HTAD be offered pre-conception genetic counselling.
I
C
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy.
I
C
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth.
I
C
Intake of BBs during pregnancy is recommended.
I
C
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm.
I
C
ARBs are not recommended during pregnancy.
III
B
Recommendations for physical exercise in patients with Marfan syndrome
It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and 
pre-existing fitness.
I
C
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS.
I
C
Continued


<!-- PAGE 124 -->

### Page 124

### 16 Evidence tables

Evidence tables are available on the European Heart Journal website.
17. Data availability statement
No new data were generated or analysed in support of this research.
18. Author information
Author/task 
force 
Member 
Affiliations: 
Gisela 
Teixido-Tura, Cardiovascular Imaging section and Aortic diseases 
Unit (VASCERN), Department of Cardiology, Vall d’Hebron Hospital 
Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′ 
Hebron Institut de Recerca (VHIR), Barcelona, Spain, Centro de 
Investigación Biomédica en Red de Enfermedades Cardiovasculares, 
Instituto de Salud Carlos III, Madrid, Spain; Stefano Lanzi, 
Department of Angiology, Lausanne University Hospital, University of 
Lausanne, Lausanne, Switzerland; Vinko Boc, Department of 
Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, 
Slovenia; Eduardo Bossone, Department of Public Health, 
University of Naples “Federico II”, Naples, Italy, Department of 
Translational Medical Sciences, University of Naples “Federico II”, 
Naples, Italy; Marianne Brodmann, Division of Angiology, Medical 
Recommendations for imaging follow-up in Loeys–Dietz syndrome
In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth, is 
recommended.
I
C
In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance 
with CMR or CCT or DUS every 1–3 years is recommended.
I
C
Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease
Annual monitoring of the aortic root/ascending aorta with TTE to evaluate aortic root/ascending aorta enlargement is recommended.
I
C
Imaging of the aorta with CMR/CCT every 3–5 years is recommended.
I
C
Recommendations for bicuspid aortic valve-associated aortopathy management
When a BAV is first diagnosed, initial TTE to assess diameters of the aorta at several levels is recommended.
I
B
Surgery for bicuspid aortopathy is recommended when the maximum aortic diameter is ≥55 mm.
I
B
Surgery for bicuspid aortopathy of the root phenotype is recommended when the maximum aortic diameter is ≥50 mm.
I
B
CCT or CMR of the entire thoracic aorta is recommended at first diagnosis and when important discrepancies in measurements are found 
between subsequent TTE controls during surveillance, or when the diameter of the aorta exceeds 45 mm.
I
C
Screening by TTE in FDRs of BAV patients with root phenotype aortopathy and/or isolated aortic regurgitation is recommended.
I
C
Surveillance serial imaging by TTE is recommended in BAV patients with a maximum aortic diameter >40 mm, either with no indication for 
surgery or after isolated aortic valve surgery, after 1 year, then if stability is observed, every 2–3 years.
I
C
Recommendations for evaluation and medical treatment of patients with coarctation of the aorta
In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR 
every 3–5 years (adapted to clinical status and previous imaging findings).
I
B
Coarctation or re-coarctation repair (either surgical or endovascular) is indicated in patients with hypertension with an increased 
non-invasive gradient between the upper and lower limbs (decreased ABI) confirmed with invasive measurement (peak-to-peak 
>20 mmHg), with a preference for stenting when technically feasible.
I
C
In patients with coarctation, BP measurements at both arms and one lower extremity are recommended.
I
C
It is recommended to treat hypertension in patients with coarctation according to ESC hypertension guidelines.
I
C
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.
I
A
In patients with PAD and newly diagnosed AF with a CHA2DS2-VASc score ≥2, full oral anticoagulation is recommended.
I
C
Screening for ilio-femoral PAD is recommended in patients undergoing TAVI.
I
B
© ESC 2024
AAA, abdominal aortic aneurysm; AAS, acute aortic syndrome; ABI, ankle–brachial index; ACEI, angiotensin-converting enzyme inhibitor; AD, aortic dissection; ADD-RS, aortic dissection 
detection-risk score; AF, atrial fibrillation; AHI, aortic height index; ALI, acute limb ischaemia; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; ASI, aortic 
size index; BAV, bicuspid aortic valve; BB, beta-blocker; BP, blood pressure; b.p.m., beats per minute; CCT, cardiovascular computed tomography; CEA, carotid endarterectomy; CEUS, 
contrast-enhanced ultrasound; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category 
(female); CLTI, chronic limb-threatening ischaemia; CMR, cardiovascular magnetic resonance; CS, carotid artery stenosis; CTA, computed tomography angiography; CV, cardiovascular; 
CVRF, cardiovascular risk factor; DAPT, dual antiplatelet therapy; DTA, descending thoracic aorta; DUS, duplex ultrasound; ECG, electrocardiogram; ECST, European Carotid Surgery 
Trial; ESC, European Society of Cardiology; FDR, first-degree relative; FL, false lumen; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HTAD, 
heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; i.v., intravenous; LDL-C, low-density lipoprotein cholesterol; LSA, left subclavian artery; 
MACE, major adverse cardiac event; MAP, mean arterial pressure; MFS, Marfan syndrome; MHV, mechanical heart valve; MI, myocardial infarction; MRA, magnetic resonance 
angiography; NASCET, North American Symptomatic Carotid Endarterectomy Trial; o.d., once daily; OMT, optimal medical treatment; PAAD, peripheral arterial and aortic diseases; 
PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; PCSK9, proprotein convertase subtilisin/kexin type 9; PVD, polyvascular disease; RAS, renal artery stenosis; 
QoL, quality of life; SAPT, single antiplatelet therapy; SBP, systolic blood pressure; SCI, spinal cord ischaemia; SET, supervised exercise training; SGLT2i, sodium-glucose co-transporter-2 
inhibitor; SMA, superior mesenteric artery; T2DM, type 2 diabetes mellitus; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm; TAAD, type A aortic dissection; 
TAD, thoracic aortic disease; TAI, traumatic aortic injury; TAVI, transcatheter aortic valve implantation; TBAD, type B aortic dissection; TBI, toe–brachial index; TOE, transoesophageal 
echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TP, toe pressure; TS, Turner syndrome; TTE, transthoracic echocardiography; vEDS, vascular Ehlers– 
Danlos syndrome; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3661


<!-- PAGE 125 -->

### Page 125

University Graz, Graz, Austria; Alessandra Bura-Rivière, Vascular 
Medicine Department, Toulouse University Hospital, Toulouse, France, 
Faculty of Medicine, University Toulouse 3, Toulouse, France; Julie De 
Backer, Cardiology and Center for Medical Genetics, Ghent 
University 
Hospital, 
Ghent, 
Belgium; 
Sebastien 
Deglise, 
Department of Vascular Surgery, University Hospital Lausanne 
(CHUV), Lausanne, Switzerland; Alessandro Della Corte, 
Department of Translational Medical Sciences, University of 
Campania “Luigi Vanvitelli”, Naples, Italy, Unit of Cardiac Surgery, 
Monaldi Hospital, Naples, Italy; Christian Heiss, Department of 
Clinical and Experimental Medicine, University of Surrey, Guildford, 
United Kingdom, Vascular Medicine Department, Surrey and Sussex 
Healthcare 
NHS 
Trust, 
Redhill, 
United 
Kingdom; 
Marta 
Kałużna-Oleksy, 1st Department of Cardiology, Poznan University 
of Medical Sciences, Poznan, Poland; Donata Kurpas, Division of 
Research Methodology, Department of Nursing, Faculty of Nursing 
and Midwifery, Wroclaw Medical University, Poland; Carmel 
M. McEniery, Medicine, University of Cambridge, Cambridge, 
United Kingdom; Tristan Mirault, Vascular Medicine Department, 
Université Paris Cité, Paris, France, Vascular Medicine Department, 
Assistance Publique Hôpitaux de Paris-APHP, Hôpital Européen 
Georges-Pompidou, Paris, PARCC U970 team 5 Innate and 
Adaptative Immunity in Vascular Diseases, INSERM, Paris, France; 
Agnes A. Pasquet, Department of Cardiovascular Diseases, 
Cliniques Universitaires Saint Luc, Brussels, Belgium, IREC/CARD, 
UCLouvain, Brussels, Belgium; Alex Pitcher, The Heart Centre, 
Oxford University NHS Foundation Trust, Oxford, United Kingdom; 
Hannah A.I. Schaubroeck, Department of Intensive Care 
Medicine, Ghent University Hospital, Ghent, Belgium; Oliver 
Schlager, Division of Angiology, Department of Medicine II, Medical 
University of Vienna, Vienna, Austria; Per Anton Sirnes, 
Cardiology Practice, Kardiokonsult, Son, Norway, Cardiology section, 
Volvat Medical Centre, Moss, Norway; Muriel G. Sprynger, 
Cardiology, University Hospital of Liège, Liège, Belgium; Eugenio 
Stabile, Division of Cardiology, Health Science Department, 
Università della Basilicata, Potenza, Italy; Françoise Steinbach 
(France), ESC Patient Forum, Sophia Antipolis, France; Matthias 
Thielmann, Department of Thoracic and Cardiovascular Surgery, 
West-German Heart and Vascular Center, University Hospital Essen, 
University Duisburg-Essen, Essen, Germany; Roland R.J. van 
Kimmenade, Department of Cardiology, Radboud University 
Medical Center, Nijmegen, Netherlands; and Maarit Venermo, 
Department of Vascular Surgery, University of Helsinki and Helsinki 
University Hospital, Helsinki, Finland.
19. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers:
Alessia Gimelli (CPG Review Co-ordinator) (Italy), Jean-Baptiste 
Ricco (CPG Review Co-ordinator) (France), Elena Arbelo (Spain), 
Christian-Alexander Behrendt (Germany), Michael Böhm (Germany), 
Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio 
Buccheri (Sweden), Gill Louise Buchanan (United Kingdom), Christina 
Christersson (Sweden), Gert J. de Borst (Netherlands), Marco De 
Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United 
Kingdom), Lynne Hinterbuchner (Austria), Borja Ibanez (Spain), 
Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan 
(Sweden), Klaus Kallenbach2 (Luxemburg), Lars Køber (Denmark), 
Konstantinos C. Koskinas (Switzerland), Juraj Madaric1 (Slovakia), 
Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer 
(Israel), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen 
(Denmark), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Barbara Rantner (Germany), Bianca Rocca (Italy), Xavier Rossello 
(Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland), 
Sabine Steiner (Germany), Isabella Sudano (Switzerland), Martin 
Teraa 
(Netherlands), 
Ilonca 
Vaartjes 
(Netherlands), 
Rafael 
Vidal-Perez (Spain), Christiaan Vrints (Belgium), and Katja Zeppenfeld 
(Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2024 ESC Guidelines for the management of peripheral ar­
terial and aortic diseases:
Algeria: Algerian Society of Cardiology, Mohammed El Amine 
Bouzid; Armenia: Armenian Cardiologists Association, Arsen 
A. Tsaturyan; Austria: Austrian Society of Cardiology, Georg Delle 
Karth; Azerbaijan: Azerbaijan Society of Cardiology, Fuad Samadov; 
Belgium: Belgian Society of Cardiology, Antoine Bondue; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Alden Begić; Bulgaria: Bulgarian Society of Cardiology, 
Ivo Petrov; Croatia: Croatian Cardiac Society, Majda Vrkic 
Kirhmajer; Cyprus: Cyprus Society of Cardiology, Georgios 
P. Georghiou; Czechia: Czech Society of Cardiology, Pavel 
Procházka; Denmark: Danish Society of Cardiology, Torsten 
B. Rasmussen; Egypt: Egyptian Society of Cardiology, Yasser 
A. Sadek; Estonia: Estonian Society of Cardiology, Jaagup Truusalu; 
Finland: Finnish Cardiac Society, Petri Saari; France: French Society 
of Cardiology, Guillaume Jondeau; Germany: German Cardiac 
Society, Christiane Tiefenbacher; Greece: Hellenic Society of 
Cardiology, Kimon Stamatelopoulos; Hungary: Hungarian Society 
of Cardiology, Endre Kolossváry; Iceland: Icelandic Society of 
Cardiology, Elín Hanna Laxdal; Ireland: Irish Cardiac Society, Monica 
Monaghan; Israel: Israel Heart Society, Jonathan Koslowsky; Italy: 
Italian Federation of Cardiology, Ciro Indolfi; Kazakhstan: 
Association of Cardiologists of Kazakhstan, Nursultan Kospanov; 
Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera 
Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova; 
Latvia: Latvian Society of Cardiology, Ainars Rudzitis; Lithuania: 
Lithuanian Society of Cardiology, Andrius Berūkštis; Luxembourg: 
Luxembourg Society of Cardiology, Katja Lottermoser; Malta: 
Maltese Cardiac Society, Maryanne Caruana; Morocco: Moroccan 
Society of Cardiology, Raissuni Zainab; North Macedonia: 
National Society of Cardiology of North Macedonia, Marijan 
Bosevski; Norway: Norwegian Society of Cardiology, Stein Samstad; 
Portugal: Portuguese Society of Cardiology, Ana Teresa Timoteo; 
Romania: Romanian Society of Cardiology, Ovidiu Dragomir 
Chioncel; San Marino: San Marino Society of Cardiology, Pier 
Camillo Pavesi; Slovakia: Slovak Society of Cardiology, Maria 
Rasiova; Slovenia: Slovenian Society of Cardiology, Borut Jug; 
Spain: Spanish Society of Cardiology, Ariana González Gomez; 
Sweden: 
Swedish 
Society 
of 
Cardiology, 
Stefan 
James; 
Switzerland: Swiss Society of Cardiology, Marc Righini; Tunisia: 
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Amine 
Tarmiz; Turkey: Turkish Society of Cardiology, Eralp Tutar; and 
Ukraine: Ukrainian Association of Cardiology, Maksym Sokolov.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom),


<!-- PAGE 126 -->

### Page 126

Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez 
(Spain), 
Lars 
Køber 
(Denmark), 
Konstantinos 
C. 
Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
20. References
1. van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chonchol M, Vidakovic R, et al. Long-term 
prognosis of patients with peripheral arterial disease with or without polyvascular ath­
erosclerotic disease. Eur Heart J 2010;31:992–9. https://doi.org/10.1093/eurheartj/ 
ehp553
2. Dolmaci OB, El Mathari S, Driessen AHG, Klautz RJM, Poelmann RE, Lindeman JHN, 
et al. Are thoracic aortic aneurysm patients at increased risk for cardiovascular dis­
eases? J Clin Med 2023;12:272. https://doi.org/10.3390/jcm12010272
3. Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, Schwartzbard A, et al. Suboptimal risk 
factor control in patients undergoing elective coronary or peripheral percutaneous 
intervention. Am Heart J 2014;168:310–6.e3. https://doi.org/10.1016/j.ahj.2014.05.011
4. Saratzis A, Jaspers NEM, Gwilym B, Thomas O, Tsui A, Lefroy R, et al. Observational 
study of the medical management of patients with peripheral artery disease. Br J Surg 
2019;106:1168–77. https://doi.org/10.1002/bjs.11214
5. McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, et al. Knowledge 
and attitudes regarding cardiovascular disease risk and prevention in patients with cor­
onary or peripheral arterial disease. Arch Intern Med 2003;163:2157–62. https://doi. 
org/10.1001/archinte.163.18.2157
6. Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022 
American College of Rheumatology/EULAR classification criteria for Takayasu arter­
itis. Ann Rheum Dis 2022;81:1654–60. https://doi.org/10.1136/ard-2022-223482
7. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 up­
date of the EULAR recommendations for the management of large vessel vasculitis. 
Ann Rheum Dis 2020;79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672
8. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 
American College of Rheumatology/EULAR classification criteria for giant cell arteritis. 
Ann Rheum Dis 2022;81:1647–53. https://doi.org/10.1136/ard-2022-223480
9. Stone JR, Bruneval P, Angelini A, Bartoloni G, Basso C, Batoroeva L, et al. Consensus 
statement on surgical pathology of the aorta from the Society for Cardiovascular 
Pathology and the Association for European Cardiovascular Pathology: 
I. Inflammatory diseases. Cardiovasc Pathol 2015;24:267–78. https://doi.org/10. 
1016/j.carpath.2015.05.001
10. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 coun­
tries and territories, 1990-2019: a systematic analysis for the Global Burden of 
Disease study 2019. Lancet 2020;396:1204–22. https://doi.org/10.1016/S0140- 
6736(20)30925-9
11. Lin J, Chen Y, Jiang N, Li Z, Xu S. Burden of peripheral artery disease and its attributable 
risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med 
2022;9:868370. https://doi.org/10.3389/fcvm.2022.868370
12. GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral ar­
tery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden 
of Disease study 2019. Lancet Glob Health 2023;11:e1553–65. https://doi.org/10.1016/ 
S2214-109X(23)00355-8
13. Liu W, Yang C, Chen, Lei F, Qin J-J, Liu H, et al. Global death burden and attributable 
risk factors of peripheral artery disease by age, sex, SDI regions, and countries from 
1990 to 2030: results from the Global Burden of Disease study 2019. Atherosclerosis 
2022;347:17–27. https://doi.org/10.1016/j.atherosclerosis.2022.03.002
14. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. 
Global burden of cardiovascular diseases and risk factors, 1990–2019: update from 
the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. https://doi.org/10.1016/j. 
jacc.2020.11.010
15. Pu L, Wang L, Zhang R, Zhao T, Jiang Y, Han L. Projected global trends in ischemic 
stroke incidence, deaths and disability-adjusted life years from 2020 to 2030. Stroke 
2023;54:1330–9. https://doi.org/10.1161/STROKEAHA.122.040073
16. Summers KL, Kerut EK, Sheahan CM, Sheahan MG, III. Evaluating the prevalence of ab­
dominal aortic aneurysms in the United States through a national screening database. 
J Vasc Surg 2021;73:61–8. https://doi.org10.1016/j.jvs.2020.03.046
17. Behrendt CA, Thomalla G, Rimmele DL, Petersen EL, Twerenbold R, Debus ES, et al. 
Editor’s choice—prevalence of peripheral arterial disease, abdominal aortic aneurysm, 
and risk factors in the Hamburg city health study: a cross sectional analysis. Eur J Vasc 
Endovasc Surg 2023;65:590–8. https://doi.org/10.1016/j.ejvs.2023.01.002
18. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, 
Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention: 
a report from the ESC Prevention of CVD programme led by the European 
Association of Preventive Cardiology (EAPC) in collaboration with the Acute 
Cardiovascular Care Association (ACCA) and the Association of Cardiovascular 
Nursing and Allied Professions (ACNAP). Eur Heart J Acute Cardiovasc Care 2020;9: 
522–32. https://doi.org/10.1177/2048872619858285
19. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
20. Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular 
disease. Circ Res 2021;128:1818–32. https://doi.org/10.1161/CIRCRESAHA.121. 
318535
21. Pabon M, Cheng S, Altin SE, Sethi SS, Nelson MD, Moreau KL, et al. Sex differences in 
peripheral artery disease. Circ Res 2022;130:496–511. https://doi.org/10.1161/ 
CIRCRESAHA.121.320702
22. Khawaja T, Janus SE, Tashtish N, Janko M, Baeza C, Gilkeson R, et al. Prevalence of 
thoracic aortic aneurysm in patients referred for no/low-charge coronary artery cal­
cium scoring: insights from the CLARIFY registry. Am J Prev Cardiol 2022;12:100378. 
https://doi.org/10.1016/j.ajpc.2022.100378
23. Obel LM, Diederichsen AC, Steffensen FH, Frost L, Lambrechtsen J, Busk M, et al. 
Population-based risk factors for ascending, arch, descending, and abdominal aortic di­
lations for 60-74-year-old individuals. J Am Coll Cardiol 2021;78:201–11. https://doi.org/ 
10.1016/j.jacc.2021.04.094
24. Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneur­
ysms and acute aortic syndromes. Nat Rev Cardiol 2021;18:331–48. https://doi.org/ 
10.1038/s41569-020-00472-6
25. Verhagen JMA, Kempers M, Cozijnsen L, Bouma BJ, Duijnhouwer AL, Post JG, et al. 
Expert consensus recommendations on the cardiogenetic care for patients with thor­
acic aortic disease and their first-degree relatives. Int J Cardiol 2018;258:243–8. https:// 
doi.org/10.1016/j.ijcard.2018.01.145
26. Burger PM, Pradhan AD, Dorresteijn JAN, Koudstaal S, Teraa M, de Borst GJ, et al. 
C-reactive protein and risk of cardiovascular events and mortality in patients with vari­
ous cardiovascular disease locations. Am J Cardiol 2023;197:13–23. https://doi.org/10. 
1016/j.amjcard.2023.03.025
27. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine 
in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47. https://doi. 
org/10.1056/NEJMoa2021372
28. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and 
safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381: 
2497–505. https://doi.org/10.1056/NEJMoa1912388
29. Parkkila K, Kiviniemi A, Tulppo M, Perkiömäki J, Kesäniemi YA, Ukkola O. Carotid and 
femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population: a 
20-year prospective study. PLoS One 2022;17:e0278901. https://doi.org/10.1371/ 
journal.pone.0278901
30. Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruits as a prognostic indica­
tor of cardiovascular death and myocardial infarction: a meta-analysis. Lancet 2008; 
371:1587–94. https://doi.org/10.1016/s0140-6736(08)60691-1
31. Charry D, Gouskova N, Meyer ML, Ring K, Nambi V, Heiss G, et al. Arterial stiffness 
and contralateral differences in blood pressure: the Atherosclerosis Risk in 
Communities (ARIC) study. J Clin Hypertens (Greenwich) 2022;24:878–84. https://doi. 
org/10.1111/jch.14493
32. Aboyans V, Criqui MH, McDermott MM, Allison MA, Denenberg JO, Shadman R, et al. 
The vital prognosis of subclavian stenosis. J Am Coll Cardiol 2007;49:1540–5. https://doi. 
org/10.1016/j.jacc.2006.09.055
33. Marcovina SM, Shapiro MD. Measurement of lipoprotein(a): a once in a lifetime op­
portunity. J Am Coll Cardiol 2022;79:629–31. https://doi.org/10.1016/j.jacc.2021.11. 
053
34. Arndt H, Nordanstig J, Bertges DJ, Budtz-Lilly J, Venermo M, Espada CL, et al. A Delphi 
consensus on patient reported outcomes for registries and trials including patients 
with intermittent claudication: recommendations and reporting standard. Eur J Vasc 
Endovasc Surg 2022;64:526–33. https://doi.org/10.1016/j.ejvs.2022.08.011
35. Rymer JA, Narcisse D, Cosiano M, Tanaka J, McDermott MM, Treat-Jacobson DJ, et al. 
Patient-reported outcome measures in symptomatic, non-limb-threatening peripheral 
artery disease: a state-of-the-art review. Circ Cardiovasc Interv 2022;15:e011320. 
https://doi.org/10.1161/circinterventions.121.011320
36. Raja A, Spertus J, Yeh RW, Secemsky EA. Assessing health-related quality of life among 
patients with peripheral artery disease: a review of the literature and focus on patient- 
reported outcome measures. Vasc Med 2021;26:317–25. https://doi.org/10.1177/ 
1358863x20977016
37. Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, 
et al. Optimal exercise programs for patients with peripheral artery disease: a scientific 
statement from the American Heart Association. Circulation 2019;139:e10–33. https:// 
doi.org/10.1161/cir.0000000000000623
38. Poku E, Duncan R, Keetharuth A, Essat M, Phillips P, Woods HB, et al. Patient-reported 
outcome measures in patients with peripheral arterial disease: a systematic review of 
ESC Guidelines                                                                                                                                                                                          3663


<!-- PAGE 127 -->

### Page 127

psychometric properties. Health Qual Life Outcomes 2016;14:161. https://doi.org/10. 
1186/s12955-016-0563-y
39. Mays RJ, Casserly IP, Kohrt WM, Ho PM, Hiatt WR, Nehler MR, et al. Assessment of 
functional status and quality of life in claudication. J Vasc Surg 2011;53:1410–21. https:// 
doi.org/10.1016/j.jvs.2010.11.092
40. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, 
et al. The impact of peripheral arterial disease on health-related quality of life in the 
peripheral arterial disease awareness, risk, and treatment: new resources for sur­
vival (PARTNERS) program. Vasc Med 2008;13:15–24. https://doi.org/10.1177/ 
1358863x07084911
41. Harwood AE, King S, Totty J, Smith GE, Vanicek N, Chetter IC. A systematic review of 
muscle morphology and function in intermittent claudication. J Vasc Surg 2017;66: 
1241–57. https://doi.org/10.1016/j.jvs.2017.05.106
42. Schieber MN, Hasenkamp RM, Pipinos II, Johanning JM, Stergiou N, DeSpiegelaere HK, 
et al. Muscle strength and control characteristics are altered by peripheral artery dis­
ease. J Vasc Surg 2017;66:178–86.e12. https://doi.org/10.1016/j.jvs.2017.01.051
43. Gohil RA, Mockford KA, Mazari F, Khan J, Vanicek N, Chetter IC, et al. Balance impair­
ment, physical ability, and its link with disease severity in patients with intermittent 
claudication. Ann Vasc Surg 2013;27:68–74. https://doi.org/10.1016/j.avsg.2012.05.005
44. Mockford KA, Mazari FA, Jordan AR, Vanicek N, Chetter IC, Coughlin PA. 
Computerized dynamic posturography in the objective assessment of balance in pa­
tients with intermittent claudication. Ann Vasc Surg 2011;25:182–90. https://doi.org/ 
10.1016/j.avsg.2010.07.021
45. Gardner AW, Montgomery PS. Impaired balance and higher prevalence of falls in sub­
jects with intermittent claudication. J Gerontol A Biol Sci Med Sci 2001;56:M454–8. 
https://doi.org/10.1093/gerona/56.7.m454
46. McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian Lu, Liao Y, et al. Leg symptom 
categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr 
Soc 2010;58:1256–62. https://doi.org/10.1111/j.1532-5415.2010.02941.x
47. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional 
decline in peripheral arterial disease: associations with the ankle brachial index and leg 
symptoms. JAMA 2004;292:453–61. https://doi.org/10.1001/jama.292.4.453
48. McDermott MM, Greenland P, Guralnik JM, Guralnik JM, Criqui MH, Chan C, et al. 
Depressive symptoms and lower extremity functioning in men and women with per­
ipheral arterial disease. J Gen Intern Med 2003;18:461–7. https://doi.org/10.1046/j. 
1525-1497.2003.20527.x
49. Ramirez JL, Drudi LM, Grenon SM. Review of biologic and behavioral risk factors link­
ing depression and peripheral artery disease. Vasc Med 2018;23:478–88. https://doi. 
org/10.1177/1358863X18773161
50. Golledge J, Leicht AS, Yip L, Rowbotham SE, Pinchbeck J, Jenkins JS, et al. Relationship 
between disease specific quality of life measures, physical performance, and activity in 
people with intermittent claudication caused by peripheral artery disease. Eur J Vasc 
Endovasc Surg 2020;59:957–64. https://doi.org/10.1016/j.ejvs.2020.02.006
51. Gardner AW, Montgomery PS, Wang M, Xu C. Predictors of health-related quality of 
life in patients with symptomatic peripheral artery disease. J Vasc Surg 2018;68: 
1126–34. https://doi.org/10.1016/j.jvs.2017.12.074
52. McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al. Prognostic value of 
functional performance for mortality in patients with peripheral artery disease. J Am 
Coll Cardiol 2008;51:1482–9. https://doi.org/10.1016/j.jacc.2007.12.034
53. McDermott MM, Guralnik JM, Tian L, Ferrucci L, Liu K, Liao Y, et al. Baseline functional 
performance predicts the rate of mobility loss in persons with peripheral arterial dis­
ease. J Am Coll Cardiol 2007;50:974–82. https://doi.org/10.1016/j.jacc.2007.05.030
54. Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC. Quality of 
life in patients with no-option critical limb ischemia underlines the need for new effect­
ive treatment. J Vasc Surg 2010;52:843–9.e1. https://doi.org/10.1016/j.jvs.2010.04.057
55. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field 
surveys. Bull World Health Organ 1962;27:645–58 .
56. Leng GC, Fowkes FG. The Edinburgh claudication questionnaire: an improved version 
of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 
1992;45:1101–9. https://doi.org/10.1016/0895-4356(92)90150-l
57. Birkett ST, Harwood AE, Caldow E, Ibeggazene S, Ingle L, Pymer S. A systematic review 
of exercise testing in patients with intermittent claudication: a focus on test standard­
isation and reporting quality in randomised controlled trials of exercise interventions. 
PLoS One 2021;16:e0249277. https://doi.org/10.1371/journal.pone.0249277
58. Harwood AE, Pymer S, Ingle L, Doherty P, Chetter IC, Parmenter B. Exercise training 
for intermittent claudication: a narrative review and summary of guidelines for practi­
tioners. BMJ Open Sport Exerc Med 2020;6:e000897. https://doi.org/10.1136/bmjsem- 
2020-000897
59. Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, 
et al. Implementation of supervised exercise therapy for patients with symptomatic 
peripheral artery disease: a science advisory from the American Heart Association. 
Circulation 2019;140:e700–10. https://doi.org/10.1161/cir.0000000000000727
60. Hiatt WR, Rogers RK, Brass EP. The treadmill is a better functional test than the 6-mi­
nute walk test in therapeutic trials of patients with peripheral artery disease. Circulation 
2014;130:69–78. https://doi.org/10.1161/circulationaha.113.007003
61. Nicolaï SP, Viechtbauer W, Kruidenier LM, Candel MJJM, Prins MH, Teijink JAW. 
Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. 
J Vasc Surg 2009;50:322–9. https://doi.org/10.1016/j.jvs.2009.01.042
62. Mazzolai L, Belch J, Venermo M, Aboyans V, Brodmann M, Bura-Rivière A, et al. 
Exercise therapy for chronic symptomatic peripheral artery disease. Eur Heart J 
2024;45:1303–21. https://doi.org/10.1093/eurheartj/ehad734
63. McDermott MM, Guralnik JM, Criqui MH, Liu K, Kibbe MR, Ferrucci L. Six-minute walk 
is a better outcome measure than treadmill walking tests in therapeutic trials of pa­
tients with peripheral artery disease. Circulation 2014;130:61–8. https://doi.org/10. 
1161/circulationaha.114.007002
64. McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based 
functional performance measures correlate better with physical activity during daily life 
than treadmill measures in persons with peripheral arterial disease. J Vasc Surg 2008; 
48:1231–7.e1. https://doi.org/10.1016/j.jvs.2008.06.050
65. ATS Committee on Proficiency Standards for Clinical Pulmonary Function 
Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit 
Care Med 2002;166:111–7. https://doi.org/10.1164/ajrccm.166.1.at1102
66. Verdijk LB, van Loon L, Meijer K, Savelberg HH. One-repetition maximum strength 
test represents a valid means to assess leg strength in vivo in humans. J Sports Sci 
2009;27:59–68. https://doi.org/10.1080/02640410802428089
67. Ritti-Dias RM, Basyches M, Câmara L, Puech-Leao P, Battistella L, Wolosker N. 
Test-retest reliability of isokinetic strength and endurance tests in patients with 
intermittent claudication. Vasc Med 2010;15:275–8. https://doi.org/10.1177/ 
1358863x10371415
68. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short 
physical performance battery assessing lower extremity function: association with self- 
reported disability and prediction of mortality and nursing home admission. J Gerontol 
1994;49:M85–94. https://doi.org/10.1093/geronj/49.2.m85
69. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity func­
tion in persons over the age of 70 years as a predictor of subsequent disability. N Engl J 
Med 1995;332:556–62. https://doi.org/10.1056/nejm199503023320902
70. Isselbacher EM, Preventza O, Hamilton Black J III, Augoustides JG, Beck AW, Bolen 
MA, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic dis­
ease: a report of the American Heart Association/American College of Cardiology 
Joint Committee on clinical practice guidelines. J Am Coll Cardiol 2022;80:e223–393. 
https://doi.org/10.1016/j.jacc.2022.08.004
71. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines 
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 
2021;42:17–96. https://doi.org/10.1093/eurheartj/ehaa605
72. de Heer F, Gökalp AL, Kluin J, Takkenberg JJM. Measuring what matters to the patient: 
health related quality of life after aortic valve and thoracic aortic surgery. Gen Thorac 
Cardiovasc Surg 2019;67:37–43. https://doi.org/10.1007/s11748-017-0830-9
73. Chaddha A, Kline-Rogers E, Braverman AC, Erickson SR, Jackson EA, Franklin BA, et al. 
Survivors of aortic dissection: activity, mental health, and sexual function. Clin Cardiol 
2015;38:652–9. https://doi.org/10.1002/clc.22418
74. Andonian C, Freilinger S, Achenbach S, Ewert P, Gundlach U, Kaemmerer H, et al. 
Quality of life in patients with Marfan syndrome: a cross-sectional study of 102 adult 
patients. Cardiovasc Diagn Ther 2021;11:602–10. https://doi.org/10.21037/cdt-20-692
75. Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related quality 
of life in Marfan syndrome: a 10-year follow-up. Health Qual Life Outcomes 2020;18: 
376. https://doi.org/10.1186/s12955-020-01633-4
76. Cervin A, Wanhainen A, Björck M. Popliteal aneurysms are common among men with 
screening detected abdominal aortic aneurysms, and prevalence correlates with the 
diameters of the common iliac arteries. Eur J Vasc Endovasc Surg 2020;59:67–72. 
https://doi.org/10.1016/j.ejvs.2019.07.042
77. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 
ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in col­
laboration with the European Society for Vascular Surgery (ESVS): document cov­
ering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, 
renal, upper and lower extremity arteries. Endorsed by: the European Stroke 
Organization (ESO), the task force for the diagnosis and treatment of peripheral ar­
terial diseases of the European Society of Cardiology (ESC) and of the European 
Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/ 
10.1093/eurheartj/ehx095
78. Ichihashi S, Desormais I, Hashimoto T, Magne J, Kichikawa K, Aboyans V. Accuracy and 
reliability of the ankle brachial index measurement using a multicuff oscillometric de­
vice versus the Doppler method. Eur J Vasc Endovasc Surg 2020;60:462–8. https://doi. 
org/10.1016/j.ejvs.2020.06.013
79. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. 
Measurement and interpretation of the ankle-brachial index: a scientific statement 
from the American Heart Association. Circulation 2012;126:2890–909. https://doi. 
org/10.1161/CIR.0b013e318276fbcb
80. Høyer C, Strandberg J, Overvad Jordansen MK, Zacho HD. The ability of the 
toe-brachial index to predict the outcome of treadmill exercise testing in patients 
with a normal resting ankle-brachial index. Ann Vasc Surg 2020;64:263–9. https://doi. 
org/10.1016/j.avsg.2019.10.041


<!-- PAGE 128 -->

### Page 128

81. Godet R, Bruneau A, Vielle B, Vincent F, Le Tourneau T, Carre F, et al. Post-exercise 
ankle blood pressure and ankle to brachial index after heavy load bicycle exercise. 
Scand J Med Sci Sports 2018;28:2144–52. https://doi.org/10.1111/sms.13234
82. van Langen H, van Gurp J, Rubbens L. Interobserver variability of ankle-brachial index 
measurements at rest and post exercise in patients with intermittent claudication. Vasc 
Med 2009;14:221–6. https://doi.org/10.1177/1358863x08101017
83. Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW, Limitation of the 
resting ankle-brachial index in symptomatic patients with peripheral arterial disease. 
Vasc Med 2006;11:29–33. https://doi.org/10.1191/1358863x06vm663oa
84. Abraham P, Desvaux B, Saumet JL. Ankle-brachial index after maximum exercise in 
treadmill and cycle ergometers in athletes. Clin Physiol 1998;18:321–6. https://doi. 
org/10.1046/j.1365-2281.1998.00100.x
85. Stoffers HE, Kester AD, Kaiser V, Rinkens PELM, Kitslaar PJEHM, Knottnerus JA, The 
diagnostic value of the measurement of the ankle-brachial systolic pressure index in 
primary health care. J Clin Epidemiol 1996;49:1401–5. https://doi.org/10.1016/s0895- 
4356(96)00275-2
86. Ouriel K, McDonnell AE, Metz CE, Zarins CK. Critical evaluation of stress testing in the 
diagnosis of peripheral vascular disease. Surgery 1982;91:686–93 .
87. Laing S, Greenhalgh RM. The detection and progression of asymptomatic peripheral 
arterial disease. Br J Surg 2005;70:628–30. https://doi.org/10.1002/bjs.1800701017
88. Ankle Brachial Index Collaboration; Fowkes FG, Murray GD, Butcher I, Heald CL, Lee 
RJ, et al. Ankle brachial index combined with Framingham risk score to predict cardio­
vascular events and mortality: a meta-analysis. JAMA 2008;300:197–208. https://doi. 
org/10.1001/jama.300.2.197
89. Criqui MH, McClelland RL, McDermott MM, McDermott MM, Allison MA, Blumenthal 
RS, et al. The ankle-brachial index and incident cardiovascular events in the MESA 
(multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2010;56:1506–12. https:// 
doi.org/10.1016/j.jacc.2010.04.060
90. Herraiz-Adillo Á, Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, 
Solera-Martínez M. The accuracy of toe brachial index and ankle brachial index in 
the diagnosis of lower limb peripheral arterial disease: a systematic review and 
meta-analysis. 
Atherosclerosis 
2020;315:81–92. 
https://doi.org/10.1016/j. 
atherosclerosis.2020.09.026
91. Tehan PE, Santos D, Chuter VH. A systematic review of the sensitivity and specificity of 
the toe-brachial index for detecting peripheral artery disease. Vasc Med 2016;21: 
382–9. https://doi.org/10.1177/1358863x16645854
92. Fukui M, Tanaka M, Hamaguchi M, Senmaru T, Sakabe K, Asano M, et al. Toe-brachial 
index is associated more strongly with albuminuria or glomerular filtration rate than 
ankle-brachial index in patients with type 2 diabetes. Hypertens Res 2012;35:745–9. 
https://doi.org/10.1038/hr.2012.16
93. Dachun X, Jue L, Liling Z, Xu Y, Hu D, Pagoto SL, et al. Sensitivity and specificity of the 
ankle—brachial index to diagnose peripheral artery disease: a structured review. Vasc 
Med 2010;15:361–9. https://doi.org/10.1177/1358863x10378376
94. Morimoto S, Nakajima F, Yurugi T, Morita T, Jo F, Nishikawa M, et al. Risk factors of 
normal ankle-brachial index and low toe-brachial index in hemodialysis patients. 
Ther Apher Dial 2009;13:103–7. https://doi.org/10.1111/j.1744-9987.2009.00663.x
95. Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcifica­
tion in the feet of diabetic patients and matched non-diabetic control subjects. 
Diabetologia 1993;36:615–21. https://doi.org/10.1007/bf00404070
96. Carter SA, Lezack JD. Digital systolic pressures in the lower limb in arterial disease. 
Circulation 1971;43:905–14. https://doi.org/10.1161/01.cir.43.6.905
97. Watanabe Y, Masaki H, Kojima K, Tanemoto K. Toe-brachial index in the second toe: 
substitutability to toe-brachial index in the great toe and ankle-brachial index. Ann Vasc 
Dis 2016;9:300–6. https://doi.org/10.3400/avd.oa.16-00078
98. Pérez-Martin A, Meyer G, Demattei C, Böge G, Laroche J-P, Quéré I, et al. Validation of 
a fully automatic photoplethysmographic device for toe blood pressure measurement. 
Eur J Vasc Endovasc Surg 2010;40:515–20. https://doi.org/10.1016/j.ejvs.2010.06.008
99. Hoyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of periph­
eral arterial disease. J Vasc Surg 2013;58:231–8. https://doi.org/10.1016/j.jvs.2013.03. 
044
100. Monti M, Calanca L, Alatri A, Mazzolai L. Accuracy of in-patients ankle-brachial index 
measurement by medical students. Vasa 2016;45:43–8. https://doi.org/10.1024/0301- 
1526/a000494
101. Kaiser V, Kester AD, Stoffers HE, Kitslaar PJ, Knottnerus JA. The influence of experi­
ence on the reproducibility of the ankle-brachial systolic pressure ratio in peripheral 
arterial occlusive disease. Eur J Vasc Endovasc Surg 1999;18:25–9. https://doi.org/10. 
1053/ejvs.1999.0843
102. Ray SA, Srodon PD, Taylor RS, Dormandy JA. Reliability of ankle:brachial pressure in­
dex measurement by junior doctors. Br J Surg 1994;81:188–90. https://doi.org/10. 
1002/bjs.1800810208
103. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman 
DE, et al. 2016 AHA/ACC Guideline on the management of patients with lower ex­
tremity peripheral artery disease: a report of the American College of Cardiology/ 
American Heart Association task force on clinical practice guidelines. Circulation 
2017;135:e726–79. https://doi.org/10.1161/CIR.0000000000000471
104. Stivalet O, Paisant A, Belabbas D, Omarjee L, Le Faucheur A, Landreau P, et al. Exercise 
testing criteria to diagnose lower extremity peripheral artery disease assessed by 
computed-tomography angiography. PLoS One 2019;14:e0219082. https://doi.org/10. 
1371/journal.pone.0219082
105. Abraham P, Picquet J, Vielle B, Sigaudo-Roussel D, Paisant-Thouveny F, Enon B, et al. 
Transcutaneous oxygen pressure measurements on the buttocks during exercise to 
detect proximal arterial ischemia: comparison with arteriography. Circulation 2003; 
107:1896–900. https://doi.org/10.1161/01.Cir.0000060500.60646.E0
106. Yamamoto K, Miyata T, Onozuka A, Koyama H, Ohtsu H, Nagawa H. Plantar flexion 
as an alternative to treadmill exercise for evaluating patients with intermittent clau­
dication. Eur J Vasc Endovasc Surg 2007;33:325–9. https://doi.org/10.1016/j.ejvs. 
2006.10.012
107. Maufus M, Sevestre-Pietri MA, Sessa C, Pignon B, Egelhofer H, Dupas S, et al. Critical 
limb ischaemia and the response to bone marrow-derived cell therapy according to 
tcPO(2) measurement. Vasa 2017;46:23–8. https://doi.org/10.1024/0301-1526/ 
a000590
108. Leenstra B, Wijnand J, Verhoeven B, Koning O, Teraa M, Verhaar MC, et al. 
Applicability of transcutaneous oxygen tension measurement in the assessment of 
chronic limb-threatening ischemia. Angiology 2020;71:208–16. https://doi.org/10. 
1177/0003319719866958
109. Ott A. Inflammation and transcutaneous measurement of oxygen pressure in 
dermatology. Adv Exp Med Biol 1987;220:79–82. https://doi.org/10.1007/978-1- 
4613-1927-6_14
110. Woo Y, Suh YJ, Lee H, Jeong E, Park SC, Yun SS, et al. TcPO2 value can predict wound 
healing time in clinical practice of CLTI patients. Ann Vasc Surg 2023;91:249–56. https:// 
doi.org/10.1016/j.avsg.2022.11.020
111. Wang Z, Hasan R, Firwana B, Elraiyah T, Tsapas A, Prokop L, et al. A systematic review 
and meta-analysis of tests to predict wound healing in diabetic foot. J Vasc Surg 2016; 
63:29S–36S.e2. https://doi.org/10.1016/j.jvs.2015.10.004
112. Yamada T, Ohta T, Ishibashi H, Sugimoto I, Iwata H, Takahashi M, et al. Clinical reliabil­
ity and utility of skin perfusion pressure measurement in ischemic limbs—comparison 
with other noninvasive diagnostic methods. J Vasc Surg 2008;47:318–23. https://doi. 
org/10.1016/j.jvs.2007.10.045
113. Noori N, Haruno L, Schroeder I, Vrahas M, Little M, Moon C, et al. Preoperative trans­
cutaneous oxygen perfusion measurements in predicting atraumatic wound healing 
after major lower extremity amputation. Orthopedics 2022;45:174–80. https://doi. 
org/10.3928/01477447-20220128-05
114. Nishio H, Minakata K, Kawaguchi A, Kumagai M, Ikeda T, Shimizu A, et al. 
Transcutaneous oxygen pressure as a surrogate index of lower limb amputation. Int 
Angiol 2016;35:565–72. 
115. Sarin S, Shami S, Shields DA, Scurr JH, Smith PD. Selection of amputation level: a re­
view. Eur J Vasc Surg 1991;5:611–20. https://doi.org/10.1016/s0950-821x(05)80894-1
116. Abraham P, Ramondou P, Hersant J, Sempore WY, Feuilloy M, Henni S. 
Investigation of arterial claudication with transcutaneous oxygen pressure at exer­
cise: interests and limits. Trends Cardiovasc Med 2021;31:218–23. https://doi.org/10. 
1016/j.tcm.2020.03.003
117. Abraham P, Gu Y, Guo L, Kroeger K, Ouedraogo N, Wennberg P, et al. Clinical ap­
plication of transcutaneous oxygen pressure measurements during exercise. 
Atherosclerosis 2018;276:117–23. https://doi.org/10.1016/j.atherosclerosis.2018. 
07.023
118. Colas-Ribas C, Signolet I, Henni S, Feuillloy M, Gagnadoux F, Abraham P. High preva­
lence of known and unknown pulmonary diseases in patients with claudication during 
exercise oximetry: a retrospective analysis. Medicine (Baltimore) 2016;95:e4888. 
https://doi.org/10.1097/md.0000000000004888
119. Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. ESVM guideline on 
peripheral arterial disease. Vasa 2019;48:1–79. https://doi.org/10.1024/0301-1526/ 
a000834
120. Schlager O, Francesconi M, Haumer M, Dick P, Sabeti S, Amighi J, et al. Duplex son­
ography versus angiography for assessment of femoropopliteal arterial disease in a 
‘real-world’ setting. J Endovasc Ther 2007;14:452–9. https://doi.org/10.1177/ 
152660280701400404
121. Collins R, Burch J, Cranny G, Aguiar-Ibáñez R, Craig D, Wright K, et al. Duplex ultra­
sonography, magnetic resonance angiography, and computed tomography angiog­
raphy for diagnosis and assessment of symptomatic, lower limb peripheral arterial 
disease: systematic review. BMJ 2007;334:1257. https://doi.org/10.1136/bmj.39217. 
473275.55
122. Sprynger M, Rigo F, Moonen M, Aboyans V, Edvardsen T, de Alcantara ML, et al. Focus 
on echovascular imaging assessment of arterial disease: complement to the ESC 
Guidelines (PARTIM 1) in collaboration with the working group on aorta and periph­
eral vascular diseases. Eur Heart J Cardiovasc Imaging 2018;19:1195–221. https://doi. 
org/10.1093/ehjci/jey103
123. Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, et al. A systematic 
review of duplex ultrasound, magnetic resonance angiography and computed tomog­
raphy angiography for the diagnosis and assessment of symptomatic, lower limb per­
ipheral arterial disease. Health Technol Assess 2007;11:iii–iv, xi-xiii, 1–184. https://doi. 
org/10.3310/hta11200
ESC Guidelines                                                                                                                                                                                          3665


<!-- PAGE 129 -->

### Page 129

124. Rodway AD, Cheal D, Allan C, Pazos-Casal F, Hanna L, Field BCT, et al. Ankle Doppler 
for cuffless ankle brachial index estimation and peripheral artery disease diagno­
sis independent of diabetes. J Clin Med 2022;12:97. https://doi.org/10.3390/ 
jcm12010097
125. Katsanos K, Tepe G, Tsetis D, Fanelli F. Standards of practice for superficial femoral 
and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014;37: 
592–603. https://doi.org/10.1007/s00270-014-0876-3
126. Coffi SB, Ubbink DT, Zwiers I, van Gurp JA, Legemate DA. Improved assessment of 
the hemodynamic significance of borderline iliac stenoses with use of hyperemic du­
plex scanning. J Vasc Surg 2002;36:575–80. https://doi.org/10.1067/mva.2002.126086
127. Elsman BH, Legemate DA, de Vos HJ, Mali WP, Eikelboom BC. Hyperaemic colour du­
plex scanning for the detection of aortoiliac stenoses. a comparative study with 
intra-arterial pressure measurement. Eur J Vasc Endovasc Surg 1997;14:462–7. 
https://doi.org/10.1016/s1078-5884(97)80125-6
128. Venermo M, Sprynger M, Desormais I, Björck M, Brodmann M, Cohnert T, et al. 
Follow-up of patients after revascularisation for peripheral arterial diseases: a consen­
sus document from the European Society of Cardiology working group on aorta and 
peripheral vascular diseases and the European Society for Vascular Surgery. Eur J Prev 
Cardiol 2019;26:1971–84. https://doi.org/10.1177/2047487319846999
129. Golemati S, Cokkinos DD. Recent advances in vascular ultrasound imaging technology 
and their clinical implications. Ultrasonics 2022;119:106599. https://doi.org/10.1016/j. 
ultras.2021.106599
130. Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, et al. 
Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with 
the ABI test. Vasc Med 2018;23:97–106. https://doi.org/10.1177/1358863X17745371
131. Xu D, Zou L, Xing Y, Hou L, Wei Y, Zhang J, et al. Diagnostic value of ankle-brachial 
index in peripheral arterial disease: a meta-analysis. Can J Cardiol 2013;29:492–8. 
https://doi.org/10.1016/j.cjca.2012.06.014
132. Hashimoto T, Ichihashi S, Iwakoshi S, Kichikawa K. Combination of pulse volume re­
cording (PVR) parameters and ankle-brachial index (ABI) improves diagnostic accuracy 
for peripheral arterial disease compared with ABI alone. Hypertens Res 2016;39:430–4. 
https://doi.org/10.1038/hr.2016.13
133. Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the foot with dia­
betes: sensitivity and specificity of the ankle brachial index, toe brachial index and con­
tinuous wave Doppler for detecting peripheral arterial disease. J Diabetes Complications 
2016;30:155–60. https://doi.org/10.1016/j.jdiacomp.2015.07.019
134. Loukas M, Bilinsky E, Bilinsky S, Blaak C, Tubbs RS, Anderson RH. The anatomy of the 
aortic root. Clin Anat 2014;27:748–56. https://doi.org/10.1002/ca.22295
135. Dagenais F. Anatomy of the thoracic aorta and of its branches. Thorac Surg Clin 2011; 
21:219–27, viii. https://doi.org/10.1016/j.thorsurg.2010.12.004
136. Lombardi JV, Hughes GC, Appoo JJ, Bavaria JE, Beck AW, Cambria RP, et al. Society for 
Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for 
type B aortic dissections. Ann Thorac Surg 2020;109:959–81. https://doi.org/10.1016/j. 
athoracsur.2019.10.005
137. Rodríguez-Palomares JF, Teixidó-Tura G, Galuppo V, Cuéllar H, Laynez A, Gutiérrez L, 
et al. Multimodality assessment of ascending aortic diameters: comparison of different 
measurement methods. J Am Soc Echocardiogr 2016;29:819–26.e4. https://doi.org/10. 
1016/j.echo.2016.04.006
138. Saura D, Dulgheru R, Caballero L, Bernard A, Kou S, Gonjilashvili N, et al. 
Two-dimensional transthoracic echocardiographic normal reference ranges for prox­
imal aorta dimensions: results from the EACVI NORRE study. Eur Heart J Cardiovasc 
Imaging 2017;18:167–79. https://doi.org/10.1093/ehjci/jew053
139. Bons LR, Duijnhouwer AL, Boccalini S, van den Hoven AT, van der Vlugt MJ, Chelu RG, 
et al. Intermodality variation of aortic dimensions: how, where and when to measure 
the ascending aorta. Int J Cardiol 2019;276:230–5. https://doi.org/10.1016/j.ijcard.2018. 
08.067
140. Amsallem M, Ou P, Milleron O, Henry-Feugeas M-C, Detaint D, Arnoult F, et al. 
Comparative assessment of ascending aortic aneurysms in Marfan patients using 
ECG-gated computerized tomographic angiography versus trans-thoracic echocardi­
ography. Int J Cardiol 2015;184:22–7. https://doi.org/10.1016/j.ijcard.2015.01.086
141. Matthews EO, Pinchbeck J, Elmore K, Jones RE, Moxon JV, Golledge J. The reprodu­
cibility of measuring maximum abdominal aortic aneurysm diameter from ultrasound 
images. Ultrasound J 2021;13:13. https://doi.org/10.1186/s13089-021-00211-z
142. Bonnafy T, Lacroix P, Desormais I, Labrunie A, Marin B, Leclerc A, et al. Reliability of 
the measurement of the abdominal aortic diameter by novice operators using a 
pocket-sized ultrasound system. Arch Cardiovasc Dis 2013;106:644–50. https://doi. 
org/10.1016/j.acvd.2013.08.004
143. Fitzgerald BT, Kwon A, Scalia GM. The new dimension in aortic measurements—use 
of the inner edge measurement for the thoracic aorta in Australian patients. Heart Lung 
Circ 2015;24:1104–10. https://doi.org/10.1016/j.hlc.2015.05.001
144. Burman ED, Keegan J, Kilner PJ. Aortic root measurement by cardiovascular magnetic 
resonance: specification of planes and lines of measurement and corresponding nor­
mal values. Circ Cardiovasc Imaging 2008;1:104–13. https://doi.org/10.1161/ 
circimaging.108.768911
145. Muraru D, Maffessanti F, Kocabay G, Peluso D, Bianco LD, Piasentini E, et al. Ascending 
aorta diameters measured by echocardiography using both leading edge-to-leading 
edge and inner edge-to-inner edge conventions in healthy volunteers. Eur Heart J 
Cardiovasc Imaging 2014;15:415–22. https://doi.org/10.1093/ehjci/jet173
146. Vis JC, Rodríguez-Palomares JF, Teixidó-Tura G, Galian-Gay L, Granato C, Guala A, 
et al. Implications of asymmetry and valvular morphotype on echocardiographic mea­
surements of the aortic root in bicuspid aortic valve. J Am Soc Echocardiogr 2019;32: 
105–12. https://doi.org/10.1016/j.echo.2018.08.004
147. Ghulam Ali S, Fusini L, Dalla Cia A, Tamborini G, Gripari P, Muratori M, et al. 
Technological advancements in echocardiographic assessment of thoracic aortic dila­
tation: head to head comparison among multidetector computed tomography, 2-di­
mensional, and 3-dimensional echocardiography measurements. J Thorac Imaging 
2018;33:232–9. https://doi.org/10.1097/rti.0000000000000330
148. Mendoza DD, Kochar M, Devereux RB, Basson CT, Min JK, Holmes K, et al. Impact of 
image analysis methodology on diagnostic and surgical classification of patients with 
thoracic aortic aneurysms. Ann Thorac Surg 2011;92:904–12. https://doi.org/10.1016/ 
j.athoracsur.2011.03.130
149. Campens L, Demulier L, De Groote K, Vandekerckhove K, De Wolf D, Roman MJ, 
et al. Reference values for echocardiographic assessment of the diameter of the aortic 
root and ascending aorta spanning all age categories. Am J Cardiol 2014;114:914–20. 
https://doi.org/10.1016/j.amjcard.2014.06.024
150. Pedersen OM, Aslaksen A, Vik-Mo H. Ultrasound measurement of the luminal diam­
eter of the abdominal aorta and iliac arteries in patients without vascular disease. J Vasc 
Surg 1993;17:596–601. https://doi.org/10.1067/mva.1993.39525
151. Kim H, Kwon TW, Choi E, Jeong S, Kim H-K, Han Y, et al. Aortoiliac diameter and 
length in a healthy cohort. PLoS One 2022;17:e0268077. https://doi.org/10.1371/ 
journal.pone.0268077
152. Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C, Rocchi 
G, et al. Echocardiography in aortic diseases: EAE recommendations for clinical prac­
tice. Eur J Echocardiogr 2010;11:645–58. https://doi.org/10.1093/ejechocard/jeq056
153. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al. Height alone, 
rather than body surface area, suffices for risk estimation in ascending aortic aneurysm. 
J Thorac Cardiovasc Surg 2018;155:1938–50. https://doi.org/10.1016/j.jtcvs.2017.10.140
154. Masri A, Kalahasti V, Svensson LG, Roselli EE, Johnston D, Hammer D, et al. Aortic 
cross-sectional area/height ratio and outcomes in patients with a trileaflet aortic valve 
and a dilated aorta. Circulation 2016;134:1724–37. https://doi.org/10.1161/ 
circulationaha.116.022995
155. Wu J, Zafar MA, Li Y, Saeyeldin A, Huang Y, Zhao R, et al. Ascending aortic length and 
risk of aortic adverse events: the neglected dimension. J Am Coll Cardiol 2019;74: 
1883–94. https://doi.org/10.1016/j.jacc.2019.07.078
156. Pham MHC, Ballegaard C, de Knegt MC, Sigvardsen PE, Sørgaard MH, Fuchs A, et al. 
Normal values of aortic dimensions assessed by multidetector computed tomography 
in the Copenhagen general population study. Eur Heart J Cardiovasc Imaging 2019;20: 
939–48. https://doi.org/10.1093/ehjci/jez012
157. Davis AE, Lewandowski AJ, Holloway CJ, Ntusi NAB, Banerjee R, Nethononda R, et al. 
Observational study of regional aortic size referenced to body size: production of a 
cardiovascular magnetic resonance nomogram. J Cardiovasc Magn Reson 2014;16:9. 
https://doi.org/10.1186/1532-429x-16-9
158. Braley KT, Tang X, Makil ES, Borroughs-Ray D, Collins RT. The impact of body weight 
on the diagnosis of aortic dilation—misdiagnosis in overweight and underweight 
groups. Echocardiography 2017;34:1029–34. https://doi.org/10.1111/echo.13565
159. Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al. Multimodality 
imaging in thoracic aortic diseases: a clinical consensus statement from the European 
Association of Cardiovascular Imaging and the European Society of Cardiology work­
ing group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging 
2023;24:e65–85. https://doi.org/10.1093/ehjci/jead024
160. Macdonald DB, Hurrell C, Costa AF, McInnes MDF, O’Malley ME, Barrett B, et al. 
Canadian Association of Radiologists Guidance on contrast associated acute kid­
ney injury. Can Assoc Radiol J 2022;73:499–514. https://doi.org/10.1177/ 
08465371221083970
161. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and 
lactation. Obstet Gynecol 2017;130:e210–6. https://doi.org/10.1097/AOG.000000000 
0002355
162. von Kodolitsch Y, Nienaber CA, Dieckmann C, Schwartz AG, Hofmann T, Brekenfeld 
C, et al. Chest radiography for the diagnosis of acute aortic syndrome. Am J Med 2004; 
116:73–7. https://doi.org/10.1016/j.amjmed.2003.08.030
163. Nazerian P, Pivetta E, Veglia S, Cavigli E, Mueller C, de Matos Soeiro A, et al. Integrated 
use of conventional chest radiography cannot rule out acute aortic syndromes in 
emergency department patients at low clinical probability. Acad Emerg Med 2019; 
26:1255–65. https://doi.org/10.1111/acem.13819
164. Hartnell GG, Wakeley CJ, Tottle A, Papouchado M, Wilde RP. Limitations of chest 
radiography in discriminating between aortic dissection and myocardial infarction: im­
plications for thrombolysis. J Thorac Imaging 1993;8:152–5. https://doi.org/10.1097/ 
00005382-199321000-00008
165. Evangelista A, Avegliano G, Aguilar R, Cuellar H, Igual A, Gonzalez-Alujas T, et al. 
Impact of contrast-enhanced echocardiography on the diagnostic algorithm of acute 
aortic dissection. Eur Heart J 2010;31:472–9. https://doi.org/10.1093/eurheartj/ehp505


<!-- PAGE 130 -->

### Page 130

166. Litmanovich D, Bankier AA, Cantin L, Raptopoulos V, Boiselle PM. CT and MRI in dis­
eases of the aorta. AJR Am J Roentgenol 2009;193:928–40. https://doi.org/10.2214/ajr. 
08.2166
167. Pennell DJ, Sechtem UP, Higgins CB, Manning W, Pohost G, Rademakers F, et al. 
Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel re­
port. J Cardiovasc Magn Reson 2004;6:727–65. https://doi.org/10.1081/jcmr- 
200038581
168. Yoshioka K, Tanaka R. MRI and MRA of aortic disease. Ann Vasc Dis 2010;3:196–201. 
https://doi.org/10.3400/avd.sasdi10003
169. Fadel BM, Mohty D, Kazzi BE, Alamro B, Arshi F, Mustafa M, et al. Ultrasound imaging of 
the abdominal aorta: a comprehensive review. J Am Soc Echocardiogr 2021;34:1119–36. 
https://doi.org/10.1016/j.echo.2021.06.012
170. Bhave NM, Nienaber CA, Clough RE, Eagle KA. Multimodality imaging of thoracic aor­
tic diseases in adults. JACC Cardiovasc Imaging 2018;11:902–19. https://doi.org/10.1016/ 
j.jcmg.2018.03.009
171. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality 
imaging of diseases of the thoracic aorta in adults: from the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging: endorsed 
by the Society of Cardiovascular Computed Tomography and Society for 
Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119–82. https:// 
doi.org/10.1016/j.echo.2014.11.015
172. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering 
acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The 
task force for the diagnosis and treatment of aortic diseases of the European Society of 
Cardiology (ESC). Eur Heart J 2014;35:2873–926. https://doi.org/10.1093/eurheartj/ 
ehu281
173. Bossone E, Czerny M, Lerakis S, Rodríguez-Palomares J, Kukar N, Ranieri B, et al. 
Imaging and biomarkers in acute aortic syndromes: diagnostic and prognostic implica­
tions. Curr Probl Cardiol 2021;46:100654. https://doi.org/10.1016/j.cpcardiol.2020. 
100654
174. Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and manage­
ment, an update. Eur Heart J 2018;39:739–49d. https://doi.org/10.1093/eurheartj/ 
ehx319
175. Vardhanabhuti V, Nicol E, Morgan-Hughes G, Roobottom CA, Roditi G, Hamilton 
MCK, et al. Recommendations for accurate CT diagnosis of suspected acute aortic 
syndrome (AAS)—on behalf of the British Society of Cardiovascular Imaging (BSCI)/ 
British Society of Cardiovascular CT (BSCCT). Br J Radiol 2016;89:20150705. 
https://doi.org/10.1259/bjr.20150705
176. Carstensen M, Keer D, Rempel J, Jeon P, Barrett B. Prevalence of risk factors for 
contrast-induced 
nephrotoxicity 
in 
outpatients 
undergoing 
intravenous 
contrast-enhanced computed tomography studies. Can Assoc Radiol J 2012;63: 
177–82. https://doi.org/10.1016/j.carj.2010.12.004
177. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation expos­
ure. N Engl J Med 2007;357:2277–84. https://doi.org/10.1056/NEJMra072149
178. Barra L, Kanji T, Malette J, Pagnoux C. Imaging modalities for the diagnosis and disease 
activity assessment of Takayasu’s arteritis: a systematic review and meta-analysis. 
Autoimmun Rev 2018;17:175–87. https://doi.org/10.1016/j.autrev.2017.11.021
179. Dyverfeldt P, Bissell M, Barker AJ, Bolger AF, Carlhäll C-J, Ebbers T, et al. 4D flow car­
diovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson 2015; 
17:72. https://doi.org/10.1186/s12968-015-0174-5
180. Rodriguez-Palomares JF. Genetics of bicuspid aortic valve: ready for clinical use? Heart 
2022;108:1078–9. https://doi.org/10.1136/heartjnl-2021-320742
181. Guala A, Teixido-Tura G, Dux-Santoy L, Granato C, Ruiz-Muñoz A, Valente F, et al. 
Decreased rotational flow and circumferential wall shear stress as early markers of 
descending aorta dilation in Marfan syndrome: a 4D flow CMR study. J Cardiovasc 
Magn Reson 2019;21:63. https://doi.org/10.1186/s12968-019-0572-1
182. Horowitz MJ, Kupsky DF, El-Said HG, Alshawabkeh L, Kligerman SJ, Hsiao A. 4D flow 
MRI quantification of congenital shunts: comparison to invasive catheterization. Radiol 
Cardiothorac Imaging 2021;3:e200446. https://doi.org/10.1148/ryct.2021200446
183. Rizk J. 4D flow MRI applications in congenital heart disease. Eur Radiol 2021;31: 
1160–74. https://doi.org/10.1007/s00330-020-07210-z
184. Gupta SK, Ya’qoub L, Wimmer AP, Fisher S, Saeed IM. Safety and clinical impact of MRI 
in patients with non-MRI-conditional cardiac devices. Radiol Cardiothorac Imaging 2020; 
2:e200086. https://doi.org/10.1148/ryct.2020200086
185. Munawar DA, Chan JEZ, Emami M, Kadhim K, Khokhar K, O’Shea C, et al. Magnetic 
resonance imaging in non-conditional pacemakers and implantable cardioverter- 
defibrillators: a systematic review and meta-analysis. Europace 2020;22:288–98. 
https://doi.org/10.1093/europace/euz343
186. Nienaber CA. The role of imaging in acute aortic syndromes. Eur Heart J Cardiovasc 
Imaging 2013;14:15–23. https://doi.org/10.1093/ehjci/jes215
187. van der Geest KSM, Treglia G, Glaudemans A, Brouwer E, Sandovici M, Jamar F, et al. 
Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vascu­
litis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021;48: 
3886–902. https://doi.org/10.1007/s00259-021-05362-8
188. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR re­
commendations for the use of imaging in large vessel vasculitis in clinical practice. 
Ann Rheum Dis 2018;77:636–43. https://doi.org/10.1136/annrheumdis-2017-212649
189. Forsythe RO, Dweck MR, McBride OMB, Vesey AT, Semple SI, Shah ASV, et al. (18) 
F-sodium fluoride uptake in abdominal aortic aneurysms: the SoFIA(3) study. J Am 
Coll Cardiol 2018;71:513–23. https://doi.org/10.1016/j.jacc.2017.11.053
190. Roque A, Pizzi MN. (18)F-FDG PET/CT: not only a promise for complex scenarios- 
let’s talk about aortic grafts. J Nucl Cardiol 2022;29:2949–51. https://doi.org/10.1007/ 
s12350-021-02888-0
191. Roque A, Pizzi MN, Fernández-Hidalgo N, Permanyer E, Cuellar-Calabria H, 
Romero-Farina G, et al. Morpho-metabolic post-surgical patterns of non-infected 
prosthetic heart valves by [18F]FDG PET/CTA: ‘normality’ is a possible diagnosis. 
Eur Heart J Cardiovasc Imaging 2020;21:24–33. https://doi.org/10.1093/ehjci/jez222
192. Pizzi MN, Roque A, Cuéllar-Calabria H, Fernández-Hidalgo N, Ferreira-González I, 
González-Alujas MT, et al. (18)F-FDG-PET/CTA of prosthetic cardiac valves and valve- 
tube grafts: infective versus inflammatory patterns. JACC Cardiovasc Imaging 2016;9: 
1224–7. https://doi.org/10.1016/j.jcmg.2016.05.013
193. Pizzi MN, Roque A, Fernández-Hidalgo N, Cuéllar-Calabria H, Ferreira-González I, 
Gonzàlez-Alujas MT, et al. Improving the diagnosis of infective endocarditis in pros­
thetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission 
tomography/computed tomography angiography: initial results at an infective endocar­
ditis referral center. Circulation 2015;132:1113–26. https://doi.org/10.1161/ 
circulationaha.115.015316
194. Teraa M, Hazenberg CE, Houben IB, Trimarchi S, van Herwaarden JA. Important issues 
regarding planning and sizing for emergent TEVAR. J Cardiovasc Surg (Torino) 2020;61: 
708–12. https://doi.org/10.23736/S0021-9509.20.11571-4
195. Lindholt JS, Sogaard R. Population screening and intervention for vascular disease in 
Danish men (VIVA): a randomised controlled trial. Lancet 2017;390:2256–65. 
https://doi.org/10.1016/S0140-6736(17)32250-X
196. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk 
factors in cardiovascular disease risk assessment: updated evidence report and system­
atic review for the US preventive services task force. JAMA 2018;320:281–97. https:// 
doi.org/10.1001/jama.2018.4242
197. Normahani P, Burgess L, Norrie J, Epstein DM, Kandiyil N, Saratzis A, et al. Study 
protocol for a multicentre comparative diagnostic accuracy study of tools to establish 
the presence and severity of peripheral arterial disease in people with diabetes melli­
tus: the DM PAD study. BMJ Open 2022;12:e066950. https://doi.org/10.1136/ 
bmjopen-2022-066950
198. Ueshima D, Barioli A, Nai Fovino L, D’Amico G, Fabris T, Brener SJ, et al. The impact of 
pre-existing peripheral artery disease on transcatheter aortic valve implantation out­
comes: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2020;95: 
993–1000. https://doi.org/10.1002/ccd.28335
199. de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O’Leary DH, et al. 
Prevalence of asymptomatic carotid artery stenosis in the general population: an indi­
vidual participant data meta-analysis. Stroke 2010;41:1294–7. https://doi.org/10.1161/ 
STROKEAHA.110.581058
200. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. 
Screening for asymptomatic carotid artery stenosis: US preventive services task force 
recommendation statement. JAMA 2021;325:476–81. https://doi.org/10.1001/jama. 
2020.26988
201. AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al. 
Society for Vascular Surgery clinical practice guidelines for management of extracranial 
cerebrovascular disease. J Vasc Surg 2022;75:4S–22S. https://doi.org/10.1016/j.jvs.2021. 
04.073
202. Howard DPJ, Gaziano L, Rothwell PM. Risk of stroke in relation to degree of asymp­
tomatic carotid stenosis: a population-based cohort study, systematic review, and 
meta-analysis. Lancet Neurol 2021;20:193–202. https://doi.org/10.1016/s1474- 
4422(20)30484-1
203. Paraskevas KI, Spence JD, Mikhailidis DP, Antignani PL, Gloviczki P, Eckstein H-H, et al. 
Why do guidelines recommend screening for abdominal aortic aneurysms, but not for 
asymptomatic carotid stenosis? A plea for a randomized controlled trial. Int J Cardiol 
2023;371:406–12. https://doi.org/10.1016/j.ijcard.2022.09.045
204. Kobo O, Saada M, von Birgelen C, Tonino PAL, Íñiguez-Romo A, Fröbert O, et al. 
Impact of multisite artery disease on clinical outcomes after percutaneous coronary 
intervention: an analysis from the e-Ultimaster registry. Eur Heart J Qual Care Clin 
Outcomes 2023;9:417–26. https://doi.org/10.1093/ehjqcco/qcac043
205. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS 
trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin 
in patients with chronic vascular disease. Circulation 2020;142:40–8. https://doi.org/10. 
1161/CIRCULATIONAHA.120.046048
206. Del Giorno R, Reveilhac M, Stauffer I, Berthoud M, Mazzolai L, Depairon M, et al. A 
new score for improving cardiovascular risk prediction and prevention. Nutr Metab 
Cardiovasc Dis 2023;33:1546–55. https://doi.org/10.1016/j.numecd.2023.04.019
207. Mehta A, Rigdon J, Tattersall MC, German CA, Barringer TA, Joshi PH, et al. 
Association of carotid artery plaque with cardiovascular events and incident coronary 
ESC Guidelines                                                                                                                                                                                          3667


<!-- PAGE 131 -->

### Page 131

artery calcium in individuals with absent coronary calcification: the MESA. Circ 
Cardiovasc Imaging 2021;14:e011701. https://doi.org/10.1161/circimaging.120.011701
208. Gepner AD, Young R, Delaney JA, Budoff MJ, Polak JF, Blaha MJ, et al. Comparison of 
carotid plaque score and coronary artery calcium score for predicting cardiovascular 
disease events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2017;6: 
e005179. https://doi.org/10.1161/jaha.116.005179
209. Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, 
Jiménez-Borreguero LJ, et al. Femoral and carotid subclinical atherosclerosis associ­
ation with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol 
2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056
210. Jacobowitz GR, Rockman CB, Gagne PJ, Adelman MA, Lamparello PJ, Landis R, et al. 
A model for predicting occult carotid artery stenosis: screening is justified in a se­
lected population. J Vasc Surg 2003;38:705–9. https://doi.org/10.1016/s0741- 
5214(03)00730-4
211. Rockman CB, Jacobowitz GR, Gagne PJ, Adelman MA, Lamparello PJ, Landis R, et al. 
Focused screening for occult carotid artery disease: patients with known heart disease 
are at high risk. J Vasc Surg 2004;39:44–50. https://doi.org/10.1016/j.jvs.2003.07.008
212. Yuo TH, Sidaoui J, Marone LK, Makaroun MS, Chaer RA. Revascularization of asymp­
tomatic carotid stenosis is not appropriate in patients on dialysis. J Vasc Surg 2015;61: 
670–4. https://doi.org/10.1016/j.jvs.2014.10.002
213. Ramos MJ, González-Fajardo JA, Vaquero-Puerta C, Vallina-Victorero M, 
Vicente-Santiago M, Vaquero-Lorenzo F, et al. Asymptomatic carotid stenosis in pa­
tients with intermittent claudication: epidemiological study. J Cardiovasc Surg (Torino) 
2011;52:761–8 .
214. Aboyans V, Lacroix P, Guilloux J, Rollé F, Le Guyader A, Cautrès M, et al. A predictive 
model for screening cerebrovascular disease in patient undergoing coronary artery by­
pass grafting. Interact Cardiovasc Thorac Surg 2005;4:90–5. https://doi.org/10.1510/icvts. 
2004.092262
215. Cornily JC, Le Saux D, Vinsonneau U, Bezon E, Le Ven F, Le Gal G, et al. Assessment of 
carotid artery stenosis before coronary artery bypass surgery. Is it always necessary? 
Arch Cardiovasc Dis 2011;104:77–83. https://doi.org/10.1016/j.acvd.2010.11.008
216. Johansson EP, Wester P. Carotid bruits as predictor for carotid stenoses detected by 
ultrasonography: an observational study. BMC Neurol 2008;8:23. https://doi.org/10. 
1186/1471-2377-8-23
217. Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, et al. Accelerated ca­
rotid artery disease after high-dose head and neck radiotherapy: is there a role for rou­
tine carotid duplex surveillance? J Vasc Surg 1999;30:1045–51. https://doi.org/10.1016/ 
s0741-5214(99)70042-x
218. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and 
national prevalence and risk factors for peripheral artery disease in 2015: an updated 
systematic review and analysis. Lancet Glob Health 2019;7:e1020–30. https://doi.org/10. 
1016/s2214-109x(19)30255-4
219. Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease: 
past, present, and future. Am J Med 2019;132:1133–41. https://doi.org/10.1016/j. 
amjmed.2019.04.043
220. Søgaard R, Lindholt JS. Cost-effectiveness of population-based vascular disease screen­
ing and intervention in men from the Viborg Vascular (VIVA) trial. Br J Surg 2018;105: 
1283–93. https://doi.org/10.1002/bjs.10872
221. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneur­
ysms: single centre randomised controlled trial. BMJ 2005;330:750. https://doi.org/ 
10.1136/bmj.38369.620162.82
222. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, et al. 
Population based randomised controlled trial on impact of screening on mortality 
from abdominal aortic aneurysm. BMJ 2004;329:1259. https://doi.org/10.1136/bmj. 
38272.478438.55
223. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et al. The multicentre 
aneurysm screening study (MASS) into the effect of abdominal aortic aneurysm 
screening on mortality in men: a randomised controlled trial. Lancet 2002;360: 
1531–9. https://doi.org/10.1016/s0140-6736(02)11522-4
224. Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the incidence of 
ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. 
Br J Surg 1995;82:1066–70. https://doi.org/10.1002/bjs.1800820821
225. Duncan A, Maslen C, Gibson C, Hartshorne T, Farooqi A, Saratzis A, et al. Ultrasound 
screening for abdominal aortic aneurysm in high-risk women. Br J Surg 2021;108: 
1192–8. https://doi.org/10.1093/bjs/znab220
226. Lindholt JS, Sogaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. 
Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl 
J Med 2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681
227. Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM. 
Population-based study of incidence of acute abdominal aortic aneurysms with pro­
jected impact of screening strategy. J Am Heart Assoc 2015;4:e001926. https://doi. 
org/10.1161/JAHA.115.001926
228. Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM. Age-specific 
incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined 
population. Br J Surg 2015;102:907–15. https://doi.org/10.1002/bjs.9838
229. Sprynger M, Willems M, Van Damme H, Drieghe B, Wautrecht JC, Moonen M. 
Screening program of abdominal aortic aneurysm. Angiology 2019;70:407–13. https:// 
doi.org/10.1177/0003319718824940
230. Larsson E, Granath F, Swedenborg J, Hultgren R. A population-based case-control 
study of the familial risk of abdominal aortic aneurysm. J Vasc Surg 2009;49:47–50; dis­
cussion 51. https://doi.org/10.1016/j.jvs.2008.08.012
231. Linné A, Forsberg J, Lindström D, Ideskog E, Hultgren R. Age at detection of abdominal 
aortic aneurysms in siblings of patients with abdominal aortic aneurysms. J Vasc Surg 
2016;63:883–7. https://doi.org/10.1016/j.jvs.2015.10.057
232. Aboyans V, Bataille V, Bliscaux P, Ederhy S, Filliol D, Honton B, et al. Effectiveness of 
screening for abdominal aortic aneurysm during echocardiography. Am J Cardiol 
2014;114:1100–4. https://doi.org/10.1016/j.amjcard.2014.07.024
233. Hicks CW, Al-Qunaibet A, Ding N, Kwak L, Folsom AR, Tanaka H, et al. Symptomatic 
and asymptomatic peripheral artery disease and the risk of abdominal aortic aneurysm: 
the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021;333:32–8. 
https://doi.org/10.1016/j.atherosclerosis.2021.08.016
234. Benson RA, Poole R, Murray S, Moxey P, Loftus IM. Screening results from a large 
United Kingdom abdominal aortic aneurysm screening center in the context of opti­
mizing United Kingdom National Abdominal Aortic Aneurysm Screening Programme 
protocols. J Vasc Surg 2016;63:301–4. https://doi.org/10.1016/j.jvs.2015.08.091
235. Sciria CT, Osorio B, Wang J, Lu DY, Amin N, Vohra A, et al. Sex-based disparities in 
outcomes with abdominal aortic aneurysms. Am J Cardiol 2021;155:135–48. https:// 
doi.org/10.1016/j.amjcard.2021.06.023
236. Carter JL, Morris DR, Sherliker P, Clack R, Lam KBH, Halliday A, et al. Sex-specific as­
sociations of vascular risk factors with abdominal aortic aneurysm: findings from 1.5 
million women and 0.8 million men in the United States and United Kingdom. J Am 
Heart Assoc 2020;9:e014748. https://doi.org/10.1161/JAHA.119.014748
237. Wanhainen A, Lundkvist J, Bergqvist D, Bjorck M. Cost-effectiveness of screening wo­
men for abdominal aortic aneurysm. J Vasc Surg 2006;43:908–14; discussion 914. 
https://doi.org/10.1016/j.jvs.2005.12.064
238. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to 
the Mediterranean diet on health: an updated systematic review and meta-analysis. Am 
J Clin Nutr 2010;92:1189–96. https://doi.org/10.3945/ajcn.2010.29673
239. Mente A, Dehghan M, Rangarajan S, O’Donnell M, Hu W, Dagenais G, et al. Diet, car­
diovascular disease, and mortality in 80 countries. Eur Heart J 2023;44:2560–79. 
https://doi.org/10.1093/eurheartj/ehad269
240. Wan D, Dehghan M, de Souza RJ, Ramasundarahettige C, Eikelboom JW, Bosch J, et al. 
Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: 
insights from the COMPASS trial cohort. Eur J Prev Cardiol 2023;30:709–18. https://doi. 
org/10.1093/eurjpc/zwad062
241. Adegbola A, Behrendt CA, Zyriax BC, Windler E, Kreutzburg T. The impact of nutri­
tion on the development and progression of peripheral artery disease: a systematic re­
view. Clin Nutr 2022;41:49–70. https://doi.org/10.1016/j.clnu.2021.11.005
242. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce car­
diovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455
243. Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee B-C, et al. Benefit of tar­
geting a LDL (low-density lipoprotein) cholesterol <70 mg/dL during 5 years after is­
chemic stroke. Stroke 2020;51:1231–9. https://doi.org/10.1161/strokeaha.119.028718
244. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral ar­
terial disease of the lower limb. Cochrane Database Syst Rev 2007;4:CD000123. https:// 
doi.org/10.1002/14651858.CD000123.pub2
245. Heart Protection Study Collaborative Group. Randomized trial of the effects of 
cholesterol-lowering with simvastatin on peripheral vascular and other major vascular 
outcomes in 20,536 people with peripheral arterial disease and other high-risk condi­
tions. J Vasc Surg 2007;45:645–54; discussion 653–644. https://doi.org/10.1016/j.jvs. 
2006.12.054
246. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and 
safety of cholesterol-lowering treatment: prospective meta-analysis of data from 
90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78. 
https://doi.org/10.1016/S0140-6736(05)67394-1
247. Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park J-G, et al. 
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis 
of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018;6:934–43. https://doi.org/10. 
1016/s2213-8587(18)30290-0
248. Yu E, Malik VS, Hu FB. Cardiovascular disease prevention by diet modification: JACC 
health promotion series. J Am Coll Cardiol 2018;72:914–26. https://doi.org/10.1016/j. 
jacc.2018.02.085
249. López-Laguna N, Martínez-González MA, Toledo E, Babio N, Sorlí JV, Ros E, et al. Risk 
of peripheral artery disease according to a healthy lifestyle score: the PREDIMED 
study. Atherosclerosis 2018;275:133–40. https://doi.org/10.1016/j.atherosclerosis. 
2018.05.049
250. Kaluza J, Stackelberg O, Harris HR, Akesson A, Björck M, Wolk A. Mediterranean diet 
is associated with reduced risk of abdominal aortic aneurysm in smokers: results of 
two prospective cohort studies. Eur J Vasc Endovasc Surg 2021;62:284–93. https:// 
doi.org/10.1016/j.ejvs.2021.04.017


<!-- PAGE 132 -->

### Page 132

251. Liu L, Yang Y. Nutritional management mode of early cardiac rehabilitation in patients 
with Stanford type A aortic dissection. Comput Math Methods Med 2022;2022: 
2124636. https://doi.org/10.1155/2022/2124636
252. Lauret GJ, Fokkenrood HJ, Bendermacher BL, Scheltinga MR, Teijink JA. Physical activ­
ity monitoring in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2014; 
47:656–63. https://doi.org/10.1016/j.ejvs.2014.03.001
253. Gardner AW, Addison O, Katzel LI, Montgomery PS, Prior SJ, Serra MC, et al. 
Association between physical activity and mortality in patients with claudication. 
Med Sci Sports Exerc 2021;53:732–9. https://doi.org/10.1249/mss.0000000000002526
254. Gardner AW, Montgomery PS, Parker DE. Physical activity is a predictor of all-cause 
mortality in patients with intermittent claudication. J Vasc Surg 2008;47:117–22. https:// 
doi.org/10.1016/j.jvs.2007.09.033
255. Gardner AW, Montgomery PS, Wang M, Shen B, Zhang S, Pomilla WA. Association 
between meeting physical activity time-intensity guidelines with ambulation, quality 
of life, and inflammation in claudication. J Cardiopulm Rehabil Prev 2022;42:E82–9. 
https://doi.org/10.1097/hcr.0000000000000686
256. Thijssen CGE, Bons LR, Gökalp AL, Van Kimmenade RRJ, Mokhles MM, Pelliccia A, 
et al. Exercise and sports participation in patients with thoracic aortic disease: a review. 
Expert Rev Cardiovasc Ther 2019;17:251–66. https://doi.org/10.1080/14779072.2019. 
1585807
257. Delsart P, Maldonado-Kauffmann P, Bic M, Boudghene-Stambouli F, Sobocinski J, 
Juthier F, et al. Post aortic dissection: gap between activity recommendation and 
real life patients aerobic capacities. Int J Cardiol 2016;219:271–6. https://doi.org/10. 
1016/j.ijcard.2016.06.026
258. Chaddha A, Eagle KA, Braverman AC, Kline-Rogers E, Hirsch AT, Brook R, et al. 
Exercise and physical activity for the post-aortic dissection patient: the clinician’s con­
undrum. Clin Cardiol 2015;38:647–51. https://doi.org/10.1002/clc.22481
259. Chaddha A, Kline-Rogers E, Woznicki EM, Brook R, Housholder-Hughes S, Braverman 
AC, et al. Cardiology patient page. Activity recommendations for postaortic dissection 
patients. Circulation 2014;130:e140–2. https://doi.org/10.1161/circulationaha.113. 
005819
260. Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: 
are all forms of smoking harmful to all types of vascular disease? Public Health 2013; 
127:435–41. https://doi.org/10.1016/j.puhe.2012.12.021
261. Wu CW, Chuang HY, Watanabe K, Wu P-S, Pan H-C, Wang C-L, et al. Association 
between secondhand smoke and peripheral arterial disease: a meta-analysis of cross- 
sectional studies. Int Arch Occup Environ Health 2022;95:1091–101. https://doi.org/10. 
1007/s00420-022-01837-9
262. Sode BF, Nordestgaard BG, Gronbaek M, Dahl M. Tobacco smoking and aortic aneur­
ysm: two population-based studies. Int J Cardiol 2013;167:2271–7. https://doi.org/10. 
1016/j.ijcard.2012.06.003
263. Altobelli E, Rapacchietta L, Profeta VF, Fagnano R. Risk factors for abdominal aortic 
aneurysm in population-based studies: a systematic review and meta-analysis. Int J 
Environ Res Public Health 2018;15:2805. https://doi.org/10.3390/ijerph15122805
264. Lederle FA, Nelson DB, Joseph AM. Smokers’ relative risk for aortic aneurysm com­
pared with other smoking-related diseases: a systematic review. J Vasc Surg 2003;38: 
329–34. https://doi.org/10.1016/s0741-5214(03)00136-8
265. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and 
risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control 
study. Lancet 2006;368:647–58. https://doi.org/10.1016/S0140-6736(06)69249-0
266. Mahtta D, Ramsey D, Krittanawong C, Al Rifai M, Khurram N, Samad Z, et al. 
Recreational substance use among patients with premature atherosclerotic cardiovas­
cular disease. Heart 2021;107:650–6. https://doi.org/10.1136/heartjnl-2020-318119
267. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The ef­
fects of a smoking cessation intervention on 14.5-year mortality: a randomized clin­
ical trial. Ann Intern Med 2005;142:233–9. https://doi.org/10.7326/0003-4819-142- 
4-200502150-00005
268. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety 
of smoking cessation interventions in patients with cardiovascular disease: a network 
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: 
e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458
269. Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman 
L, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database 
Syst Rev 2023;5:CD006103. https://doi.org/10.1002/14651858.CD006103.pub8
270. Rose JJ, Krishnan-Sarin S, Exil VJ, Hamburg NM, Fetterman JL, Ichinose F, et al. 
Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific 
statement from the American Heart Association. Circulation 2023;148:703–28. 
https://doi.org/10.1161/CIR.0000000000001160
271. Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R, et al. Electronic cigar­
ettes for smoking cessation. Cochrane Database Syst Rev 2024;1:CD010216. https://doi. 
org/10.1002/14651858.CD010216.pub8
272. Travis N, Knoll M, Cadham CJ, Cook S, Warner KE, Fleischer NL, et al. Health effects of 
electronic cigarettes: an umbrella review and methodological considerations. Int J 
Environ Res Public Health 2022;19:9054. https://doi.org/10.3390/ijerph19159054
273. Abbott AJ, Reibel YG, Arnett MC, Marka N, Drake MA. Oral and systemic health im­
plications of electronic cigarette usage as compared to conventional tobacco cigar­
ettes: a review of the literature. J Dent Hyg 2023;97:21–35.
274. Hamann SL, Kungskulniti N, Charoenca N, Kasemsup V, Ruangkanchanasetr S, 
Jongkhajornpong P. Electronic cigarette harms: aggregate evidence shows damage to 
biological systems. Int J Environ Res Public Health 2023;20:6808. https://doi.org/10. 
3390/ijerph20196808
275. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al. 
Electronic cigarettes and health with special focus on cardiovascular effects: position 
paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev 
Cardiol 2021;28:1552–66. https://doi.org/10.1177/2047487320941993
276. Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, et al. Patients’ 
perceptions of cholesterol, cardiovascular disease risk, and risk communication strat­
egies. Ann Fam Med 2006;4:205–12. https://doi.org/10.1370/afm.534
277. Howarth M, Lister C. Social prescribing in cardiology: rediscovering the nature within 
us. Br J Card Nurs 2019;14:1–9. https://doi.org/10.12968/bjca.2019.0036
278. Nichols LO, Martindale-Adams J, Burns R, Graney MJ, Zuber J. Translation of a demen­
tia caregiver support program in a health care system—REACH VA. Arch Intern Med 
2011;171:353–9. https://doi.org/10.1001/archinternmed.2010.548
279. Martire LM, Schulz R, Keefe FJ, Rudy TE, Starz TW. Couple-oriented education and 
support intervention for osteoarthritis: effects on spouses’ support and responses 
to patient pain. Fam Syst Health 2008;26:185–95. https://doi.org/10.1037/1091-7527. 
26.2.185
280. Morris SM, King C, Turner M, Payne S. Family carers providing support to a person 
dying in the home setting: a narrative literature review. Palliat Med 2015;29:487–95. 
https://doi.org/10.1177/0269216314565706
281. Ventura AD, Burney S, Brooker J, Fletcher J, Ricciardelli L. Home-based palliative care: 
a systematic literature review of the self-reported unmet needs of patients and carers. 
Palliat Med 2014;28:391–402. https://doi.org/10.1177/0269216313511141
282. Reynolds CF, III, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults: 
recent advances and new directions in clinical practice and research. World Psychiatry 
2022;21:336–63. https://doi.org/10.1002/wps.20996
283. Katch H. The role of self-efficacy in cardiovascular disease self-management: a review 
of effective programs. Patient Intelligence 2010;2:33–4. doi: https://doi.org/10.2147/PI. 
S12624]
284. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al. The REduction of 
Atherothrombosis for Continued Health (REACH) registry: an international, pro­
spective, observational investigation in subjects at risk for atherothrombotic events– 
study design. Am Heart J 2006;151:786.e1–10. https://doi.org/10.1016/j.ahj.2005.11. 
004
285. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifesta­
tions of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15: 
773–81. https://doi.org/10.1023/a:1007621514757
286. Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJA, Steyerberg EW, Ridker PM, 
et al. Development and validation of a prediction rule for recurrent vascular events 
based on a cohort study of patients with arterial disease: the SMART risk score. 
Heart 2013;99:866–72. https://doi.org/10.1136/heartjnl-2013-303640
287. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB, Massaro JM, 
et al. Estimated life expectancy without recurrent cardiovascular events in patients 
with vascular disease: the SMART-REACH model. J Am Heart Assoc 2018;7: 
e009217. https://doi.org/10.1161/JAHA.118.009217
288. Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of 
recurrent atherosclerotic cardiovascular event risk in patients with established cardio­
vascular disease: the updated SMART2 algorithm. Eur Heart J 2022;43:1715–27. 
https://doi.org/10.1093/eurheartj/ehac056
289. van Trier TJ, Snaterse M, Boekholdt SM, Scholte Op Reimer WJM, Hageman SHJ, 
Visseren FLJ, et al. Validation of systematic coronary risk evaluation 2 (SCORE2) 
and SCORE2-older persons in the EPIC Norfolk prospective population cohort. Eur 
J Prev Cardiol 2024;31:182–9. https://doi.org/10.1093/eurjpc/zwad318
290. Wan D, Li V, Banfield L, Azab S, de Souza RJ, Anand SS, et al. Diet and nutrition in per­
ipheral artery disease: a systematic review. Can J Cardiol 2022;38:672–80. https://doi. 
org/10.1016/j.cjca.2022.01.021
291. Sesso HD, Rist PM, Aragaki AK, Rautiainen S, Johnson LG, Friedenberg G, et al. 
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa 
Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. 
Am J Clin Nutr 2022;115:1501–10. https://doi.org/10.1093/ajcn/nqac056
292. Bondonno NP, Murray K, Cassidy A, Bondonno CP, Lewis JR, Croft KD, et al. Higher 
habitual flavonoid intakes are associated with a lower risk of peripheral artery disease 
hospitalizations. Am J Clin Nutr 2021;113:187–99. https://doi.org/10.1093/ajcn/ 
nqaa300
293. Bapir M, Untracht GR, Cooke D, McVey JH, Skene SS, Campagnolo P, et al. Cocoa fla­
vanol consumption improves lower extremity endothelial function in healthy indivi­
duals and people with type 2 diabetes. Food Funct 2022;13:10439–48. https://doi. 
org/10.1039/d2fo02017c
294. Fassora M, Calanca L, Jaques C, Mazzolai L, Kayser B, Lanzi S. Intensity-dependent 
effects of exercise therapy on walking performance and aerobic fitness in 
ESC Guidelines                                                                                                                                                                                          3669


<!-- PAGE 133 -->

### Page 133

symptomatic patients with lower-extremity peripheral artery disease: a systematic 
review and meta-analysis. Vasc Med 2022;27:158–70. https://doi.org/10.1177/ 
1358863x211034577
295. O’Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to 
promote a healthy diet and physical activity for cardiovascular disease prevention in 
adults with cardiovascular risk factors: updated evidence report and systematic review 
for the US preventive services task force. JAMA 2020;324:2076–94. https://doi.org/10. 
1001/jama.2020.17108
296. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. 
Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2021;4: 
CD010216. https://doi.org/10.1002/14651858.CD010216.pub5
297. Krabbe B, Espinola-Klein C, Malyar N, Brodmann M, Mazzolai L, Belch JJF, et al. Health 
effects of e-cigarettes and their use for smoking cessation from a vascular perspective. 
Vasa 2023;52:81–5. https://doi.org/10.1024/0301-1526/a001056
298. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. 
American College of Sports Medicine position stand. Quantity and quality of exercise 
for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor 
fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports 
Exerc 2011;43:1334–59. https://doi.org/10.1249/MSS.0b013e318213fefb
299. Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt C-A, Bellmunt-Montoya S, 
et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2023 clinical 
practice guidelines on antithrombotic therapy for vascular diseases. Eur J Vasc 
Endovasc Surg 2023;65:627–89. https://doi.org/10.1016/j.ejvs.2023.03.042
300. McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 
sion. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178
301. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and 
blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for 
the prevention of cardiovascular disease and death: an individual participant-level 
data meta-analysis. Lancet 2021;398:1053–64. https://doi.org/10.1016/S0140- 
6736(21)01921-8
302. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood 
pressure lowering for prevention of cardiovascular disease and death: a systematic re­
view and meta-analysis. Lancet 2016;387:957–67. https://doi.org/10.1016/s0140- 
6736(15)01225-8
303. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow 
GM, et al. Intensive vs standard blood pressure control and cardiovascular disease out­
comes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673–82. 
https://doi.org/10.1001/jama.2016.7050
304. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure 
control in older patients with hypertension. N Engl J Med 2021;385:1268–79. https:// 
doi.org/10.1056/NEJMoa2111437
305. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out­
come incidence in hypertension. 1. Overview, meta-analyses, and meta-regression 
analyses of randomized trials. J Hypertens 2014;32:2285–95. https://doi.org/10.1097/ 
hjh.0000000000000378
306. Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A ran­
domized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 
373:2103–16. https://doi.org/10.1056/NEJMoa1511939
307. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an 
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high- 
risk patients. N Engl J Med 2000;342:145–53. https://doi.org/10.1056/ 
nejm200001203420301
308. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, 
et al. Outcomes among hypertensive patients with concomitant peripheral and coron­
ary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. 
Hypertension 2010;55:48–53. https://doi.org/10.1161/hypertensionaha.109.142240
309. Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, et al. 
Association of hypertension and arterial blood pressure on limb and cardiovascular 
outcomes in symptomatic peripheral artery disease: the EUCLID trial. Circ 
Cardiovasc Qual Outcomes 2020;13:e006512. https://doi.org/10.1161/circoutcomes. 
120.006512
310. Thomas Manapurathe D, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J, Effect 
of blood pressure lowering medications on leg ischemia in peripheral artery disease 
patients: a meta-analysis of randomised controlled trials. PLoS One 2017;12: 
e0178713. https://doi.org/10.1371/journal.pone.0178713
311. Lu Y, Ballew SH, Tanaka H, Szklo M, Heiss G, Coresh J, et al. 2017 ACC/AHA blood 
pressure classification and incident peripheral artery disease: the Atherosclerosis Risk 
in Communities (ARIC) study. Eur J Prev Cardiol 2020;27:51–9. https://doi.org/10.1177/ 
2047487319865378
312. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, 
or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. 
https://doi.org/10.1056/NEJMoa0801317
313. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril 
in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 
2004;25:17–24. https://doi.org/10.1016/j.ehj.2003.10.033
314. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. 
Cochrane Database Syst Rev 2013;9:CD005508. https://doi.org/10.1002/14651858. 
CD005508.pub3
315. Kray JE, Dombrovskiy VY, Vogel TR. Use of angiotensin-converting enzyme inhibitors 
and freedom from amputation after lower extremity revascularization. Vasc Health 
Risk Manag 2017;13:269–74. https://doi.org/10.2147/vhrm.S137698
316. Høgh A, Lindholt JS, Nielsen H, Jensen LP, Johnsen SP. Use of angiotensin-converting 
enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a 
nationwide propensity score matched follow-up study. Vasc Endovascular Surg 2012; 
46:515–23. https://doi.org/10.1177/1538574412455229
317. Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major 
adverse cardiovascular events among patients with critical limb ischemia. Vasc Med 
2015;20:237–44. https://doi.org/10.1177/1358863x15574321
318. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in 
older persons with prior myocardial infarction and symptomatic peripheral arterial 
disease. Am J Cardiol 2001;87:1284–6. https://doi.org/10.1016/s0002-9149(01) 
01521-1
319. Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D. Beta-blocker treatment 
does not worsen critical limb ischemia in patients receiving endovascular therapy. 
J Atheroscler Thromb 2015;22:481–9. https://doi.org/10.5551/jat.27359
320. Carey RM, Wright JT, Jr, Taler SJ, Whelton PK. Guideline-driven management of 
hypertension: an evidence-based update. Circ Res 2021;128:827–46. https://doi.org/ 
10.1161/circresaha.121.318083
321. Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, et al. Use of 
renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc 
Nephrol 2014;9:1199–206. https://doi.org/10.2215/cjn.11611113
322. Hackam DG, Duong-Hua ML, Mamdani M, Li Ping, Tobe SW, Spence JD, et al. 
Angiotensin inhibition in renovascular disease: a population-based cohort study. Am 
Heart J 2008;156:549–55. https://doi.org/10.1016/j.ahj.2008.05.013
323. Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, et al. Renal func­
tion and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients 
with chronic stable coronary disease in the Prevention of Events with ACE inhibition 
(PEACE) trial. Circulation 2006;114:26–31. https://doi.org/10.1161/circulationaha.105. 
592733
324. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting 
and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370: 
13–22. https://doi.org/10.1056/NEJMoa1310753
325. Mayr NP, Hapfelmeier A, Martin K, Kurz A, van der Starre P, Babik B, et al. Comparison 
of sedation and general anaesthesia for transcatheter aortic valve implantation on 
cerebral oxygen saturation and neurocognitive outcomedagger. Br J Anaesth 2016; 
116:90–9. https://doi.org/10.1093/bja/aev294
326. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for 
abdominal aortic aneurysms in a population-based study: the Tromsø study. Am J 
Epidemiol 2001;154:236–44. https://doi.org/10.1093/aje/154.3.236
327. Vogel TR, Dombrovskiy VY, Galiñanes EL, Kruse RL. Preoperative statins and limb 
salvage after lower extremity revascularization in the Medicare population. Circ 
Cardiovasc Interv 2013;6:694–700. https://doi.org/10.1161/circinterventions.113. 
000274
328. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy 
and long-term adverse limb outcomes in patients with peripheral artery disease: in­
sights from the REACH registry. Eur Heart J 2014;35:2864–72. https://doi.org/10. 
1093/eurheartj/ehu080
329. Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al. Statins 
and major adverse limb events in patients with peripheral artery disease: a systematic 
review and meta-analysis. Thromb Haemost 2020;120:866–75. https://doi.org/10.1055/ 
s-0040-1709711
330. Su Z, Guo J, Gu Y. Pharmacotherapy in clinical trials for abdominal aortic aneurysms: a 
systematic review and meta-analysis. Clin Appl Thromb Hemost 2022;28: 
10760296221120423. https://doi.org/10.1177/10760296221120423
331. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. 
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 
2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489
332. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al. 
Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a 
secondary prevention population. Circulation 2016;134:1419–29. https://doi.org/10. 
1161/CIRCULATIONAHA.116.021314
333. Clavijo LC, Caro J, Choi J, Caro JA, Tun H, Rowe V, et al. The addition of evolocumab 
to maximal tolerated statin therapy improves walking performance in patients with 
peripheral arterial disease and intermittent claudication (Evol-PAD study). 
Cardiovasc Revasc Med 2023;55:1–5. https://doi.org/10.1016/j.carrev.2023.04.020
334. Cholesterol Treatment Trialists Collaboration; Fulcher J, O’Connell R, Voysey M, 
Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among 
men and women: meta-analysis of individual data from 174,000 participants in 27 ran­
domised trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/S0140-6736(14) 
61368-4


<!-- PAGE 134 -->

### Page 134

335. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, et al. 
Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coron­
ary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol 2016;67:353–61. https://doi.org/ 
10.1016/j.jacc.2015.10.077
336. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. 
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J 
Med 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664
337. Westin GG, Armstrong EJ, Bang H, Yeo K-K, Anderson D, Dawson DL, et al. 
Association between statin medications and mortality, major adverse cardiovascular 
event, and amputation-free survival in patients with critical limb ischemia. J Am Coll 
Cardiol 2014;63:682–90. https://doi.org/10.1016/j.jacc.2013.09.073
338. Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, et al. 
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. 
Vasa 2021;50:401–11. https://doi.org/10.1024/0301-1526/a000969
339. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, 
Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: 
a systematic review and meta-analysis of robust randomised controlled studies. Eur J 
Vasc Endovasc Surg 2009;38:463–74. https://doi.org/10.1016/j.ejvs.2009.06.002
340. Flint AC, Conell C, Ren X, Kamel H, Chan SL, Rao VA, et al. Statin adherence is asso­
ciated with reduced recurrent stroke risk in patients with or without atrial fibrillation. 
Stroke 2017;48:1788–94. https://doi.org/10.1161/strokeaha.117.017343
341. Merwick Á, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, et al. Reduction in early 
stroke risk in carotid stenosis with transient ischemic attack associated with statin 
treatment. Stroke 2013;44:2814–20. https://doi.org/10.1161/strokeaha.113.001576
342. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and 
updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–63. 
https://doi.org/10.1016/s1474-4422(09)70058-4
343. Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, Hennerici M, Rudolph AE, 
et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 
2006;355:549–59. https://doi.org/10.1056/NEJMoa061894
344. Hackam DG, Wu F, Li P, Austin PC, Tobe SW, Mamdani MM, et al. Statins and reno­
vascular disease in the elderly: a population-based cohort study. Eur Heart J 2011;32: 
598–610. https://doi.org/10.1093/eurheartj/ehq452
345. Peng M, Dong H, Jiang X, Che W, Zou Y, Zhang Y, et al. A randomized unblinded trial 
to compare effects of intensive versus conventional lipid-lowering therapy in patients 
undergoing renal artery stenting. J Cardiol 2019;74:443–50. https://doi.org/10.1016/j. 
jjcc.2019.04.010
346. Vashist A, Heller EN, Brown EJ, Jr, Alhaddad IA. Renal artery stenosis: a cardiovascular 
perspective. Am Heart J 2002;143:559–64. https://doi.org/10.1067/mhj.2002.120769
347. Pan Z, Cui H, Wu N, Zhang H. Effect of statin therapy on abdominal aortic aneurysm 
growth rate and mortality: a systematic review and meta-analysis. Ann Vasc Surg 2020; 
67:503–10. https://doi.org/10.1016/j.avsg.2020.03.036
348. Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, et al. Statins reduce 
abdominal aortic aneurysm growth, rupture, and perioperative mortality: a systematic 
review and meta-analysis. J Am Heart Assoc 2018;7:e008657. https://doi.org/10.1161/ 
jaha.118.008657
349. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on ab­
dominal aortic aneurysm growth: a meta-analysis and meta-regression of observational 
comparative studies. Eur J Vasc Endovasc Surg 2012;44:287–92. https://doi.org/10.1016/ 
j.ejvs.2012.06.021
350. Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic 
aneurysms. Am J Cardiol 2013;112:1240–5. https://doi.org/10.1016/j.amjcard.2013.05. 
081
351. Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M, et al. Comparison of the 
effect on long-term outcomes in patients with thoracic aortic aneurysms of taking ver­
sus not taking a statin drug. Am J Cardiol 2012;109:1050–4. https://doi.org/10.1016/j. 
amjcard.2011.11.038
352. Skovbo Kristensen JS, Krasniqi L, Obel LM, Kavaliunaite E, Liisberg M, Lindholt JS. 
Exploring drug repurposing for treatment of abdominal aortic aneurysms: a systematic 
review and meta-analysis. Eur J Vasc Endovasc Surg 2024;67:570–82. https://doi.org/10. 
1016/j.ejvs.2023.11.037
353. Rahman MN, Khan JA, Mazari FA, Mockford K, McCollum PT, Chetter IC. A rando­
mized placebo controlled trial of the effect of preoperative statin use on matrix me­
talloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and 
peak wall stress in patients undergoing elective open repair of abdominal aortic aneur­
ysm. Ann Vasc Surg 2011;25:32–8. https://doi.org/10.1016/j.avsg.2010.06.006
354. Periard D, Guessous I, Mazzolai L, Haesler E, Monney P, Hayoz D. Reduction of small 
infrarenal abdominal aortic aneurysm expansion rate by statins. Vasa 2012;41:35–42. 
https://doi.org/10.1024/0301-1526/a000161
355. Angeloni E, Vitaterna A, Pirelli M, Refice S. Effects of statin therapy on ascending aorta 
aneurysms growth: a propensity-matched analysis. Int J Cardiol 2015;191:52–5. https:// 
doi.org/10.1016/j.ijcard.2015.05.001
356. Rowbotham SE, Krishna SM, Moran CS, Golledge J. Fenofibrate and telmisartan in the 
management of abdominal aortic aneurysm. Curr Drug Targets 2018;19:1241–6. https:// 
doi.org/10.2174/1389450119666171227224655
357. Pinchbeck JL, Moxon JV, Rowbotham SE, Bourke M, Lazzaroni S, Morton SK, et al. 
Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate ther­
apy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2 
trial. J Am Heart Assoc 2018;7:e009866. https://doi.org/10.1161/JAHA.118.009866
358. Lamb YN. Inclisiran: first approval. Drugs 2021;81:389–95. https://doi.org/10.1007/ 
s40265-021-01473-6
359. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and 
efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380: 
1022–32. https://doi.org/10.1056/NEJMoa1803917
360. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy 
and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with 
hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 2018; 
277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002
361. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic 
acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 
388:1353–64. https://doi.org/10.1056/NEJMoa2215024
362. Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al. Elevated 
LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023;81:136–52. https:// 
doi.org/10.1016/j.jacc.2022.10.019
363. Gao JW, Hao QY, Gao M, Zhang K, Li X-Z, Wang J-F, et al. Triglyceride-glucose index 
in the development of peripheral artery disease: findings from the Atherosclerosis Risk 
in Communities (ARIC) study. Cardiovasc Diabetol 2021;20:126. https://doi.org/10. 
1186/s12933-021-01319-1
364. Britton KA, Mukamal KJ, Ix JH, Siscovick DS, Newman AB, de Boer IH, et al. Insulin re­
sistance and incident peripheral artery disease in the cardiovascular health study. Vasc 
Med 2012;17:85–93. https://doi.org/10.1177/1358863X11436195
365. Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and 
inflammation with peripheral arterial disease: the National Health and Nutrition 
Examination Survey, 1999 to 2004. Circulation 2008;118:33–41. https://doi.org/10. 
1161/CIRCULATIONAHA.107.721878
366. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovas­
cular disease and stroke. Cochrane Database Syst Rev 2015;10:CD009580. https://doi. 
org/10.1002/14651858.CD009580.pub2
367. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arter­
ial disease: randomised controlled trial. BMJ 2002;325:1139. https://doi.org/10.1136/ 
bmj.325.7373.1139
368. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. 
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J 
Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792
369. Bhatt DS, Steg PG, Miller M, Brinton E, Jacobson T, Tardif J-C, et al. Abstract 10627: 
benefits of icosapent ethyl in patients with prior peripheral artery disease: 
REDUCE-IT PAD. Circulation 2021;144:A10627. https://doi.org/10.1161/circ.144. 
suppl_1.10627
370. Kobayashi Y, Fujikawa T, Haruna A, Kawano R, Ozawa M, Haze T, et al. Omega-3 fatty 
acids reduce remnant-like lipoprotein cholesterol and improve the ankle-brachial in­
dex of hemodialysis patients with dyslipidemia: a pilot study. Medicina (Kaunas) 
2024;60:75. https://doi.org/10.3390/medicina60010075
371. Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, et al. Adherence to sta­
tin therapy favours survival of patients with symptomatic peripheral artery disease. Eur 
Heart J Cardiovasc Pharmacother 2021;7:263–70. https://doi.org/10.1093/ehjcvp/ 
pvz081
372. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. 
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in pa­
tients with peripheral artery disease: insights from the FOURIER trial (further cardio­
vascular outcomes research with PCSK9 inhibition in subjects with elevated risk). 
Circulation 2018;137:338–50. https://doi.org/10.1161/circulationaha.117.032235
373. Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al. Effect of evo­
locumab on acute arterial events across all vascular territories: results from the 
FOURIER trial. Eur Heart J 2021;42:4821–9. https://doi.org/10.1093/eurheartj/ 
ehab604
374. Marx N, Federici M, Schutt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
375. Lazzarini PA, Cramb SM, Golledge J, Morton JI, Magliano DJ, Van Netten JJ. Global 
trends in the incidence of hospital admissions for diabetes-related foot disease and am­
putations: a review of national rates in the 21st century. Diabetologia 2023;66:267–87. 
https://doi.org/10.1007/s00125-022-05845-9
376. Armstrong PA. Visceral duplex scanning: evaluation before and after artery interven­
tion for chronic mesenteric ischemia. Perspect Vasc Surg Endovasc Ther 2007;19: 
386–92; discussion 393–384. https://doi.org/10.1177/1531003507311802
377. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116: 
1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849
378. McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al. 
Development and validation of a cardiovascular risk prediction model in type 1 dia­
betes. Diabetologia 2021;64:2001–11. https://doi.org/10.1007/s00125-021-05478-4
ESC Guidelines                                                                                                                                                                                          3671


<!-- PAGE 135 -->

### Page 135

379. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl 
J Med 2017;376:2367–75. https://doi.org/10.1056/NEJMra1615439
380. Malyar NM, Freisinger E, Meyborg M, Lüders F, Gebauer K, Reinecke H, et al. 
Amputations and mortality in in-hospital treated patients with peripheral artery dis­
ease and diabetic foot syndrome. J Diabetes Complications 2016;30:1117–22. https:// 
doi.org/10.1016/j.jdiacomp.2016.03.033
381. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. 
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and 
peripheral artery disease. Diabetes Obes Metab 2022;24:1288–99. https://doi.org/10. 
1111/dom.14700
382. Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. 
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes 
mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. 
Circulation 2018;137:405–7. https://doi.org/10.1161/circulationaha.117.032031
383. American Diabetes Association. Standards of care in diabetes–2023 abridged for pri­
mary care providers. Clin Diabetes 2022;41:4–31. https://doi.org/10.2337/cd23-as01
384. Sattar N, McGuire DK. Prevention of CV outcomes in antihyperglycaemic 
drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start 
or not to start with metformin. Eur Heart J 2021;42:2574–6. https://doi.org/10. 
1093/eurheartj/ehaa879
385. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. 
Canagliflozin for primary and secondary prevention of cardiovascular events: results 
from the CANVAS program (canagliflozin cardiovascular assessment study). 
Circulation 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117. 
032038
386. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. 
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 
2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925
387. Goldenberg RM, Cheng AYY, Fitzpatrick T, Gilbert JD, Verma S, Hopyan JJ. Benefits of 
GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 dia­
betes: a call to action for neurologists. Stroke 2022;53:1813–22. https://doi.org/10. 
1161/STROKEAHA.121.038151
388. Malhotra K, Katsanos AH, Lambadiari V, Goyal N, Palaiodimou L, Kosmidou M, et al. 
GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and 
meta-analysis. J Neurol 2020;267:2117–22. https://doi.org/10.1007/s00415-020- 
09813-4
389. Tsai WH, Chuang SM, Liu SC, Lee C-C, Chien M-N, Leung C-H, et al. Effects of 
SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a sys­
tematic review and meta-analysis. Sci Rep 2021;11:15364. https://doi.org/10.1038/ 
s41598-021-94945-4
390. Effect of intensive blood-glucose control with metformin on complications in over­
weight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study 
(UKPDS) Group. Lancet 1998;352:854–65 .
391. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJM, et al. Long-term ef­
fects of metformin on metabolism and microvascular and macrovascular disease in pa­
tients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616–25. https://doi.org/ 
10.1001/archinternmed.2009.20
392. Tan S, Goudot G, Arnoux A, Tran Y, Maissoro H, Poenou G, et al. Occurrence of ma­
jor local lower limb events in type 2 diabetic patients with lower extremity arterial dis­
ease: impact of metformin. Ann Vasc Surg 2023;90:153–61. https://doi.org/10.1016/j. 
avsg.2022.09.064
393. Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, et al. Similar car­
diovascular outcomes in patients with diabetes and established or high risk for coron­
ary vascular disease treated with dulaglutide with and without baseline metformin. Eur 
Heart J 2021;42:2565–73. https://doi.org/10.1093/eurheartj/ehaa777
394. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects 
of intensive glucose control on microvascular outcomes in patients with type 2 dia­
betes: a meta-analysis of individual participant data from randomised controlled trials. 
Lancet Diabetes Endocrinol 2017;5:431–7. https://doi.org/10.1016/S2213-8587(17) 
30104-3
395. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood 
glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J 
Med 2008;358:2560–72. https://doi.org/10.1056/NEJMoa0802987
396. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complica­
tions in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. https:// 
doi.org/10.1016/S0140-6736(98)07019-6
397. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, 
Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes 
on the development and progression of long-term complications in insulin-dependent 
diabetes mellitus. N Engl J Med 1993;329:977–86. https://doi.org/10.1056/ 
NEJM199309303291401
398. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. 
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients 
with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–58. https://doi.org/10. 
1001/jamacardio.2020.4511
399. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in 
patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384: 
117–28. https://doi.org/10.1056/NEJMoa2030183
400. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in 
patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129–39. 
https://doi.org/10.1056/NEJMoa2030186
401. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi. 
org/10.1056/NEJMoa1812389
402. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 
2117–28. https://doi.org/10.1056/NEJMoa1504720
403. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa­
tients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. 
Lancet Diabetes Endocrinol 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21) 
00203-5
404. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, 
et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N 
Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269
405. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. 
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double- 
blind, randomised placebo-controlled trial. Lancet 2019;394:121–30. https://doi.org/ 
10.1016/S0140-6736(19)31149-3
406. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. 
Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 
311–22. https://doi.org/10.1056/NEJMoa1603827
407. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide 
and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 
375:1834–44. https://doi.org/10.1056/NEJMoa1607141
408. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and 
mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes 
Endocrinol 2019;7:385–96. https://doi.org/10.1016/S2213-8587(18)30315-2
409. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of 
HbA1c levels with vascular complications and death in patients with type 2 diabetes: 
evidence of glycaemic thresholds. Diabetologia 2012;55:636–43. https://doi.org/10. 
1007/s00125-011-2404-1
410. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function 
of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 
375:481–9. https://doi.org/10.1016/S0140-6736(09)61969-3
411. Control G, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. 
Intensive glucose control and macrovascular outcomes in type 2 diabetes. 
Diabetologia 2009;52:2288–98. https://doi.org/10.1007/s00125-009-1470-0
412. Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al. Does a 
strict glycemic control during acute coronary syndrome play a cardioprotective effect? 
Pathophysiology and clinical evidence. Diabetes Res Clin Pract 2021;178:108959. 
https://doi.org/10.1016/j.diabres.2021.108959
413. Soehnlein O, Libby P. Targeting inflammation in atherosclerosis—from experimental 
insights to the clinic. Nat Rev Drug Discov 2021;20:589–610. https://doi.org/10.1038/ 
s41573-021-00198-1
414. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. 
Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J 
Med 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914
415. Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé M-P, Blondeau L, et al. 
Colchicine for secondary prevention of cardiovascular disease: a systematic review 
and meta-analysis of randomized controlled trials. Can J Cardiol 2021;37:776–85. 
https://doi.org/10.1016/j.cjca.2020.10.006
416. Antonopoulos AS, Papanikolaou E, Vogiatzi G, Oikonomou E, Tousoulis D. 
Anti-inflammatory agents in peripheral arterial disease. Curr Opin Pharmacol 2018; 
39:1–8. https://doi.org/10.1016/j.coph.2017.11.001
417. Mills JL, Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. 
The Society for Vascular Surgery lower extremity threatened limb classification sys­
tem: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc 
Surg 2014;59:220–34.e1–2. https://doi.org/10.1016/j.jvs.2013.08.003
418. Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UKA, Criqui MH, 
Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol 
2017;14:156–70. https://doi.org/10.1038/nrcardio.2016.179
419. Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and 
vascular morbidity in older adults with asymptomatic versus symptomatic peripheral 
artery disease. Circulation 2009;120:2053–61. https://doi.org/10.1161/circulationaha. 
109.865600
420. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg 
symptoms in peripheral arterial disease: associated clinical characteristics and function­
al impairment. JAMA 2001;286:1599–606. https://doi.org/10.1001/jama.286.13.1599
421. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, 
et al. A population-based study of peripheral arterial disease prevalence with special


<!-- PAGE 136 -->

### Page 136

focus on critical limb ischemia and sex differences. J Vasc Surg 2007;45:1185–91. 
https://doi.org/10.1016/j.jvs.2007.02.004
422. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, et al. 
Inter-society consensus for the management of peripheral arterial disease (TASC II). 
Eur J Vasc Endovasc Surg 2007;33:S1–75. https://doi.org/10.1016/j.ejvs.2006.09.024
423. Buso G, Aboyans V, Mazzolai L. Lower extremity artery disease in patients with type 2 
diabetes. Eur J Prev Cardiol 2019;26:114–24. https://doi.org/10.1177/20474873198 
80044
424. Porras CP, Bots ML, Teraa M, van Doorn S, Vernooij RWM. Differences in symptom 
presentation in women and men with confirmed lower limb peripheral artery disease: 
a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2022;63:602–12. 
https://doi.org/10.1016/j.ejvs.2021.12.039
425. Fereydooni A, Gorecka J, Dardik A. Using the epidemiology of critical limb ischemia to 
estimate the number of patients amenable to endovascular therapy. Vasc Med 2020; 
25:78–87. https://doi.org/10.1177/1358863X19878271
426. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular 
guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc 
Endovasc Surg 2019;58:S1–109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006
427. Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial 
disease is higher than expected: a meta-analysis of mortality and disease progression in 
peripheral arterial disease. Eur J Vasc Endovasc Surg 2016;51:395–403. https://doi.org/ 
10.1016/j.ejvs.2015.10.022
428. Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, Westerink J, Asselbergs FW, 
et al. Cardiovascular risk factors and the risk of major adverse limb events in patients 
with symptomatic cardiovascular disease. Heart 2020;106:1686–92. https://doi.org/10. 
1136/heartjnl-2019-316088
429. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb 
events and mortality in patients with peripheral artery disease: the COMPASS trial. 
J Am Coll Cardiol 2018;71:2306–15. https://doi.org/10.1016/j.jacc.2018.03.008
430. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. 
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 
2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118
431. Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality 
associated with atherosclerotic peripheral artery disease: a systematic review. 
Atherosclerosis 2020;293:94–100. https://doi.org/10.1016/j.atherosclerosis.2019. 
09.012
432. Wijnand JGJ, van Koeverden ID, Teraa M, Spreen MI, Mali WPTM, van Overhagen H, 
et al. Validation of randomized controlled trial-derived models for the prediction of 
postintervention outcomes in chronic limb-threatening ischemia. J Vasc Surg 2020; 
71:869–79. https://doi.org/10.1016/j.jvs.2019.06.195
433. Jaramillo EA, Smith EJT, Matthay ZA, Sanders KM, Hiramoto JS, Gasper WJ, et al. Racial 
and ethnic disparities in major adverse limb events persist for chronic limb threatening 
ischemia despite presenting limb threat severity after peripheral vascular intervention. 
J Vasc Surg 2023;77:848–57.e2. https://doi.org/10.1016/j.jvs.2022.10.043
434. Brizuela Sanz JA, Gonzalez Fajardo JA, Taylor JH, Río Solá L, Muñoz Moreno MF, 
Vaquero Puerta C, et al. Design of a new risk score in critical limb ischaemia: the 
ERICVA model. Eur J Vasc Endovasc Surg 2016;51:90–9. https://doi.org/10.1016/j.ejvs. 
2015.09.025
435. Kreutzburg T, Peters F, Kuchenbecker J, Marschall U, Lee R, Kriston L, et al. Editor’s 
choice—the GermanVasc score: a pragmatic risk score predicts five year amputation 
free survival in patients with peripheral arterial occlusive disease. Eur J Vasc Endovasc 
Surg 2021;61:248–56. https://doi.org/10.1016/j.ejvs.2020.11.013
436. Niazi K, Khan TH, Easley KA. Diagnostic utility of the two methods of ankle brachial 
index in the detection of peripheral arterial disease of lower extremities. Catheter 
Cardiovasc Interv 2006;68:788–92. https://doi.org/10.1002/ccd.20906
437. Crawford F, Welch K, Andras A, Chappell FM. Ankle brachial index for the diagnosis of 
lower limb peripheral arterial disease. Cochrane Database Syst Rev 2016;9:CD010680. 
https://doi.org/10.1002/14651858.CD010680.pub2
438. Aday AW, Kinlay S, Gerhard-Herman MD. Comparison of different exercise ankle 
pressure indices in the diagnosis of peripheral artery disease. Vasc Med 2018;23: 
541–8. https://doi.org/10.1177/1358863X18781723
439. Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexer­
cise ankle-brachial index for detecting peripheral artery disease in suspected claudi­
cants with and without diabetes. Vasc Med 2018;23:116–25. https://doi.org/10.1177/ 
1358863X17751259
440. Manu CA, Freedman B, Rashid H, Winkley K, Edmonds ME. Peripheral arterial disease 
located in the feet of patients with diabetes and foot ulceration demands a new ap­
proach to the assessment of ischemia. Int J Low Extrem Wounds 2022;21:397–404. 
https://doi.org/10.1177/1534734620947979
441. Salaun P, Desormais I, Lapébie FX, Rivière AB, Aboyans V, Lacroix P, et al. Comparison 
of ankle pressure, systolic toe pressure, and transcutaneous oxygen pressure to pre­
dict major amputation after 1 year in the copart cohort. Angiology 2019;70:229–36. 
https://doi.org/10.1177/0003319718793566
442. Fowkes FG, Murray GD, Butcher I, Folsom AR, Hirsch AT, Couper DJ, et al. 
Development and validation of an ankle brachial index risk model for the prediction 
of cardiovascular events. Eur J Prev Cardiol 2014;21:310–20. https://doi.org/10.1177/ 
2047487313516564
443. Wang FM, Yang C, Ballew SH, Kalbaugh CA, Meyer ML, Tanaka H, et al. Ankle-brachial 
index and subsequent risk of incident and recurrent cardiovascular events in older 
adults: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021; 
336:39–47. https://doi.org/10.1016/j.atherosclerosis.2021.09.028
444. Cull DL, Manos G, Hartley MC, Taylor SM, Langan EM, Eidt JF, et al. An early validation 
of the Society for Vascular Surgery lower extremity threatened limb classification sys­
tem. J Vasc Surg 2014;60:1535–42. https://doi.org/10.1016/j.jvs.2014.08.107
445. Liette MD, Crisologo PA, Masadeh S, Yang SH, Bergmann CB, Caldwell CC, et al. A 
prospective analysis of the SVS WIfI classification system to stratify immediate and 
1-year patient outcomes. J Foot Ankle Surg 2023;62:661–5. https://doi.org/10.1053/j. 
jfas.2023.02.003
446. van Reijen NS, Ponchant K, Ubbink DT, Koelemay MJW. Editor’s choice—the prog­
nostic value of the WIfI classification in patients with chronic limb threatening ischae­
mia: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2019;58:362–71. 
https://doi.org/10.1016/j.ejvs.2019.03.040
447. Eiberg JP, Gronvall Rasmussen JB, Hansen MA, Schroeder TV. Duplex ultrasound scan­
ning of peripheral arterial disease of the lower limb. Eur J Vasc Endovasc Surg 2010;40: 
507–12. https://doi.org/10.1016/j.ejvs.2010.06.002
448. Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJ. Diagnostic performance of 
computed tomography angiography in peripheral arterial disease: a systematic review 
and meta-analysis. JAMA 2009;301:415–24. https://doi.org/10.1001/jama.301.4.415
449. Itoga NK, Kim T, Sailer AM, Fleischmann D, Mell MW. Lower extremity computed 
tomography angiography can help predict technical success of endovascular revascu­
larization in the superficial femoral and popliteal artery. J Vasc Surg 2017;66:835–43.e1. 
https://doi.org/10.1016/j.jvs.2017.02.031
450. Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in in­
dividuals with peripheral arterial disease: NHANES 1999–2004. Atherosclerosis 2008; 
201:425–33. https://doi.org/10.1016/j.atherosclerosis.2008.02.002
451. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality 
in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 
2004. Circulation 2011;124:17–23. https://doi.org/10.1161/circulationaha.110.003954
452. Krishnamurthy V, Munir K, Rectenwald JE, Mansour A, Hans S, Eliason JL, et al. 
Contemporary outcomes with percutaneous vascular interventions for peripheral 
critical limb ischemia in those with and without poly-vascular disease. Vasc Med 
2014;19:491–9. https://doi.org/10.1177/1358863x14552013
453. Penin-Grandes S, Lopez-Ortiz S, Maroto-Izquierdo S, Menéndez H, Pinto-Fraga J, 
Martín-Hernández J, et al. Winners do what they fear: exercise and peripheral arterial 
disease–an umbrella review. Eur J Prev Cardiol 2024;31:380–388. https://doi.org/10. 
1093/eurjpc/zwad261
454. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of 
claudication pain. A meta-analysis. JAMA 1995;274:975–80.
455. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized 
controlled trials: walking versus alternative exercise prescription as treatment for 
intermittent claudication. Atherosclerosis 2011;218:1–12. https://doi.org/10.1016/j. 
atherosclerosis.2011.04.024
456. Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MGGM, Rouwet EV, 
et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg 
2012;56:1132–42. https://doi.org/10.1016/j.jvs.2012.04.046
457. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral 
arterial disease: a systematic review and meta-analysis. Sports Med 2015;45:231–44. 
https://doi.org/10.1007/s40279-014-0261-z
458. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. 
Cochrane Database Syst Rev 2017;12:CD000990. https://doi.org/10.1002/14651858. 
CD000990.pub4
459. Parmenter BJ, Mavros Y, Ritti Dias R, King S, Fiatarone Singh M. Resistance training as a 
treatment for older persons with peripheral artery disease: a systematic review and 
meta-analysis. Br J Sports Med 2020;54:452–61. https://doi.org/10.1136/bjsports- 
2018-100205
460. Perks J, Zaccardi F, Paterson C, Houghton JSM, Nickinson ATO, Pepper CJ, et al. Effect 
of high-pain versus low-pain structured exercise on walking ability in people with inter­
mittent claudication: meta-analysis. Br J Surg 2022;109:686–94. https://doi.org/10. 
1093/bjs/znac134
461. Guidon M, McGee H. Exercise-based interventions and health-related quality of life in 
intermittent claudication: a 20-year (1989–2008) review. Eur J Cardiovasc Prev Rehabil 
2010;17:140–54. https://doi.org/10.1097/HJR.0b013e3283377f08
462. Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related 
quality of life in peripheral artery disease: a systematic review and meta-analysis. 
Vasc Med 2015;20:30–40. https://doi.org/10.1177/1358863x14559092
463. Gommans LN, Fokkenrood HJ, van Dalen HC, Scheltinga MRM, Teijink JAW, Peters 
RJG. Safety of supervised exercise therapy in patients with intermittent claudication. 
J Vasc Surg 2015;61:512–8.e2. https://doi.org/10.1016/j.jvs.2014.08.070
464. Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exer­
cise services in patients with peripheral artery disease in the United Kingdom. Vascular 
2022;30:874–81. https://doi.org/10.1177/17085381211035259
ESC Guidelines                                                                                                                                                                                          3673


<!-- PAGE 137 -->

### Page 137

465. Lanzi S, Belch J, Brodmann M, Madaric J, Bura-Riviere A, Visonà A, et al. Supervised ex­
ercise training in patients with lower extremity peripheral artery disease. Vasa 2022; 
51:267–74. https://doi.org/10.1024/0301-1526/a001024
466. Gommans LN, Saarloos R, Scheltinga MR, Houterman S, de Bie RA, Fokkenrood HJP, 
et al. Editor’s choice—the effect of supervision on walking distance in patients with 
intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 2014;48:169–84. 
https://doi.org/10.1016/j.ejvs.2014.04.019
467. Vemulapalli S, Dolor RJ, Hasselblad V, Schmit K, Banks A, Heidenfelder B, et al. 
Supervised vs unsupervised exercise for intermittent claudication: a systematic re­
view and meta-analysis. Am Heart J 2015;169:924–37.e3. https://doi.org/10.1016/j. 
ahj.2015.03.009
468. Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. 
Supervised exercise therapy versus home-based exercise therapy versus walking ad­
vice for intermittent claudication. Cochrane Database Syst Rev 2018;4:CD005263. 
https://doi.org/10.1002/14651858.CD005263.pub4
469. Pymer S, Ibeggazene S, Palmer J, Tew GA, Ingle L, Smith GE, et al. An updated system­
atic review and meta-analysis of home-based exercise programs for individuals with 
intermittent claudication. J Vasc Surg 2021;74:2076–85.e20. https://doi.org/10.1016/j. 
jvs.2021.03.063
470. Waddell A, Seed S, Broom DR, McGregor G, Birkett ST, Harwood AE. Safety of home- 
based exercise for people with intermittent claudication: a systematic review. Vasc 
Med 2022;27:186–92. https://doi.org/10.1177/1358863x211060388
471. Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, Moxon JV, et al. Meta-analysis of 
clinical trials examining the benefit of structured home exercise in patients with per­
ipheral artery disease. Br J Surg 2019;106:319–31. https://doi.org/10.1002/bjs.11101
472. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. 
Sports Med 2004;34:983–1003. https://doi.org/10.2165/00007256-200434140-00004
473. Ehrman JK, Gardner AW, Salisbury D, Lui K, Treat-Jacobson D. Supervised exercise 
therapy for symptomatic peripheral artery disease: a review of current experience 
and practice-based recommendations. J Cardiopulm Rehabil Prev 2023;43:15–21. 
https://doi.org/10.1097/hcr.0000000000000723
474. McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, et al. 
Effect of low-intensity vs high-intensity home-based walking exercise on walk distance 
in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA 2021; 
325:1266–76. https://doi.org/10.1001/jama.2021.2536
475. Jansen SC, Abaraogu UO, Lauret GJ, Fakhry F, Fokkenrood HJP, Teijink JAW. Modes of 
exercise training for intermittent claudication. Cochrane Database Syst Rev 2020;8: 
CD009638. https://doi.org/10.1002/14651858.CD009638.pub3
476. Gardner AW, Parker DE, Montgomery PS, Blevins SM. Diabetic women are poor re­
sponders to exercise rehabilitation in the treatment of claudication. J Vasc Surg 2014; 
59:1036–43. https://doi.org/10.1016/j.jvs.2013.10.058
477. Gommans LN, Scheltinga MR, van Sambeek MR, Maas AHEM, Bendermacher BLW, 
Teijink JAW. Gender differences following supervised exercise therapy in patients 
with intermittent claudication. J Vasc Surg 2015;62:681–8. https://doi.org/10.1016/j. 
jvs.2015.03.076
478. Dipnarine K, Barak S, Martinez CA, Carmeli E, Stopka CB. Pain-free treadmill exercise 
for patients with intermittent claudication: are there gender differences? Vascular 2016; 
24:304–14. https://doi.org/10.1177/1708538115592800
479. Gardner AW, Parker DE, Montgomery PS. Sex-specific predictors of improved walk­
ing with step-monitored, home-based exercise in peripheral artery disease. Vasc Med 
2015;20:424–31. https://doi.org/10.1177/1358863x15596237
480. Ney B, Lanzi S, Calanca L, Mazzolai L. Multimodal supervised exercise training is effect­
ive in improving long term walking performance in patients with symptomatic lower 
extremity peripheral artery disease. J Clin Med 2021;10:2057.https://doi.org/10.3390/ 
jcm10102057
481. Lanzi S, Pousaz A, Calanca L, Mazzolai L. Sex-based differences in supervised exercise 
therapy outcomes for symptomatic peripheral artery disease. Vasc Med 2023;28: 
147–9. https://doi.org/10.1177/1358863x221149454
482. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. 
Endovascular revascularization and supervised exercise for peripheral artery disease 
and intermittent claudication: a randomized clinical trial. JAMA 2015;314:1936–44. 
https://doi.org/10.1001/jama.2015.14851
483. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, et al. Comparative efficacy 
of endovascular revascularization versus supervised exercise training in patients with 
intermittent claudication: meta-analysis of randomized controlled trials. JACC 
Cardiovasc Interv 2017;10:712–24. https://doi.org/10.1016/j.jcin.2017.01.027
484. Dorn A, Dorweiler B, Ahmad W, Mylonas S, Becker I, Majd P. Low and high 
ankle-brachial index are both associated with mortality in German nursing home resi­
dents–the five-year follow-up of the ‘allo-study’ Cohort. J Clin Med 2023;12:4411. 
https://doi.org/10.3390/jcm12134411
485. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for pre­
vention of cardiovascular events in a general population screened for a low ankle bra­
chial index: a randomized controlled trial. JAMA 2010;303:841–8. https://doi.org/10. 
1001/jama.2010.221
486. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of 
progression of arterial disease and diabetes (POPADAD) trial: factorial randomised 
placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymp­
tomatic peripheral arterial disease. BMJ 2008;337:a1840. https://doi.org/10.1136/bmj. 
a1840
487. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of 
aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 
379:1529–39. https://doi.org/10.1056/NEJMoa1804988
488. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. BMJ 2002;324:71–86. https://doi.org/10.1136/bmj.324.7329.71
489. De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C. Efficacy and 
safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic 
review and network meta-analysis. Curr Vasc Pharmacol 2021;19:542–55. https://doi. 
org/10.2174/1570161118666200820141131
490. Willems LH, Maas D, Kramers K, Reijnen MMPJ, Riksen NP, Ten Cate H, et al. 
Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic re­
view and network meta-analysis. Drugs 2022;82:1287–302. https://doi.org/10.1007/ 
s40265-022-01756-6
491. Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, 
et al. Comparative efficacy and safety of different antiplatelet agents for prevention 
of major cardiovascular events and leg amputations in patients with peripheral arterial 
disease: a systematic review and network meta-analysis. PLoS One 2015;10:e0135692. 
https://doi.org/10.1371/journal.pone.0135692
492. Basili S, Raparelli V, Vestri A, Di Tanna GL, Violi F. Comparison of efficacy of antiplate­
let treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010; 
103:766–73. https://doi.org/10.1160/th09-09-0635
493. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin 
in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 
1996;348:1329–39. https://doi.org/10.1016/s0140-6736(96)09457-3
494. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovas­
cular events in patients with peripheral artery disease: a meta-analysis of randomized 
trials. JAMA 2009;301:1909–19. https://doi.org/10.1001/jama.2009.623
495. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, et al. Ticagrelor ver­
sus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376: 
32–40. https://doi.org/10.1056/NEJMoa1611688
496. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and 
aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J 
Med 2006;354:1706–17. https://doi.org/10.1056/NEJMoa060989
497. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with 
prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the 
CHARISMA trial. J Am Coll Cardiol 2007;49:1982–8. https://doi.org/10.1016/j.jacc. 
2007.03.025
498. Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. 
Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral ar­
tery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 
2021;6:21–9. https://doi.org/10.1001/jamacardio.2020.4390
499. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban 
with or without aspirin in patients with stable peripheral or carotid artery disease: an 
international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391: 
219–29. https://doi.org/10.1016/s0140-6736(17)32409-1
500. Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et al. Twelve-month 
results of a randomized trial comparing mono with dual antiplatelet therapy in endo­
vascularly treated patients with peripheral artery disease. J Endovasc Ther 2013;20: 
699–706. https://doi.org/10.1583/13-4275mr.1
501. Tsai SY, Li YS, Lee CH, Cha S-W, Wang Y-C, Su T-W, et al. Mono or dual antiplatelet 
therapy for treating patients with peripheral artery disease after lower extremity re­
vascularization: a systematic review and meta-analysis. Pharmaceuticals (Basel) 2022; 
15:596. https://doi.org/10.3390/ph15050596
502. Thott O, Granath F, Malmstedt J, Wahlgren CM. Editor’s choice—dual antiplatelet 
therapy improves outcome in diabetic patients undergoing endovascular femoropopli­
teal stenting for critical limb ischaemia. Eur J Vasc Endovasc Surg 2017;53:403–10. 
https://doi.org/10.1016/j.ejvs.2016.12.014
503. Cho S, Lee YJ, Ko YG, Kang TS, Lim S-H, Hong S-J, et al. Optimal strategy for antiplate­
let therapy after endovascular revascularization for lower extremity peripheral artery 
disease. JACC Cardiovasc Interv 2019;12:2359–70. https://doi.org/10.1016/j.jcin.2019.08. 
006
504. Ipema J, Welling RHA, Bakker OJ, Bokkers RPH, de Vries J-PPM, Ünlü Ç. Short-term 
clinical outcomes of single versus dual antiplatelet therapy after infrainguinal endovas­
cular treatment for peripheral arterial disease. J Clin Med 2020;9:3515. https://doi.org/ 
10.3390/jcm9113515
505. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. 
Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 
382:1994–2004. https://doi.org/10.1056/NEJMoa2000052
506. Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al. Rivaroxaban 
and aspirin in peripheral artery disease lower extremity revascularization: impact of 
concomitant clopidogrel on efficacy and safety. Circulation 2020;142:2219–30. 
https://doi.org/10.1161/circulationaha.120.050465


<!-- PAGE 138 -->

### Page 138

507. Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a 
review of recent literature. Vasc Health Risk Manag 2019;15:187–208. https://doi.org/ 
10.2147/VHRM.S209241
508. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin im­
proves the outcome of infrainguinal vein bypass grafting at high risk for failure. 
J Vasc Surg 1998;28:446–57. https://doi.org/10.1016/s0741-5214(98)70130-2
509. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery 
(the Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet 
2000;355:346–51. https://doi.org/10.1016/S0140-6736(99)07199-8
510. Belch JJ, Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al. Results of the 
randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery 
for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825–33.e2. 
https://doi.org/10.1016/j.jvs.2010.04.027
511. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL, et al. 
The relative importance of graft surveillance and warfarin therapy in infrainguinal pros­
thetic bypass failure. J Vasc Surg 2007;46:1160–6. https://doi.org/10.1016/j.jvs.2007.07. 
046
512. Van Gelder IC, Kotecha D, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, et al. 
https://doi.org/10.1093/eurheartj/ehae176
513. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet 
responsiveness to clopidogrel treatment after peripheral endovascular procedures: 
the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high 
platelet reactivity. J Am Coll Cardiol 2013;61:2428–34. https://doi.org/10.1016/j.jacc. 
2013.03.036
514. Busch L, Stern M, Dannenberg L, Mourikis P, Gröne M, Özaslan G, et al. Impact of high 
on-treatment platelet reactivity after angioplasty in patients with peripheral arterial 
disease. Platelets 2021;32:391–7. https://doi.org/10.1080/09537104.2020.1742314
515. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin 
and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 
2014;5:CD001999. https://doi.org/10.1002/14651858.CD001999.pub2
516. Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS. Effect of verapamil in inter­
mittent claudication. A randomized, double-blind, placebo-controlled, cross-over 
study after individual dose-response assessment. Circulation 1997;95:411–4. https:// 
doi.org/10.1161/01.cir.95.2.411
517. Gargiulo G, Giugliano G, Brevetti L, Sannino A, Schiattarella GG, Serino F, et al. Use of 
statins in lower extremity artery disease: a review. BMC Surg 2012;12:S15. https://doi. 
org/10.1186/1471-2482-12-s1-s15
518. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin 
use and leg functioning in patients with and without lower-extremity peripheral arter­
ial disease. Circulation 2003;107:757–61. https://doi.org/10.1161/01.cir.0000050380. 
64025.07
519. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database 
Syst Rev 2013;4:CD000986. https://doi.org/10.1002/14651858.CD000986.pub3
520. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic re­
view of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treat­
ment of intermittent claudication. Br J Surg 2012;99:1630–8. https://doi.org/10.1002/ 
bjs.8895
521. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for 
intermittent claudication. Cochrane Database Syst Rev 2014;10:CD003748. https://doi. 
org/10.1002/14651858.CD003748.pub4
522. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with periph­
eral artery disease: the CASTLE study (cilostazol: a study in long-term effects). J Vasc 
Surg 2008;47:330–6. https://doi.org/10.1016/j.jvs.2007.10.009
523. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al. Cilostazol reduces angio­
graphic restenosis after endovascular therapy for femoropopliteal lesions in the suffi­
cient treatment of peripheral intervention by cilostazol study. Circulation 2013;127: 
2307–15. https://doi.org/10.1161/circulationaha.112.000711
524. de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent 
claudication. Cochrane Database Syst Rev 2012;12:Cd001368. https://doi.org/10.1002/ 
14651858.CD001368.pub4
525. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking dis­
tance in patients with intermittent claudication. Ann Cardiol Angeiol 2001;50:175–82. 
https://doi.org/10.1016/s0003-3928(01)00016-6
526. Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent clau­
dication. Cochrane Database Syst Rev 2020;10:Cd005262. https://doi.org/10.1002/ 
14651858.CD005262.pub4
527. Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Stokmans RA, Broos PPHL, 
et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2013; 
6:Cd006888. https://doi.org/10.1002/14651858.CD006888.pub3
528. Premaratne S, Newman J, Hobbs S, Garnham A, Wall M. Meta-analysis of direct sur­
gical versus endovascular revascularization for aortoiliac occlusive disease. J Vasc Surg 
2020;72:726–37. https://doi.org/10.1016/j.jvs.2019.12.035
529. Aboyans V, Björck M, Brodmann M, Collet J-P, Czerny M, De Carlo M, et al. Questions 
and answers on diagnosis and management of patients with peripheral arterial dis­
eases: a companion document of the 2017 ESC Guidelines for the diagnosis and 
treatment of peripheral arterial diseases, in collaboration with the European Society 
for Vascular Surgery (ESVS): Endorsed by: the European Stroke Organisation (ESO), 
The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of 
the European Society of Cardiology (ESC) and of the European Society for Vascular 
Surgery (ESVS). Eur Heart J 2018;39:e35–41. https://doi.org/10.1093/eurheartj/ehx499
530. McQuade K, Gable D, Pearl G, Theune B, Black S. Four-year randomized prospective 
comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic 
femoral-popliteal bypass in the treatment of superficial femoral artery occlusive dis­
ease. J Vasc Surg 2010;52:584–91.e7. https://doi.org/10.1016/j.jvs.2010.03.071
531. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, et al. Results of the 
Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal 
lesions. J Vasc Surg 2011;54:1042–50. https://doi.org/10.1016/j.jvs.2011.03.272
532. Farhan S, Enzmann FK, Bjorkman P, Kamran H, Zhang Z, Sartori S, et al. 
Revascularization strategies for patients with femoropopliteal peripheral artery dis­
ease. J Am Coll Cardiol 2023;81:358–70. https://doi.org/10.1016/j.jacc.2022.10.036
533. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death follow­
ing application of paclitaxel-coated balloons and stents in the femoropopliteal artery of 
the leg: a systematic review and meta-analysis of randomized controlled trials. J Am 
Heart Assoc 2018;7:e011245. https://doi.org/10.1161/jaha.118.011245
534. Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Peña C, et al. Safety of 
paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. 
JACC Cardiovasc Interv 2019;12:2515–24. https://doi.org/10.1016/j.jcin.2019.08.025
535. Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, et al. Mortality 
after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. 
Eur Heart J 2020;41:3732–9. https://doi.org/10.1093/eurheartj/ehz698
536. Lyden SP, Brodmann M, Parikh SA, Krishnan P, Schroeder H, Werner M, et al. 
Four-year patient-level pooled mortality analysis of the ILLUMENATE US pivotal 
and EU randomized controlled trials. J Vasc Surg 2022;75:600–7. https://doi.org/10. 
1016/j.jvs.2021.07.244
537. Secemsky EA, Song Y, Schermerhorn M, Yeh RW. Update from the longitudinal as­
sessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated 
devices among medicare beneficiaries: the SAFE-PAD study. Circ Cardiovasc Interv 
2022;15:e012074. https://doi.org/10.1161/circinterventions.122.012074
538. Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, et al. 
Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med 
2020;383:2538–46. https://doi.org/10.1056/NEJMoa2005206
539. Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR, Robinson WP. Major 
adverse limb events and major adverse cardiac events after contemporary lower ex­
tremity bypass and infrainguinal endovascular intervention in patients with claudica­
tion. J Vasc Surg 2018;68:1817–23. https://doi.org/10.1016/j.jvs.2018.06.193
540. Koelemay MJW, van Reijen NS, van Dieren S, Frans FA, Vermeulen EJG, Buscher HCJL, 
et al. Editor’s choice—randomised clinical trial of supervised exercise therapy vs. en­
dovascular revascularisation for intermittent claudication caused by iliac artery ob­
struction: the SUPER study. Eur J Vasc Endovasc Surg 2022;63:421–9. https://doi.org/ 
10.1016/j.ejvs.2021.09.042
541. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, et al. Fate of the 
patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989;30: 
50–7.
542. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. 
Fate in intermittent claudication: outcome and risk factors. BMJ 1986;293:1137–40. 
https://doi.org/10.1136/bmj.293.6555.1137
543. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, nat­
ural history and cardiovascular events in symptomatic and asymptomatic peripheral 
arterial disease in the general population. Int J Epidemiol 1996;25:1172–81. https:// 
doi.org/10.1093/ije/25.6.1172
544. Bloor K. Natural history of arteriosclerosis of the lower extremities: Hunterian lecture 
delivered at the Royal College of Surgeons of England on 22nd April 1960. Ann R Coll 
Surg Engl 1961;28:36–52.
545. Goode SD, Cleveland TJ, Gaines PA, Collaborators S. Randomized clinical trial of 
stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br 
J Surg 2013;100:1148–53. https://doi.org/10.1002/bjs.9197
546. Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Covered vs uncov­
ered stents for aortoiliac and femoropopliteal arterial disease: a systematic review and 
meta-analysis. 
J 
Endovasc 
Ther 
2016;23:442–52. 
https://doi.org/10.1177/ 
1526602816643834
547. Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, et al. 
Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: 
the randomized ICE trial. JACC Cardiovasc Interv 2017;10:1694–704. https://doi.org/ 
10.1016/j.jcin.2017.05.015
548. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angio­
plasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204:87–96. 
https://doi.org/10.1148/radiology.204.1.9205227
549. Committee TS, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, et al. An update 
on methods for revascularization and expansion of the TASC lesion classification to 
include below-the-knee arteries: a supplement to the inter-society consensus for 
ESC Guidelines                                                                                                                                                                                          3675


<!-- PAGE 139 -->

### Page 139

the management of peripheral arterial disease (TASC II). J Endovasc Ther 2015;22: 
663–77. https://doi.org/10.1177/1526602815592206
550. Boc V, Kozak M, Erzen B, Božič Mijovski M, Boc A, Blinc A. Prognostic factors for re­
stenosis of superficial femoral artery after endovascular treatment. J Clin Med 2023;12: 
6343. https://doi.org/10.3390/jcm12196343
551. Alves-Cabratosa L, Comas-Cufi M, Ponjoan A, Garcia-Gil M, Martí-Lluch R, Blanch J, 
et al. Levels of ankle-brachial index and the risk of diabetes mellitus complications. 
BMJ Open Diabetes Res Care 2020;8:e000977. https://doi.org/10.1136/bmjdrc-2019- 
000977
552. Heiss C, Olinic DM, Belch JJF, Brodmann M, Mazzolai L, Stanek A, et al. Management of 
chronic peripheral artery disease patients with indication for endovascular revascular­
ization. Vasa 2022;51:121–37. https://doi.org/10.1024/0301-1526/a000998
553. Hajibandeh S, Hajibandeh S, Shah S, Child E, Antoniou GA, Torella F. Prognostic sig­
nificance of ankle brachial pressure index: a systematic review and meta-analysis. 
Vascular 2017;25:208–24. https://doi.org/10.1177/1708538116658392
554. Meza-Torres B, Cunningham SG, Heiss C, Joy M, Feher M, Leese GP, et al. Adherence 
to general diabetes and foot care processes, with prompt referral, are associated with 
amputation-free survival in people with type 2 diabetes and foot ulcers: a Scottish na­
tional registry analysis. J Diabetes Res 2022;2022:7414258. https://doi.org/10.1155/ 
2022/7414258
555. Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein R, Rosenfield K, et al. 
Critical limb ischemia: an expert statement. J Am Coll Cardiol 2016;68:2002–15. 
https://doi.org/10.1016/j.jacc.2016.04.071
556. Misra S, Shishehbor MH, Takahashi EA, Aronow HD, Brewster LP, Bunte MC, et al. 
Perfusion assessment in critical limb ischemia: principles for understanding and the de­
velopment of evidence and evaluation of devices: a scientific statement from the 
American Heart Association. Circulation 2019;140:e657–72. https://doi.org/10.1161/ 
cir.0000000000000708
557. Sukul D, Grey SF, Henke PK, Gurm HS, Grossman PM. Heterogeneity of ankle-brachial 
indices in patients undergoing revascularization for critical limb ischemia. JACC 
Cardiovasc Interv 2017;10:2307–16. https://doi.org/10.1016/j.jcin.2017.08.026
558. Shishehbor MH, Hammad TA, Zeller T, Baumgartner I, Scheinert D, Rocha-Singh KJ. 
An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guide­
lines–recommended hemodynamic parameters to diagnose critical limb ischemia. 
J Vasc Surg 2016;63:1311–7. https://doi.org/10.1016/j.jvs.2015.11.042
559. Randhawa MS, Reed GW, Grafmiller K, Gornik HL, Shishehbor MH. Prevalence of tib­
ial artery and pedal arch patency by angiography in patients with critical limb ischemia 
and noncompressible ankle brachial index. Circ Cardiovasc Interv 2017;10:e004605. 
https://doi.org/10.1161/CIRCINTERVENTIONS.116.004605
560. Mustapha JA, Saab FA, Martinsen BJ, Pena CS, Zeller T, Driver VR, et al. Digital subtrac­
tion angiography prior to an amputation for critical limb ischemia (CLI): an expert rec­
ommendation statement from the CLI global society to optimize limb salvage. 
J Endovasc Ther 2020;27:540–6. https://doi.org/10.1177/1526602820928590
561. Menke J, Larsen J. Meta-analysis: accuracy of contrast-enhanced magnetic resonance 
angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern 
Med 2010;153:325–34. https://doi.org/10.7326/0003-4819-153-5-201009070-00007
562. Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Luders F, et al. 
Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack 
of guideline adherence. Eur Heart J 2015;36:932–8. https://doi.org/10.1093/ 
eurheartj/ehv006
563. Hess CN, Wang TY, Weleski Fu J, Gundrum J, Allen LaPointe NM, Rogers RK, et al. 
Long-term outcomes and associations with major adverse limb events after peripheral 
artery revascularization. J Am Coll Cardiol 2020;75:498–508. https://doi.org/10.1016/j. 
jacc.2019.11.050
564. Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FGR, Gillespie I, et al. Bypass versus 
angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to 
facilitate clinical decision making. J Vasc Surg 2010;51:52s–68s. https://doi.org/10.1016/j. 
jvs.2010.01.077
565. Meltzer AJ, Graham A, Connolly PH, Meltzer EC, Karwowski JK, Bush HL, et al. The 
comprehensive risk assessment for bypass (CRAB) facilitates efficient perioperative 
risk assessment for patients with critical limb ischemia. J Vasc Surg 2013;57:1186–95. 
https://doi.org/10.1016/j.jvs.2012.09.083
566. van Netten JJ, Fortington LV, Hinchliffe RJ, Hijmans JM. Early post-operative mortality 
after major lower limb amputation: a systematic review of population and regional 
based studies. Eur J Vasc Endovasc Surg 2016;51:248–57. https://doi.org/10.1016/j. 
ejvs.2015.10.001
567. Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al. Surgery 
or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med 2022; 
387:2305–16. https://doi.org/10.1056/NEJMoa2207899
568. Meza-Torres B, Carinci F, Heiss C, Joy M, de Lusignan S. Health service organisation 
impact on lower extremity amputations in people with type 2 diabetes with foot ul­
cers: systematic review and meta-analysis. Acta Diabetol 2021;58:735–47. https://doi. 
org/10.1007/s00592-020-01662-x
569. Peters EJ, Lipsky BA, Berendt AR, Embil JM, Lavery LA, Senneville E, et al. A systematic 
review of the effectiveness of interventions in the management of infection in the 
diabetic foot. Diabetes Metab Res Rev 2012;28:142–62. https://doi.org/10.1002/dmrr. 
2247
570. Peters EJG, Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, et al. 
Interventions in the management of infection in the foot in diabetes: a systematic re­
view. Diabetes Metab Res Rev 2020;36:e3282. https://doi.org/10.1002/dmrr.3282
571. Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial 
agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 
2017;6:CD011038. https://doi.org/10.1002/14651858.CD011038.pub2
572. Luo Y, Li L, Zhao P, Yang C, Zhang J. Effectiveness of silver dressings in the treatment of 
diabetic foot ulcers: a systematic review and meta-analysis. J Wound Care 2022;31: 
979–86. https://doi.org/10.12968/jowc.2022.31.11.979
573. Shu H, Xia Z, Qin X, Wang X, Lu W, Luo Q, et al. The clinical efficacy of collagen dress­
ing on chronic wounds: a meta-analysis of 11 randomized controlled trials. Front Surg 
2022;9:978407. https://doi.org/10.3389/fsurg.2022.978407
574. Zhang F, Chen Z, Su F, Zhang T. Comparison of topical honey and povidone iodine- 
based dressings for wound healing: a systematic review and meta-analysis. J Wound 
Care 2021;30:S28–s36. https://doi.org/10.12968/jowc.2021.30.Sup4.S28
575. Yin XL, Hu L, Li T, Zou Y, Li HL. A meta-analysis on the efficacy of vacuum sealing 
drainage combined with autologous platelet-rich plasma in the treatment of grade 2 
and grade 3 diabetic foot ulcers. Int Wound J 2022;20:1033–41. https://doi.org/10. 
1111/iwj.13956
576. Lim K, Lim X, Hong Q, Yong E, Chandrasekar S, Tan GWL, et al. Use of home negative 
pressure wound therapy in peripheral artery disease and diabetic limb salvage. Int 
Wound J 2020;17:531–9. https://doi.org/10.1111/iwj.13307
577. Uddin A, Russell D, Game F, Santos D, Siddle HJ. The effectiveness of systemic antibio­
tics for osteomyelitis of the foot in adults with diabetes mellitus: a systematic review 
protocol. J Foot Ankle Res 2022;15:48. https://doi.org/10.1186/s13047-022-00554-3
578. O’Meara S, Nelson EA, Golder S, Dalton JE, Craig D, Iglesias C. Systematic review of 
methods to diagnose infection in foot ulcers in diabetes. Diabet Med 2006;23:341–7. 
https://doi.org/10.1111/j.1464-5491.2006.01830.x
579. Nelson A, Wright-Hughes A, Backhouse MR, Lipsky BA, Nixon J, Bhogal MS, et al. 
CODIFI (concordance in diabetic foot ulcer infection): a cross-sectional study of 
wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ 
Open 2018;8:e019437. https://doi.org/10.1136/bmjopen-2017-019437
580. Gardner SE, Frantz RA. Wound bioburden and infection-related complications in 
diabetic foot ulcers. Biol Res Nurs 2008;10:44–53. https://doi.org/10.1177/ 
1099800408319056
581. Selva Olid A, Solà I, Barajas-Nava LA, Gianneo OD, Bonfill Cosp X, Lipsky BA. Systemic 
antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev 2015;9: 
CD009061. https://doi.org/10.1002/14651858.CD009061.pub2
582. Patton D, Avsar P, Sayeh A, Budri A, O’Connor T, Walsh S, et al. A meta-review of the 
impact of compression therapy on venous leg ulcer healing. Int Wound J 2023;20: 
430–47. https://doi.org/10.1111/iwj.13891
583. Lazzarini PA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Moller K, et al. 
Effectiveness of offloading interventions for people with diabetes-related foot ulcers: a 
systematic review and meta-analysis. Diabetes Metab Res Rev 2024;40:e3650. https:// 
doi.org/10.1002/dmrr.3650
584. Elraiyah T, Prutsky G, Domecq JP, Tsapas A, Nabhan M, Frykberg RG, et al. A system­
atic review and meta-analysis of off-loading methods for diabetic foot ulcers. J Vasc Surg 
2016;63:59S–68S.e2. https://doi.org/10.1016/j.jvs.2015.10.006
585. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical 
limb ischemia. J Endovasc Ther 2009;16:Ii31–62. https://doi.org/10.1583/08-2657.1
586. Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with 
crural and pedal disease. J Cardiovasc Surg 2011;52:485–92.
587. Dominguez A, III, Bahadorani J, Reeves R, Mahmud E, Patel M. Endovascular therapy for 
critical limb ischemia. Expert Rev Cardiovasc Ther 2015;13:429–44. https://doi.org/10. 
1586/14779072.2015.1019472
588. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al. The natural 
history of untreated severe or critical limb ischemia. J Vasc Surg 2015;62:1642–51.e3. 
https://doi.org/10.1016/j.jvs.2015.07.065
589. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus 
angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled 
trial. Lancet 2005;366:1925–34. https://doi.org/10.1016/s0140-6736(05)67704-5
590. Bradbury AW, Moakes CA, Popplewell M, Meecham L, Bate GR, Kelly L, et al. A vein 
bypass first versus a best endovascular treatment first revascularisation strategy for pa­
tients with chronic limb threatening ischaemia who required an infra-popliteal, with or 
without an additional more proximal infra-inguinal revascularisation procedure to re­
store limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. 
Lancet 2023;401:1798–809. https://doi.org/10.1016/S0140-6736(23)00462-2
591. Popplewell MA, Davies H, Jarrett H, Bate G, Grant M, Patel S, et al. Bypass versus angio 
plasty in severe ischaemia of the leg—2 (BASIL-2) trial: study protocol for a rando­
mised controlled trial. Trials 2016;17:11. https://doi.org/10.1186/s13063-015-1114-2
592. Patel K, Liu Y, Etaee F, Patel C, Monteleone P, Patel M, et al. Differences between pa­
tients with intermittent claudication and critical limb ischemia undergoing endovascu­
lar intervention: insights from the excellence in peripheral artery disease registry. Circ


<!-- PAGE 140 -->

### Page 140

Cardiovasc Interv 2021;14:e010635. https://doi.org/10.1161/CIRCINTERVENTIONS. 
121.010635
593. Almasri J, Adusumalli J, Asi N, Lakis S, Alsawas M, Prokop LJ, et al. A systematic review 
and meta-analysis of revascularization outcomes of infrainguinal chronic limb- 
threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S110–s119. https://doi.org/10. 
1016/j.ejvs.2019.04.013
594. Söder HK, Manninen HI, Jaakkola P, Matsi PJ, Räsänen HT, Kaukanen E, et al. 
Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: 
angiographic and clinical results. J Vasc Interv Radiol 2000;11:1021–31. https://doi.org/ 
10.1016/s1051-0443(07)61332-3
595. Balmer H, Mahler F, Do DD, Triller J, Baumgartner I. Balloon angioplasty in chronic 
critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc 
Ther 2002;9:403–10. https://doi.org/10.1177/152660280200900403
596. Kudo T, Chandra FA, Kwun WH, Haas BT, Ahn SS. Changing pattern of surgical revas­
cularization for critical limb ischemia over 12 years: endovascular vs. open bypass sur­
gery. J Vasc Surg 2006;44:304–13. https://doi.org/10.1016/j.jvs.2006.03.040
597. Kim KG, Meshkin DH, Tirrell AR, Bekeny JC, Tefera EA, Fan KL, et al. A systematic re­
view and meta-analysis of endovascular angiosomal revascularization in the setting of 
collateral vessels. J Vasc Surg 2021;74:1406–16.e3. https://doi.org/10.1016/j.jvs.2021. 
04.026
598. Shishehbor MH, Powell RJ, Montero-Baker MF, Dua A, Martínez-Trabal JL, Bunte MC, 
et al. Transcatheter arterialization of deep veins in chronic limb-threatening ischemia. 
N Engl J Med 2023;388:1171–80. https://doi.org/10.1056/NEJMoa2212754
599. Salem M, Hosny MS, Francia F, Sallam M, Saratzis A, Saha P, et al. Management of ex­
tensive aorto-iliac disease: a systematic review and meta-analysis of 9319 patients. 
Cardiovasc Intervent Radiol 2021;44:1518–35. https://doi.org/10.1007/s00270-021- 
02785-6
600. Bekken JA, Vroegindeweij D, Vos JA, de Vries J-PPM, Lardenoije JWHP, Petri B-J, et al. 
Editor’s choice—two year results of the randomised DISCOVER trial comparing cov­
ered versus bare metal stents in the common iliac artery. Eur J Vasc Endovasc Surg 2023; 
65:359–68. https://doi.org/10.1016/j.ejvs.2022.11.008
601. Jongkind V, Akkersdijk GJ, Yeung KK, Wisselink W. A systematic review of endovascu­
lar treatment of extensive aortoiliac occlusive disease. J Vasc Surg 2010;52:1376–83. 
https://doi.org/10.1016/j.jvs.2010.04.080
602. Ye W, Liu CW, Ricco JB, Mani K, Zeng R, Jiang J. Early and late outcomes of percutan­
eous treatment of TransAtlantic inter-society consensus class C and D aorto-iliac le­
sions. J Vasc Surg 2011;53:1728–37. https://doi.org/10.1016/j.jvs.2011.02.005
603. Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, et al. BRAVISSIMO: 
12-month results from a large scale prospective trial. J Cardiovasc Surg 2013;54: 
235–53.
604. Danczyk RC, Mitchell EL, Petersen BD, Edwards J, Liem TK, Landry GJ, et al. Outcomes 
of open operation for aortoiliac occlusive disease after failed endovascular therapy. 
Arch Surg 2012;147:841–5. https://doi.org/10.1001/archsurg.2012.1649
605. Fereydooni A, Zhou B, Xu Y, Deng Y, Dardik A, Ochoa Chaar CI. Rapid increase in 
hybrid surgery for the treatment of peripheral artery disease in the vascular quality ini­
tiative database. J Vasc Surg 2020;72:977–86.e1. https://doi.org/10.1016/j.jvs.2019.11. 
041
606. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. 
Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial re­
vascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP 
randomized trial. J Am Coll Cardiol 2014;64:1568–76. https://doi.org/10.1016/j.jacc. 
2014.06.1198
607. Zeller T, Micari A, Scheinert D, Baumgartner I, Bosiers M, Vermassen FEG, et al. The 
IN.PACT DEEP clinical drug-coated balloon trial: 5-year outcomes. JACC Cardiovasc 
Interv 2020;13:431–43. https://doi.org/10.1016/j.jcin.2019.10.059
608. Brizzi V, Caradu C, Berard X, Sassoust G, Midy D, Ducasse E. Six-year multicenter ex­
perience of standard endovascular treatment of critical limb ischemia in the era of 
drug-eluting devices. J Cardiovasc Surg 2018;59:707–15. https://doi.org/10.23736/ 
S0021-9509.16.09737-8
609. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and 
nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24: 
1433–7. https://doi.org/10.2337/diacare.24.8.1433
610. Ozkan U, Oguzkurt L, Tercan F. Atherosclerotic risk factors and segmental distribu­
tion in symptomatic peripheral artery disease. J Vasc Interv Radiol 2009;20:437–41. 
https://doi.org/10.1016/j.jvir.2009.01.010
611. Todd KE, Jr, Ahanchi SS, Maurer CA, Kim JH, Chipman CR, Panneton JM. Atherectomy 
offers no benefits over balloon angioplasty in tibial interventions for critical limb ische­
mia. J Vasc Surg 2013;58:941–8. https://doi.org/10.1016/j.jvs.2013.04.024
612. Teichgraber U, Lehmann T, Thieme M, Wahl K-U, Stelzner C, Bormann A, et al. 
Drug-coated balloon angioplasty of infrapopliteal lesions in patients with critical limb 
ischaemia: 1-year results of the APOLLO trial. Cardiovasc Intervent Radiol 2019;42: 
1380–90. https://doi.org/10.1007/s00270-019-02279-6
613. Yang X, Lu X, Ye K, Li X, Qin J, Jiang M. Systematic review and meta-analysis of balloon 
angioplasty versus primary stenting in the infrapopliteal disease. Vasc Endovascular Surg 
2014;48:18–26. https://doi.org/10.1177/1538574413510626
614. Zhang J, Xu X, Kong J, Xu R, Fan X, Chen J, et al. Systematic review and meta-analysis of 
drug-eluting balloon and stent for infrapopliteal artery revascularization. Vasc 
Endovascular Surg 2017;51:72–83. https://doi.org/10.1177/1538574416689426
615. Matsuoka EK, Hasebe T, Ishii R, Miyazaki N, Soejima K, Iwasaki K. Comparative per­
formance analysis of interventional devices for the treatment of ischemic disease in 
below-the-knee lesions: a systematic review and meta-analysis. Cardiovasc Interv Ther 
2022;37:145–57. https://doi.org/10.1007/s12928-021-00758-7
616. Fong KY, Xin L, Ng J, Loh SEK, Ng JJ, Choong AMTL. A systematic review and 
meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial dis­
ease. J Vasc Surg 2023;77:1264–73.e3. https://doi.org/10.1016/j.jvs.2022.09.022
617. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic 
critical leg ischaemia. Cochrane Database Syst Rev 2013;2:CD004001. https://doi.org/ 
10.1002/14651858.CD004001.pub3
618. Asimakidou E, Matis GK. Spinal cord stimulation in the treatment of peripheral vascular 
disease: a systematic review—revival of a promising therapeutic option? Br J Neurosurg 
2022;36:555–63. https://doi.org/10.1080/02688697.2021.1884189
619. Nicoloff AD, Taylor LM, Jr, Sexton GJ, Schuff RA, Edwards JM, Yeager RA, et al. 
Relationship between site of initial symptoms and subsequent progression of disease 
in a prospective study of atherosclerosis progression in patients receiving long-term 
treatment for symptomatic peripheral arterial disease. J Vasc Surg 2002;35:38–46; dis­
cussion 46–37.
620. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International preva­
lence, recognition, and treatment of cardiovascular risk factors in outpatients with 
atherothrombosis. JAMA 2006;295:180–9. https://doi.org/10.1001/jama.295.2.180
621. Wilson YG, Davies AH, Currie IC, Morgan M, McGrath C, Baird RN, et al. Vein graft 
stenosis: incidence and intervention. Eur J Vasc Endovasc Surg 1996;11:164–9. https:// 
doi.org/10.1016/s1078-5884(96)80046-3
622. Armstrong PA, Bandyk DF, Wilson JS, Shames ML, Johnson BL, Back MR. Optimizing 
infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovas­
cular therapy. J Vasc Surg 2004;40:724–31; discussion 730–721. https://doi.org/10. 
1016/j.jvs.2004.07.037
623. Pulli R, Dorigo W, Fargion A, Innocenti AA, Pratesi G, Marek J, et al. Early and long- 
term comparison of endovascular treatment of iliac artery occlusions and stenosis. 
J Vasc Surg 2011;53:92–8. https://doi.org/10.1016/j.jvs.2010.08.034
624. Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, et al. Outcomes fol­
lowing infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg 2013;57: 
1455–64; discussion 1463–1454. https://doi.org/10.1016/j.jvs.2012.10.109
625. Rodway AD, Hanna L, Harris J, Jarrett R, Allan C, Pazos Casal F, et al. Prognostic and 
predictive value of ultrasound-based estimated ankle brachial pressure index at early 
follow-up after endovascular revascularization of chronic limb-threatening ischaemia: 
a prospective, single-centre, service evaluation. EClinicalMedicine 2024;68:102410. 
https://doi.org/10.1016/j.eclinm.2023.102410
626. Poursina O, Elizondo-Adamchik H, Montero-Baker M, Pallister ZS, Mills JL, Chung J. 
Safety and efficacy of an endovascular-first approach to acute limb ischemia. J Vasc 
Surg 2021;73:1741–9. https://doi.org/10.1016/j.jvs.2020.10.002
627. Hawkins KE, Valentine RJ, Duke JM, Wang Q, Reed AB. Ankle-brachial index use in 
peripheral vascular interventions for claudication. J Vasc Surg 2022;76:196–201. 
https://doi.org/10.1016/j.jvs.2022.02.049
628. Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, et al. Adherence 
to guideline-recommended therapy is associated with decreased major adverse car­
diovascular events and major adverse limb events among patients with peripheral ar­
terial disease. J Am Heart Assoc 2014;3:e000697. https://doi.org/10.1161/jaha.113. 
000697
629. Araujo ST, Moreno DH, Cacione DG. Percutaneous thrombectomy or 
ultrasound-accelerated thrombolysis for initial management of acute limb ischaemia. 
Cochrane Database Syst Rev 2022;1:CD013486. https://doi.org/10.1002/14651858. 
CD013486.pub2
630. Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, Katsaros I, Jawaid O, Jonnalagadda 
AK, et al. Statin therapy for reduction of cardiovascular and limb-related events in crit­
ical limb ischemia: a systematic review and meta-analysis. Vasc Med 2020;25:106–17. 
https://doi.org/10.1177/1358863x19894055
631. Londero LS, Nørgaard B, Houlind K. Patient delay is the main cause of treatment delay 
in acute limb ischemia: an investigation of pre- and in-hospital time delay. World J Emerg 
Surg 2014;9:56. https://doi.org/10.1186/1749-7922-9-56
632. Duval S, Keo HH, Oldenburg NC, Baumgartner I, Jaff MR, Peacock JM, et al. The impact 
of prolonged lower limb ischemia on amputation, mortality, and functional status: the 
FRIENDS registry. Am Heart J 2014;168:577–87. https://doi.org/10.1016/j.ahj.2014.06. 
013
633. Kulezic A, Macek M, Acosta S. Inadequacies of physical examination in patients with 
acute lower limb ischemia are associated with dreadful consequences. Ann Vasc Surg 
2022;82:190–6. https://doi.org/10.1016/j.avsg.2021.10.067
634. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syn­
drome: a review. Cardiovasc Surg 2002;10:620–30. https://doi.org/10.1016/s0967- 
2109(02)00070-4
ESC Guidelines                                                                                                                                                                                          3677


<!-- PAGE 141 -->

### Page 141

635. Jivegård L, Bergqvist D, Holm J. When is urgent revascularization unnecessary for acute 
lower limb ischaemia? Eur J Vasc Endovasc Surg 1995;9:448–53. https://doi.org/10.1016/ 
s1078-5884(05)80014-0
636. Crawford JD, Perrone KH, Jung E, Mitchell EL, Landry GJ, Moneta GL, et al. Arterial 
duplex for diagnosis of peripheral arterial emboli. J Vasc Surg 2016;64:1351–6. 
https://doi.org/10.1016/j.jvs.2016.04.005
637. Hemingway J, Emanuels D, Aarabi S, Quiroga E, Tran N, Starnes B, et al. Safety of trans­
fer, type of procedure, and factors predictive of limb salvage in a modern series of 
acute limb ischemia. J Vasc Surg 2019;69:1174–9. https://doi.org/10.1016/j.jvs.2018. 
08.174
638. Currie IS, Wakelin SJ, Lee AJ, Chalmers RT. Plasma creatine kinase indicates major am­
putation or limb preservation in acute lower limb ischemia. J Vasc Surg 2007;45:733–9. 
https://doi.org/10.1016/j.jvs.2006.12.050
639. Brow TD, Kakkar VV, Das SK. The significance of creatine kinase in cardiac patients 
with acute limb ischaemia. J Cardiovasc Surg 1999;40:637–44.
640. Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective 
study in patients with acute limb ischaemia and claudicants treated by revasculariza­
tion. Br J Surg 2005;79:1026–9. https://doi.org/10.1002/bjs.1800791013
641. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. 
Recommended standards for reports dealing with lower extremity ischemia: revised 
version. J Vasc Surg 1997;26:517–38. https://doi.org/10.1016/s0741-5214(97)70045-4
642. Ontario Health. Mechanical thrombectomy for acute and subacute blocked arteries 
and veins in the lower limbs: a health technology assessment. Ont Health Technol 
Assess Ser 2023;23:1–244.
643. Gong M, He X, Zhao B, Kong J, Gu J, Chen G, et al. Endovascular revascularization 
strategies using catheter-based thrombectomy versus conventional catheter-directed 
thrombolysis for acute limb ischemia. Thromb J 2021;19:96. https://doi.org/10.1186/ 
s12959-021-00349-9
644. Doelare SAN, Koedam TWA, Ebben HP, Tournoij E, Hoksbergen AWJ, Yeung KK, 
et al. Catheter directed thrombolysis for not immediately threatening acute limb is­
chaemia: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2023;65: 
537–45. https://doi.org/10.1016/j.ejvs.2022.12.030
645. Veenstra EB, van der Laan MJ, Zeebregts CJ, de Heide E-J, Kater M, Bokkers RPH. A 
systematic review and meta-analysis of endovascular and surgical revascularization 
techniques in acute limb ischemia. J Vasc Surg 2020;71:654–68.e3. https://doi.org/10. 
1016/j.jvs.2019.05.031
646. Kolte D, Kennedy KF, Shishehbor MH, Mamdani ST, Stangenberg L, Hyder ON, et al. 
Endovascular versus surgical revascularization for acute limb ischemia: a propensity- 
score matched analysis. Circ Cardiovasc Interv 2020;13:e008150. https://doi.org/10. 
1161/CIRCINTERVENTIONS.119.008150
647. Grip O, Wanhainen A, Michaelsson K, Lindhagen L, Bjorck M. Open or endovascular 
revascularization in the treatment of acute lower limb ischaemia. Br J Surg 2018;105: 
1598–606. https://doi.org/10.1002/bjs.10954
648. Darwood R, Berridge DC, Kessel DO, Robertson I, Forster R. Surgery versus thromb­
olysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev 2018; 
8:CD002784. https://doi.org/10.1002/14651858.CD002784.pub3
649. Schrijver AM, van Leersum M, Fioole B, Reijnen MMPJ, Hoksbergen AWJ, Vahl AC, 
et al. Dutch randomized trial comparing standard catheter-directed thrombolysis 
and ultrasound-accelerated thrombolysis for arterial thromboembolic infrainguinal 
disease 
(DUET). 
J 
Endovasc 
Ther 
2015;22:87–95. 
https://doi.org/10.1177/ 
1526602814566578
650. Juneja A, Garuthara M, Talathi S, Rao A, Landis G, Etkin Y. Predictors of poor out­
comes after lower extremity revascularization for acute limb ischemia. Vascular 
2024;32:632–9. https://doi.org/10.1177/17085381231154290
651. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. Surgery 1998; 
124:336–41; discussion 341–332. https://doi.org/10.1016/S0039-6060(98)70139-4
652. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: 
American College of Chest Physicians evidence-based clinical practice guidelines (8th 
edition). Chest 2008;133:815s–43s. https://doi.org/10.1378/chest.08-0686
653. Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, et al. Reduction in 
acute limb ischemia with rivaroxaban versus placebo in peripheral artery disease after 
lower extremity revascularization: insights from VOYAGER PAD. Circulation 2021; 
144:1831–41. https://doi.org/10.1161/circulationaha.121.055146
654. Jivegård L, Holm J, Bergqvist D, Björck CG, Björkman H, Brunius U, et al. Acute lower 
limb ischemia: failure of anticoagulant treatment to improve one-month results of ar­
terial thromboembolectomy. A prospective randomized multi-center study. Surgery 
1991;109:610–6.
655. Jivegård L, Holm J, Scherstén T. Arterial thromboembolectomy—should anticoagu­
lants be administered? Acta Chir Scand 1986;152:493–7.
656. Campbell WB, Ridler BM, Szymanska TH. Two-year follow-up after acute thrombo­
embolic limb ischaemia: the importance of anticoagulation. Eur J Vasc Endovasc Surg 
2000;19:169–73. https://doi.org/10.1053/ejvs.1999.0999
657. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. 
Heart disease and stroke statistics–2018 update: a report from the American 
Heart Association. Circulation 2018;137:e67–492. https://doi.org/10.1161/cir. 
0000000000000558
658. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. 
Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). 
An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk 
symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, 
Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc 
Dis 2012;34:290–6. https://doi.org/10.1159/000343145
659. Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al. 
Recommendations for the assessment of carotid arterial plaque by ultrasound for 
the characterization of atherosclerosis and evaluation of cardiovascular risk: from 
the American Society of Echocardiography. J Am Soc Echocardiogr 2020;33:917–33. 
https://doi.org/10.1016/j.echo.2020.04.021
660. Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, et al. 
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade 
carotid stenosis. N Engl J Med 1991;325:445–53. https://doi.org/10.1056/ 
nejm199108153250701
661. Gornik HL, Rundek T, Gardener H, Benenati JF, Dahiya N, Hamburg NM, et al. 
Optimization of duplex velocity criteria for diagnosis of internal carotid artery (ICA) 
stenosis: a report of the Intersocietal Accreditation Commission (IAC) Vascular 
Testing Division Carotid Diagnostic Criteria Committee. Vasc Med 2021;26:515–25. 
https://doi.org/10.1177/1358863X211011253
662. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid 
artery stenosis: grayscale and Doppler ultrasound diagnosis—Society of Radiologists in 
ultrasound consensus conference. Ultrasound Q 2003;19:190–8. https://doi.org/10. 
1097/00013644-200312000-00005
663. Rustempasic N, Gengo M. Assesment of carotid stenosis with CT angiography and col­
or Doppler ultrasonography. Med Arch 2019;73:321–5. https://doi.org/10.5455/ 
medarh.2019.73.321-325
664. Clezar CN, Flumignan CD, Cassola N, Nakano LCU, Trevisani VFM, Flumignan RLG. 
Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database 
Syst Rev 2023;8:CD013573. https://doi.org/10.1002/14651858.CD013573.pub2
665. Côté R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, Mackey A. Lack of effect 
of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrow­
ing. The asymptomatic cervical bruit study group. Ann Intern Med 1995;123:649–55. 
https://doi.org/10.7326/0003-4819-123-9-199511010-00002
666. Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. 
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consen­
sus document from the ESC working group on aorta and peripheral vascular diseases, 
the ESC working group on thrombosis, and the ESC working group on cardiovascular 
pharmacotherapy. Eur Heart J 2021;42:4013–24. https://doi.org/10.1093/eurheartj/ 
ehab390
667. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and 
aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25. 
https://doi.org/10.1056/NEJMoa1800410
668. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in 
acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9. https:// 
doi.org/10.1056/NEJMoa1215340
669. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assess­
ment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a 
randomised controlled pilot trial. Lancet Neurol 2007;6:961–9. https://doi.org/10.1016/ 
S1474-4422(07)70250-8
670. Murphy SJX, Naylor AR, Ricco JB, Sillesen H, Kakkos S, Halliday A, et al. Optimal anti­
platelet therapy in moderate to severe asymptomatic and symptomatic carotid sten­
osis: a comprehensive review of the literature. Eur J Vasc Endovasc Surg 2019;57: 
199–211. https://doi.org/10.1016/j.ejvs.2018.09.018
671. King A, Shipley M, Markus H, Investigators A. The effect of medical treatments on 
stroke risk in asymptomatic carotid stenosis. Stroke 2013;44:542–6. https://doi.org/ 
10.1161/STROKEAHA.112.673608
672. Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for 
the asymptomatic carotid atherosclerosis study. JAMA 1995;273:1421–8.
673. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al. Prevention of disabling 
and fatal strokes by successful carotid endarterectomy in patients without recent 
neurological symptoms: randomised controlled trial. Lancet 2004;363:1491–502. 
https://doi.org/10.1016/s0140-6736(04)16146-1
674. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al. 10-year stroke 
prevention after successful carotid endarterectomy for asymptomatic stenosis 
(ACST-1): a multicentre randomised trial. Lancet 2010;376:1074–84. https://doi.org/ 
10.1016/s0140-6736(10)61197-x
675. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid sten­
osis: asymptomatic carotid surgery trial. Stroke 2004;35:2425–7. https://doi.org/10. 
1161/01.STR.0000141706.50170.a7
676. Hadar N, Raman G, Moorthy D, O’Donnell TF, Thaler DE, Feldmann E, et al. 
Asymptomatic carotid artery stenosis treated with medical therapy alone: temporal 
trends and implications for risk assessment and the design of future studies. 
Cerebrovasc Dis 2014;38:163–73. https://doi.org/10.1159/000365206
677. Reiff T, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, et al. Angioplasty 
in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical


<!-- PAGE 142 -->

### Page 142

treatment: one-year interim results of SPACE-2. Int J Stroke 2020;15:638–49. https:// 
doi.org/10.1177/1747493019833017
678. Naylor AR, Schroeder TV, Sillesen H. Clinical and imaging features associated with an 
increased risk of late stroke in patients with asymptomatic carotid disease. Eur J Vasc 
Endovasc Surg 2014;48:633–40. https://doi.org/10.1016/j.ejvs.2014.08.017
679. Paraskevas KI, Brown MM, Lal BK, Myrcha P, Lyden SP, Schneider PA, et al. Recent ad­
vances and controversial issues in the optimal management of asymptomatic carotid 
stenosis. J Vasc Surg 2024;79:695–703. https://doi.org/10.1016/j.jvs.2023.11.004
680. Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al. Editor’s 
choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guide­
lines on the management of atherosclerotic carotid and vertebral artery disease. Eur 
J Vasc Endovasc Surg 2023;65:7–111. https://doi.org/10.1016/j.ejvs.2022.04.011
681. Kashyap VS, Schneider PA, Foteh M, Motaganahalli R, Shah R, Eckstein H-H, et al. Early 
outcomes in the ROADSTER 2 study of transcarotid artery revascularization in pa­
tients with significant carotid artery disease. Stroke 2020;51:2620–9. https://doi.org/ 
10.1161/strokeaha.120.030550
682. Nicolaides AN, Kakkos SK, Griffin M, Sabetai M, Dhanjil S, Tegos T, et al. Severity of 
asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: re­
sults from the ACSRS study. Eur J Vasc Endovasc Surg 2005;30:275–84. https://doi.org/ 
10.1016/j.ejvs.2005.04.031
683. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic 
stroke in population-based incidence studies. Neurology 2004;62:569–73. https://doi. 
org/10.1212/01.wnl.0000110311.09970.83
684. Kakkos SK, Sabetai M, Tegos T, Stevens J, Thomas D, Griffin M, et al. Silent embolic 
infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events 
in patients with asymptomatic internal carotid artery stenosis. J Vasc Surg 2009;49: 
902–9. https://doi.org/10.1016/j.jvs.2008.10.059
685. Kakkos SK, Nicolaides AN, Charalambous I, Thomas D, Giannopoulos A, Naylor AR, 
et al. Predictors and clinical significance of progression or regression of asymptomatic 
carotid stenosis. J Vasc Surg 2014;59:956–67.e1. https://doi.org/10.1016/j.jvs.2013.10. 
073
686. Markus HS, King A, Shipley M, Topakian R, Cullinane M, Reihill S, et al. Asymptomatic 
embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study 
(ACES): a prospective observational study. Lancet Neurol 2010;9:663–71. https://doi. 
org/10.1016/s1474-4422(10)70120-4
687. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral 
ischemia. Stroke 1977;8:301–14. https://doi.org/10.1161/01.str.8.3.301
688. King A, Serena J, Bornstein NM, Markus HS. Does impaired cerebrovascular reactivity 
predict stroke risk in asymptomatic carotid stenosis? A prospective substudy of the 
asymptomatic carotid emboli study. Stroke 2011;42:1550–5. https://doi.org/10.1161/ 
strokeaha.110.609057
689. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and 
safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of ath­
erosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, 
controlled trial. Lancet Neurol 2017;16:301–10. https://doi.org/10.1016/s1474- 
4422(17)30038-8
690. Kakkos SK, Griffin MB, Nicolaides AN, Kyriacou E, Sabetai MM, Tegos T, et al. The size 
of juxtaluminal hypoechoic area in ultrasound images of asymptomatic carotid plaques 
predicts the occurrence of stroke. J Vasc Surg 2013;57:609–18.e1; discussion 617–608. 
https://doi.org/10.1016/j.jvs.2012.09.045
691. Gupta A, Kesavabhotla K, Baradaran H, Kamel H, Pandya A, Giambrone AE, et al. 
Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic re­
view and meta-analysis. Stroke 2015;46:91–7. https://doi.org/10.1161/strokeaha.114. 
006091
692. Palacio S, Hart RG, Pearce LA, Anderson DC, Sharma M, Birnbaum LA, et al. Effect of 
addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized 
trials. Int J Stroke 2015;10:686–91. https://doi.org/10.1111/ijs.12050
693. Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, et al. Carotid 
plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 2013;44: 
3071–7. https://doi.org/10.1161/strokeaha.113.002551
694. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus 
aspirin versus aspirin alone for reducing embolisation in patients with acute symptom­
atic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, 
blinded-endpoint trial. Lancet Neurol 2010;9:489–97. https://doi.org/10.1016/s1474- 
4422(10)70060-0
695. Karlöf E, Buckler A, Liljeqvist ML, Lengquist M, Kronqvist M, Toonsi MA, et al. Carotid 
plaque phenotyping by correlating plaque morphology from computed tomography 
angiography with transcriptional profiling. Eur J Vasc Endovasc Surg 2021;62:716–26. 
https://doi.org/10.1016/j.ejvs.2021.07.011
696. Silver FL, Mackey A, Clark WM, Brooks W, Timaran CH, Chiu D, et al. Safety of stent­
ing and endarterectomy by symptomatic status in the Carotid Revascularization 
Endarterectomy Versus Stenting Trial (CREST). Stroke 2011;42:675–80. https://doi. 
org/10.1161/strokeaha.110.610212
697. Baker WH, Howard VJ, Howard G, Toole JF. Effect of contralateral occlusion on long- 
term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study 
(ACAS). ACAS Investigators. Stroke 2000;31:2330–4. https://doi.org/10.1161/01.str. 
31.10.2330
698. Kamtchum-Tatuene J, Noubiap JJ, Wilman AH, Saqqur M, Shuaib A, Jickling GC. 
Prevalence of high-risk plaques and risk of stroke in patients with asymptomatic ca­
rotid stenosis: a meta-analysis. JAMA Neurol 2020;77:1524–35. https://doi.org/10. 
1001/jamaneurol.2020.2658
699. Saratzis A, Naylor R. 30 day outcomes after carotid interventions: an updated 
meta-analysis of randomised controlled trials in asymptomatic patients. Eur J Vasc 
Endovasc Surg 2022;63:157–8. https://doi.org/10.1016/j.ejvs.2021.10.029
700. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, et al. 
Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic 
attack of atherosclerotic origin. Stroke 2020;51:3504–13. https://doi.org/10.1161/ 
strokeaha.120.032239
701. Halliday A, Bulbulia R, Bonati LH, Chester J, Cradduck-Bamford A, Peto R, et al. Second 
asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid ar­
tery stenting versus carotid endarterectomy. Lancet 2021;398:1065–73. https://doi. 
org/10.1016/s0140-6736(21)01910-3
702. Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, et al. 
Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J 
Med 2016;374:1011–20. https://doi.org/10.1056/NEJMoa1515706
703. Brott TG, Howard G, Roubin GS, Meschia JF, Mackey A, Brooks W, et al. Long-term 
results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 
2016;374:1021–31. https://doi.org/10.1056/NEJMoa1505215
704. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et al. Protected 
carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 
2004;351:1493–501. https://doi.org/10.1056/NEJMoa040127
705. Karpenko A, Bugurov S, Ignatenko P, Starodubtsev V, Popova I, Malinowski K, et al. 
Randomized controlled trial of conventional versus micronet-covered stent in carotid 
artery revascularization. JACC Cardiovasc Interv 2021;14:2377–87. https://doi.org/10. 
1016/j.jcin.2021.08.005
706. Karpenko A, Bugurov S, Ignatenko P, Starodubtsev V, Popova I, Malinowski K, et al. 
Randomized controlled trial of conventional versus micronet-covered stent in carotid 
artery revascularization: 12-month outcomes. JACC Cardiovasc Interv 2023;16:878–80. 
https://doi.org/10.1016/j.jcin.2023.01.369
707. Columbo JA, Martinez-Camblor P, Stone DH, Goodney PP, O’Malley AJ. Procedural 
safety comparison between transcarotid artery revascularization, carotid endarterec­
tomy, and carotid stenting: perioperative and 1-year rates of stroke or death. J Am 
Heart Assoc 2022;11:e024964. https://doi.org/10.1161/jaha.121.024964
708. de Borst GJ. Transcarotid artery revascularization. Br J Surg 2023;110:127–8. https:// 
doi.org/10.1093/bjs/znac421
709. Hawkins BM, Kennedy KF, Aronow HD, Nguyen LL, White CJ, Rosenfield K, et al. 
Hospital variation in carotid stenting outcomes. JACC Cardiovasc Interv 2015;8: 
858–63. https://doi.org/10.1016/j.jcin.2015.01.026
710. Paraskevas KI, Kalmykov EL, Naylor AR. Stroke/death rates following carotid artery 
stenting and carotid endarterectomy in contemporary administrative dataset regis­
tries: a systematic review. Eur J Vasc Endovasc Surg 2016;51:3–12. https://doi.org/10. 
1016/j.ejvs.2015.07.032
711. Brott TG, Hobson RW, II, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting 
versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 
363:11–23. https://doi.org/10.1056/NEJMoa0912321
712. Sacco RL, Diener HC, Yusuf S, Cotton D, Ôunpuu S, Lawton WA, et al. Aspirin and 
extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J 
Med 2008;359:1238–51. https://doi.org/10.1056/NEJMoa0805002
713. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral antic­
oagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a rando­
mised controlled trial. Lancet Neurol 2007;6:115–24. https://doi.org/10.1016/s1474- 
4422(06)70685-8
714. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet 
therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using 
Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli 
in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111:2233–40. https:// 
doi.org/10.1161/01.Cir.0000163561.90680.1c
715. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. 
Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 
2020;383:207–17. https://doi.org/10.1056/NEJMoa1916870
716. Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, et al. Efficacy and safety of 
ticagrelor and aspirin in patients with moderate ischemic stroke: an exploratory ana­
lysis of the THALES randomized clinical trial. JAMA Neurol 2021;78:1091–8. https://doi. 
org/10.1001/jamaneurol.2021.2440
717. Messas E, Goudot G, Halliday A, Sitruk J, Mirault T, Khider L, et al. Management of ca­
rotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a 
critical review. Eur Heart J Suppl 2020;22:M35–42. https://doi.org/10.1093/eurheartj/ 
suaa162
718. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, et al. Analysis 
of pooled data from the randomised controlled trials of endarterectomy for 
ESC Guidelines                                                                                                                                                                                          3679


<!-- PAGE 143 -->

### Page 143

symptomatic carotid stenosis. Lancet 2003;361:107–16. https://doi.org/10.1016/ 
s0140-6736(03)12228-3
719. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final 
results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351: 
1379–87. https://doi.org/10.1016/S0140-6736(97)09292-1
720. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, et al. Carotid end­
arterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. 
Veterans affairs cooperative studies program 309 trialist group. JAMA 1991;266: 
3289–94.
721. Naylor AR, Sillesen H, Schroeder TV. Clinical and imaging features associated with an 
increased risk of early and late stroke in patients with symptomatic carotid disease. Eur 
J Vasc Endovasc Surg 2015;49:513–23. https://doi.org/10.1016/j.ejvs.2015.01.011
722. Tsantilas P, Kuehnl A, König T, Breitkreuz T, Kallmayer M, Knappich C, et al. Short time 
interval between neurologic event and carotid surgery is not associated with an in­
creased procedural risk. Stroke 2016;47:2783–90. https://doi.org/10.1161/strokeaha. 
116.014058
723. Loftus IM, Paraskevas KI, Johal A, Waton S, Heikkila K, Naylor AR, et al. Editor’s choice 
—delays to surgery and procedural risks following carotid endarterectomy in the UK 
national vascular registry. Eur J Vasc Endovasc Surg 2016;52:438–43. https://doi.org/10. 
1016/j.ejvs.2016.05.031
724. Strömberg S, Gelin J, Osterberg T, Bergström GML, Karlström L, Österberg K, et al. 
Very urgent carotid endarterectomy confers increased procedural risk. Stroke 2012; 
43:1331–5. https://doi.org/10.1161/strokeaha.111.639344
725. Bush CK, Kurimella D, Cross LJ, Conner KR, Martin-Schild D, He J, et al. Endovascular 
treatment with stent-retriever devices for acute ischemic stroke: a meta-analysis of 
randomized controlled trials. PLoS One 2016;11:e0147287. https://doi.org/10.1371/ 
journal.pone.0147287
726. Savardekar AR, Narayan V, Patra DP, Spetzler RF, Sun H. Timing of carotid endarter­
ectomy for symptomatic carotid stenosis: a snapshot of current trends and systematic 
review of literature on changing paradigm towards early surgery. Neurosurgery 2019; 
85:E214–25. https://doi.org/10.1093/neuros/nyy557
727. Hill MD, Brooks W, Mackey A, Clark WM, Meschia JF, Morrish WF, et al. Stroke after 
carotid stenting and endarterectomy in the carotid revascularization endarterectomy 
versus stenting trial (CREST). Circulation 2012;126:3054–61. https://doi.org/10.1161/ 
circulationaha.112.120030
728. Blackshear JL, Cutlip DE, Roubin GS, Hill MD, Leimgruber PP, Begg RJ, et al. Myocardial 
infarction after carotid stenting and endarterectomy: results from the carotid revascu­
larization endarterectomy versus stenting trial. Circulation 2011;123:2571–8. https:// 
doi.org/10.1161/circulationaha.110.008250
729. Howard G, Roubin GS, Jansen O, Hendrikse J, Halliday A, Fraedrich G, et al. 
Association between age and risk of stroke or death from carotid endarterectomy 
and carotid stenting: a meta-analysis of pooled patient data from four randomised 
trials. Lancet 2016;387:1305–11. https://doi.org/10.1016/s0140-6736(15)01309-4
730. Alamowitch S, Eliasziw M, Algra A, Meldrum H, Barnett HJ. Risk, causes, and preven­
tion of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery 
stenosis. Lancet 2001;357:1154–60. https://doi.org/10.1016/s0140-6736(00)04332-4
731. Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM. Percutaneous transluminal 
balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst 
Rev 2012;9:CD000515. https://doi.org/10.1002/14651858.CD000515.pub4
732. Economopoulos KP, Sergentanis TN, Tsivgoulis G, Mariolis AD, Stefanadis C. Carotid 
artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of 
short-term and long-term outcomes. Stroke 2011;42:687–92. https://doi.org/10. 
1161/strokeaha.110.606079
733. Bonati LH, Dobson J, Featherstone RL, Ederle J, van der Worp HB, de Borst GJ, et al. 
Long-term outcomes after stenting versus endarterectomy for treatment of symp­
tomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised 
trial. Lancet 2015;385:529–38. https://doi.org/10.1016/s0140-6736(14)61184-3
734. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for 
symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. 
Lancet 2004;363:915–24. https://doi.org/10.1016/s0140-6736(04)15785-1
735. Rantner B, Kollerits B, Roubin GS, Ringleb PA, Jansen O, Howard G, et al. Early end­
arterectomy carries a lower procedural risk than early stenting in patients with symp­
tomatic stenosis of the internal carotid artery: results from 4 randomized controlled 
trials. Stroke 2017;48:1580–7. https://doi.org/10.1161/strokeaha.116.016233
736. Schermerhorn ML, Fokkema M, Goodney P, Dillavou ED, Jim J, Kenwood CT, et al. The 
impact of centers for medicare and medicaid services high-risk criteria on outcome 
after carotid endarterectomy and carotid artery stenting in the SVS vascular registry. 
J Vasc Surg 2013;57:1318–24. https://doi.org/10.1016/j.jvs.2012.10.107
737. Schermerhorn ML, Liang P, Eldrup-Jorgensen J, Cronenwett JL, Nolan BW, Kashyap 
VS, et al. Association of transcarotid artery revascularization vs transfemoral carotid 
artery stenting with stroke or death among patients with carotid artery stenosis. 
JAMA 2019;322:2313–22. https://doi.org/10.1001/jama.2019.18441
738. Pineau S, Fajardo A, Saqib NU, Tanaka A, Motaganahalli RL, Keyhani A, et al. 
Transcarotid revascularization timing and early postoperative outcomes in symptom­
atic patients. Vasc Endovascular Surg 2023;57:344–9. https://doi.org/10.1177/ 
15385744221146678
739. Kieffer E, Praquin B, Chiche L, Koskas F, Bahnini A. Distal vertebral artery reconstruc­
tion: long-term outcome. J Vasc Surg 2002;36:549–54. https://doi.org/10.1067/mva. 
2002.126092
740. Berguer R, Flynn LM, Kline RA, Caplan L. Surgical reconstruction of the extracranial 
vertebral artery: management and outcome. J Vasc Surg 2000;31:9–18. https://doi. 
org/10.1016/s0741-5214(00)70063-2
741. Markus HS, Harshfield EL, Compter A, Kuker W, Kappelle LJ, Clifton A, et al. Stenting 
for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data 
analysis. Lancet Neurol 2019;18:666–73. https://doi.org/10.1016/s1474-4422(19) 
30149-8
742. Hanel RA, Brasiliense LB, Spetzler RF. Microsurgical revascularization of proximal ver­
tebral artery: a single-center, single-operator analysis. Neurosurgery 2009;64:1043–51; 
discussion 1051. https://doi.org/10.1227/01.Neu.0000347099.17437.64
743. Asiddao CB, Donegan JH, Whitesell RC, Kalbfleisch JH. Factors associated with peri­
operative complications during carotid endarterectomy. Anesth Analg 1982;61:631–7.
744. Obeid T, Arhuidese I, Gaidry A, Qazi U, Abularrage C, Goodney P, et al. Beta-blocker 
use is associated with lower stroke and death after carotid artery stenting. J Vasc Surg 
2016;63:363–9. https://doi.org/10.1016/j.jvs.2015.08.108
745. Abou-Chebl A, Reginelli J, Bajzer CT, Yadav JS. Intensive treatment of hypertension 
decreases the risk of hyperperfusion and intracerebral hemorrhage following carotid 
artery stenting. Catheter Cardiovasc Interv 2007;69:690–6. https://doi.org/10.1002/ccd. 
20693
746. Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid 
prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized 
trial. Stroke 1993;24:1125–8. https://doi.org/10.1161/01.str.24.8.1125
747. Kretschmer G, Pratschner T, Prager M, Wenzi E, Polterauer P, Schemper M, et al. 
Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. 
Analysis of the clinical series followed by a controlled trial. Ann Surg 1990;211: 
317–22. https://doi.org/10.1097/00000658-199003000-00002
748. Dalainas I, Nano G, Bianchi P, Stegher S, Malacrida G, Tealdi DG. Dual antiplatelet re­
gime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol 
2006;29:519–21. https://doi.org/10.1007/s00270-005-5288-y
749. AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al. 
The Society for Vascular Surgery implementation document for management of extra­
cranial cerebrovascular disease. J Vasc Surg 2022;75:26s–98s. https://doi.org/10.1016/j. 
jvs.2021.04.074
750. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor’s choice— 
management of atherosclerotic carotid and vertebral artery disease: 2017 clinical prac­
tice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc 
Surg 2018;55:3–81. https://doi.org/10.1016/j.ejvs.2017.06.021
751. Ghamraoui AK, Chang H, Maldonado TS, Ricotta JJ, II. Clopidogrel versus ticagrelor for 
antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular 
Surgery vascular quality initiative. J Vasc Surg 2022;75:1652–60. https://doi.org/10. 
1016/j.jvs.2021.11.060
752. Marcaccio CL, Patel PB, Liang P, Rastogi V, Stangenberg L, Jim J, et al. Efficacy and safety 
of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid 
artery stenting. J Vasc Surg 2022;75:1293–303.e8. https://doi.org/10.1016/j.jvs.2021.09. 
045
753. Ghamraoui AK, Ricotta JJ, II. Outcomes and strategy of tailored antiplatelet therapy 
with ticagrelor in patients undergoing transcarotid artery revascularization. J Vasc 
Surg 2021;73:132–41. https://doi.org/10.1016/j.jvs.2020.04.518
754. Zierler RE, Jordan WD, Lal BK, Mussa F, Leers S, Fulton J, et al. The Society for Vascular 
Surgery practice guidelines on follow-up after vascular surgery arterial procedures. J 
Vasc Surg 2018;68:256–84. https://doi.org/10.1016/j.jvs.2018.04.018
755. Cheun TJ, Jayakumar L, Sheehan MK, Sideman MJK, Pounds LL, Davies MG. Outcomes 
of upper extremity interventions for chronic critical ischemia. J Vasc Surg 2019;69: 
120–8.e2. https://doi.org/10.1016/j.jvs.2018.04.056
756. Awad El-Karim G, Kennedy SA, Ferraresi R, Addas JAK, Oreopoulos GD, Jaberi A, et al. 
Percutaneous transluminal angioplasty for below-the-elbow critical hand ischemia: a 
systematic review. J Endovasc Ther 2022;29:468–77. https://doi.org/10.1177/ 
15266028211050309
757. Raimbeau A, Pistorius MA, Goueffic Y, Connault J, Plissonneau-Duquene P, Maurel B, 
et al. Digital ischaemia aetiologies and mid-term follow-up: a cohort study of 323 pa­
tients. Medicine 2021;100:e25659. https://doi.org/10.1097/md.0000000000025659
758. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a differ­
ence in systolic blood pressure between arms with vascular disease and mortality: a 
systematic review and meta-analysis. Lancet 2012;379:905–14. https://doi.org/10. 
1016/s0140-6736(11)61710-8
759. Aboyans V, Kamineni A, Allison MA, McDermott MM, Crouse JR, Ni H, et al. The epi­
demiology of subclavian stenosis and its association with markers of subclinical athero­
sclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2010;211: 
266–70. https://doi.org/10.1016/j.atherosclerosis.2010.01.013
760. Labropoulos N, Nandivada P, Bekelis K. Prevalence and impact of the subclavian steal 
syndrome. 
Ann 
Surg 
2010;252:166–70. 
https://doi.org/10.1097/SLA. 
0b013e3181e3375a


<!-- PAGE 144 -->

### Page 144

761. Zhang J, Wang L, Chen Y, Wang S, Xing Y, Cui L. Color Doppler ultrasonography for 
the evaluation of subclavian artery stenosis. Front Neurol 2022;13:804039. https://doi. 
org/10.3389/fneur.2022.804039
762. Harper C, Cardullo PA, Weyman AK, Patterson RB. Transcranial Doppler ultrasonog­
raphy of the basilar artery in patients with retrograde vertebral artery flow. J Vasc Surg 
2008;48:859–64. https://doi.org/10.1016/j.jvs.2008.05.057
763. Chidambaram PK, Swaminathan RK, Ganesan P, Mayavan M. Segmental comparison of 
peripheral arteries by Doppler ultrasound and CT angiography. J Clin Diagn Res 2016; 
10:TC12–16. https://doi.org/10.7860/JCDR/2016/17191.7242
764. Tsao TF, Cheng KL, Shen CY, Wu M-C, Huang H-H, Su C-H, et al. Diagnostic perform­
ance of combined contrast-enhanced magnetic resonance angiography and phase- 
contrast magnetic resonance imaging in suspected subclavian steal syndrome. Can 
Assoc Radiol J 2016;67:190–201. https://doi.org/10.1016/j.carj.2015.08.007
765. Klitfod L, Jensen LP. Treatment of chronic upper limb ischaemia is safe and results are 
good. Dan Med J 2014;61:A4859.
766. Duran M, Grotemeyer D, Danch MA, Grabitz K, Schelzig H, Sagban TA. Subclavian ca­
rotid transposition: immediate and long-term outcomes of 126 surgical reconstruc­
tions. Ann Vasc Surg 2015;29:397–403. https://doi.org/10.1016/j.avsg.2014.09.030
767. Daniel VT, Madenci AL, Nguyen LL, Eslami MH, Kalish JA, Farber A, et al. 
Contemporary comparison of supra-aortic trunk surgical reconstructions for occlu­
sive disease. J Vasc Surg 2014;59:1577–82, 1582.e1–2. https://doi.org/10.1016/j.jvs. 
2013.12.017
768. Burihan E, Soma F, Iared W. Angioplasty versus stenting for subclavian artery stenosis. 
Cochrane Database Syst Rev 2011;10:CD008461. https://doi.org/10.1002/14651858. 
CD008461.pub2
769. Hüttl K, Nemes B, Simonffy A, Entz L, Bérczi V. Angioplasty of the innominate artery in 
89 patients: experience over 19 years. Cardiovasc Intervent Radiol 2002;25:109–14. 
https://doi.org/10.1007/s00270-001-0074-y
770. Modarai B, Ali T, Dourado R, Reidy JF, Taylor PR, Burnand KG. Comparison of extra- 
anatomic bypass grafting with angioplasty for atherosclerotic disease of the 
supra-aortic trunks. Br J Surg 2004;91:1453–7. https://doi.org/10.1002/bjs.4751
771. Song L, Zhang J, Li J, Gu Y, Yu H, Chen B, et al. Endovascular stenting vs. extrathoracic 
surgical bypass for symptomatic subclavian steal syndrome. J Endovasc Ther 2012;19: 
44–51. https://doi.org/10.1583/11-3692.1
772. Owens LV, Tinsley EA, Jr, Criado E, Burnham SJ, Keagy BA. Extrathoracic reconstruc­
tion of arterial occlusive disease involving the supraaortic trunks. J Vasc Surg 1995;22: 
217–21; discussion 221–2. https://doi.org/10.1016/s0741-5214(95)70133-8
773. Huijben M, Meershoek AJA, de Borst GJ, Toorop RJ. Long-term outcome of 
axillo-axillary bypass in patients with subclavian or innominate artery stenosis. Ann 
Vasc Surg 2021;73:321–8. https://doi.org/10.1016/j.avsg.2020.10.029
774. Lee AD, Agarwal S, Sadhu D. A 7-year experience with thoracoscopic sympathectomy 
for critical upper limb ischemia. World J Surg 2006;30:1644–7. https://doi.org/10.1007/ 
s00268-005-0559-y
775. Schillinger M, Haumer M, Schillinger S, Mlekusch W, Ahmadi R, Minar E. Outcome of 
conservative versus interventional treatment of subclavian artery stenosis. J Endovasc 
Ther 2002;9:139–46. https://doi.org/10.1177/152660280200900201
776. Ahmed AT, Mohammed K, Chehab M, Brinjikji W, Hassan Murad M, Cloft H, et al. 
Comparing percutaneous transluminal angioplasty and stent placement for treatment 
of subclavian arterial occlusive disease: a systematic review and meta-analysis. 
Cardiovasc Intervent Radiol 2016;39:652–67. https://doi.org/10.1007/s00270-015- 
1250-9
777. Che W, Dong H, Jiang X, Peng M, Zou Y, Song L, et al. Subclavian artery stenting for 
coronary-subclavian steal syndrome. Catheter Cardiovasc Interv 2017;89:601–8. https:// 
doi.org/10.1002/ccd.26902
778. Hamdan R, Guilleminot P, Leclercq T, Monin A. Coronary-subclavian steal syndrome 
causing myocardial infarction after arteriovenous fistula creation: a case report. ESC 
Heart Fail 2023;10:2084–9. https://doi.org/10.1002/ehf2.14341
779. Che WQ, Dong H, Jiang XJ, Peng M, Zou Y, Qian H, et al. Stenting for left subclavian 
artery stenosis in patients scheduled for left internal mammary artery-coronary artery 
bypass grafting. Catheter Cardiovasc Interv 2016;87:579–88. https://doi.org/10.1002/ 
ccd.26477
780. Muller AM, Bertram J, Bradaric C, Koppara T, Cassese S, Xhepa E, et al. Frequency of 
subclavian artery stenosis in patients with mammarian artery coronary bypass and sus­
pected coronary artery disease progression. Clin Res Cardiol 2023;112:1204–11. 
https://doi.org/10.1007/s00392-022-02113-z
781. Angle JF, Matsumoto AH, McGraw JK, Spinosa DJ, Hagspiel KD, Leung DA, et al. 
Percutaneous angioplasty and stenting of left subclavian artery stenosis in patients 
with left internal mammary-coronary bypass grafts: clinical experience and long-term 
follow-up. 
Vasc 
Endovascular 
Surg 
2003;37:89–97. 
https://doi.org/10.1177/ 
153857440303700202
782. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431–42. https:// 
doi.org/10.1056/nejm200102083440607
783. Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, et al. Prevalence 
of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002;36: 
443–51. https://doi.org/10.1067/mva.2002.127351
784. Aboyans V, Desormais I, Magne J, Morange G, Mohty D, Lacroix P. Renal artery sten­
osis in patients with peripheral artery disease: prevalence, risk factors and long-term 
prognosis. Eur J Vasc Endovasc Surg 2017;53:380–5. https://doi.org/10.1016/j.ejvs. 
2016.10.029
785. Safian RD. Renal artery stenosis. Prog Cardiovasc Dis 2021;65:60–70. https://doi.org/10. 
1016/j.pcad.2021.03.003
786. Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, et al. Flash pul­
monary oedema and bilateral renal artery stenosis: the pickering syndrome. Eur Heart J 
2011;32:2231–5. https://doi.org/10.1093/eurheartj/ehr056
787. Zeller T, Bonvini RF, Sixt S. Color-coded duplex ultrasound for diagnosis of renal ar­
tery stenosis and as follow-up examination after revascularization. Catheter Cardiovasc 
Interv 2008;71:995–9. https://doi.org/10.1002/ccd.21525
788. Prince M, Tafur JD, White CJ. When and how should we revascularize patients with 
atherosclerotic renal artery stenosis? JACC Cardiovasc Interv 2019;12:505–17. https:// 
doi.org/10.1016/j.jcin.2018.10.023
789. AbuRahma AF, Yacoub M. Renal imaging: duplex ultrasound, computed tomography 
angiography, magnetic resonance angiography, and angiography. Semin Vasc Surg 
2013;26:134–43. https://doi.org/10.1053/j.semvascsurg.2014.06.001
790. Staub D, Canevascini R, Huegli RW, Aschwanden M, Thalhammer C, Imfeld S, et al. 
Best duplex-sonographic criteria for the assessment of renal artery stenosis—correl­
ation with intra-arterial pressure gradient. Ultraschall Med 2007;28:45–51. https://doi. 
org/10.1055/s-2007-962881
791. Williams GJ, Macaskill P, Chan SF, Karplus TE, Yung W, Hodson EM, et al. Comparative 
accuracy of renal duplex sonographic parameters in the diagnosis of renal artery sten­
osis: paired and unpaired analysis. AJR Am J Roentgenol 2007;188:798–811. https://doi. 
org/10.2214/ajr.06.0355
792. Parikh SA, Shishehbor MH, Gray BH, White CJ, Jaff MR. SCAI expert consensus state­
ment for renal artery stenting appropriate use. Catheter Cardiovasc Interv 2014;84: 
1163–71. https://doi.org/10.1002/ccd.25559
793. Caps MT, Perissinotto C, Zierler RE, Polissar NL, Bergelin RO, Tullis MJ, et al. 
Prospective study of atherosclerotic disease progression in the renal artery. 
Circulation 1998;98:2866–72. https://doi.org/10.1161/01.cir.98.25.2866
794. Amighi J, Schlager O, Haumer M, Dick P, Mlekusch W, Loewe C, et al. Renal artery 
stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral 
artery disease. Eur J Clin Invest 2009;39:784–92. https://doi.org/10.1111/j.1365-2362. 
2009.02180.x
795. Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal dis­
ease attributed to renovascular disease in the United States. Am J Kidney Dis 2001;37: 
1184–90. https://doi.org/10.1053/ajkd.2001.24521
796. Ritchie J, Green D, Alderson HV, Chrysochou C, Vassallo D, Sinha S, et al. Associations 
of antiplatelet therapy and beta blockade with patient outcomes in atherosclerotic re­
novascular disease. J Am Soc Hypertens 2016;10:149–58.e3. https://doi.org/10.1016/j. 
jash.2015.12.002
797. Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Balk EM. Comparative 
effectiveness of management strategies for renal artery stenosis: an updated system­
atic review. Ann Intern Med 2016;165:635–49. https://doi.org/10.7326/M16-1053
798. Bhalla V, Textor SC, Beckman JA, Casanegra AI, Cooper CJ, Kim ESH, et al. 
Revascularization for renovascular disease: a scientific statement from the American 
Heart Association. Hypertension 2022;79:e128–43. https://doi.org/10.1161/hyp. 
0000000000000217
799. Piaggio D, Bracale U, Pecchia L, Di Taranto MD, Sodo M, Bracale UM. Endovascular 
treatment versus medical therapy for hypertensive patients with renal artery stenosis: 
an updated systematic review. Ann Vasc Surg 2019;61:445–54. https://doi.org/10.1016/ 
j.avsg.2019.04.050
800. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization ver­
sus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953–62. https:// 
doi.org/10.1056/NEJMoa0905368
801. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al. Stent placement 
in patients with atherosclerotic renal artery stenosis and impaired renal function: a ran­
domized trial. Ann Intern Med 2009;150:840–8, w150–1. https://doi.org/10.7326/0003- 
4819-150-12-200906160-00119
802. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, et al. 
Randomised comparison of percutaneous angioplasty vs continued medical therapy 
for hypertensive patients with atheromatous renal artery stenosis. Scottish and 
Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998;12: 
329–35. https://doi.org/10.1038/sj.jhh.1000599
803. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FHM, Deinum J, Postma CT, et al. The 
effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. 
Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 
2000;342:1007–14. https://doi.org/10.1056/nejm200004063421403
804. Plouin PF, Chatellier G, Darné B, Raynaud A. Blood pressure outcome of angioplasty in 
atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique 
Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;31:823–9. 
https://doi.org/10.1161/01.hyp.31.3.823
ESC Guidelines                                                                                                                                                                                          3681


<!-- PAGE 145 -->

### Page 145

805. Abela R, Ivanova S, Lidder S, Morris R, Hamilton G. An analysis comparing open surgical 
and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc 
Endovasc Surg 2009;38:666–75. https://doi.org/10.1016/j.ejvs.2009.08.002
806. Balzer KM, Pfeiffer T, Rossbach S, Voiculescu A, Mödder U, Godehardt E, et al. 
Prospective randomized trial of operative vs interventional treatment for renal artery 
ostial occlusive disease (RAOOD). J Vasc Surg 2009;49:667–75; discussion 674–665. 
https://doi.org/10.1016/j.jvs.2008.10.006
807. Mohler ER, III, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE. ACCF/ 
ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS/SVU [corrected] 2012 ap­
propriate use criteria for peripheral vascular ultrasound and physiological testing 
part I: arterial ultrasound and physiological testing: a report of the American 
College of Cardiology Foundation appropriate use criteria task force, American 
College of Radiology, American Institute of Ultrasound in Medicine, American 
Society of Echocardiography, American Society of Nephrology, Intersocietal 
Commission for the Accreditation of Vascular Laboratories, Society for 
Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed 
Tomography, Society for Interventional Radiology, Society for Vascular Medicine, 
Society for Vascular Surgery, [corrected] and Society for Vascular Ultrasound. [cor­
rected]. J Am Coll Cardiol 2012;60:242–76. https://doi.org/10.1016/j.jacc.2012.02.009
808. Davies MG, Saad WA, Bismuth JX, Peden EK, Naoum JJ, Lumsden AB. Outcomes of 
endoluminal reintervention for restenosis after percutaneous renal angioplasty and 
stenting. J Vasc Surg 2009;49:946–52. https://doi.org/10.1016/j.jvs.2008.11.039
809. Hicks CW, Clark TWI, Cooper CJ, de Bhailís ÁM, De Carlo M, Green D, et al. 
Atherosclerotic renovascular disease: A KDIGO (kidney disease: improving global out­
comes) controversies conference. Am J Kidney Dis 2022;79:289–301. https://doi.org/ 
10.1053/j.ajkd.2021.06.025
810. Johansen KL, Garimella PS, Hicks CW, Kalra PA, Kelly DM, Martens S, et al. Central and 
peripheral arterial diseases in chronic kidney disease: conclusions from a kidney dis­
ease: improving global outcomes (KDIGO) controversies conference. Kidney Int 
2021;100:35–48. https://doi.org/10.1016/j.kint.2021.04.029
811. Pappaccogli M, Robberechts T, Lengele JP, Van der Niepen P, Sarafidis P, Rabbia F, et al. 
Endovascular versus medical management of atherosclerotic renovascular disease: up­
date and emerging concepts. Hypertension 2023;80:1150–61. https://doi.org/10.1161/ 
HYPERTENSIONAHA.122.17965
812. Tian Y, Yuan B, Zhang N, Huang Z. Outcomes following the endovascular treatment of 
renal artery stenosis caused by fibromuscular dysplasia: a systematic review and 
meta-analysis. Ann Vasc Surg 2022;78:362–72. https://doi.org/10.1016/j.avsg.2021.06. 
042
813. Persu A, Giavarini A, Touzé E, Januszewicz A, Sapoval M, Azizi M, et al. European con­
sensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014; 
32:1367–78. https://doi.org/10.1097/hjh.0000000000000213
814. Zeller T, Krankenberg H, Erglis A, Blessing E, Fuss T, Scheinert D, et al. A randomized, 
multi-center, prospective study comparing best medical treatment versus best medical 
treatment plus renal artery stenting in patients with hemodynamically relevant athero­
sclerotic renal artery stenosis (RADAR)—one-year results of a pre-maturely termi­
nated study. Trials 2017;18:380. https://doi.org/10.1186/s13063-017-2126-x
815. Tamme K, Reintam Blaser A, Laisaar KT, Mändul M, Kals J, Forbes A, et al. Incidence and 
outcomes of acute mesenteric ischaemia: a systematic review and meta-analysis. BMJ 
Open 2022;12:e062846. https://doi.org/10.1136/bmjopen-2022-062846
816. Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc 
Surg 2010;23:4–8. https://doi.org/10.1053/j.semvascsurg.2009.12.001
817. Acosta S, Ogren M, Sternby NH, Bergqvist D, Björck M. Incidence of acute thrombo- 
embolic occlusion of the superior mesenteric artery—a population-based study. Eur J 
Vasc Endovasc Surg 2004;27:145–50. https://doi.org/10.1016/j.ejvs.2003.11.003
818. Carver TW, Vora RS, Taneja A. Mesenteric ischemia. Crit Care Clin 2016;32:155–71. 
https://doi.org/10.1016/j.ccc.2015.11.001
819. Klass AA. Embolectomy in acute mesenteric occlusion. Ann Surg 1951;134:913–7. 
https://doi.org/10.1097/00000658-195111000-00016
820. Acosta S, Björck M. Acute thrombo-embolic occlusion of the superior mesenteric ar­
tery: a prospective study in a well defined population. Eur J Vasc Endovasc Surg 2003;26: 
179–83. https://doi.org/10.1053/ejvs.2002.1893
821. Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (part I)—incidence, etiologies, 
and how to improve early diagnosis. Best Pract Res Clin Gastroenterol 2017;31: 
15–25. https://doi.org/10.1016/j.bpg.2016.10.018
822. Kärkkäinen JM. Acute mesenteric ischemia: a challenge for the acute care surgeon. 
Scand J Surg 2021;110:150–8. https://doi.org/10.1177/14574969211007590
823. Powell A, Armstrong P. Plasma biomarkers for early diagnosis of acute intestinal ische­
mia. Semin Vasc Surg 2014;27:170–5. https://doi.org/10.1053/j.semvascsurg.2015.01. 
008
824. Block T, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for 
intestinal ischaemia. Scand J Clin Lab Invest 2008;68:242–8. https://doi.org/10.1080/ 
00365510701646264
825. Kougias P, Lau D, El Sayed HF, Zhou W, Huynh TT, Lin PH. Determinants of mortality 
and treatment outcome following surgical interventions for acute mesenteric ischemia. 
J Vasc Surg 2007;46:467–74. https://doi.org/10.1016/j.jvs.2007.04.045
826. Lehtimäki TT, Kärkkäinen JM, Saari P, Manninen H, Paajanen H, Vanninen R. Detecting 
acute mesenteric ischemia in CT of the acute abdomen is dependent on clinical suspi­
cion: review of 95 consecutive patients. Eur J Radiol 2015;84:2444–53. https://doi.org/ 
10.1016/j.ejrad.2015.09.006
827. Kirkpatrick ID, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiog­
raphy in the evaluation of acute mesenteric ischemia: initial experience. Radiology 2003; 
229:91–8. https://doi.org/10.1148/radiol.2291020991
828. Oliva IB, Davarpanah AH, Rybicki FJ, Desjardins B, Flamm SD, Francois CJ, et al. ACR 
appropriateness Criteria ® imaging of mesenteric ischemia. Abdom Imaging 2013;38: 
714–9. https://doi.org/10.1007/s00261-012-9975-2
829. Salsano G, Salsano A, Sportelli E, Petrocelli F, Dahmane M, Spinella G, et al. What is the 
best revascularization strategy for acute occlusive arterial mesenteric ischemia: sys­
tematic review and meta-analysis. Cardiovasc Intervent Radiol 2018;41:27–36. https:// 
doi.org/10.1007/s00270-017-1749-3
830. El Farargy M, Abdel Hadi A, Abou Eisha M, Bashaeb K, Antoniou GA. Systematic review 
and meta-analysis of endovascular treatment for acute mesenteric ischaemia. Vascular 
2017;25:430–8. https://doi.org/10.1177/1708538116689353
831. Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (part II)—vascular and endovas­
cular surgical approaches. Best Pract Res Clin Gastroenterol 2017;31:27–38. https://doi. 
org/10.1016/j.bpg.2016.11.003
832. Wyers MC, Powell RJ, Nolan BW, Cronenwett JL. Retrograde mesenteric stenting 
during laparotomy for acute occlusive mesenteric ischemia. J Vasc Surg 2007;45: 
269–75. https://doi.org/10.1016/j.jvs.2006.10.047
833. Tilsed JV, Casamassima A, Kurihara H, Mariani D, Martinez I, Pereira J, et al. ESTES 
guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg 2016;42:253–70. 
https://doi.org/10.1007/s00068-016-0634-0
834. Tallarita T, Oderich GS, Gloviczki P, Duncan AA, Kalra M, Cha S, et al. Patient survival 
after open and endovascular mesenteric revascularization for chronic mesenteric is­
chemia. J Vasc Surg 2013;57:747–55; discussion 754–745. https://doi.org/10.1016/j. 
jvs.2012.09.047
835. Alahdab F, Arwani R, Pasha AK, Razouki ZA, Prokop LJ, Huber TS, et al. A systematic 
review and meta-analysis of endovascular versus open surgical revascularization for 
chronic mesenteric ischemia. J Vasc Surg 2018;67:1598–605. https://doi.org/10.1016/ 
j.jvs.2017.12.046
836. Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointestinal ischaemia: shifting para­
digms. Gut 2011;60:722–37. https://doi.org/10.1136/gut.2009.199695
837. Roobottom CA, Dubbins PA. Significant disease of the celiac and superior mesenteric 
arteries in asymptomatic patients: predictive value of Doppler sonography. AJR Am J 
Roentgenol 1993;161:985–8. https://doi.org/10.2214/ajr.161.5.8273642
838. Høyer C, Christensen MH, Sandermann J, Leusink R, Abrahamsen J. Chronic mesen­
teric ischaemia: the importance of the individual mesenteric artery. Clin Physiol Funct 
Imaging 2022;42:15–22. https://doi.org/10.1111/cpf.12730
839. Mensink PB, van Petersen AS, Geelkerken RH, Otte JA, Huisman AB, Kolkman JJ, et al. 
Clinical significance of splanchnic artery stenosis. Br J Surg 2006;93:1377–82. https:// 
doi.org/10.1002/bjs.5481
840. van Noord D, Mensink PB, de Knegt RJ, Ouwendijk M, Francke J, van Vuuren AJ, et al. 
Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia. Dig 
Dis Sci 2011;56:506–12. https://doi.org/10.1007/s10620-010-1303-5
841. Mensink PB, Hol L, Borghuis-Koertshuis N, Geelkerken RH, Huisman AB, 
Doelman CJA, et al. Transient postprandial ischemia is associated with increased 
intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 
Eur J Gastroenterol Hepatol 2009;21:278–82. https://doi.org/10.1097/MEG. 
0b013e32832183a7
842. van Noord D, Kolkman JJ. Functional testing in the diagnosis of chronic mesenteric is­
chemia. Best Pract Res Clin Gastroenterol 2017;31:59–68. https://doi.org/10.1016/j.bpg. 
2016.12.002
843. van Petersen AS, Meerwaldt R, Kolkman JJ, Huisman AB, van der Palen J, van Bockel JH, 
et al. The influence of respiration on criteria for transabdominal duplex examination of 
the splanchnic arteries in patients with suspected chronic splanchnic ischemia. J Vasc 
Surg 2013;57:1603–11, 1611.e1–10. https://doi.org/10.1016/j.jvs.2012.11.120
844. Zwolak RM, Fillinger MF, Walsh DB, LaBombard FA, Musson A, Darling CE, et al. 
Mesenteric and celiac duplex scanning: a validation study. J Vasc Surg 1998;27: 
1078–88; discussion 1088. https://doi.org/10.1016/s0741-5214(98)60010-0
845. Schaefer PJ, Pfarr J, Trentmann J, Wulff A, Langer C, Siggelkow M, et al. Comparison of 
noninvasive imaging modalities for stenosis grading in mesenteric arteries. Rofo 2013; 
185:628–34. https://doi.org/10.1055/s-0033-1335212
846. Cademartiri F, Palumbo A, Maffei E, Martini C, Malagò R, Belgrano M, et al. Noninvasive 
evaluation of the celiac trunk and superior mesenteric artery with multislice CT in pa­
tients with chronic mesenteric ischaemia. Radiol Med 2008;113:1135–42. https://doi. 
org/10.1007/s11547-008-0330-1
847. Pecoraro F, Rancic Z, Lachat M, Mayer D, Amann-Vesti B, Pfammatter T, et al. Chronic 
mesenteric ischemia: critical review and guidelines for management. Ann Vasc Surg 
2013;27:113–22. https://doi.org/10.1016/j.avsg.2012.05.012
848. Gupta PK, Horan SM, Turaga KK, Miller WJ, Pipinos II. Chronic mesenteric ischemia: 
endovascular versus open revascularization. J Endovasc Ther 2010;17:540–9. https:// 
doi.org/10.1583/09-2935.1


<!-- PAGE 146 -->

### Page 146

849. Huber TS, Björck M, Chandra A, Clouse WD, Dalsing MC, Oderich GS, et al. Chronic 
mesenteric ischemia: clinical practice guidelines from the society for vascular surgery. 
J Vasc Surg 2021;73:87s–115s. https://doi.org/10.1016/j.jvs.2020.10.029
850. Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, Sánchez-González J, Macías A, 
et al. Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. 
J Am Coll Cardiol 2019;73:1371–82. https://doi.org/10.1016/j.jacc.2018.12.075
851. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, et al. 
Prevalence of potential risk factors for stroke assessed by transesophageal echocardi­
ography and carotid ultrasonography: the SPARC study. Stroke prevention: assess­
ment of risk in a community. Mayo Clin Proc 1999;74:862–9. https://doi.org/10.4065/ 
74.9.862
852. Russo C, Jin Z, Rundek T, Homma S, Sacco RL, Di Tullio MR. Atherosclerotic disease of 
the proximal aorta and the risk of vascular events in a population-based cohort: the 
Aortic Plaques and Risk of Ischemic Stroke (APRIS) study. Stroke 2009;40:2313–8. 
https://doi.org/10.1161/strokeaha.109.548313
853. Oyama N, Gona P, Salton CJ, Chuang ML, Jhaveri RR, Blease SJ, et al. Differential impact 
of age, sex, and hypertension on aortic atherosclerosis: the Framingham heart study. 
Arterioscler Thromb Vasc Biol 2008;28:155–9. https://doi.org/10.1161/atvbaha.107. 
153544
854. Montgomery DH, Ververis JJ, McGorisk G, Frohwein S, Martin RP, Taylor WR. Natural 
history of severe atheromatous disease of the thoracic aorta: a transesophageal echo­
cardiographic study. J Am Coll Cardiol 1996;27:95–101. https://doi.org/10.1016/0735- 
1097(95)00431-9
855. Amarenco P, Cohen A, Hommel M, Moulin T, Leys D, Bousser M-G. Atherosclerotic 
disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 
1996;334:1216–21. https://doi.org/10.1056/nejm199605093341902
856. Fujimoto S, Yasaka M, Otsubo R, Oe H, Nagatsuka K, Minematsu K. Aortic arch ath­
erosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004;35:1426–9. 
https://doi.org/10.1161/01.STR.0000127788.32550.d4
857. Koren MJ, Bryant B, Hilton TC. Atherosclerotic disease of the aortic arch and the risk 
of ischemic stroke. N Engl J Med 1995;332:1237–8. author reply 1237-1238. https:// 
doi.org/10.1056/NEJM199505043321815
858. Meissner I, Khandheria BK, Sheps SG, Schwartz GL, Wiebers DO, Whisnant JP, et al. 
Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A pro­
spective population-based transesophageal echocardiography study. J Am Coll Cardiol 
2004;44:1018–24. https://doi.org/10.1016/j.jacc.2004.05.075
859. Mitusch R, Doherty C, Wucherpfennig H, Memmesheimer C, Tepe C, Stierle U, et al. 
Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke 
1997;28:36–9. https://doi.org/10.1161/01.str.28.1.36
860. Tunick PA, Rosenzweig BP, Katz ES, Freedberg RS, Perez JL, Kronzon I. High risk for 
vascular events in patients with protruding aortic atheromas: a prospective study. 
J Am Coll Cardiol 1994;23:1085–90. https://doi.org/10.1016/0735-1097(94)90595-9
861. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S. Aortic arch plaques and risk 
of recurrent stroke and death. Circulation 2009;119:2376–82. https://doi.org/10.1161/ 
circulationaha.108.811935
862. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, 
et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients 
with severe thoracic aortic plaque. Am J Cardiol 2002;90:1320–5. https://doi.org/10. 
1016/s0002-9149(02)02870-9
863. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin 
and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or 
transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, 
placebo-controlled trial. Lancet 2004;364:331–7. https://doi.org/10.1016/s0140- 
6736(04)16721-4
864. Bowdish ME, Weaver FA, Liebman HA, Rowe VL, Hood DB. Anticoagulation is an ef­
fective treatment for aortic mural thrombi. J Vasc Surg 2002;36:713–9.
865. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill 
D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and 
transient ischemic attack: a guideline from the American Heart Association/ 
American Stroke Association. Stroke 2021;52:e364–467. https://doi.org/10.1161/ 
str.0000000000000375
866. Amarenco P, Davis S, Jones EF, Cohen AA, Heiss W-D, Kaste M, et al. Clopidogrel plus 
aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014;45: 
1248–57. https://doi.org/10.1161/strokeaha.113.004251
867. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of 
clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 
367:817–25. https://doi.org/10.1056/NEJMoa1204133
868. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. A comparison of 
two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020;382:9. https:// 
doi.org/10.1056/NEJMoa1910355
869. Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV, et al. 
Normal limits in relation to age, body size and gender of two-dimensional echocardio­
graphic aortic root dimensions in persons ≥15 years of age. Am J Cardiol 2012;110: 
1189–94. https://doi.org/10.1016/j.amjcard.2012.05.063
870. van Kimmenade RR, Kempers M, de Boer MJ, Loeys BL, Timmermans J. A clinical ap­
praisal of different Z-score equations for aortic root assessment in the diagnostic 
evaluation of Marfan syndrome. Genet Med 2013;15:528–32. https://doi.org/10. 
1038/gim.2012.172
871. Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B, et al. Novel measure­
ment of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac 
Surg 2006;81:169–77. https://doi.org/10.1016/j.athoracsur.2005.06.026
872. Hannawa KK, Eliason JL, Upchurch GR, Jr. Gender differences in abdominal aortic an­
eurysms. Vascular 2009;17:30–9. https://doi.org/10.2310/6670.2008.00092
873. Boczar KE, Cheung K, Boodhwani M, Beauchesne L, Dennie C, Nagpal S, et al. Sex dif­
ferences in thoracic aortic aneurysm growth. Hypertension 2019;73:190–6. https://doi. 
org/10.1161/hypertensionaha.118.11851
874. Hultgren R, Larsson E, Wahlgren CM, Swedenborg J. Female and elderly abdominal 
aortic aneurysm patients more commonly have concurrent thoracic aortic aneurysm. 
Ann Vasc Surg 2012;26:918–23. https://doi.org/10.1016/j.avsg.2012.01.023
875. Chaer RA, Vasoncelos R, Marone LK, Al-Khoury G, Rhee RY, Cho JS, et al. 
Synchronous and metachronous thoracic aneurysms in patients with abdominal aortic 
aneurysms. J Vasc Surg 2012;56:1261–5. https://doi.org/10.1016/j.jvs.2012.04.056
876. Olsen PS, Schroeder T, Agerskov K, Agerskov K, Røder O, Sørensen S, et al. Surgery 
for abdominal aortic aneurysms. A survey of 656 patients. J Cardiovasc Surg 1991;32: 
636–42.
877. Tuveson V, Löfdahl HE, Hultgren R. Patients with abdominal aortic aneurysm have a 
high prevalence of popliteal artery aneurysms. Vasc Med 2016;21:369–75. https:// 
doi.org/10.1177/1358863x16648404
878. Brunkwall J, Hauksson H, Bengtsson H, Bergqvist D, Takolander R, Bergentz S-E. 
Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occur­
rence. J Vasc Surg 1989;10:381–4. https://doi.org/10.1067/mva.1989.13733
879. Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, Cherry KJ, et al. 
Thoracic aortic aneurysms: a population-based study. Surgery 1982;92:1103–8.
880. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and 
etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999;17:615–35; vii. 
https://doi.org/10.1016/s0733-8651(05)70105-3
881. Diwan A, Sarkar R, Stanley JC, Zelenock GB, Wakefield TW. Incidence of femoral and 
popliteal artery aneurysms in patients with abdominal aortic aneurysms. J Vasc Surg 
2000;31:863–9. https://doi.org/10.1067/mva.2000.105955
882. Brown LC, Thompson SG, Greenhalgh RM, Powell JT. Incidence of cardiovascular 
events and death after open or endovascular repair of abdominal aortic aneurysm in 
the randomized EVAR trial 1. Br J Surg 2011;98:935–42. https://doi.org/10.1002/bjs. 
7485
883. Hammo S, Grannas D, Wahlgren CM. High risk of early and late cardiovascular events 
after endovascular aortic aneurysm repair. Ann Vasc Surg 2022;86:320–7. https://doi. 
org/10.1016/j.avsg.2022.04.028
884. Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. 
J Vasc Surg 2012;56:565–71. https://doi.org/10.1016/j.jvs.2012.04.053
885. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dis­
section: increasing prevalence and improved outcomes reported in a nationwide 
population-based study of more than 14,000 cases from 1987 to 2002. Circulation 
2006;114:2611–8. https://doi.org/10.1161/circulationaha.106.630400
886. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, et al. 2010 ACCF/ 
AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and man­
agement of patients with thoracic aortic disease: a report of the American College of 
Cardiology Foundation/American Heart Association task force on practice guidelines, 
American Association for Thoracic Surgery, American College of Radiology, American 
Stroke Association, Society of Cardiovascular Anesthesiologists, Society for 
Cardiovascular Angiography and Interventions, Society of Interventional Radiology, 
Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 
121:e266–369. https://doi.org/10.1161/CIR.0b013e3181d4739e
887. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic 
aneurysm and dissection. J Am Coll Cardiol 2014;64:1725–39. https://doi.org/10.1016/j. 
jacc.2014.08.025
888. Caruana M, Baars MJ, Bashiardes E, Benke K, Björck E, Codreanu A, et al. HTAD pa­
tient pathway: strategy for diagnostic work-up of patients and families with (suspected) 
heritable thoracic aortic diseases (HTAD). A statement from the HTAD working 
group of VASCERN. Eur J Med Genet 2023;66:104673. https://doi.org/10.1016/j. 
ejmg.2022.104673
889. Patel HJ, Deeb GM. Ascending and arch aorta: pathology, natural history, and treat­
ment. 
Circulation 
2008;118:188–95. 
https://doi.org/10.1161/circulationaha.107. 
690933
890. Boodhwani M, de Kerchove L, Glineur D, Poncelet A, Rubay J, Astarci P, et al. 
Repair-oriented classification of aortic insufficiency: impact on surgical techniques 
and clinical outcomes. J Thorac Cardiovasc Surg 2009;137:286–94. https://doi.org/10. 
1016/j.jtcvs.2008.08.054
891. Ganapathi AM, Ranney DN, Peterson MD, Lindsay ME, Patel HJ, Pyeritz RE, et al. 
Location of aortic enlargement and risk of type A dissection at smaller diameters. 
J Am Coll Cardiol 2022;79:1890–7. https://doi.org/10.1016/j.jacc.2022.02.053
892. Kalogerakos PD, Zafar MA, Li Y, Mukherjee SK, Ziganshin BA, Rizzo JA, et al. Root dila­
tation is more malignant than ascending aortic dilation. J Am Heart Assoc 2021;10: 
e020645. https://doi.org/10.1161/jaha.120.020645
ESC Guidelines                                                                                                                                                                                          3683


<!-- PAGE 147 -->

### Page 147

893. Della Corte A, Bancone C, Buonocore M, Dialetto G, Covino FE, Manduca S, et al. 
Pattern of ascending aortic dimensions predicts the growth rate of the aorta in pa­
tients with bicuspid aortic valve. JACC Cardiovasc Imaging 2013;6:1301–10. https:// 
doi.org/10.1016/j.jcmg.2013.07.009
894. Kim JB, Spotnitz M, Lindsay ME, MacGillivray TE, Isselbacher EM, Sundt TM. Risk of aor­
tic dissection in the moderately dilated ascending aorta. J Am Coll Cardiol 2016;68: 
1209–19. https://doi.org/10.1016/j.jacc.2016.06.025
895. Saeyeldin A, Zafar MA, Velasquez CA, Ip K, Gryaznov A, Brownstein AJ, et al. Natural 
history of aortic root aneurysms in Marfan syndrome. Ann Cardiothorac Surg 2017;6: 
625–32. https://doi.org/10.21037/acs.2017.11.10
896. Cheung K, Boodhwani M, Chan KL, Beauchesne L, Dick A, Coutinho T. Thoracic aortic 
aneurysm growth: role of sex and aneurysm etiology. J Am Heart Assoc 2017;6: 
e003792. https://doi.org/10.1161/jaha.116.003792
897. Nataf P, Lansac E. Dilation of the thoracic aorta: medical and surgical management. 
Heart 2006;92:1345–52. https://doi.org/10.1136/hrt.2005.074781
898. Yiu RS, Cheng SW. Natural history and risk factors for rupture of thoracic aortic arch 
aneurysms. J Vasc Surg 2016;63:1189–94. https://doi.org/10.1016/j.jvs.2015.12.043
899. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the 
appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac 
Cardiovasc Surg 1997;113:476–91; discussion 489–491. https://doi.org/10.1016/ 
s0022-5223(97)70360-x
900. Safi HJ, Winnerkvist A, Miller CC, III, Iliopoulos DC, Reardon MJ, Espada R, et al. Effect 
of extended cross-clamp time during thoracoabdominal aortic aneurysm repair. Ann 
Thorac Surg 1998;66:1204–8. https://doi.org/10.1016/s0003-4975(98)00781-4
901. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005;111: 
816–28. https://doi.org/10.1161/01.Cir.0000154569.08857.7a
902. Zafar MA, Chen JF, Wu J, Li Y, Papanikolaou D, Abdelbaky M, et al. Natural history of 
descending thoracic and thoracoabdominal aortic aneurysms. J Thorac Cardiovasc Surg 
2021;161:498–511.e1. https://doi.org/10.1016/j.jtcvs.2019.10.125
903. Oladokun D, Patterson BO, Sobocinski J, Karthikesalingam A, Loftus I, Thompson MM, 
et al. Systematic review of the growth rates and influencing factors in thoracic aortic 
aneurysms. Eur J Vasc Endovasc Surg 2016;51:674–81. https://doi.org/10.1016/j.ejvs. 
2016.01.017
904. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture 
or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann 
Thorac Surg 2002;73:17–28; discussion 27–18. https://doi.org/10.1016/s0003-4975(01) 
03236-2
905. Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: 
familial and genetic aspects in three hundred thirteen pedigrees. J Vasc Surg 1995; 
21:646–55. https://doi.org/10.1016/s0741-5214(95)70196-6
906. Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, et al. Systematic 
review and meta-analysis of the growth and rupture rates of small abdominal aortic 
aneurysms: implications for surveillance intervals and their cost-effectiveness. Health 
Technol Assess 2013;17:1–118. https://doi.org/10.3310/hta17410
907. Sakalihasan N, Defraigne JO, Kerstenne MA, Cheramy-Bien J-P, Smelser DT, Tromp G, 
et al. Family members of patients with abdominal aortic aneurysms are at increased risk 
for aneurysms: analysis of 618 probands and their families from the Liege AAA family 
study. Ann Vasc Surg 2014;28:787–97. https://doi.org/10.1016/j.avsg.2013.11.005
908. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultra­
sound surveillance. UK small aneurysm trial participants. Ann Surg 1999;230:289–96; 
discussion 296–287. https://doi.org/10.1097/00000658-199909000-00002
909. Mani K, Wanhainen A. Accurate and reproducible diameter measurement is essential 
in surveillance and treatment of thoracic aortic aneurysms. Eur J Vasc Endovasc Surg 
2014;47:27. https://doi.org/10.1016/j.ejvs.2013.10.004
910. Isselbacher EM, Preventza O, Hamilton Black J, III, Augoustides JG, Beck AW, Bolen 
MA, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic dis­
ease: a report of the American Heart Association/American College of Cardiology 
joint committee on clinical practice guidelines. Circulation 2022;146:e334-482. 
https://doi.org/10.1161/cir.0000000000001106
911. Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm. 
Am Heart J 2011;162:38–46.e1. https://doi.org/10.1016/j.ahj.2011.04.010
912. Wang TKM, Desai MY. Thoracic aortic aneurysm: optimal surveillance and treatment. 
Cleve Clin J Med 2020;87:557–68. https://doi.org/10.3949/ccjm.87a.19140-1
913. Roberts DA. Magnetic resonance imaging of thoracic aortic aneurysm and dissection. 
Semin Roentgenol 2001;36:295–308. https://doi.org/10.1053/sroe.2001.26938
914. Rajiah P. CT and MRI in the evaluation of thoracic aortic diseases. Int J Vasc Med 2013; 
2013:797189. https://doi.org/10.1155/2013/797189
915. Lin FY, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A, et al. Assessment of the 
thoracic aorta by multidetector computed tomography: age- and sex-specific refer­
ence values in adults without evident cardiovascular disease. J Cardiovasc Comput 
Tomogr 2008;2:298–308. https://doi.org/10.1016/j.jcct.2008.08.002
916. McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and 
mortality of abdominal aortic aneurysm in the United States, 2001–2004. J Vasc Surg 
2007;45:891–9. https://doi.org/10.1016/j.jvs.2007.01.043
917. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneur­
ysms: a 7-year prospective study: the Tromsø study, 1994–2001. Circulation 2009;119: 
2202–8. https://doi.org/10.1161/circulationaha.108.817619
918. Jahangir E, Lipworth L, Edwards TL, Kabagambe EK, Mumma MT, Mensah GA, et al. 
Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of 
18 782 persons aged above 65 years in the southern community cohort study. 
J Epidemiol Community Health 2015;69:481–8. https://doi.org/10.1136/jech-2014- 
204920
919. Strachan DP. Predictors of death from aortic aneurysm among middle-aged men: the 
Whitehall study. Br J Surg 2005;78:401–4. https://doi.org/10.1002/bjs.1800780407
920. Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegård J, Björck M. Risk factors 
associated with abdominal aortic aneurysm: a population-based study with historical 
and current data. J Vasc Surg 2005;41:390–6. https://doi.org/10.1016/j.jvs.2005.01.002
921. Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, et al. 
Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 mil­
lion individuals. J Vasc Surg 2010;52:539–48. https://doi.org/10.1016/j.jvs.2010.05.090
922. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Diabetes and 
aortic aneurysm: current state of the art. Cardiovasc Res 2018;114:1702–13. https:// 
doi.org/10.1093/cvr/cvy174
923. Avdic T, Franzén S, Zarrouk M, Acosta S, Nilsson P, Gottsäter A, et al. Reduced long- 
term risk of aortic aneurysm and aortic dissection among individuals with type 2 dia­
betes mellitus: a nationwide observational study. J Am Heart Assoc 2018;7:e007618. 
https://doi.org/10.1161/jaha.117.007618
924. Nordness MJ, Baxter BT, Matsumura J, Terrin M, Zhang K, Ye F, et al. The effect of 
diabetes on abdominal aortic aneurysm growth over 2 years. J Vasc Surg 2022;75: 
1211–22.e1. https://doi.org/10.1016/j.jvs.2021.10.019
925. Yusuf K, Murat B, Unal A, Ulku K, Taylan K, Ozerdem O, et al. Inflammatory abdominal 
aortic aneurysm: predictors of long-term outcome in a case-control study. Surgery 
2007;141:83–9. https://doi.org/10.1016/j.surg.2006.04.007
926. Oliver-Williams C, Sweeting MJ, Turton G, Parkin D, Cooper D, Rodd C, et al. Lessons 
learned about prevalence and growth rates of abdominal aortic aneurysms from a 
25-year ultrasound population screening programme. Br J Surg 2018;105:68–74. 
https://doi.org/10.1002/bjs.10715
927. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic 
aneurysm presence and progression. Circulation 2008;118:2382–92. https://doi.org/10. 
1161/circulationaha.108.802074
928. Vermeulen JJM, Meijer M, de Vries FBG, Reijnen MMPJ, Holewijn S, Thijssen DHJ, et al. 
A systematic review summarizing local vascular characteristics of aneurysm wall to 
predict for progression and rupture risk of abdominal aortic aneurysms. J Vasc Surg 
2023;77:288–98.e2. https://doi.org/10.1016/j.jvs.2022.07.008
929. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT. Abdominal aortic 
aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004; 
110:16–21. https://doi.org/10.1161/01.Cir.0000133279.07468.9f
930. Malayala SV, Raza A, Vanaparthy R. Gender-based differences in abdominal aortic an­
eurysm rupture: a retrospective study. J Clin Med Res 2020;12:794–802. https://doi. 
org/10.14740/jocmr4376
931. Skibba AA, Evans JR, Hopkins SP, Yoon HR, Katras T, Kalbfleisch JH, et al. 
Reconsidering gender relative to risk of rupture in the contemporary management 
of abdominal aortic aneurysms. J Vasc Surg 2015;62:1429–36. https://doi.org/10. 
1016/j.jvs.2015.07.079
932. Catalano O, Siani A. Ruptured abdominal aortic aneurysm: categorization of sono­
graphic findings and report of 3 new signs. J Ultrasound Med 2005;24:1077–83. 
https://doi.org/10.7863/jum.2005.24.8.1077
933. Schermerhorn ML, Bensley RP, Giles KA, Hurks R, O’Malley AJ, Cotterill P, et al. 
Changes in abdominal aortic aneurysm rupture and short-term mortality, 
1995-2008: a retrospective observational study. Ann Surg 2012;256:651–8. https:// 
doi.org/10.1097/SLA.0b013e31826b4f91
934. Rakita D, Newatia A, Hines JJ, Siegel DN, Friedman B. Spectrum of CT findings in rup­
ture and impending rupture of abdominal aortic aneurysms. Radiographics 2007;27: 
497–507. https://doi.org/10.1148/rg.272065026
935. Schwartz SA, Taljanovic MS, Smyth S, O’Brien MJ, Rogers LF. CT findings of rupture, 
impending rupture, and contained rupture of abdominal aortic aneurysms. AJR Am J 
Roentgenol 2007;188:W57–62. https://doi.org/10.2214/ajr.05.1554
936. Tomee SM, Bulder RMA, Meijer CA, van Berkum I, Hinnen J-W, Schoones JW, et al. 
Excess mortality for abdominal aortic aneurysms and the potential of strict implemen­
tation of cardiovascular risk management: a multifaceted study integrating 
meta-analysis, national registry, and PHAST and TEDY trial data. Eur J Vasc Endovasc 
Surg 2023;65:348–57. https://doi.org/10.1016/j.ejvs.2022.11.019
937. Freiberg MS, Arnold AM, Newman AB, Edwards MS, Kraemer KL, Kuller LH. 
Abdominal aortic aneurysms, increasing infrarenal aortic diameter, and risk of total 
mortality and incident cardiovascular disease events: 10-year follow-up data from 
the cardiovascular health study. Circulation 2008;117:1010–7. https://doi.org/10. 
1161/circulationaha.107.720219
938. Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG. Surveillance intervals for 
small abdominal aortic aneurysms: a meta-analysis. JAMA 2013;309:806–13. https://doi. 
org/10.1001/jama.2013.950


<!-- PAGE 148 -->

### Page 148

939. Dugas A, Therasse E, Kauffmann C, Tang A, Elkouri S, Nozza A, et al. Reproducibility of 
abdominal aortic aneurysm diameter measurement and growth evaluation on axial and 
multiplanar computed tomography reformations. Cardiovasc Intervent Radiol 2012;35: 
779–87. https://doi.org/10.1007/s00270-011-0259-y
940. Kontopodis N, Metaxa E, Gionis M, Papaharilaou Y, Ioannou CV. Discrepancies in de­
termination of abdominal aortic aneurysms maximum diameter and growth rate, using 
axial and orhtogonal computed tomography measurements. Eur J Radiol 2013;82: 
1398–403. https://doi.org/10.1016/j.ejrad.2013.04.031
941. Foo FJ, Hammond CJ, Goldstone AR, Abuhamdiah M, Rashid ST, West RM, et al. 
Agreement between computed tomography and ultrasound on abdominal aortic an­
eurysms and implications on clinical decisions. Eur J Vasc Endovasc Surg 2011;42: 
608–14. https://doi.org/10.1016/j.ejvs.2011.07.003
942. Zhu C, Tian B, Leach JR, Liu Q, Lu J, Chen L, et al. Non-contrast 3D black blood MRI for 
abdominal aortic aneurysm surveillance: comparison with CT angiography. Eur Radiol 
2017;27:1787–94. https://doi.org/10.1007/s00330-016-4559-0
943. Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne J-O, Nchimi A, et al. 
Abdominal aortic aneurysms. Nat Rev Dis Primers 2018;4:34. https://doi.org/10.1038/ 
s41572-018-0030-7
944. Wemmelund H, Jørgensen TM, Høgh A, Behr-Rasmussen C, Johnsen SP, Lindholt JS, 
et al. Low-dose aspirin and rupture of abdominal aortic aneurysm. J Vasc Surg 2017;65: 
616–5.e4. https://doi.org/10.1016/j.jvs.2016.04.061
945. Wanhainen A, Mani K, Kullberg J, Svensjö S, Bersztel A, Karlsson L, et al. The effect of 
ticagrelor on growth of small abdominal aortic aneurysms–a randomized controlled 
trial. Cardiovasc Res 2020;116:450–6. https://doi.org/10.1093/cvr/cvz133
946. Golledge J, Thanigaimani S, Powell JT, Tsao PS. Pathogenesis and management of ab­
dominal aortic aneurysm. Eur Heart J 2023;44:2682–97. https://doi.org/10.1093/ 
eurheartj/ehad386
947. Sweeting MJ, Thompson SG, Brown LC, Powell JT, Collaborators R. Meta-analysis of 
individual patient data to examine factors affecting growth and rupture of small ab­
dominal aortic aneurysms. Br J Surg 2012;99:655–65. https://doi.org/10.1002/bjs.8707
948. Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J, et al. 
Association between metformin prescription and growth rates of abdominal aortic an­
eurysms. Br J Surg 2017;104:1486–93. https://doi.org/10.1002/bjs.10587
949. Thanigaimani S, Singh TP, Unosson J, Phie J, Moxon J, Wanhainen A, et al. Editor’s 
choice—association between metformin prescription and abdominal aortic aneurysm 
growth and clinical events: a systematic review and meta-analysis. Eur J Vasc Endovasc 
Surg 2021;62:747–56. https://doi.org/10.1016/j.ejvs.2021.06.013
950. Wong KHF, Zlatanovic P, Bosanquet DC, Saratzis A, Kakkos SK, Aboyans V, et al. 
Antithrombotic therapy for aortic aneurysms: a systematic review and meta-analysis. 
Eur J Vasc Endovasc Surg 2022;64:544–56. https://doi.org/10.1016/j.ejvs.2022.07.008
951. Newton ER, Akerman AW, Strassle PD, Kibbe MR. Association of fluoroquinolone use 
with short-term risk of development of aortic aneurysm. JAMA Surg 2021;156:264–72. 
https://doi.org/10.1001/jamasurg.2020.6165
952. Wee I, Chin B, Syn N, Lee KS, Ng JJ, Choong AMTL. The association between fluor­
oquinolones and aortic dissection and aortic aneurysms: a systematic review and 
meta-analysis. Sci Rep 2021;11:11073. https://doi.org/10.1038/s41598-021-90692-8
953. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic an­
eurysm and dissection: nationwide cohort study. BMJ 2018;360:k678. https://doi. 
org/10.1136/bmj.k678
954. Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Park H, et al. Oral fluoroqui­
nolones and risk of aortic aneurysm or dissection: a nationwide population-based pro­
pensity score-matched cohort study. Pharmacotherapy 2023;43:883–93. https://doi. 
org/10.1002/phar.2841
955. Fatima K, Uzair SU, Salman A, Jawed A, Husain MA, Shah MG, et al. Fluoroquinolones 
and the risk of aortic aneurysm or aortic dissection: an updated systematic review and 
meta-analysis including 53,651,283 patients. Minerva Cardiol Angiol 2023;71:485–93. 
https://doi.org/10.23736/S2724-5683.22.06124-5
956. LeMaire SA, Zhang L, Luo W, Ren P, Azares AR, Wang Y, et al. Effect of ciprofloxacin 
on susceptibility to aortic dissection and rupture in mice. JAMA Surg 2018;153: 
e181804. https://doi.org/10.1001/jamasurg.2018.1804
957. Brown JP, Wing K, Leyrat C, Evans SJ, Mansfield KE, Wong AYS, et al. Association be­
tween fluoroquinolone use and hospitalization with aortic aneurysm or aortic dissec­
tion. JAMA Cardiol 2023;8:865. https://doi.org/10.1001/jamacardio.2023.2418
958. Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association 
of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern 
Med 2020;180:1596–605. https://doi.org/10.1001/jamainternmed.2020.4199
959. Lee CC, Lee MT, Chen YS, Lee S-H, Chen Y-S, Chen S-C, et al. Risk of aortic dissection 
and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med 2015; 
175:1839–47. https://doi.org/10.1001/jamainternmed.2015.5389
960. Huh K, Kang M, Jung J. Lack of association between fluoroquinolone and aortic aneur­
ysm or dissection. Eur Heart J 2023;44:4476–84. https://doi.org/10.1093/eurheartj/ 
ehad627
961. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al. Survival and re­
operation pattern after 20 years of experience with aortic valve-sparing root replace­
ment in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155: 
1403–11.e1. https://doi.org/10.1016/j.jtcvs.2017.12.039
962. Lee H, Cho YH, Sung K, Kim WS, Park K-H, Jeong DS, et al. Clinical outcomes of root 
reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac 
Surg 2018;106:539–47. https://doi.org/10.1016/j.athoracsur.2018.02.057
963. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al. 
Long-term experience with valve-sparing reimplantation technique for the treatment 
of aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14–23. 
https://doi.org/10.1016/j.jtcvs.2018.10.155
964. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al. 
Early and late results after David vs Bentall procedure: a propensity matched analysis. 
Ann Thorac Surg 2020;110:120–6. https://doi.org/10.1016/j.athoracsur.2019.10.020
965. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al. 
Valve-sparing root replacement versus composite valve grafting in aortic root dilation: 
a meta-analysis. Ann Thorac Surg 2020;110:296–306. https://doi.org/10.1016/j. 
athoracsur.2019.11.054
966. Leyh RG, Fischer S, Kallenbach K, Kofidis T, Pethig K, Harringer W, et al. High failure 
rate after valve-sparing aortic root replacement using the “remodeling technique” in 
acute type A aortic dissection. Circulation 2002;106:I229–33.
967. Schäfers H, Fries R, Langer F, Nikoloudakis N, Graeter T, Grundmann U. 
Valve-preserving replacement of the ascending aorta: remodeling versus reimplanta­
tion. J Thorac Cardiovasc Surg 1998;116:990–6. https://doi.org/10.1016/s0022- 
5223(98)70051-0
968. Rahnavardi M, Yan TD, Bannon PG, Wilson MK. Aortic valve-sparing operations in 
aortic root aneurysms: remodeling or reimplantation? Interact Cardiovasc Thorac Surg 
2011;13:189–97. https://doi.org/10.1510/icvts.2011.267401
969. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ 
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 
561–632. https://doi.org/10.1093/eurheartj/ehab395
970. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, et al. Warfarin versus 
dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart 
valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72: 
1059–63. https://doi.org/10.1161/01.cir.72.5.1059
971. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications 
in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41. https:// 
doi.org/10.1161/01.cir.89.2.635
972. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. Early an­
ticoagulation of bioprosthetic aortic valves in older patients: results from the Society of 
Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; 
60:971–7. https://doi.org/10.1016/j.jacc.2012.05.029
973. Rafiq S, Steinbrüchel DA, Lilleør NB, Møller CH, Lund JT, Thiis JJ, et al. Antithrombotic 
therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a rando­
mized controlled trial. Thromb Res 2017;150:104–10. https://doi.org/10.1016/j. 
thromres.2016.11.021
974. Czerny M, Rylski B, Della Corte A, Krüger T. Decision-making to perform elective sur­
gery for patients with proximal thoracic aortic pathology: a European perspective. 
J Thorac Cardiovasc Surg 2022;163:2025–30. https://doi.org/10.1016/j.jtcvs.2021.01.141
975. Vorp DA, Schiro BJ, Ehrlich MP, Juvonen TS, Ergin MA, Griffith BP. Effect of aneurysm 
on the tensile strength and biomechanical behavior of the ascending thoracic aorta. 
Ann Thorac Surg 2003;75:1210–4. https://doi.org/10.1016/s0003-4975(02)04711-2
976. Della Corte A, Lo Presti F, Saade W, Rubino AS, Palmieri L, Patanè F, et al. Acute type 
A aortic dissection in bicuspid versus tricuspid aortic valve patients: focus on geomet­
rical features of the aorta. Eur J Cardiothorac Surg 2023;63:ezac576. https://doi.org/10. 
1093/ejcts/ezac576
977. Mullan CW, Mori M, Bin Mahmood SU, Yousef S, Mangi AA, Elefteriades JA, et al. 
Incidence and characteristics of hospitalization for proximal aortic surgery for acute 
syndromes and for aneurysms in the USA from 2005 to 2014. Eur J Cardiothorac 
Surg 2020;58:583–9. https://doi.org/10.1093/ejcts/ezaa067
978. Williams JB, Peterson ED, Zhao Y, O’Brien SM, Andersen ND, Miller DC, et al. 
Contemporary results for proximal aortic replacement in North America. J Am Coll 
Cardiol 2012;60:1156–62. https://doi.org/10.1016/j.jacc.2012.06.023
979. Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al. Elective 
aortic root replacement in North America: analysis of STS adult cardiac surgery data­
base. Ann Thorac Surg 2019;107:1307–12. https://doi.org/10.1016/j.athoracsur.2018. 
12.039
980. Mori M, Shioda K, Wang X, Mangi AA, Yun JJ, Darr U, et al. Perioperative risk profiles 
and volume-outcome relationships in proximal thoracic aortic surgery. Ann Thorac Surg 
2018;106:1095–104. https://doi.org/10.1016/j.athoracsur.2018.05.081
981. Wojnarski CM, Svensson LG, Roselli EE, Idrees JJ, Lowry AM, Ehrlinger J, et al. Aortic 
dissection in patients with bicuspid aortic valve-associated aneurysms. Ann Thorac Surg 
2015;100:1666–73; discussion 1673–74. https://doi.org/10.1016/j.athoracsur.2015.04. 
126
982. Wu J, Zafar MA, Liu Y, Chen JF, Li Y, Ziganshin BA, et al. Fate of the unoperated as­
cending thoracic aortic aneurysm: three-decade experience from the Aortic 
Institute at Yale University. Eur Heart J 2023;44:4579–88. https://doi.org/10.1093/ 
eurheartj/ehad148
ESC Guidelines                                                                                                                                                                                          3685


<!-- PAGE 149 -->

### Page 149

983. Ziganshin BA, Zafar MA, Elefteriades JA. Descending threshold for ascending aortic an­
eurysmectomy: is it time for a “left-shift” in guidelines? J Thorac Cardiovasc Surg 2019; 
157:37–42. https://doi.org/10.1016/j.jtcvs.2018.07.114
984. Rylski B, Branchetti E, Bavaria JE, Vallabhajosyula P, Szeto WY, Milewski RK, et al. 
Modeling of predissection aortic size in acute type A dissection: more than 90% fail 
to meet the guidelines for elective ascending replacement. J Thorac Cardiovasc Surg 
2014;148:944–8.e1. https://doi.org/10.1016/j.jtcvs.2014.05.050
985. Mansour AM, Peterss S, Zafar MA, Rizzo JA, Fang H, Charilaou P, et al. Prevention of 
aortic dissection suggests a diameter shift to a lower aortic size threshold for interven­
tion. Cardiology 2018;139:139–46. https://doi.org/10.1159/000481930
986. Masri A, Kalahasti V, Alkharabsheh S, Svensson LG, Sabik JF, Roselli EE, et al. 
Characteristics and long-term outcomes of contemporary patients with bicuspid aor­
tic valves. J Thorac Cardiovasc Surg 2016;151:1650–9.e1. https://doi.org/10.1016/j.jtcvs. 
2015.12.019
987. Winkler A, Puiu P, Krombholz-Reindl P, Vötsch A, Steindl J, Neuner M, et al. Impact of 
concomitant replacement of the ascending aorta in patients undergoing aortic valve 
replacement on operative morbidity and mortality. Eur J Cardiothorac Surg 2022;61: 
587–93. https://doi.org/10.1093/ejcts/ezab420
988. Peterss S, Charilaou P, Dumfarth J, Li Y, Bhandari R, Tranquilli M, et al. Aortic valve 
disease with ascending aortic aneurysm: impact of concomitant root-sparing (supra­
coronary) aortic replacement in nonsyndromic patients. J Thorac Cardiovasc Surg 
2016;152:791–8.e1. https://doi.org/10.1016/j.jtcvs.2016.05.020
989. Lim JY, Jung SH, Kim JB, Kim DK, Chung CH, Song H, et al. Concomitant replacement 
of the dilated ascending aorta during aortic valve replacement; does it increase the 
perioperative morbidity and mortality risks? J Card Surg 2013;28:285–90. https://doi. 
org/10.1111/jocs.12111
990. Idrees JJ, Roselli EE, Lowry AM, Reside JM, Javadikasgari H, Johnson DJ, et al. Outcomes 
after elective proximal aortic replacement: a matched comparison of isolated versus 
multicomponent operations. Ann Thorac Surg 2016;101:2185–92. https://doi.org/10. 
1016/j.athoracsur.2015.12.026
991. Idrees JJ, Roselli EE, Blackstone EH, Lowry AM, Soltesz EG, Johnston DR, et al. Risk of 
adding prophylactic aorta replacement to a cardiac operation. J Thorac Cardiovasc Surg 
2020;159:1669–78.e10. https://doi.org/10.1016/j.jtcvs.2019.05.001
992. Grabenwöger M, Alfonso F, Bachet J, Bonser R, Czerny M, Eggebrecht H, et al. 
Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: 
a position statement from the European Association for Cardio-Thoracic Surgery 
(EACTS) and the European Society of Cardiology (ESC), in collaboration with the 
European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur 
Heart J 2012;33:1558–63. https://doi.org/10.1093/eurheartj/ehs074
993. Eggebrecht H, Thompson M, Rousseau H, Czerny M, Lö nn L, Mehta RH, et al. 
Retrograde ascending aortic dissection during or after thoracic aortic stent graft place­
ment: insight from the European registry on endovascular aortic repair complications. 
Circulation 2009;120:S276–281. https://doi.org/10.1161/circulationaha.108.835926
994. Zerwes S, Leissner G, Gosslau Y, Jakob R, Bruijnen H-K, Oertl F, et al. Clinical out­
comes in hybrid repair procedures for pathologies involving the aortic arch. Vascular 
2015;23:9–16. https://doi.org/10.1177/1708538114525608
995. Czerny M, Weigang E, Sodeck G, Schmidli J, Antona C, Gelpi G, et al. Targeting landing 
zone 0 by total arch rerouting and TEVAR: midterm results of a transcontinental regis­
try. Ann Thorac Surg 2012;94:84–9. https://doi.org/10.1016/j.athoracsur.2012.03.024
996. Chiesa R, Melissano G, Tshomba Y, Civilini E, Marone EM, Bertoglio L, et al. Ten years 
of endovascular aortic arch repair. J Endovasc Ther 2010;17:1–11. https://doi.org/10. 
1583/09-2884.1
997. Shrestha M, Bachet J, Bavaria J, Carrel TP, De Paulis R, Di Bartolomeo R, et al. Current 
status and recommendations for use of the frozen elephant trunk technique: a position 
paper by the vascular domain of EACTS. Eur J Cardiothorac Surg 2015;47:759–69. 
https://doi.org/10.1093/ejcts/ezv085
998. Czerny M, Schmidli J, Adler S, van den Berg JC, Bertoglio L, Carrel T, et al. Current 
options and recommendations for the treatment of thoracic aortic pathologies involv­
ing the aortic arch: an expert consensus document of the European Association for 
Cardio-Thoracic Surgery (EACTS) and the European Society for Vascular Surgery 
(ESVS). Eur J Cardiothorac Surg 2019;55:133–62. https://doi.org/10.1093/ejcts/ezy313
999. Abjigitova D, Veen KM, van Tussenbroek G, Mokhles MM, Bekkers JA, Takkenberg JJM, 
et al. Cerebral protection in aortic arch surgery: systematic review and meta-analysis. 
Interact Cardiovasc Thorac Surg 2022;35:ivac270. https://doi.org/10.1093/icvts/ivac128
1000. Malaisrie SC, Duncan BF, Mehta CK, Badiwala MV, Rinewalt D, Kruse J, et al. The add­
ition of hemiarch replacement to aortic root surgery does not affect safety. J Thorac 
Cardiovasc Surg 2015;150:118–24.e2. https://doi.org/10.1016/j.jtcvs.2015.03.020
1001. Borger MA, Fedak PWM, Stephens EH, Gleason TG, Girdauskas E, Ikonomidis JS, 
et al. The American Association for Thoracic Surgery consensus guidelines on bicus­
pid aortic valve-related aortopathy: full online-only version. J Thorac Cardiovasc Surg 
2018;156:e41–74. https://doi.org/10.1016/j.jtcvs.2018.02.115
1002. Kim JB, Kim K, Lindsay ME, MacGillivray T, Isselbacher EM, Cambria RP, et al. Risk of 
rupture or dissection in descending thoracic aortic aneurysm. Circulation 2015;132: 
1620–9. https://doi.org/10.1161/circulationaha.114.015177
1003. Chen JF, Zafar MA, Wu J, Li Y, Rizzo JA, Papanikolaou D, et al. Increased virulence of 
descending thoracic and thoracoabdominal aortic aneurysms in women. Ann Thorac 
Surg 2021;112:45–52. https://doi.org/10.1016/j.athoracsur.2020.08.026
1004. Lobato AC, Puech-Leão P. Predictive factors for rupture of thoracoabdominal aortic 
aneurysm. J Vasc Surg 1998;27:446–53. https://doi.org/10.1016/s0741-5214(98) 
70319-2
1005. Harris DG, Olson SL, Panthofer AM, Matsumura JS, DiMusto PD. A frailty-based risk 
score predicts morbidity and mortality after elective endovascular repair of descend­
ing thoracic aortic aneurysms. Ann Vasc Surg 2020;67:90–9. https://doi.org/10.1016/j. 
avsg.2019.10.090
1006. Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC, Cronenwett JL, et al. 
Survival after open versus endovascular thoracic aortic aneurysm repair in an obser­
vational study of the Medicare population. Circulation 2011;124:2661–9. https://doi. 
org/10.1161/circulationaha.111.033944
1007. Grausgruber W, Scharfen E. Problems of the fight against zoonoses in Austria. Wien 
Tierarztl Monatsschr 1968;55:625–36.
1008. Chiu P, Goldstone AB, Schaffer JM, Lingala B, Miller DC, Mitchell RS, et al. 
Endovascular versus open repair of intact descending thoracic aortic aneurysms. 
J Am Coll Cardiol 2019;73:643–51. https://doi.org/10.1016/j.jacc.2018.10.086
1009. Fairman RM, Criado F, Farber M, Kwolek C, Mehta M, White R, et al. Pivotal results of 
the medtronic vascular talent thoracic stent graft system: the VALOR trial. J Vasc Surg 
2008;48:546–54.e2. https://doi.org/10.1016/j.jvs.2008.03.061
1010. Matsumura JS, Cambria RP, Dake MD, Moore RD, Svensson LG, Snyder S. 
International controlled clinical trial of thoracic endovascular aneurysm repair with 
the Zenith TX2 endovascular graft: 1-year results. J Vasc Surg 2008;47:247–57; dis­
cussion 257. https://doi.org/10.1016/j.jvs.2007.10.032
1011. Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal 
aortic aneurysms. Ann Thorac Surg 2007;83:S862–4; discussion S890–862. https://doi. 
org/10.1016/j.athoracsur.2006.10.088
1012. Coselli JS, Green SY, Price MD, Hash JA, Ouyang Y, Volguina IV, et al. Results of open 
surgical repair in patients with Marfan syndrome and distal aortic dissection. Ann 
Thorac Surg 2016;101:2193–201. https://doi.org/10.1016/j.athoracsur.2015.11.008
1013. Tong MZ, Eagleton MJ, Roselli EE, Blackstone EH, Xiang F, Ibrahim M, et al. Outcomes 
of open versus endovascular repair of descending thoracic and thoracoabdominal 
aortic aneurysms. Ann Thorac Surg 2022;113:1144–52. https://doi.org/10.1016/j. 
athoracsur.2021.04.100
1014. Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, et al. Stroke in 
surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac 
Cardiovasc Surg 2001;122:935–45. https://doi.org/10.1067/mtc.2001.117276
1015. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience with 1509 pa­
tients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993;17:357– 
68; discussion 368–70.
1016. Schermerhorn ML, Giles KA, Hamdan AD, Dalhberg SE, Hagberg R, Pomposelli F. 
Population-based outcomes of open descending thoracic aortic aneurysm repair. 
J Vasc Surg 2008;48:821–7. https://doi.org/10.1016/j.jvs.2008.05.022
1017. Yamauchi T, Takano H, Nishimura M, Matsumiya G, Sawa Y. Paraplegia and parapar­
esis after descending thoracic aortic aneurysm repair: a risk factor analysis. Ann Thorac 
Cardiovasc Surg 2006;12:179–83.
1018. Patel VI, Mukhopadhyay S, Ergul E, Aranson N, Conrad MF, LaMuraglia GM, et al. 
Impact of hospital volume and type on outcomes of open and endovascular repair 
of descending thoracic aneurysms in the United States Medicare population. J Vasc 
Surg 2013;58:346–54. https://doi.org/10.1016/j.jvs.2013.01.035
1019. Cheng D, Martin J, Shennib H, Dunning J, Muneretto C, Schueler S, et al. Endovascular 
aortic repair versus open surgical repair for descending thoracic aortic disease a sys­
tematic review and meta-analysis of comparative studies. J Am Coll Cardiol 2010;55: 
986–1001. https://doi.org/10.1016/j.jacc.2009.11.047
1020. Harky A, Kai Chan JS, Ming Wong CH, Bashir M. Open versus endovascular repair of 
descending thoracic aortic aneurysm disease: a systematic review and meta-analysis. 
Ann Vasc Surg 2019;54:304–15.e5. https://doi.org/10.1016/j.avsg.2018.05.043
1021. Ranney DN, Cox ML, Yerokun BA, Benrashid E, McCann RL, Hughes GC. Long-term 
results of endovascular repair for descending thoracic aortic aneurysms. J Vasc Surg 
2018;67:363–8. https://doi.org/10.1016/j.jvs.2017.06.094
1022. Biancari F, Mariscalco G, Mariani S, Saari P, Satta J, Juvonen T. Endovascular treatment 
of degenerative aneurysms involving only the descending thoracic aorta: systematic 
review and meta-analysis. J Endovasc Ther 2016;23:387–92. https://doi.org/10.1177/ 
1526602815626560
1023. Mousa AY, Morcos R, Broce M, Bates MC, AbuRahma AF. New preoperative spinal 
cord ischemia risk stratification model for patients undergoing thoracic endovascular 
aortic repair. Vasc Endovascular Surg 2020;54:487–96. https://doi.org/10.1177/ 
1538574420929135
1024. Walsh SR, Tang TY, Sadat U, Naik J, Gaunt ME, Boyle JR, et al. Endovascular stenting 
versus open surgery for thoracic aortic disease: systematic review and meta-analysis 
of perioperative results. J Vasc Surg 2008;47:1094–8.e3. https://doi.org/10.1016/j.jvs. 
2007.09.062
1025. Kotelis D, Geisbüsch P, Hinz U, Hyhlik-Dürr A, von Tengg-Kobligk H, Allenberg JR, 
et al. Short and midterm results after left subclavian artery coverage during


<!-- PAGE 150 -->

### Page 150

endovascular repair of the thoracic aorta. J Vasc Surg 2009;50:1285–92. https://doi. 
org/10.1016/j.jvs.2009.07.106
1026. Cooper DG, Walsh SR, Sadat U, Noorani A, Hayes PD, Boyle JR, et al. Neurological 
complications after left subclavian artery coverage during thoracic endovascular aor­
tic repair: a systematic review and meta-analysis. J Vasc Surg 2009;49:1594–601. 
https://doi.org/10.1016/j.jvs.2008.12.075
1027. Buth J, Harris PL, Hobo R, van Eps R, Cuypers P, Duijm L, et al. Neurologic complica­
tions associated with endovascular repair of thoracic aortic pathology: incidence and 
risk factors. a study from the European Collaborators on Stent/Graft Techniques for 
Aortic Aneurysm Repair (EUROSTAR) registry. J Vasc Surg 2007;46:1103–10; discus­
sion 1110–1. https://doi.org/10.1016/j.jvs.2007.08.020
1028. Teixeira PG, Woo K, Beck AW, Scali ST, Weaver FA. Association of left subclavian 
artery coverage without revascularization and spinal cord ischemia in patients under­
going thoracic endovascular aortic repair: a Vascular Quality Initiative® analysis. 
Vascular 2017;25:587–97. https://doi.org/10.1177/1708538116681910
1029. Chen X, Wang J, Premaratne S, Zhao J, Zhang WW. Meta-analysis of the outcomes of 
revascularization after intentional coverage of the left subclavian artery for thoracic 
endovascular aortic repair. J Vasc Surg 2019;70:1330–40. https://doi.org/10.1016/j.jvs. 
2019.03.022
1030. Banno H, Ikeda S, Kawai Y, Meshii K, Takahashi N, Sugimoto M, et al. Early and mid­
term outcomes of celiac artery coverage during thoracic endovascular aortic repair. 
J Vasc Surg 2020;72:1552–7. https://doi.org/10.1016/j.jvs.2020.02.025
1031. Argyriou C, Spiliopoulos S, Katsanos K, Papatheodorou N, Lazarides MK, Georgiadis 
GS. Safety and efficacy of intentional celiac artery coverage in endovascular manage­
ment of thoracoabdominal aortic diseases: a systematic review and meta-analysis. 
J Endovasc Ther 2022;29:646–58. https://doi.org/10.1177/15266028211059451
1032. Hanna L, Lam K, Agbeko AE, Amoako JK, Ashrafian H, Sounderajah V, et al. Coverage 
of the coeliac artery during thoracic endovascular aortic repair: a systematic review 
and meta-analysis. Eur J Vasc Endovasc Surg 2022;63:828–37. https://doi.org/10.1016/j. 
ejvs.2022.02.026
1033. Cambria RA, Gloviczki P, Stanson AW, Cherry KJ, Bower TC, Hallett JW, et al. 
Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms managed 
nonoperatively. Am J Surg 1995;170:213–7. https://doi.org/10.1016/s0002-9610(99) 
80289-x
1034. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, 
and surgical versus nonsurgical risks. Ann Thorac Surg 2002;74:S1877–80; discussion 
S1892–8. https://doi.org/10.1016/s0003-4975(02)04147-4
1035. Girardi LN, Ohmes LB, Lau C, Di Franco A, Gambardella I, Elsayed M, et al. Open 
repair of descending thoracic and thoracoabdominal aortic aneurysms in patients 
with preoperative renal failure. Eur J Cardiothorac Surg 2017;51:971–7. https://doi. 
org/10.1093/ejcts/ezx007
1036. LeMaire SA, Miller CC, III, Conklin LD, Schmittling ZC, Köksoy C, Coselli JS, et al. A 
new predictive model for adverse outcomes after elective thoracoabdominal aortic 
aneurysm repair. Ann Thorac Surg 2001;71:1233–8. https://doi.org/10.1016/s0003- 
4975(00)02678-3
1037. Suzuki S, Davis CA, III, Miller CC, III, Huynh TT, Estrera AL, Porat EE, et al. Cardiac 
function predicts mortality following thoracoabdominal and descending thoracic aor­
tic aneurysm repair. Eur J Cardiothorac Surg 2003;24:119–24; discussion 124. https:// 
doi.org/10.1016/s1010-7940(03)00170-2
1038. Mohebali J, Carvalho S, Lancaster RT, Ergul EA, Conrad MF, Clouse WD, et al. Use of 
extracorporeal bypass is associated with improved outcomes in open thoracic and 
thoracoabdominal aortic aneurysm repair. J Vasc Surg 2018;68:941–7. https://doi. 
org/10.1016/j.jvs.2017.12.072
1039. Coselli JS, LeMaire SA, Preventza O, de la Cruz KI, Cooley DA, Price MD, et al. 
Outcomes of 3309 thoracoabdominal aortic aneurysm repairs. J Thorac Cardiovasc 
Surg 2016;151:1323–38. https://doi.org/10.1016/j.jtcvs.2015.12.050
1040. Drinkwater SL, Goebells A, Haydar A, Bourke P, Brown L, Hamady M, et al.. The in­
cidence of spinal cord ischaemia following thoracic and thoracoabdominal aortic en­
dovascular intervention. Eur J Vasc Endovasc Surg 2010;40:729–35. https://doi.org/10. 
1016/j.ejvs.2010.08.013
1041. Bicknell CD, Riga CV, Wolfe JH. Prevention of paraplegia during thoracoabdominal 
aortic aneurysm repair. Eur J Vasc Endovasc Surg 2009;37:654–60. https://doi.org/ 
10.1016/j.ejvs.2009.02.008
1042. Von Aspern K, Luehr M, Mohr FW, Etz CD. Spinal cord protection in open- and en­
dovascular thoracoabdominal aortic aneurysm repair: critical review of current con­
cepts and future perspectives. J Cardiovasc Surg (Torino) 2015;56:745–9.
1043. Hsu CC, Kwan GN, van Driel ML, Rophael JA. Distal aortic perfusion during thora­
coabdominal aneurysm repair for prevention of paraplegia. Cochrane Database Syst 
Rev 2012;3:CD008197. https://doi.org/10.1002/14651858.CD008197.pub2
1044. Bischoff MS, Di Luozzo G, Griepp EB, Griepp RB. Spinal cord preservation in thora­
coabdominal aneurysm repair. Perspect Vasc Surg Endovasc Ther 2011;23:214–22. 
https://doi.org/10.1177/1531003511400622
1045. Cowan JA, Jr, Dimick JB, Henke PK, Huber TS, Stanley JC, Upchurch GR. Surgical 
treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital 
and surgeon volume-related outcomes. J Vasc Surg 2003;37:1169–74. https://doi.org/ 
10.1016/s0741-5214(03)00085-5
1046. Rigberg DA, McGory ML, Zingmond DS, Maggard MA, Agustin M, Lawrence PF, et al. 
Thirty-day mortality statistics underestimate the risk of repair of thoracoabdominal 
aortic aneurysms: a statewide experience. J Vasc Surg 2006;43:217–22; discussion 
223. https://doi.org/10.1016/j.jvs.2005.10.070
1047. Pomy BJ, Rosenfeld ES, Lala S, Lee KB, Sparks AD, Amdur RL, et al. Fenestrated en­
dovascular aneurysm repair affords fewer renal complications than open surgical re­
pair for juxtarenal abdominal aortic aneurysms in patients with chronic renal 
insufficiency. Ann Vasc Surg 2021;75:349–57. https://doi.org/10.1016/j.avsg.2021.03. 
026
1048. Varkevisser RRB, O’Donnell TFX, Swerdlow NJ, Liang P, Li C, Ultee KHJ, et al. 
Fenestrated endovascular aneurysm repair is associated with lower perioperative 
morbidity and mortality compared with open repair for complex abdominal aortic 
aneurysms. J Vasc Surg 2019;69:1670–8. https://doi.org/10.1016/j.jvs.2018.08.192
1049. Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Lenti M, et al. Preoperative 
and postoperative predictors of clinical outcome of fenestrated and branched endo­
vascular repair for complex abdominal and thoracoabdominal aortic aneurysms in an 
Italian multicenter registry. J Vasc Surg 2021;74:1795–806.e6. https://doi.org/10.1016/ 
j.jvs.2021.04.072
1050. Silverberg D, Bar-Dayan A, Hater H, Khaitovich B, Halak M. Short-term outcomes 
of inner branches for endovascular repair of complex abdominal and thoracoab­
dominal aortic aneurysms. Vascular 2021;29:644–51. https://doi.org/10.1177/ 
1708538120977279
1051. Hu Z, Li Y, Peng R, Liu J, Jia X, Liu X, et al. Multibranched stent-grafts for the treat­
ment of thoracoabdominal aortic aneurysms: a systematic review and meta-analysis. 
J Endovasc Ther 2016;23:626–33. https://doi.org/10.1177/1526602816647723
1052. Simonte G, Isernia G, Gatta E, Neri E, Parlani G, Candeloro L, et al. Inner branched 
complex aortic repair outcomes from a national multicenter registry using the E-xtra 
design platform. J Vasc Surg 2023;77:338–46. https://doi.org/10.1016/j.jvs.2022.08. 
034
1053. Gallitto E, Faggioli G, Pini R, Logiacco A, Mascoli C, Fenelli C, et al. Proximal aortic 
coverage and clinical results of the endovascular repair of juxta-/para-renal and 
type IV thoracoabdominal aneurysm with custom-made fenestrated endografts. 
Ann Vasc Surg 2021;73:397–406. https://doi.org/10.1016/j.avsg.2020.12.008
1054. Sultan S, Concannon J, Veerasingam D, Tawfick W, McHugh P, Jordan F, et al. 
Endovascular versus conventional open surgical repair for thoracoabdominal aortic 
aneurysms. Cochrane Database Syst Rev 2022;4:CD012926. https://doi.org/10.1002/ 
14651858.CD012926.pub2
1055. Kölbel T, Spanos K, Jama K, Behrendt CA, Panuccio G, Eleshra A, et al. Early out­
comes of the t-Branch off-the-shelf multi-branched stent graft in 542 patients for 
elective and urgent aortic pathologies: a retrospective observational study. J Vasc 
Surg 2021;74:1817–24. https://doi.org/10.1016/j.jvs.2021.05.041
1056. Oderich GS, Ribeiro M, Hofer J, Wigham J, Cha S, Chini J, et al. Prospective, nonran­
domized study to evaluate endovascular repair of pararenal and thoracoabdominal 
aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing 
zones. J Vasc Surg 2017;65:1249–59.e10. https://doi.org/10.1016/j.jvs.2016.09.038
1057. Oderich GS, Tenorio ER, Mendes BC, Lima GBB, Marcondes GB, Saqib N, et al. 
Midterm outcomes of a prospective, nonrandomized study to evaluate endovascular 
repair of complex aortic aneurysms using fenestrated-branched endografts. Ann Surg 
2021;274:491–9. https://doi.org/10.1097/sla.0000000000004982
1058. Konstantinou N, Antonopoulos CN, Jerkku T, Banafsche R, Kölbel T, Fiorucci B, et al. 
Systematic review and meta-analysis of published studies on endovascular repair of 
thoracoabdominal aortic aneurysms with the t-Branch off-the-shelf multibranched 
endograft. J Vasc Surg 2020;72:716–25.e1. https://doi.org/10.1016/j.jvs.2020.01.049
1059. Ellahi A, Shaikh FN, Kashif H, Khan H, Ali E, Nasim B, et al. Effectiveness of endovas­
cular repair versus open surgery for the treatment of thoracoabdominal aneurysm: a 
systematic review and meta analysis. Ann Med Surg 2022;81:104477. https://doi.org/ 
10.1016/j.amsu.2022.104477
1060. Hongku K, Sonesson B, Bjorses K, Holst J, Resch T, Dias NV, et al. Mid-term 
Outcomes of Endovascular Repair of Ruptured Thoraco-abdominal Aortic 
Aneurysms with Off the Shelf Branched Stent Grafts. Eur J Vasc Endovasc Surg 
2018;55:377–84. https://doi.org/10.1016/j.ejvs.2017.11.021
1061. Youssef M, Deglise S, Szopinski P, Jost-Philipp S, Jomha A, Vahl CF, et al. A multicenter 
experience with a new fenestrated-branched device for endovascular repair of thor­
acoabdominal aortic aneurysms. J Endovasc Ther 2018;25:209–19. https://doi.org/10. 
1177/1526602817752147
1062. Ouzounian M, Tadros RO, Svensson LG, Lyden SP, Oderich GS, Coselli JS 
Thoracoabdominal aortic disease and repair: JACC focus seminar, part 3. J Am Coll 
Cardiol 2022;80:845–56. https://doi.org/10.1016/j.jacc.2021.05.056
1063. Hofmann Bowman MA, Eagle KA, Milewicz DM. Update on clinical trials of losartan 
with and without β-blockers to block aneurysm growth in patients with Marfan syn­
drome: a review. JAMA Cardiol 2019;4:702–7. https://doi.org/10.1001/jamacardio. 
2019.1176
1064. Mortality results for randomised controlled trial of early elective surgery or ultra­
sonographic surveillance for small abdominal aortic aneurysms. The UK Small 
Aneurysm Trial Participants. Lancet 1998;352:1649–55.
ESC Guidelines                                                                                                                                                                                          3687


<!-- PAGE 151 -->

### Page 151

1065. Powell JT, Brady AR, Brown LC, Fowkes FG, Greenhalgh RM, Ruckley CV, et al. 
Long-term outcomes of immediate repair compared with surveillance of small ab­
dominal aortic aneurysms. N Engl J Med 2002;346:1445–52. https://doi.org/10. 
1056/NEJMoa013527
1066. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al. 
Immediate repair compared with surveillance of small abdominal aortic aneurysms. 
N Engl J Med 2002;346:1437–44. https://doi.org/10.1056/NEJMoa012573
1067. Shirasu T, Takagi H, Yasuhara J, Kuno T, Kent KC, Clouse WD. Smaller size is more 
suitable for pharmacotherapy among undersized abdominal aortic aneurysm: a sys­
tematic review and meta-analysis. Vasc Med 2022;27:261–8. https://doi.org/10. 
1177/1358863x211061603
1068. Ouriel K, Clair DG, Kent KC, Zarins CK. Endovascular repair compared with surveil­
lance for patients with small abdominal aortic aneurysms. J Vasc Surg 2010;51:1081–7. 
https://doi.org/10.1016/j.jvs.2009.10.113
1069. Golledge J, Parr A, Boult M, Maddern G, Fitridge R. The outcome of endovascular re­
pair of small abdominal aortic aneurysms. Ann Surg 2007;245:326–33. https://doi.org/ 
10.1097/01.sla.0000253965.95368.52
1070. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic ab­
dominal aortic aneurysms. Cochrane Database Syst Rev 2015;2:CD001835. https:// 
doi.org/10.1002/14651858.CD001835.pub4
1071. Cao P, De Rango P, Verzini F, Parlani G, Romano L, Cieri E. Comparison of surveil­
lance versus aortic endografting for small aneurysm repair (CAESAR): results from a 
randomised trial. Eur J Vasc Endovasc Surg 2011;41:13–25. https://doi.org/10.1016/j. 
ejvs.2010.08.026
1072. Lo RC, Lu B, Fokkema MT, Conrad M, Patel VI, Fillinger M, et al. Relative importance 
of aneurysm diameter and body size for predicting abdominal aortic aneurysm rup­
ture in men and women. J Vasc Surg 2014;59:1209–16. https://doi.org/10.1016/j.jvs. 
2013.10.104
1073. Bath MF, Gokani VJ, Sidloff DA, Jones LR, Choke E, Sayers RD, et al. Systematic review 
of cardiovascular disease and cardiovascular death in patients with a small abdominal 
aortic aneurysm. Br J Surg 2015;102:866–72. https://doi.org/10.1002/bjs.9837
1074. Kristensen SD, Knuuti J. New ESC/ESA Guidelines on non-cardiac surgery: cardiovas­
cular assessment and management. Eur Heart J 2014;35:2344–5. https://doi.org/10. 
1093/eurheartj/ehu285
1075. Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, et al. 
Association between postoperative troponin levels and 30-day mortality among pa­
tients undergoing noncardiac surgery. JAMA 2012;307:2295–304. https://doi.org/10. 
1001/jama.2012.5502
1076. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients 
with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 
2005;365:2179–86. https://doi.org/10.1016/s0140-6736(05)66627-5
1077. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT, Jr, Matsumura JS, Kohler TR, 
et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: 
a randomized trial. JAMA 2009;302:1535–42. https://doi.org/10.1001/jama.2009.1426
1078. Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y, Lermusiaux P, et al. A ran­
domized controlled trial of endovascular aneurysm repair versus open surgery for ab­
dominal aortic aneurysms in low- to moderate-risk patients. J Vasc Surg 2011;53: 
1167–73.e1. https://doi.org/10.1016/j.jvs.2010.10.124
1079. Antoniou GA, Antoniou SA, Torella F. Editor’s choice—endovascular vs. open repair 
for abdominal aortic aneurysm: systematic review and meta-analysis of updated peri- 
operative and long term data of randomised controlled trials. Eur J Vasc Endovasc Surg 
2020;59:385–97. https://doi.org/10.1016/j.ejvs.2019.11.030
1080. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC 
Guidelines on cardiovascular assessment and management of patients undergoing 
non-cardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/ 
eurheartj/ehac270
1081. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. 
Coronary-artery revascularization before elective major vascular surgery. N Engl J 
Med 2004;351:2795–804. https://doi.org/10.1056/NEJMoa041905
1082. Saida T, Mori K, Sato F, Shindo M, Takahashi H, Takahashi N, et al. Prospective intrain­
dividual 
comparison 
of 
unenhanced 
magnetic 
resonance 
imaging 
vs 
contrast-enhanced computed tomography for the planning of endovascular abdom­
inal aortic aneurysm repair. J Vasc Surg 2012;55:679–87. https://doi.org/10.1016/j.jvs. 
2011.09.091
1083. Parker MV, O’Donnell SD, Chang AS, Johnson CA, Gillespie DL, Goff JM, et al. What 
imaging studies are necessary for abdominal aortic endograft sizing? A prospective 
blinded study using conventional computed tomography, aortography, and three- 
dimensional computed tomography. J Vasc Surg 2005;41:199–205. https://doi.org/ 
10.1016/j.jvs.2004.12.010
1084. Schanzer A, Greenberg RK, Hevelone N, Robinson WP, Eslami MH, Goldberg RJ, 
et al. Predictors of abdominal aortic aneurysm sac enlargement after endovascular 
repair. Circulation 2011;123:2848–55. https://doi.org/10.1161/circulationaha.110. 
014902
1085. Protto S, Hahl T, Koskinen KJA, Järvenpää V, Uurto I, Väärämäki S, et al. Endovascular 
repair of abdominal aortic aneurysms is a valid alternative to open repair also in 
patients treated outside of instructions for use criteria. Cardiovasc Intervent Radiol 
2022;45:1765–73. https://doi.org/10.1007/s00270-022-03297-7
1086. Charbonneau P, Hongku K, Herman CR, Habib M, Girsowicz E, Doonan RJ, et al. 
Long-term survival after endovascular and open repair in patients with anatomy out­
side instructions for use criteria for endovascular aneurysm repair. J Vasc Surg 2019; 
70:1823–30. https://doi.org/10.1016/j.jvs.2019.01.081
1087. O’Donnell TFX, McElroy IE, Boitano LT, Mohebali J, Lamuraglia GM, Kwolek CJ, et al. 
Comparison of treatment options for aortic necks outside standard endovascular an­
eurysm repair instructions for use. J Vasc Surg 2021;74:1548–57. https://doi.org/10. 
1016/j.jvs.2021.04.052
1088. Antoniou GA, Juszczak MT, Nasr H, Narlawar R, Antoniou SA, Matsagkas M, et al. 
Prognosis review and time-to-event data meta-analysis of endovascular aneurysm re­
pair outside versus within instructions for use of aortic endograft devices. J Vasc Surg 
2020;71:1415–31.e15. https://doi.org/10.1016/j.jvs.2019.08.247
1089. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK, Bernhard VM, et al. 
Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002;35: 
1048–60. https://doi.org/10.1067/mva.2002.123763
1090. Falster MO, Garland SK, Jorm LR, Beiles CB, Freeman AJ, Sedrakyan A, et al. Editor’s 
choice—comparison of outcomes for major contemporary endograft devices used 
for endovascular repair of intact abdominal aortic aneurysms. Eur J Vasc Endovasc 
Surg 2023;65:272–80. https://doi.org/10.1016/j.ejvs.2022.11.005
1091. van Laarhoven C, Jorritsma NKN, Balderston J, Brinjikji W, Björck M, van 
Herwaarden JA, et al. Systematic review of the co-prevalence of arterial aneurysms 
within the vasculature. Eur J Vasc Endovasc Surg 2021;61:473–83. https://doi.org/10. 
1016/j.ejvs.2020.10.002
1092. Hohneck A, Keese M, Ruemenapf G, Amendt K, Muertz H, Janda K, et al. Prevalence 
of abdominal aortic aneurysm and associated lower extremity artery aneurysm in 
men hospitalized for suspected or known cardiopulmonary disease. BMC 
Cardiovasc Disord 2019;19:284. https://doi.org/10.1186/s12872-019-1265-2
1093. D’Oria M, Scali S, Mao J, Szeberin Z, Thomson I, Beiles B, et al. Association be­
tween hospital volume and failure to rescue after open or endovascular repair 
of intact abdominal aortic aneurysms in the vascunet and international consortium 
of vascular registries. Ann Surg 2021;274:e452–9. https://doi.org/10.1097/sla. 
0000000000005044
1094. Scali ST, Columbo JA, Suckow BD, D’Oria M, Neal D, Goodney PP, et al. Center vol­
ume is associated with diminished failure to rescue and improved outcomes following 
elective open abdominal aortic aneurysm repair. J Vasc Surg 2022;76:400–8.e2. 
https://doi.org/10.1016/j.jvs.2021.12.076
1095. Eid MA, Barnes JA, Mehta K, Wanken Z, Columbo J, Kang R, et al. Factors associated 
with preference of choice of aortic aneurysm repair in the PReference for Open 
Versus Endovascular repair of AAA (PROVE-AAA) study. J Vasc Surg 2022;76: 
1556–64. https://doi.org/10.1016/j.jvs.2022.06.018
1096. Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, et al. Editor’s 
choice—European Society for Vascular Surgery (ESVS) 2019 clinical practice guide­
lines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc 
Endovasc Surg 2019;57:8–93. https://doi.org/10.1016/j.ejvs.2018.09.020
1097. Reise JA, Sheldon H, Earnshaw J, Naylor AR, Dick F, Powell JT, et al. Patient prefer­
ence for surgical method of abdominal aortic aneurysm repair: postal survey. Eur J 
Vasc Endovasc Surg 2010;39:55–61. https://doi.org/10.1016/j.ejvs.2009.08.008
1098. EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit 
for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled 
trial. Lancet 2005;365:2187–92. https://doi.org/10.1016/s0140-6736(05)66628-7
1099. Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D. Endovascular repair 
of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med 2010; 
362:1872–80. https://doi.org/10.1056/NEJMoa0911056
1100. Patel R, Sweeting MJ, Powell JT, Greenhalgh RM. Endovascular versus open repair of 
abdominal aortic aneurysm in 15-years’ follow-up of the UK endovascular aneurysm 
repair trial 1 (EVAR trial 1): a randomised controlled trial. Lancet 2016;388:2366–74. 
https://doi.org/10.1016/s0140-6736(16)31135-7
1101. Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT, Matsumura JS, et al. 
Open versus endovascular repair of abdominal aortic aneurysm. N Engl J Med 2019; 
380:2126–35. https://doi.org/10.1056/NEJMoa1715955
1102. Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT, Kohler TR, et al. 
Long-term comparison of endovascular and open repair of abdominal aortic aneur­
ysm. N Engl J Med 2012;367:1988–97. https://doi.org/10.1056/NEJMoa1207481
1103. Schermerhorn ML, Buck DB, O’Malley AJ, Curran T, McCallum JC, Darling J, et al. 
Long-term outcomes of abdominal aortic aneurysm in the Medicare population. N 
Engl J Med 2015;373:328–38. https://doi.org/10.1056/NEJMoa1405778
1104. Nana P, Dakis K, Brodis A, Spanos K, Kouvelos G, Eckstein H-H, et al. A systematic 
review and meta-analysis on early mortality after abdominal aortic aneurysm repair in 
females in urgent and elective settings. J Vasc Surg 2022;75:1082–8.e6. https://doi.org/ 
10.1016/j.jvs.2021.10.040
1105. Böckler D, Power AH, Bouwman LH, van Sterkenburg S, Bosiers M, Peeters P, et al. 
Improvements in patient outcomes with next generation endovascular aortic repair 
devices in the ENGAGE global registry and the EVAR-1 clinical trial. J Cardiovasc Surg 
2020;61:604–9. https://doi.org/10.23736/s0021-9509.19.11021-x


<!-- PAGE 152 -->

### Page 152

1106. Teijink JAW, Power AH, Böckler D, Peeters P, van Sterkenburg S, Bouwman LH, et al. 
Editor’s choice—five year outcomes of the endurant stent graft for endovascular ab­
dominal aortic aneurysm repair in the ENGAGE registry. Eur J Vasc Endovasc Surg 
2019;58:175–81. https://doi.org/10.1016/j.ejvs.2019.01.008
1107. Oliveira-Pinto J, Oliveira NFG, Bastos-Gonçalves FM, Hoeks S, Rijn MJV, Raa ST, et al. 
Long-term results after standard endovascular aneurysm repair with the endurant 
and excluder stent grafts. J Vasc Surg 2020;71:64–74. https://doi.org/10.1016/j.jvs. 
2019.03.039
1108. Deery SE, Shean KE, Pothof AB, O'Donnell TFX, Dalebout BA, Darling JD, et al. 
Three-Year Results of the Endurant Stent Graft System Post Approval Study. Ann 
Vasc Surg 2018;50:202–8. https://doi.org/10.1016/j.avsg.2017.12.017
1109. Prinssen M, Verhoeven EL, Buth J, Cuypers PWM, van Sambeek MRHM, Balm R, et al. 
A randomized trial comparing conventional and endovascular repair of abdominal 
aortic aneurysms. N Engl J Med 2004;351:1607–18. https://doi.org/10.1056/ 
NEJMoa042002
1110. Dakour-Aridi H, Paracha NZ, Locham S, Nejim B, Malas MB. Assessment of failure to 
rescue after abdominal aortic aneurysm repair using the National Surgical Quality 
Improvement Program procedure-targeted data set. J Vasc Surg 2018;68: 
1335–44.e1. https://doi.org/10.1016/j.jvs.2018.01.059
1111. Scali ST, Giles KA, Kubilis P, Beck AW, Crippen CJ, Hughes SJ, et al. Impact of hospital 
volume on patient safety indicators and failure to rescue following open aortic aneur­
ysm repair. J Vasc Surg 2020;71:1135–46.e4. https://doi.org/10.1016/j.jvs.2019.06.194
1112. Ma B, Wang YN, Chen KY, Zhang Y, Pan H, Yang K. Transperitoneal versus retro­
peritoneal approach for elective open abdominal aortic aneurysm repair. Cochrane 
Database 
Syst 
Rev 
2016;2:CD010373. 
https://doi.org/10.1002/14651858. 
CD010373.pub2
1113. Camazine M, Bath J, Singh P, Kruse RL, Vogel TR. Characteristics associated with fail­
ure to rescue after open abdominal aortic aneurysm repair. J Surg Res 2023;283: 
683–9. https://doi.org/10.1016/j.jss.2022.11.018
1114. Blair R, Harkin D, Johnston D, Lim A, McFetridge L, Mitchell H. Open surgery for ab­
dominal aortic aneurysm: 980 consecutive patient outcomes from a high-volume 
centre in the United Kingdom. Vasc Endovascular Surg 2023;57:463–70. https://doi. 
org/10.1177/15385744221149585
1115. Hoornweg LL, Storm-Versloot MN, Ubbink DT, Koelemay MJW, Legemate DA, 
Balm R, et al. Meta analysis on mortality of ruptured abdominal aortic aneurysms. 
Eur J Vasc Endovasc Surg 2008;35:558–70. https://doi.org/10.1016/j.ejvs.2007.11.019
1116. Kontopodis N, Galanakis N, Antoniou SA, Tsetis D, Ioannou CV, Veith FJ, et al. 
Meta-analysis and meta-regression analysis of outcomes of endovascular and open 
repair for ruptured abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2020;59: 
399–410. https://doi.org/10.1016/j.ejvs.2019.12.023
1117. Wang LJ, Locham S, Al-Nouri O, Eagleton MJ, Clouse WD, Malas MB. Endovascular 
repair of ruptured abdominal aortic aneurysm is superior to open repair: propensity- 
matched analysis in the vascular quality initiative. J Vasc Surg 2020;72:498–507. https:// 
doi.org/10.1016/j.jvs.2019.11.063
1118. Tan TW, Eslami M, Rybin D, Doros G, Zhang WW, Farber A. Outcomes of endovas­
cular and open surgical repair of ruptured abdominal aortic aneurysms in elderly pa­
tients. J Vasc Surg 2017;66:64–70. https://doi.org/10.1016/j.jvs.2016.10.119
1119. Dewulf M, Muysoms F, Vierendeels T, Huyghe M, Miserez M, Ruppert M, et al. 
Prevention of incisional hernias by prophylactic mesh-augmented reinforcement of 
midline laparotomies for abdominal aortic aneurysm treatment: five-year follow-up 
of a randomized controlled trial. Ann Surg 2022;276:e217–22. https://doi.org/10. 
1097/sla.0000000000005545
1120. Honig S, Diener H, Kölbel T, Reinpold W, Zapf A, Bibiza-Freiwald E, et al. Abdominal 
incision defect following AAA-surgery (AIDA): 2-year results of prophylactic onlay- 
mesh augmentation in a multicentre, double-blind, randomised controlled trial. 
Updates Surg 2022;74:1105–16. https://doi.org/10.1007/s13304-021-01125-0
1121. Indrakusuma R, Jalalzadeh H, van der Meij JE, Balm R, Koelemay MJW. Prophylactic 
mesh reinforcement versus sutured closure to prevent incisional hernias after 
open abdominal aortic aneurysm repair via midline laparotomy: a systematic review 
and meta-analysis. Eur J Vasc Endovasc Surg 2018;56:120–8. https://doi.org/10.1016/j. 
ejvs.2018.03.021
1122. van Keulen JW, de Vries JP, Dekker H, Gonçalves FB, Moll FL, Verhagen HJ, et al. 
One-year multicenter results of 100 abdominal aortic aneurysm patients treated 
with the endurant stent graft. J Vasc Surg 2011;54:609–15. https://doi.org/10.1016/j. 
jvs.2011.02.053
1123. Piazza M, Squizzato F, Suominen V, Grego F, Trimarchi S, Antonello M, et al. Early and 
long-term outcomes of endovascular aortic repair in young and low surgical risk pa­
tients in the global registry for endovascular aortic treatment. J Endovasc Ther 2022; 
29:248–57. https://doi.org/10.1177/15266028211045703
1124. Paravastu SC, Jayarajasingam R, Cottam R, Palfreyman SJ, Michaels JA, Thomas SM. 
Endovascular repair of abdominal aortic aneurysm. Cochrane Database Syst Rev 
2014;1:CD004178. https://doi.org/10.1002/14651858.CD004178.pub2
1125. Dosluoglu HH, Lall P, Blochle R, Harris LM, Dryjski ML. Ambulatory percutaneous 
endovascular abdominal aortic aneurysm repair. J Vasc Surg 2014;59:58–64. https:// 
doi.org/10.1016/j.jvs.2013.06.076
1126. Geragotellis A, Cox K, Yip HCA, Jubouri M, Williams IM, Bailey DM, et al. Renal out­
comes of suprarenal vs. infrarenal endograft fixation in endovascular abdominal aortic 
aneurysm repair: a narrative review. Cardiovasc Diagn Ther 2022;12:531–44. https:// 
doi.org/10.21037/cdt-22-196
1127. Verhoeven EL, Katsargyris A, Bachoo P, Larzon T, Fisher R, Ettles D, et al. Real-world 
performance of the new C3 gore excluder stent-graft: 1-year results from the 
European C3 module of the global registry for endovascular aortic treatment 
(GREAT). Eur J Vasc Endovasc Surg 2014;48:131–7. https://doi.org/10.1016/j.ejvs. 
2014.04.009
1128. Torsello G, Scheinert D, Brunkwall JS, Chiesa R, Coppi G, Pratesi C. Safety and effect­
iveness of the INCRAFT AAA stent graft for endovascular repair of abdominal aortic 
aneurysms. J Vasc Surg 2015;61:1–8. https://doi.org/10.1016/j.jvs.2014.06.007
1129. Kontopodis N, Galanakis N, Tzartzalou I, Tavlas E, Georgakarakos E, Dimopoulos I, 
et al. An update on the improvement of patient eligibility with the use of new gener­
ation endografts for the treatment of abdominal aortic aneurysms. Expert Rev Med 
Devices 2020;17:1231–8. https://doi.org/10.1080/17434440.2020.1841629
1130. Kontopodis N, Papadopoulos G, Galanakis N, Tsetis D, Ioannou CV. Improvement of 
patient eligibility with the use of new generation endografts for the treatment of ab­
dominal aortic aneurysms. A comparison study among currently used endografts and 
literature review. Expert Rev Med Devices 2017;14:245–50. https://doi.org/10.1080/ 
17434440.2017.1281738
1131. Zlatanovic P, Mascia D, Ancetti S, Yeung KK, Graumans MJ, Jongkind V, et al. Short 
term and long term clinical outcomes of endovascular versus open repair for juxtar­
enal and pararenal abdominal aortic aneurysms using propensity score matching: re­
sults from juxta- and pararenal aortic aneurysm multicentre European study (JAMES). 
Eur J Vasc Endovasc Surg 2023;65:828–36. https://doi.org/10.1016/j.ejvs.2023.02.070
1132. Hajibandeh S, Hajibandeh S, Antoniou SA, Child E, Torella F, Antoniou GA. 
Percutaneous access for endovascular aortic aneurysm repair: a systematic 
review and meta-analysis. Vascular 2016;24:638–48. https://doi.org/10.1177/ 
1708538116639201
1133. Antoniou GA, Antoniou SA. Editor’s choice—percutaneous access does not confer 
superior clinical outcomes over cutdown access for endovascular aneurysm repair: 
meta-analysis and trial sequential analysis of randomised controlled trials. Eur J Vasc 
Endovasc Surg 2021;61:383–94. https://doi.org/10.1016/j.ejvs.2020.11.008
1134. Cao Z, Wu W, Zhao K, Yang Yu, Jiang C, Zhu R. Safety and efficacy of totally percu­
taneous access compared with open femoral exposure for endovascular aneurysm 
repair: a meta-analysis. J Endovasc Ther 2017;24:246–53. https://doi.org/10.1177/ 
1526602816689679
1135. Wang Q, Wu J, Ma Y, Zhu Y, Song X, Xie S, et al. Totally percutaneous versus surgical 
cut-down femoral artery access for elective bifurcated abdominal endovascular an­
eurysm repair. Cochrane Database Syst Rev 2023;1:CD010185. https://doi.org/10. 
1002/14651858.CD010185.pub4
1136. Antoniou GA, Georgiadis GS, Antoniou SA, Neequaye S, Brennan JA, Torella F, et al. 
Late rupture of abdominal aortic aneurysm after previous endovascular repair: a sys­
tematic review and meta-analysis. J Endovasc Ther 2015;22:734–44. https://doi.org/10. 
1177/1526602815601405
1137. Fransen GA, Vallabhaneni SR, Sr, van Marrewijk CJ, Laheij RJF, Harris PL, Buth J. 
Rupture of infra-renal aortic aneurysm after endovascular repair: a series from 
EUROSTAR registry. Eur J Vasc Endovasc Surg 2003;26:487–93. https://doi.org/10. 
1016/s1078-5884(03)00350-2
1138. Marcaccio CL, Patel PB, de Guerre L, Wade JE, Rastogi V, Anjorin A, et al. Disparities 
in 5-year outcomes and imaging surveillance following elective endovascular repair of 
abdominal aortic aneurysm by sex, race, and ethnicity. J Vasc Surg 2022;76: 
1205–15.e4. https://doi.org/10.1016/j.jvs.2022.03.886
1139. Schlösser FJ, Gusberg RJ, Dardik A, Lin PH, Verhagen HJM, Moll FL, et al. Aneurysm 
rupture after EVAR: can the ultimate failure be predicted? Eur J Vasc Endovasc Surg 
2009;37:15–22. https://doi.org/10.1016/j.ejvs.2008.10.011
1140. Stather PW, Sidloff D, Dattani N, Choke E, Bown MJ, Sayers RD. Systematic review 
and meta-analysis of the early and late outcomes of open and endovascular repair of 
abdominal aortic aneurysm. Br J Surg 2013;100:863–72. https://doi.org/10.1002/bjs. 
9101
1141. Swart M, McCarthy R. Shared decision making for elective abdominal aortic aneurysm 
surgery. Clin Med (Lond) 2019;19:473–7. https://doi.org/10.7861/clinmed.2019-0352
1142. Stubenrouch FE, Peters LJ, de Mik SML, Klemm PL, Peppelenbosch AG, Schreurs 
SCWM, et al. Improving shared decision making in vascular surgery: a stepped wedge 
cluster randomised trial. Eur J Vasc Endovasc Surg 2022;64:73–81. https://doi.org/10. 
1016/j.ejvs.2022.04.016
1143. Machin M, Van Herzeele I, Ubbink D, Powell JT. Shared decision making in and man­
agement of intact abdominal aortic aneurysm: a scoping review of the literature. Eur J 
Vasc Endovasc Surg 2023;65:839–49. https://doi.org/10.1016/j.ejvs.2023.01.036
1144. Karthaus EG, Tong TML, Vahl A, Hamming JF. Saccular abdominal aortic aneur­
ysms: patient characteristics, clinical presentation, treatment, and outcomes in 
the 
Netherlands. 
Ann 
Surg 
2019;270:852–8. 
https://doi.org/10.1097/sla.


<!-- PAGE 153 -->

### Page 153

1145. O’Donnell TF, McElroy IE, Mohebali J, Boitano LT, Lamuraglia GM, Kwolek CJ, et al. 
Late type 1A endoleaks: associated factors, prognosis and management strategies. 
Ann Vasc Surg 2022;80:273–82. https://doi.org/10.1016/j.avsg.2021.08.057
1146. De Rango P, Verzini F, Parlani G, Cieri E, Simonte G, Farchioni L, et al. Safety of chron­
ic anticoagulation therapy after endovascular abdominal aneurysm repair (EVAR). Eur 
J Vasc Endovasc Surg 2014;47:296–303. https://doi.org/10.1016/j.ejvs.2013.12.009
1147. Rokosh RS, Wu WW, Dalman RL, Chaikof EL. Society for Vascular Surgery imple­
mentation of clinical practice guidelines for patients with an abdominal aortic aneur­
ysm. Endoleak management. J Vasc Surg 2021;74:1792–4. https://doi.org/10.1016/j.jvs. 
2021.04.042
1148. Jordan WD, Jr, Mehta M, Varnagy D, Moore WM, Arko FR, Joye J, et al. Results of the 
ANCHOR prospective, multicenter registry of EndoAnchors for type Ia endoleaks 
and endograft migration in patients with challenging anatomy. J Vasc Surg 2014;60: 
885–92.e2. https://doi.org/10.1016/j.jvs.2014.04.063
1149. Sidloff DA, Stather PW, Choke E, Bown MJ, Sayers RD. Type II endoleak after endo­
vascular aneurysm repair. Br J Surg 2013;100:1262–70. https://doi.org/10.1002/bjs. 
9181
1150. Daye D, Walker TG. Complications of endovascular aneurysm repair of the thoracic 
and abdominal aorta: evaluation and management. Cardiovasc Diagn Ther 2018;8: 
S138–56. https://doi.org/10.21037/cdt.2017.09.17
1151. Latson LA, Jr, DeAnda A, Jr, Ko JP. Imaging of the postsurgical thoracic aorta: a 
state-of-the-art review. J Thorac Imaging 2017;32:1–25. https://doi.org/10.1097/rti. 
0000000000000246
1152. Prescott-Focht JA, Martinez-Jimenez S, Hurwitz LM, Hoang JK, Christensen JD, 
Ghoshhajra BB, et al. Ascending thoracic aorta: postoperative imaging evaluation. 
Radiographics 2013;33:73–85. https://doi.org/10.1148/rg.331125090
1153. Riambau V, Böckler D, Brunkwall J, Cao P, Chiesa R, Coppi G, et al. Editor’s choice— 
management of descending thoracic aorta diseases: clinical practice guidelines of the 
European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2017;53:4–52. 
https://doi.org/10.1016/j.ejvs.2016.06.005
1154. Quevedo HC, Santiago-Trinidad R, Castellanos J, Atianzar K, Anwar A, Abi Rafeh N. 
Systematic review of interventions to repair ascending aortic pseudoaneurysms. 
Ochsner J 2014;14:576–85.
1155. Mesana TG, Caus T, Gaubert J, Collart F, Ayari R, Bartoli J-M, et al. Late complications 
after prosthetic replacement of the ascending aorta: what did we learn from routine 
magnetic resonance imaging follow-up? Eur J Cardiothorac Surg 2000;18:313–20. 
https://doi.org/10.1016/s1010-7940(00)00512-1
1156. Bianco V, Kilic A, Gleason TG, Arnaoutakis GJ, Sultan I. Management of thoracic aor­
tic graft infections. J Card Surg 2018;33:658–65. https://doi.org/10.1111/jocs.13792
1157. Liisberg M, Baudier F, Akgül C, Lindholt JS. Long-term thoracic endovascular repair 
follow-up from 1999 to 2019: a single-center experience. Ann Vasc Surg 2022;86: 
399–407. https://doi.org/10.1016/j.avsg.2022.04.013
1158. Nakhaei P, Bashir M, Jubouri M, Banar S, Ilkhani S, Borzeshi EZ, et al. Aortic remod­
eling, distal stent-graft induced new entry and endoleak following frozen elephant 
trunk: a systematic review and meta-analysis. J Card Surg 2022;37:3848–62. https:// 
doi.org/10.1111/jocs.16918
1159. Iribarne A, Keenan J, Benrashid E, Wang H, Meza JM, Ganapathi A, et al. Imaging sur­
veillance after proximal aortic operations: is it necessary? Ann Thorac Surg 2017;103: 
734–41. https://doi.org/10.1016/j.athoracsur.2016.06.085
1160. Hensley SE, Upchurch GR, Jr. Repair of abdominal aortic aneurysms: JACC focus 
seminar, part 1. J Am Coll Cardiol 2022;80:821–31. https://doi.org/10.1016/j.jacc. 
2022.04.066
1161. Bastos Gonçalves F, Baderkhan H, Verhagen HJ, Wanhainen A, Björck M, Stolker RJ, 
et al. Early sac shrinkage predicts a low risk of late complications after endovascular 
aortic aneurysm repair. Br J Surg 2014;101:802–10. https://doi.org/10.1002/bjs.9516
1162. Troutman DA, Chaudry M, Dougherty MJ, Calligaro KD. Endovascular aortic aneur­
ysm repair surveillance may not be necessary for the first 3 years after an initially nor­
mal duplex postoperative study. J Vasc Surg 2014;60:558–62. https://doi.org/10.1016/ 
j.jvs.2014.03.278
1163. Jean-Baptiste E, Feugier P, Cruzel C, Sarlon-Bartoli G, Reix T, Steinmetz E, et al. 
Computed tomography-aortography versus color-duplex ultrasound for surveillance 
of endovascular abdominal aortic aneurysm repair: a prospective multicenter 
diagnostic-accuracy study (the ESSEA trial). Circ Cardiovasc Imaging 2020;13: 
e009886. https://doi.org/10.1161/circimaging.119.009886
1164. Johnsen L, Hisdal J, Jonung T, Braaten A, Pedersen G. Contrast-enhanced ultrasound 
detects type II endoleaks during follow-up for endovascular aneurysm repair. J Vasc 
Surg 2020;72:1952–9. https://doi.org/10.1016/j.jvs.2020.02.020
1165. George J, Tadros RO, Rao A, Png CYM, Han DK, Ilonzo N, et al. Duplex ultrasound 
can successfully identify endoleaks and renovisceral stent patency in patients under­
going complex endovascular aneurysm repair. Vasc Endovascular Surg 2021;55:234–8. 
https://doi.org/10.1177/1538574420980605
1166. Smith L, Thomas N, Arnold A, Bell R, Zayed H, Tyrrell M, et al. Editor’s choice—a 
comparison of computed tomography angiography and colour duplex ultrasound 
surveillance post infrarenal endovascular aortic aneurysm repair: financial implica­
tions and impact of different international surveillance guidelines. Eur J Vasc 
Endovasc Surg 2021;62:193–201. https://doi.org/10.1016/j.ejvs.2021.04.005
1167. Iscan HZ, Unal EU, Akkaya B, Daglı M, Karahan M, Civelek I, et al. Color Doppler 
ultrasound for surveillance following EVAR as the primary tool. J Card Surg 2021; 
36:111–7. https://doi.org/10.1111/jocs.15194
1168. Antoniou GA, Kontopodis N, Rogers SK, Golledge J, Forbes TL, Torella F, et al. 
Editor’s choice—meta-analysis of compliance with endovascular aneurysm repair 
surveillance: the EVAR surveillance paradox. Eur J Vasc Endovasc Surg 2023;65: 
244–54. https://doi.org/10.1016/j.ejvs.2022.10.033
1169. Baderkhan H, Haller O, Wanhainen A, Björck M, Mani K. Follow-up after endovascu­
lar aortic aneurysm repair can be stratified based on first postoperative imaging. Br J 
Surg 2018;105:709–18. https://doi.org/10.1002/bjs.10766
1170. Png CY, Tadros RO, Faries PL, Torres MR, Kim SY, Lookstein R, et al. The effect of 
age on post-EVAR outcomes. Ann Vasc Surg 2016;35:156–62. https://doi.org/10. 
1016/j.avsg.2016.01.022
1171. Xiong X, Wu Z, Qin X, Huang Q, Wang X, Qin J, et al. Meta-analysis suggests statins 
reduce mortality after abdominal aortic aneurysm repair. J Vasc Surg 2022;75: 
356–62.e4. https://doi.org/10.1016/j.jvs.2021.06.033
1172. Schrimpf C, Teebken OE, Wilhelmi M. Thoracic endovascular aortic repair after iat­
rogenic aortic dissection and false lumen stent grafting. Ann Thorac Surg 2015;99: 
1447–9. https://doi.org/10.1016/j.athoracsur.2014.05.101
1173. Sampson UK, Norman PE, Fowkes FG, Aboyans V, Song Y, Harrell FE, Jr, et al. Global 
and regional burden of aortic dissection and aneurysms: mortality trends in 21 world 
regions, 1990 to 2010. Glob Heart 2014;9:171–80.e110. https://doi.org/10.1016/j. 
gheart.2013.12.010
1174. Clough RE, Nienaber CA. Management of acute aortic syndrome. Nat Rev Cardiol 
2015;12:103–14. https://doi.org/10.1038/nrcardio.2014.203
1175. Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem U, et al. 
Insights from the international registry of acute aortic dissection: a 20-year experi­
ence of collaborative clinical research. Circulation 2018;137:1846–60. https://doi. 
org/10.1161/circulationaha.117.031264
1176. Booher AM, Isselbacher EM, Nienaber CA, Trimarchi S, Evangelista A, Montgomery 
DG, et al. The IRAD classification system for characterizing survival after aortic dis­
section. Am J Med 2013;126:730.e19–24. https://doi.org/10.1016/j.amjmed.2013.01. 
020
1177. Howard C, Ponnapalli A, Shaikh S, Idhrees M, Bashir M. Non-A non-B aortic dissec­
tion: a literature review. J Card Surg 2021;36:1806–13. https://doi.org/10.1111/jocs. 
15349
1178. Urbanski PP, Wagner M. Acute non-A-non-B aortic dissection: surgical or conserva­
tive approach? Eur J Cardiothorac Surg 2016;49:1249–54. https://doi.org/10.1093/ 
ejcts/ezv301
1179. Carino D, Singh M, Molardi A, Agostinelli A, Goldoni M, Pacini D, et al. Non-A non-B 
aortic dissection: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2019; 
55:653–9. https://doi.org/10.1093/ejcts/ezy337
1180. Sievers HH, Rylski B, Czerny M, Baier ALM, Kreibich M, Siepe M, et al. Aortic dissec­
tion reconsidered: type, entry site, malperfusion classification adding clarity and en­
abling outcome prediction. Interact Cardiovasc Thorac Surg 2020;30:451–7. https:// 
doi.org/10.1093/icvts/ivz281
1181. Aboyans V, Boukhris M. Dissecting the epidemiology of aortic dissection. Eur Heart J 
Acute Cardiovasc Care 2021;10:710–1. https://doi.org/10.1093/ehjacc/zuab065
1182. Pape LA, Awais M, Woznicki EM, Suzuki T, Trimarchi S, Evangelista A, et al. 
Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends 
from the international registry of acute aortic dissection. J Am Coll Cardiol 2015;66: 
350–8. https://doi.org/10.1016/j.jacc.2015.05.029
1183. Januzzi JL, Isselbacher EM, Fattori R, Cooper JV, Smith DE, Fang J, et al. Characterizing 
the young patient with aortic dissection: results from the international registry of aor­
tic dissection (IRAD). J Am Coll Cardiol 2004;43:665–9. https://doi.org/10.1016/j.jacc. 
2003.08.054
1184. Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: 
coronary heart disease. Am J Med 2014;127:807–12. https://doi.org/10.1016/j. 
amjmed.2014.04.015
1185. Bossone E, Pyeritz RE, O’Gara P, Harris KM, Braverman AC, Pape L, et al. Acute aor­
tic dissection in blacks: insights from the international registry of acute aortic dissec­
tion. Am J Med 2013;126:909–15. https://doi.org/10.1016/j.amjmed.2013.04.020
1186. Rylski B, Hoffmann I, Beyersdorf F, Suedkamp M, Siepe M, Nitsch B, et al. Iatrogenic 
acute aortic dissection type A: insight from the German registry for acute aortic dis­
section type A (GERAADA). Eur J Cardiothorac Surg 2013;44:353–9; discussion 359. 
https://doi.org/10.1093/ejcts/ezt055
1187. Núñez-Gil IJ, Bautista D, Cerrato E, Salinas P, Varbella F, Omedè P, et al. Incidence, 
management, and immediate- and long-term outcomes after iatrogenic aortic dissec­
tion during diagnostic or interventional coronary procedures. Circulation 2015;131: 
2114–9. https://doi.org/10.1161/circulationaha.115.015334
1188. Carbone A, Ranieri B, Castaldo R, Franzese M, Rega S, Cittadini A, et al. Sex differ­
ences in type A acute aortic dissection: a systematic review and meta-analysis. Eur J 
Prev Cardiol 2023;30:1074–89. https://doi.org/10.1093/eurjpc/zwad009
1189. Nienaber CA, Fattori R, Mehta RH, Richartz BM, Evangelista A, Petzsch M, et al. 
Gender-related differences in acute aortic dissection. Circulation 2004;109: 
3014–21. https://doi.org/10.1161/01.Cir.0000130644.78677.2c


<!-- PAGE 154 -->

### Page 154

1190. Manalo-Estrella P, Barker AE. Histopathologic findings in human aortic media asso­
ciated with pregnancy. Arch Pathol 1967;83:336–41.
1191. Lempel JK, Frazier AA, Jeudy J, Kligerman SJ, Schultz R, Ninalowo HA, et al. Aortic 
arch dissection: a controversy of classification. Radiology 2014;271:848–55. https:// 
doi.org/10.1148/radiol.14131457
1192. Mussa FF, Horton JD, Moridzadeh R, Nicholson J, Trimarchi S, Eagle KA. Acute aortic 
dissection and intramural hematoma: a systematic review. JAMA 2016;316:754–63. 
https://doi.org/10.1001/jama.2016.10026
1193. Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspectives from the 
international registry of acute aortic dissection (IRAD). Eur J Vasc Endovasc Surg 
2009;37:149–59. https://doi.org/10.1016/j.ejvs.2008.11.032
1194. Neri E, Toscano T, Papalia U, Frati G, Massetti M, Capannini G, et al. Proximal aortic 
dissection with coronary malperfusion: presentation, management, and outcome. 
J Thorac Cardiovasc Surg 2001;121:552–60. https://doi.org/10.1067/mtc.2001.112534
1195. Trimarchi S, Tsai T, Eagle KA, Isselbacher EM, Froehlich J, et al. Acute abdominal aor­
tic dissection: insight from the International Registry of Acute Aortic Dissection 
(IRAD). J Vasc Surg 2007;46:913–9. https://doi.org/10.1016/j.jvs.2007.07.030
1196. Gorla R, Erbel R, Kahlert P, Tsagakis K, Jakob H, Mahabadi A-A, et al. Accuracy of a 
diagnostic strategy combining aortic dissection detection risk score and D-dimer le­
vels in patients with suspected acute aortic syndrome. Eur Heart J Acute Cardiovasc 
Care 2017;6:371–8. https://doi.org/10.1177/2048872615594497
1197. Strayer RJ, Shearer PL, Hermann LK. Screening, evaluation, and early management of 
acute aortic dissection in the ED. Curr Cardiol Rev 2012;8:152–7. https://doi.org/10. 
2174/157340312801784970
1198. Nazerian P, Mueller C, Soeiro AM, Leidel BA, Salvadeo SAT, Giachino F, et al. 
Diagnostic accuracy of the aortic dissection detection risk score plus D-dimer for 
acute aortic syndromes: the ADvISED prospective multicenter study. Circulation 
2018;137:250–8. https://doi.org/10.1161/circulationaha.117.029457
1199. Bima P, Pivetta E, Nazerian P, Toyofuku M, Gorla R, Bossone E, et al. Systematic re­
view of aortic dissection detection risk score plus d-dimer for diagnostic rule-out of 
suspected acute aortic syndromes. Acad Emerg Med 2020;27:1013–27. https://doi. 
org/10.1111/acem.13969
1200. Rogers AM, Hermann LK, Booher AM, Nienaber CA, Williams DM, Kazerooni EA, 
et al. Sensitivity of the aortic dissection detection risk score, a novel guideline-based 
tool for identification of acute aortic dissection at initial presentation: results from the 
international registry of acute aortic dissection. Circulation 2011;123:2213–8. https:// 
doi.org/10.1161/CIRCULATIONAHA.110.988568
1201. Suzuki T, Distante A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA, et al. 
Diagnosis of acute aortic dissection by D-dimer: the international registry of acute 
aortic dissection substudy on biomarkers (IRAD-bio) experience. Circulation 2009; 
119:2702–7. https://doi.org/10.1161/circulationaha.108.833004
1202. Baliga RR, Nienaber CA, Bossone E, Oh JK, Isselbacher EM, Sechtem U, et al. The role 
of imaging in aortic dissection and related syndromes. JACC Cardiovasc Imaging 2014;7: 
406–24. https://doi.org/10.1016/j.jcmg.2013.10.015
1203. Nazerian P, Mueller C, Vanni S, Soeiro AM, Leidel BA, Cerini G, et al. Integration of 
transthoracic focused cardiac ultrasound in the diagnostic algorithm for suspected 
acute aortic syndromes. Eur Heart J 2019;40:1952–60. https://doi.org/10.1093/ 
eurheartj/ehz207
1204. Shiga T, Wajima Z, Apfel CC, Inoue T, Ohe Y. Diagnostic accuracy of transesophageal 
echocardiography, helical computed tomography, and magnetic resonance imaging 
for suspected thoracic aortic dissection: systematic review and meta-analysis. Arch 
Intern Med 2006;166:1350–6. https://doi.org/10.1001/archinte.166.13.1350
1205. Nienaber CA, Clough RE. Management of acute aortic dissection. Lancet 2015;385: 
800–11. https://doi.org/10.1016/s0140-6736(14)61005-9
1206. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 
44:3720–826. https://doi.org/10.1093/eurheartj/ehad191
1207. Rogers IS, Banerji D, Siegel EL, Truong QA, Ghoshhajra BB, Irlbeck T, et al. Usefulness 
of comprehensive cardiothoracic computed tomography in the evaluation of acute 
undifferentiated chest discomfort in the emergency department (CAPTURE). Am J 
Cardiol 2011;107:643–50. https://doi.org/10.1016/j.amjcard.2010.10.039
1208. Evangelista A, Maldonado G, Gruosso D, Gutiérrez L, Granato C, Villalva N, et al. The 
current role of echocardiography in acute aortic syndrome. Echo Res Pract 2019;6: 
R53–r63. https://doi.org/10.1530/erp-18-0058
1209. Vignon P, Guéret P, Vedrinne JM, Lagrange P, Cornu E, Abrieu O, et al. Role of trans­
esophageal echocardiography in the diagnosis and management of traumatic aortic 
disruption. Circulation 1995;92:2959–68. https://doi.org/10.1161/01.cir.92.10.2959
1210. Moral S, Avegliano G, Cuéllar H, Ballesteros E, Rodríguez-Palomares J, Teixidó G, 
et al. Usefulness of transesophageal echocardiography in the evaluation of celiac trunk 
and superior mesenteric artery involvement in acute aortic dissection. J Am Soc 
Echocardiogr 2021;34:327–35. https://doi.org/10.1016/j.echo.2020.12.019
1211. Nienaber CA, Clough RE, Sakalihasan N, Suzuki T, Gibbs R, Mussa F, et al. Aortic dis­
section. Nat Rev Dis Primers 2016;2:16053. https://doi.org/10.1038/nrdp.2016.53
1212. Vilacosta I, San Román JA, di Bartolomeo R, Eagle K, Estrera AL, Ferrera C, et al. 
Acute aortic syndrome revisited: JACC state-of-the-art review. J Am Coll Cardiol 
2021;78:2106–25. https://doi.org/10.1016/j.jacc.2021.09.022
1213. Tadros RO, Tang GHL, Barnes HJ, Mousavi I, Kovacic JC, Faries P, et al. Optimal treat­
ment of uncomplicated type B aortic dissection: JACC review topic of the week. J Am 
Coll Cardiol 2019;74:1494–504. https://doi.org/10.1016/j.jacc.2019.07.063
1214. Kodama K, Nishigami K, Sakamoto T, Sawamura T, Hirayama T, Misumi H, et al. Tight 
heart rate control reduces secondary adverse events in patients with type B acute 
aortic 
dissection. 
Circulation 
2008;118:S167–70. 
https://doi.org/10.1161/ 
circulationaha.107.755801
1215. Estrera AL, Miller CC, III, Safi HJ, Goodrick JS, Keyhani A, Porat EE, et al. Outcomes of 
medical management of acute type B aortic dissection. Circulation 2006;114: 
I384–389. https://doi.org/10.1161/circulationaha.105.001479
1216. Nejim B, Mathlouthi A, Naazie I, Malas MB. The effect of intravenous and oral beta- 
blocker use in patients with type B thoracic aortic dissection. Ann Vasc Surg 2022;80: 
170–9. https://doi.org/10.1016/j.avsg.2021.07.056
1217. Hameed I, Cifu AS, Vallabhajosyula P. Management of thoracic aortic dissection. JAMA 
2023;329:756–7. https://doi.org/10.1001/jama.2023.0265
1218. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. J Intensive 
Care 2018;6:15. https://doi.org/10.1186/s40560-018-0287-7
1219. Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, et al. Clinical profiles and 
outcomes of acute type B aortic dissection in the current era: lessons from the inter­
national registry of aortic dissection (IRAD). Circulation 2003;108:Ii312–7. https://doi. 
org/10.1161/01.cir.0000087386.07204.09
1220. Mehta RH, Suzuki T, Hagan PG, Bossone E, Gilon D, Llovet A, et al. Predicting death in 
patients with acute type a aortic dissection. Circulation 2002;105:200–6. https://doi. 
org/10.1161/hc0202.102246
1221. Mészáros I, Mórocz J, Szlávi J, Schmidt J, Tornóci L, Nagy L, et al. Epidemiology and 
clinicopathology of aortic dissection. Chest 2000;117:1271–8. https://doi.org/10. 
1378/chest.117.5.1271
1222. Glower DD, Speier RH, White WD, Smith LR, Rankin JS, Wolfe WG. Management 
and long-term outcome of aortic dissection. Ann Surg 1991;214:31–41. https://doi. 
org/10.1097/00000658-199107000-00006
1223. Nallamothu BK, Mehta RH, Saint S, Llovet A, Bossone E, Cooper JV, et al. Syncope in 
acute aortic dissection: diagnostic, prognostic, and clinical implications. Am J Med 
2002;113:468–71. https://doi.org/10.1016/s0002-9343(02)01254-8
1224. Suzuki T, Isselbacher EM, Nienaber CA, Pyeritz RE, Eagle KA, Tsai TT, et al. 
Type-selective benefits of medications in treatment of acute aortic dissection 
(from the international registry of acute aortic dissection [IRAD]). Am J Cardiol 
2012;109:122–7. https://doi.org/10.1016/j.amjcard.2011.08.012
1225. Palmer J, Gelmann D, Engelbrecht-Wiggans E, Hollis G, Hart E, Ali A, et al. Invasive 
arterial blood pressure monitoring may aid in the medical management of hyperten­
sive patients with acute aortic disease. Am J Emerg Med 2022;59:85–93. https://doi. 
org/10.1016/j.ajem.2022.06.054
1226. Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, et al. 
Endovascular repair of type B aortic dissection: long-term results of the randomized 
investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013;6: 
407–16. https://doi.org/10.1161/circinterventions.113.000463
1227. Fattori R, Montgomery D, Lovato L, Kische S, Di Eusanio M, Ince H, et al. Survival after 
endovascular therapy in patients with type B aortic dissection: a report from the 
international registry of acute aortic dissection (IRAD). JACC Cardiovasc Interv 
2013;6:876–82. https://doi.org/10.1016/j.jcin.2013.05.003
1228. Durham CA, Cambria RP, Wang LJ, Ergul EA, Aranson NJ, Patel VI, et al. The natural 
history of medically managed acute type B aortic dissection. J Vasc Surg 2015;61: 
1192–8. https://doi.org/10.1016/j.jvs.2014.12.038
1229. Lou X, Chen EP, Duwayri YM, Veeraswamy RK, Jordan WD, Zehner CA, et al. The 
impact of thoracic endovascular aortic repair on long-term survival in type B aortic 
dissection. Ann Thorac Surg 2018;105:31–8. https://doi.org/10.1016/j.athoracsur. 
2017.06.016
1230. Lou X, Duwayri YM, Chen EP, Jordan WD, Forcillo J, Zehner CA, et al. Predictors of 
failure of medical management in uncomplicated type B aortic dissection. Ann Thorac 
Surg 2019;107:493–8. https://doi.org/10.1016/j.athoracsur.2018.08.012
1231. Lou X, Duwayri YM, Jordan WD, Jr, Chen EP, Veeraswamy RK, Leshnower BG. The 
safety and efficacy of extended TEVAR in acute type B aortic dissection. Ann Thorac 
Surg 2020;110:799–806. https://doi.org/10.1016/j.athoracsur.2019.12.036
1232. Hirst AE, Jr, Johns VJ, Jr, Kime SW, Jr. Dissecting aneurysm of the aorta: a review of 
505 cases. Medicine 1958;37:217–79. https://doi.org/10.1097/00005792-195809000- 
00003
1233. Chiappini B, Schepens M, Tan E, Amore AD, Morshuis W, Dossche K, et al. Early and 
late outcomes of acute type A aortic dissection: analysis of risk factors in 487 con­
secutive patients. Eur Heart J 2005;26:180–6. https://doi.org/10.1093/eurheartj/ 
ehi024
1234. Harris KM, Nienaber CA, Peterson MD, Woznicki EM, Braverman AC, Trimarchi S, 
et al. Early mortality in type A acute aortic dissection: insights from the international 
registry of acute aortic dissection. JAMA Cardiol 2022;7:1009–15. https://doi.org/10. 
1001/jamacardio.2022.2718
1235. Zhu Y, Lingala B, Baiocchi M, Tao JJ, Toro Arana V, Khoo JW, et al. Type A aortic 
dissection-experience over 5 decades: JACC historical breakthroughs in perspective. 
J Am Coll Cardiol 2020;76:1703–13. https://doi.org/10.1016/j.jacc.2020.07.061
ESC Guidelines                                                                                                                                                                                          3691


<!-- PAGE 155 -->

### Page 155

1236. Czerny M, Siepe M, Beyersdorf F, Feisst M, Gabel M, Pilz M, et al. Prediction of mor­
tality rate in acute type A dissection: the German registry for acute type A aortic dis­
section score. Eur J Cardiothorac Surg 2020;58:700–6. https://doi.org/10.1093/ejcts/ 
ezaa156
1237. Perko MJ, Nørgaard M, Herzog TM, Olsen PS, Schroeder TV, Pettersson G. 
Unoperated aortic aneurysm: a survey of 170 patients. Ann Thorac Surg 1995;59: 
1204–9. https://doi.org/10.1016/0003-4975(95)00132-5
1238. Wolfe SB, Sundt TM, III, Isselbacher EM, Cameron DE, Trimarchi S, Bekeredjian R, 
et al. Survival after operative repair of acute type A aortic dissection varies according 
to the presence and type of preoperative malperfusion. J Thorac Cardiovasc Surg 2024; 
168:37–49.e6. https://doi.org/10.1016/j.jtcvs.2022.09.034
1239. Trimarchi S, Eagle KA, Nienaber CA, Rampoldi V, Jonker FHW, De Vincentiis C, et al. 
Role of age in acute type A aortic dissection outcome: report from the international 
registry of acute aortic dissection (IRAD). J Thorac Cardiovasc Surg 2010;140:784–9. 
https://doi.org/10.1016/j.jtcvs.2009.11.014
1240. Shrestha M, Khaladj N, Haverich A, Hagl C. Is treatment of acute type A aortic dis­
section in septuagenarians justifiable? Asian Cardiovasc Thorac Ann 2008;16:33–6. 
https://doi.org/10.1177/021849230801600109
1241. Bonser RS, Ranasinghe AM, Loubani M, Evans JD, Thalji NMA, Bachet JE, et al. 
Evidence, lack of evidence, controversy, and debate in the provision and performance 
of the surgery of acute type A aortic dissection. J Am Coll Cardiol 2011;58:2455–74. 
https://doi.org/10.1016/j.jacc.2011.06.067
1242. Subramanian S, Leontyev S, Borger MA, Trommer C, Misfeld M, Mohr FW. 
Valve-sparing root reconstruction does not compromise survival in acute type A aor­
tic dissection. Ann Thorac Surg 2012;94:1230–4. https://doi.org/10.1016/j.athoracsur. 
2012.04.094
1243. Urbanski PP, Hijazi H, Dinstak W, Diegeler A. Valve-sparing aortic root repair in 
acute type A dissection: how many sinuses have to be repaired for curative surgery? 
Eur J Cardiothorac Surg 2013;44:439–43; discussion 443–4. https://doi.org/10.1093/ 
ejcts/ezt042
1244. Shrestha M, Baraki H, Maeding I, Fitzner S, Sarikouch S, Khaladj N, et al. Long-term 
results after aortic valve-sparing operation (David I). Eur J Cardiothorac Surg 2012; 
41:56–61; discussion 61–2. https://doi.org/10.1016/j.ejcts.2011.04.012
1245. Tsagakis K, Pacini D, Di Bartolomeo R, Gorlitzer M, Weiss G, Grabenwoger M, et al. 
Multicenter early experience with extended aortic repair in acute aortic dissection: is 
simultaneous descending stent grafting justified? J Thorac Cardiovasc Surg 2010;140: 
S116–20; discussion S142–S146. https://doi.org/10.1016/j.jtcvs.2010.07.066
1246. Tsagakis K, Pacini D, Grabenwöger M, Borger MA, Goebel N, Hemmer W, et al. 
Results of frozen elephant trunk from the international E-vita Open registry. Ann 
Cardiothorac Surg 2020;9:178–88. https://doi.org/10.21037/acs-2020-fet-25
1247. Beckmann E, Martens A, Kaufeld T, Natanov R, Krueger H, Rudolph L, et al. Frozen 
elephant trunk in acute aortic type a dissection: risk analysis of concomitant root re­
placement. Eur J Cardiothorac Surg 2022;62:ezac051. https://doi.org/10.1093/ejcts/ 
ezac051
1248. Cruz I, Stuart B, Caldeira D, Morgado G, Gomes AC, Almeida AR, et al. Controlled 
pericardiocentesis in patients with cardiac tamponade complicating aortic dissection: 
experience of a centre without cardiothoracic surgery. Eur Heart J Acute Cardiovasc 
Care 2015;4:124–8. https://doi.org/10.1177/2048872614549737
1249. Hayashi T, Tsukube T, Yamashita T, Haraguchi T, Matsukawa R, Kozawa S, et al. 
Impact of controlled pericardial drainage on critical cardiac tamponade with acute 
type A aortic dissection. Circulation 2012;126:S97–101. https://doi.org/10.1161/ 
CIRCULATIONAHA.111.082685
1250. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, et al. 
The international registry of acute aortic dissection (IRAD): new insights into an old 
disease. JAMA 2000;283:897–903. https://doi.org/10.1001/jama.283.7.897
1251. Saczkowski R, Malas T, Mesana T, de Kerchove L, El Khoury G, Boodhwani M. Aortic 
valve preservation and repair in acute type A aortic dissection. Eur J Cardiothorac Surg 
2014;45:e220–226. https://doi.org/10.1093/ejcts/ezu099
1252. Hysi I, Juthier F, Fabre O, Fouquet O, Rousse N, Banfi C, et al. Aortic root surgery 
improves long-term survival after acute type A aortic dissection. Int J Cardiol 2015; 
184:285–90. https://doi.org/10.1016/j.ijcard.2015.02.020
1253. Peterss S, Dumfarth J, Rizzo JA, Bonaros N, Fang H, Tranquilli M, et al. Sparing the 
aortic root in acute aortic dissection type A: risk reduction and restored integrity 
of the untouched root. Eur J Cardiothorac Surg 2016;50:232–9. https://doi.org/10. 
1093/ejcts/ezw012
1254. Chen SK, Qiu ZH, Fang GH, Wu XJ, Chen LW. Reported outcomes after aortic valve 
resuspension for acute type A aortic dissection: a systematic review and 
meta-analysis. Interact Cardiovasc Thorac Surg 2019;29:331–8. https://doi.org/10. 
1093/icvts/ivz080
1255. Qiu J, Wu J, Xie E, Luo X, Chen JF, Gao W, et al. Surgical management and outcomes 
of the aortic root in acute type A aortic dissection. Ann Thorac Surg 2020;110: 
136–43. https://doi.org/10.1016/j.athoracsur.2019.10.014
1256. Umana-Pizano JB, Nissen AP, Sandhu HK, Miller CC, Loghin A, Safi HJ, et al. Acute 
type A dissection repair by high-volume vs low-volume surgeons at a high-volume 
aortic center. Ann Thorac Surg 2019;108:1330–6. https://doi.org/10.1016/j. 
athoracsur.2019.04.040
1257. Goldstone AB, Chiu P, Baiocchi M, Lingala B, Lee J, Rigdon J, et al. Interfacility transfer 
of medicare beneficiaries with acute type A aortic dissection and regionalization of 
care in the United States. Circulation 2019;140:1239–50. https://doi.org/10.1161/ 
circulationaha.118.038867
1258. Mosbahi S, Stak D, Gravestock I, Burgstaller JM, Steurer J, Eckstein F, et al. A systemic 
review and meta-analysis: Bentall versus David procedure in acute type A aortic dis­
section. Eur J Cardiothorac Surg 2019;55:201–9. https://doi.org/10.1093/ejcts/ezy266
1259. Beckmann E, Martens A, Pertz J, Kaufeld T, Umminger J, Hanke JS, et al. Valve-sparing 
David I procedure in acute aortic type A dissection: a 20-year experience with more 
than 100 patients. Eur J Cardiothorac Surg 2017;52:319–24. https://doi.org/10.1093/ 
ejcts/ezx170
1260. Weiss G, Tsagakis K, Jakob H, Di Bartolomeo R, Pacini D, Barberio G, et al. The fro­
zen elephant trunk technique for the treatment of complicated type B aortic dissec­
tion with involvement of the aortic arch: multicentre early experience. Eur J 
Cardiothorac Surg 2015;47:106–14; discussion 114. https://doi.org/10.1093/ejcts/ 
ezu067
1261. Iafrancesco M, Goebel N, Mascaro J, Franke UFW, Pacini D, Di Bartolomeo R, et al. 
Aortic diameter remodelling after the frozen elephant trunk technique in aortic dis­
section: results from an international multicentre registry. Eur J Cardiothorac Surg 
2017;52:310–8. https://doi.org/10.1093/ejcts/ezx131
1262. Tsagakis K, Wendt D, Dimitriou AM, Thielmann M, Shehada S-D, El Gabry M, et al. 
The frozen elephant trunk treatment is the operation of choice for all kinds of arch 
disease. J Cardiovasc Surg (Torino) 2018;59:540–6. https://doi.org/10.23736/s0021- 
9509.18.10597-0
1263. Widenka KJ, Kosiorowska M, Jakob H, Pacini D, Hemmer W, Grabenwoeger M, et al. 
Early and midterm results of frozen elephant trunk operation with Evita open stent- 
graft in patients with Marfan syndrome: results of a multicentre study. BMC Cardiovasc 
Disord 2022;22:333. https://doi.org/10.1186/s12872-022-02777-5
1264. Jakob H, Shehada SE, Dohle D, Wendt D, El Gabry M, Schlosser T, et al. New 3-zone 
hybrid graft: first-in-man experience in acute type I dissection. J Thorac Cardiovasc Surg 
2022;163:568–74.e1. https://doi.org/10.1016/j.jtcvs.2020.04.113
1265. Tsagakis K, Osswald A, Weymann A, Demircioglu A, Schmack B, Wendt D, et al. The 
frozen elephant trunk technique: impact of proximalization and the four-sites perfu­
sion technique. Eur J Cardiothorac Surg 2021;61:195–203. https://doi.org/10.1093/ 
ejcts/ezab295
1266. Rampoldi V, Trimarchi S, Eagle KA, Nienaber CA, Oh JK, Bossone E, et al. Simple risk 
models to predict surgical mortality in acute type A aortic dissection: the internation­
al registry of acute aortic dissection score. Ann Thorac Surg 2007;83:55–61. https://doi. 
org/10.1016/j.athoracsur.2006.08.007
1267. Lawton JS, Liu J, Kulshrestha K, Moon MR, Damiano RJ, Maniar H, et al. The impact of 
surgical strategy on survival after repair of type A aortic dissection. J Thorac Cardiovasc 
Surg 2015;150:294–301.e1. https://doi.org/10.1016/j.jtcvs.2015.03.023
1268. Malvindi PG, Modi A, Miskolczi S, Kaarne M, Velissaris T, Barlow C, et al. Open and 
closed distal anastomosis for acute type A aortic dissection repair. Interact Cardiovasc 
Thorac Surg 2016;22:776–83. https://doi.org/10.1093/icvts/ivw044
1269. Geirsson A, Shioda K, Olsson C, Ahlsson A, Gunn J, Hansson EC, et al. Differential 
outcomes of open and clamp-on distal anastomosis techniques in acute type A aortic 
dissection. J Thorac Cardiovasc Surg 2019;157:1750–8. https://doi.org/10.1016/j.jtcvs. 
2018.09.020
1270. Yan Y, Xu L, Zhang H, Xu Z-Y, Ding X-Y, Wang S-W, et al. Proximal aortic repair 
versus extensive aortic repair in the treatment of acute type A aortic dissection: a 
meta-analysis. Eur J Cardiothorac Surg 2016;49:1392–401. https://doi.org/10.1093/ 
ejcts/ezv351
1271. Poon SS, Theologou T, Harrington D, Kuduvalli M, Oo A, Field M. Hemiarch versus 
total aortic arch replacement in acute type A dissection: a systematic review and 
meta-analysis. Ann Cardiothorac Surg 2016;5:156–73. https://doi.org/10.21037/acs. 
2016.05.06
1272. Hsieh WC, Kan CD, Yu HC, Aboud A, Lindner J, Henry BM, et al. Ascending aorta 
replacement vs. total aortic arch replacement in the treatment of acute type A dis­
section: a meta-analysis. Eur Rev Med Pharmacol Sci 2019;23:9590–611. https://doi. 
org/10.26355/eurrev_201911_19454
1273. Preventza O, Cervera R, Cooley DA, Bakaeen FG, Mohamed AS, Cheong BYC, et al. 
Acute type I aortic dissection: traditional versus hybrid repair with antegrade stent 
delivery to the descending thoracic aorta. J Thorac Cardiovasc Surg 2014;148: 
119–25. https://doi.org/10.1016/j.jtcvs.2013.07.055
1274. Roselli EE, Idrees JJ, Bakaeen FG, Tong MZ, Soltesz EG, Mick S, et al. Evolution of sim­
plified frozen elephant trunk repair for acute DeBakey type I dissection: midterm out­
comes. Ann Thorac Surg 2018;105:749–55. https://doi.org/10.1016/j.athoracsur.2017. 
08.037
1275. Berretta P, Trimarchi S, Patel HJ, Gleason TG, Eagle KA, Di Eusanio M. Malperfusion 
syndromes in type A aortic dissection: what we have learned from IRAD. J Vis Surg 
2018;4:65. https://doi.org/10.21037/jovs.2018.03.13
1276. Benedetto U, Mohamed H, Vitulli P, Petrou M. Axillary versus femoral arterial cannu­
lation in type A acute aortic dissection: evidence from a meta-analysis of comparative 
studies and adjusted risk estimates. Eur J Cardiothorac Surg 2015;48:953–9. https://doi. 
org/10.1093/ejcts/ezv035


<!-- PAGE 156 -->

### Page 156

1277. Geirsson A, Szeto WY, Pochettino A, McGarvey ML, Keane MG, Woo YJ, et al. 
Significance of malperfusion syndromes prior to contemporary surgical repair for 
acute type A dissection: outcomes and need for additional revascularizations. Eur J 
Cardiothorac Surg 2007;32:255–62. https://doi.org/10.1016/j.ejcts.2007.04.012
1278. Yang B, Norton EL, Rosati CM, Wu X, Kim KM, Khaja MS, et al. Managing patients 
with acute type A aortic dissection and mesenteric malperfusion syndrome: a 
20-year experience. J Thorac Cardiovasc Surg 2019;158:675–87.e4. https://doi.org/ 
10.1016/j.jtcvs.2018.11.127
1279. Yang B, Rosati CM, Norton EL, Kim KM, Khaja MS, Dasika N, et al. Endovascular fen­
estration/stenting first followed by delayed open aortic repair for acute type A aortic 
dissection with malperfusion syndrome. Circulation 2018;138:2091–103. https://doi. 
org/10.1161/circulationaha.118.036328
1280. Leshnower BG, Keeling WB, Duwayri YM, Jordan WD, Jr, Chen EP. The “thoracic 
endovascular aortic repair-first” strategy for acute type A dissection with mesenteric 
malperfusion: initial results compared with conventional algorithms. J Thorac 
Cardiovasc Surg 2019;158:1516–24. https://doi.org/10.1016/j.jtcvs.2019.01.116
1281. Rylski B, Szeto WY, Bavaria JE, Branchetti E, Moser W, Milewski RK. Development of 
a single endovascular device for aortic valve replacement and ascending aortic repair. 
J Card Surg 2014;29:371–6. https://doi.org/10.1111/jocs.12348
1282. Kreibich M, Rylski B, Kondov S, Morlock J, Scheumann J, Kari FA, et al. Endovascular 
treatment of acute type A aortic dissection-the Endo Bentall approach. J Vis Surg 
2018;4:69. https://doi.org/10.21037/jovs.2018.03.14
1283. Brown CR, Chen Z, Khurshan F, Kreibich M, Bavaria J, Groeneveld P, et al. Outcomes 
after thoracic endovascular aortic repair in patients with chronic kidney disease in the 
Medicare population. J Thorac Cardiovasc Surg 2020;159:402–13. https://doi.org/10. 
1016/j.jtcvs.2019.01.118
1284. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Bossone E, et al. Role and 
results of surgery in acute type B aortic dissection: insights from the international 
registry of acute aortic dissection (IRAD). Circulation 2006;114:I357–64. https://doi. 
org/10.1161/circulationaha.105.000620
1285. Tolenaar JL, Froehlich W, Jonker FH, Upchurch GR, Rampoldi V, Tsai TT, et al. 
Predicting in-hospital mortality in acute type B aortic dissection: evidence from inter­
national registry of acute aortic dissection. Circulation 2014;130:S45–50. https://doi. 
org/10.1161/circulationaha.113.007117
1286. Martin G, Patel N, Grant Y, Jenkins M, Gibbs R, Bicknell C. Antihypertensive medica­
tion adherence in chronic type B aortic dissection is an important consideration in the 
management debate. J Vasc Surg 2018;68:693–9.e2. https://doi.org/10.1016/j.jvs.2017. 
12.063
1287. Brooke BS, Griffin CL, Glotzbach JP, Horns JJ, Patel S, Kraiss LW, et al. Predictors of 
adherence to anti-impulse therapy among patients treated for acute type-B aortic 
dissections. Ann Vasc Surg 2021;76:95–103. https://doi.org/10.1016/j.avsg.2021.04. 
011
1288. Zeeshan A, Woo EY, Bavaria JE, Fairman RM, Desai ND, Pochettino A, et al. Thoracic 
endovascular aortic repair for acute complicated type B aortic dissection: superiority 
relative to conventional open surgical and medical therapy. J Thorac Cardiovasc Surg 
2010;140:S109–115; discussion S142–S146. https://doi.org/10.1016/j.jtcvs.2010.06. 
024
1289. Steuer J, Eriksson MO, Nyman R, Björck M, Wanhainen A. Early and long-term out­
come after thoracic endovascular aortic repair (TEVAR) for acute complicated type B 
aortic dissection. Eur J Vasc Endovasc Surg 2011;41:318–23. https://doi.org/10.1016/j. 
ejvs.2010.11.024
1290. Zipfel B, Czerny M, Funovics M, Coppi G, Ferro C, Rousseau H, et al. Endovascular 
treatment of patients with types A and B thoracic aortic dissection using Relay thor­
acic stent-grafts: results from the RESTORE patient registry. J Endovasc Ther 2011;18: 
131–43. https://doi.org/10.1583/10-3233mr.1
1291. Hanna JM, Andersen ND, Ganapathi AM, McCann RL, Hughes GC. Five-year results 
for endovascular repair of acute complicated type B aortic dissection. J Vasc Surg 
2014;59:96–106. https://doi.org/10.1016/j.jvs.2013.07.001
1292. Stelzmueller ME, Nolz R, Mahr S, Beitzke D, Wolf F, Funovics M, et al. Thoracic en­
dovascular repair for acute complicated type B aortic dissections. J Vasc Surg 2019;69: 
318–26. https://doi.org/10.1016/j.jvs.2018.05.234
1293. Wilson-Smith AR, Muston B, Kamalanathan H, Yung A, Chen C-HJ, Sahai P, et al. 
Endovascular repair of acute complicated type B aortic dissection-systematic review 
and meta-analysis of long-term survival and reintervention. Ann Cardiothorac Surg 
2021;10:723–30. https://doi.org/10.21037/acs-2021-taes-17
1294. MacGillivray TE, Gleason TG, Patel HJ, Aldea GS, Bavaria JE, Beaver TM, et al. The 
Society of Thoracic Surgeons/American Association for Thoracic Surgery clinical 
practice guidelines on the management of type B aortic dissection. J Thorac 
Cardiovasc Surg 2022;163:1231–49. https://doi.org/10.1016/j.jtcvs.2021.11.091
1295. Brunkwall J, Kasprzak P, Verhoeven E, Heijmen R, Taylor P, Alric P, et al. Endovascular 
repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 
1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg 2014;48:285–91. https:// 
doi.org/10.1016/j.ejvs.2014.05.012
1296. Hossack M, Patel S, Gambardella I, Neequaye S, Antoniou GA, Torella F. 
Endovascular vs. medical management for uncomplicated acute and sub-acute type 
B aortic dissection: a meta-analysis. Eur J Vasc Endovasc Surg 2020;59:794–807. 
https://doi.org/10.1016/j.ejvs.2019.08.003
1297. Sa MP, Jacquemyn X, Van den Eynde J, Chu D, Serna-Gallegos D, Singh MJ, et al. 
Midterm outcomes of endovascular vs. medical therapy for uncomplicated type B 
aortic dissection: meta-analysis of reconstructed time to event data. Eur J Vasc 
Endovasc Surg 2023;66:609–19. https://doi.org/10.1016/j.ejvs.2023.07.004
1298. Sa MP, Jacquemyn X, Brown JA, Ahmad D, Serna-Gallegos D, Arnaoutakis GJ, et al. 
Thoracic endovascular aortic repair for hyperacute, acute, subacute and chronic 
type B aortic dissection: meta-analysis of reconstructed time-to-event data. Trends 
Cardiovasc Med 2023:S1050-1738(23)00113-5. https://doi.org/10.1016/j.tcm.2023. 
12.005
1299. Jubouri M, Al-Tawil M, Yip HCA, Bashir A, Tan SZCP, Bashir M, et al. Mid- and long- 
term outcomes of thoracic endovascular aortic repair in acute and subacute uncom­
plicated type B aortic dissection. J Card Surg 2022;37:1328–39. https://doi.org/10. 
1111/jocs.16349
1300. Torrent DJ, McFarland GE, Wang G, Malas M, Pearce BJ, Aucoin V, et al. Timing of 
thoracic endovascular aortic repair for uncomplicated acute type B aortic dissection 
and the association with complications. J Vasc Surg 2021;73:826–35. https://doi.org/ 
10.1016/j.jvs.2020.05.073
1301. Schwartz SI, Durham C, Clouse WD, Patel VI, Lancaster RT, Cambria RP, et al. 
Predictors of late aortic intervention in patients with medically treated type B aortic 
dissection. J Vasc Surg 2018;67:78–84. https://doi.org/10.1016/j.jvs.2017.05.128
1302. Onitsuka S, Akashi H, Tayama K, Okazaki T, Ishihara K, Hiromatsu S, et al. Long-term 
outcome and prognostic predictors of medically treated acute type B aortic dissec­
tions. Ann Thorac Surg 2004;78:1268–73. https://doi.org/10.1016/j.athoracsur.2004. 
02.031
1303. Hughes GC, Ganapathi AM, Keenan JE, Englum BR, Hanna JM, Schechter MA, et al. 
Thoracic endovascular aortic repair for chronic DeBakey IIIb aortic dissection. Ann 
Thorac Surg 2014;98:2092–7; discussion 2098. https://doi.org/10.1016/j.athoracsur. 
2014.06.066
1304. Jánosi RA, Tsagakis K, Bettin M, Kahlert P, Horacek M, Al-Rashid F, et al. Thoracic aor­
tic aneurysm expansion due to late distal stent graft-induced new entry. Catheter 
Cardiovasc Interv 2015;85:E43–53. https://doi.org/10.1002/ccd.25614
1305. Cheng L, Xiang D, Zhang S, Zheng C, Wu X. Reintervention after thoracic endovas­
cular aortic repair of uncomplicated type B aortic dissection. J Clin Med 2023;12: 
1418. https://doi.org/10.3390/jcm12041418
1306. Akutsu K, Nejima J, Kiuchi K, Sasaki K, Ochi M, Tanaka K, et al. Effects of the patent 
false lumen on the long-term outcome of type B acute aortic dissection. Eur J 
Cardiothorac Surg 2004;26:359–66. https://doi.org/10.1016/j.ejcts.2004.03.026
1307. Tsai TT, Evangelista A, Nienaber CA, Myrmel T, Meinhardt G, Cooper JV, et al. Partial 
thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J 
Med 2007;357:349–59. https://doi.org/10.1056/NEJMoa063232
1308. Dake MD, Thompson M, van Sambeek M, Vermassen F, Morales JP. DISSECT: a new 
mnemonic-based approach to the categorization of aortic dissection. Eur J Vasc 
Endovasc Surg 2013;46:175–90. https://doi.org/10.1016/j.ejvs.2013.04.029
1309. Wang J, Jin T, Chen B, Pan Y, Shao C. Systematic review and meta-analysis of current 
evidence in endograft therapy vs medical treatment for uncomplicated type B aortic 
dissection. J Vasc Surg 2022;76:1099–108.e3. https://doi.org/10.1016/j.jvs.2022.03. 
876
1310. Umaña JP, Lai DT, Mitchell RS, Moore KA, Rodriguez F, Robbins RC, et al. Is medical 
therapy still the optimal treatment strategy for patients with acute type B aortic dis­
sections? J Thorac Cardiovasc Surg 2002;124:896–910. https://doi.org/10.1067/mtc. 
2002.123131
1311. Umaña JP, Miller DC, Mitchell RS. What is the best treatment for patients with acute 
type B aortic dissections—medical, surgical, or endovascular stent-grafting? Ann 
Thorac Surg 2002;74:S1840–3; discussion S1857–63. https://doi.org/10.1016/s0003- 
4975(02)04140-1
1312. Morello F, Santoro M, Fargion AT, Grifoni S, Nazerian P. Diagnosis and management 
of acute aortic syndromes in the emergency department. Intern Emerg Med 2021;16: 
171–81. https://doi.org/10.1007/s11739-020-02354-8
1313. Marui A, Mochizuki T, Mitsui N, Koyama T, Kimura F, Horibe M. Toward the best 
treatment for uncomplicated patients with type B acute aortic dissection: a consid­
eration for sound surgical indication. Circulation 1999;100:II275–80. https://doi.org/ 
10.1161/01.cir.100.suppl_2.ii-275
1314. Crawford ES. The diagnosis and management of aortic dissection. JAMA 1990;264: 
2537–41.
1315. Hata M, Shiono M, Inoue T, Sezai A, Niino T, Negishi N, et al. Optimal treatment of 
type B acute aortic dissection: long-term medical follow-up results. Ann Thorac Surg 
2003;75:1781–4. https://doi.org/10.1016/s0003-4975(03)00113-9
1316. Oda T, Minatoya K, Sasaki H, Tanaka H, Seike Y, Itonaga T, et al. Surgical indication for 
chronic aortic dissection in descending thoracic and thoracoabdominal aorta. Circ 
Cardiovasc Interv 2017;10:e004292. https://doi.org/10.1161/circinterventions.116. 
004292
1317. Conrad MF, Chung TK, Cambria MR, Paruchuri V, Brady TJ, Cambria RP. Effect of 
chronic dissection on early and late outcomes after descending thoracic and 
ESC Guidelines                                                                                                                                                                                          3693


<!-- PAGE 157 -->

### Page 157

thoracoabdominal aneurysm repair. J Vasc Surg 2011;53:600–7; discussion 607. 
https://doi.org/10.1016/j.jvs.2010.09.053
1318. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, et al. 
Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors deter­
mining immediate and long-term results of operations in 605 patients. J Vasc Surg 
1986;3:389–404. https://doi.org/10.1067/mva.1986.avs0030389
1319. Zoli S, Etz CD, Roder F, Mueller CS, Brenner RM, Bodian CA, et al. Long-term survival 
after open repair of chronic distal aortic dissection. Ann Thorac Surg 2010;89: 
1458–66. https://doi.org/10.1016/j.athoracsur.2010.02.014
1320. Etz CD, Zoli S, Mueller CS, Bodian CA, Di Luozzo G, Lazala R, et al. Staged repair 
significantly reduces paraplegia rate after extensive thoracoabdominal aortic aneur­
ysm repair. J Thorac Cardiovasc Surg 2010;139:1464–72. https://doi.org/10.1016/j. 
jtcvs.2010.02.037
1321. Conrad MF, Ergul EA, Patel VI, Paruchuri V, Kwolek CJ, Cambria RP. Management 
of diseases of the descending thoracic aorta in the endovascular era: a Medicare 
population study. Ann Surg 2010;252:603–10. https://doi.org/10.1097/SLA. 
0b013e3181f4eaef
1322. Sobocinski J, Dias NV, Berger L, Midulla M, Hertault A, Sonesson B, et al. Endograft 
repair of complicated acute type B aortic dissections. Eur J Vasc Endovasc Surg 2013; 
45:468–74. https://doi.org/10.1016/j.ejvs.2013.01.031
1323. Conrad MF, Carvalho S, Ergul E, Kwolek CJ, Lancaster RT, Patel VI, et al. Late aortic 
remodeling persists in the stented segment after endovascular repair of acute com­
plicated type B aortic dissection. J Vasc Surg 2015;62:600–5. https://doi.org/10.1016/j. 
jvs.2015.03.064
1324. Thrumurthy SG, Karthikesalingam A, Patterson BO, Holt PJE, Hinchliffe RJ, Loftus IM, 
et al. A systematic review of mid-term outcomes of thoracic endovascular repair 
(TEVAR) of chronic type B aortic dissection. Eur J Vasc Endovasc Surg 2011;42: 
632–47. https://doi.org/10.1016/j.ejvs.2011.08.009
1325. Boufi M, Patterson BO, Loundou AD, Boyer L, Grima MJ, Loftus IM, et al. 
Endovascular versus open repair for chronic type B dissection treatment: a 
meta-analysis. Ann Thorac Surg 2019;107:1559–70. https://doi.org/10.1016/j. 
athoracsur.2018.10.045
1326. Conway AM, Qato K, Mondry LR, Stoffels GJ, Giangola G, Carroccio A. Outcomes of 
thoracic endovascular aortic repair for chronic aortic dissections. J Vasc Surg 2018;67: 
1345–52. https://doi.org/10.1016/j.jvs.2017.08.098
1327. Tenorio ER, Oderich GS, Farber MA, Schneider DB, Timaran CH, Schanzer A, et al. 
Outcomes of endovascular repair of chronic postdissection compared with degen­
erative thoracoabdominal aortic aneurysms using fenestrated-branched stent grafts. 
J Vasc Surg 2020;72:822–36.e9. https://doi.org/10.1016/j.jvs.2019.10.091
1328. Marques De Marino P, Ibraheem A, Gafur N, Verhoeven EL, Katsargyris A. 
Outcomes of fenestrated and branched endovascular aortic repair for chronic post- 
dissection thoracoabdominal aortic aneurysms. J Cardiovasc Surg 2020;61:427–34. 
https://doi.org/10.23736/s0021-9509.20.11367-3
1329. Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Bertoglio L, et al. Fenestrated 
and branched endografts for post-dissection thoraco-abdominal aneurysms: results 
of a national multicentre study and literature review. Eur J Vasc Endovasc Surg 
2022;64:630–8. https://doi.org/10.1016/j.ejvs.2022.06.019
1330. Geisbüsch S, Kuehnl A, Salvermoser M, Reutersberg B, Trenner M, Eckstein H-H. 
Editor’s choice—hospital incidence, treatment, and in hospital mortality following 
open and endovascular surgery for thoraco-abdominal aortic aneurysms in 
Germany from 2005 to 2014: secondary data analysis of the Nationwide German 
DRG microdata. Eur J Vasc Endovasc Surg 2019;57:488–98. https://doi.org/10.1016/ 
j.ejvs.2018.10.030
1331. Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M. Chronic beta-blocker ther­
apy improves outcome and reduces treatment costs in chronic type B aortic dissec­
tion. Eur J Cardiothorac Surg 2001;19:606–10. https://doi.org/10.1016/s1010-7940(01) 
00662-5
1332. Chen SW, Chan YH, Lin CP, Wu VC-C, Cheng Y-T, Chen D-Y, et al. Association of 
long-term use of antihypertensive medications with late outcomes among patients 
with aortic dissection. JAMA Netw Open 2021;4:e210469. https://doi.org/10.1001/ 
jamanetworkopen.2021.0469
1333. Smedberg C, Hultgren R, Leander K, Steuer J. Pharmacological treatment in patients 
with aortic dissection. Open Heart 2022;9:e002082. https://doi.org/10.1136/openhrt- 
2022-002082
1334. Xiong J, Jiang B, Guo W, Wang SM, Tong XY. Endovascular stent graft placement in 
patients with type B aortic dissection: a meta-analysis in China. J Thorac Cardiovasc 
Surg 2009;138:865–72.e1. https://doi.org/10.1016/j.jtcvs.2009.02.005
1335. Zhu JM, Ma WG, Peterss S, Wang L-F, Qiao Z-Y, Ziganshin BA, et al. Aortic dissection 
in pregnancy: management strategy and outcomes. Ann Thorac Surg 2017;103: 
1199–206. https://doi.org/10.1016/j.athoracsur.2016.08.089
1336. Yates MT, Soppa G, Smelt J, Fletcher N, van Besouw J-P, Thilaganathan B, et al. 
Perioperative management and outcomes of aortic surgery during pregnancy. J 
Thorac Cardiovasc Surg 2015;149:607–10. https://doi.org/10.1016/j.jtcvs.2014.10.038
1337. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, 
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of 
cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241. https:// 
doi.org/10.1093/eurheartj/ehy340
1338. DeMartino RR, Sen I, Huang Y, Bower TC, Oderich GS, Pochettino A, et al. 
Population-based assessment of the incidence of aortic dissection, intramural hema­
toma, and penetrating ulcer, and its associated mortality from 1995 to 2015. Circ 
Cardiovasc Qual Outcomes 2018;11:e004689. https://doi.org/10.1161/circoutcomes. 
118.004689
1339. Evangelista A, Dominguez R, Sebastia C, Salas A, Permanyer-Miralda G, Avegliano G, 
et al. Long-term follow-up of aortic intramural hematoma: predictors of outcome. 
Circulation 2003;108:583–9. https://doi.org/10.1161/01.Cir.0000081776.49923.5a
1340. Moral S, Ballesteros E, Roque M, Carrato C, Vilardell P, Brugada R, et al. Intimal dis­
ruption in type B aortic intramural hematoma. Does size matter? A systematic review 
and meta-analysis. Int J Cardiol 2018;269:298–303. https://doi.org/10.1016/j.ijcard. 
2018.07.111
1341. Moral S, Ballesteros E, Evangelista A. Conservative vs surgical treatment in type A 
intramural hematoma. What is new? J Card Surg 2020;35:1758–60. https://doi.org/ 
10.1111/jocs.14739
1342. Ishizu K, Kaji S, Nakashima M, Kitai T, Kim K, Ehara N, et al. Focal intimal disruption 
size at multidetector CT and disease progression in type B aortic intramural hema­
toma. Radiology 2021;301:311–9. https://doi.org/10.1148/radiol.2021204385
1343. Chou AS, Ziganshin BA, Charilaou P, Tranquilli M, Rizzo JA, Elefteriades JA. 
Long-term behavior of aortic intramural hematomas and penetrating ulcers. J 
Thorac Cardiovasc Surg 2016;151:361–72, 373.e1. https://doi.org/10.1016/j.jtcvs. 
2015.09.012
1344. Evangelista A, Mukherjee D, Mehta RH, O’Gara PT, Fattori R, Cooper JV, et al. Acute 
intramural hematoma of the aorta: a mystery in evolution. Circulation 2005;111: 
1063–70. https://doi.org/10.1161/01.Cir.0000156444.26393.80
1345. Song JK. Update in acute aortic syndrome: intramural hematoma and incomplete dis­
section as new disease entities. J Cardiol 2014;64:153–61. https://doi.org/10.1016/j. 
jjcc.2014.05.005
1346. Song JK, Kim HS, Kang DH, Lim T-H, Song M-G, Park S-W, et al. Different clinical fea­
tures of aortic intramural hematoma versus dissection involving the ascending aorta. 
J Am Coll Cardiol 2001;37:1604–10. https://doi.org/10.1016/s0735-1097(01)01184-6
1347. Evangelista A, Maldonado G, Moral S, Teixido-Tura G, Lopez A, Cuellar H, et al. 
Intramural hematoma and penetrating ulcer in the descending aorta: differences 
and similarities. Ann Cardiothorac Surg 2019;8:456–70. https://doi.org/10.21037/acs. 
2019.07.05
1348. Wee I, Varughese RS, Syn N, Choong A. Non-operative management of type A acute 
aortic syndromes: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 
2019;58:41–51. https://doi.org/10.1016/j.ejvs.2018.10.015
1349. Chow SCY, Wong RHL, Lakhani I, Wong MV, Tse G, Yu PSY, et al. Management of 
acute type A intramural hematoma: upfront surgery or individualized approach? A 
retrospective analysis and meta-analysis. J Thorac Dis 2020;12:680–9. https://doi. 
org/10.21037/jtd.2019.12.109
1350. Evangelista A, Czerny M, Nienaber C, Schepens M, Rousseau H, Cao P, et al. 
Interdisciplinary expert consensus on management of type B intramural haematoma 
and penetrating aortic ulcer. Eur J Cardiothorac Surg 2015;47:209–17. https://doi.org/ 
10.1093/ejcts/ezu386
1351. Sa MP, Jacquemyn X, Tasoudis P, Dufendach K, Singh MJ, de la Cruz KI, et al. Five year 
results of endovascular versus medical therapy in acute type B aortic intramural 
haematoma: meta-analysis of reconstructed time to event data. Eur J Vasc Endovasc 
Surg 2024;67:584–92. https://doi.org/10.1016/j.ejvs.2023.12.024
1352. Moral S, Cuéllar H, Avegliano G, Ballesteros E, Salcedo MT, Ferreira-González I, et al. 
Clinical implications of focal intimal disruption in patients with type B intramural 
hematoma. J Am Coll Cardiol 2017;69:28–39. https://doi.org/10.1016/j.jacc.2016.10. 
045
1353. Chakos A, Twindyawardhani T, Evangelista A, Maldonado G, Piffaretti G, Yan TD, 
et al. Endovascular versus medical management of type B intramural hematoma: a 
meta-analysis. Ann Cardiothorac Surg 2019;8:447–55. https://doi.org/10.21037/acs. 
2019.06.11
1354. Song JK, Yim JH, Ahn JM, Kim D-H, Kang JW, Lee TY, et al. Outcomes of patients with 
acute type a aortic intramural hematoma. Circulation 2009;120:2046–52. https://doi. 
org/10.1161/circulationaha.109.879783
1355. Ahn JM, Kim H, Kwon O, Om SY, Heo R, Lee S, et al. Differential clinical features and 
long-term prognosis of acute aortic syndrome according to disease entity. Eur Heart J 
2019;40:2727–36. https://doi.org/10.1093/eurheartj/ehz153
1356. Kitamura T, Torii S, Miyamoto T, Mishima T, Ohkubo H, Fujioka S, et al. 
Watch-and-wait strategy for type A intramural haematoma and acute aortic dissec­
tion with thrombosed false lumen of the ascending aorta: a Japanese single-centre ex­
perience. Eur J Cardiothorac Surg 2020;58:590–7. https://doi.org/10.1093/ejcts/ 
ezaa080
1357. Jánosi RA, Gorla R, Tsagakis K, Kahlert P, Horacek M, Bruckschen F, et al. Thoracic 
endovascular repair of complicated penetrating aortic ulcer: an 11-year single-center 
experience. 
J 
Endovasc 
Ther 
2016;23:150–9. 
https://doi.org/10.1177/ 
1526602815613790


<!-- PAGE 158 -->

### Page 158

1358. Nguyen VX, Nguyen BD. PET/CT imaging of abdominal aorta with intramural hema­
tomas, penetrating ulcer, and saccular pseudoaneurysm. Clin Nucl Med 2014;39: 
467–9. https://doi.org/10.1097/RLU.0b013e318292f152
1359. Gorla R, Erbel R, Kuehl H, Kahlert P, Tsagakis K, Jakob H, et al. Prognostic value of 
(18)F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison 
with serological biomarkers of inflammation. Int J Cardiovasc Imaging 2015;31: 
1677–85. https://doi.org/10.1007/s10554-015-0725-8
1360. Eggebrecht H, Plicht B, Kahlert P, Erbel R. Intramural hematoma and penetrating ul­
cers: indications to endovascular treatment. Eur J Vasc Endovasc Surg 2009;38:659–65. 
https://doi.org/10.1016/j.ejvs.2009.09.001
1361. Salim S, Locci R, Martin G, Gibbs R, Jenkins M, Hamady M, et al. Short- and long-term 
outcomes in isolated penetrating aortic ulcer disease. J Vasc Surg 2020;72:84–91. 
https://doi.org/10.1016/j.jvs.2019.09.039
1362. Überall MA, Elling C, Eibl C, Müller-Schwefe GHH, Lefeber C, Heine M, et al. 
Tapentadol prolonged release in patients with chronic low back pain: real-world 
data from the German Pain eRegistry. Pain Manag 2022;12:211–27. https://doi.org/ 
10.2217/pmt-2021-0058
1363. Ganaha F, Miller DC, Sugimoto K, Do YS, Minamiguchi H, Saito H, et al. Prognosis of 
aortic intramural hematoma with and without penetrating atherosclerotic ulcer: a 
clinical and radiological analysis. Circulation 2002;106:342–8. https://doi.org/10. 
1161/01.cir.0000022164.26075.5a
1364. DeCarlo C, Latz CA, Boitano LT, Waller HD, Kim Y, Sumpio BJ, et al. Natural history 
of penetrating atherosclerotic ulcers in aortic branch vessels. J Vasc Surg 2021;74: 
1904–9. https://doi.org/10.1016/j.jvs.2021.06.035
1365. Piazza M, Squizzato F, Porcellato L, Casali E, Grego F, Antonello M. Predictors of 
intervention in acute type B aortic penetrating ulcer and intramural hematoma. 
Semin Thorac Cardiovasc Surg 2022;36:1–10. https://doi.org/10.1053/j.semtcvs.2022. 
07.009
1366. Kotsis T, Spyropoulos BG, Asaloumidis N, Christoforou P, Katseni K, 
Papaconstantinou I. Penetrating atherosclerotic ulcers of the abdominal aorta: a 
case report and review of the literature. Vasc Specialist Int 2019;35:152–9. https:// 
doi.org/10.5758/vsi.2019.35.3.152
1367. DeCarlo C, Latz CA, Boitano LT, Kim Y, Tanious A, Schwartz SI, et al. Prognostication 
of asymptomatic penetrating aortic ulcers: a modern approach. Circulation 2021;144: 
1091–101. https://doi.org/10.1161/circulationaha.121.054710
1368. Demetriades D, Velmahos GC, Scalea TM, Jurkovich GJ, Karmy-Jones R, Teixeira PG, 
et al. Operative repair or endovascular stent graft in blunt traumatic thoracic aortic 
injuries: results of an American Association for the Surgery of Trauma Multicenter 
Study. J Trauma 2008;64:561–70; discussion 570–1. https://doi.org/10.1097/TA. 
0b013e3181641bb3
1369. Katzenschlager R, Ugurluoglu A, Ahmadi A, Hülsmann M, Koppensteiner R, Larch E, 
et al. Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. 
Radiology 1995;195:463–6. https://doi.org/10.1148/radiology.195.2.7724767
1370. Mulder EJ, van Bockel JH, Maas J, van den Akker PJ, Hermans J. Morbidity and mor­
tality of reconstructive surgery of noninfected false aneurysms detected long after 
aortic prosthetic reconstruction. Arch Surg 1998;133:45–9. https://doi.org/10.1001/ 
archsurg.133.1.45
1371. Chaud GJ, Mohammadi S, Cervetti MR, Guimaron S, Sebestyen A, Dagenais F, et al. 
Aortic pseudoaneurysm after type A aortic dissection: results of conservative man­
agement. Semin Thorac Cardiovasc Surg 2022;35:457–64. https://doi.org/10.1053/j. 
semtcvs.2022.04.004
1372. Richens D, Kotidis K, Neale M, Oakley C, Fails A. Rupture of the aorta following road 
traffic accidents in the United Kingdom 1992–1999. The results of the co-operative 
crash injury study. Eur J Cardiothorac Surg 2003;23:143–8. https://doi.org/10.1016/ 
s1010-7940(02)00720-0
1373. Harky A, Bleetman D, Chan JSK, Eriksen P, Chaplin G, MacCarthy-Ofosu B, et al. A 
systematic review and meta-analysis of endovascular versus open surgical repair for 
the traumatic ruptured thoracic aorta. J Vasc Surg 2020;71:270–82. https://doi.org/10. 
1016/j.jvs.2019.05.011
1374. Heneghan RE, Aarabi S, Quiroga E, Gunn ML, Singh N, Starnes BW. Call for a new 
classification system and treatment strategy in blunt aortic injury. J Vasc Surg 2016; 
64:171–6. https://doi.org/10.1016/j.jvs.2016.02.047
1375. Januzzi JL, Sabatine MS, Eagle KA, Evangelista A, Bruckman D, Fattori R, et al. 
Iatrogenic aortic dissection. Am J Cardiol 2002;89:623–6. https://doi.org/10.1016/ 
s0002-9149(01)02312-8
1376. Gómez-Moreno S, Sabaté M, Jiménez-Quevedo P, Vázquez P, Alfonso F, Angiolillo 
DJ, et al. Iatrogenic dissection of the ascending aorta following heart catheterisation: 
incidence, management and outcome. EuroIntervention 2006;2:197–202.
1377. Dunning DW, Kahn JK, Hawkins ET, O’Neill W. Iatrogenic coronary artery dissec­
tions extending into and involving the aortic root. Catheter Cardiovasc Interv 2000; 
51:387–93. 
https://doi.org/10.1002/1522-726x(200012)51:4<387::aid-ccd3>3.0. 
co;2-b
1378. Bekkers JA, te Riele RJ, Takkenberg JJ, Bol Raap G, Hofland J, Roos-Hesselink JW, et al. 
Thoracic aortic surgery: an overview of 40 years clinical practice. J Thorac Cardiovasc 
Surg 2014;147:332–43. https://doi.org/10.1016/j.jtcvs.2012.11.036
1379. Meena RA, Benarroch-Gampel J, Leshnower BG, Escobar GA, Duwayri Y, Jordan 
WD, et al. Surveillance recommendations after thoracic endovascular aortic repair 
should be based on initial indication for repair. Ann Vasc Surg 2019;57:51–9. https:// 
doi.org/10.1016/j.avsg.2018.11.001
1380. Giles KA, Beck AW, Lala S, Patterson S, Back M, Fatima J, et al. Implications of second­
ary aortic intervention after thoracic endovascular aortic repair for acute and chronic 
type B dissection. J Vasc Surg 2019;69:1367–78. https://doi.org/10.1016/j.jvs.2018.07. 
080
1381. Kimura N, Itoh S, Yuri K, Adachi K, Matsumoto H, Yamaguchi A, et al. Reoperation 
for enlargement of the distal aorta after initial surgery for acute type A aortic dissec­
tion. J Thorac Cardiovasc Surg 2015;149:S91–8.e1. https://doi.org/10.1016/j.jtcvs.2014. 
08.008
1382. Ameli-Renani S, Das R, Morgan RA. Thoracic endovascular aortic repair for the treat­
ment of aortic dissection: post-operative imaging, complications and secondary inter­
ventions. Cardiovasc Intervent Radiol 2015;38:1391–404. https://doi.org/10.1007/ 
s00270-015-1072-9
1383. Fleischmann D, Afifi RO, Casanegra AI, Elefteriades JA, Gleason TG, Hanneman K, 
et al. Imaging and surveillance of chronic aortic dissection: a scientific statement 
from the American Heart Association. Circ Cardiovasc Imaging 2022;15:e000075. 
https://doi.org/10.1161/hci.0000000000000075
1384. Colacchio EC, Squizzato F, Piazza M, Menegolo M, Grego F, Antonello M. Clinical and 
imaging predictors of disease progression in type B aortic intramural hematomas and 
penetrating aortic ulcers: a systematic review. Diagnostics (Basel) 2022;12:2727. 
https://doi.org/10.3390/diagnostics12112727
1385. Vapnik JS, Kim JB, Isselbacher EM, Ghoshhajra BB, Cheng Y, Sundt TM, et al. 
Characteristics and outcomes of ascending versus descending thoracic aortic aneur­
ysms. Am J Cardiol 2016;117:1683–90. https://doi.org/10.1016/j.amjcard.2016.02.048
1386. Gökalp AL, Takkenberg JJM. Decision-making in thoracic aortic aneurysm surgery- 
clinician and patient view. Semin Thorac Cardiovasc Surg 2019;31:638–42. https://doi. 
org/10.1053/j.semtcvs.2019.05.032
1387. Treasure T, King A, Hidalgo Lemp L, Golesworthy T, Pepper J, Takkenberg JJM. 
Developing a shared decision support framework for aortic root surgery in Marfan 
syndrome. Heart 2018;104:480–6. https://doi.org/10.1136/heartjnl-2017-311598
1388. Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al. 
International registry of patients carrying TGFBR1 or TGFBR2 mutations: results 
of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet 2016;9: 
548–58. https://doi.org/10.1161/circgenetics.116.001485
1389. Thakker PD, Braverman AC. Cardiogenetics: genetic testing in the diagnosis and man­
agement of patients with aortic disease. Heart 2021;107:619–26. https://doi.org/10. 
1136/heartjnl-2020-317036
1390. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. 
Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 
2006;355:788–98. https://doi.org/10.1056/NEJMoa055695
1391. Regalado ES, Morris SA, Braverman AC, Hostetler EM, De Backer J, Li R, et al. 
Comparative risks of initial aortic events associated with genetic thoracic aortic dis­
ease. J Am Coll Cardiol 2022;80:857–69. https://doi.org/10.1016/j.jacc.2022.05.054
1392. Huguenard AL, Johnson GW, Desai RR, Osbun JW, Dacey RG, Braverman AC. 
Relationship between phenotypic features in Loeys-Dietz syndrome and the pres­
ence of intracranial aneurysms. J Neurosurg 2022;138:1385–92. https://doi.org/10. 
3171/2022.9.Jns221373
1393. Lopez-Sainz A, Mila L, Rodriguez-Palomares J, Limeres J, Granato C, La Mura L, et al. 
Aortic branch aneurysms and vascular risk in patients with Marfan syndrome. J Am 
Coll Cardiol 2021;77:3005–12. https://doi.org/10.1016/j.jacc.2021.04.054
1394. Kaw A, Kaw K, Hostetler EM, Beleza-Meireles A, Smith-Collins A, Armstrong C, et al. 
Expanding ACTA2 genotypes with corresponding phenotypes overlapping with 
smooth muscle dysfunction syndrome. Am J Med Genet A 2022;188:2389–96. 
https://doi.org/10.1002/ajmg.a.62775
1395. Velvin G, Wilhelmsen JE, Johansen H, Bathen T, Geirdal AO. Systematic review of 
quality of life in persons with hereditary thoracic aortic aneurysm and dissection diag­
noses. Clin Genet 2019;95:661–76. https://doi.org/10.1111/cge.13522
1396. Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic review of 
studies that have evaluated screening tests in relatives of patients affected by nonsyn­
dromic thoracic aortic disease. J Am Heart Assoc 2018;7:e009302. https://doi.org/10. 
1161/jaha.118.009302
1397. Cecchi AC, Boerio ML, Marin I, Pinard A, Milewicz DM. Preventing acute aortic dis­
sections: the power of familial screening and risk assessment. J Am Heart Assoc 2022; 
11:e025441. https://doi.org/10.1161/jaha.122.025441
1398. Abbasciano RG, Mariscalco G, Barwell J, Owens G, Zakkar M, Joel-David L, et al. 
Evaluating the feasibility of screening relatives of patients affected by nonsyndromic 
thoracic aortic diseases: the REST study. J Am Heart Assoc 2022;11:e023741. 
https://doi.org/10.1161/jaha.121.023741
1399. Musunuru K, Hershberger RE, Day SM, Klinedinst NJ, Landstrom AP, Parikh VN, et al. 
Genetic testing for inherited cardiovascular diseases: a scientific statement from the 
American Heart Association. Circ Genom Precis Med 2020;13:e000067. https://doi. 
org/10.1161/hcg.0000000000000067
ESC Guidelines                                                                                                                                                                                          3695


<!-- PAGE 159 -->

### Page 159

1400. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al. Familial 
thoracic aortic aneurysms and dissections—incidence, modes of inheritance, and 
phenotypic patterns. Ann Thorac Surg 2006;82:1400–5. https://doi.org/10.1016/j. 
athoracsur.2006.04.098
1401. Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and 
dissections: a case control study. J Vasc Surg 1997;25:506–11. https://doi.org/10.1016/ 
s0741-5214(97)70261-1
1402. Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al. 
Familial non-syndromal thoracic aortic aneurysms and dissections—incidence and 
family screening outcomes. Int J Cardiol 2016;220:43–51. https://doi.org/10.1016/j. 
ijcard.2016.06.086
1403. De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, et al. Genetic 
counselling and testing in adults with congenital heart disease: a consensus document 
of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC 
Working Group on Aorta and Peripheral Vascular Disease and the European 
Society of Human Genetics. Eur J Prev Cardiol 2020;27:1423–35. https://doi.org/10. 
1177/2047487319854552
1404. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, et al. Clinical implica­
tions of identifying pathogenic variants in individuals with thoracic aortic dissection. 
Circ Genom Precis Med 2019;12:e002476. https://doi.org/10.1161/circgen.118.002476
1405. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical validity 
of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2018; 
72:605–15. https://doi.org/10.1016/j.jacc.2018.04.089
1406. De Backer J, Jondeau G, Boileau C. Genetic testing for aortopathies: primer for the 
nongeneticist. Curr Opin Cardiol 2019;34:585–93. https://doi.org/10.1097/hco. 
0000000000000669
1407. Milewicz DM, Guo D, Hostetler E, Marin I, Pinard AC, Cecchi AC, et al. Update on 
the genetic risk for thoracic aortic aneurysms and acute aortic dissections: implica­
tions for clinical care. J Cardiovasc Surg 2021;62:203–10. https://doi.org/10.23736/ 
s0021-9509.21.11816-6
1408. Chou EL, Lindsay ME. The genetics of aortopathies: hereditary thoracic aortic aneur­
ysms and dissections. Am J Med Genet C Semin Med Genet 2020;184:136–48. https:// 
doi.org/10.1002/ajmg.c.31771
1409. Harris SL, Lindsay ME. Role of clinical genetic testing in the management of aortopa­
thies. Curr Cardiol Rep 2021;23:10. https://doi.org/10.1007/s11886-020-01435-6
1410. Regalado ES, Guo DC, Prakash S, Bensend TA, Flynn K, Estrera A, et al. Aortic disease 
presentation and outcome associated with ACTA2 mutations. Circ Cardiovasc Genet 
2015;8:457–64. https://doi.org/10.1161/circgenetics.114.000943
1411. Teixidó-Tura G, Franken R, Galuppo V, Gutiérrez García-Moreno L, Borregan M, 
Mulder BJM, et al. Heterogeneity of aortic disease severity in patients with 
Loeys-Dietz syndrome. Heart 2016;102:626–32. https://doi.org/10.1136/heartjnl- 
2015-308535
1412. Baudhuin LM, Kotzer KE, Lagerstedt SA. Increased frequency of FBN1 truncating and 
splicing variants in Marfan syndrome patients with aortic events. Genet Med 2015;17: 
177–87. https://doi.org/10.1038/gim.2014.91
1413. Franken R, Teixido-Tura G, Brion M, Forteza A, Rodriguez-Palomares J, Gutierrez L, 
et al. Relationship between fibrillin-1 genotype and severity of cardiovascular involve­
ment in Marfan syndrome. Heart 2017;103:1795–9. https://doi.org/10.1136/heartjnl- 
2016-310631
1414. Wallace SE, Regalado ES, Gong L, Janda AL, Guo D, Russo CF, et al. MYLK pathogenic 
variants aortic disease presentation, pregnancy risk, and characterization of patho­
genic missense variants. Genet Med 2019;21:144–51. https://doi.org/10.1038/ 
s41436-018-0038-0
1415. Seike Y, Matsuda H, Ishibashi-Ueda H, Morisaki H, Morisaki T, Minatoya K, et al. 
Surgical outcome and histological differences between individuals with TGFBR1 
and TGFBR2 mutations in Loeys-Dietz syndrome. Ann Thorac Cardiovasc Surg 2021; 
27:56–63. https://doi.org/10.5761/atcs.oa.20-00223
1416. Arnaud P, Milleron O, Hanna N, Ropers J, Ould Ouali N, Affoune A, et al. Clinical 
relevance of genotype-phenotype correlations beyond vascular events in a cohort 
study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet 
Med 2021;23:1296–304. https://doi.org/10.1038/s41436-021-01132-x
1417. Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N, Collins 
RT, et al. Cardiovascular health in Turner syndrome: a scientific statement from the 
American Heart Association. Circ Genom Precis Med 2018;11:e000048. https://doi. 
org/10.1161/hcg.0000000000000048
1418. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al. 
Clinical practice guidelines for the care of girls and women with Turner syndrome: 
proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur 
J Endocrinol 2017;177:G1–70. https://doi.org/10.1530/eje-17-0430
1419. van den Hoven AT, Chelu RG, Duijnhouwer AL, Demulier L, Devos D, Nieman K, 
et al. Partial anomalous pulmonary venous return in Turner syndrome. Eur J Radiol 
2017;95:141–6. https://doi.org/10.1016/j.ejrad.2017.07.024
1420. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicus­
pid aortic valve are associated with aortic dissection in Turner syndrome: report of 
the international Turner syndrome aortic dissection registry. Circulation 2012;126: 
2220–6. https://doi.org/10.1161/circulationaha.111.088633
1421. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner 
syndrome. Circulation 2007;116:1663–70. https://doi.org/10.1161/circulationaha.106. 
685487
1422. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in wo­
men with Turner syndrome in Great Britain: a national cohort study. J Clin 
Endocrinol Metab 2008;93:4735–42. https://doi.org/10.1210/jc.2008-1049
1423. Duijnhouwer AL, Bons LR, Timmers H, van Kimmenade RRL, Snoeren M, 
Timmermans J, et al. Aortic dilatation and outcome in women with Turner syndrome. 
Heart 2019;105:693–700. https://doi.org/10.1136/heartjnl-2018-313716
1424. Donadille B, Tuffet S, Cholet C, Nedelcu M, Bourcigaux N, Iserin L, et al. Prevalence 
and progression of aortic dilatation in adult patients with Turner syndrome: a cohort 
study. Eur J Endocrinol 2020;183:463–70. https://doi.org/10.1530/eje-20-0284
1425. Meccanici F, Schotte MH, Snoeren M, Bons LR, van den Hoven AT, Kardys I, et al. 
Aortic dilation and growth in women with Turner syndrome. Heart 2023;109: 
102–10. https://doi.org/10.1136/heartjnl-2022-320922
1426. Galian-Gay L, Rodriguez-Palomares JF. Turner syndrome and aortic complications: 
more benign than previously thought. Heart 2022;109:82–3. https://doi.org/10. 
1136/heartjnl-2022-321330
1427. Silberbach M, Braverman AC, Prakash SK, Roos-Hesselink JW, Quezada E, Scurlock 
C. Preventing aortic dissection in Turner syndrome: who faces the risk? Int J Cardiol 
2023;377:44. https://doi.org/10.1016/j.ijcard.2023.01.075
1428. Prakash S, Gen TACRI, Milewicz D. Turner syndrome-specific and general population 
Z-scores are equivalent for most adults with Turner syndrome. Am J Med Genet A 
2017;173:1094–6. https://doi.org/10.1002/ajmg.a.38100
1429. Corbitt H, Maslen C, Prakash S, Morris SA, Silberbach M. Allometric considerations 
when assessing aortic aneurysms in Turner syndrome: implications for activity re­
commendations and medical decision-making. Am J Med Genet A 2018;176:277–82. 
https://doi.org/10.1002/ajmg.a.38584
1430. Quigley CA, Fechner PY, Geffner ME, Eugster EA, Ross JL, Habiby RL, et al. 
Prevention of growth failure in Turner syndrome: long-term results of early growth 
hormone treatment in the “Toddler Turner” Cohort. Horm Res Paediatr 2021;94: 
18–35. https://doi.org/10.1159/000513788
1431. Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, et al. 
Estrogen replacement in Turner syndrome: literature review and practical considera­
tions. J Clin Endocrinol Metab 2018;103:1790–803. https://doi.org/10.1210/jc.2017- 
02183
1432. Quigley CA, Wan X, Garg S, Kowal K, Cutler GB, Ross JL. Effects of low-dose estro­
gen replacement during childhood on pubertal development and gonadotropin con­
centrations in patients with Turner syndrome: results of a randomized, double-blind, 
placebo-controlled clinical trial. J Clin Endocrinol Metab 2014;99:E1754–1764. https:// 
doi.org/10.1210/jc.2013-4518
1433. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al. Growth 
hormone treatment of early growth failure in toddlers with Turner syndrome: a ran­
domized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406–16. 
https://doi.org/10.1210/jc.2006-2874
1434. Stephure DK; Canadian Growth Hormone Advisory Committee. Impact of growth 
hormone supplementation on adult height in Turner syndrome: results of the 
Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360–6. 
https://doi.org/10.1210/jc.2004-2187
1435. Campens L, Baris L, Scott NS, Broberg CS, Bondue A, Jondeau G, et al. Pregnancy 
outcome in thoracic aortic disease data from the registry of pregnancy and cardiac 
disease. Heart 2021;107:1704–9. https://doi.org/10.1136/heartjnl-2020-318183
1436. Grewal J, Valente AM, Egbe AC, Wu FM, Krieger EV, Sybert VP, et al. Cardiovascular 
outcomes of pregnancy in Turner syndrome. Heart 2021;107:61–6. https://doi.org/ 
10.1136/heartjnl-2020-316719
1437. Thompson T, Zieba B, Howell S, Karakash W, Davis S. A mixed methods study of 
physical activity and quality of life in adolescents with Turner syndrome. Am J Med 
Genet A 2020;182:386–96. https://doi.org/10.1002/ajmg.a.61439
1438. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of 
Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342: 
673–80. https://doi.org/10.1056/nejm200003093421001
1439. Byers PH, Belmont J, Black J, De Backer J, Frank M, Jeunemaitre X, et al. Diagnosis, 
natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med 
Genet C Semin Med Genet 2017;175:40–7. https://doi.org/10.1002/ajmg.c.31553
1440. Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al. The 
spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 
30-year experience. J Vasc Surg 2005;42:98–106. https://doi.org/10.1016/j.jvs.2005. 
03.053
1441. Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al. Vascular 
Ehlers-Danlos syndrome: long-term observational study. J Am Coll Cardiol 2019;73: 
1948–57. https://doi.org/10.1016/j.jacc.2019.01.058
1442. Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by 
mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS 
type IV). Genet Med 2014;16:881–8. https://doi.org/10.1038/gim.2014.72
1443. van de Laar I, Baas AF, De Backer J, Blankenstein JD, Dulfer E, Helderman-van den 
Enden ATJM, et al. Surveillance and monitoring in vascular Ehlers-Danlos syndrome


<!-- PAGE 160 -->

### Page 160

in European reference network for rare vascular diseases (VASCERN). Eur J Med 
Genet 2022;65:104557. https://doi.org/10.1016/j.ejmg.2022.104557
1444. Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Bjorck M. Celiprolol treatment in 
patients with vascular Ehlers-Danlos syndrome. Eur J Vasc Endovasc Surg 2021;61: 
326–31. https://doi.org/10.1016/j.ejvs.2020.10.020
1445. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celi­
prolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a 
prospective randomised, open, blinded-endpoints trial. Lancet 2010;376:1476–84. 
https://doi.org/10.1016/s0140-6736(10)60960-9
1446. Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complica­
tions in women with vascular Ehlers-Danlos syndrome. Genet Med 2014;16:874–80. 
https://doi.org/10.1038/gim.2014.53
1447. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. 
The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476–85. 
https://doi.org/10.1136/jmg.2009.072785
1448. Yildiz M, Nucera M, Jungi S, Heinisch PP, Mosbahi S, Becker D, et al. Outcome of 
Stanford type B dissection in patients with Marfan syndrome. Eur J Cardiothorac 
Surg 2023;64:ezad178. https://doi.org/10.1093/ejcts/ezad178
1449. Narula N, Devereux RB, Arbustini E, Ma X, Weinsaft JW, Girardi L, et al. Risk of type 
B dissection in Marfan syndrome: the Cornell aortic aneurysm registry. J Am Coll 
Cardiol 2023;82:2009–17. https://doi.org/10.1016/j.jacc.2023.08.055
1450. Senemaud J, Gaudry M, Jouve E, Blanchard A, Milleron O, Dulac Y, et al. Primary non- 
aortic lesions are not rare in Marfan syndrome and are associated with aortic dissec­
tion independently of age. J Clin Med 2023;12:2902. https://doi.org/10.3390/ 
jcm12082902
1451. Judge DP, Rouf R, Habashi J, Dietz HC. Mitral valve disease in Marfan syndrome and 
related disorders. J Cardiovasc Transl Res 2011;4:741–7. https://doi.org/10.1007/ 
s12265-011-9314-y
1452. Demolder A, Bianco L, Caruana M, Cervi E, Evangelista A, Jondeau G, et al. 
Arrhythmia and impaired myocardial function in heritable thoracic aortic disease: 
an international retrospective cohort study. Eur J Med Genet 2022;65:104503. 
https://doi.org/10.1016/j.ejmg.2022.104503
1453. Pyeritz RE. Marfan syndrome: improved clinical history results in expanded natural 
history. Genet Med 2019;21:1683–90. https://doi.org/10.1038/s41436-018-0399-4
1454. Jondeau G, Detaint D, Tubach F, Arnoult F, Milleron O, Raoux F, et al. Aortic event 
rate in the Marfan population: a cohort study. Circulation 2012;125:226–32. https:// 
doi.org/10.1161/circulationaha.111.054676
1455. Requejo-Garcia L, Martinez-Lopez R, Plana-Andani E, Medina-Badenes P, 
Hernándiz-Martínez A, Torres-Blanco A, et al. Extrathoracic aneurysms in Marfan 
syndrome: a systematic review of the literature. Ann Vasc Surg 2022;87:548–59. 
https://doi.org/10.1016/j.avsg.2022.08.005
1456. Guala A, Teixidó-Tura G, Rodríguez-Palomares J, Ruiz-Muñoz A, Dux-Santoy L, 
Villalva N, et al. Proximal aorta longitudinal strain predicts aortic root dilation rate 
and aortic events in Marfan syndrome. Eur Heart J 2019;40:2047–55. https://doi. 
org/10.1093/eurheartj/ehz191
1457. Teixido-Tura G, Redheuil A, Rodríguez-Palomares J, Gutiérrez L, Sánchez V, Forteza 
A, et al. Aortic biomechanics by magnetic resonance: early markers of aortic disease 
in Marfan syndrome regardless of aortic dilatation? Int J Cardiol 2014;171:56–61. 
https://doi.org/10.1016/j.ijcard.2013.11.044
1458. Kuijpers JM, Mulder BJ. Aortopathies in adult congenital heart disease and genetic 
aortopathy syndromes: management strategies and indications for surgery. Heart 
2017;103:952–66. https://doi.org/10.1136/heartjnl-2015-308626
1459. Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al. 
Marfan syndrome. Nat Rev Dis Primers 2021;7:64. https://doi.org/10.1038/s41572- 
021-00298-7
1460. Doyle JJ, Doyle AJ, Wilson NK, Habashi JP, Bedja D, Whitworth RE, et al. A deleteri­
ous gene-by-environment interaction imposed by calcium channel blockers in Marfan 
syndrome. Elife 2015;4:e08648. https://doi.org/10.7554/eLife.08648
1461. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol 
versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 
2014;371:2061–71. https://doi.org/10.1056/NEJMoa1404731
1462. Teixido-Tura G, Forteza A, Rodríguez-Palomares J, González Mirelis J, Gutiérrez L, 
Sánchez V, et al. Losartan versus atenolol for prevention of aortic dilation in patients 
with Marfan syndrome. J Am Coll Cardiol 2018;72:1613–8. https://doi.org/10.1016/j. 
jacc.2018.07.052
1463. Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al. Angiotensin recep­
tor blockers and β blockers in Marfan syndrome: an individual patient data 
meta-analysis of randomised trials. Lancet 2022;400:822–31. https://doi.org/10. 
1016/s0140-6736(22)01534-3
1464. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, 
et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a ran­
domized controlled trial. Eur Heart J 2013;34:3491–500. https://doi.org/10.1093/ 
eurheartj/eht334
1465. Nucera M, Kreibich M, Yildiz M, Berger T, Kolb RK, Kondov S, et al. Endovascular aor­
tic repair in patients with Marfan and Loeys-Dietz syndrome is safe and durable when 
employed by a multi-disciplinary aortic team. Eur J Cardiothorac Surg 2024;65: 
ezae069. https://doi.org/10.1093/ejcts/ezae069
1466. Czerny M, Grabenwoger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. 
EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of 
the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ 
ejcts/ezad426
1467. Milleron O, Arnoult F, Delorme G, Detaint D, Pellenc Q, Raffoul R, et al. Pathogenic 
FBN1 genetic variation and aortic dissection in patients with Marfan syndrome. J Am 
Coll Cardiol 2020;75:843–53. https://doi.org/10.1016/j.jacc.2019.12.043
1468. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al. 
J 2021;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554
1469. Martín C, Evangelista A, Serrano-Fiz S, Villar S, Ospina V, Martínez D, et al. Aortic 
complications in Marfan syndrome: should we anticipate preventive aortic root sur­
gery? Ann Thorac Surg 2020;109:1850–7. https://doi.org/10.1016/j.athoracsur.2019. 
08.096
1470. Roman MJ, Pugh NL, Hendershot TP, Devereux RB, Dietz H, Holmes K, et al. Aortic 
complications associated with pregnancy in Marfan syndrome: the NHLBI national 
registry of genetically triggered thoracic aortic aneurysms and cardiovascular condi­
tions (GenTAC). J Am Heart Assoc 2016;5:e004052. https://doi.org/10.1161/jaha.116. 
004052
1471. Braverman AC, Mittauer E, Harris KM, Evangelista A, Pyeritz RE, Brinster D, et al. 
Clinical features and outcomes of pregnancy-related acute aortic dissection. JAMA 
Cardiol 2021;6:58–66. https://doi.org/10.1001/jamacardio.2020.4876
1472. Narula N, Devereux RB, Malonga GP, Hriljac I, Roman MJ. Pregnancy-related aortic 
complications in women with Marfan syndrome. J Am Coll Cardiol 2021;78:870–9. 
https://doi.org/10.1016/j.jacc.2021.06.034
1473. Davis MB, Arendt K, Bello NA, Brown H, Briller J, Epps K, et al. Team-based care of 
women with cardiovascular disease from pre-conception through pregnancy and 
postpartum: JACC focus seminar 1/5. J Am Coll Cardiol 2021;77:1763–77. https:// 
doi.org/10.1016/j.jacc.2021.02.033
1474. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJM. 
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. 
Eur Heart J 2005;26:914–20. https://doi.org/10.1093/eurheartj/ehi103
1475. Kuperstein R, Cahan T, Yoeli-Ullman R, Ben Zekry S, Shinfeld A, Simchen MJ. Risk of 
aortic dissection in pregnant patients with the Marfan syndrome. Am J Cardiol 2017; 
119:132–7. https://doi.org/10.1016/j.amjcard.2016.09.024
1476. Roberts EA, Pistner A, Osobamiro O, Banning S, Shalhub S, Albright C, et al. 
Beta-blocker use during pregnancy correlates with less aortic root dilatation in pa­
tients with Marfan’s syndrome. Aorta (Stamford) 2023;11:63–70. https://doi.org/10. 
1055/a-2072-0469
1477. Roman MJ, Devereux RB. Aortic dissection risk in Marfan syndrome. J Am Coll Cardiol 
2020;75:854–6. https://doi.org/10.1016/j.jacc.2019.12.042
1478. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhi­
bitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23–8. https://doi. 
org/10.1016/j.earlhumdev.2005.11.001
1479. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angio­
tensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31: 
465–72. https://doi.org/10.3109/01443615.2011.579197
1480. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. 
Major congenital malformations after first-trimester exposure to ACE inhibitors. N 
Engl J Med 2006;354:2443–51. https://doi.org/10.1056/NEJMoa055202
1481. Mas-Stachurska A, Siegert AM, Batlle M, Gorbenko del Blanco D, Meirelles T, Rubies 
C, et al. Cardiovascular benefits of moderate exercise training in Marfan syndrome: 
insights from an animal model. J Am Heart Assoc 2017;6:e006438. https://doi.org/10. 
1161/jaha.117.006438
1482. Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, et al. Mild aerobic ex­
ercise blocks elastin fiber fragmentation and aortic dilatation in a mouse model of 
Marfan syndrome associated aortic aneurysm. J Appl Physiol 2017;123:147–60. 
https://doi.org/10.1152/japplphysiol.00132.2017
1483. Selamet Tierney ES, Chung S, Stauffer KJ, Brabender J, Collins RT, Folk R, et al. Can 10  
000 healthy steps a day slow aortic root dilation in pediatric patients with Marfan syn­
drome? J Am Heart Assoc 2022;11:e027598. https://doi.org/10.1161/jaha.122.027598
1484. Jouini S, Milleron O, Eliahou L, Jondeau G, Vitiello D. Effects of a personalized home- 
based training program among patients suffering from Marfan syndrome: a pilot ran­
domized and controlled study. Intractable Rare Dis Res 2021;10:263–8. https://doi.org/ 
10.5582/irdr.2021.01080
1485. Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J, Schroeder 
F, et al. Inpatient rehabilitation for adult patients with Marfan syndrome: an observa­
tional pilot study. Orphanet J Rare Dis 2017;12:127. https://doi.org/10.1186/s13023- 
017-0679-0
1486. Fuglsang S, Heiberg J, Hjortdal VE, Laustsen S. Exercise-based cardiac rehabilitation in 
surgically treated type-A aortic dissection patients. Scand Cardiovasc J 2017;51: 
99–105. https://doi.org/10.1080/14017431.2016.1257149
1487. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of 
altered cardiovascular, craniofacial, neurocognitive and skeletal development caused 
ESC Guidelines                                                                                                                                                                                          3697


<!-- PAGE 161 -->

### Page 161

by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275–81. https://doi.org/10. 
1038/ng1511
1488. MacCarrick G, Black JH, III, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, 
Guerrerio AL, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. 
Genet Med 2014;16:576–87. https://doi.org/10.1038/gim.2014.11
1489. Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, et al. 
Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic 
aortic aneurysm. Nat Genet 2012;44:922–7. https://doi.org/10.1038/ng.2349
1490. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 muta­
tions cause familial thoracic aortic aneurysms and dissections associated with mild 
systemic features of Marfan syndrome. Nat Genet 2012;44:916–21. https://doi.org/ 
10.1038/ng.2348
1491. van der Linde D, van de Laar IM, Bertoli-Avella AM, Oldenburg RA, Bekkers JA, 
Mattace-Raso 
FUS, 
et 
al. 
Aggressive 
cardiovascular 
phenotype 
of 
aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am 
Coll Cardiol 2012;60:397–403. https://doi.org/10.1016/j.jacc.2011.12.052
1492. Hostetler EM, Regalado ES, Guo DC, Hanna N, Arnaud P, Muiño-Mosquera L, et al. 
SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complica­
tions from the Montalcino Aortic Consortium. J Med Genet 2019;56:252–60. https:// 
doi.org/10.1136/jmedgenet-2018-105583
1493. Renard M, Callewaert B, Malfait F, Campens L, Sharif S, del Campo M, et al. Thoracic 
aortic-aneurysm and dissection in association with significant mitral valve disease 
caused by mutations in TGFB2. Int J Cardiol 2013;165:584–7. https://doi.org/10. 
1016/j.ijcard.2012.09.029
1494. Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JMA, de Graaf BM, van de Beek G, 
et al. Mutations in a TGF-beta ligand, TGFB3, cause syndromic aortic aneurysms and 
dissections. J Am Coll Cardiol 2015;65:1324–36. https://doi.org/10.1016/j.jacc.2015.01. 
040
1495. Marsili L, Overwater E, Hanna N, Baujat G, Baars MJH, Boileau C, et al. Phenotypic 
spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first re­
port of a homozygous patient. Clin Genet 2020;97:723–30. https://doi.org/10.1111/ 
cge.13700
1496. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al. Mutations in 
smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissec­
tions. Nat Genet 2007;39:1488–93. https://doi.org/10.1038/ng.2007.6
1497. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. 
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, 
stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 
2009;84:617–27. https://doi.org/10.1016/j.ajhg.2009.04.007
1498. van de Laar I, Arbustini E, Loeys B, Björck E, Murphy L, Groenink M, et al. European 
reference network for rare vascular diseases (VASCERN) consensus statement for 
the screening and management of patients with pathogenic ACTA2 variants. 
Orphanet J Rare Dis 2019;14:264. https://doi.org/10.1186/s13023-019-1186-2
1499. Brownstein AJ, Ziganshin BA, Kuivaniemi H, Body Simon, Bale A, Elefteriades J. Genes 
associated with thoracic aortic aneurysm and dissection: an update and clinical impli­
cations. Aorta (Stamford) 2017;5:11–20. https://doi.org/10.12945/j.aorta.2017.17.003
1500. Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve 
and aortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152–64. https://doi.org/10. 
1093/eurheartj/ehad320
1501. Michelena HI, Vallabhajosyula S, Prakash SK. Nosology spectrum of the bicuspid aor­
tic valve condition: complex-presentation valvulo-aortopathy. Circulation 2020;142: 
294–9. https://doi.org/10.1161/circulationaha.120.046892
1502. Prakash SK, Bosse Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A, 
et al. A roadmap to investigate the genetic basis of bicuspid aortic valve and its com­
plications: insights from the International BAVCon (Bicuspid Aortic Valve 
Consortium). J Am Coll Cardiol 2014;64:832–9. https://doi.org/10.1016/j.jacc.2014. 
04.073
1503. Fulmer D, Toomer K, Guo L, Moore K, Glover J, Moore R, et al. Defects in the 
exocyst-cilia machinery cause bicuspid aortic valve disease and aortic stenosis. 
Circulation 2019;140:1331–41. https://doi.org/10.1161/circulationaha.119.038376
1504. Luyckx I, Kumar AA, Reyniers E, Dekeyser E, Vanderstraeten K, Vandeweyer G, et al. 
Copy number variation analysis in bicuspid aortic valve-related aortopathy identifies 
TBX20 as a contributing gene. Eur J Hum Genet 2019;27:1033–43. https://doi.org/10. 
1038/s41431-019-0364-y
1505. Xu YJ, Di RM, Qiao Q, Li X-M, Huang R-T, Xue S, et al. GATA6 loss-of-function mu­
tation contributes to congenital bicuspid aortic valve. Gene 2018;663:115–20. https:// 
doi.org/10.1016/j.gene.2018.04.018
1506. Gehlen J, Stundl A, Debiec R, Fontana F, Krane M, Sharipova D, et al. Elucidation of the 
genetic causes of bicuspid aortic valve disease. Cardiovasc Res 2023;119:857–66. 
https://doi.org/10.1093/cvr/cvac099
1507. Gago-Díaz M, Brion M, Gallego P, Calvo F, Robledo-Carmona J, Saura D, et al. The 
genetic component of bicuspid aortic valve and aortic dilation. An exome-wide asso­
ciation study. J Mol Cell Cardiol 2017;102:3–9. https://doi.org/10.1016/j.yjmcc.2016. 
11.012
1508. Girdauskas E, Geist L, Disha K, Kazakbaev I, Groß T, Schulz S, et al. Genetic abnor­
malities in bicuspid aortic valve root phenotype: preliminary results. Eur J 
Cardiothorac Surg 2017;52:156–62. https://doi.org/10.1093/ejcts/ezx065
1509. Mansoorshahi S, Yetman AT, Bissell MM, Kim YY, Michelena H, Hui DS, et al. Whole 
exome sequencing uncovers the genetic complexity of bicuspid aortic valve in families 
with early onset complications. medRxiv 2024. https://doi.org/10.1101/2024.02.07. 
24302406.
1510. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, 
et al. International consensus statement on nomenclature and classification of the 
congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional 
and research purposes. Eur J Cardiothorac Surg 2021;60:448–76. https://doi.org/10. 
1093/ejcts/ezab038
1511. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 
2014;370:1920–9. https://doi.org/10.1056/NEJMra1207059
1512. Yang LT, Ye Z, Wajih Ullah M, Maleszewski JJ, Scott CG, Padang R, et al. Bicuspid aor­
tic valve: long-term morbidity and mortality. Eur Heart J 2023;44:4549–62. https://doi. 
org/10.1093/eurheartj/ehad477
1513. Guo MH, Appoo JJ, Saczkowski R, Smith HN, Ouzounian M, Gregory AJ, et al. 
Association of mortality and acute aortic events with ascending aortic aneurysm: a 
systematic review and meta-analysis. JAMA Netw Open 2018;1:e181281. https://doi. 
org/10.1001/jamanetworkopen.2018.1281
1514. Dayan V, Zuasnabar A, Citro R, Bossone E, Michelena HI, Parma G, et al. Aortopathy 
and regurgitation in bicuspid valve patients increase the risk of aortopathy in relatives. 
Int J Cardiol 2019;286:117–20. https://doi.org/10.1016/j.ijcard.2019.03.031
1515. Galian-Gay L, Carro Hevia A, Teixido-Turà G, Rodríguez Palomares J, 
Gutiérrez-Moreno L, Maldonado G, et al. Familial clustering of bicuspid aortic valve 
and its relationship with aortic dilation in first-degree relatives. Heart 2019;105: 
603–8. https://doi.org/10.1136/heartjnl-2018-313802
1516. Tessler I, Leshno M, Shmueli A, Shpitzen S, Durst R, Gilon D. Cost-effectiveness ana­
lysis of screening for first-degree relatives of patients with bicuspid aortic valve. Eur 
Heart J Qual Care Clin Outcomes 2021;7:447–57. https://doi.org/10.1093/ehjqcco/ 
qcab047
1517. Girdauskas E, Rouman M, Disha K, Espinoza A, Misfeld M, Borger MA, et al. Aortic 
dissection after previous aortic valve replacement for bicuspid aortic valve disease. 
J Am Coll Cardiol 2015;66:1409–11. https://doi.org/10.1016/j.jacc.2015.07.022
1518. Masri A, Kalahasti V, Svensson LG, Alashi A, Schoenhagen P, Roselli EE, et al. Aortic 
cross-sectional area/height ratio and outcomes in patients with bicuspid aortic valve 
and a dilated ascending aorta. Circ Cardiovasc Imaging 2017;10:e006249. https://doi. 
org/10.1161/circimaging.116.006249
1519. Della Corte A, Michelena HI, Citarella A, Votta E, Piatti F, Lo Presti F, et al. Risk strati­
fication in bicuspid aortic valve aortopathy: emerging evidence and future perspec­
tives. Curr Probl Cardiol 2021;46:100428. https://doi.org/10.1016/j.cpcardiol.2019.06. 
002
1520. Ye Z, Lane C, Beachey JD. Clinical outcomes in patients with bicuspid aortic valves 
and ascending aorta ≥50 mm under surveillance. JACC: Advances 2023;2:100626. 
https://doi.org/10.1016/j.jacadv.2023.100626.
1521. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, et al. 
Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 
2011;306:1104–12. https://doi.org/10.1001/jama.2011.1286
1522. Michelena HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM, et al. 
Natural history of asymptomatic patients with normally functioning or minimally dys­
functional bicuspid aortic valve in the community. Circulation 2008;117:2776–84. 
https://doi.org/10.1161/CIRCULATIONAHA.107.740878
1523. Girdauskas E, Disha K, Secknus M, Borger M, Kuntze T. Increased risk of late aortic 
events after isolated aortic valve replacement in patients with bicuspid aortic valve 
insufficiency versus stenosis. J Cardiovasc Surg (Torino) 2013;54:653–9.
1524. Cortenbach KRG, Yosofi B, Rodwell L, Meek J, Patel R, Prakash SK, et al. Editor’s 
choice—therapeutic options and outcomes in midaortic syndrome: a systematic re­
view and meta-analysis. Eur J Vasc Endovasc Surg 2023;65:120–30. https://doi.org/10. 
1016/j.ejvs.2022.10.017
1525. Teo LL, Cannell T, Babu-Narayan SV, Hughes M, Mohiaddin RH. Prevalence of asso­
ciated cardiovascular abnormalities in 500 patients with aortic coarctation referred 
for cardiovascular magnetic resonance imaging to a tertiary center. Pediatr Cardiol 
2011;32:1120–7. https://doi.org/10.1007/s00246-011-9981-0
1526. Spaziani G, Girolami F, Arcieri L, Calabri GB, Porcedda G, Di Filippo C, et al. Bicuspid 
aortic valve in children and adolescents: a comprehensive review. Diagnostics (Basel) 
2022;12:1751. https://doi.org/10.3390/diagnostics12071751
1527. Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late causes of death after 
pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol 2016;68: 
487–98. https://doi.org/10.1016/j.jacc.2016.05.038
1528. Panzer J, Bové T, Vandekerckhove K, De Wolf D. Hypertension after coarctation re­
pair–a systematic review. Transl Pediatr 2022;11:270–9. https://doi.org/10.21037/tp- 
21-418
1529. Batlivala SP, Goldstein BH. Current transcatheter approaches for the treatment of 
aortic coarctation in children and adults. Interv Cardiol Clin 2019;8:47–58. https:// 
doi.org/10.1016/j.iccl.2018.08.001


<!-- PAGE 162 -->

### Page 162

1530. Egbe AC, Miranda WR, Bonnichsen CR, Warnes CA, Connolly HM. Potential bene­
fits of ambulatory blood pressure monitoring in coarctation of aorta. J Am Coll Cardiol 
2020;75:2089–90. https://doi.org/10.1016/j.jacc.2020.02.053
1531. Luitingh TL, Lee MGY, Jones B, Kowalski R, Weskamp Aguero S, Koleff J, et al. A 
cross-sectional study of the prevalence of exercise-induced hypertension in child­
hood following repair of coarctation of the aorta. Heart Lung Circ 2019;28:792–9. 
https://doi.org/10.1016/j.hlc.2018.03.015
1532. Brown ML, Burkhart HM, Connolly HM, Dearani JA, Cetta F, Li Z, et al. Coarctation 
of the aorta: lifelong surveillance is mandatory following surgical repair. J Am Coll 
Cardiol 2013;62:1020–5. https://doi.org/10.1016/j.jacc.2013.06.016
1533. Somers T, Nies H, van Kimmenade RRJ, Bosboom DGH, Geuzebroek GSC, Morshuis 
WJ. Necessity of life-long follow-up after surgery for coarctation of the aorta: a case 
series of very late false aneurysm formation. Eur Heart J Case Rep 2022;6:ytac073. 
https://doi.org/10.1093/ehjcr/ytac073
1534. Padang R, Dennis M, Semsarian C, Bannon PG, Tanous DJ, Celermajer DS, et al. 
Detection of serious complications by MR imaging in asymptomatic young adults 
with repaired coarctation of the aorta. Heart Lung Circ 2014;23:332–8. https://doi. 
org/10.1016/j.hlc.2013.10.055
1535. Bhatt AB, Lantin-Hermoso MR, Daniels CJ, Jaquiss R, Landis BJ, Marino BS, et al. 
Isolated coarctation of the aorta: current concepts and perspectives. Front 
Cardiovasc Med 2022;9:817866. https://doi.org/10.3389/fcvm.2022.817866
1536. Erben Y, Oderich GS, Verhagen HJM, Witsenburg M, van den Hoven AT, Debus ES, 
et al. Multicenter experience with endovascular treatment of aortic coarctation in 
adults. J Vasc Surg 2019;69:671–9.e1. https://doi.org/10.1016/j.jvs.2018.06.209
1537. Meijs TA, Warmerdam EG, Slieker MG, Krings GJ, Molenschot MMC, Meijboom FJ, 
et al. Medium-term systemic blood pressure after stenting of aortic coarctation: a sys­
tematic review and meta-analysis. Heart 2019;105:1464–70. https://doi.org/10.1136/ 
heartjnl-2019-314965
1538. Layton KF, Kallmes DF, Cloft HJ, Lindell EP, Cox VS. Bovine aortic arch variant in hu­
mans: clarification of a common misnomer. AJNR Am J Neuroradiol 2006;27:1541–2.
1539. Berko NS, Jain VR, Godelman A, Stein EG, Ghosh S, Haramati LB. Variants 
and anomalies of thoracic vasculature on computed tomographic angiography in 
adults. J Comput Assist Tomogr 2009;33:523–8. https://doi.org/10.1097/RCT. 
0b013e3181888343
1540. Dumfarth J, Peterss S, Kofler M, Plaikner M, Ziganshin BA, Schachner T, et al. In 
DeBakey type I aortic dissection, bovine aortic arch is associated with arch tears 
and stroke. Ann Thorac Surg 2017;104:2001–8. https://doi.org/10.1016/j.athoracsur. 
2017.05.026
1541. Hornick M, Moomiaie R, Mojibian H, Ziganshin B, Almuwaqqat Z, Lee ES, et al. 
‘Bovine’ aortic arch—a marker for thoracic aortic disease. Cardiology 2012;123: 
116–24. https://doi.org/10.1159/000342071
1542. Yousef S, Singh S, Alkukhun A, Alturkmani B, Mori M, Chen J, et al. Variants of the 
aortic arch in adult general population and their association with thoracic aortic an­
eurysm disease. J Card Surg 2021;36:2348–54. https://doi.org/10.1111/jocs.15563
1543. Tanaka A, Milner R, Ota T. Kommerell’s diverticulum in the current era: a compre­
hensive review. Gen Thorac Cardiovasc Surg 2015;63:245–59. https://doi.org/10.1007/ 
s11748-015-0521-3
1544. Upchurch GR, Jr, Escobar GA, Azizzadeh A, Beck AW, Conrad MF, Matsumura JS, 
et al. Society for Vascular Surgery clinical practice guidelines of thoracic endovascular 
aortic repair for descending thoracic aortic aneurysms. J Vasc Surg 2021;73:55s–83s. 
https://doi.org/10.1016/j.jvs.2020.05.076
1545. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, 
et al. Peripheral arterial disease detection, awareness, and treatment in primary 
care. JAMA 2001;286:1317–24. https://doi.org/10.1001/jama.286.11.1317
1546. Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, et al. 
Influence of polyvascular disease on cardiovascular event rates. Insights from the 
REACH registry. Vasc Med 2010;15:259–65. https://doi.org/10.1177/1358863x 
10373299
1547. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, et al. Three-year 
follow-up and event rates in the international REduction of atherothrombosis for 
continued health registry. Eur Heart J 2009;30:2318–26. https://doi.org/10.1093/ 
eurheartj/ehp355
1548. van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, et al. 
Identification of vascular patients at very high risk for recurrent cardiovascular events: 
validation of the current ACC/AHA very high risk criteria. Eur Heart J 2017;38: 
3211–8. https://doi.org/10.1093/eurheartj/ehx102
1549. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, et al. Polyvascular 
disease and long-term cardiovascular outcomes in older patients with 
non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 
2012;5:541–9. https://doi.org/10.1161/circoutcomes.111.964379
1550. van der Meer MG, Cramer MJ, van der Graaf Y, Appelman Y, Doevendans PA, 
Nathoe HM. The impact of polyvascular disease on long-term outcome in percutan­
eous coronary intervention patients. Eur J Clin Invest 2014;44:231–9. https://doi.org/ 
10.1111/eci.12222
1551. Steinvil A, Sadeh B, Arbel Y, Justo D, Belei A, Borenstein N, et al. Prevalence and pre­
dictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll 
Cardiol 2011;57:779–83. https://doi.org/10.1016/j.jacc.2010.09.047
1552. Ahmed B, Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease 
in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg 
2009;37:262–71. https://doi.org/10.1016/j.ejvs.2008.10.017
1553. Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard J-M, Agnelli G, et al. Impact 
of prior peripheral arterial disease and stroke on outcomes of acute coronary syn­
dromes and effect of evidence-based therapies (from the global registry of acute cor­
onary events). Am J Cardiol 2007;100:1–6. https://doi.org/10.1016/j.amjcard.2007.02. 
046
1554. Fowkes FG, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of athero­
thrombosis in 8891 patients with or at risk of vascular disease: results of the inter­
national AGATHA study. Eur Heart J 2006;27:1861–7. https://doi.org/10.1093/ 
eurheartj/ehl114
1555. Durand DJ, Perler BA, Roseborough GS, Grega MA, Borowicz LM, Baumgartner WA, 
et al. Mandatory versus selective preoperative carotid screening: a retrospective ana­
lysis. Ann Thorac Surg 2004;78:159–66; discussion 159–66. https://doi.org/10.1016/j. 
athoracsur.2004.02.024
1556. Naylor AR, Mehta Z, Rothwell PM, Bell PR. Carotid artery disease and stroke during 
coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg 
2002;23:283–94. https://doi.org/10.1053/ejvs.2002.1609
1557. Jens S, Koelemay MJ, Reekers JA, Bipat S. Diagnostic performance of computed tom­
ography angiography and contrast-enhanced magnetic resonance angiography in pa­
tients with critical limb ischaemia and intermittent claudication: systematic review and 
meta-analysis. Eur Radiol 2013;23:3104–14. https://doi.org/10.1007/s00330-013- 
2933-8
1558. Illuminati G, Schneider F, Greco C, Mangieri E, Schiariti M, Tanzilli G, et al. Long-term 
results of a randomized controlled trial analyzing the role of systematic pre-operative 
coronary angiography before elective carotid endarterectomy in patients with 
asymptomatic coronary artery disease. Eur J Vasc Endovasc Surg 2015;49:366–74. 
https://doi.org/10.1016/j.ejvs.2014.12.030
1559. Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, et al. Mortality 
benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral ar­
tery disease. J Am Coll Cardiol 2021;78:14–23. https://doi.org/10.1016/j.jacc.2021.04. 
083
1560. Aboyans V, Lacroix P, Postil A, Guilloux J, Rollé F, Cornu E, et al. Subclinical peripheral 
arterial disease and incompressible ankle arteries are both long-term prognostic fac­
tors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2005;46: 
815–20. https://doi.org/10.1016/j.jacc.2005.05.066
1561. Rihal CS, Sutton-Tyrrell K, Guo P, Keller NM, Jandova R, Sellers MA, et al. Increased 
incidence of periprocedural complications among patients with peripheral vascular 
disease undergoing myocardial revascularization in the bypass angioplasty revascular­
ization investigation. Circulation 1999;100:171–7. https://doi.org/10.1161/01.cir.100. 
2.171
1562. Aboyans V, Lacroix P. Indications for carotid screening in patients with coronary ar­
tery disease. Presse Med 2009;38:977–86. https://doi.org/10.1016/j.lpm.2009.02.015
1563. Collet JP, Cayla G, Ennezat PV, Leclercq F, Cuisset T, Elhadad S, et al. Systematic de­
tection of polyvascular disease combined with aggressive secondary prevention in pa­
tients presenting with severe coronary artery disease: the randomized AMERICA 
study. Int J Cardiol 2018;254:36–42. https://doi.org/10.1016/j.ijcard.2017.11.081
1564. Neufang A, Dorweiler B, Espinola-Klein C, Savvidis S, Doemland M, Schotten S, et al. 
Outcomes of complex femorodistal sequential autologous vein and biologic pros­
thesis composite bypass grafts. J Vasc Surg 2014;60:1543–53. https://doi.org/10. 
1016/j.jvs.2014.07.103
1565. Calvet D, Touzé E, Varenne O, Sablayrolles J-L, Weber S, Mas J-L. Prevalence of 
asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS 
study. Circulation 2010;121:1623–9. https://doi.org/10.1161/circulationaha.109. 
906958
1566. Hofmann R, Kypta A, Steinwender C, Kerschner K, Grund M, Leisch F. Coronary 
angiography in patients undergoing carotid artery stenting shows a high incidence 
of significant coronary artery disease. Heart 2005;91:1438–41. https://doi.org/10. 
1136/hrt.2004.050906
1567. Masabni K, Raza S, Blackstone EH, Gornik HL, Sabik JF, III. Does preoperative carotid 
stenosis screening reduce perioperative stroke in patients undergoing coronary ar­
tery bypass grafting? J Thorac Cardiovasc Surg 2015;149:1253–60. https://doi.org/10. 
1016/j.jtcvs.2015.02.003
1568. Klarin D, Patel VI, Zhang S, Xian Y, Kosinski A, Yerokun B, et al. Concomitant carotid 
endarterectomy and cardiac surgery does not decrease postoperative stroke rates. J 
Vasc Surg 2020;72:589–96.e3. https://doi.org/10.1016/j.jvs.2019.10.072
1569. D’Agostino RS, Svensson LG, Neumann DJ, Balkhy HH, Williamson WA, Shahian 
DM. Screening carotid ultrasonography and risk factors for stroke in coronary artery 
surgery patients. Ann Thorac Surg 1996;62:1714–23. https://doi.org/10.1016/s0003- 
4975(96)00885-5
1570. Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, et al. 
Polyvascular disease: a narrative review of current evidence and a consideration of 
ESC Guidelines                                                                                                                                                                                          3699


<!-- PAGE 163 -->

### Page 163

the role of antithrombotic therapy. Atherosclerosis 2020;315:10–7. https://doi.org/10. 
1016/j.atherosclerosis.2020.11.001
1571. Alkhalil M, Kuzemczak M, Whitehead N, Kavvouras C, Džavík V. Meta-analysis of in­
tensive lipid-lowering therapy in patients with polyvascular disease. J Am Heart Assoc 
2021;10:e017948. https://doi.org/10.1161/jaha.120.017948
1572. Ward RP, Goonewardena SN, Lammertin G, Lang RM. Comparison of the frequency 
of abnormal cardiac findings by echocardiography in patients with and without per­
ipheral arterial disease. Am J Cardiol 2007;99:499–503. https://doi.org/10.1016/j. 
amjcard.2006.09.102
1573. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The 
prevalence of treatable left ventricular systolic dysfunction in patients who present 
with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol 2002;39: 
219–24. https://doi.org/10.1016/s0735-1097(01)01725-9
1574. Samsky MD, Hellkamp A, Hiatt WR, Fowkes FGR, Baumgartner I, Berger JS, et al. 
Association of heart failure with outcomes among patients with peripheral artery dis­
ease: insights from EUCLID. J Am Heart Assoc 2021;10:e018684. https://doi.org/10. 
1161/jaha.120.018684
1575. Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. J 
Hypertens 2012;30:685–7. https://doi.org/10.1097/HJH.0b013e328350e5db
1576. O’Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging ef­
fects on the aorta and microvasculature. Vasc Med 2010;15:461–8. https://doi.org/10. 
1177/1358863x10382946
1577. Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to ex­
plain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll 
Cardiol 2002;39:1170–4. https://doi.org/10.1016/s0735-1097(02)01740-0
1578. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. 
Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle 
metabolism in heart failure. Circulation 1992;85:1364–73. https://doi.org/10.1161/ 
01.cir.85.4.1364
1579. Hedberg P, Hammar C, Selmeryd J, Viklund J, Leppert J, Hellberg A, et al. Left ven­
tricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular 
disease: prevalence and association with location of arterial disease. Eur J Heart Fail 
2014;16:625–32. https://doi.org/10.1002/ejhf.95
1580. Sandesara PB, Hammadah M, Samman-Tahhan A, Kelli HM, O’Neal WT. Peripheral 
artery disease and risk of adverse outcomes in heart failure with preserved ejection 
fraction. Clin Cardiol 2017;40:692–6. https://doi.org/10.1002/clc.22716
1581. Nakamura Y, Kunii H, Yoshihisa A, Takiguchi M, Shimizu T, Yamauchi H, et al. Impact 
of peripheral artery disease on prognosis in hospitalized heart failure patients. Circ J 
2015;79:785–93. https://doi.org/10.1253/circj.CJ-14-1280
1582. Inglis SC, Bebchuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, et al. Peripheral 
artery disease and outcomes after myocardial infarction: an individual-patient 
meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and 
VALIANT. Int J Cardiol 2013;168:1094–101. https://doi.org/10.1016/j.ijcard.2012.11. 
033
1583. Jones WS, Clare R, Ellis SJ, Mills JS, Fischman DL, Kraus WE, et al. Effect of peripheral 
arterial disease on functional and clinical outcomes in patients with heart failure (from 
HF-ACTION). Am J Cardiol 2011;108:380–4. https://doi.org/10.1016/j.amjcard.2011. 
03.057
1584. van Straten AH, Firanescu C, Soliman Hamad MA, Tan MESH, ter Woorst JFJ, 
Martens EJ, et al. Peripheral vascular disease as a predictor of survival after coronary 
artery bypass grafting: comparison with a matched general population. Ann Thorac 
Surg 2010;89:414–20. https://doi.org/10.1016/j.athoracsur.2009.11.036
1585. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical pro­
file, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. 
Am Heart J 2008;156:855–63, 863.e2. https://doi.org/10.1016/j.ahj.2008.06.029
1586. Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY. Atrial fibrillation and vascular dis­
ease—a bad combination. Clin Cardiol 2012;35:15–20. https://doi.org/10.1002/clc. 
20955
1587. Parvar SL, Thiyagarajah A, Nerlekar N, King P, Nicholls SJ. A systematic review and 
meta-analysis of gender differences in long-term mortality and cardiovascular events 
in peripheral artery disease. J Vasc Surg 2021;73:1456–65.e7. https://doi.org/10.1016/ 
j.jvs.2020.09.039
1588. Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often 
overlapping clinical syndromes. Thromb Haemost 2010;104:657–63. https://doi.org/ 
10.1160/th10-05-0332
1589. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and pre­
disposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 
1998;82:2n–9n. https://doi.org/10.1016/s0002-9149(98)00583-9
1590. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent 
risk factors for atrial fibrillation in a population-based cohort. The Framingham heart 
study. JAMA 1994;271:840–4.
1591. Zhu J, Tan X, Zhou JZ. Peripheral artery disease and clinical outcomes in patients with 
atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2021;44:1050–7. 
https://doi.org/10.1002/clc.23678
1592. Olesen JB, Lip GY, Lane DA, Køber L, Hansen ML, Karasoy D, et al. Vascular disease 
and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012;125: 
826.e13–23. https://doi.org/10.1016/j.amjmed.2011.11.024
1593. Skelding KA, Yakubov SJ, Kleiman NS, Reardon MJ, Adams DH, Huang J, et al. 
Transcatheter aortic valve replacement versus surgery in women at high risk for sur­
gical aortic valve replacement (from the CoreValve US High Risk Pivotal Trial). Am J 
Cardiol 2016;118:560–6. https://doi.org/10.1016/j.amjcard.2016.05.051
1594. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, et al. 
Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J 
Med 2012;366:1705–15. https://doi.org/10.1056/NEJMoa1114705
1595. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter 
aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. 
N Engl J Med 2010;363:1597–607. https://doi.org/10.1056/NEJMoa1008232
1596. Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al. Cardiac 
magnetic resonance imaging versus computed tomography to guide transcatheter 
aortic valve replacement (TAVR-CMR): a randomized, open-label, non-inferiority 
trial. Circulation 2023;148:1220–30. https://doi.org/10.1161/CIRCULATIONAHA. 
123.066498
1597. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 
oped in collaboration with the European Association for Cardio-Thoracic Surgery 
(EACTS): The Task Force for the diagnosis and management of atrial fibrillation of 
the European Society of Cardiology (ESC) developed with the special contribution 
of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 
42:373–498. https://doi.org/10.1093/eurheartj/ehaa612
1598. Fanaroff AC, Manandhar P, Holmes DR, Cohen DJ, Harrison JK, Hughes GC, et al. 
Peripheral artery disease and transcatheter aortic valve replacement outcomes: a re­
port from the Society of Thoracic Surgeons/American College of Cardiology 
Transcatheter Therapy Registry. Circ Cardiovasc Interv 2017;10:e005456. https://doi. 
org/10.1161/CIRCINTERVENTIONS.117.005456
